PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	C3	RP	EM	RI	OI	FU	FP	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	DL	D2	EA	PG	WC	WE	SC	GA	PM	OA	HC	HP	DA	UT
J	Sandler, AD; Sutton, KA; DeWeese, J; Girardi, MA; Sheppard, V; Bodfish, JW				Sandler, AD; Sutton, KA; DeWeese, J; Girardi, MA; Sheppard, V; Bodfish, JW			Lack of benefit of a single dose of synthetic human secretin in the treatment of autism and pervasive developmental disorder	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOUBLE-BLIND; BEHAVIORAL TREATMENT; YOUNG-CHILDREN; PLACEBO; CLOMIPRAMINE; ADULTS	Background: Secretin is a peptide hormone that stimulates pancreatic secretion. After recent publicity about a child with autism whose condition markedly improved after a single dose of secretin, thousands of children with autistic disorders may have received secretin injections. Methods: We conducted a double-blind, placebo-controlled trial of a single intravenous dose of synthetic human secretin in 60 children (age, 3 to 14 years) with autism or pervasive developmental disorder. The children were randomly assigned to treatment with an intravenous infusion of synthetic human secretin (0.4 microg per kilogram of body weight) or saline placebo. We used standardized behavioral measures of the primary and secondary features of autism, including the Autism Behavior Checklist, to assess the degree of impairment at base line and over the course of a four-week period after treatment. Results: Of the 60 children, 4 could not be evaluated -- 2 received secretin outside the study, and 2 did not return for follow-up. Thus, 56 children (28 in each group) completed the study. As compared with placebo, secretin treatment was not associated with significant improvements in any of the outcome measures. Among the children in the secretin group, the mean total score on the Autism Behavior Checklist at base line was 59.0 (range of possible values, 0 to 158, with a larger value corresponding to greater impairment), and among those in the placebo group it was 63.2. The mean decreases in scores over the four-week period were 8.9 in the secretin group and 17.8 in the placebo group (mean difference, -8.9; 95 percent confidence interval, -19.4 to 1.6; P = 0.11). None of the children had treatment-limiting adverse effects. After they were told the results, 69 percent of the parents of the children in this study said they remained interested in secretin as a treatment for their children. Conclusions: A single dose of synthetic human secretin is not an effective treatment for autism or pervasive developmental disorder. (N Engl J Med 1999;341:1801-6.) (C)1999, Massachusetts Medical Society.	Thoms Rehabil Hosp, Olson Huff Ctr Child Dev, Asheville, NC 28803 USA; Western Carolina Ctr, Human Dev Res & Training Inst, Morganton, NC USA; Univ N Carolina, Dept Psychiat, Chapel Hill, NC USA	University of North Carolina; Western Carolina University; University of North Carolina; University of North Carolina Chapel Hill	Sandler, AD (corresponding author), Thoms Rehabil Hosp, Olson Huff Ctr Child Dev, 68 Sweeten Creek Rd, Asheville, NC 28803 USA.	adsandler@pol.net			PHS HHS [30615] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; ANDERSON GM, 1987, J CHILD PSYCHOL PSYC, V28, P885, DOI 10.1111/j.1469-7610.1987.tb00677.x; ANDERSON LT, 1984, AM J PSYCHIAT, V141, P1195; BECK G, 1998, UNLOCKING POTENTIAL; Birnbrauer J.S., 1993, BEHAV CHANGE, V10, P63, DOI [DOI 10.1017/S0813483900005556, 10.1017/S0813483900005556]; Campbell M, 1996, J AM ACAD CHILD PSY, V35, P134, DOI 10.1097/00004583-199602000-00005; CHRIST A, 1988, GASTROENTEROLOGY, V94, P311, DOI 10.1016/0016-5085(88)90417-9; DeLong GR, 1998, DEV MED CHILD NEUROL, V40, P551; GORDON CT, 1993, ARCH GEN PSYCHIAT, V50, P441; Hays W., 1981, STAT SOCIAL SCI; Horvath K, 1998, J Assoc Acad Minor Phys, V9, P9; JOHANNES L, 1999, WALL STREET J   0311, P1; Kastner T, 1998, EXCEPT HLTH CARE, V9, P45; KOLMEN BK, 1995, J AM ACAD CHILD PSY, V34, P223, DOI 10.1097/00004583-199502000-00018; KOLTS BE, 1977, GASTROENTEROLOGY, V72, P55; Krug D. A., 1980, AUTISM SCREENING INS; LEWIS MH, 1995, AM J MENT RETARD, V100, P299; LORD C, 1994, J AUTISM DEV DISORD, V24, P659, DOI 10.1007/BF02172145; LOVAAS OI, 1987, J CONSULT CLIN PSYCH, V55, P3, DOI 10.1037/0022-006X.55.1.3; Matson JL, 1996, RES DEV DISABIL, V17, P433, DOI 10.1016/S0891-4222(96)00030-3; McDougle CJ, 1998, ARCH GEN PSYCHIAT, V55, P633, DOI 10.1001/archpsyc.55.7.633; McDougle CJ, 1996, ARCH GEN PSYCHIAT, V53, P1001; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P839; National Institute of Mental Health, 1985, PSYCHOPHARMACOL BULL, V21, P1069; Nickel RE, 1996, INFANT YOUNG CHILD, V8, P29, DOI 10.1097/00001163-199604000-00005; Rapin I, 1997, NEW ENGL J MED, V337, P97, DOI 10.1056/NEJM199707103370206; Schopler E., 1986, CHILDHOOD AUTISM RAT; SHATTOCK P, 1991, BRAIN DYSFUNCT, V4, P308; Sparrow S.S., 2005, VINELAND 2 ADAPTIVE	29	163	194	0	3	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1801	1806		10.1056/NEJM199912093412404	http://dx.doi.org/10.1056/NEJM199912093412404			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	262NU	10588965				2022-12-28	WOS:000084074000004
J	Singh, JK; Kusior, MF				Singh, JK; Kusior, MF			Cystine crystals in Fanconi's syndrome	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA		Singh, JK (corresponding author), Samuel S Stratton Vet Affairs Med Ctr, Albany, NY 12208 USA.								0	1	1	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1807	1807		10.1056/NEJM199912093412405	http://dx.doi.org/10.1056/NEJM199912093412405			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588966				2022-12-28	WOS:000084074000005
J	Gray, JAM; de Lusignan, S				Gray, JAM; de Lusignan, S			National electronic Library for Health (NeLH)	BRITISH MEDICAL JOURNAL			English	Article									Univ London St Georges Hosp, Sch Med, London SW17 0RE, England; Natl Elect Lib Hlth Sci, Oxford OX3 7LF, England	St Georges University London; University of Oxford	de Lusignan, S (corresponding author), Univ London St Georges Hosp, Sch Med, Hunter Wing, London SW17 0RE, England.		de Lusignan, Smion/S-7838-2019; de Lusignan, Simon/A-6609-2011	de Lusignan, Smion/0000-0002-8553-2641; de Lusignan, Simon/0000-0002-8553-2641				*COCHR COLL, 1999, COCH LIB; *DEP ED EMPL, 1999, NAT GRID LEARN; Gray JAM, 1998, BRIT MED J, V317, P832, DOI 10.1136/bmj.317.7162.832; *HLTH NET FDN, 1999, SURV INT US HLTH MED; Library and Information Commission, 1997, NEW LIB PEOPL NETW; *NHS INF AUTH, 1999, NAT EL LIB HLTH NELH; *NHS INF AUTH, 1999, INF HLTH CONT; Sandvik H, 1999, BRIT MED J, V319, P29, DOI 10.1136/bmj.319.7201.29; Williams JG, 1999, BRIT MED J, V318, P942, DOI 10.1136/bmj.318.7188.942a; 1999, WELCOME MY YAHOO; 1999, DOCTORS DESK EBM SEA	11	53	53	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1476	1479		10.1136/bmj.319.7223.1476	http://dx.doi.org/10.1136/bmj.319.7223.1476			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582933	Green Submitted, Green Published, Bronze			2022-12-28	WOS:000084129200024
J	Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V				Stepp, SE; Dufourcq-Lagelouse, R; Le Deist, F; Bhawan, S; Certain, S; Mathew, PA; Henter, JI; Bennett, M; Fischer, A; Saint Basile, GD; Kumar, V			Perforin gene defects in familiar hemophagocytic lymphohistiocytosis	SCIENCE			English	Article							LYMPHOCYTIC CHORIOMENINGITIS VIRUS; CYTOTOXIC T-LYMPHOCYTES; DENDRITIC CELLS; LYMPHOPROLIFERATIVE SYNDROME; FAS; AUTOIMMUNITY; EXHAUSTION; MUTATIONS; CHILDREN; MICE	Familiar hemophagocytic Lymphohistiocytosis (FHL) is a rare, rapidly fatal, autosomal recessive immune disorder characterized by uncontrolled activation of T cells and macrophages and overproduction of inflammatory cytokines. Linkage analyses indicate that FHL is genetically heterogeneous and Linked to 9q21.3-22, 10q21-22, or another as yet undefined Locus. Sequencing of the coding regions of the perforin gene of eight unrelated 10q21-22-linked FHL patients revealed homozygous nonsense mutations in four patients and missense mutations in the other four patients. Cultured Lymphocytes from patients had defective cytotoxic activity, and immunostaining revealed Little or no perforin in the granules. Thus, defects in perforin are responsible for 10q21-22-linked FHL. Perforin-based effector systems are, therefore, involved not only in the Lysis of abnormal cells but also in the downregulation of cellular immune activation.	INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France; Univ Texas, SW Med Sch, Dept Pathol, Dallas, TX 75235 USA; Univ Texas, SW Med Sch, Grad Program Immunol, Dallas, TX 75235 USA; Hop Necker Enfants Malad, Unite Immunol & Hematol Pediat, F-75015 Paris, France; Univ N Texas, Hlth Sci Ctr, Dept Mol Biol & Immunol, Ft Worth, TX 76107 USA; Karolinska Inst, Karolinska Hosp, Dept Pediat Hematol & Oncol, S-17177 Stockholm, Sweden	Institut National de la Sante et de la Recherche Medicale (Inserm); University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Necker-Enfants Malades - APHP; UDICE-French Research Universities; Universite Paris Cite; University of North Texas System; University of North Texas Health Science Center; Karolinska Institutet; Karolinska University Hospital	Saint Basile, GD (corresponding author), INSERM, U429, Unite Rech Dev Normal & Pathol Syst Immunitaire, F-75015 Paris, France.	sbasile@necker.fr	de Saint Basile, Genevieve/G-9731-2017	de Saint Basile, Genevieve/0000-0002-1913-5269; Henter, Jan-Inge/0000-0002-0629-2126; Nandwana, Sadhna/0000-0002-3021-3715; DOGNIAUX, Stephanie/0000-0003-3309-1204				Arico M, 1996, LEUKEMIA, V10, P197; Binder D, 1998, J EXP MED, V187, P1903, DOI 10.1084/jem.187.11.1903; BORROW P, 1995, J VIROL, V69, P1059, DOI 10.1128/JVI.69.2.1059-1070.1995; Dufourcq-Lagelouse R, 1999, AM J HUM GENET, V64, P172, DOI 10.1086/302194; Egeler RM, 1996, J PEDIAT HEMATOL ONC, V18, P340, DOI 10.1097/00043426-199611000-00002; Fadeel B, 1999, BRIT J HAEMATOL, V106, P406, DOI 10.1046/j.1365-2141.1999.01538.x; FAVARA BE, 1992, SEMIN DIAGN PATHOL, V9, P63; FINK TM, 1992, GENOMICS, V13, P1300, DOI 10.1016/0888-7543(92)90050-3; FISHER GH, 1995, CELL, V81, P935, DOI 10.1016/0092-8674(95)90013-6; Gallimore A, 1998, J EXP MED, V187, P1383, DOI 10.1084/jem.187.9.1383; Geldhof AB, 1998, BLOOD, V91, P196, DOI 10.1182/blood.V91.1.196.196_196_206; GILBERTSON SM, 1986, J IMMUNOL, V136, P3567; HENTER JI, 1993, ACTA PAEDIATR, V82, P369, DOI 10.1111/j.1651-2227.1993.tb12699.x; Henter JI, 1998, HEMATOL ONCOL CLIN N, V12, P417, DOI 10.1016/S0889-8588(05)70520-7; Hoang MP, 1998, HUM PATHOL, V29, P1074, DOI 10.1016/S0046-8177(98)90416-6; KAGI D, 1994, SCIENCE, V265, P528, DOI 10.1126/science.7518614; Knight SC, 1997, ADV EXP MED BIOL, V417, P389; LANDMANPARKER J, 1993, BRIT J HAEMATOL, V85, P37, DOI 10.1111/j.1365-2141.1993.tb08642.x; Le Deist F., UNPUB; Matloubian M, 1999, J VIROL, V73, P2527, DOI 10.1128/JVI.73.3.2527-2536.1999; Ohadi M, 1999, AM J HUM GENET, V64, P165, DOI 10.1086/302187; Peng SL, 1998, J IMMUNOL, V160, P652; RIEUXLAUCAT F, 1995, SCIENCE, V268, P1347, DOI 10.1126/science.7539157; Sambhara S, 1998, CELL IMMUNOL, V187, P13, DOI 10.1006/cimm.1998.1314; Spaner D, 1998, J IMMUNOL, V160, P2655; Spaner D, 1999, J IMMUNOL, V162, P1192; Spielman J, 1998, J IMMUNOL, V161, P7063; Sullivan KE, 1998, PEDIATR RES, V44, P465, DOI 10.1203/00006450-199810000-00001; von Herrath M, 1999, J VIROL, V73, P5918, DOI 10.1128/JVI.73.7.5918-5925.1999	29	885	936	0	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1957	1959		10.1126/science.286.5446.1957	http://dx.doi.org/10.1126/science.286.5446.1957			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583959				2022-12-28	WOS:000084003400052
J	Bloom, BR				Bloom, BR			The future of public health	NATURE			English	Article								Public health deals with the health and well-being of the population as a whole and its achievements over the past century, especially in the richer countries, have been truly impressive. What direction should public health take in the future?	Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Bloom, BR (corresponding author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.							*CDC, 1999, DEATHS FIN DAT 1997, V47; Colditz GA, 1997, J WOMENS HEALTH, V6, P49, DOI 10.1089/jwh.1997.6.49; MCGINNIS JM, 1993, JAMA-J AM MED ASSOC, V270, P2207, DOI 10.1001/jama.270.18.2207; MURRAY CJL, 1965, US PATTERNS MORTALIT; PRESTON SH, 1972, CAUSES DEATH LIFE TB; WHO, 1999, WHO LAB MAN EX HUM S, P1; *WORLD BANK, 1993, WORLD DEV REP 1993 I, P34	7	23	23	2	5	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C63	C64		10.1038/35011557	http://dx.doi.org/10.1038/35011557			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591227	Bronze			2022-12-28	WOS:000084014100009
J	Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J				Wallin, KL; Wiklund, F; Angstrom, T; Bergman, F; Stendahl, U; Wadell, G; Hallmans, G; Dillner, J			Type-specific persistence of human papillomavirus DNA before the development of invasive cervical cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							POLYMERASE CHAIN-REACTION; SMEARS; WOMEN; INFECTION; PRIMERS; RISK	Background: Infection with the human papillomavirus (HPV) has been established as a cause of cervical cancer, but the association between a positive test for HPV DNA and the risk of the subsequent development of invasive cervical cancer is unknown. Methods: In a study of women who participated in a population-based screening program for cancer of the cervix in Sweden from 1969 to 1995, we compared the proportion of normal cervical smears (Pap smears) that were positive for HPV DNA among 118 women in whom invasive cervical cancer developed an average of 5.6 years later (range, 0.5 month to 26.2 years) with the proportion of HPV DNA-positive smears from 118 women who remained healthy during a similar length of follow-up (controls). The control women were matched for age to the women with cancer, and they had had two normal Pap smears obtained at time points that were similar to the times of the base-line smear and the diagnosis of cancer confirmed by biopsy in the women with cancer. Results: At base line, 35 of the women with cancer (30 percent) and 3 of the control women (3 percent) were positive for HPV DNA (odds ratio, 16.4; 95 percent confidence interval, 4.4 to 75.1). At the time of diagnosis, 80 of the 104 women with cancer for whom tissue samples were available (77 percent) and 4 of the 104 matched control women (4 percent) were positive for HPV DNA. The HPV DNA type was the same in the base-line smear and the biopsy specimen in all of the women with cancer in whom HPV DNA was detected at base line. None of the control women had the same type of HPV in both smears. Conclusions: A single positive finding of HPV DNA in a Pap smear confers an increased risk of future invasive cervical cancer that is positive for the same type of virus. (N Engl J Med 1999;341:1633-8.) (C) 1999, Massachusetts Medical Society.	Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, S-17177 Stockholm, Sweden; Univ Hosp No Sweden, Ctr Oncol, Umea, Sweden; Univ Hosp No Sweden, Cytol Lab, Umea, Sweden; Univ Hosp No Sweden, Dept Pathol, Umea, Sweden; Univ Hosp No Sweden, Dept Oncol, Sect Gynecol, Umea, Sweden; Univ Hosp No Sweden, Dept Virol, Umea, Sweden; Univ Hosp No Sweden, Dept Publ Hlth & Clin Med, Med Bank, Umea, Sweden; Univ Tampere, Sch Publ Hlth, FIN-33101 Tampere, Finland	Karolinska Institutet; Umea University; Umea University; Umea University; Umea University; Umea University; Umea University; Tampere University	Wallin, KL (corresponding author), Karolinska Inst, Ctr Microbiol & Tumor Biol, Lab Tumor Virus Epidemiol, POB 280, S-17177 Stockholm, Sweden.							Chua KL, 1996, CANCER, V77, P121, DOI 10.1002/(SICI)1097-0142(19960101)77:1<121::AID-CNCR20>3.0.CO;2-6; CHUA KL, 1995, ANAL QUANT CYTOL, V17, P221; Chua KL, 1996, INT J CANCER, V68, P54, DOI 10.1002/(SICI)1097-0215(19960927)68:1<54::AID-IJC11>3.0.CO;2-6; EVANDER M, 1992, J CLIN MICROBIOL, V30, P987, DOI 10.1128/JCM.30.4.987-992.1992; EVANDER M, 1991, ARCH VIROL, V116, P221, DOI 10.1007/BF01319244; Ho GYF, 1998, NEW ENGL J MED, V338, P423, DOI 10.1056/NEJM199802123380703; HUSMAN AMDR, 1995, J GEN VIROL, V76, P1057; Jenkins D, 1996, INT J CANCER, V65, P768; MANOS MM, 1989, CANCER CEL, V7, P209; Meijer C J, 1992, IARC Sci Publ, P271; RHOADS DD, 1986, MOL CELL BIOL, V6, P2774, DOI 10.1128/MCB.6.8.2774; Rozendaal L, 1996, INT J CANCER, V68, P766, DOI 10.1002/(SICI)1097-0215(19961211)68:6<766::AID-IJC13>3.0.CO;2-Z; TANAKA H, 1993, CYTOPATHOLOGY, V4, P273, DOI 10.1111/j.1365-2303.1993.tb00102.x; vanBallegooijen M, 1997, BRIT J CANCER, V76, P651, DOI 10.1038/bjc.1997.440; WALBOOMERS JMM, 1995, J CLIN PATHOL, V48, P728, DOI 10.1136/jcp.48.8.728; ZURHAUSEN H, 1994, ANNU REV MICROBIOL, V48, P427, DOI 10.1146/annurev.micro.48.1.427	16	391	408	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1633	1638		10.1056/NEJM199911253412201	http://dx.doi.org/10.1056/NEJM199911253412201			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572150	Bronze			2022-12-28	WOS:000083847500001
J	Maldonado, E; Hampsey, M; Reinberg, D				Maldonado, E; Hampsey, M; Reinberg, D			Repression: Targeting the heart of the matter	CELL			English	Review							RNA-POLYMERASE-II; HISTONE DEACETYLASE; TRANSCRIPTION; PROTEIN; REGULATORS; COMPLEX; TFIIA; SPT3; MOT1; DNA		Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Nucle Acids Enzymol, Piscataway, NJ 08854 USA; Univ Chile, Fac Med, Inst Ciencias Biomed, Programa Biol Celular & Mol, Santiago 7, Chile	Rutgers State University New Brunswick; Rutgers State University Medical Center; Universidad de Chile	Reinberg, D (corresponding author), Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Biochem, Nucle Acids Enzymol, Piscataway, NJ 08854 USA.			Reinberg, Danny/0000-0003-4288-2016				Brehm A, 1998, NATURE, V391, P597, DOI 10.1038/35404; CANG Y, 1999, IN PRESS EMBO J; Colbert T, 1998, MOL CELL BIOL, V18, P1682, DOI 10.1128/MCB.18.3.1682; Collart MA, 1996, MOL CELL BIOL, V16, P6668; Hampsey M, 1998, MICROBIOL MOL BIOL R, V62, P465, DOI 10.1128/MMBR.62.2.465-503.1998; HannaRose W, 1996, TRENDS GENET, V12, P229, DOI 10.1016/0168-9525(96)10022-6; Kao HY, 1998, GENE DEV, V12, P2269, DOI 10.1101/gad.12.15.2269; Kim S, 1997, P NATL ACAD SCI USA, V94, P820, DOI 10.1073/pnas.94.3.820; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Lee TI, 1998, MOL CELL BIOL, V18, P4455, DOI 10.1128/MCB.18.8.4455; Lefstin JA, 1998, NATURE, V392, P885, DOI 10.1038/31860; Madison JM, 1997, MOL CELL BIOL, V17, P287, DOI 10.1128/MCB.17.1.287; Muldrow TA, 1999, MOL CELL BIOL, V19, P2835; Olave I, 1998, GENE DEV, V12, P1621, DOI 10.1101/gad.12.11.1621; Orphanides G, 1996, GENE DEV, V10, P2657, DOI 10.1101/gad.10.21.2657; Ross JF, 1999, MOL CELL, V3, P195, DOI 10.1016/S1097-2765(00)80310-X; Wyrick JJ, 1999, NATURE, V402, P418, DOI 10.1038/46567	17	89	92	0	0	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					455	458		10.1016/S0092-8674(00)81533-0	http://dx.doi.org/10.1016/S0092-8674(00)81533-0			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589673	Bronze			2022-12-28	WOS:000083986300004
J	Rhodes, JC; Kjerulff, KH; Langenberg, PW; Guzinski, GM				Rhodes, JC; Kjerulff, KH; Langenberg, PW; Guzinski, GM			Hysterectomy and sexual functioning	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SUPRAVAGINAL UTERINE AMPUTATION; WOMEN; OUTCOMES; OOPHORECTOMY; SYMPTOMS; PAIN	Context Women considering hysterectomy often are concerned about its potential effects on their sexual functioning but the effects of hysterectomy on sexual functioning remain unclear. Objective To examine changes in sexual functioning after hysterectomy. Design and Setting A 2-year prospective study (Maryland Women's Health Study) of hysterectomy, which included measures of sexual functioning prior to hysterectomy and at 6, 12, 18, and 24 months after hysterectomy, performed during 1992 and 1993. Patients Of 1299 women interviewed prior to hysterectomy, 1101 (84.8%) completed the study and provided information about their sexual functioning Most were between the ages of 35 and 49 years, white, married or living with a partner, and high school graduates. Main Outcome Measures Frequency of sexual relations, dyspareunia, orgasm, vaginal dryness, and sexual desire. Results The percentage of women who engaged in sexual relations increased significantly from 70.5% before hysterectomy to 77.6% and 76.7% at 12 and 24 months after hysterectomy. The rate of frequent dyspareunia dropped significantly from 18.6% before hysterectomy to 4.3% and 3.6% at 12 and 24 months after hysterectomy. The rates of not experiencing orgasms dropped significantly from 7.6% before hysterectomy to 5.2% and 4.9% at 12 and 24 months after hysterectomy. Low libido rates also decreased significantly from 10.4% before hysterectomy to 6.3% and 6.2% at 12 and 24 months after hysterectomy. The distribution of women not reporting vaginal dryness in the past month improved significantly from 37.3% before hysterectomy to 46.8% and 46.7% at 12 and 24 months after hysterectomy. Prehysterectomy depression was associated with experiencing dyspareunia, vaginal dryness, low libido, and not experiencing orgasms after hysterectomy. Conclusions Sexual functioning improved overall after hysterectomy, The frequency of sexual activity increased and problems with sexual functioning decreased.	Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Baltimore, MD 21201 USA; Univ Maryland, Sch Med, Dept Obstet & Gynecol, Baltimore, MD 21201 USA	University System of Maryland; University of Maryland Baltimore; University System of Maryland; University of Maryland Baltimore	Rhodes, JC (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Prevent Med, Room 218,Howard Hall,660 W Redwood St, Baltimore, MD 21201 USA.				AHRQ HHS [HS06865] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		Alexander DA, 1996, BRIT MED J, V312, P280; AMIAS AG, 1975, BRIT MED J, V2, P608, DOI 10.1136/bmj.2.5971.608; Bachmann G A, 1990, Womens Health Issues, V1, P41, DOI 10.1016/S1049-3867(05)80015-5; BELLEROSE SB, 1993, ARCH SEX BEHAV, V22, P435, DOI 10.1007/BF01542558; Bernhard L A, 1992, Health Care Women Int, V13, P281; CARLSON KJ, 1994, OBSTET GYNECOL, V83, P556, DOI 10.1097/00006250-199404000-00012; CARLSON KJ, 1994, OBSTET GYNECOL, V83, P566, DOI 10.1097/00006250-199404000-00013; CHAKRAVARTI S, 1977, BRIT J OBSTET GYNAEC, V84, P769, DOI 10.1111/j.1471-0528.1977.tb12491.x; COPPEN A, 1981, LANCET, V1, P126; CRAIG GA, 1975, BRIT MED J, V3, P97; DENNERSTEIN L, 1977, OBSTET GYNECOL, V49, P92; DODDS D T, 1961, S Afr Med J, V35, P53; Ewert B, 1995, J AM ASSOC GYN LAP, V3, P27, DOI 10.1016/S1074-3804(05)80133-1; FRANCIS WJA, 1961, J OBSTET GYN BR COMM, V68, P1; GATH D, 1982, BRIT J PSYCHIAT, V140, P335, DOI 10.1192/bjp.140.4.335; HASSON HM, 1993, J REPROD MED, V38, P781; HELSTROM L, 1993, OBSTET GYNECOL, V81, P357; HELSTROM L, 1994, ACTA OBSTET GYN SCAN, V73, P575, DOI 10.3109/00016349409006276; HUFFMAN JW, 1950, AM J OBSTET GYNECOL, V59, P915; JEWETT JF, 1952, AM J OBSTET GYNECOL, V63, P400, DOI 10.1016/S0002-9378(15)32835-0; KAISER R, 1989, ARCH GYNECOL OBSTET, V244, P169, DOI 10.1007/BF00931295; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P147, DOI 10.3109/00016348309155779; KILKKU P, 1983, ACTA OBSTET GYN SCAN, V62, P141, DOI 10.3109/00016348309155778; KJERULFF KH, IN PRESS OBSTET GYNE; LALINECMICHAUD M, 1985, CAN J PSYCHIAT, V30, P44; Lambden M P, 1997, J Obstet Gynecol Neonatal Nurs, V26, P540, DOI 10.1111/j.1552-6909.1997.tb02157.x; Lepine L A, 1997, MMWR CDC Surveill Summ, V46, P1; McNair D., 1971, MANUAL PROFILE MOOD; McNemar Q, 1947, PSYCHOMETRIKA, V12, P153, DOI 10.1007/BF02295996; NATHORSTBOOS J, 1992, GYNECOL OBSTET INVES, V34, P97, DOI 10.1159/000292735; NEEFUS MS, 1981, PATIENT COUNS HLTH E, V3, P150; OLDENHAVE A, 1993, AM J OBSTET GYNECOL, V168, P765, DOI 10.1016/S0002-9378(12)90816-9; POAD D, 1994, AUST NZ J OBSTET GYN, V34, P471, DOI 10.1111/j.1479-828X.1994.tb01274.x; RICHARDS DH, 1974, LANCET, V2, P983; SCHOFIELD MJ, 1991, BRIT J OBSTET GYNAEC, V98, P1129, DOI 10.1111/j.1471-0528.1991.tb15365.x; SIDDLE N, 1987, FERTIL STERIL, V47, P94; SLOAN D, 1978, AM J OBSTET GYNECOL, V131, P598, DOI 10.1016/0002-9378(78)90817-7; UTIAN W H, 1975, International Journal of Gynecology and Obstetrics, V13, P97; VIRTANEN H, 1993, BRIT J UROL, V72, P868, DOI 10.1111/j.1464-410X.1993.tb16288.x; WEBB C, 1986, J ADV NURS, V11, P167, DOI 10.1111/j.1365-2648.1986.tb01235.x	40	190	200	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1934	1941		10.1001/jama.282.20.1934	http://dx.doi.org/10.1001/jama.282.20.1934			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257BZ	10580459	Bronze			2022-12-28	WOS:000083763400028
J	Tyler, JK; Kadonaga, JT				Tyler, JK; Kadonaga, JT			The "dark side" of chromatin remodeling: Repressive effects on transcription	CELL			English	Review									Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA	University of California System; University of California San Diego; University of California System; University of California San Diego	Kadonaga, JT (corresponding author), Univ Calif San Diego, Dept Biol, 9500 Gilman Dr, La Jolla, CA 92093 USA.			Tyler, Jessica/0000-0001-9765-1659				Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Di Croce L, 1999, MOL CELL, V4, P45, DOI 10.1016/S1097-2765(00)80186-0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Kim J, 1999, IMMUNITY, V10, P345, DOI 10.1016/S1074-7613(00)80034-5; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Kornberg RD, 1999, CELL, V98, P285, DOI 10.1016/S0092-8674(00)81958-3; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; Moreira JMA, 1999, EMBO J, V18, P2836, DOI 10.1093/emboj/18.10.2836; Muchardt C, 1999, SEMIN CELL DEV BIOL, V10, P189, DOI 10.1006/scdb.1999.0300; Murphy DJ, 1999, MOL CELL BIOL, V19, P2724; Neely KE, 1999, MOL CELL, V4, P649, DOI 10.1016/S1097-2765(00)80216-6; Travers A, 1999, CELL, V96, P311, DOI 10.1016/S0092-8674(00)80543-7; TYLER JK, 1999, IN PRESS NATURE; Varga-Weisz PD, 1998, CURR OPIN CELL BIOL, V10, P346, DOI 10.1016/S0955-0674(98)80010-0	18	189	207	0	2	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					443	446		10.1016/S0092-8674(00)81530-5	http://dx.doi.org/10.1016/S0092-8674(00)81530-5			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589670	Bronze			2022-12-28	WOS:000083986300001
J	White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM				White, O; Eisen, JA; Heidelberg, JF; Hickey, EK; Peterson, JD; Dodson, RJ; Haft, DH; Gwinn, ML; Nelson, WC; Richardson, DL; Moffat, KS; Qin, HY; Jiang, LX; Pamphile, W; Crosby, M; Shen, M; Vamathevan, JJ; Lam, P; McDonald, L; Utterback, T; Zalewski, C; Makarova, KS; Aravind, L; Daly, MJ; Minton, KW; Fleischmann, RD; Ketchum, KA; Nelson, KE; Salzberg, S; Smith, HO; Venter, JC; Fraser, CM			Genome sequence of the radioresistant bacterium Deinococcus radiodurans R1	SCIENCE			English	Article							MICROCOCCUS-RADIODURANS; ESCHERICHIA-COLI; RADIATION-RESISTANT; IONIZING-RADIATION; GENUS DEINOCOCCUS; DNA-REPAIR; PROTEIN; IDENTIFICATION; MUTATION; THERMUS	The complete genome sequence of the radiation-resistant bacterium Deinococcus radiodurans R1 is composed of two chromosomes (2,648,638 and 412,348 base pairs), a megaplasmid (172,466 base pairs), and a small plasmid (45,704 base pairs), yielding a total genome of 3,284,156 base pairs. Multiple components distributed on the chromosomes and megaplasmid that contribute to the ability of D. radiodurans to survive under conditions of starvation, oxidative stress, and high amounts of DNA damage were identified. Deinococcus radiodurans represents an organism in which all systems for DNA repair, DNA damage export, desiccation and starvation recovery, and genetic redundancy are present in one cell.	Inst Genome Res, Rockville, MD 20850 USA; Natl Lib Med, Natl Ctr Biotechnol Informat, Bethesda, MD 20894 USA; Uniformed Serv Univ Hlth Sci, Dept Pathol, Bethesda, MD 20814 USA	J. Craig Venter Institute; National Institutes of Health (NIH) - USA; NIH National Library of Medicine (NLM); Uniformed Services University of the Health Sciences - USA	Fraser, CM (corresponding author), Inst Genome Res, 9712 Med Ctr Dr, Rockville, MD 20850 USA.		Salzberg, Steven/Q-6514-2019; Nelson, William C/E-9263-2016; Eisen, Jonathan A./H-2706-2019; Salzberg, Steven L/F-6162-2011	Salzberg, Steven/0000-0002-8859-7432; Nelson, William C/0000-0002-1873-3929; Eisen, Jonathan A./0000-0002-0159-2197; Salzberg, Steven L/0000-0002-8859-7432; Aravind, L/0000-0003-0771-253X; Vamathevan, Jessica/0000-0003-2016-9754; Fraser, Claire/0000-0003-1462-2428; Heidelberg, John/0000-0003-0673-3224	NATIONAL CANCER INSTITUTE [R01CA077712] Funding Source: NIH RePORTER; NCI NIH HHS [R01 CA077712] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Agostini HJ, 1996, J BACTERIOL, V178, P6759, DOI 10.1128/jb.178.23.6759-6765.1996; Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; ANDERSON AW, 1956, FOOD TECHNOL-CHICAGO, V10, P575; Battista JR, 1997, ANNU REV MICROBIOL, V51, P203, DOI 10.1146/annurev.micro.51.1.203; Bauche C, 1999, J BACTERIOL, V181, P262, DOI 10.1128/JB.181.1.262-269.1999; Bessman MJ, 1996, J BIOL CHEM, V271, P25059, DOI 10.1074/jbc.271.41.25059; BOLING ME, 1966, BIOCHIM BIOPHYS ACTA, V123, P26, DOI 10.1016/0005-2787(66)90155-9; COUNSELL TJ, 1986, INT J SYST BACTERIOL, V36, P202, DOI 10.1099/00207713-36-2-202; DALY MJ, 1994, J BACTERIOL, V176, P3508, DOI 10.1128/JB.176.12.3508-3517.1994; Eisen JA, 1995, J MOL EVOL, V41, P1105; EISEN JA, 1999, THESIS STANFORD U ST; Ferreira AC, 1997, INT J SYST BACTERIOL, V47, P939, DOI 10.1099/00207713-47-4-939; Furuya K, 1998, FEMS MICROBIOL LETT, V168, P243, DOI 10.1111/j.1574-6968.1998.tb13280.x; GUTMAN PD, 1993, J BACTERIOL, V175, P3581, DOI 10.1128/jb.175.11.3581-3590.1993; HENSEL R, 1986, INT J SYST BACTERIOL, V36, P444, DOI 10.1099/00207713-36-3-444; Kitayama S, 1997, MUTAT RES-DNA REPAIR, V385, P151, DOI 10.1016/S0921-8777(97)00048-7; Koonin EV, 1997, MOL MICROBIOL, V25, P619, DOI 10.1046/j.1365-2958.1997.4821861.x; Lawrence JG, 1997, J MOL EVOL, V44, P383, DOI 10.1007/PL00006158; Lin CS, 1998, BIOCHEM MOL BIOL INT, V45, P651; Markillie LM, 1999, J BACTERIOL, V181, P666, DOI 10.1128/JB.181.2.666-669.1999; MASTERS CI, 1991, J GEN MICROBIOL, V137, P1459, DOI 10.1099/00221287-137-7-1459; Mattimore V, 1996, J BACTERIOL, V178, P633, DOI 10.1128/jb.178.3.633-637.1996; MINTON KW, 1994, MOL MICROBIOL, V13, P9, DOI 10.1111/j.1365-2958.1994.tb00397.x; MITCHEL REJ, 1980, BIOCHIM BIOPHYS ACTA, V621, P138, DOI 10.1016/0005-2795(80)90069-0; MOSELEY BEB, 1983, J GEN MICROBIOL, V129, P2437; MUN C, 1994, RADIAT RES, V138, P282, DOI 10.2307/3578599; Nelson KE, 1999, NATURE, V399, P323, DOI 10.1038/20601; RILEY M, 1993, MICROBIOL REV, V57, P862, DOI 10.1128/MMBR.57.4.862-952.1993; Salzberg SL, 1998, NUCLEIC ACIDS RES, V26, P544, DOI 10.1093/nar/26.2.544; Salzberg SL, 1998, GENE, V217, P57, DOI 10.1016/S0378-1119(98)00374-6; Sandigursky M, 1999, CURR BIOL, V9, P531, DOI 10.1016/S0960-9822(99)80237-1; SETLOW JK, 1964, BIOCHIM BIOPHYS ACTA, V87, P664, DOI 10.1016/0926-6550(64)90284-1; SHARPLES GJ, 1995, MOL MICROBIOL, V17, P1215, DOI 10.1111/j.1365-2958.1995.mmi_17061215_1.x; SWEET DM, 1976, MUTAT RES, V34, P175, DOI 10.1016/0027-5107(76)90122-6; Tanaka A, 1996, RADIAT ENVIRON BIOPH, V35, P95, DOI 10.1007/BF02434031; TEMPEST PR, 1980, MOL GEN GENET, V179, P191, DOI 10.1007/BF00268463; TIRGARI S, 1980, J GEN MICROBIOL, V119, P287; UDUPA KS, 1994, J BACTERIOL, V176, P7439, DOI 10.1128/JB.176.24.7439-7446.1994; WEISBURG WG, 1989, SYST APPL MICROBIOL, V11, P128, DOI 10.1016/S0723-2020(89)80051-7; Wolf YI, 1999, GENOME RES, V9, P17; Wootton JC, 1996, METHOD ENZYMOL, V266, P554	41	757	1348	3	135	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1571	1577		10.1126/science.286.5444.1571	http://dx.doi.org/10.1126/science.286.5444.1571			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567266	Green Accepted			2022-12-28	WOS:000083768300062
J	Hamel, MB; Davis, RB; Teno, JM; Knaus, WA; Lynn, J; Harrell, F; Galanos, AN; Wu, AW; Phillips, RS				Hamel, MB; Davis, RB; Teno, JM; Knaus, WA; Lynn, J; Harrell, F; Galanos, AN; Wu, AW; Phillips, RS		SUPPORT Investigators	Older age, aggressiveness of care, and survival for seriously ill, hospitalized adults	ANNALS OF INTERNAL MEDICINE			English	Article						age factors; severity of illness index; outcome assessment (health care); health care rationing; hospitalization	ACUTE MYOCARDIAL-INFARCTION; ELDERLY PATIENTS; INTENSIVE-CARE; CANCER-PATIENTS; PATTERNS; RISK; LESS; RESOURCES; YOUNGER; SYSTEM	Background: Older age is associated with less aggressive treatment and higher short-term mortality due to serious illness. It is not known whether less aggressive care contributes to this survival disadvantage in elderly persons. Objective: To determine the effect of age on short-term survival, independent of baseline patient characteristics and aggressiveness of care. Design: Secondary analysis of data from a prospective cohort study. Setting: Five academic medical centers participating in SUPPORT (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Patients: 9105 adults hospitalized with one of nine serious illnesses associated with an average 6-month mortality rate of 50%. Measurements: Survival through 180 days of follow-up. In Cox proportional hazards modeling, adjustment was made for patient sex; ethnicity; income; baseline physical function; severity of illness; intensity of hospital resource use; presence of do-not-resuscitate orders on study day 1; and presence and timing of decisions to withhold transfer to the intensive care unit, major surgery, dialysis blood transfusion, vasopressors, and tube feeding. Results: The mean (+/- SD) patient age was 63 +/- 16 years, 44% of patients were female, and 16% were black. Overall survival to 6 months was 53%. In analyses that adjusted for sex, ethnicity, income, baseline functional status, severity of illness, and aggressiveness of care, each additional year of age increased the hazard of death by 1.0% (hazard ratio, 1.010 [95% CI, 1.007 to 1.013]) for patients 18 to 70 years of age and by 2.0% (hazard ratio, 1.020 [CI, 1.013 to 1.026]) for patients older than 70 years of age. Adjusted estimates of age-specific 6-month mortality rates were 44% for 55-year-old patients, 48% for 65-year-old patients, 53% for 75-year-old patients, and 60% for 85-year old patients. Similar results were obtained in analyses that did not adjust for aggressiveness of care. Acute physiology and diagnosis had much larger relative contributions to prognosis than age. Conclusions: We found a modest independent association between patient age and short-term survival of serious illness. This age effect was not explained by the current practice of providing less aggressive care to elderly patients.	Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA; Brown Univ, Ctr Gerontol & Hlth Care Res, Providence, RI 02912 USA; Univ Virginia, Sch Med, Dept Hlth Evaluat Sci, Charlottesville, VA 22908 USA; George Washington Univ, Ctr Improve Care Dying, Washington, DC USA; Duke Univ, Med Ctr, Div Geriatr, Durham, NC 27710 USA; Johns Hopkins Univ, Hlth Serv Res & Dev Ctr, Baltimore, MD 21205 USA	Harvard University; Beth Israel Deaconess Medical Center; Brown University; University of Virginia; George Washington University; Duke University; Johns Hopkins University	Hamel, MB (corresponding author), Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, 330 Brookline Ave, Boston, MA 02215 USA.		Knaus, William/AAX-2138-2020; Wu, Albert/AAJ-4780-2021		NIA NIH HHS [K08 AG0075-02] Funding Source: Medline	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		BEARDEN DM, 1993, J AM GERIATR SOC, V41, P1075, DOI 10.1111/j.1532-5415.1993.tb06455.x; CHALFIN DB, 1990, CRIT CARE MED, V18, P694, DOI 10.1097/00003246-199007000-00002; CHELLURI L, 1993, JAMA-J AM MED ASSOC, V269, P3119, DOI 10.1001/jama.269.24.3119; CULLEN DJ, 1985, CRIT CARE MED, V13, P818; FEDULLO AJ, 1983, CRIT CARE MED, V11, P155, DOI 10.1097/00003246-198303000-00001; FLEMING C, 1991, AM J PUBLIC HEALTH, V81, P1121, DOI 10.2105/AJPH.81.9.1121; GLOWER DD, 1992, AM J CARDIOL, V70, P567, DOI 10.1016/0002-9149(92)90192-2; GOLDMAN L, 1977, NEW ENGL J MED, V297, P845, DOI 10.1056/NEJM197710202971601; GORDON M, 1984, J AM GERIATR SOC, V32, P930, DOI 10.1111/j.1532-5415.1984.tb00895.x; GREENFIELD S, 1987, JAMA-J AM MED ASSOC, V257, P2766, DOI 10.1001/jama.257.20.2766; GURWITZ JH, 1991, AM J EPIDEMIOL, V134, P948, DOI 10.1093/oxfordjournals.aje.a116179; Hakim RB, 1996, ANN INTERN MED, V125, P284, DOI 10.7326/0003-4819-125-4-199608150-00005; Hamel MB, 1996, J AM GERIATR SOC, V44, P1043, DOI 10.1111/j.1532-5415.1996.tb02935.x; Hamel MB, 1999, ANN INTERN MED, V130, P116, DOI 10.7326/0003-4819-130-2-199901190-00005; HANSON LC, 1991, J AM GERIATR SOC, V39, P772, DOI 10.1111/j.1532-5415.1991.tb02699.x; HLATKY MA, 1989, AM J CARDIOL, V64, P651, DOI 10.1016/0002-9149(89)90496-7; IEZZONI LI, 1994, ADJUSTMENT MEASURING; KATZ S, 1963, JAMA-J AM MED ASSOC, V185, P914, DOI 10.1001/jama.1963.03060120024016; KEENE AR, 1983, CRIT CARE MED, V11, P1, DOI 10.1097/00003246-198301000-00001; KNAUS WA, 1995, ANN INTERN MED, V122, P191, DOI 10.7326/0003-4819-122-3-199502010-00007; KNAUS WA, 1991, CHEST, V100, P1619, DOI 10.1378/chest.100.6.1619; KRUMHOLZ HM, 1993, ANN INTERN MED, V119, P1084, DOI 10.7326/0003-4819-119-11-199312010-00005; LANDEFELD CS, 1990, J CLIN EPIDEMIOL S, V43, pS75; LAYON AJ, 1995, CRIT CARE MED, V23, P829, DOI 10.1097/00003246-199505000-00009; LYNN J, 1990, J CLIN EPIDEMIOL, V43, pS1, DOI 10.1016/0895-4356(90)90211-7; MONTAGUE TJ, 1991, AM J CARDIOL, V68, P843, DOI 10.1016/0002-9149(91)90397-4; PHILLIPS RS, 1990, J CLIN EPIDEMIOL, V43, pS33, DOI 10.1016/0895-4356(90)90215-B; ROSENTHAL GE, 1994, J AM GERIATR SOC, V42, P826, DOI 10.1111/j.1532-5415.1994.tb06553.x; *SUPPORT PRINC INV, 1995, JAMA-J AM MED ASSOC, V274, P1541; TEASDALE G, 1974, LANCET, V2, P81; WEINTRAUB WS, 1991, CIRCULATION, V84, P226; WU AW, 1990, J AM GERIATR SOC, V38, P621, DOI 10.1111/j.1532-5415.1990.tb01419.x; YARZEBSKI J, 1994, CHEST, V105, P1003, DOI 10.1378/chest.105.4.1003	33	118	121	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					721	+		10.7326/0003-4819-131-10-199911160-00002	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00002			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255QC	10577294				2022-12-28	WOS:000083680100001
J	Pianko, S; McHutchinson, J				Pianko, S; McHutchinson, J			Chronic hepatitis B: new therapies on the horizon?	LANCET			English	Editorial Material							LAMIVUDINE		Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, La Jolla, CA 92037 USA	Scripps Research Institute	Pianko, S (corresponding author), Scripps Clin & Res Fdn, Div Gastroenterol & Hepatol, 10666 N Torrey Pines Rd, La Jolla, CA 92037 USA.							Boni C, 1998, J CLIN INVEST, V102, P968, DOI 10.1172/JCI3731; CHISARI FV, 1995, ANNU REV IMMUNOL, V13, P29, DOI 10.1146/annurev.iy.13.040195.000333; Couillin I, 1999, J INFECT DIS, V180, P15, DOI 10.1086/314828; Heathcote J, 1999, HEPATOLOGY, V30, P531, DOI 10.1002/hep.510300208; Kane MA, 1996, LANCET, V348, P696, DOI 10.1016/S0140-6736(05)65598-5; Lai CL, 1998, NEW ENGL J MED, V339, P61, DOI 10.1056/NEJM199807093390201; Liaw YF, 1999, HEPATOLOGY, V30, P567, DOI 10.1002/hep.510300221; Livingston BD, 1997, J IMMUNOL, V159, P1383; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Schiff E, 1998, HEPATOLOGY, V28, p388A; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	11	10	12	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1662	1663		10.1016/S0140-6736(99)00305-0	http://dx.doi.org/10.1016/S0140-6736(99)00305-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568564				2022-12-28	WOS:000083652800005
J	Landon, BE; Epstein, AM				Landon, BE; Epstein, AM			Quality management practices in Medicaid managed care - A national survey of Medicaid and commercial health plans participating in the Medicaid program	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							HEART-FAILURE; SERVICES; OUTCOMES	Context Rapid expansion of Medicaid managed care has raised concerns about the capacity and willingness of health plans enrolling Medicaid beneficiaries to provide high-quality care. Recently, legislation has facilitated market entry of Medicaid plans, health plans that draw most of their enrollment from the Medicaid; population. Objective To characterize and compare the organizational characteristics and programs related to quality of care of commercial and Medicaid health plans that participate in the Medicaid program. Design Cross-sectional survey conducted September 1997 to April 1998. Setting The Medicaid program in 11 states and the District of Columbia. Participants All 154 health plans in these localities that provided prepaid general medical care to Medicaid beneficiaries during June 1997, of which 130 (84%) responded to the survey. Main Outcome Measures Health plan reports of structural characteristics, services offered, performance measurement and feedback, disease management programs, information systems capabilities, and provider network composition and relationships. Results Half of the respondents were Medicaid plans, with 75% or more of enrollees drawn from the Medicaid population. Medicaid plans tended to be smaller and newer than commercial plans that also served the Medicaid population and had more enabling programs targeting the special needs of the Medicaid population, such as inadequate transportation (85% of Medicaid plans vs 62% of commercial plans; P =.003) and illiteracy (66% vs 38%, respectively; P =.002). Overall, 71% of Medicaid plans vs 43% of commercial plans had enabling programs targeted at 6 or more of the 8 special needs we specified (P =.001). While commercial plans had a higher proportion of board-certified primary care physicians (81% vs 73%; P =.01), we found no major differences between Medicaid plans and commercial plans in collection and dissemination of performance measures, designation of specific areas for quality improvement, or use of disease management programs targeted at conditions prevalent in the Medicaid population. Neither commercial nor Medicaid plans reported high success in improving quality of care. Conclusions Based on our survey, while Medicaid plans resemble commercial plans serving the Medicaid population in many aspects of quality management, they are more likely to target programs directed to the specific needs of the Medicaid population. Neither commercial nor Medicaid plans have notably strong records in actual quality improvement.	Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Gen Med, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center	Epstein, AM (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, 677 Huntington Ave, Boston, MA 02115 USA.	aepstein@hsph.harvard.edu						Baldwin LM, 1998, AM J PUBLIC HEALTH, V88, P1623, DOI 10.2105/AJPH.88.11.1623; Buchner DA, 1998, AM J MANAG CARE, V4, P1288; Dallek G, 1996, HEALTH AFFAIR, V15, P174, DOI 10.1377/hlthaff.15.3.174; Epstein AM, 1997, JAMA-J AM MED ASSOC, V278, P1617, DOI 10.1001/jama.278.19.1617; FeltLisk S, 1997, HEALTH AFFAIR, V16, P248, DOI 10.1377/hlthaff.16.3.248; FELTLISK S, 1996, QUALITY ASSURANCE RE; *HLTH CAR FIN ADM, 1999, MED MAN CAR ENR REP; Holahan J, 1998, HEALTH AFFAIR, V17, P43, DOI 10.1377/hlthaff.17.3.43; Landon BE, 1998, JAMA-J AM MED ASSOC, V279, P211, DOI 10.1001/jama.279.3.211; Palmer RH, 1996, MED CARE, V34, pSS29; RAMSEY PG, 1989, ANN INTERN MED, V110, P719, DOI 10.7326/0003-4819-110-9-719; RICH MW, 1995, NEW ENGL J MED, V333, P1190, DOI 10.1056/NEJM199511023331806; SCHULTE F, 1994, FT LAUDERDALE S 1211, P1; Sparer MS, 1996, J HEALTH POLIT POLIC, V21, P433, DOI 10.1215/03616878-21-3-433; Tamblyn R, 1998, JAMA-J AM MED ASSOC, V280, P989, DOI 10.1001/jama.280.11.989; Thompson RS, 1996, MILBANK Q, V74, P469, DOI 10.2307/3350390; West JA, 1997, AM J CARDIOL, V79, P58, DOI 10.1016/S0002-9149(96)00676-5; 1998, FED REG, V7, P52071	18	34	35	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1769	1775		10.1001/jama.282.18.1769	http://dx.doi.org/10.1001/jama.282.18.1769			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	251XJ	10568652				2022-12-28	WOS:000083471400034
J	Smith, BM; Rosenbaum, S				Smith, BM; Rosenbaum, S			Potential effects of the "premium-support" proposal on the security of Medicare	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									George Washington Univ, Med Ctr, Sch Publ Hlth & Hlth Serv, Ctr Hlth Serv & Policy Res, Washington, DC 20006 USA	George Washington University	Smith, BM (corresponding author), George Washington Univ, Med Ctr, Sch Publ Hlth & Hlth Serv, Ctr Hlth Serv & Policy Res, 2021 K St NW,Suite 800, Washington, DC 20006 USA.							*GEN ACC OFF, 1997, PUBL HEHS, V9735; *HLTH CAR FIN ADM, 1998, SUPPL INS ACC CAR OU; *KAIS FAM FDN, 1999, MED GLANC WHAT IS ME; MOON M, 1993, MEDICARE NOW FUTURE, P165; MOON M, 1999, GROWTH MEDICARE SPEN; MOON M, 1999, RESTRUCTURING MEDICA; MORROW DJ, 1998, NY TIMES        0909, pC1; *NAT BIP COMM FUT, 1999, BUILD BETT MED TOD T; *NAT HLTH MED RES, 1999, DIET GUID OLD AUSTR, P1; PEAR R, 1999, NY TIMES        0317, V17, pA1; Pear Robert, 1999, N Y Times Web, pA20; *PHYS PAYM REV COM, 1996, 1996 ANN REP; *US GOV PRINT OFF, 1999, 1999 ANN REP BOARD T; Wilensky GR, 1999, HEALTH AFFAIR, V18, P92, DOI 10.1377/hlthaff.18.1.92	14	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1760	1763		10.1001/jama.282.18.1760	http://dx.doi.org/10.1001/jama.282.18.1760			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568649				2022-12-28	WOS:000083471400031
J	Hart, RG; Halperin, JL				Hart, RG; Halperin, JL			Atrial fibrillation and thromboembolism: A decade of progress in stroke prevention	ANNALS OF INTERNAL MEDICINE			English	Article							RISK-FACTORS; ISCHEMIC STROKE; TRANSESOPHAGEAL ECHOCARDIOGRAPHY; ELDERLY PATIENTS; ANTICOAGULATION; CARDIOVERSION; WARFARIN; DISEASE; PREVALENCE; EMBOLISM	Atrial fibrillation is associated with a sixfold increased risk for stroke. More than a dozen published randomized trials of anticoagulants or antiplatelet agents for stroke prevention provide solid evidence on which to base antithrombotic prophylaxis. Adjusted-dose warfarin reduces risk for stroke by about 60% compared with placebo, aspirin reduces this risk (primarily for nondisabling stroke) by about 20% compared with placebo, and warfarin reduces it by about 40% compared with aspirin. Warfarin provides maximal protection against stroke at international normalized ratios of 2.0 to 3.0. Risk stratification of patients with atrial Fibrillation identifier those who potentially benefit most or least from anticoagulation; this is important because a substantial percentage of patients with atrial fibrillation have relatively low rates of stroke if they are given aspirin. Many elderly patients with recurrent intermittent atrial fibrillation experience high rates of stroke and benefit from anticoagulation. The value of precordial or trans-esophageal echocardiography in addition to clinical risk stratifiers for stratifying stroke risk is controversial, Altered hemostasis favoring thrombosis may contribute to formation of atrial appendage thrombus, but these conditions remain ill defined. The past decade has brought unprecedented progress toward understanding thromboembolism in patients with atrial fibrillation and has changed the clinical perspective of a prevalent cardiac arrhythmia into an important opportunity for stroke prevention. Making the most of this promise calls for appreciation of the epidemiology of atrial fibrillation and the concept of risk specificity in the face of diverse therapeutic options.	Univ Texas, Hlth Sci Ctr, Dept Med Neurol, San Antonio, TX 78284 USA; Mt Sinai Med Ctr, Cardiovasc Inst, New York, NY 10029 USA	University of Texas System; University of Texas Health San Antonio; Icahn School of Medicine at Mount Sinai	Hart, RG (corresponding author), Univ Texas, Hlth Sci Ctr, Dept Med Neurol, 7703 Floyd Curl Dr, San Antonio, TX 78284 USA.	hartr@uthscsa.edu	Halperin, Jonathan/AAJ-4721-2020	Halperin, Jonathan/0000-0002-8318-5471				AMARENCO P, 1995, NEW ENGL J MED, V332, P1237; AMARENCO P, 1994, NEW ENGL J MED, V331, P1474, DOI 10.1056/NEJM199412013312202; ANDERSON DC, 1992, ANN INTERN MED, V116, P1, DOI 10.7326/0003-4819-116-1-1; Anderson DC, 1998, JAMA-J AM MED ASSOC, V279, P1273; [Anonymous], 1997, Arch Intern Med, V157, P1237; ARONOW WS, 1989, AM J CARDIOL, V63, P366, DOI 10.1016/0002-9149(89)90349-4; Aronow WS, 1998, AM J CARDIOL, V82, P119, DOI 10.1016/S0002-9149(98)00247-1; ASAKURA H, 1992, BLOOD COAGUL FIBRIN, V3, P469, DOI 10.1097/00001721-199203040-00015; ASINGER RW, IN PRESS J AM SOC EC; Blackshear JL, 1996, LANCET, V348, P633; Blackshear JL, 1999, STROKE, V30, P834, DOI 10.1161/01.STR.30.4.834; BLACKSHEAR JL, 1993, AM J CARDIOL, V72, P840, DOI 10.1016/0002-9149(93)91079-W; Catherwood E, 1999, ANN INTERN MED, V130, P625, DOI 10.7326/0003-4819-130-8-199904200-00002; Chan Kwan-Leung, 1998, Annals of Internal Medicine, V128, P639; Chesebro JH, 1996, ARCH INTERN MED, V156, P409; Corrado G, 1999, CHEST, V115, P140, DOI 10.1378/chest.115.1.140; Cushman M, 1996, ARTERIOSCL THROM VAS, V16, P1163, DOI 10.1161/01.ATV.16.9.1163; Davila-Roman VG, 1999, J AM COLL CARDIOL, V33, P1308, DOI 10.1016/S0735-1097(99)00034-0; Dittrich HC, 1999, AM HEART J, V137, P494, DOI 10.1016/S0002-8703(99)70498-9; Ezekowitz M, 1998, ARCH INTERN MED, V158, P1316; EZEKOWITZ MD, 1992, NEW ENGL J MED, V327, P1406, DOI 10.1056/NEJM199211123272002; Feinberg WM, 1999, J GEN INTERN MED, V14, P56, DOI 10.1046/j.1525-1497.1999.00281.x; Feinberg WM, 1997, STROKE, V28, P1101, DOI 10.1161/01.STR.28.6.1101; FEINBERG WM, 1995, ARCH INTERN MED, V155, P469, DOI 10.1001/archinte.155.5.469; FEINBERG WM, IN PRESS STROKE; Ferrari E, 1999, J AM COLL CARDIOL, V33, P1317, DOI 10.1016/S0735-1097(99)00003-0; Fihn SD, 1996, ANN INTERN MED, V124, P970, DOI 10.7326/0003-4819-124-11-199606010-00004; FISHER CM, 1979, GERIATRICS, V34, P59; FLEGEL KM, 1989, STROKE, V20, P1000, DOI 10.1161/01.STR.20.8.1000; FRIEDMAN GD, 1968, CIRCULATION, V38, P533, DOI 10.1161/01.CIR.38.3.533; FROHLICH ED, 1992, NEW ENGL J MED, V327, P998, DOI 10.1056/NEJM199210013271406; GOLDMAN ME, IN PRESS J AM SOC EN; GORTER JW, IN PRESS NEUROLOGY; Gullov AL, 1998, ARCH INTERN MED, V158, P1513, DOI 10.1001/archinte.158.14.1513; Hart RG, 1999, STROKE, V30, P1223, DOI 10.1161/01.STR.30.6.1223; Hart RG, 1999, ANN INTERN MED, V131, P492, DOI 10.7326/0003-4819-131-7-199910050-00003; Hart RG, 1998, ANN INTERN MED, V128, P408, DOI 10.7326/0003-4819-128-5-199803010-00012; Hart RG, 1999, CEREBROVASC DIS, V9, P215, DOI 10.1159/000015958; HART RG, IN PRESS CEREBROVASC; HART RG, IN PRESS J AM CARDIO; Hellemons BSP, 1997, CEREBROVASC DIS, V7, P11; HINTON RC, 1977, AM J CARDIOL, V40, P509, DOI 10.1016/0002-9149(77)90064-9; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; HYLEK EM, 1994, ANN INTERN MED, V120, P897, DOI 10.7326/0003-4819-120-11-199406010-00001; Hylek EM, 1996, NEW ENGL J MED, V335, P540, DOI 10.1056/NEJM199608223350802; JONES EF, 1995, STROKE, V26, P218; Kahn SR, 1997, CAN MED ASSOC J, V157, P685; Kalra L, 1999, STROKE, V30, P1218, DOI 10.1161/01.STR.30.6.1218; KISTLER JP, 1990, NEW ENGL J MED, V323, P1505; KOPECKY SL, 1987, NEW ENGL J MED, V317, P669, DOI 10.1056/NEJM198709103171104; Kowey PR, 1998, AM J CARDIOL, V82, p86N, DOI 10.1016/S0002-9149(98)00741-3; Laupacis A, 1998, CHEST, V114, p579S, DOI 10.1378/chest.114.5_Supplement.579S; LAUPACIS A, 1994, ARCH INTERN MED, V154, P1449; LIP GYH, 1995, INT J CARDIOL, V51, P245, DOI 10.1016/0167-5273(95)02434-X; Manning WJ, 1998, ANN INTERN MED, V128, P685, DOI 10.7326/0003-4819-128-8-199804150-00013; MCBRIDE R, 1994, LANCET, V343, P687; MILLER VT, 1993, NEUROLOGY, V43, P32, DOI 10.1212/WNL.43.1_Part_1.32; Minematsu K, 1999, STROKE, V30, P241; MITUSCH R, 1995, INT J CARDIAC IMAG, V11, P27, DOI 10.1007/BF01148951; MOULTON AW, 1991, AM J MED, V91, P156, DOI 10.1016/0002-9343(91)90008-L; Nakagami H, 1998, AM HEART J, V136, P528, DOI 10.1016/S0002-8703(98)70231-5; PETERSEN P, 1990, ARCH INTERN MED, V150, P819, DOI 10.1001/archinte.150.4.819; PETERSEN P, 1989, J CEREBR BLOOD F MET, V9, P422, DOI 10.1038/jcbfm.1989.62; Pongratz G, 1997, CHEST, V111, P929, DOI 10.1378/chest.111.4.929; Schmieder RE, 1996, JAMA-J AM MED ASSOC, V275, P1507, DOI 10.1001/jama.275.19.1507; Sohara H, 1997, J AM COLL CARDIOL, V29, P106, DOI 10.1016/S0735-1097(96)00427-5; Stollberger C, 1998, ANN INTERN MED, V128, P630, DOI 10.7326/0003-4819-128-8-199804150-00004; Stroke Prevention in Atrial Fibrillation Investigators, 1995, J Stroke Cerebrovasc Dis, V5, P147, DOI 10.1016/S1052-3057(10)80166-1; Sudlow M, 1998, LANCET, V352, P1167, DOI 10.1016/S0140-6736(98)01401-9; Tsai LM, 1997, INT J CARDIOL, V58, P163, DOI 10.1016/S0167-5273(96)02862-8; VANGELDER IC, 1993, AM J CARDIOL, V72, P560, DOI 10.1016/0002-9149(93)90352-D; VanGelder IC, 1996, ARCH INTERN MED, V156, P2585, DOI 10.1001/archinte.156.22.2585; VANLATUM JC, 1995, STROKE, V26, P801, DOI 10.1161/01.STR.26.5.801; WOLF PA, 1978, NEUROLOGY, V28, P973, DOI 10.1212/WNL.28.10.973; Yoshida M, 1996, INT J CARDIOL, V56, P61, DOI 10.1016/0167-5273(96)02726-X; Zabalgoitia M, 1998, J AM COLL CARDIOL, V31, P1622, DOI 10.1016/S0735-1097(98)00146-6; 1993, LANCET, V342, P1255; 1993, J STROKE CEREVROSVAS, V3, P181; 1995, N ENGL, V333, P5	79	181	212	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					688	695		10.7326/0003-4819-131-9-199911020-00010	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00010			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577332				2022-12-28	WOS:000083446200008
J	Belizan, JM; Althabe, F; Barros, FC; Alexander, S				Belizan, JM; Althabe, F; Barros, FC; Alexander, S			Rates and implications of caesarean sections in Latin America: ecological study	BMJ-BRITISH MEDICAL JOURNAL			English	Article							CESAREAN-SECTION; BRAZIL; TRENDS	Objectives To estimate the incidences of caesarean sections in Latin American countries and correlate these with socioeconomic, demographic, and healthcare are variables. Design Descriptive and ecological study. Setting 19 Latin American countries. Main outcome measures National estimates of caesarean section rates in each country. Results Seven countries had caesarean section rates below 15%. The remaining 12 countries had rates above 15% (range 16.8% to 40.0%). These 12 countries account for 81% of the deliveries in the region. A positive and significant correlation was observed between the gross national product per capita and rare of caesarean section (r(s) = 0.746), and higher rates were observed in private hospitals than in public ones. Taking 15% as a medically justified accepted rate, over 850 000 unnecessary caesarean sections are performed each year in the region. Conclusions The reported figures represent an unnecessary increased risk for young women and their babies. From the economic perspective, this is a burden to health systems that work with limited budgets.	Pan Amer Hlth Org, WHO, Latin Amer Ctr Perinatol, Montevideo 11000, Uruguay; Free Univ Brussels, Ecole Sante Publ, Brussels, Belgium	Pan American Health Organization; World Health Organization; Universite Libre de Bruxelles; Vrije Universiteit Brussel	Belizan, JM (corresponding author), Pan Amer Hlth Org, WHO, Latin Amer Ctr Perinatol, Hosp Clin S-N, Montevideo 11000, Uruguay.	belizanj@clap.ops-oms.org	Barros, Fernando C/D-4857-2013	Belizan, Jose/0000-0002-8412-3010				[Anonymous], 1985, LANCET, V2, P436; [Anonymous], 1997, LANCET, V349, P815; Ballacci F, 1996, Epidemiol Prev, V20, P105; BARROS FC, 1991, LANCET, V338, P167, DOI 10.1016/0140-6736(91)90149-J; BELITZKY R, 1988, NACIMIENTO CESAREA I; Belizan JM, 1998, PAEDIATR PERINAT EP, V12, P1, DOI 10.1046/j.1365-3016.12.s2.4.x; Centers for Disease Control and Prevention, 1995, MMWR-MORBID MORTAL W, V44, P303; FAUNDES A, 1993, HEALTH POLICY PLANN, V8, P33, DOI 10.1093/heapol/8.1.33; Flamm BL, 1998, BIRTH-ISS PERINAT C, V25, P117, DOI 10.1046/j.1523-536x.1998.00117.x; GOULD JB, 1989, NEW ENGL J MED, V321, P233, DOI 10.1056/NEJM198907273210406; *MACR INT, 1998, DEM HLTH SURV MEAS D; MORGENSTERN H, 1998, MODERN EPIDEMIOLOGY; Murray SF, 1997, BIRTH-ISS PERINAT C, V24, P258, DOI 10.1111/j.1523-536X.1997.tb00600.x; *NAT I CHILD HLTH, 1981, CES CHILDB REP CONS; NOTZON FC, 1994, AM J OBSTET GYNECOL, V170, P495, DOI 10.1016/S0002-9378(94)70217-9; *PAN AM HLTH ORG, 1997, HLTH SIT AM BAS IND; *PAN AM HLTH ORG, 1998, EPIDEMIOL B, V19, P10; SHEARER EL, 1993, SOC SCI MED, V37, P1223, DOI 10.1016/0277-9536(93)90334-Z; SOUZA CD, 1994, CAMB Q HEALTHC ETHIC, V3, P358, DOI 10.1017/S096318010000517X; *US DEP HHS, 1991, 9150212 DHHS PHS; Wilkinson C, 1998, BRIT J OBSTET GYNAEC, V105, P45, DOI 10.1111/j.1471-0528.1998.tb09349.x; Wolfram S., 1994, PUBLIC CITIZEN HLTH, V10, P1; 1999, SAFE MOTHERHOOD MATE	23	285	316	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1397	1400		10.1136/bmj.319.7222.1397	http://dx.doi.org/10.1136/bmj.319.7222.1397			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10574855	Bronze, Green Published			2022-12-28	WOS:000083995200023
J	Runyon, BA				Runyon, BA			Albumin infusion for spontaneous bacterial peritonitis	LANCET			English	Editorial Material							PARACENTESIS; CIRRHOSIS		Loma Linda Univ, Med Ctr, Inst Transplantat, Loma Linda, CA 92354 USA	Loma Linda University	Runyon, BA (corresponding author), Loma Linda Univ, Med Ctr, Inst Transplantat, Loma Linda, CA 92354 USA.							FOLLO A, 1994, HEPATOLOGY, V20, P1495, DOI 10.1002/hep.1840200619; Gines A, 1996, GASTROENTEROLOGY, V111, P1002, DOI 10.1016/S0016-5085(96)70068-9; GINES P, 1988, GASTROENTEROLOGY, V94, P1493, DOI 10.1016/0016-5085(88)90691-9; Roberts I, 1998, BMJ-BRIT MED J, V317, P235; RuizdelArbol L, 1997, GASTROENTEROLOGY, V113, P579, DOI 10.1053/gast.1997.v113.pm9247479; RUNYON BA, 1991, GASTROENTEROLOGY, V100, P1737, DOI 10.1016/0016-5085(91)90677-D; Runyon BA, 1998, HEPATOLOGY, V27, P264, DOI 10.1002/hep.510270139; Runyon BA, 1997, AM J GASTROENTEROL, V92, P371; Sort P, 1999, NEW ENGL J MED, V341, P403, DOI 10.1056/NEJM199908053410603; Such J, 1998, CLIN INFECT DIS, V27, P669, DOI 10.1086/514940	10	23	23	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1838	1839		10.1016/S0140-6736(99)00303-7	http://dx.doi.org/10.1016/S0140-6736(99)00303-7			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584717				2022-12-28	WOS:000083909100006
J	Yamey, G				Yamey, G			UK community groups reject mental health reforms	BRITISH MEDICAL JOURNAL			English	News Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1389	1389		10.1136/bmj.319.7222.1389	http://dx.doi.org/10.1136/bmj.319.7222.1389			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574842	Green Published			2022-12-28	WOS:000083995200010
J	Black, DE; Peterson, LC; Overpeck, JT; Kaplan, A; Evans, MN; Kashgarian, M				Black, DE; Peterson, LC; Overpeck, JT; Kaplan, A; Evans, MN; Kashgarian, M			Eight centuries of North Atlantic Ocean atmosphere variability	SCIENCE			English	Article							SEA-SURFACE TEMPERATURE; TROPICAL ATLANTIC; CLIMATE-CHANGE; LAST DEGLACIATION; GREENLAND SEA; UNITED-STATES; CARIACO BASIN; ICE-AGE; CIRCULATION; MODEL	Climate in the tropical North Atlantic is controlled Largely by variations in the strength of the trade winds, the position of the Intertropical Convergence Zone, and sea surface temperatures. A high-resolution study of Caribbean sediments provides a subdecadally resolved record of tropical upwelling and trade wind Variability spanning the past 825 years. These results confirm the importance of a decadal (12- to 13-year) mode of Atlantic variability believed to be driven by coupled tropical ocean-atmosphere dynamics. Although a well-defined interdecadal mode of variability does not appear to be characteristic of the tropical Atlantic, there is evidence that century-scale variability is substantial. The tropical Atlantic may also have been involved in a major shift in Northern Hemisphere climate variability that took place about 700 years ago.	Univ Miami, Rosenstiel Sch Marine & Atmospher Sci, Miami, FL 33149 USA; Univ Colorado, NOAA, Paleoclimatol Program, Boulder, CO 80309 USA; Univ Colorado, Inst Arctic & Alpine Res, Boulder, CO 80309 USA; Columbia Univ, Lamont Doherty Earth Observ, Palisades, NY 10964 USA; Univ Calif Lawrence Livermore Natl Lab, Ctr Accelerator Mass Spectrometry, Livermore, CA 94551 USA	University of Miami; National Oceanic Atmospheric Admin (NOAA) - USA; University of Colorado System; University of Colorado Boulder; University of Colorado System; University of Colorado Boulder; Columbia University; United States Department of Energy (DOE); Lawrence Livermore National Laboratory; University of California System	Black, DE (corresponding author), Univ S Carolina, Dept Geol Sci, Columbia, SC 29208 USA.		Kashgarian, Michaele/E-1665-2011	Kashgarian, Michaele/0000-0001-7824-8418; Black, David/0000-0002-9601-6642				Anderson, 1996, GEOLOGICAL SOC SPECI, V116, P171, DOI [10.1144/GSL.SP.1996.116.01.15, DOI 10.1144/GSL.SP.1996.116.01.15]; Barlow LK, 1997, HOLOCENE, V7, P489, DOI 10.1177/095968369700700411; BLACK DE, 1998, THESIS U MIAMI CORAL; Chang P, 1997, NATURE, V385, P516, DOI 10.1038/385516a0; DANSGAARD W, 1975, NATURE, V255, P24, DOI 10.1038/255024a0; Delworth TL, 1997, GEOPHYS RES LETT, V24, P257, DOI 10.1029/96GL03927; DEMIRO MD, 1971, ACTA GEOL HISP, V6, P102; DICKSON RR, 1988, PROG OCEANOGR, V20, P103, DOI 10.1016/0079-6611(88)90049-3; ELY LL, 1993, SCIENCE, V262, P410, DOI 10.1126/science.262.5132.410; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; GLYNN PW, 1983, J MAR RES, V41, P605, DOI 10.1357/002224083788519740; GRAY WM, 1990, SCIENCE, V249, P1251, DOI 10.1126/science.249.4974.1251; GREATBATCH RJ, 1991, J GEOPHYS RES-OCEANS, V96, P22009, DOI 10.1029/91JC02423; GrissinoMayer HD, 1996, TREE RINGS, ENVIRONMENT AND HUMANITY, P191; HASTENRATH S, 1984, MON WEATHER REV, V112, P1097, DOI 10.1175/1520-0493(1984)112<1097:IVAACM>2.0.CO;2; HASTENRATH S, 1993, J GEOPHYS RES-ATMOS, V98, P5093, DOI 10.1029/92JD02646; Haug GH, 1998, PALEOCEANOGRAPHY, V13, P427, DOI 10.1029/98PA01976; Hughen KA, 1996, NATURE, V380, P51, DOI 10.1038/380051a0; Hughen KA, 1998, NATURE, V391, P65, DOI 10.1038/34150; HUGHES MK, 1996, CLIMATIC VARIATIONS, P109; Jennings AE, 1996, HOLOCENE, V6, P179, DOI 10.1177/095968369600600205; Kaplan A, 1998, J GEOPHYS RES-OCEANS, V103, P18567, DOI 10.1029/97JC01734; Keigwin LD, 1996, SCIENCE, V274, P1504, DOI 10.1126/science.274.5292.1504; KOCH L, 1945, MEDDELESER GRONLAND, V130; KUSHNIR Y, 1994, J CLIMATE, V7, P141, DOI 10.1175/1520-0442(1994)007<0141:IVINAS>2.0.CO;2; Laird KR, 1996, NATURE, V384, P552, DOI 10.1038/384552a0; Laird KR, 1998, J PALEOLIMNOL, V19, P161, DOI 10.1023/A:1007929006001; LEVITUS S, 1989, J GEOPHYS RES-OCEANS, V94, P9679, DOI 10.1029/JC094iC07p09679; Lin HL, 1997, PALEOCEANOGRAPHY, V12, P415, DOI 10.1029/97PA00230; Manabe S, 1996, J CLIMATE, V9, P376, DOI 10.1175/1520-0442(1996)009<0376:LFVOSA>2.0.CO;2; Mann ME, 1996, CLIMATIC CHANGE, V33, P409, DOI 10.1007/BF00142586; MANN ME, 1995, NATURE, V378, P266, DOI 10.1038/378266a0; Mann ME, 1998, NATURE, V392, P779, DOI 10.1038/33859; MANN ME, 1994, J GEOPHYS RES-ATMOS, V99, P25819, DOI 10.1029/94JD02396; MEHTA VM, 1995, J CLIMATE, V8, P172, DOI 10.1175/1520-0442(1995)008<0172:DVOTTA>2.0.CO;2; MIKOLAJEWICZ U, 1990, CLIM DYNAM, V2, P63; MOURA AD, 1981, J ATMOS SCI, V38, P2653, DOI 10.1175/1520-0469(1981)038<2653:OTDODI>2.0.CO;2; MULLERKARGER FE, 1994, CONT SHELF RES, V14, P199, DOI 10.1016/0278-4343(94)90013-2; MYSAK LA, 1991, CLIMATOL B, V25, P81; Ogilvie A., 1991, ACTA ARCHAEOL, V61, P233; OGILVIE AEJ, 1992, CLIMATE AD 1500, P92; OVERPECK JT, 1989, NATURE, V338, P553, DOI 10.1038/338553a0; Peterson LC, 1991, PALEOCEANOGRAPHY, V6, P99, DOI 10.1029/90PA02497; Richards F. A., 1975, OCEANOGR MAR BIOL AN, V13, P11; RIND D, 1993, QUATERNARY SCI REV, V12, P357, DOI 10.1016/S0277-3791(05)80002-2; ROBERTSON AW, IN PRESS J CLIM; SANCHEZ WA, 1974, QUATERNARY RES, V4, P128, DOI 10.1016/0033-5894(74)90002-7; SCHLESINGER ME, 1994, NATURE, V367, P723, DOI 10.1038/367723a0; SCHLOSSER P, 1991, SCIENCE, V251, P1054, DOI 10.1126/science.251.4997.1054; SERVAIN J, 1991, J GEOPHYS RES-OCEANS, V96, P15137, DOI 10.1029/91JC01046; STUIVER M, 1993, RADIOCARBON, V35, P137; STUIVER M, 1980, SCIENCE, V207, P11, DOI 10.1126/science.207.4426.11; TAURSSOV A, 1992, CLIMATE AD 1500, P505; TEDESCO KA, 1997, EOS S, V78, pF342; Timmermann A, 1998, J CLIMATE, V11, P1906, DOI 10.1175/1520-0442-11.8.1906; Wagner RG, 1996, J CLIMATE, V9, P2010, DOI 10.1175/1520-0442(1996)009<2010:MCVOTI>2.0.CO;2; Woodhouse CA, 1998, B AM METEOROL SOC, V79, P2693, DOI 10.1175/1520-0477(1998)079<2693:YODVIT>2.0.CO;2; WOODRUFF SD, 1987, B AM METEOROL SOC, V68, P1239, DOI 10.1175/1520-0477(1987)068<1239:ACOADS>2.0.CO;2	58	171	172	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1709	1713		10.1126/science.286.5445.1709	http://dx.doi.org/10.1126/science.286.5445.1709			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576732				2022-12-28	WOS:000083912200030
J	Kobe, B; Kemp, BE				Kobe, B; Kemp, BE			Active site-directed protein regulation	NATURE			English	Article							TYROSINE KINASE HCK; CRYSTAL-STRUCTURE; BOVINE TRYPSINOGEN; KARYOPHERIN-ALPHA; INSULIN-RECEPTOR; DOMAIN; ACTIVATION; SRC; RESOLUTION; INSIGHTS	Regulation of protein function is vital for the control of cellular processes. Proteins are often regulated by allosteric mechanisms, in which effecters bind to regulatory sites distinct from the active sites and alter protein function. Intrasteric regulation, directed at the active site and thus the counterpart of allosteric control, is now emerging as an important regulatory mechanism.	St Vincents Inst Med Res, Fitzroy, Vic 3065, Australia	St. Vincent's Institute of Medical Research	Kobe, B (corresponding author), St Vincents Inst Med Res, 41 Victoria Parade, Fitzroy, Vic 3065, Australia.		Kemp, Bruce E/L-2633-2014; Kemp, Bruce/G-9602-2019; Kobe, Bostjan/D-1292-2009	Kemp, Bruce E/0000-0001-6735-5082; Kemp, Bruce/0000-0001-6735-5082; Kobe, Bostjan/0000-0001-9413-9166				Barford D, 1998, ANNU REV BIOPH BIOM, V27, P133, DOI 10.1146/annurev.biophys.27.1.133; Bilwes AM, 1996, NATURE, V382, P555, DOI 10.1038/382555a0; BODE W, 1992, EUR J BIOCHEM, V204, P433, DOI 10.1111/j.1432-1033.1992.tb16654.x; Canagarajah BJ, 1997, CELL, V90, P859, DOI 10.1016/S0092-8674(00)80351-7; Carr PD, 1999, STRUCTURE, V7, P461, DOI 10.1016/S0969-2126(99)80058-6; CHINKERS M, 1989, SCIENCE, V245, P1392, DOI 10.1126/science.2571188; CIGNOLANI G, 1999, NATURE, V399, P221; Conti E, 1998, CELL, V94, P193, DOI 10.1016/S0092-8674(00)81419-1; FEHLHAMMER H, 1977, J MOL BIOL, V111, P415, DOI 10.1016/S0022-2836(77)80062-4; FREER ST, 1970, BIOCHEMISTRY-US, V9, P1997, DOI 10.1021/bi00811a022; Goldberg J, 1996, CELL, V84, P875, DOI 10.1016/S0092-8674(00)81066-1; Gorlich D, 1996, EMBO J, V15, P1810, DOI 10.1002/j.1460-2075.1996.tb00530.x; Heierhorst J, 1996, NATURE, V380, P636, DOI 10.1038/380636a0; Hof P, 1998, CELL, V92, P441, DOI 10.1016/S0092-8674(00)80938-1; HU SH, 1994, NATURE, V369, P581, DOI 10.1038/369581a0; Hubbard SR, 1997, EMBO J, V16, P5572, DOI 10.1093/emboj/16.18.5572; HUBBARD SR, 1994, NATURE, V372, P746, DOI 10.1038/372746a0; HURLEY JH, 1990, SCIENCE, V249, P1012, DOI 10.1126/science.2204109; Jiang GL, 1999, NATURE, V401, P606, DOI 10.1038/44170; Johansson K, 1999, BIOCHEMISTRY-US, V38, P4319, DOI 10.1021/bi982876c; Johnson LN, 1997, ADV SEC MESS PHOSPH, V31, P11; KEMP BE, 1991, BIOCHIM BIOPHYS ACTA, V1094, P67, DOI 10.1016/0167-4889(91)90027-U; KEMP BE, 1994, PROTEIN KINASES, P30; Khan AR, 1998, PROTEIN SCI, V7, P815; KISSINGER CR, 1995, NATURE, V378, P641, DOI 10.1038/378641a0; KNIGHTON DR, 1991, SCIENCE, V253, P414, DOI 10.1126/science.1862343; Kobe B, 1999, NAT STRUCT BIOL, V6, P442, DOI 10.1038/8247; Kobe B, 1996, EMBO J, V15, P6810, DOI 10.1002/j.1460-2075.1996.tb01072.x; Kobe B, 1999, NAT STRUCT BIOL, V6, P388, DOI 10.1038/7625; KOSSIAKOFF AA, 1977, BIOCHEMISTRY-US, V16, P654, DOI 10.1021/bi00623a016; Lin K, 1997, STRUCTURE, V5, P1511, DOI 10.1016/S0969-2126(97)00300-6; Mayans O, 1998, NATURE, V395, P863, DOI 10.1038/27603; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; MONOD J, 1963, J MOL BIOL, V6, P306, DOI 10.1016/S0022-2836(63)80091-1; MORGAN DO, 1995, NATURE, V374, P131, DOI 10.1038/374131a0; Moroianu J, 1996, P NATL ACAD SCI USA, V93, P6572, DOI 10.1073/pnas.93.13.6572; Morshauser RC, 1999, J MOL BIOL, V289, P1387, DOI 10.1006/jmbi.1999.2776; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Park HW, 1997, SCIENCE, V275, P1800, DOI 10.1126/science.275.5307.1800; Sicheri F, 1997, NATURE, V385, P602, DOI 10.1038/385602a0; Wang H, 1998, BIOCHEMISTRY-US, V37, P7929, DOI 10.1021/bi9800855; Weis K, 1996, EMBO J, V15, P1818, DOI 10.1002/j.1460-2075.1996.tb00531.x; Weiss A, 1998, CELL, V94, P277, DOI 10.1016/S0092-8674(00)81469-5; Williams JC, 1997, J MOL BIOL, V274, P757, DOI 10.1006/jmbi.1997.1426; Xu WQ, 1997, NATURE, V385, P595, DOI 10.1038/385595a0; ZHANG F, 1993, NATURE, V367, P704	46	163	166	1	21	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					373	376		10.1038/46478	http://dx.doi.org/10.1038/46478			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586874				2022-12-28	WOS:000083913600045
J	Soltis, PS; Soltis, DE; Chase, MW				Soltis, PS; Soltis, DE; Chase, MW			Angiosperm phylogeny inferred from multiple genes as a tool for comparative biology	NATURE			English	Article							LARGE DATA SETS; COMPLEX PHYLOGENIES; SEQUENCES; EVOLUTION; PARSIMONY; ORIGIN; RBCL	Comparative biology requires a firm phylogenetic foundation to uncover and understand patterns of diversification and evaluate hypotheses of the processes responsible for these patterns. In the angiosperms, studies of diversification in floral form(1,2), stamen organization(3), reproductive biology(4), photosynthetic pathway(5), nitrogen-fixing symbioses(6) and life histories(7) have relied on either explicit or implied phylogenetic trees, Furthermore, to understand the evolution of specific genes and gene families, evaluate the extent of conservation of plant genomes and make proper sense of the huge volume of molecular genetic data available for model organisms(8) such as Arabidopsis, Antirrhinum, maize, rice and wheat, a phylogenetic perspective is necessary. Here we report the results of parsimony analyses of DNA sequences of the plastid genes rbcL and atpB and the nuclear 18S rDNA for 560 species of angiosperms and seven non-flowering seed plants and show a well-resolved and well-supported phylogenetic tree for the angiosperms for use in comparative biology.	Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	Washington State University; Royal Botanic Gardens, Kew	Soltis, PS (corresponding author), Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA.	psoltis@wsu.edu	Chase, Mark W/A-6642-2011; Soltis, Pamela S/L-5184-2015; Soltis, Douglas/L-5957-2015; Soltis, Pamela S/GNH-5557-2022	Soltis, Pamela S/0000-0001-9310-8659; Chase, Mark/0000-0002-9927-4938				CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; Chase MW, 1998, AUST SYST BOT, V11, P215, DOI 10.1071/SB97010; CHASE MW, IN PRESS P MON 2 2 I, V2; Crepet WL, 1998, AM J BOT, V85, P1122, DOI 10.2307/2446345; Cronquist A, 1981, INTEGRATED SYSTEM CL; Cronquist A., 1988, EVOLUTION CLASSIFICA; Dodd ME, 1999, EVOLUTION, V53, P732, DOI [10.2307/2640713, 10.1111/j.1558-5646.1999.tb05367.x]; Donoghue MJ, 1998, TRENDS PLANT SCI, V3, P311, DOI 10.1016/S1360-1385(98)01278-3; DOYLE JA, 1994, ANN MO BOT GARD, V81, P419, DOI 10.2307/2399899; ENDRESS PK, 1994, PLANT SYST EVOL, V192, P79, DOI 10.1007/BF00985910; Farris JS, 1996, CLADISTICS, V12, P99, DOI 10.1111/j.1096-0031.1996.tb00196.x; FELSENSTEIN J, 1978, SYST ZOOL, V27, P401, DOI 10.2307/2412923; Gale MD, 1998, SCIENCE, V282, P656, DOI 10.1126/science.282.5389.656; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; KELLOGG EA, 1998, BIOL C4 PHOTOSYNTHES, P411; Kramer EM, 1998, GENETICS, V149, P765; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Nandi OI, 1998, ANN MO BOT GARD, V85, P137, DOI 10.2307/2992003; Qiu YL, 1999, NATURE, V402, P404, DOI 10.1038/46536; Rice KA, 1997, SYST BIOL, V46, P554, DOI 10.2307/2413696; RONSEDECRAENE LP, 1987, NORD J BOT, V7, P239; SAVOLAINEN V, IN PRESS SYST BIOL; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; SOLTIS DE, 1995, P NATL ACAD SCI USA, V92, P2647, DOI 10.1073/pnas.92.7.2647; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; Swofford D. L., 1998, PAUP PHYLOGENETIC AN; Takhtajan A, 1991, EVOLUTIONARY TRENDS; Takhtajan A, 1997, DIVERSITY CLASSIFICA; WELLER SG, 1995, MONOG SYST BOTAN, V53, P355	30	653	697	1	107	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					402	404		10.1038/46528	http://dx.doi.org/10.1038/46528			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586878				2022-12-28	WOS:000083913600053
J	Langman, MJ; Jensen, DM; Watson, DJ; Harper, SE; Zhao, PL; Quan, H; Bolognese, JA; Simon, TJ				Langman, MJ; Jensen, DM; Watson, DJ; Harper, SE; Zhao, PL; Quan, H; Bolognese, JA; Simon, TJ			Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; BLEEDING PEPTIC-ULCER; H SYNTHASE; CYCLOOXYGENASE; INHIBITORS	Context Nonsteroidal anti-inflammatory drug (NSAID)-induced gastrointestinal (GI) toxic effects, such as upper GI tract perforations, symptomatic gastroduodenal ulcers, and upper GI tract bleeding (PUBs), are thought to be attributable to cyclooxygenase 1 (COX-1) inhibition. Rofecoxib specifically inhibits COX-2 and has demonstrated a low potential for causing upper GI injury. Objective To compare the incidence of PUBs in patients with osteoarthritis treated with rofecoxib vs NSAIDs. Design Prespecified analysis of all 8 double-blind, randomized phase 2b/3 rofecoxib osteoarthritis trials conducted from December 1996 through March 1998, including one 6-week dose-ranging study, two 6-week efficacy studies vs ibuprofen and placebo, two 1-year efficacy studies vs diclofenac, two 6-month endoscopy studies vs ibuprofen and placebo, and one g-week efficacy study vs nabumetone and placebo. Setting Multinational sites. Participants Osteoarthritis patients (N = 5435; mean age, 63 years [range, 38-94 years]; 72.9% women). Interventions Rofecoxib, 12.5, 25, or 50 mg/d (n = 1209, 1603, and 545, respectively, combined) vs ibuprofen, 800 mg 3 times per day (n = 847), diclofenac, 50 mg 3 times per day (n = 590); or nabumetone, 1500 mg/d (n = 127) (combined). Main Outcome Measure Cumulative incidence of PUBs for rofecoxib vs NSAIDs, based on survival analysis of time to first PUB diagnosis, using PUBs that met prespecified criteria judged by a blinded, external adjudication committee. Results The incidence of PUBs over 12 months was significantly lower with rofecoxib vs NSAIDs (12-month cumulative incidence, 1.3% vs 1.8%; P = .046; rate per 100 patient-years, 1.33 vs 2.60; relative risk, 0.51; 95% confidence interval, 0.26-1.00). The cumulative incidence of dyspeptic GI adverse experiences was also lower with rofecoxib vs NSAIDS over 6 months (23.5% vs 25.5%; P = .02), after which the incidence rates converged. Conclusion In a combined analysis of 8 trials of patients with osteoarthritis, treatment with rofecoxib was associated with a significantly lower incidence of PUBs than treatment with NSAIDs.	Univ Birmingham, Dept Med, Birmingham, W Midlands, England; Univ Calif Los Angeles, Ctr Hlth Sci, Dept Med, Los Angeles, CA 90024 USA; Merck & Co Inc, Merck Res Labs, West Point, PA USA	University of Birmingham; University of California System; University of California Los Angeles; Merck & Company	Watson, DJ (corresponding author), Merck Res Labs, 10 Sentry Pkwy,BL1-7, Blue Bell, PA 19422 USA.							Barner A, 1996, SCAND J RHEUMATOL, P29, DOI 10.3109/03009749609097228; BJARNASON I, 1998, AM J GASTROENTEROL, V93, P1670; BRESLOW N, 1974, ANN STAT, V2, P437, DOI 10.1214/aos/1176342705; Brideau C, 1996, INFLAMM RES, V45, P68, DOI 10.1007/BF02265118; Cannon G, 1998, ARTHRITIS RHEUM, V41, pS196; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CRYER B, 1998, SLEISENGER FORDTRANS, P343; CRYER B, 1996, AM J GASTROENTEROL, V91, P1907; DEPRE M, 1998, RHEUMATOL EUR S2, V27, P196; Ehrich EW, 1999, CLIN PHARMACOL THER, V65, P336, DOI 10.1016/S0009-9236(99)70113-X; Fosslien E, 1998, ANN CLIN LAB SCI, V28, P67; GRIFFIN MR, 1988, ANN INTERN MED, V109, P359, DOI 10.7326/0003-4819-109-5-359; HLA T, 1992, P NATL ACAD SCI USA, V89, P7384, DOI 10.1073/pnas.89.16.7384; HOLTZMAN MJ, 1992, J BIOL CHEM, V267, P21438; HUNT R, 1998, AM J GASTROENTEROL, V93, P1671; Laine L, 1999, GASTROENTEROLOGY, V116, pA229; LANGMAN MJS, 1994, LANCET, V343, P1075, DOI 10.1016/S0140-6736(94)90185-6; Lanza FL, 1997, GASTROENTEROLOGY, V112, pA194; MEADE EA, 1993, J BIOL CHEM, V268, P6610; *MED EC CO, 1999, PHYS DESK REF, P2001; *MED EC CO, 1999, PHYS DESK REF, P1674; MITCHELL JA, 1993, P NATL ACAD SCI USA, V90, P11693, DOI 10.1073/pnas.90.24.11693; Saag K, 1998, ARTHRITIS RHEUM, V41, pS196; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Singh G, 1998, AM J MED, V105, P315; SIROIS J, 1992, J BIOL CHEM, V267, P11586; SOMERVILLE K, 1986, LANCET, V1, P462	27	508	518	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1929	1933		10.1001/jama.282.20.1929	http://dx.doi.org/10.1001/jama.282.20.1929			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580458	Bronze			2022-12-28	WOS:000083763400027
J	Hargreave, TB				Hargreave, TB			Understanding the Y chromosome	LANCET			English	Editorial Material							GENE; SPERMATOGENESIS; MICRODELETIONS; INTERVAL-6; DELETIONS; LOCUS; MEN		Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland	University of Edinburgh	Hargreave, TB (corresponding author), Western Gen Hosp, Dept Urol, Edinburgh EH4 2XU, Midlothian, Scotland.							BERTA P, 1990, NATURE, V348, P448, DOI 10.1038/348448A0; Brown GM, 1998, HUM MOL GENET, V7, P97, DOI 10.1093/hmg/7.1.97; Cooke HJ, 1998, FERTIL STERIL, V69, P989, DOI 10.1016/S0015-0282(98)00071-5; KOBAYASHI K, 1994, HUM MOL GENET, V3, P1965, DOI 10.1093/hmg/3.11.1965; Kuroki Y, 1999, J HUM GENET, V44, P289, DOI 10.1007/s100380050162; MA K, 1993, CELL, V75, P1287, DOI 10.1016/0092-8674(93)90616-X; MA K, 1992, HUM MOL GENET, V1, P29, DOI 10.1093/hmg/1.1.29; Pryor JL, 1997, NEW ENGL J MED, V336, P534, DOI 10.1056/NEJM199702203360802; REIJO R, 1995, NAT GENET, V10, P383, DOI 10.1038/ng0895-383; Short RV, 1997, ACTA PAEDIATR, V86, P3; Silber SJ, 1998, HUM REPROD, V13, P3332, DOI 10.1093/humrep/13.12.3332; Stuppia L, 1997, J MED GENET, V34, P881, DOI 10.1136/jmg.34.11.881	12	6	6	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1746	1747		10.1016/S0140-6736(99)00311-6	http://dx.doi.org/10.1016/S0140-6736(99)00311-6			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577631				2022-12-28	WOS:000083853000004
J	Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL				Bortolotto, ZA; Clarke, VRJ; Delany, CM; Parry, MC; Smolders, I; Vignes, M; Ho, KH; Miu, P; Brinton, BT; Fantaske, R; Ogden, A; Gates, M; Ornstein, PL; Lodge, D; Bleakman, D; Collingridge, GL			Kainate receptors are involved in synaptic plasticity	NATURE			English	Article							LONG-TERM POTENTIATION; RAT HIPPOCAMPUS; GLUR5 SUBTYPE; TRANSMISSION; ACTIVATION; AMPA; ACID; CA3; DESENSITIZATION; ANTAGONISTS	The ability of synapses to modify their synaptic strength in response to activity is a fundamental property of the nervous system and may be an essential component of learning and memory(1). There are three classes of ionotropic glutamate receptor, namely NMDA (N-methyl-D-aspartate), AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazole-4-propionic acid) and kainate receptors(2); critical roles in synaptic plasticity have been identified for two of these. Thus, at many synapses in the brain, transient activation of NMDA receptors leads to a persistent modification in the strength of synaptic transmission mediated by AMPA receptors(3,4). Here, to determine whether kainate receptors(5-7) are involved in synaptic plasticity, we have used a new antagonist, LY382884 ((3S, 4aR, 6S, 8aR)-6-( (4-carboxyphenyl)methyl-1,2,3,4,4a,5,6,7,8,8a-decahydroisoquinoline-3-carboxylic acid), which antagonizes kainate receptors at concentrations that do not affect AMPA or NMDA receptors. We find that LY382884 is a selective antagonist at neuronal kainate receptors containing the GluR5 subunit. it has no effect on long-term potentiation (LTP) that is dependent on NMDA receptors but prevents the induction of mossy fibre LTP, which is independent of NMDA receptors. Thus, kainate receptors can act as the induction trigger for longterm changes in synaptic transmission.	Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England; Free Univ Brussels, Inst Pharmaceut, Dept Pharmaceut Chem & Drug Anal, B-1090 Brussels, Belgium; Univ Montpellier 2, Lab Plasticite Cerebrale, CNRS, F-34095 Montpellier, France; Allelix Biopharmaceut, Mississauga, ON L4V 1V7, Canada; Eli Lilly & Co, Lilly Corp Ctr, Indianapolis, IN 46285 USA	University of Bristol; Universite Libre de Bruxelles; Vrije Universiteit Brussel; Centre National de la Recherche Scientifique (CNRS); Universite de Montpellier; Eli Lilly	Bortolotto, ZA (corresponding author), Univ Bristol, Sch Med, Dept Anat, MRC Ctr Synapt Plast, Bristol BS8 1TD, Avon, England.		Collingridge, Graham L/C-4605-2015; Ornstein, Paul/E-4212-2016; Vignes, Michel/AAA-7693-2019; collingridge, graham/AAI-8362-2020; Smolders, Ilse J/J-9399-2013	Collingridge, Graham L/0000-0002-9572-5359; Ornstein, Paul/0000-0002-4335-1877; Vignes, Michel/0000-0003-0969-2966; Smolders, Ilse J/0000-0003-2140-0751; Clarke, Vernon/0000-0002-6154-6555				BASHIR ZI, 1993, NATURE, V363, P347, DOI 10.1038/363347a0; Bear MF, 1996, ANNU REV NEUROSCI, V19, P437, DOI 10.1146/annurev.ne.19.030196.002253; BETTLER B, 1995, NEUROPHARMACOLOGY, V34, P123, DOI 10.1016/0028-3908(94)00141-E; Bleakman D, 1998, NEUROPHARMACOLOGY, V37, P1187, DOI 10.1016/S0028-3908(98)00139-7; Bleakman D, 1996, MOL PHARMACOL, V49, P581; BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; CASTILLO PE, 1994, NEURON, V12, P261, DOI 10.1016/0896-6273(94)90269-0; Castillo PE, 1997, NATURE, V388, P182, DOI 10.1038/40645; Chittajallu R, 1999, TRENDS PHARMACOL SCI, V20, P26, DOI 10.1016/S0165-6147(98)01286-3; Clarke VRJ, 1997, NATURE, V389, P599, DOI 10.1038/39315; Cossart R, 1998, NAT NEUROSCI, V1, P470, DOI 10.1038/2185; DAVIES SN, 1989, PROC R SOC SER B-BIO, V236, P373, DOI 10.1098/rspb.1989.0028; HARRIS EW, 1986, NEUROSCI LETT, V70, P132, DOI 10.1016/0304-3940(86)90451-9; Hebb Donald O., 1949, ORG BEHAV; HUETTNER JE, 1990, NEURON, V5, P255, DOI 10.1016/0896-6273(90)90163-A; ITO I, 1991, NEUROREPORT, V2, P333, DOI 10.1097/00001756-199106000-00008; Li H, 1998, NEUROPHARMACOLOGY, V37, P1279, DOI 10.1016/S0028-3908(98)00109-9; MONAGHAN DT, 1982, BRAIN RES, V252, P91, DOI 10.1016/0006-8993(82)90981-7; Mulle C, 1998, NATURE, V392, P601, DOI 10.1038/33408; NICOLL RA, 1995, NATURE, V377, P115, DOI 10.1038/377115a0; O'Neill MJ, 1998, NEUROPHARMACOLOGY, V37, P1211, DOI 10.1016/S0028-3908(98)00134-8; PARTIN KM, 1993, NEURON, V11, P1069, DOI 10.1016/0896-6273(93)90220-L; Procter MJ, 1998, NEUROPHARMACOLOGY, V37, P1287, DOI 10.1016/S0028-3908(98)00136-1; Simmons RMA, 1998, NEUROPHARMACOLOGY, V37, P25, DOI 10.1016/S0028-3908(97)00188-3; Vignes M, 1997, NEUROPHARMACOLOGY, V36, P1477, DOI 10.1016/S0028-3908(97)00158-5; Vignes M, 1998, NEUROPHARMACOLOGY, V37, P1269, DOI 10.1016/S0028-3908(98)00148-8; Vignes M, 1997, NATURE, V388, P179, DOI 10.1038/40639; WATKINS JC, 1981, ANNU REV PHARMACOL, V21, P165, DOI 10.1146/annurev.pa.21.040181.001121; WEISSKOPF MG, 1994, SCIENCE, V265, P1878, DOI 10.1126/science.7916482; Yeckel MF, 1999, NAT NEUROSCI, V2, P625, DOI 10.1038/10180	30	259	264	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					297	301		10.1038/46290	http://dx.doi.org/10.1038/46290			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580501				2022-12-28	WOS:000083813700051
J	Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM				Cunha, A; Azevedo, RBR; Emmons, SW; Leroi, AM			Developmental biology - Variable cell number in nematodes	NATURE			English	Article							CAENORHABDITIS-ELEGANS; LINEAGES		Univ London Imperial Coll Sci Technol & Med, Dept Biol, Ascot SL5 7PY, Berks, England; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA	Imperial College London; Yeshiva University; Albert Einstein College of Medicine	Cunha, A (corresponding author), Univ London Imperial Coll Sci Technol & Med, Dept Biol, Silwood Pk, Ascot SL5 7PY, Berks, England.		Azevedo, Ricardo/AAV-3963-2021	Azevedo, Ricardo/0000-0001-5402-7071				Ambros V., 1987, Development as an Evolutionary Process. MBL Lectures in Biology, vol.8, P139; AZEVEDO RBR, IN PRESS NEMATOLOGY; Blaxter ML, 1998, NATURE, V392, P71, DOI 10.1038/32160; FITCH DHA, 1995, MOL BIOL EVOL, V12, P346; KIMBLE J, 1979, DEV BIOL, V70, P396, DOI 10.1016/0012-1606(79)90035-6; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; Rusin L. Y., 1998, Doklady, Biological Sciences, V361, P331; SOMMER RJ, 1994, DEVELOPMENT, V120, P85; STERNBERG PW, 1982, DEV BIOL, V93, P181, DOI 10.1016/0012-1606(82)90251-2; SULSTON JE, 1977, DEV BIOL, V56, P110, DOI 10.1016/0012-1606(77)90158-0; SULSTON JE, 1983, DEV BIOL, V100, P64, DOI 10.1016/0012-1606(83)90201-4; van Cleave HJ, 1932, Q REV BIOL, V7, P59, DOI 10.1086/394396; Voronov DA, 1998, DEVELOPMENT, V125, P143	13	32	33	0	8	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					253	253		10.1038/46211	http://dx.doi.org/10.1038/46211			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580494	Bronze			2022-12-28	WOS:000083813700037
J	Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG				Migliaccio, E; Giorgio, M; Mele, S; Pelicci, G; Reboidl, P; Pandolfi, PP; Lanfrancone, L; Pelicci, PG			The p66(shc) adaptor protein controls oxidative stress response and life span in mammals	NATURE			English	Article							DROSOPHILA-MELANOGASTER; DIETARY RESTRICTION; PATHWAY; MICE; RESISTANCE; ACTIVATION; MUTATION; UV; EXPRESSION; EXTENSION	Gene mutations in invertebrates have been identified that extend Life span and enhance resistance to environmental stresses such as ultraviolet light or reactive oxygen species(1). In mammals, the mechanisms that regulate stress response are poorly understood and no genes are known to increase individual life span. Here we report that targeted mutation of the mouse p66(shc) gene induces stress resistance and prolongs life span. p66(shc) is a splice variant of p52(shc)/p46(shc) (ref. 2), a cytoplasmic signal transducer involved in the transmission of mitogenic signals from activated receptors to Ras(3). We show that: (1) p66(shc) is serine phosphorylated upon treatment with hydrogen peroxide (H2O2) Or irradiation with ultraviolet light; (2) ablation of p66(shc) enhances cellular resistance to apoptosis induced by H2O2 or ultraviolet light; (3) a serine-phosphorylation defective mutant of p66(shc) cannot restore the normal stress response in p66(shc-/-) cells; (4) the p53 and p21 stress response is impaired in p66(shc-/-) cells; (5) p66(shc-/-) mice have increased resistance to paraquat and a 30% increase in life span. We propose that p66(shc) is part of a signal transduction pathway that regulates stress apoptotic responses and life span in mammals.	Mem Sloan Kettering Canc Ctr, Dept Human Genet, Program Mol Biol, Sloan Kettering Inst, New York, NY 10021 USA; Mem Sloan Kettering Canc Ctr, Dept Human Genet, Cell Biol Program, Sloan Kettering Inst, New York, NY 10021 USA; Univ Perugia, Ist Patol Med, I-06100 Perugia, Italy; Univ Perugia, Ist Med Interna & Sci Oncol, I-06100 Perugia, Italy	Memorial Sloan Kettering Cancer Center; Memorial Sloan Kettering Cancer Center; University of Perugia; University of Perugia	Pelicci, PG (corresponding author), European Inst Oncol, Dept Expt Oncol, I-20141 Milan, Italy.		Giorgio, Marco/I-9425-2012; Lanfrancone, Luisa/AAC-8671-2019; Reboldi, Gianpaolo/A-3444-2009; Pelicci, Giuliana/AAA-8921-2022; Pelicci, Pier Giuseppe/AAL-6572-2020; Migliaccio, Enrica/AAQ-8880-2020; Franzeck, Fabian C/B-5055-2011	Giorgio, Marco/0000-0002-5842-6042; Lanfrancone, Luisa/0000-0002-4523-3815; Reboldi, Gianpaolo/0000-0002-9877-0702; Pelicci, Giuliana/0000-0003-0986-8255; 				Bonfini L, 1996, TRENDS BIOCHEM SCI, V21, P257, DOI 10.1016/S0968-0004(96)10033-5; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; DENG CX, 1995, CELL, V82, P675, DOI 10.1016/0092-8674(95)90039-X; Ishii N, 1998, NATURE, V394, P694, DOI 10.1038/29331; KENNEDY BK, 1995, CELL, V80, P485, DOI 10.1016/0092-8674(95)90499-9; LARSEN PL, 1995, GENETICS, V139, P1576; Lin YJ, 1998, SCIENCE, V282, P943, DOI 10.1126/science.282.5390.943; Lithgow GJ, 1996, SCIENCE, V273, P80, DOI 10.1126/science.273.5271.80; LU X, 1993, CELL, V75, P765, DOI 10.1016/0092-8674(93)90496-D; MACLEOD KF, 1995, GENE DEV, V9, P935, DOI 10.1101/gad.9.8.935; Martin GM, 1996, NAT GENET, V13, P25, DOI 10.1038/ng0596-25; Marubini E, 1995, ANAL SURVIVAL DATA C; Medawar P. B., 1952, MODERN Q, V1, P30; Migliaccio E, 1997, EMBO J, V16, P706, DOI 10.1093/emboj/16.4.706; Murakami S, 1996, GENETICS, V143, P1207; ORR WC, 1994, SCIENCE, V263, P1128, DOI 10.1126/science.8108730; PELICCI G, 1992, CELL, V70, P93, DOI 10.1016/0092-8674(92)90536-L; Renzing J, 1996, J CELL SCI, V109, P1105; ROZAKISADCOCK M, 1992, NATURE, V360, P689, DOI 10.1038/360689a0; RUSSO T, 1995, J BIOL CHEM, V270, P29386, DOI 10.1074/jbc.270.49.29386; Sen CK, 1996, FASEB J, V10, P709, DOI 10.1096/fasebj.10.7.8635688; SERVICE PM, 1985, PHYSIOL ZOOL, V58, P380, DOI 10.1086/physzool.58.4.30156013; Sohal RS, 1996, SCIENCE, V273, P59, DOI 10.1126/science.273.5271.59; STEVENSON MA, 1994, CANCER RES, V54, P12; SUN JY, 1994, J BIOL CHEM, V269, P18638; Taub J, 1999, NATURE, V399, P162, DOI 10.1038/20208; WEINDRUCH R, 1982, SCIENCE, V215, P1415, DOI 10.1126/science.7063854; WEINDRUCH R, 1986, J NUTR, V116, P641, DOI 10.1093/jn/116.4.641; Yin YX, 1999, MOL CARCINOGEN, V24, P15, DOI 10.1002/(SICI)1098-2744(199901)24:1<15::AID-MC3>3.3.CO;2-P; Yin YX, 1998, NATURE, V391, P707, DOI 10.1038/35648	30	1383	1453	2	73	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					309	313		10.1038/46311	http://dx.doi.org/10.1038/46311			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580504				2022-12-28	WOS:000083813700054
J	Schieve, LA; Peterson, HB; Meikle, SF; Jeng, G; Danel, I; Burnett, NM; Wilcox, LS				Schieve, LA; Peterson, HB; Meikle, SF; Jeng, G; Danel, I; Burnett, NM; Wilcox, LS			Live-birth rates and multiple-birth risk using in vitro fertilization	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ELECTIVE TRANSFER; TWIN PREGNANCIES; EMBRYO-TRANSFER; 2 EMBRYOS; NUMBER; QUALITY; WOMEN; AGE	Context To maximize birth rates, physicians who perform in vitro fertilization (IVF) often transfer multiple embryos, but this increases the multiple-birth risk. Live-birth and multiple-birth rates may vary by patient age and embryo quality, One marker for embryo quality is cryopreservation of extra embryos (if embryos are set aside for cryopreservation, higher quality embryos may have been available for transfer). Objective To examine associations between the number of embryos transferred during IVF and live-birth and multiple-birth rates stratified by maternal age and whether extra embryos were available tie, extra embryos cryopreserved). Design and Setting Retrospective cohort of 300 US clinics reporting IVF transfer procedures to the Centers for Disease Control and Prevention in 1996. Subjects A total of 35 554 IVF transfer procedures. Main Outcome Measures Live-birth and multiple-birth rates (percentage of live births that were multiple). Results A total number of 9873 live births were reported (multiple births from 1 pregnancy were counted as 1 live birth). The number of embryos needed to achieve maximum live-birth rates varied by age and whether extra embryos were cryopreserved. Among women 20 to 29 years and 30 to 34 years of age, maximum live-birth rates (43% and 36%, respectively) were achieved when 2 embryos were transferred and extra embryos were cryopreserved. Among women 35 years of age and older, live-birth rates were lower overall and regardless of whether embryos were cryopreserved, live-birth rates increased if more than 2 embryos were transferred, Multiple-birth rates varied by age and the number of embryos transferred, but not by whether embryos were cryopreserved. With 2 embryos transferred, multiple-birth rates were 22.7%, 19.7%, 11.6%,and 10.8% for women aged 20 to 29, 30 to 34, 35 to 39, and 40 to 44 years, respectively. Multiple-birth rates increased as high as 45.7% for women aged 20 to 29 years and 39.8% for women aged 30 to 34 years if 3 embryos were transferred. Among women aged 35 to 39 years, the multiple-birth rate was 29.4% if 3 embryos were transferred. Among women 40 to 44 years of age, the multiple-birth rate was less than 25% even if 5 embryos were transferred. Conclusions Based on these data, the risk of multiple births from IVF varies by maternal age and number of embryos transferred, Embryo quality was not related to multiple birth risk but was associated with increased live-birth rates when fewer embryos were transferred.	Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA 30341 USA	Centers for Disease Control & Prevention - USA	Schieve, LA (corresponding author), Ctr Dis Control & Prevent, Div Reprod Hlth, Natl Ctr Chron Dis Prevent & Hlth Promot, Mailstop K-34,4770 Buford Hwy NE, Atlanta, GA 30341 USA.							American Society for Reproductive Medicine. Practice Committee Opinion, 1998, GUID NUMB EMBR TRANS; Bustillo M, 1997, HUM REPROD, V12, P1616; *CDCP, 1999, 1996 ASS REPR TECHN; DeJonge CJ, 1997, FERTIL STERIL, V68, P784, DOI 10.1016/S0015-0282(97)00355-5; Elsner CW, 1997, AM J OBSTET GYNECOL, V177, P350, DOI 10.1016/S0002-9378(97)70197-2; Gardner DK, 1998, FERTIL STERIL, V69, P84, DOI 10.1016/S0015-0282(97)00438-X; GARDNER MO, 1995, OBSTET GYNECOL, V85, P553, DOI 10.1016/0029-7844(94)00455-M; Guyer B, 1997, PEDIATRICS, V100, P905, DOI 10.1542/peds.100.6.905; Hu YX, 1998, FERTIL STERIL, V69, P650, DOI 10.1016/S0015-0282(98)00024-7; JONES HW, 1995, FERTIL STERIL, V63, P701, DOI 10.1016/S0015-0282(16)57468-8; Kiely JL, 1998, CLIN OBSTET GYNECOL, V41, P3, DOI 10.1097/00003081-199803000-00005; *NY STAT TASK FORC, 1998, ASS REPR TECHN AN RE; Pharoah POD, 1996, ARCH DIS CHILD-FETAL, V75, pF174, DOI 10.1136/fn.75.3.F174; Senoz S, 1997, J ASSIST REPROD GEN, V14, P192, DOI 10.1007/BF02766109; SPELLACY WN, 1990, OBSTET GYNECOL, V75, P168; STAESSEN C, 1993, HUM REPROD, V8, P1650, DOI 10.1093/oxfordjournals.humrep.a137907; STAESSEN C, 1992, FERTIL STERIL, V57, P626; STEPTOE PC, 1978, LANCET, V2, P336; Svendsen TO, 1996, FERTIL STERIL, V65, P561, DOI 10.1016/S0015-0282(16)58154-0; TASDEMIR M, 1995, HUM REPROD, V10, P2155; Templeton A, 1998, NEW ENGL J MED, V339, P573, DOI 10.1056/NEJM199808273390901; WATERSTONE J, 1991, LANCET, V337, P975, DOI 10.1016/0140-6736(91)91605-T; Widra EA, 1996, FERTIL STERIL, V65, P103, DOI 10.1016/S0015-0282(16)58035-2	23	170	181	0	6	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1832	1838		10.1001/jama.282.19.1832	http://dx.doi.org/10.1001/jama.282.19.1832			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573274	Bronze			2022-12-28	WOS:000083615700026
J	Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM				Marszalek, PE; Lu, H; Li, HB; Carrion-Vazquez, M; Oberhauser, AF; Schulten, K; Fernandez, JM			Mechanical unfolding intermediates in titin modules	NATURE			English	Article							IMMUNOGLOBULIN-LIKE MODULES; MOLECULAR-DYNAMICS; CARDIAC MYOCYTES; PROTEIN TITIN; ELASTICITY; DOMAINS; FORCE; EXTENSIBILITY; REGION	The modular protein titin, which is responsible for the passive elasticity of muscle, is subjected to stretching forces. Previous work on the experimental elongation of single titin molecules has suggested that force causes consecutive unfolding of each domain in an all-or-none fashion(1-6). To avoid problems associated with the heterogeneity of the modular, naturally occurring titin, we engineered single proteins to have multiple copies of single immunoglobulin domains of human cardiac titin(7). Here we report the elongation of these molecules using the atomic force microscope. We find an abrupt extension of each domain by similar to 7 Angstrom before the first unfolding event. This fast initial extension before a full unfolding event produces a reversible 'unfolding intermediate'. Steered molecular dynamics(8,9) simulations show that the rupture of a pair of hydrogen bonds near the amino terminus of the protein domain causes an extension of about 6 Angstrom, which is in good agreement with our observations. Disruption of these hydrogen bonds by site-directed mutagenesis eliminates the unfolding intermediate. The unfolding intermediate extends titin domains by similar to 15% of their slack length, and is, therefore a likely to be an important previously unrecognized component of titin elasticity.	Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA; Univ Illinois, Beckman Inst Adv Sci & Technol, Urbana, IL 61801 USA	Mayo Clinic; University of Illinois System; University of Illinois Urbana-Champaign	Fernandez, JM (corresponding author), Mayo Clin & Mayo Fdn, Dept Physiol & Biophys, Rochester, MN 55905 USA.	fernandez-julio@mayo.edu	Lu, Hui/K-3264-2019; Li, Hongbin/G-2949-2012; Schulten, Klaus/D-5561-2009; Carrion-Vazquez, Mariano/Y-3741-2018	Li, Hongbin/0000-0001-7813-1332; Carrion-Vazquez, Mariano/0000-0001-7319-406X; Lu, Hui/0000-0001-8347-0830				BrUnger A. T., 1992, X PLOR VERSION 3 1 S; Carrion-Vazquez M, 1999, P NATL ACAD SCI USA, V96, P3694, DOI 10.1073/pnas.96.7.3694; Erickson HP, 1997, SCIENCE, V276, P1090, DOI 10.1126/science.276.5315.1090; Evans E, 1999, BIOPHYS J, V76, P2439, DOI 10.1016/S0006-3495(99)77399-6; FLORIN EL, 1995, BIOSENS BIOELECTRON, V10, P895, DOI 10.1016/0956-5663(95)99227-C; Gautel M, 1996, FEBS LETT, V385, P11, DOI 10.1016/0014-5793(96)00338-9; Granzier H, 1997, BIOPHYS J, V73, P2043, DOI 10.1016/S0006-3495(97)78234-1; Granzier H, 1996, BIOPHYS J, V70, P430, DOI 10.1016/S0006-3495(96)79586-3; HERMANS J, 1984, BIOPOLYMERS, V23, P1513, DOI 10.1002/bip.360230807; Humphrey W, 1996, J MOL GRAPH MODEL, V14, P33, DOI 10.1016/0263-7855(96)00018-5; Improta S, 1998, J MOL BIOL, V284, P761, DOI 10.1006/jmbi.1998.2028; Kellermayer MSZ, 1997, SCIENCE, V276, P1112, DOI 10.1126/science.276.5315.1112; Kellermayer MSZ, 1998, J STRUCT BIOL, V122, P197, DOI 10.1006/jsbi.1998.3988; LABEIT S, 1995, SCIENCE, V270, P293, DOI 10.1126/science.270.5234.293; Labeit S, 1997, CIRC RES, V80, P290, DOI 10.1161/01.RES.80.2.290; Linke WA, 1998, J CELL SCI, V111, P1567; Lu H, 1998, BIOPHYS J, V75, P662, DOI 10.1016/S0006-3495(98)77556-3; Lu H, 1999, PROTEINS, V35, P453, DOI 10.1002/(SICI)1097-0134(19990601)35:4<453::AID-PROT9>3.3.CO;2-D; Marszalek PE, 1998, NATURE, V396, P661, DOI 10.1038/25322; Nelson MT, 1996, INT J SUPERCOMPUT AP, V10, P251, DOI 10.1177/109434209601000401; Oberhauser AF, 1998, NATURE, V393, P181, DOI 10.1038/30270; Politou AS, 1996, J MOL BIOL, V255, P604, DOI 10.1006/jmbi.1996.0050; Politou AS, 1995, BIOPHYS J, V69, P2601, DOI 10.1016/S0006-3495(95)80131-1; Rief M, 1997, SCIENCE, V276, P1109, DOI 10.1126/science.276.5315.1109; Rief M, 1998, PHYS REV LETT, V81, P4764, DOI 10.1103/PhysRevLett.81.4764; Rief M, 1999, J MOL BIOL, V286, P553, DOI 10.1006/jmbi.1998.2466; SOTERIOU A, 1993, P ROY SOC B-BIOL SCI, V254, P83, DOI 10.1098/rspb.1993.0130; Trombitas K, 1998, J CELL BIOL, V140, P853, DOI 10.1083/jcb.140.4.853; Tskhovrebova L, 1997, NATURE, V387, P308, DOI 10.1038/387308a0	30	666	681	2	126	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					100	103		10.1038/47083	http://dx.doi.org/10.1038/47083			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573426				2022-12-28	WOS:000083638600052
J	Rogers, J				Rogers, J			Sequencing - Gels and genomes	SCIENCE			English	Article									Wellcome Trust, Sanger Ctr, Cambridge CB10 1SA, England	Wellcome Trust Sanger Institute	Rogers, J (corresponding author), Wellcome Trust, Sanger Ctr, Genome Campus, Cambridge CB10 1SA, England.								0	1	1	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					429	429		10.1126/science.286.5439.429	http://dx.doi.org/10.1126/science.286.5439.429			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577205				2022-12-28	WOS:000083121200033
J	Higashi, M; Takimoto, G; Yamamura, N				Higashi, M; Takimoto, G; Yamamura, N			Sympatric speciation by sexual selection	NATURE			English	Article							COSTLY MATE PREFERENCES; EVOLUTION; CHOICE; MODEL; DIVERSIFICATION; REINFORCEMENT; CICHLIDS		Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan	Kyoto University	Higashi, M (corresponding author), Kyoto Univ, Ctr Ecol Res, Kyoto 6068502, Japan.							Albertson RC, 1999, P NATL ACAD SCI USA, V96, P5107, DOI 10.1073/pnas.96.9.5107; BUSH GL, 1994, TRENDS ECOL EVOL, V9, P285, DOI 10.1016/0169-5347(94)90031-0; Deutsch JC, 1997, BIOL J LINN SOC, V62, P1; Dieckmann U, 1999, NATURE, V400, P354, DOI 10.1038/22521; Doebeli M, 1996, J EVOLUTION BIOL, V9, P893, DOI 10.1046/j.1420-9101.1996.9060893.x; Fisher R.A., 1930, GENETICAL THEORY NAT; IWASA Y, 1991, EVOLUTION, V45, P1431, DOI [10.1111/j.1558-5646.1991.tb02646.x, 10.2307/2409890]; Kawecki TJ, 1997, EVOLUTION, V51, P1751, DOI 10.1111/j.1558-5646.1997.tb05099.x; KODRASHOV AS, 1999, NATURE, V400, P351; LANDE R, 1981, P NATL ACAD SCI-BIOL, V78, P3721, DOI 10.1073/pnas.78.6.3721; LIOU LW, 1994, EVOLUTION, V48, P1451, DOI 10.1111/j.1558-5646.1994.tb02187.x; MAYNARD SMITH J., 1966, AMER NATUR, V100, P637; POMIANKOWSKI A, 1991, EVOLUTION, V45, P1422, DOI 10.1111/j.1558-5646.1991.tb02645.x; POMIANKOWSKI A, 1987, J THEOR BIOL, V128, P195, DOI 10.1016/S0022-5193(87)80169-8; Ritchie MG, 1998, ENDLESS FORMS, P291; Seehausen O, 1997, SCIENCE, V277, P1808, DOI 10.1126/science.277.5333.1808; Seehausen O, 1998, BEHAV ECOL SOCIOBIOL, V42, P1, DOI 10.1007/s002650050405; SEGER J, 1985, EVOLUTION, V39, P1185, DOI [10.2307/2408776, 10.1111/j.1558-5646.1985.tb05685.x]; Tauber C.A., 1989, P307; TAUBER CA, 1977, NATURE, V268, P702, DOI 10.1038/268702a0; Turner G.F., 1994, Advances in Limnology, V44, P139; TURNER GF, 1995, P ROY SOC B-BIOL SCI, V260, P287, DOI 10.1098/rspb.1995.0093; WU GI, 1985, EVOLUTION, V39, P66	23	256	264	0	94	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					523	526		10.1038/990087	http://dx.doi.org/10.1038/990087			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591210				2022-12-28	WOS:000084013200054
J	Carbajal, R; Chauvet, X; Couderc, S; Olivier-Martin, M				Carbajal, R; Chauvet, X; Couderc, S; Olivier-Martin, M			Randomised trial of analgesic effects of sucrose, glucose, and pacifiers in term neonates	BRITISH MEDICAL JOURNAL			English	Article							PAIN; INFANTS; CIRCUMCISION; RESPONSES; NEWBORNS	Objectives To assess and compare the analgesic effects of orally administered glucose and sucrose and pacifiers. To determine the synergistic analgesic effect of sucrose and pacifiers. Design Randomised prospective study with validated behavioural acute pain rating scale. Setting Maternity ward. Participants 150 term newborns undergoing venepuncture randomly assigned to one of six treatment groups: no treatment; placebo (2 ml sterile water); 2 ml 30% glucose; 2 ml 30% sucrose; a pacifier; and 2 ml 30% sucrose followed by a pacifier. Results Median (interquartile) pain scores during venepuncture were 7 (5-10) for no treatment; 7 (6-10) for placebo (sterile water); 5 (3-7) for 30% glucose; 5 (2-8) for 30%, sucrose; 2 (1-4) for pacifier; and 1 (1-2) for 30% sucrose plus pacifier. Mann-Whitney U test P values for comparisons of 30% glucose, 30% sucrose, pacifier, and 30% sucrose plus pacifier versus placebo (sterile water) were 0.005, 0.01, < 0.0001, and < 0.0001, respectively. Differences between group median pain scores for these comparisons were 2 (95% confidence interval 1 to 4), 2 (0 to 4), 5 (4 to 7), and 0 (5 to 8), respectively P values for comparisons of 30% glucose, 30% sucrose, and 30% sucrose plus pacifier versus pacifier were 0.0001, 0.001, and 0.06, respectively. Differences between group medians for these comparisons were 3 (2 to 5), 3 (1 to 5), and 1 (0 to 2), respectively. Conclusion nle analgesic effects of concentrated sucrose and glucose and pacifiers are clinically apparent in newborns, pacifiers being more effective than sweet solutions. The association of sucrose and pacifier showed a trend towards lower scores compared with pacifiers alone. These simple and safe interventions should be widely used for minor procedures in neonates.	Poissy Hosp, Dept Paediat, F-78300 Poissy, France; Poissy Hosp, Matern Ward, F-78300 Poissy, France	Hospital Chi of Poissy Saint Germain; Hospital Chi of Poissy Saint Germain	Carbajal, R (corresponding author), Poissy Hosp, Dept Paediat, F-78300 Poissy, France.							Allen KD, 1996, ARCH PEDIAT ADOL MED, V150, P270, DOI 10.1001/archpedi.1996.02170280040007; ANAND KJS, 1989, PEDIATR CLIN N AM, V36, P795; ANAND KJS, 1987, NEW ENGL J MED, V317, P1321, DOI 10.1056/NEJM198711193172105; BLASS EM, 1992, DEV PSYCHOL, V28, P804, DOI 10.1037/0012-1649.28.5.804; BLASS EM, 1988, PHARMACOL BIOCHEM BE, V29, P9, DOI 10.1016/0091-3057(88)90266-3; BLASS EM, 1991, PEDIATRICS, V87, P215; Blass EM, 1997, PEDIATRICS, V99, P825, DOI 10.1542/peds.99.6.825; BUCHER HU, 1995, PEDIATR RES, V38, P332, DOI 10.1203/00006450-199509000-00010; CAMPOS RG, 1994, RES NURS HEALTH, V17, P321, DOI 10.1002/nur.4770170503; Carbajal R, 1997, ARCH PEDIATRIE, V4, P623, DOI 10.1016/S0929-693X(97)83360-X; FIELD T, 1984, PEDIATRICS, V74, P1002; GUNNAR MR, 1984, J AM ACAD CHILD PSY, V23, P34, DOI 10.1097/00004583-198401000-00005; HAOUARI N, 1995, BRIT MED J, V310, P1498, DOI 10.1136/bmj.310.6993.1498; Herschel M, 1998, ARCH PEDIAT ADOL MED, V152, P279; PRECHTL HFR, 1964, CLIN DEV MED, V12; Ramenghi LA, 1996, ARCH DIS CHILD-FETAL, V74, pF129, DOI 10.1136/fn.74.2.F129; Ramenghi LA, 1996, ARCH DIS CHILD-FETAL, V74, pF126, DOI 10.1136/fn.74.2.F126; RUSHFORTH JA, 1993, ARCH DIS CHILD, V69, P388, DOI 10.1136/adc.69.3.388; Skogsdal Y, 1997, ACTA PAEDIATR, V86, P217, DOI 10.1111/j.1651-2227.1997.tb08872.x; Stevens B, 1997, ACTA PAEDIATR, V86, P837, DOI 10.1111/j.1651-2227.1997.tb08607.x; TADDIO A, 1995, LANCET, V345, P291, DOI 10.1016/S0140-6736(95)90278-3; 1992, LANCET, V39, P275	22	194	208	0	8	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1393	1397		10.1136/bmj.319.7222.1393	http://dx.doi.org/10.1136/bmj.319.7222.1393			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574854	Green Published, Bronze			2022-12-28	WOS:000083995200022
J	Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA				Jernstrom, H; Lerman, C; Ghadirian, P; Lynch, HT; Weber, B; Garber, J; Daly, M; Olopade, OI; Foulkes, WD; Warner, E; Brunet, JS; Narod, SA			Pregnancy and risk of early breast cancer in carriers of BRCA1 and BRCA2	LANCET			English	Article							FAMILY HISTORY; MUTATION CARRIERS; AGE; DIFFERENTIATION; PATTERN; PARITY; WOMEN	Background Early age at first full-term pregnancy and increasing parity are associated with a reduced risk of breast cancer. However, whether pregnancy decreases the risk of early-onset hereditary breast cancer is unknown. There is concern that pregnancy may increase breast-cancer risk in carriers of BRCA1 and BRCA2 germline mutations. We aimed to establish whether pregnancy is a risk factor for hereditary breast cancer. Methods We did a matched case-control study of breast cancer in women who carry deleterious BRCA1 or BRCA2 mutations. Cases were carriers who developed breast cancer by age 40 years, and controls were carriers of the same age without breast cancer, or who were diagnosed with breast cancer after age 40 years. Women who had undergone preventive mastectomy, hysterectomy, or oophorectomy, or who were diagnosed with ovarian cancer before the age at which breast cancer was diagnosed in the matched case were excluded. Information about pregnancies and pregnancy outcome was derived from a questionnaire completed by women in the course of genetic counselling. Findings A higher proportion of cases than controls had had a full term pregnancy (173/236 vs 146/236; odds ratio 1.71 [95% CI 1.13-2.62], p=0.01). The mean number of births was also greater for cases than for controls (1.62 vs 1.38, p=0.04). The risk increased with the number of births and did not diminish with time since last pregnancy. There were no significant differences in age at first birth or age at last birth between cases and controls. Interpretation Carriers of the BRCA1 and BRCA2 mutations who have children are significantly more likely to develop breast cancer by age 40 than carriers who are nulliparous. Each pregnancy is associated with an increased cancer risk. An early first pregnancy does not confer protection for carriers of BRCA1 or BRCA2 mutations.	Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, Toronto, ON M5G 1N8, Canada; Georgetown Univ, Med Ctr, Vincent T Lombardi Canc Res Ctr, Washington, DC 20007 USA; Ctr Hosp Univ Montreal, Epidemiol Res Unit, Res Ctr, Montreal, PQ, Canada; Creighton Univ, Sch Med, Dept Prevent Med & Publ Hlth, Omaha, NE USA; Univ Penn, Dept Med, Philadelphia, PA 19104 USA; Univ Penn, Dept Genet, Philadelphia, PA 19104 USA; Dana Farber Canc Inst, Div Canc Epidemiol & Control, Boston, MA 02115 USA; Fox Chase Canc Ctr, Div Basic Sci & Populat Sci, Philadelphia, PA 19111 USA; Univ Chicago, Med Ctr, Canc Risk Clin, Sect Hematol & Oncol, Chicago, IL 60637 USA; McGill Univ, Dept Med, Montreal, PQ, Canada; McGill Univ, Dept Human Genet, Montreal, PQ, Canada; McGill Univ, Dept Oncol, Montreal, PQ, Canada; Toronto Sunnybrook Reg Canc Ctr, Div Med Oncol, Toronto, ON, Canada; Univ Lund Hosp, Dept Oncol, Jubileum Inst, S-22185 Lund, Sweden	University of Toronto; University Toronto Affiliates; Womens College Hospital; Georgetown University; Universite de Montreal; Creighton University; University of Pennsylvania; University of Pennsylvania; Harvard University; Dana-Farber Cancer Institute; Fox Chase Cancer Center; University of Chicago; University of Chicago Medical Center; McGill University; McGill University; McGill University; University of Toronto; Sunnybrook Research Institute; University Toronto Affiliates; Sunnybrook Health Science Center; Lund University; Skane University Hospital	Narod, SA (corresponding author), Univ Toronto, Womens Coll Hosp, Ctr Res Womens Hlth, 790 Bay St,Room 750, Toronto, ON M5G 1N8, Canada.	steven.narod@swchsc.on.ca	Foulkes, William D./AAR-9586-2021; Narod, Steven A/AAA-6112-2022	Foulkes, William D./0000-0001-7427-4651; 	NATIONAL CANCER INSTITUTE [R01CA063678, R01CA057601, R01CA063682] Funding Source: NIH RePORTER; NCI NIH HHS [CA57601, R01 CA63682, CA63678] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Bassler R, 1970, Curr Top Pathol, V53, P1; BERAL V, 1993, LANCET, V341, P1102, DOI 10.1016/0140-6736(93)92469-A; Colditz GA, 1996, J NATL CANCER I, V88, P365, DOI 10.1093/jnci/88.6.365; DICKSON R, 1996, DIS BREAST, P15; DICKSON RB, 1995, ENDOCR REV, V16, P559, DOI 10.1210/er.16.5.559; EASTON DF, 1995, AM J HUM GENET, V56, P265; Egan KM, 1998, CANCER EPIDEM BIOMAR, V7, P359; Fan S, 1999, SCIENCE, V284, P1354, DOI 10.1126/science.284.5418.1354; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Jernstrom H, 1998, BREAST, V7, P320, DOI 10.1016/S0960-9776(98)90074-1; Johannsson O, 1998, LANCET, V352, P1359, DOI 10.1016/S0140-6736(05)60750-7; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; LYNCH HT, 1984, J MED GENET, V21, P96, DOI 10.1136/jmg.21.2.96; MACMAHON B, 1970, B WORLD HEALTH ORGAN, V43, P209; Magnusson C, 1998, CANCER CAUSE CONTROL, V9, P259, DOI 10.1023/A:1008817018942; MARQUIS ST, 1995, NAT GENET, V11, P17, DOI 10.1038/ng0995-17; McCredie M, 1997, INT J CANCER, V73, P503, DOI 10.1002/(SICI)1097-0215(19971114)73:4<503::AID-IJC8>3.0.CO;2-3; McCredie MRE, 1998, CANCER CAUSE CONTROL, V9, P189, DOI 10.1023/A:1008886328352; Narod SA, 1995, INT J CANCER, V64, P394, DOI 10.1002/ijc.2910640608; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; Rajan JV, 1996, P NATL ACAD SCI USA, V93, P13078, DOI 10.1073/pnas.93.23.13078; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P219; RUSSO J, 1992, BREAST CANCER RES TR, V23, P211, DOI 10.1007/BF01833517; RUSSO J, 1994, CANCER EPIDEM BIOMAR, V3, P353; Russo J, 1982, Breast Cancer Res Treat, V2, P5, DOI 10.1007/BF01805718; Russo J, 1997, PROG CLIN BIOL RES, V396, P1; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TONIN P, 1995, J MED GENET, V32, P982, DOI 10.1136/jmg.32.12.982; Xu XL, 1999, NAT GENET, V22, P37, DOI 10.1038/8743	30	151	156	0	10	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1846	1850		10.1016/S0140-6736(99)04336-6	http://dx.doi.org/10.1016/S0140-6736(99)04336-6			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584720	hybrid			2022-12-28	WOS:000083909100009
J	Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW				Bruner, JP; Tulipan, N; Paschall, RL; Boehm, FH; Walsh, WF; Silva, SR; Hernanz-Schulman, M; Lowe, LH; Reed, GW			Fetal surgery for myelomeningocele and the incidence of shunt-dependent hydrocephalus	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							GESTATIONAL-AGE; IN-UTERO; INFANTS; INJURY; REPAIR; MODEL	Context Intrauterine closure of exposed spinal cord tissue prevents secondary neurologic injury in animals with a surgically created spinal defect; however, whether in utero repair of myelomeningocele improves neurologic outcome in infants with spina bifida is not known. Objective To determine whether intrauterine repair of myelomeningocele improves patient outcomes compared with standard care. Design Single-institution, nonrandomized observational study conducted between January 1990 and February 1999. Setting Tertiary care medical center. Participants A sample of 29 study patients with isolated fetal myelomeningocele referred for intrauterine repair that was performed between 24 and 30 gestational weeks and 23 controls matched to cases for diagnosis, level of lesion, practice parameters, and calendar time. All infants were followed up for a minimum of 6 months after delivery. Main Outcome Measures Requirement for ventriculoperitoneal shunt placement, obstetrical complications, gestational age at delivery, and birth weight for study vs control subjects. Results The requirement for ventriculoperitoneal shunt placement for decompression of hydrocephalus was significantly decreased among study infants (59% vs 91%, P =.01). The median age at shunt placement was also older among study infants (50 vs 5 days; P =.006). This may be explained by the reduced incidence of hindbrain herniation among study infants (38% vs 95%; P<.001), Following hysterotomy, study patients had an increased risk of oligohydramnios (48% vs 4%; P =.001) and admission to the hospital for preterm uterine contractions (50% vs 9%; P =.002). The estimated gestational age at delivery was earlier for study patients (33.2 vs 37.0 weeks; P<.001), and the birth weight of study neonates was less (2171 vs 3075 g; P<.001). Conclusions Our study suggests that intrauterine repair of myelomeningocele decreases the incidence of hindbrain herniation and shunt-dependent hydrocephalus in infants with spina bifida, but increases the incidence of premature delivery.	Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Pediat Neurosurg, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Obstet Anesthesia, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Neonatol, Nashville, TN 37232 USA; Vanderbilt Univ, Med Ctr, Dept Radiol, Nashville, TN 37232 USA; New England Res Inst, Watertown, MA 02172 USA	Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; Vanderbilt University; HealthCore, Inc	Bruner, JP (corresponding author), Vanderbilt Univ, Med Ctr, Dept Obstet & Gynecol, B-1100 Med Ctr N, Nashville, TN 37232 USA.							BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; BABSON SG, 1976, J PEDIATR-US, V89, P814, DOI 10.1016/S0022-3476(76)80815-3; BEALER JF, 1995, J PEDIATR SURG, V30, P1150, DOI 10.1016/0022-3468(95)90009-8; BRUNER JP, IN PRESS AM J OBSTET; CANTOR AB, 1992, STAT MED, V11, P931, DOI 10.1002/sim.4780110710; FLETCHER JC, 1991, UNBORN PATIENT, P12; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HEFFEZ DS, 1993, NEUROSURGERY, V32, P1005, DOI 10.1227/00006123-199306000-00021; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; MEULI M, 1995, J PEDIATR SURG, V30, P1028, DOI 10.1016/0022-3468(95)90335-6; MICHEJDA M, 1984, Z KINDERCHIR, V39, P259; Ranzini AC, 1999, OBSTET GYNECOL, V93, P826, DOI 10.1016/S0029-7844(98)00423-2; Rekate H L, 1985, Clin Neurosurg, V32, P593; RUTHERFORD SE, 1987, J REPROD MED, V32, P587; SCHLIEVERT P, 1977, SEMIN PERINATOL, V1, P59; SCHROEDER SA, 1992, CHEST, V101, P1065, DOI 10.1378/chest.101.4.1065; SPOSTO R, 1992, BIOMETRICS, V48, P87, DOI 10.2307/2532741; STEINBOK P, 1992, CHILD NERV SYST, V8, P92, DOI 10.1007/BF00298448; Storrs BB, 1988, CONCEPTS PEDIAT NEUR, V8, P51; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WERNER EE, 1966, CHILD DEV, V37, P39, DOI 10.1111/j.1467-8624.1966.tb05367.x	22	296	300	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1819	1825		10.1001/jama.282.19.1819	http://dx.doi.org/10.1001/jama.282.19.1819			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573272	Bronze			2022-12-28	WOS:000083615700024
J	Beck, LH; Kumar, SP				Beck, LH; Kumar, SP			Update in preventive medicine	ANNALS OF INTERNAL MEDICINE			English	Article							CHOLESTEROL; WOMEN		Cleveland Clin, Dept Internal Med, Ft Lauderdale, FL USA; Georgetown Univ, Med Ctr, Dept Med, Washington, DC 20007 USA	Cleveland Clinic Foundation; Georgetown University	Beck, LH (corresponding author), Cleveland Clin, Dept Internal Med, 2900 W Cypress Creek Rd, Ft Lauderdale, FL USA.							Delmas PD, 1997, NEW ENGL J MED, V337, P1641, DOI 10.1056/NEJM199712043372301; Lewis SJ, 1998, J AM COLL CARDIOL, V32, P140, DOI 10.1016/S0735-1097(98)00202-2	2	3	3	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					681	687		10.7326/0003-4819-131-9-199911020-00009	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577331				2022-12-28	WOS:000083446200007
J	Jee, SH; Suh, I; Kim, IS; Appel, LJ				Jee, SH; Suh, I; Kim, IS; Appel, LJ			Smoking and atherosclerotic cardiovascular disease in men with low levels of serum cholesterol - The Korea Medical Insurance Corporation Study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CIGARETTE-SMOKING; RISK-FACTORS; JAPANESE MEN; MORTALITY; STROKE; FRAMINGHAM; HAWAII; DEATH	Context Few studies have examined the interactive effects of smoking and serum cholesterol level on morbidity and mortality from cardiovascular dieseases. In East Asia, where the prevalence of smoking is among the highest in the world, morbidity and mortality from ischemic heart disease (IHD) is rapidly escalating. Objectives To determine whether cigarette smoking is an independent risk factor for atherosclerotic cardiovascular disease (ASCVD) in the Republic of Korea (South Korea), a population that has relatively low levels of serum cholesterol, and to determine whether serum cholesterol levels modify the risk relationship between smoking and ASCVD, Design Prospective cohort study with a follow-up period of 6 years (1993-1998). Setting and Subjects A total of 106745 Korean men aged 35 to 59 years who received health insurance from the Korea Medical Insurance Corporation and who had biennial medical evaluations in 1990 and 1992. Main Outcome Measures Hospital admissions and deaths from IHD, cerebrovascular disease (CVD), and total ASCVD. Results At baseline, 61 389 (58%) were current cigarette smokers and 64 482 (60%) had a total cholesterol level of less than 5.17 mmol/L (200 mg/dL). Between 1993 and 1998, 1006 IHD events (176 per 100 000 person-years), 1364 CVD events (238 per 100 000 person-years), and 716 other ASCVD events (125 per 100 000 person-years) occurred. In multivariate Cox proportional hazard models controlling for age, hypertension, hypercholesterolemia, and diabetes, current smoking increased the risk of IHD (risk ratio [RR], 2.2; 95% confidence interval [CI], 1.8-2.8), CVD (RR, 1.6, 95% CI, 1.4-1.8), and total ASCVD (RR, 1.6, 95% CI, 1.5-1.8). For each outcome, there were significant dose-response relationships with amount and duration of smoking. Throughout the range of serum cholesterol levels, current smoking significantly increased the risk of IHD and CVD. In the lowest quartile of serum cholesterol levels (<4.42 mmol/L [171 mg/dL]), the RR from current smoking was 3.3 (95% CI, 1.7-6.2) for IHD and 1.6 (95% CI, 1.2-2.3) for CVD. There was no evidence of an interaction between smoking and serum cholesterol (P for interaction = .75, .87, and .92 for IHD, CVD, and total ASCVD, respectively). Conclusions This study demonstrates that in Korea smoking is a major independent risk factor for IHD, CVD, and ASCVD and that a low cholesterol level confers no protective benefit against smoking-related ASCVD.	Yonsei Univ, Grad Sch Hlth Sci & Management, Dept Epidemiol & Dis Control, Seoul, South Korea; Yonsei Univ, Coll Med, Dept Prevent Med & Publ Hlth, Seoul, South Korea; Johns Hopkins Med Inst, Welch Ctr Prevent Epidemiol & Clin Res, Baltimore, MD 21205 USA	Yonsei University; Yonsei University; Yonsei University Health System; Johns Hopkins University; Johns Hopkins Medicine	Appel, LJ (corresponding author), Johns Hopkins Univ, Welch Ctr Prevent Epidemiol & Clin Res, 2024 E Monument St,Suite 2-600, Baltimore, MD 21205 USA.		Appel, Larry/GLT-2608-2022	Jee, Sun Ha/0000-0001-9519-3068; Suh, Il/0000-0002-9689-7849				ABBOTT RD, 1986, NEW ENGL J MED, V315, P717, DOI 10.1056/NEJM198609183151201; BRESLOW NE, 1980, IARC SCI PUBL, V32, P146; DOLL R, 1976, BRIT MED J, V2, P1525, DOI 10.1136/bmj.2.6051.1525; *GALL KOR, 1994, KOR GALL REP 1994; Gavin JR, 1997, DIABETES CARE, V20, P1183; GOLDBERG RJ, 1992, PREVENTION CORONARY, P3; GORDON T, 1974, J CHRON DIS, V27, P329, DOI 10.1016/0021-9681(74)90013-7; Jee SH, 1998, ANN EPIDEMIOL, V8, P14, DOI 10.1016/S1047-2797(97)00131-2; Kannel W.B., 1984, J CARDIAC REHABIL, V4, P267; Kawane H, 1998, THORAX, V53, P328, DOI 10.1136/thx.53.4.328a; KIYOHARA Y, 1990, J HYPERTENS, V8, pS9; LEVIN M L, 1953, Acta Unio Int Contra Cancrum, V9, P531; Morgenstern H, 1982, EPIDEMIOLOGIC RES PR, P403; *NAT CHOL ED PROGR, 1994, NIH PUBL; *NAT STAT OFF, 1996, ANN REP CAUS DEATH S; NEATON JD, 1992, ARCH INTERN MED, V152, P56, DOI 10.1001/archinte.152.1.56; *NIH, 1997, NIH PUBL; OKUMIYA N, 1985, AM J CARDIOL, V56, P62, DOI 10.1016/0002-9149(85)90567-3; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROBERTSON TL, 1977, AM J CARDIOL, V39, P244, DOI 10.1016/S0002-9149(77)80198-7; STAMLER J, 1986, JAMA-J AM MED ASSOC, V256, P2823, DOI 10.1001/jama.256.20.2823; SUH I, 1996, J HYPERTENS S1, V14, pS234; WIHELMSEN L, 1977, BRIT MED J, V39, P1179; WILLETT WC, 1987, NEW ENGL J MED, V317, P1303, DOI 10.1056/NEJM198711193172102; WOLF PA, 1988, JAMA-J AM MED ASSOC, V259, P1025, DOI 10.1001/jama.259.7.1025; YANO K, 1988, AM J EPIDEMIOL, V127, P476, DOI 10.1093/oxfordjournals.aje.a114824; Yuan JM, 1996, JAMA-J AM MED ASSOC, V275, P1646, DOI 10.1001/jama.275.21.1646	27	155	158	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2149	2155		10.1001/jama.282.22.2149	http://dx.doi.org/10.1001/jama.282.22.2149			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591337	Bronze, Green Published			2022-12-28	WOS:000083971400034
J	Van Dam, J; Brugge, WR				Van Dam, J; Brugge, WR			Medical progress: Endoscopy of the upper gastrointestinal tract.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							EXPANDABLE METAL STENTS; EARLY GASTRIC-CANCER; CISPLATIN/EPINEPHRINE-INJECTABLE GEL; MALIGNANT ESOPHAGEAL OBSTRUCTION; DIGESTIVE-RESPIRATORY FISTULAS; OPEN-ACCESS ENDOSCOPY; HIGH-GRADE DYSPLASIA; BARRETTS-ESOPHAGUS; PHOTODYNAMIC THERAPY; BOTULINUM TOXIN		Brigham & Womens Hosp, Dept Med, Div Gastroenterol, Boston, MA 02115 USA; Massachusetts Gen Hosp, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Van Dam, J (corresponding author), Brigham & Womens Hosp, Dept Med, Div Gastroenterol, 75 Francis St, Boston, MA 02115 USA.							Adachi Y, 1997, AM J GASTROENTEROL, V92, P872; Akahoshi K, 1997, ENDOSCOPY, V29, P614, DOI 10.1055/s-2007-1004266; Akahoshi K, 1998, GASTROINTEST ENDOSC, V48, P470, DOI 10.1016/S0016-5107(98)70087-2; *AM JOINT COMM CAN, 1997, AJCC CANC STAG MAN; *AM SOC GASTR END, 1998, GASTROINTEST ENDOSC, V48, P669; *AM SOC GASTR END, 1998, GASTROINTEST ENDOSC, V48, P697; Barr H, 1996, LANCET, V348, P584, DOI 10.1016/S0140-6736(96)03054-1; Berenson MM, 1998, AM J GASTROENTEROL, V93, P1794, DOI 10.1111/j.1572-0241.1998.01794.x; Bethge N, 1998, AM J GASTROENTEROL, V93, P643; Bethge N, 1998, AM J GASTROENTEROL, V93, P1829; Bhargava DK, 1997, AM J GASTROENTEROL, V92, P950; BLOT WJ, 1991, JAMA-J AM MED ASSOC, V265, P1287, DOI 10.1001/jama.265.10.1287; Boyce, 1999, Cancer Control, V6, P28; Brugge WR, 1997, GASTROINTEST ENDOSC, V45, P147, DOI 10.1016/S0016-5107(97)70238-4; Brugge WR, 1998, GASTROENTEROLOGY, V115, P1577, DOI 10.1016/S0016-5085(98)70039-3; Burris HA, 1998, OTOLARYNG HEAD NECK, V118, P496, DOI 10.1016/S0194-5998(98)70208-6; BURT M, 1991, ANN THORAC SURG, V52, P1222, DOI 10.1016/0003-4975(91)90005-B; Buscarini E, 1999, GASTROINTEST ENDOSC, V49, P184, DOI 10.1016/S0016-5107(99)70484-0; Byrne JP, 1998, AM J GASTROENTEROL, V93, P1810; CATALANO MF, 1995, GASTROINTEST ENDOSC, V42, P540, DOI 10.1016/S0016-5107(95)70007-2; CHAK A, 1995, GASTROINTEST ENDOSC, V42, P501, DOI 10.1016/S0016-5107(95)70001-3; Chak A, 1998, GASTROINTEST ENDOSC, V47, P144, DOI 10.1016/S0016-5107(98)70347-5; Chau TN, 1998, GASTROENTEROLOGY, V114, P981, DOI 10.1016/S0016-5085(98)00640-4; CHONG J, 1994, AM J GASTROENTEROL, V89, P2143; Cooper GS, 1999, GASTROINTEST ENDOSC, V49, P145, DOI 10.1016/S0016-5107(99)70478-5; Craig A, 1999, GASTROINTEST ENDOSC, V49, P292, DOI 10.1016/S0016-5107(99)70003-9; Cuilliere C, 1997, GUT, V41, P87, DOI 10.1136/gut.41.1.87; Dumonceau JM, 1999, GASTROINTEST ENDOSC, V49, P70, DOI 10.1016/S0016-5107(99)70448-7; Dumortier J, 1999, GASTROINTEST ENDOSC, V49, P285, DOI 10.1016/S0016-5107(99)70002-7; Dumoulin FL, 1997, ENDOSCOPY, V29, P751, DOI 10.1055/s-2007-1004302; Ell C, 1998, ENDOSCOPY, V30, P408, DOI 10.1055/s-2007-1001290; Faigel DO, 1998, AM J GASTROENTEROL, V93, P2257; Falk GW, 1998, ENDOSCOPY, V30, P61, DOI 10.1055/s-2007-1001232; Froehlich F, 1997, GASTROINTEST ENDOSC, V45, P13, DOI 10.1016/S0016-5107(97)70330-4; Froehlich F, 1997, GASTROENTEROLOGY, V112, P690, DOI 10.1053/gast.1997.v112.pm9041229; FUCHS CS, 1995, NEW ENGL J MED, V333, P32, DOI 10.1056/NEJM199507063330107; GELLER AJ, 1995, GASTROINTEST ENDOSC, V41, pS321; Gevers AM, 1998, GASTROINTEST ENDOSC, V48, P383, DOI 10.1016/S0016-5107(98)70007-0; GINMOELLER KF, 1998, ENDOSCOPY, V30, P105; Gopal DV, 1999, GASTROINTEST ENDOSC, V49, P379, DOI 10.1016/S0016-5107(99)70017-9; Gordon JM, 1997, AM J GASTROENTEROL, V92, P1812; Gossner L, 1998, GASTROENTEROLOGY, V114, P448, DOI 10.1016/S0016-5085(98)70527-X; Gossner L, 1999, GASTROINTEST ENDOSC, V49, P8, DOI 10.1016/S0016-5107(99)70438-4; Gostout CJ, 1998, GASTROINTEST ENDOSC, V47, P311; Gralnek IM, 1998, AM J GASTROENTEROL, V93, P2047; Hirota WK, 1999, GASTROENTEROLOGY, V116, P277, DOI 10.1016/S0016-5085(99)70123-X; Hosokawa O, 1998, ENDOSCOPY, V30, P669, DOI 10.1055/s-2007-1001386; Hsu PI, 1996, GASTROINTEST ENDOSC, V44, P382, DOI 10.1016/S0016-5107(96)70085-8; Inai M, 1996, GASTROINTEST ENDOSC, V44, P714, DOI 10.1016/S0016-5107(96)70057-3; Jensen DM, 1999, NEW ENGL J MED, V340, P799, DOI 10.1056/NEJM199903113401010; Katz D, 1998, AM J GASTROENTEROL, V93, P536; KNYRIM K, 1993, NEW ENGL J MED, V329, P1302, DOI 10.1056/NEJM199310283291803; Kolve M, 1999, GASTROINTEST ENDOSC, V49, P307, DOI 10.1016/S0016-5107(99)70006-4; KRASNA MJ, 1993, ANN THORAC SURG, V56, P671, DOI 10.1016/0003-4975(93)90948-H; Lagergren J, 1999, NEW ENGL J MED, V340, P825, DOI 10.1056/NEJM199903183401101; Laine L, 1996, GASTROENTEROLOGY, V110, P529, DOI 10.1053/gast.1996.v110.pm8566601; LAINE L, 1995, ANN INTERN MED, V123, P280, DOI 10.7326/0003-4819-123-4-199508150-00007; Landis SH, 1998, CA-CANCER J CLIN, V48, P192; Lau C, 1998, AM J GASTROENTEROL, V93, P2559, DOI 10.1016/S0002-9270(98)00600-5; Lau JYW, 1999, NEW ENGL J MED, V340, P751, DOI 10.1056/NEJM199903113401002; Levy M, 1997, GASTROINTEST ENDOSC, V46, P328, DOI 10.1016/S0016-5107(97)70120-2; Lightdale CJ, 1999, AM J GASTROENTEROL, V94, P20; Lightdale CJ, 1999, GASTROINTEST ENDOSC, V49, P122, DOI 10.1016/S0016-5107(99)70461-X; LIGHTDALE CJ, 1995, GASTROINTEST ENDOSC, V42, P507, DOI 10.1016/S0016-5107(95)70002-1; Longstreth GF, 1998, GASTROINTEST ENDOSC, V47, P219, DOI 10.1016/S0016-5107(98)70316-5; Lorimier G, 1998, ENDOSCOPY, V30, P800, DOI 10.1055/s-2007-1001425; Malesci A, 1996, GASTROINTEST ENDOSC, V44, P700, DOI 10.1016/S0016-5107(96)70055-X; Massari M, 1996, HEPATO-GASTROENTEROL, V43, P542; Monga SPS, 1998, GASTROINTEST ENDOSC, V48, P415, DOI 10.1016/S0016-5107(98)70014-8; Morales TG, 1999, ARCH INTERN MED, V159, P1411, DOI 10.1001/archinte.159.13.1411; MORSON BC, 1990, MORSON DAWSONS GASTR, P170; MOTOO Y, 1994, ENDOSCOPY, V26, P239, DOI 10.1055/s-2007-1008951; Mulcahy HE, 1998, GASTROINTEST ENDOSC, V48, P618, DOI 10.1016/S0016-5107(98)70045-8; Nandurkar S, 1999, AM J GASTROENTEROL, V94, P30; Nandurkar S, 1999, AM J GASTROENTEROL, V94, P1719; Nelson DB, 1997, GASTROINTEST ENDOSC, V45, P31, DOI 10.1016/S0016-5107(97)70325-0; Nelson DB, 1998, GASTROINTEST ENDOSC, V48, P563, DOI 10.1016/S0016-5107(98)70036-7; NELSON DB, 1994, GASTROINTEST ENDOSC, V40, P497, DOI 10.1016/S0016-5107(94)70221-7; Nevitt AW, 1998, GASTROINTEST ENDOSC, V47, P271, DOI 10.1016/S0016-5107(98)70326-8; *NEW TNM CLASS GAS, 1998, ENDOSCOPY, V30, P643; Nobre-Leitao C, 1998, AM J GASTROENTEROL, V93, P732, DOI 10.1111/j.1572-0241.1998.215_a.x; Ohta S, 1996, AM J GASTROENTEROL, V91, P701; Ouatu-Lascar R, 1998, AM J GASTROENTEROL, V93, P711; Overholt BF, 1999, GASTROINTEST ENDOSC, V49, P1, DOI 10.1016/S0016-5107(99)70437-2; PASRICHA PJ, 1994, ANN INTERN MED, V121, P590, DOI 10.7326/0003-4819-121-8-199410150-00006; Pasricha PJ, 1996, GASTROENTEROLOGY, V110, P1410, DOI 10.1053/gast.1996.v110.pm8613045; PASRICHA PJ, 1995, NEW ENGL J MED, V332, P774, DOI 10.1056/NEJM199503233321203; PASRICHA PJ, 1995, NEW ENGL J MED, V333, P75; POSTLETHWAIT RW, 1983, SURG CLIN N AM, V63, P925; Quirk DM, 1997, GASTROENTEROLOGY, V113, P1443, DOI 10.1053/gast.1997.v113.pm9352845; Raijman I, 1997, AM J GASTROENTEROL, V92, P2188; Raijman I, 1998, GASTROINTEST ENDOSC, V48, P172, DOI 10.1016/S0016-5107(98)70159-2; Raijman I, 1998, AM J GASTROENTEROL, V93, P496, DOI 10.1111/j.1572-0241.1998.496_b.x; Rice T W, 1997, Oncology (Williston Park), V11, P58; Roberts LR, 1996, MAYO CLIN PROC, V71, P973; Sackmann M, 1997, GASTROENTEROLOGY, V113, P1087, DOI 10.1053/gast.1997.v113.pm9322502; Salo JA, 1998, ANN SURG, V227, P40, DOI 10.1097/00000658-199801000-00006; Sampliner RE, 1998, AM J GASTROENTEROL, V93, P1028; Sampliner RE, 1996, GASTROINTEST ENDOSC, V44, P532, DOI 10.1016/S0016-5107(96)70004-4; Sarin SK, 1999, NEW ENGL J MED, V340, P988, DOI 10.1056/NEJM199904013401302; Segalin A, 1997, ENDOSCOPY, V29, P701, DOI 10.1055/s-2007-1004293; Sharma P, 1998, AM J GASTROENTEROL, V93, P332, DOI 10.1016/S0002-9270(97)00100-7; Sharma P, 1997, AM J GASTROENTEROL, V92, P582; SIBILLE A, 1995, GASTROENTEROLOGY, V108, P337, DOI 10.1016/0016-5085(95)90058-6; Siersema PD, 1998, GASTROINTEST ENDOSC, V47, P113, DOI 10.1016/S0016-5107(98)70342-6; Sivak MV, 1999, GASTROINTEST ENDOSC, V49, P395, DOI 10.1016/S0016-5107(99)70023-4; SLEISENGER MH, 1989, GASTROINTESTINAL DIS, V1, P766; Soetikno RM, 1998, GASTROINTEST ENDOSC, V47, P267, DOI 10.1016/S0016-5107(98)70325-6; Sperber AD, 1997, AM J GASTROENTEROL, V92, P1823; Suzuki Y, 1999, GASTROINTEST ENDOSC, V49, P192, DOI 10.1016/S0016-5107(99)70485-2; Vaezi MF, 1999, GUT, V44, P231, DOI 10.1136/gut.44.2.231; Vakil N, 1997, AM J GASTROENTEROL, V92, P425; VANDAM J, 1994, ENDOSCOPY, V26, P772, DOI 10.1055/s-2007-1009102; VanDam J, 1997, CHEST, V112, pS184, DOI 10.1378/chest.112.4_Supplement.184S; VANSTIEGMANN G, 1988, GASTROINTEST ENDOSC, V34, P113, DOI 10.1016/S0016-5107(88)71274-2; Wayman J, 1998, GASTROINTEST ENDOSC, V47, P286, DOI 10.1016/S0016-5107(98)70328-1; Wengrower D, 1998, GASTROINTEST ENDOSC, V48, P376, DOI 10.1016/S0016-5107(98)70006-9; WONG RCK, 1998, PRACT GASTROENTEROL, V22, P13; Wong RH, 1998, ENDOSCOPY, V30, P774, DOI 10.1055/s-2007-1001420; Yanai H, 1997, GASTROINTEST ENDOSC, V46, P212, DOI 10.1016/S0016-5107(97)70088-9; Yates MR, 1998, ENDOSCOPY, V30, P266, DOI 10.1055/s-2007-1001253; Yoshida S, 1996, AM J GASTROENTEROL, V91, P839; Zaman A, 1998, AM J GASTROENTEROL, V93, P1260; Zaman A, 1999, GASTROINTEST ENDOSC, V49, P279, DOI 10.1016/S0016-5107(99)70001-5	124	46	46	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1738	1748		10.1056/NEJM199912023412306	http://dx.doi.org/10.1056/NEJM199912023412306			11	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580074				2022-12-28	WOS:000083955800006
J	Aragane, K; Akao, N; Matsuyama, T; Sugita, M; Natsuaki, M; Kitada, O				Aragane, K; Akao, N; Matsuyama, T; Sugita, M; Natsuaki, M; Kitada, O			Fever, cough, and nodules on ankles	LANCET			English	Article									Hyogo Coll Med, Dept Internal Med 5, Nishinomiya, Hyogo 6638501, Japan; Tokyo Med & Dent Univ, Fac Med, Dept Med Zool, Tokyo 113, Japan; Hyogo Coll Med, Dept Dermatol, Nishinomiya, Hyogo 6638501, Japan	Hyogo College of Medicine; Tokyo Medical & Dental University (TMDU); Hyogo College of Medicine	Aragane, K (corresponding author), Hyogo Coll Med, Dept Internal Med 5, 1-1 Mukogawa Cho, Nishinomiya, Hyogo 6638501, Japan.							BEAVER PC, 1952, PEDIATRICS, V9, P7; EMMANUELLE W, 1995, LANCET, V345, P196; ISHIBASHI H, 1992, J CLIN ULTRASOUND, V20, P204, DOI 10.1002/jcu.1870200309; OSHIMA T, 1990, RINSHO I, V16, P318; WILDER H C, 1950, Trans Am Acad Ophthalmol Otolaryngol, V55, P99	5	17	18	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1872	1872		10.1016/S0140-6736(99)09189-8	http://dx.doi.org/10.1016/S0140-6736(99)09189-8			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584725				2022-12-28	WOS:000083909100014
J	Kilian, JG; Kerr, K; Lawrence, C; Celermajer, DS				Kilian, JG; Kerr, K; Lawrence, C; Celermajer, DS			Myocarditis and cardiomyopathy associated with clozapine	LANCET			English	Article							MANAGEMENT; MORTALITY; CLOZARIL; THERAPY; DEATH	Background Clozapine is effective for resistant schizophrenia. After two sudden deaths in physically well young men soon after starting clozapine, we investigated the cardiovascular complications for this drug. Methods From January, 1993, to March, 1999, 8000 patients started clozapine treatment in Australia, and were registered with a mandatory monitoring service. We identified cases of myocarditis and cardiomyopathy from voluntary reports to the Australian Adverse Drug Reaction Committee and sought details of the relevant diagnostic studies, necropsies that had been done in suspicious cases, or both. Findings 23 cases (20 men, three women, mean age 36 years [SD 9]) were identified: 15 of myocarditis and eight of cardiomyopathy associated with clozapine treatment. Six patients died. All cases of myocarditis(five deaths) occurred within 3 weeks of starting clozapine. Cardiomyopathy (one death) was diagnosed up to 36 months after clozapine was started. Necropsy results showed mainly eosinophilic infiltrates with myocytolysis, consistent with an acute drug reaction. Interpretation Clozapine therapy may be associated with potentially fatal myocarditis and cardiomyopathy in physically healthy young adults with schizophrenia.	Royal Prince Alfred Hosp, Dept Cardiol, Camperdown, NSW 2050, Australia; Royal Prince Alfred Hosp, Dept Psychiat, Camperdown, NSW 2050, Australia; Univ Sydney, Dept Med, Sydney, NSW 2006, Australia; Inst Forens Sci, Glebe, NSW, Australia	University of Sydney; University of Sydney; University of Sydney	Celermajer, DS (corresponding author), Royal Prince Alfred Hosp, Dept Cardiol, Camperdown, NSW 2050, Australia.							ALVIR JMJ, 1993, NEW ENGL J MED, V329, P162, DOI 10.1056/NEJM199307153290303; Bandelow B, 1995, SCHIZOPHR RES, V17, P293, DOI 10.1016/0920-9964(95)00047-X; BANDELOW B, 1998, INT J PSYCHIAT CLIN, V2, P49; Brown S, 1997, BRIT J PSYCHIAT, V171, P502, DOI 10.1192/bjp.171.6.502; Conley RR, 1998, J CLIN PSYCHIAT, V59, P44; DOSSING M, 1993, DRUG SAFETY, V9, P441, DOI 10.2165/00002018-199309060-00007; Elias TJ, 1999, LANCET, V354, P1180, DOI 10.1016/S0140-6736(99)01508-1; Fauci AS, 2015, HARRISONS PRINCIPLES; FENOGLIO JJ, 1981, HUM PATHOL, V12, P900, DOI 10.1016/S0046-8177(81)80195-5; FERRIS JAJ, 1979, FORENSIC SCI INT, V13, P261, DOI 10.1016/0379-0738(79)90293-7; Friman G, 1995, EUR HEART J, V16, P36, DOI 10.1093/eurheartj/16.suppl_O.36; HOITSMA AJ, 1991, DRUG SAFETY, V6, P131, DOI 10.2165/00002018-199106020-00004; Honigfeld G, 1998, J CLIN PSYCHIAT, V59, P3; Jensen V E, 1994, Ugeskr Laeger, V156, P4151; Karjalainen J, 1999, EUR HEART J, V20, P1120, DOI 10.1053/euhj.1998.1444; Khalil N, 1997, PSYCHIAT PRAX, V24, P46; Leo RJ, 1996, ANN PHARMACOTHER, V30, P603, DOI 10.1177/106002809603000606; LILLENG P, 1995, TIDSSKR NOR LAEGEFOR, V115, P293; MEEKER JE, 1992, J ANAL TOXICOL, V16, P54, DOI 10.1093/jat/16.1.54; MULLICK FG, 1977, JAMA-J AM MED ASSOC, V237, P1699, DOI 10.1001/jama.237.16.1699; MURRAY D, 1992, AUSTR GRAIN, V2, P1; Owens DGC, 1996, DRUGS, V51, P895; PHILLIPS M, 1986, JAMA-J AM MED ASSOC, V256, P2696, DOI 10.1001/jama.256.19.2696; PLAFKER J, 1971, SOUTHERN MED J, V64, P852, DOI 10.1097/00007611-197107000-00015; SHEN WK, 1995, AM J CARDIOL, V76, P148, DOI 10.1016/S0002-9149(99)80047-2; Walker AM, 1997, EPIDEMIOLOGY, V8, P671, DOI 10.1097/00001648-199710000-00010; WINTROUB BU, 1998, HARRISONS PRINCIPLES; Young CR, 1998, SCHIZOPHRENIA BULL, V24, P381, DOI 10.1093/oxfordjournals.schbul.a033333	28	343	355	1	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1841	1845		10.1016/S0140-6736(99)10385-4	http://dx.doi.org/10.1016/S0140-6736(99)10385-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584719				2022-12-28	WOS:000083909100008
J	Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A				Bouillet, P; Metcalf, D; Huang, DCS; Tarlinton, DM; Kay, TWH; Kontgen, F; Adams, JM; Strasser, A			Proapoptotic Bcl-2 relative bim required for certain apoptotic responses, leukocyte homeostasis, and to preclude autoimmunity	SCIENCE			English	Article							CELL-DEATH; PROTEIN; FAMILY; MICE; ACTIVATION; THYMOCYTES; CASPASE-9; SURVIVAL; PATHWAYS; DELETION	Apoptosis can be triggered by members of the Bcl-2 protein family, such as Bim, that share only the BH3 domain with this family. Gene targeting in mice revealed important physiological lores for sim. Lymphoid and myeloid cells accumulated, T cell development was perturbed, and most older mice accumulated plasma cells and succumbed to autoimmune kidney disease. Lymphocytes were refractory to apoptotic stimuli such as cytokine deprivation, calcium ion flux, and microtubule perturbation but not to others. Thus, Bim is required for hematopoietic homeostasis and as a barrier to autoimmunity. Moreover, particular death stimuli appear to activate apoptosis through distinct BH3-only proteins.	Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia	Walter & Eliza Hall Institute	Adams, JM (corresponding author), Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.		Strasser, Andreas/C-7581-2013; Adams, Jerry M/E-1199-2013; Bouillet, Philippe/E-1241-2013; Huang, David C. S./C-7586-2013	Strasser, Andreas/0000-0002-5020-4891; Bouillet, Philippe/0000-0002-9012-6058; Huang, David C. S./0000-0002-3101-4873; Adams, Jerry/0000-0002-4360-8628; Tarlinton, David/0000-0001-9928-686X	NCI NIH HHS [CA80188, CA43540] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA080188, R01CA043540] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		Adams JM, 1998, SCIENCE, V281, P1322, DOI 10.1126/science.281.5381.1322; Conradt B, 1998, CELL, V93, P519, DOI 10.1016/S0092-8674(00)81182-4; Downward J, 1999, NAT CELL BIOL, V1, pE33, DOI 10.1038/10026; Gross A, 1999, GENE DEV, V13, P1899, DOI 10.1101/gad.13.15.1899; GUILLEMOT F, 1994, NATURE, V371, P333, DOI 10.1038/371333a0; Hakem R, 1998, CELL, V94, P339, DOI 10.1016/S0092-8674(00)81477-4; JACKS T, 1994, CURR BIOL, V4, P1, DOI 10.1016/S0960-9822(00)00002-6; Knudson CM, 1997, NAT GENET, V16, P358, DOI 10.1038/ng0897-358; Kuida K, 1998, CELL, V94, P325, DOI 10.1016/S0092-8674(00)81476-2; Kuida K, 1996, NATURE, V384, P368, DOI 10.1038/384368a0; Li HL, 1998, CELL, V94, P491, DOI 10.1016/S0092-8674(00)81590-1; Luo X, 1998, CELL, V94, P481, DOI 10.1016/S0092-8674(00)81589-5; Newton K, 1998, EMBO J, V17, P706, DOI 10.1093/emboj/17.3.706; O'Connor L, 1998, EMBO J, V17, P384, DOI 10.1093/emboj/17.2.384; O'Reilly LA, 1998, BIOTECHNIQUES, V25, P824, DOI 10.2144/98255st03; Puthalakath H, 1999, MOL CELL, V3, P287, DOI 10.1016/S1097-2765(00)80456-6; Reed JC, 1997, NATURE, V387, P773, DOI 10.1038/42867; Salvesen GS, 1997, CELL, V91, P443, DOI 10.1016/S0092-8674(00)80430-4; Schwenk F, 1995, NUCLEIC ACIDS RES, V23, P5080, DOI 10.1093/nar/23.24.5080; SENTMAN CL, 1991, CELL, V67, P879, DOI 10.1016/0092-8674(91)90361-2; STRASSER A, 1991, P NATL ACAD SCI USA, V88, P8661, DOI 10.1073/pnas.88.19.8661; STRASSER A, 1991, CELL, V67, P889, DOI 10.1016/0092-8674(91)90362-3; Strasser A, 1995, EMBO J, V14, P6136, DOI 10.1002/j.1460-2075.1995.tb00304.x; STRASSER A, 1997, BIOCHIM BIOPHYS ACTA, V1333, pR151; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; Woo M, 1998, GENE DEV, V12, P806, DOI 10.1101/gad.12.6.806; Yin XM, 1999, NATURE, V400, P886, DOI 10.1038/23730; Zha JP, 1996, CELL, V87, P619, DOI 10.1016/S0092-8674(00)81382-3	30	1230	1274	0	87	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1735	1738		10.1126/science.286.5445.1735	http://dx.doi.org/10.1126/science.286.5445.1735			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576740				2022-12-28	WOS:000083912200038
J	Zimmermann, S; Moelling, K				Zimmermann, S; Moelling, K			Phosphorylation and regulation of Raf by Akt (protein kinase B)	SCIENCE			English	Article							TRANSLOCATION; ACTIVATION; C-RAF-1	Activation of the protein kinase Raf can lead to opposing cellular responses such as proliferation, growth arrest, apoptosis, br differentiation. Akt (protein kinase B), a member of a different signaling pathway that also regulates these responses, interacted with Raf and phosphorylated this protein at a highly conserved serine residue in its regulatory domain in vivo. This phosphorylation of Raf by Akt inhibited activation of the Raf-MEK-ERK signaling pathway and shifted the cellular response in a human breast cancer cell line from cell cycle arrest to proliferation. These observations provide a molecular basis for cross talk between two signaling pathways at the level of Raf and Akt.	Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	University of Zurich	Moelling, K (corresponding author), Univ Zurich, Inst Med Virol, Gloriastr 30-32, CH-8028 Zurich, Switzerland.							ALBAS J, 1998, ONCOGENE, V16, P131; Alessi DR, 1996, FEBS LETT, V399, P333, DOI 10.1016/S0014-5793(96)01370-1; Andjelkovic M, 1997, J BIOL CHEM, V272, P31515, DOI 10.1074/jbc.272.50.31515; BEIMLING P, 1994, BIOCHEM BIOPH RES CO, V204, P841, DOI 10.1006/bbrc.1994.2536; Brunet A, 1999, CELL, V96, P857, DOI 10.1016/S0092-8674(00)80595-4; Datta SR, 1997, CELL, V91, P231, DOI 10.1016/S0092-8674(00)80405-5; Dufourny B, 1997, J BIOL CHEM, V272, P31163, DOI 10.1074/jbc.272.49.31163; GOSH S, 1996, J BIOL CHEM, V271, P8472; Hu E., 1996, SCIENCE, V274, P100; Jiang BH, 1999, P NATL ACAD SCI USA, V96, P2077, DOI 10.1073/pnas.96.5.2077; Khwaja A, 1999, NATURE, V401, P33, DOI 10.1038/43354; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; KOLCH W, 1993, NATURE, V364, P249, DOI 10.1038/364249a0; Kops GJPL, 1999, NATURE, V398, P630, DOI 10.1038/19328; MARAIS R, 1995, EMBO J, V14, P3136, DOI 10.1002/j.1460-2075.1995.tb07316.x; Meier R, 1999, J RECEPT SIGNAL TR R, V19, P121, DOI 10.3109/10799899909036639; MICHAUD NR, 1995, MOL CELL BIOL, V15, P3390; MOELLING K, 1984, NATURE, V312, P558, DOI 10.1038/312558a0; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1996, ONCOGENE, V12, P609; Rommel C, 1999, SCIENCE, V286, P1738, DOI 10.1126/science.286.5445.1738; Zimmermann S, 1997, ONCOGENE, V15, P1503, DOI 10.1038/sj.onc.1201322; ZIMMERMANN S, UNPUB	24	885	916	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1741	1744		10.1126/science.286.5445.1741	http://dx.doi.org/10.1126/science.286.5445.1741			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576742				2022-12-28	WOS:000083912200040
J	Lee, MM; Schiefelbein, J				Lee, MM; Schiefelbein, J			WEREWOLF, a MYB-related protein in arabidopsis, is a position-dependent regulator of epidermal cell patterning	CELL			English	Article							ROOT HAIR DEVELOPMENT; GENE ENCODES; THALIANA; DIFFERENTIATION; PLANTS; SEQUENCE; GLABRA2; FAMILY; LEAVES; FATE	The formation of the root epidermis of Arabidopsis provides a simple and elegant model for the analysis of cell patterning. A novel gene, WEREWOLF(WER), is described here that is required for position-dependent patterning of the epidermal cell types. The WER gene encodes a MYB-type protein and is preferentially expressed within cells destined to adopt the non-hair fate. Furthermore, WER is shown to regulate the position-dependent expression of the GLABRA2 homeobox gene, to interact with a bHLH protein, and to act in opposition to the CAPRICE MYB. These results suggest a simple model to explain the specification of the two root epidermal cell types, and they provide insight into the molecular mechanisms used to control cell patterning.	Univ Michigan, Dept Biol, Ann Arbor, MI 48109 USA	University of Michigan System; University of Michigan	Schiefelbein, J (corresponding author), Univ Michigan, Dept Biol, Nat Sci Bldg, Ann Arbor, MI 48109 USA.							BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Berger F, 1998, DEV BIOL, V194, P235, DOI 10.1006/dbio.1997.8813; Berger F, 1998, CURR BIOL, V8, P421, DOI 10.1016/S0960-9822(98)70176-9; Berger F, 1998, DEV BIOL, V194, P226, DOI 10.1006/dbio.1997.8836; BIEDENKAPP H, 1988, NATURE, V335, P835, DOI 10.1038/335835a0; BUNNING E, 1951, PLANTA, V39, P126; Cormack RGH., 1935, NEW PHYTOL, V34, P30, DOI 10.1111/j.1469-8137.1935.tb06826.x; CUTTER EG, 1978, EPIDERMIS PLANT ANAT, P94; Di Cristina M, 1996, PLANT J, V10, P393, DOI 10.1046/j.1365-313X.1996.10030393.x; DOLAN L, 1994, DEVELOPMENT, V120, P2465; Esau K, 1965, PLANT ANATOMY, V2, P429; ESTELLE MA, 1987, MOL GEN GENET, V206, P200, DOI 10.1007/BF00333575; FIELDS S, 1994, TRENDS GENET, V10, P286, DOI 10.1016/0168-9525(90)90012-U; GALWAY ME, 1994, DEV BIOL, V166, P740, DOI 10.1006/dbio.1994.1352; GROTEWOLD E, 1994, CELL, V76, P543, DOI 10.1016/0092-8674(94)90117-1; HABERLANDT G, 1887, BERICHTE DTSCH BOT G, V5, P205; Haseloff J, 1997, P NATL ACAD SCI USA, V94, P2122, DOI 10.1073/pnas.94.6.2122; Hung CY, 1998, PLANT PHYSIOL, V117, P73, DOI 10.1104/pp.117.1.73; Koornneef M., 1981, ARABID INF SERV, V18, P45; Kranz HD, 1998, PLANT J, V16, P263, DOI 10.1046/j.1365-313x.1998.00278.x; LARKIN JC, 1993, PLANT CELL, V5, P1739, DOI 10.1105/tpc.5.12.1739; Larkin JC, 1997, PLANT CELL, V9, P1109, DOI 10.1105/tpc.9.7.1109; Leavitt RG, 1904, P BOSTON SOC NATURAL, V31, P273; LUDWIG SR, 1989, P NATL ACAD SCI USA, V86, P7092, DOI 10.1073/pnas.86.18.7092; MAJELLO B, 1986, P NATL ACAD SCI USA, V83, P9636, DOI 10.1073/pnas.83.24.9636; Martin C, 1997, TRENDS GENET, V13, P67, DOI 10.1016/S0168-9525(96)10049-4; Masucci JD, 1996, DEVELOPMENT, V122, P1253; Mol J, 1998, TRENDS PLANT SCI, V3, P212, DOI 10.1016/S1360-1385(98)01242-4; OPPENHEIMER DG, 1991, CELL, V67, P483, DOI 10.1016/0092-8674(91)90523-2; RERIE WG, 1994, GENE DEV, V8, P1388, DOI 10.1101/gad.8.12.1388; RESTREPO MA, 1990, PLANT CELL, V2, P987, DOI 10.1105/tpc.2.10.987; Romero I, 1998, PLANT J, V14, P273, DOI 10.1046/j.1365-313X.1998.00113.x; SCHERES B, 1994, DEVELOPMENT, V120, P2475; SCHIEFELBEIN JW, 1990, PLANT CELL, V2, P235, DOI 10.1105/tpc.2.3.235; Sinnott EW, 1939, P NATL ACAD SCI USA, V25, P248, DOI 10.1073/pnas.25.5.248; Szymanski DB, 1998, DEVELOPMENT, V125, P1161; THOMPSON MA, 1995, BIOESSAYS, V17, P341, DOI 10.1002/bies.950170410; Wada T, 1997, SCIENCE, V277, P1113, DOI 10.1126/science.277.5329.1113; Walker AR, 1999, PLANT CELL, V11, P1337, DOI 10.1105/tpc.11.7.1337; Wang HY, 1997, GENE DEV, V11, P799, DOI 10.1101/gad.11.6.799	40	418	463	0	58	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					473	483		10.1016/S0092-8674(00)81536-6	http://dx.doi.org/10.1016/S0092-8674(00)81536-6			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589676	Bronze			2022-12-28	WOS:000083986300007
J	Sun, FL; Elgin, SCR				Sun, FL; Elgin, SCR			Putting boundaries on silence	CELL			English	Review							BITHORAX COMPLEX; DOMAINS		Washington Univ, Dept Biol, St Louis, MO 63130 USA	Washington University (WUSTL)	Sun, FL (corresponding author), Washington Univ, Dept Biol, Campus Box 1137, St Louis, MO 63130 USA.			Elgin, Sarah C. R./0000-0002-5176-2510				Bell AC, 1999, CURR OPIN GENET DEV, V9, P191, DOI 10.1016/S0959-437X(99)80029-X; Bell AC, 1999, CELL, V98, P387, DOI 10.1016/S0092-8674(00)81967-4; Bi X, 1999, GENE DEV, V13, P1089, DOI 10.1101/gad.13.9.1089; Donze D, 1999, GENE DEV, V13, P698, DOI 10.1101/gad.13.6.698; Dorsett D, 1999, CURR OPIN GENET DEV, V9, P505, DOI 10.1016/S0959-437X(99)00002-7; Elgin SCR, 1996, CURR OPIN GENET DEV, V6, P193, DOI 10.1016/S0959-437X(96)80050-5; Fourel G, 1999, EMBO J, V18, P2522, DOI 10.1093/emboj/18.9.2522; Geyer PK, 1997, CURR OPIN GENET DEV, V7, P242, DOI 10.1016/S0959-437X(97)80134-7; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; Kellum R, 1998, CURR BIOL, V8, pR521, DOI 10.1016/S0960-9822(07)00337-5; KELLUM R, 1991, CELL, V64, P941, DOI 10.1016/0092-8674(91)90318-S; LOO S, 1994, SCIENCE, V264, P1768, DOI 10.1126/science.8209257; Mihaly J, 1997, DEVELOPMENT, V124, P1809; Mihaly J, 1998, CELL MOL LIFE SCI, V54, P60, DOI 10.1007/s000180050125; Pikaart MI, 1998, GENE DEV, V12, P2852, DOI 10.1101/gad.12.18.2852; Prioleau MN, 1999, EMBO J, V18, P4035, DOI 10.1093/emboj/18.14.4035; Pryde FE, 1999, EMBO J, V18, P2538, DOI 10.1093/emboj/18.9.2538; ROSEMAN RR, 1993, EMBO J, V12, P435, DOI 10.1002/j.1460-2075.1993.tb05675.x	18	125	129	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					459	462		10.1016/S0092-8674(00)81534-2	http://dx.doi.org/10.1016/S0092-8674(00)81534-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589674	Bronze			2022-12-28	WOS:000083986300005
J	Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM				Bewley, MC; Springer, K; Zhang, YB; Freimuth, P; Flanagan, JM			Structural analysis of the mechanism of adenovirus binding to its human cellular receptor, CAR	SCIENCE			English	Article							GP120 ENVELOPE GLYCOPROTEIN; TYPE-5 FIBER PROTEIN; CRYSTAL-STRUCTURE; DOMAIN; HIV; RESOLUTION; CD4	Binding of virus particles to specific host cell surface receptors is known to be an obligatory step in infection even though the molecular basis for these interactions is not well characterized. The crystal structure of the adenovirus fiber knob domain in complex with domain I of its human cellular receptor, coxsackie and adenovirus receptor (CAR), is presented here. Surface-exposed Loops on knob contact one face of CAR, forming a high-affinity complex. Topology mismatches between interacting surfaces create interfacial solvent-filled cavities and channels that may be targets for antiviral drug therapy. The structure identifies key determinants of binding specificity, which may suggest ways to modify the tropism of adenovirus-based gene therapy vectors.	Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA	United States Department of Energy (DOE); Brookhaven National Laboratory	Flanagan, JM (corresponding author), Brookhaven Natl Lab, Dept Biol, Upton, NY 11973 USA.			bewley, maria/0000-0001-7097-0123	NATIONAL CENTER FOR RESEARCH RESOURCES [P41RR012408] Funding Source: NIH RePORTER; NCRR NIH HHS [1P41 RR12408-01A1] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		Bella J, 1998, P NATL ACAD SCI USA, V95, P4140, DOI 10.1073/pnas.95.8.4140; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; *CCP4, 1991, 4 DARS LAB SRC UK CO; FENDER P, 1995, VIROLOGY, V214, P110, DOI 10.1006/viro.1995.9949; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Ikemizu S, 1999, P NATL ACAD SCI USA, V96, P4289, DOI 10.1073/pnas.96.8.4289; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LEE B, 1971, J MOL BIOL, V55, P379, DOI 10.1016/0022-2836(71)90324-X; MUCKELBAUER JK, 1995, STRUCTURE, V3, P653, DOI 10.1016/S0969-2126(01)00201-5; Nabel GJ, 1999, P NATL ACAD SCI USA, V96, P324, DOI 10.1073/pnas.96.2.324; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROSSMANN MG, 1989, J BIOL CHEM, V264, P14587; RYU SE, 1994, STRUCTURE, V2, P59, DOI 10.1016/S0969-2126(00)00008-3; Shapiro L, 1996, NEURON, V17, P435, DOI 10.1016/S0896-6273(00)80176-2; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	23	349	360	2	21	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1579	1583		10.1126/science.286.5444.1579	http://dx.doi.org/10.1126/science.286.5444.1579			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567268	Green Submitted			2022-12-28	WOS:000083768300064
J	Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW				Carbone, C; Mace, GM; Roberts, SC; Macdonald, DW			Energetic constraints on the diet of terrestrial carnivores	NATURE			English	Article							CONSUMPTION	Species in the mammalian order Carnivora exhibit a huge diversity of life histories with body sizes spanning more than three orders of magnitude. Despite this diversity, most terrestrial carnivores can be classified as either feeding on invertebrates and small vertebrates or on large vertebrates. Small carnivores feed predominantly on invertebrates probably because they are a superabundant: resource (sometimes 90% of animal biomass(1-3)); however, intake rates of invertebrate feeders are low, about one tenth of those of vertebrate feeders(4,5). Although small carnivores can subsist on this diet because of low absolute energy requirements, invertebrate feeding appears to be unsustainable for larger carnivores. Here we show, by reviewing the most common live prey in carnivore diets, that there is a striking transition from feeding on small prey (less than half of predator mass) to large prey (near predator mass), occurring at predator masses of 21.5-25kg. We test the hypothesis that this dichotomy is the consequence of mass-related energetic requirements and we determine the predicted maximum mass that an invertebrate diet can sustain. Using a simple energetic model and known invertebrate intake rates, we predict a maximum sustainable mass of 21.5 kg, which matches the point where predators shift from small to large prey.	Zool Soc London, Inst Zool, London NW1 4RY, England; Univ Oxford, Dept Zool, Wildlife Conservat Res Unit, Oxford OX1 3PS, England	Zoological Society of London; University of Oxford	Carbone, C (corresponding author), Zool Soc London, Inst Zool, Regents Pk, London NW1 4RY, England.		Roberts, Craig/E-6919-2011; Mace, Georgina M/I-3072-2016	Roberts, Craig/0000-0002-9641-6101; Mace, Georgina M/0000-0001-8965-5211				BININDAEDMONDS ORP, 1994, BIOL REV, V74, P143; BININDAEMONDS ORP, 1998, THESIS U OXFORD; Estes RD., 1991, BEHAV GUIDE AFRICAN, P1; Gittleman J.L., 1989, P183; GITTLEMAN JL, 1995, OECOLOGIA, V67, P50; Gorman ML, 1998, NATURE, V391, P479, DOI 10.1038/35131; GRIFFITHS D, 1980, AM NAT, V116, P743, DOI 10.1086/283666; Joshi AR, 1997, J MAMMAL, V78, P584, DOI 10.2307/1382910; KAVANAU JL, 1975, AM NAT, V109, P391, DOI 10.1086/283009; Kingdon J, 1997, KINGDON FIELD GUIDE, P1; Kruuk H., 1989, SOCIAL BADGER; LAMPRECHT J, 1978, Z SAUGETIERKD, V43, P210; MACDONALD D. W., 1995, ENCY MAMMALS; MACDONALD DW, 1980, Z TIERPSYCHOL, V52, P171; MALCOLM JR, 1986, J ZOOL LOND, V208, P743; MAY RM, 1988, SCIENCE, V241, P1441, DOI 10.1126/science.241.4872.1441; Nowak RM, 1991, WALKERS MAMMALS WORL; PURVIS A, 1995, COMPUT APPL BIOSCI, V11, P247; PURVIS A, IN PRESS CARNIVORE C; RICHARDSON PRK, 1987, Z SAUGETIERKD, V52, P307; ROOD J P, 1975, East African Wildlife Journal, V13, P89; Schaller G., 1972, SERENGETI LION STUDY, P1; SCHMIDTNIELSEN, 1984, SCALING WHY ANIMAL S, P1; Skinner J. D., 1990, MAMMALS SO AFRICAN S; TAYLOR CR, 1982, J EXP BIOL, V97, P1; WASER PM, 1980, AFR J ECOL, V18, P167, DOI 10.1111/j.1365-2028.1980.tb00640.x; Williams JB, 1997, ECOLOGY, V78, P2588; Wilson E.O., 1987, Conservation Biology, V1, P344, DOI 10.1111/j.1523-1739.1987.tb00055.x; Wilson E.O, 1990, SUCCESS DOMINANCE EC	29	411	427	3	133	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					286	288		10.1038/46266	http://dx.doi.org/10.1038/46266			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580498				2022-12-28	WOS:000083813700047
J	Landi, F; Gambassi, G; Cocchi, A; Bernabei, R				Landi, F; Gambassi, G; Cocchi, A; Bernabei, R			Therapy for stroke patients living at home	LANCET			English	Letter							OCCUPATIONAL-THERAPY; TRIAL; CARE		Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Inst Med Interna & Geriatr, I-00168 Rome, Italy	Catholic University of the Sacred Heart; IRCCS Policlinico Gemelli	Landi, F (corresponding author), Univ Cattolica Sacro Cuore, Ctr Med Invecchiamento, Inst Med Interna & Geriatr, I-00168 Rome, Italy.		Bernabei, Roberto/AAB-2704-2019	Bernabei, Roberto/0000-0002-9197-004X				Bernabei R, 1998, BMJ-BRIT MED J, V316, P1348, DOI 10.1136/bmj.316.7141.1348; Clark F, 1997, JAMA-J AM MED ASSOC, V278, P1321, DOI 10.1001/jama.278.16.1321; Landi F, 1997, AM J PHYS MED REHAB, V76, P38, DOI 10.1097/00002060-199701000-00007; LANDI F, 1996, EUR J PHYS MED REHAB, V6, P1; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	5	1	1	1	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1731	1731		10.1016/S0140-6736(05)76719-2	http://dx.doi.org/10.1016/S0140-6736(05)76719-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568600				2022-12-28	WOS:000083652800057
J	Webster, G; Beynon, H				Webster, G; Beynon, H			Weak at the knees	LANCET			English	Article							INCLUSION-BODY MYOSITIS		Royal Free Hosp, London NW3 2PF, England	University of London; University College London; Royal Free London NHS Foundation Trust; UCL Medical School	Beynon, H (corresponding author), Royal Free Hosp, Pond St, London NW3 2PF, England.							Amato AA, 1996, ANN NEUROL, V40, P581, DOI 10.1002/ana.410400407; Barohn RJ, 1997, NEUROLOGY, V48, P567, DOI 10.1212/WNL.48.3.567; Carpenter S, 1996, J NEUROPATH EXP NEUR, V55, P1105, DOI 10.1097/00005072-199611000-00001; Sivakumar K, 1997, CURR OPIN NEUROL, V10, P413, DOI 10.1097/00019052-199710000-00010	4	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1696	1696		10.1016/S0140-6736(99)08318-X	http://dx.doi.org/10.1016/S0140-6736(99)08318-X			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568573				2022-12-28	WOS:000083652800014
J	van Hoof, A; Parker, R				van Hoof, A; Parker, R			The exosome: A proteasome for RNA?	CELL			English	Review							SACCHAROMYCES-CEREVISIAE; MITOTIC CONTROL; RIBOSOMAL-RNA; PROTEIN; COMPLEX		Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA; Univ Arizona, Howard Hughes Med Inst, Tucson, AZ 85721 USA	University of Arizona; Howard Hughes Medical Institute; University of Arizona	van Hoof, A (corresponding author), Univ Arizona, Dept Mol & Cellular Biol, Tucson, AZ 85721 USA.			van Hoof, Ambro/0000-0002-7800-9764				Allmang C, 1999, GENE DEV, V13, P2148, DOI 10.1101/gad.13.16.2148; Allmang C, 1999, EMBO J, V18, P5399, DOI 10.1093/emboj/18.19.5399; Anderson JSJ, 1998, EMBO J, V17, P1497, DOI 10.1093/emboj/17.5.1497; Baumeister W, 1998, CELL, V92, P367, DOI 10.1016/S0092-8674(00)80929-0; Briggs MW, 1998, J BIOL CHEM, V273, P13255, DOI 10.1074/jbc.273.21.13255; BURKARD KTD, 2000, IN PRESS MOL CELL BI; Carpousis AJ, 1999, TRENDS GENET, V15, P24, DOI 10.1016/S0168-9525(98)01627-8; de la Cruz J, 1999, TRENDS BIOCHEM SCI, V24, P192, DOI 10.1016/S0968-0004(99)01376-6; de la Cruz J, 1998, EMBO J, V17, P1128, DOI 10.1093/emboj/17.4.1128; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; KADOWAKI T, 1994, J CELL BIOL, V126, P649, DOI 10.1083/jcb.126.3.649; KINOSHITA N, 1991, MOL CELL BIOL, V11, P5839, DOI 10.1128/MCB.11.12.5839; MATSUMOTO Y, 1990, P NATL ACAD SCI USA, V87, P7628, DOI 10.1073/pnas.87.19.7628; Mian IS, 1997, NUCLEIC ACIDS RES, V25, P3187, DOI 10.1093/nar/25.16.3187; Mitchell P, 1997, CELL, V91, P457, DOI 10.1016/S0092-8674(00)80432-8; Noguchi E, 1996, EMBO J, V15, P5595, DOI 10.1002/j.1460-2075.1996.tb00944.x; QU X, 1998, J BIOCHEM-TOKYO, V123, P883; VANHOOF A, 2000, IN PRESS MOL CELL BI; Zanchin NIT, 1999, NUCLEIC ACIDS RES, V27, P1283, DOI 10.1093/nar/27.5.1283	20	181	183	0	32	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					347	350		10.1016/S0092-8674(00)81520-2	http://dx.doi.org/10.1016/S0092-8674(00)81520-2			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571176	Bronze			2022-12-28	WOS:000083709300001
J	Spitzer, RL; Kroenke, K; Williams, JBW				Spitzer, RL; Kroenke, K; Williams, JBW		Patient Hlth Questionnaire Primary	Validation and utility of a self-report version of PRIME-MD - The PHQ primary care study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CASE-FINDING INSTRUMENTS; MENTAL-DISORDERS; PSYCHIATRIC-DISORDERS; DIAGNOSTIC INSTRUMENT; COMPETING DEMANDS; DEPRESSION; INTERVENTION; INTERVIEW	Context The Primary Care Evaluation of Mental Disorders (PRIME-MD) was developed as a screening instrument but its administration time has limited its clinical usefulness. Objective To determine if the self-administered PRIME-MD Patient Health Questionnaire (PHQ) has validity and utility for diagnosing mental disorders in primary care comparable to the original clinician-administered PRIME-MD. Design Criterion standard study undertaken between May 1997 and November 1998. Setting Eight primary care clinics in the United States. Participants Of a total of 3000 adult patients (selected by site-specific methods to avoid sampling bias) assessed by 62 primary care physicians (21 general internal medicine, 41 family practice), 585 patients had an interview with a mental health professional within 48 hours of completing the PHQ. Main Outcome Measures Patient Health Questionnaire diagnoses compared with independent diagnoses made by mental health professionals; functional status measures; disability days; health care use; and treatment/referral decisions. Results A total of 825 (28%) of the 3000 individuals and 170 (29%) of the 585 had a PHQ diagnosis. There was good agreement between PHQ diagnoses and those of independent mental health professionals (for the diagnosis of any 1 or more PHQ disorder, kappa = 0.65; overall accuracy, 85%; sensitivity, 75%; specificity, 90%), similar to the original PRIME-MD. Patients with PHQ diagnoses had more functional impairment, disability days, and health care use than did patients without PHQ diagnoses (for all group main effects, P<.001), The average time required of the physician to review the PHQ was far less than to administer the original PRIME-MD (<3 minutes for 85% vs 16% of the cases). Although 80% of the physicians reported that routine use of the PHQ would be useful, new management actions were initiated or planned for only 117 (32%) of the 363 patients with 1 or more PHQ diagnoses not previously recognized. Conclusion Our study suggests that the PHQ has diagnostic validity comparable to the original clinician-administered PRIME-MD, and is more efficient to use.	New York State Psychiat Inst, Biometr Res Dept, Unit 60, New York, NY 10032 USA; Columbia Univ, Dept Psychiat, New York, NY USA; Indiana Univ, Regenstrief Inst Hlth Care, Indianapolis, IN 46202 USA; Indiana Univ, Dept Psychiat, Indianapolis, IN 46202 USA	New York State Psychiatry Institute; Columbia University; Indiana University System; Indiana University-Purdue University Indianapolis; Regenstrief Institute Inc; Indiana University System; Indiana University-Purdue University Indianapolis	Spitzer, RL (corresponding author), New York State Psychiat Inst, Biometr Res Dept, Unit 60, 1051 Riverside Dr, New York, NY 10032 USA.			Kroenke, Kurt/0000-0002-0114-4669				American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DSM 4 DIAGN STAT MAN, V4th ed., DOI DOI 10.1001/JAMA.1994.03520100096; Beck AT, 1997, BEHAV RES THER, V35, P785, DOI 10.1016/S0005-7967(97)00025-9; Bensenor IM, 1998, ARQ NEURO-PSIQUIAT, V56, P406, DOI 10.1590/S0004-282X1998000300009; *DEPR GUID PAN, 1993, CLIN PRACT GUID, V5; GOLDMAN L, 1998, HDB PSYCHIAT PRIMARY; GRECO PJ, 1993, NEW ENGL J MED, V329, P1271, DOI 10.1056/NEJM199310213291714; Hahn SR, 1999, USE PSYCHOL TESTING; Higgins E S, 1994, Arch Fam Med, V3, P908, DOI 10.1001/archfami.3.10.908; Jackson JL, 1999, MIL MED, V164, P112, DOI 10.1093/milmed/164.2.112; KATON W, 1994, PSYCHOSOMATICS, V35, P268, DOI 10.1016/S0033-3182(94)71775-8; Katon W, 1996, ARCH GEN PSYCHIAT, V53, P924; KATON W, 1995, JAMA-J AM MED ASSOC, V273, P1026, DOI 10.1001/jama.273.13.1026; Klinkman MS, 1997, GEN HOSP PSYCHIAT, V19, P98, DOI 10.1016/S0163-8343(96)00145-4; Kobak KA, 1997, JAMA-J AM MED ASSOC, V278, P905, DOI 10.1001/jama.278.11.905; Kroenke K, 1997, AM J MED, V103, P339, DOI 10.1016/S0002-9343(97)00241-6; Kroenke K, 1997, ANN INTERN MED, V126, P463, DOI 10.7326/0003-4819-126-6-199703150-00008; KROENKE K, IN PRESS PSYCHOSOMAT; Leopold KA, 1998, INT J RADIAT ONCOL, V42, P1105, DOI 10.1016/S0360-3016(98)00346-0; Miranda J, 1998, AM J OBSTET GYNECOL, V178, P212, DOI 10.1016/S0002-9378(98)80002-1; MIRANDA J, 1994, MENTAL DISORDERS PRI; MULROW CD, 1995, ANN INTERN MED, V122, P913, DOI 10.7326/0003-4819-122-12-199506150-00004; Nease D E Jr, 1999, J Am Board Fam Pract, V12, P21; O'Malley PG, 1998, J PSYCHOSOM RES, V44, P279, DOI 10.1016/S0022-3999(97)00250-X; O'Malley PG, 1998, ARCH INTERN MED, V158, P2357, DOI 10.1001/archinte.158.21.2357; ORMEL J, 1994, JAMA-J AM MED ASSOC, V272, P1741, DOI 10.1001/jama.272.22.1741; Parker T, 1997, INT J PSYCHIAT MED, V27, P107, DOI 10.2190/C6FD-7QWB-KNGR-M844; Philbrick JT, 1996, J GEN INTERN MED, V11, P9, DOI 10.1007/BF02603478; SCHATZ RT, 1992, POLIT PSYCHOL, V13, P1, DOI 10.2307/3791421; Schmidt V M, 1998, Ugeskr Laeger, V160, P5370; Schwartz DA, 1997, JAMA-J AM MED ASSOC, V277, P238, DOI 10.1001/jama.277.3.238; SPITZER RL, 1992, ARCH GEN PSYCHIAT, V49, P624; SPITZER RL, 1994, JAMA-J AM MED ASSOC, V272, P1749, DOI 10.1001/jama.272.22.1749; STEWART AL, 1988, MED CARE, V26, P724, DOI 10.1097/00005650-198807000-00007; USTUN TB, 1995, MENTAL ILLNESS GEN H; Valenstein M, 1997, J GEN INTERN MED, V12, P679, DOI 10.1046/j.1525-1497.1997.07141.x; Valenstein M, 1998, J AM GERIATR SOC, V46, P1499, DOI 10.1111/j.1532-5415.1998.tb01533.x; Whooley MA, 1997, J GEN INTERN MED, V12, P439, DOI 10.1046/j.1525-1497.1997.00076.x; Williams JW, 1998, J GEN INTERN MED, V13, P137, DOI 10.1046/j.1525-1497.1998.00032.x	39	6308	6413	23	229	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1737	1744		10.1001/jama.282.18.1737	http://dx.doi.org/10.1001/jama.282.18.1737			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	251XJ	10568646	Bronze			2022-12-28	WOS:000083471400028
J	Cooper, KG; Bain, C; Parkin, DE				Cooper, KG; Bain, C; Parkin, DE			Comparison of microwave endometrial ablation and transcervical resection of the endometrium for treatment of heavy menstrual loss a randomised trial	LANCET			English	Article							HEALTH SURVEY QUESTIONNAIRE; QUALITY-OF-LIFE; LASER-ABLATION; OUTCOME MEASURE; MENORRHAGIA; HYSTERECTOMY; SF-36; IMPROVEMENT; MULTICENTER; MANAGEMENT	Background Various new endometrial ablation techniques have emerged for the treatment of menorrhagia. We undertook a randomised controlled trial comparing one new technique, microwave endometrial ablation (MEA), with a proven procedure, transcervical resection of the endometrium (TCRE), for women with heavy menstrual loss. Methods 263 eligible and consenting women, referred for endometrial ablative surgery, were randomly assigned MEA (Microsulis plc, Waterlooville, Hampshire, UK; n=129) or TCRE (n=134). 230 participants were needed to give 80% power of demonstrating a 15% difference in satisfaction with treatment All procedures were done under general anaesthesia 5 weeks after endometrial thinning with goserelin 3.6 mg. Questionnaires were completed at recruitment and at 12 months' follow-up. The primary outcome measures were patients' satisfaction with and the acceptability of treatment. Analysis was by intention to treat among women followed up to 12 months (n=116 MEA, n=124 TCRE). Findings At 12 months, 89 (77%) women in the MEA group and 93 (75%) in the TCRE group were totally or generally satisfied with their treatment (95% CI for difference -12 to 17) and 109 (94%) versus 112 (90%) found it acceptable (-11 to 35), Mean operating limes were shorter for MEA than for TCRE (11.4 vs 15.0 min, p=0.001) and the postoperative stay slightly but not significantly shorter. One blunt perforation occurred in each study group resulting in one immediate hysterectomy (TCRE group). Of eight health-related quality of life dimensions, ail were improved after MEA (six significantly) and seven were improved after TCRE (all significantly). Interpretation Both techniques achieved high rates of satisfaction and acceptability and both improved quality of life after 1 year. However, we cannot exclude a difference in satisfaction between the groups of less than 15%. MEA seems a suitable alternative to TCRE.	Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB9 2ZB, Scotland	University of Aberdeen	Cooper, KG (corresponding author), Aberdeen Royal Infirm, Dept Obstet & Gynaecol, Aberdeen AB9 2ZB, Scotland.			cooper, kevin/0000-0003-1486-0071				ABRAMOVICH DR, 1995, BRIT J OBSTET GYNAEC, V102, P249; Alexander DA, 1996, BRIT MED J, V312, P280; Bhattacharya S, 1997, BRIT J OBSTET GYNAEC, V104, P601, DOI 10.1111/j.1471-0528.1997.tb11540.x; Byers G, 1993, GYNAECOL ENDOSC, V2, P21; Cooper KG, 1999, BRIT J OBSTET GYNAEC, V106, P258, DOI 10.1111/j.1471-0528.1999.tb08240.x; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1360, DOI 10.1111/j.1471-0528.1997.tb11004.x; Cooper KG, 1997, BRIT J OBSTET GYNAEC, V104, P1367, DOI 10.1111/j.1471-0528.1997.tb11005.x; Crosignani PG, 1997, AM J OBSTET GYNECOL, V177, P95, DOI 10.1016/S0002-9378(97)70445-9; DWYER N, 1993, BRIT J OBSTET GYNAEC, V100, P237, DOI 10.1111/j.1471-0528.1993.tb15237.x; GARRATT AM, 1993, BMJ-BRIT MED J, V306, P1440, DOI 10.1136/bmj.306.6890.1440; Grant A, 1999, BRIT J OBSTET GYNAEC, V106, P360; JENKINSON C, 1994, QUAL LIFE RES, V3, P317, DOI 10.1007/BF00451723; JENKINSON C, 1993, BRIT MED J, V306, P1437, DOI 10.1136/bmj.306.6890.1437; LEFLER HT, 1992, J REPROD MED, V37, P596; LEFLER HT, 1989, J REPROD MED, V34, P905; LEFLER HT, 1994, J AM ASSOC GYN LAP, V1, P20715; MAGOS AL, 1991, LANCET, V337, P1074, DOI 10.1016/0140-6736(91)91718-A; Meyer WR, 1998, OBSTET GYNECOL, V92, P98, DOI 10.1016/S0029-7844(98)00141-0; OConnor H, 1997, LANCET, V349, P897, DOI 10.1016/S0140-6736(96)07285-6; Overton C, 1997, BRIT J OBSTET GYNAEC, V104, P1351, DOI 10.1111/j.1471-0528.1997.tb11003.x; PINION SB, 1994, BRIT MED J, V309, P979, DOI 10.1136/bmj.309.6960.979; PITTROF R, 1994, INT J GYNECOL OBSTET, V47, P135, DOI 10.1016/0020-7292(94)90353-0; RUSSELL I, 1995, BRIT MED J, V311, P1243, DOI 10.1136/bmj.311.7015.1243; SCHWARTZ D, 1967, J CHRON DIS, V20, P637, DOI 10.1016/0021-9681(67)90041-0; Sculpher MJ, 1996, BRIT J OBSTET GYNAEC, V103, P142, DOI 10.1111/j.1471-0528.1996.tb09666.x; SHARP NC, 1995, LANCET, V346, P1003, DOI 10.1016/S0140-6736(95)91689-X; Vercellini P, 1996, BRIT J OBSTET GYNAEC, V103, P562, DOI 10.1111/j.1471-0528.1996.tb09807.x; WARE JE, 1993, BRIT MED J, V306, P1429, DOI 10.1136/bmj.306.6890.1429; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002	29	118	120	0	6	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1859	1863		10.1016/S0140-6736(99)04101-X	http://dx.doi.org/10.1016/S0140-6736(99)04101-X			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584722				2022-12-28	WOS:000083909100011
J	Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ				Rommel, C; Clarke, BA; Zimmermann, S; Nunez, L; Rossman, R; Reid, K; Moelling, K; Yancopoulos, GD; Glass, DJ			Differentiation stage-specific inhibition of the Raf-MEK-ERK pathway by Akt	SCIENCE			English	Article							PROTEIN-KINASE CASCADE; PHOSPHATIDYLINOSITOL 3-KINASE; EXPRESSION; ACTIVATION; RECEPTOR; MYOGENESIS; TARGET; CELLS	Extracellular signals often result in simultaneous activation of both the Raf-MEK-ERK and PI3K-Akt pathways (where ERK is extracellular-regulated kinase, MEK is mitogen-activated protein kinase or ERK kinase, and PI3K is phosphatidylinositol 3-kinase). However, these two signaling pathways were shown to exert opposing effects on muscle cell hypertrophy. Furthermore, the PI3K-Akt pathway was shown to inhibit the Raf-MEK-ERK pathway: this cross-regulation depended on the differentiation state of the cell: Akt activation inhibited the Raf-MEK-ERK pathway in differentiated myotubes, but not in their myoblast precursors. The stage-specific inhibitory action of Akt correlated with its stage-specific ability to form a complex with Raf, suggesting the existence of differentially expressed mediators of an inhibitory Akt-Raf complex.	Regeneron Pharmaceut Inc, Tarrytown, NY 10591 USA; Univ Zurich, Inst Med Virol, CH-8028 Zurich, Switzerland	Regeneron; University of Zurich	Glass, DJ (corresponding author), Regeneron Pharmaceut Inc, 777 Old Saw Mill River Rd, Tarrytown, NY 10591 USA.		Glass, David/AAI-3910-2021; Glass, David/C-4782-2012	Glass, David/0000-0001-6187-4164				Andres V, 1996, J CELL BIOL, V132, P657, DOI 10.1083/jcb.132.4.657; Avruch J, 1998, MOL CELL BIOCHEM, V182, P31, DOI 10.1023/A:1006823109415; BELLACOSA A, 1991, SCIENCE, V254, P274, DOI 10.1126/science.1833819; Bennett AM, 1997, SCIENCE, V278, P1288, DOI 10.1126/science.278.5341.1288; BRUDER JT, 1992, GENE DEV, V6, P545, DOI 10.1101/gad.6.4.545; COLEMAN ME, 1995, J BIOL CHEM, V270, P12109, DOI 10.1074/jbc.270.20.12109; Coolican SA, 1997, J BIOL CHEM, V272, P6653, DOI 10.1074/jbc.272.10.6653; Cossu G, 1996, TRENDS GENET, V12, P218, DOI 10.1016/0168-9525(96)10025-1; DUDLEY DT, 1995, P NATL ACAD SCI USA, V92, P7686, DOI 10.1073/pnas.92.17.7686; Eves EM, 1998, MOL CELL BIOL, V18, P2143, DOI 10.1128/MCB.18.4.2143; Florini JR, 1996, ENDOCR REV, V17, P481, DOI 10.1210/edrv-17-5-481; FRANKE TF, 1995, CELL, V81, P727, DOI 10.1016/0092-8674(95)90534-0; GLASS DJ, 1991, CELL, V66, P405, DOI 10.1016/0092-8674(91)90629-D; Glass DJ, 1996, CELL, V85, P513, DOI 10.1016/S0092-8674(00)81252-0; HEIDECKER G, 1990, MOL CELL BIOL, V10, P2503, DOI 10.1128/MCB.10.6.2503; Hunter T, 1997, CELL, V88, P333, DOI 10.1016/S0092-8674(00)81872-3; JAYNES JB, 1988, MOL CELL BIOL, V8, P62, DOI 10.1128/MCB.8.1.62; Jiang BH, 1998, P NATL ACAD SCI USA, V95, P14179, DOI 10.1073/pnas.95.24.14179; Katz ME, 1997, CURR OPIN GENET DEV, V7, P75, DOI 10.1016/S0959-437X(97)80112-8; Khwaja A, 1998, J BIOL CHEM, V273, P18793, DOI 10.1074/jbc.273.30.18793; King AJ, 1998, NATURE, V396, P180, DOI 10.1038/24184; Klippel A, 1996, MOL CELL BIOL, V16, P4117; Kohn AD, 1996, J BIOL CHEM, V271, P31372, DOI 10.1074/jbc.271.49.31372; MARSHALL CJ, 1995, CELL, V80, P179, DOI 10.1016/0092-8674(95)90401-8; Mason CS, 1999, EMBO J, V18, P2137, DOI 10.1093/emboj/18.8.2137; Morrison DK, 1997, CURR OPIN CELL BIOL, V9, P174, DOI 10.1016/S0955-0674(97)80060-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; Rommel C, 1997, MECH DEVELOP, V64, P95, DOI 10.1016/S0925-4773(97)00052-X; Rommel C, 1998, CURR OPIN GENET DEV, V8, P412, DOI 10.1016/S0959-437X(98)80111-1; SAMUELS ML, 1993, MOL CELL BIOL, V13, P6241, DOI 10.1128/MCB.13.10.6241; Zimmermann S, 1999, SCIENCE, V286, P1741, DOI 10.1126/science.286.5445.1741	31	652	677	1	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1738	1741		10.1126/science.286.5445.1738	http://dx.doi.org/10.1126/science.286.5445.1738			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576741				2022-12-28	WOS:000083912200039
J	Heeschen, C; Hamm, CW; Goldmann, B; Deu, A; Langenbrink, L; White, HD				Heeschen, C; Hamm, CW; Goldmann, B; Deu, A; Langenbrink, L; White, HD		PRISM Study Investigators	Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban	LANCET			English	Article; Proceedings Paper	72nd Annual Scientific Session of the American-Heart-Association	NOV 07-10, 1999	ATLANTA, GA	Amer Heart Assoc			ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA-PECTORIS; KINASE ISOENZYME-MB; PROGNOSTIC VALUE; DEATH; RISK; THROMBOSIS; MASS	Background A major challenge for physicians is to identify patients with acute coronary syndromes who may benefit from treatment with glycoprotein-IIb/IIIa-receptor antagonists. We investigated whether troponin concentrations can be used to stratify patients for benefit from treatment with tirofiban, Methods We enrolled 2222 patients of the Platelet Receptor Inhibition in Ischemic Syndrome Management study with coronary artery disease and who had had chest pain in the previous 24 h. All patients received aspirin and were randomly assigned treatment with tirofiban or heparin. We took baseline measurements of troponin I and troponin T. We recorded death, myocardial infarction, or recurrent ischaemia after 48 h infusion treatment and at 7 days and 30 days. Findings 629 (28.3%) patients had troponin I concentrations higher than the diagnostic threshold of 1.0 mu g/L and 644 (29.0%) troponin T concentrations higher than 0.1 mu g/L. 30-day event rates (death, myocardial infarction) were 13.0% for troponin-I-positive patients compared with 4.9% for troponin-I-negative patients (p<0.001), and 13.7% compared wth 3.5% for troponin T (p<0.001). At 30 days, in troponin-I-positive patients, tirofiban had lowered the risk of death (adjusted hazard ratio 0.25 [95% CI 0.09-0.68], p=0.004) and myocardial infarction (0.37 [0.16-0.84], p=0.01). This benefit was seen in medically managed patients (0.30 [0.10-0.84], p=0.004) and those undergoing revascularisation (0.37 [0.15-0.93] p=0.02) after 48 h infusion treatment. By contrast, no treatment effect was seen for troponin-I-negative patients. Similar benefits were seen for troponin-I-positive patients. Interpretation Troponin I and troponin T reliably identified high-risk patients with acute coronary syndromes, managed medically and by revascularisation, who would benefit from tirofiban.	Kerckhoff Heart Ctr, Dept Cardiol, D-61231 Bad Nauheim, Germany; Stanford Univ, Sch Med, Dept Cardiovasc Med, Stanford, CA 94305 USA; Univ Hamburg Hosp, Dept Cardiol, D-2000 Hamburg, Germany; Green Lane Hosp, Dept Cardiol, Auckland 3, New Zealand	Kerckhoff Clinic; Stanford University; University of Hamburg; University Medical Center Hamburg-Eppendorf	Hamm, CW (corresponding author), Kerckhoff Heart Ctr, Dept Cardiol, Benekestr 2-8, D-61231 Bad Nauheim, Germany.	Christian.hamm@kerckhoff.med.uni-giessen.de	Hamm, Christian W./I-3155-2017; Guba, Markus/M-4309-2019	Hamm, Christian W./0000-0001-6763-4161; Heeschen, Christopher/0000-0002-1158-8554				Antman EM, 1996, NEW ENGL J MED, V335, P1342, DOI 10.1056/NEJM199610313351802; Apple FS, 1999, CLIN CHEM, V45, P206; Bazzino O, 1998, NEW ENGL J MED, V338, P1498; Bazzino O, 1998, NEW ENGL J MED, V338, P1488; Benamer H, 1999, AM HEART J, V137, P815, DOI 10.1016/S0002-8703(99)70404-7; BRAUNWALD E, 1994, CIRCULATION, V90, P613, DOI 10.1161/01.CIR.90.1.613; Braunwald E, 1998, CIRCULATION, V98, P2219, DOI 10.1161/01.CIR.98.21.2219; Davies MJ, 1997, NEW ENGL J MED, V336, P1312, DOI 10.1056/NEJM199705013361809; DAVIES MJ, 1986, CIRCULATION, V73, P418, DOI 10.1161/01.CIR.73.3.418; DAVIES MJ, 1985, BRIT HEART J, V53, P363; FALK E, 1985, CIRCULATION, V71, P699, DOI 10.1161/01.CIR.71.4.699; Farb A, 1996, CIRCULATION, V93, P1354, DOI 10.1161/01.CIR.93.7.1354; GERHARDT W, 1991, CLIN CHEM, V37, P1405; Hamm CW, 1997, NEW ENGL J MED, V337, P1648, DOI 10.1056/NEJM199712043372302; Hamm CW, 1999, NEW ENGL J MED, V340, P1623, DOI 10.1056/NEJM199905273402103; HAMM CW, 1992, NEW ENGL J MED, V327, P146, DOI 10.1056/NEJM199207163270302; Hanrath P, 1997, CIRCULATION, V96, P1445; HARRELL FE, 1988, J NATL CANCER I, V80, P1198, DOI 10.1093/jnci/80.15.1198; Heeschen C, 1999, CIRCULATION, V100, P1509, DOI 10.1161/01.CIR.100.14.1509; HOSMER DW, 1989, APPL LOGISTIC REGRES; Kampmann M, 1997, CLIN CHEM, V43, P244; KATUS HA, 1991, CIRCULATION, V83, P902, DOI 10.1161/01.CIR.83.3.902; KATUS HA, 1992, CLIN CHEM, V38, P386; Klein G, 1998, WIEN KLIN WOCHENSCHR, V110, P40; Lindahl B, 1997, J AM COLL CARDIOL, V29, P43, DOI 10.1016/S0735-1097(96)00447-0; Luscher MS, 1997, CIRCULATION, V96, P2578, DOI 10.1161/01.CIR.96.8.2578; LYNCH JJ, 1995, J PHARMACOL EXP THER, V272, P20; Ohman EM, 1996, NEW ENGL J MED, V335, P1333, DOI 10.1056/NEJM199610313351801; PEERLINCK K, 1993, CIRCULATION, V88, P1512, DOI 10.1161/01.CIR.88.4.1512; Pettijohn TL, 1997, AM J CARDIOL, V80, P510, DOI 10.1016/S0002-9149(97)00405-0; RAVKILDE J, 1995, J AM COLL CARDIOL, V25, P574, DOI 10.1016/0735-1097(94)00430-X; Simoons ML, 1997, LANCET, V349, P1429; Stubbs P, 1996, CIRCULATION, V94, P1291, DOI 10.1161/01.CIR.94.6.1291; WU AHB, 1995, AM J CARDIOL, V76, P970, DOI 10.1016/S0002-9149(99)80274-4	34	379	389	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1757	1762		10.1016/S0140-6736(99)10285-X	http://dx.doi.org/10.1016/S0140-6736(99)10285-X			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	258RM	10577636				2022-12-28	WOS:000083853000009
J	Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD				Ramratnam, B; Bonhoeffer, S; Binley, J; Hurley, A; Zhang, LQ; Mittler, JE; Markowitz, M; Moore, JP; Perelson, AS; Ho, DD			Rapid production and clearance of HIV-1 and hepatitis C virus assessed by large volume plasma apheresis	LANCET			English	Article							DYNAMICS IN-VIVO; ACQUIRED IMMUNODEFICIENCY SYNDROME; INTERFERON-ALPHA; MONKEY MODEL; TURNOVER; INFECTION; THERAPY; TYPE-1; SYSTEM	Background In chronic HIV-1 infection, dynamic equilibrium exists between viral production and clearance. The half-life of free virions can be estimated by inhibiting virion production with antiretroviral agents and modelling the resulting decline in plasma HIV-1 RNA. To define HIV-1 and hepatitis C virus (HCV) dynamics, we used plasma apheresis to increase virion clearance temporarily while leaving Virion production unaffected. Methods Plasma virus loads were measured frequently before, during, and after apheresis in four HIV-1-infected patients, two of whom were also co-infected with HCV. Rates of virion clearance were derived by non-linear least-square fitting of plasma virus load to a model of Viral dynamics. Findings Virion clearance rate constants were 0.0063/min (9.1/day) to 0.025/min (36.0/day; half-life 28-110 min) for HIV-1 and 0.0038/min (5.5/day) to 0.0069/min (9.9/day; half-life 100-182 min) for HCV. These values provided estimates of daily particle production of 9.3 log(10)-10.2 log(10) particles for HIV-1 and 11.6 log(10)-13.0 log(10) particles for HCV. Interpretation Our findings confirm that HIV-1 and HCV are produced and cleared extremely rapidly. New estimates for HIV-1 clearance are up to ten times higher than previous ones, whereas HCV clearance is similar to previous estimates.	Rockefeller Univ, Aaron Diamond AIDS Res Ctr, New York, NY 10016 USA; ETH Zentrum NW, Zurich, Switzerland; Friedrich Miescher Inst, CH-4002 Basel, Switzerland; Los Alamos Natl Lab, Los Alamos, NM USA	Rockefeller University; Swiss Federal Institutes of Technology Domain; ETH Zurich; Friedrich Miescher Institute for Biomedical Research; United States Department of Energy (DOE); Los Alamos National Laboratory	Ho, DD (corresponding author), Rockefeller Univ, Aaron Diamond AIDS Res Ctr, 455 1st Ave, New York, NY 10016 USA.	dho@ADARC.org	Perelson, Alan S/Z-1959-2019; Bonhoeffer, Sebastian/A-2735-2008	Perelson, Alan S/0000-0002-2455-0002; Bonhoeffer, Sebastian/0000-0001-8052-3925	NCRR NIH HHS [MO1-RR00102] Funding Source: Medline; NIAID NIH HHS [AI40387, AI41534] Funding Source: Medline; NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR000102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [U01AI041534, R01AI040387] Funding Source: NIH RePORTER	NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Bagnarelli P, 1997, J INFECT DIS, V176, P801, DOI 10.1086/517306; BALDWIN GC, 1990, P NATL ACAD SCI USA, V87, P3933, DOI 10.1073/pnas.87.10.3933; BENDER BS, 1988, REV INFECT DIS, V10, P1142; BENDER BS, 1987, J CLIN INVEST, V79, P715, DOI 10.1172/JCI112876; Binley JM, 1997, J VIROL, V71, P2799, DOI 10.1128/JVI.71.4.2799-2809.1997; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Harrigan PR, 1999, AIDS, V13, pF59, DOI 10.1097/00002030-199905280-00001; HO DD, 1995, NATURE, V373, P123, DOI 10.1038/373123a0; Mittler JE, 1999, AIDS, V13, P1415, DOI 10.1097/00002030-199907300-00023; Neumann AU, 1999, AIDS, V13, P677, DOI 10.1097/00002030-199904160-00008; Neumann AU, 1998, SCIENCE, V282, P103, DOI 10.1126/science.282.5386.103; Ortiz GM, 1999, J CLIN INVEST, V104, pR13, DOI 10.1172/JCI7371; Perelson AS, 1996, SCIENCE, V271, P1582, DOI 10.1126/science.271.5255.1582; Perelson AS, 1997, NATURE, V387, P188, DOI 10.1038/387188a0; Taylor RP, 1997, J IMMUNOL, V158, P842; Taylor RP, 1997, CLIN IMMUNOL IMMUNOP, V82, P49, DOI 10.1006/clin.1996.4286; WEI XP, 1995, NATURE, V373, P117, DOI 10.1038/373117a0; Zeuzem S, 1998, HEPATOLOGY, V28, P245, DOI 10.1002/hep.510280132; Zeuzem S, 1996, HEPATOLOGY, V23, P366; Zhang LQ, 1999, J VIROL, V73, P855, DOI 10.1128/JVI.73.1.855-860.1999	20	375	377	0	6	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1782	1785		10.1016/S0140-6736(99)02035-8	http://dx.doi.org/10.1016/S0140-6736(99)02035-8			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577640				2022-12-28	WOS:000083853000013
J	Sloan, EP; Koenigsberg, M; Gens, D; Cipolle, M; Runge, J; Mallory, MN; Rodman, G				Sloan, EP; Koenigsberg, M; Gens, D; Cipolle, M; Runge, J; Mallory, MN; Rodman, G		DCLHb Traumatic Hemorrhagic Shoc	Diaspirin cross-linked hemoglobin (DCLHb) in the treatment of severe traumatic hemorrhagic shock - A randomized controlled efficacy trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DELAYED FLUID RESUSCITATION; MULTIPLE ORGAN FAILURE; UNCONTROLLED HEMORRHAGE; BASE DEFICIT; EMERGENCY RESEARCH; HYPERTONIC SALINE; INFORMED CONSENT; BLOOD SUBSTITUTE; VASCULAR INJURY; SCORE	Context Severe, uncompensated, traumatic hemorrhagic shock causes significant morbidity and mortality, but resuscitation with an oxygen-carrying fluid might improve patient outcomes. Objective To determine if the infusion of up to 1000 mt of diaspirin cross-linked hemoglobin (DCLHb) during the initial hospital resuscitation could reduce 28-day mortality in traumatic hemorrhagic shock patients. Design and Setting Multicenter, randomized, controlled, single-blinded efficacy trial conducted between February 1997 and January 1998 at 18 US trauma centers selected for their high volume of critically injured trauma patients, but 1 did not enroll patients. Patients A total of 112 patients with traumatic hemorrhagic shock and unstable vital signs or a critical base deficit, who had a mean (SD) patient age of 39 (20) years. Of the infused patients, 79% were male and 56% were white. An exception to informed consent was used when necessary. Intervention All patients were to be infused with 500 mL of DCLHb or saline solution. Critically ill patients who still met entry criteria could have received up to an additional 500 mt during the 1-hour infusion period. Main Outcome Measures Twenty-eight day mortality, 28-day morbidity, 48-hour mortality, and 24-hour lactate levels. Results Of the 112 patients, 98 (88%) were infused with DCLHb or saline solution. At 28 days, 24 (46%) of the 52 patients infused with DCLHb died, and 8 (17%) of the 46 patients infused with the saline solution died (P =.003). At 48 hours, 20 (38%) of the 52 patients infused with DCLHb died and 7 (15%) of the 46 patients infused with the saline solution died (P = .01). The 28-day morbidity rate, as measured by the multiple organ dysfunction score, was 72% higher in the DCLHb group (P =.03). There was no difference in adverse event rates or the 24-hour lactate levels. Conclusions Mortality was higher for patients treated with DCLHb. Although further analysis should investigate whether the mortality difference was solely due to a direct treatment effect or to other factors, DCLHb does not appear to be an effective resuscitation fluid.	Univ Illinois, Coll Med, Dept Emergency Med, Chicago, IL 60612 USA; Univ Maryland, Ctr Shock Trauma, Baltimore, MD 21201 USA; Lehigh Valley Hosp Ctr, Allentown, PA USA; Carolinas Med Ctr, Charlotte, NC 28203 USA; Univ Louisville Hosp, Louisville, KY USA; Methodist Hosp Indiana, Indianapolis, IN 46202 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University System of Maryland; University of Maryland Baltimore; Lehigh Valley Hospital; Carolinas Medical Center; University of Louisville; Indiana University System	Sloan, EP (corresponding author), Univ Illinois, Coll Med, Dept Emergency Med, Mail Code 724 Room,471H CME,808 S Wood ST, Chicago, IL 60612 USA.							BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BEAL AL, 1994, JAMA-J AM MED ASSOC, V271, P226, DOI 10.1001/jama.271.3.226; BICKELL WH, 1991, SURGERY, V110, P529; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; BIROS MH, 1995, JAMA-J AM MED ASSOC, V273, P1283, DOI 10.1001/jama.273.16.1283; Biros MH, 1998, ACAD EMERG MED, V5, P359, DOI 10.1111/j.1553-2712.1998.tb02722.x; Bourguignon PR, 1998, ARCH SURG-CHICAGO, V133, P390, DOI 10.1001/archsurg.133.4.390; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CAMPBELL JP, 1995, ANN EMERG MED, V26, P590, DOI 10.1016/S0196-0644(95)70009-9; CAPONE AC, 1995, J AM COLL SURGEONS, V180, P49; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CIVIL ID, 1988, J TRAUMA, V28, P87, DOI 10.1097/00005373-198801000-00012; COHN SM, 1995, J TRAUMA, V39, P210, DOI 10.1097/00005373-199508000-00005; COX D, 1992, J R STAT SOC B, P187; DAVIS JW, 1988, J TRAUMA, V28, P1464, DOI 10.1097/00005373-198810000-00010; Davis JW, 1996, J TRAUMA, V41, P769, DOI 10.1097/00005373-199611000-00001; DeAngeles DA, 1997, J TRAUMA, V42, P406, DOI 10.1097/00005373-199703000-00007; Fitzgerald RD, 1997, CRIT CARE MED, V25, P726, DOI 10.1097/00003246-199705000-00004; Frankel HL, 1996, J TRAUMA, V40, P231, DOI 10.1097/00005373-199602000-00010; GERVIN AS, 1984, J TRAUMA, V24, P327, DOI 10.1097/00005373-198404000-00008; Gould SA, 1998, J AM COLL SURGEONS, V187, P113, DOI 10.1016/S1072-7515(98)00095-7; Gulati A, 1998, SHOCK, V9, P65, DOI 10.1097/00024382-199801000-00010; Gulati A, 1997, AM J PHYSIOL-HEART C, V273, pH827, DOI 10.1152/ajpheart.1997.273.2.H827; Hart JL, 1997, J LAB CLIN MED, V129, P356, DOI 10.1016/S0022-2143(97)90184-0; Heckbert SR, 1998, J TRAUMA, V45, P545, DOI 10.1097/00005373-199809000-00022; HESS JR, 1993, J APPL PHYSIOL, V74, P1769, DOI 10.1152/jappl.1993.74.4.1769; HOSMER DW, 1989, APPL LOGISTIC REGRES; JESCH FH, 1982, CRIT CARE MED, V10, P270, DOI 10.1097/00003246-198204000-00007; Kim SH, 1997, J TRAUMA, V42, P213, DOI 10.1097/00005373-199702000-00006; LAMY M, 1997, CLIN BENEFITS DCLHB; Leppaniemi A, 1996, J SURG RES, V63, P413, DOI 10.1006/jsre.1996.0285; Leppaniemi A, 1996, J TRAUMA, V40, P242, DOI 10.1097/00005373-199602000-00011; MANIKIS P, 1995, AM J EMERG MED, V13, P619, DOI 10.1016/0735-6757(95)90043-8; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MATTS JP, 1988, CONTROL CLIN TRIALS, V9, P327, DOI 10.1016/0197-2456(88)90047-5; MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO;2-6; MOORE EE, 1981, J TRAUMA, V21, P439; NELSON D, 1992, BIOMAT ARTIF CELL IM, V20, P423, DOI 10.3109/10731199209119662; OWENS TM, 1995, J TRAUMA, V39, P200, DOI 10.1097/00005373-199508000-00004; Patel MJ, 1998, BLOOD, V91, P710, DOI 10.1182/blood.V91.2.710.710_710_716; PRZYBELSKI R, 1998, AM J CRIT CARE MED, V157, pA295; PRZYBELSKI R, 1991, CRIT CARE MED, V22, pA231; Przybelski RJ, 1996, CRIT CARE MED, V24, P1993, DOI 10.1097/00003246-199612000-00011; Przybelski RJ, 1997, TRANSFUSION, V37, P749, DOI 10.1046/j.1537-2995.1997.37797369452.x; Reah G, 1997, CRIT CARE MED, V25, P1480, DOI 10.1097/00003246-199709000-00014; Reppucci AJ, 1997, TRANSFUSION, V37, P1143, DOI 10.1046/j.1537-2995.1997.37111298088043.x; ROUMEN RMH, 1993, J TRAUMA, V35, P349, DOI 10.1097/00005373-199309000-00004; RUTHERFORD EJ, 1992, J TRAUMA, V33, P417, DOI 10.1097/00005373-199209000-00014; SCHILLER HJ, 1993, CURR SURG THER, P1067; SCHULTZ SC, 1993, J TRAUMA, V35, P619, DOI 10.1097/00005373-199310000-00019; SCHULTZ SC, 1994, J TRAUMA, V37, P408, DOI 10.1097/00005373-199409000-00013; SHIMAZU S, 1983, J TRAUMA, V23, P213, DOI 10.1097/00005373-198303000-00006; SLOAN EP, 1995, ACAD EMERG MED, V2, P364; SPRUNG J, 1995, CRIT CARE MED, V23, P1540, DOI 10.1097/00003246-199509000-00015; Standl T, 1997, ANAESTHESIST, V46, P763, DOI 10.1007/s001010050466; STERN SA, 1993, ANN EMERG MED, V22, P155, DOI 10.1016/S0196-0644(05)80195-7; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; Vignali A, 1996, VOX SANG, V71, P170, DOI 10.1046/j.1423-0410.1996.7130170.x; 1996, FED REG, P51528	61	336	345	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1857	1864		10.1001/jama.282.19.1857	http://dx.doi.org/10.1001/jama.282.19.1857			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573278	Bronze			2022-12-28	WOS:000083615700030
J	Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G				Lalani, AS; Masters, J; Zeng, W; Barrett, J; Pannu, R; Everett, H; Arendt, CW; McFadden, G			Use of chemokine receptors by poxviruses	SCIENCE			English	Article							VACCINIA VIRUS-INFECTION; CC-CHEMOKINE; HIV-1 CORECEPTOR; T1/35KDA FAMILY; GROWTH-FACTOR; A27L PROTEIN; ANIMAL-CELLS; MYXOMA VIRUS; RESISTANCE; ALLELE	Chemokine receptors serve as portals of entry for certain intracellular pathogens, most notably human immunodeficiency virus (HIV). Myxoma virus is a member of the poxvirus family that induces a Lethal systemic disease in rabbits, but no poxvirus receptor has ever been defined. Rodent fibroblasts (3T3) that cannot be infected with myxoma virus could be made fully permissive for myxoma virus infection by expression of any one of several human chemokine receptors, including CCR1, CCR5, and CXCR4. Conversely, infection of 3T3-CCR5; cells can be inhibited by RANTES, anti-CCR5 polyclonal antibody, or herbimycin A but not by monoclonal antibodies that block HIV-1 infection or by pertussis toxin. These findings suggest that poxviruses, Like HIV, are able to use chemokine receptors to infect specific cell subtypes, notably migratory Leukocytes, but that their mechanisms of receptor interactions are distinct.	Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada; Univ Western Ontario, Dept Immunol, London, ON N6G 2V4, Canada; Univ Alberta, Dept Biochem, Edmonton, AB T6G 2H7, Canada; NYU, Med Ctr, Skirball Inst, New York, NY 10016 USA	Western University (University of Western Ontario); Western University (University of Western Ontario); University of Alberta; New York University	McFadden, G (corresponding author), Univ Western Ontario, John P Robarts Res Inst, London, ON N6G 2V4, Canada.	mcfadden@rri.on.ca	Everett, Helen E/D-7123-2011	Everett, Helen/0000-0002-1233-4265				Alkhatib G, 1997, VIROLOGY, V234, P340, DOI 10.1006/viro.1997.8673; Aramori I, 1997, EMBO J, V16, P4606, DOI 10.1093/emboj/16.15.4606; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; Berson JF, 1998, SEMIN IMMUNOL, V10, P237, DOI 10.1006/smim.1998.0130; Carrington M, 1999, HUM MOL GENET, V8, P1939, DOI 10.1093/hmg/8.10.1939; Cecilia D, 1998, J VIROL, V72, P6988, DOI 10.1128/JVI.72.9.6988-6996.1998; CHANG W, 1995, J VIROL, V69, P517, DOI 10.1128/JVI.69.1.517-522.1995; Chung CS, 1998, J VIROL, V72, P1577, DOI 10.1128/JVI.72.2.1577-1585.1998; COCCHI F, 1995, SCIENCE, V270, P1811, DOI 10.1126/science.270.5243.1811; Cundell DR, 1996, ADV EXP MED BIOL, V416, P89; Czaplewski LG, 1999, J BIOL CHEM, V274, P16077, DOI 10.1074/jbc.274.23.16077; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; Deng HK, 1996, NATURE, V381, P661, DOI 10.1038/381661a0; DOMS RW, 1990, J VIROL, V64, P4884, DOI 10.1128/JVI.64.10.4884-4892.1990; EPPSTEIN DA, 1985, NATURE, V318, P663, DOI 10.1038/318663a0; FENNER F, 1965, MYXOMATOSIS; Gong JH, 1996, J BIOL CHEM, V271, P10521, DOI 10.1074/jbc.271.18.10521; Graham KA, 1997, VIROLOGY, V229, P12, DOI 10.1006/viro.1996.8423; GRIST NR, 1988, J INFECTION, V16, P117, DOI 10.1016/S0163-4453(88)93822-4; Hollinshead M, 1999, J VIROL, V73, P1503, DOI 10.1128/JVI.73.2.1503-1517.1999; Holmes Kathryn V., 1997, P35; Horuk R, 1999, IMMUNOL TODAY, V20, P89, DOI 10.1016/S0167-5699(98)01396-6; HORUK R, 1993, SCIENCE, V261, P1182, DOI 10.1126/science.7689250; Hsiao JC, 1999, J VIROL, V73, P8750, DOI 10.1128/JVI.73.10.8750-8761.1999; Hsiao JC, 1998, J VIROL, V72, P8374, DOI 10.1128/JVI.72.10.8374-8379.1998; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JANECZKO RA, 1987, ARCH VIROL, V92, P135, DOI 10.1007/BF01310068; Klasse PJ, 1998, ADV DRUG DELIVER REV, V34, P65, DOI 10.1016/S0169-409X(98)00002-7; Kuhmann SE, 1997, J VIROL, V71, P8642, DOI 10.1128/JVI.71.11.8642-8656.1997; Lalani AS, 1998, VIROLOGY, V250, P173, DOI 10.1006/viro.1998.9340; Lalani AS, 1997, J VIROL, V71, P4356, DOI 10.1128/JVI.71.6.4356-4363.1997; Lalani AS, 1997, J LEUKOCYTE BIOL, V62, P570, DOI 10.1002/jlb.62.5.570; LALANI AS, UNPUB; Libert F, 1998, HUM MOL GENET, V7, P399, DOI 10.1093/hmg/7.3.399; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Locati M, 1999, ANNU REV MED, V50, P425, DOI 10.1146/annurev.med.50.1.425; MOSS B, 1996, REPLICATION POXVIRUS, P2637; Nash P, 1999, IMMUNOL REV, V168, P103, DOI 10.1111/j.1600-065X.1999.tb01286.x; OPGENORTH A, 1992, J VIROL, V66, P4720, DOI 10.1128/JVI.66.8.4720-4731.1992; Pakianathan DR, 1997, BIOCHEMISTRY-US, V36, P9642, DOI 10.1021/bi970593z; Pease JE, 1998, SEMIN IMMUNOL, V10, P169, DOI 10.1006/smim.1998.0129; Samson M, 1996, NATURE, V382, P722, DOI 10.1038/382722a0; Siciliano SJ, 1999, J BIOL CHEM, V274, P1905, DOI 10.1074/jbc.274.4.1905; Smith GL, 1998, ADV EXP MED BIOL, V440, P395; Stephens JC, 1998, AM J HUM GENET, V62, P1507, DOI 10.1086/301867; Trkola A, 1999, J VIROL, V73, P6370, DOI 10.1128/JVI.73.8.6370-6379.1999; Ugolini S, 1999, TRENDS MICROBIOL, V7, P144, DOI 10.1016/S0966-842X(99)01474-2; Vanderplasschen A, 1997, J VIROL, V71, P4032, DOI 10.1128/JVI.71.5.4032-4041.1997; Vanderplasschen A, 1998, J GEN VIROL, V79, P877, DOI 10.1099/0022-1317-79-4-877; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665	50	124	128	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1968	1971		10.1126/science.286.5446.1968	http://dx.doi.org/10.1126/science.286.5446.1968			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583963				2022-12-28	WOS:000084003400056
J	Towner, D; Castro, MA; Eby-Wilkens, E; Gilbert, WM				Towner, D; Castro, MA; Eby-Wilkens, E; Gilbert, WM			Effect of mode of delivery in nulliparous women on neonatal intracranial injury.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							VACUUM EXTRACTION DELIVERY; SILICONE-RUBBER CUP; SUBGALEAL HEMATOMA; FORCEPS DELIVERY; RISK-FACTORS; CALIFORNIA; HEMORRHAGE; BIRTH; TRIAL	Background: Infants delivered by vacuum extraction or other operative techniques may be more likely to sustain major injuries than those delivered spontaneously, but the extent of the risk is unknown. Methods: From a California data base, we identified 583,340 live-born singleton infants born to nulliparous women between 1992 and 1994 and weighing between 2500 and 4000 g. One third of the infants were delivered by operative techniques. We evaluated the relation between the mode of delivery and morbidity in the infants. Results: Intracranial hemorrhage occurred in 1 of 860 infants delivered by vacuum extraction, 1 of 664 delivered with the use of forceps, 1 of 907 delivered by cesarean section during labor, 1 of 2750 delivered by cesarean section with no labor, and 1 of 1900 delivered spontaneously. As compared with the infants delivered spontaneously, those delivered by vacuum extraction had a significantly higher rate of subdural or cerebral hemorrhage (odds ratio, 2.7; 95 percent confidence interval, 1.9 to 3.9), as did the infants delivered with the use of forceps (odds ratio, 3.4; 95 percent confidence interval, 1.9 to 5.9) or cesarean section during labor (odds ratio, 2.5; 95 percent confidence interval, 1.8 to 3.4), but the rate of subdural or cerebral hemorrhage associated with vacuum extraction did not differ significantly from that associated with forceps use (odds ratio for the comparison with vacuum extraction, 1.2; 95 percent confidence interval, 0.7 to 2.2) or cesarean section during labor (odds ratio, 0.9; 95 percent confidence interval, 0.6 to 1.4). Conclusions: The rate of intracranial hemorrhage is higher among infants delivered by vacuum extraction, forceps, or cesarean section during labor than among infants delivered spontaneously, but the rate among infants delivered by cesarean section before labor is not higher, suggesting that the common risk factor for hemorrhage is abnormal labor. (N Engl J Med 1999;341:1709-14.) (C) 1999, Massachusetts Medical Society.	Univ Calif Davis, Med Ctr, Dept Obstet & Gynecol, Div Mat Fetal Med, Sacramento, CA 95817 USA; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Boston, MA 02114 USA	University of California System; University of California Davis; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital	Towner, D (corresponding author), Univ Calif Davis, Med Ctr, Dept Obstet & Gynecol, Div Mat Fetal Med, 4860 Y St,Suite 2500, Sacramento, CA 95817 USA.			Towner, Dena/0000-0002-1767-4197				Bofill JA, 1997, J REPROD MED, V42, P565; Braveman P, 1998, AM J PUBLIC HEALTH, V88, P813, DOI 10.2105/AJPH.88.5.813; CASTILLO M, 1995, AM J NEURORADIOL, V16, P816; Chadwick LM, 1996, J PAEDIATR CHILD H, V32, P228, DOI 10.1111/j.1440-1754.1996.tb01559.x; COHN M, 1989, BRIT J OBSTET GYNAEC, V96, P545, DOI 10.1111/j.1471-0528.1989.tb03253.x; Drife JO, 1996, BRIT J OBSTET GYNAEC, V103, P608, DOI 10.1111/j.1471-0528.1996.tb09825.x; Hickey K, 1996, OBSTET GYNECOL, V88, P671, DOI 10.1016/0029-7844(96)00227-X; HOFMEYR GJ, 1990, BRIT J OBSTET GYNAEC, V97, P681, DOI 10.1111/j.1471-0528.1990.tb16238.x; Huang LT, 1995, PEDIATR RADIOL, V25, pS230; JOHANSON R, 1989, BRIT J OBSTET GYNAEC, V96, P537, DOI 10.1111/j.1471-0528.1989.tb03252.x; JOHANSON RB, 1993, BRIT J OBSTET GYNAEC, V100, P524, DOI 10.1111/j.1471-0528.1993.tb15301.x; KUIT JA, 1993, OBSTET GYNECOL, V82, P280; LOGHIS C, 1992, EUR J OBSTET GYN R B, V45, P173, DOI 10.1016/0028-2243(92)90079-E; MEUX EF, 1990, REPORT RESULTS OSHPD; Nesbitt TS, 1998, AM J OBSTET GYNECOL, V179, P476, DOI 10.1016/S0002-9378(98)70382-5; Odita JC, 1996, PEDIATR RADIOL, V26, P782, DOI 10.1007/BF01396201; Office of Surveillance and Biometrics. Food and Drug Administration, 1998, FDA PUBL HLTH ADV NE; Perrin RG, 1997, NEUROSURGERY, V40, P1190, DOI 10.1097/00006123-199706000-00016; PLAUCHE WC, 1979, OBSTET GYNECOL, V53, P750; Posen R, 1998, J Matern Fetal Med, V7, P132, DOI 10.1002/(SICI)1520-6661(199805/06)7:3<132::AID-MFM6>3.0.CO;2-L; Rijhsinghani A, 1997, J REPROD MED, V42, P127; SMITH SA, 1995, J FAM PRACTICE, V41, P569; Teng FY, 1997, OBSTET GYNECOL, V89, P281, DOI 10.1016/S0029-7844(96)00495-4; Vacca A, 1996, J PAEDIATR CHILD H, V32, P204, DOI 10.1111/j.1440-1754.1996.tb01553.x; VENTURA SJ, 1994, MON VITAL STAT R S20, V43; WILLIAMS MC, 1991, OBSTET GYNECOL, V78, P789	26	479	487	0	12	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1709	1714		10.1056/NEJM199912023412301	http://dx.doi.org/10.1056/NEJM199912023412301			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580069				2022-12-28	WOS:000083955800001
J	Anand, SS; Yusuf, S				Anand, SS; Yusuf, S			Oral anticoagulant therapy in patients with coronary artery disease: A meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							ACUTE MYOCARDIAL-INFARCTION; UNSTABLE ANGINA; ANTITHROMBOTIC THERAPY; BYPASS GRAFTS; PATENCY; WARFARIN; ASPIRIN; DIPYRIDAMOLE; IMPROVE; PLACEBO	Context Despite years of use in coronary,artery disease (CAD) and several studies of its effectiveness, the role of oral anticoagulants (OAs) remains controversial. Objective To determine the effects of long-term OA therapy, stratified by the intensities of anticoagulation and aspirin therapy, on outcomes in patients with CAD. Data Sources Studies were identified by MEDLINE, EMBASE, and CURRENT CONTENTS searches (1960-July 1999) and by reviewing reference lists and inquiring with experts and pharmaceutical companies. Study Selection Studies were included if they were published between 1960 and July 1999, were randomized, had recruited patients with CAD, who had used OA therapy for at least 3 months; Of 43 articles identified, 30 articles (31 trials) were analyzed. Data Extraction Information on type, duration, and method of monitoring OA therapy, as well as rates of death, myocardial infarction (MI), thromboembolic complications, stroke, and bleeding were abstracted by 2 independent observers. Data Synthesis With high-intensity (international normalized ratio [INR], 2.8-4.8) OAs vs control (16 trials, 10 056 patients), clear reductions in mortality (odds reduction [ORed] 22%; 95% confidence interval [CI], 13%-31%), MIs (ORed, 42%; 95% CI, 34%-48%), and thromboembolic complications including stroke (ORed, 63%; 95% CI, 53-71%) were observed, but were associated with a 6.0-fold (95% CI, 4.4- to 8.2-fold) increase in major bleeding. For moderate OAs (INR, 2-3) vs control (4 trials, 1365 patients) the ORed for death was 18% (95% CI, -6% to 37%); for MI, 52% (95% CI, 37%-64%); and for stroke, 53% (95% CI, 19%-73%), but it increased bleeding by 7.7-fold (95% CI, 3.3- to 18-fold). For moderate- to high-intensity OAs (INR, greater than or equal to 2) vs aspirin (7 trials, 3457 patients), no reduction in death, MI, or stroke was observed, and it was associated with a 2.4-fold (95% CI, 1.6- to 3.6-fold) increase in major bleeding. For moderate- to high-intensity OAs and aspirin vs aspirin alone (3 trials, 480 patients), the ORed for death, MI, or stroke was 56% (95% CI, 17%-77%) and major bleeding increased by 1.9-fold (0.6- to 6.0-fold). For low-intensity OAs (INR, <2.0) and aspirin vs aspirin alone (3 trials, 8435 patients), no significant reduction in death, Mi, or stroke was observed, and major bleeding increased by 1.3-fold (95% CI, 1.0- to 1.8-fold). Conclusions Among patients with CAD, high-intensity and moderate-intensity OA are effective in reducing MI and stroke but increase the risk of bleeding, in the presence of aspirin, low-intensity OA does nat appear to be superior to aspirin alone, while moderate- to high-intensity OA and aspirin vs aspirin alone appears promising and the bleeding risk is modest, but this requires confirmation from ongoing trials.	McMaster Univ, Div Cardiol, Hamilton, ON, Canada; McMaster Univ, Hamilton Civ Hosp, Res Ctr, Program Prevent Cardiol & Therapeut, Hamilton, ON, Canada	McMaster University; McMaster University	Anand, SS (corresponding author), Hamilton Gen Hosp, McMaster Clin, 237 Barton St E, Hamilton, ON L8L 2X2, Canada.	anands@fhs.mcmaster.ca		Yusuf, Salim/0000-0003-4776-5601				ALTMAN R, 1994, BMJ-BRIT MED J, V308, P81, DOI 10.1136/bmj.308.6921.81; Anand SS, 1998, CIRCULATION, V98, P1064, DOI 10.1161/01.CIR.98.11.1064; [Anonymous], 1970, LANCET, V1, P203; APENSTROM G, 1964, ACTA MED SCAND, V176, P563; Blackshear JL, 1996, LANCET, V348, P633; BOISSEL JP, 1982, NEW ENGL J MED, V307, P701; BORCHGREVINK CF, 1960, ACTA MED SCAND  S, V359, P1; BREDDIN K, 1980, CIRCULATION, V62, P63; BROWN KWG, 1964, CAN MED ASSOC J, V90, P1345; Campeau L, 1997, NEW ENGL J MED, V336, P153; CHALMERS TC, 1977, NEW ENGL J MED, V297, P1091, DOI 10.1056/NEJM197711172972004; CLAUSEN J, 1901, ACTA MED SCAND, V123, P987; COHEN M, 1994, CIRCULATION, V89, P81, DOI 10.1161/01.CIR.89.1.81; COHEN M, 1990, AM J CARDIOL, V66, P1287, DOI 10.1016/0002-9149(90)91155-Y; CONRAD LL, 1964, ARCH INTERN MED, V114, P348, DOI 10.1001/archinte.1964.03860090082008; DRAPKIN A, 1972, J AMER MED ASSOC, V222, P541, DOI 10.1001/jama.222.5.541; DRAPKIN A, 1974, JAMA-J AM MED ASSOC, V230, P208; EBERT RV, 1969, J AMER MED ASSOC, V207, P2263, DOI 10.1001/jama.207.12.2263; Eritsland J, 1996, AM J CARDIOL, V77, P31, DOI 10.1016/S0002-9149(97)89130-8; Ferguson JJ, 1999, CIRCULATION, V100, P570, DOI 10.1161/01.CIR.100.6.570; Fuster V, 1997, LANCET, V350, P389; Gent M, 1996, LANCET, V348, P1329, DOI 10.1016/s0140-6736(96)09457-3; HARVALD B, 1961, ACTA MED SCAND, V21, P983; HESS H, 1975, P COLFARIT S, V3, P80; HIRSH J, 1995, CHEST, V108, pS231, DOI 10.1378/chest.108.4_Supplement.231S; JONKER JJC, 1994, LANCET, V343, P499; Kraska T, 1981, Kardiol Pol, V24, P593; LE DT, 1994, ANN INTERN MED, V120, P552, DOI 10.7326/0003-4819-120-7-199404010-00004; Leon MB, 1996, CIRCULATION, V94, P1206; LOELIGER EA, 1967, ACTA MED SCAND, V182, P549; Lovell R R, 1967, Med J Aust, V2, P97; MACMILLAN R L, 1960, Can Med Assoc J, V83, P567; MANTEL N, 1959, J NATL CANCER I, V22, P719; MCENANY MT, 1982, J THORAC CARDIOV SUR, V83, P81; Meade TW, 1998, LANCET, V351, P233; *MED RES COUNC WOR, 1959, BMJ-BRIT MED J, V1, P803; *MED RES COUNC WOR, 1964, BMJ-BRIT MED J, V2, P837; MERLINI PA, 1994, CIRCULATION, V90, P61, DOI 10.1161/01.CIR.90.1.61; MEUWISSE.OJ, 1969, ACTA MED SCAND, V186, P361; OLLIVIER JP, 1991, ARCH MAL COEUR VAISS, V84, P537; PANTELY GA, 1979, NEW ENGL J MED, V301, P962, DOI 10.1056/NEJM197911013011803; RAJAH SM, 1985, J THORAC CARDIOV SUR, V90, P373; RITLAND S, 1969, LANCET, V1, P122; ROOS J, 1980, LANCET, V2, P989; ROTHLIN ME, 1982, CORONARY ARTERY DIS, V557, P413; Schomig A, 1996, NEW ENGL J MED, V334, P1084, DOI 10.1056/NEJM199604253341702; SEAMAN AJ, 1969, NEW ENGL J MED, V281, P115, DOI 10.1056/NEJM196907172810301; SMITH P, 1990, NEW ENGL J MED, V323, P147, DOI 10.1056/NEJM199007193230302; SORENSEN OH, 1969, ACTA MED SCAND, V185, P65; TRAMARIN R, 1986, EUR HEART J, V7, P482, DOI 10.1093/oxfordjournals.eurheartj.a062095; TURPIE AGG, 1993, NEW ENGL J MED, V329, P524, DOI 10.1056/NEJM199308193290802; URBAN P, 1988, BRIT HEART J, V60, P485; VANDERMEER J, 1993, LANCET, V342, P257, DOI 10.1016/0140-6736(93)91815-4; WASSERMAN AJ, 1966, AM HEART J, V71, P43, DOI 10.1016/0002-8703(66)90655-7; WILLIAMS DO, 1986, BRIT J CLIN PRACT, V40, P114; Yusuf S, 1998, LANCET, V352, P507, DOI 10.1016/S0140-6736(97)11162-X; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	57	206	220	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2058	2067		10.1001/jama.282.21.2058	http://dx.doi.org/10.1001/jama.282.21.2058			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591389				2022-12-28	WOS:000083908700026
J	Shor, A; Phillips, JI				Shor, A; Phillips, JI			Chlamydia pneumoniae and atherosclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; MYOCARDIAL-INFARCTION; ARTERY DISEASE; STRAIN TWAR; INFECTIONS; LESIONS; AZITHROMYCIN; ATHERECTOMY; ASSOCIATION; ATHEROMA		Natl Ctr Occupat Hlth, ZA-2000 Johannesburg, South Africa; Univ Witwatersrand, S African Inst Med Res, Sch Pathol, Johannesburg, South Africa	University of Witwatersrand	Shor, A (corresponding author), Natl Ctr Occupat Hlth, POB 4788, ZA-2000 Johannesburg, South Africa.	AShor@ncoh.pwv.gov.za						Anderson JL, 1999, CIRCULATION, V99, P1540, DOI 10.1161/01.CIR.99.12.1540; Bartels C, 1999, CIRCULATION, V99, P879, DOI 10.1161/01.CIR.99.7.879; Bauriedel G, 1999, DEUT MED WOCHENSCHR, V124, P375, DOI 10.1055/s-2007-1024309; CAMPBELL LA, 1995, J INFECT DIS, V172, P585, DOI 10.1093/infdis/172.2.585; Danesh J, 1997, LANCET, V350, P430, DOI 10.1016/S0140-6736(97)03079-1; Esposito G, 1999, ANN VASC SURG, V13, P421, DOI 10.1007/s100169900277; Grayston JT, 1999, CLIN INFECT DIS, V28, P993, DOI 10.1086/514764; GRAYSTON JT, 1992, CLIN INFECT DIS, V15, P757, DOI 10.1093/clind/15.5.757; GRAYSTON JT, 1986, NEW ENGL J MED, V315, P161, DOI 10.1056/NEJM198607173150305; Gupta S, 1998, CORONARY ARTERY DIS, V9, P339, DOI 10.1097/00019501-199809060-00004; Gupta S, 1997, BRIT MED J, V314, P1778, DOI 10.1136/bmj.314.7097.1778; Gupta S, 1997, CIRCULATION, V96, P404; Gupta S, 1999, ATHEROSCLEROSIS, V143, P1, DOI 10.1016/S0021-9150(98)00317-7; Gurfinkel E, 1999, EUR HEART J, V20, P121, DOI 10.1053/euhj.1998.1283; HAJJAR DP, 1995, AM SCI, V83, P460; Hammerschlag MR, 1998, EUR J CLIN MICROBIOL, V17, P305, DOI 10.1007/s100960050072; Jackson LA, 1997, AM J PATHOL, V150, P1785; Jackson LA, 1997, J INFECT DIS, V176, P292, DOI 10.1086/517270; Kuo CC, 1998, MOL MED TODAY, V4, P426, DOI 10.1016/S1357-4310(98)01351-3; KUO CC, 1993, J INFECT DIS, V167, P841, DOI 10.1093/infdis/167.4.841; KUO CC, 1993, ARTERIOSCLER THROMB, V13, P1501, DOI 10.1161/01.ATV.13.10.1501; KUO CC, 1995, P NATL ACAD SCI USA, V92, P6911, DOI 10.1073/pnas.92.15.6911; Lindholt JS, 1998, EUR J VASC ENDOVASC, V15, P161, DOI 10.1016/S1078-5884(98)80138-X; Maass M, 1998, J AM COLL CARDIOL, V31, P827, DOI 10.1016/S0735-1097(98)00016-3; Muhlestein JB, 1998, CIRCULATION, V97, P633, DOI 10.1161/01.CIR.97.7.633; PHILLIPS J, IN PRESS CARDIOVASC; Quinn TC, 1998, CURR OPIN INFECT DIS, V11, P301, DOI 10.1097/00001432-199806000-00006; Ramirez JA, 1996, ANN INTERN MED, V125, P979, DOI 10.7326/0003-4819-125-12-199612150-00008; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; SAIKKU P, 1988, LANCET, V2, P983, DOI 10.1016/S0140-6736(88)90741-6; Saikku P, 1997, SCAND J INFECT DIS, P53; SHOR A, 1992, S AFR MED J, V82, P158; Shor A, 1998, J CLIN PATHOL, V51, P812, DOI 10.1136/jcp.51.11.812; SHOR A, IN PRESS CARDIOVASC; STARY HC, 1995, ARTERIOSCL THROM VAS, V15, P1512, DOI 10.1161/01.ATV.15.9.1512; Taylor-Robinson D, 1998, J CLIN PATHOL, V51, P793, DOI 10.1136/jcp.51.11.793; TaylorRobinson D, 1997, BRIT MED J, V315, P1538, DOI 10.1136/bmj.315.7121.1538; TaylorRobinson D, 1997, J INFECTION, V35, P97, DOI 10.1016/S0163-4453(97)91314-1; THOM DH, 1991, ARTERIOSCLER THROMB, V11, P547, DOI 10.1161/01.ATV.11.3.547; Torgano G, 1999, CIRCULATION, V99, P1555, DOI 10.1161/01.CIR.99.12.1555; Weiss SM, 1996, J INFECT DIS, V173, P957, DOI 10.1093/infdis/173.4.957; Yamashita K, 1998, STROKE, V29, P773, DOI 10.1161/01.STR.29.4.773	42	46	49	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2071	2073		10.1001/jama.282.21.2071	http://dx.doi.org/10.1001/jama.282.21.2071			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591391				2022-12-28	WOS:000083908700028
J	Garg, PP; Frick, KD; Diener-West, M; Powe, NR				Garg, PP; Frick, KD; Diener-West, M; Powe, NR			Effect of the ownership of dialysis facilities on patients' survival and referral for transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article; Proceedings Paper	16th Annual Meeting of the Association-for-Heart-Services-Research	JUN 27-29, 1999	CHICAGO, ILLINOIS	Assoc Heart Serv Res			STAGE RENAL-DISEASE; HEALTH-CARE; FOR-PROFIT; HEMODIALYSIS; COMPETITION; PROVIDERS; PROGRAM; SELECTION; MORTALITY; ACCESS	Background: More than 200,000 patients with end-stage renal disease undergo dialysis in the United States each year, about two thirds in for-profit centers. Economic pressures, such as the decline in inflation-adjusted Medicare payments for dialysis, may compromise the quality of care. Facilities may also be reluctant to refer patients to be evaluated for transplantation because of the loss of revenues from dialysis after patients receive transplants. It is unknown whether for-profit facilities respond more aggressively than not-for-profit facilities to these financial pressures. Therefore, we examined the effect of for-profit ownership of dialysis facilities on patients' survival and referral for possible transplantation. Methods: We used data from the U.S. Renal Data System to assemble a nationally representative cohort of patients with end-stage renal disease of recent onset. We followed patients for a minimum of three years and a maximum of six years, until death, placement on the waiting list for a renal transplant, or loss to follow-up, or until May 31, 1996. We used proportional-hazards models to assess the effect of the profit status of the dialysis facility on patients' outcomes and adjusted for differences in sociodemographic, clinical, and facility-level characteristics. Results: Of the 3681 patients who were eligible for inclusion, we included 3569 in the analysis of mortality and 3441 in the analysis of the waiting list. The crude mortality rate per 100 person-years of end-stage renal disease was 21.2 for patients treated in for-profit facilities and 17.1 for patients treated in not-for-profit centers (adjusted relative hazard, 1.20; 95 percent confidence interval, 1.02 to 1.42). The likelihood of being placed on the waiting list for a renal transplant was lower for patients treated at for-profit centers (adjusted relative hazard, 0.74; 95 percent confidence interval, 0.56 to 0.98). Conclusions: In the United States, for-profit ownership of dialysis facilities, as compared with not-for-profit ownership, is associated with increased mortality and decreased rates of placement on the waiting list for a renal transplant. (N Engl J Med 1999;341:1653-60.) (C) 1999, Massachusetts Medical Society.	Johns Hopkins Univ, Robert Wood Johnson Clin Scholars Program, Baltimore, MD USA; Johns Hopkins Univ, Dept Med, Baltimore, MD USA; Johns Hopkins Univ, Dept Hlth Policy & Management, Baltimore, MD USA; Johns Hopkins Univ, Dept Biostat, Baltimore, MD USA; Johns Hopkins Univ, Dept Epidemiol, Baltimore, MD USA	Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University; Johns Hopkins University	Garg, PP (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.			Frick, Kevin/0000-0002-0178-5319	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [K24DK002643] Funding Source: NIH RePORTER; NIDDK NIH HHS [K24 DK02643] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Bender FH, 1996, AM J KIDNEY DIS, V28, P67, DOI 10.1016/S0272-6386(96)90132-8; BLAKESLEE S, 1989, NY TIMES        0124, pC1; BOVBJERG RR, 1987, MILBANK Q, V65, P177, DOI 10.2307/3350019; Cleary P D, 1991, Health Care Financ Rev, V13, P49; COX DR, 1972, J R STAT SOC B, V34, P187; DELISSOVOY G, 1994, MED CARE, V32, P130, DOI 10.1097/00005650-199402000-00004; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Farley DO, 1996, MED CARE RES REV, V53, P330, DOI 10.1177/107755879605300307; FARLEY DO, 1993, THESIS RAND GRADUATE; Feldman HI, 1999, J CLIN EPIDEMIOL, V52, P209, DOI 10.1016/S0895-4356(98)00162-0; GARDNER KD, 1981, NEW ENGL J MED, V305, P461; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; GRAY BH, 1986, NEW ENGL J MED, V314, P1523, DOI 10.1056/NEJM198606053142335; Gray Bradford H., 1991, PROFIT MOTIVE PATIEN, P71; GRIFFITHS RI, 1994, HEALTH SERV RES, V29, P473; Hakim RM, 1996, KIDNEY INT, V50, P566, DOI 10.1038/ki.1996.350; HELD PJ, 1990, AM J KIDNEY DIS, V15, P441, DOI 10.1016/S0272-6386(12)70362-1; HELD PJ, 1991, JAMA-J AM MED ASSOC, V265, P871, DOI 10.1001/jama.265.7.871; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HELD PJ, 1983, J HEALTH ECON, V2, P95, DOI 10.1016/0167-6296(83)90001-2; Hirth RA, 1999, HEALTH SERV RES, V33, P1567; Hirth RA, 1997, MED CARE RES REV, V54, P414, DOI 10.1177/107755879705400402; HOLLEY JL, 1993, AM J KIDNEY DIS, V21, P628, DOI 10.1016/S0272-6386(12)80035-7; Kendix M, 1997, HEALTH CARE FINANC R, V18, P3; Lee E, 2013, STAT METHODS SURVIVA; LIN DY, 1989, J AM STAT ASSOC, V84, P1074, DOI 10.2307/2290085; McArthur JH, 1997, JAMA-J AM MED ASSOC, V277, P985, DOI 10.1001/jama.277.12.985; McClellan WM, 1998, AM J KIDNEY DIS, V31, P584, DOI 10.1053/ajkd.1998.v31.pm9531173; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; *REN DAT SYST, 1999, 1999 ANN DAT REP; *REN DAT SYST, 1999, RES GUID USRDS DAT; RETTIG RA, 1991, KIDNEY FAILURE FED G; SCHLESINGER M, 1989, MED CARE, V27, P244, DOI 10.1097/00005650-198903000-00003; Zar J. H., 1996, BIOSTATISTICAL ANAL	36	190	191	0	4	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1653	1660		10.1056/NEJM199911253412205	http://dx.doi.org/10.1056/NEJM199911253412205			8	Medicine, General & Internal	Conference Proceedings Citation Index - Science (CPCI-S); Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258PL	10572154	Bronze			2022-12-28	WOS:000083847500005
J	Holgate, ST				Holgate, ST			The epidemic of allergy and asthma	NATURE			English	Editorial Material								Allergic diseases, such as asthma, rhinitis, eczema and food allergies, are reaching epidemic proportions in both the developed and developing world. Key factors driving these rising trends are increased exposure to sensitizing allergens and reduced stimulation of the immune system during critical periods of development. In allergic disease, there is a polarization of T-lymphocyte responses, and enhanced secretion of cytokines involved in regulation of immunoglobulin E, mast cells, basophils and eosinophils, ultimately leading to inflammation and disease. A clear understanding of the cellular and molecular mechanisms of allergic disease and the complex interplay between genetic and environmental factors will undoubtedly create new opportunities for public health and therapeutic interventions.	Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Southampton SO16 6YD, Hants, England	University of Southampton	Holgate, ST (corresponding author), Univ Southampton, Southampton Gen Hosp, Sch Med, Resp Cell & Mol Biol Res Div, Mail Point 810,Tremona Rd, Southampton SO16 6YD, Hants, England.	sth@soton.ac.uk						Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; COHEN SG, 1992, CLASSICS ALLERGY; CORRIS PA, 1993, LANCET, V341, P1369, DOI 10.1016/0140-6736(93)90941-9; Cowburn AS, 1998, J CLIN INVEST, V101, P834, DOI 10.1172/JCI620; Dabbagh K, 1999, J IMMUNOL, V162, P6233; Davies DE, 1999, ALLERGY, V54, P771; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; EVANS MJ, IN PRESS AM J RESP C; HER E, 1991, J CLIN INVEST, V88, P1982, DOI 10.1172/JCI115524; HOLGATE ST, 1998, 30 YEARS IGE, P91; Jones CA, 1998, CLIN EXP ALLERGY, V28, P655; Kapsenberg ML, 1999, CLIN EXP ALLERGY, V29, P33, DOI 10.1046/j.1365-2222.1999.00006.x-i2; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Lee SC, 1999, J IMMUNOL, V162, P6867; Mattey DL, 1997, ANN RHEUM DIS, V56, P426, DOI 10.1136/ard.56.7.426; O'Byrne PM, 1999, CLIN EXP ALLERGY, V29, P27, DOI 10.1046/j.1365-2222.1999.00005.x-i2; Peat JK, 1999, J ALLERGY CLIN IMMUN, V103, P1, DOI 10.1016/S0091-6749(99)70517-8; Robinson C, 1997, CLIN EXP ALLERGY, V27, P10, DOI 10.1111/j.1365-2222.1997.tb00667.x; Schulz O, 1999, CLIN EXP ALLERGY, V29, P439, DOI 10.1046/j.1365-2222.1999.00464.x; WALLS AF, IN PRESS ASTHMA RHIN; Zhou Z, 1999, J CLIN INVEST, V103, P779, DOI 10.1172/JCI5909	23	455	478	0	38	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B2	B4		10.1038/35037000	http://dx.doi.org/10.1038/35037000			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586888				2022-12-28	WOS:000083913900002
J	Lima, CD; Wang, LK; Shuman, S				Lima, CD; Wang, LK; Shuman, S			Structure and mechanism of yeast RNA triphosphatase: An essential component of the mRNA capping apparatus	CELL			English	Article							CARBOXY-TERMINAL DOMAIN; MESSENGER-RNA; POLYMERASE-II; SACCHAROMYCES-CEREVISIAE; NUCLEOSIDE TRIPHOSPHATASE; CAP METHYLTRANSFERASE; MUTATIONAL ANALYSIS; ENZYME BINDS; DNA-LIGASE; PROTEIN	RNA triphosphatase is an essential mRNA processing enzyme that catalyzes the first step in cap formation. The 2.05 Angstrom crystal structure of yeast RNA triphosphatase Cet1p reveals a novel active site fold whereby an eight-stranded beta barrel forms a topologically closed triphosphate tunnel. Interactions of a sulfate in the center of the tunnel with a divalent cation and basic amino acids projecting into the tunnel suggest a catalytic mechanism that is supported by mutational data. Discrete surface domains mediate Cet1p homodimerization and Cet1p binding to the guanylyltransferase component of the capping apparatus. The structure and mechanism of fungal RNA triphosphatases are completely different from those of mammalian mRNA capping enzymes. Hence, RNA triphosphatase presents an ideal target for structure-based antifungal drug discovery.	Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA; Cornell Univ, Weill Med Coll, Dept Biochem, New York, NY 10021 USA	Memorial Sloan Kettering Cancer Center; Cornell University	Shuman, S (corresponding author), Sloan Kettering Inst, Program Mol Biol, New York, NY 10021 USA.	s-shuman@ski.mskcc.org		Lima, Christopher/0000-0002-9163-6092				Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; BRUNGER AT, 1987, SCIENCE, V235, P458, DOI 10.1126/science.235.4787.458; Cho EJ, 1998, GENE DEV, V12, P3482, DOI 10.1101/gad.12.22.3482; Cho EJ, 1997, GENE DEV, V11, P3319, DOI 10.1101/gad.11.24.3319; EVANS SV, 1993, J MOL GRAPHICS, V11, P134, DOI 10.1016/0263-7855(93)87009-T; Gross CH, 1998, J VIROL, V72, P10020, DOI 10.1128/JVI.72.12.10020-10028.1998; Hakansson K, 1997, CELL, V89, P545, DOI 10.1016/S0092-8674(00)80236-6; Ho CK, 1998, J BIOL CHEM, V273, P34151, DOI 10.1074/jbc.273.51.34151; Ho CK, 1998, MOL CELL BIOL, V18, P5189, DOI 10.1128/MCB.18.9.5189; Ho CK, 1998, J BIOL CHEM, V273, P9577, DOI 10.1074/jbc.273.16.9577; HO CK, 1999, IN PRESS NUCL ACIDS; HOLM L, 1993, J MOL BIOL, V233, P123, DOI 10.1006/jmbi.1993.1489; Hosfield DJ, 1999, CELL, V98, P397, DOI 10.1016/S0092-8674(00)81968-6; Jin JP, 1998, J VIROL, V72, P10011, DOI 10.1128/JVI.72.12.10011-10019.1998; LAMZIN VS, 1993, ACTA CRYSTALLOGR D, V49, P129, DOI 10.1107/S0907444992008886; Lehman K, 1999, J BIOL CHEM, V274, P22668, DOI 10.1074/jbc.274.32.22668; Mao XD, 1996, MOL CELL BIOL, V16, P475; McCracken S, 1997, GENE DEV, V11, P3306, DOI 10.1101/gad.11.24.3306; Murshudov GN, 1997, ACTA CRYSTALLOGR D, V53, P240, DOI 10.1107/S0907444996012255; MURZIN AG, 1995, J MOL BIOL, V247, P536, DOI 10.1006/jmbi.1995.0159; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pei Y, 1999, J BIOL CHEM, V274, P28865, DOI 10.1074/jbc.274.41.28865; Rodriguez CR, 1999, NUCLEIC ACIDS RES, V27, P2181, DOI 10.1093/nar/27.10.2181; SCHWER B, 1994, P NATL ACAD SCI USA, V91, P4328, DOI 10.1073/pnas.91.10.4328; SHIBAGAKI Y, 1992, J BIOL CHEM, V267, P9521; SHUMAN S, 1981, P NATL ACAD SCI-BIOL, V78, P187, DOI 10.1073/pnas.78.1.187; SHUMAN S, 1995, MOL MICROBIOL, V17, P405, DOI 10.1111/j.1365-2958.1995.mmi_17030405.x; SHUMAN S, 1995, PROG NUCLEIC ACID RE, V50, P101, DOI 10.1016/S0079-6603(08)60812-0; Subramanya HS, 1996, CELL, V85, P607, DOI 10.1016/S0092-8674(00)81260-X; Takagi T, 1997, CELL, V89, P867, DOI 10.1016/S0092-8674(00)80272-X; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Tsukamoto T, 1997, BIOCHEM BIOPH RES CO, V239, P116, DOI 10.1006/bbrc.1997.7439; Wang SP, 1997, P NATL ACAD SCI USA, V94, P9573, DOI 10.1073/pnas.94.18.9573; Wang SP, 1997, J BIOL CHEM, V272, P14683, DOI 10.1074/jbc.272.23.14683; Wen YX, 1998, P NATL ACAD SCI USA, V95, P12226, DOI 10.1073/pnas.95.21.12226; Yamada-Okabe T, 1998, FEBS LETT, V435, P49, DOI 10.1016/S0014-5793(98)01037-0; Yu L, 1997, J VIROL, V71, P9837, DOI 10.1128/JVI.71.12.9837-9843.1997; Yue ZY, 1997, P NATL ACAD SCI USA, V94, P12898, DOI 10.1073/pnas.94.24.12898	42	108	109	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					533	543		10.1016/S0092-8674(00)81541-X	http://dx.doi.org/10.1016/S0092-8674(00)81541-X			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589681	Bronze			2022-12-28	WOS:000083986300012
J	Martin-Hirsch, P; Lilford, R; Jarvis, G; Kitchener, HC				Martin-Hirsch, P; Lilford, R; Jarvis, G; Kitchener, HC			Efficacy of cervical-smear collection devices: a systematic review and meta-analysis	LANCET			English	Article							RANDOMIZED CONTROLLED TRIAL; PAPANICOLAOU SMEARS; ENDOCERVICAL CELLS; INTRAEPITHELIAL NEOPLASIA; COTTON SWAB; SAMPLING TECHNIQUES; CERVEX-BRUSH; AYRE SPATULA; CYTOBRUSH; CYTOLOGY	Background Few randomised controlled trials have sufficient power to show clear advantages of different designs of cervical-smear collection devices. We studied by systematic review whether the design of cervical-smear devices affects rates of inadequate smears and detection of disease and whether the presence of endocervical cells in the smear affects detection of disease. Methods We sought relevant randomised controlled trials by computer literature review by MEDLINE backed up by a manual search of 16 journals. Each trial was classified according to methodological quality criteria. Odds ratios were calculated where data allowed. Findings 34 randomised controlled trials investigating cervical Papanicolaou smear collection devices were identified. All 34 trials compared the ability of devices to collect endocervical cells, and 19 compared the ability of devices to detect dyskaryosis. Meta-analyses showed that compared with other collection devices, the Ayre's spatula is an ineffective device for collecting endocervical cells (for example, odds ratio for comparison of extended-tip spatulas vs Ayre's spatula 2.25 [95% CI 2.06-2.44]) and also gives a lower yield of dyskaryosis (odds ratio for comparison of extended-tip spatulas vs Ayre's spatula 1.21 [1.20-1.33]). Devices that effectively collect endocervical cells also detect a higher proportion of abnormal cytology than those that do not. Interpretation The widely used Ayre's spatula is the least effective device for cervical sampling and should be superseded by extended-tip spatulas for primary screening and investigation of women before and after treatment for cervical intraepithelial neoplasia. The presence of endocervical cells is a valid and convenient surrogate for the ability to detect dyskaryosis.	Univ Manchester, St Marys Hosp, Dept Obstet & Gynaecol, Manchester M13 0JH, Lancs, England; Univ Birmingham, Dept Publ Hlth Med, Birmingham, W Midlands, England; St Jamess Hosp, Leeds, W Yorkshire, England	University of Manchester; University of Birmingham; Saint James's University Hospital	Martin-Hirsch, P (corresponding author), Univ Manchester, St Marys Hosp, Dept Obstet & Gynaecol, Manchester M13 0JH, Lancs, England.							BOON ME, 1981, CANCER, V48, P768, DOI 10.1002/1097-0142(19810801)48:3<768::AID-CNCR2820480318>3.0.CO;2-L; BOON ME, 1987, CANCER-AM CANCER SOC, V59, P862, DOI 10.1002/1097-0142(19870215)59:4<862::AID-CNCR2820590434>3.0.CO;2-P; BOON ME, 1989, ACTA CYTOL, V33, P843; BOUNDS W, 1976, BRIT J OBSTET GYNAEC, V3, P981; Buntinx F, 1996, BMJ-BRIT MED J, V313, P1285; BUNTINX F, 1993, BRIT J GEN PRACT, V43, P194; CECHINI S, 1989, LANCET, V2, P393; DECKERT JJ, 1988, J FAM PRACTICE, V26, P636; Dey P, 1996, BRIT MED J, V313, P721; Dickersin K., 1994, COCHRANE COLLABORATI; DUGUID HLD, 1985, LANCET, V2, P1053; ELIAS A, 1983, ACTA CYTOL, V27, P225; GARITE TJ, 1978, ACTA CYTOL, V22, P83; GILES R, 1991, OBSTET GYNECOL, V11, P72; GOORNEY BP, 1989, GENITOURIN MED, V65, P161; HAMBLIN JE, 1985, J FAM PRACTICE, V3, P257; HERBERT A, 1995, CYTOPATHOLOGY, V6, P301, DOI 10.1111/j.1365-2303.1995.tb00575.x; Hjersing M, 1991, Acta Obstet Gynecol Scand, V70, P595, DOI 10.3109/00016349109007923; HOWE DT, 1991, BRIT J OBSTET GYNAEC, V98, P588, DOI 10.1111/j.1471-0528.1991.tb10376.x; HUGHES RG, 1992, BRIT J OBSTET GYNAEC, V99, P498, DOI 10.1111/j.1471-0528.1992.tb13790.x; JOHNSON N, 1991, Journal of Obstetrics and Gynaecology (Abingdon), V11, P215, DOI 10.3109/01443619109013565; KIVLAHAN C, 1986, ACTA CYTOL, V30, P258; KOONINGS PP, 1992, OBSTET GYNECOL, V80, P241; KRISTENSEN GB, 1989, ACTA CYTOL, V33, P849; LAVERTY CR, 1988, AUST NZ J OBSTET GYN, V28, P307, DOI 10.1111/j.1479-828X.1988.tb01688.x; LONGFIELD JC, 1993, ACTA CYTOL, V37, P472; MANTEL N, 1959, J NATL CANCER I, V22, P719; MAUNEY M, 1990, DIAGN CYTOPATHOL, V6, P18, DOI 10.1002/dc.2840060106; MCCORD ML, 1992, AM J OBSTET GYNECOL, V166, P1772, DOI 10.1016/0002-9378(92)91568-U; METCALF KS, 1994, CYTOPATHOLOGY, V5, P219, DOI 10.1111/j.1365-2303.1994.tb00423.x; MITCHELL H, 1988, ACTA CYTOL, V32, P288; MITCHELL H, 1993, BRIT J CANCER, V67, P585, DOI 10.1038/bjc.1993.107; MORRIS JA, 1988, BRIT MED J, V296, P1313, DOI 10.1136/bmj.296.6632.1313; NEINSTEIN LS, 1989, J ADOLESCENT HEALTH, V10, P305, DOI 10.1016/0197-0070(89)90062-4; *NHSCSP, 1996, NHSCSP PUBL, V3; Noel M L, 1993, J Am Board Fam Pract, V6, P103; PARAISO MFR, 1994, OBSTET GYNECOL, V84, P539; PARKIN DM, 1985, BRIT J OBSTET GYNAEC, V92, P150, DOI 10.1111/j.1471-0528.1985.tb01067.x; PARTOLL LM, 1993, ACTA CYTOL, V37, P867; PATERSON MEL, 1984, BRIT MED J, V289, P896, DOI 10.1136/bmj.289.6449.896; PISTOFIDES GA, 1988, ACTA OBSTET GYN SCAN, V67, P153, DOI 10.3109/00016348809004189; PRETORIUS RG, 1991, OBSTET GYNECOL, V78, P831; Schettino F., 1993, European Journal of Gynaecological Oncology, V14, P234; SELVAGGI SM, 1991, DIAGN CYTOPATHOL, V7, P318, DOI 10.1002/dc.2840070322; STOCK RJ, 1988, ACTA CYTOL, V32, P307; SZAREWSKI A, 1990, GENITOURIN MED, V66, P439; SZAREWSKI A, 1993, ACTA CYTOL, V37, P457; SZAREWSKI A, 1991, GENITOURIN MED, V66, P439; VANDERGRAAF Y, 1987, J CLIN PATHOL, V40, P438, DOI 10.1136/jcp.40.4.438; VIERHOUT ME, 1987, EUR J OBSTET GYN R B, V26, P343, DOI 10.1016/0028-2243(87)90132-8; VOOJIS PG, 1986, ACTA CYTOL, V30, P251; VOOJIS PG, 1985, ACTA CYTOL, V29, P323; Waddell C A, 1990, Cytopathology, V1, P171, DOI 10.1111/j.1365-2303.1990.tb00343.x; WOLFENDALE MR, 1987, BRIT MED J, V297, P33; WOODMAN CJB, 1991, BRIT J OBSTET GYNAEC, V98, P21, DOI 10.1111/j.1471-0528.1991.tb10305.x; 1992, J REPROD MED, V37, P383	56	65	66	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1763	1770		10.1016/S0140-6736(99)02353-3	http://dx.doi.org/10.1016/S0140-6736(99)02353-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577637				2022-12-28	WOS:000083853000010
J	Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI				Ernst, RK; Yi, EC; Guo, L; Lim, KB; Burns, JL; Hackett, M; Miller, SI			Specific lipopolysaccharide found in cystic fibrosis airway Pseudomonas aeruginosa	SCIENCE			English	Article							LIPID-A; SALMONELLA-TYPHIMURIUM; ESCHERICHIA-COLI; REGULATED GENES; PHOP-PHOQ; RESISTANCE; QUADRUPOLE; VIRULENCE; PEPTIDES; MUTANT	Cystic fibrosis (CF) patients develop chronic airway infections with Pseudomonas aeruginosa (PA), Pseudomonas aeruginosa synthesized lipopolysaccharide (LPS) with a variety of penta- and hexa-acylated lipid A structures under different environmental conditions. CF patient PA synthesized LPS with specific Lipid A structures indicating unique recognition of the CF airway environment. CF-specific Lipid A forms containing palmitate and aminoarabinose were associated with resistance to cationic antimicrobial peptides and increased inflammatory responses, indicating that they are likely to be involved in airway disease.	Univ Washington, Dept Med, Seattle, WA 98195 USA; Univ Washington, Dept Microbiol, Seattle, WA 98195 USA; Univ Washington, Dept Med Chem, Seattle, WA 98195 USA; Univ Washington, Dept Pediat, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Miller, SI (corresponding author), Univ Washington, Dept Med, Seattle, WA 98195 USA.	millersi@u.washingtan.edu		Ernst, Robert/0000-0001-5016-8694	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R55HL048888] Funding Source: NIH RePORTER; NHLBI NIH HHS [R55 HL 48888] Funding Source: Medline; PHS HHS [R21 R13400] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		*AM SOC MASS SPECT, 1998, P 46 ASMS C MASS SPE; [Anonymous], 1997, NIH Consens Statement, V15, P1; Basu SS, 1999, J BIOL CHEM, V274, P11150, DOI 10.1074/jbc.274.16.11150; BELL A, 1989, J BACTERIOL, V171, P3211, DOI 10.1128/jb.171.6.3211-3217.1989; BHAT R, 1990, J BACTERIOL, V172, P6631, DOI 10.1128/jb.172.12.6631-6636.1990; BIER ME, 1997, ELECTROSPRAY IONIZAT, P235; CAROFF M, 1988, CARBOHYD RES, V175, P273, DOI 10.1016/0008-6215(88)84149-1; DARVEAU RP, 1995, INFECT IMMUN, V63, P1311, DOI 10.1128/IAI.63.4.1311-1317.1995; DARVEAU RP, 1992, J CLIN INVEST, V90, P447, DOI 10.1172/JCI115880; DARVEAU RP, 1983, J BACTERIOL, V155, P831, DOI 10.1128/JB.155.2.831-838.1983; ERNST RK, UNPUB; GOLDMAN RC, 1988, J BIOL CHEM, V263, P5217; Govan JRW, 1996, MICROBIOL REV, V60, P539, DOI 10.1128/MMBR.60.3.539-574.1996; Gunn JS, 1996, J BACTERIOL, V178, P6369, DOI 10.1128/jb.178.21.6369-6373.1996; Gunn JS, 1996, J BACTERIOL, V178, P6857, DOI 10.1128/jb.178.23.6857-6864.1996; Gunn JS, 1998, MOL MICROBIOL, V27, P1171, DOI 10.1046/j.1365-2958.1998.00757.x; Guo L, 1998, CELL, V95, P189, DOI 10.1016/S0092-8674(00)81750-X; Guo L, 1997, SCIENCE, V276, P250, DOI 10.1126/science.276.5310.250; Hancock R E, 1995, Adv Microb Physiol, V37, P135, DOI 10.1016/S0065-2911(08)60145-9; Jonscher KR, 1997, ANAL BIOCHEM, V244, P1, DOI 10.1006/abio.1996.9877; KARUNARATNE DN, 1992, ARCH BIOCHEM BIOPHYS, V299, P368, DOI 10.1016/0003-9861(92)90289-9; KULSHIN VA, 1991, EUR J BIOCHEM, V198, P697, DOI 10.1111/j.1432-1033.1991.tb16069.x; MILLER SI, 1989, P NATL ACAD SCI USA, V86, P5054, DOI 10.1073/pnas.86.13.5054; NUMMILA K, 1995, MOL MICROBIOL, V16, P271, DOI 10.1111/j.1365-2958.1995.tb02299.x; RAETZ CRH, 1996, ESCHERICHIA COLI SAL, P1035; Somerville JE, 1996, J CLIN INVEST, V97, P359, DOI 10.1172/JCI118423; Soncini FC, 1996, J BACTERIOL, V178, P5092, DOI 10.1128/jb.178.17.5092-5099.1996; Steinberg DA, 1997, ANTIMICROB AGENTS CH, V41, P1738, DOI 10.1128/AAC.41.8.1738; Vescovi EG, 1996, CELL, V84, P165, DOI 10.1016/S0092-8674(00)81003-X; Wang HL, 1998, ANAL CHEM, V70, P205, DOI 10.1021/ac971036l; Wong P.S., 1997, CURRENT SEPARATIONS, V16, P85; Xu NX, 1997, J AM SOC MASS SPECTR, V8, P116, DOI 10.1016/S1044-0305(96)00233-4; Yi E., UNPUB; YOST RA, 1990, METHOD ENZYMOL, V193, P154, DOI 10.1016/0076-6879(90)93415-H	34	387	399	2	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1561	1565		10.1126/science.286.5444.1561	http://dx.doi.org/10.1126/science.286.5444.1561			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567263				2022-12-28	WOS:000083768300059
J	Tamada, JA; Garg, S; Jovanovic, L; Pitzer, KR; Fermi, S; Potts, RO				Tamada, JA; Garg, S; Jovanovic, L; Pitzer, KR; Fermi, S; Potts, RO		Cygnus Res Team	Noninvasive glucose monitoring - Comprehensive clinical results	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BLOOD-GLUCOSE; DIABETES-MELLITUS; MICRODIALYSIS; ACCURACY; INSULIN; TISSUE; METERS; SENSOR	Context Intensive diabetes management using frequent blood glucose measurements to guide therapy has been shown to significantly improve short- and long-term outcomes. Development of a device that makes possible frequent, automatic, painless, and accurate measurements of glucose would facilitate intensive management. Objective To determine the accuracy of the GlucoWatch automatic glucose biographer (Cygnus Inc) compared with that of serial blood glucose measurements. Design Multicenter comparative study of the GlucoWatch biographer and the HemoCue blood glucose analyzer (Aktiebolaget Lee) performed between August 29 and October 17, 1998, Participants wore up to 2 biographers during the 15-hour study session and performed 2 fingersticks per hour for comparative blood glucose measurements, The biographers were calibrated with a single HemoCue measurement after a 3-hour warm-up period, Diet and insulin were manipulated to produce a broad glycemic range during the study. Setting Controlled clinical environment at 2 diabetes centers and 3 contract research organizations in the United States. Participants A total of 92 subjects (mean [SD] age, 42.1 [15.1] years; 59.8% women) with type 1 or 2 diabetes requiring treatment with insulin. Main Outcome Measures Mean error, mean absolute error, correlation, slope, and intercept using Deming regression, and clinical significance of differences between biographer readings and blood glucose measurements using the Clarke error grid. Results Results showed close tracking of blood glucose over a range of 2.2 to 22.2 mmol/L (40-400 mg/dL) for up to 12 hours using a single point calibration. The biographer readings lagged behind serial blood glucose values by a mean of 18 minutes. An analysis of 2167 data pairs shows a linear relationship (r = 0.88; slope = 1.03; intercept = -0.33 mmol/L [-6 mg/dL]) between biographer readings and serial glucose measurements. The mean absolute error between the 2 measurements was 15.6% (mean error [SD], -0.07 [1.82] mmol/L [-1 (33) mg/dL]), and 96.8% of the data fell in the therapeutically relevant regions of the error grid analysis. Conclusion These results demonstrate close agreement between GlucoWatch biographer readings and blood glucose measurements using repeated fingerstick blood samples. The automatic, frequent, and noninvasive measurements obtained with the biographer provides more information about glucose levels than the current standard of care.	Cygnus Inc, Redwood City, CA 94063 USA; Univ Colorado, Hlth Sci Ctr, Barbara Davis Ctr Childhood Diabet, Denver, CO 80262 USA	University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver	Potts, RO (corresponding author), Cygnus Inc, 400 Penobscot Dr, Redwood City, CA 94063 USA.							Bolinder J, 1997, DIABETES CARE, V20, P64, DOI 10.2337/diacare.20.1.64; Brunner GA, 1998, DIABETES CARE, V21, P585, DOI 10.2337/diacare.21.4.585; CLARKE WL, 1987, DIABETES CARE, V10, P622, DOI 10.2337/diacare.10.5.622; Diabetes Control and Complications Trial Research Group, 1993, NEW ENGL J MED, V329, P997; Draize JH, 1944, J PHARMACOL EXP THER, V82, P377; GLIKFELD P, 1989, PHARMACEUT RES, V6, P988, DOI 10.1023/A:1015957816254; Kurnik RT, 1999, SENSOR ACTUAT B-CHEM, V60, P19, DOI 10.1016/S0925-4005(99)00239-7; Kurnik RT, 1998, J ELECTROCHEM SOC, V145, P4119, DOI 10.1149/1.1838924; KURNIK RT, 1997, Patent No. 24059; MEYERHOFF C, 1992, DIABETOLOGIA, V35, P1087, DOI 10.1007/BF02221686; OHKUBO Y, 1995, DIABETES RES CLIN PR, V28, P103, DOI 10.1016/0168-8227(95)01064-K; PICKUP JC, 1989, DIABETOLOGIA, V32, P213, DOI 10.1007/BF00265097; RAO G, 1996, PHARMACEUT RES, V12, P1322; Schmidtke DW, 1998, P NATL ACAD SCI USA, V95, P294, DOI 10.1073/pnas.95.1.294; Singh J., 1998, ELECT CONTROLLED DRU, P47; TAMADA JA, 1995, NAT MED, V1, P1198, DOI 10.1038/nm1195-1198; ThomeDuret V, 1996, ANAL CHEM, V68, P3822, DOI 10.1021/ac960069i; TIESZEN KL, 1995, DIABETIC MED, V12, P173, DOI 10.1111/j.1464-5491.1995.tb00449.x; Trajanoski Z, 1996, DIABETES CARE, V19, P1412, DOI 10.2337/diacare.19.12.1412; Turner RC, 1998, LANCET, V352, P837, DOI 10.1016/s0140-6736(98)07019-6	20	194	227	1	30	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1839	1844		10.1001/jama.282.19.1839	http://dx.doi.org/10.1001/jama.282.19.1839			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573275				2022-12-28	WOS:000083615700027
J	Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A				Osmond, DH; Bindman, AB; Vranizan, K; Lehman, JS; Hecht, FM; Keane, D; Reingold, A		Multistate Evaluation Surveillance	Name-based surveillance and public health interventions for persons with HIV infection	ANNALS OF INTERNAL MEDICINE			English	Article							PARTNER NOTIFICATION; EPIDEMIC	Name-based surveillance of HIV infection is the law in 31 U.S. states but remains controversial, This policy can be advocated solely to support surveillance of the epidemic, but a frequent argument is that it also provides a public health benefit by allowing follow-up of HIV-infected persons. These persons can then receive timely medical care and can be assisted with notifying sex and needle-sharing partners. Few comparative data are available to evaluate the outcomes of these interventions, In five states with name-based surveillance of HIV infection, the Multistate Evaluation of Surveillance for HIV Study Group surveyed a cross-sectional probability sample of persons with AIDS who tested positive for HIV before the date of their AIDS diagnosis, Health department follow-up of a reported HIV infection was not associated with more timely receipt of medical care after a positive HIV test result. Only 8.6% of persons who delayed medical care after their first positive HIV test result gave concern about being reported by name as a reason; no person gave it as the main reason. Persons who were tested anonymously and those who were tested confidentially did not differ in the mean number of sex and needle-sharing partners notified: Those tested anonymously reported personally notifying 3.85 sex and needle-sharing partners, and those tested confidentially reported notifying-personally and through the health department-3.80 partners. Many researchers and policymakers believe that name-based surveillance of HIV infection will have positive or negative effects on partner notification and access to health care, These results suggest that the potential for such effects has been exaggerated.	Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA	University of California System; University of California San Francisco	Osmond, DH (corresponding author), Univ Calif San Francisco, Dept Epidemiol & Biostat, Box 0866, San Francisco, CA 94143 USA.	dosmond@psg.ucsf.edu		Hecht, Frederick/0000-0002-5782-1171				ANDRUS JK, 1990, ANN INTERN MED, V112, P539, DOI 10.7326/0003-4819-112-7-539; Bindman AB, 1998, JAMA-J AM MED ASSOC, V280, P1416, DOI 10.1001/jama.280.16.1416; Colfax GN, 1998, AM J PUBLIC HEALTH, V88, P876, DOI 10.2105/AJPH.88.6.876; *COUNC STAT TERR E, 1997, POSITION STATEMENT N; Cowan FM, 1996, GENITOURIN MED, V72, P247; FIUMARAN, 1957, NEW ENGL J MED, V256, P982; FRANCIS DP, 1993, J ACQ IMMUN DEF SYND, V6, P285; GERTIG DM, 1991, AIDS, V5, P1157, DOI 10.1097/00002030-199110000-00001; Gostin LO, 1997, NEW ENGL J MED, V337, P1162, DOI 10.1056/NEJM199710163371611; HIRANO D, 1994, AM J PUBLIC HEALTH, V84, P2008, DOI 10.2105/AJPH.84.12.2008; HOFFMAN RE, 1995, J ACQ IMMUN DEF SYND, V8, P406; LANDIS SE, 1992, NEW ENGL J MED, V326, P101, DOI 10.1056/NEJM199201093260205; OXMAN AD, 1994, CAN J PUBLIC HEALTH, V85, pS41; PAVIA AT, 1993, AM J PUBLIC HEALTH, V83, P1418, DOI 10.2105/AJPH.83.10.1418; POTTERAT JJ, 1977, AM J PUBLIC HEALTH, V67, P174, DOI 10.2105/AJPH.67.2.174; Steinbrook LD, 1997, NEW ENGL J MED, V337, P779, DOI 10.1056/NEJM199709113371109; WYKOFF RF, 1988, JAMA-J AM MED ASSOC, V259, P3563, DOI 10.1001/jama.259.24.3563; 1998, MMWR MORB MORTAL WKL, V47, P1086; 1992, MMWR MORB MORTAL WKL, V41, P247; 1998, MMWR MORB MORTAL WKL, V47, P309; 1998, MMWR MORB MORTAL WKL, V46, P1254	21	37	38	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					775	779		10.7326/0003-4819-131-10-199911160-00010	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00010			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255QC	10577302				2022-12-28	WOS:000083680100009
J	Pincus, T; O'Dell, JR; Kremer, JM				Pincus, T; O'Dell, JR; Kremer, JM			Combination therapy with multiple disease-modifying antirheumatic drugs in rheumatoid arthritis: A preventive strategy	ANNALS OF INTERNAL MEDICINE			English	Review							CONTROLLED CLINICAL-TRIAL; CORONARY-ARTERY DISEASE; LONG-TERM OUTCOMES; FOLLOW-UP; DOUBLE-BLIND; RADIOGRAPHIC DAMAGE; REACTIVE ARTHRITIS; WORK DISABILITY; NATURAL-HISTORY; JOINT DAMAGE	The traditional "pyramid" or sequential approach to treatment of patients with rheumatoid arthritis involved use of a nonsteroidal anti-inflammatory drug for months to years while seeking to avoid use of second-line antirheumatic drugs until evidence of joint damage was seen. This approach led to short-term reduction of inflammation and a few remissions. However, long-term remissions were rare, and most patients experienced poor long-term outcomes, including joint destruction, severe functional declines, considerable economic losses, work disability, and premature mortality. At this time, a "preventive" strategy is evolving in which early aggressive treatment with disease-modifying antirheumatic drugs is used, seeking to minimize long-term joint damage. When residual inflammation remains after maximum doses of single agents, as is usually the case, combinations of disease-modifying antirheumatic drugs appear to be a reasonable consideration for many patients. Methotrexate is the most commonly used "anchor drug" in combination therapy. Evidence from randomized, controlled clinical trials and observational studies have indicated increased efficacy and acceptable land often lower) toxicity for combinations of methotrexate plus cyclosporine, hydroxychloroquine, sulfasalazine, leflunomide, etanercept, and infliximab. Further studies lasting 5 years or more are needed to determine the long-term effectiveness, toxicities, and optimal clinical use of disease-modifying antirheumatic drug combinations. At this time, such combinations are taken by at least some patients under care of almost all rheumatologists, and it appears likely that they will be used increasingly in the coming decades.	Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, Nashville, TN 37232 USA; Univ Nebraska, Med Ctr, Dept Internal Med, Omaha, NE 68198 USA; Albany Med Coll, Div Rheumatol, Albany, NY 12208 USA	Vanderbilt University; University of Nebraska System; University of Nebraska Medical Center; Albany Medical College	Pincus, T (corresponding author), Vanderbilt Univ, Sch Med, Div Rheumatol & Immunol, 203 Oxford House,Box 5, Nashville, TN 37232 USA.							Abu-Shakra M, 1998, ARTHRITIS RHEUM, V41, P1190, DOI 10.1002/1529-0131(199807)41:7<1190::AID-ART7>3.0.CO;2-B; BENSEN W, 1994, J RHEUMATOL, V21, P2034; BENSEN WG, 1990, J RHEUMATOL, V17, P987; BOERS M, 1994, J RHEUMATOL, V21, P86; Boers M, 1997, LANCET, V350, P309, DOI 10.1016/S0140-6736(97)01300-7; BOMBARDIER C, 1985, J RHEUMATOL, V12, P403; BROOK A, 1977, ANN RHEUM DIS, V36, P71, DOI 10.1136/ard.36.1.71; Callahan LF, 1997, ARTHRIT CARE RES, V10, P381, DOI 10.1002/art.1790100606; CORRIGAN AB, 1974, BRIT MED J, V1, P444, DOI 10.1136/bmj.1.5905.444; CSUKA ME, 1986, JAMA-J AM MED ASSOC, V255, P2315, DOI 10.1001/jama.255.17.2315; EMERY P, 1995, ANN RHEUM DIS, V54, P944, DOI 10.1136/ard.54.12.944; Emery P, 1997, LANCET, V350, P304, DOI 10.1016/S0140-6736(97)22031-3; FAARVANG KL, 1993, ANN RHEUM DIS, V52, P711, DOI 10.1136/ard.52.10.711; FEINSTEIN AR, 1983, ANN INTERN MED, V99, P544, DOI 10.7326/0003-4819-99-4-544; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FELSON DT, 1990, ARTHRITIS RHEUM, V33, P140, DOI 10.1002/art.1780330119; Fex E, 1996, BRIT J RHEUMATOL, V35, P1106; Fleming TR, 1996, ANN INTERN MED, V125, P605, DOI 10.7326/0003-4819-125-7-199610010-00011; FORRE O, 1994, ARTHRITIS RHEUM, V37, P1506; FREIREICH EJ, 1983, CONTROVERSY SURG, P5; Fries JF, 1996, J RHEUMATOL, V23, P102; FRIES JF, 1994, RHEUMATOID ARTHRITIS, P403; FUCHS HA, 1989, J RHEUMATOL, V16, P585; GRANFORS K, 1989, NEW ENGL J MED, V320, P216, DOI 10.1056/NEJM198901263200404; Haagsma CJ, 1997, BRIT J RHEUMATOL, V36, P1082; Harrison BJ, 1996, J RHEUMATOL, V23, P1326; Hawley D J, 1992, Arthritis Care Res, V5, P130, DOI 10.1002/art.1790050304; HAWLEY DJ, 1991, J RHEUMATOL, V18, P1008; HEALEY LA, 1988, J RHEUMATOL, V15, P750; KANTOR TG, 1990, J RHEUMATOL, V17, P1580; KAPLAN HS, 1972, HODGKINS DISEASE, P372; KEAT A, 1987, LANCET, V1, P72; Koopman WJ, 1998, ANN INTERN MED, V128, P231, DOI 10.7326/0003-4819-128-3-199802010-00010; Kremer JM, 1996, J RHEUMATOL, V23, P34; Kremer JM, 1998, ARTHRITIS RHEUM, V41, P1548, DOI 10.1002/1529-0131(199809)41:9<1548::AID-ART4>3.0.CO;2-I; KREMER JM, 1986, ARTHRITIS RHEUM, V29, P822, DOI 10.1002/art.1780290702; Kremer JM, 1997, ARTHRITIS RHEUM, V40, P984, DOI 10.1002/art.1780400533; KREMER JM, 1998, RHEUMATIC DIS CLIN N; LIGHTFOOT RW, 1985, ARTHRITIS ALLIED CON, P668; LUUKKAINEN R, 1977, SCAND J RHEUMATOL, V6, P189, DOI 10.3109/03009747709095448; Maini RN, 1998, ARTHRITIS RHEUM, V41, P1552, DOI 10.1002/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W; MCCARTY DJ, 1995, J RHEUMATOL, V22, P1636; MIKKELSE.WM, 1969, ARTHRITIS RHEUM, V12, P87, DOI 10.1002/art.1780120205; MLADENOVIC V, 1995, ARTHRITIS RHEUM-US, V38, P1595, DOI 10.1002/art.1780381111; MORELAND LW, 1995, ARTHRITIS RHEUM, V38, P1581, DOI 10.1002/art.1780381109; Moreland LW, 1997, NEW ENGL J MED, V337, P141, DOI 10.1056/NEJM199707173370301; Mottonen T, 1999, LANCET, V353, P1568, DOI 10.1016/S0140-6736(98)08513-4; Mulherin D, 1996, BRIT J RHEUMATOL, V35, P1263; O'Dell J., 1997, Arthritis and Rheumatism, V40, pS50; ODell JR, 1996, J RHEUMATOL, V23, P72; ODell JR, 1996, ANN RHEUM DIS, V55, P781, DOI 10.1136/ard.55.11.781; ODell JR, 1996, NEW ENGL J MED, V334, P1287, DOI 10.1056/NEJM199605163342002; OSULLIVAN JB, 1972, ANN INTERN MED, V76, P573, DOI 10.7326/0003-4819-76-4-573; Pasero G, 1996, ARTHRITIS RHEUM, V39, P1006, DOI 10.1002/art.1780390618; PINCUS T, 1984, ARTHRITIS RHEUM-US, V27, P864, DOI 10.1002/art.1780270805; PINCUS T, 1990, J RHEUMATOL, V17, P1582; PINCUS T, 1993, BRIT J RHEUMATOL, V32, P28; Pincus T, 1998, J RHEUMATOL, V25, P636; Pincus T, 1997, CLIN EXP RHEUMATOL, V15, P591; Pincus T, 1999, ARTHRITIS RHEUM, V42, P1572, DOI 10.1002/1529-0131(199908)42:8<1572::AID-ANR2>3.0.CO;2-G; Pincus T, 1997, CLIN EXP RHEUMATOL, V15, pS27; Pincus T, 1996, Arthritis Care Res, V9, P339, DOI 10.1002/1529-0131(199610)9:5<339::AID-ANR1790090502>3.0.CO;2-M; PINCUS T, 1988, J CLIN EPIDEMIOL, V41, P1037, DOI 10.1016/0895-4356(88)90072-8; PINCUS T, 1986, J RHEUMATOL, V13, P841; Pincus T, 1995, BRIT J RHEUMATOL, V34, P59; PINCUS T, 1995, J RHEUMATOL, V22, P1611; PINCUS T, 1994, J RHEUMATOL, V21, P1385; PINCUS T, 1993, SEMIN ARTHRITIS RHEU, V23, P2, DOI 10.1016/S0049-0172(10)80002-2; PINCUS T, 1992, J RHEUMATOL, V19, P1885; PINCUS T, 1995, BRIT J RHEUMATOL, V34, P196; PORTER DR, 1993, J RHEUMATOL, V20, P645; PROUDFIT WL, 1978, PROG CARDIOVASC DIS, V21, P53, DOI 10.1016/S0033-0620(78)80004-8; RASKER JJ, 1984, CLIN RHEUMATOL, V3, P11, DOI 10.1007/BF02715690; RAU R, 1987, Clinical Rheumatology, V6, P43, DOI 10.1007/BF02203384; SACKETT DL, 1979, NEW ENGL J MED, V301, P1410, DOI 10.1056/NEJM197912273012602; SCOTT DL, 1984, ANN RHEUM DIS, V43, P8, DOI 10.1136/ard.43.1.8; Stein CM, 1997, ARTHRITIS RHEUM, V40, P1843, DOI 10.1002/art.1780401018; Strand V, 1996, J RHEUMATOL, V23, P91; THOULD AK, 1966, ANN RHEUM DIS, V25, P220, DOI 10.1136/ard.25.3.220; TUGWELL P, 1995, NEW ENGL J MED, V333, P137, DOI 10.1056/NEJM199507203330301; vanderHeide A, 1996, ANN INTERN MED, V124, P699, DOI 10.7326/0003-4819-124-8-199604150-00001; VANDERHEIJDE DM, 1989, LANCET, V1, P1036, DOI 10.1016/S0140-6736(89)92442-2; VANRIEL PLC, 1994, BR J RHEUMATOL, V31, P793; VANRIEL PLCM, 1995, J RHEUMATOL, V22, P1797; Verhoeven AC, 1998, BRIT J RHEUMATOL, V37, P612; Weinblatt M. E., 1997, Arthritis and Rheumatism, V40, pS193; Weinblatt ME, 1998, J RHEUMATOL, V25, P238; WEINBLATT ME, 1985, NEW ENGL J MED, V312, P818, DOI 10.1056/NEJM198503283121303; Weinblatt ME, 1999, NEW ENGL J MED, V340, P253, DOI 10.1056/NEJM199901283400401; Weinblatt ME, 1995, BRIT J RHEUMATOL, V34, P43; Weinblatt ME, 1996, ANN INTERN MED, V124, P773, DOI 10.7326/0003-4819-124-8-199604150-00012; WILLIAMS HJ, 1992, ARTHRITIS RHEUM, V35, P259, DOI 10.1002/art.1780350304; WILLKENS RF, 1992, ARTHRITIS RHEUM-US, V35, P849, DOI 10.1002/art.1780350802; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1985, J RHEUMATOL, V12, P245; WOLFE F, 1993, J RHEUMATOL, V20, P2005; WOLFE F, 1990, J RHEUMATOL, V17, P994; WOLFE F, 1986, J RHEUMATOL, V13, P277; Wolfe F., 1997, Arthritis and Rheumatism, V40, pS218; Wolfe F, 1996, J RHEUMATOL, V23, P13; YELIN E, 1980, ANN INTERN MED, V93, P551, DOI 10.7326/0003-4819-93-4-551; Yelin E, 1996, J RHEUMATOL, V23, P47	103	110	122	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					768	774		10.7326/0003-4819-131-10-199911160-00009	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00009			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577301				2022-12-28	WOS:000083680100008
J	de Bie, RMA; de Haan, RJ; Nijssen, PCG; Rutgers, AWF; Beute, GN; Bosch, DA; Haaxma, R; Schmand, B; Schuurman, PR; Staal, MJ; Speelman, JD				de Bie, RMA; de Haan, RJ; Nijssen, PCG; Rutgers, AWF; Beute, GN; Bosch, DA; Haaxma, R; Schmand, B; Schuurman, PR; Staal, MJ; Speelman, JD			Unilateral pallidotomy in Parkinson's disease: a randomised, single-blind, multicentre trial	LANCET			English	Article							CORE ASSESSMENT PROGRAM; STEREOTAXIC PALLIDOTOMY; MEDIAL PALLIDOTOMY; GPI PALLIDOTOMY; MOTOR FUNCTION; EFFICACY	Background The results of several cohort studies suggest that patients with advanced Parkinson's disease would benefit from unilateral pallidotomy. We have assessed the efficacy of unilateral pallidotomy in a randomised, single-blind, multicentre trial. Methods We enrolled 37 patients with advanced Parkinson's disease who had, despite optimum pharmacological treatment, at least one of the following symptoms: severe response fluctuations, dyskinesias, painful dystonias, or bradykinesia, Patients were randomly assigned to unilateral pallidotomy within 1 month or to pallidotomy after the primary outcome assessment (6 months later). The primary outcome was the difference between the groups in median changes on the motor examination section of the unified Parkinson's disease rating scale (UPDRS 3) score done in the off phase. Secondary outcome measures included levodopa-induced dyskinesias (dyskinesia rating scale [DRS]) and extent of disability (UPDRS 2). Findings The median UPDRS 3 off score of the pallidotomy patients improved from 47 to 32.5, whereas that of control patients slightly worsened from 52.5 to 56.5 (p < 0.001). In the on phase the median DRS score improved 50% in pallidotomy patients compared with no change in controls. The UPDRS 2 off score improved with a median of 7 in the pallidotomy group. Two treated patients had major adverse effects. Interpretation Unilateral pallidotomy is an effective treatment in patients with advanced Parkinson's disease, who have an unsatisfactory response to pharmacological treatment.	Univ Amsterdam, Acad Med Ctr, Dept Neurol H2 222, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Clin Epidemiol & Biostat, NL-1100 DE Amsterdam, Netherlands; Univ Amsterdam, Acad Med Ctr, Dept Neurosurg, NL-1100 DE Amsterdam, Netherlands; St Elisabeth Hosp, Dept Neurol, Tilburg, Netherlands; St Elisabeth Hosp, Dept Neurosurg, Tilburg, Netherlands; Martini Hosp, Dept Neurol, Groningen, Netherlands; State Univ Groningen, Acad Hosp Groningen, Dept Neurol, Groningen, Netherlands; State Univ Groningen, Acad Hosp Groningen, Dept Neurosurg, Groningen, Netherlands	University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; University of Amsterdam; Academic Medical Center Amsterdam; Elisabeth-TweeSteden Ziekenhuis (ETZ); Elisabeth-TweeSteden Ziekenhuis (ETZ); Martini Hospital; University of Groningen; University of Groningen; University of Groningen	de Bie, RMA (corresponding author), Univ Amsterdam, Acad Med Ctr, Dept Neurol H2 222, POB 22700, NL-1100 DE Amsterdam, Netherlands.		Schuurman, Rick/ABE-9100-2021	de Bie, Rob/0000-0001-5267-0784				Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; de Haan R, 1993, Ned Tijdschr Geneeskd, V137, P917; deBoer AGEM, 1996, J NEUROL NEUROSUR PS, V61, P70, DOI 10.1136/jnnp.61.1.70; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Fahn S., 1987, RECENT DEV PARKINSON, VVol. 2, P153; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOETZ CG, 1994, MOVEMENT DISORD, V9, P390, DOI 10.1002/mds.870090403; HOEHN MM, 1967, NEUROLOGY, V17, P427, DOI 10.1212/WNL.17.5.427; HUGHES AJ, 1992, J NEUROL NEUROSUR PS, V55, P181, DOI 10.1136/jnnp.55.3.181; JENSEN MP, 1992, HDB PAIN ASSESSMENT, P135; Johansson F, 1997, J NEUROL NEUROSUR PS, V62, P125, DOI 10.1136/jnnp.62.2.125; Kishore A, 1997, BRAIN, V120, P729, DOI 10.1093/brain/120.5.729; LANG AE, 1995, MOVEMENT DISORD, V10, P527, DOI 10.1002/mds.870100426; Lang AE, 1997, NEW ENGL J MED, V337, P1036, DOI 10.1056/NEJM199710093371503; LANGSTON JW, 1992, MOVEMENT DISORD, V7, P2, DOI 10.1002/mds.870070103; Limousin P, 1998, NEW ENGL J MED, V339, P1105, DOI 10.1056/NEJM199810153391603; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; MAHONEY F I, 1965, Md State Med J, V14, P61; Masterman D, 1998, ARCH NEUROL-CHICAGO, V55, P1201, DOI 10.1001/archneur.55.9.1201; Merello M, 1997, J NEUROL NEUROSUR PS, V63, P210, DOI 10.1136/jnnp.63.2.210; Ondo WG, 1998, NEUROLOGY, V50, P266, DOI 10.1212/WNL.50.1.266; POCOCK SJ, 1975, BIOMETRICS, V31, P103, DOI 10.2307/2529712; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Shannon KM, 1998, NEUROLOGY, V50, P434, DOI 10.1212/WNL.50.2.434; Uitti RJ, 1997, NEUROLOGY, V49, P1072, DOI 10.1212/WNL.49.4.1072	25	111	110	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1665	1669		10.1016/S0140-6736(99)03556-4	http://dx.doi.org/10.1016/S0140-6736(99)03556-4			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568567				2022-12-28	WOS:000083652800008
J	Morgentaler, A				Morgentaler, A			Male impotence	LANCET			English	Article							ERECTILE DYSFUNCTION; INTRACAVERNOUS INJECTION; RADICAL PROSTATECTOMY; CORPUS CAVERNOSUM; ORAL SILDENAFIL; NITRIC-OXIDE; MEN; RELAXATION; VIAGRA	Erectile dysfunction can be devastating for men and for their partners. A good sexual history and focused physical examination can provide clues as to whether the underlying cause is psychogenic or organic. Diagnostic investigation should be tailored to the clinical picture. Oral medications now represent first-line therapy. Penile injection therapy and vacuum constrictive devices are reasonable choices for men in whom oral therapy fails or is contraindicated. The penile prosthesis provides a reliable long-term solution with high satisfaction rates. Psychotherapy may be indicated. Physicians can have a positive impact on the quality of life of patients by providing a non-judgmental and supportive environment for discussion and management of impotence.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Div Urol,Male Infertil & Impotence Program, Boston, MA USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School	Morgentaler, A (corresponding author), 330 Brookline Ave, Boston, MA 02215 USA.	amorgent@caregroup.harvard.edu						Ballard SA, 1998, J UROLOGY, V159, P2164, DOI 10.1016/S0022-5347(01)63299-3; Becker AJ, 1998, J UROLOGY, V159, P1214, DOI 10.1016/S0022-5347(01)63559-6; BERMAN J, 1998, MED ASPECTS HUM SEX, V1, P15; Cheitlin MD, 1999, J AM COLL CARDIOL, V33, P273, DOI 10.1016/S0735-1097(98)00656-1; Derry FA, 1998, NEUROLOGY, V51, P1629, DOI 10.1212/WNL.51.6.1629; FELDMAN HA, 1994, J UROLOGY, V151, P54, DOI 10.1016/S0022-5347(17)34871-1; Goldstein I, 1998, NEW ENGL J MED, V338, P1397, DOI 10.1056/NEJM199805143382001; Gupta R, 1997, J UROLOGY, V157, P1681, DOI 10.1016/S0022-5347(01)64834-1; HEATON JPW, 1995, UROLOGY, V45, P200, DOI 10.1016/0090-4295(95)80005-0; Jarow JP, 1996, J UROLOGY, V155, P1609, DOI 10.1016/S0022-5347(01)66142-1; KARACAN I, 1970, MED ASPECTS HUM SEX, V4, P227; Khoudary KP, 1997, UROLOGY, V50, P395, DOI 10.1016/S0090-4295(97)00280-X; Laumann EO, 1999, JAMA-J AM MED ASSOC, V281, P537, DOI 10.1001/jama.281.6.537; MASTERS WH, 1990, HUMAN SEXUAL INADEQU; MONTORSI F, 1993, SCAND J UROL NEPHROL, V27, P399, DOI 10.3109/00365599309180453; MORALES A, 1988, UROL CLIN N AM, V15, P87; Morgentaler A, 1996, JAMA-J AM MED ASSOC, V276, P1904, DOI 10.1001/jama.276.23.1904; MORGENTALER A, 1996, AM UROLOGICAL ASS UP, V15, P70; MORLEY JE, 1988, AM J MED, V84, P445, DOI 10.1016/0002-9343(88)90264-1; MORLEY JE, 1988, HOSP PRACT, V23, P139; *NIH, 1998, JAMA-J AM MED ASSOC, V270, P83; Penson DF, 1996, BIOL REPROD, V55, P567, DOI 10.1095/biolreprod55.3.567; Porst H, 1997, INT J IMPOT RES, V9, P187, DOI 10.1038/sj.ijir.3900318; RAJFER J, 1992, NEW ENGL J MED, V326, P90, DOI 10.1056/NEJM199201093260203; Rendell MS, 1999, JAMA-J AM MED ASSOC, V281, P421, DOI 10.1001/jama.281.5.421; SCHRAMEK P, 1990, BRIT J UROL, V65, P68, DOI 10.1111/j.1464-410X.1990.tb14664.x; SOHN MHH, 1994, J ANDROL, V15, P183; VIRAG R, 1982, LANCET, V2, P938; Wespes E, 1997, J UROLOGY, V157, P1678, DOI 10.1016/S0022-5347(01)64833-X; Zippe CD, 1998, UROLOGY, V52, P963, DOI 10.1016/S0090-4295(98)00443-9	30	53	58	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1713	1718		10.1016/S0140-6736(99)06586-1	http://dx.doi.org/10.1016/S0140-6736(99)06586-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568586				2022-12-28	WOS:000083652800040
J	Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK				Taylor, KA; Schmitz, H; Reedy, MC; Goldman, YE; Franzini-Armstrong, C; Sasaki, H; Tregear, RT; Poole, K; Lucaveche, C; Edwards, RJ; Chen, LF; Winkler, H; Reedy, MK			Tomographic 3D reconstruction of quick-frozen, Ca2+-activated contracting insect flight muscle	CELL			English	Article							RABBIT SKELETAL-MUSCLE; MYOSIN HEADS; CROSS-BRIDGES; LIGHT-CHAIN; 3-DIMENSIONAL STRUCTURE; ELECTRON-MICROSCOPY; FORCE GENERATION; FISH MUSCLE; ADP RELEASE; ACTIN	Motor actions of myosin were directly visualized by electron tomography of insect flight muscle quick-frozen during contraction. In 3D images, active crossbridges are usually single myosin heads, bound preferentially to actin target zones sited midway between troponins. Active attached bridges (similar to 30% of all heads) depart markedly in axial and azimuthal angles from Rayment's rigor acto-S1 model, one-third requiring motor domain (MD) tilting on actin, and two-thirds keeping rigor contact with actin while the light chain domain (LCD) tilts axially from similar to 105 degrees to similar to 70 degrees. The results suggest the MD tilts and slews on actin from weak to strong binding, followed by swinging of the LCD through an similar to 35 degrees axial angle, giving an similar to 13 nm interaction distance and an similar to 4-6 nm working stroke.	Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA; Univ Penn, Penn Muscle Inst, Philadelphia, PA 19104 USA; MRC, Mol Biol Lab, Cambridge CB2 2QH, England; Duke Univ, Med Ctr, Dept Cell Biol, Durham, NC 27710 USA; Max Planck Inst Med Forsch, Biophys Abt, D-69120 Heidelberg, Germany	State University System of Florida; Florida State University; University of Pennsylvania; MRC Laboratory Molecular Biology; Duke University; Max Planck Society	Taylor, KA (corresponding author), Florida State Univ, Inst Mol Biophys, Tallahassee, FL 32306 USA.			Edwards, Robert/0000-0003-4446-1194; Sasaki, Hiroyuki/0000-0002-5358-5853	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR014317] Funding Source: NIH RePORTER; NIAMS NIH HHS [R01 AR014317] Funding Source: Medline	NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		Adhikari B, 1997, P NATL ACAD SCI USA, V94, P9643, DOI 10.1073/pnas.94.18.9643; Bershitsky SY, 1997, NATURE, V388, P186, DOI 10.1038/40651; Brenner B., 1990, MUSCLE MECH BIOLOGIC, P77; Conibear PB, 1998, BIOPHYS J, V75, P926, DOI 10.1016/S0006-3495(98)77581-2; Cooke R, 1997, PHYSIOL REV, V77, P671, DOI 10.1152/physrev.1997.77.3.671; Corrie JET, 1999, NATURE, V400, P425, DOI 10.1038/22704; DANTZIG JA, 1992, J PHYSIOL-LONDON, V451, P247, DOI 10.1113/jphysiol.1992.sp019163; Dobbie I, 1998, NATURE, V396, P383, DOI 10.1038/24647; Dominguez R, 1998, CELL, V94, P559, DOI 10.1016/S0092-8674(00)81598-6; FLICKER PF, 1982, J MOL BIOL, V162, P495, DOI 10.1016/0022-2836(82)90540-X; Frank J, 1992, ELECT TOMOGRAPHY; Goldman YE, 1998, CELL, V93, P1, DOI 10.1016/S0092-8674(00)81137-X; Gulick AM, 1997, BIOESSAYS, V19, P561, DOI 10.1002/bies.950190707; GUTH K, 1986, PFLUG ARCH EUR J PHY, V407, P552, DOI 10.1007/BF00657515; HARFORD JJ, 1992, BIOPHYS J, V63, P387, DOI 10.1016/S0006-3495(92)81613-2; HEINRICH B, 1996, HTERMAL WARRIORS STR, P127; HIROSE K, 1993, J MUSCLE RES CELL M, V14, P432, DOI 10.1007/BF00121295; HIROSE K, 1994, J CELL BIOL, V127, P763, DOI 10.1083/jcb.127.3.763; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Holmes KC, 1996, CURR OPIN STRUC BIOL, V6, P781, DOI 10.1016/S0959-440X(96)80008-X; Hopkins SC, 1998, BIOPHYS J, V74, P3093, DOI 10.1016/S0006-3495(98)78016-6; Houdusse A, 1999, CELL, V97, P459, DOI 10.1016/S0092-8674(00)80756-4; IRVING M, 1995, NATURE, V375, P688, DOI 10.1038/375688a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; JONTES JD, 1995, NATURE, V378, P751, DOI 10.1038/378751a0; Lenart TD, 1996, BIOPHYS J, V71, P2289, DOI 10.1016/S0006-3495(96)79464-X; LOMBARDI V, 1995, NATURE, V374, P553, DOI 10.1038/374553a0; MOLLOY JE, 1995, NATURE, V378, P209, DOI 10.1038/378209a0; MORRIS EP, 1991, J STRUCT BIOL, V107, P237, DOI 10.1016/1047-8477(91)90049-3; OSTAP EM, 1995, BIOPHYS J, V69, P177, DOI 10.1016/S0006-3495(95)79888-5; RAYMENT I, 1993, SCIENCE, V261, P58, DOI 10.1126/science.8316858; RAYMENT I, 1993, SCIENCE, V261, P50, DOI 10.1126/science.8316857; REEDY MC, 1994, J MOL BIOL, V239, P52, DOI 10.1006/jmbi.1994.1350; REEDY MC, 1988, J MOL BIOL, V204, P357, DOI 10.1016/0022-2836(88)90582-7; REEDY MK, 1985, J MOL BIOL, V185, P145, DOI 10.1016/0022-2836(85)90188-3; REEDY MK, 1968, J MOL BIOL, V31, P155, DOI 10.1016/0022-2836(68)90437-3; REEDY MK, 1993, ADV EXP MED BIOL, V332, P33; Schmitz H, 1996, J MOL BIOL, V264, P279, DOI 10.1006/jmbi.1996.0641; Schmitz H, 1997, J CELL BIOL, V139, P695, DOI 10.1083/jcb.139.3.695; Taylor KA, 1997, J STRUCT BIOL, V120, P372, DOI 10.1006/jsbi.1997.3932; Tregear RT, 1998, BIOPHYS J, V74, P1439, DOI 10.1016/S0006-3495(98)77856-7; Tsaturyan AK, 1999, BIOPHYS J, V77, P354, DOI 10.1016/S0006-3495(99)76895-5; VARRIANOMARSTON E, 1984, J MUSCLE RES CELL M, V5, P363, DOI 10.1007/BF00818256; Walker M, 1999, P NATL ACAD SCI USA, V96, P465, DOI 10.1073/pnas.96.2.465; Wendt T, 1997, J STRUCT BIOL, V118, P1, DOI 10.1006/jsbi.1996.3834; WHITTAKER M, 1995, NATURE, V378, P748, DOI 10.1038/378748a0; Winkler H, 1996, J MOL BIOL, V264, P302, DOI 10.1006/jmbi.1996.0642; Winkler H, 1996, ULTRAMICROSCOPY, V63, P125, DOI 10.1016/0304-3991(96)00024-1; Wong WNW, 1999, BIOCHEMISTRY-US, V38, P1365, DOI 10.1021/bi982467g	49	134	137	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					421	431		10.1016/S0092-8674(00)81528-7	http://dx.doi.org/10.1016/S0092-8674(00)81528-7			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571184	Bronze			2022-12-28	WOS:000083709300009
J	Tan, Y; Li, WH				Tan, Y; Li, WH			Vision - Trichromatic vision in prosimians	NATURE			English	Article							COLOR-VISION; BUSH-BABY; PIGMENTS; PHOTOPIGMENTS; MONKEY; GENE; RED		Univ Chicago, Dept Ecol & Evolut, Chicago, IL 60637 USA	University of Chicago	Tan, Y (corresponding author), Univ Chicago, Dept Ecol & Evolut, 1101 E 57th St, Chicago, IL 60637 USA.			Li, Wen-Hsiung/0000-0003-1086-1456				ASENJO AB, 1994, NEURON, V12, P1131, DOI 10.1016/0896-6273(94)90320-4; Casagrande Vivien A., 1994, Cerebral Cortex, V10, P201; Deegan JF, 1996, AM J PRIMATOL, V40, P55, DOI 10.1002/(SICI)1098-2345(1996)40:1<55::AID-AJP4>3.0.CO;2-#; HUNT DM, 1993, VISION RES, V33, P147, DOI 10.1016/0042-6989(93)90153-N; JACOBS GH, 1993, AM J PRIMATOL, V30, P243, DOI 10.1002/ajp.1350300307; Jacobs GH, 1996, NATURE, V382, P156, DOI 10.1038/382156a0; JACOBS GH, 1993, BIOL REV, V68, P413, DOI 10.1111/j.1469-185X.1993.tb00738.x; MERBS SL, 1993, PHOTOCHEM PHOTOBIOL, V58, P706, DOI 10.1111/j.1751-1097.1993.tb04956.x; NEITZ M, 1991, SCIENCE, V252, P971, DOI 10.1126/science.1903559; Shyue SK, 1998, J MOL EVOL, V46, P697, DOI 10.1007/PL00006350; TRAVIS DS, 1988, VISION RES, V28, P481, DOI 10.1016/0042-6989(88)90170-8; Yamada ES, 1998, VISION RES, V38, P3345, DOI 10.1016/S0042-6989(97)00412-4; Zhou YH, 1997, J MOL EVOL, V45, P610, DOI 10.1007/PL00006265	13	130	130	1	38	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					36	36		10.1038/46947	http://dx.doi.org/10.1038/46947			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573416	Bronze			2022-12-28	WOS:000083638600033
J	Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H				Askling, J; Sorensen, P; Ekbom, A; Frisch, M; Melbye, M; Glimelius, B; Hjalgrim, H			Is history of squamous-cell skin cancer a marker of poor prognosis in patients with cancer?	ANNALS OF INTERNAL MEDICINE			English	Article						carcinoma, squamous cell; lymphoma, non-Hodgkin; colonic neoplasms; prostatic neoplasms; lung neoplasms; breast neoplasms	CYTOKINE DYSREGULATION; CARCINOMA; RISK; LYMPHOMA	Background: Nonmelanoma skin cancer is associated with increased occurrence of subsequent cancer and death from cancer, but it is not known whether a history of skin cancer is associated with poor prognosis after a second diagnosis of cancer. Objective: To determine whether history of squamous-cell skin cancer is a marker of poor prognosis in patients with cancer. Design: Population-based cohort study. Setting: Sweden, 1958 to 1996. Patients: All patients in the Swedish Cancer Registry with or without a first diagnosis of squamous-cell skin cancer and a subsequent or first diagnosis of non-Hodgkin lymphoma (including chronic lymphocytic leukemia) or cancer of the colon, breast, prostate, or lung. Measurements: Relative risk (RR) for death determined by using Cox proportional hazards regression analysis. Results: Patients with a history of squamous-cell skin cancer had a significantly greater risk for death than those with no such history after receiving a diagnosis of non-Hodgkin lymphoma (RR, 1.33). colon cancer (RR, 1.24), breast cancer (RR, 1.19), or prostate cancer (RR, 1.17). Patients with lung cancer and a history of squamous-cell skin cancer who survived for 1 year after diagnosis of lung cancer also had an increased risk for death (RR, 1.29). Conclusion: Patients with a registered history of squamous-cell skin cancer have a poor prognosis after diagnosis of subsequent cancer and warrant careful medical attention.	Karolinska Inst, Dept Med Epidemiol, S-17177 Stockholm, Sweden; State Serum Inst, Dept Epidemiol Res, DK-2300 Copenhagen S, Denmark; Harvard Sch Publ Hlth, Boston, MA USA; NCI, Viral Epidemiol Branch, Rockville, MD 20852 USA; Univ Uppsala Hosp, Uppsala, Sweden	Karolinska Institutet; Statens Serum Institut; Harvard University; Harvard T.H. Chan School of Public Health; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Uppsala University; Uppsala University Hospital	Askling, J (corresponding author), Karolinska Inst, Dept Med Epidemiol, Box 281, S-17177 Stockholm, Sweden.	Johan.Askling@mep.ki.se	Frisch, Morten/E-9206-2016; Hjalgrim, Henrik/AAG-4973-2021	Frisch, Morten/0000-0002-3864-8860; melbye, mads/0000-0001-8264-6785; Sorensen, Per Soelberg/0000-0002-2818-3780				Adami HO, 1996, INT J CANCER, V67, P764, DOI 10.1002/(SICI)1097-0215(19960917)67:6<764::AID-IJC3>3.0.CO;2-P; ADAMI J, 1995, BRIT MED J, V310, P1491, DOI 10.1136/bmj.310.6993.1491; [Anonymous], 1996, ACTA ONCOL, V35, P47; Au WW, 1996, ENVIRON HEALTH PERSP, V104, P579, DOI 10.2307/3432826; BIRKELAND SA, 1995, INT J CANCER, V60, P183, DOI 10.1002/ijc.2910600209; BRASH DE, 1991, P NATL ACAD SCI USA, V88, P10124, DOI 10.1073/pnas.88.22.10124; CLAYTON D, 1993, STAT METHODS EPIDEMI; Clerici M, 1998, J NATL CANCER I, V90, P261, DOI 10.1093/jnci/90.4.261; Dreyer L, 1997, APMIS, V105, P9; Frisch M, 1996, ANN INTERN MED, V125, P815, DOI 10.7326/0003-4819-125-10-199611150-00005; FRISCH M, 1995, AM J EPIDEMIOL, V141, P916, DOI 10.1093/oxfordjournals.aje.a117358; HARRIS NL, 1994, BLOOD, V84, P1361; HJALGRIM H, IN PRESS INT J CANC; Kahn HS, 1998, JAMA-J AM MED ASSOC, V280, P910, DOI 10.1001/jama.280.10.910; KINLEN LJ, 1992, IARC SCI PUBL, V116, P237; Levi F, 1998, AM J EPIDEMIOL, V147, P722; Levi F, 1996, BRIT J CANCER, V74, P1847, DOI 10.1038/bjc.1996.642; Levi F, 1997, AM J EPIDEMIOL, V146, P734; Lucey DR, 1996, CLIN MICROBIOL REV, V9, P532, DOI 10.1128/CMR.9.4.532; Lunde A S, 1980, Vital Health Stat 2, P1; MATTSSON B, 1984, ACTA RADIOL ONCOL, V23, P305, DOI 10.3109/02841868409136026; STENBECK M, 1995, ACTA ONCOL, V34, P881, DOI 10.3109/02841869509127200; Teppo L, 1999, ACTA ONCOL, V38, P283; TEPPO L, 1985, J NATL CANCER I, V75, P207; Wassberg C, 1999, INT J CANCER, V80, P511, DOI 10.1002/(SICI)1097-0215(19990209)80:4<511::AID-IJC5>3.3.CO;2-G; WEI QY, 1994, CANCER RES, V54, P437	26	21	21	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					655	+		10.7326/0003-4819-131-9-199911020-00004	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00004			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577327				2022-12-28	WOS:000083446200003
J	Zollman, C; Vickers, A				Zollman, C; Vickers, A			ABC of complementary medicine - Complementary medicine and the patient	BRITISH MEDICAL JOURNAL			English	Review									Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA; Res Council Complementary Med, London, England	Memorial Sloan Kettering Cancer Center								Benson Herbert, 1996, TIMELESS HEALING POW; BISHOP B, 1996, TIME HEL; SHARMA U, 1995, COMPLEMENTARY MED TO	3	40	40	0	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1486	1489		10.1136/bmj.319.7223.1486	http://dx.doi.org/10.1136/bmj.319.7223.1486			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582937	Green Published			2022-12-28	WOS:000084129200026
J	Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH				Reinherz, EL; Tan, KM; Tang, L; Kern, P; Liu, JH; Xiong, Y; Hussey, RE; Smolyar, A; Hare, B; Zhang, RG; Joachimiak, A; Chang, HC; Wagner, G; Wang, JH			The crystal structure of a T cell receptor in complex with peptide and MHC class II	SCIENCE			English	Review							TOXIC LYMPHOCYTES-T; BOUND SINGLE PEPTIDES; MYELIN BASIC-PROTEIN; TCR FAB FRAGMENT; ALPHA-CHAIN; ANTIGEN RECEPTOR; 3-DIMENSIONAL STRUCTURE; BETA-CHAIN; SUPERANTIGEN RECOGNITION; POSITIVE SELECTION	The crystal structure of a complex involving the D10 T cell receptor (TCR), 16-residue foreign peptide antigen, and the I-A(k) self major histocompatibility complex (MHC) class II molecule is reported at 3.2 angstrom resolution. The D10 TCR is oriented in an orthogonal mode relative to its peptide-MHC (pMHC) Ligand, necessitated by the amino-terminal extension of peptide residues projecting from the MHC class II antigen-binding groove as part of a mini beta sheet. Consequently, the disposition of D10 complementarity-determining region Loops is altered relative to that of most pMHCI-specific TCRs; the Latter TCRs assume a diagonal orientation, although with substantial variability. Peptide recognition, which involves P-1 to P8 residues, is dominated by the V alpha domain, which also binds to the class II MHC beta(1) helix. That docking is Limited to one segment of MHC-bound peptide offers an explanation for epitope recognition and altered peptide Ligand effects, suggests a structural basis for alloreactivity, and illustrates how bacterial superantigens can span the TCR-pMHCII surface.	Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Biol Chem & Mol Pharmacol, Boston, MA 02115 USA; Argonne Natl Lab, Biosci Div, Argonne, IL 60439 USA	Harvard University; Dana-Farber Cancer Institute; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; United States Department of Energy (DOE); Argonne National Laboratory	Reinherz, EL (corresponding author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Immunobiol Lab, 44 Binney St, Boston, MA 02115 USA.	ellis_reinherz@dfci.harvard.edu; jwang@red.dfci.harvard.edu			NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI037581, R01AI019807, R37AI019807] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM056008] Funding Source: NIH RePORTER; NIAID NIH HHS [AI/CA37581, AI19807] Funding Source: Medline; NIGMS NIH HHS [GM56008] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ACUTO O, 1984, P NATL ACAD SCI-BIOL, V81, P3851, DOI 10.1073/pnas.81.12.3851; ALLEN PM, 1987, NATURE, V327, P713, DOI 10.1038/327713a0; ANDREANI M, 1994, INT J MULTIPHAS FLOW, V20, P1, DOI 10.1016/0301-9322(94)90069-8; ASHWELL JD, 1990, ANNU REV IMMUNOL, V8, P139, DOI 10.1146/annurev.immunol.8.1.139; Backstrom BT, 1998, SCIENCE, V281, P835, DOI 10.1126/science.281.5378.835; Benacerraf B, 1973, Harvey Lect, V67, P109; BENACERRAF B, 1978, J IMMUNOL, V120, P1809; BENTLEY GA, 1995, SCIENCE, V267, P1984, DOI 10.1126/science.7701320; BEVAN MJ, 1977, NATURE, V269, P417, DOI 10.1038/269417a0; BIDDISON WE, 1982, J EXP MED, V156, P1065, DOI 10.1084/jem.156.4.1065; Blackman MA, 1996, IMMUNOL RES, V15, P98, DOI 10.1007/BF02918500; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Carson RT, 1997, IMMUNITY, V7, P387, DOI 10.1016/S1074-7613(00)80360-X; CHAN SH, 1993, CELL, V73, P225, DOI 10.1016/0092-8674(93)90225-F; CHAN SH, 1993, IMMUNOL REV, V135, P119, DOI 10.1111/j.1600-065X.1993.tb00646.x; CHANG HC, 1994, P NATL ACAD SCI USA, V91, P11408, DOI 10.1073/pnas.91.24.11408; CHICZ RM, 1992, NATURE, V358, P764, DOI 10.1038/358764a0; CHOTHIA C, 1975, NATURE, V256, P705, DOI 10.1038/256705a0; CHOTHIA C, 1988, EMBO J, V7, P3745, DOI 10.1002/j.1460-2075.1988.tb03258.x; CLEVERS H, 1988, ANNU REV IMMUNOL, V6, P629, DOI 10.1146/annurev.iy.06.040188.003213; CONNOLLY JM, 1990, P NATL ACAD SCI USA, V87, P2137, DOI 10.1073/pnas.87.6.2137; DALY K, 1995, J IMMUNOL, V155, P27; Daniel C, 1998, IMMUNITY, V8, P543, DOI 10.1016/S1074-7613(00)80559-2; DAVIS CB, 1993, CELL, V73, P237, DOI 10.1016/0092-8674(93)90226-G; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DECKHUT AM, 1994, J EXP MED, V180, P1931, DOI 10.1084/jem.180.5.1931; Dessen A, 1997, IMMUNITY, V7, P473, DOI 10.1016/S1074-7613(00)80369-6; Ding YH, 1999, IMMUNITY, V11, P45, DOI 10.1016/S1074-7613(00)80080-1; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Donson D, 1997, J IMMUNOL, V158, P5229; DOYLE C, 1987, NATURE, V330, P256, DOI 10.1038/330256a0; EVAVOLD BD, 1995, IMMUNITY, V2, P655, DOI 10.1016/1074-7613(95)90010-1; FABBI M, 1984, NATURE, V312, P269, DOI 10.1038/312269a0; FEHLING HJ, 1995, NATURE, V375, P795, DOI 10.1038/375795a0; FIELDS BA, 1995, SCIENCE, V270, P1821, DOI 10.1126/science.270.5243.1821; FOWLKES BJ, 1989, ADV IMMUNOL, V44, P207, DOI 10.1016/S0065-2776(08)60643-4; Frelinger JA, 1996, IMMUNOL REV, V154, P45, DOI 10.1111/j.1600-065X.1996.tb00929.x; Fremont DH, 1996, SCIENCE, V272, P1001, DOI 10.1126/science.272.5264.1001; FREMONT DH, 1992, SCIENCE, V257, P919, DOI 10.1126/science.1323877; Fremont DH, 1998, IMMUNITY, V8, P305, DOI 10.1016/S1074-7613(00)80536-1; Gao GF, 1997, NATURE, V387, P630, DOI 10.1038/42523; Garboczi DN, 1996, NATURE, V384, P134, DOI 10.1038/384134a0; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; GASCOIGNE NRJ, 1984, NATURE, V310, P387, DOI 10.1038/310387a0; GERMAIN RN, 1994, CELL, V76, P287, DOI 10.1016/0092-8674(94)90336-0; Ghendler Y, 1998, P NATL ACAD SCI USA, V95, P10061, DOI 10.1073/pnas.95.17.10061; Hare BJ, 1999, NAT STRUCT BIOL, V6, P574; HAYDAY AC, 1985, NATURE, V316, P828, DOI 10.1038/316828a0; HEDRICK SM, 1984, NATURE, V308, P153, DOI 10.1038/308153a0; HEDRICK SM, 1984, NATURE, V308, P149, DOI 10.1038/308149a0; HONG SC, 1992, CELL, V69, P999, DOI 10.1016/0092-8674(92)90618-M; Hong SC, 1997, J IMMUNOL, V159, P4395; Housset D, 1997, EMBO J, V16, P4205, DOI 10.1093/emboj/16.14.4205; HUNT DF, 1992, SCIENCE, V256, P1817, DOI 10.1126/science.1319610; Ignatowicz L, 1997, IMMUNITY, V7, P179, DOI 10.1016/S1074-7613(00)80521-X; JARDETZKY TS, 1994, NATURE, V368, P711, DOI 10.1038/368711a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KAYE J, 1983, J EXP MED, V158, P836, DOI 10.1084/jem.158.3.836; Kersh GJ, 1996, J EXP MED, V184, P1259, DOI 10.1084/jem.184.4.1259; Kersh GJ, 1998, IMMUNITY, V9, P817, DOI 10.1016/S1074-7613(00)80647-0; KONIG R, 1992, NATURE, V356, P796, DOI 10.1038/356796a0; Koyasu S, 1997, INT IMMUNOL, V9, P1475, DOI 10.1093/intimm/9.10.1475; KOZONO H, 1994, NATURE, V369, P151, DOI 10.1038/369151a0; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KRENSKY AM, 1982, P NATL ACAD SCI-BIOL, V79, P2365, DOI 10.1073/pnas.79.7.2365; KRUISBEEK AM, 1993, CURR OPIN IMMUNOL, V5, P227, DOI 10.1016/0952-7915(93)90009-H; LABRECQUE N, 1994, J EXP MED, V180, P1921, DOI 10.1084/jem.180.5.1921; LAWRENCE MC, 1993, J MOL BIOL, V234, P946, DOI 10.1006/jmbi.1993.1648; LEVELT CN, 1995, EUR J IMMUNOL, V25, P1257, DOI 10.1002/eji.1830250519; Li HM, 1998, IMMUNITY, V9, P807, DOI 10.1016/S1074-7613(00)80646-9; Liu CP, 1997, J EXP MED, V186, P1441, DOI 10.1084/jem.186.9.1441; Liu J, 1996, J BIOL CHEM, V271, P33639, DOI 10.1074/jbc.271.52.33639; Lyons DS, 1996, IMMUNITY, V5, P53, DOI 10.1016/S1074-7613(00)80309-X; MADDEN DR, 1992, CELL, V70, P1035, DOI 10.1016/0092-8674(92)90252-8; MADDEN DR, 1995, ANNU REV IMMUNOL, V13, P587, DOI 10.1146/annurev.iy.13.040195.003103; Marrack P, 1986, Adv Immunol, V38, P1, DOI 10.1016/S0065-2776(08)60005-X; MATSUI K, 1994, P NATL ACAD SCI USA, V91, P12862, DOI 10.1073/pnas.91.26.12862; MATSUMURA M, 1992, SCIENCE, V257, P927, DOI 10.1126/science.1323878; MCKENZIE IFC, 1979, J EXP MED, V150, P1323, DOI 10.1084/jem.150.6.1323; MEUER SC, 1982, P NATL ACAD SCI-BIOL, V79, P4395, DOI 10.1073/pnas.79.14.4395; MOEBIUS U, 1993, P NATL ACAD SCI USA, V90, P8259, DOI 10.1073/pnas.90.17.8259; MOMBURG F, 1994, J EXP MED, V179, P1613, DOI 10.1084/jem.179.5.1613; Mosyak L, 1998, IMMUNITY, V9, P377, DOI 10.1016/S1074-7613(00)80620-2; Murthy VL, 1997, STRUCTURE, V5, P1385, DOI 10.1016/S0969-2126(97)00288-8; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; NOVOTNY J, 1986, P NATL ACAD SCI USA, V83, P742, DOI 10.1073/pnas.83.3.742; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PATTEN P, 1984, NATURE, V312, P40, DOI 10.1038/312040a0; PORTOLES P, 1989, J MOL CELL IMMUNOL, V4, P129; REAY PA, 1994, J IMMUNOL, V152, P3946; REINHERZ EL, 1980, CELL, V19, P821, DOI 10.1016/0092-8674(80)90072-0; REINHERZ EL, 1980, P NATL ACAD SCI-BIOL, V77, P1588, DOI 10.1073/pnas.77.3.1588; REINHERZ EL, 1983, IMMUNOL REV, V74, P83, DOI 10.1111/j.1600-065X.1983.tb01085.x; REINHERZ EL, UNPUB; RUDENSKY AY, 1991, NATURE, V353, P622, DOI 10.1038/353622a0; SAITO H, 1984, NATURE, V312, P36, DOI 10.1038/312036a0; SALTER RD, 1990, NATURE, V345, P41, DOI 10.1038/345041a0; SantAngelo DB, 1996, IMMUNITY, V4, P367, DOI 10.1016/S1074-7613(00)80250-2; SCHERER MT, 1993, ANNU REV CELL BIOL, V9, P101, DOI 10.1146/annurev.cb.09.110193.000533; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; SHERIFF S, 1987, J MOL BIOL, V197, P273, DOI 10.1016/0022-2836(87)90124-0; SHERMAN LA, 1993, ANNU REV IMMUNOL, V11, P385, DOI 10.1146/annurev.immunol.11.1.385; SHINKAI Y, 1993, SCIENCE, V259, P822, DOI 10.1126/science.8430336; SIM GK, 1984, NATURE, V312, P771; Smith KJ, 1998, J EXP MED, V188, P1511, DOI 10.1084/jem.188.8.1511; Speir JA, 1998, IMMUNITY, V8, P553, DOI 10.1016/S1074-7613(00)80560-9; STERN LJ, 1994, STRUCTURE, V2, P245, DOI 10.1016/S0969-2126(00)00026-5; STERN LJ, 1994, NATURE, V368, P215, DOI 10.1038/368215a0; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; TEH HS, 1988, NATURE, V335, P229, DOI 10.1038/335229a0; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; van Meerwijk J P, 1994, Semin Immunol, V6, P231, DOI 10.1006/smim.1994.1030; VANMEERWIJK JPM, 1993, SCIENCE, V261, P911, DOI 10.1126/science.8102208; Wang JH, 1998, EMBO J, V17, P10, DOI 10.1093/emboj/17.1.10; WEBB SR, 1994, CURR OPIN IMMUNOL, V6, P467, DOI 10.1016/0952-7915(94)90129-5; WOODLAND DL, 1993, IMMUNOL TODAY, V14, P208, DOI 10.1016/0167-5699(93)90164-G; WUCHERPFENNIG KW, 1995, CELL, V80, P695, DOI 10.1016/0092-8674(95)90348-8; Xu Y, 1996, P NATL ACAD SCI USA, V93, P2169, DOI 10.1073/pnas.93.5.2169; YANAGI Y, 1984, NATURE, V308, P145, DOI 10.1038/308145a0; Ysern X, 1998, NAT STRUCT BIOL, V5, P412, DOI 10.1038/nsb0698-412; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0; ZINKERNAGEL RM, 1978, J EXP MED, V147, P882, DOI 10.1084/jem.147.3.882	127	347	357	0	22	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1913	1921		10.1126/science.286.5446.1913	http://dx.doi.org/10.1126/science.286.5446.1913			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583947				2022-12-28	WOS:000084003400040
J	Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E				Wodarz, A; Ramrath, A; Kuchinke, U; Knust, E			Bazooka provides an apical cue for Inscuteable localization in Drosophila neuroblasts	NATURE			English	Article							ASYMMETRIC CELL-DIVISION; CAENORHABDITIS-ELEGANS; DAUGHTER-CELL; PROSPERO; PROTEIN; STAUFEN; MIRANDA; GENE; SEGREGATION; POLARITY	Asymmetric cell division generates daughter cells with different developmental fates from progenitor cells that contain localized determinants. During this division, the asymmetric localization of cell-fate determinants and the orientation of the mitotic spindle must be precisely coordinated. In Drosophila neuroblasts, inscuteable controls both spindle orientation and the asymmetric localization of the cell-fate determinants Prospero and Numb(1). Inscuteable itself is localized in an apical cortical crescent and thus reflects the intrinsic asymmetry of the neuroblast(1,2). Here we show that localization of Inscuteable depends on Bazooka, a protein containing three PDZ domains with overall sequence similarity to Par-3 of Caenorhabditis elegans(3). Bazooka and Inscuteable form a complex that also contains Staufen, a protein responsible for the asymmetric localization of prospero messenger RNA. We propose that, after delamination of the neuroblast from the neuroepithelium, Bazooka provides an asymmetric cue in the apical cytocortex that is required to anchor Inscuteable, As Bazooka is also responsible for the maintenance of apical-basal polarity in epithelial tissues(4), it may be the missing link between epithelial polarity and neuroblast polarity.	Univ Dusseldorf, Inst Genet, D-40225 Dusseldorf, Germany	Heinrich Heine University Dusseldorf	Wodarz, A (corresponding author), Univ Dusseldorf, Inst Genet, Univ Str 1, D-40225 Dusseldorf, Germany.		Knust, Elisabeth/B-4338-2017; Wodarz, Andreas/D-4642-2013	Wodarz, Andreas/0000-0002-0007-6289				BRAND AH, 1993, DEVELOPMENT, V118, P401; Broadus J, 1998, NATURE, V391, P792, DOI 10.1038/35861; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Gonczy P, 1996, TRENDS CELL BIOL, V6, P382, DOI 10.1016/0962-8924(96)10035-0; HIRATA J, 1995, NATURE, V377, P627, DOI 10.1038/377627a0; Hung TJ, 1999, DEVELOPMENT, V126, P127; IkeshimaKataoka H, 1997, NATURE, V390, P625, DOI 10.1038/37641; Izumi Y, 1998, J CELL BIOL, V143, P95, DOI 10.1083/jcb.143.1.95; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; KOELLE MR, 1991, CELL, V67, P59, DOI 10.1016/0092-8674(91)90572-G; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Li P, 1997, CELL, V90, P437, DOI 10.1016/S0092-8674(00)80504-8; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; Schuldt AJ, 1998, GENE DEV, V12, P1847, DOI 10.1101/gad.12.12.1847; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; Shen CP, 1998, GENE DEV, V12, P1837, DOI 10.1101/gad.12.12.1837; SPANA EP, 1995, DEVELOPMENT, V121, P3187; STJOHNSTON D, 1991, CELL, V66, P51, DOI 10.1016/0092-8674(91)90138-O; Tabuse Y, 1998, DEVELOPMENT, V125, P3607; TEPASS U, 1990, CELL, V61, P787, DOI 10.1016/0092-8674(90)90189-L; Willert K, 1997, EMBO J, V16, P3089, DOI 10.1093/emboj/16.11.3089	27	359	363	0	4	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					544	547		10.1038/990128	http://dx.doi.org/10.1038/990128			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591216				2022-12-28	WOS:000084013200060
J	Brandom, BW; Herlich, A				Brandom, BW; Herlich, A			Safety of outpatient dental anaesthesia for children	LANCET			English	Editorial Material							HALOTHANE; SEVOFLURANE; ANESTHESIA		Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Temple Univ, Philadelphia, PA 19122 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Brandom, BW (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA.							Cartwright DP, 1999, ANAESTHESIA, V54, P105, DOI 10.1046/j.1365-2044.1999.471-azedit.x; CRAWFORD MW, 1992, ANESTH ANALG, V75, P1000; D'Eramo EM, 1999, J ORAL MAXIL SURG, V57, P531, DOI 10.1016/S0278-2391(99)90069-1; Friesen RH, 1996, J CLIN MONITOR, V12, P155, DOI 10.1007/BF02078136; KAUFFMAN RE, 1992, PEDIATRICS, V89, P1110; Lerman J, 1996, ANESTHESIOLOGY, V84, P1332, DOI 10.1097/00000542-199606000-00009; SIGURDSSON GH, 1983, ACTA ANAESTH SCAND, V27, P484, DOI 10.1111/j.1399-6576.1983.tb01992.x; Skeehan TM, 1995, J CARDIOTHOR VASC AN, V9, P706, DOI 10.1016/S1053-0770(05)80233-2; THOMAS VJE, 1976, BRIT J ANAESTH, V48, P919, DOI 10.1093/bja/48.9.919; WEAVER JM, 1999, ANESTH PROG, V45, P131; Wodey E, 1997, ANESTHESIOLOGY, V87, P795, DOI 10.1097/00000542-199710000-00012	11	0	0	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1836	1837		10.1016/S0140-6736(99)00278-0	http://dx.doi.org/10.1016/S0140-6736(99)00278-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584715				2022-12-28	WOS:000083909100004
J	Martin, SL; Kilgallen, B; Tsui, AO; Maitra, K; Singh, KK; Kupper, LL				Martin, SL; Kilgallen, B; Tsui, AO; Maitra, K; Singh, KK; Kupper, LL			Sexual behaviors and reproductive health outcomes - Associations with wife abuse in India	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							INFECTION; AGREEMENT; VIOLENCE	Context Wife abuse has been associated with a variety of health concerns. Associations between abuse and reproductive health in India are not well known. Objective To examine relationships between men's reports of wife abuse and reproductive health issues in northern India. Design Structured face-to-face interviews were conducted as part of the male reproductive health supplement of the PERFORM System of Indicators Survey, a systematic multistage survey conducted in 1995-1996. Setting The northern state of Uttar Pradesh, one of the least developed states in India. Participants A total of 6632 married men aged 15 to 65 years who lived with their wives and completed all survey questions for the study variables reported here. Main Measures Physically and sexually abusive behaviors toward wives, sexual activities outside marriage, sexually transmitted disease (STD) symptoms, contraception use, unplanned pregnancies, and sociodemographic characteristics. Results Fifty-four percent of men reported not abusing their wives, while 17% reported physically but not sexually abusing their wives, 22% reported sexual abuse without physical force, and 7% reported sexual abuse with physical force. Abuse was more common among men who had extramarital sex (for sexual abuse using force: odds ratio [OR], 6.22; 95% confidence interval [CI], 3.98-9.72), Similarly, men who had STD symptoms were more likely to abuse their wives (with current symptoms: OR, 2.43; 95% CI, 1.73-3.42). Unplanned pregnancies were significantly more common among wives of abusive men, especially sexually abusive men who used force (OR, 2.62; 95% CI, 1.91-3.60). Conclusions Wife abuse appears to be fairly common in northern India. Our findings that abusive men were more likely to engage in extramarital sex and have STD symptoms suggest that these men may be acquiring STDs from their extramarital relationships, thereby placing their wives at risk for STD acquisition, sometimes via sexual abuse. These abusive sexual behaviors also may result in an elevated rate of unplanned pregnancies.	Univ N Carolina, Dept Maternal & Child Hlth, Chapel Hill, NC 27599 USA; Univ N Carolina, Dept Biostat, Chapel Hill, NC 27599 USA; Univ N Carolina, Carolina Populat Ctr, Chapel Hill, NC 27599 USA; Banaras Hindu Univ, Fac Sci, Dept Stat, Varanasi 221005, Uttar Pradesh, India	University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Banaras Hindu University (BHU)	Martin, SL (corresponding author), Univ N Carolina, Dept Maternal & Child Hlth, CB 7400, Chapel Hill, NC 27599 USA.			Singh, Kaushalendra/0000-0002-8776-6126				Bhatti R. S., 1990, VIOLENCE AGAINST WOM, P45; Bosu WK, 1999, TROP MED INT HEALTH, V4, P114, DOI 10.1046/j.1365-3156.1999.00360.x; FATHALLA M, 1987, RES HUMAN REPROD BIA; Fernandez M, 1997, J INTERPERS VIOLENCE, V12, P433, DOI 10.1177/088626097012003008; Filmer D., 1998, 1994 WORLD BANK; Gangakhedkar RR, 1997, JAMA-J AM MED ASSOC, V278, P2090, DOI 10.1001/jama.278.23.2090; *GOV IND, 1988, WOM IND STAT PROF; Heise L., 1995, SEXUAL COERCION REPR; HEISE L, 1995, WORLD BANK DISCUSSIO, V255; HOSMER DW, 1989, APPL LOGISTIC REGRES; Jain R., 1992, CRITICAL ISSUES VICT, P80; JAIN RS, 1989, AGGRESSION CHILDREN, P105; JEJEEBHOY SJ, 1997, LANCET, V349, pS610; KHAN ME, 1997, SEM MAL INV REPR HLT; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; MANE P, 1992, AIDS PREVENTION; MAYDEO A, 1990, VIOLENCE AGAINST WOM, P267; Miller B. D., 1992, SANCTIONS SANCTUARY, P173; Moffitt TE, 1997, PSYCHOL ASSESSMENT, V9, P47, DOI 10.1037/1040-3590.9.1.47; MONGOMERY MR, 1997, 97201 PAA POP COUNC; Nag M., 1995, HLTH T REV, V5, P293; NAG M, 1996, SEXUAL BEHAV AIDS IN, P26; NAG M, 1996, IASP CORT SPONS WORK; NANDI DN, 1985, AM J PSYCHOTHER, V39, P247, DOI 10.1176/appi.psychotherapy.1985.39.2.247; *NAT STAT OFF PHIL, 1994, NAT SAF MOTH SURV 19; PACHAURI S, 1995, SE ASIA REGIONAL WOR, V4; PLUMMER FA, 1991, J INFECT DIS, V163, P233, DOI 10.1093/infdis/163.2.233; *POP RES CTR LUCKN, 1994, NAT FAM HLTH MCH FAM; RAMASUBBAN R, 1994, WOMEN HLTH DEV INDIA, P212; Rao V, 1997, SOC SCI MED, V44, P1169, DOI 10.1016/S0277-9536(96)00252-3; RAO V, 1995, 1995 POP ASS AM M AP; Schafer J, 1998, AM J PUBLIC HEALTH, V88, P1702, DOI 10.2105/AJPH.88.11.1702; Shah BV, 1996, SUDAAN USERS MANUAL; Singh G., 1986, RESPONSE VICTIMIZATI, V9, P16; Singh K. K., 1997, SURV METHODOL, V23, P137; Sood S., 1990, VIOLENCE AGAINST WOM, P1; Sood S., 1990, VIOLENCE AGAINST WOM, P23; *STAT INN FAM PLAN, 1996, PERF IND INN FAM PLA; *U N CAR CAR POP C, 1997, EV PROJ UTT PRAD MAL; *UNAIDS WHO, 1997, GLOB PROGR AIDS MAN; WASSERHEIT JN, 1992, SEX TRANSM DIS, V19, P61, DOI 10.1097/00007435-199219020-00001; *WORLD BANK, 1993, INV HLTH WORLD DEV R, P50	42	142	142	0	8	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1967	1972		10.1001/jama.282.20.1967	http://dx.doi.org/10.1001/jama.282.20.1967			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257BZ	10580466				2022-12-28	WOS:000083763400036
J	Parker, RA; Hartman, EE				Parker, RA; Hartman, EE			An 87-year-old woman taking a benzodiazepine 1 year later	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article																		Salzman C, 1999, JAMA-J AM MED ASSOC, V281, P1121, DOI 10.1001/jama.281.12.1121	1	1	2	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1960	1960		10.1001/jama.282.20.1960	http://dx.doi.org/10.1001/jama.282.20.1960			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580463				2022-12-28	WOS:000083763400032
J	Fukumoto, M; Ushida, T; Zinchuk, VS; Yamamoto, H; Yoshida, S				Fukumoto, M; Ushida, T; Zinchuk, VS; Yamamoto, H; Yoshida, S			Contralateral thalamic perfusion in patients with reflex sympathetic dystrophy syndrome	LANCET			English	Article							PAIN	Iodine-123-labelled iodoamphetamine single-photon emission computed tomography of patients with reflex sympathetic dystrophy syndrome showed substantial variation in thalamic perfusion of the side contralateral to the painful limb. The variations are related to time from the onset of symptoms, which suggests that the thalamus undergoes adaptive changes in the course of this neurological disorder.	Kochi Med Sch, Dept Radiol, Nanko Ku, Kochi 7838505, Japan; Kochi Med Sch, Dept Orthopaed, Nanko Ku, Kochi 7838505, Japan; Kochi Med Sch, Dept Anat & Cell Biol, Nanko Ku, Kochi 7838505, Japan	Kochi University; Kochi University; Kochi University	Fukumoto, M (corresponding author), Kochi Med Sch, Dept Radiol, Nanko Ku, Kochi 7838505, Japan.							BARNES R, 1953, J BONE JOINT SURG BR, V35, P172, DOI 10.1302/0301-620X.35B2.172; Bonica JJ, 1953, MANAGEMENT PAIN, P913; IADAROLA MJ, 1995, PAIN, V63, P55, DOI 10.1016/0304-3959(95)00015-K; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; Svensson P, 1997, J NEUROPHYSIOL, V78, P450, DOI 10.1152/jn.1997.78.1.450	5	86	88	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1790	1791		10.1016/S0140-6736(99)03746-0	http://dx.doi.org/10.1016/S0140-6736(99)03746-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577646				2022-12-28	WOS:000083853000019
J	Goldrath, AW; Bevan, MJ				Goldrath, AW; Bevan, MJ			Selecting and maintaining a diverse T-cell repertoire	NATURE			English	Review							SINGLE MHC/PEPTIDE LIGAND; ANTIGEN RECEPTOR GENES; CLASS-II MOLECULES; ATHYMIC NUDE RATS; POSITIVE SELECTION; SELF-PEPTIDES; HISTOCOMPATIBILITY ANTIGEN; HOMEOSTATIC REGULATION; THYMOCYTE DEVELOPMENT; LYMPHOID HOMEOSTASIS	To provide a T-cell population that will respond promptly to foreign antigen, the immune system looks inward, using the variety of self-antigens to select and maintain a diverse repertoire of receptors. A protective Immune system must include a T-lymphocyte population that is poised to respond to foreign antigenic peptides presented by self-major histocompatibility complex molecules. As the organism cannot predict the precise pathogen-derived antigens that will he encountered, the system uses the diverse array of self-peptides bound to self-major histocompatibility complex molecules, not only to select a receptor repertoire in the thymus, but also to keep naive T cells alive and 'ready for action' in the periphery.	Univ Washington, Dept Immunol, Seattle, WA 98195 USA; Univ Washington, Howard Hughes Med Inst, Seattle, WA 98195 USA	University of Washington; University of Washington Seattle; Howard Hughes Medical Institute; University of Washington; University of Washington Seattle	Bevan, MJ (corresponding author), Univ Washington, Dept Immunol, Seattle, WA 98195 USA.	mbevan@u.washington.edu	Calabrese, Massimiliano/I-6195-2012					Alam SM, 1996, NATURE, V381, P616, DOI 10.1038/381616a0; ASHTONRICKARDT PG, 1993, CELL, V73, P1041, DOI 10.1016/0092-8674(93)90281-T; ASHTONRICKARDT PG, 1994, CELL, V76, P651, DOI 10.1016/0092-8674(94)90505-3; BABBITT BP, 1985, NATURE, V317, P359, DOI 10.1038/317359a0; Baldwin KK, 1999, J EXP MED, V189, P13, DOI 10.1084/jem.189.1.13; Barton GM, 1999, SCIENCE, V283, P67, DOI 10.1126/science.283.5398.67; Bell E B, 1997, Semin Immunol, V9, P347, DOI 10.1006/smim.1997.0092; BELL EB, 1989, IMMUNOLOGY, V68, P547; BELL EB, 1987, J IMMUNOL, V139, P1379; Bender J, 1999, J EXP MED, V190, P367, DOI 10.1084/jem.190.3.367; Berzins SP, 1998, J EXP MED, V187, P1839, DOI 10.1084/jem.187.11.1839; Beutner U, 1998, INT IMMUNOL, V10, P305, DOI 10.1093/intimm/10.3.305; BJORKMAN PJ, 1987, NATURE, V329, P506, DOI 10.1038/329506a0; Brocker T, 1997, J EXP MED, V186, P1223, DOI 10.1084/jem.186.8.1223; BROWN JH, 1993, NATURE, V364, P33, DOI 10.1038/364033a0; Bruno L, 1996, EUR J IMMUNOL, V26, P3179, DOI 10.1002/eji.1830261251; Busch DH, 1998, IMMUNITY, V8, P353, DOI 10.1016/S1074-7613(00)80540-3; Busch DH, 1998, J EXP MED, V188, P61, DOI 10.1084/jem.188.1.61; Butz EA, 1998, IMMUNITY, V8, P167, DOI 10.1016/S1074-7613(00)80469-0; Callan MFC, 1998, J EXP MED, V187, P1395, DOI 10.1084/jem.187.9.1395; Cose SC, 1997, EUR J IMMUNOL, V27, P2310, DOI 10.1002/eji.1830270927; Davey GM, 1998, J EXP MED, V188, P1867, DOI 10.1084/jem.188.10.1867; Davis MM, 1998, ANNU REV IMMUNOL, V16, P523, DOI 10.1146/annurev.immunol.16.1.523; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; Ding YH, 1998, IMMUNITY, V8, P403, DOI 10.1016/S1074-7613(00)80546-4; Ernst B, 1999, IMMUNITY, V11, P173, DOI 10.1016/S1074-7613(00)80092-8; Fehling HJ, 1997, CURR OPIN IMMUNOL, V9, P263, DOI 10.1016/S0952-7915(97)80146-X; Flynn KJ, 1998, IMMUNITY, V8, P683, DOI 10.1016/S1074-7613(00)80573-7; Freitas AA, 1999, CURR OPIN IMMUNOL, V11, P152, DOI 10.1016/S0952-7915(99)80026-0; Fukui Y, 1997, IMMUNITY, V6, P401, DOI 10.1016/S1074-7613(00)80283-6; FungLeung WP, 1996, SCIENCE, V271, P1278, DOI 10.1126/science.271.5253.1278; Garbe TR, 1996, MOL MED, V2, P134, DOI 10.1007/BF03402209; Garcia KC, 1998, SCIENCE, V279, P1166, DOI 10.1126/science.279.5354.1166; Garcia KC, 1999, ANNU REV IMMUNOL, V17, P369, DOI 10.1146/annurev.immunol.17.1.369; Garcia KC, 1996, SCIENCE, V274, P209, DOI 10.1126/science.274.5285.209; Garcia S, 1999, IMMUNITY, V11, P163, DOI 10.1016/S1074-7613(00)80091-6; Goldrath AW, 1999, IMMUNITY, V11, P183, DOI 10.1016/S1074-7613(00)80093-X; Grubin CE, 1997, IMMUNITY, V7, P197, DOI 10.1016/S1074-7613(00)80523-3; HOGQUIST KA, 1993, J EXP MED, V177, P1469, DOI 10.1084/jem.177.5.1469; HOGQUIST KA, 1995, IMMUNITY, V3, P79, DOI 10.1016/1074-7613(95)90160-4; HOGQUIST KA, 1994, CELL, V76, P17, DOI 10.1016/0092-8674(94)90169-4; HOGQUIST KA, 1997, IMMUNITY, V7, P221; Hu QH, 1997, IMMUNITY, V7, P221, DOI 10.1016/S1074-7613(00)80525-7; Ignatowicz L, 1996, CELL, V84, P521, DOI 10.1016/S0092-8674(00)81028-4; Irving BA, 1998, SCIENCE, V280, P905, DOI 10.1126/science.280.5365.905; Jacob J, 1999, NATURE, V399, P593, DOI 10.1038/21208; JAMESON SC, 1995, ANNU REV IMMUNOL, V13, P93, DOI 10.1146/annurev.iy.13.040195.000521; Kersh GJ, 1996, NATURE, V380, P495, DOI 10.1038/380495a0; KIEPER WC, IN PRESS P NATL ACAD; Kirberg J, 1997, J EXP MED, V186, P1269, DOI 10.1084/jem.186.8.1269; KISIELOW P, 1995, ADV IMMUNOL, V58, P87, DOI 10.1016/S0065-2776(08)60620-3; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Kuo CT, 1997, SCIENCE, V277, P1986, DOI 10.1126/science.277.5334.1986; Lodolce JP, 1998, IMMUNITY, V9, P669, DOI 10.1016/S1074-7613(00)80664-0; Lucas B, 1999, IMMUNITY, V10, P367, DOI 10.1016/S1074-7613(00)80036-9; Mackall CL, 1996, J IMMUNOL, V156, P4609; Markiewicz MA, 1998, P NATL ACAD SCI USA, V95, P3065, DOI 10.1073/pnas.95.6.3065; Martin WD, 1996, CELL, V84, P543, DOI 10.1016/S0092-8674(00)81030-2; MCDONAGH M, 1995, IMMUNOLOGY, V84, P514; Merkenschlager M, 1997, J EXP MED, V186, P1149, DOI 10.1084/jem.186.7.1149; Miyazaki T, 1996, CELL, V84, P531, DOI 10.1016/S0092-8674(00)81029-6; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; Murali-Krishna K, 1998, IMMUNITY, V8, P177, DOI 10.1016/S1074-7613(00)80470-7; MURALIKRISHNA K, IN PRESS SCIENCE; Nakajima H, 1997, J EXP MED, V185, P189, DOI 10.1084/jem.185.2.189; Nesic D, 1998, J IMMUNOL, V160, P3705; NIKOLICZUGIC J, 1990, NATURE, V344, P65, DOI 10.1038/344065a0; OCHEN S, 1999, EUR J IMMUNOL, V29, P608; Oukka M, 1998, IMMUNITY, V9, P295, DOI 10.1016/S1074-7613(00)80612-3; PEREIRA P, 1991, INT IMMUNOL, V3, P1077, DOI 10.1093/intimm/3.11.1077; RAZVI ES, 1995, AM J PATHOL, V147, P79; ROBERTSON JIS, 1994, CARDIOVASC DRUG THER, V8, P675, DOI 10.1007/BF00877423; ROCHA B, 1989, EUR J IMMUNOL, V19, P905, DOI 10.1002/eji.1830190518; Rooke R, 1997, IMMUNITY, V7, P123, DOI 10.1016/S1074-7613(00)80515-4; Sallusto F, 1999, NATURE, V401, P708, DOI 10.1038/44385; SantAngelo DB, 1997, IMMUNITY, V7, P517, DOI 10.1016/S1074-7613(00)80373-8; Scott CA, 1998, IMMUNITY, V8, P319, DOI 10.1016/S1074-7613(00)80537-3; Sebzda E, 1996, J EXP MED, V183, P1093, DOI 10.1084/jem.183.3.1093; SHA WC, 1990, P NATL ACAD SCI USA, V87, P6186, DOI 10.1073/pnas.87.16.6186; Shortman K, 1996, ANNU REV IMMUNOL, V14, P29, DOI 10.1146/annurev.immunol.14.1.29; Sim BC, 1996, SCIENCE, V273, P963, DOI 10.1126/science.273.5277.963; Sim BC, 1998, CURR BIOL, V8, P701, DOI 10.1016/S0960-9822(98)70276-3; SPRENT J, 1993, CURR OPIN IMMUNOL, V5, P433, DOI 10.1016/0952-7915(93)90065-Z; SPRENT J, 1991, J EXP MED, V174, P717, DOI 10.1084/jem.174.3.717; SPRENT J, 1994, RES IMMUNOL, V145, P328, DOI 10.1016/S0923-2494(94)80194-0; Surh CD, 1997, IMMUNITY, V7, P209, DOI 10.1016/S1074-7613(00)80524-5; SWAIN S, IN PRESS SCIENCE; Takeda S, 1996, IMMUNITY, V5, P217, DOI 10.1016/S1074-7613(00)80317-9; TANCHOT C, 1995, EUR J IMMUNOL, V25, P2127, DOI 10.1002/eji.1830250802; Tanchot C, 1997, Semin Immunol, V9, P331, DOI 10.1006/smim.1997.0090; Tanchot C, 1997, J EXP MED, V186, P1099, DOI 10.1084/jem.186.7.1099; Tanchot C, 1997, SCIENCE, V276, P2057, DOI 10.1126/science.276.5321.2057; Teng MK, 1998, CURR BIOL, V8, P409, DOI 10.1016/S0960-9822(98)70160-5; TOUGH DF, 1994, J EXP MED, V179, P1127, DOI 10.1084/jem.179.4.1127; Tourne S, 1997, IMMUNITY, V7, P187, DOI 10.1016/S1074-7613(00)80522-1; TOWNSEND ARM, 1985, CELL, V42, P457, DOI 10.1016/0092-8674(85)90103-5; vanMeerwijk JPM, 1997, J EXP MED, V185, P377, DOI 10.1084/jem.185.3.377; VEIS DJ, 1993, CELL, V75, P229, DOI 10.1016/0092-8674(93)80065-M; Viret C, 1999, IMMUNITY, V10, P559, DOI 10.1016/S1074-7613(00)80055-2; VONBOEHMER H, 1993, J EXP MED, V177, P891, DOI 10.1084/jem.177.4.891; Zerrahn J, 1997, CELL, V88, P627, DOI 10.1016/S0092-8674(00)81905-4; Zimmermann C, 1999, J IMMUNOL, V162, P5178; ZINKERNA.RM, 1974, NATURE, V248, P701, DOI 10.1038/248701a0	103	669	691	1	31	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					255	262		10.1038/35005508	http://dx.doi.org/10.1038/35005508			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580495	Bronze			2022-12-28	WOS:000083813700039
J	Trewavas, A				Trewavas, A			Much food, many problems	NATURE			English	Editorial Material									Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland	University of Edinburgh	Trewavas, A (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JH, Midlothian, Scotland.							Ames B. N., 1990, P NATL ACAD SCI USA, V87, P777; AVERY D, 1999, FEARING FOOD RISK HL, P3; BAUM M, 1992, ANNU REV PLANT PHYS, V43, P117, DOI 10.1146/annurev.pp.43.060192.001001; *BR MED ASS, 1999, IMP GEN MOD AGR FOOD; Chrispeels MJ, 1994, PLANTS GENES AGR; *CHRIST AID, 1999, SELL SUIC FARM FALS; Daniell H, 1998, NAT BIOTECHNOL, V16, P345, DOI 10.1038/nbt0498-345; de Maagd RA, 1999, TRENDS PLANT SCI, V4, P9, DOI 10.1016/S1360-1385(98)01356-9; Evans L.T, 1998, FEEDING 10 BILLION P; FITT GP, 1994, BIOCONTROL SCI TECHN, V4, P535, DOI 10.1080/09583159409355367; HOLLIDAY RJ, 1980, J APPL ECOL, V17, P779, DOI 10.2307/2402655; Kota M, 1999, P NATL ACAD SCI USA, V96, P1840, DOI 10.1073/pnas.96.5.1840; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; MacKenzie D, 1999, NEW SCI, V162, P4; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; RAYBOUD RF, 1999, TRENDS PLANT SCI, V4, P247; Richards A.J, 1997, PLANT BREEDING SYSTE; Schuler TH, 1999, NATURE, V400, P825, DOI 10.1038/23605; Tilman D, 1998, NATURE, V396, P211, DOI 10.1038/24254; *US FAO, 1992, WORLD FOOD SUPPL PRE	20	25	25	2	24	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					231	232		10.1038/46157	http://dx.doi.org/10.1038/46157			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580487				2022-12-28	WOS:000083813700021
J	Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E				Luo, D; Carpenter, R; Copsey, L; Vincent, C; Clark, J; Coen, E			Control of organ asymmetry in flowers of Antirrhinum	CELL			English	Article							BITHORAX COMPLEX; IDENTITY GENES; ABDOMINAL-B; MAJUS; DROSOPHILA; EXPRESSION; MERISTEM; BOUNDARY; ELEMENT; DOMAIN	Organ asymmetry is thought to have evolved many times independently in plants. In Antirrhinum, asymmetry of the flower and its component organs requires eye and dich gene activity. We show that, like eye, the dich gene encodes a product belonging to the TCP family of DNA-binding proteins that is first expressed in the dorsal domain of early floral meristems. However, whereas eye continues to be expressed throughout dorsal regions, expression of dich eventually becomes restricted to the most dorsal half of each dorsal petal. This correlates with the effects of dich mutations and ectopic eye expression on petal shape, providing an indication that plant organ asymmetry can reflect subdomains of gene activity. Taken together, the results indicate that plant organ asymmetry can arise through a series of steps during which early asymmetry in the developing meristem is progressively built upon.	John Innes Ctr Plant Sci Res, Dept Genet, Norwich NR4 7UH, Norfolk, England	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center	Coen, E (corresponding author), John Innes Ctr Plant Sci Res, Dept Genet, Colney Lane, Norwich NR4 7UH, Norfolk, England.							Almeida J, 1997, DEVELOPMENT, V124, P1387; Carpenter R, 1995, PLANT CELL, V7, P2001, DOI 10.1105/tpc.7.12.2001; CARPENTER R, 1990, GENE DEV, V4, P1483, DOI 10.1101/gad.4.9.1483; CARPENTER R, 1987, MOL GEN GENET, V207, P82, DOI 10.1007/BF00331494; CELNIKER SE, 1990, EMBO J, V9, P4277, DOI 10.1002/j.1460-2075.1990.tb07876.x; Charlton W.A., 1998, SYMMETRY PLANTS, P61; COEN ES, 1990, CELL, V63, P1311, DOI 10.1016/0092-8674(90)90426-F; Coen ES, 1996, EMBO J, V15, P6777, DOI 10.1002/j.1460-2075.1996.tb01069.x; Cubas P, 1999, PLANT J, V18, P215, DOI 10.1046/j.1365-313X.1999.00444.x; DINGWALL C, 1991, TRENDS BIOCHEM SCI, V16, P478, DOI 10.1016/0968-0004(91)90184-W; Doebley J, 1997, NATURE, V386, P485, DOI 10.1038/386485a0; Goodrich J, 1997, NATURE, V386, P44, DOI 10.1038/386044a0; GYURKOVICS H, 1990, EMBO J, V9, P2579, DOI 10.1002/j.1460-2075.1990.tb07439.x; Ingram GC, 1997, EMBO J, V16, P6521, DOI 10.1093/emboj/16.21.6521; Kosugi S, 1997, PLANT CELL, V9, P1607, DOI 10.1105/tpc.9.9.1607; KUCKUCK H, 1930, Z IND ABST VER, V56, P51; Luo D, 1996, NATURE, V383, P794, DOI 10.1038/383794a0; LUO D, 1991, PLANT J, V1, P59, DOI 10.1111/j.1365-313X.1991.00059.x; Mihaly J, 1997, DEVELOPMENT, V124, P1809; SANCHEZHERRERO E, 1991, DEVELOPMENT, V111, P437; SIMON J, 1992, DEVELOPMENT, V114, P493; SIMON R, 1994, CELL, V78, P99, DOI 10.1016/0092-8674(94)90576-2; SOMMER H, 1990, EMBO J, V9, P605, DOI 10.1002/j.1460-2075.1990.tb08152.x; STUBBE H, 1966, GENETIK ZYTOLOGIE AN; Wolpert L., 1998, PRINCIPLES DEV; ZINK D, 1995, EMBO J, V14, P5660, DOI 10.1002/j.1460-2075.1995.tb00253.x	26	302	353	4	66	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					367	376						10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571179	Bronze			2022-12-28	WOS:000083709300004
J	Antman, KH; Heitjan, DF; Hortobagyi, GN				Antman, KH; Heitjan, DF; Hortobagyi, GN			High-dose chemotherapy for breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							RANDOMIZED TRIAL; CELL SUPPORT; FOLLOW-UP		Columbia Univ, Herbert Irving Comprehens Canc Ctr, New York, NY USA; Univ Texas, MD Anderson Canc Ctr, Austin, TX USA	Columbia University; University of Texas System; University of Texas Austin; UTMD Anderson Cancer Center	Antman, KH (corresponding author), MHB 6N 435,177 Ft Washington Ave, New York, NY 10032 USA.		Heitjan, Daniel F./D-1116-2009	/0000-0002-1093-8356				Antman KH, 1997, J CLIN ONCOL, V15, P1870, DOI 10.1200/JCO.1997.15.5.1870; BERGH J, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1995, J CLIN ONCOL, V13, P2483, DOI 10.1200/JCO.1995.13.10.2483; BEZWODA WR, 1999, P AN M AM SOC CLIN, V18, pA2; BEZWODA WR, 1998, P AN M AM SOC CLIN, V17, pA115; BONADONNA G, 1995, NEW ENGL J MED, V332, P901, DOI 10.1056/NEJM199504063321401; CLARK GM, 1987, J CLIN ONCOL, V5, P55, DOI 10.1200/JCO.1987.5.1.55; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; FREI E, 1980, AM J MED, V69, P585, DOI 10.1016/0002-9343(80)90472-6; Greenberg PAC, 1996, J CLIN ONCOL, V14, P2197, DOI 10.1200/JCO.1996.14.8.2197; HORTOBAGYI GN, 1998, P AN M AM SOC CLIN, V17, P12; Landis SH, 1999, CA-CANCER J CLIN, V49, P8, DOI 10.3322/canjclin.49.1.8; LOTZ JP, 1999, P AN M AM SOC CLIN, V18, pA43; MICK R, 1989, BREAST CANCER RES TR, V13, P33, DOI 10.1007/BF01806548; PETERS W, 1999, P AN M AM SOC CLIN, V18, pA1; PETERS WP, 1996, P AN M AM SOC CLIN, V15, P121; Rodenhuis S, 1998, LANCET, V352, P515, DOI 10.1016/S0140-6736(98)01350-6; STADTMAUER EA, 1999, P AN M AM SOC CLIN, V18, pA1; Wingo PA, 1998, CANCER-AM CANCER SOC, V82, P1197, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1197::AID-CNCR26>3.0.CO;2-0	19	16	17	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1701	1703		10.1001/jama.282.18.1701	http://dx.doi.org/10.1001/jama.282.18.1701			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568629				2022-12-28	WOS:000083471400001
J	Johansen, HK; Gotzsche, PC				Johansen, HK; Gotzsche, PC			Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL AMPHOTERICIN-B; PREVENTING FUNGAL INFECTION; NEUTROPENIC PATIENTS; ACUTE-LEUKEMIA; HEMATOLOGICAL MALIGNANCIES; OROPHARYNGEAL CANDIDIASIS; GRANULOCYTOPENIC PATIENTS; REMISSION INDUCTION; FLUCONAZOLE; NYSTATIN	Meta-analyses may become biased if the reported data in the individual trials are biased and if overlap among trials cannot be identified. We describe the unanticipated problems we encountered in collecting data for a metaanalysis comparing a new antifungal agent, fluconazole, with amphotericin B in patients with cancer complicated by neutropenia. In 3 large trials that comprised 43% of the patients identified for the meta-analysis, results for amphotericin B were combined with results for nystatin in a "polyene" group. Because nystatin is recognized as an ineffective drug in these circumstances, this approach creates a bias in favor of fluconazole. Furthermore, 79% of the patients were randomized to receive oral amphotericin B, which is poorly absorbed and not an established treatment, in contrast to intravenous amphotericin B, which was administered in 4 of 5 placebo-controlled trials, or 86% of patients. It was unclear whether there was overlap among the "polyene" trials, and it is possible that results from single-center trials were included in multicenter trial reports. We were unable to obtain information to clarify these issues from the trial authors or the manufacturer of fluconazole. Two of 11 responding authors replied that the data were with the drug manufacturer and two indicated that they did not have access to their data because of change of affiliation. In the meta-analyses, fluconazole and amphotericin B (mostly given orally) had similar effects (13 trials), whereas nystatin was no better than placebo (3 trials). Since individual trials are rarely conclusive, investigators, institutions, and pharmaceutical companies should provide essential details about their work to ensure that meta-analyses can accurately reflect: the studies conducted and that patients will realize maximum benefits from treatments. We recommend that: investigators keep copies of their trial data to help facilitate accurate and unbiased meta-analyses.	Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark	Rigshospitalet	Gotzsche, PC (corresponding author), Rigshosp, Nord Cochrane Ctr, Dept 7112, DK-2100 Copenhagen O, Denmark.							AKIYAMA H, 1993, MYCOSES, V36, P373, DOI 10.1111/j.1439-0507.1993.tb00725.x; Anaissie EJ, 1996, CLIN INFECT DIS, V23, P964, DOI 10.1093/clinids/23.5.964; BODEY GP, 1994, CANCER-AM CANCER SOC, V73, P2099, DOI 10.1002/1097-0142(19940415)73:8&lt;2099::AID-CNCR2820730814&gt;3.0.CO;2-N; BODEY GP, 1974, MEDICINE, V53, P209, DOI 10.1097/00005792-197405000-00004; BOW EJ, 1997, 37 INT C ANT AG CHEM; Brammer K W, 1990, Haematol Blood Transfus, V33, P546; BUCHANAN AG, 1985, CLIN INVEST MED, V8, P139; *COCHR COLL, 1998, REV MAN REVM COMP PR; DERSIMONIAN R, 1986, CONTROL CLIN TRIALS, V7, P177, DOI 10.1016/0197-2456(86)90046-2; EGGER T, 1995, SUPPORT CARE CANCER, V3, P139, DOI 10.1007/BF00365855; ELLIS ME, 1994, J ANTIMICROB CHEMOTH, V33, P1223, DOI 10.1093/jac/33.6.1223; ELLIS ME, 1994, EUR J CLIN MICROBIOL, V13, P3, DOI 10.1007/BF02026116; ELLIS ME, 1995, J INFECTION, V30, P141, DOI 10.1016/S0163-4453(95)80009-3; EPSTEIN JB, 1992, ORAL SURG ORAL MED O, V73, P682, DOI 10.1016/0030-4220(92)90009-F; Finke R, 1990, Mycoses, V33 Suppl 1, P42; FLYNN PM, 1995, J PEDIATR-US, V127, P322, DOI 10.1016/S0022-3476(95)70321-7; GOTZSCHE PC, 1989, EUR J CLIN PHARMACOL, V36, P429, DOI 10.1007/BF00558064; Gotzsche PC, 1997, BMJ-BRIT MED J, V314, P1238, DOI 10.1136/bmj.314.7089.1238; GOTZSCHE PC, 1998, COCHRANE REV CD ROM; Groll AH, 1997, J ANTIMICROB CHEMOTH, V40, P855, DOI 10.1093/jac/40.6.855; HEMMINKI E, 1980, BRIT MED J, V280, P833, DOI 10.1136/bmj.280.6217.833; HOPPE JE, 1995, MYCOSES, V38, P41, DOI 10.1111/j.1439-0507.1995.tb00007.x; Huston P, 1996, LANCET, V347, P1024, DOI 10.1016/S0140-6736(96)90153-1; JOHANSEN HK, 1998, COCHRANE REV; Lake DE, 1996, CHEMOTHERAPY, V42, P308, DOI 10.1159/000239459; Lapierre V, 1992, 32 INT C ANT AG CHEM, P214; Lumbreras C, 1996, J INFECT DIS, V174, P583, DOI 10.1093/infdis/174.3.583; MARIE JP, 1993, CAH ONCOL, V2, P171; MENICHETTI F, 1994, ANN INTERN MED, V120, P913, DOI 10.7326/0003-4819-120-11-199406010-00003; MEUNIER F, 1991, DRUG INVEST, V3, P258, DOI 10.1007/BF03259575; NAKIELNY J, 1993, BRIT MED J, V306, P1125, DOI 10.1136/bmj.306.6885.1125-b; NINANE J, 1994, EUR J CLIN MICROBIOL, V13, P330, DOI 10.1007/BF01974614; PHILPOTTHOWARD JN, 1993, J ANTIMICROB CHEMOTH, V31, P973, DOI 10.1093/jac/31.6.973; Pons V, 1997, CLIN INFECT DIS, V24, P1204, DOI 10.1086/513664; Rogers TRF, 1995, J ANTIMICROB CHEMOTH, V36, P899, DOI 10.1093/jac/36.6.899; ROZENBERGARSKA M, 1991, J ANTIMICROB CHEMOTH, V27, P369, DOI 10.1093/jac/27.3.369; SAVINO JA, 1994, J TRAUMA, V36, P20, DOI 10.1097/00005373-199401000-00004; Silling-Engelhardt G, 1994, BLOOD S, V10, p306a; Smith GD, 1998, BMJ-BRIT MED J, V316, P221; SONG FJ, 1993, BMJ-BRIT MED J, V306, P683, DOI 10.1136/bmj.306.6879.683; Stern JM, 1997, BMJ-BRIT MED J, V315, P640, DOI 10.1136/bmj.315.7109.640; Teshima H, 1994, DRUG EVALUATION, V7, P535; Tian D, 1997, 20 INT C CHEM JUN 29, P87; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Viscoli C, 1996, EUR J CANCER, V32A, P814, DOI 10.1016/0959-8049(95)00619-2; VISCOLI C, 1995, 7 EUR C CLIN MICR IN; WILLIAMS C, 1977, MED PEDIATR ONCOL, V3, P275, DOI 10.1002/mpo.2950030309; WINSTON DJ, 1997, 20 INT C CHEM JUN 29	48	101	104	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1752	1759		10.1001/jama.282.18.1752	http://dx.doi.org/10.1001/jama.282.18.1752			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568648				2022-12-28	WOS:000083471400030
J	Friedlander, AM; Pittman, PR; Parker, GW				Friedlander, AM; Pittman, PR; Parker, GW			Anthrax vaccine - Evidence for safety and efficacy against inhalational anthrax	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							PROTECTIVE ANTIGEN; GUINEA-PIGS; SPORE CHALLENGE; ADJUVANTS		USA, Med Res Inst Infect Dis, Ft Detrick, Frederick, MD 21702 USA		Friedlander, AM (corresponding author), USA, Med Res Inst Infect Dis, Ft Detrick, 1425 Porter St, Frederick, MD 21702 USA.	friedlan@ncifcrf.gov	Pittman, Phillip/S-3203-2019; Pittman, Phillip/ADI-6097-2022	Pittman, Phillip/0000-0003-1787-759X; 				AUERBACH S, 1955, J IMMUNOL, V75, P129; Brachman P. S., 1999, VACCINES, P629; BRACHMAN PS, 1962, AM J PUBLIC HEALTH N, V52, P632, DOI 10.2105/AJPH.52.4.632; FELLOWS PF, 1998, 3 INT C ANTHR SEPT P; FRIEDLANDER A, 1997, TXB MILITARY MED MED, P467; FRITZ DL, 1995, LAB INVEST, V73, P691; Inglesby TV, 1999, JAMA-J AM MED ASSOC, V281, P1735, DOI 10.1001/jama.281.18.1735; Ivins B, 1995, VACCINE, V13, P1779, DOI 10.1016/0264-410X(95)00139-R; Ivins B.E., 1996, SALISBURY MED B, V87, P125; IVINS BE, 1992, INFECT IMMUN, V60, P662, DOI 10.1128/IAI.60.2.662-668.1992; Ivins BE, 1998, VACCINE, V16, P1141, DOI 10.1016/S0264-410X(98)80112-6; IVINS BE, 1994, VACCINE, V12, P872, DOI 10.1016/0264-410X(94)90027-2; IVINS BE, 1999, COMMUNICATION    JUL; LITTLE SF, 1986, INFECT IMMUN, V52, P509, DOI 10.1128/IAI.52.2.509-512.1986; PITT ML, 1999, COMMUNICATION    JUL; Pitt MLM, 1999, J APPL MICROBIOL, V87, P304, DOI 10.1046/j.1365-2672.1999.00897.x; PITT MLM, 1996, SALISBURY MED B S, V87, P130; PITTMAN PR, 1999, COMMUNICATION    JUL; STRAWDER G, 1999, COMMUNICATION    AUG; TURNBULL PCB, 1986, INFECT IMMUN, V52, P356, DOI 10.1128/IAI.52.2.356-363.1986; 1985, FED REG, V50, P51058	21	131	137	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2104	2106		10.1001/jama.282.22.2104	http://dx.doi.org/10.1001/jama.282.22.2104			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591317				2022-12-28	WOS:000083971400002
J	Lissauer, JJ				Lissauer, JJ			How common are habitable planets?	NATURE			English	Article							IMPACTS; ASTEROIDS; SYSTEMS; COMETS; EARTH	The Earth is teeming with life, which occupies a diverse array of environments; other bodies in our Solar System offer fewer, if any, niches that are habitable by life as we know it. Nonetheless, astronomical studies suggest that many habitable planets may be present within our Galaxy.	NASA, Ames Res Ctr, Div Space Sci, Moffett Field, CA 94035 USA	National Aeronautics & Space Administration (NASA); NASA Ames Research Center	Lissauer, JJ (corresponding author), NASA, Ames Res Ctr, Div Space Sci, MS 245-3, Moffett Field, CA 94035 USA.							CHAPMAN CR, 1994, NATURE, V367, P33, DOI 10.1038/367033a0; Joshi MM, 1997, ICARUS, V129, P450, DOI 10.1006/icar.1997.5793; LEWIS JS, 1998, WORLDS END EXPLORATI; Lissauer JJ, 1999, REV MOD PHYS, V71, P835, DOI 10.1103/RevModPhys.71.835; LISSAUER JJ, 1995, ICARUS, V114, P217, DOI 10.1006/icar.1995.1057; McKay CP, 1997, ORIGINS LIFE EVOL B, V27, P263, DOI 10.1023/A:1006500116990; Pollack JB, 1996, ICARUS, V124, P62, DOI 10.1006/icar.1996.0190; SAFRONOV VS, 1972, PUBLICATION NASA; SLEEP NH, 1989, NATURE, V342, P139, DOI 10.1038/342139a0; Toon OB, 1997, REV GEOPHYS, V35, P41, DOI 10.1029/96RG03038; Weidenschilling S.J., 1993, PROTOSTARS PLANETS, P1031; WETHERILL GW, 1994, ASTROPHYS SPACE SCI, V212, P23, DOI 10.1007/BF00984505	12	17	18	0	11	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C11	C14		10.1038/35011503	http://dx.doi.org/10.1038/35011503			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591221	Green Submitted			2022-12-28	WOS:000084014100002
J	Egan, JJ				Egan, JJ			New treatments for pulmonary fibrosis?	LANCET			English	Editorial Material							NITRIC-OXIDE; HYPERTENSION; ALVEOLITIS		Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England	Wythenshawe Hospital NHS Foundation Trust; Wythenshawe Hospital	Egan, JJ (corresponding author), Wythenshawe Hosp, NW Lung Ctr, Manchester M23 9LT, Lancs, England.							Bjoraker JA, 1998, AM J RESP CRIT CARE, V157, P199, DOI 10.1164/ajrccm.157.1.9704130; CHANNICK RN, 1994, AM J RESP CRIT CARE, V149, P811, DOI 10.1164/ajrccm.149.3.8118653; CHRISTMAN BW, 1992, NEW ENGL J MED, V327, P70, DOI 10.1056/NEJM199207093270202; Coker RK, 1998, EUR RESPIR J, V11, P1218, DOI 10.1183/09031936.98.11061218; Hubbard R, 1998, CHEST, V113, P396, DOI 10.1378/chest.113.2.396; JOHNSON MA, 1989, THORAX, V44, P280, DOI 10.1136/thx.44.4.280; Katzenstein ALA, 1998, AM J RESP CRIT CARE, V157, P1301, DOI 10.1164/ajrccm.157.4.9707039; Lok SS, 1999, J HEART LUNG TRANSPL, V18, P884, DOI 10.1016/S1053-2498(99)00050-9; Olschewski H, 1999, AM J RESP CRIT CARE, V160, P600, DOI 10.1164/ajrccm.160.2.9810008; Raghu G, 1999, AM J RESP CRIT CARE, V159, P1061, DOI 10.1164/ajrccm.159.4.9805017; Stewart JP, 1999, AM J RESP CRIT CARE, V159, P1336, DOI 10.1164/ajrccm.159.4.9807077; Warren JB, 1996, LANCET, V348, P629, DOI 10.1016/S0140-6736(05)65068-4; Wells AU, 1997, AM J RESP CRIT CARE, V155, P1657, DOI 10.1164/ajrccm.155.5.9154872; Xie GY, 1998, CHEST, V114, P477, DOI 10.1378/chest.114.2.477; Ziesche R, 1999, NEW ENGL J MED, V341, P1264, DOI 10.1056/NEJM199910213411703	15	11	12	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1839	1840		10.1016/S0140-6736(99)00347-5	http://dx.doi.org/10.1016/S0140-6736(99)00347-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584718				2022-12-28	WOS:000083909100007
J	Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP				Forsen, T; Eriksson, JG; Tuomilehto, J; Osmond, C; Barker, DJP			Growth in utero and during childhood among women who develop coronary heart disease: longitudinal study	BRITISH MEDICAL JOURNAL			English	Article							FETAL GROWTH; CARDIOVASCULAR-DISEASE; ADULT LIFE; IN-UTERO; MEN; COHORT; DEATH; SIZE; VALIDITY; FINLAND	Objective To examine whether women who develop coronary heart disease have different patterns of fetal and childhood growth from men in the same cohort who develop the disease. Design Follow up study of women whose body size at birth was recorded and who had an average of 10 measurements of height and weight during childhood. Setting Helsinki, Finland. Subjects 3447 women who were born in Helsinki University Central Hospital during 1924-33 and who went to school in Helsinki. Main outcome measures Hazard ratios for hospital admission for or death from coronary heart disease. Results Coronary heart disease among women was associated with low birth weight (P = 0.08 after adjustment for gestation, P = 0.007 after adjustment for placental weight) and was more strongly associated with short body length at birth (P = 0.001 and P < 0.0001, respectively). The hazard ratio for women developing coronary heart disease increased by 10.2% (95% confidence interval 4.3 to 15.7) for each rm decrease in length at birth. The effect of short length at birth was greatest in women whose height "caught up" after birth so that as girls they were tall. Such girls tended to have tall mothers. In contrast, men in the same cohort who developed the disease were thin at birth rather than short, showed "catch up" growth in weight rather than height, and their mothers tended to be overweight rather than tall. Conclusion Coronary heart disease among both women and men reflects poor prenatal nutrition and consequent small body size at birth combined with improved postnatal nutrition and "catch up" growth in childhood. The disease is associated with reductions in those aspects of body proportions at birth that distinguish die two sexes-short body length in women and thinness in men.	Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England; Natl Publ Hlth Inst, Dept Epidemiol & Hlth Promot, Diabet & Genet Epidemiol Unit, Helsinki, Finland	University of Southampton; Finland National Institute for Health & Welfare	Barker, DJP (corresponding author), Univ Southampton, Southampton Gen Hosp, MRC, Environm Epidemiol Unit, Southampton SO16 6YD, Hants, England.			Osmond, Clive/0000-0002-9054-4655				Barker D J, 1992, Paediatr Perinat Epidemiol, V6, P35, DOI 10.1111/j.1365-3016.1992.tb00741.x; BARKER DJP, 1995, BRIT MED J, V311, P171, DOI 10.1136/bmj.311.6998.171; BARKER DJP, 1993, BRIT MED J, V307, P1524, DOI 10.1136/bmj.307.6918.1524; Barker DJP, 1998, MOTHERS BABIES HLTH; Eriksson JG, 1999, BMJ-BRIT MED J, V318, P427, DOI 10.1136/bmj.318.7181.427; Forsen T, 1997, BRIT MED J, V315, P837, DOI 10.1136/bmj.315.7112.837; GARN SM, 1974, AM J PHYS ANTHROPOL, V41, P353, DOI 10.1002/ajpa.1330410302; HARDING J, 1992, EARLY HUM DEV, V29, P193, DOI 10.1016/0378-3782(92)90149-B; HARDING JE, 1995, REPROD FERT DEVELOP, V7, P539, DOI 10.1071/RD9950539; Leon DA, 1998, BMJ-BRIT MED J, V317, P241, DOI 10.1136/bmj.317.7153.241; Lithell HO, 1996, BMJ-BRIT MED J, V312, P406; Mahonen M, 1997, EUR J EPIDEMIOL, V13, P403, DOI 10.1023/A:1007306110822; Martyn CN, 1996, LANCET, V348, P1264, DOI 10.1016/S0140-6736(96)04257-2; MARTYN CN, 1995, BRIT J HAEMATOL, V89, P142, DOI 10.1111/j.1365-2141.1995.tb08920.x; MARTYN CN, 1995, BRIT HEART J, V73, P116; OSMOND C, 1993, BRIT MED J, V307, P1519, DOI 10.1136/bmj.307.6918.1519; OUNSTED M, 1986, ANN HUM BIOL, V13, P143, DOI 10.1080/03014468600008281; PEDERSEN JF, 1980, BRIT MED J, V281, P1253, DOI 10.1136/bmj.281.6250.1253; PITTS GC, 1986, GROWTH, V50, P419; Rapola JM, 1997, EUR J EPIDEMIOL, V13, P133, DOI 10.1023/A:1007380408729; RichEdwards JW, 1997, BRIT MED J, V315, P396, DOI 10.1136/bmj.315.7105.396; ROYSTON P, 1991, STAT MED, V10, P675, DOI 10.1002/sim.4780100502; Stein CE, 1996, LANCET, V348, P1269, DOI 10.1016/S0140-6736(96)04547-3; TANNER JM, 1989, FOETUS MAN; WIDDOWSON EM, 1963, PROC R SOC SER B-BIO, V158, P329, DOI 10.1098/rspb.1963.0051	25	334	335	0	9	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1403	1407		10.1136/bmj.319.7222.1403	http://dx.doi.org/10.1136/bmj.319.7222.1403			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574856	Green Published, Bronze			2022-12-28	WOS:000083995200027
J	Kumar, S; Gantley, M				Kumar, S; Gantley, M			Tensions between policy makers and general practitioners in implementing new genetics: grounded theory interview study	BRITISH MEDICAL JOURNAL			English	Article							QUALITATIVE RESEARCH	Objective To explore general practitioners' perceptions of their role in implementing genetic technology. Design Grounded theory interview study. Setting Primary care. Subjects Purposive sample of 30 general practitioners with a further theoretical sample of 14. Results inconsistencies were identified between policy makers' and general practitioners' definitions of general practitioners' role in implementing the new genetics. General practitioners emphasised the need to build on current practice, whereas policy makers focused on transforming practice to include the new specialised roles and skills. Two cure themes were identified: genetics in a generalist context, which included appropriate generalist intervention, the ethical dilemmas implicit in the "therapeutic gap," the familial-hereditary distinction in primary care, and the implications for generalist identity, including die potential marginalisation of generalism. Conclusion New technologies such as genetics that require implementation in general practice should be integrated within existing generalist frameworks.	Univ Southampton, Dept Primary Med Care, Southampton SO16 5ST, Hants, England; Univ London Queen Mary & Westfield Coll, St Bartholomews & Royal London Sch Med & Dent, Dept Gen Practice & Primary Care, London E1 4NS, England	University of Southampton; University of London; Queen Mary University London	Kumar, S (corresponding author), Univ Southampton, Dept Primary Med Care, Southampton SO16 5ST, Hants, England.		Sandall, Jane/D-4146-2009	Sandall, Jane/0000-0003-2000-743X				AUSTOKER J, 1994, BMJ-BRIT MED J, V309, P517, DOI 10.1136/bmj.309.6953.517; BRITTEN N, 1995, BRIT MED J, V311, P251, DOI 10.1136/bmj.311.6999.251; CALMAN K, 1995, BRIT MED J, V310, P1142; Chard J, 1999, LANCET, V353, P486, DOI 10.1016/S0140-6736(98)07304-8; CLARKE A, 1995, BMJ-BRIT MED J, V311, P35, DOI 10.1136/bmj.311.6996.35; Fugelli P, 1996, BRIT MED J, V312, P456, DOI 10.1136/bmj.312.7029.456; Glaser B.G., 1965, AWARENESS DYING; Glaser BG, 1978, THEORETICAL SENSITIV; HARRIS R, 1992, J ROY COLL PHYS LOND, V26, P437; Hayflick S J, 1998, Community Genet, V1, P18, DOI 10.1159/000016131; Heath I., 1995, MYSTERY GEN PRACTICE; Horton R, 1999, LANCET, V353, P609, DOI 10.1016/S0140-6736(99)00056-2; Kinmonth AL, 1998, BMJ-BRIT MED J, V316, P767, DOI 10.1136/bmj.316.7133.767; Kirk J., 1988, RELIABILITY VALIDITY; LENAGHAN J, 1998, BRAVE NEW NHS IMPACT; MAYS N, 1995, BRIT MED J, V311, P109, DOI 10.1136/bmj.311.6997.109; MCCRAKEN G, 1998, LONG INTERVIEW QUALI, V13; Murphy E., 1998, HLTH TECHNOLOGY ASSE, V2; NEIGHBOUR R, 1992, INNER CONSULTATION D; OELSEN NDL, 1996, BRIT MED J, V312, P525; Patton M. Q., 1990, QUALITATIVE EVALUATI; Pringle M, 1997, BRIT MED J, V314, P595; *ROYAL COLL GEN PR, 1996, NAT GEN MED PRACT RE; *ROYAL COLL GEN PR, 1998, 77 RCGP; Strauss A., 1990, BASICS QUALITATIVE R; SWEENEY B, 1997, J R COLL GEN PRACT, V44, P544	26	55	55	0	6	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1410	1413		10.1136/bmj.319.7222.1410	http://dx.doi.org/10.1136/bmj.319.7222.1410			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574861	Bronze, Green Published			2022-12-28	WOS:000083995200030
J	Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A				Thompson, F; George, S; Lattimer, V; Smith, H; Moore, M; Turnbull, J; Mullee, M; Thomas, E; Bond, H; Glasper, A			Overnight calls in primary care: randomised controlled trial of management using nurse telephone consultation	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England; Aldemoor Hlth Ctr, Acad Dept Primary Med Care, Southampton SO9 5NH, Hants, England; Univ Southampton, Southampton Gen Hosp, Dept Med Stat, Southampton SO9 5NH, Hants, England; Queen Alexandra Hosp, Postgrad Med Sch, Portsmouth PO6 3LY, Hants, England; Sch Nursing, Southampton SO17 1BJ, Hants, England	University of Southampton; University of Southampton; Portsmouth Hospitals NHS Trust; Queen Alexandra Hospital	George, S (corresponding author), Southampton Gen Hosp, Hlth Care Res Unit, Southampton SO16 6YD, Hants, England.	pluto@soton.ac.uk	Smith, Helen E/M-2449-2016; Moore, Michael/C-3447-2011	Smith, Helen E/0000-0003-1883-6124; Moore, Michael/0000-0002-5127-4509; Turnbull, Joanne/0000-0002-5006-4438				Brogan C, 1998, BRIT MED J, V316, P524, DOI 10.1136/bmj.316.7130.524; *COLL HLTH, 1998, DEV NHS DIR; Jones E, 1996, BMJ-BRIT MED J, V313, P36, DOI 10.1136/bmj.313.7048.36; Lattimer V, 1998, BMJ-BRIT MED J, V317, P1054	4	31	31	0	5	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1408	1408		10.1136/bmj.319.7222.1408	http://dx.doi.org/10.1136/bmj.319.7222.1408			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574857	Green Published, Green Accepted, Bronze			2022-12-28	WOS:000083995200028
J	Webster, NR				Webster, NR			Importance of position in which patients are nursed in intensive-care units	LANCET			English	Editorial Material							VENTILATOR-ASSOCIATED PNEUMONIA; NOSOCOMIAL PNEUMONIA; RISK		Univ Aberdeen, Acad Unit Anaesthesia & Intens Care, Aberdeen AB25 2ZD, Scotland	University of Aberdeen	Webster, NR (corresponding author), Univ Aberdeen, Acad Unit Anaesthesia & Intens Care, Aberdeen AB25 2ZD, Scotland.							Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P308, DOI 10.1001/jama.275.4.308; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; KOLLEF MH, 1995, CHEST, V108, P1655, DOI 10.1378/chest.108.6.1655; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; PINGLETON SK, 1989, EUR J CLIN MICROBIOL, V8, P51, DOI 10.1007/BF01964120; STEVENSON GW, 1990, ANESTHESIOLOGY, V72, P542, DOI 10.1097/00000542-199003000-00024; Stoutenbeek C P, 1997, Semin Respir Infect, V12, P294; TORRES A, 1990, AM REV RESPIR DIS, V142, P523, DOI 10.1164/ajrccm/142.3.523; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639	11	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1835	1836		10.1016/S0140-6736(99)00271-8	http://dx.doi.org/10.1016/S0140-6736(99)00271-8			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584714				2022-12-28	WOS:000083909100003
J	Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G				Sutovsky, P; Moreno, RD; Ramalho-Santos, J; Dominko, T; Simerly, C; Schatten, G			Development - Ubiquitin tag for sperm mitochondria	NATURE			English	Article							DNA; INHERITANCE; FATE		Oregon Reg Primate Res Ctr, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Cell Dev Biol, Beaverton, OR 97006 USA; Oregon Hlth & Sci Univ, Dept Obstet Gynecol, Beaverton, OR 97006 USA; Int Ctr Canc Res & Dev Biol, Santiago, Chile; Univ Coimbra, Dept Zool, Ctr Neurosci, Coimbra, Portugal	Oregon Health & Science University; Oregon National Primate Research Center; Oregon Health & Science University; Oregon Health & Science University; Universidade de Coimbra	Sutovsky, P (corresponding author), Oregon Reg Primate Res Ctr, 505 NW 185th Ave, Beaverton, OR 97006 USA.	schatten@ohsu.edu	simerly, Calvin/AAC-9564-2021; Santos, João/HHZ-5595-2022; Moreno, Ricardo R/C-6802-2011; Schatten, Gerald/B-3253-2009; Ramalho-Santos, João/F-8641-2012	Schatten, Gerald/0000-0001-5206-7782; Ramalho-Santos, João/0000-0002-1172-4018; Sutovsky, Peter/0000-0002-9231-2823; Moreno, Ricardo/0000-0002-7499-5501				BARRIT J, 1999, FERTIL STERIL, V72, P31; CHOONGKITTAWORN NM, 1993, BIOL REPROD, V49, P300, DOI 10.1095/biolreprod49.2.300; CIECHANOVER A, 1994, CELL, V79, P13, DOI 10.1016/0092-8674(94)90396-4; Cummins JM, 1997, ZYGOTE, V5, P301, DOI 10.1017/S0967199400003889; Fisk HA, 1999, J CELL BIOL, V145, P1199, DOI 10.1083/jcb.145.6.1199; GILES RE, 1980, P NATL ACAD SCI-BIOL, V77, P6715, DOI 10.1073/pnas.77.11.6715; GYLLENSTEN U, 1991, NATURE, V352, P255, DOI 10.1038/352255a0; HUTCHINSON SA, 1974, NATURE, V251, P536; KANEDA H, 1995, P NATL ACAD SCI USA, V92, P4542, DOI 10.1073/pnas.92.10.4542; Kato Y, 1998, SCIENCE, V282, P2095, DOI 10.1126/science.282.5396.2095; PERREAULT SD, 1984, DEV BIOL, V101, P160, DOI 10.1016/0012-1606(84)90126-X; Renard JP, 1999, LANCET, V353, P1489, DOI 10.1016/S0140-6736(98)12173-6; Sutovsky P, 1996, BIOL REPROD, V55, P1195, DOI 10.1095/biolreprod55.6.1195; SZOLLOSI D, 1965, J EXP ZOOL, V159, P367, DOI 10.1002/jez.1401590309	14	446	474	3	7	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					371	372		10.1038/46466	http://dx.doi.org/10.1038/46466			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586873				2022-12-28	WOS:000083913600042
J	Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA				Ohnuma, S; Philpott, A; Wang, K; Holt, CE; Harris, WA			p27(Xic1), a cdk inhibitor, promotes the determination of glial cells in Xenopus retina	CELL			English	Article							DEPENDENT-KINASE INHIBITOR; PROGENITOR CELLS; RAT RETINA; ROD PHOTORECEPTORS; NERVOUS-SYSTEM; PROTEIN-KINASE; MOUSE RETINA; MICE LACKING; CYCLIN-A; P27(KIP1)	p27(Xic1), a member of the Cip/Kip family of Cdk inhibitors, besides its known function of inhibiting cell division, induces Muller glia from retinoblasts. This novel gliogenic function of p27(Xic1) is mediated by part of the N-terminal domain near but distinct from the region that inhibits cyclin-dependent kinases. Cotransfections with dominant-negative and constitutively active Delta and Notch constructs indicate that the gliogenic effects of p27(Xic1) work within the context of an active Notch pathway. The gradual increase of p27(Xic1) in the developing retina thus not only limits the number of retinal cells but also increasingly favors the fate of the last cell type to be born in the retina, the Muller glia.	Univ Cambridge, Dept Anat, Cambridge CB2 3DY, England; Univ Cambridge, Dept Oncol, Cambridge Inst Med Res, Cambridge CB2 2XY, England	University of Cambridge; University of Cambridge	Harris, WA (corresponding author), Univ Cambridge, Dept Anat, Downing St, Cambridge CB2 3DY, England.			Ohnuma, Shin-ichi/0000-0002-3305-5126; Philpott, Anna/0000-0003-3789-2463; Holt, Christine Elizabeth/0000-0003-2829-121X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Belliveau MJ, 1999, DEVELOPMENT, V126, P555; Bohner AP, 1997, DEVELOPMENT, V124, P915; CasacciaBonnefil P, 1997, GENE DEV, V11, P2335, DOI 10.1101/gad.11.18.2335; Cepko CL, 1999, CURR OPIN NEUROBIOL, V9, P37, DOI 10.1016/S0959-4388(99)80005-1; Chang WS, 1998, J NEUROBIOL, V35, P227; CHEN JJ, 1995, NATURE, V374, P386, DOI 10.1038/374386a0; Dorsky RI, 1997, NATURE, V385, P67, DOI 10.1038/385067a0; DORSKY RI, 1995, NEURON, V14, P487, DOI 10.1016/0896-6273(95)90305-4; Dowling J. E., 1987, RETINA APPROACHABLE; DRAGER UC, 1984, J NEUROSCI, V4, P2025; Durand B, 1998, CURR BIOL, V8, P431, DOI 10.1016/S0960-9822(98)70177-0; EAGLESON GW, 1990, J NEUROBIOL, V21, P427, DOI 10.1002/neu.480210305; Edlund T, 1999, CELL, V96, P211, DOI 10.1016/S0092-8674(00)80561-9; Ericson J, 1996, CELL, V87, P661, DOI 10.1016/S0092-8674(00)81386-0; Ezzeddine ZD, 1997, DEVELOPMENT, V124, P1055; Faber J., 1994, NORMAL TABLE XENOPUS, P2; Fero ML, 1996, CELL, V85, P733, DOI 10.1016/S0092-8674(00)81239-8; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; HARLAND RM, 1991, METHOD CELL BIOL, V36, P685; HARPER JW, 1993, CELL, V75, P805; HARRIS WA, 1991, NEURON, V6, P499, DOI 10.1016/0896-6273(91)90053-3; Harris WA, 1997, CURR OPIN GENET DEV, V7, P651, DOI 10.1016/S0959-437X(97)80013-5; Henrique D, 1997, CURR BIOL, V7, P661, DOI 10.1016/S0960-9822(06)00293-4; HOLT CE, 1988, NEURON, V1, P15, DOI 10.1016/0896-6273(88)90205-X; HOLT CE, 1990, NEURON, V4, P203, DOI 10.1016/0896-6273(90)90095-W; HOWE JA, 1995, GENE DEV, V9, P1164, DOI 10.1101/gad.9.10.1164; Jensen AM, 1997, DEV BIOL, V188, P267, DOI 10.1006/dbio.1997.8645; Kanekar S, 1997, NEURON, V19, P981, DOI 10.1016/S0896-6273(00)80391-8; Kiyokawa H, 1996, CELL, V85, P721, DOI 10.1016/S0092-8674(00)81238-6; Lillien L, 1998, MOL CELL NEUROSCI, V10, P296, DOI 10.1006/mcne.1997.0659; MCCONNELL SK, 1991, SCIENCE, V254, P282, DOI 10.1126/science.1925583; McFarlane S, 1998, DEVELOPMENT, V125, P3967; Meikrantz W, 1996, J BIOL CHEM, V271, P10205, DOI 10.1074/jbc.271.17.10205; Morrow EM, 1999, DEVELOPMENT, V126, P23; Nakayama K, 1996, CELL, V85, P707, DOI 10.1016/S0092-8674(00)81237-4; NEBREDA AR, 1995, EMBO J, V14, P5597, DOI 10.1002/j.1460-2075.1995.tb00247.x; PARIS J, 1991, P NATL ACAD SCI USA, V88, P1039, DOI 10.1073/pnas.88.3.1039; Park DS, 1997, J NEUROSCI, V17, P8975; Perron M, 1998, DEV BIOL, V199, P185, DOI 10.1006/dbio.1998.8939; Philpott A, 1997, GENE DEV, V11, P1409, DOI 10.1101/gad.11.11.1409; PICKHAM KM, 1992, MOL CELL BIOL, V12, P3192, DOI 10.1128/MCB.12.7.3192; POLYAK K, 1994, CELL, V78, P59, DOI 10.1016/0092-8674(94)90572-X; PRICE J, 1987, P NATL ACAD SCI USA, V84, P156, DOI 10.1073/pnas.84.1.156; Raff MC, 1998, INT J DEV BIOL, V42, P263; Rivard N, 1996, J BIOL CHEM, V271, P18337, DOI 10.1074/jbc.271.31.18337; Russo AA, 1996, NATURE, V382, P325, DOI 10.1038/382325a0; Shou WY, 1996, MOL BIOL CELL, V7, P457, DOI 10.1091/mbc.7.3.457; SU JY, 1995, P NATL ACAD SCI USA, V92, P10187, DOI 10.1073/pnas.92.22.10187; Tikoo R, 1998, J NEUROBIOL, V36, P431, DOI 10.1002/(SICI)1097-4695(19980905)36:3<431::AID-NEU10>3.3.CO;2-N; Tikoo R, 1997, J BIOL CHEM, V272, P442; TOYOSHIMA H, 1994, CELL, V78, P67, DOI 10.1016/0092-8674(94)90573-8; TURNER DL, 1994, GENE DEV, V8, P1434, DOI 10.1101/gad.8.12.1434; TURNER DL, 1990, NEURON, V4, P833, DOI 10.1016/0896-6273(90)90136-4; TURNER DL, 1987, NATURE, V328, P131, DOI 10.1038/328131a0; WAGA S, 1994, NATURE, V369, P574, DOI 10.1038/369574a0; WATANABE T, 1990, NEURON, V4, P461, DOI 10.1016/0896-6273(90)90058-N; Welcker M, 1998, CANCER RES, V58, P5053; WETTS R, 1988, SCIENCE, V239, P1142, DOI 10.1126/science.2449732; Zhang PM, 1998, GENE DEV, V12, P3162, DOI 10.1101/gad.12.20.3162; Zhang PM, 1999, GENE DEV, V13, P213, DOI 10.1101/gad.13.2.213; Zhao SL, 1996, BRAIN RES, V723, P169, DOI 10.1016/0006-8993(96)00237-5; Zuber ME, 1999, CELL, V98, P341, DOI 10.1016/S0092-8674(00)81963-7	62	189	189	0	4	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					499	510		10.1016/S0092-8674(00)81538-X	http://dx.doi.org/10.1016/S0092-8674(00)81538-X			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589678	Bronze			2022-12-28	WOS:000083986300009
J	Compston, JE; Vedi, S; Stephen, AB; Bord, S; Lyons, AR; Hodges, SJ; Scammell, BE				Compston, JE; Vedi, S; Stephen, AB; Bord, S; Lyons, AR; Hodges, SJ; Scammell, BE			Reduced bone formation after exposure to organophosphates	LANCET			English	Article								Bone histomorphometric analysis in 24 agricultural workers with chronic organophosphate exposure showed significantly lower bone formation at tissue and cellular level than in healthy controls.	Univ Cambridge, Dept Med, Sch Med, Cambridge CB2 2QQ, England; Univ Nottingham Hosp, Queens Med Ctr, Dept Orthopaed & Accid Surg, Nottingham NG7 2UH, England; Univ Essex, Dept Biol Sci, Colchester CO4 3SQ, Essex, England	University of Cambridge; University of Nottingham; University of Essex	Compston, JE (corresponding author), Addenbrookes Hosp, Dept Med, Box 157,Level 5, Cambridge CB2 2QQ, England.				Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		COMPSTON JE, 1997, VITAMIN D, P576; Genever PG, 1999, BONE, V24, P297, DOI 10.1016/S8756-3282(98)00187-2; Grisaru D, 1999, MOL CELL BIOL, V19, P788; STEPHEN AB, 1998, BONE, V23, pS395; VEDI S, 1982, METAB BONE DIS RELAT, V4, P231, DOI 10.1016/0221-8747(82)90032-7	5	26	26	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1791	1792		10.1016/S0140-6736(99)04466-9	http://dx.doi.org/10.1016/S0140-6736(99)04466-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577647				2022-12-28	WOS:000083853000020
J	Murphy, PC; Duckett, SG; Sillito, AM				Murphy, PC; Duckett, SG; Sillito, AM			Feedback connections to the lateral geniculate nucleus and cortical response properties	SCIENCE			English	Article							CAT VISUAL-CORTEX; CORTICOFUGAL FEEDBACK; NEURONS; PATHWAY; CELLS; AREA-17; HYPOTHESIS; MORPHOLOGY	The cerebral cortex receives sensory input from the periphery by means of thalamic relay nuclei, but the flow of information goes both ways. Each cortical area sends a reciprocal projection back to the thalamus. In the visual system, the synaptic relations that govern the influence of thalamic afferents on orientation selectivity in the cortex have been studied extensively. It now appears that the connectivity of the corticofugal feedback pathway is also fundamentally linked to the orientation preference of the cortical cells involved.	Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England; UCL, Inst Ophthalmol, Dept Visual Sci, London EC1V 9EL, England	St Georges University London; University of London; University College London	Murphy, PC (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Physiol, London SW17 0RE, England.	p.murphy@sghms.ac.uk						AHMED B, 1994, J COMP NEUROL, V341, P39, DOI 10.1002/cne.903410105; ALBUS K, 1975, EXP BRAIN RES, V24, P181, DOI 10.1007/BF00234062; ANDOLINA IM, UNPUB; Cudeiro J, 1996, J PHYSIOL-LONDON, V490, P481, DOI 10.1113/jphysiol.1996.sp021159; Das A, 1999, NATURE, V399, P655, DOI 10.1038/21371; DAVIES OL, 1984, STAT METHODS RES PRO, P208; Erisir A, 1997, P NATL ACAD SCI USA, V94, P1517, DOI 10.1073/pnas.94.4.1517; GRIEVE KL, 1995, J NEUROSCI, V15, P4868; HARVEY AR, 1980, J PHYSIOL-LONDON, V302, P507; HENRY GH, 1994, PROG NEUROBIOL, V43, P381, DOI 10.1016/0301-0082(94)90061-2; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; KATZ LC, 1987, J NEUROSCI, V7, P1223; KOCH C, 1987, NEUROSCIENCE, V23, P399, DOI 10.1016/0306-4522(87)90064-9; Maldonado PE, 1996, VISUAL NEUROSCI, V13, P509, DOI 10.1017/S095252380000818X; MCCORMICK DA, 1992, P NATL ACAD SCI USA, V89, P2774, DOI 10.1073/pnas.89.7.2774; MONTERO VM, 1991, EXP BRAIN RES, V86, P257; MURPHY PC, 1987, NATURE, V329, P727, DOI 10.1038/329727a0; Murphy PC, 1996, J NEUROSCI, V16, P1180; Murphy PC, 1996, J PHYSIOL-LONDON, V494P, pP17; Pinault D, 1996, J NEUROSCI METH, V65, P113, DOI 10.1016/0165-0270(95)00144-1; SANDERUD A, 1971, Scandinavian Journal of Thoracic and Cardiovascular Surgery, V5, P143, DOI 10.3109/14017437109135546; SILLITO AM, 1993, EXP BRAIN RES, V93, P6; SILLITO AM, 1995, NATURE, V378, P492, DOI 10.1038/378492a0; SILLITO AM, 1994, NATURE, V369, P479, DOI 10.1038/369479a0; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; Usrey WM, 1999, ANNU REV PHYSIOL, V61, P435, DOI 10.1146/annurev.physiol.61.1.435; VARELA FJ, 1987, EXP BRAIN RES, V66, P10; WILSON JR, 1984, PROC R SOC SER B-BIO, V221, P411, DOI 10.1098/rspb.1984.0042	28	114	116	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1552	1554		10.1126/science.286.5444.1552	http://dx.doi.org/10.1126/science.286.5444.1552			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567260				2022-12-28	WOS:000083768300056
J	Horowitz, HW				Horowitz, HW			Millennial child - Intern's admission note, November 17, 2150	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	1	1	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1799	1799		10.1001/jama.282.19.1799	http://dx.doi.org/10.1001/jama.282.19.1799			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573257				2022-12-28	WOS:000083615700001
J	Arango, NA; Lovell-Badge, R; Behringer, RR				Arango, NA; Lovell-Badge, R; Behringer, RR			Targeted mutagenesis of the endogenous mouse Mis gene promoter: In vivo definition of genetic pathways of vertebrate sexual development	CELL			English	Article							MULLERIAN-INHIBITING SUBSTANCE; STEROIDOGENIC FACTOR-I; SRY-RELATED GENE; NUCLEAR RECEPTOR SF-1; CAMPOMELIC DYSPLASIA; GONADAL DEVELOPMENT; HORMONE-RECEPTOR; TRANSGENIC MICE; SOX9 EXPRESSION; DIFFERENTIATION	Mutations were introduced into conserved steroidogenic factor 1 (SF1)- and SOX9-binding sites within the endogenous mouse Mullerian inhibiting substance (Mis) promoter. Male mice homozygous for the mutant SF1-binding site correctly initiated Mis transcription in fetal testes, although at significantly reduced levels. Surprisingly, sufficient MIS was produced to eliminate the Mullerian ducts. In contrast, males homozygous for the mutant SOX9-binding site did not initiate Mis transcription, resulting in pseudohermaphrodites. These studies suggest an essential role for SOX9 in the initiation of Mis transcription, whereas SF1 appears to act as a quantitative regulator of Mis transcript levels, perhaps for influencing non-Mullerian duct tissues. Comparative studies of Mis expression in vertebrates indicate that the Mis promoter receives transcriptional inputs that vary between species but result in the same functional readout.	Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA; Natl Inst Med Res, Div Dev Genet, London NW7 1AA, England	University of Texas System; UTMD Anderson Cancer Center; MRC National Institute for Medical Research	Behringer, RR (corresponding author), Univ Texas, MD Anderson Canc Ctr, Dept Mol Genet, Houston, TX 77030 USA.	rrb@notes.mdacc.tmc.edu		Lovell-Badge, Robin/0000-0001-9364-4179	Medical Research Council [MC_U117562207] Funding Source: Medline; NCI NIH HHS [CA09299] Funding Source: Medline; NICHD NIH HHS [HD30284] Funding Source: Medline; MRC [MC_U117562207] Funding Source: UKRI; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT [R37HD030284, R01HD030284] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTE [T32CA009299] Funding Source: NIH RePORTER	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		ARCECI RJ, 1993, MOL CELL BIOL, V13, P2235, DOI 10.1128/MCB.13.4.2235; BAARENDS WM, 1994, DEVELOPMENT, V120, P189; Baroiller JF, 1999, CELL MOL LIFE SCI, V55, P910, DOI 10.1007/s000180050344; BEHRINGER RR, 1990, NATURE, V345, P167, DOI 10.1038/345167a0; BEHRINGER RR, 1994, CELL, V79, P415, DOI 10.1016/0092-8674(94)90251-8; CALL KM, 1990, CELL, V60, P509, DOI 10.1016/0092-8674(90)90601-A; CARREEUSEBE D, 1996, J BIOL CHEM, V271, P4798; CATE RL, 1986, CELL, V45, P685, DOI 10.1016/0092-8674(86)90783-X; CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1006/abio.1987.9999; daSilva SM, 1996, NAT GENET, V14, P62, DOI 10.1038/ng0996-62; De Santa Barbara P, 1998, MOL CELL BIOL, V18, P6653, DOI 10.1128/MCB.18.11.6653; DICLEMENTE N, 1994, MOL ENDOCRINOL, V8, P1006, DOI 10.1210/me.8.8.1006; DRESSER DW, 1995, HUM MOL GENET, V4, P1613, DOI 10.1093/hmg/4.9.1613; ELBRECHT A, 1992, SCIENCE, V255, P467, DOI 10.1126/science.1734525; FOSTER JW, 1994, NATURE, V372, P525, DOI 10.1038/372525a0; Giuili G, 1997, DEVELOPMENT, V124, P1799; GOODFELLOW PN, 1993, ANNU REV GENET, V27, P71, DOI 10.1146/annurev.ge.27.120193.000443; GUBBAY J, 1990, NATURE, V346, P245, DOI 10.1038/346245a0; HACKER A, 1995, DEVELOPMENT, V121, P1603; HAQQ C, 1992, GENOMICS, V12, P665, DOI 10.1016/0888-7543(92)90291-Y; HAQQ CM, 1994, SCIENCE, V266, P1494, DOI 10.1126/science.7985018; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; HONDA S, 1993, J BIOL CHEM, V268, P7494; IKEDA Y, 1994, MOL ENDOCRINOL, V8, P654, DOI 10.1210/me.8.5.654; IMBEAUD S, 1995, NAT GENET, V11, P382, DOI 10.1038/ng1295-382; Josso N, 1997, CLIN ENDOCRINOL, V47, P137, DOI 10.1046/j.1365-2265.1997.2411044.x; JOSSO N, 1993, RECENT PROG HORM RES, V48, P1; JOST A, 1953, RECENT PROG HORM RES, V8, P379; Kent J, 1996, DEVELOPMENT, V122, P2813; Ketola I, 1999, ENDOCRINOLOGY, V140, P1470, DOI 10.1210/en.140.3.1470; Koopman P, 1993, ESSENTIAL DEV BIOL P, P233; KREIDBERG JA, 1993, CELL, V74, P679, DOI 10.1016/0092-8674(93)90515-R; LALA DS, 1992, MOL ENDOCRINOL, V6, P1249, DOI 10.1210/me.6.8.1249; Lee MM, 1999, ENDOCRINOLOGY, V140, P2819, DOI 10.1210/en.140.6.2819; LUO XR, 1994, CELL, V77, P481, DOI 10.1016/0092-8674(94)90211-9; LYET L, 1995, BIOL REPROD, V52, P444, DOI 10.1095/biolreprod52.2.444; MANSOUR S, 1995, J MED GENET, V32, P415, DOI 10.1136/jmg.32.6.415; MANSOUR SL, 1988, NATURE, V336, P348, DOI 10.1038/336348a0; MATZUK MM, 1995, MOL ENDOCRINOL, V9, P1337, DOI 10.1210/me.9.10.1337; MCMAHON AP, 1990, CELL, V62, P1073, DOI 10.1016/0092-8674(90)90385-R; Meier C, 1998, CAN J ZOOL, V76, P1188, DOI 10.1139/cjz-76-6-1188; Mishina Y, 1996, GENE DEV, V10, P2577, DOI 10.1101/gad.10.20.2577; MOROHASHI K, 1992, J BIOL CHEM, V267, P17913; MUNSTERBERG A, 1991, DEVELOPMENT, V113, P613; MUSCATELLI F, 1994, NATURE, V372, P672, DOI 10.1038/372672a0; Nachtigal MW, 1998, CELL, V93, P445, DOI 10.1016/S0092-8674(00)81172-1; Neeper M, 1996, GENE, V176, P203, DOI 10.1016/0378-1119(96)00248-X; Oreal E, 1998, DEV DYNAM, V212, P522, DOI 10.1002/(SICI)1097-0177(199808)212:4<522::AID-AJA5>3.0.CO;2-J; Parker KL, 1997, ENDOCR REV, V18, P361, DOI 10.1210/er.18.3.361; Pham CTN, 1996, P NATL ACAD SCI USA, V93, P13090, DOI 10.1073/pnas.93.23.13090; PICARD JY, 1986, P NATL ACAD SCI USA, V83, P5464, DOI 10.1073/pnas.83.15.5464; Pieau Claude, 1994, P433; Racine C, 1998, P NATL ACAD SCI USA, V95, P594, DOI 10.1073/pnas.95.2.594; RAMIREZSOLIS R, 1992, ANAL BIOCHEM, V201, P331, DOI 10.1016/0003-2697(92)90347-A; SHEN WH, 1994, CELL, V77, P651, DOI 10.1016/0092-8674(94)90050-7; Smith CA, 1999, GEN COMP ENDOCR, V113, P187, DOI 10.1006/gcen.1998.7214; Swain A, 1999, GENE DEV, V13, P755, DOI 10.1101/gad.13.7.755; Swain A, 1996, NAT GENET, V12, P404, DOI 10.1038/ng0496-404; Tremblay JJ, 1999, MOL ENDOCRINOL, V13, P1388, DOI 10.1210/me.13.8.1388; Viger RS, 1998, DEVELOPMENT, V125, P2665; WAGNER T, 1994, CELL, V79, P1111, DOI 10.1016/0092-8674(94)90041-8; Western PS, 1999, DEV DYNAM, V214, P171, DOI 10.1002/(SICI)1097-0177(199903)214:3<171::AID-AJA1>3.3.CO;2-J; WIBBELS T, 1992, J EXP ZOOL, V262, P454, DOI 10.1002/jez.1402620413; Wibbels T, 1998, J EXP ZOOL, V281, P409, DOI 10.1002/(SICI)1097-010X(19980801)281:5<409::AID-JEZ6>3.0.CO;2-S; WILSON TE, 1993, MOL CELL BIOL, V13, P5794, DOI 10.1128/MCB.13.9.5794; WRIGHT E, 1995, NAT GENET, V9, P15, DOI 10.1038/ng0195-15	66	356	364	1	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					409	419		10.1016/S0092-8674(00)81527-5	http://dx.doi.org/10.1016/S0092-8674(00)81527-5			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571183	Bronze			2022-12-28	WOS:000083709300008
J	Gibson, JR; Beierlein, M; Connors, BW				Gibson, JR; Beierlein, M; Connors, BW			Two networks of electrically coupled inhibitory neurons in neocortex	NATURE			English	Article							INTRINSIC FIRING PATTERNS; RAT FRONTAL-CORTEX; BARREL CORTEX; IN-VITRO; SOMATOSENSORY CORTEX; CIRCUIT FORMATION; GAP-JUNCTIONS; SYNCHRONIZATION; INTERNEURONS; EXCITATION	Inhibitory interneurons are critical to sensory transformations, plasticity and synchronous activity in the neocortex(1,2). There are many types of inhibitory neurons, but their synaptic organization is poorly understood. Here we describe two functionally distinct inhibitory networks comprising either fast-spiking (FS) or low-threshold spiking (LTS) neurons. Paired-cell recordings showed that inhibitory neurons of the same type were strongly interconnected by electrical synapses, but electrical synapses between different inhibitory cell types were rare. The electrical synapses;were strong enough to synchronize spikes in coupled interneurons. Inhibitory chemical synapses were also common between FS cells, and between FS and LTS cells, but LTS cells rarely inhibited one another. Thalamocortical synapses, which convey sensory information to the cortex, specifically and strongly excited only the FS cell network. The electrical and chemical synaptic connections of different types of inhibitory neurons are specific, and may allow each inhibitory network to function independently.	Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA	Brown University	Connors, BW (corresponding author), Brown Univ, Dept Neurosci, Div Biol & Med, Providence, RI 02912 USA.		Connors, Barry/AAX-1975-2020	Connors, Barry/0000-0002-3739-3157; Beierlein, Michael/0000-0003-2210-3118				AGMON A, 1992, J NEUROSCI, V12, P319; AGMON A, 1991, NEUROSCIENCE, V41, P365, DOI 10.1016/0306-4522(91)90333-J; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; Bennett M., 1977, HDB PHYSL          1, P357; BozhilovaPastirova A, 1995, NEUROSCI LETT, V201, P265, DOI 10.1016/0304-3940(95)12193-5; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; CHRISTIE MJ, 1989, J NEUROSCI, V9, P3584; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; CONNORS BW, 1983, J NEUROSCI, V3, P773; DERMIETZEL R, 1993, TRENDS NEUROSCI, V16, P186, DOI 10.1016/0166-2236(93)90151-B; Gil Z, 1999, NEURON, V23, P385, DOI 10.1016/S0896-6273(00)80788-6; JEFFERYS JGR, 1995, PHYSIOL REV, V75, P689, DOI 10.1152/physrev.1995.75.4.689; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; JOHNSTON MF, 1980, NATURE, V286, P498, DOI 10.1038/286498a0; JONES EG, 1993, CEREB CORTEX, V3, P361, DOI 10.1093/cercor/3.5.361-a; Kawaguchi Y, 1998, J NEUROSCI, V18, P6963; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; Mann-Metzer P, 1999, J NEUROSCI, V19, P3298; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; Nadarajah B, 1997, J NEUROSCI, V17, P3096; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Reyes A, 1998, NAT NEUROSCI, V1, P279, DOI 10.1038/1092; SIMONS DJ, 1984, J COMP NEUROL, V230, P119, DOI 10.1002/cne.902300111; SLOPER JJ, 1978, PROC R SOC SER B-BIO, V203, P39, DOI 10.1098/rspb.1978.0089; Somogyi P, 1998, BRAIN RES REV, V26, P113, DOI 10.1016/S0165-0173(97)00061-1; Staiger JF, 1996, EUR J NEUROSCI, V8, P2273, DOI 10.1111/j.1460-9568.1996.tb01191.x; Swadlow HA, 1998, J NEUROPHYSIOL, V79, P567, DOI 10.1152/jn.1998.79.2.567; Thomson AM, 1997, CEREB CORTEX, V7, P510, DOI 10.1093/cercor/7.6.510; Veenstra RD, 1996, J BIOENERG BIOMEMBR, V28, P327, DOI 10.1007/BF02110109; Xiang ZX, 1998, SCIENCE, V281, P985, DOI 10.1126/science.281.5379.985	30	1088	1106	1	49	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					75	79		10.1038/47035	http://dx.doi.org/10.1038/47035			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573419				2022-12-28	WOS:000083638600045
J	Ganz, T				Ganz, T			Immunology - Defensins and host defense	SCIENCE			English	Editorial Material							ANTIMICROBIAL PEPTIDES		Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Ganz, T (corresponding author), Univ Calif Los Angeles, Dept Med, CHS 37-055, Los Angeles, CA 90095 USA.		Ganz, Tomas/AAN-3308-2020; Ganz, Tomas/D-4567-2009	Ganz, Tomas/0000-0002-2830-5469				BENSCH KW, 1995, FEBS LETT, V368, P331, DOI 10.1016/0014-5793(95)00687-5; Fahrner RL, 1996, CHEM BIOL, V3, P543, DOI 10.1016/S1074-5521(96)90145-3; GANZ T, 1995, PHARMACOL THERAPEUT, V66, P191, DOI 10.1016/0163-7258(94)00076-F; Ganz T, 1998, CURR OPIN IMMUNOL, V10, P41, DOI 10.1016/S0952-7915(98)80029-0; Harder J, 1997, NATURE, V387, P861, DOI 10.1038/43088; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; KOKRYAKOV VN, 1993, FEBS LETT, V327, P231, DOI 10.1016/0014-5793(93)80175-T; MARSH J, 1994, CIBA FDN S, V186; Ouellette AJ, 1996, FASEB J, V10, P1280, DOI 10.1096/fasebj.10.11.8836041; SOLOMON S, 1991, J STEROID BIOCHEM, V40, P391, DOI 10.1016/0960-0760(91)90206-K; Tang YQ, 1999, SCIENCE, V286, P498, DOI 10.1126/science.286.5439.498; Valore EV, 1996, J CLIN INVEST, V97, P1624, DOI 10.1172/JCI118588; Valore EV, 1998, J CLIN INVEST, V101, P1633, DOI 10.1172/JCI1861; Wilson CL, 1999, SCIENCE, V286, P113, DOI 10.1126/science.286.5437.113; Yang D, 1999, SCIENCE, V286, P525, DOI 10.1126/science.286.5439.525	15	257	301	0	11	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					420	421		10.1126/science.286.5439.420	http://dx.doi.org/10.1126/science.286.5439.420			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577203				2022-12-28	WOS:000083121200029
J	Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J				Blair, PS; Fleming, PJ; Smith, IJ; Platt, MW; Young, J; Nadin, P; Berry, PJ; Golding, J		CESDI SUDI Res Grp	Babies sleeping with parents: case-control study of factors influencing the risk of the sudden infant death syndrome	BRITISH MEDICAL JOURNAL			English	Article							HONG-KONG; COT DEATH	Objective To investigate the risks of the sudden infant death syndrome and factors that may contribute to unsafe sleeping environments. Design Three year, population based case-control study. Parental interviews were conducted for each sudden infant death and for four controls matched for age, locality, and time of sleep. Setting Fire regions in England with a total population of over 17 million people. Subjects 325 babies who died and 1300 control infants. Results In die multivariate analysis infants who shared their parents' bed and were then put back in their own cot had no increased risk (odds ratio 0.67; 95% confidence interval 0.22 to 2.00). There was an increased risk for infants who shared the bed for the whole sleep or were taken to and found in the parental bed (9.78; 4.02 to 23.83), infants who slept in a separate room from their parents (10.49; 4.26 to 25.81), and infants who shared a sofa (48.99; 5.04 to 475.60). The risk associated with being found in the parental bed was not significant for older infants (> 14 weeks) or for infants of parents who did not smoke and became non-significant after adjustment for recent maternal alcohol consumption(> 2 units), use of duvets ( > 4 togs), parental tiredness (infant slept less than or equal to 4 hours for longest sleep in previous 24 hours), and overcrowded housing conditions (> 2 people per room of the house). Conclusions There are certain circumstances when bed sharing should be avoided, particularly for infants under four months old. Parents sleeping on a sofa Midi infants should always be avoided. There is no evidence that bed sharing is hazardous for infants of parents who do not smoke.	Royal Hosp Sick Children, Inst Child Hlth, Bristol BS2 8BJ, Avon, England; Nuffield Inst Hlth Serv, Leeds LS2 9PL, W Yorkshire, England; Royal Victoria Infirm, Newcastle Neonatal Serv, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England	Bristol Royal Hospital For Children; University of Bristol; University of Leeds; Newcastle University - UK	Blair, PS (corresponding author), Royal Hosp Sick Children, Inst Child Hlth, St Michaels Hill, Bristol BS2 8BJ, Avon, England.		Platt, Martin Ward/D-4008-2014; Young, Jeanine/G-2528-2010; Fleming, Peter J/A-9081-2010; Blair, Peter S/C-1213-2009; Fleming, Peter/O-3231-2019	Platt, Martin Ward/0000-0003-0536-5749; Young, Jeanine/0000-0003-3849-3392; Fleming, Peter J/0000-0003-2521-5764; Fleming, Peter/0000-0003-2521-5764; Blair, Peter/0000-0002-7832-8087; Golding, Jean/0000-0003-2826-3307				Anderson G C, 1991, J Perinatol, V11, P216; BALL HL, IN PRESS AM ANTHR; BASS M, 1986, NEW ENGL J MED, V315, P100, DOI 10.1056/NEJM198607103150206; CARPENTER RG, 1972, SUDDEN UNEXPECTED DE, P7; DAVIES DP, 1985, LANCET, V2, P1346; FAROOQI I, 1994, BMJ-BRIT MED J, V308, P204, DOI 10.1136/bmj.308.6922.204b; Fleming PJ, 1996, BMJ-BRIT MED J, V313, P191, DOI 10.1136/bmj.313.7051.191; Gantley M, 1993, BMJ-BRIT MED J, V16, P263; HOFFMAN HJ, 1988, SUDDEN INFANT DEATH, P153; KLONOFFCOHEN H, 1995, BMJ-BRIT MED J, V311, P1269, DOI 10.1136/bmj.311.7015.1269; LEACH CEA, IN PRESS PEDIATRICS; LEE NNY, 1989, BRIT MED J, V298, P721, DOI 10.1136/bmj.298.6675.721; Ludington-Hoe S M, 1991, J Perinatol, V11, P19; LUKE JL, 1978, J FORENSIC SCI, V23, P379; MCKENNA J, 1994, EARLY HUM DEV, V38, P187, DOI 10.1016/0378-3782(94)90211-9; McKenna JJ, 1996, ANNU REV ANTHROPOL, V25, P201, DOI 10.1146/annurev.anthro.25.1.201; MITCHELL EA, 1993, BMJ-BRIT MED J, V306, P13, DOI 10.1136/bmj.306.6869.13; MITCHELL EA, 1992, NJ PAEDIAT CHILD HLT, V28, pS3; Mitchell EA, 1995, SUDDEN INFANT DEATH; MOSKO S, 1993, J BEHAV MED, V16, P589, DOI 10.1007/BF00844721; Nelson EAS, 1996, NEW ZEAL MED J, V109, P144; RINTAHAKA RJ, 1986, FORENSIC SCI INT, V30, P219, DOI 10.1016/0379-0738(86)90017-4; *SAS I, 1992, P229 SAS I; TAKEDA K, 1987, Journal of Kyoto Prefectural University of Medicine, V96, P965; TUOHY PG, 1993, ARCH DIS CHILD, V69, P664, DOI 10.1136/adc.69.6.664	25	217	224	0	11	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1457	1461		10.1136/bmj.319.7223.1457	http://dx.doi.org/10.1136/bmj.319.7223.1457			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582925	Bronze, Green Published, Green Submitted			2022-12-28	WOS:000084129200016
J	Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME				Minegishi, Y; Rohrer, J; Coustan-Smith, E; Lederman, HM; Pappu, R; Campana, D; Chan, AC; Conley, ME			An essential role for BLNK in human B cell development	SCIENCE			English	Article							X-LINKED AGAMMAGLOBULINEMIA; ADAPTER PROTEIN SLP-76; TYROSINE KINASE; INTERLEUKIN-2 PRODUCTION; DEFICIENT MICE; T-CELLS; MUTATIONS; RECEPTOR; EXPRESSION; GENE	The signal transduction events that control the progenitor B cell (pro-B cell) to precursor B cell (pre-B cell) transition have not been well delineated. In evaluating patients with absent B cells, a male with a homozygous splice defect in the cytoplasmic adapter protein BLNK (B cell Linker protein) was identified. Although this patient had normal numbers of pro-B cells, he had no pre-B cells or mature B cells, indicating that BLNK plays a critical role in orchestrating the pro-B cell to pre-B cell transition. The immune system and overall growth and development were otherwise normal in this patient, suggesting that BLNK function is highly specific.	St Jude Childrens Res Hosp, Dept Immunol, Memphis, TN 38105 USA; Johns Hopkins Hosp, Dept Pediat, Div Pediat Allergy & Immunol, Baltimore, MD 21287 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Med,Div Rheumatol,Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, Dept Pathol, St Louis, MO 63110 USA; Univ Tennessee, Coll Med, Dept Pediat, Memphis, TN 38105 USA	St Jude Children's Research Hospital; Johns Hopkins University; Johns Hopkins Medicine; Howard Hughes Medical Institute; Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL); University of Tennessee System; University of Tennessee Health Science Center	Conley, ME (corresponding author), St Jude Childrens Res Hosp, Dept Immunol, 332 N Lauderdale St, Memphis, TN 38105 USA.				NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI25129, AI42787] Funding Source: Medline; NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI025129, R01AI042787, R37AI025129] Funding Source: NIH RePORTER	NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Conley ME, 1998, AM J HUM GENET, V62, P1034, DOI 10.1086/301828; CONLEY ME, 1994, HUM MOL GENET, V3, P1751, DOI 10.1093/hmg/3.10.1751; COOPER DN, 1994, HUMAN GENE MUTATION, P239; DaSilva AJ, 1997, P NATL ACAD SCI USA, V94, P7493, DOI 10.1073/pnas.94.14.7493; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Goitsuka R, 1998, J IMMUNOL, V161, P5804; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; JACKMAN JK, 1995, J BIOL CHEM, V270, P7029, DOI 10.1074/jbc.270.13.7029; KENNY RA, 1995, CARDIOL ELDER, V3, P301; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Law CL, 1999, J EXP MED, V189, P1243, DOI 10.1084/jem.189.8.1243; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marie-Cardine A, 1998, J BIOL CHEM, V273, P25789, DOI 10.1074/jbc.273.40.25789; Minegishi Y, 1999, J CLIN INVEST, V104, P1115, DOI 10.1172/JCI7696; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; Motto DG, 1996, J EXP MED, V183, P1937, DOI 10.1084/jem.183.4.1937; Pappu R, 1999, SCIENCE, V286, P1949, DOI 10.1126/science.286.5446.1949; PESCHON JJ, 1994, J EXP MED, V180, P1955, DOI 10.1084/jem.180.5.1955; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; Puel A, 1998, NAT GENET, V20, P394, DOI 10.1038/3877; Rajewsky K, 1996, NATURE, V381, P751, DOI 10.1038/381751a0; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791; Wunderlich L, 1999, EUR J IMMUNOL, V29, P1068, DOI 10.1002/(SICI)1521-4141(199904)29:04<1068::AID-IMMU1068>3.0.CO;2-P; Yel L, 1996, NEW ENGL J MED, V335, P1486, DOI 10.1056/NEJM199611143352003; Zhang WG, 1999, IMMUNITY, V10, P323, DOI 10.1016/S1074-7613(00)80032-1; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0; Zhang Y, 1998, EMBO J, V17, P7304, DOI 10.1093/emboj/17.24.7304	32	252	259	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1954	1957		10.1126/science.286.5446.1954	http://dx.doi.org/10.1126/science.286.5446.1954			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583958				2022-12-28	WOS:000084003400051
J	Frith, CD; Frith, U				Frith, CD; Frith, U			Cognitive psychology - Interacting minds - A biological basis	SCIENCE			English	Review							NORMAL-CHILDREN; ANTERIOR CINGULATE; CORTEX; AUTISM; ACTIVATION; ATTENTION; RESPONSES; MOVEMENTS; DECEPTION; NEURONS	The ability to "mentalize," that is to understand and manipulate other people's behavior in terms of their mental states, is a major ingredient in successful social interactions. A rudimentary form of this ability may be seen in great apes, but in humans it is developed to a high Level. Specific impairments of mentalizing in both developmental and acquired disorders suggest that this ability depends on a dedicated and circumscribed brain system. Functional imaging studies implicate medial prefrontal cortex and posterior superior temporal sulcus (STS) as components of this system. Clues to the specific function of these components in mentalizing come from single cell recording studies: STS is concerned with representing the actions of others through the detection of biological motion; medial prefrontal regions are concerned with explicit representation of states of the self. These observations suggest that the ability to mentalize has evolved from a system for representing actions.	UCL, Inst Neurol, Wellcome Dept Cognit Neurol, London WC1N 3BG, England; UCL, Dept Psychol, London WC1N 3AR, England; UCL, Inst Cognit Neurosci, London WC1N 3AR, England	University of London; University College London; University of London; University College London; University of London; University College London	Frith, CD (corresponding author), UCL, Inst Neurol, Wellcome Dept Cognit Neurol, 12 Queen Sq, London WC1N 3BG, England.	cfrith@fil.ion.ucl.ac.uk	Frith, Uta/C-1757-2008; Frith, Chris D/A-2171-2009	Frith, Uta/0000-0002-9063-4466; Frith, Chris D/0000-0002-8665-0690				Astington J.W., 1988, DEV THEORIES MIND; ATTWOOD A, 1988, J AUTISM DEV DISORD, V18, P241, DOI 10.1007/BF02211950; Baron-Cohen S., 1991, GOOGL SCHOL, P233; BARONCOHEN S, 1986, BRIT J DEV PSYCHOL, V4, P113, DOI 10.1111/j.2044-835X.1986.tb01003.x; BARONCOHEN S, 1996, BRIT J PSYCHIAT, V168, P158, DOI DOI 10.1192/BJP.168.2.158; Blakemore SJ, 1998, NAT NEUROSCI, V1, P635, DOI 10.1038/2870; BUTTERWORTH G., 1991, NATURAL THEORIES MIN, P223; BYRNE RW, 1998, COMP NEUROPSYCHOLOGY, P228; BYRNE RW, 1990, PRIMATE REPORT, V27, P1; Carter CS, 1998, SCIENCE, V280, P747, DOI 10.1126/science.280.5364.747; CHARMAN T, 1992, J CHILD PSYCHOL PSYC, V33, P1105, DOI 10.1111/j.1469-7610.1992.tb00929.x; CHENEY DL, 1989, BEHAVIOUR, V110, P258, DOI 10.1163/156853989X00501; CORCORAN R, 1995, SCHIZOPHR RES, V17, P5, DOI 10.1016/0920-9964(95)00024-G; DAMASIO AR, 1994, DESCARTES ERROR; Dennett, 1987, INTENTIONAL STANCE; Dennett DC., 1978, BEHAV BRAIN SCI, V4, P568, DOI [10.1017/S0140525X00076664, DOI 10.1017/S0140525X00076664]; Dunbar R.I.M., 1988, PRIMATE SOCIAL SYSTE; Emery NJ, 1997, J COMP PSYCHOL, V111, P286, DOI 10.1037/0735-7036.111.3.286; FLETCHER PC, 1995, COGNITION, V57, P109, DOI 10.1016/0010-0277(95)00692-R; Fombonne E, 1999, PSYCHOL MED, V29, P769, DOI 10.1017/S0033291799008508; Frith C, 1996, PHILOS T R SOC B, V351, P1505, DOI 10.1098/rstb.1996.0136; FRITH U, 1991, TRENDS NEUROSCI, V14, P433, DOI 10.1016/0166-2236(91)90041-R; GALLAGHER H, IN PRESS NEUROPSYCHO; Gallese V, 1998, TRENDS COGN SCI, V2, P493, DOI 10.1016/S1364-6613(98)01262-5; GOEL V, 1995, NEUROREPORT, V6, P1741, DOI 10.1097/00001756-199509000-00009; GOLDBERG TE, 1988, SCHIZOPHRENIA BULL, V14, P179, DOI 10.1093/schbul/14.2.179; Happe F, 1999, COGNITION, V70, P211, DOI 10.1016/S0010-0277(99)00005-0; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; HEYES CM, 1993, ANIM BEHAV, V46, P177, DOI 10.1006/anbe.1993.1173; HIETANEN JK, 1993, EXP BRAIN RES, V93, P117; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Jeannerod M, 1999, Q J EXP PSYCHOL-A, V52, P1, DOI 10.1080/027249899391205; Kanwisher N, 1997, J NEUROSCI, V17, P4302; KASARI C, 1993, J CHILD PSYCHOL PSYC, V34, P353, DOI 10.1111/j.1469-7610.1993.tb00997.x; Lane RD, 1997, NEUROREPORT, V8, P3969, DOI 10.1097/00001756-199712220-00024; Langdon R, 1997, Cogn Neuropsychiatry, V2, P167, DOI 10.1080/135468097396324; Leslie A.M., 1994, MAPPING MIND DOMAIN, P119, DOI [10.1017/cbo9780511752902.006, DOI 10.1017/CBO9780511752902.006]; LESLIE AM, 1992, COGNITION, V43, P225, DOI 10.1016/0010-0277(92)90013-8; LESLIE AM, 1987, PSYCHOL REV, V94, P412, DOI 10.1037/0033-295X.94.4.412; Maguire EA, 1998, SCIENCE, V280, P921, DOI 10.1126/science.280.5365.921; McGuire PK, 1996, NEUROREPORT, V7, P2095; MELTZOFF AN, 1995, DEV PSYCHOL, V31, P838, DOI 10.1037/0012-1649.31.5.838; Milner A. D., 1995, VISUAL BRAIN ACTION; MULLERPREUSS P, 1981, BRAIN RES, V215, P61, DOI 10.1016/0006-8993(81)90491-1; ORAM MW, 1994, J COGNITIVE NEUROSCI, V6, P99, DOI 10.1162/jocn.1994.6.2.99; PASSINGHAM RE, 1993, FRONTAL LOBES VOLUNT, pCH4; PERRETT DI, 1985, PROC R SOC SER B-BIO, V223, P293, DOI 10.1098/rspb.1985.0003; Premack D., 1978, BEHAVIORAL BRAIN SCI, V4, P515, DOI [10.1017/S0140525X00076512, DOI 10.1017/S0140525X00076512]; Puce A, 1998, J NEUROSCI, V18, P2188; Rainville P, 1997, SCIENCE, V277, P968, DOI 10.1126/science.277.5328.968; Rizzolatti G, 1996, COGNITIVE BRAIN RES, V3, P131, DOI 10.1016/0926-6410(95)00038-0; Russell J., 1998, AUTISM EXECUTIVE DIS; SHIMA K, 1991, J NEUROPHYSIOL, V65, P188, DOI 10.1152/jn.1991.65.2.188; SIGMAN M, 1986, J CHILD PSYCHOL PSYC, V27, P647, DOI 10.1111/j.1469-7610.1986.tb00189.x; SODIAN B, 1991, BRIT J DEV PSYCHOL, V9, P173, DOI 10.1111/j.2044-835X.1991.tb00869.x; SODIAN B, 1992, J CHILD PSYCHOL PSYC, V33, P591, DOI 10.1111/j.1469-7610.1992.tb00893.x; Stone VE, 1998, J COGNITIVE NEUROSCI, V10, P640, DOI 10.1162/089892998562942; Ungerleider L.G., 1982, ANAL VISUAL BEHAV, P549	58	1171	1204	1	182	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1692	1695		10.1126/science.286.5445.1692	http://dx.doi.org/10.1126/science.286.5445.1692			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	259UK	10576727				2022-12-28	WOS:000083912200025
J	Skouteris, D; Manolopoulos, DE; Bian, WS; Werner, HJ; Lai, LH; Liu, KP				Skouteris, D; Manolopoulos, DE; Bian, WS; Werner, HJ; Lai, LH; Liu, KP			van der Waals interactions in the Cl+HD reaction	SCIENCE			English	Article							POTENTIAL-ENERGY SURFACE; TRANSITION-STATE THEORY; CL-H2 SYSTEM; CHEMICAL-REACTIONS; F+H-2 REACTION; DYNAMICS; KINETICS; ABSTRACTION; D-2; HD	The van der Waals forces in the entrance valley of the Cl + HD reaction are shown here to play a decisive role in the reaction's dynamics. Exact quantum mechanical calculations of reactive scattering on a potential energy surface without Cl-HD van der Waals forces predict that the HCl and DCl products will be produced almost equally, whereas the same calculations on a new ab initio potential energy surface with van der Waals forces show a strong preference for the production of DCl. This preference is also seen in crossed molecular beam experiments on the reaction. The study of chemical reaction dynamics has now advanced to the stage where even comparatively weak van der Waals interactions can no longer be neglected in calculations of the potential energy surfaces of chemical reactions.	Phys & Theoret Chem Lab, Oxford OX1 3QZ, England; Univ Stuttgart, Inst Theoret Chem, D-75069 Stuttgart, Germany; Acad Sinica, Inst Atom & Mol Sci, Taipei 10764, Taiwan	University of Oxford; University of Stuttgart; Academia Sinica - Taiwan	Skouteris, D (corresponding author), Phys & Theoret Chem Lab, S Parks Rd, Oxford OX1 3QZ, England.		Werner, Hans-Joachim/G-9509-2011; Manolopoulos, David/AAV-1276-2021; Liu, Kopin/F-7929-2012; Skouteris, Dimitrios/M-9370-2015	Werner, Hans-Joachim/0000-0002-0435-539X; Liu, Kopin/0000-0001-7499-2397; Skouteris, Dimitrios/0000-0002-4741-5866; BIAN, Wensheng/0000-0003-2125-8054; Manolopoulos, David/0000-0002-7111-0763				Alagia M, 1996, SCIENCE, V273, P1519, DOI 10.1126/science.273.5281.1519; Allison TC, 1996, J PHYS CHEM-US, V100, P13575, DOI 10.1021/jp960781j; BIAN W, IN PRESS J CHEM PHYS; Castillo JF, 1996, J CHEM PHYS, V104, P6531, DOI 10.1063/1.471373; Castillo JF, 1998, FARADAY DISCUSS, V110, P119, DOI 10.1039/a801227j; CLARY DC, 1990, ANNU REV PHYS CHEM, V41, P61; HASE WL, 1994, SCIENCE, V266, P998, DOI 10.1126/science.266.5187.998; Hirschfelder J, 1936, J CHEM PHYS, V4, P170, DOI 10.1063/1.1749815; Hsu YT, 1997, J CHEM PHYS, V107, P2351, DOI 10.1063/1.474579; JOHNSTON HS, 1966, GAS PHASE REACTION R, pCH13; KUMARAN SS, 1994, J CHEM PHYS, V101, P9487, DOI 10.1063/1.468486; Laidler K. J., 1987, CHEM KINETICS; LEE SD, IN PRESS J CHEM PHYS; Lee SH, 1998, CHEM PHYS LETT, V290, P323, DOI 10.1016/S0009-2614(98)00535-1; Manolopoulos DE, 1997, J CHEM SOC FARADAY T, V93, P673, DOI 10.1039/a606090k; MATSUMI Y, 1992, J CHEM PHYS, V97, P1065, DOI 10.1063/1.463285; MILLER JC, 1983, J CHEM PHYS, V79, P1252, DOI 10.1063/1.445932; MILLER JC, 1981, J CHEM PHYS, V75, P5305, DOI 10.1063/1.441972; MILLER JC, 1983, J CHEM PHYS, V78, P3713, DOI 10.1063/1.445145; MILLER WH, 1993, ACCOUNTS CHEM RES, V26, P174, DOI 10.1021/ar00028a007; SAITO S, 1955, J CHEM PHYS, V23, P2465; Samartzis PC, 1999, J CHEM PHYS, V110, P5201, DOI 10.1063/1.478415; Stark K, 1996, J CHEM PHYS, V104, P6515, DOI 10.1063/1.471372; TOMLINSON HL, UNPUB; TRUHLAR DG, 1983, J PHYS CHEM-US, V87, P2664, DOI 10.1021/j100238a003; WERNER HJ, 1988, J CHEM PHYS, V89, P5803, DOI 10.1063/1.455556; WHEELER A, 1936, J CHEM PHYS, V4, P178; YAAKOV YB, 1973, J CHEM PHYS, V59, P2415, DOI 10.1063/1.1680351	28	272	273	0	66	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1713	1716		10.1126/science.286.5445.1713	http://dx.doi.org/10.1126/science.286.5445.1713			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576733				2022-12-28	WOS:000083912200031
J	Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D				Burt, DW; Bruley, C; Dunn, IC; Jones, CT; Ramage, A; Law, AS; Morrice, DR; Paton, IR; Smith, J; Windsor, D; Sazanov, A; Fries, R; Waddington, D			The dynamics of chromosome evolution in birds and mammals	NATURE			English	Article							RATES; TREE	Comparative mapping, which compares the location of homologous genes in different species, is a powerful tool for studying genome evolution(1). Comparative maps suggest that rates of chromosomal change in mammals can vary from one to ten rearrangements per million years(1-4). On the basis of these rates we would expect 84 to 600 conserved segments in a chicken comparison with human or mouse. Here we build comparative maps between these species and estimate that numbers of conserved segments are in the lower part of this range. We conclude that the organization of the human genome is closer to that of the chicken than the mouse and by adding comparative mapping results from a range of vertebrates, we identify three possible phases of chromosome evolution. The relative stability of genomes such as those of the chicken and human will enable the reconstruction of maps of ancestral vertebrates.	Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland; TUM, Lehrstuhl Tierzucht, D-85350 Munich, Germany	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Roslin Institute; Technical University of Munich	Burt, DW (corresponding author), Roslin Inst, Roslin EH25 9PS, Midlothian, Scotland.	Dave-Burt@bbsrc.ac.uk	Burt, David W/C-7802-2013; Smith, Jacqueline/C-7719-2013; Sazanov, Alexei/A-6980-2014; Dunn, Ian/C-7689-2013	Burt, David W/0000-0002-9991-1028; Smith, Jacqueline/0000-0002-2813-7872; Sazanov, Alexei/0000-0002-5273-5397; Dunn, Ian/0000-0003-3630-0120				Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; Burt David W., 1998, ILAR J, V39, P229; BUSH GL, 1977, P NATL ACAD SCI USA, V74, P3942, DOI 10.1073/pnas.74.9.3942; Davisson Muriel T., 1998, ILAR J, V39, P96; de Jong WW, 1998, TRENDS ECOL EVOL, V13, P270, DOI 10.1016/S0169-5347(98)01335-4; Hastie TJ., 1990, GEN ADDITIVE MODELS, Vvol. 43, DOI DOI 10.1201/9780203753781; Hurvich CM, 1998, J ROY STAT SOC B, V60, P271, DOI 10.1111/1467-9868.00125; Kosambi DD, 1943, ANN EUGENIC, V12, P172, DOI 10.1111/j.1469-1809.1943.tb02321.x; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li WH, 1996, MOL PHYLOGENET EVOL, V5, P182, DOI 10.1006/mpev.1996.0012; Morizot D. C., 1994, Animal Biotechnology, V5, P113, DOI 10.1080/10495399409525812; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; NADEAU JH, 1984, P NATL ACAD SCI-BIOL, V81, P814, DOI 10.1073/pnas.81.3.814; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; O'Neill RJW, 1998, NATURE, V393, P68, DOI 10.1038/29985; OBrien SJ, 1997, TRENDS GENET, V13, P393, DOI 10.1016/S0168-9525(97)01297-3; OHTA T, 1993, P NATL ACAD SCI USA, V90, P10676, DOI 10.1073/pnas.90.22.10676; SARICH VM, 1967, SCIENCE, V158, P1200, DOI 10.1126/science.158.3805.1200; WADDINGTON D, IN PRESS GENETICS; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; Wienberg Johannes, 1998, ILAR J, V39, P77; [No title captured]	22	229	233	0	18	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					411	413		10.1038/46555	http://dx.doi.org/10.1038/46555			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586880				2022-12-28	WOS:000083913600056
J	Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW				Wakker, BP; Howk, JC; Savage, BD; van Woerden, H; Tufte, SL; Schwarz, UJ; Benjamin, R; Reynolds, RJ; Peletier, RF; Kalberla, PMW			Accretion of low-metallicity gas by the Milky Way	NATURE			English	Article							HIGH-VELOCITY CLOUDS; H-II REGIONS; ABUNDANCES; GALAXIES; LINE; ORIGIN; HALO	Models of the chemical evolution of the Milky Way suggest that: the observed abundances of elements heavier than helium ('metals') require a continuous infall of gas with metallicity (metal abundance) about 0.1 times the solar value. An infall rate integrated over the entire disk of the Milky Way of similar to 1 solar mass per year can solve the 'G-dwarf problem'-the observational fact that the metallicities of most long-lived stars near the Sun lie in a relatively narrow range(1-3). This infall dilutes the enrichment arising from the production of heavy elements in stars, and thereby prevents the metallicity of the interstellar medium from increasing steadily with time. However, in other spiral galaxies, the low-metallicity gas needed to provide this infall has been observed only in associated dwarf galaxies(4) and in the extreme outer disk of the Milky Way(5,6). In the distant Universe, low-metallicity hydrogen clouds (known as 'damped Ly alpha absorbers') are sometimes seen near galaxies(7,8). Here we report a metallicity of 0.09 times solar for a massive cloud that is falling into the disk of the Milky Way. The mass now associated with this cloud represents an infall per unit area of about the theoretically expected rate, and similar to 0.1-0.2 times the amount required for the whole Galaxy.	Univ Wisconsin, Dept Astron, Madison, WI 53706 USA; Univ Wisconsin, Dept Phys, Madison, WI 53706 USA; Johns Hopkins Univ, Dept Phys & Astron, Baltimore, MD 21218 USA; Kapteyn Astron Inst, NL-9700 AV Groningen, Netherlands; Lewis & Clark Coll, Dept Phys, Portland, OR 97219 USA; Univ Nijmegen, NL-6500 GL Nijmegen, Netherlands; Univ Durham, Dept Phys, Durham DH1 3LE, England; Univ Bonn, Inst Radioastron, D-53121 Bonn, Germany	University of Wisconsin System; University of Wisconsin Madison; University of Wisconsin System; University of Wisconsin Madison; Johns Hopkins University; University of Groningen; Radboud University Nijmegen; Durham University; University of Bonn	Wakker, BP (corresponding author), Univ Wisconsin, Dept Astron, Madison, WI 53706 USA.		Peletier, Reynier F/B-9633-2012; Howk, Jay/D-2577-2013	Peletier, Reynier/0000-0001-7621-947X; Kalberla, Peter/0000-0002-8381-7889; Howk, J. Christopher/0000-0002-2591-3792				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; Ferguson AMN, 1998, ASTRON J, V116, P673, DOI 10.1086/300456; Gardiner LT, 1996, MON NOT R ASTRON SOC, V278, P191, DOI 10.1093/mnras/278.1.191; GIOVAGNOLI A, 1995, MON NOT R ASTRON SOC, V273, P499, DOI 10.1093/mnras/273.2.499; Haffner LM, 1999, ASTROPHYS J, V523, P223, DOI 10.1086/307734; Hartmann D., 1997, ATLAS GALACTIC NEUTR; Lu LM, 1998, ASTRON J, V115, P55, DOI 10.1086/300180; Lu LM, 1998, ASTRON J, V115, P162, DOI 10.1086/300181; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; Pagel B.E.J., 1997, NUCLEOSYNTHESIS CHEM; Pettini M, 1999, ASTROPHYS J, V510, P576, DOI 10.1086/306635; Reynolds RJ, 1998, PUBL ASTRON SOC AUST, V15, P14, DOI 10.1071/AS98014; Rudolph AL, 1997, ASTROPHYS J, V489, P94, DOI 10.1086/304758; Savage BD, 1996, ANNU REV ASTRON ASTR, V34, P279, DOI 10.1146/annurev.astro.34.1.279; Skillman ED, 1997, ASTROPHYS J, V474, P205, DOI 10.1086/303464; Snowden SL, 1998, ASTROPHYS J, V493, P715, DOI 10.1086/305135; van Woerden H, 1999, ASTR SOC P, V166, P1; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; VANDENBERGH S, 1962, ASTRON J, V67, P486, DOI 10.1086/108757; VERNER DA, 1994, ASTRON ASTROPHYS SUP, V108, P287; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; Wakker BP, 1997, ANNU REV ASTRON ASTR, V35, P217, DOI 10.1146/annurev.astro.35.1.217; Wakker BP, 1999, ASTR SOC P, V166, P26; Wakker BP, 1996, ASTRON ASTROPHYS, V306, pL25; WOLFIRE MG, 1995, ASTROPHYS J, V453, P673, DOI 10.1086/176429; YANNY B, 1992, ASTROPHYS J, V391, P569, DOI 10.1086/171371; Zwaan MA, 1997, ASTROPHYS J, V490, P173, DOI 10.1086/304872	29	180	181	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					388	390		10.1038/46498	http://dx.doi.org/10.1038/46498			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586877				2022-12-28	WOS:000083913600048
J	Simon, LS; Weaver, AL; Graham, DY; Kivitz, AJ; Lipsky, PE; Hubbard, RC; Isakson, PC; Verburg, KM; Yu, SS; Zhao, WW; Geis, GS				Simon, LS; Weaver, AL; Graham, DY; Kivitz, AJ; Lipsky, PE; Hubbard, RC; Isakson, PC; Verburg, KM; Yu, SS; Zhao, WW; Geis, GS			Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis - A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NONSTEROIDAL ANTIINFLAMMATORY DRUGS; PEPTIC-ULCER DISEASE; SELECTIVE-INHIBITION; MESSENGER-RNA; CYCLOOXYGENASE-2 INHIBITOR; SYNTHASE CYCLOOXYGENASE; PROSTAGLANDIN SYNTHASE; PHORBOL ESTER; IN-VIVO; EXPRESSION	Context In vitro studies have shown that celecoxib inhibits cyclooxygenase 2 (COX-2) but not COX-1, suggesting that this drug may have anti-inflammatory and analgesic activity without adverse upper gastrointestinal (GI) tract effects that result from COX-1 inhibition. Objective To test whether celecoxib has efficacy as an anti inflammatory and analgesic with reduced GI tract mucosal damage compared with conventional nonsteroidal anti-inflammatory drugs in patients with rheumatoid arthritis. Design Randomized, multicenter, placebo-controlled, double-blind trial lasting 12 weeks, with follow-up at weeks 2, 6, and 12, from September 1996 through February 1998, Setting Seventy-nine clinical sites in the United States and Canada. Patients A total of 1149 patients aged 18 years or older with symptomatic rheumatoid arthritis who met inclusion criteria were randomized; 688 (60%) of these completed the study. Interventions Patients were randomized to receive celecoxib, 100 mg, 200 mg, or 400 mg twice per day (n = 240, 235, and 218, respectively); naproxen, 500 mg twice per day (n = 225); or placebo (n = 231). Main Outcome Measures Improvement in signs and symptoms of rheumatoid arthritis as assessed using standard measures of efficacy and GI tract safety as assessed by upper GI tract endoscopy before and after treatment, compared among treatment groups. Results All dosages of celecoxib and naproxen significantly improved the signs and symptoms of arthritis compared with placebo. Maximal anti-inflammatory and analgesic activity was evident within 2 weeks of initiating treatment and was sustained throughout the 12 weeks. The incidence of endoscopically determined gastroduodenal ulcers in placebo-treated patients was 4 (4%) of 99, and the incidences across all dosages of celecoxib were not significantly different (P>.40): 9 (6%) of 148 with 100 mg twice per day, 6 (4%) of 145 with 200 mg twice per day, and 8 (6%) of 130 with 400 mg twice per day. In contrast, the incidence with naproxen was 36 (26%) of 137, significantly greater than either placebo or celecoxib (P<.001). The overall incidences of GI tract adverse effects were 19% for placebo; 28%, 25%, and 26% for celecoxib 100 mg, 200 mg, and 400 mg twice per day, respectively; and 31% for naproxen. Conclusion In this study, all dosages of celecoxib were efficacious in the treatment of rheumatoid arthritis and did not affect COX-1 activity in the GI tract mucosa as evidenced by less frequent incidence of endoscopic ulcers compared with naproxen.	Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div rheumatol & Metab Bone Dis, Boston, MA 02215 USA; Arthrit Ctr Nebraska, Lincoln, NE USA; Baylor Coll Med, Vet Affairs Med Ctr, Dept Med, Houston, TX 77030 USA; Altoona Ctr Clin Res, Altoona, PA USA; Univ Texas, SW Med Ctr, Div Rheumat Dis, Dallas, TX USA; Searle Res & Dev, Dept Clin Res, Skokie, IL USA; Searle Res & Dev, COX2 Technol, Skokie, IL USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard Medical School; Baylor College of Medicine; US Department of Veterans Affairs; Veterans Health Administration (VHA); Altoona Center for Clinical Research; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; Pfizer; Pfizer	Simon, LS (corresponding author), Harvard Univ, Sch Med, Beth Israel Deaconess Med Ctr, Dept Med,Div rheumatol & Metab Bone Dis, 110 Francis St,Suite 5C, Boston, MA 02215 USA.		Graham, David/AAL-2165-2021					ABRAMSON SB, 1989, ARTHRITIS RHEUM, V32, P1, DOI 10.1002/anr.1780320102; AGRAWAL NM, 1995, DIGEST DIS SCI, V40, P1125, DOI 10.1007/BF02064210; AKDAMAR K, 1986, GASTROINTEST ENDOSC, V32, P78, DOI 10.1016/S0016-5107(86)71760-4; Anderson GD, 1996, J CLIN INVEST, V97, P2672, DOI 10.1172/JCI118717; ARNETT FC, 1988, ARTHRITIS RHEUM, V31, P315, DOI 10.1002/art.1780310302; CHAN CC, 1995, J PHARMACOL EXP THER, V274, P1531; Cheatum DE, 1999, CLIN THER, V21, P992, DOI 10.1016/S0149-2918(99)80020-4; CROFFORD LJ, 1994, J CLIN INVEST, V93, P1095, DOI 10.1172/JCI117060; CROFFORD LJ, 1990, J BIOL CHEM, V265, P16737; DAY RO, 1982, CLIN PHARMACOL THER, V31, P733, DOI 10.1038/clpt.1982.103; DUBOIS RN, 1994, J CLIN INVEST, V93, P493, DOI 10.1172/JCI116998; EGGER MJ, 1985, ARTHRITIS RHEUM, V28, P613, DOI 10.1002/art.1780280603; FELSON DT, 1993, ARTHRITIS RHEUM-US, V36, P729, DOI 10.1002/art.1780360601; FELSON DT, 1995, ARTHRITIS RHEUM, V38, P727, DOI 10.1002/art.1780380602; FU JY, 1990, J BIOL CHEM, V265, P16737; FUTAKI N, 1993, J PHARM PHARMACOL, V45, P753, DOI 10.1111/j.2042-7158.1993.tb07103.x; GABRIEL SE, 1991, ANN INTERN MED, V115, P787, DOI 10.7326/0003-4819-115-10-787; GALL EP, 1982, J RHEUMATOL, V9, P402; GIERSE JK, 1995, BIOCHEM J, V305, P479, DOI 10.1042/bj3050479; GRAHAM DY, 1993, ANN INTERN MED, V119, P257, DOI 10.7326/0003-4819-119-4-199308150-00001; GRAHAM DY, 1989, GASTROENTEROLOGY, V96, P675, DOI 10.1016/S0016-5085(89)80064-2; Graham DY, 1996, AM J GASTROENTEROL, V91, P2080; GRIFFIN MR, 1991, ANN INTERN MED, V114, P257, DOI 10.7326/0003-4819-114-4-257; HENRY D, 1993, GASTROENTEROLOGY, V105, P1078, DOI 10.1016/0016-5085(93)90952-9; HOCHBERG MC, 1992, ARTHRITIS RHEUM, V35, P498, DOI 10.1002/art.1780350502; HOCHBERG Y, 1988, BIOMETRIKA, V75, P800, DOI 10.1093/biomet/75.4.800; IHAMAKI T, 1979, SCAND J GASTROENTERO, V14, P801, DOI 10.3109/00365527909181408; Kargman S, 1996, GASTROENTEROLOGY, V111, P445, DOI 10.1053/gast.1996.v111.pm8690211; KUJUBU DA, 1992, J BIOL CHEM, V267, P7991; LANGLEY GB, 1984, CLIN EXP RHEUMATOL, V2, P231; LEQUESNE MG, 1987, SCAND J RHEUMATOL, P85; MacDonald TM, 1997, BMJ-BRIT MED J, V315, P1333, DOI 10.1136/bmj.315.7119.1333; MASFERRER JL, 1994, J PHARMACOL EXP THER, V270, P1340; MASFERRER JL, 1990, J CLIN INVEST, V86, P1375, DOI 10.1172/JCI114850; MASFERRER JL, 1994, P NATL ACAD SCI USA, V91, P3228, DOI 10.1073/pnas.91.8.3228; OBANION MK, 1991, J BIOL CHEM, V266, P23261; ONEILL GP, 1993, FEBS LETT, V330, P156, DOI 10.1016/0014-5793(93)80263-T; Penning TD, 1997, J MED CHEM, V40, P1347, DOI 10.1021/jm960803q; RAZ A, 1989, P NATL ACAD SCI USA, V86, P1657, DOI 10.1073/pnas.86.5.1657; ROTH SH, 1995, CLIN DRUG INVEST, V9, P171, DOI 10.2165/00044011-199509030-00007; SCHOEN RT, 1989, AM J MED, V86, P449, DOI 10.1016/0002-9343(89)90344-6; SEIBERT K, 1994, P NATL ACAD SCI USA, V91, P12013, DOI 10.1073/pnas.91.25.12013; SHORROCK CJ, 1989, AM J MED, V86, P2, DOI 10.1016/0002-9343(89)90148-4; SILVERSTEIN FE, 1995, ANN INTERN MED, V123, P241, DOI 10.7326/0003-4819-123-4-199508150-00001; Simon LS, 1998, ARTHRITIS RHEUM-US, V41, P1591, DOI 10.1002/1529-0131(199809)41:9<1591::AID-ART9>3.0.CO;2-J; Smith WL, 1996, ADV IMMUNOL, V62, P167, DOI 10.1016/S0065-2776(08)60430-7; SOLL AH, 1991, ANN INTERN MED, V114, P307, DOI 10.7326/0003-4819-114-4-307; Taha AS, 1996, NEW ENGL J MED, V334, P1435, DOI 10.1056/NEJM199605303342204; VANE JR, 1994, LIPID MEDIATORS, P61; WELL J, 1995, BRIT MED J, V310, P827; WILSKE KR, 1989, J RHEUMATOL, V16, P565; WOLFE F, 1988, J RHEUMATOL, V15, P1480; XIE WL, 1991, P NATL ACAD SCI USA, V88, P2692, DOI 10.1073/pnas.88.7.2692	53	636	660	0	20	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1921	1928		10.1001/jama.282.20.1921	http://dx.doi.org/10.1001/jama.282.20.1921			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580457	Bronze			2022-12-28	WOS:000083763400026
J	Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T				Oya, T; Enoki, T; Grosberg, AY; Masamune, S; Sakiyama, T; Takeoka, Y; Tanaka, K; Wang, GQ; Yilmaz, Y; Feld, MS; Dasari, R; Tanaka, T			Reversible molecular adsorption based on multiple-point interaction by shrinkable gels	SCIENCE			English	Article							N-ISOPROPYLACRYLAMIDE	A general approach is presented for creating polymer-gels that can recognize and capture a target molecule by multiple-point interaction and that can reversibly change their affinity to the target by more than one order of magnitude. The polymers consist of majority monomers that make the gel reversibly swell and shrink and minority monomers that constitute multiple-point adsorption centers for the target molecule, Multiple-point interaction is experimentally proven by power Laws found between the affinity and the concentration of the adsorbing monomers within the gels.	MIT, Dept Phys, Cambridge, MA 02139 USA; MIT, Ctr Mat Sci & Engn, Cambridge, MA 02139 USA; MIT, Dept Chem, Cambridge, MA 02139 USA; MIT, George R Harrison Spect Lab, Cambridge, MA 02139 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT)	Oya, T (corresponding author), MIT, Dept Phys, Cambridge, MA 02139 USA.		Takeoka, Yukikazu/I-6785-2014; Grosberg, Alexander Y/O-2122-2015; Grosberg, Alexander/AAD-9614-2019; yilmaz, yasar/D-6190-2014; Takeoka, Yukikazu/W-9627-2019	Takeoka, Yukikazu/0000-0002-1406-0704; Grosberg, Alexander Y/0000-0002-4230-8690; Grosberg, Alexander/0000-0002-4230-8690; yilmaz, yasar/0000-0003-2352-4723; Takeoka, Yukikazu/0000-0002-1406-0704				HIROTSU S, 1987, J CHEM PHYS, V87, P1392, DOI 10.1063/1.453267; RICKA J, 1985, MACROMOLECULES, V18, P83, DOI 10.1021/ma00143a013; SCHILD HG, 1992, PROG POLYM SCI, V17, P163, DOI 10.1016/0079-6700(92)90023-R; Tanaka T, 1995, FARADAY DISCUSS, V101, P201, DOI 10.1039/fd9950100201; YAMATO M, 1999, CONNECT TISSUE, V31, P13	5	179	186	1	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1543	1545		10.1126/science.286.5444.1543	http://dx.doi.org/10.1126/science.286.5444.1543			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567256				2022-12-28	WOS:000083768300052
J	Rastogi, VK; Girvin, ME				Rastogi, VK; Girvin, ME			Structural changes linked to proton translocation by subunit c of the ATP synthase	NATURE			English	Article							PROTEIN-STRUCTURE DETERMINATION; ESCHERICHIA-COLI; CHEMICAL-SHIFTS; CROSS-LINKING; DIRECT REFINEMENT; NMR; F1-ATPASE; ROTATION; F-0; SECTOR	F1F0 ATP synthases use a transmembrane proton gradient to drive the synthesis of cellular ATP. The structure of the cytosolic F-1 portion of the enzyme and the basic mechanism of ATP hydrolysis by F-1 are now well established, but how proton translocation through the transmembrane F-0 portion drives these catalytic changes is less clear. Here we describe the structural changes in the proton-translocating F-0 subunit c that are induced by deprotonating the specific aspartic acid involved in proton transport. conformational changes between the protonated and deprotonated forms of subunit c provide the structural basis for an explicit mechanism to explain coupling of proton translocation by F-0 to the rotation of subunits within the core of F-1. Rotation of these subunits within F-1 causes the catalytic conformational changes in the active sites of F-1 that result in ATP synthesis.	Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, Bronx, NY 10461 USA	Yeshiva University; Albert Einstein College of Medicine	Girvin, ME (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Biochem, 1300 Morris Pk Ave, Bronx, NY 10461 USA.	girvin@aecom.yu.edu						ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; ARIS JP, 1983, J BIOL CHEM, V258, P4599; AssadiPorter FM, 1995, BIOCHEMISTRY-US, V34, P16186, DOI 10.1021/bi00049a034; Baxter NJ, 1997, J BIOMOL NMR, V9, P359, DOI 10.1023/A:1018334207887; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; BIRKENHAGER R, 1995, EUR J BIOCHEM, V230, P58, DOI 10.1111/j.1432-1033.1995.tb20534.x; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; ERMLER U, 1994, STRUCTURE, V2, P925, DOI 10.1016/S0969-2126(94)00094-8; Fillingame RH, 1998, ACTA PHYSIOL SCAND, V163, P163; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; GIRVIN ME, 1995, BIOCHEMISTRY-US, V34, P1635, DOI 10.1021/bi00005a020; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; HERMOLIN J, 1983, J BIOL CHEM, V258, P4550; Howitt SM, 1996, J BIOENERG BIOMEMBR, V28, P415, DOI 10.1007/BF02113983; Jager H, 1998, EUR J BIOCHEM, V251, P122, DOI 10.1046/j.1432-1327.1998.2510122.x; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Koradi R, 1996, J MOL GRAPHICS, V14, P51, DOI 10.1016/0263-7855(96)00009-4; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KUSZEWSKI J, 1995, J MAGN RESON SER B, V107, P293, DOI 10.1006/jmrb.1995.1093; KUSZEWSKI J, 1995, J MAGN RESON SER B, V106, P92, DOI 10.1006/jmrb.1995.1017; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MILLER MJ, 1990, P NATL ACAD SCI USA, V87, P4900, DOI 10.1073/pnas.87.13.4900; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; NORWOOD TJ, 1992, BIOCHEMISTRY-US, V31, P6285, DOI 10.1021/bi00142a017; Rastogi VK, 1999, J BIOMOL NMR, V13, P91, DOI 10.1023/A:1008379624478; Rodgers AJW, 1997, J BIOL CHEM, V272, P31058, DOI 10.1074/jbc.272.49.31058; Sabbert D, 1996, NATURE, V381, P623, DOI 10.1038/381623a0; SIGRISTNELSON K, 1979, J BIOL CHEM, V254, P4470; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valiyaveetil FI, 1998, J BIOL CHEM, V273, P16241, DOI 10.1074/jbc.273.26.16241; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wada T, 1999, J BIOL CHEM, V274, P17353, DOI 10.1074/jbc.274.24.17353; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yamada H, 1996, FEBS LETT, V390, P34, DOI 10.1016/0014-5793(96)00621-7; ZUIDERWEG ERP, 1989, BIOCHEMISTRY-US, V28, P2387, DOI 10.1021/bi00432a008	50	381	387	1	48	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					263	268		10.1038/46224	http://dx.doi.org/10.1038/46224			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580496				2022-12-28	WOS:000083813700040
J	Rogers, J; Joyce, GF				Rogers, J; Joyce, GF			A ribozyme that lacks cytidine	NATURE			English	Article							IN-VITRO EVOLUTION; RNA; SEQUENCES	The RNA-world hypothesis proposes that, before the advent of DNA and protein, life was based on RNA, with RNA serving as both the repository of genetic information and the chief agent of catalytic function(1). An argument against an RNA world is that the components of RNA lack the chemical diversity necessary to sustain life. Unlike proteins, which contain 20 different aminoacid subunits, nucleic acids are composed of only four subunits which have very similar chemical properties. Yet RNA is capable of a broad range of catalytic functions(2-7). Here we show that even three nucleic-acid subunits are sufficient to provide a substantial increase in the catalytic rate. Starting from a molecule that contained roughly equal proportions of all four nucleosides, we used in vitro evolution to obtain an RNA ligase ribozyme that lacks cytidine. This ribozyme folds into a defined structure and has a catalytic rate that is about 10(5)-fold faster than the uncatalysed rate of template-directed RNA ligation.	Scripps Res Inst, Dept Chem, La Jolla, CA 92037 USA; Scripps Res Inst, Dept Mol Biol, La Jolla, CA 92037 USA; Scripps Res Inst, Skaggs Inst Chem Biol, La Jolla, CA 92037 USA	Scripps Research Institute; Scripps Research Institute; Scripps Research Institute	Joyce, GF (corresponding author), Scripps Res Inst, Dept Chem, 10550 N Torrey Pines Rd, La Jolla, CA 92037 USA.	gjoyce@scripps.edu						Atkins J.F, 1999, RNA WORLD; BARTEL DP, 1993, SCIENCE, V261, P1411, DOI 10.1126/science.7690155; Cadwell R C, 1992, PCR Methods Appl, V2, P28, DOI 10.1101/gr.2.1.28; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; EKLAND EH, 1995, SCIENCE, V269, P364, DOI 10.1126/science.7618102; Ekland EH, 1996, NATURE, V382, P373, DOI 10.1038/382373a0; GOODALL GJ, 1989, CELL, V58, P473, DOI 10.1016/0092-8674(89)90428-5; GUERRIERTAKADA C, 1983, CELL, V35, P849, DOI 10.1016/0092-8674(83)90117-4; HAYATSU H, 1970, J AM CHEM SOC, V92, P724, DOI 10.1021/ja00706a062; KRUGER K, 1982, CELL, V31, P147, DOI 10.1016/0092-8674(82)90414-7; Levy M, 1998, P NATL ACAD SCI USA, V95, P7933, DOI 10.1073/pnas.95.14.7933; LORSCH JR, 1994, NATURE, V371, P31, DOI 10.1038/371031a0; Rohatgi R, 1996, J AM CHEM SOC, V118, P3332, DOI 10.1021/ja953712b; SHU HH, 1991, MOL CELL BIOL, V11, P1662, DOI 10.1128/MCB.11.3.1662; STERN S, 1988, METHOD ENZYMOL, V164, P481; Unrau PJ, 1998, NATURE, V395, P260, DOI 10.1038/26193; Vartanian JP, 1996, NUCLEIC ACIDS RES, V24, P2627, DOI 10.1093/nar/24.14.2627; Wright MC, 1997, SCIENCE, V276, P614, DOI 10.1126/science.276.5312.614; YOSHIDA H, 1994, NUCLEIC ACIDS RES, V22, P41, DOI 10.1093/nar/22.1.41; Zhang BL, 1998, CHEM BIOL, V5, P539, DOI 10.1016/S1074-5521(98)90113-2	20	68	69	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					323	325		10.1038/46335	http://dx.doi.org/10.1038/46335			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580507				2022-12-28	WOS:000083813700057
J	Ruckdeschel, JC				Ruckdeschel, JC			Update in oncology	ANNALS OF INTERNAL MEDICINE			English	Bibliography									H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA	H Lee Moffitt Cancer Center & Research Institute	Ruckdeschel, JC (corresponding author), H Lee Moffitt Canc Ctr & Res Inst, 12902 Magnolia Dr, Tampa, FL 33612 USA.		Ruckdeschel, John/AAU-2137-2020	Ruckdeschel, John/0000-0002-7977-4257					0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					760	767		10.7326/0003-4819-131-10-199911160-00008	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577300				2022-12-28	WOS:000083680100007
J	Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D				Marcotte, EM; Pellegrini, M; Thompson, MJ; Yeates, TO; Eisenberg, D			A combined algorithm for genome-wide prediction of protein function	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; COLON-CANCER; GENES; YEAST; DATABASE; INTERACT; MUTATION; HOMOLOG; MSH6	The availability of over 20 fully sequenced genomes has driven the development of new methods to find protein function and interactions. Here we group proteins by correlated evolution(1), correlated messenger RNA expression patterns(2) and patterns of domain fusion(3) to determine functional relationships among the 6,217 proteins of the yeast Saccharomyces cervisiae. Using these methods, we discover over 93,000 pairwise links between functionally related yeast proteins. Links between characterized and uncharacterized proteins allow a general function to be assigned to more than half of the 2,557 previously uncharacterized yeast proteins. Examples of functional links are given for a protein family of previously unknown function, a protein whose human homologues are implicated in colon cancer and the yeast prion Sup35.	Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, Los Angeles, CA 90095 USA	United States Department of Energy (DOE); University of California System; University of California Los Angeles	Eisenberg, D (corresponding author), Univ Calif Los Angeles, Inst Mol Biol, US DOE, Lab Struct Biol & Mol Med, POB 951570, Los Angeles, CA 90095 USA.			Pellegrini, Matteo/0000-0001-9355-9564; Thompson, Michael/0000-0002-2914-1080; Marcotte, Edward/0000-0001-8808-180X; Yeates, Todd/0000-0001-5709-9839				Altschul SF, 1997, NUCLEIC ACIDS RES, V25, P3389, DOI 10.1093/nar/25.17.3389; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; BARDOSI A, 1990, ACTA NEUROPATHOL, V79, P387, DOI 10.1007/BF00308714; CHEN XY, 1994, P NATL ACAD SCI USA, V91, P9111, DOI 10.1073/pnas.91.19.9111; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; FISHEL R, 1993, CELL, V75, P1027, DOI 10.1016/0092-8674(93)90546-3; Horton Paul, 1997, INTELLIGENT SYSTEMS, V5, P147; Johnson RE, 1996, J BIOL CHEM, V271, P7285, DOI 10.1074/jbc.271.13.7285; Karp PD, 1998, NUCLEIC ACIDS RES, V26, P50, DOI 10.1093/nar/26.1.50; KUSHNIROV VV, 1988, GENE, V66, P45, DOI 10.1016/0378-1119(88)90223-5; Lynch HT, 1997, ANN NY ACAD SCI, V833, P1, DOI 10.1111/j.1749-6632.1997.tb48588.x; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mewes HW, 1998, NUCLEIC ACIDS RES, V26, P33, DOI 10.1093/nar/26.1.33; Miyaki M, 1997, NAT GENET, V17, P271, DOI 10.1038/ng1197-271; Myers LC, 1999, P NATL ACAD SCI USA, V96, P67, DOI 10.1073/pnas.96.1.67; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; PAPADOPOULOS N, 1994, SCIENCE, V263, P1625, DOI 10.1126/science.8128251; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STANSFIELD I, 1995, EMBO J, V14, P4365, DOI 10.1002/j.1460-2075.1995.tb00111.x; West MG, 1996, BIOCHEMISTRY-US, V35, P3122, DOI 10.1021/bi952713d; WICKNER RB, 1994, SCIENCE, V264, P566, DOI 10.1126/science.7909170; 1997, NATURE S, V387, P1	26	681	723	0	25	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					83	86		10.1038/47048	http://dx.doi.org/10.1038/47048			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573421				2022-12-28	WOS:000083638600047
J	Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB				Reynolds, AJ; Lawrence, C; Cserhalmi-Friedman, PB; Christiano, AM; Jahoda, CAB			Trans-gender induction of hair follicles	NATURE			English	Article							DERMAL PAPILLA CELLS; GROWTH		Univ Durham, Dept Biol Sci, Durham DH1 3LE, England; Royal Victoria Infirm, Dept Dermatol, Newcastle Upon Tyne NE1 4LP, Tyne & Wear, England; Columbia Univ, Dept Dermatol, New York, NY 10032 USA; Columbia Univ, Dept Genet & Dev, New York, NY 10032 USA	Durham University; Newcastle University - UK; Columbia University; Columbia University	Reynolds, AJ (corresponding author), Univ Durham, Dept Biol Sci, South Rd, Durham DH1 3LE, England.	c.a.b.jahoda@durham.ac.uk		Jahoda, Colin/0000-0002-1762-1220				CHONG SS, 1993, HUM MOL GENET, V2, P1187, DOI 10.1093/hmg/2.8.1187; FABRE JW, 1987, TRANSPLANT P, V19, P45; GIBSON WT, 1991, ANN NY ACAD SCI, V642, P291; Halloran P F, 1993, Transpl Immunol, V1, P3, DOI 10.1016/0966-3274(93)90055-D; HARDY MH, 1992, TRENDS GENET, V8, P55, DOI 10.1016/0168-9525(92)90350-D; IBRAHIM MAA, 1995, IMMUNOL TODAY, V16, P181, DOI 10.1016/0167-5699(95)80118-9; JAHODA CAB, 1993, J INVEST DERMATOL, V101, P584, DOI 10.1111/1523-1747.ep12366039; REYNOLDS AJ, 1992, DEVELOPMENT, V115, P587; Simone NL, 1998, TRENDS GENET, V14, P272, DOI 10.1016/S0168-9525(98)01489-9; STREILEIN JW, 1995, SCIENCE, V270, P1158, DOI 10.1126/science.270.5239.1158	10	173	198	0	5	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					33	34		10.1038/46938	http://dx.doi.org/10.1038/46938			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573414				2022-12-28	WOS:000083638600030
J	Holland, PWH				Holland, PWH			The future of evolutionary developmental biology	NATURE			English	Article							HOX GENES; DROSOPHILA; ULTRABITHORAX; ANTENNAPEDIA; COMPLEXES; SEQUENCE; PLAN	Combining fields as diverse as comparative embryology, palaeontology, molecular phylogenetics and genome analysis, the new discipline of evolutionary developmental biology aims at explaining how developmental processes and mechanisms become modified during evolution, and how these modifications produce changes in animal morphology and body plans. In the next century this should give us far greater mechanistic insight into how evolution has produced the vast diversity of living organisms, past and present.	Univ Reading, Sch Anim & Microbial Sci, Reading RG6 6AJ, Berks, England	University of Reading	Holland, PWH (corresponding author), Univ Reading, Sch Anim & Microbial Sci, POB 228, Reading RG6 6AJ, Berks, England.			Holland, Peter/0000-0003-1533-9376				Aguinaldo AMA, 1997, NATURE, V387, P489, DOI 10.1038/387489a0; Aldridge RJ, 1996, TRENDS ECOL EVOL, V11, P463, DOI 10.1016/0169-5347(96)10048-3; [Anonymous], 1861, ORIGIN SPECIES MEANS; Aparicio S, 1997, NAT GENET, V16, P79, DOI 10.1038/ng0597-79; Brooke NM, 1998, NATURE, V392, P920, DOI 10.1038/31933; Budd GE, 1999, BIOESSAYS, V21, P326, DOI 10.1002/(SICI)1521-1878(199904)21:4<326::AID-BIES9>3.0.CO;2-0; BURKE AC, 1995, DEVELOPMENT, V121, P333; COATES MI, 1994, DEVELOPMENT, P169; Cockell M, 1999, CURR OPIN GENET DEV, V9, P199, DOI 10.1016/S0959-437X(99)80030-6; Cohn MJ, 1999, NATURE, V399, P474, DOI 10.1038/20944; de Rosa R, 1999, NATURE, V399, P772, DOI 10.1038/21631; DeRobertis EM, 1996, NATURE, V380, P37, DOI 10.1038/380037a0; FIELD KG, 1988, SCIENCE, V239, P748, DOI 10.1126/science.3277277; Force A, 1999, GENETICS, V151, P1531; Gaunt SJ, 1999, MECH DEVELOP, V82, P109, DOI 10.1016/S0925-4773(99)00018-0; HAECKEL E, 1903, PEDIGREE MAN OTHER E; Holland PWH, 1996, DEV BIOL, V173, P382, DOI 10.1006/dbio.1996.0034; Mackay TFC, 1996, BIOESSAYS, V18, P113, DOI 10.1002/bies.950180207; MCGINNIS W, 1984, NATURE, V308, P428, DOI 10.1038/308428a0; MCGINNIS W, 1994, GENETICS, V137, P607; MORRIS SC, 1995, PHILOS T ROY SOC B, V347, P305, DOI 10.1098/rstb.1995.0029; Mouchel-Vielh E, 1998, MOL PHYLOGENET EVOL, V9, P382, DOI 10.1006/mpev.1998.0498; Rutherford SL, 1998, NATURE, V396, P336, DOI 10.1038/24550; Ruvkun G, 1998, SCIENCE, V282, P2033, DOI 10.1126/science.282.5396.2033; SCOTT MP, 1984, P NATL ACAD SCI-BIOL, V81, P4115, DOI 10.1073/pnas.81.13.4115; Shashikant CS, 1998, P NATL ACAD SCI USA, V95, P15446, DOI 10.1073/pnas.95.26.15446; Simmen MW, 1998, P NATL ACAD SCI USA, V95, P4437, DOI 10.1073/pnas.95.8.4437; Stern DL, 1998, NATURE, V396, P463, DOI 10.1038/24863; Willmer P., 1990, INVERTEBRATE RELATIO	29	56	59	2	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C41	C44		10.1038/35011536	http://dx.doi.org/10.1038/35011536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591224	Bronze			2022-12-28	WOS:000084014100006
J	Saxena, D; Flores, S; Stotzky, G				Saxena, D; Flores, S; Stotzky, G			Transgenic plants - Insecticidal toxin in root exudates from Bt corn	NATURE			English	Article							THURINGIENSIS SUBSP KURSTAKI; BACILLUS-THURINGIENSIS; SOIL; TENEBRIONIS		NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA; Inst Venezolano Invest Cient, Caracas 1020A, Venezuela	New York University; Venezuelan Institute Science Research	Saxena, D (corresponding author), NYU, Dept Biol, Microbial Ecol Lab, New York, NY 10003 USA.	gs5@is2.nyu.edu	Saxena, Deepak/K-1864-2019					BENIZRI E, 1995, SOIL BIOL BIOCHEM, V27, P71, DOI 10.1016/0038-0717(94)00131-J; Crecchio C, 1998, SOIL BIOL BIOCHEM, V30, P463, DOI 10.1016/S0038-0717(97)00147-8; Hilbeck A, 1998, ENVIRON ENTOMOL, V27, P480, DOI 10.1093/ee/27.2.480; Koskella J, 1997, APPL ENVIRON MICROB, V63, P3561, DOI 10.1128/AEM.63.9.3561-3568.1997; Losey JE, 1999, NATURE, V399, P214, DOI 10.1038/20338; LOWRY OH, 1951, J BIOL CHEM, V193, P265; TAPP H, 1994, SOIL BIOL BIOCHEM, V26, P663, DOI 10.1016/0038-0717(94)90258-5; Tapp H, 1998, SOIL BIOL BIOCHEM, V30, P471, DOI 10.1016/S0038-0717(97)00148-X; TAPP H, 1995, APPL ENVIRON MICROB, V61, P1786, DOI 10.1128/AEM.61.5.1786-1790.1995; Wadman M, 1999, NATURE, V397, P639, DOI 10.1038/17655	10	282	391	0	93	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					480	480		10.1038/44997	http://dx.doi.org/10.1038/44997			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591205	Bronze			2022-12-28	WOS:000084013200041
J	Dyer, C				Dyer, C			Health authority loses cervical smear appeal	BRITISH MEDICAL JOURNAL			English	News Item																		Martin-Hirsch P, 1999, LANCET, V354, P1763, DOI 10.1016/S0140-6736(99)02353-3	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1391	1391		10.1136/bmj.319.7222.1391	http://dx.doi.org/10.1136/bmj.319.7222.1391			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574848	Green Published			2022-12-28	WOS:000083995200016
J	Karki, BB; Wentzcovitch, RM; de Gironcoli, S; Baroni, S				Karki, BB; Wentzcovitch, RM; de Gironcoli, S; Baroni, S			First-principles determination of elastic anisotropy and wave velocities of MgO at lower mantle conditions	SCIENCE			English	Article							SINGLE-CRYSTAL MGO; HIGH-PRESSURES; SEISMIC TOMOGRAPHY; MGSIO3 PEROVSKITE; MAGNESIUM-OXIDE; DEEP MANTLE; EQUATION; DYNAMICS; STATE; SHEAR	The individual elastic constants of magnesium oxide (MgO) have been determined throughout Earth's Lower mantle (LM) pressure-temperature regime with density functional perturbation theory. It is shown that temperature effects on seismic observables (density, velocities, and anisotropy) are monotonically suppressed with increasing pressure. Therefore, at realistic LM conditions, the isotropic wave velocities of MgO remain comparable to seismic velocities, as previously noticed in athermal high-pressure calculations. Also, the predicted strong pressure-induced anisotropy is preserved toward the bottom of the LM, so lattice-preferred orientations in MgO may contribute substantially to the observed seismic anisotropy in the D " Layer.	Univ Minnesota, Minnesota Supercomp Inst, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA; Scuola Int Super Studi Avanzati, I-34014 Trieste, Italy	University of Minnesota System; University of Minnesota Twin Cities; International School for Advanced Studies (SISSA)	Karki, BB (corresponding author), Univ Minnesota, Minnesota Supercomp Inst, Dept Chem Engn & Mat Sci, Minneapolis, MN 55455 USA.		Baroni, Stefano/ABB-5297-2020; de Gironcoli, Stefano/G-7236-2011; Wentzcovitch, Renata M/J-8768-2015; Baroni, Stefano/F-2982-2011	Baroni, Stefano/0000-0002-3508-6663; de Gironcoli, Stefano/0000-0002-2307-0998; Baroni, Stefano/0000-0002-3508-6663				ANDERSON OL, 1995, MINERAL PHYS CRYSTAL, P64; BARONI S, 1987, PHYS REV LETT, V58, P1861, DOI 10.1103/PhysRevLett.58.1861; Bass J.D., 1995, MINERAL PHYS CRYSTAL, P45, DOI DOI 10.1029/RF002P0045; Chen GL, 1998, SCIENCE, V280, P1913, DOI 10.1126/science.280.5371.1913; DUFFY TS, 1993, GEOPHYS RES LETT, V20, P1103, DOI 10.1029/93GL00479; DUFFY TS, 1995, PHYS REV LETT, V74, P1371, DOI 10.1103/PhysRevLett.74.1371; DUFFY TS, 1989, J GEOPHYS RES-SOLID, V94, P1895, DOI 10.1029/JB094iB02p01895; DZIEWONSKI AM, 1987, SCIENCE, V236, P37, DOI 10.1126/science.236.4797.37; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; Fei YW, 1999, AM MINERAL, V84, P272; Fiquet G, 1998, PHYS EARTH PLANET IN, V105, P21, DOI 10.1016/S0031-9201(97)00077-0; Garnero EJ, 1997, J GEOPHYS RES-SOL EA, V102, P8121, DOI 10.1029/96JB03830; GIANNOZZI P, 1991, PHYS REV B, V43, P7231, DOI 10.1103/PhysRevB.43.7231; GRAND SP, 1994, J GEOPHYS RES-SOL EA, V99, P11591, DOI 10.1029/94JB00042; ISAAK DG, 1990, J GEOPHYS RES-SOLID, V95, P7055, DOI 10.1029/JB095iB05p07055; ISAAK DG, 1989, PHYS CHEM MINER, V16, P704; ISAAK DG, 1992, GEOPHYS RES LETT, V19, P741, DOI 10.1029/92GL00774; JEANLOZ R, 1983, REV GEOPHYS, V21, P51, DOI 10.1029/RG021i001p00051; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; Karato SI, 1998, PURE APPL GEOPHYS, V151, P565, DOI 10.1007/s000240050130; Karki BB, 1997, AM MINERAL, V82, P51; Karki BB, 1997, AM MINERAL, V82, P635; Karki BB, 1999, J GEOPHYS RES-SOL EA, V104, P13025, DOI 10.1029/1999JB900069; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; Matzel E, 1996, GEOPHYS RES LETT, V23, P2417, DOI 10.1029/96GL02186; PERDEW JP, 1981, PHYS REV B, V23, P5048, DOI 10.1103/PhysRevB.23.5048; Ringwood A.E, 1975, COMPOSITION PETROLOG; SANGSTER MJ, 1970, J PHYS PART C SOLID, V3, P1026, DOI 10.1088/0022-3719/3/5/017; Saxena SK, 1999, AM MINERAL, V84, P226; Sinogeikin SV, 1999, PHYS REV B, V59, pR14141, DOI 10.1103/PhysRevB.59.R14141; SPETZLER H, 1970, J GEOPHYS RES, V75, P2073, DOI 10.1029/JB075i011p02073; Touloukian Y., 1977, THERMOPHYSICAL PROPE, V13; VONBARTH U, 1991, UNPUB PHYS REV B, V43, P1993; WENTZCOVITCH RM, 1993, PHYS REV LETT, V70, P3947, DOI 10.1103/PhysRevLett.70.3947; Zha CS, 1998, EARTH PLANET SC LETT, V159, P25, DOI 10.1016/S0012-821X(98)00063-6	35	197	198	3	67	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1705	1707		10.1126/science.286.5445.1705	http://dx.doi.org/10.1126/science.286.5445.1705			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576730				2022-12-28	WOS:000083912200028
J	Glynn, I				Glynn, I			Two millennia of animal spirits	NATURE			English	Article									Univ Cambridge Trinity Coll, Cambridge CB2 1TQ, England	University of Cambridge	Glynn, I (corresponding author), Univ Cambridge Trinity Coll, Cambridge CB2 1TQ, England.								0	5	5	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					353	353		10.1038/46428	http://dx.doi.org/10.1038/46428			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586866				2022-12-28	WOS:000083913600029
J	Coleman, AL				Coleman, AL			Glaucoma	LANCET			English	Review							OPEN-ANGLE GLAUCOMA; BALTIMORE EYE SURVEY; LOW-TENSION GLAUCOMA; BLUE MOUNTAINS EYE; QUALITY-OF-LIFE; BEAVER-DAM EYE; INTRAOCULAR-PRESSURE; CLOSURE GLAUCOMA; RISK-FACTORS; VISUAL-FIELD	In 2000 an estimated 66.8 million people worldwide will have glaucoma, 6.7 million of whom will be bilaterally blind from irreversible optic-nerve damage. Yet even in developed countries with public educational programmes that target glaucoma, half of the individuals with glaucoma remain undiagnosed. Patients with even mild visual impairment secondary to glaucoma may have difficulties with mobility, driving, and social interactions. Although glaucoma may be associated with increased eye pressures, its diagnosis does not rely on a specific level of eye pressure. Diagnosis of glaucoma often relies on examination of the optic disc and assessment of the visual field. The two most common types of glaucoma-primary open-angle glaucoma and primary angle-closure glaucoma-have different risk factors. Although similar medications can be used to treat these two types of glaucoma, the overall management of patients differs in important ways. Until recently, there were no randomised clinical trials that showed the effectiveness of lowering eye pressures with medications or surgery in patients with glaucoma. However, in 1998 a randomised clinical trial showed the benefit of lowering eye pressure in patients with glaucoma who had eye pressures of 24 mm Hg or less. Because glaucoma is treatable, and because the visual impairment from glaucoma is irreversible, early detection of the disease is critically important.	Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Glaucoma Div, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles	Coleman, AL (corresponding author), Univ Calif Los Angeles, Jules Stein Eye Inst, Dept Ophthalmol, Glaucoma Div, Los Angeles, CA 90095 USA.	coleman@jsei.ucla.edu						ALSBIRK PH, 1976, ACTA OPHTHALMOL, P5; Alward WL, 1998, AM J OPHTHALMOL, V126, P498; Alward WLM, 1996, AM J OPHTHALMOL, V121, P349; *AM AC OPHTH, 1996, PREF PRACT PATT PRIM; [Anonymous], 1995, Am J Ophthalmol, V120, P718; ARKELL SM, 1987, ARCH OPHTHALMOL-CHIC, V105, P482; Caprioli J, 1997, ACTA OPHTHALMOL SCAN, V75, P364; CARTWRIGHT MJ, 1988, ARCH OPHTHALMOL-CHIC, V106, P898; COFFEY M, 1993, BRIT J OPHTHALMOL, V77, P17, DOI 10.1136/bjo.77.1.17; CONGDON N, 1992, SURV OPHTHALMOL, V36, P411, DOI 10.1016/S0039-6257(05)80022-0; Congdon NG, 1996, ACTA OPHTHALMOL SCAN, V74, P113; Cox JE, 1984, GLAUCOMA, V6, P135; DIELEMANS I, 1994, OPHTHALMOLOGY, V101, P1851; DIELEMANS I, 1995, OPHTHALMOLOGY, V102, P54; Dreyer EB, 1999, JAMA-J AM MED ASSOC, V281, P306, DOI 10.1001/jama.281.4.306; Erie JC, 1997, ARCH OPHTHALMOL-CHIC, V115, P177, DOI 10.1001/archopht.1997.01100150179005; *EUR GLAUC SOC, 1998, TERM GUID EUR GLAUC; Gaasterland DE, 1998, OPHTHALMOLOGY, V105, P1146; GLYNN RJ, 1991, ARCH OPHTHALMOL-CHIC, V109, P205, DOI 10.1001/archopht.1991.01080020051041; Gordon MO, 1999, ARCH OPHTHALMOL-CHIC, V117, P573; GRAHAM P, 1966, BR J OPHTHALMOL, V50, P570; GRANT WM, 1982, OPHTHALMOLOGY, V89, P991; Gutierrez P, 1997, ARCH OPHTHALMOL-CHIC, V115, P777, DOI 10.1001/archopht.1997.01100150779014; HEPLER RS, 1971, J AMER MED ASSOC, V217, P1392, DOI 10.1001/jama.1971.03190100074024; HU Z, 1989, CHIN J OPHTHALMOL, V22, P301; *INT BANK REC DEV, 1993, WORLD DEV REP 1993; Jacob Aby, 1998, Indian Journal of Ophthalmology, V46, P81; JAY JL, 1989, EYE, V3, P528, DOI 10.1038/eye.1989.84; KITAZAWA Y, 1989, GRAEF ARCH CLIN EXP, V227, P408, DOI 10.1007/BF02172889; KLEIN BEK, 1994, OPHTHALMOLOGY, V101, P1173; KLEIN BEK, 1992, OPHTHALMOLOGY, V99, P1499; KLEIN BEK, 1993, INVEST OPHTH VIS SCI, V34, P3024; LESKE MC, 1995, ARCH OPHTHALMOL-CHIC, V113, P918, DOI 10.1001/archopht.1995.01100070092031; LESKE MC, 1994, ARCH OPHTHALMOL-CHIC, V112, P821, DOI 10.1001/archopht.1994.01090180121046; LESKE MC, IN PRESS OPHTHALMOLO; Lim AS, 1979, AUST J OPHTHALMOL, V7, P23; LOWE RF, 1990, ASIAN PAC J OPHTHALM, V2, P91; Lowe RF, 1977, AUSTR NZ J OPHTHALMO, V5, P9; MASON RP, 1989, OPHTHALMOLOGY, V96, P1363; MCHORNEY CA, 1993, MED CARE, V31, P247, DOI 10.1097/00005650-199303000-00006; MIGDAL C, 1994, OPHTHALMOLOGY, V101, P1651; Mitchell P, 1996, OPHTHALMOLOGY, V103, P1661, DOI 10.1016/S0161-6420(96)30449-1; Mitchell P, 1997, OPHTHALMOLOGY, V104, P712, DOI 10.1016/S0161-6420(97)30247-4; MOLTENO ACB, 1977, BRIT J OPHTHALMOL, V61, P120, DOI 10.1136/bjo.61.2.120; Musch DC, 1999, OPHTHALMOLOGY, V106, P653, DOI 10.1016/S0161-6420(99)90147-1; Nelson P, 1999, BRIT J OPHTHALMOL, V83, P546, DOI 10.1136/bjo.83.5.546; NETLAND PA, 1993, AM J OPHTHALMOL, V115, P608, DOI 10.1016/S0002-9394(14)71458-8; Nygaard H A, 1997, Tidsskr Nor Laegeforen, V117, P2019; Owsley C, 1998, Ophthalmic Epidemiol, V5, P101, DOI 10.1076/opep.5.2.101.1574; Parrish RK, 1997, ARCH OPHTHALMOL-CHIC, V115, P1447, DOI 10.1001/archopht.1997.01100160617016; PERKINS ES, 1982, ARCH OPHTHALMOL-CHIC, V100, P1464; PONTE F, 1994, DOC OPHTHALMOL, V85, P203, DOI 10.1007/BF01664928; Quigley HA, 1997, INVEST OPHTH VIS SCI, V38, P83; QUIGLEY HA, 1980, INVEST OPHTH VIS SCI, V19, P137; Quigley HA, 1996, BRIT J OPHTHALMOL, V80, P389, DOI 10.1136/bjo.80.5.389; QUIGLEY HA, 1995, INVEST OPHTH VIS SCI, V36, P774; Quigley HA, 1998, J GLAUCOMA, V7, P210; QUIGLEY HA, 1992, OPHTHALMOLOGY, V99, P19; Sarfarazi M, 1998, AM J HUM GENET, V62, P641, DOI 10.1086/301767; Schulzer M, 1998, AM J OPHTHALMOL, V126, P487; Seah SKL, 1997, ARCH OPHTHALMOL-CHIC, V115, P1436, DOI 10.1001/archopht.1997.01100160606014; Sherwood MB, 1998, OPHTHALMOLOGY, V105, P561, DOI 10.1016/S0161-6420(98)93043-3; SHIOSE Y, 1991, JPN J OPHTHALMOL, V35, P133; Singh K, 1997, AM J OPHTHALMOL, V123, P48, DOI 10.1016/S0002-9394(14)70991-2; SOMMER A, 1991, ARCH OPHTHALMOL-CHIC, V109, P1090, DOI 10.1001/archopht.1991.01080080050026; SPONSEL WE, 1995, AM J OPHTHALMOL, V120, P699, DOI 10.1016/S0002-9394(14)72723-0; Stoilova D, 1996, GENOMICS, V36, P142, DOI 10.1006/geno.1996.0434; Stone EM, 1997, SCIENCE, V275, P668, DOI 10.1126/science.275.5300.668; SUN SJ, 1985, CHIN J OPHTHALMOL, V21, P32; TIELSCH JM, 1995, OPHTHALMOLOGY, V102, P48; TIELSCH JM, 1995, ARCH OPHTHALMOL-CHIC, V113, P216, DOI 10.1001/archopht.1995.01100020100038; TIELSCH JM, 1991, JAMA-J AM MED ASSOC, V266, P369, DOI 10.1001/jama.266.3.369; TIELSCH JM, 1991, AM J EPIDEMIOL, V134, P1102, DOI 10.1093/oxfordjournals.aje.a116013; TIELSCH JM, 1994, ARCH OPHTHALMOL-CHIC, V112, P69, DOI 10.1001/archopht.1994.01090130079022; TjonFoSang MJ, 1997, AM J OPHTHALMOL, V123, P62, DOI 10.1016/S0002-9394(14)70993-6; Trifan OC, 1998, AM J OPHTHALMOL, V126, P17, DOI 10.1016/S0002-9394(98)00073-7; Wang JJ, 1997, OPHTHALMOLOGY, V104, P1714, DOI 10.1016/S0161-6420(97)30075-X; Wensor MD, 1998, OPHTHALMOLOGY, V105, P733, DOI 10.1016/S0161-6420(98)94031-3; WEST RH, 1992, AUST NZ J OPHTHALMOL, V20, P23, DOI 10.1111/j.1442-9071.1992.tb00699.x; WILSON MR, 1987, ARCH OPHTHALMOL-CHIC, V105, P1066; Wilson MR, 1998, OPHTHALMOLOGY, V105, P2112, DOI 10.1016/S0161-6420(98)91135-6; Wirtz MK, 1997, AM J HUM GENET, V60, P296; Wirtz MK, 1999, ARCH OPHTHALMOL-CHIC, V117, P237; Wolfs RCW, 1998, ARCH OPHTHALMOL-CHIC, V116, P1640, DOI 10.1001/archopht.116.12.1640; ZIMMERMAN TJ, 1984, ARCH OPHTHALMOL-CHIC, V102, P551	85	201	272	0	23	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1803	1810		10.1016/S0140-6736(99)04240-3	http://dx.doi.org/10.1016/S0140-6736(99)04240-3			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577657				2022-12-28	WOS:000083853000043
J	Stachowicz, JJ; Whitlatch, RB; Osman, RW				Stachowicz, JJ; Whitlatch, RB; Osman, RW			Species diversity and invasion resistance in a marine ecosystem	SCIENCE			English	Article							BIOLOGICAL INVASIONS; COMMUNITY; BIODIVERSITY; INVASIBILITY; ENVIRONMENTS; COMPETITION; RECRUITMENT; CALIFORNIA; GRASSLAND; STABILITY	Theory predicts that systems that are more diverse should be more resistant to exotic species, but experimental tests are needed to verify this. In experimental communities of sessile marine invertebrates, increased species richness Significantly decreased invasion success, apparently because species-rich communities more completely and efficiently used available space, the limiting resource in this system. Declining biodiversity thus facilitates invasion in this system, potentially accelerating the loss of biodiversity and the homogenization of the world's biota.	Univ Connecticut, Dept Marine Sci, Groton, CT 06340 USA; Acad Nat Sci, Estuarine Res Ctr, St Leonard, MD 20685 USA	University of Connecticut	Stachowicz, JJ (corresponding author), Univ Connecticut, Dept Marine Sci, 1084 Shennecossett Rd, Groton, CT 06340 USA.	jstach@uconnvm.uconn.edu	Ross, Donald J/F-7607-2012	Ross, Donald J/0000-0002-8659-3833				BERMAN J, 1992, CONSERV BIOL, V6, P435, DOI 10.1046/j.1523-1739.1992.06030435.x; BUSS LW, 1979, AM NAT, V113, P223, DOI 10.1086/283381; CARLTON JT, 1993, SCIENCE, V261, P78, DOI 10.1126/science.261.5117.78; CARLTON JT, 1989, CONSERV BIOL, V3, P265, DOI 10.1111/j.1523-1739.1989.tb00086.x; Carlton JT, 1979, SAN FRANCISCO BAY UR, P427; CASE TJ, 1990, P NATL ACAD SCI USA, V87, P9610, DOI 10.1073/pnas.87.24.9610; Cohen AN, 1998, SCIENCE, V279, P555, DOI 10.1126/science.279.5350.555; DAYTON PK, 1971, ECOL MONOGR, V41, P351, DOI 10.2307/1948498; Elton C. S., 1958, ECOLOGY INVASIONS AN; Fox M.D., 1986, P57; GROSBERG RK, 1988, EVOLUTION, V42, P900, DOI 10.1111/j.1558-5646.1988.tb02510.x; Knops JMH, 1999, ECOL LETT, V2, P286, DOI 10.1046/j.1461-0248.1999.00083.x; McDougall Kenneth Dougal, 1943, ECOL MONOGR, V13, P321, DOI 10.2307/1943225; McGradySteed J, 1997, NATURE, V390, P162, DOI 10.1038/36561; Naeem S, 1997, NATURE, V390, P507, DOI 10.1038/37348; NICHOLS FH, 1990, MAR ECOL PROG SER, V66, P95, DOI 10.3354/meps066095; Office of Technology Assessment, 1993, US; OSMAN RW, 1995, J EXP MAR BIOL ECOL, V190, P199, DOI 10.1016/0022-0981(95)00036-Q; OSMAN RW, 1995, MAR ECOL PROG SER, V117, P111, DOI 10.3354/meps117111; OSMAN RW, 1977, ECOL MONOGR, V47, P37, DOI 10.2307/1942223; Pimm SL, 1989, BIOL INVASIONS GLOBA, P351; PlantyTabacchi AM, 1996, CONSERV BIOL, V10, P598, DOI 10.1046/j.1523-1739.1996.10020598.x; ROBINSON GR, 1995, ECOLOGY, V76, P786, DOI 10.2307/1939344; ROBINSON JV, 1984, OECOLOGIA, V61, P169, DOI 10.1007/BF00396755; Simberloff D., 1986, Ecological Studies, P3; Stohlgren TJ, 1999, ECOL MONOGR, V69, P25, DOI 10.1890/0012-9615(1999)069[0025:EPSIHS]2.0.CO;2; SUTHERLAND JP, 1977, ECOL MONOGR, V47, P425, DOI 10.2307/1942176; Tilman D, 1997, SCIENCE, V277, P1300, DOI 10.1126/science.277.5330.1300; Tilman D, 1997, ECOLOGY, V78, P81, DOI 10.1890/0012-9658(1997)078[0081:CIRLAG]2.0.CO;2; TILMAN D, 1994, NATURE, V367, P363, DOI 10.1038/367363a0; TRAVIS J, 1993, SCIENCE, V262, P1366, DOI 10.1126/science.262.5138.1366; USHER MB, 1988, BIOL CONSERV, V44, P119, DOI 10.1016/0006-3207(88)90007-9; Wilcove DS, 1998, BIOSCIENCE, V48, P607, DOI 10.2307/1313420; Wiser SK, 1998, ECOLOGY, V79, P2071, DOI 10.1890/0012-9658(1998)079[2071:CSAFIB]2.0.CO;2	34	518	545	7	176	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1577	1579		10.1126/science.286.5444.1577	http://dx.doi.org/10.1126/science.286.5444.1577			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567267				2022-12-28	WOS:000083768300063
J	Orgel, LE				Orgel, LE			Are you serious, Dr Mitchell?	NATURE			English	Article									Salk Inst Biol Studies, La Jolla, CA 92037 USA	Salk Institute	Orgel, LE (corresponding author), Salk Inst Biol Studies, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.								0	14	14	0	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					17	17		10.1038/46903	http://dx.doi.org/10.1038/46903			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573410	Bronze			2022-12-28	WOS:000083638600020
J	Lloyd, D				Lloyd, D			Microbial ecology - How to avoid oxygen	SCIENCE			English	Editorial Material							GENUS; NOV		Cardiff Univ, Sch Biosci, Cardiff CF10 3TL, S Glam, Wales	Cardiff University	Lloyd, D (corresponding author), Cardiff Univ, Sch Biosci, POB 915, Cardiff CF10 3TL, S Glam, Wales.		Lloyd, David/D-2483-2010	Lloyd, David/0000-0002-5656-0571				Alban PS, 1998, J APPL MICROBIOL, V85, P875, DOI 10.1046/j.1365-2672.1998.00602.x; FIALA G, 1986, ARCH MICROBIOL, V145, P56, DOI 10.1007/BF00413027; Fry J.C, 1990, MICROBIOLOGY EXTREME, P93; HUBER G, 1991, SYST APPL MICROBIOL, V14, P397, DOI 10.1016/S0723-2020(11)80317-6; Jenney FE, 1999, SCIENCE, V286, P306, DOI 10.1126/science.286.5438.306; Liochev SI, 1997, J BIOL CHEM, V272, P25573, DOI 10.1074/jbc.272.41.25573; LLOYD D, 1979, BIOCHEM J, V184, P149, DOI 10.1042/bj1840149; Stetter KO, 1999, FEBS LETT, V452, P22, DOI 10.1016/S0014-5793(99)00663-8; STETTER KO, 1983, SYST APPL MICROBIOL, V4, P535, DOI 10.1016/S0723-2020(83)80011-3; Tapley DW, 1999, BIOL BULL, V196, P52, DOI 10.2307/1543166	10	6	6	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					249	249		10.1126/science.286.5438.249	http://dx.doi.org/10.1126/science.286.5438.249			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10577191				2022-12-28	WOS:000083024400031
J	Vinnikov, KY; Robock, A; Stouffer, RJ; Walsh, JE; Parkinson, CL; Cavalieri, DJ; Mitchell, JFB; Garrett, D; Zakharov, VF				Vinnikov, KY; Robock, A; Stouffer, RJ; Walsh, JE; Parkinson, CL; Cavalieri, DJ; Mitchell, JFB; Garrett, D; Zakharov, VF			Global warming and Northern Hemisphere sea ice extent	SCIENCE			English	Article							OCEAN ATMOSPHERE MODEL; NATURAL VARIABILITY; TRANSIENT RESPONSES; GRADUAL CHANGES; CLIMATE; CO2	Surface and satellite-based observations show a decrease in Northern Hemisphere sea ice extent during the past 45 years. A comparison of these trends to control and transient integrations (forced by observed greenhouse gases and tropospheric sulfate aerosols) from the Geophysical Fluid Dynamics Laboratory and Hadley Centre climate models reveals that the observed decrease in Northern Hemisphere sea ice extent agrees with the transient simulations, and both trends are much Larger than would be expected from natural climate variations. From Long-term control runs of climate models, it was found that the probability of the observed trends resulting from natural climate variability, assuming that the models' natural variability is similar to that found in nature, is Less than 2 percent for the 1978-98 sea ice trends and Less than 0.1 percent for the 1953-98 sea ice trends. Both models used here project continued decreases in sea ice thickness and extent throughout the next century.	Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA; Rutgers State Univ, Dept Environm Sci, New Brunswick, NJ 08901 USA; NOAA, Geophys Fluid Dynam Lab, Princeton, NJ 08542 USA; Univ Illinois, Dept Atmospher Sci, Urbana, IL 61801 USA; NASA, Goddard Space Flight Ctr, Oceans & Ice Branch, Greenbelt, MD 20771 USA; Meteorol Off, Hadley Ctr Climate Predict & Res, Bracknell RG12 2SZ, Berks, England; NOAA, Climate Predict Ctr, Natl Weather Serv, Natl Ctr Environm Predict, Camp Springs, MD 20746 USA; Arctic & Antarctic Res Inst, St Petersburg 199397, Russia	University System of Maryland; University of Maryland College Park; Rutgers State University New Brunswick; National Oceanic Atmospheric Admin (NOAA) - USA; University of Illinois System; University of Illinois Urbana-Champaign; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; Met Office - UK; Hadley Centre; National Oceanic Atmospheric Admin (NOAA) - USA; Arctic & Antarctic Research Institute	Vinnikov, KY (corresponding author), Univ Maryland, Dept Meteorol, College Pk, MD 20742 USA.		Parkinson, Claire L/E-1747-2012; Robock, Alan/B-6385-2016; Vinnikov, Konstantin/F-9348-2010	Parkinson, Claire L/0000-0001-6730-4197; Robock, Alan/0000-0002-6319-5656; Walsh, John/0000-0001-9541-5927				Battisti DS, 1997, J CLIMATE, V10, P1909, DOI 10.1175/1520-0442(1997)010<1909:DGCMUT>2.0.CO;2; Bjorgo E, 1997, GEOPHYS RES LETT, V24, P413, DOI 10.1029/96GL04021; BUDYKO MI, 1969, TELLUS, V21, P611, DOI 10.3402/tellusa.v21i5.10109; Cavalieri DJ, 1999, J GEOPHYS RES-OCEANS, V104, P15803, DOI 10.1029/1999JC900081; Cavalieri DJ, 1997, SCIENCE, V278, P1104, DOI 10.1126/science.278.5340.1104; CHAPMAN WL, 1993, B AM METEOROL SOC, V74, P33, DOI 10.1175/1520-0477(1993)074<0033:RVOSIA>2.0.CO;2; GLOERSEN P, 1988, J GEOPHYS RES-OCEANS, V93, P10666, DOI 10.1029/JC093iC09p10666; GLOERSEN P, 1992, NASA SPEC PUBL, P1; Haywood JM, 1997, GEOPHYS RES LETT, V24, P1335, DOI 10.1029/97GL01163; Johns TC, 1997, CLIM DYNAM, V13, P103, DOI 10.1007/s003820050155; KUKLA G, 1981, SCIENCE, V214, P497, DOI 10.1126/science.214.4520.497; Manabe S, 1997, B AM METEOROL SOC, V78, P1177; MANABE S, 1992, J CLIMATE, V5, P105, DOI 10.1175/1520-0442(1992)005<0105:TROACO>2.0.CO;2; MANABE S, 1979, NATURE, V282, P491, DOI 10.1038/282491a0; MANABE S, 1991, J CLIMATE, V4, P785, DOI 10.1175/1520-0442(1991)004<0785:TROACO>2.0.CO;2; PARKINSON CL, 1989, J GEOPHYS RES-OCEANS, V94, P14499, DOI 10.1029/JC094iC10p14499; Parkinson CL, 1999, J GEOPHYS RES-OCEANS, V104, P20837, DOI 10.1029/1999JC900082; Ropelewski C. F., 1985, Advances in Space Research, V5, P275, DOI 10.1016/0273-1177(85)90331-X; ROTHROCK DA, IN PRESS GEOPHYS RES; SANDERSON RM, 1975, METEOROL MAG, V104, P313; STOUFFER RJ, 1994, NATURE, V367, P634, DOI 10.1038/367634a0; Vinnikov K. Ya, 1980, SOV METEOROL HYDROL, V6, P1; WALSH JE, 1979, J PHYS OCEANOGR, V9, P580, DOI 10.1175/1520-0485(1979)009<0580:AAOASI>2.0.CO;2; ZAKHAROV VF, 1997, WMOTD782	24	303	323	1	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1934	1937		10.1126/science.286.5446.1934	http://dx.doi.org/10.1126/science.286.5446.1934			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583952				2022-12-28	WOS:000084003400045
J	Liu, G; Duranteau, L; Carel, J; Monroe, J; Doyle, DA; Shenker, A				Liu, G; Duranteau, L; Carel, J; Monroe, J; Doyle, DA; Shenker, A			Leydig-cell tumors caused by an activating mutation of the gene encoding the luteinizing hormone receptor.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PROTEIN-COUPLED RECEPTORS; STIMULATORY G-PROTEIN; PRECOCIOUS PUBERTY; THYROTROPIN RECEPTOR; CHORIOGONADOTROPIN RECEPTOR; GONADOTROPIN RECEPTOR; ADENYLYL-CYCLASE; PHOSPHOLIPASE-C; PROLIFERATION; HYPERPLASIA		Northwestern Univ, Dept Pediat, Div Endocrinol, Sch Med, Chicago, IL 60611 USA; Childrens Mem Inst Educ & Res, Chicago, IL USA; Grp Hosp Cochin St Vincent De Paul, Serv Endocrinol Pediat, Paris, France; Temple Univ, Childrens Med Ctr, Div Pediat Endocrinol, Philadelphia, PA 19122 USA	Northwestern University; Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Cochin - APHP; UDICE-French Research Universities; Universite Paris Cite; Pennsylvania Commonwealth System of Higher Education (PCSHE); Temple University	Shenker, A (corresponding author), Childrens Mem Hosp, 2300 Childrens Plaza,Box 225, Chicago, IL 60614 USA.		Carel, Jean-Claude/AAZ-7691-2020	Carel, Jean-Claude/0000-0002-0424-6767	NIDDK NIH HHS [5T32-DK07169-19A1] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [T32DK007169] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ATGER M, 1995, MOL CELL ENDOCRINOL, V111, P113, DOI 10.1016/0303-7207(95)03557-N; Chan WY, 1998, MOL GENET METAB, V63, P75, DOI 10.1006/mgme.1997.2650; Clegg ED, 1997, REPROD TOXICOL, V11, P107, DOI 10.1016/S0890-6238(96)00203-1; Dufau ML, 1998, ANNU REV PHYSIOL, V60, P461, DOI 10.1146/annurev.physiol.60.1.461; Fragoso MCBV, 1998, J CLIN ENDOCR METAB, V83, P2074, DOI 10.1210/jc.83.6.2074; Greulich WW., 1959, CALIF MED, V91, P53; Herrlich A, 1996, J BIOL CHEM, V271, P16764, DOI 10.1074/jbc.271.28.16764; HOLLAND FJ, 1991, ENDOCRIN METAB CLIN, V20, P191, DOI 10.1016/S0889-8529(18)30288-3; Huseby R, 1996, LEYDIG CELL, P555; KIM I, 1985, AM J SURG PATHOL, V9, P177, DOI 10.1097/00000478-198503000-00002; Kosugi S, 1996, J BIOL CHEM, V271, P31813, DOI 10.1074/jbc.271.50.31813; Latronico AC, 1996, NEW ENGL J MED, V334, P507, DOI 10.1056/NEJM199602223340805; LAUE L, 1995, P NATL ACAD SCI USA, V92, P1906, DOI 10.1073/pnas.92.6.1906; Ledent C, 1997, ENDOCRINOLOGY, V138, P369, DOI 10.1210/en.138.1.369; Lejeune H, 1998, J MOL ENDOCRINOL, V20, P1, DOI 10.1677/jme.0.0200001; MARSHALL WA, 1970, ARCH DIS CHILD, V45, P13, DOI 10.1136/adc.45.239.13; Martin MM, 1998, EUR J ENDOCRINOL, V139, P101, DOI 10.1530/eje.0.1390101; MATZUK MM, 1995, MOL ENDOCRINOL, V9, P1337, DOI 10.1210/me.9.10.1337; McCluggage WG, 1998, HISTOPATHOLOGY, V33, P361, DOI 10.1046/j.1365-2559.1998.00484.x; MOOLENAAR WH, 1991, CELL GROWTH DIFFER, V2, P359; Muller J, 1998, J MED GENET, V35, P340, DOI 10.1136/jmg.35.4.340; Naughton CK, 1998, BRIT J UROL, V81, P282; Parma J, 1997, J CLIN ENDOCR METAB, V82, P2695, DOI 10.1210/jc.82.8.2695; Paschke R, 1997, NEW ENGL J MED, V337, P1675, DOI 10.1056/NEJM199712043372307; Russo D, 1997, J CLIN ENDOCR METAB, V82, P735, DOI 10.1210/jc.82.3.735; SARKAR FH, 1993, BIOTECHNIQUES, V15, P36; Scully RE., 1995, ENDOCRINOLOGY, P2442; SEGALOFF DL, 1993, ENDOCR REV, V14, P324, DOI 10.1210/er.14.3.324; SHENKER A, 1993, NATURE, V365, P652, DOI 10.1038/365652a0; Spiegel AM, 1996, J CLIN ENDOCR METAB, V81, P2434, DOI 10.1210/jc.81.7.2434; STUDER H, 1995, ENDOCR REV, V16, P411, DOI 10.1210/er.16.4.411; Themmen APN, 1996, EUR J ENDOCRINOL, V134, P533, DOI 10.1530/eje.0.1340533; vanBiesen T, 1996, ENDOCR REV, V17, P698, DOI 10.1210/er.17.6.698; WEINSTEIN LS, 1991, NEW ENGL J MED, V325, P1688, DOI 10.1056/NEJM199112123252403; WILSON BE, 1983, ANN CLIN LAB SCI, V13, P315; Wu N, 1996, ANDROLOGIA, V28, P247	36	166	175	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1731	1736		10.1056/NEJM199912023412304	http://dx.doi.org/10.1056/NEJM199912023412304			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580072				2022-12-28	WOS:000083955800004
J	Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT				Tyler, JK; Adams, CR; Chen, SR; Kobayashi, R; Kamakaka, RT; Kadonaga, JT			The RCAF complex mediates chromatin assembly during DNA replication and repair	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; II TRANSCRIPTION; YEAST; PROTEIN; GENES; IDENTIFICATION; ACETYLATION; REPRESSION; TELOMERES; INVITRO	Chromatin assembly is a fundamental biological process that is essential for the replication and maintenance of the eukaryotic genome(1-4). In dividing cells, newly synthesized DNA is rapidly assembled into chromatin by the deposition of a tetramer of the histone proteins H3 and H4, followed by the deposition of two dimers of histones H2A and H2B to complete the nucleosome-the fundamental repeating unit of chromatin(5). Here we describe the identification, purification, cloning, and characterization of replication-coupling assembly factor (RCAF), a novel protein complex that facilitates the assembly of nucleosomes onto newly replicated DNA in vitro. RCAF comprises the Drosophila homologue of anti-silencing function 1 protein ASF1(6) and histones H3 and H4. The specific acetylation pattern of H3 and H4 in RCAF is identical to that of newly synthesized histones. Genetic analyses in Saccharomyces cerevisiae demonstrate that ASF1 is essential for normal fell cycle progression, and suggest that RCAF mediates chromatin assembly after DNA replication and the repair of double-strand DNA damage in vivo.	Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA; Univ Calif San Diego, Ctr Mol Genet, La Jolla, CA 92093 USA; NICHD, NIH, Bethesda, MD 20892 USA; Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA	University of California System; University of California San Diego; University of California System; University of California San Diego; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Cold Spring Harbor Laboratory	Tyler, JK (corresponding author), Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA.		Kamakaka, Rohinton/K-3140-2019	Kamakaka, Rohinton/0000-0003-1931-7000; Tyler, Jessica/0000-0001-9765-1659	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [Z01HD008731] Funding Source: NIH RePORTER	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Adams CR, 1999, CURR OPIN GENET DEV, V9, P185, DOI 10.1016/S0959-437X(99)80028-8; Elledge SJ, 1996, SCIENCE, V274, P1664, DOI 10.1126/science.274.5293.1664; GOTTSCHLING DE, 1990, CELL, V63, P751, DOI 10.1016/0092-8674(90)90141-Z; Grunstein M, 1997, NATURE, V389, P349, DOI 10.1038/38664; HAN M, 1987, CELL, V48, P589, DOI 10.1016/0092-8674(87)90237-6; Ito T, 1997, GENES CELLS, V2, P593, DOI 10.1046/j.1365-2443.1997.1500348.x; Ito T, 1996, MOL CELL BIOL, V16, P3112; Ito T, 1997, CELL, V90, P145, DOI 10.1016/S0092-8674(00)80321-9; Ito T, 1996, J BIOL CHEM, V271, P25041, DOI 10.1074/jbc.271.40.25041; KAMAKAKA RT, 1993, GENE DEV, V7, P1779, DOI 10.1101/gad.7.9.1779; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; Kornberg RD, 1999, CURR OPIN GENET DEV, V9, P148, DOI 10.1016/S0959-437X(99)80022-7; Le SY, 1997, YEAST, V13, P1029, DOI 10.1002/(SICI)1097-0061(19970915)13:11<1029::AID-YEA160>3.0.CO;2-1; Ling XF, 1996, GENE DEV, V10, P686, DOI 10.1101/gad.10.6.686; Luger K, 1997, NATURE, V389, P251, DOI 10.1038/38444; MCINTOSH EM, 1993, CURR GENET, V24, P185, DOI 10.1007/BF00351790; Monson EK, 1997, P NATL ACAD SCI USA, V94, P13081, DOI 10.1073/pnas.94.24.13081; Povirk LF, 1996, MUTAT RES-FUND MOL M, V355, P71, DOI 10.1016/0027-5107(96)00023-1; SCHWARTZ JL, 1989, MUTAT RES, V216, P111, DOI 10.1016/0165-1161(89)90011-3; Singer MS, 1998, GENETICS, V150, P613; SMITH S, 1989, CELL, V58, P15, DOI 10.1016/0092-8674(89)90398-X; SOBEL RE, 1995, P NATL ACAD SCI USA, V92, P1237, DOI 10.1073/pnas.92.4.1237; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; STILLMAN B, 1986, CELL, V45, P555, DOI 10.1016/0092-8674(86)90287-4; STILLMAN BW, 1985, MOL CELL BIOL, V5, P2051, DOI 10.1128/MCB.5.8.2051; Tyler JK, 1996, MOL CELL BIOL, V16, P6149; Verreault A, 1996, CELL, V87, P95, DOI 10.1016/S0092-8674(00)81326-4	28	438	445	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					555	560		10.1038/990147	http://dx.doi.org/10.1038/990147			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591219				2022-12-28	WOS:000084013200063
J	Wolfe, RA; Ashby, VB; Milford, EL; Ojo, AO; Ettenger, RE; Agodoa, LYC; Held, PJ; Port, FK				Wolfe, RA; Ashby, VB; Milford, EL; Ojo, AO; Ettenger, RE; Agodoa, LYC; Held, PJ; Port, FK			Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							STAGE RENAL-DISEASE; QUALITY-OF-LIFE; FOLLOW-UP; SURVIVAL; IMPACT; ACCESS; RATES	Background: The extent to which renal allotransplantation -- as compared with long-term dialysis -- improves survival among patients with end-stage renal disease is controversial, because those selected for transplantation may have a lower base-line risk of death. Methods: In an attempt to distinguish the effects of patient selection from those of transplantation itself, we conducted a longitudinal study of mortality in 228,552 patients who were receiving long-term dialysis for end-stage renal disease. Of these patients, 46,164 were placed on a waiting list for transplantation, 23,275 of whom received a first cadaveric transplant between 1991 and 1997. The relative risk of death and survival were assessed with time-dependent nonproportional-hazards analysis, with adjustment for age, race, sex, cause of end-stage renal disease, geographic region, time from first treatment for end-stage renal disease to placement on the waiting list, and year of initial placement on the list. Results: Among the various subgroups, the standardized mortality ratio for the patients on dialysis who were awaiting transplantation (annual death rate, 6.3 per 100 patient-years) was 38 to 58 percent lower than that for all patients on dialysis (annual death rate, 16.1 per 100 patient-years). The relative risk of death during the first 2 weeks after transplantation was 2.8 times as high as that for patients on dialysis who had equal lengths of follow-up since placement on the waiting list, but at 18 months the risk was much lower (relative risk, 0.32; 95 percent confidence interval, 0.30 to 0.35; P<0.001). The likelihood of survival became equal in the two groups within 5 to 673 days after transplantation in all the subgroups of patients we examined. The long-term mortality rate was 48 to 82 percent lower among transplant recipients (annual death rate, 3.8 per 100 patient-years) than patients on the waiting list, with relatively larger benefits among patients who were 20 to 39 years old, white patients, and younger patients with diabetes. Conclusions: Among patients with end-stage renal disease, healthier patients are placed on the waiting list for transplantation, and long-term survival is better among those on the waiting list who eventually undergo transplantation. (N Engl J Med 1999;341:1725-30.) (C)1999, Massachusetts Medical Society.	Univ Michigan, US Renatl Data Syst Coordinating Ctr, Ann Arbor, MI 48103 USA; Univ Michigan, Dept Biostat, Ann Arbor, MI 48103 USA; Univ Michigan, Dept Internal Med, Ann Arbor, MI 48103 USA; Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48103 USA; Brigham & Womens Hosp, Boston, MA 02115 USA; Univ Calif Los Angeles, Dept Pediat Nephrol, Los Angeles, CA 90024 USA; NIDDKD, Bethesda, MD 20892 USA; Univ Renal Res Educ Assoc, Ann Arbor, MI USA	University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; University of Michigan System; University of Michigan; Harvard University; Brigham & Women's Hospital; University of California System; University of California Los Angeles; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Wolfe, RA (corresponding author), Univ Michigan, US Renatl Data Syst Coordinating Ctr, 315 W Huron,Suite 240, Ann Arbor, MI 48103 USA.	bobwolfe@umich.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [N01DK032202] Funding Source: NIH RePORTER; NIDDK NIH HHS [N01-DK-3-2202] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Arend SM, 1997, NEPHROL DIAL TRANSPL, V12, P1672, DOI 10.1093/ndt/12.8.1672; Cecka J M, 1998, Clin Transpl, P1; Cosio FG, 1998, KIDNEY INT, V53, P767, DOI 10.1046/j.1523-1755.1998.00787.x; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; Kasiske BL, 1998, J AM SOC NEPHROL, V9, P2142; Laupacis A, 1996, KIDNEY INT, V50, P235, DOI 10.1038/ki.1996.307; MAUGER EA, 1995, STAT MED, V14, P1553, DOI 10.1002/sim.4780141406; OJO AO, 1994, AM J KIDNEY DIS, V24, P59, DOI 10.1016/S0272-6386(12)80160-0; OJO AO, 1995, AM J KIDNEY DIS, V25, P623, DOI 10.1016/0272-6386(95)90134-5; PORT FK, 1993, JAMA-J AM MED ASSOC, V270, P1339, DOI 10.1001/jama.270.11.1339; *REN DAT SYST, 1999, USRDS 1999 ANN DAT R; RUSSELL JD, 1992, TRANSPLANTATION, V54, P656, DOI 10.1097/00007890-199210000-00018; Schaubel D, 1995, TRANSPLANTATION, V60, P1389, DOI 10.1097/00007890-199560120-00003; Schnuelle P, 1998, J AM SOC NEPHROL, V9, P2135; TERASAKI PI, 1995, NEW ENGL J MED, V333, P333, DOI 10.1056/NEJM199508103330601; WELLER JM, 1982, KIDNEY INT, V21, P78, DOI 10.1038/ki.1982.11; WOLFE RA, 1992, KIDNEY INT, V42, P991, DOI 10.1038/ki.1992.378; Wolfe RA, 1998, AM J KIDNEY DIS, V32, pS1, DOI 10.1016/S0272-6386(14)70017-4	20	3594	3670	4	88	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1725	1730		10.1056/NEJM199912023412303	http://dx.doi.org/10.1056/NEJM199912023412303			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580071	Bronze			2022-12-28	WOS:000083955800003
J	Henney, JE				Henney, JE			Parkinson treatment approval	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-28	WOS:000083908700006
J	Walker, A				Walker, A			Meta-style and expert review	LANCET			English	Editorial Material							RANDOMIZED CONTROLLED TRIALS; QUALITY; CONSORT		Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health	Walker, A (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.							Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berlin JA, 1999, JAMA-J AM MED ASSOC, V281, P830, DOI 10.1001/jama.281.9.830; CHALMERS TC, 1991, STAT MED, V10, P971, DOI 10.1002/sim.4780100618; Hayashi K, 1996, CONTROL CLIN TRIALS, V17, P99, DOI 10.1016/S0197-2456(96)80001-8; Juni P, 1999, JAMA-J AM MED ASSOC, V282, P1054, DOI 10.1001/jama.282.11.1054; Meinert CL, 1998, JAMA-J AM MED ASSOC, V279, P1487, DOI 10.1001/jama.279.18.1487; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1998, JAMA-J AM MED ASSOC, V279, P1489, DOI 10.1001/jama.279.18.1489; Temple R, 1999, JAMA-J AM MED ASSOC, V281, P841, DOI 10.1001/jama.281.9.841	9	5	5	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1834	1835		10.1016/S0140-6736(99)00355-4	http://dx.doi.org/10.1016/S0140-6736(99)00355-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584713				2022-12-28	WOS:000083909100002
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60607 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60607 USA.								0	1	1	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1828	1828						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577679				2022-12-28	WOS:000083853000069
J	Topol, E				Topol, E			ACE inhibitors still the drug of choice for heart failure - and more	LANCET			English	News Item														Topol, Eric/0000-0002-1478-4729					0	4	4	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1797	1797		10.1016/S0140-6736(05)70567-5	http://dx.doi.org/10.1016/S0140-6736(05)70567-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577651				2022-12-28	WOS:000083853000029
J	Kelber, A				Kelber, A			Why 'false' colours are seen by butterflies	NATURE			English	Article							POLARIZATION; VISION; TWIST		Australian Natl Univ, Res Sch Biol Sci, Canberra, ACT 2601, Australia; Lund Univ, Dept Zool, S-22362 Lund, Sweden	Australian National University; Lund University	Kelber, A (corresponding author), Australian Natl Univ, Res Sch Biol Sci, POB 475, Canberra, ACT 2601, Australia.	almut.kelber@zool.lu.se	Kelber, Almut/H-6216-2014	Kelber, Almut/0000-0003-3937-2808				Arikawa K, 1996, J COMP PHYSIOL A, V178, P55, DOI 10.1007/BF00189590; Kelber A, 1999, J EXP BIOL, V202, P2619; LAND MF, 1993, NATURE, V363, P581, DOI 10.1038/363581a0; Marshall J, 1999, CURR BIOL, V9, P755, DOI 10.1016/S0960-9822(99)80336-4; Nilsson DE, 1999, CURR BIOL, V9, pR535, DOI 10.1016/S0960-9822(99)80330-3; Rojas JC, 1999, ENTOMOL EXP APPL, V91, P59, DOI 10.1023/A:1003605125191; SCHWIND R, 1991, J COMP PHYSIOL A, V169, P531; Shashar N, 1998, BIOTROPICA, V30, P275, DOI 10.1111/j.1744-7429.1998.tb00061.x; WEHNER R, 1993, P NATL ACAD SCI USA, V90, P4132, DOI 10.1073/pnas.90.9.4132	9	56	59	1	16	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					251	251		10.1038/46204	http://dx.doi.org/10.1038/46204			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580493	Bronze			2022-12-28	WOS:000083813700035
J	Cox, JS; Chen, B; McNeil, M; Jacobs, WR				Cox, JS; Chen, B; McNeil, M; Jacobs, WR			Complex lipid determine tissue specific replication of Mycobacterium tuberculosis in mice	NATURE			English	Article							MYCOCEROSIC ACID SYNTHASE; BOVIS BCG; TRANSPOSON MUTAGENESIS; VIRULENCE GENES; COENZYME-A; IDENTIFICATION; ADJACENT	Tuberculosis is the leading cause of death in the world resulting from a single bacterial infection(1). Despite its enormous burden on world health, little is known about the molecular mechanisms of pathogenesis of Mycobacterium tuberculosis. Bacterial multiplication and concomitant tissue damage within an infected host, including experimentally infected mice, occurs primarily in the lungs-the favoured niche of M. tuberculosis(2). Although it has been proposed that the distinctive cell wall of M. tuberculosis is important for virulence, rigorous genetic proof has been lacking. Here, using signature-tagged mutagenesis, we isolated three attenuated M. tuberculosis mutants that cannot synthesize or transport a complex, cell wall-associated lipid called phthiocerol dimycocerosate (PDIM) which is found only in pathogenic mycobacteria(3,4), Two mutants have transposon insertions affecting genes implicated in PDIM synthesis; the third has a disruption in a gene encoding a large transmembrane protein required for proper subcellular localization of PDIM. Synthesis and transport of this complex lipid is only required for growth in the lung; all three mutants are unaffected for growth in the liver and spleen. This clearly shows that a lipid is required for M. tuberculosis virulence.	Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, Bronx, NY 10461 USA; Colorado State Univ, Dept Microbiol, Ft Collins, CO 80523 USA	Howard Hughes Medical Institute; Yeshiva University; Albert Einstein College of Medicine; Colorado State University	Jacobs, WR (corresponding author), Yeshiva Univ Albert Einstein Coll Med, Dept Microbiol & Immunol, Howard Hughes Med Inst, 1300 Morris Pk Ave, Bronx, NY 10461 USA.		McNeil, Michael/G-3325-2019	Jacobs, William/0000-0003-3321-3080				[Anonymous], 1999, WORLD HLTH REPORT 19; Azad AK, 1997, J BIOL CHEM, V272, P16741, DOI 10.1074/jbc.272.27.16741; Azad AK, 1996, P NATL ACAD SCI USA, V93, P4787, DOI 10.1073/pnas.93.10.4787; Bardarov S, 1997, P NATL ACAD SCI USA, V94, P10961, DOI 10.1073/pnas.94.20.10961; Besra Gurdyal S., 1994, P285; BRENNAN PJ, 1995, ANNU REV BIOCHEM, V64, P29, DOI 10.1146/annurev.bi.64.070195.000333; Bystrykh LV, 1996, J BACTERIOL, V178, P2238, DOI 10.1128/jb.178.8.2238-2244.1996; Chiang SL, 1998, MOL MICROBIOL, V27, P797, DOI 10.1046/j.1365-2958.1998.00726.x; Cole ST, 1998, NATURE, V393, P537, DOI 10.1038/31159; Fitzmaurice AM, 1997, J BACTERIOL, V179, P2608, DOI 10.1128/jb.179.8.2608-2615.1997; Fitzmaurice AM, 1998, J BIOL CHEM, V273, P8033, DOI 10.1074/jbc.273.14.8033; FOLCH J, 1957, J BIOL CHEM, V226, P497; Garay S, 1996, TUBERCULOSIS, P373; HENSEL M, 1995, SCIENCE, V269, P400, DOI 10.1126/science.7618105; HUNTER SW, 1983, J BIOL CHEM, V258, P7556; Kolattukudy PE, 1997, MOL MICROBIOL, V24, P263, DOI 10.1046/j.1365-2958.1997.3361705.x; MATHUR M, 1992, J BIOL CHEM, V267, P19388; MCADAM RA, 1995, INFECT IMMUN, V63, P1004, DOI 10.1128/IAI.63.3.1004-1012.1995; Mei JM, 1997, MOL MICROBIOL, V26, P399, DOI 10.1046/j.1365-2958.1997.5911966.x; MIDDLEBROOK G, 1947, J EXP MED, V86, P175, DOI 10.1084/jem.86.2.175; OCHMAN H, 1988, GENETICS, V120, P621; PIERCE CH, 1956, AM REV TUBERC PULM, V74, P667; RAINWATER DL, 1983, J BIOL CHEM, V258, P2979	23	586	614	1	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					79	83		10.1038/47042	http://dx.doi.org/10.1038/47042			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573420				2022-12-28	WOS:000083638600046
J	Baffis, V; Shrier, I; Sherker, AH; Szilagyi, A				Baffis, V; Shrier, I; Sherker, AH; Szilagyi, A			Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis B virus infection	ANNALS OF INTERNAL MEDICINE			English	Article							COMPENSATED CIRRHOSIS; POSITIVE PATIENTS; RANDOMIZED TRIAL; FOLLOW-UP; ALPHA; ALFA; METAANALYSIS; THERAPY; LIVER	The incidence of hepatocellular carcinoma in North America is increasing. Current debate focuses on whether interferon administered to cirrhotic patients-with or without biochemical or virologic response-delays or prevents cancer of the liver. Review of the literature revealed several studies that showed improvement in or delay in progression of histologic fibrosis in patients with hepatitis C virus (HCV) infection. In patients with hepatitis B virus (HBV) infection, conversion to the nonreplicative stage may be associated with histologic improvement. However, only 11 studies (6 of HCV, 3 of HBV, and 2 of HCV and HBV) compared development of hepatocellular carcinoma in interferon-treated patients with cirrhosis and cirrhotic patients who were not treated with interferon. Although no firm statistical conclusions could be drawn, the literature suggests that interferon therapy may prevent hepatocellular carcinoma in patients with cirrhosis, particularly those infected with HCV. Interferon treatment cannot be recommended for all persons with cirrhosis and HBV or HCV infection because the current evidence is only suggestive. Long-term randomized, controlled trials may provide definitive data; however, it will be difficult, if not impossible, to conduct such trials because of the improved efficacy of combination therapy with interferon and ribavirin in patients with chronic HCV infection and the development of new therapies for patients with HBV infection.	Sir Mortimer B Davis Jewish Hosp, Montreal, PQ H3T 1E2, Canada; McGill Univ, Montreal Gen Hosp, Montreal, PQ H3G 1A4, Canada	McGill University; McGill University	Szilagyi, A (corresponding author), 6000 Cote des Neiges,Suite 100, Montreal, PQ H3S 1Z8, Canada.	asherker@gas.jgh.mcgill.ca	Sherker, Averell H/A-2889-2013; Shrier, Ian/AAI-6502-2020	Sherker, Averell H/0000-0003-0409-6938; Shrier, Ian/0000-0001-9914-3498				Andreone P, 1996, LANCET, V347, P195; Brunetto MR, 1998, LANCET, V351, P1535; Bruno S, 1997, HEPATOLOGY, V25, P754, DOI 10.1002/hep.510250344; Camma C, 1999, AM J GASTROENTEROL, V94, P581, DOI 10.1111/j.1572-0241.1999.00919.x; Camma C, 1997, J HEPATOL, V26, P1187, DOI 10.1016/S0168-8278(97)80451-5; COLLEONI M, 1993, CANCER, V72, P3196, DOI 10.1002/1097-0142(19931201)72:11<3196::AID-CNCR2820721111>3.0.CO;2-Q; Di Bisceglie Adrian M., 1998, Hepatology, V28, P1161, DOI 10.1002/hep.510280436; El-Serag HB, 1999, NEW ENGL J MED, V340, P745, DOI 10.1056/NEJM199903113401001; Everson GT, 1999, HEPATOLOGY, V30, P271, DOI 10.1002/hep.510300116; Fattovich G, 1997, HEPATOLOGY, V26, P1338; Fattovich G, 1997, J HEPATOL, V27, P201, DOI 10.1016/S0168-8278(97)80302-9; Fattovich G, 1997, GASTROENTEROLOGY, V112, P463, DOI 10.1053/gast.1997.v112.pm9024300; Grimm I, 1996, Gastroenterology, V110, P2019, DOI 10.1053/gast.1996.v110.agast962019; Harper SE, 1996, HEPATOLOGY, V23, P930; Ikeda K, 1998, CANCER-AM CANCER SOC, V82, P827, DOI 10.1002/(SICI)1097-0142(19980301)82:5<827::AID-CNCR5>3.0.CO;2-G; Imai Y, 1998, ANN INTERN MED, V129, P94, DOI 10.7326/0003-4819-129-2-199807150-00005; Koretz RL, 1996, LANCET, V347, P194, DOI 10.1016/S0140-6736(96)90379-7; LAI CL, 1989, BRIT J CANCER, V60, P928, DOI 10.1038/bjc.1989.392; LAUPACIS A, 1988, NEW ENGL J MED, V318, P1728, DOI 10.1056/NEJM198806303182605; LIN HJ, 1986, BRIT J CANCER, V54, P67, DOI 10.1038/bjc.1986.153; Lin SM, 1999, HEPATOLOGY, V29, P971, DOI 10.1002/hep.510290312; Marcellin P, 1997, ANN INTERN MED, V127, P875, DOI 10.7326/0003-4819-127-10-199711150-00003; Mazzella G, 1996, J HEPATOL, V24, P141, DOI 10.1016/S0168-8278(96)80022-5; McHutchison JG, 1998, NEW ENGL J MED, V339, P1485, DOI 10.1056/NEJM199811193392101; Moriya K, 1998, NAT MED, V4, P1065, DOI 10.1038/2053; Niederau C, 1996, NEW ENGL J MED, V334, P1422, DOI 10.1056/NEJM199605303342202; Niederau C, 1998, HEPATOLOGY, V28, P1687, DOI 10.1002/hep.510280632; NISHIGUCHI S, 1995, LANCET, V346, P1051, DOI 10.1016/S0140-6736(95)91739-X; OON CJ, 1992, CANCER CHEMOTH PHARM, V31, pS137, DOI 10.1007/BF00687123; PERRILLO RP, 1993, DIGEST DIS SCI, V38, P577, DOI 10.1007/BF01316785; Pitot HC, 1998, HEPATOLOGY, V28, P1, DOI 10.1002/hep.510280101; POYNARD T, 1995, NEW ENGL J MED, V332, P1457, DOI 10.1056/NEJM199506013322201; Serfaty L, 1998, HEPATOLOGY, V27, P1435, DOI 10.1002/hep.510270535; SHERKER AH, 1991, ANNU REV MICROBIOL, V45, P475; SZILAGYI A, 1995, AM J GASTROENTEROL, V90, P15; Valla DC, 1999, HEPATOLOGY, V29, P1870, DOI 10.1002/hep.510290616; WONG DKH, 1993, ANN INTERN MED, V119, P312, DOI 10.7326/0003-4819-119-4-199308150-00011	37	59	85	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					696	701		10.7326/0003-4819-131-9-199911020-00011	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00011			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577333				2022-12-28	WOS:000083446200009
J	Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I				Fine, JT; Colditz, GA; Coakley, EH; Moseley, G; Manson, JAE; Willett, WC; Kawachi, I			A prospective study of weight change and health-related quality of life in women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BODY-MASS INDEX; SYMPTOMATIC GALLSTONES; DIABETES-MELLITUS; OLDER WOMEN; RISK FACTOR; OF-LIFE; QUESTIONNAIRE; OBESE; ASSOCIATION; MORTALITY	Context The mean body weight of US adults increased by 3.6 kg (7.6 lb) during the past 15 years, but few studies exist that examine the impact of such weight change on functional health status. Objective To investigate, prospectively, the association between weight change and health-related quality of life in women. Design and Setting Nurses' Health Study, a 4-year prospective observational study from 1992 to 1996, using the Medical Outcomes Study Short-Form 36 Health Status Survey (a self-administered 36-item questionnaire) to measure quality of life. Participants A cohort of 40 098 women (from 46-71 years old in 1992) grouped according to 3 patterns of weight change over the 4-year period: women whose weight remained within 2.25 kg (5 lb) of their baseline weight, women who lost 2.25 kg (5 lb) or more, and women who gained 2.25 kg (5 lb) or more. Main Outcome Measures Change in scores on 7 health-related quality-of-life dimensions: physical functioning, vitality, bodily pain, limitations in role functioning due to emotional or physical problems, social functioning, and mental health, measured by the Short-Form 36 Health Status Survey, Results A total of 15 602 women (39%) maintained their weight, 15 160 (38%) gained between 2.25 and 9.0 kg (5-20 lb), and 6667 (17%) lost between 2.25 and 9.0 kg (5-20 Ib), Weight gain was associated with decreased physical function and vitality, and increased bodily pain regardless of baseline weight. For example, the odds ratio for developing role limitations due to physical problems was 2.05 (95% confidence interval, 1.69-2.49) for the leanest women who gained 9.0 kg (20 lb) or more. Weight loss in overweight women was associated with improved physical function and vitality as well as decreased bodily pain. Weight change was more strongly associated with physical rather than mental health. The impact of weight change, especially weight gain, was just as strong in women 65 years and older as in women younger than 65 years. Conclusions These longitudinal data support current US guidelines for women of all body mass index levels to avoid weight gain. Weight maintenance and, in cases of overweight, weight loss are desirable and likely to be beneficial for physical function, vitality, and bodily pain.	Harvard Univ, Sch Med, Channing Lab, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Med, Div Prevent Med, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth & Social Behav, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA; Brigham & Womens Hosp, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Brigham & Women's Hospital	Kawachi, I (corresponding author), Harvard Univ, Sch Med, Channing Lab, 181 Longwood Ave, Boston, MA 02115 USA.	ichiro.kawachi@channing.harvard.edu	Colditz, Graham/A-3963-2009	Colditz, Graham/0000-0002-7307-0291	NATIONAL CANCER INSTITUTE [R01CA040356, R37CA040356] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL034594] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGING [R01AG012806] Funding Source: NIH RePORTER; NCI NIH HHS [CA 40356] Funding Source: Medline; NHLBI NIH HHS [HL 34594] Funding Source: Medline; NIA NIH HHS [AG 12806] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; BRAZIER JE, 1992, BMJ-BRIT MED J, V305, P160, DOI 10.1136/bmj.305.6846.160; Coakley EH, 1998, INT J OBESITY, V22, P958, DOI 10.1038/sj.ijo.0800698; COLDITZ GA, 1995, ANN INTERN MED, V122, P481, DOI 10.7326/0003-4819-122-7-199504010-00001; COLDITZ GA, 1990, AM J EPIDEMIOL, V132, P501, DOI 10.1093/oxfordjournals.aje.a115686; Colditz GA, 1990, CURR PROB OBST GYN F, V13, P129; Fontaine KR, 1996, J FAM PRACTICE, V43, P265; GIOVANNUCCI E, 1991, AM J EPIDEMIOL, V133, P810; HENRY RR, 1986, DIABETES, V35, P990, DOI 10.2337/diabetes.35.9.990; Huang ZP, 1998, ANN INTERN MED, V128, P81, DOI 10.7326/0003-4819-128-2-199801150-00001; KATZEL LI, 1995, JAMA-J AM MED ASSOC, V274, P1915, DOI 10.1001/jama.274.24.1915; KOLOTKIN RL, 1995, OBES RES, V3, P49, DOI 10.1002/j.1550-8528.1995.tb00120.x; KRAL JG, 1992, AM J CLIN NUTR, V55, P611, DOI 10.1093/ajcn/55.2.611s; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAUNER LJ, 1994, JAMA-J AM MED ASSOC, V271, P1093, DOI 10.1001/jama.271.14.1093; MACLURE KM, 1989, NEW ENGL J MED, V321, P563, DOI 10.1056/NEJM198908313210902; MANSON JAE, 1990, NEW ENGL J MED, V322, P882, DOI 10.1056/NEJM199003293221303; MANSON JE, 1995, NEW ENGL J MED, V333, P677, DOI 10.1056/NEJM199509143331101; MARTON KI, 1981, ANN INTERN MED, V95, P568, DOI 10.7326/0003-4819-95-5-568; MCHORNEY CA, 1992, MED CARE, V30, pMS253, DOI 10.1097/00005650-199205001-00025; Rexrode KM, 1997, JAMA-J AM MED ASSOC, V277, P1539, DOI 10.1001/jama.277.19.1539; Rimm E B, 1990, Epidemiology, V1, P466, DOI 10.1097/00001648-199011000-00009; RUMPEL C, 1994, INT J OBESITY, V18, P179; STAMPFER MJ, 1992, AM J CLIN NUTR, V55, P652, DOI 10.1093/ajcn/55.3.652; Stevens J, 1998, NEW ENGL J MED, V338, P1, DOI 10.1056/NEJM199801013380101; STEWART AL, 1989, JAMA-J AM MED ASSOC, V262, P907, DOI 10.1001/jama.262.7.907; Ware J. E., 1993, SF36 HLTH SURVEY MAN; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; WILLETT WC, 1995, JAMA-J AM MED ASSOC, V273, P461, DOI 10.1001/jama.273.6.461; WOLF AM, 1994, INT J EPIDEMIOL, V23, P991, DOI 10.1093/ije/23.5.991	30	294	300	0	13	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2136	2142		10.1001/jama.282.22.2136	http://dx.doi.org/10.1001/jama.282.22.2136			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591335	Bronze			2022-12-28	WOS:000083971400032
J	Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R				Lord, J; Ducharme, FM; Stamp, RJ; Littlejohns, P; Churchill, R			Cost effectiveness analysis of inhaled anticholinergics for acute childhood and adolescent asthma	BRITISH MEDICAL JOURNAL			English	Article							EMERGENCY; ACCIDENT		Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England; McGill Univ, Montreal Childrens Hosp, Dept Pediat, Montreal, PQ H3H 1P3, Canada; McGill Univ, Montreal Childrens Hosp, Dept Epidemiol & Biostat, Montreal, PQ H3H 1P3, Canada; Univ Southampton, Wessex Inst Hlth Res & Dev, Biomed Serv, Southampton SO16 7PX, Hants, England	St Georges University London; McGill University; McGill University; University of Southampton	Lord, J (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, Hlth Care Evaluat Unit, London SW17 0RE, England.		Ducharme, Francine/N-8332-2013; Lord, Joanne/H-1417-2011	Ducharme, Francine/0000-0001-5096-0614; Lord, Joanne/0000-0003-1086-1624; Churchill, Rachel/0000-0002-1751-0512				BRIGGS A, 1994, HEALTH ECON, V3, P95, DOI 10.1002/hec.4730030206; Lord J, 1999, HEALTH ECON, V8, P323, DOI 10.1002/(SICI)1099-1050(199906)8:4<323::AID-HEC431>3.0.CO;2-0; Partridge MR, 1997, J ACCID EMERG MED, V14, P16; Plotnick LH, 1998, BMJ-BRIT MED J, V317, P971, DOI 10.1136/bmj.317.7164.971; Stell IM, 1996, J ACCID EMERG MED, V13, P392	5	9	9	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1470	1471		10.1136/bmj.319.7223.1470	http://dx.doi.org/10.1136/bmj.319.7223.1470			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582930	Green Published, Bronze			2022-12-28	WOS:000084129200022
J	Johannessen, OM; Shalina, EV; Miles, MW				Johannessen, OM; Shalina, EV; Miles, MW			Satellite evidence for an Arctic sea ice cover in transformation	SCIENCE			English	Article							PASSIVE MICROWAVE; OCEAN; NORTH	Recent research using microwave satellite remote sensing data has established that there has been a reduction of about 3 percent per decade in the areal extent of the Arctic sea ice cover since 1978, although it is unknown whether the nature of the perennial ice pack has changed. These data were used to quantify changes in the ice cover's composition, revealing a substantial reduction of about 14 percent in the area of multiyear ice in winter during the period from 1978 to 1998, There also appears to be a strong correlation between the area of multiyear ice and the spatially averaged thickness of the perennial ice pack, which suggests that the satellite-derived areal decreases represent substantial rather than only peripheral changes. If this apparent transformation continues, it may Lead to a markedly different ice regime in the Arctic, altering heat and mass exchanges as well as ocean stratification.	Univ Bergen, Inst Geophys, N-5007 Bergen, Norway; Nansen Environm & Remote Sensing Ctr, N-5059 Bergen, Norway; Nansen Int Environm & Remote Sensing Ctr, St Petersburg 197110, Russia; Univ Bergen, Dept Geog, N-5045 Bergen, Norway	University of Bergen; Nansen Environmental & Remote Sensing Center (NERSC); Nansen Environmental & Remote Sensing Center (NERSC); University of Bergen	Johannessen, OM (corresponding author), Univ Bergen, Inst Geophys, N-5007 Bergen, Norway.	Ola.Johannessen@nrsc.no						[Anonymous], 1983, SCIENCE, V220, P781, DOI 10.1126/science.220.4599.781; Bjorgo E, 1997, GEOPHYS RES LETT, V24, P413, DOI 10.1029/96GL04021; Cavalieri DJ, 1999, J GEOPHYS RES-OCEANS, V104, P15803, DOI 10.1029/1999JC900081; Cavalieri DJ, 1997, SCIENCE, V278, P1104, DOI 10.1126/science.278.5340.1104; COMISO JC, 1990, J GEOPHYS RES-OCEANS, V95, P13411, DOI 10.1029/JC095iC08p13411; GLOERSEN P, 1986, J GEOPHYS RES-OCEANS, V91, P3913, DOI 10.1029/JC091iC03p03913; Gloersen P, 1992, ARCTIC ANTARCTIC SEA; GRENFELL TC, 1992, J GEOPHYS RES-OCEANS, V97, P3485, DOI 10.1029/91JC02651; HURRELL JW, 1995, SCIENCE, V269, P676, DOI 10.1126/science.269.5224.676; JOHANNESSEN OM, 1995, NATURE, V376, P126, DOI 10.1038/376126a0; Kwok R, 1999, J GEOPHYS RES-OCEANS, V104, P5177, DOI 10.1029/1998JC900103; MANABE S, 1992, J CLIMATE, V5, P105, DOI 10.1175/1520-0442(1992)005<0105:TROACO>2.0.CO;2; Maslanik JA, 1996, GEOPHYS RES LETT, V23, P1677, DOI 10.1029/96GL01426; McPhee MG, 1998, GEOPHYS RES LETT, V25, P1729, DOI 10.1029/98GL00933; MITCHELL JFB, 1995, NATURE, V376, P501, DOI 10.1038/376501a0; Mysak LA, 1998, GEOPHYS RES LETT, V25, P3607, DOI 10.1029/98GL02782; Nagurny A. P., 1994, Bulletin of the Russian Academy of Sciences. Physics, V58, P168; Nagurny A.P., 1999, METEOROL HYDROL, V3, P72; Parkinson CL, 1999, J GEOPHYS RES-OCEANS, V104, P20837, DOI 10.1029/1999JC900082; Peacock NR, 1998, INT GEOSCI REMOTE SE, P1964, DOI 10.1109/IGARSS.1998.703709; ROTHROCK DA, IN PRESS GEOPHYS RES; Smith DM, 1998, GEOPHYS RES LETT, V25, P655, DOI 10.1029/98GL00251; Stroeve J, 1998, REMOTE SENS ENVIRON, V64, P132, DOI 10.1016/S0034-4257(97)00174-0; SVENDSEN E, 1983, J GEOPHYS RES-OCEANS, V88, P2781, DOI 10.1029/JC088iC05p02781; WADHAMS P, 1990, NATURE, V345, P795, DOI 10.1038/345795a0; Wadhams P, 1997, J GEOPHYS RES-OCEANS, V102, P27951, DOI 10.1029/97JC02503	26	285	309	1	61	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1937	1939		10.1126/science.286.5446.1937	http://dx.doi.org/10.1126/science.286.5446.1937			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583953				2022-12-28	WOS:000084003400046
J	Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B				Fatkin, D; MacRae, C; Sasaki, T; Wolff, MR; Porcu, M; Frenneaux, M; Atherton, J; Vidaillet, HJ; Spudich, S; De Girolami, U; Seidman, JG; Seidman, CE; Muntoni, F; Muehle, G; Johnson, W; McDonough, B			Missense mutations in the rod domain of the lamin A/C gene as causes of dilated cardiomyopathy and conduction-system disease.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DREIFUSS MUSCULAR-DYSTROPHY; HEART-FAILURE; ORGANIZATION; LOCUS; DEFICIENCY; FREQUENCY; LINKAGE; CDNA	Background: Inherited mutations cause approximately 35 percent of cases of dilated cardiomyopathy; however, few genes associated with this disease have been identified. Previously, we located a gene defect that was responsible for autosomal dominant dilated cardiomyopathy and conduction-system disease on chromosome 1p1-q21, where nuclear-envelope proteins lamin A and lamin C are encoded by the LMNA (lamin A/C) gene. Mutations in the head or tail domain of this gene cause Emery-Dreifuss muscular dystrophy, a childhood-onset disease characterized by joint contractures and in some cases by abnormalities of cardiac conduction during adulthood. Methods: We evaluated 11 families with autosomal dominant dilated cardiomyopathy and conduction-system disease. Sequences of the lamin A/C exons were determined in probands from each family, and variants were confirmed by restriction-enzyme digestion. The genotypes of the family members were ascertained. Results: Five novel missense mutations were identified: four in the (alpha)-helical rod domain of the lamin A/C gene, and one in the lamin C tail domain. Each mutation caused heritable, progressive conduction-system disease (sinus bradycardia, atrioventricular conduction block, or atrial arrhythmias) and dilated cardiomyopathy. Heart failure and sudden death occurred frequently within these families. No family members with mutations had either joint contractures or skeletal myopathy. Serum creatine kinase levels were normal in family members with mutations of the lamin rod but mildly elevated in some family members with a defect in the tail domain of lamin C. Conclusions: Genetic defects in distinct domains of the nuclear-envelope proteins lamin A and lamin C selectively cause dilated cardiomyopathy with conduction-system disease or autosomal dominant Emery-Dreifuss muscular dystrophy. Missense mutations in the rod domain of the lamin A/C gene provide a genetic cause for dilated cardiomyopathy and indicate that this intermediate filament protein has an important role in cardiac conduction and contractility. (N Engl J Med 1999;341:1715-24.) (C)1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA; Brigham & Womens Hosp, Howard Hughes Med Inst, Boston, MA 02115 USA; Brigham & Womens Hosp, Div Neuropathol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA USA; Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA; Univ Wisconsin, Div Cardiovasc, Madison, WI USA; Hosp G Brotzu, Div Cardiovasc, Cagliari, Italy; Cardiff Univ, Wales Heart Res Inst, Dept Cardiol, Cardiff CF4 4XN, S Glam, Wales; Royal Brisbane Hosp, Dept Cardiol, Brisbane, Qld 4029, Australia; Marshfield Clin Fdn Med Res & Educ, Div Cardiovasc, Marshfield, WI USA; Hammersmith Hosp, London, England	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Brigham & Women's Hospital; Howard Hughes Medical Institute; Harvard University; Brigham & Women's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Howard Hughes Medical Institute; University of Wisconsin System; University of Wisconsin Madison; Cardiff University; Royal Brisbane & Women's Hospital; Marshfield Clinic; Imperial College London	Seidman, CE (corresponding author), Harvard Univ, Sch Med, Dept Genet, Alpert Rm 533,200 Longwood Ave, Boston, MA 02115 USA.	cseidman@rascal.med.harvard.edu	Atherton, John J/B-9994-2011	Atherton, John J/0000-0003-2271-578X				Barresi R, 1997, ACTA NEUROPATHOL, V94, P28, DOI 10.1007/s004010050668; BHARATI S, 1992, PACE, V15, P1720, DOI 10.1111/j.1540-8159.1992.tb02960.x; BIONE S, 1994, NAT GENET, V8, P323, DOI 10.1038/ng1294-323; Bonne G, 1999, NAT GENET, V21, P285, DOI 10.1038/6799; Bowles KR, 1996, J CLIN INVEST, V98, P1355, DOI 10.1172/JCI118922; Broers JLV, 1997, HISTOCHEM CELL BIOL, V107, P505, DOI 10.1007/s004180050138; Cohn JN, 1997, CIRCULATION, V95, P766; DEC GW, 1994, NEW ENGL J MED, V331, P1564, DOI 10.1056/NEJM199412083312307; DURAND JB, 1995, CIRCULATION, V92, P3387, DOI 10.1161/01.CIR.92.12.3387; EMERY AEH, 1987, CLIN GENET, V32, P360; FISHER DZ, 1986, P NATL ACAD SCI USA, V83, P6450, DOI 10.1073/pnas.83.17.6450; Fuchs E, 1998, SCIENCE, V279, P514, DOI 10.1126/science.279.5350.514; GERACE L, 1980, CELL, V19, P277, DOI 10.1016/0092-8674(80)90409-2; GERACE L, 1986, TRENDS BIOCHEM SCI, V11, P443, DOI 10.1016/0968-0004(86)90243-4; Grunig E, 1998, J AM COLL CARDIOL, V31, P186, DOI 10.1016/S0735-1097(97)00434-8; Herrmann H, 1998, CURR OPIN STRUC BIOL, V8, P177, DOI 10.1016/S0959-440X(98)80035-3; HOFFMAN EP, 1987, CELL, V51, P919, DOI 10.1016/0092-8674(87)90579-4; HOFFMAN EP, 1988, NEW ENGL J MED, V318, P1363, DOI 10.1056/NEJM198805263182104; Jung M, 1998, CIRCULATION, V98, P246; KASPER EK, 1994, J AM COLL CARDIOL, V23, P586, DOI 10.1016/0735-1097(94)90740-4; KASS S, 1994, NAT GENET, V7, P546, DOI 10.1038/ng0894-546; KEELING PJ, 1995, BRIT HEART J, V73, P417; KOENIG M, 1987, CELL, V50, P509, DOI 10.1016/0092-8674(87)90504-6; KRAJINOVIC M, 1995, AM J HUM GENET, V57, P846; Ku NO, 1996, CANCER METAST REV, V15, P429, DOI 10.1007/BF00054011; Manilal S, 1999, HUM MOL GENET, V8, P353, DOI 10.1093/hmg/8.2.353; MAWATARI S, 1973, ARCH NEUROL-CHICAGO, V28, P55, DOI 10.1001/archneur.1973.00490190073010; MICHELS VV, 1992, NEW ENGL J MED, V326, P77, DOI 10.1056/NEJM199201093260201; MUNTONI F, 1993, NEW ENGL J MED, V329, P921, DOI 10.1056/NEJM199309233291304; Nagano A, 1996, NAT GENET, V12, P254, DOI 10.1038/ng0396-254; Olson TM, 1996, J CLIN INVEST, V97, P528, DOI 10.1172/JCI118445; Olson TM, 1998, SCIENCE, V280, P750, DOI 10.1126/science.280.5364.750; Siu BL, 1999, CIRCULATION, V99, P1022, DOI 10.1161/01.CIR.99.8.1022; Spann TP, 1997, J CELL BIOL, V136, P1201, DOI 10.1083/jcb.136.6.1201; Stuurman N, 1998, J STRUCT BIOL, V122, P42, DOI 10.1006/jsbi.1998.3987; TOWBIN JA, 1993, CIRCULATION, V87, P1854, DOI 10.1161/01.CIR.87.6.1854; VOIT T, 1988, NEUROPEDIATRICS, V19, P62, DOI 10.1055/s-2008-1052404; WATERS DD, 1975, NEW ENGL J MED, V293, P1017, DOI 10.1056/NEJM197511132932004; Wydner KL, 1996, GENOMICS, V32, P474, DOI 10.1006/geno.1996.0146; Yates JRW, 1999, NEUROMUSCULAR DISORD, V9, P199, DOI 10.1016/S0960-8966(98)00095-9	40	950	983	1	37	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1715	1724		10.1056/NEJM199912023412302	http://dx.doi.org/10.1056/NEJM199912023412302			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580070				2022-12-28	WOS:000083955800002
J	Hartwell, LH; Hopfield, JJ; Leibler, S; Murray, AW				Hartwell, LH; Hopfield, JJ; Leibler, S; Murray, AW			From molecular to modular cell biology	NATURE			English	Article							ARTIFICIAL CHROMOSOMES; YEAST; TRANSDUCTION; NETWORKS; EXTRACTS; PATHWAYS; LAMBDA	Cellular functions, such as signal transmission, are carried out by 'modules' made up of many species of interacting molecules, Understanding how modules work has depended on combining phenomenological analysis with molecular studies. General principles that govern the structure and behaviour of modules may be discovered with help from synthetic sciences such as engineering and computer science, from stronger interactions between experiment and theory in cell biology, and from an appreciation of evolutionary constraints.	Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08542 USA; Princeton Univ, Dept Phys & Mol Biol, Princeton, NJ 08542 USA; Univ Calif San Francisco, Dept Physiol, San Francisco, CA 94143 USA	Fred Hutchinson Cancer Center; Princeton University; Princeton University; University of California System; University of California San Francisco	Hartwell, LH (corresponding author), Fred Hutchinson Canc Res Ctr, Seattle, WA 98109 USA.							ADAMS SR, 1993, ANNU REV PHYSIOL, V55, P755, DOI 10.1146/annurev.ph.55.030193.003543; ALBERTS B, 1992, CELL, V68, P415, DOI 10.1016/0092-8674(92)90179-G; ANDERSON PW, 1972, SCIENCE, V177, P393, DOI 10.1126/science.177.4047.393; Barkai N, 1997, NATURE, V387, P913, DOI 10.1038/43199; BELMONT LD, 1990, CELL, V62, P579, DOI 10.1016/0092-8674(90)90022-7; BERG HC, 1988, COLD SPRING HARB SYM, V53, P1, DOI 10.1101/SQB.1988.053.01.003; BRAY D, 1995, NATURE, V376, P307, DOI 10.1038/376307a0; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Dill KA, 1997, NAT STRUCT BIOL, V4, P10, DOI 10.1038/nsb0197-10; GLIKSMAN NR, 1992, J CELL BIOL, V119, P1271, DOI 10.1083/jcb.119.5.1271; GOY MF, 1977, P NATL ACAD SCI USA, V74, P4964, DOI 10.1073/pnas.74.11.4964; Heald R, 1996, NATURE, V382, P420, DOI 10.1038/382420a0; HERSKOWITZ I, 1980, ANNU REV GENET, V14, P399, DOI 10.1146/annurev.ge.14.120180.002151; HERSKOWITZ I, 1995, CELL, V80, P187, DOI 10.1016/0092-8674(95)90402-6; HODGKIN AL, 1952, J PHYSIOL-LONDON, V117, P500, DOI 10.1113/jphysiol.1952.sp004764; HOPFIELD JJ, 1994, J THEOR BIOL, V171, P53, DOI 10.1006/jtbi.1994.1211; HSU HO, 1993, BIOPHYS J, V65, P1196, DOI 10.1016/S0006-3495(93)81153-6; JACOB F, 1977, SCIENCE, V196, P1161, DOI 10.1126/science.860134; Kirschner M, 1998, P NATL ACAD SCI USA, V95, P8420, DOI 10.1073/pnas.95.15.8420; KONOPKA JB, 1988, CELL, V54, P609, DOI 10.1016/S0092-8674(88)80005-9; LWOFF A, 1953, BACTERIOL REV, V17, P269, DOI 10.1128/MMBR.17.4.269-337.1953; MCADAMS HH, 1995, SCIENCE, V269, P650, DOI 10.1126/science.7624793; Morgan DO, 1997, ANNU REV CELL DEV BI, V13, P261, DOI 10.1146/annurev.cellbio.13.1.261; MURRAY AW, 1983, NATURE, V305, P189, DOI 10.1038/305189a0; Nurse P, 1998, CIBA F SYMP, V213, P93; Posas F, 1998, CURR OPIN MICROBIOL, V1, P175, DOI 10.1016/S1369-5274(98)80008-8; PTASHNE M, 1967, NATURE, V214, P232, DOI 10.1038/214232a0; PTASHNE M, 1980, CELL, V19, P1, DOI 10.1016/0092-8674(80)90383-9; SCHENA M, 1995, SCIENCE, V270, P467, DOI 10.1126/science.270.5235.467; Sejnowski T. J., 1987, Complex Systems, V1, P145; Shapiro JA, 1999, ANN NY ACAD SCI, V870, P23, DOI 10.1111/j.1749-6632.1999.tb08862.x; STOCK JB, 1996, CELLULAR MOL BIOL, P1103; Strohman RC, 1997, NAT BIOTECHNOL, V15, P194, DOI 10.1038/nbt0397-194; Waxman D, 1998, SCIENCE, V279, P1210, DOI 10.1126/science.279.5354.1210	34	2510	2597	8	214	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C47	C52		10.1038/35011540	http://dx.doi.org/10.1038/35011540			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591225	Bronze			2022-12-28	WOS:000084014100007
J	Nichols, MJ; Newsome, WT				Nichols, MJ; Newsome, WT			The neurobiology of cognition	NATURE			English	Article							HUMAN BRAIN; STIMULATION; PERCEPTION; CORTEX; SIGNAL; REWARD	Perhaps the deepest mysteries facing the natural sciences concern the higher functions of the central nervous system. Understanding how the brain gives rise to mental experiences looms as one of the central challenges for science in the new millennium.	Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA; Stanford Univ, Sch Med, Dept Neurobiol, Stanford, CA 94305 USA	Howard Hughes Medical Institute; Stanford University; Stanford University	Nichols, MJ (corresponding author), Stanford Univ, Sch Med, Howard Hughes Med Inst, Stanford, CA 94305 USA.		Newsome, William T./W-7171-2019					Colby CL, 1999, ANNU REV NEUROSCI, V22, P319, DOI 10.1146/annurev.neuro.22.1.319; DESIMONE R, 1995, ANNU REV NEUROSCI, V18, P193, DOI 10.1146/annurev.ne.18.030195.001205; Fuster JM, 1995, MEMORY CEREBRAL CORT; GALLISTEL CR, 1994, COGNITION, V50, P151, DOI 10.1016/0010-0277(94)90026-4; GEORGE JS, 1995, J CLIN NEUROPHYSIOL, V12, P406, DOI 10.1097/00004691-199509010-00002; GoldmanRakic PS, 1996, P NATL ACAD SCI USA, V93, P13473, DOI 10.1073/pnas.93.24.13473; Hubel David H, 1995, EYE BRAIN VISION, P6; Hubener M, 1997, J NEUROSCI, V17, P9270; JACKSON F, 1982, PHILOS QUART, V32, P127, DOI 10.2307/2960077; MARTINEZ, 1999, NATURE NEUROSCI, V2, P364; MAUNSELL JHR, 1995, SCIENCE, V270, P764, DOI 10.1126/science.270.5237.764; NAGEL T, 1974, PHILOS REV, V83, P435, DOI 10.2307/2183914; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; Parker AJ, 1998, ANNU REV NEUROSCI, V21, P227, DOI 10.1146/annurev.neuro.21.1.227; Platt ML, 1999, NATURE, V400, P233, DOI 10.1038/22268; Posner MI, 1998, P NATL ACAD SCI USA, V95, P763, DOI 10.1073/pnas.95.3.763; Romo R, 1999, CURR OPIN NEUROBIOL, V9, P487, DOI 10.1016/S0959-4388(99)80073-7; SALZMAN CD, 1992, J NEUROSCI, V12, P2331; Schall JD, 1999, ANNU REV NEUROSCI, V22, P241, DOI 10.1146/annurev.neuro.22.1.241; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; Schultz W, 1998, J NEUROPHYSIOL, V80, P1, DOI 10.1152/jn.1998.80.1.1; Sell LA, 1999, EUR J NEUROSCI, V11, P1042, DOI 10.1046/j.1460-9568.1999.00522.x; Shadlen MN, 1996, P NATL ACAD SCI USA, V93, P628, DOI 10.1073/pnas.93.2.628; Svoboda K, 1999, NAT NEUROSCI, V2, P65, DOI 10.1038/4569; Tanaka K, 1992, Curr Opin Neurobiol, V2, P502, DOI 10.1016/0959-4388(92)90187-P; THOMPSON E, 1992, PHILOS STUD, V68, P321, DOI 10.1007/BF00694850; Wandell BA, 1999, ANNU REV NEUROSCI, V22, P145, DOI 10.1146/annurev.neuro.22.1.145; WANG SSH, 1995, NEURON, V15, P755, DOI 10.1016/0896-6273(95)90167-1	28	42	43	0	6	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C35	C38		10.1038/35011531	http://dx.doi.org/10.1038/35011531			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Arts &amp; Humanities Citation Index (A&amp;HCI)	Science & Technology - Other Topics	261MZ	10591223	Bronze			2022-12-28	WOS:000084014100005
J	Arnesen, T; Nord, E				Arnesen, T; Nord, E			The value of DALY life: problems with ethics and validity of disability adjusted life years	BMJ-BRITISH MEDICAL JOURNAL			English	Article									Natl Publ Hlth Inst, N-0403 Oslo, Norway		Arnesen, T (corresponding author), Natl Publ Hlth Inst, PB 4404 Torshov, N-0403 Oslo, Norway.	trude.arnesen@folkehelsa.no						Anand S, 1998, WORLD DEV, V26, P307, DOI 10.1016/S0305-750X(97)10019-5; Anand S, 1997, J HEALTH ECON, V16, P685, DOI 10.1016/S0167-6296(97)00005-2; COHEN GA, 1989, ETHICS, V99, P906, DOI 10.1086/293126; Gwatkin DR, 1997, LANCET, V350, P141, DOI 10.1016/S0140-6736(97)26028-9; HARRIS J, 1987, J MED ETHICS, V13, P117, DOI 10.1136/jme.13.3.117; Harris J, 1996, BIOETHICS, V10, P269, DOI 10.1111/j.1467-8519.1996.tb00129.x; *INT BURD DIS NETW, 1998, REP FDN M; MENZEI P, 1990, STRONG MED; Murray C, 1996, SUMMARY GLOBAL BURDE; Murray C. J. L., 1996, GLOBAL BURDEN DIS; Murrill W.A., 1907, N AM FLORA, V9, P1; NORD E, 1992, SOC SCI MED, V34, P559, DOI 10.1016/0277-9536(92)90211-8; Nord E, 1999, HEALTH ECON, V8, P25; Patrick D L, 1973, Health Serv Res, V8, P228; Savulescu J, 1998, BIOETHICS, V12, P212, DOI 10.1111/1467-8519.00109; Sayers BM, 1997, B WORLD HEALTH ORGAN, V75, P383; Stouthard MEA, 1997, DISABILITY WEIGHTS D; *WORLD BANK, 1993, WORLD DEV REP 1993 I	18	166	175	0	12	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1423	1425		10.1136/bmj.319.7222.1423	http://dx.doi.org/10.1136/bmj.319.7222.1423			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10574867	Green Published			2022-12-28	WOS:000083995200035
J	Jones, AL; Volans, G				Jones, AL; Volans, G			Recent advances - Management of self poisoning	BMJ-BRITISH MEDICAL JOURNAL			English	Review							FULMINANT HEPATIC-FAILURE; CARBON-MONOXIDE; ACTIVATED-CHARCOAL; OXYGEN-TRANSPORT; N-ACETYLCYSTEINE; PREVENTION; ECSTASY; HARM; GHB		Guys & St Thomas NHS Trust, Med Toxicol Unit, Natl Poisons Informat Serv London, London SE14 5ER, England	Guy's & St Thomas' NHS Foundation Trust	Jones, AL (corresponding author), Guys & St Thomas NHS Trust, Med Toxicol Unit, Natl Poisons Informat Serv London, London SE14 5ER, England.	aj@medtox.demon.co.uk						*AM AC CLIN TOX, 1997, J TOXICOL-CLIN TOXIC, V35, P753; *AM AC CLIN TOX EU, 1997, J TOXICOL-CLIN TOXIC, V35, P721; *AM AC CLIN TOX EU, IN PRESS J CLIN TOXI; Bismuth C, 1997, J TOXICOL-CLIN TOXIC, V35, P595, DOI 10.3109/15563659709001238; Brent J, 1999, NEW ENGL J MED, V340, P832, DOI 10.1056/NEJM199903183401102; BROWN SD, 1990, J APPL PHYSIOL, V68, P604, DOI 10.1152/jappl.1990.68.2.604; Choudhary AM, 1998, J CLIN GASTROENTEROL, V27, P155, DOI 10.1097/00004836-199809000-00013; DAWSON AH, 1989, MED J AUSTRALIA, V150, P329, DOI 10.5694/j.1326-5377.1989.tb136496.x; Denborough MA, 1997, MED J AUSTRALIA, V166, P165, DOI 10.5694/j.1326-5377.1997.tb140056.x; DUCASSE JL, 1995, UNDERSEA HYPERBAR M, V22, P9; Greaves I, 1996, J ACCID EMERG MED, V13, P46; HARRISON PM, 1991, NEW ENGL J MED, V324, P1852, DOI 10.1056/NEJM199106273242604; Hawton K, 1997, BRIT J PSYCHIAT, V171, P556, DOI 10.1192/bjp.171.6.556; Hawton K, 1996, BRIT J PSYCHIAT, V168, P43, DOI 10.1192/bjp.168.1.43; Henry JA, 1998, LANCET, V352, P420, DOI 10.1016/S0140-6736(05)79183-2; HENRY JA, 1992, LANCET, V340, P384, DOI 10.1016/0140-6736(92)91469-O; Jacobsen D, 1996, J TOXICOL-CLIN TOXIC, V34, P379, DOI 10.3109/15563659609013807; Jones AL, 1999, ALIMENT PHARM THER, V13, P129; Jones AL, 1998, J TOXICOL-CLIN TOXIC, V36, P277, DOI 10.3109/15563659809028022; Krenzelok E. P., 1997, J TOXICOL-CLIN TOXIC, V35, P699; LANCASHIRE MJR, 1988, BRIT MED J, V296, P1035, DOI 10.1136/bmj.296.6628.1035; Louagie HK, 1997, J TOXICOL-CLIN TOXIC, V35, P591, DOI 10.3109/15563659709001237; Mathieu D., 1996, UNDERSEA HYPERBARIC, V23, P7; MENZIES DG, 1988, BRIT MED J, V297, P459, DOI 10.1136/bmj.297.6646.459; NEUVONEN PJ, 1983, EUR J CLIN PHARMACOL, V24, P557, DOI 10.1007/BF00609903; OGRADY JG, 1991, BRIT MED J, V303, P221, DOI 10.1136/bmj.303.6796.221; PACE N, 1950, SCIENCE, V111, P652, DOI 10.1126/science.111.2894.652; *PAR INF CTR, 1999, GUID MAN PAR POIS; POND SM, 1995, MED J AUSTRALIA, V163, P345, DOI 10.5694/j.1326-5377.1995.tb124625.x; PRESCOTT LF, 1979, BMJ-BRIT MED J, V2, P1098; RAPHAEL JC, 1989, LANCET, V2, P414; Routledge P, 1998, BRIT MED J, V317, P1609; SAETTA JP, 1991, J ROY SOC MED, V84, P35, DOI 10.1177/014107689108400113; Scheinkestel CD, 1999, MED J AUSTRALIA, V170, P203, DOI 10.5694/j.1326-5377.1999.tb140318.x; THORN SR, 1995, ANN EMERG MED, V25, P474, DOI 10.1016/S0196-0644(95)70261-X; Vale JA, 1997, J TOXICOL-CLIN TOXIC, V35, P711; Visser L, 1998, LANCET, V352, P1352, DOI 10.1016/S0140-6736(98)08302-0; Walsh TS, 1998, HEPATOLOGY, V27, P1332, DOI 10.1002/hep.510270520; Wilson RC, 1998, OCCUP ENVIRON MED, V55, P723, DOI 10.1136/oem.55.11.723; Winstock AR, 1996, BRIT MED J, V313, P423	40	39	41	0	6	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1414	1417		10.1136/bmj.319.7222.1414	http://dx.doi.org/10.1136/bmj.319.7222.1414			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574863	Green Published			2022-12-28	WOS:000083995200031
J	Rivlin, M				Rivlin, M			Personal view - Should age based rationing of health care be illegal?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Univ Leeds, Dept Philosophy, Leeds LS2 9JT, W Yorkshire, England	University of Leeds	Rivlin, M (corresponding author), Univ Leeds, Dept Philosophy, Leeds LS2 9JT, W Yorkshire, England.							RIVLIN MM, 1995, BRIT MED J, V310, P1179, DOI 10.1136/bmj.310.6988.1179; Sutton GC, 1997, BMJ-BRIT MED J, V315, P1032, DOI 10.1136/bmj.315.7115.1032	2	10	11	2	2	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 20	1999	319	7221					1379	1379		10.1136/bmj.319.7221.1379	http://dx.doi.org/10.1136/bmj.319.7221.1379			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567167	Green Published			2022-12-28	WOS:000083930200067
J	Stegeman, GI; Segev, M				Stegeman, GI; Segev, M			Optical spatial solitons and their interactions: Universality and diversity	SCIENCE			English	Review							PHOTOREFRACTIVE SCREENING SOLITONS; ALGAAS WAVE-GUIDES; SOLITARY WAVES; QUADRATIC SOLITONS; NONLINEAR MEDIUM; VECTOR SOLITONS; KERR MEDIA; BRIGHT; COLLISION; FIBERS	Spatial solitons, beams that do not spread owing to diffraction when they propagate, have been demonstrated to exist by virtue of a variety of nonlinear self-trapping mechanisms. Despite the diversity of these mechanisms, many of the features of soliton interactions and collisions are universal. Spatial solitons exhibit a richness of phenomena not found with temporal solitons in fibers, including effects such as fusion, fission, annihilation, and stable orbiting in three dimensions. Here the current state of knowledge on spatial soliton interactions is reviewed.	Univ Cent Florida, Sch Opt, Orlando, FL 32826 USA; Univ Cent Florida, CREOL, Orlando, FL 32826 USA; Technion Israel Inst Technol, Dept Phys, IL-32000 Haifa, Israel; Technion Israel Inst Technol, Inst Solid State, IL-32000 Haifa, Israel; Princeton Univ, Dept Elect Engn, Princeton, NJ 08544 USA; Princeton Univ, Ctr Photon & Optoelect Mat, Princeton, NJ 08544 USA	State University System of Florida; University of Central Florida; State University System of Florida; University of Central Florida; Technion Israel Institute of Technology; Technion Israel Institute of Technology; Princeton University; Princeton University	Stegeman, GI (corresponding author), Univ Cent Florida, Sch Opt, 4000 Cent Florida Blvd, Orlando, FL 32826 USA.							AITCHISON JS, 1992, ELECTRON LETT, V28, P1879, DOI 10.1049/el:19921203; AITCHISON JS, 1991, OPT LETT, V16, P15, DOI 10.1364/OL.16.000015; AITCHISON JS, 1990, OPT LETT, V15, P471, DOI 10.1364/OL.15.000471; Akhmediev N, 1998, PHYS REV LETT, V81, P4632, DOI 10.1103/PhysRevLett.81.4632; Anastassiou C, 1999, PHYS REV LETT, V83, P2332, DOI 10.1103/PhysRevLett.83.2332; ANDERSEN D, 1995, PHYS REV A, V32, P2270; ASKARYAN GA, 1962, ZH EKSP TEOR FIZ, V15, P1088; BABOIU DM, 1995, OPT LETT, V20, P2282, DOI 10.1364/OL.20.002282; Baek Y, 1997, OPT LETT, V22, P1550, DOI 10.1364/OL.22.001550; BARTHELEMY A, 1993, SPIE, V2041, P104; BARTHOLINI G, 1985, MED RES REV, V5, P55, DOI 10.1002/med.2610050103; Bartuch U, 1997, OPT COMMUN, V134, P49, DOI 10.1016/S0030-4018(96)00500-7; Belic MR, 1999, PHYS REV LETT, V82, P544, DOI 10.1103/PhysRevLett.82.544; BJORKHOL.JE, 1974, PHYS REV LETT, V32, P129, DOI 10.1103/PhysRevLett.32.129; Buryak AV, 1999, PHYS REV LETT, V82, P81, DOI 10.1103/PhysRevLett.82.81; CASTILLO MDI, 1994, APPL PHYS LETT, V64, P408, DOI 10.1063/1.111163; Chen ZG, 1996, OPT LETT, V21, P1821, DOI 10.1364/OL.21.001821; Chen ZG, 1996, OPT LETT, V21, P1436, DOI 10.1364/OL.21.001436; CHRISTODOULIDES DN, 1995, J OPT SOC AM B, V12, P1628, DOI 10.1364/JOSAB.12.001628; Christodoulides DN, 1996, APPL PHYS LETT, V68, P1763, DOI 10.1063/1.116659; CHRISTODOULIDES DN, 1988, OPT LETT, V13, P53, DOI 10.1364/OL.13.000053; CHRISTODOULIDES DN, 1988, PHYS LETT A, V132, P451, DOI 10.1016/0375-9601(88)90511-7; Crosignani B, 1998, RIV NUOVO CIMENTO, V21, P1, DOI 10.1007/BF02874290; Di Trapani P, 1998, PHYS REV LETT, V80, P265, DOI 10.1103/PhysRevLett.80.265; DUREE GC, 1993, PHYS REV LETT, V71, P533, DOI 10.1103/PhysRevLett.71.533; Fuerst RA, 1997, OPT LETT, V22, P1748, DOI 10.1364/OL.22.001748; GATZ S, 1992, IEEE J QUANTUM ELECT, V28, P1732, DOI 10.1109/3.142561; GORDON JP, 1983, OPT LETT, V8, P596, DOI 10.1364/OL.8.000596; HASEGAWA A, 1973, APPL PHYS LETT, V23, P142, DOI 10.1063/1.1654836; Jakubowski MH, 1998, PHYS REV E, V58, P6752, DOI 10.1103/PhysRevE.58.6752; Kang JU, 1996, OPT LETT, V21, P189, DOI 10.1364/OL.21.000189; Kang JU, 1996, PHYS REV LETT, V76, P3699, DOI 10.1103/PhysRevLett.76.3699; Karamzin Y. N., 1976, SOV PHYS JETP, V41, P414; KELLEY PL, 1965, PHYS REV LETT, V15, P1005, DOI 10.1103/PhysRevLett.15.1005; KHITROVA G, 1993, PHYS REV LETT, V70, P920, DOI 10.1103/PhysRevLett.70.920; Kip D, 1998, OPT LETT, V23, P921, DOI 10.1364/OL.23.000921; Kivshar YS, 1998, PHYS REP, V298, P81, DOI 10.1016/S0370-1573(97)00073-2; Krolikowski W, 1998, OPT LETT, V23, P97, DOI 10.1364/OL.23.000097; Krolikowski W, 1997, OPT LETT, V22, P369, DOI 10.1364/OL.22.000369; LONNGREN KE, 1983, PLASMA PHYS CONTR F, V25, P943, DOI 10.1088/0032-1028/25/9/001; Manakov S V, 1974, SOV PHYS JETP, V38, P248; Meng HX, 1997, OPT LETT, V22, P448, DOI 10.1364/OL.22.000448; Mitchell M, 1997, NATURE, V387, P880, DOI 10.1038/43079; Mitchell M, 1996, PHYS REV LETT, V77, P490, DOI 10.1103/PhysRevLett.77.490; Mitchell M, 1998, PHYS REV LETT, V80, P4657, DOI 10.1103/PhysRevLett.80.4657; MUSSLIMANI ZH, IN PRESS OPT LETT; Ostrovskaya EA, 1999, OPT LETT, V24, P327, DOI 10.1364/OL.24.000327; Ostrovskaya EA, 1999, PHYS REV LETT, V83, P296, DOI 10.1103/PhysRevLett.83.296; Petrov DV, 1998, OPT LETT, V23, P1444, DOI 10.1364/OL.23.001444; POLADIAN L, 1991, OPT COMMUN, V85, P59, DOI 10.1016/0030-4018(91)90052-F; POLTURAK E, 1981, PHYS REV LETT, V46, P1588, DOI 10.1103/PhysRevLett.46.1588; Radhakrishnan R, 1997, PHYS REV E, V56, P2213, DOI 10.1103/PhysRevE.56.2213; Russell J.S, 1844, 14 M BRIT ASS REP YO; Schiek R, 1996, PHYS REV E, V53, P1138, DOI 10.1103/PhysRevE.53.1138; Segev M, 1998, OPT QUANT ELECTRON, V30, P503, DOI 10.1023/A:1006915021865; SEGEV M, 1994, PHYS REV LETT, V73, P3211, DOI 10.1103/PhysRevLett.73.3211; SEGEV M, 1992, PHYS REV LETT, V68, P923, DOI 10.1103/PhysRevLett.68.923; Segev M, 1998, PHYS TODAY, V51, P42, DOI 10.1063/1.882370; Segev M, 1996, J OPT SOC AM B, V13, P706, DOI 10.1364/JOSAB.13.000706; SHALABY M, 1992, OPT LETT, V17, P778, DOI 10.1364/OL.17.000778; SHALABY M, 1992, IEEE J QUANTUM ELECT, V28, P2736, DOI 10.1109/3.166467; SHEPPARD AP, 1994, OPT LETT, V19, P859, DOI 10.1364/OL.19.000859; SHIH MF, 1995, ELECTRON LETT, V31, P826, DOI 10.1049/el:19950570; Shih MF, 1997, PHYS REV LETT, V78, P2551, DOI 10.1103/PhysRevLett.78.2551; Shih MF, 1996, OPT LETT, V21, P1538, DOI 10.1364/OL.21.001538; SNYDER AW, 1993, OPT LETT, V18, P482, DOI 10.1364/OL.18.000482; SNYDER AW, 1994, PHYS REV LETT, V72, P1012, DOI 10.1103/PhysRevLett.72.1012; Soljacic M, 1998, PHYS REV LETT, V81, P4851, DOI 10.1103/PhysRevLett.81.4851; Steblina VV, 1998, OPT LETT, V23, P156, DOI 10.1364/OL.23.000156; Stepken A, 1999, PHYS REV LETT, V82, P540, DOI 10.1103/PhysRevLett.82.540; Stepken A, 1998, PHYS REV E, V58, pR4112, DOI 10.1103/PhysRevE.58.R4112; Tikhonenko V, 1996, PHYS REV LETT, V76, P2698, DOI 10.1103/PhysRevLett.76.2698; Torner L, 1996, OPT LETT, V21, P462, DOI 10.1364/OL.21.000462; Torruellas W, 1996, ELECTRON LETT, V32, P2092, DOI 10.1049/el:19961400; TORRUELLAS WE, 1995, PHYS REV LETT, V74, P5036, DOI 10.1103/PhysRevLett.74.5036; TRILLO S, 1988, OPT LETT, V13, P871, DOI 10.1364/OL.13.000871; ZABUSKY NJ, 1965, PHYS REV LETT, V15, P240, DOI 10.1103/PhysRevLett.15.240; ZAKHAROV VE, 1972, SOV PHYS JETP-USSR, V34, P62; ZAKHAROV VE, 1974, ZH EKSP TEOR FIZ, V38, P494	79	969	999	3	113	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1518	1523		10.1126/science.286.5444.1518	http://dx.doi.org/10.1126/science.286.5444.1518			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567250				2022-12-28	WOS:000083768300046
J	Dano, S; Sorensen, PG; Hynne, F				Dano, S; Sorensen, PG; Hynne, F			Sustained oscillations in living cells	NATURE			English	Article							BELOUSOV-ZHABOTINSKY REACTION; BRIGGS-RAUSCHER REACTION; METABOLIC OSCILLATIONS; GLYCOLYTIC OSCILLATIONS; HOPF-BIFURCATION; HEART-CELLS; YEAST-CELLS; BETA-CELLS; MAKE-UP; MUSCLE	Glycolytic oscillations in yeast have been studied for many years simply by adding a glucose pulse to a suspension of cells and measuring the resulting transient oscillations of NADH(1-12). Here we show, using a suspension of yeast cells, that living cells can be kept ia a well defined oscillating state indefinitely when starved cells, glucose and cyanide are pumped into a cuvette with outflow of surplus liquid. Our results show that the transitions between stationary and oscillatory behaviour are uniquely described mathematically by the Hopf bifurcation(13). This result characterizes the dynamical properties close to the transition point. Our perturbation experiments show that the cells remain strongly coupled very close to the transition. Therefore, the transition takes place in each of the cells and is not a desynchronization phenomenon. With these two observations, a study of the kinetic details of glycolysis, as it actually takes place in a living cell, is possible using experiments designed in the framework of nonlinear dynamics. Acetaldehyde is known to synchronize the oscillations(10). Our results show that glucose is another messenger substance, as long as the glucose transporter is not saturated.	Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, DK-2100 Copenhagen, Denmark	University of Copenhagen	Dano, S (corresponding author), Univ Copenhagen, HC Orsted Inst, Dept Chem & CATS, Univ Pk 5, DK-2100 Copenhagen, Denmark.							ALDRIDGE J, 1976, NATURE, V259, P670, DOI 10.1038/259670a0; CHOU HF, 1992, AM J PHYSIOL, V262, pE800, DOI 10.1152/ajpendo.1992.262.6.E800; Civelek VN, 1997, DIABETES, V46, P51, DOI 10.2337/diabetes.46.1.51; DUYSENS LNM, 1957, BIOCHIM BIOPHYS ACTA, V24, P19, DOI 10.1016/0006-3002(57)90141-5; FRENKEL R, 1968, ARCH BIOCHEM BIOPHYS, V125, P157, DOI 10.1016/0003-9861(68)90650-4; GHOSH A, 1964, BIOCHEM BIOPH RES CO, V16, P174, DOI 10.1016/0006-291X(64)90357-2; GHOSH AK, 1971, ARCH BIOCHEM BIOPHYS, V145, P319, DOI 10.1016/0003-9861(71)90042-7; GOLDBETER A, 1996, BIOCH OSCILLATIONS C, P6; HESS B, 1968, H-S Z PHYSIOL CHEM, V349, P1567, DOI 10.1515/bchm2.1968.349.2.1567; HYNNE F, 1993, J CHEM PHYS, V98, P219, DOI 10.1063/1.464667; HYNNE F, 1990, J CHEM PHYS, V92, P1747, DOI 10.1063/1.458056; KOSEK J, 1994, J PHYS CHEM-US, V98, P6128, DOI 10.1021/j100075a015; KREUZBERG KH, 1979, J INTERDISCIPL CYCLE, V10, P41; MATTHEWS PC, 1991, PHYSICA D, V52, P293, DOI 10.1016/0167-2789(91)90129-W; OROURKE B, 1994, SCIENCE, V265, P962, DOI 10.1126/science.8052856; OROURKE B, 1995, ADV EXP MED BIOL, V382, P165; PYE EK, 1969, CAN J BOTANY, V47, P271, DOI 10.1139/b69-040; Richard P, 1996, YEAST, V12, P731; Richard P, 1996, EUR J BIOCHEM, V235, P238, DOI 10.1111/j.1432-1033.1996.00238.x; RICHARD P, 1994, FEBS LETT, V341, P223, DOI 10.1016/0014-5793(94)80461-3; RICHARD P, 1993, FEBS LETT, V318, P80, DOI 10.1016/0014-5793(93)81332-T; Siegel G, 1997, INT J MICROCIRC, V17, P360, DOI 10.1159/000179252; Teusink B, 1996, J BIOL CHEM, V271, P24442, DOI 10.1074/jbc.271.40.24442; TORNHEIM K, 1973, J BIOL CHEM, V248, P2670; Tornheim K, 1997, DIABETES, V46, P1375, DOI 10.2337/diabetes.46.9.1375; VUKOJEVIC V, 1993, J PHYS CHEM-US, V97, P4091, DOI 10.1021/j100118a027; Vukojevic V, 1996, J PHYS CHEM-US, V100, P17175, DOI 10.1021/jp960785o; WINFREE AT, 1972, ARCH BIOCHEM BIOPHYS, V149, P388, DOI 10.1016/0003-9861(72)90337-2	28	208	210	2	59	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					320	322		10.1038/46329	http://dx.doi.org/10.1038/46329			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580506				2022-12-28	WOS:000083813700056
J	Eisenberg, JM				Eisenberg, JM			Ten lessons for evidence-based technology assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							LAPAROSCOPIC CHOLECYSTECTOMY; HEALTH-CARE; OUTCOMES; QUALITY		US Dept HHS, Agcy Hlth Care Policy & Res, Off Hlth Care Informat, Rockville, MD 20852 USA	Agency for Healthcare Research & Quality	Eisenberg, JM (corresponding author), US Dept HHS, Agcy Hlth Care Policy & Res, Off Hlth Care Informat, 2101 E Jefferson St,Suite 501, Rockville, MD 20852 USA.	kmigdail@ahcpr.gov						*AG HLTH CAR POL R, 1999, EV CERV CYT; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; CRECO PJ, 1993, NEW ENGL J MED, V329, P1271; DAVIS AB, 1981, MED ITS TECHNOLOGY, P88; Eisenberg DM, 1998, JAMA-J AM MED ASSOC, V280, P1569, DOI 10.1001/jama.280.18.1569; EISENBERG JM, 1989, JAMA-J AM MED ASSOC, V262, P1196, DOI 10.1001/jama.262.9.1196; ESCARCE JJ, 1995, JAMA-J AM MED ASSOC, V273, P1581, DOI 10.1001/jama.273.20.1581; GOLD M, 1995, ARRANGEMENTS MANAGED; Holohan T V, 1996, Health Technol Assess (Rockv), P1; LEE PR, 1992, WESTERN J MED, V157, P576; MCNEIL BJ, 1981, NEW ENGL J MED, V305, P982, DOI 10.1056/NEJM198110223051704; Rosenbaum S, 1999, NEW ENGL J MED, V340, P229, DOI 10.1056/NEJM199901213400312; Shea JA, 1998, ANN SURG, V227, P343, DOI 10.1097/00000658-199803000-00005; Soumerai SB, 1998, JAMA-J AM MED ASSOC, V279, P1358, DOI 10.1001/jama.279.17.1358; STEINER CA, 1994, NEW ENGL J MED, V330, P403, DOI 10.1056/NEJM199402103300607; Wennberg JE, 1999, DARTMOUTH ATLAS HLTH; 1999, SUMM M COND COV NEW	17	65	70	0	2	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1865	1869		10.1001/jama.282.19.1865	http://dx.doi.org/10.1001/jama.282.19.1865			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573279				2022-12-28	WOS:000083615700031
J	Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L				Guardiola, J; Xiol, X; Sallie, R; Nolla, JM; Roig-Escofet, D; Jaurrieta, E; Casais, L			Influence of the vitamin D receptor gene polymorphism on bone loss in men after liver transplantation	ANNALS OF INTERNAL MEDICINE			English	Article							MINERAL DENSITY; RHEUMATOID-ARTHRITIS; WOMEN; ALLELES; CALCIUM; GENOTYPE; DISEASE; RATES; LOCUS	Background: Bone loss is a frequent complication after liver transplantation. Objective: To investigate whether vitamin D receptor gene polymorphism influences bone loss in men after liver transplantation. Design: Prospective cohort study. Setting: University hospital. Patients: 55 male candidates for liver transplantation. Measurements: Lumbar spine bone mineral density was measured before and 3, 6, 12, and 24 months after liver transplantation. Vitamin D receptor genotype was determined by restriction endonuclease Bsml. Results: Vitamin D receptor genotypes were significantly associated with post-transplantation changes in bone mineral density (P = 0.028). Within 3 months after transplantation, patients with the genotypes Bb or BE showed a vertebral bone loss substantially greater than that in patients with the bb genotype (between-group difference in the percentage change with respect to baseline bone mineral density, 3.7% [95% CI, 0.6% to 6.9%]). In 3 to 24 months after transplantation, bone mineral density increased steadily in the three allelic groups. Conclusions: Vitamin D receptor gene polymorphism influences bone loss after liver transplantation. Patients with the bb genotype are, to some extent, protected against post-transplantation bone loss.	Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gastroenterol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Rheumatol, Barcelona 08907, Spain; Ciudad Sanitaria & Univ Bellvitge, Hosp Princeps Espanya, Dept Gen Surg, Barcelona 08907, Spain; NIDDKD, Liver Unit, NIH, Bethesda, MD 20892 USA	Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; Institut d'Investigacio Biomedica de Bellvitge (IDIBELL); Bellvitge University Hospital; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Guardiola, J (corresponding author), Hosp Comarcal LAlt Penedes, Gastroenterol Unit, Espriall S-N, Barcelona 08720, Spain.			Xiol, Xavier/0000-0002-4461-4704; Guardiola, Jordi/0000-0002-0464-241X				AN SF, 1991, J CLIN PATHOL, V44, P924, DOI 10.1136/jcp.44.11.924; Buckley LM, 1996, ANN INTERN MED, V125, P961, DOI 10.7326/0003-4819-125-12-199612150-00004; DAWSONHUGHES B, 1995, J CLIN ENDOCR METAB, V80, P3657, DOI 10.1210/jc.80.12.3657; DIAMOND TH, 1989, GASTROENTEROLOGY, V96, P213, DOI 10.1016/0016-5085(89)90783-X; EASTELL R, 1991, HEPATOLOGY, V14, P296, DOI 10.1002/hep.1840140215; FERRARI S, 1995, LANCET, V345, P423, DOI 10.1016/S0140-6736(95)90404-2; FLEET JC, 1995, J BONE MINER RES, V10, P985; GARNERO P, 1995, J BONE MINER RES, V10, P1283; Gough A, 1998, J RHEUMATOL, V25, P864; HAY JE, 1993, GASTROENTEROL CLIN N, V22, P337; HUSTMYER FG, 1994, J CLIN INVEST, V94, P2130, DOI 10.1172/JCI117568; Jorgensen HL, 1996, BRIT MED J, V313, P586, DOI 10.1136/bmj.313.7057.586; KRALL EA, 1995, J BONE MINER RES, V10, P978; MCDONALD JA, 1991, HEPATOLOGY, V14, P613, DOI 10.1002/hep.1840140407; MEYS E, 1994, AM J MED, V97, P445, DOI 10.1016/0002-9343(94)90324-7; MORRISON NA, 1994, NATURE, V367, P284, DOI 10.1038/367284a0; RIGGS BL, 1995, J BONE MINER RES, V10, P991; Sainz J, 1997, NEW ENGL J MED, V337, P77, DOI 10.1056/NEJM199707103370202; SPECTOR TD, 1995, BRIT MED J, V310, P1357, DOI 10.1136/bmj.310.6991.1357; WILLETT WC, 1985, AM J EPIDEMIOL, V122, P51, DOI 10.1093/oxfordjournals.aje.a114086	20	17	17	0	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					752	755		10.7326/0003-4819-131-10-199911160-00006	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00006			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577298				2022-12-28	WOS:000083680100005
J	Hamerton, JL; Stranc, L				Hamerton, JL; Stranc, L			Defining the chromosomal basis of mental handicap	LANCET			English	Editorial Material							TRANSLOCATION; 22Q11; DELETIONS		Univ Manitoba, Fac Med, Dept Biochem & Mol Genet, Winnipeg, MB R3E 0W3, Canada	University of Manitoba	Hamerton, JL (corresponding author), Univ Manitoba, Fac Med, Dept Biochem & Mol Genet, Winnipeg, MB R3E 0W3, Canada.							ALVARADO M, 1993, AM J DIS CHILD, V147, P1291, DOI 10.1001/archpedi.1993.02160360033012; BREG WR, 1972, AM J DIS CHILD, V123, P561, DOI 10.1001/archpedi.1972.02110120085007; BrondumNielsen K, 1997, HUM GENET, V99, P56; CAREY AH, 1992, MAMM GENOME, V3, P101, DOI 10.1007/BF00431253; Devriendt K, 1997, CLIN GENET, V51, P246; Kasprzak L, 1998, AM J MED GENET, V75, P288, DOI 10.1002/(SICI)1096-8628(19980123)75:3<288::AID-AJMG12>3.3.CO;2-S; LAMB J, 1989, LANCET, V2, P819; Raynham H, 1996, QJM-MON J ASSOC PHYS, V89, P169	8	2	2	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1659	1660		10.1016/S0140-6736(99)00246-9	http://dx.doi.org/10.1016/S0140-6736(99)00246-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255CW	10568562				2022-12-28	WOS:000083652800003
J	Hu, X; Lazar, MA				Hu, X; Lazar, MA			The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors	NATURE			English	Article							RETINOID-X-RECEPTOR; PROMYELOCYTIC LEUKEMIA; HISTONE DEACETYLASE; LIGAND-BINDING; CO-REPRESSOR; ACTIVATION; DOMAINS; SPECIFICITY; COMPLEX; BETA	N-CoR1 and SMRT2 are transcriptional corepressors that associate with nuclear hormone receptors (NRs) in the absence of ligand. This interaction is the molecular target of differentiation therapy for acute promyelocytic leukaemia, wherein retinoic acid dissociates corepressor from leukaemogenic receptor fusion pioteins(3,4). Binding of ligand to NRs induces a conformation that attracts coactivator proteins containing an Leu-x-x-Leu-Leu motif (the 'NR box')(5,6). Here we show that N-CoR and SMRT contain sequences that are similar to the NR pox and are repeated in each of two NR interaction domains(7-10). We show that this CoRNR ('corner') box is required for NR interaction, and that CoRNR box peptides specifically block corepressor interaction in vitro and repression in vivo. Sequences flanking the CoRNR box determine NR specificity. Thus, the key feature of hormone action, differential recognition of unliganded and liganded NRs by coactivators and corepressors, is due to very subtle differences between CoRNR and NR boxes. The molecular mechanisms of repression and activation by NRs are thus linked in an unexpected manner.	Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Genet, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Penn Diabet Ctr, Philadelphia, PA 19104 USA	University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Lazar, MA (corresponding author), Univ Penn, Sch Med, Dept Med, Div Endocrinol Diabet & Metab, Philadelphia, PA 19104 USA.		Lazar, Mitchell A/AAF-3738-2019					CHEN JD, 1995, NATURE, V377, P454, DOI 10.1038/377454a0; Cohen RN, 1998, MOL ENDOCRINOL, V12, P1567, DOI 10.1210/me.12.10.1567; Collingwood TN, 1997, J BIOL CHEM, V272, P13060, DOI 10.1074/jbc.272.20.13060; Darimont BD, 1998, GENE DEV, V12, P3343, DOI 10.1101/gad.12.21.3343; Dressel U, 1999, MOL CELL BIOL, V19, P3383; Feng WJ, 1998, SCIENCE, V280, P1747, DOI 10.1126/science.280.5370.1747; Forman BM, 1998, NATURE, V395, P612, DOI 10.1038/26996; Grignani F, 1998, NATURE, V391, P815, DOI 10.1038/35901; Heery DM, 1997, NATURE, V387, P733, DOI 10.1038/42750; HORLEIN AJ, 1995, NATURE, V377, P397, DOI 10.1038/377397a0; LeDouarin B, 1996, EMBO J, V15, P6701, DOI 10.1002/j.1460-2075.1996.tb01060.x; Lin RJ, 1998, NATURE, V391, P811, DOI 10.1038/35895; Mak HY, 1999, MOL CELL BIOL, V19, P3895; McInerney EM, 1998, GENE DEV, V12, P3357, DOI 10.1101/gad.12.21.3357; Moras D, 1998, CURR OPIN CELL BIOL, V10, P384, DOI 10.1016/S0955-0674(98)80015-X; Nolte RT, 1998, NATURE, V395, P137, DOI 10.1038/25931; Onate SA, 1998, J BIOL CHEM, V273, P12101, DOI 10.1074/jbc.273.20.12101; Schulman IG, 1996, MOL CELL BIOL, V16, P3807; Seol W, 1996, MOL ENDOCRINOL, V10, P1646, DOI 10.1210/me.10.12.1646; Shiau AK, 1998, CELL, V95, P927, DOI 10.1016/S0092-8674(00)81717-1; Voegel JJ, 1996, EMBO J, V15, P3667, DOI 10.1002/j.1460-2075.1996.tb00736.x; WAGNER RL, 1995, NATURE, V378, P690, DOI 10.1038/378690a0; Wong CW, 1998, MOL CELL BIOL, V18, P5724, DOI 10.1128/MCB.18.10.5724; Yoh SM, 1997, MOL ENDOCRINOL, V11, P470, DOI 10.1210/me.11.4.470; Zamir I, 1997, P NATL ACAD SCI USA, V94, P14400, DOI 10.1073/pnas.94.26.14400; Zamir I, 1997, GENE DEV, V11, P835, DOI 10.1101/gad.11.7.835; Zamir I, 1996, MOL CELL BIOL, V16, P5458; Zhang JS, 1999, MOL CELL BIOL, V19, P6448; Zhang JS, 1997, MOL CELL BIOL, V17, P6887, DOI 10.1128/MCB.17.12.6887	29	501	510	0	12	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					93	96		10.1038/47069	http://dx.doi.org/10.1038/47069			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573424				2022-12-28	WOS:000083638600050
J	Roper, TA				Roper, TA			Time for a sinister practice	BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	3	3	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1509	1509		10.1136/bmj.319.7223.1509	http://dx.doi.org/10.1136/bmj.319.7223.1509			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582961	Green Published			2022-12-28	WOS:000084129200063
J	Mitchell, JR; Wood, E; Collins, K				Mitchell, JR; Wood, E; Collins, K			A telomerase component is defective in the human disease dyskeratosis congenita	NATURE			English	Article							SMALL NUCLEOLAR RNAS; EPSTEIN-BARR-VIRUS; RIBOSOMAL-RNA; PSEUDOURIDINE SYNTHASE; FIBROBLASTS; PROTEIN; CELLS; CBF5P	The X-linked form of the human disease dyskeratosis congenita (DKC) is caused by mutations in the gene encoding dyskerin(1). Sufferers have defects in highly regenerative tissues such as skin and bone marrow, chromosome instability and a predisposition to develop certain types of malignancy. Dyskerin is a putative pseudouridine synthase, and it has been suggested that DKC may be caused by a defect in ribosomal RNA processing. Here we show that dyskerin is associated not only with H/ACA small nucleolar RNAs2, but also with human telomerase RNA, which contains an H/ACA RNA motif(3). Telomerase adds simple sequence repeats to chromosome ends using an internal region of its RNA as a template(4), and is required for the indefinite proliferation of primary human cells(5). We find that primary fibroblasts and lymphoblasts from DKC-affected males are not detectably deficient in conventional H/ACA small nucleolar RNA accumulation or function; however, DKC cells have a lower level of telomerase RNA, produce lower levels of telomerase activity and have shorter telomeres than matched normal cells. The pathology of DKC is consistent with compromised telomerase function leading to a defect in telomere maintenance, which may limit the proliferative capacity of human somatic cells in epithelia and blood.	Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, Berkeley, CA 94720 USA	University of California System; University of California Berkeley	Mitchell, JR (corresponding author), Univ Calif Berkeley, Dept Mol & Cell Biol, Div Biochem & Mol Biol, 401 Barker Hall, Berkeley, CA 94720 USA.							BAKIN A, 1993, BIOCHEMISTRY-US, V32, P9754, DOI 10.1021/bi00088a030; BRYAN TM, 1995, EMBO J, V14, P4240, DOI 10.1002/j.1460-2075.1995.tb00098.x; Colgin LM, 1999, CURR OPIN GENET DEV, V9, P97, DOI 10.1016/S0959-437X(99)80014-8; COUNTER CM, 1994, J VIROL, V68, P3410, DOI 10.1128/JVI.68.5.3410-3414.1994; Dokal I, 1996, BRIT J HAEMATOL, V92, P775, DOI 10.1046/j.1365-2141.1996.355881.x; DOKAL I, 1992, BLOOD, V80, P3090; DRACHTMAN RA, 1992, AM J PEDIAT HEMATOL, V14, P297; FENG JL, 1995, SCIENCE, V269, P1236, DOI 10.1126/science.7544491; Ganot P, 1997, CELL, V89, P799, DOI 10.1016/S0092-8674(00)80263-9; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; HASTIE ND, 1990, NATURE, V346, P866, DOI 10.1038/346866a0; Heiss NS, 1998, NAT GENET, V19, P32, DOI 10.1038/ng0598-32; KIM NW, 1994, SCIENCE, V266, P2011, DOI 10.1126/science.7605428; Lafontaine DLJ, 1998, GENE DEV, V12, P527, DOI 10.1101/gad.12.4.527; Luzzatto L, 1998, NAT GENET, V19, P6, DOI 10.1038/ng0598-6; MARSH JCW, 1992, BLOOD, V79, P3138; MEIER UT, 1994, J CELL BIOL, V127, P1505, DOI 10.1083/jcb.127.6.1505; Mitchell JR, 1999, MOL CELL BIOL, V19, P567; Ni JW, 1997, CELL, V89, P565, DOI 10.1016/S0092-8674(00)80238-X; Nugent CI, 1998, GENE DEV, V12, P1073, DOI 10.1101/gad.12.8.1073; PROWSE KR, 1995, P NATL ACAD SCI USA, V92, P4818, DOI 10.1073/pnas.92.11.4818; SIRINAVIN C, 1975, J MED GENET, V12, P339, DOI 10.1136/jmg.12.4.339; Tahara H, 1997, ONCOGENE, V15, P1911, DOI 10.1038/sj.onc.1201377; Tollervey D, 1997, CURR OPIN CELL BIOL, V9, P337, DOI 10.1016/S0955-0674(97)80005-1; TROWBRIDGE AA, 1977, AM J HEMATOL, V3, P143, DOI 10.1002/ajh.2830030205; Watkins NJ, 1998, RNA, V4, P1549, DOI 10.1017/S1355838298980761; YU GL, 1990, NATURE, V344, P126, DOI 10.1038/344126a0	27	849	887	0	55	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					551	555		10.1038/990141	http://dx.doi.org/10.1038/990141			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591218				2022-12-28	WOS:000084013200062
J	Malek, AM; Alper, SL; Izumo, S				Malek, AM; Alper, SL; Izumo, S			Hemodynamic shear stress and its role in atherosclerosis	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							HUMAN-ENDOTHELIAL-CELLS; NITRIC-OXIDE SYNTHASE; CORONARY-ARTERY DISEASE; CANINE CAROTID-ARTERY; WHO-ISFC PBDAY; WALL SHEAR; BLOOD-FLOW; IN-VIVO; GENE-EXPRESSION; SMOOTH-MUSCLE	Atherosclerosis, the leading cause of death in the developed world and nearly the leading cause in the developing world, is associated with systemic risk factors including hypertension, smoking, hyperlipidemia, and diabetes mellitus, among others, Nonetheless, atherosclerosis remains a geometrically focal disease, preferentially affecting the outer edges of vessel bifurcations. In these predisposed areas, hemodynamic shear stress, the frictional force acting on the endothelial cell surface as a result of blood flow, is weaker than in protected regions, Studies have identified hemodynamic shear stress as an important determinant of endothelial function and phenotype, Arterial-level shear stress (>15 dyne/cm(2)) induces endothelial quiescence and an atheroprotective gene expression profile, while low shear stress (<4 dyne/cm(2)), which is prevalent at atherosclerosis-prone sites, stimulates an atherogenic phenotype, The functional regulation of the endothelium by local hemodynamic shear stress provides a model for understanding the focal propensity of atherosclerosis in the setting of systemic factors and may help guide future therapeutic strategies.	Brigham & Womens Hosp, Boston, MA 02115 USA; Childrens Hosp, Boston, MA 02115 USA; Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; Harvard Univ, Sch Med, Dept Med, Boston, MA USA; Harvard Univ, Sch Med, Dept Cell Biol, Boston, MA USA; Beth Israel Deaconess Med Ctr, Div Cardiovasc, Boston, MA USA; Beth Israel Deaconess Med Ctr, Mol Med Unit, Boston, MA USA; Beth Israel Deaconess Med Ctr, Renal Unit, Boston, MA USA; Univ Calif San Francisco, Div Intervent Neurovasc Radiol, San Francisco, CA 94143 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Boston Children's Hospital; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Harvard Medical School; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Beth Israel Deaconess Medical Center; University of California System; University of California San Francisco	Malek, AM (corresponding author), Brigham & Womens Hosp, Bader 3,300 Longwood Ave, Boston, MA 02115 USA.	ammalek@bics.bwh.harvard.edu			NHLBI NIH HHS [HL15175] Funding Source: Medline	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Ando J, 1996, BIOCHEM BIOPH RES CO, V225, P347, DOI 10.1006/bbrc.1996.1178; ANDO J, 1994, AM J PHYSIOL, V267, pC679, DOI 10.1152/ajpcell.1994.267.3.C679; ASAKURA T, 1990, CIRC RES, V66, P1045, DOI 10.1161/01.RES.66.4.1045; Aschoff L, 1912, BEITR PATHOL ANAT AL, V52, P0205; BASSIOUNY HS, 1994, J VASC SURG, V19, P426, DOI 10.1016/S0741-5214(94)70069-9; BEERE PA, 1992, ARTERIOSCLER THROMB, V12, P1245, DOI 10.1161/01.ATV.12.11.1245; BenDriss A, 1997, AM J PHYSIOL-HEART C, V272, pH851, DOI 10.1152/ajpheart.1997.272.2.H851; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BERTHIAUME F, 1992, FEBS LETT, V308, P277, DOI 10.1016/0014-5793(92)81292-T; BHARADVAJ BK, 1982, J BIOMECH, V15, P349, DOI 10.1016/0021-9290(82)90057-4; Busse R., 1994, Arzneimittel-Forschung, V44, P392; BUTTERFIELD AB, 1977, ATHEROSCLEROSIS, V26, P215, DOI 10.1016/0021-9150(77)90104-6; CARO CG, 1971, PROC R SOC SER B-BIO, V177, P109, DOI 10.1098/rspb.1971.0019; Chappell DC, 1998, CIRC RES, V82, P532, DOI 10.1161/01.RES.82.5.532; Chien S, 1998, HYPERTENSION, V31, P162, DOI 10.1161/01.HYP.31.1.162; Chiu JJ, 1998, J BIOMECH ENG-T ASME, V120, P2, DOI 10.1115/1.2834303; Cho A, 1997, CIRC RES, V81, P328, DOI 10.1161/01.RES.81.3.328; Chun TH, 1997, HYPERTENSION, V29, P1296, DOI 10.1161/01.HYP.29.6.1296; DAVIES PF, 1995, PHYSIOL REV, V75, P519, DOI 10.1152/physrev.1995.75.3.519; DAVIES PF, 1986, P NATL ACAD SCI USA, V83, P2114, DOI 10.1073/pnas.83.7.2114; De Keulenaer GW, 1998, CIRC RES, V82, P1094, DOI 10.1161/01.RES.82.10.1094; DEGRAAF JC, 1992, CIRCULATION, V85, P2284, DOI 10.1161/01.CIR.85.6.2284; DEPAOLA N, 1992, ARTERIOSCLER THROMB, V12, P1254, DOI 10.1161/01.ATV.12.11.1254; DIAMOND SL, 1989, SCIENCE, V243, P1483, DOI 10.1126/science.2467379; Dimmeler S, 1996, FEBS LETT, V399, P71, DOI 10.1016/S0014-5793(96)01289-6; Fleming I, 1997, J VASC RES, V34, P165, DOI 10.1159/000159220; FRIEDMAN MH, 1993, ATHEROSCLEROSIS, V98, P193, DOI 10.1016/0021-9150(93)90128-H; FRY DL, 1969, CIRC RES, V24, P93, DOI 10.1161/01.RES.24.1.93; Fung Y. C., 1997, BIOMECHANICS CIRCULA; FURCHGOTT RF, 1980, NATURE, V288, P373, DOI 10.1038/288373a0; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARG UC, 1989, J CLIN INVEST, V83, P1774, DOI 10.1172/JCI114081; GIBBONS GH, 1994, NEW ENGL J MED, V330, P1431; GIBSON CM, 1993, ARTERIOSCLER THROMB, V13, P310, DOI 10.1161/01.ATV.13.2.310; GIMBRONE MA, 1995, AM J CARDIOL, V75, pB67, DOI 10.1016/0002-9149(95)80016-L; Girerd X, 1996, HYPERTENSION, V27, P799, DOI 10.1161/01.HYP.27.3.799; Gnasso A, 1997, STROKE, V28, P993, DOI 10.1161/01.STR.28.5.993; Gnasso A, 1996, CIRCULATION, V94, P3257, DOI 10.1161/01.CIR.94.12.3257; Grabowski EF, 1995, J VASC INTERV RADIOL, V6, pS25, DOI 10.1016/S1051-0443(95)71245-3; Guzman RJ, 1997, SURGERY, V122, P273, DOI 10.1016/S0039-6060(97)90018-0; HELMLINGER G, 1995, AM J PHYSIOL-CELL PH, V269, pC367, DOI 10.1152/ajpcell.1995.269.2.C367; HISHIKAWA K, 1995, HYPERTENSION, V25, P449, DOI 10.1161/01.HYP.25.3.449; Howard G, 1998, JAMA-J AM MED ASSOC, V279, P119, DOI 10.1001/jama.279.2.119; Inoue N, 1996, CIRC RES, V79, P32, DOI 10.1161/01.RES.79.1.32; Ishida T, 1997, ANN NY ACAD SCI, V811, P12, DOI 10.1111/j.1749-6632.1997.tb51984.x; Janssens S, 1998, CIRCULATION, V97, P1274, DOI 10.1161/01.CIR.97.13.1274; Jou LD, 1996, MAGN RESON MED, V35, P577, DOI 10.1002/mrm.1910350418; Kaiser D, 1997, BIOCHEM BIOPH RES CO, V231, P586, DOI 10.1006/bbrc.1997.6146; KAMIYA A, 1984, B MATH BIOL, V46, P127, DOI 10.1016/S0092-8240(84)80038-5; KAMIYA A, 1980, AM J PHYSIOL, V239, pH14, DOI 10.1152/ajpheart.1980.239.1.H14; Kawai Y, 1996, BLOOD, V87, P2314, DOI 10.1182/blood.V87.6.2314.bloodjournal8762314; Kerber CW, 1996, AM J NEURORADIOL, V17, P1417; Kingwell BA, 1997, AM J PHYSIOL-HEART C, V272, pH1070, DOI 10.1152/ajpheart.1997.272.3.H1070; KJAERNES M, 1981, ACTA PATH MICRO IM A, V89, P35; Kolpakov V, 1996, ATHEROSCLEROSIS, V122, P173, DOI 10.1016/0021-9150(95)05735-8; Korenaga R, 1997, AM J PHYSIOL-CELL PH, V273, pC1506; Kosaki K, 1998, CIRC RES, V82, P794, DOI 10.1161/01.RES.82.7.794; KRAISS LW, 1991, ARTERIOSCLER THROMB, V11, P1844, DOI 10.1161/01.ATV.11.6.1844; Kraiss LW, 1996, CIRC RES, V79, P45, DOI 10.1161/01.RES.79.1.45; LABARBERA M, 1990, SCIENCE, V249, P992, DOI 10.1126/science.2396104; LANGILLE BL, 1986, SCIENCE, V231, P405, DOI 10.1126/science.3941904; Laurila A, 1997, ARTERIOSCL THROM VAS, V17, P2910, DOI 10.1161/01.ATV.17.11.2910; LEVESQUE MJ, 1990, BIOMATERIALS, V11, P702, DOI 10.1016/0142-9612(90)90031-K; Lynch J, 1997, CIRCULATION, V96, P302; MALEK A, 1992, AM J PHYSIOL, V263, pC389, DOI 10.1152/ajpcell.1992.263.2.C389; MALEK AM, 1994, CIRC RES, V74, P852, DOI 10.1161/01.RES.74.5.852; MALEK AM, 1994, J HYPERTENS, V12, P989; Malek AM, 1995, J BIOMECH, V28, P1515, DOI 10.1016/0021-9290(95)00099-2; Marks DS, 1995, J CLIN INVEST, V96, P2630, DOI 10.1172/JCI118328; Masatsugu K, 1998, J CARDIOVASC PHARM, V31, pS42, DOI 10.1097/00005344-199800001-00014; MASUDA H, 1989, ARTERIOSCLEROSIS, V9, P812, DOI 10.1161/01.ATV.9.6.812; Mattsson EJR, 1997, ARTERIOSCL THROM VAS, V17, P2245, DOI 10.1161/01.ATV.17.10.2245; Mayer-Davis EJ, 1998, JAMA-J AM MED ASSOC, V279, P669, DOI 10.1001/jama.279.9.669; MELKUMYANTS AM, 1989, CARDIOVASC RES, V23, P741, DOI 10.1093/cvr/23.9.741; Mondy JS, 1997, CIRC RES, V81, P320, DOI 10.1161/01.RES.81.3.320; MOTOMIYA M, 1984, STROKE, V15, P50, DOI 10.1161/01.STR.15.1.50; Murata M, 1997, CIRCULATION, V96, P3281; Nadaud S, 1996, CIRC RES, V79, P857, DOI 10.1161/01.RES.79.4.857; Nerem RM, 1998, AM J MED SCI, V316, P169, DOI 10.1097/00000441-199809000-00004; Nicholson AC, 1998, ARTERIOSCL THROM VAS, V18, P339, DOI 10.1161/01.ATV.18.3.339; OHNO M, 1995, J CLIN INVEST, V95, P1363, DOI 10.1172/JCI117787; OKAHARA K, 1995, FEBS LETT, V373, P108, DOI 10.1016/0014-5793(95)01027-C; Okahara K, 1998, ARTERIOSCL THROM VAS, V18, P1922, DOI 10.1161/01.ATV.18.12.1922; Oshinski JN, 1995, JMRI-J MAGN RESON IM, V5, P640; Oyre S, 1997, EUR J VASC ENDOVASC, V13, P263, DOI 10.1016/S1078-5884(97)80097-4; PALMER RMJ, 1988, NATURE, V333, P664, DOI 10.1038/333664a0; Pedersen EM, 1997, EUR J VASC ENDOVASC, V13, P443, DOI 10.1016/S1078-5884(97)80171-2; RANJAN V, 1995, AM J PHYSIOL-HEART C, V269, pH550, DOI 10.1152/ajpheart.1995.269.2.H550; Ravensbergen J, 1998, ARTERIOSCL THROM VAS, V18, P708, DOI 10.1161/01.ATV.18.5.708; RESNICK N, 1993, P NATL ACAD SCI USA, V90, P4591, DOI 10.1073/pnas.90.10.4591; Rieder MJ, 1997, CIRC RES, V80, P312, DOI 10.1161/01.RES.80.3.312; RODBARD S, 1975, CARDIOLOGY, V60, P4, DOI 10.1159/000169701; Ross R, 1999, NEW ENGL J MED, V340, P115, DOI 10.1056/NEJM199901143400207; Rossitti S, 1995, ACTA NEUROCHIR, V137, P138, DOI 10.1007/BF02187185; Rudic RD, 1998, J CLIN INVEST, V101, P731, DOI 10.1172/JCI1699; Ruggeri ZM, 1997, THROMB HAEMOSTASIS, V78, P611; SAWCHUK AP, 1994, J VASC SURG, V19, P58, DOI 10.1016/S0741-5214(94)70120-2; SHAREFKIN JB, 1991, J VASC SURG, V14, P1; SHYY YJ, 1994, P NATL ACAD SCI USA, V91, P4678, DOI 10.1073/pnas.91.11.4678; Sloop GD, 1996, MED HYPOTHESES, V47, P321, DOI 10.1016/S0306-9877(96)90073-0; TANGANELLI P, 1993, ARTERIOSCLER THROMB, V13, P1700, DOI 10.1161/01.ATV.13.11.1700; Topper JN, 1996, P NATL ACAD SCI USA, V93, P10417, DOI 10.1073/pnas.93.19.10417; Traub O, 1998, ARTERIOSCL THROM VAS, V18, P677, DOI 10.1161/01.ATV.18.5.677; Uematsu M, 1995, AM J PHYSIOL-CELL PH, V269, pC1371, DOI 10.1152/ajpcell.1995.269.6.C1371; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P429; WALPOLA PL, 1995, ARTERIOSCL THROM VAS, V15, P2, DOI 10.1161/01.ATV.15.1.2; WALPOLA PL, 1993, AM J PATHOL, V142, P1392; WATERS D, 1995, CIRCULATION, V92, P2404, DOI 10.1161/01.CIR.92.9.2404; WEBER G, 1993, CLIN EXP HYPERTENS, V15, P31; ZAMIR M, 1976, J GEN PHYSIOL, V67, P213, DOI 10.1085/jgp.67.2.213; ZARINS CK, 1987, J VASC SURG, V5, P413, DOI 10.1067/mva.1987.avs0050413; ZARINS CK, 1983, CIRC RES, V53, P502, DOI 10.1161/01.RES.53.4.502; Ziegler T, 1998, ARTERIOSCL THROM VAS, V18, P686, DOI 10.1161/01.ATV.18.5.686	113	2421	2583	18	300	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2035	2042		10.1001/jama.282.21.2035	http://dx.doi.org/10.1001/jama.282.21.2035			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591386				2022-12-28	WOS:000083908700023
J	Norheim, OF				Norheim, OF			Healthcare rationing-are additional criteria needed for assessing evidence based clinical practice guidelines?	BRITISH MEDICAL JOURNAL			English	Article							MEDICAL LITERATURE; USERS GUIDES; PRIORITIES; RECOMMENDATIONS; POLICY		Univ Bergen, Div Gen Practice, N-5009 Bergen, Norway	University of Bergen	Norheim, OF (corresponding author), Univ Bergen, Div Gen Practice, N-5009 Bergen, Norway.		Norheim, Ole Frithjof/AAC-8771-2020	Norheim, Ole Frithjof/0000-0002-5748-5956				CHARLES C, 1993, J HEALTH POLIT POLIC, V18, P881, DOI 10.1215/03616878-18-4-881; Cluzeau F, 1997, APPRAISAL INSTRUMENT; Cohen J., 1989, GOOD POLITY, P17; Conway T, 1997, J COMMUN HEALTH, V22, P57, DOI 10.1023/A:1025198924501; Crisp R, 1996, BRIT MED J, V312, P1528, DOI 10.1136/bmj.312.7045.1528; CRISP R, 1996, BRIT MED J, V312, P1531; Daniels N, 1997, PHILOS PUBLIC AFF, V26, P303, DOI 10.1111/j.1088-4963.1997.tb00082.x; Eddy David M., 1990, JAMA-J AM MED ASSOC, V263, P3081; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P3077, DOI 10.1001/jama.263.22.3077; EDDY DM, 1990, JAMA-J AM MED ASSOC, V263, P2243; Eddy DM., 1990, JAMA-J AM MED ASSOC, V263, P3084; Entwistle VA, 1996, BRIT MED J, V312, P1587, DOI 10.1136/bmj.312.7046.1587; GRIMSHAW JM, 1995, BRIT MED BULL, V51, P927, DOI 10.1093/oxfordjournals.bmb.a073006; GRIMSHAW JM, 1993, LANCET, V342, P1317, DOI 10.1016/0140-6736(93)92244-N; Gutman A., 1996, DEMOCRACY DISAGREEME; Ham C, 1998, BRIT MED J, V316, P1965, DOI 10.1136/bmj.316.7149.1965; HAYWARD RSA, 1995, JAMA-J AM MED ASSOC, V274, P570, DOI 10.1001/jama.274.7.570; KLEIN R, 1993, BRIT MED J, V307, P309, DOI 10.1136/bmj.307.6899.309; Lenaghan J, 1996, BRIT MED J, V312, P1591, DOI 10.1136/bmj.312.7046.1591; NAYLOR CD, 1995, LANCET, V345, P840, DOI 10.1016/S0140-6736(95)92969-X; New B, 1996, BRIT MED J, V312, P1593, DOI 10.1136/bmj.312.7046.1593; PRINGLE M, 1996, EUR J GEN PRACT, V2, P5; Rawls J, 1993, POLITICAL LIBERALISM; Redman S, 1997, AUST NZ J PUBL HEAL, V21, P250, DOI 10.1111/j.1467-842X.1997.tb01695.x; Sackett D. L., 1997, EVIDENCE BASED MED P; Scanlon T. M, 1998, WHAT WE OWE EACH OTH; WILSON MC, 1995, JAMA-J AM MED ASSOC, V274, P1630, DOI 10.1001/jama.274.20.1630	27	55	58	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1426	1429		10.1136/bmj.319.7222.1426	http://dx.doi.org/10.1136/bmj.319.7222.1426			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10574869	Green Published			2022-12-28	WOS:000083995200036
J	Holt, PG; Macaubas, C; Stumbles, PA; Sly, PD				Holt, PG; Macaubas, C; Stumbles, PA; Sly, PD			The role of allergy in the development of asthma	NATURE			English	Review							T-CELL ACTIVATION; DENDRITIC CELLS; ENVIRONMENTAL ALLERGENS; AIRWAY INFLAMMATION; INHALANT ALLERGENS; BRONCHIAL HYPERREACTIVITY; ALVEOLAR MACROPHAGES; DOWN-REGULATION; B-LYMPHOCYTES; NITRIC-OXIDE	Recent studies have shown that initial sensitization to airborne environmental allergens occurs typically in early childhood, but subsequent progression to persistent atopic asthma, which may not manifest for several years, is restricted to only a subset of atopics. The key to establishing the link between atopy and asthma lies in the development of persistent inflammation in the airway wall, resulting in structural and functional changes in local tissues which are responsible for the symptoms of the disease. This review summarizes recent findings on the nature of the cellular and molecular mechanisms underlying this process, and addresses the issue of why the intensity and duration of these tissue-damaging responses in the airway wall apparently exceeds the critical threshold required for development of persistent asthma in only a minority of allergy sufferers.	TVW Telethon Inst Child Hlth Res, Perth, WA 6872, Australia; Univ Western Australia, Dept Microbiol, Perth, WA 6009, Australia; Univ Western Australia, Dept Paediat, Perth, WA 6009, Australia	Telethon Kids Institute; University of Western Australia; University of Western Australia; University of Western Australia	Holt, PG (corresponding author), TVW Telethon Inst Child Hlth Res, POB 855, Perth, WA 6872, Australia.		Study, Raine/K-4517-2013; Sly, Peter D/F-1486-2010; Holt, Patrick G/H-1548-2011	Sly, Peter D/0000-0001-6305-2201; Holt, Patrick G/0000-0003-1193-0935				Armour C, 1997, CLIN EXP PHARMACOL P, V24, P269, DOI 10.1111/j.1440-1681.1997.tb01818.x; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; BARNES PJ, 1990, FREE RADICAL BIO MED, V9, P235, DOI 10.1016/0891-5849(90)90034-G; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Bingisser RM, 1998, J IMMUNOL, V160, P5729; Borish L, 1997, J ALLERGY CLIN IMMUN, V99, P161, DOI 10.1016/S0091-6749(97)70090-3; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; BREWSTER CEP, 1990, AM J RESP CELL MOL, V3, P507, DOI 10.1165/ajrcmb/3.5.507; BYRON KA, 1994, CLIN EXP ALLERGY, V24, P878, DOI 10.1111/j.1365-2222.1994.tb01810.x; COFFMAN RL, 1988, IMMUNOL REV, V102, P5, DOI 10.1111/j.1600-065X.1988.tb00739.x; DICOSMO BF, 1994, J CLIN INVEST, V94, P2028, DOI 10.1172/JCI117556; DUGAS B, 1993, EUR J IMMUNOL, V23, P1687, DOI 10.1002/eji.1830230743; Essayan DM, 1996, J ALLERGY CLIN IMMUN, V98, P1035, DOI 10.1016/S0091-6749(96)80188-6; Foster PS, 1996, J EXP MED, V183, P195, DOI 10.1084/jem.183.1.195; GALLI SJ, 1995, ALLERGY, V50, P851, DOI 10.1111/j.1398-9995.1995.tb02490.x; Gizycki MJ, 1997, AM J RESP CELL MOL, V16, P664, DOI 10.1165/ajrcmb.16.6.9191468; Godthelp T, 1996, CLIN EXP ALLERGY, V26, P677, DOI 10.1046/j.1365-2222.1996.1072451.x; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; HANTOS Z, 1995, J APPL PHYSIOL, V79, P1440, DOI 10.1152/jappl.1995.79.5.1440; Hogan SP, 1998, AM J RESP CRIT CARE, V157, P210, DOI 10.1164/ajrccm.157.1.9702074; Holgate ST, 1998, CLIN EXP ALLERGY, V28, P97; HOLT PG, 1992, CLIN EXP ALLERGY, V22, P1093, DOI 10.1111/j.1365-2222.1992.tb00135.x; Holt PG, 1997, CURR OPIN IMMUNOL, V9, P782, DOI 10.1016/S0952-7915(97)80178-1; Holt PG, 1997, PEDIATR ALLERGY IMMU, V8, P53, DOI 10.1111/j.1399-3038.1997.tb00145.x; HOLT PG, 1993, J EXP MED, V177, P397, DOI 10.1084/jem.177.2.397; HOLT PG, 1995, PEDIATR ALLERGY IMMU, V6, P85, DOI 10.1111/j.1399-3038.1995.tb00264.x; HOLT PG, 1995, PEDIAT ALLERG IMM-UK, V6, P1, DOI 10.1111/j.1399-3038.1995.tb00250.x; Johnston SL, 1998, ALLERGY, V53, P922, DOI 10.1111/j.1398-9995.1998.tb03792.x; Johnston SL, 1996, AM J RESP CRIT CARE, V154, P654, DOI 10.1164/ajrccm.154.3.8810601; Kay AB, 1997, ALLERGY ALLERGIC DIS, P23; Knight DA, 1999, AM J RESP CELL MOL, V20, P834, DOI 10.1165/ajrcmb.20.4.3429; Kraft M, 1996, AM J RESP CRIT CARE, V154, P1505, DOI 10.1164/ajrccm.154.5.8912772; KUNG TT, 1995, AM J RESP CELL MOL, V12, P404, DOI 10.1165/ajrcmb.12.4.7695919; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; LANDAU LI, 1999, PEDIAT RESP MED, P935; Lee JS, 1997, J FOOD DRUG ANAL, V5, P185; LIEW FY, 1995, CURR OPIN IMMUNOL, V7, P396, DOI 10.1016/0952-7915(95)80116-2; Macaubas C, 1999, CLIN EXP ALLERGY, V29, P1223; MACKLEM PT, 1985, CHEST, V87, pS158, DOI 10.1378/chest.87.5_Supplement.158S; MAESTRELLI P, 1995, AM J RESP CRIT CARE, V151, P607; MARTINEZ FD, 1994, THORAX, V49, P1189, DOI 10.1136/thx.49.12.1189; Michel O, 1997, AM J RESP CRIT CARE, V156, P1157, DOI 10.1164/ajrccm.156.4.97-02002; Mishima H, 1998, AM J RESP CRIT CARE, V158, P1863, DOI 10.1164/ajrccm.158.6.9709123; Moller GM, 1996, CLIN EXP ALLERGY, V26, P517, DOI 10.1111/j.1365-2222.1996.tb00571.x; OByrne PM, 1997, CHEST, V111, pS27, DOI 10.1378/chest.111.2_Supplement.27S; OHURI T, 1992, AM REV RESPIR DIS, V146, P1501; Peat JK, 1996, AM J RESP CRIT CARE, V153, P141, DOI 10.1164/ajrccm.153.1.8542107; PETITFRERE C, 1993, IMMUNOLOGY, V79, P146; POSTON RN, 1992, AM REV RESPIR DIS, V145, P918, DOI 10.1164/ajrccm/145.4_Pt_1.918; POULTER LW, 1994, IMMUNOL TODAY, V15, P258, DOI 10.1016/0167-5699(94)90004-3; Prescott SL, 1999, LANCET, V353, P196, DOI 10.1016/S0140-6736(98)05104-6; Prescott SL, 1998, J IMMUNOL, V160, P4730; RENZ H, 1993, J IMMUNOL, V151, P1907; ROMAGNANI S, 1991, IMMUNOL TODAY, V12, P256, DOI 10.1016/0167-5699(91)90120-I; Rott LS, 1997, J CLIN INVEST, V100, P1204, DOI 10.1172/JCI119633; Sly PD, 1996, AM J RESP CRIT CARE, V154, P161, DOI 10.1164/ajrccm.154.1.8680673; SLY PD, 1991, J APPL PHYSIOL, V71, P886, DOI 10.1152/jappl.1991.71.3.886; STRACHAN DP, 1989, BRIT MED J, V299, P1259, DOI 10.1136/bmj.299.6710.1259; Strickland D, 1996, IMMUNOLOGY, V87, P250, DOI 10.1046/j.1365-2567.1996.459542.x; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; Tang WL, 1996, J CLIN INVEST, V98, P2845, DOI 10.1172/JCI119113; TunonDeLara JM, 1996, CLIN EXP ALLERGY, V26, P648, DOI 10.1046/j.1365-2222.1996.1095481.x; vonMutius E, 1996, THORAX, V51, pS3, DOI 10.1136/thx.51.Suppl_1.S3; WEGMANN TG, 1993, IMMUNOL TODAY, V14, P353, DOI 10.1016/0167-5699(93)90235-D; WERSHIL BK, 1991, J CLIN INVEST, V87, P446, DOI 10.1172/JCI115016; WIERENGA EA, 1990, J IMMUNOL, V144, P4651; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Woolcock AJ, 1995, ALLERGY, V50, P935, DOI 10.1111/j.1398-9995.1995.tb02504.x; Yabuhara A, 1997, CLIN EXP ALLERGY, V27, P1261, DOI 10.1111/j.1365-2222.1997.tb01170.x; Ying S, 1997, J IMMUNOL, V158, P3539; Zhang SL, 1999, LAB INVEST, V79, P395	71	360	369	1	15	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760		S			B12	B17						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586890				2022-12-28	WOS:000083913900004
J	Friedman, CP; Elstein, AS; Wolf, FM; Murphy, GC; Franz, TM; Heckerling, PS; Fine, PL; Miller, TM; Abraham, V				Friedman, CP; Elstein, AS; Wolf, FM; Murphy, GC; Franz, TM; Heckerling, PS; Fine, PL; Miller, TM; Abraham, V			Enhancement of clinicians' diagnostic reasoning by computer-based consultation - A multisite study of 2 systems	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							DECISION-SUPPORT SYSTEMS; PERFORMANCE; MEDICINE; SERVICE	Context Computer-based diagnostic decision support systems (DSSs) were developed to improve health care quality by providing accurate, useful, and timely diagnostic information to clinicians. However, most studies have emphasized the accuracy of the computer system alone, without placing clinicians in the role of direct users. Objective To explore the extent to which consultations with DSSs improve clinicians' diagnostic hypotheses in a set of diagnostically challenging cases. Design Partially randomized controlled trial conducted in a laboratory setting, using a prospective balanced experimental design in 1995-1998, Setting Three academic medical centers, none of which were involved in the development of the DSSs, Participants A total of 216 physicians: 72 at each site, including 24 internal medicine faculty members, 24 senior residents, and 24 fourth-year medical students. One physician's data were lost to analysis. Intervention Two DSSs, ILIAD (version 4.2) and Quick Medical Reference (QMR; version 3.7.1), were used by participants for diagnostic evaluation of a total of 36 cases based on actual patients. After training, each subject evaluated 9 of the 36 cases, first without and then using a DSS, and suggested an ordered list of diagnostic hypotheses after each evaluation. Main Outcome Measure Diagnostic accuracy, measured as the presence of the correct diagnosis on the hypothesis list and also using a derived diagnostic quality score, before and after consultation with the DSSs. Results Correct diagnoses appeared in subjects' hypothesis lists for 39.5% of cases prior to consultation and 45.4% of cases after consultation. Subjects' mean diagnostic quality scores increased from 5.7 (95% confidence interval [CI], 5.5-5.9) to 6.1 (95% CI, 5.9-6.3) (effect size: Cohen d = 0.32; 95% CI, 0.23-0.41; P<.001). Larger increases (P = .048) were observed for students than for residents and faculty. Effect size varied significantly (P<.02) by DSS (Cohen d = 0.20; 95% CI, 0.08-0.32 for ILIAD vs Cohen d = 0.45; 95% CI, 0.31-0.59 for QMR). Conclusions Our study supports the idea that "hands-on" use of diagnostic DSSs can influence diagnostic reasoning of clinicians. The larger effect for students suggests a possible educational role for these systems.	Univ Pittsburgh, Ctr Biomed Informat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Dept Med, Pittsburgh, PA 15213 USA; Univ Illinois, Dept Med Educ, Chicago, IL USA; Univ Illinois, Dept Med, Chicago, IL USA; Univ Washington, Dept Med Educ, Div Med Informat, Seattle, WA 98195 USA; Univ N Carolina, Dept Nutr, Chapel Hill, NC USA; Univ N Carolina, Dept Med, Chapel Hill, NC USA; Indiana Univ, Dept Psychol, South Bend, IN 46615 USA; Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Washington; University of Washington Seattle; University of North Carolina; University of North Carolina Chapel Hill; University of North Carolina; University of North Carolina Chapel Hill; Indiana University System; Indiana University South Bend; University of Michigan System; University of Michigan	Friedman, CP (corresponding author), Univ Pittsburgh, Ctr Biomed Informat, 8084 Forbes Tower,200 Lothrop St, Pittsburgh, PA 15213 USA.	cpf@cbmi.upmc.edu	Elstein, Arthur/AAI-9222-2020		NATIONAL LIBRARY OF MEDICINE [R01LM005630] Funding Source: NIH RePORTER	NATIONAL LIBRARY OF MEDICINE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM))		*APPL MED INF, 1994, ILIAD 4 2 US MAN; Bankowitz R. A., 1987, Proceedings of the Eleventh Annual Symposium on Computer Applications in Medical Care (Cat. No.87CH2446-3), P68; BANKOWITZ RA, 1989, METHOD INFORM MED, V28, P352; BANKOWITZ RA, 1989, ANN INTERN MED, V110, P824, DOI 10.7326/0003-4819-110-10-824; Barnett G. O., 1987, Proceedings of the Eleventh Annual Symposium on Computer Applications in Medical Care (Cat. No.87CH2446-3), P150; BARNETT GO, 1987, JAMA-J AM MED ASSOC, V258, P67, DOI 10.1001/jama.258.1.67; BERNER ES, 1994, NEW ENGL J MED, V330, P1792, DOI 10.1056/NEJM199406233302506; Cohen J., 2013, STAT POWER ANAL BEHA, DOI DOI 10.4324/9780203771587; Detmer WM, 1997, J AM MED INFORM ASSN, P490; Elhanan G, 1996, Proc AMIA Annu Fall Symp, P348; Elstein AS, 1996, J AM MED INFORM ASSN, V3, P422, DOI 10.1136/jamia.1996.97084515; Fleiss JL., 1986, DESIGN ANAL CLIN EXP, DOI [10.1002/9781118032923.ch1, DOI 10.1002/9781118032923.CH1, DOI 10.1002/9781118032923]; FRIEDMAN C, 1998, P 9 WORLD C MED INF, P864; Friedman C.P., 1997, EVALUATION METHODS M, P41; GOZUM ME, 1994, J AM MED INFORM ASSN, P991; Hammersley J. R., 1988, Proceedings. The Twelfth Annual Symposium on Computer Applications in Medical Care (IEEE Cat. No.88CH2616-1), P229; JOHNSTON ME, 1994, ANN INTERN MED, V120, P135, DOI 10.7326/0003-4819-120-2-199401150-00007; KASSIRER JP, 1994, NEW ENGL J MED, V330, P1824, DOI 10.1056/NEJM199406233302512; MILLER R, 1986, M D COMPUT, V3, P34; MILLER RA, 1990, METHOD INFORM MED, V29, P1; MILLER RA, 1982, NEW ENGL J MED, V307, P468, DOI 10.1056/NEJM198208193070803; MILLER RA, 1986, WESTERN J MED, V145, P816; MILLER RA, 1994, J AM MED INFORM ASSN, V1, P8, DOI 10.1136/jamia.1994.95236141; MYERS D, 1987, HIST MED INF P BETH, P195; NELSON S J, 1985, Journal of Medical Systems, V9, P379, DOI 10.1007/BF00992575; NORUSIS MJ, 1998, SPSS 8 0 GUIDE DATA; RUBECK RF, 1989, TEACH LEARN MED, V1, P221; Shea S, 1996, J AM MED INFORM ASSN, V3, P399, DOI 10.1136/jamia.1996.97084513; Warner H. R., 1988, Proceedings. The Twelfth Annual Symposium on Computer Applications in Medical Care (IEEE Cat. No.88CH2616-1), P371; WARNER HR, 1989, METHOD INFORM MED, V28, P370; YU H, 1988, P 12 ANN S COMP APPL, P126	31	125	130	0	8	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1851	1856		10.1001/jama.282.19.1851	http://dx.doi.org/10.1001/jama.282.19.1851			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	254MD	10573277				2022-12-28	WOS:000083615700029
J	Fetscher, S				Fetscher, S			An entirely benign disorder	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Univ Freiburg, Med Ctr, Dept Hematol & Oncol, D-79106 Freiburg, Germany	University of Freiburg	Fetscher, S (corresponding author), Univ Freiburg, Med Ctr, Dept Hematol & Oncol, Hugstetter Str 55, D-79106 Freiburg, Germany.	fetscher@mml1.ukl.uni-freiburg.de							0	1	1	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					786	788		10.7326/0003-4819-131-10-199911160-00014	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00014			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577305				2022-12-28	WOS:000083680100012
J	Quinn, N				Quinn, N			Progress in functional neurosurgery for Parkinson's disease	LANCET			English	Editorial Material							SUBTHALAMIC NUCLEUS; GPI PALLIDOTOMY; STIMULATION		Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England	University of London; University College London	Quinn, N (corresponding author), Inst Neurol, Dept Clin Neurol, Queen Sq, London WC1N 3BG, England.							Baron MS, 1996, ANN NEUROL, V40, P355, DOI 10.1002/ana.410400305; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; DOGALI M, 1995, NEUROLOGY, V45, P753, DOI 10.1212/WNL.45.4.753; Gill SS, 1997, LANCET, V350, P1224, DOI 10.1016/S0140-6736(05)63455-1; Gonzalez LA, 1999, ANN NEUROL, V46, P492; Hammerstad J, 1999, NEUROLOGY, V52, pA271; Krack P, 1998, BRAIN, V121, P451, DOI 10.1093/brain/121.3.451; Kumar R, 1998, NEUROLOGY, V51, P850, DOI 10.1212/WNL.51.3.850; LAITINEN LV, 1992, J NEUROSURG, V76, P53, DOI 10.3171/jns.1992.76.1.0053; LIMOUSIN P, 1995, LANCET, V345, P91, DOI 10.1016/S0140-6736(95)90062-4; LOZANO AM, 1995, LANCET, V346, P1383, DOI 10.1016/S0140-6736(95)92404-3; Merello M, 1999, MOVEMENT DISORD, V14, P50, DOI 10.1002/1531-8257(199901)14:1<50::AID-MDS1010>3.3.CO;2-Y; Samuel M, 1998, BRAIN, V121, P59, DOI 10.1093/brain/121.1.59; Scott R, 1998, BRAIN, V121, P659, DOI 10.1093/brain/121.4.659; Vitek JL, 1998, NEUROLOGY, V50, pA80	15	9	9	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1658	1659		10.1016/S0140-6736(99)00292-5	http://dx.doi.org/10.1016/S0140-6736(99)00292-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568561				2022-12-28	WOS:000083652800002
J	Wills, A				Wills, A			Herophilus, Evasistratus, and the birth of neuroscience	LANCET			English	Article									Univ Nottingham Hosp, Queens Med Ctr, Dept Neurol, Neurosci Directorate, Nottingham NG7 2UH, England	University of Nottingham	Wills, A (corresponding author), Univ Nottingham Hosp, Queens Med Ctr, Dept Neurol, Neurosci Directorate, Nottingham NG7 2UH, England.							[Anonymous], 1996, HUMAN BRAIN SPINAL C; CONRAD LI, 1996, W MED TRADITION; DOBSON JF, 1925, P ROY SOC MED, V1, P19; Tieleman T, 1995, Clio Med, V28, P487; von Staden H. Herophilus, 1989, ART MED EARLY ALEXAN	5	26	28	1	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1719	1720		10.1016/S0140-6736(99)02081-4	http://dx.doi.org/10.1016/S0140-6736(99)02081-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568587				2022-12-28	WOS:000083652800041
J	Kim, L; Liu, JC; Kimmel, AR				Kim, L; Liu, JC; Kimmel, AR			The novel tyrosine kinase ZAK1 activates GSK3 to direct cell fate specification	CELL			English	Article							GLYCOGEN-SYNTHASE KINASE-3; PROTEIN-KINASES; DICTYOSTELIUM-DISCOIDEUM; AXIS SPECIFICATION; RECEPTOR; XENOPUS; PHOSPHORYLATION; IDENTIFICATION; DIFFERENTIATION; CLASSIFICATION	Inhibition of GSK3 by 7-TM Wnt/wg receptor signaling is critical for specifying embryonic cell fate patterns. In Dictyostelium, the 7-TM cAMP receptors regulate GSK3 by parallel, antagonistic pathways to establish a developmental body plan. We describe here a novel tyrosine kinase, ZAK1, downstream of 7-TM cAMP receptor signaling that is required for GSK3 activation during development, zak1-nulls have reduced GSK3 activity and are defective in GSK3-regulated developmental pathways. Moreover, recombinant ZAK1 phosphorylates and activates GSK3 in vitro. We propose that ZAK1 is a positive regulator of GSK3 activity required for cell pattern formation in Dictyostelium and speculate that similar mechanisms exist to antagonize Wnt/wg signaling for metazoan cell fate specification.	NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Kimmel, AR (corresponding author), NIDDKD, Cellular & Dev Biol Lab, NIH, Bethesda, MD 20892 USA.	ark1@helix.nih.gov			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [Z01DK015503] Funding Source: NIH RePORTER	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		Adams Douglas, 1979, HITCHHIKERS GUIDE GA; Adler K, 1996, FEBS LETT, V395, P286, DOI 10.1016/0014-5793(96)01053-8; Ali MS, 1997, J BIOL CHEM, V272, P23382, DOI 10.1074/jbc.272.37.23382; Baldauf SL, 1997, P NATL ACAD SCI USA, V94, P12007, DOI 10.1073/pnas.94.22.12007; Brannon M, 1997, GENE DEV, V11, P2359, DOI 10.1101/gad.11.18.2359; Clevers H, 1997, TRENDS GENET, V13, P485, DOI 10.1016/S0168-9525(97)01305-X; COOPER JA, 1981, MOL CELL BIOL, V1, P394, DOI 10.1128/MCB.1.5.394; Darnell JE, 1997, P NATL ACAD SCI USA, V94, P11767, DOI 10.1073/pnas.94.22.11767; Ginsburg GT, 1997, GENE DEV, V11, P2112, DOI 10.1101/gad.11.16.2112; Girault JA, 1999, TRENDS BIOCHEM SCI, V24, P54, DOI 10.1016/S0968-0004(98)01331-0; GuilletDeniau I, 1997, J BIOL CHEM, V272, P14825, DOI 10.1074/jbc.272.23.14825; HANKS SK, 1995, FASEB J, V9, P576, DOI 10.1096/fasebj.9.8.7768349; HARWOOD AJ, 1995, CELL, V80, P139, DOI 10.1016/0092-8674(95)90458-1; He TC, 1998, SCIENCE, V281, P1509, DOI 10.1126/science.281.5382.1509; HE X, 1995, NATURE, V374, P617, DOI 10.1038/374617a0; HUGHES K, 1993, EMBO J, V12, P803, DOI 10.1002/j.1460-2075.1993.tb05715.x; Hunter T, 1997, TRENDS BIOCHEM SCI, V22, P18, DOI 10.1016/S0968-0004(96)10068-2; Jin T, 1998, EMBO J, V17, P5076, DOI 10.1093/emboj/17.17.5076; Johnson LN, 1996, CELL, V85, P149, DOI 10.1016/S0092-8674(00)81092-2; JOHNSON RL, 1993, GENE DEV, V7, P273, DOI 10.1101/gad.7.2.273; KAY RR, 1987, METHOD CELL BIOL, V28, P433; KIM L, 1995, MOL CELL BIOL, V15, P4553; Leonard WJ, 1998, ANNU REV IMMUNOL, V16, P293, DOI 10.1146/annurev.immunol.16.1.293; LOUIS JM, 1994, GENE DEV, V8, P2086, DOI 10.1101/gad.8.17.2086; Luo H, 1997, MOL CELL BIOL, V17, P1562, DOI 10.1128/MCB.17.3.1562; Moon RT, 1998, BIOESSAYS, V20, P536, DOI 10.1002/(SICI)1521-1878(199807)20:7<536::AID-BIES4>3.3.CO;2-U; Nusse R, 1999, TRENDS GENET, V15, P1, DOI 10.1016/S0168-9525(98)01634-5; Plyte SE, 1999, DEVELOPMENT, V126, P325; RESH MD, 1994, CELL, V76, P411, DOI 10.1016/0092-8674(94)90104-X; RICHARDSON DL, 1994, DEVELOPMENT, V120, P2891; ROGERS KC, 1997, DICTYOSTELIUM MODEL, P163; Roose J, 1998, NATURE, V395, P608, DOI 10.1038/26989; SAXE CL, 1993, GENE DEV, V7, P262, DOI 10.1101/gad.7.2.262; Shulman JM, 1998, TRENDS GENET, V14, P452, DOI 10.1016/S0168-9525(98)01584-4; TAYLOR SS, 1995, FASEB J, V9, P1255, DOI 10.1096/fasebj.9.13.7557015; Torres MA, 1996, J CELL BIOL, V133, P1123, DOI 10.1083/jcb.133.5.1123; Verkerke-Van Wijk I, 1998, MOL CELL BIOL, V18, P5744, DOI 10.1128/MCB.18.10.5744; WANG QM, 1994, J BIOL CHEM, V269, P14566	38	136	141	0	3	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					399	408		10.1016/S0092-8674(00)81526-3	http://dx.doi.org/10.1016/S0092-8674(00)81526-3			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571182	Bronze			2022-12-28	WOS:000083709300007
J	Melchers, F; Rolink, AG; Schaniel, C				Melchers, F; Rolink, AG; Schaniel, C			The role of chemokines in regulating cell migration during humoral immune responses	CELL			English	Review							CHEMOTAXIS; RECEPTOR		Basel Inst Immunol, CH-4005 Basel, Switzerland		Melchers, F (corresponding author), Basel Inst Immunol, Grenzacherstr 487, CH-4005 Basel, Switzerland.		Schaniel, Christoph/P-3836-2019; Schaniel, Chrisoph/C-9655-2012	Schaniel, Christoph/0000-0002-1343-4858; 				Ansel KM, 1999, J EXP MED, V190, P1123, DOI 10.1084/jem.190.8.1123; Butcher EC, 1999, ADV IMMUNOL, V72, P209, DOI 10.1016/S0065-2776(08)60022-X; Campbell JJ, 1999, J IMMUNOL, V163, P2353; Forster R, 1999, CELL, V99, P23, DOI 10.1016/S0092-8674(00)80059-8; Forster R, 1996, CELL, V87, P1037, DOI 10.1016/S0092-8674(00)81798-5; Foxman EF, 1997, J CELL BIOL, V139, P1349, DOI 10.1083/jcb.139.5.1349; Gunn MD, 1999, J EXP MED, V189, P451, DOI 10.1084/jem.189.3.451; Gunn MD, 1998, P NATL ACAD SCI USA, V95, P258, DOI 10.1073/pnas.95.1.258; Ma Q, 1999, IMMUNITY, V10, P463, DOI 10.1016/S1074-7613(00)80046-1; Melchers F, 1999, FUNDAMENTAL IMMUNOLO, V4th, P183; Ngo VN, 1999, J EXP MED, V189, P403, DOI 10.1084/jem.189.2.403; Sallusto F, 1998, EUR J IMMUNOL, V28, P2760, DOI 10.1002/(SICI)1521-4141(199809)28:09<2760::AID-IMMU2760>3.0.CO;2-N; Schaniel C, 1999, EUR J IMMUNOL, V29, P2934, DOI 10.1002/(SICI)1521-4141(199909)29:09<2934::AID-IMMU2934>3.3.CO;2-H; SPRINGER TA, 1994, CELL, V76, P310; Zlotnik A, 1999, CRIT REV IMMUNOL, V19, P1	15	104	108	0	6	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					351	354		10.1016/S0092-8674(00)81521-4	http://dx.doi.org/10.1016/S0092-8674(00)81521-4			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571177	Bronze			2022-12-28	WOS:000083709300002
J	Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA				Wang, YX; Neamati, N; Jacob, J; Palmer, I; Stahl, SJ; Kaufman, JD; Huang, PL; Huang, PL; Winslow, HE; Pommier, Y; Wingfield, PT; Lee-Huang, S; Bax, A; Torchia, DA			Solution structure of anti-HIV-1 and anti-tumor protein MAP30: Structural insights into its multiple functions	CELL			English	Article							RIBOSOME-INACTIVATING PROTEINS; POKEWEED ANTIVIRAL PROTEIN; ADENOSINE GLYCOSIDASE ACTIVITY; RICIN A-CHAIN; CRYSTAL-STRUCTURE; STAPHYLOCOCCAL NUCLEASE; BACKBONE DYNAMICS; STRANDED-DNA; J-COUPLINGS; NMR	We present the solution structure of MAP30, a plant protein with anti-HIV and anti-tumor activities. Structural analysis and subsequent biochemical assays lead to several novel discoveries. First, MAP30 acts like a DNA glycosylase/apurinic (ap) lyase, an additional activity distinct from its known RNA N-glycosidase activity toward the 28S rRNA. Glycosylase/ap lyase activity explains MAP30's apparent inhibition of the HIV-1 integrase, MAP30's ability to irreversibly relax supercoiled DNA, and may be an alternative cytotoxic pathway that contributes to MAP30's anti-HIV/anti-tumor activities. Second, two distinct, but contiguous, subsites are responsible for MAP30's glycosylase/ap lyase activity. Third, Mn2+ and Zn2+ interact with negatively charged surfaces next to the catalytic sites, facilitating DNA substrate binding instead of directly participating in catalysis.	NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA; Natl Inst Dent & Craniofacial Res, Mol Struct Biol Lab, NIH, Bethesda, MD 20892 USA; NIAMSD, Prot Express Lab, NIH, Bethesda, MD 20892 USA; Amer BioSci, New York, NY 10021 USA; Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA; Harvard Univ, Sch Med, Boston, MA 02114 USA; NYU, Sch Med, Dept Biochem, New York, NY 10016 USA; NIDDKD, Chem Phys Lab, NIH, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Institute of Dental & Craniofacial Research (NIDCR); National Institutes of Health (NIH) - USA; NIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS); Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School; New York University; National Institutes of Health (NIH) - USA; NIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)	Lee-Huang, S (corresponding author), NCI, Mol Pharmacol Lab, NIH, Bethesda, MD 20892 USA.			Huang, Paul/0000-0002-5436-8658; Lee-Huang, Sylvia/0000-0003-3302-241X; Wingfield, Paul/0000-0002-9515-4752	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031343] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [ZIAAR041115, Z01AR041115] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH [Z01DE000687] Funding Source: NIH RePORTER; NIAID NIH HHS [R01 AI-31343] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF DENTAL &CRANIOFACIAL RESEARCH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARCHER SJ, 1991, J MAGN RESON, V95, P636, DOI 10.1016/0022-2364(91)90182-S; Barbieri L, 1997, NUCLEIC ACIDS RES, V25, P518, DOI 10.1093/nar/25.3.518; Barbieri L, 1996, BIOCHEM J, V319, P507, DOI 10.1042/bj3190507; BARBIERI L, 1993, BIOCHIM BIOPHYS ACTA, V1154, P237, DOI 10.1016/0304-4157(93)90002-6; BEHMOARAS T, 1981, NATURE, V292, P858, DOI 10.1038/292858a0; Clore GM, 1998, J MAGN RESON, V133, P216, DOI 10.1006/jmre.1998.1419; Cornilescu G, 1999, J BIOMOL NMR, V13, P289, DOI 10.1023/A:1008392405740; Day PJ, 1998, EUR J BIOCHEM, V258, P540, DOI 10.1046/j.1432-1327.1998.2580540.x; Garrett DS, 1997, BIOCHEMISTRY-US, V36, P2517, DOI 10.1021/bi962924y; GRZESIEK S, 1993, J BIOMOL NMR, V3, P627; GRZESIEK S, 1995, J AM CHEM SOC, V117, P5312, DOI 10.1021/ja00124a014; GRZESIEK S, 1995, J AM CHEM SOC, V117, P9594, DOI 10.1021/ja00142a040; HUANG PL, 1992, BIOFACTORS, V4, P37; HUSAIN J, 1994, FEBS LETT, V342, P154, DOI 10.1016/0014-5793(94)80491-5; IRVIN JD, 1992, PHARMACOL THERAPEUT, V55, P279, DOI 10.1016/0163-7258(92)90053-3; Jones S, 1999, J MOL BIOL, V287, P877, DOI 10.1006/jmbi.1999.2659; KAY LE, 1989, BIOCHEMISTRY-US, V28, P8972, DOI 10.1021/bi00449a003; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kuszewski J, 1997, J MAGN RESON, V125, P171, DOI 10.1006/jmre.1997.1116; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; LEEHUANG S, 1991, FEBS LETT, V291, P139, DOI 10.1016/0014-5793(91)81122-O; LEEHUANG S, 1995, GENE, V161, P151, DOI 10.1016/0378-1119(95)00186-A; LEEHUANG S, 1990, FEBS LETT, V272, P12, DOI 10.1016/0014-5793(90)80438-O; LEEHUANG S, 1995, P NATL ACAD SCI USA, V92, P8818, DOI 10.1073/pnas.92.19.8818; LI MX, 1991, NUCLEIC ACIDS RES, V19, P6309, DOI 10.1093/nar/19.22.6309; LING J, 1994, FEBS LETT, V345, P143, DOI 10.1016/0014-5793(94)00421-8; Mazumder A, 1996, J BIOL CHEM, V271, P27330, DOI 10.1074/jbc.271.44.27330; MAZUMDER A, 1995, NUCLEIC ACIDS RES, V23, P3865; MCGRATH MS, 1989, P NATL ACAD SCI USA, V86, P2844, DOI 10.1073/pnas.86.8.2844; MLSNA D, 1993, PROTEIN SCI, V2, P429; MONTFORT W, 1987, J BIOL CHEM, V262, P5398; MONZINGO AF, 1993, J MOL BIOL, V233, P705, DOI 10.1006/jmbi.1993.1547; MONZINGO AF, 1992, J MOL BIOL, V227, P1136, DOI 10.1016/0022-2836(92)90526-P; Neamati N, 1998, J MED CHEM, V41, P3202, DOI 10.1021/jm9801760; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Nicolas E, 1998, J BIOL CHEM, V273, P17216, DOI 10.1074/jbc.273.27.17216; Nicolas E, 1997, BIOCHEM J, V327, P413, DOI 10.1042/bj3270413; NILGES M, 1988, FEBS LETT, V239, P129, DOI 10.1016/0014-5793(88)80559-3; Ottiger M, 1999, J BIOMOL NMR, V13, P187, DOI 10.1023/A:1008395916985; Roncuzzi L, 1996, FEBS LETT, V392, P16, DOI 10.1016/0014-5793(96)00776-4; Sawa R., 1995, NATURE, V373, P487; Slupphaug G, 1996, NATURE, V384, P87, DOI 10.1038/384087a0; Stein EG, 1997, J MAGN RESON, V124, P154, DOI 10.1006/jmre.1996.1027; SUN B, 1995, J BIOL CHEM, V270, P19501, DOI 10.1074/jbc.270.33.19501; SZEWCZAK AA, 1993, P NATL ACAD SCI USA, V90, P9581, DOI 10.1073/pnas.90.20.9581; THAYER MM, 1995, EMBO J, V14, P4108, DOI 10.1002/j.1460-2075.1995.tb00083.x; Tjandra N, 1997, SCIENCE, V278, P1111, DOI 10.1126/science.278.5340.1111; Tjandra N, 1997, NAT STRUCT BIOL, V4, P443, DOI 10.1038/nsb0697-443; Tjandra N, 1996, J AM CHEM SOC, V118, P6986, DOI 10.1021/ja960510m; Tumer NE, 1997, P NATL ACAD SCI USA, V94, P3866, DOI 10.1073/pnas.94.8.3866; Tumer NE, 1998, J VIROL, V72, P1036, DOI 10.1128/JVI.72.2.1036-1042.1998; VASSYLYEV DG, 1995, CELL, V83, P773, DOI 10.1016/0092-8674(95)90190-6; VUISTER GW, 1993, J MAGN RESON SER B, V101, P210, DOI 10.1006/jmrb.1993.1035; VUISTER GW, 1994, J BIOMOL NMR, V4, P193; Wang P, 1999, NUCLEIC ACIDS RES, V27, P1900, DOI 10.1093/nar/27.8.1900; Wang YX, 1998, J AM CHEM SOC, V120, P7385, DOI 10.1021/ja980862o; Wang YX, 1999, J BIOMOL NMR, V14, P181, DOI 10.1023/A:1008346517302; WANG YX, 1999, IN PRESS PROTEIN SCI; WISHART DS, 1994, METHOD ENZYMOL, V239, P363; Wuthrich K., 1986, NMR PROTEINS NUCL AC; Xiong JP, 1997, CHINESE J CHEM, V15, P265; Yamazaki T, 1996, PROTEIN SCI, V5, P495; ZARLING JM, 1990, NATURE, V347, P92, DOI 10.1038/347092a0	63	66	79	1	12	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					433	442		10.1016/S0092-8674(00)81529-9	http://dx.doi.org/10.1016/S0092-8674(00)81529-9			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571185	Bronze			2022-12-28	WOS:000083709300010
J	McLellan, F				McLellan, F			W;t	ANNALS OF INTERNAL MEDICINE			English	Article									Amer Coll Physicians, Amer Soc Internal Med, Philadelphia, PA 19106 USA	American College of Physicians	McLellan, F (corresponding author), Amer Coll Physicians, Amer Soc Internal Med, 190 N Independence Mall W, Philadelphia, PA 19106 USA.	fmclellan@mail.acponline.org		McLellan, Faith/0000-0003-0744-1450				DONNE J, 1959, DEVOTIONS UPON EMERG; EDSON M, 1999, FABER FABER; Hawkins Anne Hunsaker, 1999, STUDIES PATHOGRAPHY; JONES AH, 1994, 23 ANN M AM OSL SOC; McLellan MF, 1996, LANCET, V348, P458, DOI 10.1016/S0140-6736(96)02421-X; McLellan MF, 1997, LANCET, V349, P1618, DOI 10.1016/S0140-6736(97)04429-2; TOLSTOY L, 1981, DEATH IVAN IIYICH; ZUGER A, PATIENT DOCTOR HERO	8	3	3	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					718	719		10.7326/0003-4819-131-9-199911020-00030	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00030			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577347				2022-12-28	WOS:000083446200027
J	Messing, EM; Manola, J; Sarosdy, M; Wilding, G; Crawford, ED; Trump, D				Messing, EM; Manola, J; Sarosdy, M; Wilding, G; Crawford, ED; Trump, D			Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							RADIATION-THERAPY; ONCOLOGY GROUP; DEFINITIVE RADIOTHERAPY; ANDROGEN SUPPRESSION; DOUBLE-BLIND; LYMPH-NODES; CARCINOMA; TRIAL; FLUTAMIDE; ANTIGEN	Background: Because the optimal timing of the institution of antiandrogen therapy for prostate cancer is controversial, we compared immediate and delayed treatment in patients who had minimal residual disease after radical prostatectomy. Methods: Ninety-eight men who underwent radical prostatectomy and pelvic lymphadenectomy and who were found to have nodal metastases were randomly assigned to receive immediate antiandrogen therapy, with either goserelin, a synthetic agonist of gonadotropin-releasing hormone, or bilateral orchiectomy, or to be followed until disease progression. The patients were assessed quarterly during the first year and then semiannually. Results: After a median of 7.1 years of follow-up, 7 of 47 men who received immediate antiandrogen treatment had died, as compared with 18 of 51 men in the observation group (P = 0.02). The cause of death was prostate cancer in 3 men in the immediate-treatment group and in 16 men in the observation group (P<0.01). At the time of the last follow-up, 36 men in the immediate-treatment group (77 percent) and 9 men in the observation group (18 percent) were alive and had no evidence of recurrent disease, including undetectable serum prostate-specific antigen levels (P<0.001). In the observation group, the disease recurred in 42 men; 13 of the 36 who were treated had a complete response to local treatment or hormonal therapy (or both), 16 died of prostate cancer, and 1 died of another disease. The remaining men in this group were alive with progressive disease at the time of the last follow-up or had had a recent relapse. Except for the treatment group (immediate therapy or observation), no clinical or histologic characteristic significantly influenced the outcome. Conclusions: Immediate antiandrogen therapy after radical prostatectomy and pelvic lymphadenectomy improves survival and reduces the risk of recurrence in patients with node-positive prostate cancer. (N Engl J Med 1999;341:1781-8.) (C)1999, Massachusetts Medical Society.	Univ Rochester, Med Ctr, Dept Urol, Rochester, NY 14642 USA; Dana Farber Canc Inst, Boston, MA 02115 USA; Univ Texas San Antonio, San Antonio, TX 78285 USA; Univ Wisconsin, Ctr Comprehens Canc, Madison, WI USA; Univ Colorado, Hlth Sci Ctr, Denver, CO USA; Univ Pittsburgh, Inst Canc, Pittsburgh, PA USA	University of Rochester; Harvard University; Dana-Farber Cancer Institute; University of Texas System; University of Texas at San Antonio (UTSA); University of Wisconsin System; University of Wisconsin Madison; University of Colorado System; University of Colorado Anschutz Medical Campus; University of Colorado Denver; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Messing, EM (corresponding author), Univ Rochester, Med Ctr, Dept Urol, 601 Elmwood Ave,Box 656, Rochester, NY 14642 USA.	edward_messing@urmc.rochester.edu			NATIONAL CANCER INSTITUTE [U10CA011083, U10CA023318, U10CA022433] Funding Source: NIH RePORTER; NCI NIH HHS [CA11083, CA22433, CA23318] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		AKAKURA K, 1993, CANCER, V71, P2782, DOI 10.1002/1097-0142(19930501)71:9<2782::AID-CNCR2820710916>3.0.CO;2-Z; Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; Andriole GL, 1998, UROLOGY, V52, P195, DOI 10.1016/S0090-4295(98)00184-8; Angell M, 1998, NEW ENGL J MED, V339, P839, DOI 10.1056/NEJM199809173391210; [Anonymous], 1997, Br J Urol, V79, P235; [Anonymous], 1995, Lancet, V346, P265; BARNES S, 1995, J CELL BIOCHEM, P181; Blasko JC, 1996, UROL CLIN N AM, V23, P633, DOI 10.1016/S0094-0143(05)70342-6; Bolla M, 1997, NEW ENGL J MED, V337, P295, DOI 10.1056/NEJM199707313370502; BYAR DP, 1977, UROLOGIC PATHOLOGY P, P241; Caubet JF, 1997, UROLOGY, V49, P71, DOI 10.1016/S0090-4295(96)00325-1; Chang A, 1996, J CLIN ONCOL, V14, P2250, DOI 10.1200/JCO.1996.14.8.2250; Clark LC, 1997, JAMA-J AM MED ASSOC, V277, P1520; Connolly JA, 1996, UROL CLIN N AM, V23, P623, DOI 10.1016/S0094-0143(05)70341-4; COX DR, 1972, J R STAT SOC B, V34, P187; CRAWFORD ED, 1989, NEW ENGL J MED, V321, P1420; Deguchi T, 1997, J NATL CANCER I, V89, P1471, DOI 10.1093/jnci/89.20.1471; DiPaola RS, 1998, NEW ENGL J MED, V339, P785, DOI 10.1056/NEJM199809173391201; Edelstein RA, 1996, UROLOGY, V47, P370, DOI 10.1016/S0090-4295(99)80455-5; Eisenberger MA, 1998, NEW ENGL J MED, V339, P1036, DOI 10.1056/NEJM199810083391504; Fair WR, 1997, UROLOGY, V50, P840, DOI 10.1016/S0090-4295(97)00339-7; Farkas A, 1998, UROLOGY, V52, P444, DOI 10.1016/S0090-4295(98)00242-8; GARNICK MB, 1984, NEW ENGL J MED, V311, P1281; Giovannucci E, 1998, CANCER RES, V58, P442; GROSE GS, 1994, PROSTATE CANC, P197; HAYES RB, 1999, BIOMARKERS PREV, V8, P25; Hoshi S, 1997, Urol Oncol, V3, P183, DOI 10.1016/S1078-1439(98)00023-4; Huggins C, 1941, CANCER RES, V1, P293; Huggins C, 1941, ARCH SURG-CHICAGO, V43, P209, DOI 10.1001/archsurg.1941.01210140043004; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; LAWTON C, 1999, P ASCO, V18, pA311; MANTEL NATHAN, 1966, CANCERCHEMOTHERAP REP, V50, P163; MEHTA CR, 1984, BIOMETRICS, V40, P819, DOI 10.2307/2530927; MYERS RP, 1992, J UROLOGY, V147, P910, DOI 10.1016/S0022-5347(17)37420-7; Obek C, 1999, J UROLOGY, V162, P762, DOI 10.1097/00005392-199909010-00037; PETO R, 1972, J R STAT SOC SER A-G, V135, P185, DOI 10.2307/2344317; PETROS JA, 1992, J UROLOGY, V147, P1574, DOI 10.1016/S0022-5347(17)37630-9; PILEPICH MV, 1995, INT J RADIAT ONCOL, V32, P175, DOI 10.1016/0360-3016(95)00536-8; PILEPICH MV, 1990, AM J CLIN ONCOL-CANC, V13, P461, DOI 10.1097/00000421-199012000-00001; Pilepich MV, 1997, J CLIN ONCOL, V15, P1013, DOI 10.1200/JCO.1997.15.3.1013; PILEPICH MV, 1995, UROLOGY, V45, P616, DOI 10.1016/S0090-4295(99)80053-3; PILEPICH MV, 1995, INT J RADIAT ONCOL, V16, P813; Pound CR, 1999, J UROLOGY, V162, P1337, DOI 10.1016/S0022-5347(05)68280-8; ROSE DP, 1992, LIPIDS, V27, P798, DOI 10.1007/BF02535853; SCHRODER FH, 1998, CAMPBELLS UROLOGY, P2636; Seay TM, 1998, J UROLOGY, V159, P357, DOI 10.1016/S0022-5347(01)63917-X; STONER E, 1994, UROLOGY, V43, P284, DOI 10.1016/0090-4295(94)90068-X; *VET ADM COOP UR R, 1967, SURG GYNECOL OBSTET, V124, P1011; Wilt TJ, 1998, JAMA-J AM MED ASSOC, V280, P1604, DOI 10.1001/jama.280.18.1604; Wilt TJ, 1999, JAMA-J AM MED ASSOC, V281, P515; YUSUF S, 1991, JAMA-J AM MED ASSOC, V266, P93, DOI 10.1001/jama.266.1.93; ZAGARS GK, 1988, INT J RADIAT ONCOL, V14, P1085, DOI 10.1016/0360-3016(88)90383-5; Zelefsky MJ, 1998, J CLIN ONCOL, V16, P3380, DOI 10.1200/JCO.1998.16.10.3380	53	926	964	0	18	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1781	1788		10.1056/NEJM199912093412401	http://dx.doi.org/10.1056/NEJM199912093412401			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588962				2022-12-28	WOS:000084074000001
J	Ritsema, J; van Heijst, HJ; Woodhouse, JH				Ritsema, J; van Heijst, HJ; Woodhouse, JH			Complex shear wave velocity structure imaged beneath Africa and Iceland	SCIENCE			English	Article							LOWER-MANTLE; DYNAMIC TOPOGRAPHY; BOUNDARY-LAYER; PLUME; HETEROGENEITY; CONVECTION; SUPERSWELL; MODEL; PHASE	A model of three-dimensional shear wave velocity variations in the mantle reveals a tilted Low velocity anomaly extending from the core-mantle boundary (CMB) region beneath the southeastern Atlantic Ocean into the upper mantle beneath eastern Africa. This anomaly suggests that Cenozoic flood basalt volcanism in the Afar region and active rifting beneath the East African Rift is Linked to an extensive thermal anomaly at the CMB more than 45 degrees away. In contrast, a Low velocity anomaly beneath Iceland is confined to the upper mantle.	CALTECH, Seismol Lab, Pasadena, CA 91125 USA; Univ Oxford, Dept Earth Sci, Oxford OX1 3PR, England	California Institute of Technology; University of Oxford	Ritsema, J (corresponding author), CALTECH, Seismol Lab, Pasadena, CA 91125 USA.	jeroen@gps.caltech.edu						BACKUS G, 1968, GEOPHYS J ROY ASTR S, V16, P169, DOI 10.1111/j.1365-246X.1968.tb00216.x; BERCOVICI D, 1994, SCIENCE, V266, P1367, DOI 10.1126/science.266.5189.1367; Bijwaard H, 1999, EARTH PLANET SC LETT, V166, P121, DOI 10.1016/S0012-821X(99)00004-7; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; CHRISTENSEN U, 1984, ANN GEOPHYS, V2, P311; Courtillot V, 1999, EARTH PLANET SC LETT, V166, P177, DOI 10.1016/S0012-821X(98)00282-9; DZIEWONSKI AM, 1984, J GEOPHYS RES, V89, P5929, DOI 10.1029/JB089iB07p05929; DZIEWONSKI AM, 1981, PHYS EARTH PLANET IN, V25, P297, DOI 10.1016/0031-9201(81)90046-7; DZIEWONSKI AM, 1981, J GEOPHYS RES, V86, P2825, DOI 10.1029/JB086iB04p02825; Ebinger CJ, 1998, NATURE, V395, P788, DOI 10.1038/27417; Grand SP., 1997, GSA TODAY, V7, P1; HAGER BH, 1985, NATURE, V313, P541, DOI 10.1038/313541a0; Hofmann C, 1997, NATURE, V389, P838, DOI 10.1038/39853; Ishii M, 1999, SCIENCE, V285, P1231, DOI 10.1126/science.285.5431.1231; Kellogg LH, 1999, SCIENCE, V283, P1881, DOI 10.1126/science.283.5409.1881; KINCAID C, 1995, NATURE, V376, P758, DOI 10.1038/376758a0; Lay T, 1998, NATURE, V392, P461, DOI 10.1038/33083; LAY T, 1994, ANNU REV EARTH PL SC, V22, P33, DOI 10.1146/annurev.ea.22.050194.000341; Li XD, 1996, J GEOPHYS RES-SOL EA, V101, P22245, DOI 10.1029/96JB01306; Lithgow-Bertelloni C, 1998, NATURE, V395, P269, DOI 10.1038/26212; Liu XF, 1998, GEODYNAMICS, V28, P21; Manighetti I, 1997, J GEOPHYS RES-SOL EA, V102, P2681, DOI 10.1029/96JB01185; Masters G, 1996, PHILOS T R SOC A, V354, P1385, DOI 10.1098/rsta.1996.0054; Mooney WD, 1998, J GEOPHYS RES-SOL EA, V103, P727, DOI 10.1029/97JB02122; MORGAN WJ, 1971, NATURE, V230, P42, DOI 10.1038/230042a0; NAKAKUKI T, 1994, EARTH PLANET SC LETT, V121, P369, DOI 10.1016/0012-821X(94)90078-7; NATAF HC, 1993, NATURE, V364, P115, DOI 10.1038/364115a0; NYBLADE AA, 1994, GEOPHYS RES LETT, V21, P765, DOI 10.1029/94GL00631; Prodehl C, 1997, TECTONOPHYSICS, V278, P121, DOI 10.1016/S0040-1951(97)00098-X; Resovsky JS, 1999, J GEOPHYS RES-SOL EA, V104, P993, DOI 10.1029/1998JB900025; RICHARDS MA, 1988, J GEOPHYS RES-SOLID, V93, P7690, DOI 10.1029/JB093iB07p07690; Shen Y, 1998, NATURE, V395, P62, DOI 10.1038/25714; SILVER PG, 1988, ANNU REV EARTH PL SC, V16, P477, DOI 10.1146/annurev.ea.16.050188.002401; SU WJ, 1994, J GEOPHYS RES-SOL EA, V99, P6945, DOI 10.1029/93JB03408; Tackley PJ, 1998, GEODYNAMICS, V28, P231; Van Heijst HJ, 1999, GEOPHYS J INT, V137, P601, DOI 10.1046/j.1365-246x.1999.00825.x; vanHeijst HJ, 1997, GEOPHYS J INT, V131, P209, DOI 10.1111/j.1365-246X.1997.tb01217.x; VANHEIJST HJ, 1999, EOS T AGU S, V80, pS221; WOODHOUSE JH, 1984, J GEOPHYS RES, V89, P5953, DOI 10.1029/JB089iB07p05953; Yuen DA, 1998, EARTH PLANETS SPACE, V50, P1035, DOI 10.1186/BF03352198; ZHONG SJ, 1993, J GEOPHYS RES-SOL EA, V98, P12219, DOI 10.1029/93JB00193	41	705	720	2	70	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1925	1928		10.1126/science.286.5446.1925	http://dx.doi.org/10.1126/science.286.5446.1925			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583949				2022-12-28	WOS:000084003400042
J	Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B				Sabatini, S; Beis, D; Wolkenfelt, H; Murfett, J; Guilfoyle, T; Malamy, J; Benfey, P; Leyser, O; Bechtold, N; Weisbeek, P; Scheres, B			An auxin-dependent distal organizer of pattern and polarity in the Arabidopsis root	CELL			English	Article							CELL-DIFFERENTIATION; TRANSCRIPTION FACTOR; VASCULAR DEVELOPMENT; RESPONSE ELEMENTS; AUX/IAA PROTEINS; FLORAL MERISTEM; GENE MONOPTEROS; THALIANA; ENCODES; EMBRYO	Root formation in plants involves the continuous interpretation of positional cues. Physiological studies have linked root formation to auxins. An auxin response element displays a maximum in the Arabidopsis root and we investigate its developmental significance. Auxin response mutants reduce the maximum or its perception, and interfere with distal root patterning. Polar auxin transport mutants affect its localization and distal pattern. Polar auxin transport inhibitors cause dramatic relocalization of the maximum, and associated changes in pattern and polarity. Auxin application and laser ablations correlate root pattern with a maximum adjacent to the vascular bundle. Our data indicate that an auxin maximum at a vascular boundary establishes a distal organizer in the root.	Univ Utrecht, Dept Mol Cell Biol, NL-3584 CH Utrecht, Netherlands; Univ Missouri, Dept Biochem, Columbia, MO 65211 USA; NYU, Dept Biol, New York, NY 10003 USA; Univ York, Dept Biol, York YO10 5YW, N Yorkshire, England; INRA, Ctr Versailles, Lab Genet & Ameliorat Plantes, F-78026 Versailles, France	Utrecht University; University of Missouri System; University of Missouri Columbia; New York University; University of York - UK; INRAE; UDICE-French Research Universities; Universite Paris Saclay	Scheres, B (corresponding author), Univ Utrecht, Dept Mol Cell Biol, Padualaan 8, NL-3584 CH Utrecht, Netherlands.	b.scheres@bio.uu.nl	Leyser, Ottoline/AAC-5577-2019	Beis, Dimitris/0000-0003-2579-7848; SABATINI, Sabrina/0000-0002-9691-6595; Leyser, Ottoline/0000-0003-2161-3829; Scheres, Ben/0000-0001-5400-9578				BECHTOLD N, 1993, CR ACAD SCI III-VIE, V316, P1194; Bennett MJ, 1996, SCIENCE, V273, P948, DOI 10.1126/science.273.5277.948; BERLETH T, 1993, DEVELOPMENT, V118, P575; CELENZA JL, 1995, GENE DEV, V9, P2131, DOI 10.1101/gad.9.17.2131; Chen RJ, 1998, P NATL ACAD SCI USA, V95, P15112, DOI 10.1073/pnas.95.25.15112; Clark SE, 1997, CELL, V89, P575, DOI 10.1016/S0092-8674(00)80239-1; Davies P. J, 1995, PLANT HORMONES; Delbarre A, 1996, PLANTA, V198, P532, DOI 10.1007/BF00262639; DiLaurenzio L, 1996, CELL, V86, P423, DOI 10.1016/S0092-8674(00)80115-4; DOLAN L, 1993, DEVELOPMENT, V119, P71; Fletcher LC, 1999, SCIENCE, V283, P1911, DOI 10.1126/science.283.5409.1911; Galweiler L, 1998, SCIENCE, V282, P2226, DOI 10.1126/science.282.5397.2226; Hadfi K, 1998, DEVELOPMENT, V125, P879; Hamann T, 1999, DEVELOPMENT, V126, P1387; Hardtke CS, 1998, EMBO J, V17, P1405, DOI 10.1093/emboj/17.5.1405; HOBBIE L, 1995, PLANT J, V7, P211, DOI 10.1046/j.1365-313X.1995.7020211.x; INGHAM PW, 1992, CELL, V68, P221, DOI 10.1016/0092-8674(92)90467-Q; KELLY MO, 1986, PLANT PHYSIOL, V82, P713, DOI 10.1104/pp.82.3.713; Kim J, 1997, P NATL ACAD SCI USA, V94, P11786, DOI 10.1073/pnas.94.22.11786; Lecuit T, 1996, NATURE, V381, P387, DOI 10.1038/381387a0; LEYSER HMO, 1993, NATURE, V364, P161, DOI 10.1038/364161a0; LIU CM, 1993, PLANT CELL, V5, P621, DOI 10.1105/tpc.5.6.621; Luschnig C, 1998, GENE DEV, V12, P2175, DOI 10.1101/gad.12.14.2175; Malamy JE, 1997, DEVELOPMENT, V124, P33; Malamy JE, 1997, PLANT J, V12, P957, DOI 10.1046/j.1365-313X.1997.12040957.x; Marchant A, 1999, EMBO J, V18, P2066, DOI 10.1093/emboj/18.8.2066; Mattsson J, 1999, DEVELOPMENT, V126, P2979; Muller A, 1998, EMBO J, V17, P6903, DOI 10.1093/emboj/17.23.6903; Nellen D, 1996, CELL, V85, P357, DOI 10.1016/S0092-8674(00)81114-9; Neumann C, 1997, BIOESSAYS, V19, P721, DOI 10.1002/bies.950190813; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; Przemeck GKH, 1996, PLANTA, V200, P229, DOI 10.1007/BF00208313; Rouse D, 1998, SCIENCE, V279, P1371, DOI 10.1126/science.279.5355.1371; RUBERY PH, 1990, SYM SOC EXP BIOL, V44, P119; Ruegger M, 1998, GENE DEV, V12, P198, DOI 10.1101/gad.12.2.198; SACHS T, 1991, DEVELOPMENT, P83; SCHERES B, 1994, DEVELOPMENT, V120, P2475; Sessions A, 1997, DEVELOPMENT, V124, P4481; SKOOG F, 1957, Symp Soc Exp Biol, V11, P118; Steeves T.A., 1989, PATTERNS PLANT DEV, DOI 10.1017/CBO9780511626227; STJOHNSTON D, 1992, CELL, V68, P201; Tian Q, 1999, DEVELOPMENT, V126, P711; Uggla C, 1996, P NATL ACAD SCI USA, V93, P9282, DOI 10.1073/pnas.93.17.9282; Ulmasov T, 1999, P NATL ACAD SCI USA, V96, P5844, DOI 10.1073/pnas.96.10.5844; Ulmasov T, 1997, SCIENCE, V276, P1865, DOI 10.1126/science.276.5320.1865; Ulmasov T, 1997, PLANT CELL, V9, P1963, DOI 10.1105/tpc.9.11.1963; vandenBerg C, 1997, NATURE, V390, P287, DOI 10.1038/36856; VANDENBERG C, 1995, NATURE, V378, P62, DOI 10.1038/378062a0; Walker L, 1998, CURR OPIN PLANT BIOL, V1, P434, DOI 10.1016/S1369-5266(98)80269-0; Willemsen V, 1998, DEVELOPMENT, V125, P521	50	1011	1053	9	162	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					463	472		10.1016/S0092-8674(00)81535-4	http://dx.doi.org/10.1016/S0092-8674(00)81535-4			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589675	Green Published, Bronze			2022-12-28	WOS:000083986300006
J	Bartsch, P				Bartsch, P			Platelet activation with exercise and risk of cardiac events	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; STRENUOUS EXERCISE; PHYSICAL EXERTION; FIBRINOLYSIS; COAGULATION; MODERATE; DEATH; MEN		Univ Heidelberg, Div Sports Med, Dept Internal Med, D-69115 Heidelberg, Germany	Ruprecht Karls University Heidelberg	Bartsch, P (corresponding author), Univ Heidelberg, Div Sports Med, Dept Internal Med, Bergheimer Str 58, D-69115 Heidelberg, Germany.							DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; KESTIN AS, 1993, CIRCULATION, V88, P1502, DOI 10.1161/01.CIR.88.4.1502; MARON BJ, 1986, J AM COLL CARDIOL, V7, P204, DOI 10.1016/S0735-1097(86)80283-2; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; STREIFF M, 1994, SEMIN HEMATOL, V31, P155; Wallen NH, 1999, CLIN SCI, V97, P27, DOI 10.1042/CS19990013; WANG JS, 1994, CIRCULATION, V90, P2877, DOI 10.1161/01.CIR.90.6.2877; WANG JS, 1995, ARTERIOSCL THROM VAS, V15, P1668, DOI 10.1161/01.ATV.15.10.1668; Weiss C, 1998, MED SCI SPORT EXER, V30, P246, DOI 10.1097/00005768-199802000-00012; Weiss C, 1998, AM J CARDIOL, V81, P672, DOI 10.1016/S0002-9149(97)01026-6; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WINDER WW, 1978, J APPL PHYSIOL, V45, P370, DOI 10.1152/jappl.1978.45.3.370	13	42	43	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1747	1748		10.1016/S0140-6736(99)90259-3	http://dx.doi.org/10.1016/S0140-6736(99)90259-3			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577632				2022-12-28	WOS:000083853000005
J	Hansson, L; Lindholm, LH; Ekbom, T; Dahlof, B; Lanke, J; Schersten, B; Wester, PO; Hedner, T; de Faire, U				Hansson, L; Lindholm, LH; Ekbom, T; Dahlof, B; Lanke, J; Schersten, B; Wester, PO; Hedner, T; de Faire, U		STOP Hypertension 2 Study Grp	Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study	LANCET			English	Article							ISOLATED SYSTOLIC HYPERTENSION; ACTIVE TREATMENT; PLACEBO	Background The efficacy of new antihypertensive drugs has been questioned. We compared the effects of conventional and newer antihypertensive drugs on cardiovascular mortality and morbidity in elderly patients. Methods We did a prospective, randomised trial in 6614 patients aged 70-84 years with hypertension (blood pressure greater than or equal to 180 mm Hg systolic, greater than or equal to 105 mm Hg diastolic, or both). Patients were randomly assigned conventional antihypertensive drugs (atenolol 50 mg, metoprolol 100 mg, pindolol 5 mg, or hydrochlorothiazide 25 mg plus amiloride 25 mg daily) or newer drugs (enalapril 10 mg or lisinopril 10 mg, or felodipine 2.5 mg or isradipine 2-5 mg daily). We assessed fatal stroke, fatal myocardial infarction, and other fatal cardiovascular disease. Analysis was by intention to treat. Findings Blood pressure was decreased similarly in all treatment groups. The primary combined endpoint of fatal stroke, fatal myocardial infarction, and other fatal cardiovascular disease occurred in 221 of 2213 patients in the conventional drugs group (19.8 events per 1000 patient-years) and in 438 of 4401 in the newer drugs group (19.8 per 1000; relative risk 0.99 [95% CI 0.84-1.16], p=0.89). The combined endpoint of fatal and non-fatal stroke, fatal and non-fatal myocardial infarction, and other cardiovascular mortality occurred in 460 patients taking conventional drugs and in 887 taking newer drugs (0.96 [0.86-1.08], p=0.49). Interpretation Old and new antihypertensive drugs were similar in prevention of cardiovascular mortality or major events. Decrease in blood pressure was of major importance for the prevention of cardiovascular events.	Uppsala Univ, Dept Publ Hlth & Social Sci, S-75125 Uppsala, Sweden; Umea Univ Hosp, Dept Publ Hlth & Clin Med, S-90185 Umea, Sweden; Lund Univ, Malmo Univ Hosp, Dept Community Med, Malmo, Sweden; Sahlgrens Univ Hosp, Dept Med, S-41345 Gothenburg, Sweden; Sahlgrens Univ Hosp, Dept Clin Pharmacol, S-41345 Gothenburg, Sweden; Lund Univ, Dept Stat, Lund, Sweden; Dalby Lund Univ, Dept Community Hlth Sci, Lund, Sweden; Karolinska Univ Hosp, Dept Med, Stockholm, Sweden	Uppsala University; Umea University; Lund University; Skane University Hospital; Sahlgrenska University Hospital; Sahlgrenska University Hospital; Lund University; Lund University; Karolinska Institutet; Karolinska University Hospital	Hansson, L (corresponding author), Uppsala Univ, Dept Publ Hlth & Social Sci, POB 609, S-75125 Uppsala, Sweden.							Alderman M, 1997, J HYPERTENS, V15, P105; AMERY A, 1985, LANCET, V1, P1349; [Anonymous], 1991, JAMA, V265, P3255; COOPE J, 1986, BRIT MED J, V293, P1145, DOI 10.1136/bmj.293.6555.1145; Dahlof B, 1993, Blood Press, V2, P136, DOI 10.3109/08037059309077541; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Gong LS, 1996, J HYPERTENS, V14, P1237, DOI 10.1097/00004872-199610000-00013; Hansson L, 1992, Blood Press, V1, P113, DOI 10.3109/08037059209077502; Hansson L, 1999, LANCET, V353, P611, DOI 10.1016/S0140-6736(98)05012-0; Hansson L, 1998, LANCET, V351, P1755, DOI 10.1016/S0140-6736(98)04311-6; Lindholm Lars H., 1996, Blood Pressure, V5, P300, DOI 10.3109/08037059609078063; Liu LS, 1998, J HYPERTENS, V16, P1823, DOI 10.1097/00004872-199816120-00016; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6; van Zwieten PA, 1999, BLOOD PRESSURE, V8, P5, DOI 10.1080/080370599438329	15	1050	1096	1	20	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1751	1756		10.1016/S0140-6736(99)10327-1	http://dx.doi.org/10.1016/S0140-6736(99)10327-1			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577635				2022-12-28	WOS:000083853000008
J	Russell, DF; Wilkens, LA; Moss, F				Russell, DF; Wilkens, LA; Moss, F			Use of behavioural stochastic resonance by paddle fish for feeding	NATURE			English	Article							NOISE; MECHANORECEPTORS; CRAYFISH; SYSTEM	Stochastic resonance is the phenomenon whereby the addition of an optimal level of noise to a weak information-carrying input to certain nonlinear systems can enhance the information content at their outputs(1-4). Computer analysis of spike trains has been needed to reveal stochastic resonance in the responses of sensory receptors(5-7) except for one study on human psychophysics(8). But is an animal aware of, and can it make use of, the enhanced sensory information from stochastic resonance? Here, we show that stochastic resonance enhances the normal feeding behaviour of paddlefish (Polyodon spathula)(9,10), which use passive electroreceptors(11,12) to detect electrical signals from planktonic prey(13). We demonstrate significant broadening of the spatial range for the detection of plankton when a noisy electric field of optimal amplitude is applied in the water. We also show that swarms of Daphnia plankton are a natural source of electrical noise. Our demonstration of stochastic resonance at the level of a vital animal behaviour, feeding, which has probably evolved for functional success, provides evidence that stochastic resonance in sensory nervous systems is an evolutionary adaptation(14).			Russell, DF (corresponding author), Univ Missouri, Ctr Neurodynam, St Louis, MO 63121 USA.							Bezrukov SM, 1997, NATURE, V385, P319, DOI 10.1038/385319a0; BOUCHERLE MM, 1976, OHIO J SCI, V56, P90; Bullock T.H., 1986, P651; BULLOCK TH, 1982, ANNU REV NEUROSCI, V5, P121, DOI 10.1146/annurev.ne.05.030182.001005; Bulsara AR, 1996, PHYS TODAY, V49, P39, DOI 10.1063/1.881491; BURGGREN WW, 1992, PHYSIOL ZOOL, V65, P515, DOI 10.1086/physzool.65.3.30157967; Collins JJ, 1996, J NEUROPHYSIOL, V76, P642, DOI 10.1152/jn.1996.76.1.642; DOUGLASS JK, 1993, NATURE, V365, P337, DOI 10.1038/365337a0; Gammaitoni L, 1998, REV MOD PHYS, V70, P223, DOI 10.1103/RevModPhys.70.223; GIBBONS JD, 1976, NONPARAMETRIC METHOD, P223; Gluckman BJ, 1996, PHYS REV LETT, V77, P4098, DOI 10.1103/PhysRevLett.77.4098; Jaramillo F, 1998, NAT NEUROSCI, V1, P384, DOI 10.1038/1597; JORGENSEN JM, 1972, Z ZELLFORSCH MIK ANA, V130, P362; Laming PR, 1981, BRAIN MECHANISMS BEH, P203; MARASCUILO LA, 1977, NONPARAMETRIC DISTRI, P290; NEW JG, 1985, BRAIN RES, V336, P89, DOI 10.1016/0006-8993(85)90419-6; POUGH FH, 1996, VERTEBRATE LIFE, P258; Robbins Trevor W., 1995, P703; RUELLE R, 1977, T AM FISH SOC, V106, P609, DOI 10.1577/1548-8659(1977)106<609:PPS>2.0.CO;2; STEMMLER M, 1995, SCIENCE, V269, P1877, DOI 10.1126/science.7569930; TEETER JH, 1980, J COMP PHYSIOL, V138, P213, DOI 10.1007/BF00657039; Tricas TC, 1998, J COMP PHYSIOL A, V182, P89; WIESENFELD K, 1995, NATURE, V373, P33, DOI 10.1038/373033a0; Wilkens LA, 1997, P ROY SOC B-BIOL SCI, V264, P1723, DOI 10.1098/rspb.1997.0239	26	388	397	1	53	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					291	294		10.1038/46279	http://dx.doi.org/10.1038/46279			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580499				2022-12-28	WOS:000083813700049
J	Raju, TNK				Raju, TNK			The Nobel chronicles	LANCET			English	Article									Univ Illinois, Chicago, IL 60680 USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital	Raju, TNK (corresponding author), Univ Illinois, Chicago, IL 60680 USA.								0	6	9	1	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1738	1738		10.1016/S0140-6736(05)76734-9	http://dx.doi.org/10.1016/S0140-6736(05)76734-9			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568613				2022-12-28	WOS:000083652800072
J	Page, CC; Moser, CC; Chen, XX; Dutton, PL				Page, CC; Moser, CC; Chen, XX; Dutton, PL			Natural engineering principles of electron tunnelling in biological oxidation-reduction	NATURE			English	Article							PHOTOSYNTHETIC REACTION-CENTER; DELTA-G-DEGREES; RHODOPSEUDOMONAS-VIRIDIS; RHODOBACTER-SPHAEROIDES; DESULFOVIBRIO-GIGAS; PROTEIN-STRUCTURE; CRYSTAL-STRUCTURE; NIFE HYDROGENASE; TEMPERATURE; OXIDASE	We have surveyed proteins with known atomic structure whose function involves electron transfer; in these, electrons can travel up to 14 Angstrom between redox centres through the protein medium. Transfer over longer distances always involves a chain of cofactors. This redox centre proximity alone is sufficient to allow tunnelling of electrons at rates far faster than the substrate redox reactions it supports. Consequently, there has been no necessity for proteins to evolve optimized routes between redox centres. Instead, simple geometry enables rapid tunnelling to high-energy intermediate states. This greatly simplifies any analysis of redox protein mechanisms and challenges the need to postulate mechanisms of superexchange through redox centres or the maintenance of,charge neutrality when investigating electron-transfer reactions. Such tunnelling also allows sequential electron transfer in catalytic sites to surmount radical transition states without involving the movement of hydride ions, as is generally assumed. The 14 Angstrom or less spacing of redox centres provides highly robust engineering for electron transfer, and may reflect selection against designs that have proved more vulnerable to mutations during the course of evolution.	Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA	University of Pennsylvania	Dutton, PL (corresponding author), Univ Penn, Dept Biochem & Biophys, Johnson Res Fdn, Philadelphia, PA 19104 USA.	dutton@mail.med.upenn.edu	Moser, Christopher C/O-6559-2014	Moser, Christopher C/0000-0003-4814-8568; Chen, Xiaoxi/0000-0002-1049-3537				ALEGRIA G, 1991, BIOCHIM BIOPHYS ACTA, V1057, P239, DOI 10.1016/S0005-2728(05)80107-0; Allen JP, 1998, PHOTOSYNTH RES, V55, P227, DOI 10.1023/A:1005977901937; Bahnson BJ, 1997, P NATL ACAD SCI USA, V94, P12797, DOI 10.1073/pnas.94.24.12797; BERATAN DN, 1992, SCIENCE, V258, P1740, DOI 10.1126/science.1334572; Coelho AV, 1997, J BIOL INORG CHEM, V2, P680, DOI 10.1007/s007750050184; Darwin C., 1872, ORIGIN SPECIES MEANS, V144, P971; DEVAULT D, 1980, Q REV BIOPHYS, V13, P387, DOI 10.1017/S003358350000175X; DOHSE B, 1995, BIOCHEMISTRY-US, V34, P11335, DOI 10.1021/bi00036a006; DUTTON PL, 1998, BIOL ELECT TRANSFER, P3; EBERSON L, 1987, ELECT TRANSFER REACT, P1; EHRENBERG A, 1998, 3 INT S BIOL PHYS, V1, P1; FARRINGTON JA, 1980, BIOCHIM BIOPHYS ACTA, V590, P273, DOI 10.1016/0005-2728(80)90031-6; Gray HB, 1996, ANNU REV BIOCHEM, V65, P537, DOI 10.1146/annurev.bi.65.070196.002541; Gunner M.R., 1982, FUNCTION QUINONES EN, P265; GUNNER MR, 1989, J AM CHEM SOC, V111, P3400, DOI 10.1021/ja00191a043; HOPFIELD JJ, 1974, P NATL ACAD SCI USA, V71, P3640, DOI 10.1073/pnas.71.9.3640; Huber R, 1996, P NATL ACAD SCI USA, V93, P8846, DOI 10.1073/pnas.93.17.8846; HUNT J, 1993, J BIOL CHEM, V268, P18685; Jortner J, 1998, P NATL ACAD SCI USA, V95, P12759, DOI 10.1073/pnas.95.22.12759; JORTNER J, 1976, J CHEM PHYS, V64, P4860, DOI 10.1063/1.432142; Kisker C, 1997, CELL, V91, P973, DOI 10.1016/S0092-8674(00)80488-2; KNAFF DB, 1991, BIOCHEMISTRY-US, V30, P1303, DOI 10.1021/bi00219a021; KUKI A, 1987, SCIENCE, V236, P1647, DOI 10.1126/science.3603005; Li JL, 1998, BIOCHEMISTRY-US, V37, P2818, DOI 10.1021/bi971699x; MARCUS RA, 1985, BIOCHIM BIOPHYS ACTA, V811, P265, DOI 10.1016/0304-4173(85)90014-X; MCLENDON G, 1991, STRUCT BOND, V75, P159; MEYER TE, 1993, BIOCHEMISTRY-US, V32, P4719, DOI 10.1021/bi00069a005; MICHAELIS L, 1951, ENZYMES, P1; MICHEL H, 1986, EMBO J, V5, P2445, DOI 10.1002/j.1460-2075.1986.tb04520.x; MITCHELL P, 1975, FEBS LETT, V59, P137, DOI 10.1016/0014-5793(75)80359-0; MOSER CC, 1992, BIOCHIM BIOPHYS ACTA, V1101, P171, DOI 10.1016/S0005-2728(05)80012-X; MOSER CC, 1992, NATURE, V355, P796, DOI 10.1038/355796a0; Ortega JM, 1999, PHOTOSYNTH RES, V59, P147, DOI 10.1023/A:1006149621029; POWELL MF, 1984, J AM CHEM SOC, V106, P3850, DOI 10.1021/ja00325a024; Proshlyakov DA, 1998, P NATL ACAD SCI USA, V95, P8020, DOI 10.1073/pnas.95.14.8020; PROSS A, 1985, ACCOUNTS CHEM RES, V18, P212, DOI 10.1021/ar00115a004; ROMAO MJ, 1995, SCIENCE, V270, P1170, DOI 10.1126/science.270.5239.1170; Rousset M, 1998, P NATL ACAD SCI USA, V95, P11625, DOI 10.1073/pnas.95.20.11625; SHOPES RJ, 1987, PHOTOSYNTH RES, V12, P165, DOI 10.1007/BF00047946; Siegbahn PEM, 1997, THEOR CHEM ACC, V97, P289, DOI 10.1007/s002140050264; Siegbahn PEM, 1998, J AM CHEM SOC, V120, P8417, DOI 10.1021/ja9736065; SMALLEY JF, 1995, J PHYS CHEM-US, V99, P13141, DOI 10.1021/j100035a016; SOGABE S, 1992, PHOTOSYNTH RES, V34, P154; Spee JH, 1998, FEBS LETT, V432, P55, DOI 10.1016/S0014-5793(98)00827-8; Stubbe J, 1998, CHEM REV, V98, P705, DOI 10.1021/cr9400875; TEIXEIRA M, 1989, J BIOL CHEM, V264, P16435; Venturoli G, 1998, BIOPHYS J, V74, P3226, DOI 10.1016/S0006-3495(98)78029-4; VOLBEDA A, 1995, NATURE, V373, P580, DOI 10.1038/373580a0; WOODBURY NW, 1986, BIOCHIM BIOPHYS ACTA, V851, P6, DOI 10.1016/0005-2728(86)90243-4; Zinth W, 1996, BER BUNSEN PHYS CHEM, V100, P1962, DOI 10.1002/bbpc.19961001206	50	1436	1455	9	288	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					47	52		10.1038/46972	http://dx.doi.org/10.1038/46972			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573417				2022-12-28	WOS:000083638600036
J	Ricchetti, M; Fairhead, C; Dujon, B				Ricchetti, M; Fairhead, C; Dujon, B			Mitochondrial DNA repairs double-strand breaks in yeast chromosomes	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; NONHOMOLOGOUS RECOMBINATION; NUCLEUS; GENOME; ESCAPE; GENES; INTEGRATION; MIGRATION; DELETIONS; SEQUENCE	The endosymbiotic theory for the origin of eukaryotic cells' proposes that genetic information can be transferred from mitochondria to the nucleus of a cell, and genes that are probably of mitochondrial origin have been found in nuclear chromosomes(2). Occasionally, short or rearranged sequences homologous to mitochondrial DNA are seen in the chromosomes of different organisms including yeast, plants and humans(3). Here we report a mechanism by which fragments of mitochondrial DNA, in single or tandem array, are transferred to yeast chromosomes under natural conditions during the repair of double-strand breaks in haploid mitotic cells. These repair insertions originate from noncontiguous regions of the mitochondrial genome. Our analysis of the Saccharomyces cerevisiae mitochondrial genome(4) indicates that the yeast nuclear genome does indeed contain several short sequences of mitochondrial origin which are similar in size and composition to those that repair double-strand breaks. These sequences are located predominantly in non-coding regions of the chromosomes, frequently in the vicinity of retrotransposon long terminal repeats, and appear as recent integration events. Thus, colonization of the yeast genome by mitochondrial DNA is an ongoing process.	Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, F-75724 Paris 15, France; Univ Paris 06, Inst Pasteur, UFR 927, CNRS,URA1300,Unite Genet Mol Levures, F-75724 Paris 15, France	Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; Centre National de la Recherche Scientifique (CNRS); Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris; UDICE-French Research Universities; Sorbonne Universite	Ricchetti, M (corresponding author), Inst Pasteur, CNRS, URA 1773, Unite Physicochim Macromol Biol, 25-28 Rue Docteur Roux, F-75724 Paris 15, France.	mricch@pasteur.fr	Fairhead, Cecile/D-9011-2014; Dujon, Bernard A/F-4971-2010	Fairhead, Cecile/0000-0002-0456-0377				Baudat F, 1997, P NATL ACAD SCI USA, V94, P5213, DOI 10.1073/pnas.94.10.5213; Blanchard JL, 1996, MOL BIOL EVOL, V13, P537, DOI 10.1093/oxfordjournals.molbev.a025614; Byers B, 1981, MOL BIOL YEAST SACCH, P59; Churcher C, 1997, NATURE, V387, P84, DOI 10.1038/387s084; DEZAMAROCZY M, 1986, GENE, V47, P155, DOI 10.1016/0378-1119(86)90060-0; Fairhead C, 1998, GENE, V223, P33, DOI 10.1016/S0378-1119(98)00171-1; Fairhead C, 1996, YEAST, V12, P1439; FAIRHEAD C, 1993, MOL GEN GENET, V240, P170, DOI 10.1007/BF00277054; FARRELLY F, 1983, NATURE, V301, P296, DOI 10.1038/301296a0; Feuermann M, 1997, YEAST, V13, P861, DOI 10.1002/(SICI)1097-0061(199707)13:9<861::AID-YEA125>3.3.CO;2-0; Foury F, 1998, FEBS LETT, V440, P325, DOI 10.1016/S0014-5793(98)01467-7; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Gorbunova V, 1997, NUCLEIC ACIDS RES, V25, P4650, DOI 10.1093/nar/25.22.4650; HAUSWIRTH WW, 1987, MITOCHONDRIA, P171; KRAMER KM, 1994, MOL CELL BIOL, V14, P1293, DOI 10.1128/MCB.14.2.1293; LOUIS EJ, 1991, CURR GENET, V20, P411, DOI 10.1007/BF00317070; MARGULIS L, 1970, P349; Moore JK, 1996, NATURE, V383, P644, DOI 10.1038/383644a0; Perna NT, 1996, CURR BIOL, V6, P128, DOI 10.1016/S0960-9822(02)00441-4; RESNICK MA, 1976, MOL GEN GENET, V143, P119, DOI 10.1007/BF00266917; Roth D., 1988, GENETIC RECOMBINATIO, P621; ROTH DB, 1986, MOL CELL BIOL, V6, P4295, DOI 10.1128/MCB.6.12.4295; Sargent RG, 1997, MOL CELL BIOL, V17, P267, DOI 10.1128/MCB.17.1.267; SCHIESTL RH, 1993, MOL CELL BIOL, V13, P2697, DOI 10.1128/MCB.13.5.2697; Teng SC, 1996, NATURE, V383, P641, DOI 10.1038/383641a0; Thorsness PE, 1996, INT REV CYTOL, V165, P207, DOI 10.1016/S0074-7696(08)62223-8; THORSNESS PE, 1993, GENETICS, V134, P21; THORSNESS PE, 1990, NATURE, V346, P376, DOI 10.1038/346376a0; WACH A, 1994, YEAST, V10, P1793, DOI 10.1002/yea.320101310; Wolfe KH, 1997, NATURE, V387, P708, DOI 10.1038/42711	30	185	192	0	17	NATURE PORTFOLIO	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					96	100		10.1038/47076	http://dx.doi.org/10.1038/47076			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573425				2022-12-28	WOS:000083638600051
J	Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA				Krumholz, HM; Radford, MJ; Wang, Y; Chen, J; Marciniak, TA			Early beta-blocker therapy for acute myocardial infarction in elderly patients	ANNALS OF INTERNAL MEDICINE			English	Article						myocardial infarction; age factors; adrenergic beta-antagonists; time factors; outcome assessment (health care)	COOPERATIVE CARDIOVASCULAR PROJECT; MEDICARE PATIENTS; GUIDELINES; MORTALITY; QUALITY; CARE	Background: Despite the evidence supporting the importance of early beta-blocker therapy, this intervention has received little attention as an indicator of quality of care. Objectives: To determine how often beta-blockers are administered as early treatment of acute myocardial infarction in patients 65 years of age or older, to identify predictors of the decision to use beta-blockers, and to evaluate the association between the early use of beta-blockers and in-hospital mortality. Design: Observational study. Setting: Nongovernment, acute care hospitals in the United States. Patients: Medicare beneficiaries who were 65 years of age or older, were hospitalized with an acute myocardial infarction in 1994 and 1995, and did not have a contraindication to beta-blocker therapy. Measurements: Medical chart review to obtain information about the use of beta-blockers, contraindications to these drugs, patient demographics, and clinical factors. Results: Of the 58 165 patients (from a total of 4414 hospitals), 28 256 (49%) received early beta-blocker therapy. Patients with the highest risk for in-hospital death were the least likely to receive therapy. Patients who received beta-blockers had a lower in-hospital mortality rate than patients who did not receive beta-blockers (odds ratio, 0.81 [95% CI, 0.75 to 0.87]), even after adjustment for baseline differences in demographic, clinical, and treatment characteristics between the two groups. Conclusions: Early beta-blocker therapy was not used for 51% of elderly patients who were hospitalized with an acute myocardial infarction and did not have a contraindication to this therapy. Increasing the early use of beta-blockers for these patients would provide an excellent opportunity to improve their care and outcomes.	Yale Univ, Sch Med, New Haven, CT 06520 USA; Yale New Haven Med Ctr, Ctr Outcomes Res & Evaluat, New Haven, CT USA; US Hlth Care Financing Adm, Baltimore, MD 21244 USA	Yale University; Yale University	Krumholz, HM (corresponding author), Yale Univ, Sch Med, 333 Cedar St,Room IE-61 SHM, New Haven, CT 06520 USA.	harlan.krumholz@yale.edu	, Harlan/AAI-2875-2020	Radford, Martha/0000-0001-7503-9557				[Anonymous], 1986, LANCET, V2, P57; Berger AK, 1998, AM HEART J, V135, P349, DOI 10.1016/S0002-8703(98)70104-8; *BUR CENS, 1991, STAT METR AR DAT BOO; Chen J, 1999, NEW ENGL J MED, V340, P286, DOI 10.1056/NEJM199901283400407; DALEY J, 1988, JAMA-J AM MED ASSOC, V260, P3617, DOI 10.1001/jama.260.24.3617; ELLERBECK EF, 1995, JAMA-J AM MED ASSOC, V273, P1509, DOI 10.1001/jama.273.19.1509; FLEMING C, 1992, MED CARE, V30, P377, DOI 10.1097/00005650-199205000-00001; GOLDMAN L, 1988, NEW ENGL J MED, V319, P152, DOI 10.1056/NEJM198807213190306; HANLEY JA, 1982, RADIOLOGY, V143, P29, DOI 10.1148/radiology.143.1.7063747; HJALMARSON A, 1981, LANCET, V2, P823; HJALMARSON A, 1985, EUR HEART J, V6, P199; HJALMARSON A, 1985, AM J CARDIOL, V56, pG15; HOSMER DW, 1988, BIOMETRICAL J, V30, P911, DOI 10.1002/bimj.4710300805; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Krumholz HM, 1998, JAMA-J AM MED ASSOC, V280, P623, DOI 10.1001/jama.280.7.623; McLaughlin TJ, 1996, ARCH INTERN MED, V156, P799, DOI 10.1001/archinte.156.7.799; *NAT COMM QUAL ASS, 1997, HLTH PLAN EMPL DAT I; Ryan TJ, 1996, J AM COLL CARDIOL, V28, P1328; SEDERHOLM M, 1984, NEW ENGL J MED, V310, P9; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; YUSUF S, 1985, PROG CARDIOVASC DIS, V27, P335, DOI 10.1016/S0033-0620(85)80003-7	21	78	81	1	2	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					648	+		10.7326/0003-4819-131-9-199911020-00003	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00003			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577326				2022-12-28	WOS:000083446200002
J	Chenn, A; Walsh, CA				Chenn, A; Walsh, CA			Neurobiology - Cranking it up a notch	SCIENCE			English	Editorial Material							CELL-FATE; MUTATIONS		Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA; Harvard Univ, Inst Med,Beth Israel Deaconess Med Ctr, Dept Neurol, Div Neurogenet, Boston, MA 02115 USA	Harvard University; Brigham & Women's Hospital; Harvard University; Beth Israel Deaconess Medical Center	Chenn, A (corresponding author), Brigham & Womens Hosp, Dept Pathol, 75 Francis St, Boston, MA 02115 USA.							Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; ARTAVANISTSAKONAS S, 1991, TRENDS GENET, V7, P403, DOI 10.1016/0168-9525(91)90264-Q; ARTAVANISTSAKONAS S, 1995, SCIENCE, V268, P225, DOI 10.1126/science.7716513; Berezovska O, 1999, NEUROSCIENCE, V93, P433, DOI 10.1016/S0306-4522(99)00157-8; Bray S, 1998, CELL, V93, P499, DOI 10.1016/S0092-8674(00)81180-0; De Strooper B, 1999, NATURE, V398, P518, DOI 10.1038/19083; FORTINI ME, 1993, NATURE, V365, P555, DOI 10.1038/365555a0; GINIGER E, 1993, DEVELOPMENT, V117, P431; Giniger E, 1998, NEURON, V20, P667, DOI 10.1016/S0896-6273(00)81007-7; Joutel A, 1996, NATURE, V383, P707, DOI 10.1038/383707a0; Lanford PJ, 1999, NAT GENET, V21, P289, DOI 10.1038/6804; Oda T, 1997, NAT GENET, V16, P235, DOI 10.1038/ng0797-235; Poulson DF, 1937, P NATL ACAD SCI USA, V23, P133, DOI 10.1073/pnas.23.3.133; Sestan N, 1999, SCIENCE, V286, P741, DOI 10.1126/science.286.5440.741; Song WH, 1999, P NATL ACAD SCI USA, V96, P6959, DOI 10.1073/pnas.96.12.6959; Struhl G, 1999, NATURE, V398, P522, DOI 10.1038/19091; WASSLE H, 1983, VISION RES, V23, P1151, DOI 10.1016/0042-6989(83)90029-9; Weinmaster G, 1998, CURR OPIN GENET DEV, V8, P436, DOI 10.1016/S0959-437X(98)80115-9; Ye YH, 1999, NATURE, V398, P525, DOI 10.1038/19096	19	10	12	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 22	1999	286	5440					689	690		10.1126/science.286.5440.689	http://dx.doi.org/10.1126/science.286.5440.689			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10577225				2022-12-28	WOS:000083303200032
J	Casselbrant, ML; Mandel, EM; Fall, PA; Rockette, HE; Kurs-Lasky, M; Bluestone, CD; Ferrell, RE				Casselbrant, ML; Mandel, EM; Fall, PA; Rockette, HE; Kurs-Lasky, M; Bluestone, CD; Ferrell, RE			The heritability of otitis media - A twin and triplet study	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							MULTIPLE-REGRESSION ANALYSIS; PRONE CHILDREN; FAMILY	Context Anatomical, physiological, and epidemiological data indicate that there may be a significant genetic component to prolonged time with and recurrent episodes of otitis media in children. Objective To determine the genetic component of time with and episodes of middle ear effusion and acute otitis media (AOM) during the first 2 years of life. Design Prospective twin and triplet cohort study with enrollment from 1982 through 1995. Setting Otitis Media Research Center in the ear, nose, and throat clinic of Children's Hospital of Pittsburgh, Pittsburgh, Pa. Patients A total of 168 healthy same-sex twin and 7 triplet sets were recruited within the first 2 months of life; zygosity results were available for 140 sets; 138 (99%) of these were followed up for 1 year and 126 (90%) for 2 years. Main Outcome Measures Proportion of time with middle ear effusion, episodes of middle ear effusion, and episodes of AOM by zygosity status, Results At the 2-year end point, the estimate of heritability of time with middle ear effusion was 0.73 (P < .001). The estimates of discordance for 3 or more episodes of middle ear effusion were 0.04 for monozygotic twins and 0.37 for dizygotic twins (P = .01). The estimate of discordance of an episode of AOM in monozygotic twins was 0.04 compared with 0.49 in dizygotic twins (P = .005). Conclusions Our study suggests there is a strong genetic component to the amount of time with middle ear effusion and episodes of middle ear effusion and AOM in children.	Childrens Hosp Pittsburgh, Dept Pediat Otolaryngol, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA USA; Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Human Genet, Pittsburgh, PA USA	Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Casselbrant, ML (corresponding author), Childrens Hosp Pittsburgh, Dept Pediat Otolaryngol, 3705 5th Ave & DeSoto St, Pittsburgh, PA 15213 USA.				NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R01DC002490, P01DC001260] Funding Source: NIH RePORTER; NIDCD NIH HHS [DCO1260, DC02490] Funding Source: Medline	NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		*AM NAT STAND I, 1988, S3391987 ANSI; ASHA (American Speech-Language-Hearing Association), 1990, ASHA S2, V32, P17; BERRY QC, 1980, ANN OTO RHINOL LARYN, V89, P28; CANTEKIN EI, 1983, ANN OTOL RHINOL S107, V92, P6; CHERNY SS, 1992, BEHAV GENET, V22, P489, DOI 10.1007/BF01066617; DAHLBERG GUNNAR, 1945, ACTA OTO LARYNGOL, V33, P378, DOI 10.3109/00016484509120207; Daly KA, 1996, GENET EPIDEMIOL, V13, P451, DOI 10.1002/(SICI)1098-2272(1996)13:5<451::AID-GEPI2>3.0.CO;2-5; DEFRIES JC, 1985, BEHAV GENET, V15, P467, DOI 10.1007/BF01066239; DEKA R, 1995, ELECTROPHORESIS, V16, P1659, DOI 10.1002/elps.11501601275; DIAMANT H, 1977, CHOLESTEATOMA, P319; Doyle, 1977, THESIS U PITTSBURGH; FERRELL RE, 1978, AM J HUM GENET, V30, P539; KALM O, 1994, INT J PEDIATR OTORHI, V30, P151, DOI 10.1016/0165-5876(94)90198-8; Kelly K M, 1993, Int J Pediatr Otorhinolaryngol, V25, P279; Kvaerner KJ, 1997, ANN OTO RHINOL LARYN, V106, P624, DOI 10.1177/000348949710600802; NOZZA RJ, 1992, SCREENING CHILDREN A, P315; Olson JM, 1996, GENET EPIDEMIOL, V13, P489, DOI 10.1002/(SICI)1098-2272(1996)13:5<489::AID-GEPI5>3.0.CO;2-Y; PRELLNER K, 1985, INT J PEDIATR OTORHI, V9, P219, DOI 10.1016/S0165-5876(85)80037-9; PUKANDER J, 1984, P 3 INT S FORT LAUD, P9; Rich SS, 1996, RECENT ADVANCES IN OTITIS MEDIA, P65; SEIFF E, 1979, THESIS U PITTSBURGH; SPIVEY GH, 1977, JOHNS HOPKINS MED J, V140, P43; Stenstrom C, 1997, ACTA OTO-LARYNGOL, V117, P87, DOI 10.3109/00016489709117997; STENSTROM C, 1994, INT J PEDIATR OTORHI, V29, P23, DOI 10.1016/0165-5876(94)90105-8; STOOL SE, 1993, ANN OTO RHINOL LARYN, V92, P5; TEELE DW, 1989, J INFECT DIS, V160, P83, DOI 10.1093/infdis/160.1.83	26	170	176	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2125	2130		10.1001/jama.282.22.2125	http://dx.doi.org/10.1001/jama.282.22.2125			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591333				2022-12-28	WOS:000083971400030
J	Sutton, D				Sutton, D			The whole brain atlas	BRITISH MEDICAL JOURNAL			English	Software Review																			0	7	7	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1507	1507		10.1136/bmj.319.7223.1507	http://dx.doi.org/10.1136/bmj.319.7223.1507			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582957	Green Published			2022-12-28	WOS:000084129200062
J	Schober, M; Schaefer, M; Knoblich, JA				Schober, M; Schaefer, M; Knoblich, JA			Bazooka recruits Inscuteable to orient asymmetric cell divisions in Drosophila neuroblasts	NATURE			English	Article							CAENORHABDITIS-ELEGANS; POLARITY; PROSPERO; PROTEIN; YEAST; NUMB; LOCALIZATION; MECHANISMS; MITOSIS; GENE	Asymmetric cell divisions can be generated by the segregation of determinants into one of the two daughter cells(1-4). In Drosophila, neuroblasts divide asymmetrically along the apical-basal axis shortly after their delamination from the neuroectodermal epithelium. Several proteins, including Numb and Miranda, segregate into the basal daughter cell and are needed for the determination of its correct cell fate(5-10). Both the apical-basal orientation of the mitotic spindle and the localization of Numb and Miranda to the basal cell cortex are directed by Inscuteable, a protein that localizes to the apical cell cortex before and during neuroblast mitosis(11,12). Here we show that the apical localization of Inscuteable requires Bazooka, a protein containing a PDZ domain that is essential for apical-basal polarity in epithelial cells(13,14). Bazooka localizes with Inscuteable in neuroblasts and binds to the Inscuteable localization domain in vitro and in vivo. In embryos lacking both maternal and zygotic bazooka function, Inscuteable no longer localizes asymmetrically in neuroblasts and is instead uniformly distributed in the cytoplasm. Mitotic spindles in neuroblasts are misoriented in these embryos, and the proteins Numb and Miranda fail to localize asymmetrically in metaphase. Our results suggest that direct binding to Bazooka mediates the asymmetric localization of Inscuteable and connects the asymmetric division of neuroblasts to the axis of epithelial apical-basal polarity.	Res Inst Mol Pathol, A-1030 Vienna, Austria	Vienna Biocenter (VBC); Research Institute of Molecular Pathology (IMP)	Knoblich, JA (corresponding author), Res Inst Mol Pathol, Dr Bohr Gasse 7, A-1030 Vienna, Austria.		Knoblich, Juergen A/C-2974-2015; Matthias, Schaefer Ronald/E-9157-2015	Knoblich, Juergen A/0000-0002-6751-3404; Matthias, Schaefer Ronald/0000-0003-1952-8115				Bhat MA, 1999, CELL, V96, P833, DOI 10.1016/S0092-8674(00)80593-0; Chant J, 1996, CURR OPIN CELL BIOL, V8, P557, DOI 10.1016/S0955-0674(96)80035-4; CHOU TB, 1992, GENETICS, V131, P643; ETEMADMOGHADAM B, 1995, CELL, V83, P743, DOI 10.1016/0092-8674(95)90187-6; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; HORVITZ HR, 1992, CELL, V68, P237, DOI 10.1016/0092-8674(92)90468-R; Jan YN, 1998, NATURE, V392, P775, DOI 10.1038/33854; Kennerdell JR, 1998, CELL, V95, P1017, DOI 10.1016/S0092-8674(00)81725-0; KNOBLICH JA, 1995, NATURE, V377, P624, DOI 10.1038/377624a0; Knoblich JA, 1999, CURR BIOL, V9, P155, DOI 10.1016/S0960-9822(99)80070-0; Knoblich JA, 1997, CURR OPIN CELL BIOL, V9, P833, DOI 10.1016/S0955-0674(97)80085-3; Kraut R, 1996, NATURE, V383, P50, DOI 10.1038/383050a0; Kraut R, 1996, DEV BIOL, V174, P65, DOI 10.1006/dbio.1996.0052; Kuchinke U, 1998, CURR BIOL, V8, P1357, DOI 10.1016/S0960-9822(98)00016-5; Lu BW, 1998, CURR OPIN GENET DEV, V8, P392, DOI 10.1016/S0959-437X(98)80108-1; Madden K, 1998, ANNU REV MICROBIOL, V52, P687, DOI 10.1146/annurev.micro.52.1.687; Matsuzaki F, 1998, DEVELOPMENT, V125, P4089; McKim KS, 1996, GENETICS, V144, P215; Misquitta L, 1999, P NATL ACAD SCI USA, V96, P1451, DOI 10.1073/pnas.96.4.1451; Muller HAJ, 1996, J CELL BIOL, V134, P149, DOI 10.1083/jcb.134.1.149; RHYU MS, 1994, CELL, V76, P477, DOI 10.1016/0092-8674(94)90112-0; Shen CP, 1997, CELL, V90, P449, DOI 10.1016/S0092-8674(00)80505-X; SPANA EP, 1995, DEVELOPMENT, V121, P3187; SPANA EP, 1995, DEVELOPMENT, V121, P3489; WADDLE JA, 1994, DEVELOPMENT, V120, P2317	25	297	301	1	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					548	551		10.1038/990135	http://dx.doi.org/10.1038/990135			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591217				2022-12-28	WOS:000084013200061
J	Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V				Sinha, S; Anderson, JP; Barbour, R; Basi, GS; Caccavello, R; Davis, D; Doan, M; Dovey, HF; Frigon, N; Hong, J; Jacobson-Croak, K; Jewett, N; Keim, P; Knops, J; Lieberburg, I; Power, M; Tan, H; Tatsuno, G; Tung, J; Schenk, D; Seubert, P; Suomensaari, SM; Wang, SW; Walker, D; Zhao, J; McConlogue, L; John, V			Purification and cloning of amyloid precursor protein beta-secretase from human brain	NATURE			English	Article							ALZHEIMERS-DISEASE; INHIBITOR; MUTATION; TERMINUS	Proteolytic processing of the amyloid precursor protein (APP) generates amyloid beta (A beta) peptide, which is thought to be causal for the pathology and subsequent cognitive decline in Alzheimer's disease. Cleavage by beta-secretase at the amino terminus of the A beta peptide sequence, between residues 671 and 672 of APP, leads to the generation and extracellular release of beta-cleaved soluble APP(1), and a corresponding cell-associated carboxy-terminal fragment. Cleavage of the C-terminal fragment by gamma-secretase(s) leads to the formation of A beta. The pathogenic mutation K670M671 --> N670L671 at the beta-secretase cleavage site in APP(2), which was discovered in a Swedish family with familial Alzheimer's disease, leads to increased beta-secretase cleavage of the mutant substrate(3). Here we describe a membrane-bound enzyme activity that cleaves full-length APP at the beta-secretase cleavage site, and find it to be the predominant beta-cleavage activity in human brain. We have purified this enzyme activity to homogeneity from human brain using a new substrate analogue inhibitor of the enzyme activity, and show that the purified enzyme has all the properties predicted for beta-secretase. Cloning and expression of the enzyme reveals that human brain beta-secretase is a new membrane-bound aspartic proteinase.	Elan Pharmaceut, S San Francisco, CA 94080 USA		Sinha, S (corresponding author), Elan Pharmaceut, 800 Gateway Blvd, S San Francisco, CA 94080 USA.							CITRON M, 1992, NATURE, V360, P672, DOI 10.1038/360672a0; JohnsonWood K, 1997, P NATL ACAD SCI USA, V94, P1550, DOI 10.1073/pnas.94.4.1550; KNOPS J, 1995, J BIOL CHEM, V270, P2419, DOI 10.1074/jbc.270.6.2419; KNOPS J, 1991, J BIOL CHEM, V266, P7285; Lin J H, 1998, Pharm Biotechnol, V11, P233; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Narutaki S, 1999, J BIOCHEM, V125, P75, DOI 10.1093/oxfordjournals.jbchem.a022271; Rich D. H., 1986, PROTEINASE INHIBITOR; SCHECHTER I, 1967, BIOCHEM BIOPH RES CO, V27, P157, DOI 10.1016/S0006-291X(67)80055-X; SEUBERT P, 1993, NATURE, V361, P260, DOI 10.1038/361260a0; VALDES F, 1977, BRAIN RES, V122, P95, DOI 10.1016/0006-8993(77)90665-5; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	12	1413	1554	0	77	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					537	540		10.1038/990114	http://dx.doi.org/10.1038/990114			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591214				2022-12-28	WOS:000084013200058
J	Henney, JE				Henney, JE			Complications related to vascular hemostasis devices	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-28	WOS:000083908700004
J	Steinberg, D; Gotto, AM				Steinberg, D; Gotto, AM			Preventing coronary artery disease by lowering cholesterol levels - Fifty years from bench to bedside	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							LOW-DENSITY-LIPOPROTEIN; HEART-DISEASE; MYOCARDIAL-INFARCTION; REDUCTASE INHIBITORS; ATHEROSCLEROSIS; MEN; PATHOGENESIS; REGRESSION; EVENTS; RISK	In the more than 50 years since the founding of the National Heart, Lung, and Blood Institute and the American Heart Association, medical science has moved from an era in which hypercholesterolemia, as it is now defined, was not believed to be abnormal to one in which controlling hypercholesterolemia is known to reduce not only coronary artery disease morbidity and mortality but also total mortality, While the efforts and successes of many researchers involved in this evolution are impressive, atherosclerosis is still a major cause of death and disability in many developed nations, mostly in the form of myocardial infarction and stroke, and is an increasing cause of morbidity and mortality in developing nations, Many questions about the detailed pathogenesis of the disease remain, Elucidating the roles of high-density lipoprotein, other lipoproteins, and homocysteine, as well as the roles of cytokines and growth factors, will permit better understanding and treatment of atherosclerosis, With continuing support for research and encouragement of physicians and patients to follow recommended preventive regimens, further progress can be made against this major cause of death.	Cornell Univ, Weill Med Coll, Dept Med, New York, NY 10021 USA; Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA	Cornell University; University of California System; University of California San Diego	Gotto, AM (corresponding author), Cornell Univ, Weill Med Coll, Dept Med, 445 E 69th St,Olin Hall Room 205, New York, NY 10021 USA.							Alpha-Tocopherol Beta Carotene Cancer Prevention Study Group, 1994, N Engl J Med, V330, P1029, DOI 10.1056/NEJM199404143301501; ANFINSEN CB, 1954, FAT METABOLISM, P93; BLANKENHORN DH, 1991, CIRCULATION, V83, P438, DOI 10.1161/01.CIR.83.2.438; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BROWN MS, 1986, SCIENCE, V232, P34, DOI 10.1126/science.3513311; BROWN MS, 1980, J SUPRAMOL STR CELL, V13, P67, DOI 10.1002/jss.400130107; BUCHWALD H, 1992, JAMA-J AM MED ASSOC, V268, P1429, DOI 10.1001/jama.268.11.1429; CANNER PL, 1986, J AM COLL CARDIOL, V8, P1245, DOI 10.1016/S0735-1097(86)80293-5; CASTELLI WP, 1984, AM J MED, V76, P4, DOI 10.1016/0002-9343(84)90952-5; CLEEMAN JI, 1988, ARCH INTERN MED, V148, P36, DOI 10.1001/archinte.148.1.36; DAVIES MJ, 1984, NEW ENGL J MED, V310, P1137, DOI 10.1056/NEJM198405033101801; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; ENDO A, 1992, J LIPID RES, V33, P1569; Endres M, 1998, P NATL ACAD SCI USA, V95, P8880, DOI 10.1073/pnas.95.15.8880; Ernst N.D., 1985, ARTERIOSCLEROSIS, V43, P404; ESTERBAUER H, 1991, AM J CLIN NUTR, V53, pS314, DOI 10.1093/ajcn/53.1.314S; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P148, DOI 10.1056/NEJM196701192760305; FREDRICK.DS, 1967, NEW ENGL J MED, V276, P273, DOI 10.1056/NEJM196702022760507; FREDRICKSON DONALD S., 1967, N ENGL J MED, V276, P34, DOI 10.1056/NEJM196701052760107; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P94, DOI 10.1056/NEJM196701122760206; FREDRICKSON DS, 1967, NEW ENGL J MED, V276, P215, DOI 10.1056/NEJM196701262760406; FRUCHART JC, 1992, CLIN CHEM, V38, P793; GOFMAN JW, 1954, PLASMA, V2, P414; GOLDSTEIN JL, 1973, J CLIN INVEST, V52, P1544, DOI 10.1172/JCI107332; HAVEL RJ, 1955, J CLIN INVEST, V34, P1345, DOI 10.1172/JCI103182; HENRIKSEN T, 1981, P NATL ACAD SCI-BIOL, V78, P6499, DOI 10.1073/pnas.78.10.6499; HULLEY SB, 1992, CIRCULATION, V86, P1026, DOI 10.1161/01.CIR.86.3.1026; KANE JP, 1990, JAMA-J AM MED ASSOC, V264, P3007, DOI 10.1001/jama.264.23.3007; KEYS A, 1970, CIRCULATION, V41, pI1; Kuivenhoven JA, 1995, J CLIN INVEST, V96, P2783, DOI 10.1172/JCI118348; LANGER T, 1972, J CLIN INVEST, V51, P1528, DOI 10.1172/JCI106949; LAROSA JC, 1970, BIOCHEM BIOPH RES CO, V41, P57, DOI 10.1016/0006-291X(70)90468-7; LEVY RI, 1984, CIRCULATION, V69, P325, DOI 10.1161/01.CIR.69.2.325; LIBBY P, 1995, CIRCULATION, V91, P2844, DOI 10.1161/01.CIR.91.11.2844; LUX SE, 1972, J CLIN INVEST, V51, P2505, DOI 10.1172/JCI107066; MAHLEY RW, 1985, ANN NY ACAD SCI, V454, P209, DOI 10.1111/j.1749-6632.1985.tb11860.x; MANNINEN V, 1992, CIRCULATION, V85, P37, DOI 10.1161/01.CIR.85.1.37; MCNAMARA DJ, 1987, J CLIN INVEST, V79, P1729, DOI 10.1172/JCI113013; MILLER NE, 1978, LIPIDS, V13, P914, DOI 10.1007/BF02533850; MOORE TJ, 1989, ATLANTIC, V264, P37; Muller C, 1939, ARCH INTERN MED, V64, P675; *NAT DIET HEART ST, 1968, AM HEART ASS MON, V18; OLIVER M F, 1978, British Heart Journal, V40, P1069, DOI 10.1136/hrt.40.10.1069; OLIVER MF, 1984, LANCET, V2, P600; ONCLEY JL, 1969, P NATL ACAD SCI USA, V64, P1107, DOI 10.1073/pnas.64.3.1107; PEDERSEN TR, 1994, LANCET, V344, P1383; PETERS JP, 1948, QUANTITATIVE CLIN CH, P1931; PITTMAN RC, 1986, RECEPTOR MEDIATED UP, P108; PLUMP AS, 1995, ANNU REV NUTR, V15, P495, DOI 10.1146/annurev.nu.15.070195.002431; Qizilbash N, 1995, LANCET, V346, P1647; RIFKIND BM, 1984, JAMA-J AM MED ASSOC, V251, P351; Rimm EB, 1997, CURR OPIN CARDIOL, V12, P188, DOI 10.1097/00001573-199703000-00016; ROSS R, 1974, P NATL ACAD SCI USA, V71, P1207, DOI 10.1073/pnas.71.4.1207; ROSS R, 1986, NEW ENGL J MED, V314, P488, DOI 10.1056/NEJM198602203140806; ROSS R, 1976, NEW ENGL J MED, V295, P420, DOI 10.1056/NEJM197608192950805; ROSS R, 1976, NEW ENGL J MED, V295, P369, DOI 10.1056/NEJM197608122950707; RUSK H, 1948, NY TIMES        0711, P27; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SEGREST JP, 1974, FEBS LETT, V38, P247, DOI 10.1016/0014-5793(74)80064-5; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIRTORI CR, 1985, KLIN WOCHENSCHR, V63, P481, DOI 10.1007/BF01747977; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Stein JH, 1998, ARCH INTERN MED, V158, P1301, DOI 10.1001/archinte.158.12.1301; STEINBERG D, 1983, ARTERIOSCLEROSIS, V3, P283, DOI 10.1161/01.ATV.3.4.283; Steinberg D, 1997, CIRCULATION, V95, P1062; STEINBERG D, 1989, NEW ENGL J MED, V320, P915; Stephens NG, 1996, LANCET, V347, P781, DOI 10.1016/S0140-6736(96)90866-1; Strong JP, 1997, ANN NY ACAD SCI, V811, P226, DOI 10.1111/j.1749-6632.1997.tb52004.x; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATSON AD, 1995, J CLIN INVEST, V95, P774, DOI 10.1172/JCI117726; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WOOD PDS, 1966, LANCET, V2, P604; YANG CY, 1986, NATURE, V323, P738, DOI 10.1038/323738a0; Zhong SB, 1996, J CLIN INVEST, V97, P2917, DOI 10.1172/JCI118751	74	108	115	1	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2043	2050		10.1001/jama.282.21.2043	http://dx.doi.org/10.1001/jama.282.21.2043			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591387				2022-12-28	WOS:000083908700024
J	Matsumoto, I; Staub, A; Benoist, C; Mathis, D				Matsumoto, I; Staub, A; Benoist, C; Mathis, D			Arthritis provoked by linked T and B cell recognition of a glycolytic enzyme	SCIENCE			English	Article							RHEUMATOID-ARTHRITIS; AUTOIMMUNITY; COLLAGEN; MODEL	The hallmark of rheumatoid arthritis (RA) is specific destruction of the synovial joints. In a mouse line that spontaneously develops a disorder with many of the features of human RA, disease is initiated by T cell recognition of a ubiquitously expressed self-antigen; once initiated, pathology is driven almost entirely by immunoglobulins. In this study, the target of both the initiating T cells and pathogenic immunoglobulins was identified as glucose-6-phosphate isomerase, a glycolytic enzyme, Thus, some forms of RA or related arthritides may develop by a mechanism fundamentally different from the currently popular paradigm of a joint-specific T cell response.	ULP, INSERM, CNRS, Inst Genet & Biol Mol & Cellulaire, F-67404 Illkirch, CU Strasbourg, France	Centre National de la Recherche Scientifique (CNRS); Institut National de la Sante et de la Recherche Medicale (Inserm); UDICE-French Research Universities; Universites de Strasbourg Etablissements Associes; Universite de Strasbourg	Benoist, C (corresponding author), Harvard Univ, Sch Med, Joslin Diabet Ctr, 1 Joslin Pl, Boston, MA 02215 USA.							Amigorena S, 1998, CURR OPIN IMMUNOL, V10, P88, DOI 10.1016/S0952-7915(98)80037-X; Burmester GR, 1997, ARTHRITIS RHEUM, V40, P5, DOI 10.1002/art.1780400104; Feldmann M, 1996, CELL, V85, P307, DOI 10.1016/S0092-8674(00)81109-5; Fox DA, 1997, ARTHRITIS RHEUM, V40, P598, DOI 10.1002/art.1780400403; HALLBOOK F, 1989, J NEUROSCI RES, V23, P142, DOI 10.1002/jnr.490230204; Kalden JR, 1998, ARTHRITIS RHEUM, V41, P191, DOI 10.1002/1529-0131(199802)41:2<191::AID-ART2>3.0.CO;2-C; KEFFER J, 1991, EMBO J, V10, P4025, DOI 10.1002/j.1460-2075.1991.tb04978.x; Korganow AS, 1999, IMMUNITY, V10, P451, DOI 10.1016/S1074-7613(00)80045-X; Kouskoff V, 1996, CELL, V87, P811, DOI 10.1016/S0092-8674(00)81989-3; MANGIALAIO S, IN PRESS ARTHRITIS R; MATSUMOTO I, UNPUB; NAPORSTECK Y, 1993, ANNU REV IMMUNOL, V11, P79; NERI B, 1983, ONCOLOGY, V40, P332, DOI 10.1159/000225756; OHNO O, 1978, ARTHRITIS RHEUM, V21, P516, DOI 10.1002/art.1780210505; PECCOUD J, 1990, EMBO J, V9, P4215, DOI 10.1002/j.1460-2075.1990.tb07869.x; Thomas R, 1996, ARTHRITIS RHEUM, V39, P183, DOI 10.1002/art.1780390202; TRENTHAM DE, 1977, J EXP MED, V146, P857, DOI 10.1084/jem.146.3.857; WARNER CM, 1985, GERONTOLOGY, V31, P315, DOI 10.1159/000212715; WEST JD, 1990, GENET RES, V56, P223, DOI 10.1017/S0016672300035321; Zvaifler N J, 1973, Adv Immunol, V16, P265, DOI 10.1016/S0065-2776(08)60299-0	20	462	488	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1732	1735		10.1126/science.286.5445.1732	http://dx.doi.org/10.1126/science.286.5445.1732			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576739				2022-12-28	WOS:000083912200037
J	Nassar, GM; Ayus, JC				Nassar, GM; Ayus, JC			Brown tumor in end-stage renal disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Baylor Coll Med, Houston, TX 77030 USA	Baylor College of Medicine	Nassar, GM (corresponding author), Baylor Coll Med, Houston, TX 77030 USA.		Nassar, George/T-2400-2019						0	15	17	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1652	1652		10.1056/NEJM199911253412204	http://dx.doi.org/10.1056/NEJM199911253412204			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572153				2022-12-28	WOS:000083847500004
J	Knoepfler, PS; Eisenman, RN				Knoepfler, PS; Eisenman, RN			Sin meets NuRD and other tails of repression	CELL			English	Review							HISTONE DEACETYLASE; COMPLEX		Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center	Eisenman, RN (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA.			Knoepfler, Paul/0000-0001-5444-334X				Bird AP, 1999, CELL, V99, P451, DOI 10.1016/S0092-8674(00)81532-9; Chen GQ, 1999, GENE DEV, V13, P2218, DOI 10.1101/gad.13.17.2218; Cosma MP, 1999, CELL, V97, P299, DOI 10.1016/S0092-8674(00)80740-0; Grozinger CM, 1999, P NATL ACAD SCI USA, V96, P4868, DOI 10.1073/pnas.96.9.4868; Harbour JW, 1999, CELL, V98, P859, DOI 10.1016/S0092-8674(00)81519-6; Kehle J, 1998, SCIENCE, V282, P1897, DOI 10.1126/science.282.5395.1897; Koipally J, 1999, EMBO J, V18, P3090, DOI 10.1093/emboj/18.11.3090; Krebs JE, 1999, GENE DEV, V13, P1412, DOI 10.1101/gad.13.11.1412; Maldonado E, 1999, CELL, V99, P455, DOI 10.1016/S0092-8674(00)81533-0; Mannervik M, 1999, P NATL ACAD SCI USA, V96, P6797, DOI 10.1073/pnas.96.12.6797; Miska EA, 1999, EMBO J, V18, P5099, DOI 10.1093/emboj/18.18.5099; Nomura T, 1999, GENE DEV, V13, P412, DOI 10.1101/gad.13.4.412; Solari F, 1999, DEVELOPMENT, V126, P2483; Struhl K, 1998, GENE DEV, V12, P599, DOI 10.1101/gad.12.5.599; Sun FL, 1999, CELL, V99, P459, DOI 10.1016/S0092-8674(00)81534-2; Tong JK, 1998, NATURE, V395, P917, DOI 10.1038/27699; Tsai CC, 1999, MOL CELL, V4, P175, DOI 10.1016/S1097-2765(00)80365-2; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wade PA, 1998, CURR BIOL, V8, P843, DOI 10.1016/S0960-9822(98)70328-8; Wotton D, 1999, CELL, V97, P29, DOI 10.1016/S0092-8674(00)80712-6; Xue YT, 1998, MOL CELL, V2, P851, DOI 10.1016/S1097-2765(00)80299-3; Zhang Y, 1998, CELL, V95, P279, DOI 10.1016/S0092-8674(00)81758-4	22	297	318	0	8	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					447	450		10.1016/S0092-8674(00)81531-7	http://dx.doi.org/10.1016/S0092-8674(00)81531-7			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589671	Bronze			2022-12-28	WOS:000083986300002
J	Denays, R; Collier, A; Rubinstein, M; Atsama, P				Denays, R; Collier, A; Rubinstein, M; Atsama, P			A 51-year-old woman with disorientation and amnesia	LANCET			English	Article							HERPES-SIMPLEX ENCEPHALITIS; DIAGNOSIS		Ctr Hosp Etterbeeklxelles, Serv Neurol, B-1050 Brussels, Belgium		Denays, R (corresponding author), Ctr Hosp Etterbeeklxelles, Serv Neurol, Rue Jean Paquot 63, B-1050 Brussels, Belgium.							Angus F, 1998, J S C Med Assoc, V94, P315; BHARUCHA NE, 1992, NEUROLOGY CLIN PRACT, P1049; HOOSHMAND H, 1972, J AMER MED ASSOC, V219, P726; LAUNES J, 1988, LANCET, V1, P1188; WHITLEY RJ, 1989, JAMA-J AM MED ASSOC, V262, P234, DOI 10.1001/jama.262.2.234	5	29	31	0	2	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1786	1786		10.1016/S0140-6736(99)09151-5	http://dx.doi.org/10.1016/S0140-6736(99)09151-5			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577641				2022-12-28	WOS:000083853000014
J	Dunn, MH; Ebrahimzadeh, M				Dunn, MH; Ebrahimzadeh, M			Parametric generation of tunable light from continuous-wave to femtosecond pulses	SCIENCE			English	Review							POLED LITHIUM-NIOBATE; SOLID-STATE LASER; TI-SAPPHIRE LASER; HIGH-POWER; OSCILLATOR; RBTIOASO4; LINBO3; LIB3O5	By exploiting nonlinear optical effects, a technology of unprecedented flexibility for the production of tunable coherent light has been developed. Referred to as optical parametric generation, it provides sources with spectral coverage extending all the way from the ultraviolet to the mid-infrared, and with temporal coverage extending over all time domains from the femtosecond pulse to the continuous wave. Such sources generate coherent light of outstanding optical quality and are now finding wide-ranging applications.	Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland	University of St Andrews	Dunn, MH (corresponding author), Univ St Andrews, Sch Phys & Astron, St Andrews KY16 9SS, Fife, Scotland.							Al-Tahtamouni R, 1998, APPL PHYS B-LASERS O, V66, P733, DOI 10.1007/s003400050460; Batchko RG, 1998, OPT LETT, V23, P168, DOI 10.1364/OL.23.000168; BOONENGERING JM, 1995, OPT LETT, V20, P380, DOI 10.1364/OL.20.000380; BOSENBERG WR, 1995, J OPT SOC AM B, V12, P2084; Bosenberg WR, 1998, OPT LETT, V23, P207, DOI 10.1364/OL.23.000207; BOSENBERG WR, 1993, J OPT SOC AM B, V10, P1716, DOI 10.1364/JOSAB.10.001716; Bosenberg WR, 1996, OPT LETT, V21, P713, DOI 10.1364/OL.21.000713; Bosenberg WR, 1996, OPT LETT, V21, P1336, DOI 10.1364/OL.21.001336; Britton PE, 1998, OPT LETT, V23, P582, DOI 10.1364/OL.23.000582; BROMLEY LJ, 1989, OPT COMMUN, V70, P350, DOI 10.1016/0030-4018(89)90333-7; BURNEIKA K, 1972, IEEE J QUANTUM ELECT, VQE 8, P574, DOI 10.1109/JQE.1972.1077077; Burr KC, 1997, APPL PHYS LETT, V70, P3341, DOI 10.1063/1.119164; Butterworth SD, 1996, OPT LETT, V21, P1345, DOI 10.1364/OL.21.001345; Byer R.L., 1973, TREATISE QUANTUM ELE; BYER RL, 1968, APPL PHYS LETT, V13, P109, DOI 10.1063/1.1652520; BYER RL, 1993, J OPT SOC AM B, V10, P1656, DOI 10.1364/JOSAB.10.001656; BYER RL, 1993, J OPT SOC AM B, V10, P2148; CHENG LK, 1988, APPL PHYS LETT, V53, P175, DOI 10.1063/1.100582; CONROY RS, 1999, OPTICAL SOC AM TECHN, P516; CUI Y, 1992, OPT LETT, V17, P646, DOI 10.1364/OL.17.000646; CUI Y, 1993, OPT LETT, V18, P122, DOI 10.1364/OL.18.000122; DANIELIUS R, 1993, J OPT SOC AM B, V10, P2222, DOI 10.1364/JOSAB.10.002222; DRISCOLL TJ, 1994, OPT COMMUN, V110, P638, DOI 10.1016/0030-4018(94)90265-8; DUDLEY JM, 1994, OPT COMMUN, V104, P419, DOI 10.1016/0030-4018(94)90578-9; Ebrahimzadeh M, 1999, J OPT SOC AM B, V16, P1499, DOI 10.1364/JOSAB.16.001499; EBRAHIMZADEH M, 1995, OPT LETT, V20, P166, DOI 10.1364/OL.20.000166; Ebrahimzadeh M, 1999, J OPT SOC AM B, V16, P1477, DOI 10.1364/JOSAB.16.001477; EBRAHIMZADEH M, 1992, OPT LETT, V17, P183, DOI 10.1364/OL.17.000183; EDELSTEIN DC, 1989, APPL PHYS LETT, V54, P1728, DOI 10.1063/1.101272; ELLINGSON RJ, 1993, OPT LETT, V18, P438, DOI 10.1364/OL.18.000438; FAN YX, 1988, APPL PHYS LETT, V53, P2014, DOI 10.1063/1.100492; French S, 1996, OPT LETT, V21, P976, DOI 10.1364/OL.21.000976; FU Q, 1992, OPT LETT, V17, P1006, DOI 10.1364/OL.17.001006; Gibson GM, 1998, OPT LETT, V23, P517, DOI 10.1364/OL.23.000517; Gibson GM, 1998, OPT LETT, V23, P40, DOI 10.1364/OL.23.000040; Gibson GM, 1999, OPT LETT, V24, P397, DOI 10.1364/OL.24.000397; GIORDMAINE JA, 1965, PHYS REV LETT, V14, P973, DOI 10.1103/PhysRevLett.14.973; JOHNSON, 1995, J OPT SOC AM B, V10, P2122; Karlsson H, 1997, APPL PHYS LETT, V71, P3474, DOI 10.1063/1.120363; Kennedy GT, 1998, OPT LETT, V23, P503, DOI 10.1364/OL.23.000503; KLEIN ME, 1999, OSA TECHNICAL DIGEST, P6; MAKER GT, 1990, APPL PHYS LETT, V56, P1614, DOI 10.1063/1.103142; MCCARTHY MJ, 1992, OPT LETT, V17, P402, DOI 10.1364/OL.17.000402; McGowan C, 1998, J OPT SOC AM B, V15, P694, DOI 10.1364/JOSAB.15.000694; MYERS LE, 1995, J OPT SOC AM B, V12, P2102, DOI 10.1364/JOSAB.12.002102; MYERS LE, 1995, OPT LETT, V20, P52, DOI 10.1364/OL.20.000052; NEBEL A, 1993, J OPT SOC AM B, V10, P2195, DOI 10.1364/JOSAB.10.002195; PELOUCH WS, 1992, OPT LETT, V17, P1070, DOI 10.1364/OL.17.001070; POWERS PE, 1994, OPT LETT, V19, P1439, DOI 10.1364/OL.19.001439; POWERS PE, 1994, OPT LETT, V19, P37, DOI 10.1364/OL.19.000037; POWERS PE, 1993, OPT LETT, V18, P1171, DOI 10.1364/OL.18.001171; Powers PE, 1998, OPT LETT, V23, P159, DOI 10.1364/OL.23.000159; Reid DT, 1997, OPT LETT, V22, P1397, DOI 10.1364/OL.22.001397; REID DT, 1994, OPT LETT, V19, P825, DOI 10.1364/OL.19.000825; REID DT, 1995, J OPT SOC AM B, V12, P1157, DOI 10.1364/JOSAB.12.001157; ROBERTSON G, 1994, OPT LETT, V19, P1735, DOI 10.1364/OL.19.001735; Schneider K, 1997, OPT LETT, V22, P1293, DOI 10.1364/OL.22.001293; SMITH RG, 1968, J APPL PHYS, V39, P4030, DOI 10.1063/1.1656899; SPENCE DE, 1995, OPT LETT, V20, P680, DOI 10.1364/OL.20.000680; Varanavicius A, 1997, OPT LETT, V22, P1603, DOI 10.1364/OL.22.001603; YANG ST, 1993, OPT LETT, V18, P971, DOI 10.1364/OL.18.000971	61	190	200	10	84	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1513	1517		10.1126/science.286.5444.1513	http://dx.doi.org/10.1126/science.286.5444.1513			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567249				2022-12-28	WOS:000083768300045
J	Fiscella, K; Franks, P				Fiscella, K; Franks, P			Influence of patient education on profiles of physician practices	ANNALS OF INTERNAL MEDICINE			English	Article						physician practice patterns; patient satisfaction; educational status; health status; social class	ACUTE MYOCARDIAL-INFARCTION; CASE-MIX ADJUSTMENT; FORM HEALTH SURVEY; SOCIOECONOMIC-STATUS; MEDICAL-CARE; WHITEHALL-II; PREVENTABLE HOSPITALIZATIONS; REVASCULARIZATION PROCEDURES; SOCIODEMOGRAPHIC FACTORS; RACIAL-DIFFERENCES	Background: Few data are available about the effect of patient socioeconomic status on profiles of physician practices. Objective: To determine the ways in which adjustment for patients' level of education las a measure of socioeconomic status) changes profiles of physician practices. Design: Cross-sectional survey of patients in physician practices. Setting: Managed care organization in western New York State. Participants: A random sample of 100 primary care physicians and 50 consecutive patients seen by each physician. Measurements: Ranks of physicians for patient physical and mental health (Short Form 12-item Health Survey) and satisfaction (Patient Satisfaction Questionnaire), adjusted for patient age, sex, morbidity, and education. Results: Physicians whose patients had a lower mean level of education had significantly better ranks for patient physical and mental health status after adjustment for patients' level of education level than they did before adjustment (P < 0.001); this result was not seen for patient satisfaction. After adjustment for patients' level of education, each 1-year decrease in mean educational level was associated with a rank that improved by 8.1 (95% CI, 6.6 to 9.6) for patient physical health status and by 4.9 (CI, 3.9 to 5.9) for patient mental health status. Adjustment for education had similar effects for practices with more educated patients and those with less educated patients. Conclusions: Profiles of physician practices that base ratings of physician performance on patients' physical and mental health status a re substantially affected by patients' level of education. However, these results do not suggest that physicians who care for less educated patients provide worse care. Physician profiling should account for differences in patients' level of education.	Univ Rochester, Sch Med & Dent, Rochester, NY USA	University of Rochester	Fiscella, K (corresponding author), Family Med Ctr, 885 South Ave, Rochester, NY 14620 USA.		Dalla Zuanna, Teresa/G-3133-2015; Fiscella, Kevin Anthony/AFO-3350-2022	Fiscella, Kevin Anthony/0000-0003-3613-8012	AHRQ HHS [R01 HS09397-01] Funding Source: Medline	AHRQ HHS(United States Department of Health & Human ServicesAgency for Healthcare Research & Quality)		AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; BINDMAN AB, 1995, JAMA-J AM MED ASSOC, V274, P305, DOI 10.1001/jama.274.4.305; Blustein J, 1998, HEALTH AFFAIR, V17, P177, DOI 10.1377/hlthaff.17.2.177; Brook RH, 1996, NEW ENGL J MED, V335, P966, DOI 10.1056/NEJM199609263351311; CALLE EE, 1993, AM J PUBLIC HEALTH, V83, P53, DOI 10.2105/AJPH.83.1.53; Chang J, 1996, AMERASIA J, V22, P1; Christiansen CL, 1997, ANN INTERN MED, V127, P764, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00065; Clancy CM, 1998, SCIENCE, V282, P245, DOI 10.1126/science.282.5387.245; Cooper JK, 1998, ARCH FAM MED, V7, P415, DOI 10.1001/archfami.7.5.415; Epstein AM, 1998, JAMA-J AM MED ASSOC, V279, P1691, DOI 10.1001/jama.279.21.1691; EPSTEIN AM, 1985, SOC SCI MED, V21, P1071, DOI 10.1016/0277-9536(85)90162-5; FEIN O, 1995, J GEN INTERN MED, V10, P577, DOI 10.1007/BF02640369; Ferguson JA, 1997, J AM COLL CARDIOL, V30, P1707, DOI 10.1016/S0735-1097(97)00365-3; Fiscella K, 1997, SOC SCI MED, V45, P1805, DOI 10.1016/S0277-9536(97)00111-1; Fiscella K, 1998, MED CARE, V36, P180, DOI 10.1097/00005650-199802000-00007; Fiscella K, 1999, J FAM PRACTICE, V48, P372; Fowles JB, 1996, JAMA-J AM MED ASSOC, V276, P1316, DOI 10.1001/jama.276.16.1316; Franks P, 1999, HEALTH SERV RES, V34, P323; Gandek B, 1998, J CLIN EPIDEMIOL, V51, P1171, DOI 10.1016/S0895-4356(98)00109-7; Geronimus AT, 1998, AM J EPIDEMIOL, V148, P475; GOLDBERG KC, 1992, JAMA-J AM MED ASSOC, V267, P1473, DOI 10.1001/jama.267.11.1473; Goldstein H, 1996, J ROY STAT SOC A STA, V159, P385, DOI 10.2307/2983325; GREEN J, 1995, NEW ENGL J MED, V332, P1229, DOI 10.1056/NEJM199505043321812; HALL JA, 1993, MED CARE, V31, P84, DOI 10.1097/00005650-199301000-00007; HALL JA, 1990, SOC SCI MED, V30, P811, DOI 10.1016/0277-9536(90)90205-7; Harpole LH, 1996, J GEN INTERN MED, V11, P431, DOI 10.1007/BF02600192; Hemingway H, 1997, AM J PUBLIC HEALTH, V87, P1484, DOI 10.2105/AJPH.87.9.1484; Hemingway H, 1997, BMJ-BRIT MED J, V315, P1273, DOI 10.1136/bmj.315.7118.1273; HSIA DC, 1992, JAMA-J AM MED ASSOC, V268, P896, DOI 10.1001/jama.268.7.896; Jenkinson C, 1997, J PUBLIC HEALTH MED, V19, P179, DOI 10.1093/oxfordjournals.pubmed.a024606; Johnson JA, 1998, QUAL LIFE RES, V7, P155, DOI 10.1023/A:1008809610703; Katz JN, 1996, MED CARE, V34, P73, DOI 10.1097/00005650-199601000-00006; Kikano GE, 1996, ARCH FAM MED, V5, P267, DOI 10.1001/archfami.5.5.267; KRIEGER N, 1992, AM J PUBLIC HEALTH, V82, P703, DOI 10.2105/AJPH.82.5.703; Lantz PM, 1998, JAMA-J AM MED ASSOC, V279, P1703, DOI 10.1001/jama.279.21.1703; LOHR KN, 1992, MED CARE, V30, pMS1, DOI 10.1097/00005650-199205001-00001; Lynch JW, 1996, AM J EPIDEMIOL, V144, P934, DOI 10.1093/oxfordjournals.aje.a008863; MARMOT MG, 1991, LANCET, V337, P1387, DOI 10.1016/0140-6736(91)93068-K; MCNEIL BJ, 1992, INQUIRY-J HEALTH CAR, V29, P298; Newacheck PW, 1996, PEDIATRICS, V97, P26; Normand SLT, 1997, J AM STAT ASSOC, V92, P803, DOI 10.2307/2965545; NUNNALLY JC, 1994, ANONYMOUS PSYCHOMETR; Patrick DL, 1997, MED CARE, V35, pNS49, DOI 10.1097/00005650-199711001-00006; Persky VW, 1998, ANN ALLERG ASTHMA IM, V81, P266, DOI 10.1016/S1081-1206(10)62824-4; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; PETERSON ED, 1994, JAMA-J AM MED ASSOC, V271, P1175, DOI 10.1001/jama.271.15.1175; PICKENS G, 1999, ASS HLTH SERV RES 16, P388; Powe NR, 1996, MED CARE, V34, P798, DOI 10.1097/00005650-199608000-00007; SALEMSCHATZ S, 1994, JAMA-J AM MED ASSOC, V272, P871, DOI 10.1001/jama.272.11.871; Schmittdiel J, 1997, JAMA-J AM MED ASSOC, V278, P1596, DOI 10.1001/jama.278.19.1596; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Scott A, 1996, SOC SCI MED, V42, P35, DOI 10.1016/0277-9536(95)00063-1; Selby JV, 1997, ANN INTERN MED, V127, P719, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00056; SHAPIRO DW, 1993, ANNU REV PUBL HEALTH, V14, P219, DOI 10.1146/annurev.pu.14.050193.001251; Smith GD, 1998, J EPIDEMIOL COMMUN H, V52, P153; Solberg LI, 1997, PREV MED, V26, P350, DOI 10.1006/pmed.1997.0150; SORLIE PD, 1995, AM J PUBLIC HEALTH, V85, P949, DOI 10.2105/AJPH.85.7.949; Spoeri RK, 1997, ANN INTERN MED, V127, P726, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00058; STARFIELD B, 1994, JAMA-J AM MED ASSOC, V272, P1903, DOI 10.1001/jama.272.24.1903; STARFIELD B, 1991, HEALTH SERV RES, V26, P53; Taira DA, 1997, JAMA-J AM MED ASSOC, V278, P1412, DOI 10.1001/jama.278.17.1412; VLIELAND TPMV, 1994, ANN RHEUM DIS, V53, P803, DOI 10.1136/ard.53.12.803; Ware J E Jr, 1983, Eval Program Plann, V6, P247, DOI 10.1016/0149-7189(83)90005-8; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; WEINER JP, 1991, MED CARE, V29, P452, DOI 10.1097/00005650-199105000-00006; WEISSMAN JS, 1994, INQUIRY-J HEALTH CAR, V31, P163; WEISSMAN JS, 1992, JAMA-J AM MED ASSOC, V268, P2388, DOI 10.1001/jama.268.17.2388; WELCH HG, 1995, JAMA-J AM MED ASSOC, V273, P772, DOI 10.1001/jama.273.10.772; WOOD DL, 1990, PEDIATRICS, V86, P666; ZASLAVSKY AM, 1999, ASS HLTH SERV RES 16, P327; ZEGER SL, 1992, STAT MED, V11, P1825, DOI 10.1002/sim.4780111406	71	29	29	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					745	+		10.7326/0003-4819-131-10-199911160-00005	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00005			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	255QC	10577297				2022-12-28	WOS:000083680100004
J	Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J				Knight, SJL; Regan, R; Nicod, A; Horsley, SW; Kearney, L; Homfray, T; Winter, RM; Bolton, P; Flint, J			Subtle chromosomal rearrangements in children with unexplained mental retardation	LANCET			English	Article							WOLF-HIRSCHHORN-SYNDROME; FRAGILE-X-SYNDROME; MOLECULAR CHARACTERIZATION; TRANSLOCATION; HYBRIDIZATION; RECURRENCE; TELOMERES; DELETIONS; ETIOLOGY; BORN	Background No explanation for moderate to severe mental retardation is apparent in about 40% of cases. Although small chromosomal rearrangements may account for some undiagnosed cases, a lack of genome-wide screening methods has made it impossible to ascertain the frequency of such abnormalities. Methods A fluorescence in-situ hybridisation (FISH) test was used to examine the integrity of chromosome ends in 284 children with unexplained moderate to severe retardation, and in 182 children with unexplained mild retardation. 75 normal men were also tested. When a chromosomal rearrangement was found, its size was estimated, and members of the child's family were investigated. Findings Subtle chromosomal abnormalities occurred with a frequency of 7.4% in the children with moderate to severe mental retardation, and of 0.5% in the children with mild retardation. The abnormalities had an estimated population prevalence of 2.1 per 10000, and were familial in almost half of cases. Interpretation Once recognisable syndromes have been excluded, abnormalities that include the ends of chromosomes are the commonest cause of mental retardation in children with undiagnosed moderate to severe mental retardation. Owing to the high prevalence of familial cases, screening for subtle chromosomal rearrangements is warranted in children with unexplained moderate to severe mental retardation.	John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England; Univ London, Inst Child Hlth, Mothercare Unit Paediat Genet & Fetal Med, London WC1N 1EH, England; Univ Cambridge, Dept Psychiat, Dev Psychiat Sect, Cambridge, England; Univ London St Georges Hosp, Dept Genet, London, England	University of Oxford; University of London; University College London; University of Cambridge; St Georges University London	Flint, J (corresponding author), John Radcliffe Hosp, Inst Mol Med, Mol Hematol Unit, Oxford OX3 9DS, England.			Flint, Jonathan/0000-0002-9427-4429; Knight, Samantha/0000-0002-6047-3462	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ALTHERR MR, 1991, AM J HUM GENET, V49, P1235; Altherr MR, 1997, AM J MED GENET, V71, P47, DOI 10.1002/(SICI)1096-8628(19970711)71:1<47::AID-AJMG9>3.0.CO;2-N; Birch HG, 1970, MENTAL SUBNORMALITY; Broman S., 1987, RETARDATION YOUNG CH; Buckle VJ, 1993, HUMAN GENETIC DISEAS, P59; BUNDEY S, 1989, J MED GENET, V26, P260, DOI 10.1136/jmg.26.4.260; CASSIMAN JJ, 1975, HUMANGENETIK, V28, P43, DOI 10.1007/BF00272481; CURTIS A, 1991, AM J HUM GENET, V49, P299; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; EINFELD SL, 1984, J MENT DEFIC RES, V28, P129; ELWOOD JH, 1981, J MENT DEFIC RES, V25, P147; FLINT J, 1995, NAT GENET, V9, P132, DOI 10.1038/ng0295-132; Giraudeau F, 1997, J MED GENET, V34, P314, DOI 10.1136/jmg.34.4.314; GOODSHIP J, 1992, J MED GENET, V29, P451; GRAHAM SM, 1993, J PAEDIATR CHILD H, V29, P360, DOI 10.1111/j.1440-1754.1993.tb00535.x; GRIPENBERG U, 1980, HEREDITAS, V92, P223; GUSTAVSON KH, 1977, NEUROPADIATRIE, V8, P293, DOI 10.1055/s-0028-1091525; JACOBS PA, 1993, J MED GENET, V30, P454, DOI 10.1136/jmg.30.6.454; JACOBS PA, 1978, CLIN GENET, V13, P37; Knight SJL, 1997, EUR J HUM GENET, V5, P1; LAMB J, 1989, LANCET, V2, P819; LAMONT MA, 1988, ARCH DIS CHILD, V63, P1032, DOI 10.1136/adc.63.9.1032; Law CJ, 1998, J MED GENET, V35, P685, DOI 10.1136/jmg.35.8.685; LAXOVA R, 1977, AM J MED GENET, V1, P75, DOI 10.1002/ajmg.1320010109; MCDONALD AD, 1973, AM J MENT DEF, V78, P205; Morton JE, 1997, J MED GENET, V34, P1, DOI 10.1136/jmg.34.1.1; Moser HW, 1971, NERVOUS SYSTEM, P117; NESSLINGER NJ, 1994, AM J HUM GENET, V54, P464; Ning Y, 1996, NAT GENET, V14, P86, DOI 10.1038/ng0996-86; Opitz J M, 1978, Birth Defects Orig Artic Ser, V14, P1; Rosenberg M, 1997, GENOME RES, V7, P917, DOI 10.1101/gr.7.9.917; Rutter M., 1970, ED HLTH BEHAV; Sambrook J., 2002, MOL CLONING LAB MANU; SLANEY SF, 1995, ARCH DIS CHILD, V72, P33, DOI 10.1136/adc.72.1.33; Strathdee G, 1997, AM J HUM GENET, V60, P860; SUTHERLAND GR, 1976, HUM GENET, V36, P231	36	354	417	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1676	1681		10.1016/S0140-6736(99)03070-6	http://dx.doi.org/10.1016/S0140-6736(99)03070-6			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568569				2022-12-28	WOS:000083652800010
J	Gravelle, H				Gravelle, H			Diminishing returns to aggregate level studies	BRITISH MEDICAL JOURNAL			English	Article							INCOME INEQUALITY; UNITED-STATES; MORTALITY		Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England	University of York - UK	Gravelle, H (corresponding author), Univ York, Ctr Hlth Econ, Natl Primary Care Res & Dev Ctr, York YO10 5DD, N Yorkshire, England.			Gravelle, Hugh/0000-0002-7753-4233				Daly MC, 1998, MILBANK Q, V76, P315, DOI 10.1111/1468-0009.00094; Elo IT, 1996, SOC SCI MED, V42, P47, DOI 10.1016/0277-9536(95)00062-3; Fiscella K, 1997, BRIT MED J, V314, P1724, DOI 10.1136/bmj.314.7096.1724; Kennedy BP, 1998, BRIT MED J, V317, P917	4	11	11	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					955	956						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	245MA	10576845				2022-12-28	WOS:000083111700023
J	Jha, TK; Sundar, S; Thakur, CP; Bachmann, P; Karbwang, J; Fischer, C; Voss, A; Berman, J				Jha, TK; Sundar, S; Thakur, CP; Bachmann, P; Karbwang, J; Fischer, C; Voss, A; Berman, J			Miltefosine, an oral agent, for the treatment of Indian visceral leishmaniasis	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							KALA-AZAR; AMPHOTERICIN; KETOCONAZOLE; DONOVANI; SUDAN; TRIAL	Background: There is no effective orally administered medication for any leishmania infection. We investigated miltefosine, which can be taken orally, for the treatment of Indian visceral leishmaniasis. Miltefosine is a phosphocholine analogue that affects cell-signaling pathways and membrane synthesis. Methods: The study was an open-label, multicenter, phase 2 trial in which four 30-person cohorts received 50, 100, or 150 mg of miltefosine per day for four or six weeks. The 120 patients, who ranged in age from 12 to 50 years, had anorexia, fever, and splenomegaly with at least moderate (2+) leishmania in a splenic aspirate. A parasitologic cure was defined by the absence of parasites in a splenic aspirate obtained two weeks after completion of treatment. The clinical response was assessed at six months. Results: In all 120 patients there was an initial parasitologic cure. Six patients had clinical and parasitologic relapses; the remaining 114 patients had not relapsed by six months after treatment, for a cure rate of 95 percent (95 percent confidence interval, 89 to 98 percent). With the regimen of 100 mg of miltefosine per day (approximately 2.5 mg per kilogram of body weight per day) for four weeks, 29 of 30 patients (97 percent) were cured. Gastrointestinal side effects were frequent (occurring in 62 percent of patients) but mild to moderate in severity, and no patient discontinued therapy because of gastrointestinal side effects. In two patients, treatment was discontinued because of elevated levels of aspartate aminotransferase or creatinine; in both patients the levels rapidly returned to normal. In 12 other patients, the level of aspartate aminotransferase increased to 100 to 150 U per liter during treatment. Conclusions: Orally administered miltefosine appears to be an effective treatment for Indian visceral leishmaniasis. (N Engl J Med 1999;341:1795-800.) (C)1999, Massachusetts Medical Society.	Asta Med, Med Res Oncol, D-60314 Frankfurt, Germany; Kala Azar Res Ctr, Brahmpura, Muzaffarpur, India; Banaras Hindu Univ, Inst Med Sci, Varanasi 221005, Uttar Pradesh, India; Balaji Utthan Sanastan, Patna, Bihar, India; WHO, CH-1211 Geneva, Switzerland; WHO, Rockville, MD USA	Banaras Hindu University (BHU); World Health Organization; World Health Organization	Voss, A (corresponding author), Asta Med, Med Res Oncol, Weismullerstr 45, D-60314 Frankfurt, Germany.							BADARO R, 1986, J INFECT DIS, V154, P1003, DOI 10.1093/infdis/154.6.1003; BERMAN JD, 1983, AM J TROP MED HYG, V32, P947, DOI 10.4269/ajtmh.1983.32.947; Berman JD, 1997, CLIN INFECT DIS, V24, P684, DOI 10.1093/clind/24.4.684; Berman JD, 1999, CLIN INFECT DIS, V28, P49, DOI 10.1086/515086; CHULAY JD, 1983, AM J TROP MED HYG, V32, P475, DOI 10.4269/ajtmh.1983.32.475; CROFT SL, 1987, BIOCHEM PHARMACOL, V36, P2633, DOI 10.1016/0006-2952(87)90543-0; Desjeux P, 1996, CLIN DERMATOL, V14, P417, DOI 10.1016/0738-081X(96)00057-0; Hart D, 1998, DRUG TODAY, V34, P117; HASHIM FA, 1994, T ROY SOC TROP MED H, V88, P431, DOI 10.1016/0035-9203(94)90417-0; KUHLENCORD A, 1992, ANTIMICROB AGENTS CH, V36, P1630, DOI 10.1128/AAC.36.8.1630; Meyerhoff A, 1999, CLIN INFECT DIS, V28, P42, DOI 10.1086/515085; MISHRA M, 1994, LANCET, V344, P1599, DOI 10.1016/S0140-6736(94)90406-5; Seaman J, 1996, ANN INTERN MED, V124, P664, DOI 10.7326/0003-4819-124-7-199604010-00007; Sundar S, 1999, ANN TROP MED PARASIT, V93, P589, DOI 10.1080/00034989958096; Sundar S, 1998, LANCET, V352, P1821, DOI 10.1016/S0140-6736(98)04367-0; Sundar S, 1998, AM J TROP MED HYG, V59, P139, DOI 10.4269/ajtmh.1998.59.139; Sundar S, 1996, LANCET, V348, P614, DOI 10.1016/S0140-6736(05)64828-3; SUNDAR S, 1990, LANCET, V336, P1582, DOI 10.1016/0140-6736(90)93358-V; THAKUR CP, 1994, B WORLD HEALTH ORGAN, V72, P931; Velez I, 1997, ANN INTERN MED, V126, P232, DOI 10.7326/0003-4819-126-3-199702010-00010; WALI JP, 1990, LANCET, V336, P810, DOI 10.1016/0140-6736(90)93272-Q	21	352	366	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1795	1800		10.1056/NEJM199912093412403	http://dx.doi.org/10.1056/NEJM199912093412403			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588964	Bronze			2022-12-28	WOS:000084074000003
J	Grande, GE; Todd, CJ; Barclay, SIG; Farquhar, MC				Grande, GE; Todd, CJ; Barclay, SIG; Farquhar, MC			Does hospital at home for palliative care facilitate death at home? Randomised controlled trial	BRITISH MEDICAL JOURNAL			English	Article							ILL CANCER-PATIENTS; COST-EFFECTIVENESS; TERMINALLY ILL; CLINICAL-TRIAL; SERVICE; TIME	Objective To evaluate the impact on place of death of a hospital at home service for palliative care. Design Pragmatic randomised controlled trial. Setting Former Cambridge health district. Participants 229 patients referred to the hospital at home service; 43 randomised to control group (standard care), 186 randomised to hospital at home. Intervention Hospital at home versus standard care. Main outcome measures Place of death. Results Twenty five (58%,) control patients died at home compared with 124 (67%) patients allocated to hospital at home. This difference was not significant; intention to treat analysis did not show that hospital at home increased the number of deaths at home. Seventy three patients randomised to hospital at home were not admitted to the service. Patients admitted to hospital at home were significantly more likely to die at home (88/113; 78%) than control patients. It is not possible to determine whether this was due to hospital at home itself or other characteristics of the patients admitted to the service. The study attained less statistical power than initially planned. Conclusion In a locality with good provision of standard community care we could not show that hospital at home allowed more patients: to die at home, although neither does the study refute this. Problems relating to recruitment, attrition, and the vulnerability of the patient group make randomised controlled trials in palliative care difficult While these difficulties have to be recognised they are not insurmountable with the appropriate resourcing and setting.	Univ Cambridge, Inst Publ Hlth, Dept Community Med,Hlth Serv Res Grp, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England	University of Cambridge	Grande, GE (corresponding author), Univ Cambridge, Inst Publ Hlth, Dept Community Med,Hlth Serv Res Grp, Gen Practice & Primary Care Res Unit, Cambridge CB2 2SR, England.		Todd, Chris/AAD-8661-2022; Todd, Chris/A-7904-2010; Grande, Gunn/A-6163-2011; Farquhar, Morag C/C-5666-2015	Todd, Chris/0000-0001-6645-4505; Todd, Chris/0000-0001-6645-4505; Grande, Gunn/0000-0003-2200-1680; Farquhar, Morag C/0000-0001-7991-7679; Barclay, Stephen/0000-0002-4505-7743				ADDINGTON-HALL J M, 1991, Palliative Medicine, V5, P207, DOI 10.1177/026921639100500305; ADDINGTONHALL JM, 1992, BRIT MED J, V305, P1317, DOI 10.1136/bmj.305.6865.1317; Boyd K. J., 1994, Annals Academy of Medicine Singapore, V23, P271; BREWIN CR, 1989, BRIT MED J, V299, P313, DOI 10.1136/bmj.299.6694.313; Campbell MK, 1998, BMJ-BRIT MED J, V317, P1171, DOI 10.1136/bmj.317.7167.1171; CARTWRIGHT A, 1991, BRIT J GEN PRACT, V41, P271; CHARLTON RC, 1991, FAM PRACT, V8, P356, DOI 10.1093/fampra/8.4.356; CUMMINGS JE, 1990, ARCH INTERN MED, V150, P1274, DOI 10.1001/archinte.150.6.1274; DUNLOP RJ, 1989, PALLIAT MED, V0003, P00197, DOI DOI 10.1177/026921638900300305; Hinton John, 1994, Palliative Medicine, V8, P197, DOI 10.1177/026921639400800303; HUGHES SL, 1992, HEALTH SERV RES, V26, P801; MCCORKLE R, 1989, CANCER, V64, P1375, DOI 10.1002/1097-0142(19890915)64:6<1375::AID-CNCR2820640634>3.0.CO;2-6; MCQUAY H, 1994, BMJ-BRIT MED J, V309, P1315, DOI 10.1136/bmj.309.6965.1315; MCWHINNEY IR, 1994, BRIT MED J, V309, P1340, DOI 10.1136/bmj.309.6965.1340; Raftery JP, 1996, PALLIATIVE MED, V10, P151, DOI 10.1177/026921639601000210; Smeenk FWJM, 1998, BRIT MED J, V316, P1939, DOI 10.1136/bmj.316.7149.1939; TOWNSEND J, 1990, BRIT MED J, V301, P415, DOI 10.1136/bmj.301.6749.415; WARD AWM, 1987, COMMUNITY MED, V9, P47; ZIMMER JG, 1985, AM J PUBLIC HEALTH, V75, P134, DOI 10.2105/AJPH.75.2.134	19	79	80	1	4	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1472	1475		10.1136/bmj.319.7223.1472	http://dx.doi.org/10.1136/bmj.319.7223.1472			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582932	Green Published, Bronze			2022-12-28	WOS:000084129200023
J	Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A				Golovkina, TV; Shlomchik, M; Hannum, L; Chervonsky, A			Organogenic role of B lymphocytes in mucosal immunity	SCIENCE			English	Article							MAMMARY-TUMOR VIRUS; SCANNING ELECTRON-MICROSCOPY; PEYERS PATCH LYMPHOCYTES; CELL-DEFICIENT MICE; T-CELLS; NECROSIS-FACTOR; LECTIN-BINDING; CD40 LIGAND; MOUSE; INFECTION	Follicle-associated epithelium (FAE) in the intestinal Peyer's patches contains M cells that deliver pathogens to organized Lymphoid tissue. Development of Peyer's patches, FAE, and M cells was found to be impaired in mice that had no B cells. Transgenic expression of membrane-bound immunoglobulin M restored B cells and FAE development. The Lack of M cells abrogated infection with a milk-borne retrovirus. Thus, in addition to secretion of antibodies and presentation of antigens, B cells are important for organogenesis of the mucosal immune barriers.	Jackson Lab, Bar Harbor, ME 04609 USA; Yale Univ, Sch Med, Immunobiol Sect, New Haven, CT 06510 USA; Yale Univ, Sch Med, Dept Lab Med, New Haven, CT 06510 USA	Jackson Laboratory; Yale University; Yale University	Chervonsky, A (corresponding author), Jackson Lab, 600 Main St, Bar Harbor, ME 04609 USA.		Shlomchik, Mark J./AAN-6189-2020	Shlomchik, Mark J./0000-0002-2152-0959; Chervonsky, Alexander/0000-0001-7547-871X	NATIONAL CANCER INSTITUTE [P30CA034196, R29CA065795] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK053561] Funding Source: NIH RePORTER; NCI NIH HHS [CA34196, CA65795] Funding Source: Medline; NIDDK NIH HHS [DK53561] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		ACHAORBEA H, 1995, ANNU REV IMMUNOL, V13, P459, DOI 10.1146/annurev.iy.13.040195.002331; Adachi S, 1997, INT IMMUNOL, V9, P507, DOI 10.1093/intimm/9.4.507; BEUTNER U, 1994, J EXP MED, V179, P1457, DOI 10.1084/jem.179.5.1457; BOCKMAN DE, 1973, AM J ANAT, V136, P455, DOI 10.1002/aja.1001360406; Buggiano V, 1999, SCAND J IMMUNOL, V49, P269; Chan OTM, 1999, J EXP MED, V189, P1639, DOI 10.1084/jem.189.10.1639; Chaplin DD, 1998, CURR OPIN IMMUNOL, V10, P289, DOI 10.1016/S0952-7915(98)80167-2; CHEN JZ, 1993, INT IMMUNOL, V5, P647, DOI 10.1093/intimm/5.6.647; CHERVONSKY A, UNPUB; CHERVONSKY AV, 1995, IMMUNITY, V3, P139, DOI 10.1016/1074-7613(95)90166-3; CHOI YW, 1991, NATURE, V350, P203, DOI 10.1038/350203a0; CLARK MA, 1993, J HISTOCHEM CYTOCHEM, V41, P1679, DOI 10.1177/41.11.7691933; Culkin SJ, 1997, J IMMUNOL, V158, P3277; Debard N, 1999, SEMIN IMMUNOL, V11, P183, DOI 10.1006/smim.1999.0174; Fu YX, 1998, J EXP MED, V187, P1009, DOI 10.1084/jem.187.7.1009; GOLOVKINA TV, 1992, CELL, V69, P637, DOI 10.1016/0092-8674(92)90227-4; HELD W, 1993, CELL, V74, P529, DOI 10.1016/0092-8674(93)80054-I; ITOHARA S, 1993, CELL, V72, P337, DOI 10.1016/0092-8674(93)90112-4; KARAPETIAN O, 1994, J EXP MED, V180, P1511, DOI 10.1084/jem.180.4.1511; Kerneis S, 1997, SCIENCE, V277, P949, DOI 10.1126/science.277.5328.949; KITAMURA D, 1991, NATURE, V350, P423, DOI 10.1038/350423a0; Klein MA, 1997, NATURE, V390, P687, DOI 10.1038/37789; LIN RH, 1991, J EXP MED, V173, P1433, DOI 10.1084/jem.173.6.1433; MALICK LE, 1975, STAIN TECHNOL, V50, P265, DOI 10.3109/10520297509117069; MALICK LE, 1975, SCANNING ELECT MICRO, P256; Marcotte H, 1996, J INFECT DIS, V173, P1034, DOI 10.1093/infdis/173.4.1034; Matsuzaki G, 1999, CELL IMMUNOL, V194, P178, DOI 10.1006/cimm.1999.1503; MOMBAERTS P, 1992, NATURE, V360, P225, DOI 10.1038/360225a0; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; NATION JL, 1983, STAIN TECHNOL, V58, P347, DOI 10.3109/10520298309066811; Neutra MR, 1999, SEMIN IMMUNOL, V11, P171, DOI 10.1006/smim.1999.0173; NOELLE RJ, 1992, P NATL ACAD SCI USA, V89, P6550, DOI 10.1073/pnas.89.14.6550; OWEN RL, 1983, AM J ANAT, V168, P199, DOI 10.1002/aja.1001680207; Owen RL, 1999, SEMIN IMMUNOL, V11, P157, DOI 10.1006/smim.1999.0171; OWEN RL, 1977, GASTROENTEROLOGY, V72, P440; Pasparakis M, 1997, P NATL ACAD SCI USA, V94, P6319, DOI 10.1073/pnas.94.12.6319; PFEFFER K, 1993, CELL, V73, P457, DOI 10.1016/0092-8674(93)90134-C; RANHEIM EA, 1993, J EXP MED, V177, P925, DOI 10.1084/jem.177.4.925; RENSHAW BR, 1994, J EXP MED, V180, P1889, DOI 10.1084/jem.180.5.1889; Sansonetti PJ, 1999, SEMIN IMMUNOL, V11, P193, DOI 10.1006/smim.1999.0175; Serreze DV, 1996, J EXP MED, V184, P2049, DOI 10.1084/jem.184.5.2049; Teitelbaum R, 1999, IMMUNITY, V10, P641, DOI 10.1016/S1074-7613(00)80063-1; Velin D, 1997, J EXP MED, V185, P1871, DOI 10.1084/jem.185.10.1871; Vordermeier HM, 1996, CLIN EXP IMMUNOL, V106, P312, DOI 10.1046/j.1365-2249.1996.d01-845.x; Yoshida H, 1999, INT IMMUNOL, V11, P643, DOI 10.1093/intimm/11.5.643	45	194	197	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1965	1968		10.1126/science.286.5446.1965	http://dx.doi.org/10.1126/science.286.5446.1965			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583962				2022-12-28	WOS:000084003400055
J	Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T				Kobayashi, Y; Kaya, H; Goto, K; Iwabuchi, M; Araki, T			A pair of related genes with antagonistic roles in mediating flowering signals	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; TIME; ARCHITECTURE; ACTIVATION; INITIATION; ENCODES; PLANTS	Flowering in Arabidopsis is promoted via several interacting pathways. A photoperiod-dependent pathway relays signals from photoreceptors to a transcription factor gene, CONSTANS (CO), which activates downstream meristem identity genes such as LEAFY (LFY). FT, together with LFY, promotes flowering and is positively regulated by CO. Loss of FT causes delay in flowering, whereas overexpression of FT results in precocious flowering independent of CO or photoperiod. FT acts in part downstream of CO and mediates signals for flowering in an antagonistic manner with its homologous gene, TERMINAL FLOWER1 (TFL1).	Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan; Kyoto Univ, Inst Chem Res, Kyoto 6110011, Japan	Kyoto University; Kyoto University	Araki, T (corresponding author), Kyoto Univ, Grad Sch Sci, Dept Bot, Sakyo Ku, Kyoto 6068502, Japan.	taraqui@gr.bot.kyoto-u.ac.jp	Rosa, Bruce/F-6393-2010; Araki, Takashi/G-1760-2013	Araki, Takashi/0000-0002-3616-1493; Kaya, Hidetaka/0000-0003-4711-8236				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; Guo HW, 1998, SCIENCE, V279, P1360, DOI 10.1126/science.279.5355.1360; IGENO MI, COMMUNICATION; KOBAYASHI Y, UNPUB; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, ANNU REV PLANT PHYS, V49, P345, DOI 10.1146/annurev.arplant.49.1.345; KYOZUKA J, COMMUNICATION; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; Macknight R, 1997, CELL, V89, P737, DOI 10.1016/S0092-8674(00)80256-1; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Ohshima S, 1997, MOL GEN GENET, V254, P186, DOI 10.1007/s004380050407; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1995, FEBS LETT, V369, P22, DOI 10.1016/0014-5793(95)00376-K; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0	23	972	1085	4	145	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1960	1962		10.1126/science.286.5446.1960	http://dx.doi.org/10.1126/science.286.5446.1960			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583960				2022-12-28	WOS:000084003400053
J	Campbell, P				Campbell, P			Tales of the expected - foreword	NATURE			English	Editorial Material								Forecasting the future in science is fun but often hopelessly misleading. This publication, commissioned by all the Nature journals, focuses on future developments about which we can be reasonably confident and which will have an impact on the lives of all of us.											0	3	3	0	0	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C7	+		10.1038/35011500	http://dx.doi.org/10.1038/35011500			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591220	Bronze			2022-12-28	WOS:000084014100001
J	Schopfer, CR; Nasrallah, ME; Nasrallah, JB				Schopfer, CR; Nasrallah, ME; Nasrallah, JB			The male determinant of self-incompatibility in Brassica	SCIENCE			English	Article							POLLEN COAT PROTEIN; S-LOCUS GENE; ANTIMICROBIAL PEPTIDES; OLERACEA; CAMPESTRIS; EVOLUTION; SEQUENCES; PLANTS	In the S locus-controlled self-incompatibility system of Brassica, recognition of self-related pollen at the surface of stigma epidermal cells leads to inhibition of pollen tube development. The female (stigmatic) determinant of this recognition reaction is a polymorphic transmembrane receptor protein kinase encoded at the 5 Locus. Another highly polymorphic, anther-expressed gene, SCR, also encoded at the 5 locus, fulfills the requirements for the hypothesized pollen determinant. Loss-of-function and gain-of-function studies prove that the SCR gene product is necessary and sufficient for determining pollen self-incompatibility specificity, possibly by acting as a Ligand for the stigmatic receptor.	Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA	Cornell University	Nasrallah, JB (corresponding author), Cornell Univ, Dept Plant Biol, Ithaca, NY 14853 USA.		Swaibu, Ramadhani A/H-3164-2011		NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM057527] Funding Source: NIH RePORTER; NIGMS NIH HHS [GM57527] Funding Source: Medline	NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		Boyes DC, 1997, PLANT CELL, V9, P237, DOI 10.1105/tpc.9.2.237; BOYES DC, 1995, PLANT CELL, V7, P1283, DOI 10.1105/tpc.7.8.1283; BOYES DC, 1991, GENETICS, V127, P221; BROEKAERT WF, 1995, PLANT PHYSIOL, V108, P1353, DOI 10.1016/j.chiabu.2021.105188; Broekaert WF, 1997, CRIT REV PLANT SCI, V16, P297, DOI 10.1080/713608148; CASSELMAN AL, UNPUB; Conner JA, 1998, PLANT CELL, V10, P801, DOI 10.1105/tpc.10.5.801; DIXIT R, UNPUB; Doughty J, 1998, PLANT CELL, V10, P1333, DOI 10.1105/tpc.10.8.1333; DWYER KG, 1991, PLANT MOL BIOL, V16, P481, DOI 10.1007/BF00024000; KHO YO, 1968, EUPHYTICA, V17, P298; Kusaba M, 1997, P NATL ACAD SCI USA, V94, P7673, DOI 10.1073/pnas.94.14.7673; Nasrallah JB, 1997, P NATL ACAD SCI USA, V94, P9516, DOI 10.1073/pnas.94.18.9516; NASRALLAH JB, 1994, SCIENCE, V266, P1505, DOI 10.1126/science.266.5190.1505; NASRALLAH JB, IN PRESS ANN BOT; Stanchev BS, 1996, PLANT J, V10, P303, DOI 10.1046/j.1365-313X.1996.10020303.x; Stein JC, 1996, PLANT CELL, V8, P429, DOI 10.1105/tpc.8.3.429; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Suzuki G, 1999, GENETICS, V153, P391; TERRAS FRG, 1992, J BIOL CHEM, V267, P15301; TORIYAMA K, 1991, THEOR APPL GENET, V81, P769, DOI 10.1007/BF00224988; VONHEIJNE G, 1986, NUCLEIC ACIDS RES, V14, P4683, DOI 10.1093/nar/14.11.4683; Yu KF, 1996, PLANT CELL, V8, P2369, DOI 10.1105/tpc.8.12.2369	23	563	641	2	89	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1697	1700		10.1126/science.286.5445.1697	http://dx.doi.org/10.1126/science.286.5445.1697			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576728				2022-12-28	WOS:000083912200026
J	Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM				Ayanian, JZ; Cleary, PD; Weissman, JS; Epstein, AM			The effect of patients' preferences on racial differences in access to renal transplantation	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							REVASCULARIZATION PROCEDURES; SURGICAL-PROCEDURES; HEART-DISEASE; RACE; WOMEN; ENDARTERECTOMY; ANGIOGRAPHY; DIALYSIS; QUALITY; SURGERY	Background: In the United States, black patients undergo renal transplantation less often than white patients, but few studies have directly assessed the association between race and patients' preferences with respect to transplantation. Methods: To assess preferences with respect to transplantation and experiences with medical care, we interviewed 1392 (82.9 percent) of 1679 eligible patients with end-stage renal disease (age range, 18 to 54 years) approximately 10 months after they had begun maintenance treatment with dialysis. Participants were selected from a stratified random sample of patients undergoing dialysis in four regions of the United States (Alabama, southern California, Michigan, and the mid-Atlantic region of Maryland, Virginia, and the District of Columbia) in 1996 and 1997. Patients were followed until March 1999. Results: The interviews were conducted with 384 black women, 354 white women, 337 black men, and 317 white men. Black patients were less likely than white patients to want a transplant (76.3 percent of black women reported such a preference, vs. 79.3 percent of white women, and 80.7 percent of black men vs. 85.5 percent of white men), and they were less likely to be very certain about this preference (58.3 percent vs. 65.3 percent and 64.1 percent vs. 75.7 percent, respectively; P<0.01 for each comparison with both sexes combined). However, much larger differences were evident in rates of referral for evaluation at a transplantation center (50.4 percent for black women vs. 70.5 percent for white women, and 53.9 percent for black men vs. 76.2 percent for white men; P<0.001 for each comparison) and placement on a waiting list or transplantation within 18 months after the start of dialysis therapy (31.3 percent for black women vs. 56.5 percent for white women, and 35.3 percent for black men vs. 60.6 percent for white men; P<0.001). These racial differences remained significant after adjustment for patients' preferences and expectations about transplantation, sociodemographic characteristics, the type of dialysis facility, perceptions of care, health status, the cause of renal failure, and the presence or absence of coexisting illnesses. Conclusions: In the United States, the preferences and expectations with respect to renal transplantation among patients with end-stage renal disease differ according to race. These differences, however, explain only a small fraction of the substantial racial differences in access to transplantation. Physicians should ensure that black patients who desire renal transplantation are fully informed about it and are referred for evaluation. (N Engl J Med 1999;341:1661-9.) (C) 1999, Massachusetts Medical Society.	Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Gen Med & Primary Care, Sect Hlth Serv & Policy Res, Boston, MA 02115 USA; Massachusetts Gen Hosp, Inst Hlth Policy, Boston, MA 02114 USA; Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA	Harvard University; Harvard Medical School; Harvard University; Brigham & Women's Hospital; Harvard University; Massachusetts General Hospital; Harvard University; Harvard T.H. Chan School of Public Health	Ayanian, JZ (corresponding author), Harvard Univ, Sch Med, Dept Hlth Care Policy, 180 Longwood Ave, Boston, MA 02115 USA.	ayanian@hcp.med.harvard.edu	Cleary, Paul/AAF-7048-2019					Alexander GC, 1998, JAMA-J AM MED ASSOC, V280, P1148, DOI 10.1001/jama.280.13.1148; AYANIAN JZ, 1993, JAMA-J AM MED ASSOC, V269, P2642, DOI 10.1001/jama.269.20.2642; AYANIAN JZ, 1993, NEW ENGL J MED, V329, P656, DOI 10.1056/NEJM199308263290912; Burns RB, 1996, ANN INTERN MED, V125, P173, DOI 10.7326/0003-4819-125-3-199608010-00002; EGGERS P, 1992, SEMIN NEPHROL, V12, P284; Eggers P W, 1995, Health Care Financ Rev, V17, P89; EGGERS PW, 1988, NEW ENGL J MED, V318, P223, DOI 10.1056/NEJM198801283180406; ELIXHAUSER A, 1994, AHCPR PUBLICATION; ESCARCE JJ, 1993, AM J PUBLIC HEALTH, V83, P948, DOI 10.2105/AJPH.83.7.948; EVANS RW, 1985, NEW ENGL J MED, V312, P553, DOI 10.1056/NEJM198502283120905; Garg PP, 1999, NEW ENGL J MED, V341, P1653, DOI 10.1056/NEJM199911253412205; GAYLIN DS, 1993, JAMA-J AM MED ASSOC, V269, P603, DOI 10.1001/jama.269.5.603; Giacomini MK, 1996, ARCH INTERN MED, V156, P1217, DOI 10.1001/archinte.156.11.1217; Gornick ME, 1996, NEW ENGL J MED, V335, P791, DOI 10.1056/NEJM199609123351106; GUADAGNOLI E, 1995, ARCH SURG-CHICAGO, V130, P381; HAYS RD, 1994, QUAL LIFE RES, V3, P329, DOI 10.1007/BF00451725; HELD PJ, 1988, ARCH INTERN MED, V148, P2594, DOI 10.1001/archinte.148.12.2594; HORNER RD, 1995, MILBANK Q, V73, P443, DOI 10.2307/3350374; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KASISKE BL, 1991, NEW ENGL J MED, V324, P302, DOI 10.1056/NEJM199101313240505; KJELLSTRAND CM, 1988, ARCH INTERN MED, V148, P1305; LEVY DR, 1985, PEDIATRICS, V75, P639; MAYNARD C, 1986, AM J PUBLIC HEALTH, V76, P1446, DOI 10.2105/AJPH.76.12.1446; McCauley J, 1997, AM J KIDNEY DIS, V30, P739, DOI 10.1016/S0272-6386(97)90077-9; MORT EA, 1994, ARCH INTERN MED, V154, P761, DOI 10.1001/archinte.154.7.761; ODDONE EZ, 1993, ARCH INTERN MED, V153, P2781, DOI 10.1001/archinte.153.24.2781; Oddone EZ, 1998, J NATL MED ASSOC, V90, P25; Ozminkowski RJ, 1997, AM J KIDNEY DIS, V30, P749, DOI 10.1016/S0272-6386(97)90078-0; Peterson ED, 1997, NEW ENGL J MED, V336, P480, DOI 10.1056/NEJM199702133360706; *REN DAT SYST, 1998, USRDS 1998 ANN DAT R; Saha S., 1999, JGIM, V14, P67; Satcher D, 1973, JAMA, V223, P1498; Schecter AD, 1996, AM J CARDIOL, V78, P996, DOI 10.1016/S0002-9149(96)00523-1; Schulman KA, 1999, NEW ENGL J MED, V340, P618, DOI 10.1056/NEJM199902253400806; Schulman KA, 1999, NEW ENGL J MED, V340, P1130; SOUCIE JM, 1992, AM J KIDNEY DIS, V19, P414, DOI 10.1016/S0272-6386(12)80947-4; WENNEKER MB, 1989, JAMA-J AM MED ASSOC, V261, P253, DOI 10.1001/jama.261.2.253; Whittle J, 1997, J GEN INTERN MED, V12, P267, DOI 10.1046/j.1525-1497.1997.012005267.x; WHITTLE J, 1993, NEW ENGL J MED, V329, P621, DOI 10.1056/NEJM199308263290907; Wilson Marcus Garvey, 1994, Ethnicity and Disease, V4, P57; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	41	494	494	0	11	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1661	1669		10.1056/NEJM199911253412206	http://dx.doi.org/10.1056/NEJM199911253412206			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258PL	10572155				2022-12-28	WOS:000083847500006
J	Berghammer, AJ; Klingler, M; Wimmer, EA				Berghammer, AJ; Klingler, M; Wimmer, EA			Genetic techniques - A universal marker for transgenic insects	NATURE			English	Article							YELLOW-FEVER MOSQUITO; TRANSPOSABLE ELEMENT; AEDES-AEGYPTI; TRANSFORMATION; DROSOPHILA; MARINER; FLY		Univ Munich, Inst Zool, D-80333 Munich, Germany; Univ Bayreuth, Lehrstuhl Genet, D-95447 Bayreuth, Germany	University of Munich; University of Bayreuth	Berghammer, AJ (corresponding author), Univ Munich, Inst Zool, Luisenstr 14, D-80333 Munich, Germany.		Klingler, Martin/J-8383-2013	Klingler, Martin/0000-0001-8859-1965; Wimmer, Ernst A./0000-0002-2480-2804				Callaerts P, 1997, ANNU REV NEUROSCI, V20, P483, DOI 10.1146/annurev.neuro.20.1.483; CARY LC, 1989, VIROLOGY, V172, P156, DOI 10.1016/0042-6822(89)90117-7; Coates CJ, 1998, P NATL ACAD SCI USA, V95, P3748, DOI 10.1073/pnas.95.7.3748; Handler AM, 1998, P NATL ACAD SCI USA, V95, P7520, DOI 10.1073/pnas.95.13.7520; Jasinskiene N, 1998, P NATL ACAD SCI USA, V95, P3743, DOI 10.1073/pnas.95.7.3743; LOUKERIS TG, 1995, SCIENCE, V270, P2002, DOI 10.1126/science.270.5244.2002; MEDHORA MM, 1988, EMBO J, V7, P2185, DOI 10.1002/j.1460-2075.1988.tb03057.x; OBrochta DA, 1996, INSECT BIOCHEM MOLEC, V26, P739, DOI 10.1016/S0965-1748(96)00022-7; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; Sheng GJ, 1997, GENE DEV, V11, P1122, DOI 10.1101/gad.11.9.1122; Tsien RY, 1998, ANNU REV BIOCHEM, V67, P509, DOI 10.1146/annurev.biochem.67.1.509; WARREN WD, 1994, GENET RES, V64, P87, DOI 10.1017/S0016672300032699	12	263	280	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					370	371		10.1038/46463	http://dx.doi.org/10.1038/46463			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586872				2022-12-28	WOS:000083913600041
J	Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN				Johnson, S; Samore, MH; Farrow, KA; Killgore, GE; Tenover, FC; Lyras, D; Rood, JI; DeGirolami, P; Baltch, AL; Rafferty, ME; Pear, SM; Gerding, DN			Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PERFRINGENS; LINCOSAMIDE; MACROLIDE; OUTBREAK; TETRACYCLINE; RESTRICTION; PLASMIDS; SEQUENCE; COLITIS; GENES	Background: Large outbreaks of diarrhea caused by a newly recognized strain of Clostridium difficile occurred in four hospitals located in different parts of the United States between 1989 and 1992. Since frequent use of clindamycin was associated with the outbreak in one of the hospitals, we examined the resistance genes of the epidemic-strain isolates and studied the role of clindamycin use in these outbreaks. Methods: Case-control studies were performed at three of the four hospitals to assess the relation of the use of clindamycin to C. difficile-associated diarrhea. All isolates of the epidemic strain and representative isolates of other strains identified during each outbreak were tested for susceptibility to clindamycin. Chromosomal DNA from these representative isolates was also analyzed by dot blot hybridization and amplification with the polymerase chain reaction (PCR) with the use of probes and primers from a previously described determinant of erythromycin resistance -- the erythromycin ribosomal methylase B (ermB) gene -- found in C. perfringens and C. difficile. Results: In a stratified analysis of the case-control studies with pooling of the results according to the Mantel-Haenszel method, we found that the use of clindamycin was significantly increased among patients with diarrhea due to the epidemic strain of C. difficile, as compared with patients whose diarrhea was due to nonepidemic strains (pooled odds ratio, 4.35; 95 percent confidence interval, 2.02 to 9.38; P<0.001). Exposure to other types of antibiotics or hospitalization in a surgical ward was not significantly associated with the risk of C. difficile-associated diarrhea due to the epidemic strain. All epidemic-strain isolates were highly resistant to clindamycin (minimal inhibitory concentration, >256 microg per milliliter). DNA hybridization and PCR analysis showed that all these isolates had an ermB gene, which encodes a 23S ribosomal RNA methylase that mediates resistance to macrolide, lincosamide, and streptogramin antibiotics. Only 15 percent of the nonepidemic strains were resistant to clindamycin. Conclusions: A strain of C. difficile that is highly resistant to clindamycin was responsible for large outbreaks of diarrhea in four hospitals in different states. The use of clindamycin is a specific risk factor for diarrhea due to this strain. Resistance to clindamycin further increases the risk of C. difficile-associated diarrhea, an established complication of antimicrobial use. (N Engl J Med 1999;341:1645-51.) (C) 1999, Massachusetts Medical Society.	Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Beth Israel Deaconess Med Ctr, Dept Med, Infect Dis Sect, Boston, MA USA; Harvard Univ, Sch Med, Boston, MA USA; Monash Univ, Dept Microbiol, Clayton, Vic 3168, Australia; Ctr Dis Control & Prevent, Atlanta, GA USA; Stratton Vet Affairs Med Ctr, Albany, NY USA; Albany Med Coll, Albany, NY 12208 USA; Vet Affairs Med Ctr, Tucson, AZ USA	Northwestern University; Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School; Monash University; Centers for Disease Control & Prevention - USA; Albany Medical College; US Department of Veterans Affairs; Veterans Health Administration (VHA); Southern Arizona Veterans Affairs Health Care System	Johnson, S (corresponding author), Vet Affairs Chicago Hlth Care Syst, Lakeside Div, Med Serv, Dept Med,Infect Dis Sect, 333 E Huron, Chicago, IL 60611 USA.	stu-johnson@nwu.edu	Rood, Julian I/A-4858-2008	Rood, Julian I/0000-0003-2126-7209; Johnson, Stuart/0000-0001-9548-229X; Lyras, Dena/0000-0003-2345-9271				ABRAHAM LJ, 1985, J BACTERIOL, V161, P636, DOI 10.1128/JB.161.2.636-640.1985; ARTHUR M, 1987, J ANTIMICROB CHEMOTH, V20, P783, DOI 10.1093/jac/20.6.783; BARTLETT JG, 1978, NEW ENGL J MED, V298, P531, DOI 10.1056/NEJM197803092981003; BERRYMAN DI, 1995, ANTIMICROB AGENTS CH, V39, P1830, DOI 10.1128/AAC.39.8.1830; BERRYMAN DI, 1994, ANTIMICROB AGENTS CH, V38, P1041, DOI 10.1128/AAC.38.5.1041; Brazier JS, 1998, J ANTIMICROB CHEMOTH, V41, P47, DOI 10.1093/jac/41.suppl_3.47; BREFORT G, 1977, PLASMID, V1, P52, DOI 10.1016/0147-619X(77)90008-7; CARTMILL TDI, 1994, J HOSP INFECT, V27, P1, DOI 10.1016/0195-6701(94)90063-9; CLABOTS CR, 1992, J INFECT DIS, V166, P561, DOI 10.1093/infdis/166.3.561; CLABOTS CR, 1991, 31 INT C ANT AG CHEM, P352; Climo MW, 1998, ANN INTERN MED, V128, P989, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00005; GERDING DN, 1995, INFECT CONT HOSP EP, V16, P459; JOHNSON S, 1990, LANCET, V336, P97, DOI 10.1016/0140-6736(90)91605-A; KILLGORE GE, 1994, J CLIN MICROBIOL, V32, P1591, DOI 10.1128/JCM.32.6.1591-1593.1994; LYRAS D, 1997, CLOSTRIDIA MOL BIOL, P73; MEKONEN E, 1996, INFECT CONTROL HOS S, V17, pP32; MULLANY P, 1995, J ANTIMICROB CHEMOTH, V35, P305, DOI 10.1093/jac/35.2.305; *NAT COMM CLIN LAB, 1997, M11A4 NCCLS; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P88; NELSON DE, 1994, INFECT CONT HOSP EP, V15, P366; PEAR SM, 1994, ANN INTERN MED, V120, P272, DOI 10.7326/0003-4819-120-4-199402150-00003; Rafferty ME, 1998, J CLIN MICROBIOL, V36, P2957, DOI 10.1128/JCM.36.10.2957-2963.1998; ROTHMAN KJ, 1998, MODERN EPIDEMIOLOGY, P270; Samore M, 1997, J INFECT DIS, V176, P1233, DOI 10.1086/514117; SAMORE MH, 1994, J INFECT DIS, V170, P615, DOI 10.1093/infdis/170.3.615; Samore MH, 1996, AM J MED, V100, P32, DOI 10.1016/S0002-9343(96)90008-X; SMITH CJ, 1981, ANTIMICROB AGENTS CH, V19, P997, DOI 10.1128/AAC.19.6.997; Tenover FC, 1997, INFECT CONT HOSP EP, V18, P426; WUST J, 1983, ANTIMICROB AGENTS CH, V23, P784, DOI 10.1128/AAC.23.5.784	29	254	262	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1645	1651		10.1056/NEJM199911253412203	http://dx.doi.org/10.1056/NEJM199911253412203			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572152				2022-12-28	WOS:000083847500003
J	Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P				Macedo-Ribeiro, S; Bode, W; Huber, R; Quinn-Allen, MA; Kim, SW; Ortel, TL; Bourenkov, GP; Bartunik, HD; Stubbs, MT; Kane, WH; Fuentes-Prior, P			Crystal structures of the membrane-binding C2 domain of human coagulation factor V	NATURE			English	Article							FACTOR-VIII; PROTHROMBIN ACTIVATION; PHOSPHOLIPID-VESICLES; PHOSPHATIDYLSERINE; COMPLEX; PROTEIN; ASSOCIATION; INSIGHTS; COFACTOR; MODELS	Rapid and controlled clot formation is achieved through sequential activation of circulating serine proteinase precursors on phosphatidylserine-rich procoagulant membranes of activated platelets and endothelial cells(1). The homologous complexes Xase and prothrombinase, each consisting of an active proteinase and a non-enzymatic cofactor, perform critical steps within this coagulation cascade. The activated cofactors VIIIa and Va, highly specific for their cognate proteinases, are each derived from precursors with the same A1-A2-B-A3-C1-C2 architecture(2). Membrane binding is mediated by the C2 domains of both cofactors, Here we report two crystal structures of the C2 domain of human factor Va. The conserved beta-barrel framework provides a scaffold for three protruding loops, one of which adopts markedly different conformations in the two crystal forms. We propose a mechanism of calcium-independent, stereospecific binding of factors Va and VIIIa to phospholipid membranes(3,4), on the basis of (1) immersion of hydrophobic residues at the apices of these loops in the apolar membrane core; (2) specific interactions with phosphatidylserine head groups in the groove enclosed by these loops; and (3) favourable electrostatic contacts of basic side chains with negatively charged membrane phosphate groups.	Max Planck Inst Biochem, Abt Strukturforsch, D-82152 Martinsried, Germany; Duke Univ, Med Ctr, Dept Med, Div Hematol, Durham, NC 27710 USA; DESY, MPG ASMB, Prot Dynam Grp, Max Planck Res Unit Struct Mol Biol, D-22603 Hamburg, Germany; Univ Marburg, Inst Pharmazeut Chem, D-35032 Marburg, Germany	Max Planck Society; Duke University; Helmholtz Association; Deutsches Elektronen-Synchrotron (DESY); Max Planck Society; Philipps University Marburg	Bode, W (corresponding author), Max Planck Inst Biochem, Abt Strukturforsch, Klopferspitz 18A, D-82152 Martinsried, Germany.	bode@biochem.mpg.de	Macedo-Ribeiro, Sandra/D-9258-2011; Bourenkov, Gleb P/C-7794-2017; Stubbs, Milton/ABC-7585-2020	Macedo-Ribeiro, Sandra/0000-0002-7698-1170; Bourenkov, Gleb P/0000-0002-2617-5920; Stubbs, Milton/0000-0003-1278-9013; Fuentes-Prior, Pablo/0000-0002-6618-3204				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, XPLOR VERSION 3 1 SY; COMFURIUS P, 1994, BIOCHEMISTRY-US, V33, P10319, DOI 10.1021/bi00200a012; Cutsforth GA, 1996, BIOPHYS J, V70, P2938, DOI 10.1016/S0006-3495(96)79864-8; DAVIE EW, 1991, BIOCHEMISTRY-US, V30, P10363, DOI 10.1021/bi00107a001; GERADS I, 1990, BIOCHEMISTRY-US, V29, P7967, DOI 10.1021/bi00486a027; GILBERT GE, 1993, BIOCHEMISTRY-US, V32, P9577, DOI 10.1021/bi00088a009; GILBERT GE, 1990, J BIOL CHEM, V265, P815; ITO N, 1994, J MOL BIOL, V238, P794, DOI 10.1006/jmbi.1994.1335; KALAFATIS M, 1994, BIOCHEMISTRY-US, V33, P486, DOI 10.1021/bi00168a013; KANE WH, 1988, BLOOD, V71, P539; KIM SW, IN PRESS BIOCHEMISTR; KNIGHT S, 1989, THESIS SWEDISH U AGR; Koppaka V, 1997, BIOPHYS J, V73, P2638, DOI 10.1016/S0006-3495(97)78293-6; KRISHNASWAMY S, 1988, J BIOL CHEM, V263, P5714; LESLIE AGW, 1991, CRYSTALLOGRAPHIC COM, V5, P27; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; NESHEIM ME, 1979, J BIOL CHEM, V254, P952; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; ORTEL TL, 1994, J BIOL CHEM, V269, P15898; ORTEL TL, 1992, J BIOL CHEM, V267, P4189; Ortel TL, 1998, BLOOD, V91, P4188, DOI 10.1182/blood.V91.11.4188.411k33_4188_4196; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; ROSING J, 1988, BIOCHEMISTRY-US, V27, P8, DOI 10.1021/bi00401a002; ROSING J, 1993, J BIOL CHEM, V268, P21130; Stenflo J, 1999, CRIT REV EUKAR GENE, V9, P59, DOI 10.1615/CritRevEukaryotGeneExpr.v9.i1.50; SWAIRJO MA, 1995, NAT STRUCT BIOL, V2, P968, DOI 10.1038/nsb1195-968; Villoutreix BO, 1998, J MOL MODEL, V4, P268, DOI 10.1007/s008940050084; Zwaal RFA, 1998, BBA-REV BIOMEMBRANES, V1376, P433, DOI 10.1016/S0304-4157(98)00018-5	30	210	220	0	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					434	439		10.1038/46594	http://dx.doi.org/10.1038/46594			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586886				2022-12-28	WOS:000083913600062
J	Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D				Toni, N; Buchs, PA; Nikonenko, I; Bron, CR; Muller, D			LTP promotes formation of multiple spine synapses between a single axon terminal and a dendrite	NATURE			English	Article							CENTRAL-NERVOUS-SYSTEM; POSTSYNAPTIC DENSITIES; AXOSPINOUS SYNAPSES; PYRAMIDAL CELLS; POTENTIATION; CA1; RAT; SYNAPTOGENESIS; TRANSMISSION; HIPPOCAMPUS	Structural remodelling of synapses(1-4) and formation of new synaptic contacts(5-8) has been postulated as a possible mechanism underlying the late phase of long-term potentiation (LTP), a form of plasticity which is involved in learning and memory(9). Here we use electron microscopy to analyse the morphology of synapses activated by high-frequency stimulation and identified by accumulated calcium in dendritic spines. LTP induction resulted in a sequence of morphological changes consisting of a transient remodelling of the postsynaptic membrane followed by a marked increase in the proportion of axon terminals contacting two or more dendritic spines. Three-dimensional reconstruction revealed that these spines arose from the same dendrite. As pharmacological blockade of LTP prevented these morphological changes, we conclude that LTP is associated with the formation of new, mature and probably functional synapses contacting the same presynaptic terminal and thereby duplicating activated synapses.	Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland; Univ Bern, Inst Anat, CH-3000 Bern, Switzerland	University of Geneva; University of Bern	Muller, D (corresponding author), Univ Geneva, CMU, CH-1211 Geneva 4, Switzerland.		Toni, Nicolas/M-2057-2014	Toni, Nicolas/0000-0001-5585-268X				BLISS TVP, 1993, NATURE, V361, P31, DOI 10.1038/361031a0; Bolshakov VY, 1997, NEURON, V19, P635, DOI 10.1016/S0896-6273(00)80377-3; BUCHS PA, 1994, J NEUROSCI METH, V54, P83, DOI 10.1016/0165-0270(94)90162-7; Buchs PA, 1996, P NATL ACAD SCI USA, V93, P8040, DOI 10.1073/pnas.93.15.8040; CALVERLEY RKS, 1990, BRAIN RES REV, V15, P215, DOI 10.1016/0165-0173(90)90002-6; CARLIN RK, 1983, P NATL ACAD SCI-BIOL, V80, P3517, DOI 10.1073/pnas.80.11.3517; Engert F, 1999, NATURE, V399, P66, DOI 10.1038/19978; Fiala JC, 1998, J NEUROSCI, V18, P8900; Fischer M, 1998, NEURON, V20, P847, DOI 10.1016/S0896-6273(00)80467-5; GEINISMAN Y, 1991, BRAIN RES, V566, P77, DOI 10.1016/0006-8993(91)91683-R; GEINISMAN Y, 1993, HIPPOCAMPUS, V3, P435, DOI 10.1002/hipo.450030405; Geinisman Y, 1996, J COMP NEUROL, V368, P413; Kirov SA, 1999, J NEUROSCI, V19, P2876; Kleim JA, 1997, J NEUROSCI, V17, P717; Liao DH, 1999, NAT NEUROSCI, V2, P37, DOI 10.1038/4540; Maletic-Savatic M, 1999, SCIENCE, V283, P1923, DOI 10.1126/science.283.5409.1923; McKinney RA, 1999, NAT NEUROSCI, V2, P44, DOI 10.1038/4548; MOSER MB, 1994, P NATL ACAD SCI USA, V91, P12673, DOI 10.1073/pnas.91.26.12673; NIETOSAMPEDRO M, 1982, P NATL ACAD SCI-BIOL, V79, P5718, DOI 10.1073/pnas.79.18.5718; Shi SH, 1999, SCIENCE, V284, P1811, DOI 10.1126/science.284.5421.1811; Sorra KE, 1998, J COMP NEUROL, V398, P225; SORRA KE, 1993, J NEUROSCI, V13, P3736; Spacek J, 1997, J NEUROSCI, V17, P190, DOI 10.1523/JNEUROSCI.17-01-00190.1997; STERIO DC, 1984, J MICROSC-OXFORD, V134, P127, DOI 10.1111/j.1365-2818.1984.tb02501.x; STOPPINI L, 1991, J NEUROSCI METH, V37, P173, DOI 10.1016/0165-0270(91)90128-M; Trommald M, 1997, J COMP NEUROL, V377, P15, DOI 10.1002/(SICI)1096-9861(19970106)377:1<15::AID-CNE3>3.0.CO;2-M; Woolley CS, 1996, J COMP NEUROL, V373, P108; Ziv NE, 1996, NEURON, V17, P91, DOI 10.1016/S0896-6273(00)80283-4	28	751	761	2	46	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					421	425		10.1038/46574	http://dx.doi.org/10.1038/46574			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586883				2022-12-28	WOS:000083913600059
J	Frey, JJ				Frey, JJ			Ward 55	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1897	1898		10.1001/jama.282.20.1897	http://dx.doi.org/10.1001/jama.282.20.1897			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580440				2022-12-28	WOS:000083763400001
J	Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME				Surks, HK; Mochizuki, N; Kasai, Y; Georgescu, SP; Tang, KM; Ito, M; Lincoln, TM; Mendelsohn, ME			Regulation of myosin phosphatase by a specific interaction with cGMP-dependent protein kinase I alpha	SCIENCE			English	Article							LIGHT-CHAIN PHOSPHATASE; VASCULAR SMOOTH-MUSCLE; DNA-BINDING DOMAIN; LEUCINE-ZIPPER; SIGNAL-TRANSDUCTION; TARGETING SUBUNITS; GMP; CALCIUM; PHOSPHORYLATION; IDENTIFICATION	Contraction and relaxation of smooth muscle are regulated by myosin light-chain kinase and myosin phosphatase through phosphorylation and dephosphorylation of myosin light chains. Cyclic guanosine monophosphate (cGMP)-dependent protein kinase I alpha (cGKI alpha) mediates physiologic relaxation of vascular smooth muscle in response to nitric oxide and cGMP. It is shown here that cGKI alpha is targeted to the smooth muscle cell contractile apparatus py a Leucine zipper interaction with the myosin-binding subunit (MBS) of myosin phosphatase. Uncoupling of the cGKI alpha-MBS interaction prevents cGMP-dependent dephosphorylation of myosin light chain, demonstrating that this interaction is essential to the regulation of vascular smooth muscle cell tone.	Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA; Tufts Univ, Sch Med, Dept Med, Div Cardiol, Boston, MA 02111 USA; Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Int Med Ctr Japan, Res Inst, Dept Pathol, Tokyo 1628655, Japan; Mie Univ, Sch Med, Dept Internal Med 1, Tsu, Mie 514, Japan; Univ Alabama Birmingham, Dept Pathol, Div Mol & Cellular Pathol, Birmingham, AL 35294 USA	Tufts University; Tufts University; Tufts Medical Center; National Center for Global Health & Medicine - Japan; Mie University; University of Alabama System; University of Alabama Birmingham	Mendelsohn, ME (corresponding author), Tufts Univ, Sch Med, Mol Cardiol Res Inst, Boston, MA 02111 USA.	mmendelsohn@lfespan.org			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [F32HL009330] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL09330, HL55309] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALESSI D, 1992, EUR J BIOCHEM, V210, P1023, DOI 10.1111/j.1432-1033.1992.tb17508.x; ATKINSON RA, 1991, BIOCHEMISTRY-US, V30, P9387, DOI 10.1021/bi00103a001; BRADLEY AB, 1987, J PHYSIOL-LONDON, V385, P437, DOI 10.1113/jphysiol.1987.sp016500; BRAUTIGAN DL, 1988, METHOD ENZYMOL, V159, P339; CHEVRAY PM, 1992, P NATL ACAD SCI USA, V89, P5789, DOI 10.1073/pnas.89.13.5789; CHOI KY, 1994, CELL, V78, P499; COHEN P, 1991, METHOD ENZYMOL, V201, P389; CORNWELL TL, 1989, J BIOL CHEM, V264, P1146; DellAcqua ML, 1997, J BIOL CHEM, V272, P12881, DOI 10.1074/jbc.272.20.12881; FILO RS, 1965, SCIENCE, V147, P1581, DOI 10.1126/science.147.3665.1581; GLATZ RHD, 1992, NUCLEIC ACIDS RES, V20, P1425; GONG MC, 1992, J BIOL CHEM, V267, P21492; GUTFREUND H, 1971, ENZYMES PHYSICAL PRI, P67; HARBURY PB, 1993, SCIENCE, V262, P1401, DOI 10.1126/science.8248779; HARTSHORNE DJ, 1987, PHYSL GASTROINTESTIN, V1, P423; HEIL WG, 1987, EUR J BIOCHEM, V168, P117, DOI 10.1111/j.1432-1033.1987.tb13395.x; Hirano K, 1997, J BIOL CHEM, V272, P3683, DOI 10.1074/jbc.272.6.3683; HUBBARD MJ, 1993, TRENDS BIOCHEM SCI, V18, P172, DOI 10.1016/0968-0004(93)90109-Z; ISHIHARA H, 1989, BIOCHEM BIOPH RES CO, V159, P871, DOI 10.1016/0006-291X(89)92189-X; Johnson DF, 1996, EUR J BIOCHEM, V239, P317, DOI 10.1111/j.1432-1033.1996.0317u.x; KAMM KE, 1985, ANNU REV PHARMACOL, V25, P593, DOI 10.1146/annurev.pharmtox.25.1.593; Kimura K, 1996, SCIENCE, V273, P245, DOI 10.1126/science.273.5272.245; KITAZAWA T, 1991, J BIOL CHEM, V266, P1708; Klauck TM, 1996, SCIENCE, V271, P1589, DOI 10.1126/science.271.5255.1589; KUNKEL TA, 1987, METHOD ENZYMOL, V154, P367; LANDSCHULZ WH, 1989, SCIENCE, V243, P1681, DOI 10.1126/science.2494700; LANDSCHULZ WH, 1988, SCIENCE, V240, P1759, DOI 10.1126/science.3289117; Lee MR, 1997, J BIOL CHEM, V272, P5063, DOI 10.1074/jbc.272.8.5063; Lincoln T.M., 1994, CYCLIC GMP BIOCH PHY, P97; LINCOLN TM, 1977, J BIOL CHEM, V252, P4269; LINCOLN TM, 1993, FASEB J, V7, P328, DOI 10.1096/fasebj.7.2.7680013; Lohmann SM, 1997, TRENDS BIOCHEM SCI, V22, P307, DOI 10.1016/S0968-0004(97)01086-4; MACMILLANCROW LA, 1994, BIOCHEMISTRY-US, V33, P8035, DOI 10.1021/bi00192a007; MASUO M, 1994, J GEN PHYSIOL, V104, P265, DOI 10.1085/jgp.104.2.265; MOCHLYROSEN D, 1995, SCIENCE, V268, P247, DOI 10.1126/science.7716516; MONKEN CE, 1980, J BIOL CHEM, V255, P7067; MORGAN JP, 1984, J PHYSIOL-LONDON, V357, P539, DOI 10.1113/jphysiol.1984.sp015516; Nakamura M, 1999, CELL SIGNAL, V11, P671, DOI 10.1016/S0898-6568(99)00036-4; Pawson T, 1997, SCIENCE, V278, P2075, DOI 10.1126/science.278.5346.2075; Pfeifer A, 1998, EMBO J, V17, P3045, DOI 10.1093/emboj/17.11.3045; RUBIN CS, 1994, BBA-MOL CELL RES, V1224, P467; SCOTTJD, 1996, TRENDS BIOCHEM SCI, V21, P312; SHIMIZU H, 1994, J BIOL CHEM, V269, P30407; SOMLYO AP, 1989, FASEB J, V3, P2266, DOI 10.1096/fasebj.3.11.2506092; SOMLYO AP, 1994, NATURE, V372, P231, DOI 10.1038/372231a0; SURKS HK, UNPUB; Takahashi N, 1997, GENOMICS, V44, P150, DOI 10.1006/geno.1997.4859; Tamura N, 1996, HYPERTENSION, V27, P552, DOI 10.1161/01.HYP.27.3.552; TAYLOR DA, 1988, J BIOL CHEM, V263, P14456; TURNER R, 1989, SCIENCE, V243, P1689, DOI 10.1126/science.2494701; Vidal M, 1996, P NATL ACAD SCI USA, V93, P10315, DOI 10.1073/pnas.93.19.10315; Wang GR, 1998, P NATL ACAD SCI USA, V95, P4888, DOI 10.1073/pnas.95.9.4888; Wu XQ, 1996, BIOCHEM BIOPH RES CO, V220, P658, DOI 10.1006/bbrc.1996.0460	53	401	419	0	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1583	1587		10.1126/science.286.5444.1583	http://dx.doi.org/10.1126/science.286.5444.1583			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567269				2022-12-28	WOS:000083768300065
J	Coles, AJ; Wing, N; Smith, S; Coraddu, F; Greer, S; Taylor, C; Weetman, A; Hale, G; Chatterjee, VK; Waldmann, H; Compston, A				Coles, AJ; Wing, N; Smith, S; Coraddu, F; Greer, S; Taylor, C; Weetman, A; Hale, G; Chatterjee, VK; Waldmann, H; Compston, A			Pulsed monoclonal antibody treatment and autoimmune thyroid disease in multiple sclerosis	LANCET			English	Article							RESPONSES; GRAVES; CELLS; SERUM; RATS	Background Multiple sclerosis results from T-cell-dependent inflammatory demyelination of the central nervous system. Our objective was long-term suppression of inflammation with short-term monoclonal antibody treatment. Methods We depleted 95% of circulating lymphocytes in 27 patients with multiple sclerosis by means of a 5-day pulse of the humanised anti-CD52 monoclonal antibody, Campath-1H, Clinical and haematological consequences of T-cell depletion, and in-vitro responses of patients' peripheral-blood mononuclear cells were analysed serially for 18 months after treatment. Findings Radiological and clinical markers of disease activity were significantly decreased for at least 18 months after treatment. However, a third of patients developed antibodies against the thyrotropin receptor and carbimazole-responsive autoimmune hyperthyroidism. The depleted peripheral lymphocyte pool was reconstituted with cells that had decreased mitogen-induced proliferation and interferon gamma secretion in vitro, Interpretation Campath-1H causes the immune response to change from the Th1 phenotype, suppressing multiple sclerosis disease activity, but permitting the generation of antibody-mediated thyroid autoimmunity.	Univ Cambridge, Neurol Unit, Cambridge CB2 2QQ, England; Univ Cambridge, Dept Med, Cambridge CB2 2QQ, England; Addenbrookes Hosp, Tissue Typing Lab, Ctr Brain Repair, Cambridge, England; Univ Oxford, Sir William Dunn Sch Pathol, Oxford OX1 3RE, England; Therapeut Antibody Ctr, Oxford, England; Univ Sheffield, Ctr Clin Sci, Dept Med, Sheffield, S Yorkshire, England	University of Cambridge; University of Cambridge; Cambridge University Hospitals NHS Foundation Trust; Addenbrooke's Hospital; University of Cambridge; University of Oxford; University of Oxford; University of Sheffield	Coles, AJ (corresponding author), Univ Cambridge, Addenbrookes Hosp, Neurol Unit, Box 165,Hills Rd, Cambridge CB2 2QQ, England.	alasdair_coles@hotmail.com	waldmann, herman/W-8051-2019; waldmann, herman/F-7412-2011	Hale, Geoff/0000-0001-9473-423X; Chatterjee, Vengalil Krishna/0000-0002-2654-8854; Waldmann, Herman/0000-0001-7519-6720; Coles, Alasdair/0000-0003-4738-0760				BENJAMIN RJ, 1986, NATURE, V320, P449, DOI 10.1038/320449a0; COBBOLD SP, 1990, J IMMUNOL METHODS, V127, P19, DOI 10.1016/0022-1759(90)90335-S; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Coles AJ, 1998, MULT SCLER, V4, P232, DOI 10.1177/135245859800400327; DEKEYSER J, 1988, NEUROLOGY, V38, P371; FOWELL D, 1993, J EXP MED, V177, P627, DOI 10.1084/jem.177.3.627; Gilquin J, 1998, LANCET, V352, P1907, DOI 10.1016/S0140-6736(05)60398-4; HAFLER DA, 1986, NEUROLOGY, V36, P777, DOI 10.1212/WNL.36.6.777; HIRSCH RL, 1985, J CLIN IMMUNOL, V5, P386, DOI 10.1007/BF00915335; KOSTA K, 1997, CLIN ENDOCRINOL, V46, P551; MICHELANGELI VP, 1994, CLIN ENDOCRINOL, V40, P645, DOI 10.1111/j.1365-2265.1994.tb03017.x; Moreau T, 1996, BRAIN, V119, P225, DOI 10.1093/brain/119.1.225; MOREAU T, 1994, LANCET, V344, P298, DOI 10.1016/S0140-6736(94)91339-0; OLERUP O, 1993, TISSUE ANTIGENS, V41, P119, DOI 10.1111/j.1399-0039.1993.tb01991.x; PENHALE WJ, 1975, CLIN EXP IMMUNOL, V21, P362; Schwid SR, 1997, ARCH NEUROL-CHICAGO, V54, P1169, DOI 10.1001/archneur.1997.00550210095020; SMITH BR, 1988, ENDOCR REV, V9, P106, DOI 10.1210/edrv-9-1-106; vanOosten BW, 1997, NEUROLOGY, V49, P351, DOI 10.1212/WNL.49.2.351; Watanabe M, 1997, THYROID, V7, P743, DOI 10.1089/thy.1997.7.743	19	335	350	0	15	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1691	1695		10.1016/S0140-6736(99)02429-0	http://dx.doi.org/10.1016/S0140-6736(99)02429-0			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568572				2022-12-28	WOS:000083652800013
J	Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA				Enright, AJ; Iliopoulos, I; Kyrpides, NC; Ouzounis, CA			Protein interaction maps for complete genomes based on gene fusion events	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; ENZYMES	A large-scale effort to measure, detect and analyse protein-protein interactions using experimental methods is under way(1,2). These include biochemistry such as co-immunoprecipitation or crosslinking, molecular biology such as the two-hybrid system or phage display, and genetics such as unlinked noncomplementing mutant detection). Using the two-hybrid system(4), an international effort to analyse the complete yeast genome is in progress'. Evidently, all these approaches are tedious, labour intensive and inaccurate(6). From a computational perspective, the question is how can we predict that two proteins interact from structure or sequence alone. Here we present a method that identifies gene-fusion events in complete genomes, solely based on sequence comparison. Because there must be selective pressure for certain genes to be fused over the course of evolution, we are able to predict functional associations of proteins. We show that 215 genes or proteins in the complete genomes of Escherichia coli, Haemophilus influenzae and Methanococcus jannaschii are involved in 64 unique fusion events. The approach is general, and can be applied even to genes of unknown function.	EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England; Integrated Genom Inc, Chicago, IL 60612 USA	European Molecular Biology Laboratory (EMBL)	Ouzounis, CA (corresponding author), EMBL Cambridge Outstn, European Bioinformat Inst, Computat Genom Grp, Cambridge CB10 1SD, England.	ouzounis@ebi.ac.uk	Kyrpides, Nikos C./A-6305-2014; Enright, Anton/F-3094-2011; Ouzounis, Christos A/G-2302-2010	Kyrpides, Nikos C./0000-0002-6131-0462; Enright, Anton/0000-0002-6090-3100; Ouzounis, Christos A/0000-0002-0086-8657				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Andrade MA, 1999, BIOINFORMATICS, V15, P391, DOI 10.1093/bioinformatics/15.5.391; Blackstock WP, 1999, TRENDS BIOTECHNOL, V17, P121, DOI 10.1016/S0167-7799(98)01245-1; Bulow L, 1990, Biochem Soc Symp, V57, P123; BURNS DM, 1990, J BIOL CHEM, V265, P2060; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DENISDUPHIL M, 1989, BIOCHEM CELL BIOL, V67, P612, DOI 10.1139/o89-094; DUNCAN K, 1988, FEBS LETT, V241, P83, DOI 10.1016/0014-5793(88)81036-6; Janin J, 1995, PROTEINS, V23, P580, DOI 10.1002/prot.340230413; Jones S, 1996, P NATL ACAD SCI USA, V93, P13, DOI 10.1073/pnas.93.1.13; Lakey JH, 1998, CURR OPIN STRUC BIOL, V8, P119, DOI 10.1016/S0959-440X(98)80019-5; Larsen TA, 1998, STRUCT FOLD DES, V6, P421, DOI 10.1016/S0969-2126(98)00044-6; Lecrenier N, 1998, BIOESSAYS, V20, P1; Luban Jeremy, 1995, Current Opinion in Biotechnology, V6, P59, DOI 10.1016/0958-1669(95)80010-7; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; Mendelsohn AR, 1999, SCIENCE, V284, P1948, DOI 10.1126/science.284.5422.1948; Ouzounis CA, 1997, J MOL EVOL, V45, P708, DOI 10.1007/PL00013145; Overbeek R, 1999, P NATL ACAD SCI USA, V96, P2896, DOI 10.1073/pnas.96.6.2896; Pearson WR, 1996, METHOD ENZYMOL, V266, P227; Pellegrini M, 1999, P NATL ACAD SCI USA, V96, P4285, DOI 10.1073/pnas.96.8.4285; PHIZICKY EM, 1995, MICROBIOL REV, V59, P94, DOI 10.1128/MMBR.59.1.94-123.1995; Rivera MC, 1998, P NATL ACAD SCI USA, V95, P6239, DOI 10.1073/pnas.95.11.6239; SMITH S, 1994, FASEB J, V8, P1248, DOI 10.1096/fasebj.8.15.8001737; SMITH TF, 1981, J MOL BIOL, V147, P195, DOI 10.1016/0022-2836(81)90087-5; Tamames J, 1997, J MOL EVOL, V44, P66, DOI 10.1007/PL00006122; WALES ME, 1991, METHOD ENZYMOL, V202, P687; WELCH GR, 1994, TRENDS BIOCHEM SCI, V19, P193	27	789	842	5	61	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					86	90		10.1038/47056	http://dx.doi.org/10.1038/47056			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573422				2022-12-28	WOS:000083638600048
J	Molinari, M; Helenius, A				Molinari, M; Helenius, A			Glycoproteins form mixed disulphides with oxidoreductases during folding in living cells	NATURE			English	Article							PROTEIN DISULFIDE-ISOMERASE; ENDOPLASMIC-RETICULUM	The formation of intra- and interchain disulphide bonds constitutes an integral part of the maturation of most secretory and membrane-bound proteins in the endoplasmic reticulum(1,2). Evidence indicates that members of the protein disulphide isomerase (PDI) superfamily are part of the machinery needed for proper oxidation and isomerization of disulphide bonds(3-6). Models based on in vitro studies predict that the formation of mixed disulphide bonds between oxidoreductase and substrate is intermediate in the generation of the native intrachain disulphide bond in the substrate polypeptide(7). Whether this is how thiol oxidoreductases work inside the endoplasmic reticulum is not clear. Nor has it been established which of the many members of the PDI superfamily interacts directly with newly synthesized substrate proteins, because transient mixed disulphides have never been observed in the mammalian endoplasmic reticulum during oxidative protein folding(7,8). Here we describe the mechanisms involved in co- and post-translational protein oxidation in vivo. We show that the endoplasmic-reticulum-resident oxidoreductases PDI and ERp57 are directly involved in disulphide oxidation and isomerization, and, together with the lectins calnexin and calreticulin, are central in glycoprotein folding in the endoplasmic reticulum of mammalian cells.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	ari.helenius@bc.biol.ethz.ch	Molinari, Maurizio/N-2587-2019	Molinari, Maurizio/0000-0002-7636-5829				BRAAKMAN I, 1992, NATURE, V356, P260, DOI 10.1038/356260a0; CHEN W, 1995, P NATL ACAD SCI USA, V92, P6229, DOI 10.1073/pnas.92.14.6229; FREEDMAN RB, 1994, TRENDS BIOCHEM SCI, V19, P331, DOI 10.1016/0968-0004(94)90072-8; GAROFF H, 1978, J MOL BIOL, V124, P587, DOI 10.1016/0022-2836(78)90173-0; GETHING MJ, 1992, NATURE, V355, P33, DOI 10.1038/355033a0; Gilbert HF, 1998, METHOD ENZYMOL, V290, P26, DOI 10.1016/S0076-6879(98)90005-2; GOLDBERGER RF, 1963, J BIOL CHEM, V238, P628; Helenius Ari, 1992, Trends in Cell Biology, V2, P227, DOI 10.1016/0962-8924(92)90309-B; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; KRIJNSELOCKER J, 1999, J CELL BIOL, V144, P267; MARQUARDT T, 1992, J CELL BIOL, V117, P505, DOI 10.1083/jcb.117.3.505; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Oliver JD, 1997, SCIENCE, V275, P86, DOI 10.1126/science.275.5296.86; Ruddon RW, 1997, J BIOL CHEM, V272, P3125, DOI 10.1074/jbc.272.6.3125; SOMMER A, 1974, P NATL ACAD SCI USA, V71, P3946, DOI 10.1073/pnas.71.10.3946; STRAUSS JH, 1994, MICROBIOL REV, V58, P491, DOI 10.1128/MMBR.58.3.491-562.1994; VanLeeuwen JEM, 1996, P NATL ACAD SCI USA, V93, P13997, DOI 10.1073/pnas.93.24.13997; WEISSMAN JS, 1993, NATURE, V365, P185, DOI 10.1038/365185a0; WEISSMAN JS, 1991, SCIENCE, V253, P1386, DOI 10.1126/science.1716783	19	263	268	0	6	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					90	93		10.1038/47062	http://dx.doi.org/10.1038/47062			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573423				2022-12-28	WOS:000083638600049
J	Schwartz, TB				Schwartz, TB			Henry Harrower and the turbulent beginnings of endocrinology	ANNALS OF INTERNAL MEDICINE			English	Article								The emergence of new medical science in the mid-19th century was usually greeted with derision by "practical men" who saw their academic colleagues as elitist intellectuals whose work bore little or no relation to the rough-and-tumble aspects of patient care. This schism, which was nowhere greater than in the field of endocrinology, widened in 1891 when a myxedematous patient was dramatically restored to health after the administration of a thyroid extract. On the one hand, academicians-who saw this result as a triumphal example of the transference of laboratory studies to the bedside-were encouraged to pursue further studies in endocrine pathophysiology and pharmacology. On the other hand, medical practitioners began to believe that crude extracts from glands or other organs, when prescribed as orally administered mixtures, were effective for the treatment of most human ailments. The organotherapeutic forces were ably championed by Henry R. Harrower, MD, a manufacturer as well as a dispenser of organotherapeutic products. For some years, the claims of the organotherapists remained unchallenged. Finally, in 1921, Harvey Cushing, pioneer neurosurgeon and endocrinologist, launched a crushing assault on the purveyors of pluriglandular therapy. These attacks continued over ensuing years, and organotherapy fell into disrepute. Nevertheless, the assertions of "practical men" have not subsided; rather, we are now confronted by insistent claims for a bewildering array of herbal remedies, over-the-counter hormonal products, and alternative therapies.	Rush Med Coll, Chicago, IL 60612 USA	Rush University	Schwartz, TB (corresponding author), 200 Lee St, Evanston, IL 60202 USA.							Barker L F, 1908, Science, V27, P601, DOI 10.1126/science.27.694.601; Barker LF, 1919, ENDOCRINOLOGY, V3, P253, DOI 10.1210/endo-3-3-253; Cabot RC, 1907, BOSTON MED SURG J, V157, P150, DOI 10.1056/NEJM190708011570504; Carson Gerald, 1957, CORNFLAKE CRUSADE; Clark A J, 1923, Br Med J, V2, P51; COBB I, 1924, NEW YORK MED J RECOR, V119, P6; Cushing H, 1921, J AMER MED ASSOC, V76, P1721; GLICK T F, 1976, Journal of the History of Biology, V9, P287; GREEP RO, 1966, ENDOCRINOLOGY, V79, P823, DOI 10.1210/endo-79-4-823; HARROWER HR, 1932, PRACTICAL ENDOCRINOL, P685; HARROWER HR, 1914, MANUAL ORGANOTHERAPY; HARROWER HR, 1914, MANUAL ORGANOTHERAPY, P11; HARROWER HR, 1922, INTERNAL ORGANOTHERA, P403; HARROWER HR, 1922, INTERNAL SECRETIONS, P16; HARROWER HR, 1932, PRACTICAL ENDOCRINOL, P66; HARROWER HR, 1932, PRACTICAL ENDOCRINOL, P56; HARROWER HR, 1932, PRACTICAL ENDOCRINOL, P7; HARROWER HR, 1922, INTERNAL SECRETIONS; HARROWER HR, 1932, PRACTICAL ENDOCRINOL, P64; HARROWER HR, 1922, PRACTICAL ORGANOTHER, P36; HARROWER HR, 1914, MANUAL ORGANOTHERAPY, P10; HARROWER HR, 1932, PRACTICAL ENDOCRINOL; HOLMES OW, 1891, COLLECTED ESSAYS 184, P173; Kaptchuk TJ, 1998, ANN INTERN MED, V129, P1061, DOI 10.7326/0003-4819-129-12-199812150-00011; LANDAU S, 1986, INT DICT MED BIOL, P1388; LISSER HANS, 1967, ENDOCRINOLOGY, V80, P5; Madison DL, 1996, B HIST MED, V70, P442, DOI 10.1353/bhm.1996.0128; MARKS HM, 1997, PROGRESS EXPR; Medvei Victor Cornelius, 1982, HIST ENDOCRINOLOGY; Micozzi MS, 1998, ANN INTERN MED, V129, P65, DOI 10.7326/0003-4819-129-1-199807010-00014; Murray G R, 1891, Br Med J, V2, P796; ROLLESTON HD, 1936, ENDOCRINE ORGANS HLT, P8; Rowntree LG, 1925, ENDOCRINOLOGY, V9, P181, DOI 10.1210/endo-9-3-181; Schwartz TB, 1998, ANN INTERN MED, V128, P411, DOI 10.7326/0003-4819-128-5-199803010-00018; SHERER JC, 1922, HIST GLENDALE VICINI, P402; STARR P, 1982, SOCIAL TRANSFORMATIO, P112; VINCENT S, 1923, LANCET, V1, P130; *WILL LIB, 1925, GAINS REN CAL LOC HI; Williams L, 1923, LANCET, V1, P255	39	9	9	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					702	706		10.7326/0003-4819-131-9-199911020-00012	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00012			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577334				2022-12-28	WOS:000083446200010
J	Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB				Visser, M; Bouter, LM; McQuillan, GM; Wener, MH; Harris, TB			Elevated C-reactive protein levels in overweight and obese adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; CARDIOVASCULAR-DISEASE; FAT DISTRIBUTION; NATIONAL-HEALTH; ADIPOSE-TISSUE; US ADULTS; RISK; INTERLEUKIN-6; MEN; ASSOCIATION	Context Human adipose tissue expresses and releases the proinflammatory cytokine interleukin 6, potentially inducing low-grade systemic inflammation in persons with excess body fat. Objective To test whether overweight and obesity are associated with low-grade systemic inflammation as measured by serum C-reactive protein (CRP) level. Design and Setting The Third National Health and Nutrition Examination Survey, representative of the US population from 1988 to 1994, Participants A total of 16 616 men and nonpregnant women aged 17 years or older Main Outcome Measures Elevated CRP level of 0.22 mg/dL or more and a more stringent clinically raised CRP level of more than 1.00 mg/dL. Results Elevated CRP levels and clinically raised CRP levels were present in 27.6% and 6.7% of the population, respectively. Both overweight (body mass index [BMI], 25-29.9 kg/m(2)) and obese (BMI, greater than or equal to 30 kg/m(2)) persons were more likely to have elevated CRP levels than their normal-weight counterparts (BMI, <25 kg/m(2)). After adjustment for potential confounders, including smoking and health status, the odds ratio (OR) for elevated CRP was 2.13 (95% confidence interval [CI], 1.56-2.91) for obese men and 6.21 (95% CI, 4.94-7.81) for obese women. In addition, BMI was associated with clinically raised CRP levels in women, with an OR of 4.76 (95% CI, 3.42-6.61) for obese women. Waist-to-hip ratio was positively associated with both elevated and clinically raised CRP levels, independent of BMI. Restricting the analyses to young adults (aged 17-39 years) and excluding smokers, persons with inflammatory disease, cardiovascular disease, or diabetes mellitus and estrogen users did not change the main findings. Conclusion Higher BMI is associated with higher CRP concentrations, even among young adults aged 17 to 39 years. These findings suggest a state of low-grade systemic inflammation in overweight and obese persons.	Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, NL-1081 BT Amsterdam, Netherlands; NIA, Epidemiol Demog & Biometry Program, NIH, Bethesda, MD USA; Ctr Dis Control & Prevent, Natl Ctr Hlth Stat, Hyattsville, MD USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Dept Med, Seattle, WA 98195 USA	Vrije Universiteit Amsterdam; National Institutes of Health (NIH) - USA; NIH National Institute on Aging (NIA); Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS); University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle	Visser, M (corresponding author), Vrije Univ Amsterdam, Fac Med, Inst Res Extramural Med, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.		Wener, Mark/ABE-4491-2021; Visser, Marjolein/AAP-3224-2020	Bouter, Lex/0000-0002-2659-5482; Visser, Marjolein/0000-0002-5136-298X				[Anonymous], 1998, CLIN GUID ID EV TREA; Anzai T, 1997, CIRCULATION, V96, P778; BANKS RE, 1995, CLIN EXP IMMUNOL, V102, P217; Bernert John T. Jr., 1994, Clinical Chemistry, V40, P1075; Blackburn Jr W.D., 1994, J RHEUMATOL S, V42, P9; CASSANO PA, 1992, AM J EPIDEMIOL, V136, P1474, DOI 10.1093/oxfordjournals.aje.a116468; CERMAK J, 1993, BLOOD, V82, P513, DOI 10.1182/blood.V82.2.513.513; Clark LW, 1997, CLIN CHEM, V43, P52; *CTR DIS CONTR PRE, 1996, 3 NAT HLTH NUTR EX S; Danesh J, 1998, JAMA-J AM MED ASSOC, V279, P1477, DOI 10.1001/jama.279.18.1477; FLIER JS, 1995, CELL, V80, P15, DOI 10.1016/0092-8674(95)90445-X; Folsom AR, 1998, AM J EPIDEMIOL, V148, P1187, DOI 10.1093/oxfordjournals.aje.a009608; Franzini C, 1998, CLIN CHEM LAB MED, V36, P131, DOI 10.1515/CCLM.1998.024; Fried SK, 1998, J CLIN ENDOCR METAB, V83, P847, DOI 10.1210/jc.83.3.847; Gallagher D, 1996, AM J EPIDEMIOL, V143, P228, DOI 10.1093/oxfordjournals.aje.a008733; Gavin JR, 1997, DIABETES CARE, V20, P1183; Harris MI, 1998, DIABETES CARE, V21, P518, DOI 10.2337/diacare.21.4.518; Harris TB, 1999, AM J MED, V106, P506, DOI 10.1016/S0002-9343(99)00066-2; KEYS A, 1972, J CHRON DIS, V25, P329, DOI 10.1016/0021-9681(72)90027-6; Koenig W, 1999, CIRCULATION, V99, P237, DOI 10.1161/01.CIR.99.2.237; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; Kuller LH, 1996, AM J EPIDEMIOL, V144, P537, DOI 10.1093/oxfordjournals.aje.a008963; LIUZZO G, 1994, NEW ENGL J MED, V331, P417, DOI 10.1056/NEJM199408183310701; Lohman T. G., 1998, ANTROPOMETRIC STANDA; Mendall MA, 1996, BRIT MED J, V312, P1061; Mohamed-Ali V, 1998, INT J OBESITY, V22, P1145, DOI 10.1038/sj.ijo.0800770; Mohamed-Ali V, 1997, J CLIN ENDOCR METAB, V82, P4196, DOI 10.1210/jc.82.12.4196; National Center for Health Statistics, 1994, PLAN OP 3 NAT HLTH N; Papanicolaou DA, 1998, ANN INTERN MED, V128, P127, DOI 10.7326/0003-4819-128-2-199801150-00009; Pickup JC, 1997, DIABETOLOGIA, V40, P1286, DOI 10.1007/s001250050822; Pirkle JL, 1996, JAMA-J AM MED ASSOC, V275, P1233, DOI 10.1001/jama.275.16.1233; PISUNYER FX, 1991, AM J CLIN NUTR, V53, pS1595; PUROHIT A, 1995, J CLIN ENDOCR METAB, V80, P3052, DOI 10.1210/jc.80.10.3052; Rexrode KM, 1998, JAMA-J AM MED ASSOC, V280, P1843, DOI 10.1001/jama.280.21.1843; Ridker PM, 1998, CIRCULATION, V97, P425; Ridker PM, 1998, CIRCULATION, V98, P731, DOI 10.1161/01.CIR.98.8.731; Ridker PM, 1997, NEW ENGL J MED, V336, P973, DOI 10.1056/NEJM199704033361401; RIMM EB, 1995, AM J EPIDEMIOL, V141, P1117, DOI 10.1093/oxfordjournals.aje.a117385; Rose G, 1982, CARDIOVASCULAR SURVE; Schreiner PJ, 1996, AM J EPIDEMIOL, V144, P335, DOI 10.1093/oxfordjournals.aje.a008934; Sebastian-Gambaro MA, 1997, EUR J CLIN CHEM CLIN, V35, P845; Tracy RP, 1997, ARTERIOSCL THROM VAS, V17, P1121, DOI 10.1161/01.ATV.17.6.1121; VOIGT LF, 1994, EPIDEMIOLOGY, V5, P525; WENER MH, 1997, MANUAL CLIN LAB IMMU; Zhang J, 1998, JAMA-J AM MED ASSOC, V280, P1690, DOI 10.1001/jama.280.19.1690	45	1721	1782	0	73	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2131	2135		10.1001/jama.282.22.2131	http://dx.doi.org/10.1001/jama.282.22.2131			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591334	Bronze			2022-12-28	WOS:000083971400031
J	Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G				Mundy, G; Garrett, R; Harris, S; Chan, J; Chen, D; Rossini, G; Boyce, B; Zhao, M; Gutierrez, G			Stimulation of bone formation in vitro and in rodents by statins	SCIENCE			English	Article							GROWTH-FACTOR-BETA; NORMAL MICE; CONTAINING BISPHOSPHONATES; IN-VITRO; INTERLEUKIN-1; OSTEOBLASTS; CHOLESTEROL; RESORPTION; TURNOVER; INVITRO	Osteoporosis and other diseases of bone Loss are a major public health problem. Here it is shown that the statins, drugs widely used for Lowering serum cholesterol, also enhance new bone formation in vitro and in rodents. This effect was associated with increased expression of the bone morphogenetic protein-2 (BMP-2) gene in bone cells. Lovastatin and simvastatin increased bone formation when injected subcutaneously over the calvaria of mice and increased cancellous bone volume when orally administered to rats. Thus, in appropriate doses, statins may have therapeutic applications for the treatment of osteoporosis.	OsteoScreen, San Antonio, TX 78229 USA; Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX 78284 USA	University of Texas System; University of Texas Health San Antonio	Mundy, G (corresponding author), OsteoScreen, 2040 Babcock Rd, San Antonio, TX 78229 USA.	mundy@uthscsa.edu	Chan, Jeannie/B-5060-2013					Bauer DC, 1999, J BONE MINER RES, V14, pS179; BOYCE BF, 1989, ENDOCRINOLOGY, V125, P1142, DOI 10.1210/endo-125-3-1142; CUEVAS P, 1991, SCIENCE, V254, P1208, DOI 10.1126/science.1957172; DUNSTAN CR, IN PRESS J BONE MINE; Fisher JE, 1999, P NATL ACAD SCI USA, V96, P133, DOI 10.1073/pnas.96.1.133; GARRETT IR, UNPUB; GhoshChoudhury N, 1996, ENDOCRINOLOGY, V137, P331, DOI 10.1210/en.137.1.331; GOWEN M, 1986, J IMMUNOL, V136, P2478; HARRIS SE, 1994, J BONE MINER RES, V9, P855; Harris Stephen E., 1995, Molecular and Cellular Differentiation, V3, P137; JILKA RL, 1992, SCIENCE, V257, P88, DOI 10.1126/science.1621100; LAW MR, 1994, BMJ-BRIT MED J, V308, P367, DOI 10.1136/bmj.308.6925.367; Luckman SP, 1998, J BONE MINER RES, V13, P581, DOI 10.1359/jbmr.1998.13.4.581; MARCELLI C, 1990, J BONE MINER RES, V5, P1087; MELTON LJ, 1995, J BONE MINER RES, V10, P175; Rao S, 1999, P NATL ACAD SCI USA, V96, P7797, DOI 10.1073/pnas.96.14.7797; Rogers MJ, 1996, J BONE MINER RES, V11, P1482; ROGERS MJ, 1995, MOL PHARMACOL, V47, P398; ROSSOUW JE, 1990, NEW ENGL J MED, V323, P1112, DOI 10.1056/NEJM199010183231606; SABATINI M, 1988, P NATL ACAD SCI USA, V85, P5235, DOI 10.1073/pnas.85.14.5235; Traianedes K, 1998, ENDOCRINOLOGY, V139, P3178, DOI 10.1210/en.139.7.3178; YATES AJP, 1988, J CLIN INVEST, V81, P932, DOI 10.1172/JCI113406	22	1402	1628	5	139	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1946	1949		10.1126/science.286.5446.1946	http://dx.doi.org/10.1126/science.286.5446.1946			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583956				2022-12-28	WOS:000084003400049
J	Vickers, A; Zollman, C				Vickers, A; Zollman, C			ABC of complementary medicine - Unconventional approaches to nutritional medicine	BRITISH MEDICAL JOURNAL			English	Review																		ANTHONY HM, 1997, ENV MED CLIN PRACTIC; BROSTOFF J, 1992, COMPLETE GUIDE FOOD; DAVIES S, 1987, NUTR MED; MURRAY M, 1999, ENCY NATURAL MED	4	7	8	0	3	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1419	1422		10.1136/bmj.319.7222.1419	http://dx.doi.org/10.1136/bmj.319.7222.1419			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574865	Green Published, Green Submitted			2022-12-28	WOS:000083995200033
J	[Anonymous]				[Anonymous]			Guidance needed on the use of the internet	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 27	1999	319	7222					1441	1441						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574886				2022-12-28	WOS:000083995200080
J	Hawkes, S; Morison, L; Foster, S; Gausia, K; Chakraborty, J; Peeling, RW; Mabey, D				Hawkes, S; Morison, L; Foster, S; Gausia, K; Chakraborty, J; Peeling, RW; Mabey, D			Reproductive-tract infections in women in low-income, low-prevalence situations: assessment of syndromic management in Matlab, Bangladesh	LANCET			English	Article							SEXUALLY-TRANSMITTED DISEASES; CHLAMYDIA-TRACHOMATIS; RURAL BANGLADESH; PREVENTION; HEALTH; HIV; SERVICES; TANZANIA; CLINICS; IMPACT	Background In the control of reproductive-tract infections, including sexually transmitted infections (STIs), in low-income and middle-income countries, WHO recommends syndromic management for individuals with symptoms. This intervention was initially developed in areas where prevalence of such infections is high. We investigated the clinical effectiveness and cost of this approach among a group of women with a tow prevalence of infection. Methods During a 5-month period, we investigated ail women complaining of abnormal vaginal discharge and seeking care at maternal and child health/family-planning centres in Matlab, Bangladesh, for the presence of laboratory-diagnosed reproductive-tract infections and STIs, Syndromic diagnoses made by trained health-care workers were compared with laboratory diagnosis of infection. We then calculated the costs of treating women by means of the recommended WHO algorithm and an adapted algorithm incorporating use of a speculum and simple diagnostic tests. Findings The prevalence of endogenous infections among 320 women seen was 30%. Cervical infections (Neisseria gonorrhoeae and Chlamydia trachomatis) were found in only three women. The WHO algorithm had a high sensitivity (100%) but a low specificity (zero for bacterial vaginosis, candida, and Trichomonas vaginalis). The speculum-based algorithm had a low sensitivity (between zero and 59%) but a higher specificity (79-97%). Between 36% and 87% of costs would have been spent on uninfected women. Interpretation The high rate of overtreatment in the population studied carries both financial and social costs-the latter in potentially exposing women misdiagnosed as having an STI to threats of domestic disruption or even violence. We make recommendations for management programmes in areas of low STI prevalence and low income.	Int Ctr Diarrhoeal Dis Res, Dhaka 1000, Bangladesh; Ctr Hlth & Populat Res, Dhaka, Bangladesh; Univ London London Sch Hyg & Trop Med, Clin Res Unit, London WC1E 7HT, England; Lab Ctr Dis Control, Winnipeg, MB, Canada	International Centre for Diarrhoeal Disease Research (ICDDR); University of London; London School of Hygiene & Tropical Medicine	Hawkes, S (corresponding author), Univ London London Sch Hyg & Trop Med, Clin Res Unit, Keppel St, London WC1E 7HT, England.	s.hawkes@lshtm.ac.uk	Hawkes, Sarah/AAK-7375-2020; Morison, Linda A/H-9738-2013; Gausia, Kaniz/G-8803-2013	Gausia, Kaniz/0000-0003-2499-1403; Hawkes, Sarah/0000-0003-1062-3538; Mabey, David/0000-0002-0031-8276; Foster, Susan/0000-0002-2751-7582				Alary M, 1998, SEX TRANSM INFECT, V74, pS44; ALDER MW, 1996, GENITOURIN MED, V72, P83; BHATIA S, 1980, STUD FAMILY PLANN, V11, P202, DOI 10.2307/1966377; BRABIN L, 1995, LANCET, V345, P300, DOI 10.1016/S0140-6736(95)90281-3; Cohen MS, 1997, LANCET, V349, P1868, DOI 10.1016/S0140-6736(97)02190-9; Dallabetta GA, 1998, SEX TRANSM INFECT, V74, pS1; Djajakusumah T, 1998, SEX TRANSM INFECT, V74, pS29; Fox L J, 1995, J Am Med Womens Assoc (1972), V50, P129; Gilson L, 1997, LANCET, V350, P1805, DOI 10.1016/S0140-6736(97)08222-6; GROSSKURTH H, 1995, LANCET, V346, P530, DOI 10.1016/S0140-6736(95)91380-7; HANENBERG RS, 1994, LANCET, V344, P243, DOI 10.1016/S0140-6736(94)93004-X; Hawkes S, 1998, HEALTH POLICY PLANN, V13, P121, DOI 10.1093/heapol/13.2.121; KOWNINE N, 1995, PUBLIC EXPENDITURE R; Mayaud P, 1995, B WORLD HEALTH ORGAN, V73, P621; NUGENT RP, 1991, J CLIN MICROBIOL, V29, P297, DOI 10.1128/JCM.29.2.297-301.1991; Over M, 1996, J INFECT DIS, V174, pS162, DOI 10.1093/infdis/174.Supplement_2.S162; Pachauri S, 1994, Health Transit Rev, V4 Suppl, P321; Phillips M, 1996, PHARMACOECONOMICS, V10, P225, DOI 10.2165/00019053-199610030-00004; Sarkar S, 1998, INT J STD AIDS, V9, P45, DOI 10.1258/0956462981920856; SPIEGEL CA, 1991, CLIN MICROBIOL REV, V4, P485, DOI 10.1128/CMR.4.4.485-502.1991; STAMM WE, 1984, NEW ENGL J MED, V310, P545, DOI 10.1056/NEJM198403013100901; SVENSSON L, 1980, AM J OBSTET GYNECOL, V138, P1017, DOI 10.1016/0002-9378(80)91099-6; TEMMERMAN M, 1993, HEALTH POLICY PLANN, V8, P122, DOI 10.1093/heapol/8.2.113; Toye B, 1996, J CLIN MICROBIOL, V34, P1396, DOI 10.1128/JCM.34.6.1396-1400.1996; *UN, 1994, PROGR ACT UN INT C P; VUYLSTEKE B, 1993, CLIN INFECT DIS, V17, P82, DOI 10.1093/clinids/17.1.82; WASSERHEIT JN, 1989, STUD FAMILY PLANN, V20, P69, DOI 10.2307/1966461; WASSERHEIT JN, 1989, INT J GYNECOL OBSTET, P145; *WHO, 1995, STD CAS MAN WORKB MO; *WHO, 1997, WHOGPATEM941; World Bank, 1993, WORLD DEV REP INV HL	31	123	126	0	8	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1776	1781		10.1016/S0140-6736(99)02463-0	http://dx.doi.org/10.1016/S0140-6736(99)02463-0			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258RM	10577639				2022-12-28	WOS:000083853000012
J	Sumita, I; Olson, P				Sumita, I; Olson, P			A laboratory model for convection in Earth's core driven by a thermally heterogeneous mantle	SCIENCE			English	Article							ROTATING SPHERICAL-SHELL; OUTER CORE; GEOMAGNETIC-FIELD; MAGNETIC-FIELD; BOUNDARY; GEODYNAMO; GROWTH	Thermal convection experiments in a rapidly rotating hemispherical shell suggest a model in which the convection in Earth's liquid outer core is controlled by a thermally heterogeneous mantle. Experiments show that heterogeneous boundary heating induces an eastward flow in the core, which, at a sufficiently Large magnitude, develops into a Large-scale spiral with a sharp front. The front separates the warm and cold regions in the core and includes a narrow jet flowing from the core-mantle boundary to the inner-core boundary. The existence of this front in the core may explain the Pacific quiet zone in the secular variation of the geomagnetic field and the Longitudinally heterogeneous structure of the solid inner core.	Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA	Johns Hopkins University	Sumita, I (corresponding author), Johns Hopkins Univ, Dept Earth & Planetary Sci, Baltimore, MD 21218 USA.			Sumita, Ikuro/0000-0002-7039-5082				BLOXHAM J, 1987, NATURE, V325, P511, DOI 10.1038/325511a0; BLOXHAM J, 1986, GEOPHYS J INT, V87, P669, DOI 10.1111/j.1365-246X.1986.tb06643.x; BLOXHAM J, 1990, GEOPHYS RES LETT, V17, P1997, DOI 10.1029/GL017i011p01997; BLOXHAM J, 1992, J GEOPHYS RES-SOL EA, V97, P19565, DOI 10.1029/92JB01469; Buffett BA, 1996, J GEOPHYS RES-SOL EA, V101, P7989, DOI 10.1029/95JB03539; CARDIN P, 1994, PHYS EARTH PLANET IN, V82, P235, DOI 10.1016/0031-9201(94)90075-2; Creager KC, 1999, J GEOPHYS RES-SOL EA, V104, P23127, DOI 10.1029/1999JB900162; Glatzmaier GA, 1997, CONTEMP PHYS, V38, P269, DOI 10.1080/001075197182351; GUBBINS D, 1987, NATURE, V325, P509, DOI 10.1038/325509a0; JONES GM, 1977, J GEOPHYS RES, V82, P1703, DOI 10.1029/JB082i011p01703; Kaneshima S, 1996, GEOPHYS RES LETT, V23, P3075, DOI 10.1029/96GL03026; Olson P, 1996, PHILOS T R SOC A, V354, P1413, DOI 10.1098/rsta.1996.0055; Sarson GR, 1997, PHYS EARTH PLANET IN, V101, P13, DOI 10.1016/S0031-9201(96)03248-7; STACEY FD, 1992, PHYSICS EARTH, P330; Sumita I, 1996, GEOPHYS J INT, V124, P502, DOI 10.1111/j.1365-246X.1996.tb07034.x; SUMITA I, IN PRESS PHYS EARTH; SUN ZP, 1994, GEOPHYS ASTRO FLUID, V75, P199, DOI 10.1080/03091929408203654; Tanaka S, 1997, J GEOPHYS RES-SOL EA, V102, P2925, DOI 10.1029/96JB03187; TANAKA S, 1993, GEOPH MONOG SERIES, V72, P127; van der Hilst RD, 1999, SCIENCE, V283, P1885, DOI 10.1126/science.283.5409.1885; YOSHIDA S, 1993, J GEOMAGN GEOELECTR, V45, P1497, DOI 10.5636/jgg.45.1497; Yoshida S, 1996, J GEOPHYS RES-SOL EA, V101, P28085, DOI 10.1029/96JB02700; Zhang K, 1992, GEOPHYS J INT, V108, P247, DOI 10.1111/j.1365-246X.1992.tb00853.x; Zhang K, 1996, PHYS FLUIDS, V8, P1141, DOI 10.1063/1.868914	24	84	85	0	14	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1547	1549		10.1126/science.286.5444.1547	http://dx.doi.org/10.1126/science.286.5444.1547			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567258				2022-12-28	WOS:000083768300054
J	Zeng, N; Neelin, JD; Lau, KM; Tucker, CJ				Zeng, N; Neelin, JD; Lau, KM; Tucker, CJ			Enhancement of interdecadal climate variability in the Sahel by vegetation interaction	SCIENCE			English	Article							LAND-SURFACE PROCESSES; TROPICAL NORTH-AFRICA; SUMMER RAINFALL; MODEL; DYNAMICS; DESERTS; GCM	The role of naturally varying vegetation in influencing the climate variability in the West African Sahel is explored in a coupled atmosphere-land-vegetation model. The Sahel rainfall variability is influenced by sea-surface temperature variations in the oceans. Land-surface feedback is found to increase this variability both on interannual and interdecadal time scales. Interactive vegetation enhances the interdecadal variation substantially but can reduce year-to-year variability because of a phase lag introduced by the relatively slow vegetation adjustment time. Variations in vegetation accompany the changes in rainfall in particular the multidecadal drying trend from the 1950s to the 1980s.	Univ Calif Los Angeles, Dept Atmospher Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Geophys & Planetary Phys, Los Angeles, CA 90095 USA; NASA, Goddard Space Flight Ctr, Greenbelt, MD 20771 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center	Zeng, N (corresponding author), Univ Calif Los Angeles, Dept Atmospher Sci, Los Angeles, CA 90095 USA.		Neelin, J. David/H-4337-2011; Zeng, Ning/A-3130-2008; Lau, William K/E-1510-2012	Zeng, Ning/0000-0002-7489-7629; Lau, William K/0000-0002-3587-3691				Brovkin V, 1998, J GEOPHYS RES-ATMOS, V103, P31613, DOI 10.1029/1998JD200006; CHARNEY JG, 1975, Q J ROY METEOR SOC, V101, P193, DOI 10.1002/qj.49710142802; Claussen M, 1998, GLOB CHANGE BIOL, V4, P549, DOI 10.1046/j.1365-2486.1998.t01-1-00122.x; DELWORTH T, 1993, ADV WATER RESOUR, V16, P3, DOI 10.1016/0309-1708(93)90026-C; Dickinson RE, 1998, J CLIMATE, V11, P2823, DOI 10.1175/1520-0442(1998)011<2823:ICFACM>2.0.CO;2; DICKINSON RE, 1992, CLIMATE SYSTEM MODEL, P689; Dirmeyer PA, 1996, Q J ROY METEOR SOC, V122, P451, DOI 10.1002/qj.49712253008; Foley JA, 1996, GLOBAL BIOGEOCHEM CY, V10, P603, DOI 10.1029/96GB02692; FOLLAND CK, 1986, NATURE, V320, P602, DOI 10.1038/320602a0; Goward SN, 1995, J BIOGEOGR, V22, P549, DOI 10.2307/2845953; HOLDRIDGE LR, 1947, SCIENCE, V105, P367, DOI 10.1126/science.105.2727.367; HULME M, 1994, NATO ASI SER, P387; Ji JJ, 1995, J BIOGEOGR, V22, P445, DOI 10.2307/2845941; KOSTER RD, 1995, J GEOPHYS RES-ATMOS, V100, P13775, DOI 10.1029/95JD00176; Lau KM, 1998, CLIM DYNAM, V14, P759, DOI 10.1007/s003820050253; NEELIN JD, IN PRESS J ATMOS SCI; Nicholson S. E., 1995, NATURAL CLIMATE VARI, P32; REYNOLDS RW, 1994, J CLIMATE, V7, P929, DOI 10.1175/1520-0442(1994)007<0929:IGSSTA>2.0.CO;2; Rowell DP, 1996, Q J ROY METEOR SOC, V122, P1007; ROWELL DP, 1995, Q J ROY METEOR SOC, V121, P669, DOI 10.1256/smsqj.52310; Sellers PJ, 1996, J CLIMATE, V9, P676, DOI 10.1175/1520-0442(1996)009<0676:ARLSPF>2.0.CO;2; Semazzi FHM, 1996, J CLIMATE, V9, P2480, DOI 10.1175/1520-0442(1996)009<2480:AGSOTT>2.0.CO;2; Shugart H.H., 1984, THEORY FOREST DYNAMI; SHUKLA J, 1982, SCIENCE, V215, P1498, DOI 10.1126/science.215.4539.1498; Sperber KR, 1996, J CLIMATE, V9, P2727, DOI 10.1175/1520-0442(1996)009<2727:ITRVIG>2.0.CO;2; Tucker CJ, 1999, AMBIO, V28, P587; VERSTRAETE M, 1990, J GEOPHYS RES, V95, P755; Woodward F.I., 1987, CLIMATE PLANT DISTRI; XUE Y, 1993, J CLIMATE, V5, P2232; Zeng N, 1999, J CLIMATE, V12, P857, DOI 10.1175/1520-0442(1999)012<0857:ALAITF>2.0.CO;2; ZENG N, IN PRESS J ATMOS SCI	31	422	441	2	60	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1537	1540		10.1126/science.286.5444.1537	http://dx.doi.org/10.1126/science.286.5444.1537			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567254				2022-12-28	WOS:000083768300050
J	Langhorne, P; Legg, L				Langhorne, P; Legg, L		Outpatient Therapy Trialists	Therapy for stroke patients living at home	LANCET			English	Letter									Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland	Royal Infirmary of Edinburgh	Langhorne, P (corresponding author), Royal Infirm, Acad Sect Geriatr Med, Glasgow G4 0SF, Lanark, Scotland.			BERNABEI, Roberto/0000-0002-9197-004X				LANGHORNE P, 1999, P 7 COCHR C ROM OCT; Walker MF, 1999, LANCET, V354, P278, DOI 10.1016/S0140-6736(98)11128-5	2	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1730	1731		10.1016/S0140-6736(05)76718-0	http://dx.doi.org/10.1016/S0140-6736(05)76718-0			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568599				2022-12-28	WOS:000083652800056
J	Ibba, M; Soll, D				Ibba, M; Soll, D			Quality control mechanisms during translation	SCIENCE			English	Review							TRANSFER-RNA-SYNTHETASES; PEPTIDYL-TRANSFER-RNA; ELONGATION-FACTOR TU; PROTEIN-BIOSYNTHESIS; CRYSTAL-STRUCTURE; TAGGING SYSTEM; AMINO-ACIDS; TERMINATION; AMINOACYLATION; ACCURACY	Translation uses the genetic information in messenger RNA (mRNA) to synthesize proteins. Transfer RNAs (tRNAs) are charged with an amino acid and brought to the ribosome, where they are paired with the corresponding trinucleotide codon in mRNA. The amino acid is attached to the nascent polypeptide and the ribosome moves on to the next codon. The cycle is then repeated to produce a full-length protein. Proofreading and editing processes are used throughout protein synthesis to ensure the faithful translation of genetic information. The maturation of tRNAs and mRNAs is monitored, as is the identity of amino acids attached to tRNAs. Accuracy is further enhanced during the selection of aminoacyl-tRNAs on the ribosome and their base pairing with mRNA. Recent studies have begun to reveal the molecular mechanisms underpinning quality control and go some way to explaining the phenomenal accuracy of translation first observed over three decades ago.	Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Dept Chem, New Haven, CT 06520 USA; Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Univ Copenhagen, Panum Inst, Ctr Biomol Recognit, Dept Med Biochem & Genet,Lab B, DK-2200 Copenhagen, Denmark	Yale University; Yale University; Yale University; University of Copenhagen	Soll, D (corresponding author), Yale Univ, Dept Mol Biophys & Biochem, POB 208114,266 Whitney Ave, New Haven, CT 06520 USA.	soll@trna.chem.yale.edu						Altman S., 1999, RNA WORLD, P351; Arnez JG, 1998, COLD SPRING HARBOR M, P465; Arts GJ, 1998, EMBO J, V17, P7430, DOI 10.1093/emboj/17.24.7430; Atkins J.F., 1999, RNA WORLD NATURE MOD, P637; BALDWIN AN, 1966, J BIOL CHEM, V241, P839; Ban N, 1999, NATURE, V400, P841, DOI 10.1038/23641; Becker HD, 1998, P NATL ACAD SCI USA, V95, P12832, DOI 10.1073/pnas.95.22.12832; BJORK GR, 1995, PROG NUCLEIC ACID RE, V50, P263, DOI 10.1016/S0079-6603(08)60817-X; Bjork GR, 1995, TRNA STRUCTURE BIOSY, P165; Borner GV, 1997, FEBS LETT, V409, P320, DOI 10.1016/S0014-5793(97)00357-8; Brock S, 1998, MOL MICROBIOL, V29, P409, DOI 10.1046/j.1365-2958.1998.00893.x; CALENDAR R, 1967, J MOL BIOL, V26, P39, DOI 10.1016/0022-2836(67)90259-8; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; Clark BFC, 1999, FEBS LETT, V452, P41, DOI 10.1016/S0014-5793(99)00562-1; Clemons WM, 1999, NATURE, V400, P833, DOI 10.1038/23631; Commans S, 1999, FEMS MICROBIOL REV, V23, P335, DOI 10.1111/j.1574-6976.1999.tb00403.x; CRICK F, 1970, NATURE, V227, P561, DOI 10.1038/227561a0; Culbertson MR, 1999, TRENDS GENET, V15, P74, DOI 10.1016/S0168-9525(98)01658-8; Curnow AW, 1996, NATURE, V382, P589, DOI 10.1038/382589b0; Curnow AW, 1997, P NATL ACAD SCI USA, V94, P11819, DOI 10.1073/pnas.94.22.11819; Cusack S, 1997, CURR OPIN STRUC BIOL, V7, P881, DOI 10.1016/S0959-440X(97)80161-3; Czworkowski J, 1996, PROG NUCLEIC ACID RE, V54, P293, DOI 10.1016/S0079-6603(08)60366-9; DRAPER DE, 1996, ESCHERICHIA COLI SAL, P902; EHRENBERG M, 1986, STRUCTURE FUNCTION G, P573; Farabaugh PJ, 1999, EMBO J, V18, P1427, DOI 10.1093/emboj/18.6.1427; Fersht A., 1985, ENZYME STRUCTURE MEC; Fersht A. R., 1979, TRANSFER RNA STRUCTU, P247; FORCHHAMMER K, 1989, NATURE, V342, P453, DOI 10.1038/342453a0; Fromant M, 1999, BIOCHEMISTRY-US, V38, P4982, DOI 10.1021/bi982657r; Gerber AP, 1999, SCIENCE, V286, P1146, DOI 10.1126/science.286.5442.1146; Giege R, 1998, NUCLEIC ACIDS RES, V26, P5017, DOI 10.1093/nar/26.22.5017; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Hale SP, 1997, SCIENCE, V276, P1250, DOI 10.1126/science.276.5316.1250; Hentze MW, 1999, CELL, V96, P307, DOI 10.1016/S0092-8674(00)80542-5; Heurgue-Hamard V, 1998, EMBO J, V17, P808, DOI 10.1093/emboj/17.3.808; Hilleren P, 1999, RNA, V5, P711, DOI 10.1017/S1355838299990519; HOHSAKA T, 1993, FEBS LETT, V335, P47, DOI 10.1016/0014-5793(93)80436-X; Ibba M, 1997, TRENDS BIOCHEM SCI, V22, P39, DOI 10.1016/S0968-0004(96)20033-7; Jakubowski H, 1999, BIOCHEMISTRY-US, V38, P8088, DOI 10.1021/bi990629i; JAKUBOWSKI H, 1992, MICROBIOL REV, V56, P412, DOI 10.1128/MMBR.56.3.412-429.1992; Janosi L, 1996, BIOCHIMIE, V78, P959, DOI 10.1016/S0300-9084(97)86718-1; Karimi R, 1999, MOL CELL, V3, P601, DOI 10.1016/S1097-2765(00)80353-6; Karzai AW, 1999, EMBO J, V18, P3793, DOI 10.1093/emboj/18.13.3793; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; Kozak M, 1999, GENE, V234, P187, DOI 10.1016/S0378-1119(99)00210-3; KURLAND CG, 1992, ANNU REV GENET, V26, P29, DOI 10.1146/annurev.ge.26.120192.000333; Li ZW, 1996, CELL, V86, P503, DOI 10.1016/S0092-8674(00)80123-3; Liu DR, 1999, P NATL ACAD SCI USA, V96, P4780, DOI 10.1073/pnas.96.9.4780; LOFTFIELD RB, 1972, BIOCHEM J, V128, P1353, DOI 10.1042/bj1281353; LOFTFIELD RB, 1963, BIOCHEM J, V89, P82, DOI 10.1042/bj0890082; Lund E, 1998, SCIENCE, V282, P2082, DOI 10.1126/science.282.5396.2082; MENDEL D, 1995, ANNU REV BIOPH BIOM, V24, P435, DOI 10.1146/annurev.bb.24.060195.002251; Nadassy K, 1999, BIOCHEMISTRY-US, V38, P1999, DOI 10.1021/bi982362d; Nakamura Y, 1998, GENES CELLS, V3, P265, DOI 10.1046/j.1365-2443.1998.00191.x; NIERHAUS KH, 1990, BIOCHEMISTRY-US, V29, P4997, DOI 10.1021/bi00473a001; NISSEN P, 1995, SCIENCE, V270, P1464, DOI 10.1126/science.270.5241.1464; Nomanbhoy TK, 1999, MOL CELL, V4, P519, DOI 10.1016/S1097-2765(00)80203-8; Pape T, 1999, EMBO J, V18, P3800, DOI 10.1093/emboj/18.13.3800; Pavlov MY, 1998, J MOL BIOL, V284, P579, DOI 10.1006/jmbi.1998.2220; RAJBHANDARY UL, 1994, J BACTERIOL, V176, P547, DOI 10.1128/jb.176.3.547-552.1994; Rajbhandary Uttam L., 1995, P511; Roche ED, 1999, EMBO J, V18, P4579, DOI 10.1093/emboj/18.16.4579; Rudinger J, 1996, EMBO J, V15, P650, DOI 10.1002/j.1460-2075.1996.tb00397.x; Rudinger-Thirion J, 1999, RNA, V5, P989, DOI 10.1017/S135583829999101X; SCHMIDT E, 1994, SCIENCE, V264, P265, DOI 10.1126/science.8146659; Schmitt E, 1998, EMBO J, V17, P6819, DOI 10.1093/emboj/17.23.6819; Schmitt E, 1997, EMBO J, V16, P4760, DOI 10.1093/emboj/16.15.4760; SCHON A, 1988, NATURE, V331, P187, DOI 10.1038/331187a0; SHERMAN JM, 1992, NUCLEIC ACIDS RES, V20, P2847, DOI 10.1093/nar/20.11.2847; Shi PY, 1998, EMBO J, V17, P3197, DOI 10.1093/emboj/17.11.3197; Silvian LF, 1999, SCIENCE, V285, P1074, DOI 10.1126/science.285.5430.1074; Simos G, 1998, MOL CELL, V1, P235, DOI 10.1016/S1097-2765(00)80024-6; Soutourina J, 1999, J BIOL CHEM, V274, P19109, DOI 10.1074/jbc.274.27.19109; STANZEL M, 1994, EUR J BIOCHEM, V219, P435, DOI 10.1111/j.1432-1033.1994.tb19956.x; Steitz TA, 1999, RNA WORLD, P427; Stoll A., 1958, FESTSCHRIFT A STOLL, P597; SWANSON R, 1988, SCIENCE, V242, P1548, DOI 10.1126/science.3144042; THOMPSON RC, 1988, TRENDS BIOCHEM SCI, V13, P91, DOI 10.1016/0968-0004(88)90047-3; Trotta CR, 1999, RNA WORLD, P561; von Hippel PH, 1998, SCIENCE, V281, P660, DOI 10.1126/science.281.5377.660; Wickner S, 1999, SCIENCE, V286, P1888, DOI 10.1126/science.286.5446.1888; WILCOX M, 1968, P NATL ACAD SCI USA, V61, P229, DOI 10.1073/pnas.61.1.229; Williams KP, 1999, EMBO J, V18, P5423, DOI 10.1093/emboj/18.19.5423; YAMANE T, 1981, BIOCHEMISTRY-US, V20, P7059, DOI 10.1021/bi00528a001; Yarus M, 1979, Prog Nucleic Acid Res Mol Biol, V23, P195; Yarus Michael, 1995, P443; Yokoyama Shigeyuki, 1995, P207; Yoshizawa S, 1999, SCIENCE, V285, P1722, DOI 10.1126/science.285.5434.1722; Zhao J, 1999, MICROBIOL MOL BIOL R, V63, P405, DOI 10.1128/MMBR.63.2.405-445.1999	89	172	179	0	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1893	1897		10.1126/science.286.5446.1893	http://dx.doi.org/10.1126/science.286.5446.1893			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583945				2022-12-28	WOS:000084003400038
J	Ross, FM; Tromp, RM; Reuter, MC				Ross, FM; Tromp, RM; Reuter, MC			Transition states between pyramids and domes during Ge/Si island growth	SCIENCE			English	Article							GE ISLANDS; SI(001); SURFACE	Real-time observations were made of the shape change from pyramids to domes during the growth of germanium-silicon islands on silicon (001). Small islands are pyramidal in shape, whereas Larger islands are dome-shaped. During growth, the transition from pyramids to domes occurs through a series of asymmetric transition states with increasing numbers of highly inclined facets. Postgrowth annealing of pyramids results in a similar shape change process. The transition shapes are temperature dependent and transform reversibly to the final dome shape during cooling. These results are consistent with an anomalous coarsening model for island growth.	IBM Corp, Thomas J Watson Res Ctr, Yorktown Heights, NY 10598 USA	International Business Machines (IBM)	Ross, FM (corresponding author), IBM Corp, Thomas J Watson Res Ctr, POB 218, Yorktown Heights, NY 10598 USA.		Ross, Frances/P-8919-2015	Ross, Frances/0000-0003-0838-9770				Daruka I, 1999, PHYS REV LETT, V82, P2753, DOI 10.1103/PhysRevLett.82.2753; Floro JA, 1999, PHYS REV B, V59, P1990, DOI 10.1103/PhysRevB.59.1990; Gai Z, 1998, PHYS REV B, V57, P15060, DOI 10.1103/PhysRevB.57.R15060; Goryll M, 1997, APPL PHYS LETT, V71, P410, DOI 10.1063/1.119553; Kamins TI, 1999, J APPL PHYS, V85, P1159, DOI 10.1063/1.369255; Kamins TI, 1997, J APPL PHYS, V81, P211, DOI 10.1063/1.364084; LUTZ MA, 1994, SURF SCI, V316, pL1075, DOI 10.1016/0039-6028(94)91208-4; Medeiros-Ribeiro G, 1998, SCIENCE, V279, P353, DOI 10.1126/science.279.5349.353; MO YW, 1990, PHYS REV LETT, V65, P1020, DOI 10.1142/S0217984990001732; Ross FM, 1998, PHYS REV LETT, V80, P984, DOI 10.1103/PhysRevLett.80.984; TOMITORI M, 1994, APPL SURF SCI, V76, P322, DOI 10.1016/0169-4332(94)90362-X; Tromp RM, 1998, SURF REV LETT, V5, P1189, DOI 10.1142/S0218625X98001523; TROMP RM, UNPUB; ZINKEALLMANG M, 1989, PHYS REV B, V39, P7848, DOI 10.1103/PhysRevB.39.7848	14	435	443	0	57	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1931	1934		10.1126/science.286.5446.1931	http://dx.doi.org/10.1126/science.286.5446.1931			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583951				2022-12-28	WOS:000084003400044
J	Wickner, S; Maurizi, MR; Gottesman, S				Wickner, S; Maurizi, MR; Gottesman, S			Posttranslational quality control: Folding, refolding, and degrading proteins	SCIENCE			English	Review							ENERGY-DEPENDENT PROTEASES; COLI CLPAP PROTEASE; ESCHERICHIA-COLI; TAGGING SYSTEM; DEGRADATION; CHAPERONE; PROTEOLYSIS; SPECIFICITY; TARGETS; HSP70	Polypeptides emerging from the ribosome must fold into stable three-dimensional structures and maintain that structure throughout their functional Lifetimes. Maintaining quality control over protein structure and function depends on molecular chaperones and proteases, both of which can recognize hydrophobic regions exposed on unfolded polypeptides. Molecular chaperones promote proper protein folding and prevent aggregation, and energy-dependent proteases eliminate irreversibly damaged proteins. The kinetics of partitioning between chaperones and proteases determines whether a protein will be destroyed before it folds properly. When both quality control options fail, damaged proteins accumulate as aggregates, a process associated with amyloid diseases.	NCI, Mol Biol Lab, Bethesda, MD 20892 USA; NCI, Cell Biol Lab, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)	Gottesman, S (corresponding author), NCI, Mol Biol Lab, Bethesda, MD 20892 USA.	susang@helix.nih.gov						Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bochtler M, 1999, ANNU REV BIOPH BIOM, V28, P295, DOI 10.1146/annurev.biophys.28.1.295; Braun BC, 1999, NAT CELL BIOL, V1, P221, DOI 10.1038/12043; Bukau B, 1998, CELL, V92, P351, DOI 10.1016/S0092-8674(00)80928-9; CHERNOFF YO, 1995, SCIENCE, V268, P880, DOI 10.1126/science.7754373; Cummings CJ, 1998, NAT GENET, V19, P148, DOI 10.1038/502; DebBurman SK, 1997, P NATL ACAD SCI USA, V94, P13938, DOI 10.1073/pnas.94.25.13938; DeMartino GN, 1999, J BIOL CHEM, V274, P22123, DOI 10.1074/jbc.274.32.22123; Deuerling E, 1999, NATURE, V400, P693, DOI 10.1038/23301; Ewalt KL, 1997, CELL, V90, P491, DOI 10.1016/S0092-8674(00)80509-7; Glickman MH, 1998, CELL, V94, P615, DOI 10.1016/S0092-8674(00)81603-7; Glover JR, 1998, CELL, V94, P73, DOI 10.1016/S0092-8674(00)81223-4; GOLDBERG AL, 1972, P NATL ACAD SCI USA, V69, P422, DOI 10.1073/pnas.69.2.422; Gonciarz-Swiatek M, 1999, J BIOL CHEM, V274, P13999, DOI 10.1074/jbc.274.20.13999; Gonzalez M, 1998, GENE DEV, V12, P3889, DOI 10.1101/gad.12.24.3889; Gottesman S, 1997, CELL, V91, P435, DOI 10.1016/S0092-8674(00)80428-6; Gottesman S, 1998, GENE DEV, V12, P1338, DOI 10.1101/gad.12.9.1338; Gottesman S, 1997, GENE DEV, V11, P815, DOI 10.1101/gad.11.7.815; Gottesman S, 1996, ANNU REV GENET, V30, P465, DOI 10.1146/annurev.genet.30.1.465; GOTTESMAN S, 1992, MICROBIOL REV, V56, P592, DOI 10.1128/MMBR.56.4.592-621.1992; Grimaud R, 1998, J BIOL CHEM, V273, P12476, DOI 10.1074/jbc.273.20.12476; Harris DA, 1999, CLIN MICROBIOL REV, V12, P429, DOI 10.1128/CMR.12.3.429; Herman C, 1998, GENE DEV, V12, P1348, DOI 10.1101/gad.12.9.1348; Hershko A, 1998, ANNU REV BIOCHEM, V67, P425, DOI 10.1146/annurev.biochem.67.1.425; Hochstrasser M, 1996, ANNU REV GENET, V30, P405, DOI 10.1146/annurev.genet.30.1.405; Hoskins JR, 1998, P NATL ACAD SCI USA, V95, P12135, DOI 10.1073/pnas.95.21.12135; Ibba M, 1999, SCIENCE, V286, P1893, DOI 10.1126/science.286.5446.1893; Johnston JA, 1998, J CELL BIOL, V143, P1883, DOI 10.1083/jcb.143.7.1883; Keiler KC, 1996, SCIENCE, V271, P990, DOI 10.1126/science.271.5251.990; KESSEL M, 1995, J MOL BIOL, V250, P587, DOI 10.1006/jmbi.1995.0400; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Lam YA, 1997, NATURE, V385, P737, DOI 10.1038/385737a0; Laney JD, 1999, CELL, V97, P427, DOI 10.1016/S0092-8674(00)80752-7; Levine RL, 1999, MECH AGEING DEV, V107, P323, DOI 10.1016/S0047-6374(98)00152-3; Lupas A, 1997, TRENDS BIOCHEM SCI, V22, P399, DOI 10.1016/S0968-0004(97)01117-1; Martin JB, 1999, NEW ENGL J MED, V340, P1970, DOI 10.1056/NEJM199906243402507; Maurizi MR, 1998, ADV MOL CEL, V27, P1, DOI 10.1016/S1569-2558(08)60456-7; Morimoto RI, 1998, GENE DEV, V12, P3788, DOI 10.1101/gad.12.24.3788; Motohashi K, 1999, P NATL ACAD SCI USA, V96, P7184, DOI 10.1073/pnas.96.13.7184; Neuwald AF, 1999, GENOME RES, V9, P27; Newnam GP, 1999, MOL CELL BIOL, V19, P1325; Pak M, 1999, J BIOL CHEM, V274, P19316, DOI 10.1074/jbc.274.27.19316; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Rudiger S, 1997, EMBO J, V16, P1501, DOI 10.1093/emboj/16.7.1501; SADIS S, 1995, MOL CELL BIOL, V15, P4086; Schirmer EC, 1996, TRENDS BIOCHEM SCI, V21, P289, DOI 10.1016/0968-0004(96)10038-4; Schumann W, 1999, FEMS MICROBIOL REV, V23, P1; Sigler PB, 1998, ANNU REV BIOCHEM, V67, P581, DOI 10.1146/annurev.biochem.67.1.581; Smith CK, 1999, P NATL ACAD SCI USA, V96, P6678, DOI 10.1073/pnas.96.12.6678; Stenoien DL, 1999, HUM MOL GENET, V8, P731, DOI 10.1093/hmg/8.5.731; Teter SA, 1999, CELL, V97, P755, DOI 10.1016/S0092-8674(00)80787-4; THOMPSON MW, 1994, J BIOL CHEM, V269, P18201; THOMPSON MW, 1994, J BIOL CHEM, V269, P18209; van Dijl JM, 1998, P NATL ACAD SCI USA, V95, P10584, DOI 10.1073/pnas.95.18.10584; Varshavsky A, 1997, GENES CELLS, V2, P13, DOI 10.1046/j.1365-2443.1997.1020301.x; Walz J, 1998, J STRUCT BIOL, V121, P19, DOI 10.1006/jsbi.1998.3958; Weber-Ban EU, 1999, NATURE, V401, P90, DOI 10.1038/43481; WICKNER S, 1994, P NATL ACAD SCI USA, V91, P12218, DOI 10.1073/pnas.91.25.12218; YEN C, 1980, J MOL BIOL, V143, P21, DOI 10.1016/0022-2836(80)90122-9; Yura T, 1999, CURR OPIN MICROBIOL, V2, P153, DOI 10.1016/S1369-5274(99)80027-7; Zolkiewski M, 1999, J BIOL CHEM, V274, P28083, DOI 10.1074/jbc.274.40.28083	62	871	897	5	86	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1888	1893		10.1126/science.286.5446.1888	http://dx.doi.org/10.1126/science.286.5446.1888			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583944				2022-12-28	WOS:000084003400037
J	Gibbons, M				Gibbons, M			Science's new social contract with society	NATURE			English	Article								Under the prevailing contract between science and society, science has been expected to produce 'reliable' knowledge, provided merely that it communicates its discoveries to society. A new contract must now ensure that scientific knowledge is 'socially robust', and that its production is seen by society to be both transparent and participative.	Univ Sussex, Sci Policy Res Unit, Brighton BN1 9RH, E Sussex, England	University of Sussex	Gibbons, M (corresponding author), Assoc Commonwealth Univ, 36 Gordon Sq, London WC1H 0PF, England.							DASTON L, 1992, REPRESENTATIONS, P81; Gieryn Thomas, 1995, HDB SCI TECHNOLOGY S, P393, DOI DOI 10.4135/9781412990127.N18; HUGHES TP, 1998, RESCUING PROMETHEUS, P301; NOWOTNY H, IN PRESS RETHINKING; van Duinen R. J, 1998, SCI PUBL POLICY, V25, P381; ZIMAN J, 1991, RELIABLE KNOWLEDGE C	6	468	478	0	68	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C81	C84		10.1038/35011576	http://dx.doi.org/10.1038/35011576			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	261MZ	10591229	Bronze			2022-12-28	WOS:000084014100012
J	Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM				Shin, MK; Levorse, JM; Ingram, RS; Tilghman, SM			The temporal requirement for endothelin receptor-B signalling during neural crest development	NATURE			English	Article							GENE-EXPRESSION; TRANSGENIC MICE; ENTERIC NEURONS; MAMMALIAN-CELLS; MOUSE EMBRYO; PIGMENTATION; MELANOCYTES; MUTATIONS; PROLIFERATION; DROSOPHILA	Endothelin receptor B (EDNRB) is a G-protein-coupled receptor with seven transmembrane domains which is required for the development of melanocytes and enteric neurons. Mice that are homozygous for a null mutation in the Ednrb gene are almost completely white and die as juveniles from megacolon, To determine when EDNRB signalling is required during embryogenesis, we have exploited the tetracycline-inducible system to generate strains of mice in which the endogenous Ednrb locus is under the control of the tetracycline-dependant transactivators tTa or rtTA. By using this system to express Ednrb at different stages of embryogenesis, we have determined that EDNRB is required during a restricted period of neural crest development between embryonic days 10 and 12.5. Moreover, our results imply that EDNRB is required for the migration of both melanoblasts and enteric neuroblasts.	Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA; Princeton Univ, Dept Mol Biol, Princeton, NJ 08544 USA	Howard Hughes Medical Institute; Princeton University; Princeton University	Tilghman, SM (corresponding author), Princeton Univ, Howard Hughes Med Inst, Princeton, NJ 08544 USA.							Anderson DJ, 1997, COLD SPRING HARB SYM, V62, P493; Baron U, 1999, P NATL ACAD SCI USA, V96, P1013, DOI 10.1073/pnas.96.3.1013; Barsh GS, 1996, TRENDS GENET, V12, P299, DOI 10.1016/0168-9525(96)10031-7; BAYNASH AG, 1994, CELL, V79, P1277, DOI 10.1016/0092-8674(94)90018-3; Bedell MA, 1997, GENE DEV, V11, P11, DOI 10.1101/gad.11.1.11; DIXON RAF, 1987, EMBO J, V6, P3269, DOI 10.1002/j.1460-2075.1987.tb02645.x; Ewald D, 1996, SCIENCE, V273, P1384, DOI 10.1126/science.273.5280.1384; FISCHER JA, 1988, NATURE, V332, P853, DOI 10.1038/332853a0; FURTH PA, 1994, P NATL ACAD SCI USA, V91, P9302, DOI 10.1073/pnas.91.20.9302; Gingrich JR, 1998, ANNU REV NEUROSCI, V21, P377, DOI 10.1146/annurev.neuro.21.1.377; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; GOSSEN M, 1995, SCIENCE, V268, P1766, DOI 10.1126/science.7792603; Hearn CJ, 1998, DEV BIOL, V197, P93, DOI 10.1006/dbio.1998.8876; HOSODA K, 1994, CELL, V79, P1267, DOI 10.1016/0092-8674(94)90017-5; Jackson IJ, 1997, HUM MOL GENET, V6, P1613, DOI 10.1093/hmg/6.10.1613; Jones BK, 1998, GENE DEV, V12, P2200, DOI 10.1101/gad.12.14.2200; KAPUR RP, 1995, DEVELOPMENT, V121, P3787; Kistner A, 1996, P NATL ACAD SCI USA, V93, P10933, DOI 10.1073/pnas.93.20.10933; KUHN R, 1991, SCIENCE, V254, P707, DOI 10.1126/science.1948049; Lahav R, 1996, P NATL ACAD SCI USA, V93, P3892, DOI 10.1073/pnas.93.9.3892; Lakso M, 1996, P NATL ACAD SCI USA, V93, P5860, DOI 10.1073/pnas.93.12.5860; Le Douarin N.M., 1982, NEURAL CREST; Leibl MA, 1999, GUT, V44, P246, DOI 10.1136/gut.44.2.246; MacKenzie MAF, 1997, DEV BIOL, V192, P99, DOI 10.1006/dbio.1997.8738; Mansuy IM, 1998, NEURON, V21, P257, DOI 10.1016/S0896-6273(00)80533-4; MAYER TC, 1973, DEV BIOL, V34, P39, DOI 10.1016/0012-1606(73)90337-0; Mayford M, 1996, SCIENCE, V274, P1678, DOI 10.1126/science.274.5293.1678; Nakayama A, 1998, MECH DEVELOP, V70, P155, DOI 10.1016/S0925-4773(97)00188-3; Newgreen DF, 1995, ACTA ANAT, V154, P243; PACHNIS V, 1993, DEVELOPMENT, V119, P1005; PAVAN WJ, 1994, P NATL ACAD SCI USA, V91, P7159, DOI 10.1073/pnas.91.15.7159; Reid K, 1996, DEVELOPMENT, V122, P3911; Rossant J, 1999, GENE DEV, V13, P142, DOI 10.1101/gad.13.2.142; SCHNEUWLY S, 1987, NATURE, V325, P816, DOI 10.1038/325816a0; SERBEDZIJA GN, 1990, DEVELOPMENT, V108, P605; Shin MK, 1997, P NATL ACAD SCI USA, V94, P13105, DOI 10.1073/pnas.94.24.13105; SILVERS WK (ED), 1979, COAT COLORS MICE MOD; STEEL KP, 1992, DEVELOPMENT, V115, P1111; SWIATEK PJ, 1993, GENE DEV, V7, P2071, DOI 10.1101/gad.7.11.2071; Webber AL, 1998, NATURE, V391, P711, DOI 10.1038/35655; WEHRLEHALLER B, 1995, DEVELOPMENT, V121, P731; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu JJ, 1999, DEVELOPMENT, V126, P1161; Yoshida H, 1996, DEVELOPMENT, V122, P1207	44	262	267	0	19	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					496	501		10.1038/990040	http://dx.doi.org/10.1038/990040			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591209				2022-12-28	WOS:000084013200046
J	Sloan, FA; Taylor, DH				Sloan, FA; Taylor, DH			Private and public choices in end-of-life care	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							TRENDS		Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA	Duke University	Sloan, FA (corresponding author), Duke Univ, Ctr Hlth Policy & Management, Durham, NC 27706 USA.							COVINSKY KE, 1994, JAMA-J AM MED ASSOC, V272, P1839, DOI 10.1001/jama.272.23.1839; EMANUEL EJ, 1994, NEW ENGL J MED, V330, P540, DOI 10.1056/NEJM199402243300806; Gramelspacher GP, 1997, J GEN INTERN MED, V12, P346, DOI 10.1007/s11606-006-5082-9; *I MED, 1997, APPR DEATH IMPR CAR; LUBITZ JD, 1993, NEW ENGL J MED, V328, P1092, DOI 10.1056/NEJM199304153281506; Lynn J, 1997, ANN INTERN MED, V126, P97, DOI 10.7326/0003-4819-126-2-199701150-00001; Manton KG, 1997, P NATL ACAD SCI USA, V94, P2593, DOI 10.1073/pnas.94.6.2593; Singer PA, 1999, JAMA-J AM MED ASSOC, V281, P163, DOI 10.1001/jama.281.2.163	8	3	3	0	2	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2078	2078		10.1001/jama.282.21.2078	http://dx.doi.org/10.1001/jama.282.21.2078			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591394	hybrid			2022-12-28	WOS:000083908700031
J	Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL				Pratt, KP; Shen, BW; Takeshima, K; Davie, EW; Fujikawa, K; Stoddard, BL			Structure of the C2 domain of human factor VIII at 1.5 angstrom resolution	NATURE			English	Article							COAGULATION FACTOR-V; VONWILLEBRAND-FACTOR; MONOCLONAL-ANTIBODY; BINDING; PHOSPHATIDYLSERINE; INACTIVATION; MECHANISM; INHIBITOR; PEPTIDE; MODELS	Human factor VIII is a plasma glycoprotein that has a Critical role in blood Coagulation(1,2). Factor VIII circulates as a complex with von Willebrand factor(3). After cleavage by thrombin, factor VIIIa associates with factor IXa at the surface of activated platelets or endothelial cells(4,5). This complex activates factor X (refs 6, 7), which in turn converts prothrombin to thrombin in the presence of factor Va (refs 8, 9). The carboxyl-terminal C2 domain of factor VIII contains sites that are essential for its binding to von Willebrand factor and to negatively charged phospholipid surfaces(4,10,11). Here we report the structure of human factor VIII C2 domain at 1.5 Angstrom resolution. The structure reveals a beta-sandwich core, from which two beta-turns and a loop display a group of solvent-exposed hydrophobic residues. Behind the hydrophobic surface lies a ring. of positively charged residues. This motif suggests a mechanism for membrane binding involving both hydrophobic and electrostatic interactions. The structure explains, in part, mutations in the C2 region of factor VIII that lead to bleeding disorders in haemophilia A.	Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, Seattle, WA 98109 USA; Univ Washington, Dept Biochem, Seattle, WA 98195 USA	Fred Hutchinson Cancer Center; University of Washington; University of Washington Seattle	Stoddard, BL (corresponding author), Fred Hutchinson Canc Res Ctr, Div Basic Sci, Program Struct Biol, 1100 Fairview Ave N A3-023, Seattle, WA 98109 USA.	bstoddar@fhcrc.org	Pratt, Kathleen P/E-9489-2019	Pratt, Kathleen/0000-0001-6837-6133				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baumgartner S, 1998, PROTEIN SCI, V7, P1626, DOI 10.1002/pro.5560070717; BRUNGER AT, 1993, ACTA CRYSTALLOGR D, V49, P24, DOI 10.1107/S0907444992007352; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; DUFFY EJ, 1992, J BIOL CHEM, V267, P7821; DUFFY EJ, 1992, J BIOL CHEM, V267, P17006; FAY PJ, 1991, J BIOL CHEM, V266, P2172; FOSTER PA, 1990, BLOOD, V75, P1999; GILBERT GE, 1995, BIOCHEMISTRY-US, V34, P3022, DOI 10.1021/bi00009a033; Healey JF, 1998, BLOOD, V92, P3701, DOI 10.1182/blood.V92.10.3701.422k22_3701_3709; HOYER LW, 1994, SEMIN HEMATOL, V31, P1; *IMP COLL MED SCH, HAEM MUT DAT; Jacquemin MG, 1998, BLOOD, V92, P496, DOI 10.1182/blood.V92.2.496.414k16_496_506; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KANE WH, 1988, BLOOD, V71, P539; KAUFMAN RJ, 1992, ANNU REV MED, V43, P325, DOI 10.1146/annurev.med.43.1.325; KRISHNASWAMY S, 1993, METHOD ENZYMOL, V222, P260; Kuwabara I, 1999, J IMMUNOL METHODS, V224, P89, DOI 10.1016/S0022-1759(99)00012-5; LAFORTELLE E, 1997, CRYSTALLOGRAPHIC COM, V7, P100; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; MANN KG, 1990, BLOOD, V76, P1; NIEH YP, IN PRESS ACTA CRYS D; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Pellequer JL, 1998, BLOOD CELL MOL DIS, V24, P448, DOI 10.1006/bcmd.1998.0214; SAENKO EL, 1995, J BIOL CHEM, V270, P13826, DOI 10.1074/jbc.270.23.13826; SHIMA M, 1993, THROMB HAEMOSTASIS, V69, P240; TAKESHMA K, UNPUB J BIOL CHEM; VANDERBEEKEN Y, 1981, AM J REPROD IMMUNOL, V1, P236, DOI 10.1111/j.1600-0897.1981.tb00047.x; Veeraraghavan S, 1998, BIOCHEM J, V332, P549, DOI 10.1042/bj3320549; WOLFENDEN R, 1981, BIOCHEMISTRY-US, V20, P849, DOI 10.1021/bi00507a030	30	270	288	0	17	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					439	442		10.1038/46601	http://dx.doi.org/10.1038/46601			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586887				2022-12-28	WOS:000083913600063
J	Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D				Weigert, R; Silletta, MG; Spano, S; Turacchio, G; Cericola, C; Colanzi, A; Senatore, S; Mancini, R; Polishchuk, EV; Salmona, M; Facchiano, F; Burger, KNJ; Mironov, A; Luini, A; Corda, D			CtBP/BARS induces fission of Golgi membranes by acylating lysophosphatidic acid	NATURE			English	Article							TRANSPORT VESICLES; COATED VESICLES; PROTEIN; DYNAMIN	Membrane fission is essential in intracellular transport. Acyl-coenzyme As (acyl-CoAs) are important in lipid remodelling and are required for fission of COPI-coated vesicles(1). Here we show that CtBP/BARS, a protein that functions in the dynamics of Golgi tubules(2), is an essential component of the fission machinery operating at Golgi tubular networks, including Golgi compartments involved in protein transport and sorting. CtBP/BARS-induced fission was preceded by the formation of constricted sites in Golgi tubules, whose extreme curvature is likely to involve local changes in the membrane lipid composition. We find that CtBP/BARS uses acyl-CoA to selectively catalyse the acylation of lysophosphatidic acid to phosphatidic acid both in pure lipidic systems and in Golgi membranes, and that this reaction is essential for fission. Our results indicate a key role for lipid metabolic pathways in membrane fission.	Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy; Ist Ric Farmacol Mario Negri, Dept Mol Pharmacol & Biochem, I-20157 Milan, Italy; Ist Dermopat Immacolata, Lab Vasc Pathol, Rome, Italy; Univ Utrecht, Inst Biomembranes, Dept Biochem Membranes, NL-3584 CH Utrecht, Netherlands	Consorzio Mario Negri Sud; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; Istituto di Ricerche Farmacologiche Mario Negri IRCCS; IRCCS Istituto Dermopatico dell'Immacolata (IDI); Utrecht University	Luini, A (corresponding author), Ist Ric Farmacol Mario Negri, Consorzio Mario Negri Sud, Dept Cell Biol & Oncol, I-66030 Santa Maria Imbaro, Chieti, Italy.	luini@cmns.mnegri.it; corda@cmns.mnegri.it	salmona, mario/ABI-4066-2020; Facchiano, Francesco/K-8716-2016; salmona, mario/AAA-7116-2020; Corda, Daniela/K-6385-2016; Spanò, Stefania/F-4951-2011; Colanzi, Antonino/D-6821-2012	Facchiano, Francesco/0000-0003-4313-0617; salmona, mario/0000-0002-9098-9873; Corda, Daniela/0000-0002-3614-751X; Spanò, Stefania/0000-0001-9154-7463; Colanzi, Antonino/0000-0002-5643-0216	Telethon [E.0982, E.1105] Funding Source: Medline	Telethon(Fondazione Telethon)		Altschuler Y, 1998, J CELL BIOL, V143, P1871, DOI 10.1083/jcb.143.7.1871; Bar-Tana J, 1975, Methods Enzymol, V35, P117, DOI 10.1016/0076-6879(75)35146-X; BOGGS JM, 1987, BIOCHIM BIOPHYS ACTA, V906, P353, DOI 10.1016/0304-4157(87)90017-7; Buccione R, 1996, J BIOL CHEM, V271, P3523; Cao H, 1998, MOL BIOL CELL, V9, P2595, DOI 10.1091/mbc.9.9.2595; CLUETT EB, 1992, J CELL SCI, V103, P773; Cremona O, 1997, CURR OPIN NEUROBIOL, V7, P323, DOI 10.1016/S0959-4388(97)80059-1; Jeffery CJ, 1999, TRENDS BIOCHEM SCI, V24, P8, DOI 10.1016/S0968-0004(98)01335-8; Jones SM, 1997, J CELL BIOL, V139, P339, DOI 10.1083/jcb.139.2.339; Kelly RB, 1999, NAT CELL BIOL, V1, pE8, DOI 10.1038/8957; KENT C, 1995, ANNU REV BIOCHEM, V64, P315, DOI 10.1146/annurev.bi.64.070195.001531; Griffiths Gareth, 1993, Trends in Cell Biology, V3, P214, DOI 10.1016/0962-8924(93)90114-G; MALHOTRA V, 1989, CELL, V58, P329, DOI 10.1016/0092-8674(89)90847-7; Nakamura N, 1997, CELL, V89, P445, DOI 10.1016/S0092-8674(00)80225-1; OSTERMANN J, 1993, CELL, V75, P1015, DOI 10.1016/0092-8674(93)90545-2; Rambourg A., 1997, GOLGI APPARATUS, P37; Ringstad N, 1997, P NATL ACAD SCI USA, V94, P8569, DOI 10.1073/pnas.94.16.8569; Schmidt A, 1999, NATURE, V401, P133, DOI 10.1038/43613; Simon JP, 1998, P NATL ACAD SCI USA, V95, P11181, DOI 10.1073/pnas.95.19.11181; Spanfo S, 1999, J BIOL CHEM, V274, P17705, DOI 10.1074/jbc.274.25.17705; Takei K, 1998, CELL, V94, P131, DOI 10.1016/S0092-8674(00)81228-3; Vance D., 1996, BIOCH LIPIDS LIPOPRO, V31, P1; WEIDMAN P, 1993, CELL, V75, P123, DOI 10.1016/S0092-8674(05)80089-3	23	259	269	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					429	433		10.1038/46587	http://dx.doi.org/10.1038/46587			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586885				2022-12-28	WOS:000083913600061
J	Garber, J				Garber, J			A 40-year-old woman with a strong family history of breast cancer	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							OVARIAN-CANCER; PROPHYLACTIC OOPHORECTOMY; SUSCEPTIBILITY GENES; HEREDITARY BREAST; BRCA1 MUTATIONS; RISK; WOMEN; RECOMMENDATIONS; PROBABILITIES; EPIDEMIOLOGY		Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA; Harvard Univ, Sch Med, Boston, MA USA	Harvard University; Dana-Farber Cancer Institute; Harvard University; Harvard Medical School	Garber, J (corresponding author), Dana Farber Canc Inst, Dept Adult Oncol, Boston, MA 02115 USA.							Bell R, 1998, BRIT J OBSTET GYNAEC, V105, P1136, DOI 10.1111/j.1471-0528.1998.tb09966.x; BONDY ML, 1994, J NATL CANCER I, V86, P620, DOI 10.1093/jnci/86.8.620; Burke W, 1997, JAMA-J AM MED ASSOC, V277, P997, DOI 10.1001/jama.277.12.997; Clarke M, 1998, LANCET, V351, P1451; CLAUS EB, 1991, AM J HUM GENET, V48, P232; CLAUS EB, 1994, CANCER, V73, P643, DOI 10.1002/1097-0142(19940201)73:3<643::AID-CNCR2820730323>3.0.CO;2-5; Couch FJ, 1996, HUM MUTAT, V8, P8, DOI 10.1002/humu.1380080102; Couch FJ, 1997, NEW ENGL J MED, V336, P1409, DOI 10.1056/NEJM199705153362002; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; Douglas FS, 1999, J MED GENET, V36, P309; DUPONT WD, 1985, NEW ENGL J MED, V312, P146, DOI 10.1056/NEJM198501173120303; Eisinger F, 1998, ANN ONCOL, V9, P939, DOI 10.1023/A:1008389021382; Eng C, 1997, NAT BIOTECHNOL, V15, P422, DOI 10.1038/nbt0597-422; Fisher B, 1998, J NATL CANCER I, V90, P1371, DOI 10.1093/jnci/90.18.1371; Ford D, 1998, AM J HUM GENET, V62, P676, DOI 10.1086/301749; Frank TS, 1998, J CLIN ONCOL, V16, P2417, DOI 10.1200/JCO.1998.16.7.2417; GAIL MH, 1989, J NATL CANCER I, V81, P1879, DOI 10.1093/jnci/81.24.1879; Hartmann LC, 1999, NEW ENGL J MED, V340, P77, DOI 10.1056/NEJM199901143400201; HELZLSOUER R, 1997, CURR OPIN ONCOL, V7, P489; Jacobs IJ, 1999, LANCET, V353, P1207, DOI 10.1016/S0140-6736(98)10261-1; Jacobs TW, 1999, NEW ENGL J MED, V340, P430, DOI 10.1056/NEJM199902113400604; Johannesdottir G, 1996, CANCER RES, V56, P3663; KASH KM, 1992, J NATL CANCER I, V84, P24, DOI 10.1093/jnci/84.1.24; KELSEY JL, 1993, EPIDEMIOL REV, V15, P7, DOI 10.1093/oxfordjournals.epirev.a036118; Kerlikowske K, 1996, JAMA-J AM MED ASSOC, V276, P33, DOI 10.1001/jama.276.1.33; KNUDSON AG, 1989, CANCER, V63, P1888, DOI 10.1002/1097-0142(19890515)63:10<1888::AID-CNCR2820631004>3.0.CO;2-L; Lerman C, 1996, JAMA-J AM MED ASSOC, V275, P1885, DOI 10.1001/jama.275.24.1885; Lerman C, 1998, J CLIN ONCOL, V16, P1650, DOI 10.1200/JCO.1998.16.5.1650; Malone KE, 1998, JAMA-J AM MED ASSOC, V279, P922, DOI 10.1001/jama.279.12.922; Narod SA, 1998, NEW ENGL J MED, V339, P424, DOI 10.1056/NEJM199808133390702; Newman B, 1998, JAMA-J AM MED ASSOC, V279, P915, DOI 10.1001/jama.279.12.915; Offit K, 1996, J CLIN ONCOL, V14, P1730, DOI 10.1200/JCO.1996.14.5.1730; Parmigiani G, 1998, AM J HUM GENET, V62, P145, DOI 10.1086/301670; Peters J A, 1996, Oncology (Williston Park), V10, P159; PIVER MS, 1993, CANCER-AM CANCER SOC, V71, P2751, DOI 10.1002/1097-0142(19930501)71:9<2751::AID-CNCR2820710911>3.0.CO;2-J; Powles T, 1998, LANCET, V352, P98; Rebbeck TR, 1999, J NATL CANCER I, V91, P1475, DOI 10.1093/jnci/91.17.1475; Rebbeck TR, 1997, CANCER EPIDEM BIOMAR, V6, P733; Rothenberg K, 1997, SCIENCE, V275, P1755, DOI 10.1126/science.275.5307.1755; Schneider K A, 1997, J Genet Couns, V6, P97, DOI 10.1023/A:1025699732698; Serova OM, 1997, AM J HUM GENET, V60, P486; Smith KR, 1999, CANCER EPIDEM BIOMAR, V8, P385; SPIEGELMAN D, 1994, J NATL CANCER I, V86, P600, DOI 10.1093/jnci/86.8.600; Struewing J P, 1995, J Natl Cancer Inst Monogr, P33; Struewing JP, 1997, NEW ENGL J MED, V336, P1401, DOI 10.1056/NEJM199705153362001; TOBACMAN JK, 1982, LANCET, V2, P795; Tonin P, 1996, NAT MED, V2, P1179, DOI 10.1038/nm1196-1179; Tsou HC, 1997, AM J HUM GENET, V61, P1036, DOI 10.1086/301607; Ursin G, 1997, CANCER RES, V57, P3678; Varley JM, 1997, CANCER RES, V57, P3245; Verhoog LC, 1998, LANCET, V351, P316, DOI 10.1016/S0140-6736(97)07065-7; WOOSTER R, 1995, NATURE, V378, P789, DOI 10.1038/378789a0	52	14	14	0	1	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1953	1960		10.1001/jama.282.20.1953	http://dx.doi.org/10.1001/jama.282.20.1953			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580462				2022-12-28	WOS:000083763400031
J	Schutzer, SE; Coyle, PK; Reid, P; Holland, B				Schutzer, SE; Coyle, PK; Reid, P; Holland, B			Borrelia burgdorferi-specific immune complexes in acute Lyme disease	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							SURFACE PROTEIN-A; CEREBROSPINAL-FLUID; OSPA; DIAGNOSIS; ANTIBODY; VACCINE	Context Diagnosis of infection with Borrelia burgdorferi, the cause of Lyme disease (LD), has been impeded by the lack of effective assays to detect active infection. Objective To determine whether B burgdorferi-specific immune complexes are detectable during active infection in LD. Design, Setting, and Patients Cross-sectional analysis of serum samples from 168 patients fulfilling Centers for Disease Control and Prevention surveillance criteria for LD and 145 healthy and other disease controls conducted over 8 years. Tests were performed blinded. Main Outcome Measure Detection of B burgdorferi immune complexes by enzyme-linked immunosorbent assay and Western blot. Results The B burgdorferi immune complexes were found in 25 of 26 patients with early seronegative erythema migrans (EM) LD; 105 of 107 patients with seropositive EM LD; 6 of 10 patients who were seronegative with culture-positive EM; 0 of 12 patients who were treated and recovered from LD; and 13 of 13 patients with neurologic LD without EM. Among 147 controls, B burgdorferi immune complex was found in 0 of 50 healthy individuals; 0 of 40 patients with persistent fatigue; 0 of 7 individuals with frequent tick exposure; and 2 of 50 patients with other diseases. Conclusion These data suggest that B burgdorferi immune complex formation is a common process in active LD. Analysis of the B burgdorferi immune complexes by a simple technique has the potential to support or exclude a diagnosis of early as well as active LD infection.	Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, Newark, NJ 07103 USA; Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Prevent Med, Newark, NJ 07103 USA; SUNY Stony Brook, Dept Neurol, Stony Brook, NY 11794 USA	Rutgers State University New Brunswick; Rutgers State University Medical Center; Rutgers State University New Brunswick; Rutgers State University Medical Center; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Schutzer, SE (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Med, Div Allergy & Immunol, 1855 S Orange Ave, Newark, NJ 07103 USA.				NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI031561] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR041518] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS034092] Funding Source: NIH RePORTER; NIAID NIH HHS [AI31561] Funding Source: Medline; NIAMS NIH HHS [AR41518] Funding Source: Medline; NINDS NIH HHS [NS34092] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		BAKKEN LL, 1992, JAMA-J AM MED ASSOC, V268, P891, DOI 10.1001/jama.268.7.891; BENACH JL, 1983, NEW ENGL J MED, V308, P740, DOI 10.1056/NEJM198303313081302; *CDCP, 1997, MMWR-MORBID MORTAL W, V46, P531; Centers for Disease Control and Prevention, 1997, MMWR-MORBID MORTAL W, V46, P1; Centers for Disease Control and Prevention (CDC), 1995, MMWR MORB MORTAL WKL, V44, P590; COYLE PK, 1990, ANN NEUROL, V28, P739, DOI 10.1002/ana.410280603; DATTWYLER RJ, 1988, NEW ENGL J MED, V319, P1441, DOI 10.1056/NEJM198812013192203; DIGEON M, 1977, J IMMUNOL METHODS, V16, P165, DOI 10.1016/0022-1759(77)90051-5; DOBSON SRM, 1988, J INFECT DIS, V158, P940, DOI 10.1093/infdis/158.5.940; Dunn J J, 1990, Protein Expr Purif, V1, P159, DOI 10.1016/1046-5928(90)90011-M; Fikrig E, 1997, IMMUNITY, V6, P531, DOI 10.1016/S1074-7613(00)80341-6; FIKRIG E, 1992, J INFECT DIS, V165, P1127, DOI 10.1093/infdis/165.6.1127; INMAN RD, 1982, J CLIN INVEST, V70, P271, DOI 10.1172/JCI110614; JONES VE, 1981, J IMMUNOL METHODS, V44, P249, DOI 10.1016/0022-1759(81)90045-4; RAHN DW, 1991, ANN INTERN MED, V114, P472, DOI 10.7326/0003-4819-114-6-472; RYS PN, 1993, J CLIN MICROBIOL, V31, P2356, DOI 10.1128/JCM.31.9.2356-2360.1993; Schutzer SE, 1997, J CLIN INVEST, V100, P763, DOI 10.1172/JCI119589; SCHUTZER SE, 1990, LANCET, V335, P312, DOI 10.1016/0140-6736(90)90606-6; SCHUTZER SE, 1994, J CLIN INVEST, V94, P454, DOI 10.1172/JCI117346; Schutzer SE, 1997, NEW ENGL J MED, V337, P794, DOI 10.1056/NEJM199709113371118; Sigal LH, 1998, NEW ENGL J MED, V339, P216, DOI 10.1056/NEJM199807233390402; STEERE AC, 1989, NEW ENGL J MED, V321, P586, DOI 10.1056/NEJM198908313210906; Steere AC, 1998, NEW ENGL J MED, V339, P209, DOI 10.1056/NEJM199807233390401; THEOFILOPOULOS AN, 1980, AM J PATHOL, V100, P529	24	41	42	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1942	1946		10.1001/jama.282.20.1942	http://dx.doi.org/10.1001/jama.282.20.1942			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580460				2022-12-28	WOS:000083763400029
J	Trollope-Kumar, K				Trollope-Kumar, K			Symptoms of reproductive-tract infection - not all that they seem to be	LANCET			English	Editorial Material							INDIA; WOMEN		W End Hlth Assoc, Hamilton, ON L8S 1H6, Canada		Trollope-Kumar, K (corresponding author), W End Hlth Assoc, Hamilton, ON L8S 1H6, Canada.							BANG RA, 1989, LANCET, V1, P85; Brabin L, 1998, B WORLD HEALTH ORGAN, V76, P277; EDWARDS J, 1983, MED ANRHT, V3, P51; GITTELSOHN J, 1994, LISTENING WOMEN THEI; Lambert H, 1998, TROP MED INT HEALTH, V3, P1002, DOI 10.1046/j.1365-3156.1998.00336.x; Mertens TE, 1998, PUBLIC HEALTH, V112, P123, DOI 10.1016/S0033-3506(98)00596-4; NICHTER M, 1981, CULT MED PSYCHIAT, V5, P379, DOI 10.1007/BF00054782; OBEYESEKERE G, 1976, ASIAN MED SYSTEMS	8	21	21	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1745	1746		10.1016/S0140-6736(99)00272-X	http://dx.doi.org/10.1016/S0140-6736(99)00272-X			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258RM	10577630				2022-12-28	WOS:000083853000003
J	Wynia, MK; Latham, SR; Kao, AC; Berg, JW; Emanuel, LL				Wynia, MK; Latham, SR; Kao, AC; Berg, JW; Emanuel, LL			Medical professionalism in society.	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material							MANAGED-CARE; HEALTH-CARE; PHYSICIANS; DOCTORS; LESSONS; ETHICS; MARKETPLACE; CALIFORNIA; NUREMBERG; COMMUNITY		Amer Med Assoc, Chicago, IL 60610 USA; Quinnipiac Sch Law, New Haven, CT 06518 USA	American Medical Association; Quinnipiac University	Wynia, MK (corresponding author), Amer Med Assoc, 515 N State St, Chicago, IL 60610 USA.		Wynia, Matthew/T-2210-2019	Latham, Stephen/0000-0002-3036-1400				ALEXANDER L, 1949, NEW ENGL J MED, V241, P39, DOI 10.1056/NEJM194907142410201; Anders G., 1996, HLTH WEALTH HMOS BRE; Angell M, 1993, Kennedy Inst Ethics J, V3, P279; BLUMENTHAL D, 1994, HEALTH AFFAIR, V13, P252, DOI 10.1377/hlthaff.13.1.252; Blumenthal D, 1996, HEALTH AFFAIR, V15, P170, DOI 10.1377/hlthaff.15.2.170; Boswell James, 1904, LIFE JOHNSON; Brody H, 1997, ARCH INTERN MED, V157, P2037, DOI 10.1001/archinte.157.18.2037; BUCHANAN AE, 1996, CONFLICTS INTEREST C, P105; CAUTHEN DB, 1989, JAMA-J AM MED ASSOC, V262, P1631, DOI 10.1001/jama.1989.03430120081020; COHEN C, 1989, HASTINGS CENT REP, V19, P23; Cruess RL, 1997, ACAD MED, V72, P941, DOI 10.1097/00001888-199711000-00009; Cruess RL, 1999, ACAD MED, V74, P878, DOI 10.1097/00001888-199908000-00010; Cunningham PJ, 1999, HEALTH SERV RES, V34, P255; Cunningham PJ, 1999, JAMA-J AM MED ASSOC, V281, P1087, DOI 10.1001/jama.281.12.1087; CURRY R, 1992, MED SALE; Donelan K, 1997, HEALTH AFFAIR, V16, P139, DOI 10.1377/hlthaff.16.5.139; DWORKIN R, 1998, BALTIMORE SUN   0908, pA11; Emanuel L, 1997, JAMA-J AM MED ASSOC, V277, P1004, DOI 10.1001/jama.277.12.1004; EMANUEL L, 1996, 1996 SUMM C PHIL AM, P67; Feldman DS, 1998, ARCH INTERN MED, V158, P1626, DOI 10.1001/archinte.158.15.1626; FREIDSON E, 1994, PROFESSIONALISM REFO; Freidson E., 1970, PROFESSIONAL DOMINAN; Gordon Robert W., 1992, LAWYERS IDEALS LAWYE, p[230, 235]; Gray BH, 1997, HEALTH AFFAIR, V16, P34, DOI 10.1377/hlthaff.16.1.34; Grodin MA, 1996, JAMA-J AM MED ASSOC, V276, P1682, DOI 10.1001/jama.276.20.1682; Grumbach K, 1998, NEW ENGL J MED, V339, P1516, DOI 10.1056/NEJM199811193392106; JAKLEVIC MC, 1998, MOD HEALTHCARE, V28, P3; JAMES C, 1999, NY TIMES        0923, pB9; JAMES C, 1923, NY TIMES        0923, V1, pB1; Kao AC, 1998, JAMA-J AM MED ASSOC, V280, P1708, DOI 10.1001/jama.280.19.1708; KASSIRER JP, 1995, NEW ENGL J MED, V333, P50, DOI 10.1056/NEJM199507063330110; Kerr EA, 1997, JAMA-J AM MED ASSOC, V278, P308, DOI 10.1001/jama.278.4.308; KLEIN S, 1999, AM MED NEWS, V1, P34; KRAUSE EA, 1996, DETH GUILDS PROFESSI; Larson, 1979, RISE PROFESSIONALISM, V233; LUNDBERG GD, 1987, JAMA-J AM MED ASSOC, V258, P3157, DOI 10.1001/jama.258.21.3157; Morreim E. Haavi, 1995, BALANCING ACT NEW ME; ORENTLICHER D, 1993, JAMA-J AM MED ASSOC, V269, P2533; ORENTLICHER D, 1994, ALBANY LAW REV, V57, P582; Orr RD, 1997, J CLIN ETHIC, V8, P377; Parsons T, 1939, SOC FORCES, V17, P457, DOI 10.2307/2570695; Parsons Talcott, 1954, ESSAYS SOCIOLOGICAL; Pellegrino E., 1981, PHILOS BASIS MED PRA; Pellegrino ED, 1999, JAMA-J AM MED ASSOC, V282, P984, DOI 10.1001/jama.282.10.984; PELLEGRINO ED, 1990, B NEW YORK ACAD MED, V66, P221; Pellegrino ED, 1997, ANN INTERN MED, V127, P307, DOI 10.7326/0003-4819-127-4-199708150-00010; PELLEGRINO ED, 1995, JAMA-J AM MED ASSOC, V273, P1622, DOI 10.1001/jama.273.20.1622; PELLEGRINO ED, 1987, JAMA-J AM MED ASSOC, V258, P1939, DOI 10.1001/jama.258.14.1939; REINHARDT UE, 1987, MILBANK Q, V65, P153, DOI 10.2307/3350018; REUSCHEMEYER D, 1986, AM BAR FDN RES J SUM, P415; REYNOLDS PP, 1994, ANN INTERN MED, V120, P609, DOI 10.7326/0003-4819-120-7-199404010-00013; Rodwin M. A., 1993, MED MONEY MORALS PHY; SILOVE D, 1990, SOC SCI MED, V30, P417, DOI 10.1016/0277-9536(90)90344-R; Starr P, 1982, SOCIAL TRANSFORMATIO; Sullivan WM, 1999, HASTINGS CENT REP, V29, P7, DOI 10.2307/3528344; Swick HM, 1999, JAMA-J AM MED ASSOC, V282, P830, DOI 10.1001/jama.282.9.830; Tocqueville Alexis de, 2004, DEMOCRACY AM, P1004; Veatch Robert M, 1981, THEORY MED ETHICS, V1; Vollmer HM, 1966, PROFESSIONALIZATION; Weber M., 1968, EC SOC OUTLINE INTER; WOOLHANDLER S, 1995, NEW ENGL J MED, V333, P1706, DOI 10.1056/NEJM199512213332510; ZIV TA, 1995, NEW ENGL J MED, V332, P1095, DOI 10.1056/NEJM199504203321612	62	207	213	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 18	1999	341	21					1612	1616		10.1056/NEJM199911183412112	http://dx.doi.org/10.1056/NEJM199911183412112			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	256GF	10577119				2022-12-28	WOS:000083717000012
J	Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA				Barasch, J; Yang, J; Ware, CB; Taga, T; Yoshida, K; Erdjument-Bromage, H; Tempst, P; Parravicini, E; Malach, S; Aranoff, T; Oliver, JA			Mesenchymal to epithelial conversion in rat metanephros is induced by LIF	CELL			English	Article							LEUKEMIA INHIBITORY FACTOR; ADHESION MOLECULE UVOMORULIN; IL-6 SIGNAL TRANSDUCER; GROWTH-FACTOR; EMBRYONIC KIDNEY; MOUSE KIDNEY; TARGETED DISRUPTION; TYROSINE KINASE; NERVOUS-SYSTEM; ORGAN-CULTURE	Inductive signals cause conversion of mesenchyme into epithelia during the formation of many organs. Yet a century of study has not revealed the inducing molecules. Using a standard model of induction, we found that ureteric bud cells secrete factors that convert kidney mesenchyme to epithelia that, remarkably, then form nephrons. Purification and sequencing of one such factor identified it as leukemia inhibitory factor (LIF). LIF acted on epithelial precursors that we identified by the expression of Pax2 and Wnt4. Other IL-6 type cytokines acted like LIF, and deletion of their shared receptor reduced nephron development. In situ, the ureteric bud expressed LIF, and metanephric mesenchyme expressed its receptors. The data suggest that IL-6 cytokines are candidate regulators of mesenchymal to epithelial conversion during kidney development.	Columbia Univ Coll Phys & Surg, Dept Med, New York, NY 10032 USA; Columbia Univ Coll Phys & Surg, Dept Pediat, New York, NY 10032 USA; Univ Washington, Sch Med, Dept Comparat Med, Seattle, WA 98195 USA; Tokyo Med & Dent Univ, Dept Mol Cell Biol, Chiyoda Ku, Tokyo 1010062, Japan; Osaka Univ, Dept Mol Immunol, Suita, Osaka 5650871, Japan; Mem Sloan Kettering Canc Ctr, Program Mol Biol, New York, NY 10021 USA	Columbia University; Columbia University; University of Washington; University of Washington Seattle; Tokyo Medical & Dental University (TMDU); Osaka University; Memorial Sloan Kettering Cancer Center	Barasch, J (corresponding author), Columbia Univ Coll Phys & Surg, Dept Med, 630 W 168th St, New York, NY 10032 USA.			Malach, Stephen/0000-0002-2771-4957; Erdjument-Bromage, Hediye/0000-0003-0224-3594				ABRAHAMSON DR, 1991, SEMIN NEPHROL, V11, P375; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; ARMSTRONG JF, 1992, MECH DEVELOP, V40, P85; AVNER ED, 1985, IN VITRO CELL DEV B, V21, P297; Barasch J, 1997, AM J PHYSIOL-RENAL, V273, pF757, DOI 10.1152/ajprenal.1997.273.5.F757; Barasch J, 1996, AM J PHYSIOL-RENAL, V271, pF50, DOI 10.1152/ajprenal.1996.271.1.F50; Barasch J, 1999, J CLIN INVEST, V103, P1299, DOI 10.1172/JCI4586; BARD JBL, 1991, DEVELOPMENT, V113, P193; Boccaccio C, 1998, NATURE, V391, P285, DOI 10.1038/34657; Bonni A, 1997, SCIENCE, V278, P477, DOI 10.1126/science.278.5337.477; Boyden EA, 1927, P SOC EXP BIOL MED, V24, P572; Cho EA, 1998, DEVELOPMENT, V125, P803; Dudley AT, 1999, GENE DEV, V13, P1601, DOI 10.1101/gad.13.12.1601; EKBLOM P, 1981, J CELL BIOL, V89, P276, DOI 10.1083/jcb.89.2.276; EKBLOM P, 1989, FASEB J, V3, P2141, DOI 10.1096/fasebj.3.10.2666230; EKBLOM P, 1981, J CELL BIOL, V91, P1, DOI 10.1083/jcb.91.1.1; EKBLOM P, 1983, P NATL ACAD SCI-BIOL, V80, P2651, DOI 10.1073/pnas.80.9.2651; ELICONE C, 1994, J CHROMATOGR A, V676, P121, DOI 10.1016/0021-9673(94)00089-1; Erdjument-Bromage H, 1998, J CHROMATOGR A, V826, P167, DOI 10.1016/S0021-9673(98)00705-5; GEARING DP, 1992, SCIENCE, V255, P1434, DOI 10.1126/science.1542794; GEARING DP, 1991, EMBO J, V10, P2839, DOI 10.1002/j.1460-2075.1991.tb07833.x; Gilbert T, 1996, KIDNEY INT, V50, P783, DOI 10.1038/ki.1996.377; GROBSTEIN C, 1955, J EXP ZOOL, V130, P319, DOI 10.1002/jez.1401300207; Gruenwald P, 1943, ANAT REC, V86, P321, DOI 10.1002/ar.1090860303; Hara T, 1998, DEV BIOL, V201, P144, DOI 10.1006/dbio.1998.8990; HERZLINGER D, 1992, DEVELOPMENT, V114, P565; HERZLINGER D, 1994, DEV BIOL, V166, P815, DOI 10.1006/dbio.1994.1360; HOLTHOFER H, 1984, LAB INVEST, V50, P552; IP NY, 1992, CELL, V69, P1121, DOI 10.1016/0092-8674(92)90634-O; Karavanova ID, 1996, DEVELOPMENT, V122, P4159; Kispert A, 1998, DEVELOPMENT, V125, P4225; Kispert A, 1996, DEVELOPMENT, V122, P3627; KLEIN G, 1988, DEVELOPMENT, V102, P749; KOSEKI C, 1992, J CELL BIOL, V119, P1327, DOI 10.1083/jcb.119.5.1327; Laitinen L, 1987, J HISTOCHEM CYTOCHEM, V35, P55, DOI 10.1177/35.1.3794309; LEHTONEN E, 1985, DEV BIOL, V108, P481, DOI 10.1016/0012-1606(85)90051-X; LEVINE E, 1994, DEVELOPMENT, V120, P901; LIEM KF, 1995, CELL, V82, P969, DOI 10.1016/0092-8674(95)90276-7; Lindahl P, 1998, DEVELOPMENT, V125, P3313; Lui M, 1996, ANAL BIOCHEM, V241, P156, DOI 10.1006/abio.1996.0393; MAYER M, 1994, DEVELOPMENT, V120, P143; MCNEILL H, 1990, CELL, V62, P309, DOI 10.1016/0092-8674(90)90368-O; METCALF D, 1988, LEUKEMIA, V2, P216; MURPHY M, 1993, DEVELOPMENT, V117, P1173; MURPHY M, 1991, P NATL ACAD SCI USA, V88, P3498, DOI 10.1073/pnas.88.8.3498; MURPHY M, 1994, DEVELOPMENT, V120, P3519; Nakashima K, 1999, SCIENCE, V284, P479, DOI 10.1126/science.284.5413.479; NORDLING S, 1971, J EMBRYOL EXP MORPH, V26, P231; PARTANEN AM, 1987, DEV BIOL, V120, P186, DOI 10.1016/0012-1606(87)90117-5; PRITCHARDJONES K, 1990, NATURE, V346, P194, DOI 10.1038/346194a0; REUTER R, 1993, DEVELOPMENT, V119, P1135; ROTHENPIELER UW, 1993, DEVELOPMENT, V119, P711; Sakurai H, 1997, P NATL ACAD SCI USA, V94, P6279, DOI 10.1073/pnas.94.12.6279; SARIOLA H, 1989, DEV BIOL, V132, P271, DOI 10.1016/0012-1606(89)90224-8; Saxen L., 1987, ORGANOGENESIS KIDNEY; SCHINDLER C, 1995, ANNU REV BIOCHEM, V64, P621, DOI 10.1146/annurev.bi.64.070195.003201; SCHUCHARDT A, 1994, NATURE, V367, P380, DOI 10.1038/367380a0; Seifert RA, 1998, KIDNEY INT, V54, P731, DOI 10.1046/j.1523-1755.1998.00046.x; Sheng ZL, 1996, DEVELOPMENT, V122, P419; Sierra-Honigmann MR, 1998, SCIENCE, V281, P1683, DOI 10.1126/science.281.5383.1683; SONNENBERG E, 1993, J CELL BIOL, V123, P223, DOI 10.1083/jcb.123.1.223; STARK K, 1994, NATURE, V372, P679, DOI 10.1038/372679a0; TAGA T, 1989, CELL, V58, P573, DOI 10.1016/0092-8674(89)90438-8; Takeda K, 1997, P NATL ACAD SCI USA, V94, P3801, DOI 10.1073/pnas.94.8.3801; Tempst Paul, 1994, Methods (Orlando), V6, P248, DOI 10.1006/meth.1994.1027; TEPASS U, 1994, DEVELOPMENT, V120, P579; VAINIO S, 1992, DEV BIOL, V152, P221, DOI 10.1016/0012-1606(92)90130-9; VESTWEBER D, 1985, DEV BIOL, V112, P213, DOI 10.1016/0012-1606(85)90135-6; WELLER A, 1991, DEV BIOL, V144, P248, DOI 10.1016/0012-1606(91)90419-4; WOOLF AS, 1995, J CELL BIOL, V128, P171, DOI 10.1083/jcb.128.1.171; Yoshida K, 1996, P NATL ACAD SCI USA, V93, P407, DOI 10.1073/pnas.93.1.407	71	212	222	0	3	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 12	1999	99	4					377	386		10.1016/S0092-8674(00)81524-X	http://dx.doi.org/10.1016/S0092-8674(00)81524-X			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571180	hybrid			2022-12-28	WOS:000083709300005
J	Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE				Sobel, N; Khan, RM; Saltman, A; Sullivan, EV; Gabrieli, JDE			Olfaction - The world smells different to each nostril	NATURE			English	Article							NASAL CYCLE; ODORANTS; NOSE; FLOW		Stanford Univ, Neurosci Program, Stanford, CA 94305 USA; Stanford Univ, Dept Psychol, Stanford, CA 94305 USA; Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA; Minist Environm Protect, IL-72100 Ramle, Israel	Stanford University; Stanford University; Stanford University	Sobel, N (corresponding author), Stanford Univ, Neurosci Program, Stanford, CA 94305 USA.		Sullivan, Edith V/ABD-5684-2021; Gabrieli, John/AAJ-2869-2020	Sullivan, Edith V/0000-0001-6739-3716; Sobel, Noam/0000-0002-3232-9391				BOJSENMOLLER F, 1971, J ANAT, V110, P25; ECCLES R, 1989, ACTA OTO-LARYNGOL, V108, P268, DOI 10.3109/00016488909125527; Frye RE, 1995, NEUROL DIS, P471; GILBERT AN, 1987, ACTA OTO-LARYNGOL, V104, P180, DOI 10.3109/00016488709109065; HASEGAWA M, 1977, MAYO CLIN PROC, V52, P28; Kayser R., 1895, ARCH LARYNGOL RHINOL, V8, P101; Mirza N, 1997, LARYNGOSCOPE, V107, P62, DOI 10.1097/00005537-199701000-00014; MOZELL MM, 1973, SCIENCE, V181, P1247, DOI 10.1126/science.181.4106.1247; MOZELL MM, 1991, CHEM SENSES, V16, P631, DOI 10.1093/chemse/16.6.631; PRINCIPATO JJ, 1970, ARCHIV OTOLARYNGOL, V91, P71	10	98	100	0	14	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 4	1999	402	6757					35	35		10.1038/46944	http://dx.doi.org/10.1038/46944			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573415				2022-12-28	WOS:000083638600032
J	Lynn, JT				Lynn, JT			A rainbow from Joanne	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material																			0	0	0	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2101	2101		10.1001/jama.282.22.2101	http://dx.doi.org/10.1001/jama.282.22.2101			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591316				2022-12-28	WOS:000083971400001
J	Ellgaard, L; Molinari, M; Helenius, A				Ellgaard, L; Molinari, M; Helenius, A			Setting the standards: Quality control in the secretory pathway	SCIENCE			English	Review							GLUCOSE-GLYCOPROTEIN GLUCOSYLTRANSFERASE; TRANSMEMBRANE CONDUCTANCE REGULATOR; ENDOPLASMIC-RETICULUM RETENTION; PROTEIN DISULFIDE-ISOMERASE; MHC CLASS-I; MOLECULAR CHAPERONE; INTERMEDIATE COMPARTMENT; SACCHAROMYCES-CEREVISIAE; TRANSIENT AGGREGATION; INTRACELLULAR FATE	A variety of quality control mechanisms operate in the endoplasmic reticulum and in downstream compartments of the secretory pathway to ensure the fidelity and regulation of protein expression during cell Life and differentiation. As a rule, only proteins that pass a stringent selection process are transported to their target organelles and compartments. If proper maturation fails, the aberrant products are degraded. Quality control improves folding efficiency by retaining proteins in the special folding environment of the endoplasmic reticulum, and it prevents harmful effects that could be caused by the deployment of incompletely folded or assembled proteins.	Swiss Fed Inst Technol, Inst Biochem, CH-8092 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Helenius, A (corresponding author), Swiss Fed Inst Technol, Inst Biochem, Univ Str 16, CH-8092 Zurich, Switzerland.	ari.helenius@bc.biol.ethz.ch	Molinari, Maurizio/N-2587-2019; Ellgaard, Lars/I-9034-2014	Molinari, Maurizio/0000-0002-7636-5829; Ellgaard, Lars/0000-0002-7018-0137				Amara J F, 1992, Trends Cell Biol, V2, P145, DOI 10.1016/0962-8924(92)90101-R; Andersson H, 1999, J BIOL CHEM, V274, P15080, DOI 10.1074/jbc.274.21.15080; ANFINSEN CB, 1973, SCIENCE, V181, P223, DOI 10.1126/science.181.4096.223; Annaert WG, 1997, J CELL BIOL, V139, P1397, DOI 10.1083/jcb.139.6.1397; Appenzeller C, 1999, NAT CELL BIOL, V1, P330, DOI 10.1038/14020; Aridor M, 1999, NAT MED, V5, P745, DOI 10.1038/10466; BACHHAWAT AK, 1991, J CELL BIOL, V115, P619, DOI 10.1083/jcb.115.3.619; BAKER EK, 1994, EMBO J, V13, P4886, DOI 10.1002/j.1460-2075.1994.tb06816.x; BALCH WE, 1994, CELL, V76, P841, DOI 10.1016/0092-8674(94)90359-X; Barz WP, 1999, MOL BIOL CELL, V10, P1043, DOI 10.1091/mbc.10.4.1043; Bonifacino JS, 1998, ANNU REV CELL DEV BI, V14, P19, DOI 10.1146/annurev.cellbio.14.1.19; BONIFACINO JS, 1990, CELL, V63, P503, DOI 10.1016/0092-8674(90)90447-M; BOOTH C, 1989, CELL, V59, P729, DOI 10.1016/0092-8674(89)90019-6; Brodsky JL, 1999, J BIOL CHEM, V274, P3453, DOI 10.1074/jbc.274.6.3453; Brodsky JL, 1997, TRENDS CELL BIOL, V7, P151, DOI 10.1016/S0962-8924(97)01020-9; BU GJ, 1995, EMBO J, V14, P2269, DOI 10.1002/j.1460-2075.1995.tb07221.x; Cannon KS, 1999, J BIOL CHEM, V274, P7537, DOI 10.1074/jbc.274.11.7537; Chang XB, 1999, MOL CELL, V4, P137, DOI 10.1016/S1097-2765(00)80196-3; Chen YT, 1999, J CELL BIOL, V144, P687, DOI 10.1083/jcb.144.4.687; Cooper AA, 1996, J CELL BIOL, V133, P529, DOI 10.1083/jcb.133.3.529; CREIGHTON TE, 1988, BIOESSAYS, V8, P57, DOI 10.1002/bies.950080204; Cresswell P, 1996, CELL, V84, P505, DOI 10.1016/S0092-8674(00)81025-9; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; ELGUINDI SB, 1993, CELL, V75, P717; Fleming JF, 1999, J BIOL CHEM, V274, P9509, DOI 10.1074/jbc.274.14.9509; FLYNN GC, 1991, NATURE, V353, P726, DOI 10.1038/353726a0; Gilbert A, 1998, EXP CELL RES, V242, P144, DOI 10.1006/excr.1998.4101; Graham LA, 1998, J CELL BIOL, V142, P39, DOI 10.1083/jcb.142.1.39; GRINNA LS, 1980, J BIOL CHEM, V255, P2255; HAMMOND C, 1994, P NATL ACAD SCI USA, V91, P913, DOI 10.1073/pnas.91.3.913; HAMMOND C, 1994, J CELL BIOL, V126, P41, DOI 10.1083/jcb.126.1.41; Helenius A, 1997, TRENDS CELL BIOL, V7, P193; HELENIUS A, 1994, MOL BIOL CELL, V5, P253, DOI 10.1091/mbc.5.3.253; Hong E, 1996, J CELL BIOL, V135, P623, DOI 10.1083/jcb.135.3.623; Huppa JB, 1998, CELL, V92, P145, DOI 10.1016/S0092-8674(00)80907-1; HURTLEY SM, 1989, ANNU REV CELL BIOL, V5, P277, DOI 10.1146/annurev.cb.05.110189.001425; Ihara Y, 1999, MOL CELL, V4, P331, DOI 10.1016/S1097-2765(00)80335-4; Jakob CA, 1998, J CELL BIOL, V142, P1223, DOI 10.1083/jcb.142.5.1223; Jorgensen MU, 1999, EUR J BIOCHEM, V260, P461, DOI 10.1046/j.1432-1327.1999.00176.x; Katakura Y, 1999, BBA-PROTEIN STRUCT M, V1432, P302, DOI 10.1016/S0167-4838(99)00099-0; Kellokumpu S, 1997, J BIOL CHEM, V272, P2770, DOI 10.1074/jbc.272.5.2770; KEREM A, 1993, J BIOL CHEM, V268, P180; KIM PS, 1992, J CELL BIOL, V118, P541, DOI 10.1083/jcb.118.3.541; KLAUSNER RD, 1990, CELL, V62, P611, DOI 10.1016/0092-8674(90)90104-M; KNITTLER MR, 1995, P NATL ACAD SCI USA, V92, P1764, DOI 10.1073/pnas.92.5.1764; Knop M, 1996, YEAST, V12, P1229, DOI 10.1002/(SICI)1097-0061(19960930)12:12<1229::AID-YEA15>3.0.CO;2-H; Kopito Ron R., 1999, Physiological Reviews, V79, pS167; Kopito RR, 1997, CELL, V88, P427, DOI 10.1016/S0092-8674(00)81881-4; KORNFELD S, 1989, ANNU REV CELL BIOL, V5, P483, DOI 10.1146/annurev.cb.05.110189.002411; Kowalski JM, 1998, BIOCHEMISTRY-US, V37, P1264, DOI 10.1021/bi9722397; Kowalski JM, 1998, J BIOL CHEM, V273, P19453, DOI 10.1074/jbc.273.31.19453; KREIBICH G, 1978, J CELL BIOL, V77, P464, DOI 10.1083/jcb.77.2.464; Kuehn MJ, 1997, CURR OPIN CELL BIOL, V9, P477, DOI 10.1016/S0955-0674(97)80022-1; LETOURNEUR F, 1995, J CELL BIOL, V129, P971, DOI 10.1083/jcb.129.4.971; Li Y, 1999, MOL CELL BIOL, V19, P3588; Liu Y, 1999, J BIOL CHEM, V274, P5861, DOI 10.1074/jbc.274.9.5861; LJUNGDAHL PO, 1992, CELL, V71, P463, DOI 10.1016/0092-8674(92)90515-E; Loo MA, 1998, EMBO J, V17, P6879, DOI 10.1093/emboj/17.23.6879; MACINTYRE S, 1994, J BIOL CHEM, V269, P24496; MARCUSSON EG, 1994, CELL, V77, P579, DOI 10.1016/0092-8674(94)90219-4; MARKS MS, 1995, J BIOL CHEM, V270, P10475, DOI 10.1074/jbc.270.18.10475; Martinez-Menarguez JA, 1999, CELL, V98, P81, DOI 10.1016/S0092-8674(00)80608-X; Marzioch M, 1999, MOL BIOL CELL, V10, P1923, DOI 10.1091/mbc.10.6.1923; Meacham GC, 1999, EMBO J, V18, P1492, DOI 10.1093/emboj/18.6.1492; Melchers F, 1999, P NATL ACAD SCI USA, V96, P2571, DOI 10.1073/pnas.96.6.2571; Misselwitz E, 1999, J BIOL CHEM, V274, P20110, DOI 10.1074/jbc.274.29.20110; Molinari M, 1999, NATURE, V402, P90, DOI 10.1038/47062; MOLINARI M, UNPUB; Nagata K, 1998, MATRIX BIOL, V16, P379, DOI 10.1016/S0945-053X(98)90011-7; Nieland TJF, 1996, P NATL ACAD SCI USA, V93, P6135, DOI 10.1073/pnas.93.12.6135; NILSSON T, 1994, CURR OPIN CELL BIOL, V6, P517, DOI 10.1016/0955-0674(94)90070-1; Oliver JD, 1999, MOL BIOL CELL, V10, P2573, DOI 10.1091/mbc.10.8.2573; Ortmann B, 1997, SCIENCE, V277, P1306, DOI 10.1126/science.277.5330.1306; Pamer E, 1998, ANNU REV IMMUNOL, V16, P323, DOI 10.1146/annurev.immunol.16.1.323; PARKER CG, 1995, EMBO J, V14, P1294, DOI 10.1002/j.1460-2075.1995.tb07115.x; Parodi AJ, 1999, BBA-GEN SUBJECTS, V1426, P287, DOI 10.1016/S0304-4165(98)00130-5; PELHAM HRB, 1989, ANNU REV CELL BIOL, V5, P1, DOI 10.1146/annurev.cb.05.110189.000245; Perlmutter DH, 1996, ANN MED, V28, P385, DOI 10.3109/07853899608999097; PFEFFER SR, 1987, ANNU REV BIOCHEM, V56, P829, DOI 10.1146/annurev.biochem.56.1.829; Pilon M, 1997, EMBO J, V16, P4540, DOI 10.1093/emboj/16.15.4540; PIND S, 1994, J BIOL CHEM, V269, P12784; Plemper RK, 1997, NATURE, V388, P891, DOI 10.1038/42276; Plemper RK, 1999, TRENDS BIOCHEM SCI, V24, P266, DOI 10.1016/S0968-0004(99)01420-6; Powers J, 1998, J CELL BIOL, V142, P1209, DOI 10.1083/jcb.142.5.1209; PUIG A, 1994, J BIOL CHEM, V269, P7764; Reddy PS, 1998, BIOESSAYS, V20, P546, DOI 10.1002/(SICI)1521-1878(199807)20:7<546::AID-BIES5>3.0.CO;2-I; Roberg KJ, 1999, J CELL BIOL, V145, P659, DOI 10.1083/jcb.145.4.659; SAMBROOK JF, 1990, CELL, V61, P197, DOI 10.1016/0092-8674(90)90798-J; Sherwood PW, 1999, P NATL ACAD SCI USA, V96, P7415, DOI 10.1073/pnas.96.13.7415; SITIA R, 1990, CELL, V60, P781, DOI 10.1016/0092-8674(90)90092-S; SONNICHSEN B, 1994, J CELL SCI, V107, P2705; SOUSA M, 1995, EMBO J, V14, P4196, DOI 10.1002/j.1460-2075.1995.tb00093.x; SOUSA MC, 1992, BIOCHEMISTRY-US, V31, P97, DOI 10.1021/bi00116a015; STEVENS TL, 1994, J IMMUNOL, V152, P4397; SU K, 1993, J BIOL CHEM, V268, P14301; Tatu U, 1997, J CELL BIOL, V136, P555, DOI 10.1083/jcb.136.3.555; Trilla JA, 1999, J CELL BIOL, V145, P1153, DOI 10.1083/jcb.145.6.1153; Trombetta ES, 1999, EMBO J, V18, P3282, DOI 10.1093/emboj/18.12.3282; TROMBETTA ES, UNPUB; TROMBETTA SE, 1992, J BIOL CHEM, V267, P9236; van der Spoel A, 1998, EMBO J, V17, P1588, DOI 10.1093/emboj/17.6.1588; Walmsley AR, 1999, J BIOL CHEM, V274, P14884, DOI 10.1074/jbc.274.21.14884; Warren G, 1999, CELL, V98, P125, DOI 10.1016/S0092-8674(00)81006-5; Wen CH, 1999, J CELL BIOL, V145, P1165, DOI 10.1083/jcb.145.6.1165; WIELAND FT, 1987, CELL, V50, P289, DOI 10.1016/0092-8674(87)90224-8; Wiertz EJHJ, 1996, NATURE, V384, P432, DOI 10.1038/384432a0; Wormald MR, 1999, STRUCTURE, V7, pR155, DOI 10.1016/S0969-2126(99)80095-1; YANG YP, 1993, P NATL ACAD SCI USA, V90, P9480, DOI 10.1073/pnas.90.20.9480; Zapun A, 1999, STRUCT FOLD DES, V7, pR173, DOI 10.1016/S0969-2126(99)80112-9; Zerangue N, 1999, NEURON, V22, P537, DOI 10.1016/S0896-6273(00)80708-4; Zhang JX, 1997, MOL BIOL CELL, V8, P1943, DOI 10.1091/mbc.8.10.1943; ZHEN L, 1995, J BIOL CHEM, V270, P11912, DOI 10.1074/jbc.270.20.11912	112	1002	1027	5	43	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1882	1888		10.1126/science.286.5446.1882	http://dx.doi.org/10.1126/science.286.5446.1882			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583943				2022-12-28	WOS:000084003400036
J	Lindahl, T; Wood, RD				Lindahl, T; Wood, RD			Quality control by DNA repair	SCIENCE			English	Review							BASE-EXCISION-REPAIR; TRANSCRIPTION-COUPLED REPAIR; COCKAYNE-SYNDROME PATIENTS; ESCHERICHIA-COLI; SACCHAROMYCES-CEREVISIAE; CRYSTAL-STRUCTURE; POLYMERASE-BETA; MAMMALIAN-CELLS; DAMAGED-DNA; MICE LACKING	Faithful maintenance of the genome is crucial to the individual and to species. DNA damage arises from both endogenous sources such as water and oxygen and exogenous sources such as sunlight and tobacco smoke. In human cells, base alterations are generally removed by excision repair pathways that counteract the mutagenic effects of DNA Lesions. This serves to maintain the integrity of the genetic information, although not all of the pathways are absolutely error-free. In some cases, DNA damage is not repaired but is instead bypassed by specialized DNA polymerases.	Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England		Lindahl, T (corresponding author), Imperial Canc Res Fund, Clare Hall Labs, S Mimms EN6 3LD, Herts, England.		Wood, Richard D/M-6319-2018	Wood, Richard D/0000-0002-9495-6892				Araujo SJ, 1999, MUTAT RES-DNA REPAIR, V435, P23, DOI 10.1016/S0921-8777(99)00042-7; Barrett TE, 1998, CELL, V92, P117, DOI 10.1016/S0092-8674(00)80904-6; BATTY DP, IN PRESS GENE; Baumann P, 1998, P NATL ACAD SCI USA, V95, P14066, DOI 10.1073/pnas.95.24.14066; Beard WA, 1998, CHEM BIOL, V5, pR7, DOI 10.1016/S1074-5521(98)90081-3; Bennett RAO, 1997, P NATL ACAD SCI USA, V94, P7166, DOI 10.1073/pnas.94.14.7166; Berdal KG, 1998, EMBO J, V17, P363, DOI 10.1093/emboj/17.2.363; Bhagwat AS, 1999, NUCLEIC ACIDS RES, V27, P4028, DOI 10.1093/nar/27.20.4028; Budd ME, 1997, MUTAT RES-DNA REPAIR, V384, P157, DOI 10.1016/S0921-8777(97)00024-4; Cadet J, 1998, FREE RADICAL RES, V29, P541, DOI 10.1080/10715769800300581; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; Cheo DL, 1997, MUTAT RES-FUND MOL M, V374, P1, DOI 10.1016/S0027-5107(97)00046-8; Cleaver J.E., 1995, METABOLIC MOL BASIS, P4393; Cook PR, 1999, SCIENCE, V284, P1790, DOI 10.1126/science.284.5421.1790; Cooper PK, 1997, SCIENCE, V275, P990, DOI 10.1126/science.275.5302.990; CordeiroStone M, 1997, J BIOL CHEM, V272, P13945, DOI 10.1074/jbc.272.21.13945; Cordonnier AM, 1999, MOL CELL BIOL, V19, P2206; Critchlow SE, 1998, TRENDS BIOCHEM SCI, V23, P394, DOI 10.1016/S0968-0004(98)01284-5; Cunningham RP, 1997, MUTAT RES-DNA REPAIR, V383, P189, DOI 10.1016/S0921-8777(97)00008-6; de Boer J, 1999, CANCER RES, V59, P3489; de Boer J, 1998, MOL CELL, V1, P981, DOI 10.1016/S1097-2765(00)80098-2; de Boer J, 1998, CANCER RES, V58, P89; de Laat WL, 1999, GENE DEV, V13, P768, DOI 10.1101/gad.13.7.768; DEVRIES A, 1995, NATURE, V377, P169, DOI 10.1038/377169a0; Dianov G, 1998, J BIOL CHEM, V273, P33811, DOI 10.1074/jbc.273.50.33811; Dianov GL, 1999, J BIOL CHEM, V274, P13741, DOI 10.1074/jbc.274.20.13741; Drotschmann K, 1998, NUCLEIC ACIDS RES, V26, P948, DOI 10.1093/nar/26.4.948; Fink SP, 1997, P NATL ACAD SCI USA, V94, P8652, DOI 10.1073/pnas.94.16.8652; Fortini P, 1998, BIOCHEMISTRY-US, V37, P3575, DOI 10.1021/bi972999h; Freudenreich CH, 1998, SCIENCE, V279, P853, DOI 10.1126/science.279.5352.853; Friedberg EC, 1999, CELL, V98, P413, DOI 10.1016/S0092-8674(00)81970-4; Gerlach VL, 1999, P NATL ACAD SCI USA, V96, P11922, DOI 10.1073/pnas.96.21.11922; Gibbs PEM, 1998, P NATL ACAD SCI USA, V95, P6876, DOI 10.1073/pnas.95.12.6876; Glassner BJ, 1998, P NATL ACAD SCI USA, V95, P9997, DOI 10.1073/pnas.95.17.9997; Gorman MA, 1997, EMBO J, V16, P6548, DOI 10.1093/emboj/16.21.6548; Greagg MA, 1999, P NATL ACAD SCI USA, V96, P9045, DOI 10.1073/pnas.96.16.9045; Guzder SN, 1998, J BIOL CHEM, V273, P31541, DOI 10.1074/jbc.273.47.31541; HANAWALT PC, 1994, SCIENCE, V266, P1957, DOI 10.1126/science.7801121; Hang B, 1997, P NATL ACAD SCI USA, V94, P12869, DOI 10.1073/pnas.94.24.12869; Harada YN, 1999, MOL CELL BIOL, V19, P2366, DOI 10.1128/mcb.19.3.2366; Haushalter KA, 1999, CURR BIOL, V9, P174, DOI 10.1016/S0960-9822(99)80087-6; Helbock HJ, 1998, P NATL ACAD SCI USA, V95, P288, DOI 10.1073/pnas.95.1.288; Hendrich B, 1999, NATURE, V401, P301, DOI 10.1038/45843; Hess MT, 1997, P NATL ACAD SCI USA, V94, P6664, DOI 10.1073/pnas.94.13.6664; Hess MT, 1998, J BIOL CHEM, V273, P27867, DOI 10.1074/jbc.273.43.27867; Holmquist GP, 1998, MUTAT RES-FUND MOL M, V400, P59, DOI 10.1016/S0027-5107(98)00051-7; Hoss M, 1999, EMBO J, V18, P3868, DOI 10.1093/emboj/18.13.3868; Houtsmuller AB, 1999, SCIENCE, V284, P958, DOI 10.1126/science.284.5416.958; Hwang BJ, 1998, MOL CELL BIOL, V18, P4391, DOI 10.1128/MCB.18.7.4391; Hwang BJ, 1999, P NATL ACAD SCI USA, V96, P424, DOI 10.1073/pnas.96.2.424; Jansen LET, 1998, J BIOL CHEM, V273, P33111, DOI 10.1074/jbc.273.50.33111; Jiricny J, 1998, EMBO J, V17, P6427, DOI 10.1093/emboj/17.22.6427; Johnson RE, 1999, SCIENCE, V285, P263, DOI 10.1126/science.285.5425.263; Johnson RE, 1999, J BIOL CHEM, V274, P15975, DOI 10.1074/jbc.274.23.15975; Klungland A, 1999, P NATL ACAD SCI USA, V96, P13300, DOI 10.1073/pnas.96.23.13300; Klungland A, 1997, EMBO J, V16, P3341, DOI 10.1093/emboj/16.11.3341; Klungland A, 1999, MOL CELL, V3, P33, DOI 10.1016/S1097-2765(00)80172-0; Koberle B, 1999, CURR BIOL, V9, P273, DOI 10.1016/S0960-9822(99)80118-3; Kohler JJ, 1999, P NATL ACAD SCI USA, V96, P11735, DOI 10.1073/pnas.96.21.11735; Kovalsky OI, 1996, J BIOL CHEM, V271, P33236, DOI 10.1074/jbc.271.52.33236; Krokan HE, 1997, BIOCHEM J, V325, P1; Kubota Y, 1996, EMBO J, V15, P6662, DOI 10.1002/j.1460-2075.1996.tb01056.x; Lau AY, 1998, CELL, V95, P249, DOI 10.1016/S0092-8674(00)81755-9; Lawrence CW, 1996, CANCER SURV, V28, P21; Le Rhun Y, 1998, BIOCHEM BIOPH RES CO, V245, P1; LEHMANN AR, 1975, P NATL ACAD SCI USA, V72, P219, DOI 10.1073/pnas.72.1.219; Lin WS, 1999, NUCLEIC ACIDS RES, V27, P4468, DOI 10.1093/nar/27.22.4468; LINDAHL T, 1993, NATURE, V362, P709, DOI 10.1038/362709a0; LINDAHL T, 1995, TRENDS BIOCHEM SCI, V20, P405, DOI 10.1016/S0968-0004(00)89089-1; Mackey ZB, 1999, J BIOL CHEM, V274, P21679, DOI 10.1074/jbc.274.31.21679; Mao H, 1999, P NATL ACAD SCI USA, V96, P6615, DOI 10.1073/pnas.96.12.6615; Masutani C, 1999, NATURE, V399, P700, DOI 10.1038/21447; Masutani C, 1999, EMBO J, V18, P3491, DOI 10.1093/emboj/18.12.3491; Mazur DJ, 1999, J BIOL CHEM, V274, P19655, DOI 10.1074/jbc.274.28.19655; McDonald JP, 1999, GENOMICS, V60, P20, DOI 10.1006/geno.1999.5906; MCWHIR J, 1993, NAT GENET, V5, P217, DOI 10.1038/ng1193-217; MICHAELS ML, 1992, BIOCHEMISTRY-US, V31, P10964, DOI 10.1021/bi00160a004; MINOWA O, UNPUB; Moggs JG, 1997, NUCLEIC ACIDS RES, V25, P480, DOI 10.1093/nar/25.3.480; Mohrenweiser HW, 1998, MUTAT RES-FUND MOL M, V400, P15, DOI 10.1016/S0027-5107(98)00059-1; MOORE MH, 1994, EMBO J, V13, P1495, DOI 10.1002/j.1460-2075.1994.tb06410.x; Morrison C, 1997, NAT GENET, V17, P479, DOI 10.1038/ng1297-479; Mu D, 1997, MOL CELL BIOL, V17, P760, DOI 10.1128/MCB.17.2.760; NAEGELI H, 1992, J BIOL CHEM, V267, P392; Nakamura J, 1998, CANCER RES, V58, P222; NAKANE H, 1995, NATURE, V377, P165, DOI 10.1038/377165a0; NEDDERMANN P, 1994, P NATL ACAD SCI USA, V91, P1642, DOI 10.1073/pnas.91.5.1642; Nelson JR, 1996, NATURE, V382, P729, DOI 10.1038/382729a0; Nichols AF, 1996, J BIOL CHEM, V271, P24317, DOI 10.1074/jbc.271.40.24317; Nocentini S, 1999, RADIAT RES, V151, P423, DOI 10.2307/3579829; Noll DM, 1999, BIOCHEMISTRY-US, V38, P6374, DOI 10.1021/bi990335x; Nouspikel T, 1997, P NATL ACAD SCI USA, V94, P3116, DOI 10.1073/pnas.94.7.3116; O'Driscoll M., 1998, NUCL ACID M, V12, P173; Osheroff WP, 1999, J BIOL CHEM, V274, P3642, DOI 10.1074/jbc.274.6.3642; Otrin VR, 1997, J CELL SCI, V110, P1159; Otterlei M, 1999, EMBO J, V18, P3834, DOI 10.1093/emboj/18.13.3834; Paques F, 1997, MOL CELL BIOL, V17, P6765, DOI 10.1128/MCB.17.11.6765; Parikh SS, 1997, STRUCTURE, V5, P1543, DOI 10.1016/S0969-2126(97)00303-1; Parikh SS, 1998, EMBO J, V17, P5214, DOI 10.1093/emboj/17.17.5214; Pieper RO, 1998, CONT CANC RES, P33; Rumbaugh JA, 1999, J BIOL CHEM, V274, P14602, DOI 10.1074/jbc.274.21.14602; Sancar A, 1996, ANNU REV BIOCHEM, V65, P43, DOI 10.1146/annurev.bi.65.070196.000355; SANDS AT, 1995, NATURE, V377, P162, DOI 10.1038/377162a0; Saparbaev M, 1998, P NATL ACAD SCI USA, V95, P8508, DOI 10.1073/pnas.95.15.8508; Sargent RG, 1997, P NATL ACAD SCI USA, V94, P13122, DOI 10.1073/pnas.94.24.13122; SCHEUERMANN RH, 1984, P NATL ACAD SCI-BIOL, V81, P7747, DOI 10.1073/pnas.81.24.7747; Sedgwick B, 1997, CARCINOGENESIS, V18, P1561, DOI 10.1093/carcin/18.8.1561; Slupska MM, 1996, J BACTERIOL, V178, P3885, DOI 10.1128/jb.178.13.3885-3892.1996; Sobol RW, 1996, NATURE, V379, P183, DOI 10.1038/379183a0; SPIVAK G, 1992, BIOCHEMISTRY-US, V31, P6794, DOI 10.1021/bi00144a021; STRAUSS BS, 1991, BIOESSAYS, V13, P79, DOI 10.1002/bies.950130206; Sugasawa K, 1998, MOL CELL, V2, P223, DOI 10.1016/S1097-2765(00)80132-X; Svoboda DL, 1998, CANCER RES, V58, P2445; SZYMKOWSKI DE, 1993, J MOL BIOL, V231, P251, DOI 10.1006/jmbi.1993.1280; Tang MJ, 1999, P NATL ACAD SCI USA, V96, P8919, DOI 10.1073/pnas.96.16.8919; Tishkoff DX, 1997, CELL, V88, P253, DOI 10.1016/S0092-8674(00)81846-2; Van Dyck E, 1999, NATURE, V398, P728, DOI 10.1038/43942; vanderKemp PA, 1996, P NATL ACAD SCI USA, V93, P5197, DOI 10.1073/pnas.93.11.5197; VAUGHAN P, 1993, MUTAT RES, V293, P249, DOI 10.1016/0921-8777(93)90076-S; Viswanathan A, 1999, SCIENCE, V284, P159, DOI 10.1126/science.284.5411.159; Wagner J, 1999, MOL CELL, V4, P281, DOI 10.1016/S1097-2765(00)80376-7; Wakasugi M, 1999, J BIOL CHEM, V274, P18759, DOI 10.1074/jbc.274.26.18759; Wallace SS, 1998, RADIAT RES, V150, pS60, DOI 10.2307/3579809; Waters TR, 1998, J BIOL CHEM, V273, P20007, DOI 10.1074/jbc.273.32.20007; Waters TR, 1999, J BIOL CHEM, V274, P67, DOI 10.1074/jbc.274.1.67; Weeda G, 1997, CURR BIOL, V7, P427, DOI 10.1016/S0960-9822(06)00190-4; Wilson DM, 1997, P NATL ACAD SCI USA, V94, P12754, DOI 10.1073/pnas.94.24.12754; Wood RD, 1999, BIOCHIMIE, V81, P39, DOI 10.1016/S0300-9084(99)80036-4; Wood RD, 1997, J BIOL CHEM, V272, P23465, DOI 10.1074/jbc.272.38.23465; Wood RD, 1997, CARCINOGENESIS, V18, P605, DOI 10.1093/carcin/18.4.605; Woodgate R, 1999, GENE DEV, V13, P2191, DOI 10.1101/gad.13.17.2191; Wu XT, 1996, NUCLEIC ACIDS RES, V24, P2036, DOI 10.1093/nar/24.11.2036; Zou Y, 1999, EMBO J, V18, P4889, DOI 10.1093/emboj/18.17.4889	133	1206	1259	3	188	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	DEC 3	1999	286	5446					1897	1905		10.1126/science.286.5446.1897	http://dx.doi.org/10.1126/science.286.5446.1897			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583946				2022-12-28	WOS:000084003400039
J	Hadfield, SJ; Axton, JM				Hadfield, SJ; Axton, JM			Reproduction - Germ cells colonized by endosymbiotic bacteria	NATURE			English	Article							DROSOPHILA; PLASM		Univ Oxford, Dept Zool, Oxford OX1 3PS, England	University of Oxford	Hadfield, SJ (corresponding author), Univ Oxford, Dept Zool, S Parks Rd, Oxford OX1 3PS, England.		Axton, Myles/AAZ-4093-2020	Axton, Myles/0000-0002-8042-4131				BREEUWER JAJ, 1990, NATURE, V346, P558, DOI 10.1038/346558a0; BREEUWER JAJ, 1993, GENETICS, V135, P565; CALLAINI G, 1994, J CELL SCI, V107, P673; GLOVER DM, 1990, NATURE, V348, P117, DOI 10.1038/348117a0; GONZALEZREYES A, 1995, NATURE, V375, P654, DOI 10.1038/375654a0; HOLDEN PR, 1993, MOL GEN GENET, V240, P213, DOI 10.1007/BF00277059; ILLMENSEE K, 1974, P NATL ACAD SCI USA, V71, P1016, DOI 10.1073/pnas.71.4.1016; JONGENS TA, 1992, CELL, V70, P569, DOI 10.1016/0092-8674(92)90427-E; Pereira AJ, 1997, J CELL BIOL, V136, P1081, DOI 10.1083/jcb.136.5.1081; Rongo C, 1996, TRENDS GENET, V12, P102, DOI 10.1016/0168-9525(96)81421-1; Werren JH, 1997, ANNU REV ENTOMOL, V42, P587, DOI 10.1146/annurev.ento.42.1.587	11	39	39	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					482	482		10.1038/45002	http://dx.doi.org/10.1038/45002			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591206				2022-12-28	WOS:000084013200043
J	He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK				He, JA; Ogden, LG; Vupputuri, S; Bazzano, LA; Loria, C; Whelton, PK			Dietary sodium intake and subsequent risk of cardiovascular disease in overweight adults	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NUTRITION EXAMINATION SURVEY; LOWER BLOOD-PRESSURE; NATIONAL-HEALTH; OBSERVATIONAL DATA; SALT INTAKE; WEIGHT-LOSS; MORTALITY; STROKE; HYPERTENSION; POTASSIUM	Context Dietary sodium is positively associated with blood pressure, and ecological and animal studies both have suggested that high dietary sodium intake increases stroke mortality. Objective To examine the risk of cardiovascular disease associated with dietary sodium intake in overweight and nonoverweight persons. Design Prospective cohort study. Setting The first National Health and Nutrition Examination Survey Epidemiologic Follow-up Study, conducted in 1982-1984, 1986, 1987, and 1992. Participants Of those aged 25 to 74 years when the survey was conducted in 1971-1975 (14 407 participants), a total of 2688 overweight and 6797 nonoverweight persons were included in the analysis. Main outcome Measures Dietary sodium and energy intake were estimated at baseline using a single 24-hour dietary recall method. Incidence and mortality data for cardiovascular disease were obtained from medical records and death certificates. Results For overweight and nonoverweight persons, over an average of 19 years of follow-up, the total number of documented cases were as follows: 680 stroke events (210 fatal), 1727 coronary heart disease events (614 fatal), 895 cardiovascular disease deaths, and 2486 deaths from all causes. Among overweight persons with an average energy intake of 7452 kJ, a 100 mmol higher sodium intake was associated with a 32% increase (relative risk [RR], 1.32; 95% confidence interval [CI], 1.07-1.64; P = .01) in stroke incidence, 89% increase (RR, 1.89; 95% CI, 1.31-2.74; P<.001) in stroke mortality, 44% increase (RR, 1.44; 95% CI, 1.14-1.81; P = .002) in coronary heart disease mortality, 61% increase (RR, 1.61; 95% CI, 1.32-1.96; P<.001) in cardiovascular disease mortality, and 39% increase (RR, 1.39; 95% CI, 1.23-1.58; P<.001) in mortality from all causes. Dietary sodium intake was not significantly associated with cardiovascular disease risk in nonoverweight persons. Conclusions Our analysis indicates that high sodium intake is strongly and independently associated with an increased risk of cardiovascular disease and all-cause mortality in overweight persons.	Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, New Orleans, LA 70112 USA; Tulane Univ, Sch Publ Hlth & Trop Med, Dept Biostat, New Orleans, LA 70112 USA; Natl Ctr Hlth Stat, Hyattsville, MD 20782 USA	Tulane University; Tulane University; Centers for Disease Control & Prevention - USA; CDC National Center for Health Statistics (NCHS)	He, JA (corresponding author), Tulane Univ, Sch Publ Hlth & Trop Med, Dept Epidemiol, 1430 Tulane Ave SL 18, New Orleans, LA 70112 USA.	jhe@mailhost.tcs.tulane.edu			NHLBI NIH HHS [R01 HL60300, R03 HL61954] Funding Source: Medline; NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL060300, R03HL061954] Funding Source: NIH RePORTER	NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		ALDERMAN MH, 1995, HYPERTENSION, V25, P1144, DOI 10.1161/01.HYP.25.6.1144; Alderman MH, 1998, LANCET, V351, P781, DOI 10.1016/S0140-6736(97)09092-2; ALTSCHUL AM, 1981, INT J OBESITY, V5, P27; *AM HEART ASS, 1998, 1998 HEART STROK STA; [Anonymous], 1997, ARCH INTERN MED, V157, P2413; Black HR, 1998, ARCH INTERN MED, V158, P573; Briefel RR, 1997, AM J CLIN NUTR, V65, P1203; Chen J, 1997, EXP MOL PATHOL, V64, P173, DOI 10.1006/exmp.1997.2218; COHEN JS, 1987, TRADITION, V22, P1; COOK NR, 1995, ARCH INTERN MED, V155, P701, DOI 10.1001/archinte.155.7.701; COOK NR, 1995, HYPERTENSION, V25, P1153, DOI 10.1161/01.HYP.25.6.1153; Cox C S, 1997, Vital Health Stat 1, P1; COX CS, 1992, VITAL HLTH STAT, V27, P1; COX DR, 1972, J R STAT SOC B, V34, P187; COYLE P, 1988, HYPERTENSION, V12, P96, DOI 10.1161/01.HYP.12.2.96; Cutler JA, 1997, AM J CLIN NUTR, V65, P643, DOI 10.1093/ajcn/65.2.643S; Elliot P, 1997, BMJ-BRIT MED J, V315, P458; Elliott P, 1996, BMJ-BRIT MED J, V312, P1249, DOI 10.1136/bmj.312.7041.1249; Engel A, 1978, Vital Health Stat 1, P1; Finucane F, 1990, VITAL HLTH STAT 1, V25, P1; FREGLY MJ, 1983, ANN INTERN MED, V98, P792, DOI 10.7326/0003-4819-98-5-792; FROST CD, 1991, BRIT MED J, V302, P815, DOI 10.1136/bmj.302.6780.815; Hall JE, 1997, AM J HYPERTENS, V10, pS49, DOI 10.1016/S0895-7061(97)00075-7; HE J, 1994, CIRCULATION, V90, P503; He J, 1997, CURR OPIN CARDIOL, V12, P202, DOI 10.1097/00001573-199703000-00018; IKEDA M, 1986, PREV MED, V15, P46, DOI 10.1016/0091-7435(86)90035-6; KAGAN A, 1985, STROKE, V16, P390, DOI 10.1161/01.STR.16.3.390; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KHAW KT, 1987, NEW ENGL J MED, V316, P235, DOI 10.1056/NEJM198701293160502; KLESGES RC, 1995, J CONSULT CLIN PSYCH, V63, P438; Korn EL, 1997, AM J EPIDEMIOL, V145, P72; Krauss RM, 1996, CIRCULATION, V94, P1795, DOI 10.1161/01.CIR.94.7.1795; KUCZMARSKI RJ, 1994, JAMA-J AM MED ASSOC, V272, P205, DOI 10.1001/jama.272.3.205; LAW MR, 1991, BMJ-BRIT MED J, V302, P811, DOI 10.1136/bmj.302.6780.811; LIU K, 1979, AM J EPIDEMIOL, V110, P219, DOI 10.1093/oxfordjournals.aje.a112806; Luft FC, 1997, AM J CLIN NUTR, V65, P612; MACGREGOR GA, 1997, CAN J CARDIOL SB, V13, pB272; MACHLIN SR, 1989, STAT MED, V8, P997, DOI 10.1002/sim.4780080810; MADANS JH, 1995, STAT MED, V14, P643, DOI 10.1002/sim.4780140521; MCLAUGHLIN JK, 1987, AM J EPIDEMIOL, V126, P144, DOI 10.1093/oxfordjournals.aje.a114647; MILLER HW, 1973, VITAL HLTH STAT 1 A, V10, P1; Najjar M F, 1987, Vital Health Stat 11, P1; PERRY IJ, 1992, J HUM HYPERTENS, V6, P23; ROCCHINI AP, 1989, NEW ENGL J MED, V321, P580, DOI 10.1056/NEJM198908313210905; SASAKI S, 1995, STROKE, V26, P783, DOI 10.1161/01.STR.26.5.783; TARONE RE, 1975, BIOMETRIKA, V62, P679; TOBIAN L, 1990, HYPERTENSION, V15, P900, DOI 10.1161/01.HYP.15.6.900; *TRIALS HYP PREV C, 1992, JAMA-J AM MED ASSOC, V267, P2330; UMES WP, 1987, LANCET, V1, P426; WHELTON PK, 1992, JAMA-J AM MED ASSOC, V267, P1213, DOI 10.1001/jama.1992.03480090061028; Whelton PK, 1998, JAMA-J AM MED ASSOC, V279, P839, DOI 10.1001/jama.279.11.839; *WHO, 1996, WORLD HLTH STAT ANN; YANG J, 1997, CAN J CARDIOL, V13, P448; [No title captured]	54	344	350	0	29	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2027	2034		10.1001/jama.282.21.2027	http://dx.doi.org/10.1001/jama.282.21.2027			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591385	Bronze			2022-12-28	WOS:000083908700022
J	Lehmann, F; Drewe, J; Terracciano, L; Stuber, R; Frei, R; Beglinger, C				Lehmann, F; Drewe, J; Terracciano, L; Stuber, R; Frei, R; Beglinger, C			Comparison of stool immunoassay with standard methods for detecting Helicobacter pylori infection	BRITISH MEDICAL JOURNAL			English	Article									Univ Basel Hosp, Div Gastroenterol, CH-4031 Basel, Switzerland; Univ Basel Hosp, Dept Clin Pharmacol, Basel, Switzerland; Univ Basel Hosp, Cent Lab, Dept Bacteriol, Bacteriol Lab, Basel, Switzerland; Univ Basel Hosp, Dept Pathol, CH-4031 Basel, Switzerland	University of Basel; University of Basel; University of Basel; University of Basel	Beglinger, C (corresponding author), Univ Basel Hosp, Div Gastroenterol, CH-4031 Basel, Switzerland.		Terracciano, Luigi M./AAB-5335-2022; Drewe, Juergen/ABF-8204-2021; Beglinger, Christoph/D-2247-2010	Terracciano, Luigi M./0000-0002-9393-9660; Drewe, Juergen/0000-0001-5178-7825; 				CUTLER AF, 1995, GASTROENTEROLOGY, V109, P136, DOI 10.1016/0016-5085(95)90278-3; MEGRAUD F, 1997, EUR J GASTROENTERO S, V9, P13; SIMEL DL, 1991, J CLIN EPIDEMIOL, V44, P763, DOI 10.1016/0895-4356(91)90128-V; THOMAS JE, 1992, LANCET, V340, P1194, DOI 10.1016/0140-6736(92)92894-L; Vaira D, 1998, GUT, V43, pA47	5	27	27	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1409	1409		10.1136/bmj.319.7222.1409	http://dx.doi.org/10.1136/bmj.319.7222.1409			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574858	Green Published, Bronze			2022-12-28	WOS:000083995200029
J	Moher, D; Cook, DJ; Eastwood, S; Olkin, I; Rennie, D; Stroup, DF				Moher, D; Cook, DJ; Eastwood, S; Olkin, I; Rennie, D; Stroup, DF		QUOROM Grp	Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement	LANCET			English	Review							SYSTEMATIC REVIEWS; HEALTH-CARE; COCHRANE-COLLABORATION; MEDICAL LITERATURE; EMPIRICAL-EVIDENCE; CLINICAL RESEARCH; PUBLICATION BIAS; USERS GUIDES; METAANALYSIS; DECISIONS	Background The Quality of Reporting of Meta-analyses (QUOROM) conference was convened to address standards for improving the quality of reporting of meta-analyses of clinical randomised controlled trials (RCTs). Methods The QUOROM group consisted of 30 clinical epidemiologists, clinicians, statisticians, editors, and researchers. In conference, the group was asked to identify items they thought should be included in a checklist of standards. Whenever possible, checklist items were guided by research evidence suggesting that failure to adhere to the item proposed could lead to biased results. A modified Delphi technique was used in assessing candidate items. Findings The conference resulted in the QUOROM statement, a checklist, and a flow diagram. The checklist describes our preferred way to present the abstract, introduction, methods, results, and discussion sections of a report of a metaanalysis. It is organised into 21 headings and subheadings regarding searches, selection, validity assessment, data abstraction, study characteristics, and quantitative data synthesis, and in the results with "trial flow", study characteristics, and quantitative data synthesis; research documentation was identified for eight of the 18 items. The flow diagram provides information about both the numbers of RCTs identified, included, and excluded and the reasons for exclusion of trials. Interpretation We hope this report will generate further thought about ways to improve the quality of reports of meta-analyses of RCTs and that interested readers, reviewers, researchers, and editors will use the QUOROM statement and generate ideas for its improvement.	Univ Ottawa, Thomas C Chalmers Ctr Systemat Reviews, Ottawa, ON, Canada; McMaster Univ, Hamilton, ON, Canada; Univ Calif San Francisco, San Francisco, CA 94143 USA; Stanford Univ, Stanford, CA 94305 USA; JAMA, Chicago, IL USA; Ctr Dis Control & Prevent, Atlanta, GA USA	University of Ottawa; McMaster University; University of California System; University of California San Francisco; Stanford University; Centers for Disease Control & Prevention - USA	Moher, D (corresponding author), Childrens Hosp Eastern Ontario, Thomas C Chalmers Ctr Systemat Reviews, Res Inst, 401 Smyth Rd, Ottawa, ON K1H 8L1, Canada.	dmoher@uottawa.ca		Moher, David/0000-0003-2434-4206				ANDREW E, 1994, JAMA-J AM MED ASSOC, V272, P1926, DOI 10.1001/jama.1994.03520240054041; Barnes DE, 1998, JAMA-J AM MED ASSOC, V279, P1566, DOI 10.1001/jama.279.19.1566; Begg C, 1996, JAMA-J AM MED ASSOC, V276, P637, DOI 10.1001/jama.276.8.637; Berlin JA, 1997, LANCET, V350, P185, DOI 10.1016/S0140-6736(05)62352-5; BERO L, 1995, JAMA-J AM MED ASSOC, V274, P1935, DOI 10.1001/jama.274.24.1935; CHALMERS I, 1995, SYSTEMATIC REV, P86; *COCHR COLL, 1996, COCHR LIB DAT DISK C; COOK DJ, 1993, JAMA-J AM MED ASSOC, V269, P2749, DOI 10.1001/jama.269.21.2749; COOK DJ, 1995, J CLIN EPIDEMIOL, V48, P167, DOI 10.1016/0895-4356(94)00172-M; Cook DJ, 1997, ANN INTERN MED, V126, P376, DOI 10.7326/0003-4819-126-5-199703010-00006; Davies A, 1998, CLIN THER, V20, P58, DOI 10.1016/S0149-2918(98)80034-9; DEEKS J, 1996, 4 U YORK CRD NHS CTR; DICKERSIN K, 1990, CONTROL CLIN TRIALS, V11, P52, DOI 10.1016/0197-2456(90)90032-W; DICKERSIN K, 1994, BMJ-BRIT MED J, V309, P1286, DOI 10.1136/bmj.309.6964.1286; Dickersin K, 1993, ONLINE J CURR CLIN T, V31, P4967; EASTERBROOK PJ, 1991, LANCET, V337, P867, DOI 10.1016/0140-6736(91)90201-Y; Egger E, 1997, LANCET, V350, P326, DOI 10.1016/S0140-6736(97)02419-7; Fackler ML, 1996, ANN INTERN MED, V124, P741, DOI 10.7326/0003-4819-124-8-199604150-00007; GUYATT GH, 1995, JAMA-J AM MED ASSOC, V274, P1800, DOI 10.1001/jama.274.22.1800; Huston P, 1996, CAN MED ASSOC J, V154, P1389; Jadad AR, 1997, CAN MED ASSOC J, V156, P1411; Jadad AR, 1996, CONTROL CLIN TRIALS, V17, P1, DOI 10.1016/0197-2456(95)00134-4; KENNEDY E, 1999, COCHRANE LIB; Khan KS, 1996, FERTIL STERIL, V65, P939, DOI 10.1016/S0015-0282(16)58265-X; Klassen TP, 1998, ARCH PEDIAT ADOL MED, V152, P700; LABBE KA, 1987, ANN INTERN MED, V107, P224, DOI 10.7326/0003-4819-107-2-224; LeLorier J, 1997, NEW ENGL J MED, V337, P536, DOI 10.1056/NEJM199708213370806; Leucht S, 1999, SCHIZOPHR RES, V35, P51, DOI 10.1016/S0920-9964(98)00105-4; MCAULEY L, 1999, THESIS U OTTAWA; Moher D, 1998, LANCET, V352, P609, DOI 10.1016/S0140-6736(98)01085-X; Moher D, 1996, LANCET, V347, P363, DOI 10.1016/S0140-6736(96)90538-3; Moher D, 1998, 6 COCHR C; MULROW CD, 1987, ANN INTERN MED, V106, P485, DOI 10.7326/0003-4819-106-3-485; MULROW CD, 1994, COCHRANE LIB DATABAS; OLKIN I, 1995, J CLIN EPIDEMIOL, V48, P133, DOI 10.1016/0895-4356(94)00136-E; OLKIN I, 1984, AM J EPIDEMIOL, V140, P287; OXMAN AD, 1994, JAMA-J AM MED ASSOC, V272, P1367, DOI 10.1001/jama.272.17.1367; SACKS HS, 1987, NEW ENGL J MED, V316, P450, DOI 10.1056/NEJM198702193160806; Sacks HS, 1996, MT SINAI J MED, V63, P216; SCHULZ KF, 1995, JAMA-J AM MED ASSOC, V273, P408, DOI 10.1001/jama.273.5.408; SHEA B, IN PRESS SYSTEMATIC; SIMES RJ, 1986, J CLIN ONCOL, V4, P1529, DOI 10.1200/JCO.1986.4.10.1529; Smith ML, 1980, EVALUATION ED INT RE, V4, P22, DOI DOI 10.1016/0191-765X(80)90004-X; STERLING TD, 1995, AM STAT, V49, P108, DOI 10.2307/2684823; TADDIO A, 1994, CAN MED ASSOC J, V150, P1611; THOMPSON SG, 1994, BMJ-BRIT MED J, V309, P1351, DOI 10.1136/bmj.309.6965.1351; Tramer MR, 1997, BMJ-BRIT MED J, V315, P635, DOI 10.1136/bmj.315.7109.635; Vickers A, 1998, CONTROL CLIN TRIALS, V19, P159, DOI 10.1016/S0197-2456(97)00150-5; Whitman N I, 1990, J Nurs Educ, V29, P377	49	3606	3719	4	173	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1896	1900		10.1016/S0140-6736(99)04149-5	http://dx.doi.org/10.1016/S0140-6736(99)04149-5			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584742				2022-12-28	WOS:000083909100044
J	Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM				Jog, MS; Kubota, Y; Connolly, CI; Hillegaart, V; Graybiel, AM			Building neural representations of habits	SCIENCE			English	Article							OBSESSIVE-COMPULSIVE DISORDER; BASAL GANGLIA; CAUDATE-NUCLEUS; DORSOLATERAL STRIATUM; TRIPLE DISSOCIATION; FUNCTIONAL-ANATOMY; SYSTEMATIC CHANGES; ACTION REPERTOIRES; NEURONAL-ACTIVITY; CORTEX	Memories for habits and skills ("implicit or procedural memory") and memories for facts ("explicit or episodic memory") are built up in different brain systems and are vulnerable to different neurodegenerative disorders in humans. So that the striatum-based mechanisms underlying habit formation could be studied, chronic recordings from ensembles of striatal neurons were made with multiple tetrodes as rats learned a T-maze procedural task. Large and widely distributed changes in the neuronal activity patterns occurred in the sensorimotor striatum during behavioral acquisition, culminating in task-related activity emphasizing the beginning and end of the automatized procedure. The new ensemble patterns remained stable during weeks of subsequent performance of the same task. These results suggest that the encoding of action in the sensorimotor striatum undergoes dynamic reorganization as habit learning proceeds.	MIT, Dept Brain & Cognit Sci, Cambridge, MA 02139 USA; London Hlth Sci Ctr, London, ON N6A 5A5, Canada; SRI Int, Menlo Park, CA 94025 USA; Karolinska Inst, Dept Physiol & Pharmacol, S-17177 Stockholm, Sweden	Massachusetts Institute of Technology (MIT); London Health Sciences Centre; SRI International; Karolinska Institutet	Graybiel, AM (corresponding author), MIT, Dept Brain & Cognit Sci, E25-618, Cambridge, MA 02139 USA.			Graybiel, Ann/0000-0002-4326-7720	NIMH NIH HHS [R03 MH57878] Funding Source: Medline; NATIONAL INSTITUTE OF MENTAL HEALTH [R03MH057878] Funding Source: NIH RePORTER	NIMH NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH)); NATIONAL INSTITUTE OF MENTAL HEALTH(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH))		ALBIN RL, 1989, TRENDS NEUROSCI, V12, P366, DOI 10.1016/0166-2236(89)90074-X; AOSAKI T, 1994, J NEUROSCI, V14, P3969; Apicella P, 1998, J NEUROPHYSIOL, V80, P3341, DOI 10.1152/jn.1998.80.6.3341; BENECKE R, 1987, BRAIN, V110, P361, DOI 10.1093/brain/110.2.361; Buonomano DV, 1998, ANNU REV NEUROSCI, V21, P149, DOI 10.1146/annurev.neuro.21.1.149; Carelli RM, 1997, J NEUROSCI, V17, P1804; CARELLI RM, 1991, J COMP NEUROL, V309, P231, DOI 10.1002/cne.903090205; Deadwyler SA, 1997, ANNU REV NEUROSCI, V20, P217, DOI 10.1146/annurev.neuro.20.1.217; DELONG MR, 1990, TRENDS NEUROSCI, V13, P281, DOI 10.1016/0166-2236(90)90110-V; Denny-Brown D, 1976, Res Publ Assoc Res Nerv Ment Dis, V55, P115; Donoghue JP, 1995, CURR OPIN NEUROBIOL, V5, P749, DOI 10.1016/0959-4388(95)80102-2; EICHENBAUM H, 1998, NEURONAL ENSEMBLES S; Gerloff C, 1998, BRAIN, V121, P1513, DOI 10.1093/brain/121.8.1513; Gray CM, 1995, J NEUROSCI METH, V63, P43, DOI 10.1016/0165-0270(95)00085-2; GRAYBIEL AM, 1994, SCIENCE, V265, P1826, DOI 10.1126/science.8091209; Graybiel AM, 1998, NEUROBIOL LEARN MEM, V70, P119, DOI 10.1006/nlme.1998.3843; Graybiel AM, 1995, CURR OPIN NEUROBIOL, V5, P733, DOI 10.1016/0959-4388(95)80100-6; Hanes DP, 1996, SCIENCE, V274, P427, DOI 10.1126/science.274.5286.427; HIKOSAKA O, 1989, J NEUROPHYSIOL, V61, P814, DOI 10.1152/jn.1989.61.4.814; HIRSH R, 1974, BEHAV BIOL, V12, P421, DOI 10.1016/S0091-6773(74)92231-7; James W., 1890, PRINCIPLES PSYCHOL, P449, DOI [https://doi.org/10.1037/11059-009, DOI 10.1037/11059-009]; Karni A, 1998, P NATL ACAD SCI USA, V95, P861, DOI 10.1073/pnas.95.3.861; Kawagoe R, 1998, NAT NEUROSCI, V1, P411, DOI 10.1038/1625; KESNER RP, 1993, EXP BRAIN RES, V93, P462; Knowlton BJ, 1996, SCIENCE, V273, P1399, DOI 10.1126/science.273.5280.1399; Koob GF, 1998, NEURON, V21, P467, DOI 10.1016/S0896-6273(00)80557-7; Kubota Y., 1999, Society for Neuroscience Abstracts, V25, P1384; Kubota Y., UNPUB; MCDONALD RJ, 1993, BEHAV NEUROSCI, V107, P3, DOI 10.1037/0735-7044.107.1.3; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; Mishkin M., 1984, NEUROBIOL LEARN MEM, P65, DOI DOI 10.1523/JNEUROSCI.0840-16.2016; Miyachi S, 1997, EXP BRAIN RES, V115, P1, DOI 10.1007/PL00005669; Nakamura K, 1998, J NEUROPHYSIOL, V80, P2671, DOI 10.1152/jn.1998.80.5.2671; Packard MG, 1996, NEUROBIOL LEARN MEM, V65, P65, DOI 10.1006/nlme.1996.0007; Petersen SE, 1998, P NATL ACAD SCI USA, V95, P853, DOI 10.1073/pnas.95.3.853; Picard N, 1997, J NEUROPHYSIOL, V77, P2197, DOI 10.1152/jn.1997.77.4.2197; RIDLEY RM, 1994, PROG NEUROBIOL, V44, P221, DOI 10.1016/0301-0082(94)90039-6; ROBBINS TW, 1992, SEMIN NEUROSCI, V4, P119; ROLLS ET, 1983, BEHAV BRAIN RES, V7, P179, DOI 10.1016/0166-4328(83)90191-2; Sakai K, 1998, J NEUROSCI, V18, P1827; SALMON DP, 1995, CURR OPIN NEUROBIOL, V5, P184, DOI 10.1016/0959-4388(95)80025-5; Schultz W, 1997, SCIENCE, V275, P1593, DOI 10.1126/science.275.5306.1593; SCHWAB RS, 1954, AMA ARCH NEUROL PSY, V72, P591, DOI 10.1001/archneurpsyc.1954.02330050061010; Schwartz JM, 1996, ARCH GEN PSYCHIAT, V53, P109; Shadmehr R, 1997, SCIENCE, V277, P821, DOI 10.1126/science.277.5327.821; SWEDO SE, 1992, ARCH GEN PSYCHIAT, V49, P690; Toni I, 1998, NEUROIMAGE, V8, P50, DOI 10.1006/nimg.1998.0349; Tremblay L, 1998, J NEUROPHYSIOL, V80, P964, DOI 10.1152/jn.1998.80.2.964; WEST MO, 1990, J NEUROPHYSIOL, V64, P1233, DOI 10.1152/jn.1990.64.4.1233; White NM, 1997, CURR OPIN NEUROBIOL, V7, P164, DOI 10.1016/S0959-4388(97)80004-9; Wilson C.J., 1998, SYNAPTIC ORG BRAIN, P329; WILSON MA, 1993, SCIENCE, V261, P10552; Wise SP, 1998, EXP BRAIN RES, V121, P285, DOI 10.1007/s002210050462; [No title captured]	54	601	612	3	55	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1745	1749		10.1126/science.286.5445.1745	http://dx.doi.org/10.1126/science.286.5445.1745			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576743				2022-12-28	WOS:000083912200041
J	Stock, D; Leslie, AGW; Walker, JE				Stock, D; Leslie, AGW; Walker, JE			Molecular architecture of the rotary motor in ATP synthase	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; BOVINE HEART-MITOCHONDRIA; C-SUBUNIT OLIGOMER; EPSILON-SUBUNIT; GAMMA-SUBUNIT; ENERGY TRANSDUCTION; CRYSTAL-STRUCTURE; MEMBRANE DOMAIN; CROSS-LINKING; F1F0 ATPASE	Adenosine triphosphate (ATP) synthase contains a rotary motor involved in biological energy conversion. Its membrane-embedded F-0 sector has a rotation generator fueled by the proton-motive force, which provides the energy required for the synthesis of ATP by the F-1 domain. An electron density map obtained from crystals of a subcomplex of yeast mitochondrial ATP synthase shows a ring of 10 c subunits. Each c subunit forms an alpha-helical hairpin. The interhelical loops of six to seven of the c subunits are in close contact with the gamma and delta subunits of the central stalk. The extensive contact between the c ring and the stalk suggests that they may rotate as an ensemble during catalysis.	MRC, Dunn Nutr Unit, Cambridge CB2 2XY, England; MRC, Mol Biol Lab, Cambridge CB2 2QH, England	MRC Laboratory Molecular Biology	Walker, JE (corresponding author), MRC, Dunn Nutr Unit, Hills Rd, Cambridge CB2 2XY, England.	walker@mrc-dunn.cam.ac.uk		Walker, John/0000-0001-7929-2162				ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; Abrahams JP, 1996, ACTA CRYSTALLOGR D, V52, P30, DOI 10.1107/S0907444995008754; Abrahams JP, 1996, P NATL ACAD SCI USA, V93, P9420, DOI 10.1073/pnas.93.18.9420; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; Arnold I, 1998, EMBO J, V17, P7170, DOI 10.1093/emboj/17.24.7170; Arselin G, 1996, J BIOL CHEM, V271, P20284, DOI 10.1074/jbc.271.34.20284; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bateson M, 1999, J BIOL CHEM, V274, P7462, DOI 10.1074/jbc.274.11.7462; Bateson M, 1996, ANAL BIOCHEM, V238, P14, DOI 10.1006/abio.1996.0242; Berry S, 1996, BBA-BIOENERGETICS, V1276, P51, DOI 10.1016/0005-2728(96)00031-X; Beuron F, 1998, J STRUCT BIOL, V123, P248, DOI 10.1006/jsbi.1998.4039; Bianchet MA, 1998, P NATL ACAD SCI USA, V95, P11065, DOI 10.1073/pnas.95.19.11065; Bottcher B, 1998, J MOL BIOL, V281, P757, DOI 10.1006/jmbi.1998.1957; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; BOYER PD, 1993, BIOCHIM BIOPHYS ACTA, V1140, P215, DOI 10.1016/0005-2728(93)90063-L; CHAYEN NE, 1992, J CRYST GROWTH, V122, P176, DOI 10.1016/0022-0248(92)90241-A; Cherepanov DA, 1999, FEBS LETT, V449, P1, DOI 10.1016/S0014-5793(99)00386-5; COLLINSON IR, 1994, J MOL BIOL, V242, P408; COX GB, 1993, J MOL BIOL, V229, P1159, DOI 10.1006/jmbi.1993.1113; DEVENISH RJ, 1992, ANN NY ACAD SCI, V671, P403, DOI 10.1111/j.1749-6632.1992.tb43814.x; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Engelbrecht S, 1997, FEBS LETT, V414, P485, DOI 10.1016/S0014-5793(97)00997-6; FILLINGAME RH, 1992, BIOCHIM BIOPHYS ACTA, V1101, P240, DOI 10.1016/0005-2728(92)90235-T; Fillingame RH, 1998, BBA-BIOENERGETICS, V1365, P135, DOI 10.1016/S0005-2728(98)00053-X; FILLINGAME RH, 1990, BACTERIA TREATISE ST, V12, P345; FOSTER DL, 1982, J BIOL CHEM, V257, P2009; Girvin ME, 1998, BIOCHEMISTRY-US, V37, P8817, DOI 10.1021/bi980511m; Groth G, 1997, FEBS LETT, V410, P117, DOI 10.1016/S0014-5793(97)00529-2; Groth G, 1998, J MOL BIOL, V281, P49, DOI 10.1006/jmbi.1998.1936; HENDRIX RW, 1978, P NATL ACAD SCI USA, V75, P4779, DOI 10.1073/pnas.75.10.4779; Hendrix RW, 1998, CELL, V94, P147, DOI 10.1016/S0092-8674(00)81413-0; Hermolin J, 1999, J BIOL CHEM, V274, P17011, DOI 10.1074/jbc.274.24.17011; Jiang WP, 1998, P NATL ACAD SCI USA, V95, P6607, DOI 10.1073/pnas.95.12.6607; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kaim G, 1998, EMBO J, V17, P688, DOI 10.1093/emboj/17.3.688; Karrasch S, 1999, J MOL BIOL, V290, P379, DOI 10.1006/jmbi.1999.2897; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Law RHP, 1995, METHOD ENZYMOL, V260, P133, DOI 10.1016/0076-6879(95)60135-X; Leslie AGW, 1992, JOINT CCP4 ESF EACMB; Matthey U, 1999, EUR J BIOCHEM, V261, P459, DOI 10.1046/j.1432-1327.1999.00288.x; MICHEL H, 1983, TRENDS BIOCHEM SCI, V8, P56, DOI 10.1016/0968-0004(83)90390-0; NAVAZA J, 1994, ACTA CRYSTALLOGR A, V50, P157, DOI 10.1107/S0108767393007597; Nicholls D.G., 1992, BIOENERGETICS, V2, P22; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Orriss GL, 1998, STRUCT FOLD DES, V6, P831, DOI 10.1016/S0969-2126(98)00085-9; Orriss GL, 1996, BIOCHEM J, V314, P695, DOI 10.1042/bj3140695; Panke O, 1999, BBA-BIOENERGETICS, V1412, P118, DOI 10.1016/S0005-2728(99)00059-6; Prescott M, 1997, FEBS LETT, V411, P97, DOI 10.1016/S0014-5793(97)00670-4; Ruppert C, 1999, J BIOL CHEM, V274, P25281, DOI 10.1074/jbc.274.36.25281; Sawada K, 1997, ARCH BIOCHEM BIOPHYS, V348, P183, DOI 10.1006/abbi.1997.0397; Schemidt RA, 1998, J BACTERIOL, V180, P3205, DOI 10.1128/JB.180.12.3205-3208.1998; SCHEMIDT RA, 1995, ARCH BIOCHEM BIOPHYS, V323, P423, DOI 10.1006/abbi.1995.0063; SENIOR AE, 1990, ANNU REV BIOPHYS BIO, V19, P7; Shirakihara Y, 1997, STRUCTURE, V5, P825, DOI 10.1016/S0969-2126(97)00236-0; Singh S, 1996, FEBS LETT, V397, P30, DOI 10.1016/S0014-5793(96)01127-1; Spannagel C, 1997, EUR J BIOCHEM, V247, P1111, DOI 10.1111/j.1432-1033.1997.01111.x; Takeyasu K, 1996, FEBS LETT, V392, P110, DOI 10.1016/0014-5793(96)00796-X; Thomas DR, 1999, P NATL ACAD SCI USA, V96, P10134, DOI 10.1073/pnas.96.18.10134; TURK D, 1992, THESIS TU MUNCHEN MU; Uhlin U, 1997, STRUCTURE, V5, P1219, DOI 10.1016/S0969-2126(97)00272-4; Valiyaveetil FI, 1997, J BIOL CHEM, V272, P32635, DOI 10.1074/jbc.272.51.32635; Valpuesta JM, 1999, STRUCTURE, V7, P289, DOI 10.1016/S0969-2126(99)80039-2; vanRaaij MJ, 1996, P NATL ACAD SCI USA, V93, P6913, DOI 10.1073/pnas.93.14.6913; Vik SB, 1998, J BIOL CHEM, V273, P16229, DOI 10.1074/jbc.273.26.16229; Walker JE, 1998, ANGEW CHEM INT EDIT, V37, P2309, DOI 10.1002/(SICI)1521-3773(19980918)37:17<2308::AID-ANIE2308>3.0.CO;2-W; WATTS SD, 1995, FEBS LETT, V368, P235, DOI 10.1016/0014-5793(95)00658-V; Watts SD, 1996, J BIOL CHEM, V271, P28341, DOI 10.1074/jbc.271.45.28341; WETZEL CM, 1993, PLANT PHYSIOL, V102, P241, DOI 10.1104/pp.102.1.241; Wilkens S, 1998, NATURE, V393, P29, DOI 10.1038/29908	72	1042	1075	7	149	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1700	1705		10.1126/science.286.5445.1700	http://dx.doi.org/10.1126/science.286.5445.1700			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576729				2022-12-28	WOS:000083912200027
J	Mayeux, R; Sano, M				Mayeux, R; Sano, M			Drug therapy - Treatment of Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							PLACEBO-CONTROLLED TRIAL; ACETYL-L-CARNITINE; ESTROGEN-REPLACEMENT THERAPY; RANDOMIZED CONTROLLED TRIAL; NURSING-HOME PLACEMENT; DOUBLE-BLIND; ORAL PHYSOSTIGMINE; GINKGO-BILOBA; COMMUNITY POPULATION; COGNITIVE FUNCTION		Columbia Univ, Sch Publ Hlth, Div Epidemiol, New York, NY 10032 USA; Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, Gertrude H Sergievsky Ctr, Dept Neurol, New York, NY USA; Coll Phys & Surg, Taub Inst Alzheimers Dis & Aging Brain, Gertrude H Sergievsky Ctr, Dept Psychiat, New York, NY USA	Columbia University	Mayeux, R (corresponding author), Columbia Univ, Sch Publ Hlth, Div Epidemiol, 630 W 168th St, New York, NY 10032 USA.	rpm2@columbia.edu	Mayeux, Richard/E-9788-2013	Mayeux, Richard/0000-0001-6519-9696	NIA NIH HHS [AG07232, AG08702, AG10963] Funding Source: Medline; NATIONAL INSTITUTE ON AGING [P50AG008702, R35AG010963, P01AG007232] Funding Source: NIH RePORTER	NIA NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA)); NATIONAL INSTITUTE ON AGING(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA))		ALZHEIMERS ASS, 1999, ACTION SERIES; Auchus AP, 1997, J NEUROPSYCH CLIN N, V9, P591; Baldereschi M, 1998, NEUROLOGY, V50, P996, DOI 10.1212/WNL.50.4.996; BARNES R, 1982, AM J PSYCHIAT, V139, P1170; Becker RE, 1996, ALZ DIS ASSOC DIS, V10, P124, DOI 10.1097/00002093-199601030-00003; Behl C, 1997, J NEURAL TRANSM-SUPP, P125; Bodick NC, 1997, ARCH NEUROL-CHICAGO, V54, P465, DOI 10.1001/archneur.1997.00550160091022; BUCHNER DM, 1987, JAMA-J AM MED ASSOC, V257, P1492, DOI 10.1001/jama.257.11.1492; Burns A, 1999, DEMENT GERIATR COGN, V10, P237, DOI 10.1159/000017126; Cohen-Mansfield J, 1990, J AGING HEALTH, V2, P42, DOI DOI 10.1177/089826439000200104; Conway EL, 1998, CLIN NEUROPHARMACOL, V21, P8; Corey-Bloom J, 1998, J GERIATR PSYCHOPHAR, V1, P55; Cummings JL, 1998, NEUROLOGY, V50, P1214, DOI 10.1212/WNL.50.5.1214; CUMMINGS JL, 1998, NEUROLOGY, V51, P332; Devanand D P, 1992, Int Psychogeriatr, V4 Suppl 2, P161; Devanand DP, 1998, AM J PSYCHIAT, V155, P1512, DOI 10.1176/ajp.155.11.1512; Devanand DP, 1996, ARCH GEN PSYCHIAT, V53, P175; Devanand DP, 1997, ARCH GEN PSYCHIAT, V54, P257; ETIENNE P, 1981, NEUROLOGY, V31, P1552, DOI 10.1212/WNL.31.12.1552; EVANS DA, 1989, JAMA-J AM MED ASSOC, V262, P2551, DOI 10.1001/jama.262.18.2551; FINKEL SI, 1995, INT J GERIATR PSYCH, V10, P129, DOI 10.1002/gps.930100208; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Francis PT, 1999, J NEUROL NEUROSUR PS, V66, P137, DOI 10.1136/jnnp.66.2.137; Frenchman I B, 1997, Int Psychogeriatr, V9, P431; Geldmacher David S., 1997, Comprehensive Therapy, V23, P492; Gracon SI, 1998, ALZ DIS ASSOC DIS, V12, P93, DOI 10.1097/00002093-199806000-00007; GRAY JA, 1989, TRENDS PHARMACOL SCI, P85; GREENWALD BS, 1989, AM J PSYCHIAT, V146, P1472; Grome JJ, 1996, BRAIN RES, V740, P41, DOI 10.1016/S0006-8993(96)00353-8; HALLIWELL B, 1985, TRENDS NEUROSCI, V8, P22, DOI 10.1016/0166-2236(85)90010-4; HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56; HARBAUGH RE, 1989, J NEUROSURG, V71, P481, DOI 10.3171/jns.1989.71.4.0481; HARBAUGH RE, 1984, NEUROSURGERY, V15, P514, DOI 10.1227/00006123-198410000-00007; HEBERT LE, 1995, JAMA-J AM MED ASSOC, V273, P1354, DOI 10.1001/jama.273.17.1354; Herrmann N, 1998, CAN J PSYCHIAT, V43, P69, DOI 10.1177/070674379804300108; HEYMAN A, 1987, J NEURAL TRANSM, P279; Hinz V, 1996, NEUROCHEM RES, V21, P339, DOI 10.1007/BF02531650; Hinz VC, 1996, NEUROCHEM RES, V21, P331, DOI 10.1007/BF02531649; Imbimbo BP, 1999, NEUROLOGY, V52, P700, DOI 10.1212/WNL.52.4.700; Imbimbo BP, 1999, DEMENT GERIATR COGN, V10, P139, DOI 10.1159/000017114; Imbimbo BP, 1998, ALZ DIS ASSOC DIS, V12, P313, DOI 10.1097/00002093-199812000-00011; Kanowski S, 1996, PHARMACOPSYCHIATRY, V29, P47, DOI 10.1055/s-2007-979544; Katona CLE, 1998, INT J GERIATR PSYCH, V13, P100; Katz IR, 1999, J CLIN PSYCHIAT, V60, P107, DOI 10.4088/JCP.v60n0207; Kawas C, 1997, NEUROLOGY, V48, P1517, DOI 10.1212/WNL.48.6.1517; Kittner B, 1997, ANN NY ACAD SCI, V826, P307, DOI 10.1111/j.1749-6632.1997.tb48481.x; KNAPP MJ, 1994, JAMA-J AM MED ASSOC, V271, P985, DOI 10.1001/jama.271.13.985; Knopman D, 1996, NEUROLOGY, V47, P166, DOI 10.1212/WNL.47.1.166; KNOPMAN DS, 1994, NEUROLOGY, V44, P2315, DOI 10.1212/WNL.44.12.2315; Lasser RA, 1998, J AM GERIATR SOC, V46, P202, DOI 10.1111/j.1532-5415.1998.tb02540.x; Lavretsky H, 1998, AM J GERIAT PSYCHIAT, V6, P127; LeBars PL, 1997, JAMA-J AM MED ASSOC, V278, P1327, DOI 10.1001/jama.278.16.1327; LEBER P, 1990, FDA PUBLICATION; Lendon CL, 1997, JAMA-J AM MED ASSOC, V277, P825, DOI 10.1001/jama.277.10.825; LEVY A, 1994, ALZ DIS ASSOC DIS, V8, P15, DOI 10.1097/00002093-199408010-00004; Logsdon RG, 1998, J GERONTOL B-PSYCHOL, V53, pP294, DOI 10.1093/geronb/53B.5.P294; Marcusson J, 1997, DEMENT GERIATR COGN, V8, P320, DOI 10.1159/000106650; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; MESKINI N, 1994, BIOCHEM PHARMACOL, V47, P781, DOI 10.1016/0006-2952(94)90477-4; MITTELMAN MS, 1993, GERONTOLOGIST, V33, P730, DOI 10.1093/geront/33.6.730; Mittelman MS, 1996, JAMA-J AM MED ASSOC, V276, P1725, DOI 10.1001/jama.276.21.1725; Morris JC, 1998, NEUROLOGY, V50, P1222, DOI 10.1212/WNL.50.5.1222; NAMAZI KH, 1989, GERONTOLOGIST, V29, P699; NOCHI S, 1995, BIOL PHARM BULL, V18, P1145; NORBERG A, 1999, DRUG SAFETY, V20, P146; NORBERG A, 1998, DRUG SAFETY, V19, P465; NYTH AL, 1990, BRIT J PSYCHIAT, V157, P894, DOI 10.1192/bjp.157.6.894; Ohara T, 1997, BRAIN RES BULL, V43, P39, DOI 10.1016/S0361-9230(96)00349-8; Oken BS, 1998, ARCH NEUROL-CHICAGO, V55, P1409, DOI 10.1001/archneur.55.11.1409; Overall J E, 1992, J Geriatr Psychiatry Neurol, V5, P220; Petracca G, 1996, J NEUROPSYCH CLIN N, V8, P270; PETRIE WM, 1982, J CLIN PSYCHOPHARM, V2, P122; Price DL, 1998, ANNU REV NEUROSCI, V21, P479, DOI 10.1146/annurev.neuro.21.1.479; PRICE DL, 1998, NEUROPATHOLOGY DEMEN, P121; Raskind MA, 1997, ARCH NEUROL-CHICAGO, V54, P836, DOI 10.1001/archneur.1997.00550190026010; REIFLER BV, 1989, AM J PSYCHIAT, V146, P45; Reisberg B, 1997, ALZ DIS ASSOC DIS, V11, P8; RELMAN AS, 1991, NEW ENGL J MED, V324, P349, DOI 10.1056/NEJM199101313240525; Rogers SL, 1998, NEUROLOGY, V50, P136, DOI 10.1212/WNL.50.1.136; Rogers SL, 1996, DEMENTIA, V7, P293, DOI 10.1159/000106895; Rogers SL, 1998, EUR NEUROPSYCHOPHARM, V8, P67, DOI 10.1016/S0924-977X(97)00079-5; ROSEN WG, 1984, AM J PSYCHIAT, V141, P1356; Rosler M, 1999, BMJ-BRIT MED J, V318, P633, DOI 10.1136/bmj.318.7184.633; Roth M., 1996, British Journal of Psychiatry, V168, P149, DOI 10.1192/bjp.168.2.149; ROVNER BW, 1989, AM J PSYCHIAT, V146, P350; Sano M, 1997, NEW ENGL J MED, V336, P1216, DOI 10.1056/NEJM199704243361704; SANO M, 1992, ARCH NEUROL-CHICAGO, V49, P1137, DOI 10.1001/archneur.1992.00530350051019; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; SCHNEIDER LS, 1990, J AM GERIATR SOC, V38, P553, DOI 10.1111/j.1532-5415.1990.tb02407.x; Schneider LS, 1997, ALZ DIS ASSOC DIS, V11, pS22; SENIN U, 1992, ARCH GERONTOL GERIAT, V15, P249, DOI 10.1016/0167-4943(92)90060-H; SPAGNOLI A, 1991, NEUROLOGY, V41, P1726, DOI 10.1212/WNL.41.11.1726; Sramek JJ, 1996, LIFE SCI, V58, P1201, DOI 10.1016/0024-3205(96)00081-1; STERN RG, 1994, AM J PSYCHIAT, V151, P390; STERN Y, 1988, NEUROLOGY, V38, P1837, DOI 10.1212/WNL.38.12.1837; STERN Y, 1987, ANN NEUROL, V22, P306, DOI 10.1002/ana.410220305; Stewart WF, 1997, NEUROLOGY, V48, P626, DOI 10.1212/WNL.48.3.626; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Taragano FE, 1997, PSYCHOSOMATICS, V38, P246, DOI 10.1016/S0033-3182(97)71461-0; Tariot P, 1997, New Dir Ment Health Serv, P109; Tariot PN, 1998, AM J PSYCHIAT, V155, P54, DOI 10.1176/ajp.155.1.54; THAL LJ, 1981, NEUROBIOL AGING, V2, P205, DOI 10.1016/0197-4580(81)90022-1; Thal LJ, 1999, NEUROLOGY, V52, P1146, DOI 10.1212/WNL.52.6.1146; Thal LJ, 1996, NEUROLOGY, V47, P705, DOI 10.1212/WNL.47.3.705; Thal LJ, 1996, NEUROLOGY, V47, P1389, DOI 10.1212/WNL.47.6.1389; THAL LJ, 1989, J AM GERIATR SOC, V37, P42, DOI 10.1111/j.1532-5415.1989.tb01567.x; Tsai SJ, 1996, ALZ DIS ASSOC DIS, V10, P82, DOI 10.1097/00002093-199601020-00005; Virmani MA, 1995, PHARMACOL RES, V32, P383, DOI 10.1016/S1043-6618(05)80044-1; VITIELLO MV, 1992, NEUROLOGY, V42, P83; Weyer G, 1997, NEUROPSYCHOBIOLOGY, V36, P73, DOI 10.1159/000119366; Winkler J, 1998, J MOL MED-JMM, V76, P555, DOI 10.1007/s001090050250; YOSHIDA S, 1985, J NEUROCHEM, V44, P1593, DOI 10.1111/j.1471-4159.1985.tb08800.x; Zayas EM, 1996, J CLIN PSYCHIAT, V57, P46	113	249	272	0	27	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1670	1679		10.1056/NEJM199911253412207	http://dx.doi.org/10.1056/NEJM199911253412207			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258PL	10572156				2022-12-28	WOS:000083847500007
J	Kendall, MJ				Kendall, MJ			Conventional versus newer antihypertensive therapies - a draw	LANCET			English	Editorial Material							ACUTE MYOCARDIAL-INFARCTION; HYPERTENSION; MORBIDITY; TRIAL		Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Kendall, MJ (corresponding author), Queen Elizabeth Hosp, Div Med Sci, Birmingham B15 2TH, W Midlands, England.							[Anonymous], 1991, JAMA, V265, P3255; Cleland JGF, 1997, EUR HEART J, V18, P41; DAHLOF B, 1991, LANCET, V338, P1281, DOI 10.1016/0140-6736(91)92589-T; Hennekens CH, 1996, NEW ENGL J MED, V335, P1660, DOI 10.1056/NEJM199611283352207; KOBER L, 1995, NEW ENGL J MED, V333, P1670, DOI 10.1056/NEJM199512213332503; MEADE TW, 1992, BMJ-BRIT MED J, V304, P405; Soumeral SB, 1997, JAMA-J AM MED ASSOC, V277, P115, DOI 10.1001/jama.277.2.115; Staessen JA, 1997, LANCET, V350, P757, DOI 10.1016/S0140-6736(97)05381-6	8	7	7	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 20	1999	354	9192					1744	1745		10.1016/S0140-6736(99)90397-5	http://dx.doi.org/10.1016/S0140-6736(99)90397-5			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577629				2022-12-28	WOS:000083853000002
J	Cotter, D; Manning, RJ; Blow, KJ; Ellis, AD; Kelly, AE; Nesset, D; Phillips, ID; Poustie, AJ; Rogers, DC				Cotter, D; Manning, RJ; Blow, KJ; Ellis, AD; Kelly, AE; Nesset, D; Phillips, ID; Poustie, AJ; Rogers, DC			Nonlinear optics for high-speed digital information processing	SCIENCE			English	Review							SEMICONDUCTOR-LASER AMPLIFIER; MACH-ZEHNDER INTERFEROMETER; LOOP MIRROR; WAVELENGTH CONVERSION; TRANSMISSION EXPERIMENT; ASYMMETRIC DEMULTIPLEXER; SAGNAC INTERFEROMETER; REGENERATOR; DISPERSION; OPERATION	Recent advances in developing nonlinear optical techniques for processing serial digital information at high speed are reviewed. The field has been transformed by the advent of semiconductor nonlinear devices capable of operation at 100 gigabits per second and higher, well beyond the current speed limits of commercial electronics. These devices are expected to become important in future high-capacity communications networks by allowing digital regeneration and other processing functions to be performed on data signals "on the fly" in the optical domain.	BT Adv Commun Technol Ctr, Ipswich IP5 3RE, Suffolk, England; Aston Univ, Birmingham B4 7ET, W Midlands, England	Aston University	Cotter, D (corresponding author), BT Adv Commun Technol Ctr, Adastral Pk,Martlesham Heath, Ipswich IP5 3RE, Suffolk, England.		Ellis, Andrew D/C-9253-2011	Ellis, Andrew D/0000-0002-0417-0547; Phillips, Ian D/0000-0002-2776-8939				ADAMS MJ, 1995, OPT QUANT ELECTRON, V27, P1, DOI 10.1007/BF00431029; Agrawal G.P., 2006, NONLINEAR FIBER OPTI, V4th; Ahn KH, 1999, IEEE PHOTONIC TECH L, V11, P140, DOI 10.1109/68.736422; BILLES L, 1997, IEE C PUBL, V448, P269; Bloembergen N., 1996, NONLINEAR OPTICS; BLOW KJ, 1990, ELECTRON LETT, V26, P962, DOI 10.1049/el:19900626; BLUMENTHAL DJ, 1994, P IEEE, V82, P1650, DOI 10.1109/5.333744; Butcher P. N., 1990, ELEMENTS NONLINEAR O; Carena A, 1998, J LIGHTWAVE TECHNOL, V16, P2135, DOI 10.1109/50.736581; Chan VWS, 1998, J LIGHTWAVE TECHNOL, V16, P2146, DOI 10.1109/50.736582; Chraplyvy AR, 1996, IEEE PHOTONIC TECH L, V8, P1264, DOI 10.1109/68.531857; Chraplyvy AR, 1998, IEEE J QUANTUM ELECT, V34, P2103, DOI 10.1109/3.726600; CHRAPLYVY AR, 1990, J LIGHTWAVE TECHNOL, V8, P1548, DOI 10.1109/50.59195; COTTER D, 1995, ELECTRON LETT, V31, P1475, DOI 10.1049/el:19950959; Cotter D., 1995, Nonlinear Optics, Principles, Materials, Phenomena, and Devices, V13, P185; Cotter D, 1998, J LIGHTWAVE TECHNOL, V16, P2068, DOI 10.1109/50.736576; COTTER D, 1990, Patent No. 4973122; COTTER D, 1997, PHOTONIC NETWORKS; Danielsen SL, 1996, IEEE PHOTONIC TECH L, V8, P434, DOI 10.1109/68.481141; Diez S, 1997, IEEE J SEL TOP QUANT, V3, P1131, DOI 10.1109/2944.658587; DORAN NJ, 1988, OPT LETT, V13, P56, DOI 10.1364/OL.13.000056; EISELT M, 1992, ELECTRON LETT, V28, P1505, DOI 10.1049/el:19920956; ELLIS AD, 1993, ELECTRON LETT, V29, P2115, DOI 10.1049/el:19931414; Ellis AD, 1998, ELECTRON LETT, V34, P1958, DOI 10.1049/el:19981214; Forghieri F., 1997, OPTICAL FIBER TELECO; Guillemot C, 1998, J LIGHTWAVE TECHNOL, V16, P2117, DOI 10.1109/50.736580; Hall KL, 1998, OPT LETT, V23, P1271, DOI 10.1364/OL.23.001271; HALL KL, 1994, OPT COMMUN, V111, P589, DOI 10.1016/0030-4018(94)90538-X; Hunter DK, 1999, IEEE COMMUN MAG, V37, P120, DOI 10.1109/35.751509; Hunter DK, 1998, J LIGHTWAVE TECHNOL, V16, P2081, DOI 10.1109/50.736577; Jahn E, 1996, ELECTRON LETT, V32, P782, DOI 10.1049/el:19960515; JAHN E, 1995, ELECTRON LETT, V31, P1857, DOI 10.1049/el:19951284; Jahn E, 1996, ELECTRON LETT, V32, P216, DOI 10.1049/el:19960108; JINNO M, 1992, ELECTRON LETT, V28, P1350, DOI 10.1049/el:19920857; Kamatani O, 1996, J LIGHTWAVE TECHNOL, V14, P1757, DOI 10.1109/50.532012; Kang K. I., 1996, International Journal of High Speed Electronics and Systems, V7, P125, DOI 10.1142/S0129156496000062; Kawanishi S, 1997, ELECTRON LETT, V33, P1716, DOI 10.1049/el:19971155; Kelly AE, 1997, ELECTRON LETT, V33, P2123, DOI 10.1049/el:19971380; Kelly AE, 1999, ELECTRON LETT, V35, P1477, DOI 10.1049/el:19990976; Kelly AE, 1998, ELECTRON LETT, V34, P1955, DOI 10.1049/el:19981388; LUCEK JK, 1993, OPT LETT, V18, P1226, DOI 10.1364/OL.18.001226; MANNING RJ, 1995, ELECTRON LETT, V31, P307, DOI 10.1049/el:19950204; Manning RJ, 1997, J OPT SOC AM B, V14, P3204, DOI 10.1364/JOSAB.14.003204; Marcenac DD, 1997, ELECTRON LETT, V33, P879, DOI 10.1049/el:19970583; MARCUSE D, 1988, OPTICAL FIBER TELECO, V2; Mikkelsen B, 1997, ELECTRON LETT, V33, P133, DOI 10.1049/el:19970096; MIKKELSEN B, 1994, P ECOC 94 FLOR IT SE, V4, P67; Morioka T, 1996, ELECTRON LETT, V32, P906, DOI 10.1049/el:19960604; Nakazawa M, 1998, ELECTRON LETT, V34, P907, DOI 10.1049/el:19980590; NESSET D, 1994, ELECTRON LETT, V30, P1938, DOI 10.1049/el:19941335; NESSET D, 1995, ELECTRON LETT, V31, P896, DOI 10.1049/el:19950600; ONAKA H, 1996, P OPT FIB C SAN JOS; ONEILL AW, 1990, ELECTRON LETT, V26, P2008, DOI 10.1049/el:19901298; Phillips ID, 1998, ELECTRON LETT, V34, P2340, DOI 10.1049/el:19981630; Poustie AJ, 1999, OPT COMMUN, V159, P208, DOI 10.1016/S0030-4018(98)00615-4; Poustie AJ, 1999, OPT COMMUN, V162, P37, DOI 10.1016/S0030-4018(99)00070-X; SHABEER M, 1995, ELECTRON LETT, V31, P1476, DOI 10.1049/el:19950958; SHEIKBAHAE M, 1991, IEEE J QUANTUM ELECT, V27, P1296, DOI 10.1109/3.89946; SOKOLOFF JP, 1993, IEEE PHOTONIC TECH L, V5, P787, DOI 10.1109/68.229807; SOKOLOFF JP, 1994, IEEE PHOTONIC TECH L, V6, P98, DOI 10.1109/68.265902; STEGEMAN GI, 1993, PHOTONICS SWITCHING, V1; STOLEN RH, 1980, P IEEE, V68, P1232, DOI 10.1109/PROC.1980.11837; SUZUKI K, 1994, ELECTRON LETT, V30, P1501, DOI 10.1049/el:19941026; TATHAM MC, 1993, IEEE PHOTONIC TECH L, V5, P1303, DOI 10.1109/68.250051; Thiele HJ, 1999, ELECTRON LETT, V35, P230, DOI 10.1049/el:19990184; Toliver P, 1998, J LIGHTWAVE TECHNOL, V16, P2169, DOI 10.1109/50.736583; Uchiyama K, 1998, IEEE PHOTONIC TECH L, V10, P890, DOI 10.1109/68.681520; Yamamoto T, 1998, ELECTRON LETT, V34, P1013, DOI 10.1049/el:19980712; YANO Y, P ECOC 96 EUR C OPT	69	474	487	2	94	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1523	1528		10.1126/science.286.5444.1523	http://dx.doi.org/10.1126/science.286.5444.1523			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567251				2022-12-28	WOS:000083768300047
J	Reddy, MM; Light, MJ; Quinton, PM				Reddy, MM; Light, MJ; Quinton, PM			Activation of the epithelial Na+ channel (ENaC) requires CFTR Cl- channel function	NATURE			English	Article							TRANSMEMBRANE CONDUCTANCE REGULATOR; CYSTIC-FIBROSIS; PROTEIN-KINASE; TRANSPORT; CULTURES; BINDING; GLANDS; CELLS	It is increasingly being recognized that cells coordinate the activity Of separate ion channels that allow electrolytes into the cell. However, a perplexing problem in channel regulation has arisen in the fatal genetic disease cystic fibrosis, which results fi om the loss of a specific Cl- channel (the CFTR channel) in epithelial cell membranes(1). Although this defect clearly inhibits the absorption of Na+ in sweat gands(2,3), it is widely accepted that Na+ absorption is abnormally elevated in defective airways in cystic fibrosis(4,5). The only frequently cited explanation for this hypertransport is that the activity of an epithelial Na+ channel (ENaC) is inversely related to the activity of the CFTR Cl- channel(5-7). However we report here that, in freshly isolated normal sweat ducts, ENaC activity is dependent on, and increases with, CFTR activity. Surprisingly, we also find that the primary defect in Cl- permeability in cystic fibrosis(8) is accompanied secondarily by a Na+ conductance in this tissue that cannot: be activated. Thus, reduced salt absorption in cystic fibrosis is due not only to poor Cl- conductance but also to poor Na+ conductance.	Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA	University of California System; University of California San Diego	Quinton, PM (corresponding author), Univ Calif San Diego, Sch Med, Dept Pediat 0831, La Jolla, CA 92093 USA.							BOUCHER RC, 1986, J CLIN INVEST, V78, P1245, DOI 10.1172/JCI112708; BOUCHER RC, 1994, AM J RESP CRIT CARE, V150, P271, DOI 10.1164/ajrccm.150.1.8025763; BOUCHER RC, 1988, J PHYSIOL-LONDON, V405, P77, DOI 10.1113/jphysiol.1988.sp017322; Ecke D, 1996, PFLUG ARCH EUR J PHY, V431, P984, DOI 10.1007/s004240050095; FLOCKHART DA, 1984, EUR J BIOCHEM, V140, P289, DOI 10.1111/j.1432-1033.1984.tb08100.x; GREGER R, 1983, PFLUG ARCH EUR J PHY, V396, P325, DOI 10.1007/BF01063938; Hall RA, 1998, P NATL ACAD SCI USA, V95, P8496, DOI 10.1073/pnas.95.15.8496; ISMAILOV II, 1994, J BIOL CHEM, V269, P10235; Jiang C, 1997, J PHYSIOL-LONDON, V501, P637, DOI 10.1111/j.1469-7793.1997.637bm.x; KNOWLES MR, 1983, SCIENCE, V221, P1067, DOI 10.1126/science.6308769; Kunzelmann K, 1997, FEBS LETT, V400, P341, DOI 10.1016/S0014-5793(96)01414-7; LETZ, 1997, AM J PHYSL, V272, pC657; PANAH MR, 1998, AM J PHYSIOL-CELL PH, V274, pC310; Pilewski Joseph M., 1999, Physiological Reviews, V79, pS215; Quinton Paul M., 1999, Physiological Reviews, V79, pS3; QUINTON PM, 1992, NATURE, V360, P79, DOI 10.1038/360079a0; QUINTON PM, 1983, NATURE, V301, P421, DOI 10.1038/301421a0; QUINTON PM, 1986, AM J PHYSIOL, V251, pC649, DOI 10.1152/ajpcell.1986.251.4.C649; REDDY MM, 1994, J MEMBRANE BIOL, V140, P57; REDDY MM, 1998, PED PULMONOL S, V14, pR46; SATO K, 1984, J CLIN INVEST, V73, P1763, DOI 10.1172/JCI111385; Schwiebert Erik M., 1999, Physiological Reviews, V79, pS145; Sheppard David N., 1999, Physiological Reviews, V79, pS23; Short DB, 1998, J BIOL CHEM, V273, P19797, DOI 10.1074/jbc.273.31.19797; STUTTS MJ, 1995, SCIENCE, V269, P847, DOI 10.1126/science.7543698; Stutts MJ, 1997, J BIOL CHEM, V272, P14037, DOI 10.1074/jbc.272.22.14037; VERREY F, 1994, J MEMBRANE BIOL, V138, P65; WELSH MJ, 1987, PHYSIOL REV, V67, P1143, DOI 10.1152/physrev.1987.67.4.1143	28	178	182	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					301	304		10.1038/46297	http://dx.doi.org/10.1038/46297			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580502				2022-12-28	WOS:000083813700052
J	Perry, S; Thamer, M				Perry, S; Thamer, M			Medical innovation and the critical role of health technology assessment	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CARE; STRATEGIES; PROPOSAL		Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD 21205 USA; WHO, Collaborating Ctr Hlth Technol Assessment, Med Technol & Practice Patterns Inst, Bethesda, MD USA	Johns Hopkins University; World Health Organization	Thamer, M (corresponding author), Johns Hopkins Univ, Sch Hyg & Publ Hlth, Dept Hlth Policy & Management, 624 N Broadway St,Room 306, Baltimore, MD 21205 USA.							Banta HD., 1993, HLTH CARE TECHNOLOGY; BLUMENTHAL D, 1983, MILBANK FUND Q, V61, P584, DOI 10.2307/3349874; BUNKER JP, 1982, NEW ENGL J MED, V306, P687, DOI 10.1056/NEJM198203183061131; BUNKER JP, 1982, NEW ENGL J MED, V306, P620, DOI 10.1056/NEJM198203113061029; Ferguson JH, 1996, INT J TECHNOL ASSESS, V12, P460; FINEBERG HV, 1979, NEW ENGL J MED, V301, P1086, DOI 10.1056/NEJM197911153012004; FUCHS VR, 1990, NEW ENGL J MED, V323, P673, DOI 10.1056/NEJM199009063231011; HIATT HH, 1975, NEW ENGL J MED, V293, P235, DOI 10.1056/NEJM197507312930506; *I MED COUNC HLTH, 1990, NAT PRIOR ASS CLIN C; IGLEHART JK, 1983, NEW ENGL J MED, V309, P509, DOI 10.1056/NEJM198308253090839; LEARY WE, 1995, NY TIMES        0924, P26; Levit K, 1998, HEALTH AFFAIR, V17, P99, DOI 10.1377/hlthaff.17.6.99; *MED TECHN PRACT P, 1998, DIR HLTH TECHN ASS O; MERVIS J, 1994, SCIENCE, V266, P1636, DOI 10.1126/science.266.5191.1636; *NAT AC SCI, 1994, ORG MEMB 1994; *NAT CTR HLTH CAR, 1980, PROC PRIOR POL ASS H; *OFF TECHN ASS, 1995, HLTH CAR TECHN ITS A; PERRY S, 1986, NEW ENGL J MED, V314, P240, DOI 10.1056/NEJM198601233140410; Perry S, 1997, HEALTH POLICY, V42, P269; Perry S, 1997, INT J TECHNOL ASSESS, V13, P81, DOI 10.1017/S0266462300010254; PERRY S, 1981, JAMA-J AM MED ASSOC, V245, P2510, DOI 10.1001/jama.245.24.2510; Perry S, 1990, Med Care Rev, V47, P401, DOI 10.1177/107755879004700402; PERRY S, 1982, NEW ENGL J MED, V307, P1095, DOI 10.1056/NEJM198210213071738; *PHYS PAYM REV COM, 1994, ANN REP C; RELMAN AS, 1980, NEW ENGL J MED, V303, P153, DOI 10.1056/NEJM198007173030310; RELMAN AS, 1988, NEW ENGL J MED, V319, P1220, DOI 10.1056/NEJM198811033191810; RELMAN AS, 1982, NEW ENGL J MED, V306, P669, DOI 10.1056/NEJM198203183061109; RETTIG RA, 1997, HLTH CARE TRANSITION	28	18	19	0	1	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1869	1872		10.1001/jama.282.19.1869	http://dx.doi.org/10.1001/jama.282.19.1869			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573280				2022-12-28	WOS:000083615700032
J	Golan, L; Birkmeyer, JD; Welch, HG				Golan, L; Birkmeyer, JD; Welch, HG			The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors	ANNALS OF INTERNAL MEDICINE			English	Article						cost-benefit analysis; diabetes mellitus, non-insulin-dependent; angiotensin-converting enzyme inhibitors; outcome and process assessment (health care); diabetic nephropathies	NEPHROPATHY; QUALITY; RECOMMENDATIONS; MELLITUS; OUTCOMES	Background: Although guidelines recommend angiotensin-converting enzyme inhibitors for diabetic patients with microalbuminuria, this strategy requires that providers adhere to screening recommendations. In addition, the benefit of angiotensin-converting enzyme inhibitors in normoalbuminuric patients was recently demonstrated. Objective: To evaluate the cost-effectiveness of treating all patients with type 2 diabetes. Design: Markov model simulating the progression of diabetic nephropathy. Data Sources: Randomized trials estimating the progression of diabetic nephropathy with and without angiotensin-converting enzyme inhibitors. Target Population: Patients 50 years of age with newly diagnosed type 2 diabetes (fasting plasma glucose level greater than or equal to 7.8 mmol/L [140 mg/dL]). Time Horizon: Lifetime. Perspective: Societal. Interventions: Patients received angiotensin-converting enzyme inhibitors, screening for microalbuminuria, or screening for gross proteinuria. Outcome Measures: Lifetime cost, quality-adjusted life expectancy, and marginal cost-effectiveness. Results of Base-Case Analysis: Screening for gross proteinuria had the highest cost and the lowest benefit. Compared with screening for microalbuminuria, treating all patients was more expensive ($15 240 and $14 940 per patient) but was associated with increased quality-adjusted life expectancy (11.82 and 11.78 quality-adjusted life-years). The marginal cost-effectiveness ratio was $7500 per quality-adjusted life-year gained. Results of Sensitivity Analysis: Results were sensitive to the cost, effectiveness, and quality of life associated with angiotensin-converting enzyme inhibitor therapy, as well as age at diagnosis. The model was relatively insensitive to adherence with screening and costs of treating end-stage renal disease. Conclusions: Treating all middle-aged diabetic patients with angiotensin-converting enzyme inhibitors is a simple strategy that provides additional benefit at modest additional cost. The strategy assumes that patients meet the older diagnostic criteria for diabetes and makes sense only for those who are not bothered by treatment.	Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA		Welch, HG (corresponding author), Dept Vet Affairs Med Ctr, Vet Affairs Outcomes Grp, White River Jct, VT 05009 USA.		Golan, Lubor/O-2359-2017	Golan, Lubor/0000-0003-1705-1157				BENNETT PH, 1995, AM J KIDNEY DIS, V25, P107; CHURCHILL DN, 1987, CLIN INVEST MED, V10, P14; DONOHOE JF, 1988, AM J MED, V85, P31, DOI 10.1016/0002-9343(88)90347-6; Frank E, 1997, J CLIN PSYCHIAT, V58, P11; FRYBACK DG, 1993, MED DECIS MAKING, V13, P89, DOI 10.1177/0272989X9301300202; Gaster B, 1998, ARCH INTERN MED, V158, P134, DOI 10.1001/archinte.158.2.134; ISRAILI ZH, 1992, ANN INTERN MED, V117, P234, DOI 10.7326/0003-4819-117-3-234; Kraft SK, 1999, J GEN INTERN MED, V14, P88, DOI 10.1046/j.1525-1497.1999.00292.x; LEWIS EJ, 1993, NEW ENGL J MED, V329, P1456, DOI 10.1056/NEJM199311113292004; LOVELL HG, 1998, COCHRANE DATABASE SY, V3; Miller N H, 1997, Am J Med, V102, P43; Miller NH, 1997, CIRCULATION, V95, P1085; Niskanen LK, 1996, DIABETES CARE, V19, P486, DOI 10.2337/diacare.19.5.486; PARVING HH, 1995, AM J KIDNEY DIS, V26, P99, DOI 10.1016/0272-6386(95)90162-0; PARVING HH, 1994, KIDNEY INT, V45, pS165; Ravid M, 1998, ANN INTERN MED, V128, P982, DOI 10.7326/0003-4819-128-12_Part_1-199806150-00004; RAVID M, 1993, ANN INTERN MED, V118, P577, DOI 10.7326/0003-4819-118-8-199304150-00001; *REP EXP COMM DIAG, 1997, DAIB CAR, V20, P183; Ritz E, 1996, AM J KIDNEY DIS, V27, P167, DOI 10.1016/S0272-6386(96)90538-7; RUDD P, 1995, AM HEART J, V130, P572, DOI 10.1016/0002-8703(95)90368-2; Schwartz L M, 1999, Eff Clin Pract, V2, P76; WALTERS DP, 1994, DIABETIC MED, V11, P968, DOI 10.1111/j.1464-5491.1994.tb00255.x; WEINER JP, 1995, JAMA-J AM MED ASSOC, V273, P1503, DOI 10.1001/jama.273.19.1503; 1998, AM J KIDNEY, V32, pS69; 1996, NAT CTR HLTH STAT; 1996, LIFE EXPECTANCY	26	127	131	0	7	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					660	+		10.7326/0003-4819-131-9-199911020-00005	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00005			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577328				2022-12-28	WOS:000083446200004
J	Freeland, SJ; Knight, RD; Landweber, LF				Freeland, SJ; Knight, RD; Landweber, LF			Molecular evolution - Do proteins predate DNA?	SCIENCE			English	Editorial Material							GENETIC-CODE; RNA WORLD; RIBONUCLEOTIDE REDUCTASES; ERROR MINIMIZATION; ORIGIN		Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA	Princeton University	Freeland, SJ (corresponding author), Princeton Univ, Dept Ecol & Evolutionary Biol, Princeton, NJ 08544 USA.	freeland@rnaworld.prince-ton.edu; rdknight@princeton.edu; lfl@princeton.edu		Knight, Rob/0000-0002-0975-9019				ALBERTS B, 1994, MOL BIOL CELL, pCH9; Ardell DH, 1998, J MOL EVOL, V47, P1, DOI 10.1007/PL00006356; Atkins J.F, 1999, RNA WORLD; BENNER SA, 1989, P NATL ACAD SCI USA, V86, P7054, DOI 10.1073/pnas.86.18.7054; Cate JH, 1999, SCIENCE, V285, P2095, DOI 10.1126/science.285.5436.2095; CRICK FHC, 1968, J MOL BIOL, V38, P367, DOI 10.1016/0022-2836(68)90392-6; Freeland SJ, 1998, P ROY SOC B-BIOL SCI, V265, P2111, DOI 10.1098/rspb.1998.0547; Freeland SJ, 1998, J MOL EVOL, V47, P238, DOI 10.1007/PL00006381; HAIG D, 1991, J MOL EVOL, V33, P412, DOI 10.1007/BF02103132; HIRAO I, 1995, CURR BIOL, V5, P1017, DOI 10.1016/S0960-9822(95)00205-3; Jordan A, 1998, ANNU REV BIOCHEM, V67, P71, DOI 10.1146/annurev.biochem.67.1.71; Lazcano A, 1996, CELL, V85, P793, DOI 10.1016/S0092-8674(00)81263-5; LAZCANO A, 1988, J MOL EVOL, V27, P283, DOI 10.1007/BF02101189; Leon PE, 1998, J MOL EVOL, V47, P122, DOI 10.1007/PL00006368; Logan DT, 1999, SCIENCE, V283, P1499, DOI 10.1126/science.283.5407.1499; Olsen GJ, 1996, TRENDS GENET, V12, P377, DOI 10.1016/0168-9525(96)30092-9; ORGEL LE, 1968, J MOL BIOL, V38, P381, DOI 10.1016/0022-2836(68)90393-8; REICHARD P, 1993, SCIENCE, V260, P1773, DOI 10.1126/science.8511586; Sawers G, 1998, MOL MICROBIOL, V29, P945, DOI 10.1046/j.1365-2958.1998.00941.x; Szathmary E, 1999, TRENDS GENET, V15, P223, DOI 10.1016/S0168-9525(99)01730-8; Szathmary E, 1995, MAJOR TRANSITIONS EV; WHITE HB, 1976, J MOL EVOL, V7, P101, DOI 10.1007/BF01732468; WOESE CR, 1967, GENETIC CODE; WONG JTF, 1979, J MOL EVOL, V13, P115, DOI 10.1007/BF01732867	24	67	68	0	2	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 22	1999	286	5440					690	692		10.1126/science.286.5440.690	http://dx.doi.org/10.1126/science.286.5440.690			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	248XZ	10577226				2022-12-28	WOS:000083303200033
J	Clark, WM; Wissman, S; Albers, GW; Jhamandas, JH; Madden, KP; Hamilton, S				Clark, WM; Wissman, S; Albers, GW; Jhamandas, JH; Madden, KP; Hamilton, S		ATLANTIS Study Investigators	Recombinant tissue-type plasminogen activator (alteplase) for ischemic stroke 3 to 5 hours after symptom onset - The ATLANTIS study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ECASS	Context Recombinant tissue-type plasminogen activator (rt-PA) improves outcomes for patients with acute ischemic stroke, but current approved use is limited to within 3 hours of symptom onset. This restricts the number of patients who can be treated, since most stroke patients present more than 3 hours after symptom onset. Objective To test the efficacy and safety of rt-PA in patients with acute ischemic stroke when administered between 3 and 5 hours after symptom onset. Design The Alteplase ThromboLysis for Acute Noninterventional Therapy in Ischemic Stroke (ATLANTIS) study is a phase 3, placebo-controlled, double-blind randomized study conducted between December 1993 and July 1998, with up to 90 days of follow-up. Setting One hundred forty university and community hospitals in North America. Patients An intent-to-treat population of 613 acute ischemic stroke patients was enrolled, with 547 of these treated as assigned within 3 to 5 hours of symptom onset. A total of 39 others were treated within 3 hours of symptom onset, 24 were treated more than 5 hours after symptom onset, and 3 never received any study drug. Intervention Administration of 0.9 mg/kg of rt-PA (n = 272) or placebo (n = 275) intravenously over 1 hour. Main Outcome Measures Primary efficacy was an excellent neurologic recovery at day 90 (National Institutes of Health Stroke Scale [NIHSS] score of less than or equal to 1); secondary end points included excellent recovery on functional outcome measures (Barthel index, modified Rankin scale, and Glasgow Outcome Scale) at days 30 and 90. Serious adverse events were also assessed. Results In the target population, 32% of the placebo and 34% of rt-PA patients had an excellent recovery at 90 days (P = .65). There were no differences on any of the secondary functional outcome measures. In the first 10 days treatment with rt-PA significantly increased the rate of symptomatic intracerebral hemorrhage (ICH) (1.1% vs 7.0% [P<.001]), a symptomatic ICH (4.7% vs 11.4% [P = .004]), and fatal ICH (0.3% vs 3.0% [P<.001]). Mortality at 90 days was 6.9% with placebo and 11.0% with rt-PA (P = .09). Results in the intent-to-treat population were similar. Conclusions This study found no significant rt-PA benefit on the 90-day efficacy end points in patients treated between 3 and 5 hours. The risk of symptomatic ICH increased with rt-PA treatment. These results do not support the use of intravenous rt-PA for stroke treatment beyond 3 hours.	Oregon Hlth & Sci Univ, Oregon Stroke Ctr, Portland, OR 97201 USA; Stucky Res Ctr, Ft Wayne, IN USA; Stanford Univ, Stanford Stroke Ctr, Palo Alto, CA 94304 USA; Univ Alberta, Dept Neurol, Edmonton, AB, Canada; Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA; Genentech Inc, San Francisco, CA 94080 USA	Oregon Health & Science University; Stanford University; University of Alberta; Marshfield Clinic; Roche Holding; Genentech	Clark, WM (corresponding author), Oregon Hlth & Sci Univ, Oregon Stroke Ctr, UHS 44,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA.	clarkw@ohsu.edu	Buchan, Alastair M/B-9095-2009	Buchan, Alastair M/0000-0002-2918-5200; Albers, Gregory/0000-0003-0263-4632				Albers GW, 1999, STROKE, V30, P244; ALBERTS MJ, 1993, STROKE, V24, P1817, DOI 10.1161/01.STR.24.12.1817; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Chiu D, 1998, STROKE, V29, P18, DOI 10.1161/01.STR.29.1.18; CLARK W, IN PRESS STROKE; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; JENNETT B, 1975, LANCET, V1, P480; LYDEN P, 1994, STROKE, V25, P2220, DOI 10.1161/01.STR.25.11.2220; MAHONEY F I, 1965, Md State Med J, V14, P61; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; Tanner CM, 1998, NEUROLOGY, V50, pA373; VANSWIETEN JC, 1998, STROKE, V14, P61	13	841	882	0	26	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2019	2026		10.1001/jama.282.21.2019	http://dx.doi.org/10.1001/jama.282.21.2019			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591384				2022-12-28	WOS:000083908700021
J	Drakulovic, MB; Torres, A; Bauer, TT; Nicolas, JM; Nogue, S; Ferrer, N				Drakulovic, MB; Torres, A; Bauer, TT; Nicolas, JM; Nogue, S; Ferrer, N			Supine body position as a risk factor for nosocomial pneumonia in mechanically ventilated patients: a randomised trial	LANCET			English	Article							INTENSIVE-CARE UNITS; GASTROESOPHAGEAL REFLUX; TRACHEAL COLONIZATION; MULTIVARIATE-ANALYSIS; PULMONARY ASPIRATION; RESPIRATORY-TRACT; ENTERAL NUTRITION; INFECTION; SUCRALFATE; RANITIDINE	Background Risk factors for nosocomial pneumonia, such as gastro-oesophageal reflux and subsequent aspiration, can be reduced by semirecumbent body position in intensive-care patients. The objective of this study was to assess whether the incidence of nosocomial pneumonia can also be reduced by this measure. Methods This trial was stopped after the planned interim analysis, 86 intubated and mechanically ventilated patients of one medical and one respiratory intensive-care unit at a tertiary-care university hospital were randomly assigned to semirecumbent (n=39) or supine (n=47) body position. The frequency of clinically suspected and microbiologically confirmed nosocomial pneumonia (clinical plus quantitative bacteriological criteria) was assessed in both groups. Body position was analysed together with known risk factors for nosocomial pneumonia. Findings The frequency of clinically suspected nosocomial pneumonia was lower in the semirecumbent group than in the supine group (three of 39 [8%] vs 16 of 47 [34%]; 95% CI for difference 10.0-42.0, p=0.003). This was also true for microbiologically confirmed pneumonia (semirecumbent 2/39 [5%] vs supine 11/47 [23%]; 4.2-31.8, p=0.018). Supine body position (odds ratio 6.8 [1.7-26.7], p=0.006) and enteral nutrition (5.7 [1.5-22.8], p=0.013) were independent risk factors for nosocomial pneumonia and the frequency was highest for patients receiving enteral nutrition in the supine body position (14/28, 50%). Mechanical ventilation for 7 days or more (10.9 [3.0-40.4], p=0.001) and a Glasgow coma scale score of less than 9 were additional risk factors. Interpretation The semirecumbent body position reduces frequency and risk of nosocomial pneumonia, especially in patients who receive enteral nutrition. The risk of nosocomial pneumonia is increased by long-duration mechanical ventilation and decreased consciousness.	Univ Barcelona, Hosp Clin, Serv Pneumol & Allergia Resp, Resp Intens Care Unit, Barcelona, Spain; Univ Barcelona, Hosp Clin, Area Vigilancia Intens, Inst Invest Biomed August Pi & Sunyer,Dept Med, Barcelona, Spain	University of Barcelona; Hospital Clinic de Barcelona; University of Barcelona; Hospital Clinic de Barcelona; IDIBAPS	Torres, A (corresponding author), Hosp Clin Barcelona, Serv Pneumol & Allergia Resp, Villarroel 170, E-08036 Barcelona, Spain.	atorres@medicina.ub.es	Torres, Antoni/H-6128-2017	Torres, Antoni/0000-0002-8643-2167; Ferrer, Miguel/0000-0001-8171-6673				Centers for Disease Control and Prevention (CDC), 1997, MMWR Morb Mortal Wkly Rep, V46, P1; BONTEN MJM, 1994, CHEST, V105, P878, DOI 10.1378/chest.105.3.878; CELIS R, 1988, CHEST, V93, P318, DOI 10.1378/chest.93.2.318; CONCATO J, 1993, ANN INTERN MED, V118, P201, DOI 10.7326/0003-4819-118-3-199302010-00009; Cook D, 1998, NEW ENGL J MED, V338, P791, DOI 10.1056/NEJM199803193381203; DELATORRE FJ, 1995, AM J RESP CRIT CARE, V152, P1028, DOI 10.1164/ajrccm.152.3.7663779; DUMOULIN GC, 1982, LANCET, V1, P242; ELEBIARY M, 1993, AM J RESP CRIT CARE, V147, P1552; Ewig S, 1999, AM J RESP CRIT CARE, V159, P188, DOI 10.1164/ajrccm.159.1.9803097; FABREGAS N, IN PRESS THORAX; FAGON JY, 1989, AM REV RESPIR DIS, V139, P877, DOI 10.1164/ajrccm/139.4.877; Fernandez-Crehuet R, 1997, INFECT CONT HOSP EP, V18, P825; GEORGE DL, 1993, INFECT CONT HOSP EP, V14, P163, DOI 10.1086/646705; HARDY JF, 1988, CAN J ANAESTH, V35, P162, DOI 10.1007/BF03010658; IBANEZ J, 1992, JPEN-PARENTER ENTER, V16, P419, DOI 10.1177/0148607192016005419; JACOBS S, 1990, JPEN-PARENTER ENTER, V14, P353, DOI 10.1177/0148607190014004353; JARVIS WR, 1991, AM J MED, V91, pS185, DOI 10.1016/0002-9343(91)90367-7; KOLLEF MH, 1993, JAMA-J AM MED ASSOC, V270, P1965, DOI 10.1001/jama.270.16.1965; LANGER M, 1989, AM REV RESPIR DIS, V140, P302, DOI 10.1164/ajrccm/140.2.302; MEDURI GU, 1992, CHEST, V102, pS557, DOI 10.1378/chest.102.5_Supplement_1.557S; OROZCOLEVI M, 1995, AM J RESP CRIT CARE, V152, P1387, DOI 10.1164/ajrccm.152.4.7551400; PINGLETON SK, 1986, AM J MED, V80, P827, DOI 10.1016/0002-9343(86)90623-6; PRODHOM G, 1994, ANN INTERN MED, V120, P653, DOI 10.7326/0003-4819-120-8-199404150-00005; RAMSAY MAE, 1974, BRIT MED J, V2, P656, DOI 10.1136/bmj.2.5920.656; RELLO J, 1992, CHEST, V102, P525, DOI 10.1378/chest.102.2.525; REUSSER P, 1989, J INFECT DIS, V160, P414, DOI 10.1093/infdis/160.3.414; Stoutenbeek C P, 1997, Semin Respir Infect, V12, P294; TORRES A, 1992, ANN INTERN MED, V116, P540, DOI 10.7326/0003-4819-116-7-540; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; WIMBERLEY N, 1979, AM REV RESPIR DIS, V119, P337	30	724	778	0	26	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1851	1858		10.1016/S0140-6736(98)12251-1	http://dx.doi.org/10.1016/S0140-6736(98)12251-1			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584721				2022-12-28	WOS:000083909100010
J	Price, D; Pollock, AM; Shaoul, J				Price, D; Pollock, AM; Shaoul, J			How the World Trade Organisation is shaping domestic policies in health care	LANCET			English	Article							PROFIT HOSPITAL BUSINESS; 2 PARTS; GO BAD; PRIVATISATION; COLUMBIA/HCA; RESURGENCE	High up on the agenda of the World Trade Organisation (WTO) is the privatisation of education, health, welfare, social housing and transport. The WTO's aim is to extend the free market in the provision of traditional public services. Governments in Europe and the US link the expansion of trade in public services to economic success, and with the backing of powerful medico-pharmaceutical, insurance, and service corporations, the race is on to capture the share of gross domestic product that governments currently spend on public services. They will open domestic European services and domestic markets to global competition by government procurement agreements, dispute-settlement procedures, and the investment rules of global financial institutions. The UK has already set up the necessary mechanisms: the introduction of private-sector accounting rules to public services; the funding of public-sector Investment via private-public partnerships or the private finance initiative; and the change to capitation funding streams, which allows the substitution of private for public funds and services. We explain the implications of these changes for European public-health-care systems and the threat they pose to universal coverage, solidarity through risk-pooling, equity, comprehensive care, and democratic accountability.	UCL, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England; Northumbria Univ, Social Welf Res Unit, Newcastle Upon Tyne NE1 8ST, Tyne & Wear, England; Univ Manchester, Sch Accounting & Finance, Manchester, Lancs, England	University of London; University College London; Northumbria University; University of Manchester	Pollock, AM (corresponding author), UCL, Hlth Policy & Hlth Serv Res Unit, London WC1H 9EZ, England.	allyson.pollock@ucl.ac.ukBackground		pollock, allyson/0000-0002-7388-3110				BALANYA B, 1999, CORP EUR OBSERVER, V4, P3; BERTRAND A, 1999, ECOLOGIST, V29, P365; *EUR COMM, 1996, PUBL PROC EUR UN; *EUR UN WORLD TRAD, 1999, FRONT FREE EUR, P1; Gaffney D, 1999, BMJ-BRIT MED J, V319, P48, DOI 10.1136/bmj.319.7201.48; Gaffney D, 1999, BRIT MED J, V319, P116, DOI 10.1136/bmj.319.7202.116; Gaffney D, 1999, BRIT MED J, V319, P249, DOI 10.1136/bmj.319.7204.249; Harrington C, 1998, LANCET, V351, P1805, DOI 10.1016/S0140-6736(97)09039-9; HEATH I, 1994, BRIT MED J, V309, P623, DOI 10.1136/bmj.309.6955.623; Kerrison S, 1998, J Health Serv Res Policy, V3, P20; Kuttner R, 1999, NEW ENGL J MED, V340, P664, DOI 10.1056/NEJM199902253400822; Kuttner R, 1996, NEW ENGL J MED, V335, P362, DOI 10.1056/NEJM199608013350524; Kuttner R, 1998, NEW ENGL J MED, V338, P1635, DOI 10.1056/NEJM199805283382221; Kuttner R, 1998, NEW ENGL J MED, V338, P1558, DOI 10.1056/NEJM199805213382123; Kuttner R, 1999, NEW ENGL J MED, V340, P163, DOI 10.1056/NEJM199901143400226; Kuttner R, 1996, NEW ENGL J MED, V335, P446, DOI 10.1056/NEJM199608083350620; Levit K, 1998, HEALTH AFFAIR, V17, P99, DOI 10.1377/hlthaff.17.6.99; Mishra R, 1998, SOC POLICY ADMIN, V32, P481, DOI 10.1111/1467-9515.00110; Pollock AM, 1999, BMJ-BRIT MED J, V319, P179, DOI 10.1136/bmj.319.7203.179; POLLOCK AM, 1998, NOV, P6; POLLOCK AM, 1999, BRIT MED J, V310, P1580; POLLOCK AM, 1998, HLTH SERV J     0409, P29; ROGER N, 1996, 196 WORLD BANK GROUP, P1; SHAOUL J, 1999, EMPLOYEE RELATIONS P; Stocker K, 1999, NEW ENGL J MED, V340, P1131, DOI 10.1056/NEJM199904083401425; SUZMAN M, 1999, FINANCIAL TIMES 0920, P10; *WORLD BANK GROUP, 1993, WORLD BANK DEV REP 1; *WTO SECR, 1998, HLTH SOC SERV BACKGR; 1998, ACHESON REPORT INDEP	29	81	84	0	31	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1889	1892		10.1016/S0140-6736(99)11060-2	http://dx.doi.org/10.1016/S0140-6736(99)11060-2			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TF	10584740				2022-12-28	WOS:000083909100042
J	Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S				Wilson, D; Cawthorne, P; Ford, N; Aongsonwang, S			Global trade and access to medicines: AIDS treatments in Thailand	LANCET			English	Editorial Material									Med Sans Frontieres, Bangkok 10240, Thailand		Wilson, D (corresponding author), Med Sans Frontieres, 311 Ladprao 101, Bangkok 10240, Thailand.							AONGSONWANG S, 1999, NGO M COMP LIC ESS M; Correa CM, 1997, URUGUAY ROUND DRUGS; *EC INT UN, 1999, THAIL COUNTR REP; Hemachudha T, 1999, CLIN INFECT DIS, V28, P143, DOI 10.1086/517179; KUNANUSONT C, 1996, HIV AIDS THAILAND 19, P82; LOMAR A, 1999, CUSTOS DIRECTOS TRAT; McGregor A, 1999, LANCET, V353, P1165, DOI 10.1016/S0140-6736(05)74394-4; *SAT S 21, 1995, P 3 INT C AIDS AS PA, P88; Shaffer N, 1999, LANCET, V353, P773, DOI 10.1016/S0140-6736(98)10411-7; Shakoor O, 1997, TROP MED INT HEALTH, V2, P839, DOI 10.1046/j.1365-3156.1997.d01-403.x; Suwanjandee J, 1999, LANCET, V354, P343, DOI 10.1016/S0140-6736(05)75255-7; *THAI FDA, 1995, THAI DRUG SYST SIT A; *THAI MIN PUBL HLT, 1997, GUID CLIN MAN HIV IN; UNDP,, 1990, HUMAN DEV REPORT 199; *WHO, 1997, WHODAP989 TRIPS; World Health Organization, 1999, 52 WORLD HLTH ASS 52 WORLD HLTH ASS	16	20	20	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1893	1895		10.1016/S0140-6736(99)06114-0	http://dx.doi.org/10.1016/S0140-6736(99)06114-0			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584741				2022-12-28	WOS:000083909100043
J	Chan, VZH; Hoffman, J; Lee, VY; Iatrou, H; Avgeropoulos, A; Hadjichristidis, N; Miller, RD; Thomas, EL				Chan, VZH; Hoffman, J; Lee, VY; Iatrou, H; Avgeropoulos, A; Hadjichristidis, N; Miller, RD; Thomas, EL			Ordered bicontinuous nanoporous and nanorelief ceramic films from self assembling polymer precursors	SCIENCE			English	Article							TRIBLOCK COPOLYMERS; BLOCK-COPOLYMERS; MESOSTRUCTURES; MORPHOLOGY	Three-dimensional ceramic nanostructured films were produced from silicon-containing triblock copolymer films exhibiting the double gyroid and inverse double gyroid morphologies (space group 1a3d). A one-step room-temperature oxidation process that used ozonolysis and ultraviolet irradiation effected both the selective removal of the hydrocarbon block and the conversion of the silicon-containing block to a silicon oxycarbide ceramic stable to 400 degrees C. Depending on the relative volume fraction of the hydrocarbon block to the silicon-containing block, either nanoporous or nanorelief structures were fabricated with calculated interfacial areas of similar to 40 square meters per gram and pore or strut sizes of similar to 20 nanometers.	MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA; Math Sci Res Inst, Berkeley, CA 94720 USA; IBM Corp, Almaden Res Ctr, San Jose, CA 95120 USA; Univ Athens, Dept Chem, GR-10680 Athens, Greece	Massachusetts Institute of Technology (MIT); International Business Machines (IBM); National & Kapodistrian University of Athens	Thomas, EL (corresponding author), MIT, Dept Mat Sci & Engn, Cambridge, MA 02139 USA.	ellt@mit.edu	Avgeropoulos, Apostolos/U-1381-2019; Iatrou, Hermis/E-7293-2018; Avgeropoulos, Apostolos/I-5772-2012	Avgeropoulos, Apostolos/0000-0002-6203-9942; Iatrou, Hermis/0000-0001-9358-0769; Thomas, Edwin/0000-0001-5911-6524				Avgeropoulos A, 1998, CHEM MATER, V10, P2109, DOI 10.1021/cm970682y; BELOT V, 1994, J NON-CRYST SOLIDS, V176, P33, DOI 10.1016/0022-3093(94)90208-9; Breiner U, 1998, MACROMOLECULES, V31, P135, DOI 10.1021/ma961550d; CHAN VZH, 1999, Patent No. 15068; GABOR AH, 1995, ACS SYM SER, V614, pCH19; GREINER HJ, 1971, J APPL PHYS, V42, P5151, DOI 10.1063/1.1659906; HAJDUK DA, 1994, MACROMOLECULES, V27, P4063, DOI 10.1021/ma00093a006; Hashimoto T, 1997, LANGMUIR, V13, P6869, DOI 10.1021/la970967p; Joannopoulos J. D., 1995, PHOTONIC CRYSTALS MO; Johnson SA, 1999, SCIENCE, V283, P963, DOI 10.1126/science.283.5404.963; Kim MJ, 1999, CHEM MATER, V11, P487, DOI 10.1021/cm980691m; KINNING DJ, 1987, MACROMOLECULES, V20, P1129, DOI 10.1021/ma00171a043; Lambert CA, 1996, PHILOS T R SOC A, V354, P2009, DOI 10.1098/rsta.1996.0089; LEE JS, 1989, MACROMOLECULES, V22, P2602, DOI 10.1021/ma00196a010; MONNIER A, 1993, SCIENCE, V261, P1299, DOI 10.1126/science.261.5126.1299; Morey MS, 1998, J POROUS MAT, V5, P195, DOI 10.1023/A:1009626103498; Park M, 1997, SCIENCE, V276, P1401, DOI 10.1126/science.276.5317.1401; REICHMANIS E, 1984, P SOC PHOTO-OPT INST, V469, P38, DOI 10.1117/12.941775; SIERRA L, 1999, ADV MATER, V11, P4; Sioula S, 1998, MACROMOLECULES, V31, P8429, DOI 10.1021/ma980622t; Templin M, 1997, SCIENCE, V278, P1795, DOI 10.1126/science.278.5344.1795; Urbas A, 1999, MACROMOLECULES, V32, P4748, DOI 10.1021/ma9903207; Wei Y, 1998, ADV MATER, V10, P313, DOI 10.1002/(SICI)1521-4095(199803)10:4<313::AID-ADMA313>3.0.CO;2-M; Zhao DY, 1998, SCIENCE, V279, P548, DOI 10.1126/science.279.5350.548	24	318	358	4	125	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1716	1719		10.1126/science.286.5445.1716	http://dx.doi.org/10.1126/science.286.5445.1716			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576734				2022-12-28	WOS:000083912200032
J	Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M				Sambongi, Y; Iko, Y; Tanabe, M; Omote, H; Iwamoto-Kihara, A; Ueda, I; Yanagida, T; Wada, Y; Futai, M			Mechanical rotation of the c subunit oligomer in ATP synthase (F0F1): Direct observation	SCIENCE			English	Article							ESCHERICHIA-COLI F1-ATPASE; CARBOXYL-TERMINAL REGION; GAMMA-SUBUNIT; H+-ATPASE; ENERGY TRANSDUCTION; BETA-SUBUNIT; F-TYPE; CATALYSIS; F-1-ATPASE; MUTATIONS	F0F1, found in mitochondria or bacterial membranes, synthesizes adenosine 5'-triphosphate (ATP) coupling with an electrochemical proton gradient and also reversibly hydrolyzes ATP to form the gradient. An actin filament connected to a c subunit oligomer of F-0 was able to rotate by using the energy of ATP hydrolysis. The rotary torque produced by the c subunit oligomer reached about 40 piconewton-nanometers, which is similar to that generated by the gamma subunit in the F-1 motor. These results suggest that the gamma and c subunits rotate together during ATP hydrolysis and synthesis. Thus, coupled rotation may be essential for energy coupling between proton transport through F-0 and ATP hydrolysis or synthesis in F-1.	Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan; Univ Tokyo, Grad Sch Arts & Sci, Dept Biol, Tokyo 1538902, Japan; Osaka Univ, Sch Med, Dept Physiol, Suita, Osaka 5650871, Japan	Japan Science & Technology Agency (JST); Osaka University; University of Tokyo; Osaka University	Futai, M (corresponding author), Osaka Univ, Japan Sci & Technol Corp, CREST, Inst Sci & Ind Res,Div Biol Sci, Osaka 5670047, Japan.	m-futai@sanken.osaka-u.ac.jp	OMOTE, Hiroshi/B-1635-2011; Yanagida, Toshio/D-1919-2009					ABRAHAMS JP, 1994, NATURE, V370, P621, DOI 10.1038/370621a0; AGGELER R, 1995, J BIOL CHEM, V270, P9185, DOI 10.1074/jbc.270.16.9185; AlShawi MK, 1997, J BIOL CHEM, V272, P2300; Boyer PD, 1997, ANNU REV BIOCHEM, V66, P717, DOI 10.1146/annurev.biochem.66.1.717; Dimroth P, 1999, P NATL ACAD SCI USA, V96, P4924, DOI 10.1073/pnas.96.9.4924; Dmitriev OY, 1999, P NATL ACAD SCI USA, V96, P7785, DOI 10.1073/pnas.96.14.7785; DUNCAN TM, 1995, P NATL ACAD SCI USA, V92, P10964, DOI 10.1073/pnas.92.24.10964; Elston T, 1998, NATURE, V391, P510, DOI 10.1038/35185; Fillingame RH, 1996, CURR OPIN STRUC BIOL, V6, P491, DOI 10.1016/S0959-440X(96)80114-X; FILLINGAME RH, 1991, J BIOL CHEM, V266, P20934; FUTAI M, 1989, ANNU REV BIOCHEM, V58, P111; FUTAI M, 1996, HDB BIOL PHYS, V2, P47; HUNT AJ, 1994, BIOPHYS J, V67, P766, DOI 10.1016/S0006-3495(94)80537-5; IWAMOTO A, 1990, J BIOL CHEM, V265, P5043; JEANTEURDEBEUKELAER C, 1995, J BIOL CHEM, V270, P22850; Jones PC, 1998, J BIOL CHEM, V273, P29701, DOI 10.1074/jbc.273.45.29701; Jones PC, 1998, J BIOL CHEM, V273, P17178, DOI 10.1074/jbc.273.27.17178; Junge W, 1997, TRENDS BIOCHEM SCI, V22, P420, DOI 10.1016/S0968-0004(97)01129-8; Kato-Yamada Y, 1998, J BIOL CHEM, V273, P19375, DOI 10.1074/jbc.273.31.19375; Mehta AD, 1999, SCIENCE, V283, P1689, DOI 10.1126/science.283.5408.1689; MORIYAMA Y, 1991, J BIOL CHEM, V266, P22141; NAKAMOTO RK, 1993, J BIOL CHEM, V268, P867; NAKAMOTO RK, 1995, J BIOL CHEM, V270, P14042, DOI 10.1074/jbc.270.23.14042; Noji H, 1997, NATURE, V386, P299, DOI 10.1038/386299a0; Omote H, 1999, P NATL ACAD SCI USA, V96, P7780, DOI 10.1073/pnas.96.14.7780; PENEFSKY HS, 1991, ADV ENZYMOL RELAT AR, V64, P173; PERLIN DS, 1985, BIOCHIM BIOPHYS ACTA, V807, P238, DOI 10.1016/0005-2728(85)90254-3; SHIN K, 1992, J BIOL CHEM, V267, P20835; SVOBODA K, 1993, NATURE, V365, P721, DOI 10.1038/365721a0; VIK SB, 1994, J BIOL CHEM, V269, P30364; Wang HY, 1998, NATURE, V396, P279, DOI 10.1038/24409; Weber J, 1997, BBA-BIOENERGETICS, V1319, P19, DOI 10.1016/S0005-2728(96)00121-1; Yasuda R, 1998, CELL, V93, P1117, DOI 10.1016/S0092-8674(00)81456-7	33	393	400	3	47	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1722	1724		10.1126/science.286.5445.1722	http://dx.doi.org/10.1126/science.286.5445.1722			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576736				2022-12-28	WOS:000083912200034
J	Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M				Ross-Macdonald, P; Coelho, PSR; Roemer, T; Agarwal, S; Kumar, A; Jansen, R; Cheung, KH; Sheehan, A; Symoniatis, D; Umansky, L; Heldtman, M; Nelson, FK; Iwasaki, H; Hager, K; Gerstein, M; Miller, P; Roeder, GS; Snyder, M			Large-scale analysis of the yeast genome by transposon tagging and gene disruption	NATURE			English	Article							SACCHAROMYCES-CEREVISIAE; PROTEIN LOCALIZATION; EXPRESSION; RECOMBINATION; BINDS	Economical methods by which gene function maybe analysed on a genomic scale are relatively scarce. To fill this need, we have developed a transposon-tagging strategy for the genome-wide analysis of disruption phenotypes, gene expression and protein localization, and have applied this method to the large-scale analysis of gene function in the budding yeast Saccharomyces cerevisiae. Here we present the largest collection of defined yeast mutants ever generated within a single genetic background-a collection of over 11,000 strains, each carrying a transposon inserted within a region of the genome expressed during vegetative growth and/or sporulation. These insertions affect nearly 2,000 annotated genes, representing about one-third of the 6,200 predicted genes in the yeast genome(1,2). We have used this collection to determine disruption phenotypes for nearly 8,000 strains using 20 different growth conditions; the resulting data sets were clustered to identify groups of functionally related genes. We have also identified over 300 previously non-annotated open reading frames and analysed by indirect immunofluorescence over 1,300 transposon-tagged proteins. In total, our study encompasses over 260,000 data points, constituting the largest functional analysis of the yeast genome ever undertaken.	Yale Univ, Dept Mol Cellular & Dev Biol, New Haven, CT 06520 USA; Yale Univ, Dept Mol Biophys & Biochem, New Haven, CT 06520 USA; Yale Univ, Sch Med, Dept Anesthesiol, Ctr Med Informat, New Haven, CT 06510 USA; Yale Univ, Keck Fdn, Biotechnol Resource Lab, New Haven, CT 06520 USA	Yale University; Yale University; Yale University; Yale University	Snyder, M (corresponding author), Yale Univ, Dept Mol Cellular & Dev Biol, POB 208103, New Haven, CT 06520 USA.			Snyder, Michael/0000-0003-0784-7987; Kumar, Anuj/0000-0002-8923-297X				Adams A, 1997, METHODS YEAST GENETI; ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; BURNS N, 1994, GENE DEV, V8, P1087, DOI 10.1101/gad.8.9.1087; Cherry JM, 1998, NUCLEIC ACIDS RES, V26, P73, DOI 10.1093/nar/26.1.73; CHRISTMAN MF, 1988, CELL, V55, P413, DOI 10.1016/0092-8674(88)90027-X; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; ENGEBRECHT J, 1990, MOL CELL BIOL, V10, P2379, DOI 10.1128/MCB.10.5.2379; Evangelista CC, 1996, GENETICS, V142, P1083; Felsenstein J., 2005, PHYLIP PHYLOGENY INF, DOI DOI 10.1111/J.1096-0031.1989.TB00562.X; FITCH WM, 1967, SCIENCE, V155, P279, DOI 10.1126/science.155.3760.279; Goffeau A, 1996, SCIENCE, V274, P546, DOI 10.1126/science.274.5287.546; Goode BL, 1999, J CELL BIOL, V144, P83, DOI 10.1083/jcb.144.1.83; Hieter P, 1997, SCIENCE, V278, P601, DOI 10.1126/science.278.5338.601; Kaufman L., 1990, FINDING GROUPS DATA, DOI 10.1002/9780470316801; LEE WC, 1991, J CELL BIOL, V113, P1, DOI 10.1083/jcb.113.1.1; LODI T, 1995, MICROBIOL-SGM, V141, P2201, DOI 10.1099/13500872-141-9-2201; Lussier M, 1997, GENETICS, V147, P435; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; PAGE BD, 1992, GENE DEV, V6, P1414, DOI 10.1101/gad.6.8.1414; RossMacdonald P, 1995, METHOD MOL CELL BIOL, V5, P298; RossMacdonald P, 1997, P NATL ACAD SCI USA, V94, P190, DOI 10.1073/pnas.94.1.190; Sambrook J., 2002, MOL CLONING LAB MANU; SCHATZ PJ, 1986, MOL CELL BIOL, V6, P3711, DOI 10.1128/MCB.6.11.3711; Shoemaker DD, 1996, NAT GENET, V14, P450, DOI 10.1038/ng1296-450; SHORE D, 1987, CELL, V51, P721, DOI 10.1016/0092-8674(87)90095-X; Smith V, 1996, SCIENCE, V274, P2069, DOI 10.1126/science.274.5295.2069; STEARNS T, 1990, GENETICS, V124, P251; Velculescu VE, 1997, CELL, V88, P243, DOI 10.1016/S0092-8674(00)81845-0; White WH, 1997, GENETICS, V147, P43	30	403	430	1	30	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					413	418		10.1038/46558	http://dx.doi.org/10.1038/46558			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586881				2022-12-28	WOS:000083913600057
J	Woodward, B				Woodward, B			Challenges to human subject protections in US medical research	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article								United States regulations governing federally supported research with human subjects derive in part from 2 international codes, the Nuremberg Code and the Declaration of Helsinki, The Declaration of Helsinki states that "concern for the interests of the subject must always prevail over the interests of science and society." The concept of minimal risk and the principle of informed consent are the key means by which US federal regulations seek to protect the rights and welfare of the individual in the research setting, Current trends in medical research-including increased funding, ever-greater capabilities of computers, development of new clinical tools that can also be used in research, and new research tools developed through research itself-are creating greater demand for human subjects, for easier recruitment and conscription of these subjects, and for unimpeded access to patient medical records and human biological materials. Nationally and internationally, there are new pressures to subordinate the interests of the subject to those of science and society, The National Bioethics Advisory Commission, which is about to undertake a comprehensive review of the US system of human subject protections, faces a daunting task.	Brandeis Univ, Dept Philosophy, Waltham, MA 02454 USA; Brandeis Univ, Dept Sociol, Waltham, MA 02454 USA	Brandeis University; Brandeis University	Woodward, B (corresponding author), Brandeis Univ, Dept Philosophy, Mailstop 071, Waltham, MA 02454 USA.							Adams JG, 1999, ANN EMERG MED, V33, P218, DOI 10.1016/S0196-0644(99)70398-7; Advisory Committee on Human Radiation Experiments, 1996, FIN REP ADV COMM HUM; Angell Marcia, 1992, NAZI DOCTORS NUREMBE, P278; ANNAS GJ, 1988, JUDGING MED, P325; BANKOWSKI Z, 1993, ETHICS RES HUMAN SUB; BEECHER HK, 1966, NEW ENGL J MED, V274, P1354, DOI 10.1056/NEJM196606162742405; Brennan TA, 1999, NEW ENGL J MED, V341, P527, DOI 10.1056/NEJM199908123410712; BROWN JG, 1998, PUBLICATION US DEP H; CAMPBELL PW, 1998, CHRONICLE HIGHE 0403, pA33; Capron AM, 1999, NEW ENGL J MED, V340, P1430, DOI 10.1056/NEJM199905063401812; Carome MA, 1999, NEW ENGL J MED, V341, P448; CHARO RA, 1999, CHRONICLE HIGHE 0625, pA64; Dresser R, 1999, NEW ENGL J MED, V341, P449; FREEDMAN B, 1993, HASTINGS CENT REP, V23, P13, DOI 10.2307/3562813; GROB G, 1996, PUBLICATION GEN ACCO; Grodin MA, 1999, NEW ENGL J MED, V341, P449; HAMILTON J, 1999, PHYSICIANS WEEK 0719, V16, P1; HILTS PJ, 1999, NY TIMES        0525, pD4; HILTS PJ, 1999, NY TIMES        0525, pD1; *INT COMM MED J ED, 1999, UN REQ MAN SUBM BIOM; JONAS H, 1969, DAEDALUS, V98, P219; Kaplan S, 1999, US News World Rep, V127, P34; King NMP, 1999, NEW ENGL J MED, V341, P449; Macklin R, 1999, NEW ENGL J MED, V341, P992, DOI 10.1056/NEJM199909233411312; Michels R, 1999, NEW ENGL J MED, V340, P1427, DOI 10.1056/NEJM199905063401811; MINDLING JD, IN PRESS C P RES DEC; National Bioethics Advisory Commission, 1998, RES INV PERS MENT DI, V1; National Bioethics Advisory Committee, 1999, RES INV HUM BIOL MAT, V1; Oldham JM, 1999, ARCH GEN PSYCHIAT, V56, P688, DOI 10.1001/archpsyc.56.8.688; Shuster E, 1997, NEW ENGL J MED, V337, P1436, DOI 10.1056/NEJM199711133372006; Silverman H, 1999, NEW ENGL J MED, V341, P449; Skolnick AA, 1998, JAMA-J AM MED ASSOC, V279, P257, DOI 10.1001/jama.279.4.257; Tenery RM, 1999, NEW ENGL J MED, V341, P450; Truog RD, 1999, NEW ENGL J MED, V340, P804, DOI 10.1056/NEJM199903113401013; *WORLD MED ASS DEC, 1997, JAMA-J AM MED ASSOC, V277, P925, DOI DOI 10.1001/JAMA.1997.03540350075038; 1997, FED REG         1110, V62, P60607; 1991, FED REG         0618, V56, P28003; 1998, FED REG         1109, V63, P60364; 1997, JAMA, V276, P1691; 1997, WASHINGTON POST 0923, pA16; 1997, LANCET, V350, P823; 1997, NY TIMES        0911, pA30	42	66	66	0	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1947	1952		10.1001/jama.282.20.1947	http://dx.doi.org/10.1001/jama.282.20.1947			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	257BZ	10580461				2022-12-28	WOS:000083763400030
J	Schrag, A; Ben-Shlomo, Y; Quinn, NP				Schrag, A; Ben-Shlomo, Y; Quinn, NP			Prevalence of progressive supranuclear palsy and multiple system atrophy: a cross-sectional study	LANCET			English	Article							RICHARDSON-OLSZEWSKI-SYNDROME; TO-DOOR SURVEY; PARKINSONS-DISEASE; NATURAL-HISTORY; EPIDEMIOLOGY; POPULATION; DIAGNOSIS; COUNTY	Background The prevalence of progressive supranuclear palsy (PSP) and multiple system atrophy (MSA) in the general population is unknown. Clinicopathological studies of patients diagnosed as having Parkinson's disease suggest that the two disorders may be underdiagnosed. We investigated the population prevalence of these disorders. Methods We screened computerised records of 15 general practices in London, UK, for patients with specific diagnostic labels suggestive of Parkinson's disease or parkinsonism and all patients who had ever received antiparkinsonian medication. We assessed eligible patients by review of records, interview, physical examination, and video recordings of neurological signs for independent diagnostic confirmation. We diagnosed parkinsonian disorders according to published criteria and further reviewed patients with atypical features after 1 year. Findings The participation rate was 84%. The age-adjusted prevalence for PSP was 6.4 per 100 000 (five probable and one possible case [95% CI 2.3-10.6]) and for MSA 4.4 per 100 000 (two probable and two possible cases [1.2-7.6]). An additional four atypical patients were identified at 1 year but did not fulfil criteria for PSP or MSA. Interpretation Our results suggest that the true prevalence of PSP and MSA has been underestimated, since many patients in the community remain undiagnosed or misdiagnosed.	Inst Neurol, Dept Clin Neurol, London WC1N 3BG, England; Univ Bristol, Dept Social Med, Bristol, Avon, England	University of London; University College London; University of Bristol	Quinn, NP (corresponding author), Inst Neurol, Dept Clin Neurol, Queen Sq, London WC1N 3BG, England.		Schrag, Anette/AAA-9344-2020; Schrag, Anette E/B-4181-2011; Ben-Shlomo, Yoav/ABD-2004-2021	Schrag, Anette/0000-0002-9872-6680; Schrag, Anette E/0000-0002-9872-6680; Ben-Shlomo, Yoav/0000-0001-6648-3007				Bower JH, 1997, NEUROLOGY, V49, P1284, DOI 10.1212/WNL.49.5.1284; Chio A, 1998, MOVEMENT DISORD, V13, P400, DOI 10.1002/mds.870130305; Cockerell OC, 1996, NEUROEPIDEMIOLOGY, V15, P73, DOI 10.1159/000109892; COCKERELL OC, 1993, J NEUROL NEUROSUR PS, V56, P735, DOI 10.1136/jnnp.56.7.735; deRijk MC, 1995, NEUROLOGY, V45, P2143, DOI 10.1212/WNL.45.12.2143; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GOLBE LI, 1988, NEUROLOGY, V38, P1031, DOI 10.1212/WNL.38.7.1031; HUGHES AJ, 1992, NEUROLOGY, V42, P142; Litvan I, 1996, J NEUROL NEUROSUR PS, V60, P615, DOI 10.1136/jnnp.60.6.615; Litvan I, 1996, NEUROLOGY, V47, P1, DOI 10.1212/WNL.47.1.1; Maraganore DM, 1998, NEUROLOGY, V50, pA98; MASTAGLIA F L, 1973, Proceedings of the Australian Association of Neurologists, V10, P35; MORGANTE L, 1992, NEUROLOGY, V42, P1901; *OFF NAT STAT, 1997, EUR DAT SHOP; QUINN N, 1989, J NEUROL NEUROSUR PS, P78; RADHAKRISHNAN K, 1988, NEUROEPIDEMIOLOGY, V7, P159, DOI 10.1159/000110150; RAJPUT AH, 1984, ANN NEUROL, V16, P278, DOI 10.1002/ana.410160303; RAJPUT AH, 1991, CAN J NEUROL SCI, V18, P275, DOI 10.1017/S0317167100031814; RYBICKI BA, 1995, NEUROEPIDEMIOLOGY, V14, P72, DOI 10.1159/000109781; Smith P., 1987, CANC INCIDENCE 5 CON, V88, P790; STEELE JC, 1964, ARCH NEUROL-CHICAGO, V10, P333, DOI 10.1001/archneur.1964.00460160003001; TANDBERG E, 1995, MOVEMENT DISORD, V10, P541, DOI 10.1002/mds.870100503; TISON F, 1994, ACTA NEUROL SCAND, V90, P111; TRENKWALDER C, 1995, ARCH NEUROL-CHICAGO, V52, P1017, DOI 10.1001/archneur.1995.00540340109020; WENNING GK, 1995, J NEUROL NEUROSUR PS, V58, P160, DOI 10.1136/jnnp.58.2.160; WENNING GK, 1994, BRAIN, V117, P835, DOI 10.1093/brain/117.4.835; Wermuth L, 1997, NEUROLOGY, V49, P426, DOI 10.1212/WNL.49.2.426	27	390	407	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1771	1775		10.1016/S0140-6736(99)04137-9	http://dx.doi.org/10.1016/S0140-6736(99)04137-9			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577638				2022-12-28	WOS:000083853000011
J	DesJardin, JA; Falagas, ME; Ruthazer, R; Griffith, J; Wawrose, D; Schenkein, D; Miller, K; Snydman, DR				DesJardin, JA; Falagas, ME; Ruthazer, R; Griffith, J; Wawrose, D; Schenkein, D; Miller, K; Snydman, DR			Clinical utility of blood cultures drawn from indwelling central venous catheters in hospitalized patients with cancer	ANNALS OF INTERNAL MEDICINE			English	Article; Proceedings Paper	37th Interscience Conference on Antimicrobial Agents and Chemotherapy	SEP 28-OCT 03, 1997	TORONTO, CANADA	S African Med Res Council, Harry Crossley Fdn, Univ Stellenbosch		predictive value of tests; sensitivity and specificity; cell, cultured; catheterization, central venous; phlebotomy	BACTEREMIA; VENIPUNCTURE; FUNGEMIA	Background: Because of concern about low specificity, the American College of Physicians guidelines and expert opinion discourage the use of a central venous catheter when obtaining blood for culture for bacteremia or fungemia. However, data on the reliability of cultures done with blood obtained from a central venous catheter are conflicting. Objective: To determine the sensitivity, specificity, and positive and negative predictive values of cultures done with blood obtained through a central venous catheter compared with peripheral venipuncture. Design: Retrospective cohort study of hospitalized patients with cancer in whom samples for paired cultures were drawn through a central venous catheter and peripheral venipuncture. Setting: Tertiary care, university-affiliate medical center. Patients: 185 patients hospitalized on a hematology-oncology ward between August 1994 and June 1996. Measurements: Blinded assessments of culture results done by infectious disease experts were used as the gold standard. Sensitivity, specificity, and positive and negative predictive values were compared for culture of blood from central catheters and culture of blood from peripheral venipuncture. Results: Of 551 paired cultures, 469 (85%) were catheter-negative/venipuncture-negative. 32 (6%) were catheter-positive/veni puncture-positive, 17 (3%) were catheter-negative/venipuncture-positive. and 33 (6%) were catheter-positive/venipuncture-negative pairs. For the 82 paired cultures with at least one positive result, blinded determination of true bacteremia or fungemia was made by two infectious disease specialists. For catheter draw compared with peripheral venipuncture, sensitivity was 89% (95% CI, 79% to 98%) and 78% (CI, 65% to 90%) (difference, 11 percentage points [CI, -6 to 28 percentage points]), specificity was 95% (CI, 93% to 97%) and 97% (CI, 96% to 99%) (difference, -2 percentage points [CI, -5 to 0.2 percentage points]), positive predictive value was 63% (CI, 50% to 75%) and 73% (CI, 60% to 86%) (difference, -10 percentage points [CI, -26 to 5 percentage points]), and negative predictive value was 99% [CI, 97% to 100%]) and 98% (CI, 96% to 100%) (difference, 11 percentage point [CI, -0.5 to 3 percentage points]). Conclusions: In hospitalized hematology-oncology patients, culture of blood drawn through either the central catheter or peripheral vein shows excellent negative predictive value. Culture of blood drawn through an indwelling central venous catheter has low positive predictive value, apparently less than from a peripheral venipuncture. Therefore, a positive result from a catheter needs clinical interpretation and may require confirmation. However, the use of a catheter to obtain blood for culture may be an acceptable method for ruling out bloodstream infections.	Tufts Univ New England Med Ctr, Boston, MA 02111 USA; Tufts Univ, Sch Med, Medford, MA 02155 USA	Tufts Medical Center; Tufts University	Snydman, DR (corresponding author), Tufts Univ New England Med Ctr, 750 Washington St, Boston, MA 02111 USA.	david.snydman@es.nemc.org	Snydman, David R/O-3889-2014	Snydman, David R/0000-0003-0119-3978	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [T32AI007329] Funding Source: NIH RePORTER; NIAID NIH HHS [T32-AI07329] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARBO MDJ, 1994, ARCH INTERN MED, V154, P2641, DOI 10.1001/archinte.1994.00420230024004; ARONSON MD, 1987, ANN INTERN MED, V106, P246, DOI 10.7326/0003-4819-106-2-246; BATES DW, 1991, JAMA-J AM MED ASSOC, V265, P365, DOI 10.1001/jama.265.3.365; BRYANT JK, 1987, AM J CLIN PATHOL, V88, P113, DOI 10.1093/ajcp/88.1.113; Efron B., 1995, INTRO BOOTSTRAP; FELICES FJ, 1979, CRIT CARE MED, V7, P78, DOI 10.1097/00003246-197902000-00010; KRUEGER KE, 1981, ARCH PATHOL LAB MED, V105, P343; Reimer LG, 1997, CLIN MICROBIOL REV, V10, P444, DOI 10.1128/CMR.10.3.444; Shapiro C L, 1995, Surg Oncol Clin N Am, V4, P443; TAFURO P, 1986, J HOSP INFECT, V7, P283, DOI 10.1016/0195-6701(86)90079-4; TALCOTT JA, 1988, ARCH INTERN MED, V148, P2561, DOI 10.1001/archinte.148.12.2561; TONNESEN A, 1976, JAMA-J AM MED ASSOC, V235, P1877, DOI 10.1001/jama.235.17.1877; VAISANEN IT, 1985, CRIT CARE MED, V13, P664; Weinstein MP, 1997, CLIN INFECT DIS, V24, P584, DOI 10.1093/clind/24.4.584; WEINSTEIN MP, 1983, REV INFECT DIS, V5, P35, DOI 10.1093/clinids/5.1.35; Weinstein MP, 1996, CLIN INFECT DIS, V23, P40, DOI 10.1093/clinids/23.1.40; WORMSER GP, 1990, CRIT CARE MED, V18, P152, DOI 10.1097/00003246-199002000-00005	17	106	112	0	3	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					641	+		10.7326/0003-4819-131-9-199911020-00002	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00002			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	251LB	10577325				2022-12-28	WOS:000083446200001
J	Brugge, WR; Van Dam, J				Brugge, WR; Van Dam, J			Medical progress: Pancreatic and biliary endoscopy	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							FINE-NEEDLE ASPIRATION; COMMON BILE-DUCT; SOMATOSTATIN RECEPTOR SCINTIGRAPHY; PRIMARY SCLEROSING CHOLANGITIS; CONTROLLED CLINICAL-TRIAL; CYSTIC-FIBROSIS GENE; RETROGRADE CHOLANGIOPANCREATOGRAPHY; LAPAROSCOPIC CHOLECYSTECTOMY; COMPUTED-TOMOGRAPHY; ODDI DYSFUNCTION		Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA; Brigham & Womens Hosp, Div Gastroenterol, Boston, MA 02115 USA	Harvard University; Massachusetts General Hospital; Harvard University; Brigham & Women's Hospital	Brugge, WR (corresponding author), Massachusetts Gen Hosp, Gastrointestinal Endoscopy Unit, Blake 452C, Boston, MA 02114 USA.	brugge.william@mgh.harvard.edu						ABULAFI AM, 1995, GUT, V36, P853, DOI 10.1136/gut.36.6.853; Akahoshi K, 1998, BRIT J RADIOL, V71, P492, DOI 10.1259/bjr.71.845.9691893; ASHBY K, 1995, GASTROINTEST ENDOSC, V42, P306, DOI 10.1016/S0016-5107(95)70127-3; BALLINGER AB, 1994, GUT, V35, P467, DOI 10.1136/gut.35.4.467; Bansal R, 1999, GASTROINTEST ENDOSC, V49, P19, DOI 10.1016/S0016-5107(99)70440-2; Barkun AN, 1997, GASTROINTEST ENDOSC, V45, P277, DOI 10.1016/S0016-5107(97)70270-0; BARTHET M, 1995, GASTROINTEST ENDOSC, V42, P208, DOI 10.1016/S0016-5107(95)70093-5; Barthet M, 1997, GASTROINTEST ENDOSC, V45, P59, DOI 10.1016/S0016-5107(97)70303-1; Beckingham IJ, 1999, AM J GASTROENTEROL, V94, P71; Binmoeller KF, 1995, ENDOSCOPY, V27, P638, DOI 10.1055/s-2007-1005780; BINMOELLER KF, 1995, GASTROINTEST ENDOSC, V42, P219, DOI 10.1016/S0016-5107(95)70095-1; BJORKMAN DJ, 1995, AM J GASTROENTEROL, V90, P2128; Bordas JM, 1998, GASTROINTEST ENDOSC, V47, P230, DOI 10.1016/S0016-5107(98)70318-9; Brugge WR, 1996, GASTROINTEST ENDOSC, V43, P561, DOI 10.1016/S0016-5107(96)81585-9; BRUGGE WR, 1994, AM J GASTROENTEROL, V89, P2178; Brugge WR, 1998, GASTROENTEROLOGY, V115, P1577, DOI 10.1016/S0016-5085(98)70039-3; Canto MIF, 1998, GASTROINTEST ENDOSC, V47, P439, DOI 10.1016/S0016-5107(98)70242-1; Carr-Locke DL, 1999, GASTROINTEST ENDOSC, V49, pS77, DOI 10.1016/S0016-5107(99)70532-8; Catalano MF, 1998, GASTROINTEST ENDOSC, V48, P580, DOI 10.1016/S0016-5107(98)70039-2; CATALANO MF, 1995, GASTROINTEST ENDOSC, V42, P214, DOI 10.1016/S0016-5107(95)70094-3; Catalano MF, 1998, GASTROINTEST ENDOSC, V48, P11, DOI 10.1016/S0016-5107(98)70122-1; Cavallini G, 1996, NEW ENGL J MED, V335, P919, DOI 10.1056/NEJM199609263351302; Cellier C, 1998, GASTROINTEST ENDOSC, V47, P42, DOI 10.1016/S0016-5107(98)70297-4; Chan ACW, 1998, ENDOSCOPY, V30, P356, DOI 10.1055/s-2007-1001282; Chang KJ, 1997, GASTROINTEST ENDOSC, V45, P387, DOI 10.1016/S0016-5107(97)70149-4; Chang L, 1998, AM J GASTROENTEROL, V93, P527; Chow S, 1997, AM J GASTROENTEROL, V92, P1839; Cohn JA, 1998, NEW ENGL J MED, V339, P653, DOI 10.1056/NEJM199809033391002; COTTON PB, 1985, GASTROENTEROLOGY, V89, P1431, DOI 10.1016/0016-5085(85)90667-5; DAVIDS PHP, 1992, LANCET, V340, P1488, DOI 10.1016/0140-6736(92)92752-2; DAVIDS PHP, 1993, GUT, V34, P1250, DOI 10.1136/gut.34.9.1250; DAVIDS PHP, 1993, ANN SURG, V217, P237, DOI 10.1097/00000658-199303000-00004; de Ledinghen V, 1999, GASTROINTEST ENDOSC, V49, P26, DOI 10.1016/S0016-5107(99)70441-4; Desautels SG, 1999, GASTROENTEROLOGY, V116, P900, DOI 10.1016/S0016-5085(99)70073-9; DEVIERE J, 1995, GASTROINTEST ENDOSC, V42, P445, DOI 10.1016/S0016-5107(95)70048-X; deWit AWMV, 1996, GASTROINTEST ENDOSC, V44, P293, DOI 10.1016/S0016-5107(96)70167-0; Di Francesco V, 1999, DIGEST DIS SCI, V44, P336, DOI 10.1023/A:1026658618605; Dumonceau JM, 1996, GASTROINTEST ENDOSC, V43, P547, DOI 10.1016/S0016-5107(96)81583-5; Dumonceau JM, 1998, GASTROINTEST ENDOSC, V47, P8, DOI 10.1016/S0016-5107(98)70292-5; Dumot JA, 1998, AM J GASTROENTEROL, V93, P61; Ell C, 1998, GASTROINTEST ENDOSC, V48, P244, DOI 10.1016/S0016-5107(98)70185-3; Elta GH, 1998, GASTROINTEST ENDOSC, V47, P149, DOI 10.1016/S0016-5107(98)70348-7; Elton E, 1998, GASTROINTEST ENDOSC, V47, P240, DOI 10.1016/S0016-5107(98)70320-7; ERICKSON RA, 1995, GASTROENTEROLOGY, V109, P252, DOI 10.1016/0016-5085(95)90292-9; FAN ST, 1993, NEW ENGL J MED, V328, P228, DOI 10.1056/NEJM199301283280402; Fockens P, 1997, GASTROINTEST ENDOSC, V46, P412, DOI 10.1016/S0016-5107(97)70033-6; Folsch UR, 1997, NEW ENGL J MED, V336, P237, DOI 10.1056/NEJM199701233360401; Freeman ML, 1996, NEW ENGL J MED, V335, P909, DOI 10.1056/NEJM199609263351301; FREENY PC, 1981, CANCER, V47, P1666, DOI 10.1002/1097-0142(19810315)47:6+<1666::AID-CNCR2820471435>3.0.CO;2-U; FRUCHT H, 1990, GASTROENTEROLOGY, V99, P1622, DOI 10.1016/0016-5085(90)90466-E; GEENEN JE, 1989, NEW ENGL J MED, V320, P82, DOI 10.1056/NEJM198901123200203; GHOSH S, 1994, GUT, V35, P1757, DOI 10.1136/gut.35.12.1757; Giovannini M, 1998, GASTROINTEST ENDOSC, V48, P200, DOI 10.1016/S0016-5107(98)70165-8; Gregor JC, 1996, GASTROINTEST ENDOSC, V44, P118, DOI 10.1016/S0016-5107(96)70127-X; Gress F, 1997, GASTROINTEST ENDOSC, V45, P138, DOI 10.1016/S0016-5107(97)70236-0; Gress F, 1999, AM J GASTROENTEROL, V94, P900; Gress F, 1996, GASTROINTEST ENDOSC, V43, P522; Gress FG, 1997, GASTROINTEST ENDOSC, V45, P243, DOI 10.1016/S0016-5107(97)70266-9; HAMMEL P, 1995, GASTROENTEROLOGY, V108, P1230, DOI 10.1016/0016-5085(95)90224-4; JOHLIN FC, 1993, GASTROINTEST ENDOSC, V39, P645, DOI 10.1016/S0016-5107(93)70216-3; JOHNSON GK, 1995, GASTROINTEST ENDOSC, V42, P312, DOI 10.1016/S0016-5107(95)70128-1; Kubota Y, 1998, HEPATO-GASTROENTEROL, V45, P415; LAI ECS, 1992, NEW ENGL J MED, V326, P1582, DOI 10.1056/NEJM199206113262401; LANS JI, 1992, GASTROINTEST ENDOSC, V38, P430, DOI 10.1016/S0016-5107(92)70471-4; Legmann P, 1998, AM J ROENTGENOL, V170, P1315, DOI 10.2214/ajr.170.5.9574609; Leung JW, 1998, GASTROINTEST ENDOSC, V48, P250, DOI 10.1016/S0016-5107(98)70186-5; LEUNG JWC, 1989, LANCET, V1, P1307; Maldonado ME, 1999, AM J GASTROENTEROL, V94, P387, DOI 10.1016/S0002-9270(98)00745-X; Marks JM, 1998, SURG ENDOSC-ULTRAS, V12, P327, DOI 10.1007/s004649900663; McGuire DE, 1996, GASTROINTEST ENDOSC, V44, P300, DOI 10.1016/S0016-5107(96)70168-2; Menzel J, 1999, GASTROINTEST ENDOSC, V49, P349, DOI 10.1016/S0016-5107(99)70012-X; NAKAIZUMI A, 1995, DIGEST DIS SCI, V40, P696, DOI 10.1007/BF02064392; Neuhaus H, 1998, GASTROINTEST ENDOSC, V47, P327, DOI 10.1016/S0016-5107(98)70214-7; NICKL NJ, 1991, GASTROINTEST ENDOSC, V37, P133, DOI 10.1016/S0016-5107(91)70670-6; Ortner MAEJ, 1998, GASTROENTEROLOGY, V114, P536, DOI 10.1016/S0016-5085(98)70537-2; Parasher VK, 1998, GASTROINTEST ENDOSC, V48, P288, DOI 10.1016/S0016-5107(98)70193-2; PereiraLima JC, 1996, AM J GASTROENTEROL, V91, P2179; Ponchon T, 1996, ANN SURG, V223, P26, DOI 10.1097/00000658-199601000-00005; PONCHON T, 1995, GASTROINTEST ENDOSC, V42, P452, DOI 10.1016/S0016-5107(95)70049-8; Prat F, 1998, GASTROINTEST ENDOSC, V47, P1, DOI 10.1016/S0016-5107(98)70291-3; Proye CAG, 1998, SURGERY, V124, P1134, DOI 10.1067/msy.1998.93109; Quirk DM, 1997, GASTROINTEST ENDOSC, V46, P334, DOI 10.1016/S0016-5107(97)70121-4; Raikar GV, 1996, ANN SURG ONCOL, V3, P470, DOI 10.1007/BF02305765; Ramirez FC, 1998, GASTROINTEST ENDOSC, V47, P368, DOI 10.1016/S0016-5107(98)70220-2; Reddy KR, 1999, GASTROINTEST ENDOSC, V49, P498, DOI 10.1016/S0016-5107(99)70050-7; Reinhold C, 1998, RADIOLOGY, V209, P435, DOI 10.1148/radiology.209.2.9807570; ROSCH T, 1992, GASTROENTEROLOGY, V102, P188; ROSCH T, 1992, NEW ENGL J MED, V326, P1721, DOI 10.1056/NEJM199206253262601; Roston AD, 1997, GASTROINTEST ENDOSC, V45, P394, DOI 10.1016/S0016-5107(97)70150-0; RUSZNIEWSKI P, 1995, SURGERY, V117, P629, DOI 10.1016/S0039-6060(95)80005-0; Ryan ME, 1998, GASTROINTEST ENDOSC, V47, P261, DOI 10.1016/S0016-5107(98)70324-4; Sahai AV, 1999, GASTROINTEST ENDOSC, V49, P334, DOI 10.1016/S0016-5107(99)70010-6; Schmassmann A, 1996, AM J GASTROENTEROL, V91, P654; Seo DW, 1999, GASTROINTEST ENDOSC, V49, P204, DOI 10.1016/S0016-5107(99)70487-6; Sharer N, 1998, NEW ENGL J MED, V339, P645, DOI 10.1056/NEJM199809033391001; Sharma BC, 1998, GUT, V42, P288, DOI 10.1136/gut.42.2.288; Sherman S, 1996, GASTROINTEST ENDOSC, V44, P276, DOI 10.1016/S0016-5107(96)70164-5; Shim CS, 1998, ENDOSCOPY, V30, P345, DOI 10.1055/s-2007-1001280; Shrestha R, 1999, LIVER TRANSPLANT SUR, V5, P275, DOI 10.1002/lt.500050402; SIEGEL JH, 1994, AM J GASTROENTEROL, V89, P1142; SLIVKA A, 1994, J CLIN INVEST, V94, P1792, DOI 10.1172/JCI117527; Smith MT, 1996, GASTROINTEST ENDOSC, V44, P268, DOI 10.1016/S0016-5107(96)70163-3; Smits ME, 1997, GASTROINTEST ENDOSC, V45, P52, DOI 10.1016/S0016-5107(97)70302-X; Smits ME, 1996, GASTROINTEST ENDOSC, V43, P556, DOI 10.1016/S0016-5107(96)70190-6; SNADY H, 1994, GASTROINTEST ENDOSC, V40, P326, DOI 10.1016/S0016-5107(94)70065-6; Soetikno RM, 1998, GASTROINTEST ENDOSC, V47, P267, DOI 10.1016/S0016-5107(98)70325-6; Sosa JA, 1998, ANN SURG, V228, P429, DOI 10.1097/00000658-199809000-00016; Sugiyama M, 1997, GASTROINTEST ENDOSC, V45, P143, DOI 10.1016/S0016-5107(97)70237-2; Sugiyama M, 1998, GASTROINTEST ENDOSC, V48, P164, DOI 10.1016/S0016-5107(98)70158-0; Sugiyama M, 1998, AM J GASTROENTEROL, V93, P2065; Sugiyama M, 1998, BRIT J SURG, V85, P917; SUGIYAMA M, 1995, AM J ROENTGENOL, V165, P867, DOI 10.2214/ajr.165.4.7676983; Tarnasky P R, 1995, Gastrointest Endosc, V42, P103; Tarnasky PR, 1998, GASTROENTEROLOGY, V115, P1518, DOI 10.1016/S0016-5085(98)70031-9; Tham TCK, 1998, GUT, V42, P703, DOI 10.1136/gut.42.5.703; Tham TCK, 1998, GASTROINTEST ENDOSC, V47, P50, DOI 10.1016/S0016-5107(98)70298-6; Van Laethem JL, 1998, GASTROINTEST ENDOSC, V47, P479, DOI 10.1016/S0016-5107(98)70248-2; Vij JC, 1996, GASTROINTEST ENDOSC, V43, P121, DOI 10.1016/S0016-5107(06)80112-4; Wagner S, 1996, ENDOSCOPY, V28, P546, DOI 10.1055/s-2007-1005552; Wehrmann T, 1998, ENDOSCOPY, V30, P702, DOI 10.1055/s-2007-1001392; Wiersema MJ, 1997, GASTROENTEROLOGY, V112, P1087, DOI 10.1016/S0016-5085(97)70164-1; Wiersema MJ, 1996, GASTROINTEST ENDOSC, V44, P656, DOI 10.1016/S0016-5107(96)70047-0; Woolfolk G A, 1996, Gastrointest Endosc, V44, P761; Zimmer T, 1996, GUT, V39, P562, DOI 10.1136/gut.39.4.562	124	42	45	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1808	1816		10.1056/NEJM199912093412406	http://dx.doi.org/10.1056/NEJM199912093412406			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588967				2022-12-28	WOS:000084074000006
J	Goto, A; Reich, MR; Aitken, I				Goto, A; Reich, MR; Aitken, I			Oral contraceptives and women's health in Japan	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BIRTH-CONTROL	Japan approved the use of low-dose oral contraceptives (OCs) in June 1999, after more than 35 years of debate, The debate leaves a legacy of misinformation about and various sources of resistance to OCs. Benefits are expected to include greater control for women over their fertility and a reduction in the high rates of unplanned pregnancies and abortions, Successful implementation of the new policy will require a new emphasis on women's health, including the provision of accurate information about OCs and their associated adverse effects, a women-centered approach to gynecological practice, and the promotion of condoms as protection from sexually transmitted diseases, rather than as contraception alone.	Harvard Univ, Sch Publ Hlth, Dept Populat & Int Hlth, Boston, MA 02115 USA; Harvard Univ, Sch Publ Hlth, Dept Maternal & Child Hlth, Boston, MA 02115 USA	Harvard University; Harvard T.H. Chan School of Public Health; Harvard University; Harvard T.H. Chan School of Public Health	Goto, A (corresponding author), Yamagata Univ, Sch Med, Dept Publ Hlth, 2-2-2 Iida Nishi, Yamagata 9909585, Japan.			Goto, Aya/0000-0002-7927-7648				*A GUTTM I, 1999, SHAR RESP; Arakawa O, 1999, Nihon Koshu Eisei Zasshi, V46, P204; CATES W, 1992, FAM PLANN PERSPECT, V24, P75, DOI 10.2307/2135469; COLEMAN S, 1981, STUD FAMILY PLANN, V12, P28, DOI 10.2307/1965861; COLEMAN S, 1991, FAMILY PLANNING JAPA; *HLTH WELF STAT AS, 1998, TRENDS NAT HLTH; *JAP SOC OBST GYN, 1999, GUID US LOW DOS OR C; JITSUKAWA M, 1994, SCIENCE, V265, P1048, DOI 10.1126/science.8066442; Kihara M, 1997, J ACQ IMMUN DEF SYND, V14, pS3, DOI 10.1097/00042560-199700002-00002; KITAMURA K, 1997, SHINRYO KENKYU, V334, P5; Koonin L M, 1997, MMWR CDC Surveill Summ, V46, P37; KOROKU M, 1994, SEX TRANSM DIS, V21, P329, DOI 10.1097/00007435-199411000-00006; Maruyama H, 1996, NATURE, V379, P579, DOI 10.1038/379579a0; MATSUMOTO S, 1988, CURR THER RES CLIN E, V44, P165; MATSUMOTO S, 1991, JAPAN FAMILY PLANNIN, V6, P2; *MIN HLTH WELF, 1998, ANN REP HLTH WELF; *MIN HLTH WELF MIN, 1995, EUG PROT STAT REP; Munakata T, 1996, AIDS EDUC PREV, V8, P115; Nagata C, 1997, PREV MED, V26, P565, DOI 10.1006/pmed.1997.0176; *NHK HO BUNK KENK, 1998, MIND MOD JAP; Norgren T, 1998, J JPN STUD, V24, P59, DOI 10.2307/132939; Oddens BJ, 1998, CONTRACEPTION, V58, P13, DOI 10.1016/S0010-7824(98)00056-0; *OFF NAT STAT, 1994, 1994 AB STAT; OGINO M, 1993, REPROD HEALTH MATTER, V1, P78; *POP PROBL RES COU, 1998, 24 NAT SURV FAM PLAN; *POP PROBL RES COU, 1996, 23 NAT SURV FAM PLAN; *PRIM MIN OFF, 1997, PRES STAT PLANS NAT; TAKAHASHI S, 1999, JINKO MONDAI KENKYUS, V46, P3; TANAKA T, 1990, KOSEI NO SHIHYO, V37, P21; Uchino H, 1997, Nihon Koshu Eisei Zasshi, V44, P499; *WHO, 1998, WHO TECHN REP SER, V877; World Health Organisation [WHO, 1996, WHO TECHN REP SER, V866; Yamamoto T, 1999, Nihon Koshu Eisei Zasshi, V46, P304; YAMAUCHI M, 1991, BRIT MED J, V303, P1157	34	27	27	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2173	2177		10.1001/jama.282.22.2173	http://dx.doi.org/10.1001/jama.282.22.2173			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	260UG	10591342				2022-12-28	WOS:000083971400040
J	Conway, G; Toenniessen, G				Conway, G; Toenniessen, G			Feeding the world in the twenty-first century	NATURE			English	Article								The gains in food production provided by the Green Revolution have reached their ceiling while world population continues to rise. To ensure that the world's poorest people do not still go hungry in the twenty-first century, advances in plant biotechnology must be deployed for their benefit by a strong public-sector agricultural research effort.	Rockefeller Fdn, New York, NY 10018 USA		Conway, G (corresponding author), Rockefeller Fdn, New York, NY 10018 USA.							Cassman KG, 1999, P NATL ACAD SCI USA, V96, P5952, DOI 10.1073/pnas.96.11.5952; Conway G, 1999, DOUBLY GREEN REVOLUT; LEONARD HJ, 1989, ENV POOR DEV STRATEG, P3; Mann CC, 1999, SCIENCE, V283, P310, DOI 10.1126/science.283.5400.310; Mann CC, 1999, SCIENCE, V283, P314, DOI 10.1126/science.283.5400.314; May R. M., 1999, GENETICALLY MODIFIED; *NUFF COUNC BIOETH, 1999, GEN MOD CROPS ETH SO; PARDEY PG, 1996, SUMMARY PRODUCTIVE P; PRETTY J, IN PRESS BIOCHEMIST; Rissler J, 1996, ECOLOGICAL RISKS ENG; *ROYSL SOC LONDON, 1998, GEN MOD PLANTS FOOD; SOMER A, 1966, VITAMIN A DEFICIENCY; *UN FAO, 1996, 61 FAO WHO; UNICEF, 1998, STAT WORLDS CHILDR 1; YE XD, UNPUB SCIENCE; [No title captured]	16	155	166	3	65	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C55	C58		10.1038/35011545	http://dx.doi.org/10.1038/35011545			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591226				2022-12-28	WOS:000084014100008
J	Diesmann, M; Gewaltig, MO; Aertsen, A				Diesmann, M; Gewaltig, MO; Aertsen, A			Stable propagation of synchronous spiking in cortical neural networks	NATURE			English	Article							COINCIDENCE DETECTOR; ONGOING ACTIVITY; NEURONS; SYNCHRONIZATION; INTEGRATOR; PATTERNS; CORTEX; INPUTS; MODEL	The classical view of neural coding has emphasized the importance of information carried by the rate at which neurons discharge action potentials. More recent proposals that information may be carried by precise spike timing(1-5) have been challenged by the assumption that these neurons operate in a noisy fashion-presumably reflecting fluctuations in synaptic input(6)-and, thus, incapable of transmitting signals with millisecond fidelity. Here we show that precisely synchronized action potentials can propagate within a model of cortical network activity that recapitulates many of the features of biological systems. An attractor, yielding a stable spiking precision in the (sub)millisecond range, governs the dynamics of synchronization. Our results indicate that a combinatorial neural code, based on rapid associations of groups of neurons co-ordinating their activity at the single spike level, is possible within a cortical-like network.	Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, D-79104 Freiburg, Germany	University of Freiburg	Aertsen, A (corresponding author), Univ Freiburg, Inst Biol 3, Dept Neurobiol & Biophys, Schanzlestr 1, D-79104 Freiburg, Germany.	aertsen@biologie.uni-freiburg.de	Diesmann, Markus/H-3722-2013	Diesmann, Markus/0000-0002-2308-5727				ABELES M, 1982, ISRAEL J MED SCI, V18, P83; ABELES M, 1993, J NEUROPHYSIOL, V70, P1629, DOI 10.1152/jn.1993.70.4.1629; Abeles M., 1991, CORTICONICS; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; Arnoldi HMR, 1996, BIOL CYBERN, V74, P209, DOI 10.1007/BF00652222; BERNANDER O, 1994, NEURAL COMPUT, V6, P622, DOI 10.1162/neco.1994.6.4.622; BIENENSTOCK E, 1995, NETWORK-COMP NEURAL, V6, P179, DOI 10.1088/0954-898X/6/2/004; Braitenberg V, 1991, ANATOMY CORTEX; CALVIN WH, 1968, J NEUROPHYSIOL, V31, P574, DOI 10.1152/jn.1968.31.4.574; DIESMAN M, 1995, SYNOD ENV NEURAL SYS; DIESMANN M, 1997, MEMBRANE MIND, P62; DIESMANN M, 1996, TRENDS RES 1995, P59; FETZ E, 1991, CEREB CORTEX, V9, P1; GERSTEIN GL, 1964, BIOPHYS J, V4, P41, DOI 10.1016/S0006-3495(64)86768-0; GRIFFITH JS, 1963, BIOPHYS J, V3, P299, DOI 10.1016/S0006-3495(63)86822-8; HERRMANN M, 1995, NETWORK-COMP NEURAL, V6, P403, DOI 10.1088/0954-898X/6/3/006; HOPFIELD JJ, 1982, P NATL ACAD SCI-BIOL, V79, P2554, DOI 10.1073/pnas.79.8.2554; Konig P, 1996, TRENDS NEUROSCI, V19, P130, DOI 10.1016/S0166-2236(96)80019-1; MAINEN ZF, 1995, SCIENCE, V268, P1503, DOI 10.1126/science.7770778; Marsalek PR, 1997, P NATL ACAD SCI USA, V94, P735, DOI 10.1073/pnas.94.2.735; MURTHY VN, 1994, NEURAL COMPUT, V6, P1111, DOI 10.1162/neco.1994.6.6.1111; Nowak LG, 1997, CEREB CORTEX, V7, P487, DOI 10.1093/cercor/7.6.487; PERKEL DH, 1967, BIOPHYS J, V7, P419, DOI 10.1016/S0006-3495(67)86597-4; Prut Y, 1998, J NEUROPHYSIOL, V79, P2857, DOI 10.1152/jn.1998.79.6.2857; Riehle A, 1997, SCIENCE, V278, P1950, DOI 10.1126/science.278.5345.1950; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; Shadlen MN, 1998, J NEUROSCI, V18, P3870; Tuckwell H.C., 1988, INTRO THEORETICAL NE, DOI [10.1017/CBO9780511623202, DOI 10.1017/CBO9780511623202]; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724	30	669	675	0	42	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					529	533		10.1038/990101	http://dx.doi.org/10.1038/990101			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591212				2022-12-28	WOS:000084013200056
J	Matuchansky, C; Lenormand, Y				Matuchansky, C; Lenormand, Y			Taenia saginata.	NEW ENGLAND JOURNAL OF MEDICINE			English	Article									Hop Lariboisiere, F-75010 Paris, France	Assistance Publique Hopitaux Paris (APHP); Hopital Universitaire Lariboisiere-Fernand-Widal - APHP; UDICE-French Research Universities; Universite Paris Cite	Matuchansky, C (corresponding author), Hop Lariboisiere, F-75010 Paris, France.								0	3	3	0	1	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1737	1737		10.1056/NEJM199912023412305	http://dx.doi.org/10.1056/NEJM199912023412305			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580073				2022-12-28	WOS:000083955800005
J	Cassidy, EM; O'Halloran, DJ; Barry, S				Cassidy, EM; O'Halloran, DJ; Barry, S			Lesson of the week - Insulin as a substance of misuse in a patient with insulin dependent diabetes mellitus	BRITISH MEDICAL JOURNAL			English	Review							GLYCEMIC CONTROL; ABUSE		Cluain Mhuire Serv, Dept Psychiat, Blackrock, Dublin County, Ireland; Cork Univ Hosp, Cork, Ireland	University College Cork	Barry, S (corresponding author), Cluain Mhuire Serv, Dept Psychiat, Blackrock, Dublin County, Ireland.							Caminero JA, 1996, THORAX, V51, P1130, DOI 10.1136/thx.51.11.1130; CRAIG DH, 1981, ANN EMERG MED, V10, P98, DOI 10.1016/S0196-0644(81)80347-2; DORMAN A, 1995, BRIT MED J, V311, P1502, DOI 10.1136/bmj.311.7018.1502b; Freedman JB, 1996, PSYCHOSOMATICS, V37, P43, DOI 10.1016/S0033-3182(96)71597-9; Gonder-Frederick, 1997, Semin Clin Neuropsychiatry, V2, P57; GONDERFREDERICK LA, 1989, HEALTH PSYCHOL, V8, P45, DOI 10.1037/0278-6133.8.1.45; KAMINER Y, 1989, PSYCHOSOMATICS, V30, P19, DOI 10.1016/S0033-3182(89)72313-6; Kovacs M, 1997, DIABETES CARE, V20, P36, DOI 10.2337/diacare.20.1.36; Lustman PJ, 1997, PSYCHOSOM MED, V59, P241, DOI 10.1097/00006842-199705000-00007; Morris AD, 1997, LANCET, V350, P1505, DOI 10.1016/S0140-6736(97)06234-X; ODIE ELA, 1968, BRIT MED J, V2, P346; POTTER J, 1982, BRIT MED J, V285, P1182; RETSAS S, 1972, BRIT MED J, V4, P792, DOI 10.1136/bmj.4.5843.792-e; Scaramuzza A, 1996, EUR J PEDIATR, V155, P526, DOI 10.1007/BF01955200; SCARLETT JA, 1977, NEW ENGL J MED, V297, P1029, DOI 10.1056/NEJM197711102971903; SHAMOON H, 1993, NEW ENGL J MED, V329, P977, DOI 10.1056/nejm199309303291401; Szwabo P A, 1993, Clin Geriatr Med, V9, P197; Weiss RD, 1998, J CLIN PSYCHIAT, V59, P172, DOI 10.4088/JCP.v59n0405	18	13	13	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1417	1418		10.1136/bmj.319.7222.1417	http://dx.doi.org/10.1136/bmj.319.7222.1417			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	261EE	10574864	Green Published			2022-12-28	WOS:000083995200032
J	Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA				Wyrick, JJ; Holstege, FCP; Jennings, EG; Causton, HC; Shore, D; Grunstein, M; Lander, ES; Young, RA			Chromosomal landscape of nucleosome-dependent gene expression and silencing in yeast	NATURE			English	Article							ASSEMBLY FACTOR-I; SACCHAROMYCES-CEREVISIAE; TELOMERIC HETEROCHROMATIN; CHROMATIN STRUCTURE; TRANSCRIPTION; GENOME; RAP1; DEPLETION; PROMOTER; FAMILY	Eukaryotic genomes are packaged into nucleosomes, which are thought to repress gene expression generally(1-3), Repression is particularly evident at yeast telomeres, where genes within the telomeric heterochromatin appear to be silenced by the histone-binding silent information regulator (SIR) complex (Sir2, Sir3, Sir4) and Rap1 (refs 4-10). Here, to investigate how nucleosomes and silencing factors influence global gene expression, we use high-density arrays to study the effects of depleting nucleosomal histones and silencing factors in yeast. Reducing nucleosome content by depleting histone H4 caused increased expression of 15% of genes and reduced expression of 10% of genes, hut it had little effect on expression of the majority (75%) of yeast genes, Telomere-proximal genes were found to be de-repressed over regions extending 20 kilobases from the telomeres, well beyond the extent of Sir protein binding(11,12) and the effects of loss of Sir function, These results indicate that histones make Sir-independent contributions to telomeric silencing, and that the role of histones located elsewhere in chromosomes is gene specific rather than generally repressive.	MIT, Dept Biol, Cambridge, MA 02139 USA; Whitehead Inst Biomed Res, Cambridge, MA 02142 USA; Univ Geneva, Dept Mol Biol, CH-1211 Geneva, Switzerland; Univ Calif Los Angeles, Sch Med, Dept Biol Chem, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Inst Mol Biol, Los Angeles, CA 90095 USA	Massachusetts Institute of Technology (MIT); Massachusetts Institute of Technology (MIT); Whitehead Institute; University of Geneva; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles	Young, RA (corresponding author), MIT, Dept Biol, 77 Massachusetts Ave, Cambridge, MA 02139 USA.		Young, Richard A/F-6495-2012; Shore, David/F-6240-2015; Holstege, Frank/AAM-9944-2021	Young, Richard A/0000-0001-8855-8647; Shore, David/0000-0002-9859-143X; Causton, Helen/0000-0003-4630-6569				APARICIO OM, 1991, CELL, V66, P1279, DOI 10.1016/0092-8674(91)90049-5; BRACHMANN CB, 1995, GENE DEV, V9, P2888, DOI 10.1101/gad.9.23.2888; Chavez S, 1997, P NATL ACAD SCI USA, V94, P2885, DOI 10.1073/pnas.94.7.2885; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Enomoto S, 1997, GENE DEV, V11, P358, DOI 10.1101/gad.11.3.358; Gregory PD, 1998, CURR OPIN CELL BIOL, V10, P339, DOI 10.1016/S0955-0674(98)80009-4; Grunstein M, 1998, CELL, V93, P325, DOI 10.1016/S0092-8674(00)81160-5; HAN M, 1988, CELL, V55, P1137, DOI 10.1016/0092-8674(88)90258-9; HAN M, 1988, EMBO J, V7, P2221, DOI 10.1002/j.1460-2075.1988.tb03061.x; Hecht A, 1996, NATURE, V383, P92, DOI 10.1038/383092a0; Holstege FCP, 1998, CELL, V95, P717, DOI 10.1016/S0092-8674(00)81641-4; Kaufman PD, 1997, GENE DEV, V11, P345, DOI 10.1101/gad.11.3.345; KIM UJ, 1988, EMBO J, V7, P2211, DOI 10.1002/j.1460-2075.1988.tb03060.x; KURTZ S, 1991, GENE DEV, V5, P616, DOI 10.1101/gad.5.4.616; KYRION G, 1993, GENE DEV, V7, P1146, DOI 10.1101/gad.7.7a.1146; Laroche T, 1998, CURR BIOL, V8, P653, DOI 10.1016/S0960-9822(98)70252-0; Loo S, 1995, ANNU REV CELL DEV BI, V11, P519, DOI 10.1146/annurev.cellbio.11.1.519; Lustig AJ, 1998, CURR OPIN GENET DEV, V8, P233, DOI 10.1016/S0959-437X(98)80146-9; MORETTI P, 1994, GENE DEV, V8, P2257, DOI 10.1101/gad.8.19.2257; Nislow C, 1997, MOL BIOL CELL, V8, P2421, DOI 10.1091/mbc.8.12.2421; PARANJAPE SM, 1994, ANNU REV BIOCHEM, V63, P265, DOI 10.1146/annurev.biochem.63.1.265; RINE J, 1987, GENETICS, V116, P9; SAUNDERS MJ, 1990, MOL CELL BIOL, V10, P5721, DOI 10.1128/MCB.10.11.5721; SCHILD C, 1993, EMBO J, V12, P423, DOI 10.1002/j.1460-2075.1993.tb05674.x; Shen XT, 1996, CELL, V86, P475, DOI 10.1016/S0092-8674(00)80120-8; StrahlBolsinger S, 1997, GENE DEV, V11, P83, DOI 10.1101/gad.11.1.83; Wodicka L, 1997, NAT BIOTECHNOL, V15, P1359, DOI 10.1038/nbt1297-1359; Workman JL, 1998, ANNU REV BIOCHEM, V67, P545, DOI 10.1146/annurev.biochem.67.1.545; Zakian VA, 1996, ANNU REV GENET, V30, P141, DOI 10.1146/annurev.genet.30.1.141	30	316	319	0	7	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					418	421		10.1038/46567	http://dx.doi.org/10.1038/46567			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586882				2022-12-28	WOS:000083913600058
J	Chen, J; Reed, MA; Rawlett, AM; Tour, JM				Chen, J; Reed, MA; Rawlett, AM; Tour, JM			Large on-off ratios and negative differential resistance in a molecular electronic device	SCIENCE			English	Article							VALLEY CURRENT RATIOS; ROOM-TEMPERATURE; WIRES	A molecule containing a nitroamine redox center (2'-amino-4-ethynylphenyl-4'-ethynylphenyl-5'-nitro-1-benzenethiol) was used in the active self-assembled monolayer in an electronic device. Current-voltage measurements of the device exhibited negative differential resistance and an on-off peak-to-valley ratio in excess of 1000:1.	Yale Univ, Dept Elect Engn, New Haven, CT 06520 USA; Yale Univ, Dept Appl Phys, New Haven, CT 06520 USA; Yale Univ, Dept Phys, New Haven, CT 06520 USA; Rice Univ, Ctr Nanoscale Sci & Technol, Houston, TX 77005 USA; Rice Univ, Dept Chem, Houston, TX 77005 USA	Yale University; Yale University; Yale University; Rice University; Rice University	Reed, MA (corresponding author), Yale Univ, Dept Elect Engn, POB 208284, New Haven, CT 06520 USA.		Reed, Mark/A-9970-2011	Reed, Mark/0000-0001-6479-7256; Tour, James/0000-0002-8479-9328				Aviram A., 1998, MOL ELECT SCI TECHNO; Broekaert TPE, 1998, IEEE J SOLID-ST CIRC, V33, P1342, DOI 10.1109/4.711333; BROWN ER, 1991, APPL PHYS LETT, V58, P229; Bumm LA, 1996, SCIENCE, V271, P1705, DOI 10.1126/science.271.5256.1705; DAY DJ, 1993, J APPL PHYS, V73, P1542, DOI 10.1063/1.353231; Deshpande MR, 1996, PHYS REV LETT, V76, P1328, DOI 10.1103/PhysRevLett.76.1328; Huber JL, 1997, IEEE T ELECTRON DEV, V44, P2149, DOI 10.1109/16.644628; Kergueris C, 1999, PHYS REV B, V59, P12505, DOI 10.1103/PhysRevB.59.12505; Mathews RH, 1999, P IEEE, V87, P596, DOI 10.1109/5.752517; Petty M. C., 1995, INTRO MOL ELECT; Reed MA, 1999, P IEEE, V87, P652, DOI 10.1109/5.752520; Reed MA, 1997, SCIENCE, V278, P252, DOI 10.1126/science.278.5336.252; SEABAUGH C, 1994, HETEROSTRUCTURES QUA, P351; SMET JH, 1992, J APPL PHYS, V71, P2475, DOI 10.1063/1.351085; SODERSTROM JR, 1989, J APPL PHYS, V66, P5106, DOI 10.1063/1.343742; TOUR JM, 1995, J AM CHEM SOC, V117, P9529, DOI 10.1021/ja00142a021; TSAI HH, 1994, IEEE ELECTR DEVICE L, V15, P357, DOI 10.1109/55.311133; Zhou C, 1997, APPL PHYS LETT, V71, P611, DOI 10.1063/1.120195; ZHOU C, 1999, THESIS YALE U	19	2342	2440	9	391	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1550	1552		10.1126/science.286.5444.1550	http://dx.doi.org/10.1126/science.286.5444.1550			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567259				2022-12-28	WOS:000083768300055
J	Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I				Owen, T; Mahaffy, P; Niemann, HB; Atreya, S; Donahue, T; Bar-Nun, A; de Pater, I			A low-temperature origin for the planetesimals that formed Jupiter	NATURE			English	Article							SOLAR NEBULA; WAVELENGTHS; CHEMISTRY; MODELS	The four giant planets in the Solar System have abundances of 'metals' (elements heavier than helium), relative to hydrogen, that are much higher than observed in the Sun. In order to explain this, all models for the formation of these planets rely on an influx of solid planetesimals(17). It is generally assumed that these planetesimals were similar, if not identical, to the comets from the Oort cloud that we see today. Comets that formed in the region of the giant planets should not have contained much neon, argon and nitrogen, because the temperatures were too high for these volatile gases to be trapped effectively in ice. This means that the abundances of those elements on the giant planets should be approximately solar. Here we show that argon, krypton and xenon in Jupiter's atmosphere are enriched to the same extent as the other heavy elements, which suggests that the planetesimals carrying these elements must have formed at temperatures lower than predicted by present models of giant-planet formation.	Univ Hawaii, Inst Astron, Honolulu, HI 96822 USA; NASA, Goddard Space Flight Ctr, Atmospheres Lab, Greenbelt, MD 20771 USA; Univ Michigan, Ann Arbor, MI 48109 USA; Tel Aviv Univ, Dept Geophys & Planetary Sci, IL-69978 Tel Aviv, Israel; Univ Calif Berkeley, Dept Astron, Berkeley, CA 94720 USA	University of Hawaii System; National Aeronautics & Space Administration (NASA); NASA Goddard Space Flight Center; University of Michigan System; University of Michigan; Tel Aviv University; University of California System; University of California Berkeley	Owen, T (corresponding author), Univ Hawaii, Inst Astron, 2680 Woodlawn Dr, Honolulu, HI 96822 USA.	owen@ifa.hawaii.edu	Mahaffy, Paul/E-4609-2012	Mahaffy, Paul/0000-0003-1896-1726				ANDERS E, 1989, GEOCHIM COSMOCHIM AC, V53, P197, DOI 10.1016/0016-7037(89)90286-X; ATREYA SK, IN PRESS PLANET SPAC; ATREYA SK, 1997, 3 GALILEOS MAN SPACE, P289; BARNUN A, 1988, PHYS REV B, V38, P7749, DOI 10.1103/PhysRevB.38.7749; CASSEN P, 1994, ICARUS, V112, P405, DOI 10.1006/icar.1994.1195; DEPATER I, 1986, ICARUS, V68, P344, DOI 10.1016/0019-1035(86)90027-8; DEPATER I, 1985, ICARUS, V62, P143, DOI 10.1016/0019-1035(85)90177-0; GEISS J, 1988, REV MOD ASTRON, V1, P1; JOINER J, 1991, J GEOPHYS RES-PLANET, V96, P17463, DOI 10.1029/91JE01740; KRANKOWSKY D, 1991, ASTROPHYS SPACE SC L, V167, P855; LINKE RA, 1983, ASTROPHYS J, V271, pL85, DOI 10.1086/184100; Mahaffy P. R., 1998, B AM ASTRON SOC, V30, P1066; MAHAFFY PR, 1998, PRIMORDIAL NUCL THEI, P239; MARTEN A, 1993, ASTROPHYS J, V406, P285, DOI 10.1086/172440; Niemann HB, 1998, J GEOPHYS RES-PLANET, V103, P22831, DOI 10.1029/98JE01050; OWEN T, 1995, ICARUS, V116, P215, DOI 10.1006/icar.1995.1122; Owen TC, 1997, THREE GALILEOS: THE MAN, THE SPACECRAFT, THE TELESCOPE, P289; POLKNER WM, 1998, J GEOPHYS RES, V103, P22847; ROMANI PN, 1995, B AM ASTRON SOC, V27, P81; Showman AP, 1998, ICARUS, V132, P205, DOI 10.1006/icar.1998.5898; van Dishoeck E. F., 1993, PROTOSTARS PLANETS, P163; WYCKOFF S, 1991, ASTROPHYS J, V367, P641, DOI 10.1086/169659	24	225	226	1	11	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					269	270		10.1038/46232	http://dx.doi.org/10.1038/46232			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580497	Green Published			2022-12-28	WOS:000083813700041
J	Bosma, H; Schrijvers, C; Mackenbach, JP				Bosma, H; Schrijvers, C; Mackenbach, JP			Socioeconomic inequalities in mortality and importance of perceived control: cohort study	BRITISH MEDICAL JOURNAL			English	Article									Erasmus Univ, Sch Med, Dept Publ Hlth, NL-3000 DR Rotterdam, Netherlands	Erasmus University Rotterdam	Bosma, H (corresponding author), Erasmus Univ, Sch Med, Dept Publ Hlth, POB 1738, NL-3000 DR Rotterdam, Netherlands.		Bosma, Hans/A-6184-2013					Bosma H, 1999, BRIT MED J, V318, P18; MACKENBACH JP, 1994, SOC SCI MED, V38, P299, DOI 10.1016/0277-9536(94)90399-9; Marmot MG, 1997, LANCET, V350, P235, DOI 10.1016/S0140-6736(97)04244-X; ROTTER JB, 1966, PSYCHOL MONOGR, V80, P1, DOI 10.1037/h0092976; Syme SL., 1989, STRESS, P3	5	124	128	0	5	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1469	1470		10.1136/bmj.319.7223.1469	http://dx.doi.org/10.1136/bmj.319.7223.1469			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582929	Green Published, Green Submitted, Bronze			2022-12-28	WOS:000084129200021
J	Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S				Robinson, RC; Mejillano, M; Le, VP; Burtnick, LD; Yin, HL; Choe, S			Domain movement in gelsolin: A calcium-activated switch	SCIENCE			English	Article							PLASMA GELSOLIN; BINDING-SITE; ACTIN; COMPLEX; IDENTIFICATION; FILAMENT	The actin-binding protein gelsolin is involved in remodeling the actin cytoskeleton during growth-factor signaling, apoptosis, cytokinesis, and cell movement. Calcium-activated gelsolin severs and caps actin filaments, The 3.4 angstrom x-ray structure of the carboxyl-terminal half of gelsolin (G4-G6) in complex with actin reveals the basis for gelsolin activation. Calcium binding induces a conformational rearrangement in which domain G6 is flipped over and translated by about 40 angstroms relative to G4 and G5. The structural reorganization tears apart the continuous beta sheet core of G4 and G6. This exposes the actin-binding site on G4, enabling severing and capping of actin filaments to proceed.	Salk Inst Biol Studies, Struct Biol Lab, San Diego, CA 92186 USA; Univ Texas, SW Med Ctr, Dept Physiol, Dallas, TX 75235 USA; Univ British Columbia, Dept Chem, Vancouver, BC V6T 1Z1, Canada	Salk Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of British Columbia	Choe, S (corresponding author), Salk Inst Biol Studies, Struct Biol Lab, POB 85800, San Diego, CA 92186 USA.		Robinson, Robert/G-9702-2011	Robinson, Robert/0000-0001-6367-6903				Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Burtnick LD, 1997, CELL, V90, P661, DOI 10.1016/S0092-8674(00)80527-9; HOLMES KC, 1990, NATURE, V347, P44, DOI 10.1038/347044a0; Kissinger CR, 1999, ACTA CRYSTALLOGR D, V55, P484, DOI 10.1107/S0907444998012517; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Kwiatkowski DJ, 1999, CURR OPIN CELL BIOL, V11, P103, DOI 10.1016/S0955-0674(99)80012-X; KWIATKOWSKI DJ, 1986, NATURE, V323, P455, DOI 10.1038/323455a0; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lin KM, 1997, J BIOL CHEM, V272, P20443, DOI 10.1074/jbc.272.33.20443; McGough A, 1998, BIOPHYS J, V74, P764, DOI 10.1016/S0006-3495(98)74001-9; MCLAUGHLIN PJ, 1993, NATURE, V364, P685, DOI 10.1038/364685a0; NICHOLLS A, 1991, J COMPUT CHEM, V12, P435, DOI 10.1002/jcc.540120405; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; POPE B, 1995, BIOCHEMISTRY-US, V34, P1583, DOI 10.1021/bi00005a014; SPUDICH JA, 1971, J BIOL CHEM, V246, P4866; WAY M, 1988, J MOL BIOL, V203, P1127, DOI 10.1016/0022-2836(88)90132-5; WEEDS AG, 1995, FEBS LETT, V360, P227, DOI 10.1016/0014-5793(95)00109-M; 1994, ACTA CRYSTALLOGR D, V55, P760	18	134	139	2	16	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1939	1942		10.1126/science.286.5446.1939	http://dx.doi.org/10.1126/science.286.5446.1939			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583954				2022-12-28	WOS:000084003400047
J	Olson, ES				Olson, ES			Direct measurement of intra-cochlear pressure waves	NATURE			English	Article							BASILAR-MEMBRANE; MECHANICS; POSITION; BASE	The cochlear travelling wave is fundamental to the ability of the mammalian auditory system to resolve frequency. The seashell-shaped outer bone of the cochlea (the auditory inner ear) contains a spiral of cochlear fluid and the sensory tissue known as the cochlear partition. Sound travels down the ear canal to the eardrum, causing its flexible tympanic membrane to vibrate. This vibration is transmitted to the cochlea via the ossicles. Motion of the stapes (the stirrup ossicle) sets the cochlear fluid in motion, which in turn sets the cochlear partition near the stapes in motion. The motion of the cochlear partition ripples down the cochlear spiral as a travelling wave, stimulating the cochlea's sensory hair cells. The wave peaks near the base (the stapes end) of the cochlea for high frequency tones and near the apex for low frequencies'. The fundamental elements of the cochlear travelling wave are fluid pressure and motion and partition forces and motion. However, the wave's direct experimental study has to date relied almost solely on measurements of the partition motion. Here I report finely spaced measurements of intracochlear pressure close to the partition, which reveal the fluid component of the cochlear wave. The penetration depth of the wave is very limited, similar to 15 mu m. Over a range of frequencies at least an octave wide, the depth is independent of frequency.	Princeton Univ, Dept Phys, Princeton, NJ 08544 USA	Princeton University	Olson, ES (corresponding author), Princeton Univ, Dept Phys, Princeton, NJ 08544 USA.				NIDCD NIH HHS [R29 DC003130] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS [R29DC003130] Funding Source: NIH RePORTER	NIDCD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD)); NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD))		BROWNELL WE, 1985, SCIENCE, V227, P195; COOPER NP, 1992, HEARING RES, V63, P163, DOI 10.1016/0378-5955(92)90083-Y; DANCER A, 1980, HEARING RES, V2, P191, DOI 10.1016/0378-5955(80)90057-X; DEBOER E, 1984, PHYS REP, V105, P141, DOI 10.1016/0370-1573(84)90108-X; LIBERMAN MC, 1984, HEARING RES, V16, P55, DOI 10.1016/0378-5955(84)90025-X; LIGHTHILL J, 1981, J FLUID MECH, V106, P149, DOI 10.1017/S0022112081001560; Muller M, 1996, HEARING RES, V94, P148, DOI 10.1016/0378-5955(95)00230-8; Olson ES, 1998, J ACOUST SOC AM, V103, P3445, DOI 10.1121/1.423083; PLASSMANN W, 1987, BRAIN BEHAV EVOLUT, V30, P82, DOI 10.1159/000118639; RHODE WS, 1971, J ACOUST SOC AM, V49, P1218, DOI 10.1121/1.1912485; Ruggero MA, 1997, J ACOUST SOC AM, V101, P2151, DOI 10.1121/1.418265; SELLICK PM, 1983, HEARING RES, V10, P101, DOI 10.1016/0378-5955(83)90020-5; SPOENDLIN H, 1972, ACTA OTO-LARYNGOL, V73, P235, DOI 10.3109/00016487209138937; STEELE CR, 1979, J ACOUST SOC AM, V65, P1007, DOI 10.1121/1.382570; vonBekesy G., 1960, EXPT HEARING; XUE SW, 1995, J ACOUST SOC AM, V97, P3030, DOI 10.1121/1.413103	16	95	96	1	13	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					526	529		10.1038/990092	http://dx.doi.org/10.1038/990092			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591211				2022-12-28	WOS:000084013200055
J	Ansell, BJ; Watson, KE; Fogelman, AM				Ansell, BJ; Watson, KE; Fogelman, AM			An evidence-based assessment of the NCEP Adult Treatment Panel II guidelines	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Review							CORONARY-HEART-DISEASE; SCANDINAVIAN SIMVASTATIN SURVIVAL; AVERAGE CHOLESTEROL LEVELS; GRAFT VESSEL DISEASE; EVENTS CARE TRIAL; MYOCARDIAL-INFARCTION; LOWERING THERAPY; TRANSPLANT RECIPIENTS; CARDIOVASCULAR EVENTS; PRIMARY PREVENTION	Context The Second Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II) was issued without the benefit of multiple recently published large clinical trials. Objective To analyze the panel's guidelines for treatment of high cholesterol levels in the context of currently available clinical trial results. Data Sources MEDLINE was searched for all English-language clinical trial data from 1993 through February 1999 relating to the effects of cholesterol treatment on cardiovascular clinical outcomes. Study Selection Studies that were selected for detailed review assessed the effects of cholesterol lowering on either coronary events, coronary mortality, stroke, and/or total mortality, preferably by randomized, double-blind, placebo-controlled design. Selection was by consensus of a general internist, a lipid clinic director, and a researcher in atherosclerotic plaque biology. A core of 37 of the 317 initially screened studies were selected and used as the primary means by which to assess the guidelines. Data Extraction By consensus of the group, only prespecified end points of trials were included, unless post hoc analysis addressed issues not studied elsewhere. Data Synthesis Recent clinical trial data mostly support the Adult Treatment Panel II guidelines for cholesterol management. While existing trials have validated the target low-density lipoprotein cholesterol (LDL-C) goals in the report, studies are lacking that address mortality benefit from reduction below these levels, Few lipid-lowering trials have treated patients with low high-density lipoprotein cholesterol and/or elevated triglyceride levels with LDL-C levels at or below treatment goals. Conclusions Lipid-lowering therapy generally should be more aggressively applied to patients with diabetes and/or at the time of coronary heart disease (CHD) diagnosis. The evidence for statin use in secondary CHD prevention in postmenopausal women outweighs current evidence for use of estrogen replacement in this setting. Further studies are needed to address the effects of lipid modification in primary prevention of CHD in populations other than middle-aged men and to study markers of lipid metabolism other than LDL-C.	Univ Calif Los Angeles, Sch Med, Dept Med, Div Gen Internal Med Hlth Serv Res, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Sch Med, Dept Med, Div Cardiol, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; David Geffen School of Medicine at UCLA	Ansell, BJ (corresponding author), Univ Calif Los Angeles, Sch Med, Dept Med, Div Gen Internal Med Hlth Serv Res, 200 UCLA Med Plaza,Suite 370-8, Los Angeles, CA 90095 USA.	bansell@mednet.ucla.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [P01HL030568] Funding Source: NIH RePORTER; NHLBI NIH HHS [HL 30568] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		*AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS56; *AM HEART ASS, 1998, 1999 HEART STROK STA; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; BLANKENHORN DH, 1987, JAMA-J AM MED ASSOC, V257, P3233, DOI 10.1001/jama.257.23.3233; Blauw GJ, 1997, STROKE, V28, P946, DOI 10.1161/01.STR.28.5.946; BROWN G, 1990, NEW ENGL J MED, V323, P1289, DOI 10.1056/NEJM199011083231901; BUCHWALD H, 1990, NEW ENGL J MED, V323, P946, DOI 10.1056/NEJM199010043231404; BYINGTON RP, 1995, AM J CARDIOL, V76, pC54, DOI 10.1016/S0002-9149(99)80471-8; Campeau L, 1997, NEW ENGL J MED, V336, P153; Castro R, 1997, NEPHROL DIAL TRANSPL, V12, P2140, DOI 10.1093/ndt/12.10.2140; Crouse JR, 1998, ATHEROSCLEROSIS, V138, P11, DOI 10.1016/S0021-9150(98)00014-8; Crouse JR, 1997, ARCH INTERN MED, V157, P1305, DOI 10.1001/archinte.157.12.1305; de Groot E, 1998, J AM COLL CARDIOL, V31, P1561, DOI 10.1016/S0735-1097(98)00170-3; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; Garber AM, 1996, ANN INTERN MED, V124, P515, DOI 10.7326/0003-4819-124-5-199603010-00013; Goldbourt U, 1997, ARTERIOSCL THROM VAS, V17, P107, DOI 10.1161/01.ATV.17.1.107; Goldstein J.L., 1989, METABOLIC BASIS INHE, P1215; Gotto AM, 1995, CURR OPIN LIPIDOL, V6, P341, DOI 10.1097/00041433-199512000-00001; GOULD AL, 1995, CIRCULATION, V91, P2274, DOI 10.1161/01.CIR.91.8.2274; Grodstein F, 1996, NEW ENGL J MED, V335, P453, DOI 10.1056/NEJM199608153350701; GRUNDY SM, 1993, JAMA-J AM MED ASSOC, V269, P3015, DOI 10.1001/jama.269.23.3015; Grundy SM, 1997, CIRCULATION, V95, P1683; Haffner SM, 1998, NEW ENGL J MED, V339, P229, DOI 10.1056/NEJM199807233390404; Hebert PR, 1997, JAMA-J AM MED ASSOC, V278, P313, DOI 10.1001/jama.278.4.313; HEBERT PR, 1995, ARCH INTERN MED, V155, P50, DOI 10.1001/archinte.155.1.50; Hodis HN, 1996, ANN INTERN MED, V124, P548, DOI 10.7326/0003-4819-124-6-199603150-00002; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; ISO H, 1989, NEW ENGL J MED, V320, P904, DOI 10.1056/NEJM198904063201405; Jaeger BR, 1997, CIRCULATION, V96, P154; Jenkins GH, 1996, AM J CARDIOL, V78, P1453, DOI 10.1016/S0002-9149(96)00637-6; Kakkis JL, 1997, J SURG RES, V69, P393, DOI 10.1006/jsre.1997.5107; Katznelson S, 1996, TRANSPLANTATION, V61, P1469, DOI 10.1097/00007890-199605270-00010; Kesaniemi YA, 1998, AM J CARDIOL, V81, p70B, DOI 10.1016/S0002-9149(98)00042-3; KOBASHIGAWA JA, 1995, NEW ENGL J MED, V333, P621, DOI 10.1056/NEJM199509073331003; Lewis SJ, 1998, ANN INTERN MED, V129, P681, DOI 10.7326/0003-4819-129-9-199811010-00002; Lewis SJ, 1998, J AM COLL CARDIOL, V32, P140, DOI 10.1016/S0735-1097(98)00202-2; MacMahon S, 1998, CIRCULATION, V97, P1784, DOI 10.1161/01.CIR.97.18.1784; Miettinen TA, 1997, CIRCULATION, V96, P4211; MULDOON MF, 1990, BMJ-BRIT MED J, V301, P309, DOI 10.1136/bmj.301.6747.309; Pahor M, 1999, ARCH INTERN MED, V159, P237, DOI 10.1001/archinte.159.3.237; PEDERSEN TR, 1995, LANCET, V345, P1274; PEDERSEN TR, 1994, LANCET, V344, P1383; Pedersen TR, 1998, CIRCULATION, V97, P1453, DOI 10.1161/01.CIR.97.15.1453; Pitt B, 1999, NEW ENGL J MED, V341, P70, DOI 10.1056/NEJM199907083410202; PROBSTFIELD JL, 1995, AM J CARDIOL, V76, pC47, DOI 10.1016/S0002-9149(99)80470-6; Rifkind BM, 1999, JAMA-J AM MED ASSOC, V281, P180, DOI 10.1001/jama.281.2.180; RIFKIND BM, 1984, AM J CARDIOL, V54, pC30, DOI 10.1016/0002-9149(84)90854-3; Rubins HB, 1999, NEW ENGL J MED, V341, P410, DOI 10.1056/NEJM199908053410604; Sacks FM, 1998, CIRCULATION, V97, P1446; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; Stampfer MJ, 1996, JAMA-J AM MED ASSOC, V276, P882, DOI 10.1001/jama.276.11.882; Stein EA, 1999, JAMA-J AM MED ASSOC, V281, P137, DOI 10.1001/jama.281.2.137; Thiery J, 1998, CURR OPIN LIPIDOL, V9, P521, DOI 10.1097/00041433-199812000-00002; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; Tracy RE, 1995, AM J MED SCI, V310, pS37, DOI 10.1097/00000441-199512000-00007; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; Wenke K, 1997, CIRCULATION, V96, P1398, DOI 10.1161/01.CIR.96.5.1398; Wood D, 1998, EUR HEART J, V19, P1434	59	79	82	0	7	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2051	2057		10.1001/jama.282.21.2051	http://dx.doi.org/10.1001/jama.282.21.2051			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591388				2022-12-28	WOS:000083908700025
J	Berry, PH				Berry, PH			Organ donation: Can the US do better?	BRITISH MEDICAL JOURNAL			English	Editorial Material									Texas Med Assoc, Dallas, TX USA		Berry, PH (corresponding author), Texas Med Assoc, Dallas, TX USA.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1445	1445		10.1136/bmj.319.7222.1445	http://dx.doi.org/10.1136/bmj.319.7222.1445			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574892	Green Published			2022-12-28	WOS:000083995200086
J	Stone, SL; Arnoldo, M; Goring, DR				Stone, SL; Arnoldo, M; Goring, DR			A breakdown of Brassica self-incompatibility in ARC1 antisense transgenic plants	SCIENCE			English	Article							LOCUS RECEPTOR KINASE; PROTEIN PHOSPHATASE; STIGMA PAPILLAE; GENE; OLERACEA; PHENOTYPE; DOMAIN; SLG	Self-incompatibility, the rejection of self pollen, is the most widespread mechanism by which flowering plants prevent inbreeding. In Brassica, the S receptor kinase (SRK) has been implicated in the self-incompatibility response, but the molecular mechanisms involving SRK are unknown. One putative downstream effector for SRK is ARC1, a protein that binds to the SRK kinase domain. Here it is shown that suppression of ARC1 messenger RNA levels in the self-incompatible Brassica napus W1 line is correlated with a partial breakdown of self-incompatibility, resulting in seed production. This provides strong evidence that ARC1 is a positive effector of the Brassica self-incompatibility response.	York Univ, Dept Biol, Toronto, ON M3J 1P3, Canada; Canola Res Stn, Pioneer Hi Bred Prod, Georgetown, ON L7G 4S7, Canada	York University - Canada	Goring, DR (corresponding author), York Univ, Dept Biol, 4700 Keele St, Toronto, ON M3J 1P3, Canada.			Stone, Sophia/0000-0003-2140-6037; Goring, Daphne/0000-0001-5295-4744				Becraft PW, 1998, TRENDS PLANT SCI, V3, P384, DOI 10.1016/S1360-1385(98)01301-6; Bower MS, 1996, PLANT CELL, V8, P1641, DOI 10.1105/tpc.8.9.1641; Braun DM, 1996, TRENDS BIOCHEM SCI, V21, P70, DOI 10.1016/S0968-0004(96)80185-X; Cabrillac D, 1999, PLANT CELL, V11, P971, DOI 10.1105/tpc.11.5.971; DELORME V, 1995, PLANT J, V7, P429, DOI 10.1046/j.1365-313X.1995.7030429.x; DENATTANCOURT D, 1997, SEX PLANT REPROD, V10, P185; DICKINSON H, 1995, SEX PLANT REPROD, V8, P1, DOI 10.1007/BF00228756; Franklin TM, 1996, SEX PLANT REPROD, V9, P203, DOI 10.1007/BF02173099; GAUDE T, 1995, PLANT MOL BIOL, V27, P1003, DOI 10.1007/BF00037027; GORING DR, 1992, MOL GEN GENET, V234, P185, DOI 10.1007/BF00283838; GORING DR, 1992, PLANT CELL, V4, P1273, DOI 10.1105/tpc.4.10.1273; GORING DR, 1996, SIGNAL TRANSDUCTION; Gu TS, 1998, P NATL ACAD SCI USA, V95, P382, DOI 10.1073/pnas.95.1.382; Hatzfeld M, 1999, INT REV CYTOL, V186, P179; Hiscock SJ, 1996, TRENDS CELL BIOL, V6, P421, DOI 10.1016/S0962-8924(96)10037-4; KANDASAMY MK, 1989, DEV BIOL, V134, P462, DOI 10.1016/0012-1606(89)90119-X; MATTON DP, 1994, P NATL ACAD SCI USA, V91, P1992, DOI 10.1073/pnas.91.6.1992; NASRALLAH JB, 1994, SCIENCE, V266, P1506; NASRALLAH JB, 1985, NATURE, V318, P236; STEIN JC, 1991, P NATL ACAD SCI USA, V88, P8816, DOI 10.1073/pnas.88.19.8816; Stephenson AG, 1997, PLANT J, V12, P1351, DOI 10.1046/j.1365-313x.1997.12061351.x; Stone JM, 1998, PLANT PHYSIOL, V117, P1217, DOI 10.1104/pp.117.4.1217; Sulaman W, 1997, PLANTA, V203, P327, DOI 10.1007/s004250050198; Williams RW, 1997, P NATL ACAD SCI USA, V94, P10467, DOI 10.1073/pnas.94.19.10467	24	180	223	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1729	1731		10.1126/science.286.5445.1729	http://dx.doi.org/10.1126/science.286.5445.1729			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576738				2022-12-28	WOS:000083912200036
J	Blass, JP				Blass, JP			Immunologic treatment of Alzheimer's disease	NEW ENGLAND JOURNAL OF MEDICINE			English	Editorial Material									Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA	Cornell University	Blass, JP (corresponding author), Cornell Univ, Burke Med Res Inst, White Plains, NY 10605 USA.							BLASS JP, 1995, CLIN DIAGNOSIS MANAG, P17; Davis DG, 1999, J NEUROPATH EXP NEUR, V58, P376, DOI 10.1097/00005072-199904000-00008; Guo Q, 1999, J NEUROCHEM, V72, P1019, DOI 10.1046/j.1471-4159.1999.0721019.x; Schenk D, 1999, NATURE, V400, P173, DOI 10.1038/22124; Seabrook GR, 1999, NEUROPHARMACOLOGY, V38, P349, DOI 10.1016/S0028-3908(98)00204-4	5	11	27	0	0	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1694	1695		10.1056/NEJM199911253412213	http://dx.doi.org/10.1056/NEJM199911253412213			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572162				2022-12-28	WOS:000083847500013
J	Cookson, W				Cookson, W			The alliance of genes and environment in asthma and allergy	NATURE			English	Review							INFLAMMATORY BOWEL-DISEASE; GENOME-WIDE SEARCH; SERUM IGE LEVELS; IMMUNOGLOBULIN-E RECEPTOR; QUANTITATIVE TRAIT LOCI; EPSILON-RI-BETA; SUSCEPTIBILITY LOCI; RHEUMATOID-ARTHRITIS; ATOPIC-DERMATITIS; LINKAGE ANALYSIS	The diseases of asthma, eczema and hay fever are typified by reactions to common allergens, which are mediated by immunoglobulin E. These allergic diseases are increasing in prevalence, and are now a major source of disability throughout the developed world. They are the result of complex interactions between largely unknown genetic and environmental mechanisms. The identification of the environmental factors offers the real possibility of prevention of disease, and unravelling the genetics of allergic illnesses is likely to change their classification and treatment. Early life seems particularly important, when the initiation of allergic disease may result from genetic and environmental modification of the immune interaction between mother and child.	Wellcome Trust Ctr Human Genet, Oxford OX3 7BN, England	University of Oxford; Wellcome Centre for Human Genetics	Cookson, W (corresponding author), Wellcome Trust Ctr Human Genet, Roosevelt Dr, Oxford OX3 7BN, England.	william.cookson@ndm.ox.ac.uk	Cookson, William/HHC-1790-2022					ABERG N, 1995, CLIN EXP ALLERGY, V25, P815, DOI 10.1111/j.1365-2222.1995.tb00023.x; Akolkar PN, 1997, AM J GASTROENTEROL, V92, P2241; ANTO JM, 1986, LANCET, V1, P900, DOI 10.1016/S0140-6736(86)90999-2; Baldini M, 1999, AM J RESP CELL MOL, V20, P976, DOI 10.1165/ajrcmb.20.5.3494; Barnes KC, 1996, GENOMICS, V37, P41, DOI 10.1006/geno.1996.0518; Beasley R, 1998, LANCET, V351, P1225, DOI 10.1016/S0140-6736(97)07302-9; Bennett ST, 1996, ANNU REV GENET, V30, P343, DOI 10.1146/annurev.genet.30.1.343; Bjorksten B, 1998, EUR RESPIR J, V12, P432, DOI 10.1183/09031936.98.12020432; Bjorksten B, 1999, LANCET, V353, P167, DOI 10.1016/S0140-6736(05)77212-3; BLUMENTHAL MN, 1981, AM J MED GENET, V10, P219, DOI 10.1002/ajmg.1320100304; BORECKI I B, 1985, Genetic Epidemiology, V2, P327, DOI 10.1002/gepi.1370020402; Braun-Fahrlander C, 1999, CLIN EXP ALLERGY, V29, P28, DOI 10.1046/j.1365-2222.1999.00479.x; Burney P, 1996, EUR RESPIR J, V9, P687; Chess A, 1998, SCIENCE, V279, P2067, DOI 10.1126/science.279.5359.2067; Coca AF, 1923, J IMMUNOL, V8, P163; COLLINS FS, 1995, NAT GENET, V9, P347, DOI 10.1038/ng0495-347; Cookson WOCM, 1998, CLIN EXP ALLERGY, V28, P88; COOKSON WOCM, 1989, LANCET, V1, P1292; Cox HE, 1998, BRIT J DERMATOL, V138, P182; Daniels SE, 1996, NATURE, V383, P247, DOI 10.1038/383247a0; Dizier MH, 1999, AM J RESP CRIT CARE, V159, pA649; DOLD S, 1992, ARCH DIS CHILD, V67, P1018, DOI 10.1136/adc.67.8.1018; Drazen JM, 1999, NAT GENET, V22, P168, DOI 10.1038/9680; Dubois P, 1998, THORAX, V53, P101, DOI 10.1136/thx.53.2.101; Duerr RH, 1998, AM J HUM GENET, V63, P95, DOI 10.1086/301929; DUFFY DL, 1990, AM REV RESPIR DIS, V142, P1351, DOI 10.1164/ajrccm/142.6_Pt_1.1351; EIBERG H, 1985, CYTOGENET CELL GENET, V40, P622; GODFREY R C, 1975, Clinical Allergy, V5, P201, DOI 10.1111/j.1365-2222.1975.tb01853.x; GREEN SA, 1994, BIOCHEMISTRY-US, V33, P9414, DOI 10.1021/bi00198a006; GYAPAY G, 1994, NAT GENET, V7, P246, DOI 10.1038/ng0694supp-246; Hall IP, 1996, THORAX, V51, P351, DOI 10.1136/thx.51.4.351; HALL JG, 1990, ARCH DIS CHILD-FETAL, V65, P1013, DOI 10.1136/adc.65.10_Spec_No.1013; Hardwick LJ, 1997, J RHEUMATOL, V24, P197; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; Hill MR, 1996, HUM MOL GENET, V5, P959, DOI 10.1093/hmg/5.7.959; Hizawa N, 1998, J ALLERGY CLIN IMMUN, V102, P436, DOI 10.1016/S0091-6749(98)70132-0; Holberg CJ, 1996, AM J RESP CRIT CARE, V154, P144, DOI 10.1164/ajrccm.154.1.8680670; HOLT PG, 1990, PEDIATR ALLERGY IMMU, V1, P3; Hugot JP, 1996, NATURE, V379, P821, DOI 10.1038/379821a0; Jenkins MA, 1997, GENET EPIDEMIOL, V14, P317, DOI 10.1002/(SICI)1098-2272(1997)14:3<317::AID-GEPI9>3.0.CO;2-1; Kimura K, 1999, HUM MOL GENET, V8, P1487, DOI 10.1093/hmg/8.8.1487; Koumantaki Y, 1997, J RHEUMATOL, V24, P1522; LANDER E, 1995, NAT GENET, V11, P241, DOI 10.1038/ng1195-241; LARSEN FS, 1993, J AM ACAD DERMATOL, V28, P719, DOI 10.1016/0190-9622(93)70099-F; LARSEN FS, 1986, J AM ACAD DERMATOL, V15, P487; Larsen JN, 1996, ADV EXP MED BIOL, V409, P243; LAWRENCE S, 1994, ANN HUM GENET, V58, P359, DOI 10.1111/j.1469-1809.1994.tb00732.x; MANSFIELD JC, 1994, GASTROENTEROLOGY, V106, P637, DOI 10.1016/0016-5085(94)90696-3; Marsh DG, 1997, NAT GENET, V15, P389; MARSH DG, 1994, SCIENCE, V264, P1152, DOI 10.1126/science.8178175; MEYERS DA, 1994, GENOMICS, V23, P464, DOI 10.1006/geno.1994.1524; MOFFATT F, 1994, LANCET, V343, P1597, DOI 10.1016/S0140-6736(94)93057-0; Moffatt MF, 1997, HUM MOL GENET, V6, P551, DOI 10.1093/hmg/6.4.551; Moffatt MF, 1998, CLIN EXP ALLERGY, V28, P56; Moffatt MF, 1999, AM J RESP CRIT CARE, V159, pA648; Moffatt MF, 1996, MONOGR ALLERGY, V33, P71; MOFFATT MF, 1992, CLIN EXP ALLERGY, V22, P1046, DOI 10.1111/j.1365-2222.1992.tb00128.x; Mueller GA, 1998, BIOCHEMISTRY-US, V37, P12707, DOI 10.1021/bi980578+; Nakai M, 1998, BIOL CONTROL, V13, P63, DOI 10.1006/bcon.1998.0643; *NAT ASTHM CAMP, 1998, ASTHM AG; Nickel R, 1997, GENOMICS, V46, P159, DOI 10.1006/geno.1997.5013; Nowak D, 1996, Pneumologie, V50, P364; Ober C, 1998, HUM MOL GENET, V7, P1393, DOI 10.1093/hmg/7.9.1393; Palmer LJ, 1997, AM J HUM GENET, V61, P182, DOI 10.1086/513888; Ramsay G, 1998, NAT BIOTECHNOL, V16, P40, DOI 10.1038/nbt0198-40; RISCH N, 1995, SCIENCE, V268, P1584, DOI 10.1126/science.7777857; Risch N, 1996, SCIENCE, V273, P1516, DOI 10.1126/science.273.5281.1516; RONA RJ, 1995, THORAX, V50, P992, DOI 10.1136/thx.50.9.992; Rook GAW, 1998, IMMUNOL TODAY, V19, P113, DOI 10.1016/S0167-5699(97)01204-8; Rosenwasser LJ, 1997, INT ARCH ALLERGY IMM, V113, P61, DOI 10.1159/000237509; SAMPSON HA, 1990, CLIN EXP ALLERGY, V20, P459, DOI 10.1111/j.1365-2222.1990.tb03137.x; Sanak M, 1997, LANCET, V350, P1599, DOI 10.1016/S0140-6736(05)64015-9; Satsangi J, 1996, NAT GENET, V14, P199, DOI 10.1038/ng1096-199; SHIRAKAWA T, 1994, CLIN GENET, V46, P228; Shirakawa T, 1996, HUM MOL GENET, V5, P1129, DOI 10.1093/hmg/5.8.1129; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; SIGURS N, 1994, J ALLERGY CLIN IMMUN, V94, P757, DOI 10.1016/0091-6749(94)90184-8; Smith DH, 1997, AM J RESP CRIT CARE, V156, P787, DOI 10.1164/ajrccm.156.3.9611072; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; STAINES C, 1998, AM J RESP CRIT CARE, V157, pA11; STUART M, 1999, START UP         APR, P12; VANHERWERDEN L, 1995, LANCET, V346, P1262, DOI 10.1016/S0140-6736(95)91863-9; von Mutius E, 1998, LANCET, V351, P862, DOI 10.1016/S0140-6736(97)10100-3; Von Pirquet C., 1906, MUNCHEN MED WOCHEN, V30, P1457; VONEHRENSTEIN O, 1998, EPIDEMIOLOGY, V9, pS118; VONMUTIUS E, 1994, AM J RESP CRIT CARE, V149, P358, DOI 10.1164/ajrccm.149.2.8306030; VONMUTIUS E, 1992, BMJ-BRIT MED J, V305, P1395, DOI 10.1136/bmj.305.6866.1395; VONMUTIUS E, 1994, BRIT MED J, V308, P692, DOI 10.1136/bmj.308.6930.692; Vorechovsky I, 1999, AM J HUM GENET, V64, P1096, DOI 10.1086/302326; WARRAM JH, 1984, NEW ENGL J MED, V311, P149, DOI 10.1056/NEJM198407193110304; WATSON M, 1995, ANN HUM GENET, V59, P403, DOI 10.1111/j.1469-1809.1995.tb00759.x; Wjst M, 1999, GENOMICS, V58, P1, DOI 10.1006/geno.1999.5806	92	290	311	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B5	B11		10.1038/35037002	http://dx.doi.org/10.1038/35037002			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586889	Bronze			2022-12-28	WOS:000083913900003
J	Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG				Klebanoff, MA; Levine, RJ; DerSimonian, R; Clemens, JD; Wilkins, DG			Maternal serum paraxanthine, a caffeine metabolite, and the risk of spontaneous abortion	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							PREGNANCY; CONSUMPTION; BEVERAGES; COFFEE	Background: Whether the consumption of caffeine during pregnancy increases the risk of spontaneous abortion is controversial. Prior studies have determined caffeine consumption by questionnaire. We used a biologic marker, serum paraxanthine, a metabolite of caffeine, to measure the dose of caffeine. Methods: In a nested case-control study, we measured serum paraxanthine in 591 women who had spontaneous abortions at less than 140 days' gestation and in 2558 matched women from the same clinic who gave birth to live infants at 28 weeks' gestation or later and who had serum drawn on the same day of gestation as the women who had abortions. The women were enrolled in the Collaborative Perinatal Project during the period from 1959 to 1966, and serum paraxanthine was measured over 30 years later. Results: A total of 487 women who had spontaneous abortions (82 percent) and 2087 controls (82 percent) had quantifiable serum paraxanthine concentrations. However, the mean serum paraxanthine concentration was higher in the women who had spontaneous abortions than in the controls (752 vs. 583 ng per milliliter, P<0.001). The odds ratio for spontaneous abortion was not significantly elevated in the women who had serum paraxanthine concentrations of 1845 ng per milliliter or lower, corresponding to the 95th percentile of the matched women. However, the adjusted odds ratio for spontaneous abortion among women with serum paraxanthine concentrations higher than 1845 ng per milliliter, as compared with women who had concentrations below 50 ng per milliliter, was 1.9 (95 percent confidence interval, 1.2 to 2.8). Conclusions: Only extremely high serum paraxanthine concentrations are associated with spontaneous abortion. This suggests that moderate consumption of caffeine is unlikely to increase the risk of spontaneous abortion. (N Engl J Med 1999;341:1639-44.) (C) 1999, Massachusetts Medical Society.	NICHHD, Div Epidemiol Stat & Prevent Res, NIH, Bethesda, MD 20892 USA; Univ Utah, Ctr Human Toxicol, Salt Lake City, UT USA	National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); Utah System of Higher Education; University of Utah	Klebanoff, MA (corresponding author), NICHHD, Div Epidemiol Stat & Prevent Res, NIH, 6100 Bldg,Rm 7B03,MSC 7510, Bethesda, MD 20892 USA.				EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [N01HD073262, Z01HD000373] Funding Source: NIH RePORTER; NICHD NIH HHS [N01-HD-7-3262] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		ALDRIDGE A, 1981, SEMIN PERINATOL, V5, P310; ARMSTRONG BG, 1992, AM J PUBLIC HEALTH, V82, P85, DOI 10.2105/AJPH.82.1.85; BERGSJO P, 1989, ACTA OBSTET GYN SCAN, V68, P19, DOI 10.3109/00016348909087683; Dlugosz L, 1996, EPIDEMIOLOGY, V7, P250, DOI 10.1097/00001648-199605000-00006; ESKENAZI B, 1993, JAMA-J AM MED ASSOC, V270, P2973, DOI 10.1001/jama.270.24.2973; Fenster L, 1991, Epidemiology, V2, P168, DOI 10.1097/00001648-199105000-00002; Fenster L, 1997, EPIDEMIOLOGY, V8, P515, DOI 10.1097/00001648-199709000-00008; GILBERT RM, 1984, METHYLXANTHINE BEVER, P185; INFANTERIVARD C, 1993, JAMA-J AM MED ASSOC, V270, P2940, DOI 10.1001/jama.270.24.2940; Klebanoff MA, 1998, ANN EPIDEMIOL, V8, P107, DOI 10.1016/S1047-2797(97)00125-7; KLINE J, 1991, EPIDEMIOLOGY, V2, P409, DOI 10.1097/00001648-199111000-00004; KLINE J, 1989, CONCEPTION BIRTH EPI, P81; LELO A, 1986, CLIN PHARMACOL THER, V39, P54, DOI 10.1038/clpt.1986.10; MILLS JL, 1993, JAMA-J AM MED ASSOC, V269, P593, DOI 10.1001/jama.269.5.593; Niswander K.R., 1972, WOMEN THEIR PREGNANC; *SAS I INC, 1992, P229 SAS I INC, P433; SRISUPHAN W, 1986, AM J OBSTET GYNECOL, V154, P14, DOI 10.1016/0002-9378(86)90385-6; STEIN H, 1991, ANN ONCOL, V2, P163, DOI 10.1093/annonc/2.suppl_2.163; van den Berg B J, 1988, Paediatr Perinat Epidemiol, V2, P265; Yesair D W, 1984, Prog Clin Biol Res, V158, P215	20	90	92	0	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	NOV 25	1999	341	22					1639	1644		10.1056/NEJM199911253412202	http://dx.doi.org/10.1056/NEJM199911253412202			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258PL	10572151				2022-12-28	WOS:000083847500002
J	Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY				Chang, LY; Lin, TY; Hsu, KH; Huang, YC; Lin, KL; Hsueh, C; Shih, SR; Ning, HC; Hwang, MS; Wang, HS; Lee, CY			Clinical features and risk factors of pulmonary oedema after enterovirus-71-related hand, foot, and mouth disease	LANCET			English	Article							CENTRAL NERVOUS-SYSTEM; ENCEPHALOMYELITIS; INFECTIONS; EPIDEMIC; EDEMA	Background In Taiwan, from April to July, 1998, an epidemic of hand, foot, and mouth disease associated with enterovirus 71 (EV71) occurred with fatal complications. We did a clinical study of EV71-related diseases in Taiwan. Methods We studied 154 children with virus-culture-confirmed EV71 infection. Children were divided into three groups: 11 patients with pulmonary oedema; 38 patients with central nervous system (CNS) involvement and no pulmonary oedema; and 105 children without complications. We compared the clinical features, laboratory findings, risk factors, and outcome among these three groups. Findings Nine children with pulmonary oedema had hand, foot, and mouth disease, one had herpangina, and one had febrile illness with eight children with limb weakness and one with limb hypesthesia. All children had had sudden onset of tachycardia, tachypnoea, and cyanosis 1-3 days after onset of the disease. Nine of 11 children died within 12 h of intubation; one child was braindead within 15 h and died 17 days after intubation; one child was in deep coma and died 3 months later. In children with CNS complication and no pulmonary oedema, one child died of pneumonia after 4 months of ventilator support and four children had sequelae. All 105 children without complications recovered. There was a significant association between CNS involvement and pulmonary oedema (odds ratio 12 4 [95% CI 2.6-60.1], p = 0.001). Risk factors for pulmonary oedema after CNS involvement were hyperglycaemia, leucocytosis, and limb weakness. Hyperglycaemia was tbe most significant prognostic factor for pulmonary oedema (odds ratio 21.5 [3-159], p = 0.003). Interpretation EV71 can cause hand. foot, and mouth disease, CNS involvement with severe sequelae, and fatal pulmonary oedema. Hyperglycaemia is the most important prognostic factor.	Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Neurol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Cardiol, Tao Yuan, Taiwan; Chang Gung Childrens Hosp, Dept Pathol, Tao Yuan, Taiwan; Chang Gung Univ, Coll Med, Tao Yuan, Taiwan; Chang Gung Univ, Sch Med Technol, Tao Yuan, Taiwan; Chang Gung Mem Hosp, Clin Virol Lab, Tao Yuan, Taiwan; Chang Gung Univ, Dept Hlth Care Management, Tao Yuan, Taiwan; Chang Gung Univ, Lab Epidemiol, Tao Yuan, Taiwan	Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University; Chang Gung Memorial Hospital; Chang Gung University; Chang Gung University	Lin, TY (corresponding author), Chang Gung Childrens Hosp, Dept Pediat, Div Pediat Infect Dis, 5 Fu Hsing St, Tao Yuan, Taiwan.	pidlin@adm.cgmh.com.tw	Shih, Shin-Ru/M-9711-2016	Hsueh, Chuen/0000-0001-7860-5964; CHANG, LUAN-YIN/0000-0003-2632-1956; Shih, Shin-Ru/0000-0003-4874-401X; Hsu, Kuang-Hung/0000-0003-2642-7689; LEE, CHIN-YUN/0000-0002-3938-377X				ALEXANDER JP, 1994, J INFECT DIS, V169, P905, DOI 10.1093/infdis/169.4.905; BAKER AB, 1957, NEUROLOGY, V7, P743, DOI 10.1212/WNL.7.11.743; BLOMBERG J, 1974, LANCET, V2, P112; Centers for Disease Control and Prevention (CDC), 1998, MMWR Morb Mortal Wkly Rep, V47, P629; Chang LY, 1998, LANCET, V352, P367, DOI 10.1016/S0140-6736(98)24031-1; CHEN HI, 1980, CIRC RES, V47, P366, DOI 10.1161/01.RES.47.3.366; CHUMAKOV M, 1979, ARCH VIROL, V60, P329, DOI 10.1007/BF01317504; GILBERT GL, 1988, PEDIATR INFECT DIS J, V7, P484, DOI 10.1097/00006454-198807000-00007; GRANDIEN M, 1989, DIAGNOSTIC PROCEDURE, P513; HAYWARD JC, 1989, PEDIATR INFECT DIS J, V8, P611, DOI 10.1097/00006454-198909000-00009; ISHIMARU Y, 1980, ARCH DIS CHILD, V55, P583, DOI 10.1136/adc.55.8.583; KENNETT ML, 1974, B WORLD HEALTH ORGAN, V51, P609; Lum LCS, 1998, LANCET, V352, P1391, DOI 10.1016/S0140-6736(05)60789-1; Lum LCS, 1998, J PEDIATR-US, V133, P795, DOI 10.1016/S0022-3476(98)70155-6; MATSUNAGA H, 1989, ENDOCRINOLOGY, V124, P1259, DOI 10.1210/endo-124-3-1259; MELNICK JL, 1984, REV INFECT DIS, V6, pS387; NAGAI K, 1983, AM J PHYSIOL, V245, pE14, DOI 10.1152/ajpendo.1983.245.1.E14; NAGY G, 1982, ARCH VIROL, V71, P217, DOI 10.1007/BF01314873; RICHARDSON HB, 1965, J PEDIATR-US, V67, P6, DOI 10.1016/S0022-3476(65)80297-9; SCHMIDT NJ, 1974, J INFECT DIS, V129, P304, DOI 10.1093/infdis/129.3.304; SHINDAROV LM, 1979, J HYG EPID MICROB IM, V23, P284; SIMMONS RL, 1969, ANN SURG, V170, P39, DOI 10.1097/00000658-196907000-00005; Wu TN, 1999, EMERG INFECT DIS, V5, P458, DOI 10.3201/eid0503.990321	23	322	395	0	28	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1682	1686		10.1016/S0140-6736(99)04434-7	http://dx.doi.org/10.1016/S0140-6736(99)04434-7			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568570				2022-12-28	WOS:000083652800011
J	McCarthy, M				McCarthy, M			Population health targets in Europe	LANCET			English	Editorial Material									UCL Royal Free & Univ Coll Sch Med, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England	University of London; University College London	McCarthy, M (corresponding author), UCL Royal Free & Univ Coll Sch Med, Dept Epidemiol & Publ Hlth, London WC1E 6BT, England.		McCarthy, Mark/C-1117-2009					BOSANQUET N, 1999, SUCCESSFUL NATL HLTH; *INT TASK FORC NAT, 1996, NAT HLTH PROGR 1996; SALTMAN R. B., 1998, CRITICAL CHALLENGES; VANDEWATER HPA, 1998, HLTH POLICIES TARGET; *WHO, 1998, WHO EUR SER, V83; World Health Organization, 1998, HEALTH21 HLTH ALL PO	6	1	1	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1663	1664		10.1016/S0140-6736(99)00324-4	http://dx.doi.org/10.1016/S0140-6736(99)00324-4			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568565				2022-12-28	WOS:000083652800006
J	Rucker, AT; Pearson, RM; Cooke, ED; Benjamin, N				Rucker, AT; Pearson, RM; Cooke, ED; Benjamin, N			Effect of nitric-oxide-generating system on microcirculatory blood flow in skin of patients with severe Raynaud's syndrome: a randomised trial	LANCET			English	Article							TEMPERATURE; ENDOTHELIUM; REDUCTION; ILOPROST; DISEASE	Background Patients with Raynaud's syndrome have abnormal digital vasoconstriction, which may be secondary to impaired synthesis of, or impaired sensitivity to, nitric oxide. We studied the effect on microcirculation of a nitric-oxide-generating system applied topically to the finger and forearm of healthy volunteers and patients with primary Raynaud's syndrome. Methods We did a single-blind, randomised, placebo-controlled, cross-over study of the microcirculatory response to topical application of a nitric-oxide-generating gel in 20 patients with severe Raynaud's syndrome, and ten healthy volunteers. We prepared the nitric-oxide-generating system by mixing a solution of KY jelly and sodium nitrite (5% weight/volume), with a solution of KY jelly and ascorbic acid (5% weight/volume). About 0.5 mt of each solution was separately applied to the skin of the forearm (3 cm(2)), and then mixed with a sterile cotton bud. A similar procedure was done simultaneously on the other arm with KY jelly only (placebo). The procedure was then repeated on the finger pulps. Changes in skin microcirculatory volume and flux were measured bilaterally by infrared photoplethysmography and laser doppler fluxmetry, respectively. Findings In the forearm, blood flow increased significantly after application of the active gel both in patients with Raynaud's syndrome (microcirculatory volume from mean area under the curve 98 [SE 14] to 1024 [130]; microcirculatory flux from 5060 [462] to 74800 [3940]) and in healthy controls (volume from 85 [19] to 1020 [60]; flux from 4420 [435] to 84500 [7000]). In the fingers, although baseline blood flow was lower in patients than in controls, both groups showed increases with application of active gel (volume from 1100 [194] to 3280 [672] and 2380 [441] to 6160 [1160], respectively; flux from 33400 [4200] to 108000 [13600] and 52000 [8950] to 185000 [19500]). Increases in blood flow with placebo gel were not significant. No adverse effects were reported. Interpretation In primary Raynaud's syndrome, topical application of a nitric-oxide-generating system can stimulate an increase in both microcirculatory volume and flux.	St Bartholomews & Royal London Sch Med & Dent, London EC1M 6BQ, England; St Bartholomews Hosp, Clin Microvasc Unit, London, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Benjamin, N (corresponding author), St Bartholomews & Royal London Sch Med & Dent, London EC1M 6BQ, England.	n.benjamin@qmw.co.uk						Allen EV, 1932, AM J MED SCI, V183, P187, DOI 10.1097/00000441-193202000-00004; ALMOND NE, 1987, THESIS U LONDON LOND; BEDARIDA GV, 1993, LANCET, V342, P1451, DOI 10.1016/0140-6736(93)92932-J; Belch JJF, 1996, DRUGS, V52, P682, DOI 10.2165/00003495-199652050-00006; BELCH JJF, 1995, ANN RHEUM DIS, V54, P197, DOI 10.1136/ard.54.3.197; BENJAMIN N, 1994, NATURE, V368, P502, DOI 10.1038/368502a0; BRAIN SD, 1990, BRIT J CLIN PHARMACO, V30, P853, DOI 10.1111/j.1365-2125.1990.tb05451.x; Bunker CB, 1996, BRIT J DERMATOL, V134, P399; CHALLONER AVJ, 1979, NONINVASIVE PHYSL ME, P125; CONRAD MC, 1971, FUNCTIONAL ANATOMY C, P64; COOKE ED, 1985, ANGIOLOGY, V36, P33, DOI 10.1177/000331978503600106; COOKE ED, 1993, J ROY SOC MED, V86, P690; COOKE ED, 1990, BRIT MED J, V300, P55355; COOKE ED, 1995, RAYNAUDS SYNDROME, P149; COOKE ED, 1985, VASC MED, V3, P98; Cooke J P, 1997, Vasc Med, V2, P1; DOWD PM, 1982, BRIT J DERMATOL, V106, P81, DOI 10.1111/j.1365-2133.1982.tb00905.x; FISHER M, 1993, DRUGS, V46, P961, DOI 10.2165/00003495-199346060-00003; HAAVIKNILSEN K, 1979, BRIT MED J, V1, P20, DOI 10.1136/bmj.1.6155.20-a; Kahaleh M. Bashar, 1994, Current Opinion in Rheumatology, V6, P621, DOI 10.1097/00002281-199411000-00013; KHAN F, 1996, CAMBR M RES VESS FUN; Lewis T, 1929, HEART-J STUD CIRC, V15, P7; LUSCHER TF, 1990, ENDOTHELIUM MODULATO; Millar TM, 1998, FEBS LETT, V427, P225, DOI 10.1016/S0014-5793(98)00430-X; NILSSON GE, 1980, IEEE T BIO-MED ENG, V27, P597, DOI 10.1109/TBME.1980.326582; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; RADEMAKER M, 1989, BRIT MED J, V298, P561, DOI 10.1136/bmj.298.6673.561; SCHIFFRIN EL, 1994, CLIN INVEST MED, V17, P602; SILMAN A, 1990, BMJ-BRIT MED J, V301, P590, DOI 10.1136/bmj.301.6752.590; Stellin G P, 1989, Compr Ther, V15, P11; SUNDERLAND GT, 1988, CLIN RHEUMATOL, V7, P46, DOI 10.1007/BF02284056; TOMS SL, 1995, INT ANGIOL, V14, P74; VANHOUTTE PM, 1985, CLIN SCI, V68, pS121, DOI 10.1042/cs068s121; Weller R, 1998, J AM ACAD DERMATOL, V38, P559, DOI 10.1016/S0190-9622(98)70117-3; Weller R, 1996, J INVEST DERMATOL, V107, P327, DOI 10.1111/1523-1747.ep12363167; Wigley FM, 1996, RHEUM DIS CLIN N AM, V22, P765, DOI 10.1016/S0889-857X(05)70300-8	36	73	81	1	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1670	1675		10.1016/S0140-6736(99)04095-7	http://dx.doi.org/10.1016/S0140-6736(99)04095-7			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568568				2022-12-28	WOS:000083652800009
J	Gennis, RB; Ebrey, TG				Gennis, RB; Ebrey, TG			Structural biochemistry - Proton pump caught in the act	SCIENCE			English	Editorial Material							LIPIDIC CUBIC PHASES; BACTERIORHODOPSIN; RELEASE		Univ Illinois, Dept Biochem, Urbana, IL 61801 USA; Univ Illinois, Dept Cell & Struct Biol, Urbana, IL 61801 USA	University of Illinois System; University of Illinois Urbana-Champaign; University of Illinois System; University of Illinois Urbana-Champaign	Gennis, RB (corresponding author), Univ Illinois, Dept Biochem, Urbana, IL 61801 USA.							Balashov SP, 1996, BIOPHYS J, V70, P473, DOI 10.1016/S0006-3495(96)79591-7; Balashov SP, 1997, BIOCHEMISTRY-US, V36, P8671, DOI 10.1021/bi970744y; Belrhali H, 1999, STRUCTURE, V7, P909, DOI 10.1016/S0969-2126(99)80118-X; Dioumaev AK, 1998, BIOCHEMISTRY-US, V37, P2496, DOI 10.1021/bi971842m; Ebrey T.G., 1993, THERMODYNAMICS MEMBR, P353; Landau EM, 1996, P NATL ACAD SCI USA, V93, P14532, DOI 10.1073/pnas.93.25.14532; Lanyi JK, 1998, J STRUCT BIOL, V124, P164, DOI 10.1006/jsbi.1998.4044; Luecke H, 1999, SCIENCE, V286, P255, DOI 10.1126/science.286.5438.255; Luecke H, 1998, SCIENCE, V280, P1934, DOI 10.1126/science.280.5371.1934; Luecke H, 1999, J MOL BIOL, V291, P899, DOI 10.1006/jmbi.1999.3027; Maeda A, 1997, J BIOCHEM-TOKYO, V121, P399; PebayPeyroula E, 1997, SCIENCE, V277, P1676, DOI 10.1126/science.277.5332.1676; Rammelsberg R, 1998, BIOCHEMISTRY-US, V37, P5001, DOI 10.1021/bi971701k; Subramaniam S, 1999, J MOL BIOL, V287, P145, DOI 10.1006/jmbi.1999.2589; Zscherp C, 1999, P NATL ACAD SCI USA, V96, P5498, DOI 10.1073/pnas.96.10.5498	15	12	12	1	7	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 8	1999	286	5438					252	253		10.1126/science.286.5438.252	http://dx.doi.org/10.1126/science.286.5438.252			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	243YE	10577192				2022-12-28	WOS:000083024400033
J	Horne, MK; Chang, R				Horne, MK; Chang, R			Thrombolytic therapy for deep venous thrombosis?	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ORAL ANTICOAGULANT-THERAPY; VEIN THROMBOSIS; STREPTOKINASE; HEPARIN; THROMBOEMBOLISM; EPISODE; LYSIS	We present the case of a man bedridden by deep venous thrombosis who was given intraclot instillations of recombinant tissue plasminogen activator with remarkable improvement. Although such aggressive treatment may be justified in severe cases, the role for thrombolytic agents for less symptomatic deep venous thrombosis is undefined. We discuss the question of when thrombolytic therapy should be considered. However, proper clinical trials are needed before firm recommendations can be made.	NIH, Hematol Serv, Dept Clin Pathol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA; NIH, Special Procedures Unit, Dept Radiol, Warren G Magnuson Clin Ctr, Bethesda, MD 20892 USA	National Institutes of Health (NIH) - USA; National Institutes of Health (NIH) - USA	Horne, MK (corresponding author), NIH, Hematol Serv, Dept Clin Pathol, Warren G Magnuson Clin Ctr, Bldg 10,Room 2C306,9000 Rockville Pike, Bethesda, MD 20892 USA.	mhorne@nih.gov						Akesson H, 1990, Eur J Vasc Surg, V4, P43, DOI 10.1016/S0950-821X(05)80037-4; AMESEN H, 1982, ACTA MED SCAND, V211, P65; BROWN W D, 1989, Chest, V95, p276S, DOI 10.1378/chest.95.5.276S; Centeno RF, 1999, AM SURGEON, V65, P229; COLLEN D, 1986, HAEMOSTASIS, V16, P25; COMEROTA AJ, 1995, THROMBOLYTIC THERAPY, P175; ELLIOT MS, 1979, BRIT J SURG, V66, P838, DOI 10.1002/bjs.1800661203; Holmstrom M, 1997, THROMB HAEMOSTASIS, V78, P803; KILLEWICH LA, 1985, ARCH SURG-CHICAGO, V120, P424; KILLEWICH LA, 1989, J VASC SURG, V9, P89, DOI 10.1067/mva.1989.vs0090089; Levine M, 1996, NEW ENGL J MED, V334, P677, DOI 10.1056/NEJM199603143341101; MARKEL A, 1992, ARCH INTERN MED, V152, P1265, DOI 10.1001/archinte.152.6.1265; *MED EC BOOKS, 1998, 1998 DRUG TOP RED BO; MEISSNER MH, 1993, J VASC SURG, V18, P596, DOI 10.1016/0741-5214(93)90069-X; Mewissen MW, 1999, RADIOLOGY, V211, P39, DOI 10.1148/radiology.211.1.r99ap4739; OMEARA JJ, 1994, NEW ENGL J MED, V330, P1864, DOI 10.1056/NEJM199406303302605; Patel NH, 1998, ANN VASC SURG, V12, P471, DOI 10.1007/s100169900187; Prandoni P, 1996, ANN INTERN MED, V125, P1, DOI 10.7326/0003-4819-125-1-199607010-00001; ROGERS LQ, 1990, AM J MED, V88, P389, DOI 10.1016/0002-9343(90)90494-X; Schafer AI, 1999, NEW ENGL J MED, V340, P955, DOI 10.1056/NEJM199903253401209; Schulman S, 1997, NEW ENGL J MED, V336, P393, DOI 10.1056/NEJM199702063360601; SCHULMAN S, 1995, NEW ENGL J MED, V332, P1661, DOI 10.1056/NEJM199506223322501; SHERRY S, 1980, ANN INTERN MED, V93, P141, DOI 10.7326/0003-4819-93-1-141; SUDLOW MF, 1992, LANCET, V340, P873; Tarry W C, 1994, Ann Vasc Surg, V8, P583, DOI 10.1007/BF02017416; WATZ R, 1979, ACTA MED SCAND, V205, P293	26	5	6	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2164	2166		10.1001/jama.282.22.2164	http://dx.doi.org/10.1001/jama.282.22.2164			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591339				2022-12-28	WOS:000083971400036
J	Geddes, A				Geddes, A			Sir Meilville Arnott	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1503	1503		10.1136/bmj.319.7223.1503	http://dx.doi.org/10.1136/bmj.319.7223.1503			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582953	Green Published			2022-12-28	WOS:000084129200048
J	Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D				Kardailsky, I; Shukla, VK; Ahn, JH; Dagenais, N; Christensen, SK; Nguyen, JT; Chory, J; Harrison, MJ; Weigel, D			Activation tagging of the floral inducer FT	SCIENCE			English	Article							PHOSPHATIDYLETHANOLAMINE-BINDING PROTEIN; LATE-FLOWERING MUTANTS; ARABIDOPSIS-THALIANA; CRYSTAL-STRUCTURE; BOVINE BRAIN; TIME GENES; INITIATION; ARCHITECTURE; EXPRESSION; SEQUENCE	FLOWERING LOCUS T (FT), which acts in parallel with the meristem-identity gene LEAFY (LFY) to induce flowering of Arabidopsis, was isolated by activation tagging. Like LFY, FT acts partially downstream of CONSTANS (CO), which promotes flowering in response to long days. Unlike many other floral regulators, the deduced sequence of the FT protein does not suggest that it directly controls transcription or transcript processing. Instead, it is similar to the sequence of TERMINAL FLOWER 1 (TFL1), an inhibitor of flowering that also shares sequence similarity with membrane-associated mammalian proteins.	Salk Inst Biol Studies, Plant Biol Lab, La Jolla, CA 92037 USA; Samuel Roberts Noble Fdn Inc, Div Plant Biol, Ardmore, OK 73402 USA; Salk Inst Biol Studies, Howard Hughes Med Inst, La Jolla, CA 92037 USA	Salk Institute; Noble Research Institute; Howard Hughes Medical Institute; Salk Institute	Weigel, D (corresponding author), Salk Inst Biol Studies, Plant Biol Lab, 10010 N Torrey Pines Rd, La Jolla, CA 92037 USA.		Weigel, Detlef/AAR-3312-2021; Kardailsky, Igor/AAK-8850-2021; Ahn, Ji Hoon/A-4141-2011; Weigel, Detlef/C-1418-2008; Weigel, Detlef/GSJ-0799-2022	Ahn, Ji Hoon/0000-0003-0347-3922; Weigel, Detlef/0000-0002-2114-7963; Weigel, Detlef/0000-0002-2114-7963; Harrison, Maria J/0000-0001-8716-1875				ALVAREZ J, 1992, PLANT J, V2, P103, DOI 10.1111/j.1365-313X.1992.00103.x; Banfield MJ, 1998, STRUCTURE, V6, P1245, DOI 10.1016/S0969-2126(98)00125-7; Blazquez MA, 1997, DEVELOPMENT, V124, P3835; Bradley D, 1997, SCIENCE, V275, P80, DOI 10.1126/science.275.5296.80; GRANDY DK, 1990, MOL ENDOCRINOL, V4, P1370, DOI 10.1210/mend-4-9-1370; HAYASHI H, 1992, SCIENCE, V258, P1350, DOI 10.1126/science.1455228; Hempel FD, 1997, DEVELOPMENT, V124, P3845; KOORNNEEF M, 1991, MOL GEN GENET, V229, P57, DOI 10.1007/BF00264213; Koornneef M, 1998, GENETICS, V148, P885; Levy YY, 1998, PLANT CELL, V10, P1973, DOI 10.1105/tpc.10.12.1973; Liljegren SJ, 1999, PLANT CELL, V11, P1007, DOI 10.1105/tpc.11.6.1007; MANDEL MA, 1995, NATURE, V377, P522, DOI 10.1038/377522a0; Nilsson O, 1998, GENETICS, V150, P403; Parcy F, 1998, NATURE, V395, P561, DOI 10.1038/26903; PUTTERILL J, 1995, CELL, V80, P847, DOI 10.1016/0092-8674(95)90288-0; Ratcliffe OJ, 1998, DEVELOPMENT, V125, P1609; Ratcliffe OJ, 1999, DEVELOPMENT, V126, P1109; RuizGarcia L, 1997, PLANT CELL, V9, P1921, DOI 10.1105/tpc.9.11.1921; SCHOENTGEN F, 1987, EUR J BIOCHEM, V166, P333, DOI 10.1111/j.1432-1033.1987.tb13519.x; Serre L, 1998, STRUCTURE, V6, P1255, DOI 10.1016/S0969-2126(98)00126-9; SHANNON S, 1991, PLANT CELL, V3, P877, DOI 10.1105/tpc.3.9.877; Simon R, 1996, NATURE, V384, P59, DOI 10.1038/384059a0; TOHDOH N, 1995, MOL BRAIN RES, V30, P381, DOI 10.1016/0169-328X(95)00029-R; WEIGEL D, 1995, NATURE, V377, P495, DOI 10.1038/377495a0; Yeung K, 1999, NATURE, V401, P173, DOI 10.1038/43686	25	1062	1206	7	179	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1962	1965		10.1126/science.286.5446.1962	http://dx.doi.org/10.1126/science.286.5446.1962			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583961				2022-12-28	WOS:000084003400054
J	Plomin, R				Plomin, R			Genetics and general cognitive ability	NATURE			English	Article							INTELLIGENCE	General cognitive ability (g), often referred to as 'general intelligence', predicts social outcomes such as educational and occupational levels far better than any other behavioural trait. g is one of the most heritable behavioural traits, and genes that contribute to the heritability of g will certainly be identified. What are the scientific and social implications of finding genes associated with g?	Kings Coll London, Inst Psychiat, London SE5 8AF, England	University of London; King's College London	Plomin, R (corresponding author), Kings Coll London, Inst Psychiat, DeCrespigny Pk,Denmark Hill, London SE5 8AF, England.	r.plomin@iop.kcl.ac.uk	Plomin, Robert/B-8911-2008	Plomin, Robert/0000-0002-0756-3629				BOUCHARD TJ, 1981, SCIENCE, V212, P1055, DOI 10.1126/science.7195071; BRODY N, 1992, INTELLIGENCE; Carroll JB, 1995, INTELLIGENCE, V21, P121, DOI 10.1016/0160-2896(95)90022-5; Chorney MJ, 1998, PSYCHOL SCI, V9, P159, DOI 10.1111/1467-9280.00032; Duyme M, 1999, P NATL ACAD SCI USA, V96, P8790, DOI 10.1073/pnas.96.15.8790; Fisher PJ, 1999, HUM MOL GENET, V8, P915, DOI 10.1093/hmg/8.5.915; Flynn JR, 1999, AM PSYCHOL, V54, P5, DOI 10.1037/0003-066X.54.1.5; Gottfredson LS, 1997, INTELLIGENCE, V24, P13, DOI 10.1016/S0160-2896(97)90011-8; Gould S. J., 1996, MISMEASURE MAN; Harris Judith Rich, 1998, NURTURE ASSUMPTION W; Herrnstein R., 1994, BELL CURVE INTELLIGE; Jensen A.R., 1998, G FACTOR SCI MENTAL; KOSSLYN S, IN PRESS PSYCHIAT NE; Mackintosh Nicholas J., 2011, IQ HUMAN INTELLIGENC; McClearn GE, 1997, SCIENCE, V276, P1560, DOI 10.1126/science.276.5318.1560; McGue M, 1993, NATURE NURTURE PSYCH, P59, DOI DOI 10.1037/10131-003; Migaud M, 1998, NATURE, V396, P433, DOI 10.1038/24790; Newson A, 1999, BIOETHICS, V13, P327, DOI 10.1111/1467-8519.00161; Petrill SA, 1997, CURR DIR PSYCHOL SCI, V6, P96, DOI 10.1111/1467-8721.ep11512833; Plomin R, 1998, SCI AM, V278, P62, DOI 10.1038/scientificamerican0598-62; Plomin R, 1998, CHILD DEV, V69, P1223, DOI 10.2307/1132371; PLOMIN R, 1994, SCIENCE, V264, P1733, DOI 10.1126/science.8209254; Plomin R., 1997, BEHAV GENET; PLOMIN R, IN PRESS PSYCHOL B; Plomin R., 1994, GENETICS EXPERIENCE; ROWE DC, IN PRESS CHILD DEV; Rutter M, 1997, BRIT J PSYCHIAT, V171, P209, DOI 10.1192/bjp.171.3.209; SNYDERMAN M, 1988, IQ CONTROVERSY MEDIA	28	164	164	1	26	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761		S			C25	C29		10.1038/35011520	http://dx.doi.org/10.1038/35011520			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	261MZ	10591222	Bronze			2022-12-28	WOS:000084014100004
J	Barnes, PJ				Barnes, PJ			Therapeutic strategies for allergic diseases	NATURE			English	Review							INDUCED AIRWAY HYPERRESPONSIVENESS; COLONY-STIMULATING FACTOR; CHRONIC SEVERE ASTHMA; ANTI-IGE ANTIBODY; TRANSCRIPTION FACTOR; MONOCLONAL-ANTIBODY; INTERFERON-GAMMA; CYTOKINE EXPRESSION; HUMAN EOSINOPHILS; T-LYMPHOCYTES	Many drugs are now in development for the treatment of atopic diseases, including asthma, allergic rhinitis and atopic dermatitis. These treatments are based on improvements in existing therapies or on a better understanding of the cellular and molecular mechanisms involved in atopic diseases. Although most attention has been focused on asthma, treatments that inhibit the atonic disease process would have application to all atonic diseases, as they often coincide. Most of the many new therapies in development are aimed at inhibiting components of the allergic inflammatory response, but in the future there are real possibilities for the development of preventative and even curative treatments.	Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England	Imperial College London	Barnes, PJ (corresponding author), Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, Dept Thorac Med, London SW3 6LY, England.	p.j.barnes@ic.ac.uk		Barnes, Peter/0000-0002-5122-4018				Abraham WM, 1999, AM J RESP CRIT CARE, V159, P1205, DOI 10.1164/ajrccm.159.4.9806002; ALEXANDER AG, 1992, LANCET, V339, P324, DOI 10.1016/0140-6736(92)91646-P; Amoui M, 1997, EUR J IMMUNOL, V27, P1881, DOI 10.1002/eji.1830270810; Barnes PJ, 1996, CLIN EXP ALLERGY, V26, P738; BARNES PJ, 1995, ANN MED, V27, P389, DOI 10.3109/07853899509002592; Barnes PJ, 1998, CLIN SCI, V94, P557, DOI 10.1042/cs0940557; Barnes PJ, 1998, MOL MED TODAY, V4, P452, DOI 10.1016/S1357-4310(98)01335-5; Barnes PJ, 1998, EUR RESPIR J, V12, P221, DOI 10.1183/09031936.98.12010221; Barnes PJ, 1998, PHARMACOL REV, V50, P515; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; Benjaponpitak S, 1999, J ALLERGY CLIN IMMUN, V103, P468, DOI 10.1016/S0091-6749(99)70473-2; BIANCO S, 1993, EUR RESPIR J, V6, P130; Bieber T, 1998, J ALLERGY CLIN IMMUN, V102, P555, DOI 10.1016/S0091-6749(98)70270-2; BOGUNIEWICZ M, 1995, J ALLERGY CLIN IMMUN, V95, P133, DOI 10.1016/S0091-6749(95)70162-1; Borish L, 1996, J ALLERGY CLIN IMMUN, V97, P1288, DOI 10.1016/S0091-6749(96)70197-5; Borish LC, 1998, J ALLERGY CLIN IMMUN, V101, pS8; Caramori G, 1999, AM J RESP CRIT CARE, V159, pA908; CHAN SC, 1993, J LAB CLIN MED, V121, P44; Chomarat P, 1998, Int Rev Immunol, V17, P1, DOI 10.3109/08830189809084486; Chung KF, 1999, THORAX, V54, P825, DOI 10.1136/thx.54.9.825; CLARK JM, 1995, AM J RESP CRIT CARE, V152, P2076, DOI 10.1164/ajrccm.152.6.8520778; Corne J, 1997, J CLIN INVEST, V99, P879, DOI 10.1172/JCI119252; Costello PS, 1996, ONCOGENE, V13, P2595; Coyle AJ, 1996, J EXP MED, V183, P1303, DOI 10.1084/jem.183.4.1303; Dahlen B, 1998, AM J RESP CRIT CARE, V157, P1187, DOI 10.1164/ajrccm.157.4.9707089; Drazen JM, 1999, NEW ENGL J MED, V340, P197, DOI 10.1056/NEJM199901213400306; Durham SR, 1999, NEW ENGL J MED, V341, P468, DOI 10.1056/NEJM199908123410702; Durham SR, 1996, J ALLERGY CLIN IMMUN, V97, P1356, DOI 10.1016/S0091-6749(96)70205-1; Egan RW, 1996, ALLERGY, V51, P71, DOI 10.1111/j.1398-9995.1996.tb00038.x; EISNER J, 1997, EUR J IMMUNOL, V27, P2892; Fahy JV, 1997, AM J RESP CRIT CARE, V155, P1828, DOI 10.1164/ajrccm.155.6.9196082; Feldman M, 1998, TRANSPLANT P, V30, P4126, DOI 10.1016/S0041-1345(98)01365-7; Foster PS, 1999, CLIN EXP ALLERGY, V29, P12; Gately MK, 1998, ANNU REV IMMUNOL, V16, P495, DOI 10.1146/annurev.immunol.16.1.495; Gavett SH, 1997, AM J PHYSIOL-LUNG C, V272, pL253, DOI 10.1152/ajplung.1997.272.2.L253; GAVETT SH, 1995, J EXP MED, V182, P1527, DOI 10.1084/jem.182.5.1527; Haczku A, 1999, AM J RESP CRIT CARE, V159, P1638, DOI 10.1164/ajrccm.159.5.9711040; Harbinson PL, 1997, EUR RESPIR J, V10, P1008, DOI 10.1183/09031936.97.10051008; Haselden BM, 1999, J EXP MED, V189, P1885, DOI 10.1084/jem.189.12.1885; Hay DWP, 1996, AM J RESP CRIT CARE, V154, P1594, DOI 10.1164/ajrccm.154.6.8970340; Heath H, 1997, J CLIN INVEST, V99, P178, DOI 10.1172/JCI119145; HEINKE S, 1995, BRIT J PHARMACOL, V115, P1393, DOI 10.1111/j.1476-5381.1995.tb16629.x; Herz U, 1998, J ALLERGY CLIN IMMUN, V102, P867, DOI 10.1016/S0091-6749(98)70030-2; Hogan SP, 1998, J IMMUNOL, V161, P1501; Holgate ST, 1998, ALLERGY, V53, P83, DOI 10.1111/j.1398-9995.1998.tb04946.x; Hsu CH, 1996, NAT MED, V2, P540, DOI 10.1038/nm0596-540; In KH, 1997, J CLIN INVEST, V99, P1130, DOI 10.1172/JCI119241; John M, 1998, AM J RESP CRIT CARE, V157, P256, DOI 10.1164/ajrccm.157.1.9703079; Kankaanranta H, 1999, J PHARMACOL EXP THER, V290, P621; Karin M, 1998, ANN NY ACAD SCI, V851, P139, DOI 10.1111/j.1749-6632.1998.tb08987.x; Kim MK, 1998, AM J RESP CELL MOL, V19, P836, DOI 10.1165/ajrcmb.19.5.3032; Kim TS, 1997, J IMMUNOL, V158, P4137; Kon OM, 1998, LANCET, V352, P1109, DOI 10.1016/S0140-6736(97)12261-9; KRISHNA MT, 1998, AM J RESP CRIT CARE, V157, pA456; Lack G, 1996, J IMMUNOL, V157, P1432; Leckie MJ, 1999, AM J RESP CRIT CARE, V159, pA624; Li L, 1999, J IMMUNOL, V162, P2477; Lin KC, 1999, J MED CHEM, V42, P920, DOI 10.1021/jm980673g; Losman JA, 1999, J IMMUNOL, V162, P3770; Luster AD, 1998, NEW ENGL J MED, V338, P436, DOI 10.1056/NEJM199802123380706; MORLEY J, 1992, J AUTOIMMUN, V5, P265, DOI 10.1016/0896-8411(92)90042-O; Muller T, 1996, TRENDS PHARMACOL SCI, V17, P294, DOI 10.1016/0165-6147(96)10035-3; Murphy E, 1996, J EXP MED, V183, P901, DOI 10.1084/jem.183.3.901; Mygind N, 1997, ALLERGY, V52, P39, DOI 10.1111/j.1398-9995.1997.tb04883.x; NIZANKOWSKA E, 1995, EUR RESPIR J, V8, P1091, DOI 10.1183/09031936.95.08071091; Norman PS, 1996, AM J RESP CRIT CARE, V154, P1623, DOI 10.1164/ajrccm.154.6.8970345; Nyce JW, 1997, NATURE, V385, P721, DOI 10.1038/385721a0; PILEWSKI JM, 1995, AM J RESP CELL MOL, V12, P1; Pretolani M, 1997, IMMUNOL TODAY, V18, P277, DOI 10.1016/S0167-5699(97)80023-0; Pullerits T, 1999, AM J RESP CRIT CARE, V159, P1814, DOI 10.1164/ajrccm.159.6.9810016; Roy K, 1999, NAT MED, V5, P387, DOI 10.1038/7385; Schafer PH, 1999, J IMMUNOL, V162, P7110; Schwarze J, 1999, J IMMUNOL, V162, P4207; Seldon Paul M., 1998, Cell Biochemistry and Biophysics, V29, P179, DOI 10.1007/BF02737835; SELIG W, 1992, EUR J PHARMACOL, V213, P331, DOI 10.1016/0014-2999(92)90621-A; Seybold J, 1998, J BIOL CHEM, V273, P20575, DOI 10.1074/jbc.273.32.20575; Shirakawa T, 1997, SCIENCE, V275, P77, DOI 10.1126/science.275.5296.77; Strannegard IL, 1998, ALLERGY, V53, P249, DOI 10.1111/j.1398-9995.1998.tb03884.x; SUN J, 1994, INT ARCH ALLERGY IMM, V104, P291, DOI 10.1159/000236679; Sur S, 1999, J IMMUNOL, V162, P6284; Taylor DA, 1999, AM J RESP CRIT CARE, V160, P237, DOI 10.1164/ajrccm.160.1.9809046; THOMSON AW, 1993, IMMUNOL REV, V136, P71, DOI 10.1111/j.1600-065X.1993.tb00655.x; Torphy TJ, 1998, AM J RESP CRIT CARE, V157, P351, DOI 10.1164/ajrccm.157.2.9708012; Van Neerven RJJ, 1998, CLIN EXP ALLERGY, V28, P808; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; VanGanse E, 1997, EUR RESPIR J, V10, P2216, DOI 10.1183/09031936.97.10102216; VanOosterhout AJM, 1997, AM J RESP CELL MOL, V17, P386, DOI 10.1165/ajrcmb.17.3.2679; Vayssiere BM, 1997, MOL ENDOCRINOL, V11, P1245, DOI 10.1210/me.11.9.1245; Wang CC, 1998, IMMUNOLOGY, V93, P307; Wang LH, 1999, EUR J PHARMACOL, V371, P241, DOI 10.1016/S0014-2999(99)00179-X; WEG VB, 1993, J EXP MED, V177, P561, DOI 10.1084/jem.177.2.561; Wheeler JG, 1997, ANN ALLERG ASTHMA IM, V79, P229, DOI 10.1016/S1081-1206(10)63007-4; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Xing Z, 1996, J CLIN INVEST, V97, P1102, DOI 10.1172/JCI118503; YATES DH, 1995, AM J RESP CRIT CARE, V152, P892, DOI 10.1164/ajrccm.152.3.7663801; Yousefi S, 1996, J EXP MED, V183, P1407, DOI 10.1084/jem.183.4.1407; YSSEL H, 1994, CURR OPIN IMMUNOL, V6, P847, DOI 10.1016/0952-7915(94)90003-5; Yuan Q, 1996, BIOCHEM J, V318, P591, DOI 10.1042/bj3180591; Zhang DH, 1997, J BIOL CHEM, V272, P21597, DOI 10.1074/jbc.272.34.21597	99	182	192	0	8	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B31	B38		10.1038/35037026	http://dx.doi.org/10.1038/35037026			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586893	Bronze			2022-12-28	WOS:000083913900007
J	[Anonymous]				[Anonymous]			GMC advises doctors as teachers	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	NOV 20	1999	319	7221					1375	1375						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260CF	10567163				2022-12-28	WOS:000083930200063
J	Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL				Gray, PA; Rekling, JC; Bocchiaro, CM; Feldman, JL			Modulation of respiratory frequency by peptidergic input to rhythmogenic neurons in the PreBotzinger complex	SCIENCE			English	Article							PRE-BOTZINGER COMPLEX; LATERAL TEGMENTAL FIELD; INFANT-DEATH-SYNDROME; STEM IN-VITRO; BRAIN-STEM; SUBNUCLEAR ORGANIZATION; CEREBROSPINAL-FLUID; INSPIRATORY NEURONS; GENERATION; MAMMALS	Neurokinin-1 receptor (NK1R) and mu-opioid receptor (mu OR) agonists affected respiratory rhythm when injected directly into the preBotzinger Complex (preBotC), the hypothesized site for respiratory rhythmogenesis in mammals. These effects were mediated by actions on preBotC rhythmogenic neurons. The distribution of NK1R(+) neurons anatomically defined the preBotC. Type 1 neurons in the preBotC, which have rhythmogenic properties, expressed both NK1Rs and mu ORs, whereas type 2 neurons expressed only NK1Rs. These findings suggest that the preBotC is a definable anatomic structure with unique physiological function and that a subpopulation of neurons expressing both NK1Rs and mu ORs generate respiratory rhythm and modulate respiratory frequency.	Univ Calif Los Angeles, Dept Neurobiol, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Dept Physiol Sci, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Interdept Program Neurosci PHD, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California System; University of California Los Angeles; University of California System; University of California Los Angeles	Gray, PA (corresponding author), Univ Calif Los Angeles, Dept Neurobiol, Box 951763, Los Angeles, CA 90095 USA.		feldman, jack/AAO-7505-2021	feldman, jack/0000-0003-3692-9412; Rekling, Jens C./0000-0002-8568-2332	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R37HL037941, R01HL037941, R01HL040959] Funding Source: NIH RePORTER; NHLBI NIH HHS [R01 HL040959-12, HL37941, R01 HL040959, HL40959] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		BIANCHI AL, 1995, PHYSIOL REV, V75, P1, DOI 10.1152/physrev.1995.75.1.1; BONHAM AC, 1995, RESP PHYSIOL, V101, P219, DOI 10.1016/0034-5687(95)00045-F; Brockhaus J, 1998, EUR J NEUROSCI, V10, P3823, DOI 10.1046/j.1460-9568.1998.00396.x; Butera RJ, 1999, J NEUROPHYSIOL, V82, P398, DOI 10.1152/jn.1999.82.1.398; Butera RJ, 1999, J NEUROPHYSIOL, V82, P382, DOI 10.1152/jn.1999.82.1.382; Carpentier V, 1998, NEUROSCIENCE, V86, P159, DOI 10.1016/S0306-4522(98)00002-5; COQUEREL A, 1992, NEUROCHEM INT, V20, P97, DOI 10.1016/0197-0186(92)90131-A; DOBBINS EG, 1994, J COMP NEUROL, V347, P64, DOI 10.1002/cne.903470106; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P212, DOI 10.1002/cne.902940206; ELLENBERGER HH, 1990, J COMP NEUROL, V294, P202, DOI 10.1002/cne.902940205; FELDMAN JL, 1988, ANNU REV PHYSIOL, V50, P593; FELDMAN JL, 1989, ANN NY ACAD SCI, V563, P114, DOI 10.1111/j.1749-6632.1989.tb42194.x; FIELDS HL, 1985, PHILOS T ROY SOC B, V308, P361, DOI 10.1098/rstb.1985.0037; FLEDMAN JL, 1986, HDB PHYSL NERVOUS SY, P463; Fletcher E C, 1997, Cardiologia, V42, P469; FLETCHER EC, 1986, ABNORMALITIES RESPIR, P203; FUNK GD, 1993, J NEUROPHYSIOL, V70, P1497, DOI 10.1152/jn.1993.70.4.1497; GRAY P, UNPUB; Hsieh JH, 1998, J AUTONOM NERV SYST, V73, P7, DOI 10.1016/S0165-1838(98)00117-9; Johnson SM, 1996, J APPL PHYSIOL, V80, P2120, DOI 10.1152/jappl.1996.80.6.2120; Koshiya N, 1996, J PHYSIOL-LONDON, V491, P859, DOI 10.1113/jphysiol.1996.sp021263; Koshiya N, 1999, NATURE, V400, P360, DOI 10.1038/22540; MCCRIMMON DR, 1995, REGULATION BREATHING, V79, P151; MONNIER A, 1998, SOC NEUR ABSTR, V346, P5; Onimaru H, 1997, JPN J PHYSIOL, V47, P385, DOI 10.2170/jjphysiol.47.385; ORLOWSKI JP, 1986, PEDIATRICS, V78, P233; Ramirez JM, 1998, J PHYSIOL-LONDON, V507, P895, DOI 10.1111/j.1469-7793.1998.895bs.x; Rekling JC, 1998, ANNU REV PHYSIOL, V60, P385, DOI 10.1146/annurev.physiol.60.1.385; Rekling JC, 1996, J NEUROPHYSIOL, V75, P811, DOI 10.1152/jn.1996.75.2.811; Rekling JC, 1996, J NEUROPHYSIOL, V75, P795, DOI 10.1152/jn.1996.75.2.795; REKLING JC, UNPUB; Shao XM, 1997, J NEUROPHYSIOL, V77, P1853, DOI 10.1152/jn.1997.77.4.1853; SMITH JC, 1991, SCIENCE, V254, P726, DOI 10.1126/science.1683005; Thalhofer S, 1997, RESPIRATION, V64, P2	34	471	479	0	15	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1566	1568		10.1126/science.286.5444.1566	http://dx.doi.org/10.1126/science.286.5444.1566			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567264	Green Accepted			2022-12-28	WOS:000083768300060
J	Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF				Garcia, R; Vouimba, RM; Baudry, M; Thompson, RF			The amygdala modulates prefrontal cortex activity relative to conditioned fear	NATURE			English	Article							BASOLATERAL AMYGDALA; DOPAMINE NEURONS; RAT; ORGANIZATION; PROJECTIONS; NUCLEUS; STRESS; NEUROENDOCRINE; RESPONSES; THALAMUS	Animals learn that a tone can predict the occurrence of an electric shock through classical conditioning. Mice or rats trained in this manner display fear responses, such as freezing behaviour, when they hear the conditioned tone. Studies using amygdalectomized rats have shown that the amygdala is required for both the acquisition and expression of learned fear responses(1-3) Freezing to a conditioned tone is enhanced following damage, to the dorsal part of the medial prefrontal cortex(4), indicating that this area may be involved in fear reduction, Here we show that prefrontal neurons reduce their spontaneous activity in the presence of a conditioned aversive tone as a function of the degree of fear, The depression in prefrontal spontaneous activity is related to amygdala activity but not to the freezing response itself. These data indicate that, in the presence of threatening stimuli, the amygdala controls both fear expression and prefrontal neuronal activity. They suggest that abnormal amygdala-induced modulation of prefrontal neuronal activity may be involved in the pathophysiology of certain forms of anxiety disorder.	Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, F-33405 Talence, France; Univ So Calif, Program Neurosci, Los Angeles, CA 90089 USA	Centre National de la Recherche Scientifique (CNRS); UDICE-French Research Universities; Universite de Bordeaux; University of Southern California	Garcia, R (corresponding author), Univ Bordeaux 1, Cognit Neurosci Lab, CNRS, UMR 5807, Ave Fac, F-33405 Talence, France.		anand, amit/A-7222-2009					Bechara A, 1999, J NEUROSCI, V19, P5473; Campeau S, 1997, NEUROSCIENCE, V78, P1087, DOI 10.1016/S0306-4522(96)00632-X; DAVIS M, 1994, BRAIN RES, V664, P207, DOI 10.1016/0006-8993(94)91972-0; DAVIS M, 1992, P255; Farb CR, 1997, SYNAPSE, V27, P106, DOI 10.1002/(SICI)1098-2396(199710)27:2<106::AID-SYN2>3.3.CO;2-F; FERRON A, 1984, BRAIN RES, V302, P257, DOI 10.1016/0006-8993(84)90238-5; Franklin K. B. J., 2008, PAXINOS FRANKLINS MO; FUXE K, 1974, BRAIN RES, V82, P349, DOI 10.1016/0006-8993(74)90618-0; Garcia R, 1998, EUR J NEUROSCI, V10, P457, DOI 10.1046/j.1460-9568.1998.00027.x; GARDNER RC, 1994, ONT SYMP P, V7, P1; Goldstein LE, 1996, J NEUROSCI, V16, P4787; GONZALES C, 1990, J COMP NEUROL, V297, P182; HERRY C, IN PRESS J NEUROPHYS; LaBar KS, 1996, BEHAV NEUROSCI, V110, P991, DOI 10.1037/0735-7044.110.5.991; LEDOUX JE, 1995, ANNU REV PSYCHOL, V46, P209, DOI 10.1146/annurev.ps.46.020195.001233; LEDOUX JE, 1990, J NEUROSCI, V10, P1043; LINDVALL O, 1974, BRAIN RES, V81, P325, DOI 10.1016/0006-8993(74)90947-0; MANTZ J, 1988, NEUROSCIENCE, V27, P517, DOI 10.1016/0306-4522(88)90285-0; Maren S, 1996, NEURON, V16, P237, DOI 10.1016/S0896-6273(00)80041-0; MCDONALD AJ, 1987, J COMP NEUROL, V262, P46, DOI 10.1002/cne.902620105; MCDONALD AJ, 1991, NEUROSCIENCE, V44, P1, DOI 10.1016/0306-4522(91)90247-L; MORGAN MA, 1995, BEHAV NEUROSCI, V109, P681, DOI 10.1037/0735-7044.109.4.681; PAPINI MR, 1993, J EXP PSYCHOL ANIM B, V19, P342, DOI 10.1037/0097-7403.19.4.342; PEREZJARANAY JM, 1991, BRAIN RES, V564, P97, DOI 10.1016/0006-8993(91)91357-7; RESCORLA RA, 1969, PSYCHOL BULL, V72, P77, DOI 10.1037/h0027760; Rogan MT, 1997, NATURE, V390, P604, DOI 10.1038/37601; Schoenbaum G, 1998, NAT NEUROSCI, V1, P155, DOI 10.1038/407; Schoenbaum G, 1999, J NEUROSCI, V19, P1876; THOMAS E, 1980, EXP NEUROL, V69, P50, DOI 10.1016/0014-4886(80)90142-9; TURNER BH, 1991, J COMP NEUROL, V313, P295, DOI 10.1002/cne.903130208	30	265	268	0	17	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					294	296		10.1038/46286	http://dx.doi.org/10.1038/46286			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	Science & Technology - Other Topics	257ZP	10580500				2022-12-28	WOS:000083813700050
J	Greenhalgh, T				Greenhalgh, T			Competencies for informed shared decision making - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material									UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 3UA, England	University of London; University College London; UCL Medical School	Greenhalgh, T (corresponding author), UCL Royal Free & Univ Coll Med Sch, Dept Primary Care & Populat Sci, London N19 3UA, England.	p.greenhalg@ucl.ac.uk	Greenhalgh, Trisha/B-1825-2015	Greenhalgh, Trisha/0000-0003-2369-8088				Barnett R., 1994, LIMITS COMPETENCE; ERAUT M, 1993, DEV PROFESSIONAL KNO; Greenhalgh T, 1997, J Eval Clin Pract, V3, P161, DOI 10.1046/j.1365-2753.1997.00082.x; Hager P, 1996, MED TEACH, V18, P15, DOI 10.3109/01421599609040255; Hyland T., 1993, J PHILOS EDUC, V27, P57, DOI DOI 10.1111/J.1467-9752.1993.TB00297.X; TANENBAUM SJ, 1993, NEW ENGL J MED, V329, P1268, DOI 10.1056/NEJM199310213291713; Weightman, 1994, COMPETENCIES ACTION	7	2	2	0	0	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-535X			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					770	770						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10576826				2022-12-28	WOS:000082701500028
J	Rampton, DS				Rampton, DS			Regular review - Management of Crohn's disease	BRITISH MEDICAL JOURNAL			English	Review							INFLAMMATORY BOWEL-DISEASE; CONTROLLED TRIAL; MAINTENANCE TREATMENT; ORAL BUDESONIDE; DOUBLE-BLIND; FOLLOW-UP; TERM; MESALAMINE; AZATHIOPRINE; ILEAL		St Bartholomews & Royal London Sch Med & Dent, Gastrointestinal Sci Res Unit, London E1 2AD, England; St Bartholomews & Royal London Sch Med & Dent, Digest Dis Res Ctr, London E1 2AD, England	University of London; Queen Mary University London; University of London; Queen Mary University London	Rampton, DS (corresponding author), Royal London Hosp, Dept Gastroenterol, London E1 1BB, England.		Rampton, David/AHD-0789-2022		Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		Belluzzi A, 1996, NEW ENGL J MED, V334, P1557, DOI 10.1056/NEJM199606133342401; Bhatti M, 1998, GUT, V43, P40, DOI 10.1136/gut.43.1.40; Bickston S J, 1998, Adv Intern Med, V43, P143; Bouhnik Y, 1996, LANCET, V347, P215, DOI 10.1016/S0140-6736(96)90402-X; Camma C, 1997, GASTROENTEROLOGY, V113, P1465, DOI 10.1053/gast.1997.v113.pm9352848; Campieri M, 1997, GUT, V41, P209, DOI 10.1136/gut.41.2.209; CONNELL WR, 1994, LANCET, V343, P1249, DOI 10.1016/S0140-6736(94)92150-4; CONNELL WR, 1993, GUT, V34, P1081, DOI 10.1136/gut.34.8.1081; Cosnes J, 1996, GASTROENTEROLOGY, V110, P424, DOI 10.1053/gast.1996.v110.pm8566589; COUCKUYT H, 1995, GUT, V36, P577, DOI 10.1136/gut.36.4.577; Feagan BG, 1996, GASTROENTEROLOGY, V110, P275, DOI 10.1053/gast.1996.v110.pm8536868; FEAGAN BG, 1995, NEW ENGL J MED, V332, P292, DOI 10.1056/NEJM199502023320503; Fiocchi C, 1998, GASTROENTEROLOGY, V115, P182, DOI 10.1016/S0016-5085(98)70381-6; Greenberg GR, 1996, GASTROENTEROLOGY, V110, P45, DOI 10.1053/gast.1996.v110.pm8536887; GRIFFITHS AM, 1995, GASTROENTEROLOGY, V108, P1056, DOI 10.1016/0016-5085(95)90203-1; HAGGETT PJ, 1995, GUT, V36, P407, DOI 10.1136/gut.36.3.407; Hanauer SB, 1997, AM J GASTROENTEROL, V92, P559; Hanauer SB, 1996, NEW ENGL J MED, V334, P841, DOI 10.1056/NEJM199603283341307; Hellers G, 1999, GASTROENTEROLOGY, V116, P294, DOI 10.1016/S0016-5085(99)70125-3; Hodgson HJF, 1997, INFLAMM BOWEL DIS, P329; KAUFMANN HJ, 1987, ANN INTERN MED, V107, P513, DOI 10.7326/0003-4819-107-4-513; KODNER IJ, 1997, INFLAMM BOWEL DIS, P863; LAVEY A, 1997, DIS COLON RECTUM, V40, P184; LENNARDJONES JE, 1994, ALIMENT PHARM THERAP, V8, P563; Lofberg R, 1996, GUT, V39, P82, DOI 10.1136/gut.39.1.82; Lopez-Cubero SO, 1998, GASTROENTEROLOGY, V114, P433, DOI 10.1016/S0016-5085(98)70525-6; LOWE GDO, 1992, BMJ-BRIT MED J, V305, P567; Neurath MF, 1999, GUT, V44, P625, DOI 10.1136/gut.44.5.625; Neurath MF, 1996, NAT MED, V2, P998, DOI 10.1038/nm0996-998; Ogunbiyi OA, 1998, BAILLIERE CLIN GASTR, V12, P157, DOI 10.1016/S0950-3528(98)90090-2; Oren R, 1997, AM J GASTROENTEROL, V92, P2203; Panis Y, 1996, LANCET, V347, P854, DOI 10.1016/S0140-6736(96)91344-6; PEARSON DC, 1995, ANN INTERN MED, V122, P132; PIEVY SE, 1997, GASTROENTEROLOGY, V112, pA1062; Prantera C, 1996, AM J GASTROENTEROL, V91, P328; Present DH, 1999, NEW ENGL J MED, V340, P1398, DOI 10.1056/NEJM199905063401804; RUTGEERTS P, 1995, GASTROENTEROLOGY, V108, P1617, DOI 10.1016/0016-5085(95)90121-3; Rutgeerts P, 1999, GASTROENTEROLOGY, V117, P761, DOI 10.1016/S0016-5085(99)70332-X; RUTGEERTS P, 1994, NEW ENGL J MED, V331, P841; SACHAR DB, 1994, GUT, V35, P1507, DOI 10.1136/gut.35.11.1507; Sandborn WJ, 1999, GASTROENTEROLOGY, V117, P527, DOI 10.1016/S0016-5085(99)70445-2; SINGLETON JW, 1993, GASTROENTEROLOGY, V104, P1293, DOI 10.1016/0016-5085(93)90337-C; Targan SR, 1997, NEW ENGL J MED, V337, P1029, DOI 10.1056/NEJM199710093371502; Thomas GAO, 1998, GUT, V42, P497, DOI 10.1136/gut.42.4.497; Thomsen OO, 1998, NEW ENGL J MED, V339, P370, DOI 10.1056/NEJM199808063390603; TREMAINE WJ, 1994, J CLIN GASTROENTEROL, V19, P278, DOI 10.1097/00004836-199412000-00003; vanDeventer SJH, 1997, GASTROENTEROLOGY, V113, P383, DOI 10.1053/gast.1997.v113.pm9247454; Wills JS, 1997, RADIOLOGY, V202, P597, DOI 10.1148/radiology.202.3.9051003; World MJ, 1996, NEPHROL DIAL TRANSPL, V11, P614, DOI 10.1093/oxfordjournals.ndt.a027349	49	35	36	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1480	1485		10.1136/bmj.319.7223.1480	http://dx.doi.org/10.1136/bmj.319.7223.1480			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582935	Green Published			2022-12-28	WOS:000084129200025
J	Lancaster, CRD; Kroger, A; Auer, M; Michel, H				Lancaster, CRD; Kroger, A; Auer, M; Michel, H			Structure of fumarate reductase from Wolinella succinogenes at 2.2 angstrom resolution	NATURE			English	Article							PHOSPHORYLATIVE ELECTRON-TRANSPORT; SITE-DIRECTED MUTAGENESIS; FREE R-VALUE; SUCCINATE-DEHYDROGENASE; VIBRIO-SUCCINOGENES; CRYSTAL-STRUCTURES; ESCHERICHIA-COLI; COMPLEX; REFINEMENT; EXPRESSION	Fumarate reductase couples the reduction of fumarate to succinate to the oxidation of quinol to quinone, in a reaction opposite to that catalysed by the related complex II of the respiratory chain (succinate dehydrogenase). Here we describe the crystal structure at 2.2 Angstrom resolution of the three protein subunits containing fumarate reductase from the anaerobic bacterium Wolinella succinogenes, Subunit A contains the site of fumarate reduction and a covalently bound flavin adenine dinucleotide prosthetic group. Subunit B contains three iron-sulphur centres, The menaquinol-oxidizing subunit C consists of five membrane-spanning, primarily helical segments and binds two haem b molecules. On the basis of the structure, we propose a pathway of electron transfer from the dihaem cytochrome b to the site of fumarate reduction and a mechanism of fumarate reduction. The relative orientations of the soluble and membrane-embedded subunits of succinate:quinone oxidoreductases appear to be unique.	Max Planck Inst Biophys, D-60528 Frankfurt, Germany; Goethe Univ Frankfurt, Inst Mikrobiol, D-60439 Frankfurt, Germany	Max Planck Society; Goethe University Frankfurt	Lancaster, CRD (corresponding author), Max Planck Inst Biophys, Heinrich Hoffman Str 7, D-60528 Frankfurt, Germany.	lancaster@mpibp-frankfurt.mpg.de	Lancaster, C. Roy/E-4313-2010	Lancaster, C. Roy D./0000-0002-2814-0051				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; BRONDER M, 1982, ARCH MICROBIOL, V131, P216, DOI 10.1007/BF00405882; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; COLE ST, 1985, BIOCHIM BIOPHYS ACTA, V811, P381, DOI 10.1016/0304-4173(85)90008-4; COWTAN K, 1994, JOINT CCP4 ESF EACBM, V30, P34; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; Esnouf RM, 1999, ACTA CRYSTALLOGR D, V55, P938, DOI 10.1107/S0907444998017363; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FLACHMANN R, 1988, EUR J BIOCHEM, V175, P221, DOI 10.1111/j.1432-1033.1988.tb14187.x; Hagerhall C, 1997, BBA-BIOENERGETICS, V1320, P107, DOI 10.1016/S0005-2728(97)00019-4; Hagerhall C, 1996, FEBS LETT, V389, P25, DOI 10.1016/0014-5793(96)00529-7; Hederstedt L, 1999, SCIENCE, V284, P1941, DOI 10.1126/science.284.5422.1941; Holm L, 1996, SCIENCE, V273, P595, DOI 10.1126/science.273.5275.595; Iverson TM, 1999, SCIENCE, V284, P1961, DOI 10.1126/science.284.5422.1961; IWATA S, 1995, NATURE, V376, P660, DOI 10.1038/376660a0; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; KABSCH W, 1983, BIOPOLYMERS, V22, P2577, DOI 10.1002/bip.360221211; KENNEY WC, 1977, FEBS LETT, V73, P239, DOI 10.1016/0014-5793(77)80989-7; Kleywegt GJ, 1996, STRUCTURE, V4, P897, DOI 10.1016/S0969-2126(96)00097-4; KORTNER C, 1990, MOL MICROBIOL, V4, P855, DOI 10.1111/j.1365-2958.1990.tb00657.x; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; KROGER A, 1978, BIOCHIM BIOPHYS ACTA, V505, P129, DOI 10.1016/0304-4173(78)90010-1; KROGER A, 1992, ARCH MICROBIOL, V158, P311, DOI 10.1007/BF00245358; KURIYAN J, 1991, NATURE, V352, P172, DOI 10.1038/352172a0; Lancaster CRD, 1997, STRUCTURE, V5, P1339, DOI 10.1016/S0969-2126(97)00285-2; Lancaster CRD, 1999, BIOCHEM SOC T, V27, P591, DOI 10.1042/bst0270591; LAUTERBACH F, 1990, ARCH MICROBIOL, V154, P386, DOI 10.1007/BF00276536; LUZZATI V, 1952, ACTA CRYSTALLOGR, V5, P802, DOI 10.1107/S0365110X52002161; Mattevi A, 1999, STRUCTURE, V7, P745, DOI 10.1016/S0969-2126(99)80099-9; MCPHERSON A, 1999, CRYSTALLIZATION BIOL, P304; Merritt EA, 1997, METHOD ENZYMOL, V277, P505, DOI 10.1016/S0076-6879(97)77028-9; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; Otwinowski Z., 1991, ISOMORPHOUS REPLACEM, P80; READ RJ, 1986, ACTA CRYSTALLOGR A, V42, P140, DOI 10.1107/S0108767386099622; SALERNO JC, 1991, BIOCHEM SOC T, V19, P599, DOI 10.1042/bst0190599; Saraste M, 1999, SCIENCE, V283, P1488, DOI 10.1126/science.283.5407.1488; SCHRODER I, 1991, J BIOL CHEM, V266, P13572; Simon J, 1998, EUR J BIOCHEM, V251, P418, DOI 10.1046/j.1432-1327.1998.2510418.x; SINGER TP, 1984, METHOD ENZYMOL, V106, P369; Tomb JF, 1997, NATURE, V388, P539, DOI 10.1038/41483; TSIOTIS G, 1994, PRACTICAL GUIDE MEMB, P149; TSUKIHARA T, 1990, J MOL BIOL, V216, P399, DOI 10.1016/S0022-2836(05)80330-4; UNDEN G, 1980, FEBS LETT, V117, P323, DOI 10.1016/0014-5793(80)80972-0; UNDEN G, 1980, BIOCHIM BIOPHYS ACTA, V591, P275, DOI 10.1016/0005-2728(80)90159-0; UNDEN G, 1984, BIOCHIM BIOPHYS ACTA, V767, P460, DOI 10.1016/0005-2728(84)90044-6; VANHELLEMOND JJ, 1994, BIOCHEM J, V304, P321, DOI 10.1042/bj3040321; VIK SB, 1981, P NATL ACAD SCI-BIOL, V78, P6749, DOI 10.1073/pnas.78.11.6749; Xia D, 1997, SCIENCE, V277, P60, DOI 10.1126/science.277.5322.60	50	304	315	0	34	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760					377	385		10.1038/46483	http://dx.doi.org/10.1038/46483			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586875				2022-12-28	WOS:000083913600046
J	Halperin, DT; Bailey, RC				Halperin, DT; Bailey, RC			Male circumcision and HIV infection: 10 years and counting	LANCET			English	Editorial Material							SEXUALLY-TRANSMITTED DISEASES; RISK; MEN; TRANSMISSION; PREVENTION		Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA; Univ Illinois, Dept Anthropol, Chicago, IL 60612 USA; Univ Calif San Francisco, Dept Community Hlth Syst, San Francisco, CA USA; Univ Calif San Francisco, Med Anthropol Program, San Francisco, CA USA	University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of Illinois System; University of Illinois Chicago; University of Illinois Chicago Hospital; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bailey, RC (corresponding author), Univ Illinois, Sch Publ Hlth, Div Epidemiol & Biostat, Chicago, IL 60612 USA.							BAILEY RC, 1999, PHASE 1 2 TRIAL INTE; Caldwell JC, 1996, SCI AM, V274, P62, DOI 10.1038/scientificamerican0396-62; CAMERON DW, 1989, LANCET, V2, P403; DEVINCENZI I, 1994, AIDS, V8, P153, DOI 10.1097/00002030-199402000-00002; Fleiss PM, 1998, SEX TRANSM INFECT, V74, P364, DOI 10.1136/sti.74.5.364; GREEN EC, 1993, TROP DOCT, V23, P182, DOI 10.1177/004947559302300423; HUSSAIN LA, 1995, IMMUNOLOGY, V85, P475; Kelly R, 1999, AIDS, V13, P399, DOI 10.1097/00002030-199902250-00013; Kleinbaum DG, 1982, EPIDEMIOLOGIC RES PR; MOSES S, 1994, SEX TRANSM DIS, V21, P201, DOI 10.1097/00007435-199407000-00004; Moses S, 1998, SEX TRANSM INFECT, V74, P368, DOI 10.1136/sti.74.5.368; MOSES S, 1995, HLTH TRANSITION REV, V5, P100; Padian NS, 1997, AM J EPIDEMIOL, V146, P350, DOI 10.1093/oxfordjournals.aje.a009276; SEED J, 1995, J ACQ IMMUN DEF SYND, V8, P83; SIMONSEN JN, 1988, NEW ENGL J MED, V319, P274, DOI 10.1056/NEJM198808043190504; Urassa M, 1997, AIDS, V11, P73, DOI 10.1097/00002030-199701000-00011	16	147	157	0	7	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1813	1815		10.1016/S0140-6736(99)03421-2	http://dx.doi.org/10.1016/S0140-6736(99)03421-2			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577659				2022-12-28	WOS:000083853000045
J	Mazzarello, P				Mazzarello, P			Achilles and the maggots	NATURE			English	Editorial Material									CNR, Ist Genet Biochim & Evoluzionist, I-27100 Pavia, Italy	Consiglio Nazionale delle Ricerche (CNR)	Mazzarello, P (corresponding author), CNR, Ist Genet Biochim & Evoluzionist, Via Abbiategrasso 207, I-27100 Pavia, Italy.			MAZZARELLO, PAOLO ANGELO/0000-0003-4130-5727					0	3	3	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					237	237		10.1038/46172	http://dx.doi.org/10.1038/46172			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580488				2022-12-28	WOS:000083813700025
J	Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P				Pascual, E; Batlle-Gualda, E; Martinez, A; Rosas, J; Vela, P			Synovial fluid analysis for diagnosis of intercritical gout	ANNALS OF INTERNAL MEDICINE			English	Article							MONOSODIUM URATE CRYSTALS; KNEE JOINTS; CLASSIFICATION; CRITERIA	Background: The diagnosis of gout in the intercritical phase can be difficult. Objective: To determine whether synovial fluid analysis allows the diagnosis of intercritical gout. Design: Cross-sectional study. Setting: Outpatient rheumatology clinics. Patients: 101 patients with gout. Intervention: Arthrocentesis of 80 knees and 21 first metatarsophalangeal joints teach joint from a different patient) that had been inflamed but were currently asymptomatic. Measurements: Frequency with which arthrocentesis yielded synovial fluid; presence of monosodium urate crystals in the synovial fluid sample; and, for synovial fluid with crystals, the number of microscope fields that had to be scanned before crystals were found. Results: Synovial fluid was obtained from 91 of 101 joints. The fluid from all 43 patients not receiving hypouricemic agents contained monosodium urate crystals. These crystals were found in the synovial fluid of only 34 of 48 patients receiving hypouricemic agents. In 90% of the synovial fluid samples that contained crystals, crystals were seen in the first five microscope fields examined. Conclusions: Arthrocentesis of asymptomatic knees and first metatarsophalangeal joints and synovial fluid analysis are simple procedures that facilitate the diagnosis of gout during intercritical periods.	Gen Hosp Univ Alicante, Alicante 03010, Spain; Hosp Marina Baja, Alicante 03570, Spain; Hosp Gen Elche, Alicante, Spain	General University Hospital of Alicante	Pascual, E (corresponding author), Gen Hosp Univ Alicante, Maestro Alonso 109, Alicante 03010, Spain.	e.pascual@san.gva.es	Vela Casasempere, Paloma/HCH-3831-2022	Vela Casasempere, Paloma/0000-0001-8566-5172; Pascual, Eliseo/0000-0002-3056-4478				AGUDELO CA, 1979, ARTHRITIS RHEUM, V22, P559, DOI 10.1002/art.1780220521; BLOCH DA, 1990, ARTHRITIS RHEUM, V33, P1137; BOMALASKI JS, 1986, ARTHRITIS RHEUM, V29, P1480, DOI 10.1002/art.1780291209; GORDON TP, 1982, J RHEUMATOL, V9, P967; Hunder GG, 1998, ANN INTERN MED, V129, P417, DOI 10.7326/0003-4819-129-5-199809010-00013; KENNEDY TD, 1984, J ROY SOC MED, V77, P747, DOI 10.1177/014107688407700907; PASCUAL E, 1991, ARTHRITIS RHEUM, V34, P141, DOI 10.1002/art.1780340203; Pascual E, 1996, BRIT J RHEUMATOL, V35, P306; PHELPS P, 1968, J AMER MED ASSOC, V203, P508, DOI 10.1001/jama.203.7.508; ROUAULT T, 1982, ARTHRITIS RHEUM, V25, P209, DOI 10.1002/art.1780250215; WALLACE SL, 1977, ARTHRITIS RHEUM, V20, P895, DOI 10.1002/art.1780200320; WEINBERGER A, 1979, ANN INTERN MED, V91, P56, DOI 10.7326/0003-4819-91-1-56; WOLFE F, 1991, J RHEUMATOL, V18, P1232; WYNGAARDEN JB, 1976, GOUT HYPERURICEMIA	14	149	153	0	15	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					756	759		10.7326/0003-4819-131-10-199911160-00007	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00007			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577299				2022-12-28	WOS:000083680100006
J	McAlister, FA; Straus, SE; Sackett, DL				McAlister, FA; Straus, SE; Sackett, DL		CARE-COAD1 Grp	Why we need large, simple studies of the clinical examination: the problem and a proposed solution	LANCET			English	Editorial Material							OBSTRUCTIVE AIRWAYS DISEASE; FORCED EXPIRATORY TIME; DEEP-VEIN THROMBOSIS; PHYSICAL-EXAMINATION; RESEARCH NETWORKS; PATIENT; DIAGNOSIS; HISTORY; PROBABILITY		Univ Alberta Hosp, Edmonton, AB T6G ZB7, Canada; John Radcliffe Hosp, Nuffield Dept Clin Med, Ctr Evidence Based Med, Oxford OX3 9DU, England	University of Alberta; University of Oxford	McAlister, FA (corresponding author), Univ Alberta Hosp, 2E324 WMC,8440-112 St, Edmonton, AB T6G ZB7, Canada.		McAlister, Finlay/C-4151-2013	McAlister, Finlay/0000-0001-7435-3341				Anand SS, 1998, JAMA-J AM MED ASSOC, V279, P1094, DOI 10.1001/jama.279.14.1094; BADGETT RG, 1993, AM J MED, V94, P188, DOI 10.1016/0002-9343(93)90182-O; Badgett RG, 1997, JAMA-J AM MED ASSOC, V277, P1712, DOI 10.1001/jama.277.21.1712; Cook DJ, 1996, JAMA-J AM MED ASSOC, V275, P630, DOI 10.1001/jama.275.8.630; CROMBIE D L, 1963, J Coll Gen Pract, V6, P579; DETSKY A, 1994, JAMA-J AM MED ASSOC, V271, P1114; DIAMOND GA, 1979, NEW ENGL J MED, V300, P1350, DOI 10.1056/NEJM197906143002402; Etchells E, 1997, JAMA-J AM MED ASSOC, V277, P564, DOI 10.1001/jama.277.7.564; FLEMING KA, 1997, EVIDENCE BASED MED, V2, P132; FLETCHER CM, 1952, P ROY SOC MED, V45, P577; FROOM J, 1990, BRIT MED J, V300, P582, DOI 10.1136/bmj.300.6724.582; GODFREY S, 1969, THORAX, V24, P4, DOI 10.1136/thx.24.1.4; GOLDSTEIN LB, 1994, JAMA-J AM MED ASSOC, V271, P1114, DOI 10.1001/jama.271.14.1114; GREEN LA, 1994, J FAM PRACTICE, V38, P400; GROVER SA, 1993, JAMA-J AM MED ASSOC, V270, P2218, DOI 10.1001/jama.270.18.2218; HEPPER NG, 1969, ARCH ENVIRON HEALTH, V19, P806, DOI 10.1080/00039896.1969.10666934; HOLLEMAN DR, 1993, J GEN INTERN MED, V8, P63, DOI 10.1007/BF02599985; KERN DG, 1991, CHEST, V100, P636, DOI 10.1378/chest.100.3.636; KING DK, 1989, ANN INTERN MED, V110, P451, DOI 10.7326/0003-4819-110-6-451; LAL S, 1964, BRIT MED J, V1, P814, DOI 10.1136/bmj.1.5386.814; Lederle FA, 1999, JAMA-J AM MED ASSOC, V281, P77, DOI 10.1001/jama.281.1.77; MANNINO DM, 1993, ARCH INTERN MED, V153, P1892, DOI 10.1001/archinte.153.16.1892; MARINI JJ, 1979, AM REV RESPIR DIS, V120, P1069; MULROW CD, 1986, J GEN INTERN MED, V1, P364, DOI 10.1007/BF02596418; NAIRN J R, 1969, British Journal of Diseases of the Chest, V63, P29, DOI 10.1016/S0007-0971(69)80041-0; NAYLOR CD, 1994, JAMA-J AM MED ASSOC, V271, P1859, DOI 10.1001/jama.271.23.1859; NIEBAUER L, 1994, J FAM PRACTICE, V38, P425; Nutting PA, 1996, J FAM PRACTICE, V42, P199; Panju AA, 1998, JAMA-J AM MED ASSOC, V280, P1256, DOI 10.1001/jama.280.14.1256; PARDEE NE, 1980, CHEST, V77, P354, DOI 10.1378/chest.77.3.354; PATEL A, 1992, CLIN RES, V40, pA370; PETERSDORF RG, 1983, NEW ENGL J MED, V309, P1053, DOI 10.1056/NEJM198310273091711; Sackett D. L., 1997, EVIDENCE BASED MED P; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2638, DOI 10.1001/jama.267.19.2638; SACKETT DL, 1992, JAMA-J AM MED ASSOC, V267, P2650, DOI 10.1001/jama.267.19.2650; SANDLER G, 1980, AM HEART J, V100, P928, DOI 10.1016/0002-8703(80)90076-9; SCHAPIRA RM, 1993, JAMA-J AM MED ASSOC, V270, P731, DOI 10.1001/jama.270.6.731; SCHEINHORN DJ, 1982, SOUTHERN MED J, V75, P434, DOI 10.1097/00007611-198204000-00014; Simel DL, 1997, JAMA-J AM MED ASSOC, V277, P572, DOI 10.1001/jama.277.7.572; SURPRENANT EL, 1967, DIS CHEST, V52, P760, DOI 10.1378/chest.52.6.760; TURNBULL JM, 1995, JAMA-J AM MED ASSOC, V274, P1299, DOI 10.1001/jama.274.16.1299; van Schayck C P, 1991, Scand J Prim Health Care, V9, P232, DOI 10.3109/02813439109018525; Wells PS, 1997, LANCET, V350, P1795, DOI 10.1016/S0140-6736(97)08140-3; Whited JD, 1998, JAMA-J AM MED ASSOC, V279, P696, DOI 10.1001/jama.279.9.696; WILLIAMS JW, 1993, JAMA-J AM MED ASSOC, V270, P1242, DOI 10.1001/jama.270.10.1242; WILLIAMS JW, 1992, JAMA-J AM MED ASSOC, V267, P2645, DOI 10.1001/jama.267.19.2645; YUSUF S, 1990, STAT MED, V9, P73, DOI 10.1002/sim.4780090114	47	79	80	0	5	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1721	1724		10.1016/S0140-6736(99)01174-5	http://dx.doi.org/10.1016/S0140-6736(99)01174-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568588				2022-12-28	WOS:000083652800042
J	Niehrs, C; Pollet, N				Niehrs, C; Pollet, N			Synexpression groups in eukaryotes	NATURE			English	Article							GENE-EXPRESSION; CELL-CYCLE; EVOLUTION; PATHWAYS; TRANSCRIPTION; MESODERM; YEAST; SCALE	In 1960, Jacob and Monod described the bacterial operon, a cluster of functionally interacting genes whose expression is tightly coordinated. Global expression analysis has shown that the highly coordinate expression of genes functioning in common processes is also a widespread phenomenon in eukaryotes. These sets of co-regulated genes, or 'synexpression groups', show a striking parallel to the operon, and may be a key determinant facilitating evolutionary change reading to animal diversity.	Deutsch Krebsforschungszentrum, Div Mol Embryol, D-69120 Heidelberg, Germany	Helmholtz Association; German Cancer Research Center (DKFZ)	Niehrs, C (corresponding author), Deutsch Krebsforschungszentrum, Div Mol Embryol, Neuenheimer Feld 280, D-69120 Heidelberg, Germany.		Pollet, Nicolas/A-4746-2013	Pollet, Nicolas/0000-0002-9975-9644				Artavanis-Tsakonas S, 1999, SCIENCE, V284, P770, DOI 10.1126/science.284.5415.770; Bassett DE, 1999, NAT GENET, V21, P51, DOI 10.1038/4478; Bhushan A, 1998, DEV BIOL, V200, P260, DOI 10.1006/dbio.1998.8965; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; Blumenthal T, 1998, BIOESSAYS, V20, P480, DOI 10.1002/(SICI)1521-1878(199806)20:6&lt;480::AID-BIES6&gt;3.0.CO;2-Q; Bowtell DDL, 1999, NAT GENET, V21, P25, DOI 10.1038/4455; BRITTEN RJ, 1969, SCIENCE, V165, P349, DOI 10.1126/science.165.3891.349; Brown PO, 1999, NAT GENET, V21, P33, DOI 10.1038/4462; Cheung VG, 1999, NAT GENET, V21, P15, DOI 10.1038/4439; Cheverud JM, 1996, AM ZOOL, V36, P44; Cho RJ, 1998, MOL CELL, V2, P65, DOI 10.1016/S1097-2765(00)80114-8; Chu S, 1998, SCIENCE, V282, P699, DOI 10.1126/science.282.5389.699; Dandekar T, 1998, TRENDS BIOCHEM SCI, V23, P324, DOI 10.1016/S0968-0004(98)01274-2; DeRisi JL, 1997, SCIENCE, V278, P680, DOI 10.1126/science.278.5338.680; Duboule D, 1998, TRENDS GENET, V14, P54, DOI 10.1016/S0168-9525(97)01358-9; Duggan DJ, 1999, NAT GENET, V21, P10, DOI 10.1038/4434; Eisen MB, 1998, P NATL ACAD SCI USA, V95, P14863, DOI 10.1073/pnas.95.25.14863; Fambrough D, 1999, CELL, V97, P727, DOI 10.1016/S0092-8674(00)80785-0; Frisch A, 1998, DEVELOPMENT, V125, P431; Gawantka V, 1998, MECH DEVELOP, V77, P95, DOI 10.1016/S0925-4773(98)00115-4; GERHART J, 1997, CELLLS EMBRYOS EVOLU; Gerhold D, 1999, TRENDS BIOCHEM SCI, V24, P168, DOI 10.1016/S0968-0004(99)01382-1; Hata A, 1998, GENE DEV, V12, P186, DOI 10.1101/gad.12.2.186; Huang F, 1998, INT J DEV BIOL, V42, P487; Jacob F, 1997, CR ACAD SCI III-VIE, V320, P199, DOI 10.1016/S0764-4469(97)86927-2; JAN YN, 1993, P NATL ACAD SCI USA, V90, P8305, DOI 10.1073/pnas.90.18.8305; Jen WC, 1999, GENE DEV, V13, P1486, DOI 10.1101/gad.13.11.1486; Lagna G, 1996, NATURE, V383, P832, DOI 10.1038/383832a0; Lawrence JG, 1997, TRENDS MICROBIOL, V5, P355, DOI 10.1016/S0966-842X(97)01110-4; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; McInerny CJ, 1997, GENE DEV, V11, P1277, DOI 10.1101/gad.11.10.1277; Meersseman G, 1997, MECH DEVELOP, V61, P127, DOI 10.1016/S0925-4773(96)00629-6; Niehrs Christof, 1997, Genes and Function, V1, P229; NISHIDA E, 1993, TRENDS BIOCHEM SCI, V18, P128, DOI 10.1016/0968-0004(93)90019-J; Onichtchouk D, 1999, NATURE, V401, P480, DOI 10.1038/46794; Onichtchouk D, 1996, DEVELOPMENT, V122, P3045; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; Spellman PT, 1998, MOL BIOL CELL, V9, P3273, DOI 10.1091/mbc.9.12.3273; VISHWANATH RI, 1999, SCIENCE, V283, P83; Wagner GP, 1995, LECT NOTES ARTIF INT, V929, P317; Wen XL, 1998, P NATL ACAD SCI USA, V95, P334, DOI 10.1073/pnas.95.1.334; Yuh CH, 1998, SCIENCE, V279, P1896, DOI 10.1126/science.279.5358.1896	42	301	306	3	16	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					483	487		10.1038/990025	http://dx.doi.org/10.1038/990025			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591207				2022-12-28	WOS:000084013200044
J	Redondo, P; Bauza, A				Redondo, P; Bauza, A			Topical N-acetylcysteine for lamellar ichthyosis	LANCET			English	Article								The antioxidant N-acetylcysteine has an antiproliferative effect on a culture of human keratinocytes. We report a patient with lamellar ichthyosis satisfactorily treated with topical N-acetylcysteine.	Univ Navarra Clin, Sch Med, Dept Dermatol, Pamplona 31080, Spain	University of Navarra	Redondo, P (corresponding author), Univ Navarra Clin, Sch Med, Dept Dermatol, Pamplona 31080, Spain.	predondo@unav.es	REDONDO, PEDRO/H-7989-2017	REDONDO, PEDRO/0000-0001-7899-2511				BONANOMI L, 1980, EUR J RESPIR DIS, V61, P45; KIM JA, 1983, SEMIN ONCOL, V10, P86; Redondo P, 1998, ARCH DERMATOL RES, V290, P425, DOI 10.1007/s004030050330; Sekharam M, 1998, TOXICOL APPL PHARM, V149, P210, DOI 10.1006/taap.1997.8361; VANDERSTEEN PR, 1972, ARCH DERMATOL, V106, P694, DOI 10.1001/archderm.106.5.694	5	33	33	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 27	1999	354	9193					1880	1880		10.1016/S0140-6736(99)04245-2	http://dx.doi.org/10.1016/S0140-6736(99)04245-2			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584733				2022-12-28	WOS:000083909100022
J	Corry, DB; Kheradmand, F				Corry, DB; Kheradmand, F			Induction and regulation of the IgE response	NATURE			English	Review							DUST MITE ALLERGEN; PRODUCTION IN-VITRO; FC-GAMMA-RIII; T-CELLS; IMMUNE-RESPONSES; IMMUNOGLOBULIN-E; MAST-CELLS; ANTIBODY-RESPONSE; INTERFERON-GAMMA; DENDRITIC CELLS	Immunoglobulin E (IgE) is believed to be one of the major mediators of immediate hypersensitivity reactions that underlie atopic conditions such as urticaria, seasonal allergy, asthma and anaphylaxis. Factors that control IgE production are therefore essential to the pathogenesis of these important afflictions. But a complete understanding of this topic is lacking, while new data have raised questions regarding the precise role of IgE in atopic disease. Evolving concepts of IgE production and elimination are likely to clarify the importance of IgE in health and disease.	Baylor Coll Med, Dept Med, Houston, TX 77030 USA	Baylor College of Medicine	Corry, DB (corresponding author), Baylor Coll Med, Dept Med, Houston, TX 77030 USA.							Abbas AK, 1996, NATURE, V383, P787, DOI 10.1038/383787a0; BIX M, 1995, J IMMUNOL, V155, P1020; Brown DR, 1996, J EXP MED, V184, P1295, DOI 10.1084/jem.184.4.1295; CAMPBELL KA, 1992, EUR J IMMUNOL, V22, P2107, DOI 10.1002/eji.1830220822; Cleveland MG, 1996, INFECT IMMUN, V64, P1906, DOI 10.1128/IAI.64.6.1906-1912.1996; COFFMAN RL, 1986, J IMMUNOL, V136, P949; CONSTANT S, 1995, J EXP MED, V182, P1591, DOI 10.1084/jem.182.5.1591; Corry DB, 1998, MOL MED, V4, P344, DOI 10.1007/BF03401741; DELPHIN S, 1995, J EXP MED, V181, P181, DOI 10.1084/jem.181.1.181; DOMBROWICZ D, 1993, CELL, V75, P969, DOI 10.1016/0092-8674(93)90540-7; DRESKIN SC, 1987, J CLIN INVEST, V79, P1764, DOI 10.1172/JCI113017; Emson CL, 1998, J EXP MED, V188, P399, DOI 10.1084/jem.188.2.399; FARBER DL, 1995, IMMUNITY, V2, P249, DOI 10.1016/1074-7613(95)90049-7; Ferlin WG, 1996, EUR J IMMUNOL, V26, P2911, DOI 10.1002/eji.1830261216; FINKELMAN FD, 1988, J IMMUNOL, V141, P2335; FINKELMAN FD, 1994, J EXP MED, V179, P1563, DOI 10.1084/jem.179.5.1563; FUJIWARA H, 1994, P NATL ACAD SCI USA, V91, P6835, DOI 10.1073/pnas.91.15.6835; GOUNNI AS, 1994, NATURE, V367, P183, DOI 10.1038/367183a0; Grunewald SM, 1998, J IMMUNOL, V160, P4004; Grunig G, 1998, SCIENCE, V282, P2261, DOI 10.1126/science.282.5397.2261; GUSTAVSSON S, 1994, J IMMUNOL, V152, P4793; Haczku A, 1997, AM J RESP CRIT CARE, V156, P1945, DOI 10.1164/ajrccm.156.6.9701087; HERBERT CA, 1995, AM J RESP CELL MOL, V12, P369, DOI 10.1165/ajrcmb.12.4.7695916; Hershey GKK, 1997, NEW ENGL J MED, V337, P1720, DOI 10.1056/NEJM199712113372403; HEWITT CRA, 1995, J EXP MED, V182, P1537, DOI 10.1084/jem.182.5.1537; Hogan SP, 1997, J CLIN INVEST, V99, P1329, DOI 10.1172/JCI119292; Hoshino T, 1999, J IMMUNOL, V162, P5070; HOU JZ, 1994, SCIENCE, V265, P1701, DOI 10.1126/science.8085155; HSIEH CS, 1993, SCIENCE, V260, P547, DOI 10.1126/science.8097338; Iciek LA, 1997, J IMMUNOL, V158, P4769; IIO A, 1978, J IMMUNOL, V120, P1696; ISHIZAKA K, 1970, J ALLERGY, V46, P197, DOI 10.1016/0021-8707(70)90023-7; ISHIZAKA K, 1988, ANNU REV IMMUNOL, V6, P513; ISHIZAKA K, 1989, INT ARCH ALLER A IMM, V88, P8, DOI 10.1159/000234739; Jankovic D, 1997, J IMMUNOL, V159, P1868; Kaplan MH, 1996, IMMUNITY, V4, P313, DOI 10.1016/S1074-7613(00)80439-2; KAWABE T, 1994, IMMUNITY, V1, P167, DOI 10.1016/1074-7613(94)90095-7; Keane-Myers AM, 1998, J IMMUNOL, V160, P1036; Kline JN, 1998, J IMMUNOL, V160, P2555; Klinman DM, 1996, P NATL ACAD SCI USA, V93, P2879, DOI 10.1073/pnas.93.7.2879; KUCHROO VK, 1995, CELL, V80, P707, DOI 10.1016/0092-8674(95)90349-6; LACK G, 1994, J IMMUNOL, V152, P2546; Lambrecht BN, 1998, J IMMUNOL, V160, P4090; Linehan LA, 1998, J IMMUNOL, V161, P302; LOCKSLEY RM, 1994, J EXP MED, V179, P1405, DOI 10.1084/jem.179.5.1405; MCWILLIAM AS, 1995, IMMUNOL CELL BIOL, V73, P405, DOI 10.1038/icb.1995.63; MINTY A, 1993, NATURE, V362, P248, DOI 10.1038/362248a0; Mitsuyasu H, 1998, NAT GENET, V19, P119, DOI 10.1038/472; Miyajima I, 1997, J CLIN INVEST, V99, P901, DOI 10.1172/JCI119255; Morawetz RA, 1996, J EXP MED, V184, P1651, DOI 10.1084/jem.184.5.1651; NAKAJIMA S, 1975, CLIN EXP IMMUNOL, V21, P306; NAKANISHI K, 1995, INT IMMUNOL, V7, P259, DOI 10.1093/intimm/7.2.259; NegraoCorrea D, 1996, J IMMUNOL, V157, P4037; NEWCOMB RW, 1970, J IMMUNOL, V105, P85; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Oshiba A, 1996, J CLIN INVEST, V97, P1398, DOI 10.1172/JCI118560; Oswald IP, 1997, INFECT IMMUN, V65, P1364, DOI 10.1128/IAI.65.4.1364-1369.1997; PARRONCHI P, 1991, P NATL ACAD SCI USA, V88, P4538, DOI 10.1073/pnas.88.10.4538; PENE J, 1988, P NATL ACAD SCI USA, V85, P6880, DOI 10.1073/pnas.85.18.6880; PUNNONEN J, 1993, P NATL ACAD SCI USA, V90, P3730, DOI 10.1073/pnas.90.8.3730; Qiu G, 1998, J IMMUNOL, V161, P2906; RAMASWAMY K, 1994, J EXP MED, V180, P1793, DOI 10.1084/jem.180.5.1793; Rissoan MC, 1999, SCIENCE, V283, P1183, DOI 10.1126/science.283.5405.1183; ROBINSON DS, 1992, NEW ENGL J MED, V326, P298, DOI 10.1056/NEJM199201303260504; Sabin EA, 1996, J EXP MED, V184, P1871, DOI 10.1084/jem.184.5.1871; SCHMITZ J, 1994, J EXP MED, V179, P1349, DOI 10.1084/jem.179.4.1349; SCHWARTZ RH, 1992, CELL, V71, P1065, DOI 10.1016/S0092-8674(05)80055-8; SEDER RA, 1991, INT ARCH ALLER A IMM, V94, P137, DOI 10.1159/000235345; Shimoda K, 1996, NATURE, V380, P630, DOI 10.1038/380630a0; SPORIK R, 1990, NEW ENGL J MED, V323, P502, DOI 10.1056/NEJM199008233230802; SQUIRE CM, 1994, J IMMUNOL, V152, P4388; STIEF A, 1994, J IMMUNOL, V152, P3378; Strom L, 1999, SCAND J IMMUNOL, V49, P523; Stumbles PA, 1998, J EXP MED, V188, P2019, DOI 10.1084/jem.188.11.2019; TADA T, 1975, INT ARCH ALLER A IMM, V48, P116, DOI 10.1159/000231297; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; TEXIDO G, 1994, J IMMUNOL, V153, P3028; VIEIRA P, 1988, EUR J IMMUNOL, V18, P313, DOI 10.1002/eji.1830180221; Warren WD, 1999, MOL IMMUNOL, V36, P31, DOI 10.1016/S0161-5890(98)00114-X; Wills-Karp M, 1998, SCIENCE, V282, P2258, DOI 10.1126/science.282.5397.2258; Yanagihara Y, 1998, CLIN EXP IMMUNOL, V111, P136; Ying S, 1997, J IMMUNOL, V158, P3539; YOKOTA A, 1988, CELL, V55, P611, DOI 10.1016/0092-8674(88)90219-X; Yoshimoto T, 1998, J IMMUNOL, V161, P1483; YU P, 1994, NATURE, V369, P753, DOI 10.1038/369753a0; ZURAWSKI SM, 1993, EMBO J, V12, P2663, DOI 10.1002/j.1460-2075.1993.tb05927.x	86	233	241	0	13	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 25	1999	402	6760		S			B18	B23						6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586891				2022-12-28	WOS:000083913900005
J	Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M				Mercader, N; Leonardo, E; Azpiazu, N; Serrano, A; Morata, G; Martinez, C; Torres, M			Conserved regulation of proximodistal limb axis development by Meis1/Hth	NATURE			English	Article							HOMEOBOX GENE; VERTEBRATE LIMB; FEEDBACK LOOP; MESSENGER-RNA; EXPRESSION; EXTRADENTICLE; DROSOPHILA; BUD; DIFFERENTIATION; TRANSLOCATION	Vertebrate limbs grow out from the flanks of embryos, with their main axis extending proximodistally from the trunk. Distinct limb domains, each with specific traits, are generated in a proximal-to-distal sequence during development(1). Diffusible factors expressed from signalling centres promote the outgrowth of limbs and specify their dorsoventral and anteroposterior axes(2-4). However, the molecular mechanism by which limb cells acquire their proximodistal (P-D) identity is unknown(1). Here we describe the role of the homeobox genes Meis1/2 and Pbx1 in the development of mouse, chicken and Drosophila limbs. We find that Meis1/2 expression is restricted to a proximal domain, coincident with the previously reported domain in which Pbx1 is localized to the nucleus(5), and resembling the distribution of the Drosophila homologues homothorax (hth)(5,6) and extradenticle (exd)(7); that Meis1 regulates Pbx1 activity by promoting nuclear import of the Pbx1 protein; and that ectopic expression of Meis1 in chicken and hth in Drosophila disrupts distal limb development and induces distal-to-proximal transformations. We suggest that restriction of Meis1/Hth to proximal regions of the vertebrate and insect limb is essential to specify cell fates and differentiation patterns along the P-D axis of the limb.	Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain; Univ Autonoma Madrid, CSIC, Ctr Biol Mol, E-28049 Madrid, Spain	Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro Nacional de Biotecnologia (CNB); Autonomous University of Madrid; Consejo Superior de Investigaciones Cientificas (CSIC); CSIC - Centro de Biologia Molecular Severo Ochoa (CBM)	Torres, M (corresponding author), Univ Autonoma Madrid, CSIC, Ctr Nacl Biotecnol, Dept Inmunol & Oncol, E-28049 Madrid, Spain.		Mercader, Nadia/L-2728-2014; Torres, Miguel/CAG-0003-2022; Torres, Miguel/A-7388-2013	Mercader, Nadia/0000-0002-0905-6399; Torres, Miguel/0000-0003-0906-4767; Torres, Miguel/0000-0003-0906-4767; Serrano, Antonio/0000-0003-1993-640X; Morata, Gines/0000-0003-3274-5173				Abu-Shaar M, 1998, DEVELOPMENT, V125, P3821; Abu-Shaar M, 1999, GENE DEV, V13, P935, DOI 10.1101/gad.13.8.935; Berthelsen J, 1999, GENE DEV, V13, P946, DOI 10.1101/gad.13.8.946; BRAND AH, 1993, DEVELOPMENT, V118, P401; Calleja M, 1996, SCIENCE, V274, P252, DOI 10.1126/science.274.5285.252; CAPDEVILA J, IN PRESS MOL CELL; Cecconi F, 1997, DEV DYNAM, V210, P184, DOI 10.1002/(SICI)1097-0177(199710)210:2<184::AID-AJA10>3.0.CO;2-E; CELIS JFD, 1997, DEVELOPMENT, V124, P3241; Gonzalez-Crespo S, 1998, NATURE, V394, P196, DOI 10.1038/28197; GonzalezCrespo S, 1996, DEVELOPMENT, V122, P3921; Goto S, 1999, DEVELOPMENT, V126, P3407; Johnson RL, 1997, CELL, V90, P979, DOI 10.1016/S0092-8674(00)80364-5; KAMPS MP, 1990, CELL, V60, P547, DOI 10.1016/0092-8674(90)90658-2; LAUFER E, 1994, CELL, V79, P993, DOI 10.1016/0092-8674(94)90030-2; Logan M, 1998, METHODS, V14, P407, DOI 10.1006/meth.1998.0595; MORGAN BA, 1992, NATURE, V358, P236, DOI 10.1038/358236a0; MOSKOW JJ, 1995, MOL CELL BIOL, V15, P5434; Nakamura T, 1996, ONCOGENE, V13, P2235; Nelson CE, 1996, DEVELOPMENT, V122, P1449; NISWANDER L, 1994, NATURE, V371, P609, DOI 10.1038/371609a0; NOURSE J, 1990, CELL, V60, P535, DOI 10.1016/0092-8674(90)90657-Z; OuladAbdelghani M, 1997, DEV DYNAM, V210, P173, DOI 10.1002/(SICI)1097-0177(199710)210:2<173::AID-AJA9>3.0.CO;2-D; Pai CY, 1998, GENE DEV, V12, P435, DOI 10.1101/gad.12.3.435; PARR BA, 1995, NATURE, V374, P350, DOI 10.1038/374350a0; Rieckhof GE, 1997, CELL, V91, P171, DOI 10.1016/S0092-8674(00)80400-6; ROWE DA, 1982, J EMBRYOL EXP MORPH, V68, P1; Shubin N, 1997, NATURE, V388, P639, DOI 10.1038/41710; SUMMERBELL D, 1973, NATURE, V244, P492, DOI 10.1038/244492a0; WILKINSON DG, 1993, METHOD ENZYMOL, V225, P361; Wu J, 1999, DEVELOPMENT, V126, P109; Zakany J, 1999, CELL TISSUE RES, V296, P19, DOI 10.1007/s004410051262	31	240	241	0	9	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					425	429		10.1038/46580	http://dx.doi.org/10.1038/46580			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586884				2022-12-28	WOS:000083913600060
J	Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA				Streblow, DN; Soderberg-Naucler, C; Vieira, J; Smith, P; Wakabayashi, E; Ruchti, F; Mattison, K; Altschuler, Y; Nelson, JA			The human cytomegalovirus chemokine receptor US28 mediates vascular smooth muscle cell migration	CELL			English	Article							PROTEIN-COUPLED RECEPTOR; MONOCYTE CHEMOATTRACTANT PROTEIN-1; SARCOMA-ASSOCIATED HERPESVIRUS; KAPOSIS-SARCOMA; DNA-SEQUENCE; INFECTED-CELLS; CODING CONTENT; ATHEROSCLEROSIS; EXPRESSION; VIRUS	Human cytomegalovirus (HCMV) infection of smooth muscle cells (SMCs) in vivo has been linked to a viral etiology of vascular disease. In this report, we demonstrate that HCMV infection of primary arterial SMCs results in significant cellular migration. Ablation of the chemokine receptor, US28, abrogates SMC migration, which is rescued only by expression of the viral homolog and not a cellular G protein-coupled receptor (GPCR). Expression of US28 in the presence of CC chemokines including RANTES or MCP-1 was sufficient to promote SMC migration by both chemokinesis and chemotaxis, which was inhibited by protein tyrosine kinase inhibitors. US28-mediated SMC migration provides a molecular basis for the correlative evidence that links HCMV to the acceleration of vascular disease.	Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA; Oregon Hlth & Sci Univ, Vaccine & Gene Therapy Inst, Portland, OR 97201 USA; Univ Washington, Dept Lab Med, Seattle, WA 98195 USA; Univ Washington, Program Infect Dis, Seattle, WA 98104 USA; Univ Calif San Francisco, Sch Med, Dept Anat, San Francisco, CA 94143 USA	Oregon Health & Science University; Oregon Health & Science University; University of Washington; University of Washington Seattle; University of Washington; University of Washington Seattle; University of California System; University of California San Francisco	Nelson, JA (corresponding author), Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97201 USA.	nelsonj@ohsu.edu			NIAID NIH HHS [AI 21640] Funding Source: Medline; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI021640] Funding Source: NIH RePORTER	NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		AHUJA SK, 1994, IMMUNOL TODAY, V15, P281, DOI 10.1016/0167-5699(94)90008-6; AHUJA SK, 1993, J BIOL CHEM, V268, P20691; Arai H, 1996, J BIOL CHEM, V271, P21814, DOI 10.1074/jbc.271.36.21814; Arvanitakis L, 1997, NATURE, V385, P347, DOI 10.1038/385347a0; Bacon KB, 1996, J EXP MED, V184, P873, DOI 10.1084/jem.184.3.873; BACON KB, 1995, SCIENCE, V269, P1727, DOI 10.1126/science.7569902; Bais C, 1998, NATURE, V391, P86, DOI 10.1038/34193; BENDITT EP, 1983, P NATL ACAD SCI-BIOL, V80, P6386, DOI 10.1073/pnas.80.20.6386; Billstrom MA, 1998, J VIROL, V72, P5535, DOI 10.1128/JVI.72.7.5535-5544.1998; Bodaghi B, 1998, J EXP MED, V188, P855, DOI 10.1084/jem.188.5.855; BOKOCH GM, 1995, BLOOD, V86, P1649, DOI 10.1182/blood.V86.5.1649.bloodjournal8651649; Boring L, 1998, NATURE, V394, P894, DOI 10.1038/29788; Boshoff C, 1998, NATURE, V391, P24, DOI 10.1038/34054; Boshoff C, 1997, SCIENCE, V278, P290, DOI 10.1126/science.278.5336.290; Bruning JH, 1994, TRANSPLANT INT S1, V7, P365; BURGSTAHLER R, 1995, BIOCHEM BIOPH RES CO, V215, P737, DOI 10.1006/bbrc.1995.2525; Cary LA, 1996, J CELL SCI, V109, P1787; CHEE MS, 1990, CURR TOP MICROBIOL, V154, P125; CHEE MS, 1990, NATURE, V344, P774, DOI 10.1038/344774a0; DavisPoynter NJ, 1997, J VIROL, V71, P1521, DOI 10.1128/JVI.71.2.1521-1529.1997; FABRICANT CG, 1983, FED PROC, V42, P2476; GAO JL, 1994, J BIOL CHEM, V269, P28539; Gershengorn MC, 1998, J CLIN INVEST, V102, P1469, DOI 10.1172/JCI4461; GOMPELS UA, 1995, VIROLOGY, V209, P29, DOI 10.1006/viro.1995.1228; GOSSEN M, 1992, P NATL ACAD SCI USA, V89, P5547, DOI 10.1073/pnas.89.12.5547; Gu L, 1998, MOL CELL, V2, P275, DOI 10.1016/S1097-2765(00)80139-2; Guo HG, 1997, VIROLOGY, V228, P371, DOI 10.1006/viro.1996.8386; HENDRIX MGR, 1991, AM J PATHOL, V138, P563; Hitt M. M., 1994, CELL BIOL LAB HDB, V1, P479; ILLC D, 1995, NATURE, V377, P539; Inagami T, 1999, J AM SOC NEPHROL, V10, pS2; Jarvis MA, 1999, J VIROL, V73, P4552, DOI 10.1128/JVI.73.6.4552-4560.1999; Kledal TN, 1997, SCIENCE, V277, P1656, DOI 10.1126/science.277.5332.1656; KUHN DE, 1995, BIOCHEM BIOPH RES CO, V211, P325, DOI 10.1006/bbrc.1995.1814; KUNDRA V, 1995, J CELL BIOL, V130, P725, DOI 10.1083/jcb.130.3.725; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lalani AS, 1999, VIROLOGY, V256, P233, DOI 10.1006/viro.1999.9617; LEMSTROM KB, 1993, J CLIN INVEST, V92, P549, DOI 10.1172/JCI116622; LU M, 1996, J VIROL, V70, P6097; Margulies BJ, 1996, VIROLOGY, V225, P111, DOI 10.1006/viro.1996.0579; MASSUNG RF, 1993, VIROLOGY, V197, P511, DOI 10.1006/viro.1993.1625; MCDONALD K, 1989, AM J CARDIOL, V64, P359, DOI 10.1016/0002-9149(89)90535-3; Mellado M, 1998, J IMMUNOL, V161, P805; Melnick JL, 1998, INFECT MED, V15, P479; MELNICK JL, 1983, LANCET, V2, P644; Michelson S, 1997, J VIROL, V71, P6495, DOI 10.1128/JVI.71.9.6495-6500.1997; NELKEN NA, 1991, J CLIN INVEST, V88, P1121, DOI 10.1172/JCI115411; NEOTE K, 1993, CELL, V72, P415, DOI 10.1016/0092-8674(93)90118-A; NICHOLAS J, 1992, NATURE, V355, P362, DOI 10.1038/355362a0; PETERSON PK, 1980, MEDICINE, V59, P283, DOI 10.1097/00005792-198007000-00004; Rodriguez-Frade JM, 1999, J CELL BIOL, V144, P755, DOI 10.1083/jcb.144.4.755; Rollins BJ, 1997, BLOOD, V90, P909, DOI 10.1182/blood.V90.3.909.909_909_928; SoderbergNaucler C, 1997, CELL, V91, P119, DOI 10.1016/S0092-8674(01)80014-3; SPEIR E, 1994, SCIENCE, V265, P391, DOI 10.1126/science.8023160; TELFORD EAR, 1995, J MOL BIOL, V249, P520, DOI 10.1006/jmbi.1995.0314; Terkeltaub R, 1998, CURR OPIN LIPIDOL, V9, P397, DOI 10.1097/00041433-199810000-00003; TUMILOWICZ JJ, 1985, J VIROL, V56, P839, DOI 10.1128/JVI.56.3.839-845.1985; Vieira J, 1998, J VIROL, V72, P8158, DOI 10.1128/JVI.72.10.8158-8165.1998; YLAHERTTUALA S, 1991, P NATL ACAD SCI USA, V88, P5252, DOI 10.1073/pnas.88.12.5252; Zhou YF, 1996, NEW ENGL J MED, V335, P624, DOI 10.1056/NEJM199608293350903; Zhou YF, 1999, BIOCHEM BIOPH RES CO, V256, P608, DOI 10.1006/bbrc.1999.0387	61	331	345	1	9	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					511	520		10.1016/S0092-8674(00)81539-1	http://dx.doi.org/10.1016/S0092-8674(00)81539-1			10	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589679	Bronze			2022-12-28	WOS:000083986300010
J	Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM				Kong, YY; Feige, U; Sarosi, I; Bolon, B; Tafuri, A; Morony, S; Capparelli, C; Li, J; Elliott, R; McCabe, S; Wong, T; Campagnuolo, G; Moran, E; Bogoch, ER; Van, G; Nguyen, LT; Ohashi, PS; Lacey, DL; Fish, E; Boyle, WJ; Penninger, JM			Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand	NATURE			English	Article							RHEUMATOID-ARTHRITIS; OSTEOCLAST; RECEPTOR; CYTOKINE; DENSITY; BIOLOGY; TRANCE; FAMILY; MICE	Bone remodelling and bone loss are controlled by a balance between the tumour necrosis factor family molecule osteoprotegerin ligand (OPGL) and its decoy receptor osteoprotegerin (OPG)(1-3). In addition, OPGL regulates lymph node organogenesis, lymphocyte development and interactions between T cells and dendritic cells in the immune system(3-5). The OPGL receptor, RANK, is expressed on chondrocytes, osteoclast precursors and mature osteoclasts(4,6). OPGL expression in T cells is induced by antigen receptor engagement(7), which suggests that activated T cells may influence bone metabolism through OPGL and RANK. Here we report that activated T cells can directly trigger osteoclastogenesis through OPGL. Systemic activation of T cells in vivo leads to an OPGL-mediated increase in osteoclastogenesis and bone loss. In a T-cell-dependent model of rat adjuvant arthritis characterized by severe joint inflammation, bone and cartilage destruction and crippling, blocking of OPGL through osteoprotegerin treatment at the onset of disease prevents bone and cartilage destruction but not inflammation, These results show that both systemic and local T-cell activation can lead to OPGL production and subsequent bone loss, and they provide a novel paradigm for T cells as regulators of bone physiology.	Amgen Inst, Toronto, ON M5G 2C1, Canada; Amgen Inc, Dept Pharmacol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Pathol, Thousand Oaks, CA 91320 USA; Amgen Inc, Dept Cell Biol, Thousand Oaks, CA 91320 USA; St Michaels Hosp, Dept Med Genet & Microbiol, Toronto, ON M5B 1W8, Canada; Univ Toronto, Ontario Canc Inst, Toronto, ON, Canada; Univ Toronto, Dept Med Biophys & Immunol, Toronto, ON, Canada	Amgen; Amgen; Amgen; University of Toronto; University Toronto Affiliates; Saint Michaels Hospital Toronto; University of Toronto; University Toronto Affiliates; University Health Network Toronto; University of Toronto	Penninger, JM (corresponding author), Amgen Inst, 620 Univ Ave, Toronto, ON M5G 2C1, Canada.		Penninger, Josef M/I-6860-2013	Penninger, Josef M/0000-0002-8194-3777; Ohashi, Pamela S./0000-0003-2915-9317				Anderson DM, 1997, NATURE, V390, P175, DOI 10.1038/36593; Bendele A, 1999, ARTHRITIS RHEUM, V42, P498, DOI 10.1002/1529-0131(199904)42:3<498::AID-ANR15>3.0.CO;2-A; Coleman RE, 1998, BRIT J CANCER, V77, P336, DOI 10.1038/bjc.1998.52; CONWAY JG, 1995, J EXP MED, V182, P449, DOI 10.1084/jem.182.2.449; Faust J, 1999, J CELL BIOCHEM, V72, P67, DOI 10.1002/(SICI)1097-4644(19990101)72:1<67::AID-JCB8>3.0.CO;2-A; Feldmann M, 1996, ANNU REV IMMUNOL, V14, P397, DOI 10.1146/annurev.immunol.14.1.397; Felix R, 1996, EUR J ENDOCRINOL, V134, P143, DOI 10.1530/eje.0.1340143; Hsu HL, 1999, P NATL ACAD SCI USA, V96, P3540, DOI 10.1073/pnas.96.7.3540; Josien R, 1999, J IMMUNOL, V162, P2562; Kong YY, 1999, NATURE, V397, P315, DOI 10.1038/16852; Kotake S, 1999, J CLIN INVEST, V103, P1345, DOI 10.1172/JCI5703; Lacey DL, 1998, CELL, V93, P165, DOI 10.1016/S0092-8674(00)81569-X; MOMBAERTS P, 1992, CELL, V68, P869, DOI 10.1016/0092-8674(92)90030-G; Muller-Ladner U, 1998, Curr Opin Rheumatol, V10, P212; OLIVERI M B, 1991, Henry Ford Hospital Medical Journal, V39, P45; PANAYI GS, 1992, ARTHRITIS RHEUM-US, V35, P729, DOI 10.1002/art.1780350702; Piepkorn B, 1997, HORM METAB RES, V29, P584, DOI 10.1055/s-2007-979106; Roodman GD, 1996, BONE, V19, P209, DOI 10.1016/8756-3282(96)00211-6; Roodman GD, 1996, ENDOCR REV, V17, P308, DOI 10.1210/er.17.4.308; Simonet WS, 1997, CELL, V89, P309, DOI 10.1016/S0092-8674(00)80209-3; STELLON AJ, 1985, GASTROENTEROLOGY, V89, P1078, DOI 10.1016/0016-5085(85)90212-4; WATERHOUSE P, 1995, SCIENCE, V270, P985, DOI 10.1126/science.270.5238.985; Wong BR, 1997, J BIOL CHEM, V272, P25190, DOI 10.1074/jbc.272.40.25190; Wong BR, 1997, J EXP MED, V186, P2075, DOI 10.1084/jem.186.12.2075	24	1460	1567	2	60	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 18	1999	402	6759					304	309		10.1038/35005552	http://dx.doi.org/10.1038/35005552			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580503	Bronze			2022-12-28	WOS:000083813700053
J	Winston, DJ; Pakrasi, A; Busuttil, RW				Winston, DJ; Pakrasi, A; Busuttil, RW			Prophylactic fluconazole in liver transplant recipients - A randomized, double-blind, placebo-controlled trial	ANNALS OF INTERNAL MEDICINE			English	Article						liver transplantation; fluconazole; mycoses; cyclosporine; Candida	BONE-MARROW TRANSPLANTATION; FUNGAL-INFECTIONS; AMPHOTERICIN-B; INVASIVE FUNGAL; RISK-FACTORS; CANDIDA; CYCLOSPORINE; ASSOCIATION; NYSTATIN; THERAPY	Background: Among persons who receive solid organ transplants, liver transplant recipients have the highest incidence of invasive fungal infection; however, no antifungal prophylaxis has been proven to be effective. Objective: To evaluate the efficacy and safety of prophylactic fluconazole in liver transplant recipients. Design: Randomized, double-blind, placebo-controlled trial. Setting: University-affiliated transplantation center. Patients: 212 liver transplant recipients who received fluconazole (400 mg/d) or placebo until 10 weeks after transplantation. Measurements: Fungal colonization, proven superficial or invasive fungal infection, drug-related side effects, and death. Results: Fungal colonization increased in patients who received placebo (from 60% to 90%) but decreased in patients who received fluconazole (from 70% to 28%). Proven fungal infection occurred in 45 of 104 placebo recipients (43%) but in only 10 of 108 fluconazole recipients (9%) (P < 0.001). Fluconazole prevented both superficial infection (29 of 104 placebo recipients became infected [28%] compared with 4 of 108 fluconazole recipients [4%]; P < 0.001) and invasive infection (24 of 104 placebo recipients became infected [23%] compared with 6 of 108 fluconazole recipients [6%]; P < 0.001). Fluconazole prevented infection by most Candida species, except C. glabrata. However, infection and colonization by organisms intrinsically resistant to fluconazole did not seem to increase. Fluconazole was not associated with any hepatotoxicity. Patients receiving fluconazole had higher serum cyclosporine levels and more adverse neurologic events (headaches, tremors, or seizures in 13 fluconazole recipients compared with 3 placebo recipients; P < 0.01). Although the overall mortality rate was similar in both groups (12 of 108 [11%] in the fluconazole group compared with 15 of 104 [14%] in the placebo group; P > 0.2), fewer deaths related to invasive fungal infection were seen in the fluconazole group (2 of 108 patients [2%]) than in the placebo group (13 of 104 patients [13%]) (P = 0.003). Conclusions: Prophylactic fluconazole after liver transplantation decreases fungal colonization, prevents superficial and invasive fungal infections, and has no appreciable hepatotoxicity. Although fluconazole prophylaxis is associated with fewer deaths from fungal infection,it does not improve overall survival. Patients receiving prophylactic fluconazole require close monitoring of serum cyclosporine levels to avoid neurologic toxicity.	Univ Calif Los Angeles, Med Ctr, Dept Med, Los Angeles, CA 90095 USA; Univ Calif Los Angeles, Med Ctr, Dumont UCLA Transplant Ctr, Los Angeles, CA 90095 USA	University of California System; University of California Los Angeles; University of California Los Angeles Medical Center; University of California System; University of California Los Angeles; University of California Los Angeles Medical Center	Winston, DJ (corresponding author), Univ Calif Los Angeles, Med Ctr, Dept Med, Room 42-121 CHS, Los Angeles, CA 90095 USA.							AbiSaid D, 1997, CLIN INFECT DIS, V24, P1122, DOI 10.1086/513663; BACK DJ, 1991, BRIT J CLIN PHARMACO, V32, P624, DOI 10.1111/j.1365-2125.1991.tb03963.x; BUSUTTIL RW, 1994, ANN SURG, V219, P490, DOI 10.1097/00000658-199405000-00007; CASTALDO P, 1991, ARCH SURG-CHICAGO, V126, P149, DOI 10.1001/archsurg.1991.01410260033005; COLLINS LA, 1994, J INFECT DIS, V170, P644, DOI 10.1093/infdis/170.3.644; COMO JA, 1994, NEW ENGL J MED, V330, P263, DOI 10.1056/NEJM199401273300407; COX DR, 1972, J R STAT SOC B, V34, P187; EMMANOUILIDES C, 1996, TRANSPLANTATION LIVE, P633; GOODMAN JL, 1992, NEW ENGL J MED, V326, P845, DOI 10.1056/NEJM199203263261301; HUANG WY, 1987, AM J CLIN PATHOL, V87, P528, DOI 10.1093/ajcp/87.4.528; KAHAN BD, 1989, NEW ENGL J MED, V321, P1725; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; Lee E, 1980, STAT METHODS SURVIVA; Lumbreras C, 1996, J INFECT DIS, V174, P583, DOI 10.1093/infdis/174.3.583; MEYERS B, 1997, 37 INT C ANT AG CHEM, P306; MORA NP, 1992, TRANSPLANT P, V24, P154; Patel R, 1996, TRANSPLANTATION, V62, P926, DOI 10.1097/00007890-199610150-00010; PAYA CV, 1993, CLIN INFECT DIS, V16, P677, DOI 10.1093/clind/16.5.677; ROSSI S, 1995, 14 ANN M AM SOC TRAN, P149; RUSKIN JD, 1992, ORAL SURG ORAL MED O, V74, P567, DOI 10.1016/0030-4220(92)90345-Q; SINGH N, 1993, CLIN INFECT DIS, V17, P906, DOI 10.1093/clinids/17.5.906; SLAVIN MA, 1995, J INFECT DIS, V171, P1545, DOI 10.1093/infdis/171.6.1545; TOLLEMAR J, 1995, TRANSPLANTATION, V59, P45, DOI 10.1097/00007890-199501150-00009; TORTORANO AM, 1995, J MYCOL MED, V5, P21; WAJSZCZUK CP, 1985, TRANSPLANTATION, V40, P347, DOI 10.1097/00007890-198510000-00002; WINGARD JR, 1993, ANTIMICROB AGENTS CH, V37, P1847, DOI 10.1128/AAC.37.9.1847; WINGARD JR, 1991, NEW ENGL J MED, V325, P1274, DOI 10.1056/NEJM199110313251803; WINSTON DJ, 1995, CLIN INFECT DIS, V21, P1077, DOI 10.1093/clinids/21.5.1077; WINSTON DJ, 1993, ANN INTERN MED, V118, P495, DOI 10.7326/0003-4819-118-7-199304010-00003; WINSTON DJ, 1995, LANCET, V346, P69, DOI 10.1016/S0140-6736(95)92110-9	30	167	177	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					729	+		10.7326/0003-4819-131-10-199911160-00003	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00003			10	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577295				2022-12-28	WOS:000083680100002
J	Calin, A; Brophy, S; Blake, D				Calin, A; Brophy, S; Blake, D			Impact of sex on inheritance of ankylosing spondylitis: a cohort study	LANCET			English	Article							HLA; SUSCEPTIBILITY; ARTHRITIS; HLA-B27	Background Ankylosing spondylitis is a genetically determined and commonly familial disorder. Men and women differ in their susceptibility to ankylosing spondylitis, with about 2.5 men affected for every woman with the disease. We investigated the influence of the sex of the index case on disease penetrance within families. Methods The ages at which 50% and 75% of patients were diagnosed with ankylosing spondylitis were ascertained from a database of 4400 cases. Index patients with children or siblings who were old enough to have obtained a diagnosis (50% and 75% rates) were assessed for prevalence of disease among relatives. Confirmation of diagnosis for affected relatives was sought for all offspring and a random 25% selection of siblings. Findings Ankylosing spondylitis was more prevalent among children (odds ratio 1.9 [95% CI 1.2-3.0], p < 0.005) and siblings (1.5 [1.2-1.9], p < 0.0001) of female index cases than among those of male cases. Analyses restricted to index cases with a young age at onset (less than or equal to 21 years) indicated that children of women had an even higher incidence of ankylosing spondylitis (7.2 [1.5-34], p = 0.013) than did children of men at similar age at onset. 38% of children of female cases had disease compared with 8% of male cases. There was no difference in sex distribution among affected children or siblings of female patients with ankylosing spondylitis. By contrast, the sons and brothers of male patients had a higher prevalence of the disease (odds ratio 2.6 [1.4-5.2], p = 0.003) than did daughters and sisters (1.7 [1.3-2.2], p < 0.0001). Interpretation The influence of female sex is greater than that of male sex in determining increased susceptibility to ankylosing spondylitis in children. The striking maternal effect is greatest for women with young age at onset, which is not seen in men. The sex ratio of affected children depends on the sex of the affected parent.	Royal Natl Hosp Rheumat Dis, Bath BA1 1RL, Avon, England	Royal National Hospital for Rheumatic Diseases (RNHRD)	Calin, A (corresponding author), Royal Natl Hosp Rheumat Dis, Upper Borough Walls, Bath BA1 1RL, Avon, England.			Brophy, Sinead/0000-0001-7417-2858				ARMSTRONG BD, 1985, BR J RHEUMATOL, V24, P277; Bennett PH, 1968, POPULATION STUDIES R; Brown MA, 1997, ARTHRITIS RHEUM, V40, P1823, DOI 10.1002/art.1780401015; BROWN MA, 1995, BR J RHEUMATOL S1, V34, P76; CALIN A, 1983, ARTHRITIS RHEUM, V26, P1460, DOI 10.1002/art.1780261207; CALIN A, 1985, CLIN RHEUM DIS, V11, P41; CALIN A, 1993, OXFORD TXB RHEUMATOL, V2; CALIN A, 1998, SPONDYLARTHRITIDES; CHO Y, 1997, GASTROENTEROLOGY, V112, pA948; LYNN AH, 1995, AM J HUM GENET, V57, P150; MACKAY K, 1997, ARTHRITIS RHEUM, V40, P561; MILLIGAN RA, 1984, ULTRAMICROSCOPY, V13, P1, DOI 10.1016/0304-3991(84)90051-2; Nair RP, 1997, HUM MOL GENET, V6, P1349, DOI 10.1093/hmg/6.8.1349; Simmons WA, 1997, J IMMUNOL, V159, P2750; THOMSON G, 1995, CRIT REV CL LAB SCI, V32, P183, DOI 10.3109/10408369509084684; Tromp G, 1996, AM J HUM GENET, V59, P1097; VANDERLINDEN SM, 1984, ARTHRITIS RHEUM, V27, P241	17	68	69	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1687	1690		10.1016/S0140-6736(99)03219-5	http://dx.doi.org/10.1016/S0140-6736(99)03219-5			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568571				2022-12-28	WOS:000083652800012
J	Muller-Trutwin, M; Barre-Sinoussi, F				Muller-Trutwin, M; Barre-Sinoussi, F			Towards improvements in molecular tools for diagnosis and management of HIV infections	LANCET			English	Editorial Material							POLYMERASE CHAIN-REACTION; GROUP-O; QUANTIFICATION		Inst Pasteur, Dept Virol, F-75724 Paris 15, France	Le Reseau International des Instituts Pasteur (RIIP); Institut Pasteur Paris	Muller-Trutwin, M (corresponding author), Inst Pasteur, Dept Virol, F-75724 Paris 15, France.		Barre-Sinoussi, Françoise/G-8355-2011	Muller-Trutwin, Michaela/0000-0002-3854-2396				Alaeus A, 1999, AIDS RES HUM RETROV, V15, P889, DOI 10.1089/088922299310593; Alaeus A, 1997, AIDS, V11, P859, DOI 10.1097/00002030-199707000-00004; [Anonymous], 1998, MMWR Recomm Rep, V47, P1; FRANSEN K, 1994, MOL CELL PROBE, V8, P317, DOI 10.1006/mcpr.1994.1043; Gao F, 1999, NATURE, V397, P436, DOI 10.1038/17130; HU D, 1998, AIDS OTHER MANIFESTA, P27; Le Corfec E, 1999, TRANSFUSION, V39, P1141, DOI 10.1046/j.1537-2995.1999.39101141.x; LEPONT F, 1995, TRANSFUSION, V35, P542; LOUSSERTAJAKA I, 1995, LANCET, V346, P912, DOI 10.1016/S0140-6736(95)92762-X; Parekh B, 1999, AIDS RES HUM RETROV, V15, P133, DOI 10.1089/088922299311556; Respess RA, 1997, J CLIN MICROBIOL, V35, P1284, DOI 10.1128/JCM.35.5.1284-1286.1997; Simon F, 1998, NAT MED, V4, P1032, DOI 10.1038/2017; Triques K, 1999, J CLIN MICROBIOL, V37, P110, DOI 10.1128/JCM.37.1.110-116.1999; Wilber JC, 1997, IMMUNOL INVEST, V26, P9, DOI 10.3109/08820139709048911; Yang CF, 1999, J CLIN MICROBIOL, V37, P2581, DOI 10.1128/JCM.37.8.2581-2586.1999	15	5	7	0	2	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0140-6736	1474-547X		LANCET	Lancet	NOV 13	1999	354	9191					1660	1662		10.1016/S0140-6736(99)00211-1	http://dx.doi.org/10.1016/S0140-6736(99)00211-1			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568563				2022-12-28	WOS:000083652800004
J	Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P				Shirasu, K; Lahaye, T; Tan, MW; Zhou, FS; Azevedo, C; Schulze-Lefert, P			A novel class of eukaryotic zinc-binding proteins is required for disease resistance signaling in barley and development in C-elegans	CELL			English	Article							POWDERY MILDEW INTERACTION; PROGRAMMED CELL-DEATH; OXIDATIVE BURST; GENE ML-A12; PLANTS; ARABIDOPSIS; PATHOGEN; FINGER; LOCUS; RESPONSES	Barley Rar1 is a convergence point in the signaling of resistance to powdery mildew, triggered by multiple race-specific resistance (R) genes. Rar1 is shown to function upstream of H2O2 accumulation in attacked host cells, which precedes localized host cell death. We isolated Rar1 by map-based cloning. The sequence of the deduced 25.5 kDa protein reveals two copies of a 60-amino acid domain, CHORD, conserved in tandem organization in protozoa, plants, and metazoa. CHORD defines a novel eukaryotic Zn2+-binding domain. Silencing of the C. elegans CHORD-containing gene, chp, results in semisterility and embryo lethality, suggesting an essential function of the wild-type gene in nematode development. Our findings indicate that plant R genes have recruited a fundamental cellular control element for signaling of disease resistance and cell death.	John Innes Ctr Plant Sci Res, Sainsbury Lab, Norwich NR4 7UH, Norfolk, England; Massachusetts Gen Hosp, Dept Mol Biol, Boston, MA 02114 USA; Harvard Univ, Sch Med, Dept Genet, Boston, MA 02115 USA	UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); John Innes Center; Harvard University; Massachusetts General Hospital; Harvard University; Harvard Medical School	Schulze-Lefert, P (corresponding author), John Innes Ctr Plant Sci Res, Sainsbury Lab, Colney Lane, Norwich NR4 7UH, Norfolk, England.	schlet@bbsrc.ac.uk	Azevedo, Cristina/Y-4296-2019; Shirasu, Ken/ABF-5306-2020; Shirasu, Ken/A-4455-2010; Schulze-Lefert, Paul/A-7746-2008; Schulze-Lefert, Paul/B-6707-2011	Azevedo, Cristina/0000-0002-6997-1265; Shirasu, Ken/0000-0002-0349-3870; Shirasu, Ken/0000-0002-0349-3870; 				Aarts N, 1998, P NATL ACAD SCI USA, V95, P10306, DOI 10.1073/pnas.95.17.10306; Baker B, 1997, SCIENCE, V276, P726, DOI 10.1126/science.276.5313.726; BENDAHMANE A, 1999, IN PRESS BIOTECHNIQU; Borden KLB, 1996, CURR OPIN STRUC BIOL, V6, P395, DOI 10.1016/S0959-440X(96)80060-1; CENTURY KS, 1995, P NATL ACAD SCI USA, V92, P6597, DOI 10.1073/pnas.92.14.6597; DIETRICH RA, 1994, CELL, V77, P565, DOI 10.1016/0092-8674(94)90218-6; EDWARDS A, 1999, IN PRESS EUR J BIOCH; FALK A, 1999, P NATL ACAD SCI USA, V95, P10306; Fire A, 1998, NATURE, V391, P806, DOI 10.1038/35888; FREIALDENHOVEN A, 1994, PLANT CELL, V6, P983; GIEDROC DP, 1986, P NATL ACAD SCI USA, V83, P8452, DOI 10.1073/pnas.83.22.8452; Gill GN, 1995, STRUCTURE, V3, P1285, DOI 10.1016/S0969-2126(01)00265-9; GOODALL GJ, 1991, EMBO J, V10, P2635, DOI 10.1002/j.1460-2075.1991.tb07806.x; GREENBERG JT, 1994, CELL, V77, P551, DOI 10.1016/0092-8674(94)90217-8; Groom QJ, 1996, PLANT J, V10, P515, DOI 10.1046/j.1365-313X.1996.10030515.x; Gumienny TL, 1999, DEVELOPMENT, V126, P1011; HORTON RM, 1989, GENE, V77, P61, DOI 10.1016/0378-1119(89)90359-4; Huckelhoven R, 1999, PLANT PHYSIOL, V119, P1251, DOI 10.1104/pp.119.4.1251; Jones DA, 1997, ADV BOT RES, V24, P89; JORGENSEN JH, 1988, GENOME, V30, P129, DOI 10.1139/g88-022; Jorgensen JH, 1996, GENOME, V39, P492, DOI 10.1139/g96-063; KIM JS, 1994, ANAL BIOCHEM, V219, P165, DOI 10.1006/abio.1994.1251; Kitagawa K, 1999, MOL CELL, V4, P21, DOI 10.1016/S1097-2765(00)80184-7; Lahaye T, 1998, MOL GEN GENET, V260, P92, DOI 10.1007/s004380050874; Lamb C, 1997, ANNU REV PLANT PHYS, V48, P251, DOI 10.1146/annurev.arplant.48.1.251; LEVINE A, 1994, CELL, V79, P583, DOI 10.1016/0092-8674(94)90544-4; Marcotte EM, 1999, SCIENCE, V285, P751, DOI 10.1126/science.285.5428.751; MARTIN W, 1989, NATURE, V339, P46, DOI 10.1038/339046a0; Parniske M, 1997, CELL, V91, P821, DOI 10.1016/S0092-8674(00)80470-5; Pennell RI, 1997, PLANT CELL, V9, P1157, DOI 10.1105/tpc.9.7.1157; Peterhansel C, 1997, PLANT CELL, V9, P1397, DOI 10.1105/tpc.9.8.1397; SANCHEZGARCIA I, 1994, TRENDS GENET, V10, P315, DOI 10.1016/0168-9525(94)90034-5; Schiffer R, 1997, MOL PLANT MICROBE IN, V10, P830, DOI 10.1094/MPMI.1997.10.7.830; SCHWABE JWR, 1994, NAT STRUCT BIOL, V1, P345, DOI 10.1038/nsb0694-345; Shirasu K, 1997, PLANT CELL, V9, P261, DOI 10.1105/tpc.9.2.261; ThordalChristensen H, 1997, PLANT J, V11, P1187, DOI 10.1046/j.1365-313X.1997.11061187.x; TORP J, 1986, CAN J GENET CYTOL, V28, P725, DOI 10.1139/g86-102; van der Biezen EA, 1998, CURR BIOL, V8, pR226, DOI 10.1016/S0960-9822(98)70145-9; Vaux DL, 1999, CELL, V96, P245, DOI 10.1016/S0092-8674(00)80564-4; von Ropenack E, 1998, J BIOL CHEM, V273, P9013, DOI 10.1074/jbc.273.15.9013; WEBSTER LC, 1991, P NATL ACAD SCI USA, V88, P9989, DOI 10.1073/pnas.88.22.9989; WEI F, 1999, IN PRESS GENETICS	42	280	311	2	20	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					355	366		10.1016/S0092-8674(00)81522-6	http://dx.doi.org/10.1016/S0092-8674(00)81522-6			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571178	Bronze			2022-12-28	WOS:000083709300003
J	Troemel, ER; Sagasti, A; Bargmann, CI				Troemel, ER; Sagasti, A; Bargmann, CI			Lateral signaling mediated by axon contact and calcium entry regulates asymmetric odorant receptor expression in C-elegans	CELL			English	Article							NUCLEOTIDE-GATED CHANNEL; CAENORHABDITIS-ELEGANS; SENSORY NEURONS; CHEMOSENSORY RECEPTORS; SYNAPTIC PLASTICITY; GENE; PROTEIN; ENCODES; GUIDANCE; SYSTEM	C. elegans detects several odorants with the bilaterally symmetric pair of AWC olfactory neurons. A stochastic, coordinated decision ensures that the candidate odorant receptor gene str-2 is expressed in only one AWC neuron in each animal-either the left or the right neuron, but never both. An interaction between the two AWC neurons generates asymmetric str-2 expression in a process that requires normal axon guidance and probably AWC axon contact. This interaction induces str-a expression by reducing calcium signaling through a voltage-dependent Ca2+ channel and the CaM kinase II UNC-43. CaMKII activity acts as a switch in the initial decision to express str-2; thus, calcium signals can define distinct cell types during neuronal development. A cGMP signaling pathway that is used in olfaction maintains str-2 expression after the initial decision has been made.	Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Dev Biol, San Francisco, CA 94143 USA; Univ Calif San Francisco, Program Neurosci, San Francisco, CA 94143 USA; Univ Calif San Francisco, Genet Program, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Anat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Biochem & Biophys, San Francisco, CA 94143 USA	Howard Hughes Medical Institute; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco	Bargmann, CI (corresponding author), Univ Calif San Francisco, Howard Hughes Med Inst, San Francisco, CA 94143 USA.	cori@itsa.ucsf.edu		Bargmann, Cornelia/0000-0002-8484-0618				Anderson P, 1995, METHOD CELL BIOL, V48, P31; BAIER H, 1994, P NATL ACAD SCI USA, V91, P11646, DOI 10.1073/pnas.91.24.11646; BARGMANN CI, 1991, NEURON, V7, P729, DOI 10.1016/0896-6273(91)90276-6; Bargmann CI, 1998, SCIENCE, V282, P2028, DOI 10.1126/science.282.5396.2028; BARGMANN CI, 1993, CELL, V74, P515, DOI 10.1016/0092-8674(93)80053-H; BLAIR SS, 1990, J NEUROSCI, V10, P3183; BRAUN AP, 1995, ANNU REV PHYSIOL, V57, P417, DOI 10.1146/annurev.ph.57.030195.002221; BUCK L, 1991, CELL, V65, P175, DOI 10.1016/0092-8674(91)90418-X; CHESS A, 1994, CELL, V78, P823, DOI 10.1016/S0092-8674(94)90562-2; Chou WH, 1999, DEVELOPMENT, V126, P607; Clyne PJ, 1999, NEURON, V22, P327, DOI 10.1016/S0896-6273(00)81093-4; Coburn CM, 1996, NEURON, V17, P695, DOI 10.1016/S0896-6273(00)80201-9; DeVries SH, 1997, J NEUROPHYSIOL, V78, P2048, DOI 10.1152/jn.1997.78.4.2048; Dwyer ND, 1998, CELL, V93, P455, DOI 10.1016/S0092-8674(00)81173-3; GOVIND CK, 1992, J NEUROBIOL, V23, P1423, DOI 10.1002/neu.480231006; Greenwald I, 1998, GENE DEV, V12, P1751, DOI 10.1101/gad.12.12.1751; GRUNERT U, 1994, J COMP NEUROL, V348, P607, DOI 10.1002/cne.903480410; HALL DH, 1991, CELL, V65, P837, DOI 10.1016/0092-8674(91)90391-B; HEDGECOCK EM, 1985, DEV BIOL, V111, P158, DOI 10.1016/0012-1606(85)90443-9; HUANG LS, 1994, MOL BIOL CELL, V5, P395, DOI 10.1091/mbc.5.4.395; Jansen G, 1999, NAT GENET, V21, P414, DOI 10.1038/7753; Komatsu H, 1996, NEURON, V17, P707, DOI 10.1016/S0896-6273(00)80202-0; Lee RYN, 1997, EMBO J, V16, P6066, DOI 10.1093/emboj/16.20.6066; MacNeil MA, 1998, NEURON, V20, P971, DOI 10.1016/S0896-6273(00)80478-X; Malnic B, 1999, CELL, V96, P713, DOI 10.1016/S0092-8674(00)80581-4; MARUYAMA IN, 1991, P NATL ACAD SCI USA, V88, P5729, DOI 10.1073/pnas.88.13.5729; MAYFORD M, 1992, SCIENCE, V256, P638, DOI 10.1126/science.1585176; MELLO CC, 1991, EMBO J, V10, P3959, DOI 10.1002/j.1460-2075.1991.tb04966.x; Mombaerts P, 1996, CELL, V87, P675, DOI 10.1016/S0092-8674(00)81387-2; NONET ML, 1993, CELL, V73, P1291, DOI 10.1016/0092-8674(93)90357-V; OTSUKA AJ, 1995, J CELL BIOL, V129, P1081, DOI 10.1083/jcb.129.4.1081; Papatsenko D, 1997, DEVELOPMENT, V124, P1665; REINER DJ, 1999, IN PRESS NATURE; Roayaie K, 1998, NEURON, V20, P55, DOI 10.1016/S0896-6273(00)80434-1; Robey E, 1997, CURR OPIN GENET DEV, V7, P551, DOI 10.1016/S0959-437X(97)80085-8; Sagasti A, 1999, GENE DEV, V13, P1794, DOI 10.1101/gad.13.14.1794; SCHAFER WR, 1995, NATURE, V375, P73, DOI 10.1038/375073a0; Schuster CM, 1996, NEURON, V17, P655, DOI 10.1016/S0896-6273(00)80198-1; SENGUPTA P, 1994, CELL, V79, P971, DOI 10.1016/0092-8674(94)90028-0; Sengupta P, 1996, CELL, V84, P899, DOI 10.1016/S0092-8674(00)81068-5; STARICH TA, 1993, GENETICS, V133, P527; Troemel ER, 1997, CELL, V91, P161, DOI 10.1016/S0092-8674(00)80399-2; TROEMEL ER, 1995, CELL, V83, P207, DOI 10.1016/0092-8674(95)90162-0; Vosshall LB, 1999, CELL, V96, P725, DOI 10.1016/S0092-8674(00)80582-6; WASSLE H, 1991, PHYSIOL REV, V71, P447, DOI 10.1152/physrev.1991.71.2.447; WEINSHENKER DZ, 1999, IN PRESS J NEUROSCI; WHITE JG, 1986, PHILOS T R SOC B, V314, P1, DOI 10.1098/rstb.1986.0056; WILLIAMS BD, 1992, GENETICS, V131, P609; YOCHEM J, 1989, CELL, V58, P553, DOI 10.1016/0092-8674(89)90436-4; YOCHEM J, 1988, NATURE, V335, P547, DOI 10.1038/335547a0; Yu S, 1997, P NATL ACAD SCI USA, V94, P3384, DOI 10.1073/pnas.94.7.3384; Zallen JA, 1999, DEVELOPMENT, V126, P3679; Zallen JA, 1998, CELL, V92, P217, DOI 10.1016/S0092-8674(00)80916-2; ZORAN MJ, 1993, DEV BIOL, V158, P163, DOI 10.1006/dbio.1993.1176	54	207	241	1	8	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 12	1999	99	4					387	398		10.1016/S0092-8674(00)81525-1	http://dx.doi.org/10.1016/S0092-8674(00)81525-1			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	256CX	10571181	Bronze			2022-12-28	WOS:000083709300006
J	Wilkinson, RG				Wilkinson, RG			Two pathways,but how much do they diverge?	BRITISH MEDICAL JOURNAL			English	Article									Univ Sussex, Trafford Ctr Med Res, Brighton BN1 9RY, E Sussex, England	University of Brighton; University of Sussex	Wilkinson, RG (corresponding author), Univ Sussex, Trafford Ctr Med Res, Brighton BN1 9RY, E Sussex, England.							BRUNNER E, IN PRESS SOCIAL DETE; Lynch JW, 1998, AM J PUBLIC HEALTH, V88, P1074, DOI 10.2105/AJPH.88.7.1074; Wallace R, 1998, PLAGUE YOUR HOUSES; WILKINSON RG, SOC POPULATION HLTH, V1	4	13	14	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 9	1999	319	7215					956	957						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	245MA	10576846				2022-12-28	WOS:000083111700024
J	Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A				Tsodyks, M; Kenet, T; Grinvald, A; Arieli, A			Linking spontaneous activity of single cortical neurons and the underlying functional architecture	SCIENCE			English	Article							CAT VISUAL-CORTEX; ISO-ORIENTATION DOMAINS; ELECTRICAL-ACTIVITY; ONGOING ACTIVITY; CEREBRAL-CORTEX; ORGANIZATION; PATTERNS; CONNECTIONS; DYNAMICS; STATES	The relation between the activity of a single neocortical neuron and the dynamics of the network in which it is embedded was explored by single-unit recordings and real-time optical imaging. The firing rate of a spontaneously active single neuron strongly depends on the instantaneous spatial pattern of ongoing population activity in a Large cortical area. Very similar spatial patterns of population activity were observed both when the neuron fired spontaneously and when it was driven by its optimal stimulus. The evoked patterns could be used to reconstruct the spontaneous activity of single neurons.	Weizmann Inst Sci, Dept Neurobiol, IL-76100 Rehovot, Israel; Weizmann Inst Sci, Ctr Studies Higher Brain Funct, IL-76100 Rehovot, Israel	Weizmann Institute of Science; Weizmann Institute of Science	Grinvald, A (corresponding author), Weizmann Inst Sci, Dept Neurobiol, POB 26, IL-76100 Rehovot, Israel.		tsodyks, misha/J-4430-2013	Tsodyks, Misha/0000-0002-5661-4349				Abbott LF, 1997, SCIENCE, V275, P220, DOI 10.1126/science.275.5297.221; ABELES M, 1995, P NATL ACAD SCI USA, V92, P8616, DOI 10.1073/pnas.92.19.8616; Abeles M., 1982, LOCAL CORTICAL CIRCU; Ahmed B, 1998, CEREB CORTEX, V8, P462, DOI 10.1093/cercor/8.5.462; Amit D. J., 1989, MODELING BRAIN FUNCT, DOI 10.1017/CBO9780511623257; Amit DJ, 1997, CEREB CORTEX, V7, P237, DOI 10.1093/cercor/7.3.237; ARIELI A, 1995, J NEUROPHYSIOL, V73, P2072, DOI 10.1152/jn.1995.73.5.2072; Arieli A, 1996, SCIENCE, V273, P1868, DOI 10.1126/science.273.5283.1868; ARIELI A, 1992, INFORMATION PROCESSI, P123; BenYishai R, 1997, J COMPUT NEUROSCI, V4, P57, DOI 10.1023/A:1008816611284; BONHOEFFER T, 1993, J NEUROSCI, V13, P4157; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Churchland P. S., 1992, COMPUTATIONAL BRAIN, DOI 10.7551/mitpress/2010.001.0001; CONNORS BW, 1990, TRENDS NEUROSCI, V13, P99, DOI 10.1016/0166-2236(90)90185-D; Destexhe A, 1999, J NEUROSCI, V19, P4595, DOI 10.1523/jneurosci.19-11-04595.1999; Felleman DJ, 1991, CEREB CORTEX, V1, P1, DOI 10.1093/cercor/1.1.1; FREEMAN WJ, 1985, BRAIN RES REV, V10, P147, DOI 10.1016/0165-0173(85)90022-0; GILBERT CD, 1993, CEREB CORTEX, V3, P373, DOI 10.1093/cercor/3.5.373; GRINVALD A, 1994, J NEUROSCI, V14, P2545; GRINVALD A, 1982, J PHYSIOL-LONDON, V333, P269, DOI 10.1113/jphysiol.1982.sp014453; GRINVALD A, 1984, NATURE, V308, P848, DOI 10.1038/308848a0; Grinvald A, 1999, MODERN TECHNIQUES NE, P893, DOI 10.1007/978-3-642-58552-4_34; Hansel D., 1998, METHODS NEURONAL MOD, P499; Hertz JA, 2018, INTRO THEORY NEURAL; HUBEL DH, 1977, NATURE, V269, P328, DOI 10.1038/269328a0; HUBEL DH, 1962, J PHYSIOL-LONDON, V160, P106, DOI 10.1113/jphysiol.1962.sp006837; IIJIMA T, 1992, NEUROSCIENCE, V51, P211, DOI 10.1016/0306-4522(92)90486-L; Lampl I, 1999, NEURON, V22, P361, DOI 10.1016/S0896-6273(00)81096-X; LEGENDY CR, 1985, J NEUROPHYSIOL, V53, P926, DOI 10.1152/jn.1985.53.4.926; MALACH R, 1994, CEREB CORTEX, V4, P151, DOI 10.1093/cercor/4.2.151; NODA H, 1970, BRAIN RES, V18, P672; ORBACH HS, 1983, J NEUROSCI, V3, P2251; PAISLEY AC, 1984, PROG NEUROBIOL, V22, P155, DOI 10.1016/0301-0082(84)90024-8; SALIN PA, 1995, PHYSIOL REV, V75, P107, DOI 10.1152/physrev.1995.75.1.107; SANSEVERINO E R, 1973, Brain Research, V54, P225; Shadlen Michael N., 1994, Current Opinion in Neurobiology, V4, P569, DOI 10.1016/0959-4388(94)90059-0; SHOHAM D, IN PRESS NEURON; SILLITO AM, 1980, BRAIN RES, V194, P517, DOI 10.1016/0006-8993(80)91234-2; SINGER W, 1994, INT REV NEUROBIOL, V37, P153; SOFTKY WR, 1993, J NEUROSCI, V13, P334; THOMSON AM, 1994, TRENDS NEUROSCI, V17, P119, DOI 10.1016/0166-2236(94)90121-X; Tsodyks M., 1995, NETWORK, V6, P1; Tsodyks MV, 1997, P NATL ACAD SCI USA, V94, P719, DOI 10.1073/pnas.94.2.719; ULLMAN S, 1995, CEREB CORTEX, V5, P1, DOI 10.1093/cercor/5.1.1; vanVreeswijk C, 1996, SCIENCE, V274, P1724, DOI 10.1126/science.274.5293.1724; WEBB AC, 1976, PROC R SOC SER B-BIO, V194, P239, DOI 10.1098/rspb.1976.0076	46	506	510	2	29	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1943	1946		10.1126/science.286.5446.1943	http://dx.doi.org/10.1126/science.286.5446.1943			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583955				2022-12-28	WOS:000084003400048
J	Butler, D				Butler, D			Computing 2010: from black holes to biology	NATURE			English	Article								By 2010, a click on the PC on your desktop will suffice to call up instantly all the computing power you need from what by then will be the world's largest supercomputer, the Internet itself. Supercomputing for the masses will trigger a revolution in the complexity of problems that are tackled, whole disciplines will go digital and, rather than spending time collecting their own data, scientists will organize themselves around shared data sets.	Nature, F-75749 Paris 15, France		Butler, D (corresponding author), Nature, 3 Rue Arrivee,BP 264, F-75749 Paris 15, France.								0	12	12	0	2	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C67	C70		10.1038/35011561	http://dx.doi.org/10.1038/35011561			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591228	Bronze			2022-12-28	WOS:000084014100010
J	Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP				Dunham, I; Shimizu, N; Roe, BA; Chissoe, S; Dunham, I; Hunt, AR; Collins, JE; Bruskiewich, R; Beare, DM; Clamp, M; Smink, LJ; Ainscough, R; Almeida, JP; Babbage, A; Bagguley, C; Balley, J; Barlow, K; Bates, KN; Beasley, O; Bird, CP; Blakey, S; Bridgeman, AM; Buck, D; Burgess, J; Burrill, WD; Burton, J; Carder, C; Carter, NP; Chen, Y; Clark, G; Clegg, SM; Cobley, V; Cole, CG; Collier, RE; Connor, RE; Conroy, D; Corby, N; Coville, GJ; Cox, AV; Davis, J; Dawson, E; Dhami, PD; Dockree, C; Dodsworth, SJ; Durbin, RM; Ellington, A; Evans, KL; Fey, JM; Fleming, K; French, L; Garner, AA; Gilbert, JGR; Goward, ME; Grafham, D; Griffiths, MN; Hall, C; Hall, R; Hall-Tamlyn, G; Heathcott, RW; Ho, S; Holmes, S; Hunt, SE; Jones, MC; Kershaw, J; Kimberley, A; King, A; Laird, GK; Langford, CF; Leversha, MA; Lloyd, C; Lloyd, DM; Martyn, ID; Mashreghi-Mohammadi, M; Matthews, L; McCann, OT; McClay, J; McLaren, S; McMurray, AA; Milne, SA; Mortimore, BJ; Odell, CN; Pavitt, R; Pearce, AV; Pearson, D; Phillimore, BJ; Phillips, SH; Plumb, RW; Ramsay, H; Ramsey, Y; Rogers, L; Ross, MT; Scott, CE; Sehra, HK; Skuce, CD; Smalley, S; Smith, ML; Soderlund, C; Spragon, L; Steward, CA; Sulston, JE; Swann, RM; Vaudin, M; Wall, M; Wallis, JM; Whiteley, MN; Willey, D; Williams, L; Williams, S; Williamson, H; Wilmer, TE; Wilming, L; Wright, CL; Hubbard, T; Bentley, DR; Beck, S; Rogers, J; Shimizu, N; Minoshima, S; Kawasaki, K; Sasaki, T; Asakawa, S; Kudoh, J; Shintani, A; Shibuya, K; Yoshizaki, Y; Aoki, N; Mitsuyama, S; Roe, BA; Chen, F; Chu, L; Crabtree, J; Deschamps, S; Do, A; Do, T; Dorman, A; Fang, F; Fu, Y; Hu, P; Hua, A; Kenton, S; Lai, H; Lao, HI; Lewis, J; Lewis, S; Lin, SP; Loh, P; Malaj, E; Nguyen, T; Pan, H; Phan, S; Qi, S; Qian, Y; Ray, L; Ren, Q; Shaull, S; Sloan, D; Song, L; Wang, Q; Wang, Y; Wang, Z; White, J; Willingham, D; Wu, H; Yao, Z; Zhan, M; Zhang, G; Chissoe, S; Murray, J; Miller, N; Minx, P; Fulton, R; Johnson, D; Bemis, G; Bentley, D; Bradshaw, H; Bourne, S; Cordes, M; Du, Z; Fulton, L; Goela, D; Graves, T; Hawkins, J; Hinds, K; Kemp, K; Latreille, P; Layman, D; Ozersky, P; Rohlfing, T; Scheet, P; Walker, C; Wamsley, A; Wohldmann, P; Pepin, K; Nelson, J; Korf, I; Bedell, JA; Hillier, L; Mardis, E; Waterston, R; Wilson, R; Emanuel, BS; Shaikh, T; Kurahashi, H; Saitta, S; Budarf, ML; McDermid, HE; Johnson, A; Wong, ACC; Morrow, BE; Edelman, L; Kim, UJ; Shizuya, H; Simon, MI; Dumanski, JP; Peyrard, M; Kedra, D; Seroussi, E; Fransson, I; Tapia, I; Bruder, CE; O'Brien, KP			The DNA sequence of human chromosome 22	NATURE			English	Article							WHOLE-GENOME SHOTGUN; CPG ISLANDS; YAC CONTIG; MAP; ORGANIZATION; GENES; CONSTRUCTION; REGION; MOUSE; 22Q11	Knowledge of the complete genomic DNA sequence of an organism allows a systematic approach to defining its genetic components. The genomic sequence provides access to the complete structures of all genes, including those without known function, their control elements, and, by inference, the proteins they encode, as well as all other biologically important sequences. Furthermore, the sequence is a rich and permanent source of information for the design of further biological studies of the organism and for the study of evolution through cross-species sequence comparison. The power of this approach has been amply demonstrated by the determination of the sequences of a number of microbial and model organisms, The next step is to obtain the complete sequence of the entire human genome. Here we report the sequence of the euchromatic part of human chromosome 22. The sequence obtained consists of 12 contiguous segments spanning 33.4 megabases, contains at least 545 genes and 134 pseudogenes, and provides the first view of the complex chromosomal landscapes that will be found in the rest of the genome.	Sanger Ctr, Cambridge CB10 1SA, England; Keio Univ, Sch Med, Dept Mol Biol, Shinjuku Ku, Tokyo 1608582, Japan; Univ Oklahoma, Dept Chem & Biochem, Norman, OK 73019 USA; Washington Univ, Sch Med, Genome Sequencing Ctr, St Louis, MO 63108 USA; Childrens Hosp Philadelphia, Div Human Genet & Mol Biol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Pediat, Philadelphia, PA 19104 USA; Univ Alberta, Dept Biol Sci, Edmonton, AB T6G 2E9, Canada; Yeshiva Univ Albert Einstein Coll Med, Dept Mol Genet, Bronx, NY 10461 USA; Karolinska Hosp, Dept Mol Med, Clin Genet Unit, S-17176 Stockholm, Sweden; CALTECH, Div Biol, Pasadena, CA 91125 USA	Wellcome Trust Sanger Institute; Keio University; University of Oklahoma System; University of Oklahoma - Norman; Washington University (WUSTL); University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Alberta; Yeshiva University; Albert Einstein College of Medicine; Karolinska Institutet; Karolinska University Hospital; California Institute of Technology	Dunham, I (corresponding author), Sanger Ctr, Wellcome Trust Genome Campus, Cambridge CB10 1SA, England.	idl@sanger.ac.uk	Hubbard, Tim J.P./AAT-4571-2020; Deschamps, Stephane/R-3806-2019; Tapia-Páez, Isabel/ABD-7197-2021; Tapia-Páez, Isabel/N-1210-2013; Sasaki, Takashi/AAD-1461-2019; Kedra, Darek/H-7641-2012; McClay, Joseph/C-9931-2009; Spraggon, Lee/E-5900-2012; Evans, Kathryn KL/I-5910-2012; Mardis, Elaine/W-2202-2019; Wilson, Richard K./AAF-4139-2019; Hubbard, Tim J/C-2567-2008; Durbin, Richard/AAE-7178-2019; McDermid, Heather/A-2666-2014	Hubbard, Tim J.P./0000-0002-1767-9318; Kedra, Darek/0000-0002-9723-4465; McClay, Joseph/0000-0002-3628-2447; Wilson, Richard K./0000-0002-1992-1358; Hubbard, Tim J/0000-0002-1767-9318; Durbin, Richard/0000-0002-9130-1006; Dunham, Ian/0000-0003-2525-5598; McDermid, Heather/0000-0001-7535-0927; Koculi, Eda/0000-0001-9477-555X; Fosker, Christine/0000-0002-3799-9474; Hunt, Adrienne/0000-0002-1227-0310; Evans, Kathryn/0000-0002-7884-5877; Davidson, Claire/0000-0002-4910-8202; Sasaki, Takashi/0000-0002-6275-046X; Steward, Charles/0000-0001-8829-5349; Morrow, Bernice/0000-0002-8076-4726; Pan, Huaqin/0000-0002-7166-108X; Hunt, Sarah/0000-0002-8350-1235; Lewis, Suzanna/0000-0002-8343-612X; Bridgeman, Anne/0000-0002-9478-6125; Tapia-Paez, Isabel/0000-0002-0535-4233				ALTSCHUL SF, 1990, J MOL BIOL, V215, P403, DOI 10.1006/jmbi.1990.9999; Asakawa S, 1997, GENE, V191, P69, DOI 10.1016/S0378-1119(97)00044-9; Bairoch A, 1999, NUCLEIC ACIDS RES, V27, P49, DOI 10.1093/nar/27.1.49; Bateman A, 1999, NUCLEIC ACIDS RES, V27, P260, DOI 10.1093/nar/27.1.260; Beck S, 1999, NATURE, V401, P921, DOI 10.1038/44853; Bentley DR, 1996, SCIENCE, V274, P533, DOI 10.1126/science.274.5287.533; BERNARDI G, 1985, SCIENCE, V228, P953, DOI 10.1126/science.4001930; BERNARDI G, 1989, ANNU REV GENET, V23, P637, DOI 10.1146/annurev.genet.23.1.637; Blattner FR, 1997, SCIENCE, V277, P1453, DOI 10.1126/science.277.5331.1453; BUCAN M, 1993, HUM MOL GENET, V2, P1245, DOI 10.1093/hmg/2.8.1245; Burge C, 1997, J MOL BIOL, V268, P78, DOI 10.1006/jmbi.1997.0951; C elegans Sequencing Consortium, 1998, SCIENCE, V282, P2012, DOI 10.1126/science.282.5396.2012; Carver EA, 1997, GENOME RES, V7, P1123, DOI 10.1101/gr.7.12.1123; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; Collins JE, 1997, GENOME RES, V7, P522, DOI 10.1101/gr.7.5.522; COLLINS JE, 1995, NATURE, V377, P367; CRAIG JM, 1994, NAT GENET, V7, P376, DOI 10.1038/ng0794-376; CROSS SH, 1995, CURR OPIN GENET DEV, V5, P309, DOI 10.1016/0959-437X(95)80044-1; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dunham I, 1999, GENOME ANAL, V3, P1; Edelmann L, 1999, HUM MOL GENET, V8, P1157, DOI 10.1093/hmg/8.7.1157; Edelmann L, 1999, AM J HUM GENET, V64, P1076, DOI 10.1086/302343; EPPIG JT, 1995, CURR OPIN GENET DEV, V5, P709, DOI 10.1016/0959-437X(95)80002-M; Felsenfeld A, 1999, GENOME RES, V9, P1; Gill M, 1996, AM J MED GENET, V67, P40, DOI 10.1002/(SICI)1096-8628(19960216)67:1<40::AID-AJMG6>3.0.CO;2-W; Green P, 1997, GENOME RES, V7, P410, DOI 10.1101/gr.7.5.410; Guyer M, 1998, GENOME RES, V8, P413; Hofmann K, 1999, NUCLEIC ACIDS RES, V27, P215, DOI 10.1093/nar/27.1.215; HOLMQUIST GP, 1992, AM J HUM GENET, V51, P17; Johnson A, 1999, GENOMICS, V57, P306, DOI 10.1006/geno.1999.5757; Kao HT, 1998, P NATL ACAD SCI USA, V95, P4667, DOI 10.1073/pnas.95.8.4667; Kawasaki K, 1997, GENOME RES, V7, P250, DOI 10.1101/gr.7.3.250; McDermid HE, 1996, GENOME RES, V6, P1149, DOI 10.1101/gr.6.12.1149; Mewes HW, 1997, NATURE, V387, P7, DOI 10.1038/387s007; Mittman S, 1999, NEUROSCI LETT, V269, P121, DOI 10.1016/S0304-3940(99)00319-5; MORTON NE, 1991, P NATL ACAD SCI USA, V88, P7474, DOI 10.1073/pnas.88.17.7474; Ning Y, 1996, HUM GENET, V97, P765; Nishino I, 1999, SCIENCE, V283, P689, DOI 10.1126/science.283.5402.689; Peyrard M, 1999, P NATL ACAD SCI USA, V96, P598, DOI 10.1073/pnas.96.2.598; Puech A, 1997, P NATL ACAD SCI USA, V94, P14608, DOI 10.1073/pnas.94.26.14608; PULVER AE, 1994, J NERV MENT DIS, V182, P476, DOI 10.1097/00005053-199408000-00010; Saccone S, 1996, GENE, V174, P85, DOI 10.1016/0378-1119(96)00392-7; *SANG CTR WASH U G, 1998, GENOME RES, V8, P1097; Seroussi E, 1999, GENOMICS, V57, P380, DOI 10.1006/geno.1998.5739; Seroussi E, 1999, GENOME RES, V9, P803, DOI 10.1101/gr.9.9.803; SOLOVYEV V, 1997, ISMB, V5, P294; Southard-Smith EM, 1999, MAMM GENOME, V10, P744, DOI 10.1007/s003359901083; Weber JL, 1997, GENOME RES, V7, P401, DOI 10.1101/gr.7.5.401; Zu L, 1999, AM J HUM GENET, V64, P594, DOI 10.1086/302247	50	854	1310	2	54	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	DEC 2	1999	402	6761					489	495		10.1038/990031	http://dx.doi.org/10.1038/990031			9	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591208	hybrid			2022-12-28	WOS:000084013200045
J	Francis, LP				Francis, LP			Legal eights to health care at the end of life	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Univ Utah, Salt Lake City, UT 84112 USA	Utah System of Higher Education; University of Utah	Francis, LP (corresponding author), Univ Utah, Salt Lake City, UT 84112 USA.							*US DEP HHS, 1988, HLTH US 1998	1	5	5	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2079	2079		10.1001/jama.282.21.2079	http://dx.doi.org/10.1001/jama.282.21.2079			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591395				2022-12-28	WOS:000083908700032
J	Furlan, A; Higashida, R; Wechsler, L; Gent, M; Rowley, H; Kase, C; Pessin, M; Ahuja, A; Callahan, F; Clark, WM; Silver, F; Rivera, F				Furlan, A; Higashida, R; Wechsler, L; Gent, M; Rowley, H; Kase, C; Pessin, M; Ahuja, A; Callahan, F; Clark, WM; Silver, F; Rivera, F		PROACT Investigators	Intra-arterial prourokinase for acute ischemic stroke - The PROACT II study: A randomized controlled trial	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	24th American-Heart-Association International Conference on Stroke and Cerebral Circulation	FEB 04-06, 1999	NASHVILLE, TN	Amer Heart Assoc			TISSUE-PLASMINOGEN-ACTIVATOR; MIDDLE CEREBRAL-ARTERY; THROMBOLYTIC THERAPY; INTRAARTERIAL FIBRINOLYSIS; CAROTID TERRITORY; INFARCTION; UROKINASE; OCCLUSION; TIME; HANDICAP	Context Intravenous tissue-type plasminogen activator can be beneficial to some patients when given within 3 hours of stroke onset, but many patients present later after stroke onset and alternative treatments are needed. Objective To determine the clinical efficacy and safety of intra-arterial (IA) recombinant prourokinase (r-proUK) in patients with acute stroke of less than 6 hours' duration caused by middle cerebral artery (MCA) occlusion. Design PROACT II (Prolyse in Acute Cerebral Thromboembolism II), a randomized, controlled, multicenter, open-label clinical trial with blinded follow-up conducted between February 1996 and August 1998. Setting Fifty-four centers in the United States and Canada. Patients A total of 180 patients with acute ischemic stroke of less than 6 hours' duration caused by angiographically proven occlusion of the MCA and without hemorrhage or major early infarction signs on computed tomographic scan. Intervention Patients were randomized to receive 9 mg of IA r-proUK plus heparin (n = 121)or heparin only (n = 59), Main Outcome Measures The primary outcome, analyzed by intention-to-treat, was based on the proportion of patients with slight or no neurological disability at 90 days as defined by a modified Rankin score of 2 or less. Secondary outcomes included MCA recanalization, the frequency of intracranial hemorrhage with neurological deterioration, and mortality. Results For the primary analysis, 40% of r-proUK patients and 25% of control patients had a modified Rankin score of 2 or less (P=.04). Mortality was 25% for the r-proUK group and 27% for the control group. The recanalization rate was 66% for the r-proUK group and 18% for the control group (P<.001). Intracranial hemorrhage with neurological deterioration within 24 hours occurred in 10% of r-proUK patients and 2% of control patients (P=.06). Conclusion Despite an increased frequency of early symptomatic intracranial hemorrhage, treatment with IA r-proUK within 6 hours of the onset of acute ischemic stroke caused by MCA occlusion significantly improved clinical outcome at 90 days.	Cleveland Clin Fdn, Dept Neurol, Cerebrovasc Ctr, Cleveland, OH 44195 USA; Univ Calif San Francisco, Dept Neuroradiol, San Francisco, CA 94143 USA; Univ Pittsburgh, Stroke Inst, Pittsburgh, PA USA; McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada; Hamilton Civ Hosp, Res Ctr, Clin Trials Methodol Grp, Hamilton, ON, Canada; Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; Tufts Univ New England Med Ctr, Dept Neurol, Boston, MA 02111 USA; St Lukes Med Ctr, Dept Neurosurg, Milwaukee, WI USA; Centennial Med Ctr, Neurol Consultants PC, Nashville, TN USA; Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97201 USA; Toronto Hosp, Western Div, Dept Neurol, Toronto, ON M5T 2S8, Canada; Baylor Univ, Med Ctr, Dept Vasc & Intervent Radiol, Dallas, TX USA	Cleveland Clinic Foundation; University of California System; University of California San Francisco; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh; McMaster University; McMaster University; Boston University; Tufts Medical Center; Oregon Health & Science University; University of Toronto; University Toronto Affiliates; University Health Network Toronto; Baylor University; Baylor University Medical Center	Furlan, A (corresponding author), Cleveland Clin Fdn, Dept Neurol, Cerebrovasc Ctr, 9500 Euclid Ave, Cleveland, OH 44195 USA.	furlana@ccf.org		Silver, Frank/0000-0002-7569-8429; Kase, Carlos/0000-0002-3047-5010				BARON JC, 1995, STROKE, V26, P2219, DOI 10.1161/01.STR.26.12.2219; BROTT T, 1989, STROKE, V20, P864, DOI 10.1161/01.STR.20.7.864; Brott T, 1997, STROKE, V28, P2109, DOI 10.1161/01.STR.28.11.2109; CANDELISE L, 1995, LANCET, V346, P1509; Clark WM, 1999, STROKE, V30, P234; del Zoppo GJ, 1998, STROKE, V29, P4, DOI 10.1161/01.STR.29.1.4; DELZOPPO GJ, 1992, ANN NEUROL, V32, P78, DOI 10.1002/ana.410320113; DELZOPPO GJ, 1988, STROKE, V19, P307, DOI 10.1161/01.STR.19.3.307; DELZOPPO GJ, 1994, AM J NEURORADIOL, V15, P1217; Donnan GA, 1996, JAMA-J AM MED ASSOC, V276, P961, DOI 10.1001/jama.276.12.961; *EM MAN STROK INV, 1997, STROKE, V28, P273; FERGUSON RDG, 1994, AM J NEURORADIOL, V15, P1201; FISHER M, 1995, JAMA-J AM MED ASSOC, V274, P908; Fisher M, 1996, NEUROLOGY, V47, P884, DOI 10.1212/WNL.47.4.884; FURLAN AJ, 1991, THROMBOLYTIC THERAPY, P71; *GEN APPL, PLA960350 GEN APPL; Gonner F, 1998, STROKE, V29, P1894, DOI 10.1161/01.STR.29.9.1894; Gurewich V, 1998, STROKE, V29, P1255, DOI 10.1161/01.STR.29.6.1255; Hacke W, 1998, LANCET, V352, P1245, DOI 10.1016/S0140-6736(98)08020-9; HACKE W, 1988, STROKE, V19, P1216, DOI 10.1161/01.STR.19.10.1216; HACKE W, 1995, JAMA-J AM MED ASSOC, V274, P1017, DOI 10.1001/jama.274.13.1017; Hommel M, 1996, NEW ENGL J MED, V335, P145; HORNIG CR, 1986, STROKE, V17, P179, DOI 10.1161/01.STR.17.2.179; KASAI S, 1985, J BIOL CHEM, V260, P2382; LODDER J, 1986, STROKE, V17, P626, DOI 10.1161/01.STR.17.4.626; MARLER JR, 1995, NEW ENGL J MED, V333, P1581, DOI 10.1056/nejm199512143332401; MARLER JR, 1997, RAPID IDENTIFICATION; MORI E, 1988, STROKE, V19, P802, DOI 10.1161/01.STR.19.7.802; Moulin T, 1996, NEUROLOGY, V47, P366, DOI 10.1212/WNL.47.2.366; Muir KW, 1999, STROKE, V30, P180, DOI 10.1161/01.STR.30.1.180; OKADA Y, 1989, STROKE, V20, P598, DOI 10.1161/01.STR.20.5.598; PANNELL R, 1988, J CLIN INVEST, V81, P853, DOI 10.1172/JCI113394; PANNELL R, 1986, BLOOD, V44, P217; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PESSIN MS, 1995, CEREBROVASCULAR DISEASES, P409; SANDERCOCK P, 1999, CURRENT REV CEREBROV, P217; Staroselskaya IA, 1999, NEUROLOGY, V52, pA455; TEBBE U, 1995, J AM COLL CARDIOL, V26, P365, DOI 10.1016/0735-1097(95)80008-5; THERON J, 1989, AM J NEURORADIOL, V10, P753; Tomsick T, 1996, AM J NEURORADIOL, V17, P79; TONI D, 1994, J NEUROL SCI, V123, P129, DOI 10.1016/0022-510X(94)90214-3; Ueda T, 1998, STROKE, V29, P2568, DOI 10.1161/01.STR.29.12.2568; VANSWIETEN JC, 1988, STROKE, V19, P604, DOI 10.1161/01.STR.19.5.604; vonKummer R, 1997, RADIOLOGY, V205, P327, DOI 10.1148/radiology.205.2.9356611; WOLFE CDA, 1991, STROKE, V22, P1242, DOI 10.1161/01.STR.22.10.1242; WOLPERT SM, 1993, AM J NEURORADIOL, V14, P3; ZEUMER H, 1993, NEURORADIOLOGY, V35, P159, DOI 10.1007/BF00593977	47	2227	2356	0	67	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2003	2011		10.1001/jama.282.21.2003	http://dx.doi.org/10.1001/jama.282.21.2003			9	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	259TB	10591382				2022-12-28	WOS:000083908700019
J	Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P				Stamler, J; Stamler, R; Neaton, JD; Wentworth, D; Daviglus, ML; Garside, D; Dyer, AR; Liu, KA; Greenland, P			Low risk-factor profile and long-term cardiovascular and noncardiovascular mortality and life expectancy - Findings for 5 large cohorts of young adult and middle-aged men and women	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CORONARY HEART-DISEASE; AVERAGE CHOLESTEROL LEVELS; BLOOD-PRESSURE; ATHEROSCLEROSIS; PRAVASTATIN; PREVENTION; EVENTS; TRIAL	Context Three major coronary risk factors-serum cholesterol level, blood pressure, and smoking-increase incidence of coronary heart disease (CHD) and related end points. In previous investigations, risks for low-risk reference groups were estimated statistically because samples contained too few such people to measure risk. Objective To measure long-term mortality rates for individuals with favorable levels for all 3 major risk factors, compared with others. Design Two prospective studies, involving 5 cohorts based on age and sex, that enrolled persons with a range of risk factors. Low risk was defined as serum cholesterol level less than 5.17 mmol/L (<200 mg/dL), blood pressure less than or equal to 120/80 mm Hg, and no current cigarette smoking. All persons with a history of diabetes, myocardial infarction (MI), or, in 3 of 5 cohorts, electrocardiogram (ECG) abnormalities, were excluded. Setting and Participants In 18 US cities, a total of 72 144 men aged 35 through 39 years and 270 671 men aged 40 through 57 years screened (1973-1975) for the Multiple Risk Factor Intervention Trial (MRFIT); in Chicago, a total of 10 025 men aged 18 through 39 years, 7490 men aged 40 through 59 years, and 6229 women aged 40 through 59 years screened (1967-1973) for the Chicago Heart Association Detection Project in Industry (CHA) (N=366 559). Main Outcome Measures Cause-specific mortality during 16 (MRFIT) and 22 (CHA) years, relative risks (RRs) of death, and estimated greater life expectancy, comparing low-risk subcohorts vs others by age strata; Results Low-risk persons comprised only 4.8% to 9.9% of the cohorts. All 5 low-risk groups experienced significantly and markedly lower CHD and cardiovascular disease death rates than those who had elevated cholesterol level, or blood pressure, or smoked. For example, age-adjusted RRs of CHD mortality ranged from 0.08 for CHA men aged 18 to 39 years to 0.23 for CHA men aged 40 through 59 years. The age-adjusted relative risks (RRs) for all cardiovascular disease mortality ranged from 0.15 for MRFIT men aged 35 through 39 years to 0.28 for CHA men aged 40 through 59 years. The age-adjusted RR for all-cause mortality rate ranged from 0.42 for CHA men aged 40 through 59 years to 0.60 for CHA women aged 40 through 59 years. Estimated greater life expectancy for low-risk groups ranged from 5.8 years for CHA women aged 40 through 59 years to 9.5 years for CHA men aged 18 through 39 years. Conclusions Based on these very large cohort studies, for individuals with favorable levels of cholesterol and blood pressure who do not smoke and do not have diabetes, MI, or ECG abnormalities, long-term mortality is much lower and longevity is much greater. A substantial increase in the proportion of the population at lifetime low risk could contribute decisively to ending the CMD epidemic.	Northwestern Univ, Sch Med, Dept Prevent Med, Chicago, IL 60611 USA; Univ Minnesota, Sch Publ Hlth, Div Biostat, Minneapolis, MN 55455 USA	Northwestern University; University of Minnesota System; University of Minnesota Twin Cities	Stamler, J (corresponding author), Northwestern Univ, Sch Med, Dept Prevent Med, 680 N Lake Shore Dr,Suite 1101 D335, Chicago, IL 60611 USA.		Greenland, Philip/ABD-5528-2021		NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [R01HL028715, R01HL021010] Funding Source: NIH RePORTER	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Appel LJ, 1997, NEW ENGL J MED, V336, P1117, DOI 10.1056/NEJM199704173361601; Berenson GS, 1998, NEW ENGL J MED, V338, P1650, DOI 10.1056/NEJM199806043382302; Black HR, 1997, ARCH INTERN MED, V157, P2413; BURT VL, 1995, HYPERTENSION, V25, P305, DOI 10.1161/01.HYP.25.3.305; Cutler JA, 1997, AM J CLIN NUTR, V65, P184; Daviglus ML, 1998, NEW ENGL J MED, V339, P1122, DOI 10.1056/NEJM199810153391606; Downs JR, 1998, JAMA-J AM MED ASSOC, V279, P1615, DOI 10.1001/jama.279.20.1615; KJELSBERG MO, 1982, JAMA-J AM MED ASSOC, V248, P1465; Lowe LP, 1998, ARCH INTERN MED, V158, P2007, DOI 10.1001/archinte.158.18.2007; MACMAHON S, 1990, LANCET, V335, P765, DOI 10.1016/0140-6736(90)90878-9; National Research Council (US) Committee on Diet and Health, 1989, DIET HLTH IMPL RED C; PEDERSEN TR, 1994, LANCET, V344, P1383; *POOL PROJ RES GRO, 1978, J CHRON DIS, V31, P201, DOI DOI 10.1016/0021-9681(78)90073-5; ROSE G, 1992, J EPIDEMIOL COMMUN H, V46, P75, DOI 10.1136/jech.46.1.75; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; STAMLER J, 1993, CIRCULATION, V88, P1954, DOI 10.1161/01.CIR.88.4.1954; STAMLER J, 1993, CARDIOLOGY, V82, P191, DOI 10.1159/000175868; Stamler J, 1997, AM J CLIN NUTR, V65, P626, DOI 10.1093/ajcn/65.2.626S; Stamler J, 1998, JAMA-J AM MED ASSOC, V279, P878, DOI 10.1001/jama.279.11.878; STAMLER J, 1988, ARCH PATHOL LAB MED, V112, P1032; Stamler J., 1967, LECT PREVENTIVE CARD; The Inter-Society Commission for Heart Disease Resources, 1970, CIRCULATION, V42, pA55; Tonkin A, 1998, NEW ENGL J MED, V339, P1349; WATTS GF, 1992, LANCET, V339, P563, DOI 10.1016/0140-6736(92)90863-X; WHELTON PK, 1993, ARCH INTERN MED, V153, P186, DOI 10.1001/archinte.153.2.186; WILMSHURST P, 1994, BMJ-BRIT MED J, V309, P1029, DOI 10.1136/bmj.309.6961.1029; Wilson PWF, 1998, CIRCULATION, V97, P1837, DOI 10.1161/01.CIR.97.18.1837; World Health Organization, 1977, INT CLASS DIS; [No title captured]; [No title captured]; [No title captured]	32	513	533	0	15	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2012	2018		10.1001/jama.282.21.2012	http://dx.doi.org/10.1001/jama.282.21.2012			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591383	Bronze			2022-12-28	WOS:000083908700020
J	Blayney, MR; Malins, AF; Cooper, GM				Blayney, MR; Malins, AF; Cooper, GM			Cardiac arrhythmias in children during outpatient general anaesthesia for dentistry: a prospective randomised trial	LANCET			English	Article							DENTAL-ANESTHESIA; HALOTHANE	Background Deaths in children associated with outpatient general dental anaesthesia may be attributable to sudden cardiovascular collapse precipitated by Ventricular arrhythmias. A causal link between halothane anaesthesia, Ventricular arrhythmias, and deaths has been suggested. We did a prospective, randomised trial to investigate the frequency and character of arrhythmias during anaesthesia with halothane and the alternative anaesthetic agent, sevoflurane. Methods 150 children, aged 3-15 years, who needed dental extraction under general anaesthesia were randomly assigned sevoflurane or halothane supplementation of 66% nitrous oxide in oxygen with spontaneous ventilation. The halothane group (n=50) received halothane introduced in 0.75% increments, every two to three breaths, to a maximum of 3.0%, with maintenance at 1.5%. The incremental sevoflurane group (n=50) received sevoflurane introduced in 2% increments increased to a maximum of 8%, with maintenance at 4%. The 8% sevoflurane group (n=50) received sevoflurane introduced at 8%, with. maintenance at 4%. Findings 24 (48%) children receiving halothane had arrhythmias compared with four (8%) receiving incremental sevoflurane (difference 40% [95% Ci for differences 24-56] p<0.0001), and eight (16%) receiving 8% sevoflurane (difference 32% [15-50] p=0.0013). Halothane-associated arrhythmias occurred during dental extraction or emergence and were mainly ventricular. Six (12%) children in the halothane group had ventricular tachycardia. The methods of sevoflurane administration did not differ significantly for the frequency of arrhythmias (p=0.357). Sevoflurane-associated arrhythmias were mainly single supraventricular ectopic beats. Interpretation There was a strong association between halothane and ventricular arrhythmias, especially ventricular tachycardia. The use of sevoflurane in preference to halothane could contribute to a decline in morbidity and mortality associated with dental anaesthesia.	Queen Elizabeth Hosp, Featherstone Dept Anaesthesia & Intens Care, Birmingham B15 2TH, W Midlands, England	University of Birmingham	Blayney, MR (corresponding author), Queen Elizabeth Hosp, Featherstone Dept Anaesthesia & Intens Care, North 5A, Birmingham B15 2TH, W Midlands, England.							ALEXANDER JP, 1971, BRIT J ANAESTH, V43, P773, DOI 10.1093/bja/43.8.773; *AM NAT STAND AMB, 1994, PUBL ANSI AAMI; ARRIFIN SA, 1997, BRIT J ANAESTH, V78, P157; CATTERMOLE RW, 1986, BRIT J ANAESTH, V58, P385, DOI 10.1093/bja/58.4.385; COPLANS MP, 1982, BRIT DENT J, V153, P357, DOI 10.1038/sj.bdj.4804947; COPLANS MP, 1993, ANAESTHESIA, V48, P435, DOI 10.1111/j.1365-2044.1993.tb07022.x; CRANEFIELD PF, 1973, NEW ENGL J MED, V289, P732, DOI 10.1056/NEJM197310042891407; CRIPPS TP, 1987, ANAESTHESIA, V42, P189, DOI 10.1111/j.1365-2044.1987.tb02997.x; Paris ST, 1997, BRIT J ANAESTH, V79, P280, DOI 10.1093/bja/79.3.280; Poswillo D., 1990, GEN ANAESTHESIA SEDA; RYDER W, 1981, ANAESTHESIA, V36, P492, DOI 10.1111/j.1365-2044.1981.tb10285.x; RYDER W, 1970, ANAESTHESIA, V25, P46, DOI 10.1111/j.1365-2044.1970.tb00158.x; SEEL D, 1995, DENT GEN ANAESTHESIA; TOUHY O, 1968, BR DENT J, V124, P417; Worthington LM, 1998, BRIT J ANAESTH, V80, P131, DOI 10.1093/bja/80.2.131	15	36	36	0	4	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1864	1866		10.1016/S0140-6736(99)02485-X	http://dx.doi.org/10.1016/S0140-6736(99)02485-X			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584723				2022-12-28	WOS:000083909100012
J	Shillingford, M				Shillingford, M			John ("Jack") Parsons Shillingford - Obituaries	BRITISH MEDICAL JOURNAL			English	Biographical-Item																			0	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1438	1438		10.1136/bmj.319.7222.1438	http://dx.doi.org/10.1136/bmj.319.7222.1438			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574885	Green Published			2022-12-28	WOS:000083995200065
J	Horita, J; Driesner, T; Cole, DR				Horita, J; Driesner, T; Cole, DR			Pressure effect on hydrogen isotope fractionation between brucite and water at elevated temperatures	SCIENCE			English	Article							OXYGEN; 500-DEGREES-C; EXCHANGE; MINERALS; SYSTEM; QUARTZ; 100-DEGREES-C; SPECTROSCOPY; TOURMALINE; ANORTHITE	Experimental evidence for a pressure effect on isotopic partitioning at elevated temperatures demonstrates that equilibrium deuterium-protium fractionation between the mineral brucite [Mg(OH)(2)] and pure water systematically increases by 12.4 per mil as pressure increases from 15 to 800 megapascals at 380 degrees C, A linear relation is observed between the measured fractionation factor and the density of water (0.070 to 1.035 grams per cubic centimeter). The trend of the isotope pressure effect is the same as that of recent theoretical studies, but the magnitude is smaller. The pressure effect must be accounted for in the interpretation of isotopic data of geologic systems involving water (paleotemperature, source of fluids).	Oak Ridge Natl Lab, Div Chem & Analyt Sci, Oak Ridge, TN 37831 USA	United States Department of Energy (DOE); Oak Ridge National Laboratory	Horita, J (corresponding author), Oak Ridge Natl Lab, Div Chem & Analyt Sci, POB MS 6110, Oak Ridge, TN 37831 USA.		Driesner, Thomas/N-6361-2016					Bai TB, 1998, AM MINERAL, V83, P205; BIGELEISEN J, 1952, ANAL CHEM, V24, P1356, DOI 10.1021/ac60068a025; BLAMART D, 1989, CR ACAD SCI II, V308, P39; Chacko T, 1999, GEOCHIM COSMOCHIM AC, V63, P1, DOI 10.1016/S0016-7037(99)00007-1; CLAYTON RN, 1989, GEOCHIM COSMOCHIM AC, V53, P725, DOI 10.1016/0016-7037(89)90015-X; CLAYTON RN, 1975, GEOCHIM COSMOCHIM AC, V39, P1197, DOI 10.1016/0016-7037(75)90062-9; CLAYTON RN, 1981, THERMODYNAMICS MINER, P85; Driesner T, 1997, SCIENCE, V277, P791, DOI 10.1126/science.277.5327.791; DRIESNER T, 1996, THESIS EIDGENOSSISCH; FRANTZ JD, 1993, CHEM GEOL, V106, P9, DOI 10.1016/0009-2541(93)90163-D; Gillet P, 1998, REV MINERAL, V37, P525; Gillet P, 1996, GEOCHIM COSMOCHIM AC, V60, P3471, DOI 10.1016/0016-7037(96)00178-0; GRAHAM CM, 1984, AM MINERAL, V69, P128; Haar L, 1984, NBS NRC STEAM TABLES; HAMANN SD, 1984, AUST J CHEM, V37, P1979, DOI 10.1071/CH9841979; Hoering TC, 1961, CARNEGIE I WASHINGTO, V60, P201; Jibao G., 1997, GEOCHIM COSMOCHIM AC, V61, P4679; JOY HW, 1960, J CHEM PHYS, V33, P1276, DOI 10.1063/1.1731392; KOHL W, 1991, BER BUNSEN PHYS CHEM, V95, P1586, DOI 10.1002/bbpc.19910951202; MATSUHISA Y, 1979, GEOCHIM COSMOCHIM AC, V43, P1131, DOI 10.1016/0016-7037(79)90099-1; MATTHEWS A, 1983, GEOL SOC AM BULL, V94, P396, DOI 10.1130/0016-7606(1983)94<396:OTMAKO>2.0.CO;2; MATTHEWS A, 1983, GEOCHIM COSMOCHIM AC, V47, P631, DOI 10.1016/0016-7037(83)90284-3; MINEEV SD, 1996, J C ABSTR, V1, P404; NORTHROP DA, 1966, J GEOL, V74, P174, DOI 10.1086/627153; PALMER MR, 1992, CHEM GEOL, V101, P123, DOI 10.1016/0009-2541(92)90209-N; POLYAKOV VB, 1994, GEOCHIM COSMOCHIM AC, V58, P4739, DOI 10.1016/0016-7037(94)90204-6; Polyakov VB, 1998, GEOCHIM COSMOCHIM AC, V62, P3077, DOI 10.1016/S0016-7037(98)00220-8; POLYAKOV VB, 1999, COMMUNICATION; Rosenbaum JM, 1997, GEOCHIM COSMOCHIM AC, V61, P4993, DOI 10.1016/S0016-7037(97)00362-1; Saccocia PJ, 1998, GEOCHIM COSMOCHIM AC, V62, P485, DOI 10.1016/S0016-7037(97)00346-3; SAKAI H, 1978, EARTH PLANET SC LETT, V40, P231, DOI 10.1016/0012-821X(78)90093-6; SATAKE H, 1984, CONTRIB MINERAL PETR, V86, P19, DOI 10.1007/BF00373707; SHARP ZD, 1992, CONTRIB MINERAL PETR, V112, P358, DOI 10.1007/BF00310466; Shinoda K, 1998, PHYS CHEM MINER, V25, P197, DOI 10.1007/s002690050103; SUZUOKI T, 1976, GEOCHIM COSMOCHIM AC, V40, P1229, DOI 10.1016/0016-7037(76)90158-7; Vennemann TW, 1996, GEOCHIM COSMOCHIM AC, V60, P2437, DOI 10.1016/0016-7037(96)00103-2; WALTHER JV, 1986, GEOCHIM COSMOCHIM AC, V50, P733, DOI 10.1016/0016-7037(86)90349-2; WENNER DB, 1973, AM J SCI, V273, P207, DOI 10.2475/ajs.273.3.207; Xu BL, 1999, GEOCHIM COSMOCHIM AC, V63, P2009, DOI 10.1016/S0016-7037(99)00047-2	39	31	35	0	19	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1545	1547		10.1126/science.286.5444.1545	http://dx.doi.org/10.1126/science.286.5444.1545			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567257				2022-12-28	WOS:000083768300053
J	Kreczy, A; Kofler, M; Gschwendtner, A				Kreczy, A; Kofler, M; Gschwendtner, A			Underestimated health hazard: proposal for an ergonomic microscope workstation	LANCET			English	Article							MUSCULOSKELETAL SYMPTOMS	Working daily for a long time with a standard microscope causes back pain, fibromyalgia, or tension headache in up to 80% of microscopists. These complaints may be prevented by an ergonomic design of the microscope workstation, leading to a beneficial and significant reduction of electromyographical activity in the most strained muscle groups as shown by surface electromyographic recordings.	Univ Innsbruck, Dept Anat Pathol, A-6020 Innsbruck, Austria; Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria	University of Innsbruck; University of Innsbruck	Kreczy, A (corresponding author), Univ Innsbruck, Dept Anat Pathol, Mullerstr 44, A-6020 Innsbruck, Austria.	alfons.kreczy@uibk.ac.at	Kofler, Markus/P-5585-2019	Kofler, Markus/0000-0002-2962-0903				HAINES H, 1993, US MICROSCOPY ANAL, V1, P17; Kalavar SS, 1996, LAB MED, V27, P765, DOI 10.1093/labmed/27.11.765; KRUEGER H, 1986, SOZ PRAVENTIV MED, V31, P250, DOI 10.1007/BF02083477; Sobti A, 1997, AM J IND MED, V32, P76, DOI 10.1002/(SICI)1097-0274(199707)32:1<76::AID-AJIM9>3.0.CO;2-P; Yassi A, 1997, LANCET, V349, P943, DOI 10.1016/S0140-6736(96)07221-2	5	14	14	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0140-6736			LANCET	Lancet	NOV 13	1999	354	9191					1701	1702		10.1016/S0140-6736(99)03131-1	http://dx.doi.org/10.1016/S0140-6736(99)03131-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255CW	10568578				2022-12-28	WOS:000083652800019
J	Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C				Chaix, C; Durand-Zaleski, I; Alberti, C; Brun-Buisson, C			Control of endemic methicillin-resistant Staphylococcus aureus - A cost-benefit analysis in an intensive care unit	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							NOSOCOMIAL INFECTIONS; BACTEREMIA; IMPACT; MRSA; EPIDEMIOLOGY; ERADICATION; PREVALENCE; PREVENTION; MORTALITY; OUTBREAK	Context Despite the success of some countries in controlling endemic methicillin-resistant Staphylococcus aureus (MRSA), such programs have not been implemented for some hospitals with endemic infection because of concerns that these programs would be costly and of limited benefit. Objective To compare the costs and benefits of an MRSA control program in an endemic setting. Design and Setting Case-control study conducted at a medical intensive care unit (ICU) of a French university hospital with a 4% prevalence of MRSA carriage at ICU admission. Patients Twenty-seven randomly selected patients who had ICU-acquired MRSA infection between January 1993 and June 1997, matched to 27 controls hospitalized during the same period without MRSA infection. Main Outcome Measures Intensive care unit costs attributable to MRSA infection, computed from excess therapeutic intensity in cases using estimates from a cost model derived in the same ICU, were compared with costs of the control program, derived from time-motion study of nurses and physicians. The threshold for MRSA carriage that would make the control strategy dominant was determined; sensitivity analyses varied rates of MRSA transmission and ratio of infection to transmission, length of ICU stay, and costs of isolation precautions. Results The mean cost attributable to MRSA infection was US $9275 (median, $5885; interquartile range, $1400-$16720). Total costs of the control program ranged from $340 to $1480 per patient. A 14% reduction in MRSA infection rate resulted in the control program being beneficial. In sensitivity analyses, the control strategy was dominant for a prevalence of MRSA carriage on ICU admission ranging from 1% to 7%, depending on costs of control measures and MRSA transmission, for infection rates greater than 50% following transmission. Conclusions In this example of a hospital with endemic MRSA infection, selective screening and isolation of carriers on ICU admission are beneficial compared with no isolation.	Hop Henri Mondor, Infect Control Unit, F-94010 Creteil, France; Hop Henri Mondor, Med Intens Care Unit, F-94010 Creteil, France	Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP; Assistance Publique Hopitaux Paris (APHP); Universite Paris-Est-Creteil-Val-de-Marne (UPEC); Hopital Universitaire Henri-Mondor - APHP	Brun-Buisson, C (corresponding author), Hop Henri Mondor, Assistance Publ Hop Paris, Unite Hyg & Prevent Infect, 51 Ave Marechal de Lattre de Tassigny, F-94010 Creteil, France.	christian.brun-buisson@hmn.ap-hop.paris.fr						AubryDamon H, 1997, CLIN INFECT DIS, V25, P647, DOI 10.1086/513749; Ayliffe GAJ, 1997, CLIN INFECT DIS, V24, pS74, DOI 10.1093/clinids/24.Supplement_1.S74; Barrett SP, 1998, J HOSP INFECT, V39, P85, DOI 10.1016/S0195-6701(98)90322-X; BOYCE JM, 1991, INFECT CONT HOSP EP, V12, P46, DOI 10.2307/30147088; BOYCE JM, 1990, INFECT CONT HOSP EP, V11, P639; BOYCE JM, 1983, J INFECT DIS, V148, P763, DOI 10.1093/infdis/148.4.763; Chaix C, 1999, PHARMACOECONOMICS, V15, P573, DOI 10.2165/00019053-199915060-00005; COHEN SH, 1991, AM J MED, V91, pS233, DOI 10.1016/0002-9343(91)90374-7; DRUMMOND M, 1989, METHODS EC EVALUATIO, P18; EMMERSON M, 1994, SCAND J INFECT DIS, P47; Girou E, 1998, CLIN INFECT DIS, V27, P543, DOI 10.1086/514695; HALEY RW, 1995, J INFECT DIS, V171, P614, DOI 10.1093/infdis/171.3.614; Harbarth S, 1998, ARCH INTERN MED, V158, P182, DOI 10.1001/archinte.158.2.182; Humphreys H, 1997, J HOSP INFECT, V36, P167, DOI 10.1016/S0195-6701(97)90191-2; Jarvis WR, 1996, INFECT CONT HOSP EP, V17, P552; Jernigan JA, 1995, INFECT CONT HOSP EP, V16, P686; Jernigan JA, 1996, AM J EPIDEMIOL, V143, P496, DOI 10.1093/oxfordjournals.aje.a008770; KREGER BE, 1980, AM J MED, V68, P344, DOI 10.1016/0002-9343(80)90102-3; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Miranda DR, 1997, INTENS CARE MED, V23, P760, DOI 10.1007/s001340050406; MULLIGAN ME, 1993, AM J MED, V94, P313, DOI 10.1016/0002-9343(93)90063-U; RAO N, 1988, INFECT CONT HOSP EP, V9, P255, DOI 10.1086/645848; ROBINSON R, 1993, BMJ-BRIT MED J, V307, P670, DOI 10.1136/bmj.307.6905.670; RomeroVivas J, 1995, CLIN INFECT DIS, V21, P1417, DOI 10.1093/clinids/21.6.1417; STAMM AM, 1993, AM J INFECT CONTROL, V21, P70, DOI 10.1016/0196-6553(93)90227-U; Sznajder M, 1998, INTENS CARE MED, V24, P582, DOI 10.1007/s001340050619; TABLAN OC, 1995, INFECT CONT HOSP EP, V16, P105; THOMPSON RL, 1982, ANN INTERN MED, V97, P309, DOI 10.7326/0003-4819-97-3-309; VandenbrouckeGrauls CMJE, 1996, INFECT CONT HOSP EP, V17, P512; VINCENT JL, 1995, JAMA-J AM MED ASSOC, V274, P639, DOI 10.1001/jama.274.8.639; VOSS A, 1994, EUR J CLIN MICROBIOL, V13, P50, DOI 10.1007/BF02026127; WAKEFIELD DS, 1988, AM J INFECT CONTROL, V16, P185, DOI 10.1016/0196-6553(88)90058-2; WENZEL RP, 1991, AM J MED, V91, pS221, DOI 10.1016/0002-9343(91)90372-5; WESTH H, 1992, CLIN INFECT DIS, V14, P1186, DOI 10.1093/clinids/14.6.1186	34	249	257	0	9	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1745	1751		10.1001/jama.282.18.1745	http://dx.doi.org/10.1001/jama.282.18.1745			7	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568647	Bronze			2022-12-28	WOS:000083471400029
J	Poldermans, D; Boersma, E; Bax, JJ; Thomson, IR; van de Ven, LLM; Blankensteijn, JD; Baars, HF; Yo, TI; Trocino, G; Vigna, C; Roelandt, JRTC; van Urk, H				Poldermans, D; Boersma, E; Bax, JJ; Thomson, IR; van de Ven, LLM; Blankensteijn, JD; Baars, HF; Yo, TI; Trocino, G; Vigna, C; Roelandt, JRTC; van Urk, H			The effect of bisoprolol on perioperative mortality and myocardial infarction in high-risk patients undergoing vascular surgery	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							DOBUTAMINE STRESS ECHOCARDIOGRAPHY; NONCARDIAC SURGERY; CARDIAC MORBIDITY; ISCHEMIA; ATROPINE; DISEASE	Background: Cardiovascular complications are the most important causes of perioperative morbidity and mortality among patients undergoing major vascular surgery. Methods: We performed a randomized, multicenter trial to assess the effect of perioperative blockade of beta-adrenergic receptors on the incidence of death from cardiac causes and nonfatal myocardial infarction within 30 days after major vascular surgery in patients at high risk for these events. High-risk patients were identified by the presence of both clinical risk factors and positive results on dobutamine echocardiography. Eligible patients were randomly assigned to receive standard perioperative care or standard care plus perioperative beta-blockade with bisoprolol. Results: A total of 1351 patients were screened, and 846 were found to have one or more cardiac risk factors. Of these 846 patients, 173 had positive results on dobutamine echocardiography. Fifty-nine patients were randomly assigned to receive bisoprolol, and 53 to receive standard care. Fifty-three patients were excluded from randomization because they were already taking a beta-blocker, and eight were excluded because they had extensive wall-motion abnormalities either at rest or during stress testing. Two patients in the bisoprolol group died of cardiac causes (3.4 percent), as compared with nine patients in the standard-care group (17 percent, P = 0.02). Nonfatal myocardial infarction occurred in nine patients given standard care only (17 percent) and in none of those given standard care plus bisoprolol (P<0.001). Thus, the primary study end point of death from cardiac causes or nonfatal myocardial infarction occurred in 2 patients in the bisoprolol group (3.4 percent) and 18 patients in the standard-care group (34 percent, P<0.001). Conclusions: Bisoprolol reduces the perioperative incidence of death from cardiac causes and nonfatal myocardial infarction in high-risk patients who are undergoing major vascular surgery. (N Engl J Med 1999;341:1789-94.) (C)1999, Massachusetts Medical Society.	Erasmus Univ, Med Ctr, Dept Vasc Surg, NL-3015 GD Rotterdam, Netherlands; Univ Manitoba, Winnipeg, MB, Canada; Univ Utrecht Hosp, Utrecht, Netherlands; Twee Steden Ziekenhuis, Tilburg, Netherlands; St Clara Hosp, Rotterdam, Netherlands; San Gerardo Hosp, Monza, Italy; Carattere Sci Hosp, Ist Ricovero & Cura, San Giovanni Rotondo, Italy	Erasmus University Rotterdam; Erasmus MC; University of Manitoba; Utrecht University; Utrecht University Medical Center; Elisabeth-TweeSteden Ziekenhuis (ETZ); San Gerardo Hospital	Poldermans, D (corresponding author), Erasmus Univ, Med Ctr, Dept Vasc Surg, Dr Molewaterpl 40, NL-3015 GD Rotterdam, Netherlands.	poldermans@hlkd.azr.nl	Blankensteijn, Jan D/Q-9291-2016	Blankensteijn, Jan D/0000-0002-2062-8749				[Anonymous], 1986, Lancet, V2, P57; DAVILAROMAN VG, 1993, J AM COLL CARDIOL, V21, P957, DOI 10.1016/0735-1097(93)90353-3; Eagle KA, 1996, J AM COLL CARDIOL, V27, P910; Kjekshus J, 1999, EUR HEART J SUPPL, V1, pH64; LALKA SG, 1992, J VASC SURG, V15, P831, DOI 10.1016/0741-5214(92)90718-N; LANE RT, 1991, AM J CARDIOL, V68, P976, DOI 10.1016/0002-9149(91)90424-J; Lechat P, 1999, LANCET, V353, P9; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; MANGANO DT, 1990, ANESTHESIOLOGY, V72, P153, DOI 10.1097/00000542-199001000-00025; Mangano DT, 1997, NEW ENGL J MED, V336, P1039; MCNEILL AJ, 1992, AM J CARDIOL, V70, P41, DOI 10.1016/0002-9149(92)91387-J; OBRIEN PC, 1979, BIOMETRICS, V35, P549, DOI 10.2307/2530245; PEPINE CJ, 1994, CIRCULATION, V90, P762, DOI 10.1161/01.CIR.90.2.762; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005	15	984	1032	0	22	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1789	1794		10.1056/NEJM199912093412402	http://dx.doi.org/10.1056/NEJM199912093412402			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588963				2022-12-28	WOS:000084074000002
J	Gottlieb, S				Gottlieb, S			Papillomavirus DNA in smear test raises risk of cervical cancer	BRITISH MEDICAL JOURNAL			English	News Item																		Burk RD, 1999, NEW ENGL J MED, V341, P1687, DOI 10.1056/NEJM199911253412209; Wallin KL, 1999, NEW ENGL J MED, V341, P1633, DOI 10.1056/NEJM199911253412201	2	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1454	1454		10.1136/bmj.319.7223.1454	http://dx.doi.org/10.1136/bmj.319.7223.1454			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582916	Green Published			2022-12-28	WOS:000084129200008
J	Panagiotopoulos, T; Antoniadou, I; Valassi-Adam, E				Panagiotopoulos, T; Antoniadou, I; Valassi-Adam, E			Increase in congenital rubella occurrence after immunisation in Greece: retrospective survey and systematic review	BRITISH MEDICAL JOURNAL			English	Review							DEVELOPING-COUNTRIES; SYNDROME CRS; VACCINATION; MEASLES	Objective To describe the events leading to the epidemic of congenital rubella syndrome in Greece in 1993 after a major rubella epidemic. Design Retrospective survey and systematic review Setting Greece (population 10 million), 1950-95. Subjects Children, adolescents, and women of childbearing age. Results Around 1975 in Greece the measles, mumps, and rubella vaccine started being given to boys and girls aged 1 year without policies to attain high vaccination coverage and to protect adolescents and young women. During the 1980s, vaccination coverage for rubella remained consistently below 50%, and the proportion of pregnant women susceptible to rubella gradually increased. In 1993 the incidence of rubella in young adults was higher than in any previous epidemic year. The epidemic of congenital rubella that followed, with 25 serologically confirmed cases (24.6 per 100 000 live births), was probably the largest such epidemic in Greece after 1950, Conclusions With low vaccination coverage, the immunisation of boys and girls aged 1 year against rubella carries the theoretical risk of increasing the occurrence of congenital rubella. This phenomenon, which has not been previously reported, occurred in Greece.	Agia Sophia Childrens Hosp, Inst Child Hlth, Dept Social Paediat, Athens 11527, Greece	The Aghia Sophia Children's Hospital	Panagiotopoulos, T (corresponding author), Agia Sophia Childrens Hosp, Inst Child Hlth, Dept Social Paediat, Athens 11527, Greece.							ALEXANDROUILIAD.ME, 1981, ACTA MICROBIOLOGICA, V26, P269; ANDERSON RM, 1983, J HYG-CAMBRIDGE, V90, P259, DOI 10.1017/S002217240002893X; [Anonymous], 1990, MMWR Recomm Rep, V39, P1; ANTONIADOUKOUMA.I, 1989, ARCH HELLENIC MED, V6, P156; APOSTOLIDIS G, 1991, PAEDIATRIKI, V54, P337; ARKOULIS T, 1991, P 17 PANH MED C ATH; BART KJ, 1985, REV INFECT DIS, V7, P177; BARTSOKAS S, 1953, NOSOCOMIAKA CHRONIKA, V14, P62; BEST JM, 1991, EPIDEMIOL INFECT, V107, P17, DOI 10.1017/S0950268800048640; BOTIGER M, 1997, VACCINE, V15, P1538; BRYDEN AS, 1981, ACTA MICROBIOLOGICA, V26, P59; CHOREMIS K, 1955, ANN CLIN PAEDIAT U A, V2, P201; COOPER LZ, 1985, REV INFECT DIS, V7, pS2; Cutts FT, 1997, B WORLD HEALTH ORGAN, V75, P55; DELAMATA I, 1988, EUR J EPIDEMIOL, V4, P175, DOI 10.1007/BF00144747; DELIGIORGIS D, 1978, THESIS I CHILD HLTH, P52; DUDJEON JA, 1985, REV INFECT DIS S1, V7, P185; FOTIOU K, 1988, ANN CLIN PAEDIAT U A, V35, P210; GEORGIOPOULOS A, 1994, P 8 PANH C PER MED A, P187; HATZIIOANNIDIS K, 1984, PEDIAT CHRONICA, V13, P150; HATZIPANTELIS S, 1982, PAEDIATRIKI, V45, P201; HETHCOTE HW, 1983, AM J EPIDEMIOL, V117, P2, DOI 10.1093/oxfordjournals.aje.a113511; KARABOGIAKARAFY.P, 1992, P 2 PANH C VIR ATH G, P130; KARABOGIAKARAFY.P, 1991, P 17 PANH MED C ATH; KARAVERGOS P, 1993, P 31 PANH PAED C CHA; KERAMIDAKARAMIT.P, 1972, ACTA MICROBIOLOGICA, V17, P109; KIRIAZOPOULOUDA.V, 1986, ACTA MICROBIOLOGICA, V31, P41; KIRIAZOPOULOUDA.V, 1987, GALENUS, V29, P234; KIRIAZOPOULOUDA.V, 1978, HELLENIC MED, V47, P408; KNOX EG, 1980, INT J EPIDEMIOL, V9, P13, DOI 10.1093/ije/9.1.13; KNOX EG, 1985, REV INFECT DIS SU, V7, P194; KREMENOPOULOS G, 1980, PEDIAT CHRONIKA, V9, P197; LIONIS H, 1992, P 6 MED C CRET RET A, P38; LIVADAS N, 1989, PAEDIATRIKI, V52, P274; MARAGOS C, 1989, ARCH HELLEN MED, V6, P140; METAXAS N, 1992, P 30 PANH PAED C LEM; MILLER E, 1982, LANCET, V2, P781; *MIN HLTH SOC SEC, 1983, VACC STUD; *MIN HLTH SOC SEC, 1984, 3081 MIN HLTH SOC SE; *MIN HLTH SOC SEC, 1991, NAT IMM PROGR GREEC; *MIN HLTH SOC SEC, 1987, COMP VACC SCH; *MIN HLTH SOC SEC, 1989, VACC MEASL MUMPS RUB; *NAT STAT SERV GRE, MONTHL STAT B; ORENSTEIN WA, 1985, REV INFECT DIS, V7, P22; PANAGIOTOPOULOS T, 1997, PAEDIATRIKI, V60, P582; PANAGIOTOPOULOS T, 1991, HLTH PRESCHOOL CHILD, P124; PANAGIOTOPOULOS T, 1995, ANN CLIN PAEDIAT U A, V42, P175; PANAGIOTOPOULOS T, 1995, MAJOR EPIDEMIC CONGE; PANAGIOTOPOULOS T, 1996, ARCH HELLENIC MED, V13, P211; PANTAZIHATZICON.A, 1993, P 31 PANH PAED C CHA; PAPAEVANGELOU G, 1967, THESIS U ATHENS; PAPAGEORGIOU V, 1991, ARCH HELLENIC MED, V8, P446; PAPAIOANNOU A, 1963, P ACAD ATHENS, V38, P531; PAPAPETROPOULOU M, 1987, IATRIKI, V52, P535; PATRAMANI I, 1976, ACTA MICROBIOLOGICA, V21, P10; PATRONA Z, 1984, THESIS I CHILD HLTH; PLASARA M, 1980, P 18 PANH PAED C NIC; PLASARA M, 1977, IATRIKI, V31, P500; Robertson SE, 1997, B WORLD HEALTH ORGAN, V75, P69; SIAHANIDOU T, 1993, PAEDIATRIKI, V56, P503; SKOUTARI M, 1988, P 14 PANH MED C ATH; STAVRINADIS H, 1978, P 16 PANH PAED C THE; THEODOSI A, 1991, P 29 PANH PAED C HER; TSOUKALOS S, 1982, IATRIKA CHRONIKA, V5, P465; TZIAKOS M, 1981, P 19 PANH PAED C ATH; VALASSIADAM E, 1981, ANN CLIN PAEDIAT U A, V28, P202; van Druten J A, 1986, Dev Biol Stand, V65, P53; VRIONIS G, 1991, P 29 PANH PAED C HER; Wakefield AJ, 1998, LANCET, V351, P637, DOI 10.1016/S0140-6736(97)11096-0; *WHO, 1991, EUR HLTH ALL SER, V4, P31; 1996, COMMUN DIS REP CDR W, V6, P259; 1981, ANN CLIN PAEDIAT U S, V28, P116; 1978, ANN CLIN PAED U AT S, V25, P104; 1992, P 18 PANH MED C ATH	74	164	167	0	17	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1462	1466		10.1136/bmj.319.7223.1462	http://dx.doi.org/10.1136/bmj.319.7223.1462			17	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582926	Green Published, Bronze			2022-12-28	WOS:000084129200018
J	Yamey, G				Yamey, G			Agencies urge end to global trade restrictions on essential medicines	BRITISH MEDICAL JOURNAL			English	News Item																		Wilson D, 1999, LANCET, V354, P1893, DOI 10.1016/S0140-6736(99)06114-0	1	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1455	1455		10.1136/bmj.319.7223.1455	http://dx.doi.org/10.1136/bmj.319.7223.1455			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582919	Green Published			2022-12-28	WOS:000084129200010
J	[Anonymous]				[Anonymous]			GMC agrees a change in culture is needed	BMJ-BRITISH MEDICAL JOURNAL			English	Editorial Material																			0	0	0	0	0	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	DEC 4	1999	319	7223					1505	1505						1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582954				2022-12-28	WOS:000084129200058
J	Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME				Yan, RQ; Bienkowski, MJ; Shuck, ME; Miao, HY; Tory, MC; Pauley, AM; Brashler, JR; Stratman, NC; Mathews, WR; Buhl, AE; Carter, DB; Tomasselli, AG; Parodi, LA; Heinrikson, RL; Gurney, ME			Membrane-anchored aspartyl protease with Alzheimer's disease beta-secretase activity	NATURE			English	Article							AMYLOID PRECURSOR PROTEIN; CATHEPSIN-D; MUTATION; DEFICIENCY; CLEAVAGE; NEURONS; GENE	Mutations in the gene encoding the amyloid protein precursor (APP) cause autosomal dominant Alzheimer's disease(1-3). Cleavage of APP by unidentified proteases, referred to as beta- and gamma-secretases(4-7), generates the amyloid beta-peptide, the main component of the amyloid plaques found in Alzheimer's disease patients(8). The disease-causing mutations flank the protease cleavage sites in APP and facilitate its cleavage. Here we identify a new membrane-bound aspartyl protease (Asp2) with beta-secretase activity. The Asp2 gene is expressed widely in brain and other tissues. Decreasing the expression of Asp2 in cells reduces amyloid beta-peptide production and blocks the accumulation of the carboxy-terminal APP fragment that is created by beta-secretase cleavage. Solubilized Asp2 protein cleaves a synthetic APP peptide substrate at the beta-secretase site, and the rate of cleavage is increased tenfold by a mutation associated with early-onset Alzheimer's disease in Sweden(3). Thus, Asp2 is a new protein target for drugs that are designed to block the production of amyloid beta-peptide peptide and the consequent formation of amyloid plaque in Alzheimer's disease.	Pharmacia & Upjohn Inc, Cell & Mol Biol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Genom, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Prot Sci, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Pharmacol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Struct Analyt & Med Chem, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Neurobiol, Kalamazoo, MI 49007 USA; Pharmacia & Upjohn Inc, Bioinformat, S-11287 Stockholm, Sweden	Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pfizer; Pharmacia Corporation	Yan, RQ (corresponding author), Pharmacia & Upjohn Inc, Cell & Mol Biol, 301 Henrietta St, Kalamazoo, MI 49007 USA.			Yan, Riqiang/0000-0001-7195-7617				ASAMIODAKA A, 1995, BIOCHEMISTRY-US, V34, P10272, DOI 10.1021/bi00032a022; CAI XD, 1993, SCIENCE, V259, P514, DOI 10.1126/science.8424174; CITRON M, 1992, NATURE, V360, P372; De Strooper B, 1998, NATURE, V391, P387, DOI 10.1038/34910; DREYER RN, 1994, EUR J BIOCHEM, V224, P265, DOI 10.1111/j.1432-1033.1994.00265.x; Glenner G., 1984, SCIENCE, V255, P728; GOATE A, 1991, NATURE, V349, P704, DOI 10.1038/349704a0; HUSSAIN I, MOL CELL NEUROSCI; LADROR US, 1994, J BIOL CHEM, V269, P18422; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; MURRELL J, 1991, SCIENCE, V254, P97, DOI 10.1126/science.1925564; Naruse S, 1998, NEURON, V21, P1213, DOI 10.1016/S0896-6273(00)80637-6; NEILL D, 1994, J NEUROSCI RES, V39, P482, DOI 10.1002/jnr.490390415; Pirttila T, 1998, NEUROSCI LETT, V249, P21, DOI 10.1016/S0304-3940(98)00381-4; Saftig P, 1996, J BIOL CHEM, V271, P27241, DOI 10.1074/jbc.271.44.27241; Selkoe DJ, 1998, TRENDS CELL BIOL, V8, P447, DOI 10.1016/S0962-8924(98)01363-4; SUZUKI N, 1994, SCIENCE, V264, P1336, DOI 10.1126/science.8191290; Tatnell PJ, 1998, FEBS LETT, V441, P43, DOI 10.1016/S0014-5793(98)01522-1; Vassar R, 1999, SCIENCE, V286, P735, DOI 10.1126/science.286.5440.735	19	1282	1402	1	54	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					533	537		10.1038/990107	http://dx.doi.org/10.1038/990107			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591213				2022-12-28	WOS:000084013200057
J	Sanderson, TL; Best, JJK; Doody, GA; Owens, DGC; Johnstone, EC				Sanderson, TL; Best, JJK; Doody, GA; Owens, DGC; Johnstone, EC			Neuroanatomy of comorbid schizophrenia and learning disability: a controlled study	LANCET			English	Article							ADULT MENTAL DEFECTIVES; MAGNETIC-RESONANCE; BRAIN; ABNORMALITIES; PSYCHOSES; VOLUME; TOMOGRAPHY	Background Reasons for the higher frequency of schizophrenia in learning-disabled populations are uncertain. We investigated the neuroanatomical basis for this phenomenon by structural magnetic resonance imaging (MRI) in patients with learning disability and schizophrenia, learning-disabled patients, and patients with schizophrenia. Methods Age-matched and sex-matched patients with learning disability (20 cases), schizophrenia (25), and both disorders (23) underwent MRI scans of the brain. Whole brain areas and specific regions of interest were examined. 29 normal controls were also scanned. Findings The scans of the group with both disorders were closely similar to those of the schizophrenic group, in terms of both general structures and the structure of the amygdalahippocampus. However, the amygdala-hippocampus was significantly smaller on both sides than that of normal controls (left 4.1 vs 4.5 cm(3), p=0.011; right 4.2 vs 4.99 cm(3), p<0.0001). The brains of learning-disabled patients were generally smaller than those of the other three groups, but the amygdalohippocampal complexes were larger. Interpretation In terms of brain structure, patients with comorbid learning disability and schizophrenia resemble patients with schizophrenia and not those with learning disability. We suggest that the higher frequency of schizophrenia in learning-disabled patients is due to a greater tendency of schizophrenic patients to develop cognitive deficits, and that within the learning-disabled population there may be individuals whose deficits result from undiagnosed schizophrenia.	Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Edinburgh EH10 5HF, Midlothian, Scotland	Royal Infirmary of Edinburgh; University of Edinburgh	Johnstone, EC (corresponding author), Univ Edinburgh, Royal Edinburgh Hosp, Dept Psychiat, Morningside Pk, Edinburgh EH10 5HF, Midlothian, Scotland.		Doody, Gillian A/A-8930-2011	doody, gillian/0000-0002-3494-438X	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		BREIER A, 1992, ARCH GEN PSYCHIAT, V49, P921; BRUTON CJ, 1990, PSYCHOL MED, V20, P285, DOI 10.1017/S0033291700017608; CASTLE DJ, 1991, PSYCHOL MED, V21, P565, DOI 10.1017/S0033291700022194; COOPER AF, 1974, LANCET, V2, P851; Deb S, 1997, BRIT J PSYCHIAT, V171, P417, DOI 10.1192/bjp.171.5.417; DONE DJ, 1994, BRIT MED J, V309, P699, DOI 10.1136/bmj.309.6956.699; Doody GA, 1998, BRIT J PSYCHIAT, V173, P145, DOI 10.1192/bjp.173.2.145; Fukuzako H, 1996, BIOL PSYCHIAT, V39, P938, DOI 10.1016/0006-3223(95)00251-0; GREEN MF, 1989, SCHIZOPHRENIA BULL, V15, P91, DOI 10.1093/schbul/15.1.91; GUNTHERGENTA F, 1994, BRIT J PSYCHIAT, V164, P165, DOI 10.1192/bjp.164.2.165; HAMANO K, 1990, NEURORADIOLOGY, V32, P300, DOI 10.1007/BF00593049; HEATONWARD A, 1977, BRIT J PSYCHIAT, V130, P524; JAKOB H, 1986, J NEURAL TRANSM, V65, P303, DOI 10.1007/BF01249090; KESHAVAN MS, 1994, LANCET, V344, P1434, DOI 10.1016/S0140-6736(94)90599-1; Lawrie SM, 1999, LANCET, V353, P30, DOI 10.1016/S0140-6736(98)06244-8; LAWRIE SM, 1995, BRIT J PSYCHIAT, V167, P202, DOI 10.1192/bjp.167.2.202; Lawrie SM, 1998, BRIT J PSYCHIAT, V172, P110, DOI 10.1192/bjp.172.2.110; Lewis S, 1996, BRIT MED BULL, V52, P465; LEWIS SW, 1990, BRIT J PSYCHIAT, V157, P16, DOI 10.1192/S0007125000291824; MUIR WJ, 1998, COMPANION PSYCHIAT S; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; REID AH, 1972, BRIT J PSYCHIAT, V120, P213, DOI 10.1192/bjp.120.555.213; REID AH, 1972, BRIT J PSYCHIAT, V120, P205, DOI 10.1192/bjp.120.555.205; SHENTON ME, 1992, NEW ENGL J MED, V327, P604, DOI 10.1056/NEJM199208273270905; Smith AD, 1996, BRIT MED BULL, V52, P575; Spitzer RL, 1975, RES DIAGNOSTIC CRITE; SUDDATH RL, 1990, NEW ENGL J MED, V322, P789, DOI 10.1056/NEJM199003223221201; TURNER TH, 1989, PSYCHOL MED, V19, P301, DOI 10.1017/S0033291700012344; WALKER EF, 1994, NEUROPSYCHOLOGY SCHI; WALLACE CJ, 1993, LANCET, V342, P1252, DOI 10.1016/0140-6736(93)92354-V; Ward KE, 1996, SCHIZOPHR RES, V22, P197, DOI 10.1016/S0920-9964(96)00076-X; Weinberger D. R., 1995, P293	32	46	46	0	3	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1867	1871		10.1016/S0140-6736(99)01049-1	http://dx.doi.org/10.1016/S0140-6736(99)01049-1			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TF	10584724				2022-12-28	WOS:000083909100013
J	Lee, HJ; Ho, W				Lee, HJ; Ho, W			Single-bond formation and characterization with a scanning tunneling microscope	SCIENCE			English	Article							CO; ELECTRONS; MOLECULE; SURFACE; ATOMS; TIP; DISSOCIATION; SPECTROSCOPY; FECO	A scanning tunneling microscope (STM) was used to manipulate the bonding of a carbon monoxide (CO) molecule and to analyze the structure and vibrational properties of individual products. Individual iron (Fe) atoms were evaporated and coadsorbed with CO molecules on a silver(110) surface at 13 kelvin, A CO molecule was transferred from the surface to the STM tip and bonded with an Fe atom to form Fe(CO). A second CO molecule was similarly transferred and bonded with Fe(CO) to form Fe(CO)(2). Controlled bond formation and characterization at the single-bond level probe chemistry at the spatial limit.	Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA; Cornell Univ, Cornell Ctr Mat Res, Ithaca, NY 14853 USA	Cornell University; Cornell University	Ho, W (corresponding author), Cornell Univ, Atom & Solid State Phys Lab, Ithaca, NY 14853 USA.							Bartels L, 1997, PHYS REV LETT, V79, P697, DOI 10.1103/PhysRevLett.79.697; BURGHAUS U, 1995, SURF SCI, V331, P116, DOI 10.1016/0039-6028(95)00208-1; CROMMIE MF, 1993, SCIENCE, V262, P218, DOI 10.1126/science.262.5131.218; DUJARDIN G, 1992, SCIENCE, V255, P1232, DOI 10.1126/science.255.5049.1232; EIGLER DM, 1990, NATURE, V344, P524, DOI 10.1038/344524a0; ERLEY W, 1981, J VAC SCI TECHNOL, V18, P472, DOI 10.1116/1.570768; FOURNIER R, 1993, J CHEM PHYS, V99, P1801, DOI 10.1063/1.465297; Gimzewski JK, 1999, SCIENCE, V283, P1683, DOI 10.1126/science.283.5408.1683; Gonzalez-Blanco O, 1999, J CHEM PHYS, V110, P778, DOI 10.1063/1.478045; HIROTA S, 1994, J PHYS CHEM-US, V98, P6652, DOI 10.1021/j100077a035; Lauhon LJ, 1999, PHYS REV B, V60, pR8525, DOI 10.1103/PhysRevB.60.R8525; MCINTYRE BJ, 1994, SCIENCE, V265, P1415, DOI 10.1126/science.265.5177.1415; MOON DW, 1985, SURF SCI, V163, P215, DOI 10.1016/0039-6028(85)90859-3; PELAK RA, 1994, SURF SCI, V321, pL233, DOI 10.1016/0039-6028(94)90180-5; Stipe BC, 1998, PHYS REV LETT, V81, P1263, DOI 10.1103/PhysRevLett.81.1263; Stipe BC, 1999, PHYS REV LETT, V82, P1724, DOI 10.1103/PhysRevLett.82.1724; Stipe BC, 1999, REV SCI INSTRUM, V70, P137, DOI 10.1063/1.1149555; Stipe BC, 1998, SCIENCE, V280, P1732, DOI 10.1126/science.280.5370.1732; Stipe BC, 1997, PHYS REV LETT, V78, P4410, DOI 10.1103/PhysRevLett.78.4410; Tanaka K, 1997, CHEM PHYS LETT, V281, P285, DOI 10.1016/S0009-2614(97)01123-8	20	269	286	8	157	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 26	1999	286	5445					1719	1722		10.1126/science.286.5445.1719	http://dx.doi.org/10.1126/science.286.5445.1719			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576735				2022-12-28	WOS:000083912200033
J	Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J				Richter, P; de Boer, KS; Widmann, H; Kappelmann, N; Gringel, W; Grewing, M; Barnstedt, J			Discovery of molecular hydrogen in a high-velocity cloud of the Galactic halo	NATURE			English	Article							GAS; ABSORPTION; ORIGIN; IUE	The Milky Way's halo contains clouds of neutral hydrogen with high radial velocities which do not follow the general rotational motion of the Galaxy(1). Few distances to these high-velocity clouds are known(2,3), so even gross properties such as total mass are hard to determine. As a consequence, there is no generally accepted theory regarding their origin, One idea(4,5) is that they result from gas that has cooled after being ejected from the Galaxy through fountain-like flows powered by supernovae; another is that they are composed of gas, poor in heavy elements, which is falling onto the disk of the Milky Way from intergalactic space(6,7). The presence of molecular hydrogen, whose formation generally requires the presence of dust (and therefore gas, enriched in heavy elements), could help to distinguish between these possibilities. Here we report the discovery of molecular hydrogen absorption in a high-velocity cloud along the hue of sight to the Large Magellanic Cloud. We also derive for the same cloud an iron abundance which is half of the solar value. From these data, we conclude that gas in this cloud originated in the disk of the Milky Way.	Univ Bonn, Sternwarte, D-53121 Bonn, Germany; Univ Tubingen, Inst Astron & Astrophys, D-72076 Tubingen, Germany	University of Bonn; Eberhard Karls University of Tubingen	Richter, P (corresponding author), Univ Bonn, Sternwarte, Hugel 71, D-53121 Bonn, Germany.							Akeson RL, 1999, ASTROPHYS J, V523, P163, DOI 10.1086/307728; Barnstedt J, 1999, ASTRON ASTROPHYS SUP, V134, P561, DOI 10.1051/aas:1999156; Blitz L, 1999, ASTROPHYS J, V514, P818, DOI 10.1086/306963; Bomans DJ, 1996, ASTRON ASTROPHYS, V313, P101; BREGMAN JN, 1980, ASTROPHYS J, V236, P577, DOI 10.1086/157776; BURTON MG, 1992, ASTROPHYS J, V399, P563, DOI 10.1086/171947; DEBOER KS, 1990, ASTRON ASTROPHYS, V233, P523; DEBOER KS, 1987, SCI ACCOMPLISHMENTS, P485; FIELD GB, 1966, ANNU REV ASTRON ASTR, V4, P207, DOI 10.1146/annurev.aa.04.090166.001231; GREWING M, 1981, MITT ASTRON GES, V52, P79; JURA M, 1975, ASTROPHYS J, V197, P575, DOI 10.1086/153545; MCGEE RX, 1986, P ASTRON SOC AUST, V6, P358, DOI 10.1017/S1323358000027077; MORTON DC, 1975, ASTROPHYS J, V204, P1; Nichols JS, 1996, ASTRON J, V111, P517, DOI 10.1086/117803; OORT JH, 1970, ASTRON ASTROPHYS, V7, P381; PEI YCC, 1995, ASTROPHYS J, V454, P69, DOI 10.1086/176466; Putman ME, 1999, PUBL ASTRON SOC AUST, V16, P70, DOI 10.1071/AS99070; SAVAGE BD, 1981, ASTROPHYS J, V243, P460, DOI 10.1086/158613; SAVAGE BD, 1977, ASTROPHYS J, V216, P291, DOI 10.1086/155471; SHAPIRO PR, 1976, ASTROPHYS J, V205, P762, DOI 10.1086/154332; Spitzer L.  Jr., 1974, Astrophysical Journal. Letters to the Editor, V191, pL127, DOI 10.1086/181567; van Woerden H, 1999, NATURE, V400, P138, DOI 10.1038/22061; Wakker BP, 1997, ASTROPHYS J, V488, P216, DOI 10.1086/304682; WAKKER BP, 1991, ASTRON ASTROPHYS, V250, P499	24	53	53	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					386	387		10.1038/46492	http://dx.doi.org/10.1038/46492			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586876	Green Submitted			2022-12-28	WOS:000083913600047
J	Turner, H; Kinet, JP				Turner, H; Kinet, JP			Signalling through the high-affinity IgE receptor Fc epsilon RI	NATURE			English	Review							IMMUNOGLOBULIN-E-RECEPTOR; PLECKSTRIN HOMOLOGY DOMAINS; ACTIVATED T-CELLS; TYROSINE KINASE; MAST-CELLS; BETA-SUBUNIT; NUCLEAR FACTOR; BINDING-SITE; ALPHA-CHAIN; SRC KINASE	The Fc epsilon RI complex forms a high-affinity cell-surface receptor for the Fc region of antigen-specific immunoglobulin E (IgE) molecules. Fc epsilon RI is multimeric and is a member of a family of related antigen/Fc receptors which have conserved structural features and similar roles in initiating intracellular signalling cascades. In humans, Fc epsilon RI controls the activation of mast cells and basophils, and participates in IgE-mediated antigen presentation. Multivalent antigens bind and crosslink IgE molecules held at the cell surface by Fc epsilon RI. Receptor aggregation induces multiple signalling pathways that control diverse effector responses. These include the secretion of allergic mediators and induction of cytokine gene transcription, resulting in secretion of molecules such as interleukin-4, interleukin-6, tumour-necrosis factor-alpha and granulocyte-macrophage colony-stimulating factor. Fc epsilon RI is therefore central to the induction and maintenance of an allergic response and may confer physiological protection in parasitic infections.	Beth Israel Deaconess Med Ctr, Dept Pathol, Lab Allergy & Immunol, Boston, MA 02215 USA; Harvard Univ, Sch Med, Boston, MA 02215 USA	Harvard University; Beth Israel Deaconess Medical Center; Harvard University; Harvard Medical School	Turner, H (corresponding author), Beth Israel Deaconess Med Ctr, Dept Pathol, Lab Allergy & Immunol, 99 Brookline Ave, Boston, MA 02215 USA.							Adra CN, 1999, CLIN GENET, V55, P431, DOI 10.1034/j.1399-0004.1999.550606.x; ALBER G, 1991, J BIOL CHEM, V266, P22613; BLANK U, 1991, J BIOL CHEM, V266, P2639; CAMBIER JC, 1995, J IMMUNOL, V155, P3281; Chen RH, 1997, EMBO J, V16, P1351, DOI 10.1093/emboj/16.6.1351; COHEN GB, 1995, CELL, V80, P237, DOI 10.1016/0092-8674(95)90406-9; Costello PS, 1996, ONCOGENE, V13, P2595; Crespo P, 1997, NATURE, V385, P169, DOI 10.1038/385169a0; Daeron M, 1997, ANNU REV IMMUNOL, V15, P203, DOI 10.1146/annurev.immunol.15.1.203; Dombrowicz D, 1998, IMMUNITY, V8, P517, DOI 10.1016/S1074-7613(00)80556-7; ElHillal O, 1997, P NATL ACAD SCI USA, V94, P1919, DOI 10.1073/pnas.94.5.1919; Facchetti F, 1999, AM J PATHOL, V154, P1037, DOI 10.1016/S0002-9440(10)65356-4; Finco TS, 1998, IMMUNITY, V9, P617, DOI 10.1016/S1074-7613(00)80659-7; Garman SC, 1998, CELL, V95, P951, DOI 10.1016/S0092-8674(00)81719-5; Hall A, 1998, SCIENCE, V279, P509, DOI 10.1126/science.279.5350.509; Henry AJ, 1997, BIOCHEMISTRY-US, V36, P15568, DOI 10.1021/bi971299+; HILL MR, 1995, BRIT MED J, V311, P776, DOI 10.1136/bmj.311.7008.776; Honda Z, 1997, J BIOL CHEM, V272, P25753, DOI 10.1074/jbc.272.41.25753; HOTH M, 1992, NATURE, V355, P353, DOI 10.1038/355353a0; HUTCHINSON LE, 1995, J BIOL CHEM, V270, P16333, DOI 10.1074/jbc.270.27.16333; JOUVIN MHE, 1994, J BIOL CHEM, V269, P5918; Keown MB, 1998, BIOCHEMISTRY-US, V37, P8863, DOI 10.1021/bi972354h; Kimura T, 1997, J IMMUNOL, V159, P4426; Kimura T, 1997, J BIOL CHEM, V272, P13991, DOI 10.1074/jbc.272.21.13991; Kinet JP, 1999, ANNU REV IMMUNOL, V17, P931, DOI 10.1146/annurev.immunol.17.1.931; LETOURNEUR O, 1995, J BIOL CHEM, V270, P8249, DOI 10.1074/jbc.270.14.8249; Lin SQ, 1996, CELL, V85, P985, DOI 10.1016/S0092-8674(00)81300-8; Liu SK, 1999, CURR BIOL, V9, P67, DOI 10.1016/S0960-9822(99)80017-7; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MAURER D, 1995, J IMMUNOL, V154, P6285; MAURER D, 1994, J EXP MED, V179, P745, DOI 10.1084/jem.179.2.745; Moarefi I, 1997, NATURE, V385, P650, DOI 10.1038/385650a0; Nimnual AS, 1998, SCIENCE, V279, P560, DOI 10.1126/science.279.5350.560; Nishizumi H, 1997, J IMMUNOL, V158, P2350; OETTGEN HC, 1994, NATURE, V370, P367, DOI 10.1038/370367a0; Ottinger EA, 1998, J BIOL CHEM, V273, P729, DOI 10.1074/jbc.273.2.729; PAOLINI R, 1991, NATURE, V353, P855, DOI 10.1038/353855a0; Parekh AB, 1997, PHYSIOL REV, V77, P901, DOI 10.1152/physrev.1997.77.4.901; PRESTA L, 1994, J BIOL CHEM, V269, P26368; PRIBLUDA VS, 1994, P NATL ACAD SCI USA, V91, P11246, DOI 10.1073/pnas.91.23.11246; Putney JW, 1999, BIOESSAYS, V21, P38; Rameh LE, 1997, J BIOL CHEM, V272, P22059, DOI 10.1074/jbc.272.35.22059; Rao A, 1997, ANNU REV IMMUNOL, V15, P707, DOI 10.1146/annurev.immunol.15.1.707; Rawlings DJ, 1996, SCIENCE, V271, P822, DOI 10.1126/science.271.5250.822; RETH M, 1989, NATURE, V338, P383, DOI 10.1038/338383b0; Roa M, 1997, J IMMUNOL, V159, P2815; ROBERTSON MW, 1993, J BIOL CHEM, V268, P12736; Salim K, 1996, EMBO J, V15, P6241, DOI 10.1002/j.1460-2075.1996.tb01014.x; SANDFORD AJ, 1993, LANCET, V341, P332, DOI 10.1016/0140-6736(93)90136-5; SCHARENBERG AM, 1995, EMBO J, V14, P3385, DOI 10.1002/j.1460-2075.1995.tb07344.x; Scharenberg AM, 1998, CELL, V94, P5, DOI 10.1016/S0092-8674(00)81214-3; Sheets ED, 1999, CURR OPIN CHEM BIOL, V3, P95, DOI 10.1016/S1367-5931(99)80017-9; SHIRAKAWA T, 1994, NAT GENET, V7, P125, DOI 10.1038/ng0694-125; TAKIZAWA F, 1992, J EXP MED, V176, P469, DOI 10.1084/jem.176.2.469; Thomas ML, 1999, CURR OPIN IMMUNOL, V11, P270, DOI 10.1016/S0952-7915(99)80044-2; Tuosto L, 1996, J EXP MED, V184, P1161, DOI 10.1084/jem.184.3.1161; TURNER H, 1995, J BIOL CHEM, V270, P9500, DOI 10.1074/jbc.270.16.9500; Turner H, 1998, J EXP MED, V188, P527, DOI 10.1084/jem.188.3.527; Turner H, 1997, J EXP MED, V185, P43, DOI 10.1084/jem.185.1.43; Ujike A, 1999, J EXP MED, V189, P1573, DOI 10.1084/jem.189.10.1573; Vanhaesebroeck B, 1997, TRENDS BIOCHEM SCI, V22, P267, DOI 10.1016/S0968-0004(97)01061-X; Vonakis BM, 1997, J BIOL CHEM, V272, P24072, DOI 10.1074/jbc.272.38.24072; WEISS A, 1994, CELL, V76, P263, DOI 10.1016/0092-8674(94)90334-4; Yamaguchi M, 1997, J EXP MED, V185, P663, DOI 10.1084/jem.185.4.663; Zhang J, 1996, J EXP MED, V184, P71, DOI 10.1084/jem.184.1.71; Zhang WG, 1998, CELL, V92, P83, DOI 10.1016/S0092-8674(00)80901-0	66	580	606	0	35	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760		S			B24	B30		10.1038/35037021	http://dx.doi.org/10.1038/35037021			7	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VD	10586892	Bronze			2022-12-28	WOS:000083913900006
J	Honda, A; Nogami, M; Yokozeki, T; Yamazaki, M; Nakamura, H; Watanabe, H; Kawamoto, K; Nakayama, K; Morris, AJ; Frohman, MA; Kanaho, Y				Honda, A; Nogami, M; Yokozeki, T; Yamazaki, M; Nakamura, H; Watanabe, H; Kawamoto, K; Nakayama, K; Morris, AJ; Frohman, MA; Kanaho, Y			Phosphatidylinositol 4-phosphate 5-kinase alpha is a downstream effector of the small G protein ARF6 in membrane ruffle formation	CELL			English	Article							ADP-RIBOSYLATION FACTOR; LIPID KINASE FAMILY; GTP-GAMMA-S; PHOSPHOLIPASE-D; SIGNAL TRANSDUCTION; TYROSINE PHOSPHORYLATION; INOSITOL TRISPHOSPHATE; ENDOPLASMIC-RETICULUM; ACID PHOSPHOLIPIDS; PHOSPHATIDIC-ACID	Synthesis of phosphatidylinositol 4,5-bisphosphate [PI(4,5)P-2], a signaling phospholipid, is primarily carried out by phosphatidylinositol 4-phosphate 5-kinase [PI(4)P5K], which has been reported to be regulated by RhoA and Rad. Unexpectedly, we find that the GTP gamma S-dependent activator of PI(4)P5K alpha is the small G protein ADP-ribosylation factor (ARF) and that the activation strictly requires phosphatidic acid, the product of phospholipase D (PLD). In vivo, ARF6, but not ARF1 or ARF5, spatially coincides with PI(4)P5K alpha. This colocalization occurs in ruffling membranes formed upon AIF(4) and EGF stimulation and is blocked by dominant-negative ARF6. PLD2 similarly translocates to the ruffles, as does the PH domain of phospholipase C delta 1, indicating locally elevated PI(4,5)P-2. Thus, PI(4)P5K alpha is a downstream effector of ARF6 and when ARF6 is activated by agonist stimulation, it triggers recruitment of a diverse but interactive set of signaling molecules into sites of active cytoskeletal and membrane rearrangement.	Tokyo Inst Technol, Dept Biol Informat, Midori Ku, Yokohama, Kanagawa 2268501, Japan; Univ Tsukuba, Inst Biol Sci, Tsukuba, Ibaraki 3058752, Japan; SUNY Stony Brook, Dept Pharmacol Sci, Stony Brook, NY 11794 USA; SUNY Stony Brook, Inst Cell & Dev Biol, Stony Brook, NY 11794 USA	Tokyo Institute of Technology; University of Tsukuba; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook; State University of New York (SUNY) System; State University of New York (SUNY) Stony Brook	Kanaho, Y (corresponding author), Tokyo Metropolitan Inst Med Sci, Dept Pharmacol, Bunkyo Ku, 3-18-22 Honkomagome, Tokyo 1138613, Japan.		Watanabe, Hiroshi/GOP-0177-2022; Morris, Andrew/B-7869-2010; Nakayama, Kazuhisa/ABF-2924-2020	Watanabe, Hiroshi/0000-0001-8887-5407; Nakayama, Kazuhisa/0000-0001-7701-7183	NIGMS NIH HHS [GM54813, GM50388] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM054813, R01GM050388] Funding Source: NIH RePORTER	NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		AUGER KR, 1989, CELL, V57, P167, DOI 10.1016/0092-8674(89)90182-7; Azuma T, 1998, EMBO J, V17, P1362, DOI 10.1093/emboj/17.5.1362; BALCH WE, 1992, J BIOL CHEM, V267, P13053; BERRIDGE MJ, 1987, ANNU REV BIOCHEM, V56, P159, DOI 10.1146/annurev.bi.56.070187.001111; BERRIDGE MJ, 1984, NATURE, V312, P315, DOI 10.1038/312315a0; BILLAH MM, 1993, CURR OPIN IMMUNOL, V5, P114; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; BORONENKOV IV, 1995, J BIOL CHEM, V270, P2881, DOI 10.1074/jbc.270.7.2881; BROWN HA, 1993, CELL, V75, P1137, DOI 10.1016/0092-8674(93)90323-I; CANTLEY LC, 1991, CELL, V64, P281, DOI 10.1016/0092-8674(91)90639-G; Castellino AM, 1997, J BIOL CHEM, V272, P5861, DOI 10.1074/jbc.272.9.5861; CHONG LD, 1994, CELL, V79, P507, DOI 10.1016/0092-8674(94)90259-3; COCHET C, 1986, BIOCHEM J, V237, P25, DOI 10.1042/bj2370025; COCKCROFT S, 1994, SCIENCE, V263, P523, DOI 10.1126/science.8290961; Colley WC, 1997, CURR BIOL, V7, P191, DOI 10.1016/S0960-9822(97)70090-3; D'Souza-Schorey C, 1997, EMBO J, V16, P5445, DOI 10.1093/emboj/16.17.5445; Davis JN, 1997, MOL CELL BIOL, V17, P7398, DOI 10.1128/MCB.17.12.7398; DIVECHA N, 1995, BIOCHEM J, V309, P715, DOI 10.1042/bj3090715; DURONIO RJ, 1990, P NATL ACAD SCI USA, V87, P1506, DOI 10.1073/pnas.87.4.1506; Fensome A, 1996, CURR BIOL, V6, P730, DOI 10.1016/S0960-9822(09)00454-0; Franco M, 1999, EMBO J, V18, P1480, DOI 10.1093/emboj/18.6.1480; Fujii M, 1999, BIOCHEM BIOPH RES CO, V254, P284, DOI 10.1006/bbrc.1998.9936; FUKAMI K, 1992, NATURE, V359, P150, DOI 10.1038/359150a0; Godi A, 1999, NAT CELL BIOL, V1, P280, DOI 10.1038/12993; HAMMOND SM, 1995, J BIOL CHEM, V270, P29640; Hammond SM, 1997, J BIOL CHEM, V272, P3860, DOI 10.1074/jbc.272.6.3860; HARTWIG JH, 1995, CELL, V82, P643, DOI 10.1016/0092-8674(95)90036-5; HAY JC, 1995, NATURE, V374, P173, DOI 10.1038/374173a0; Hosaka M, 1996, J BIOCHEM-TOKYO, V120, P813; Ishihara H, 1996, J BIOL CHEM, V271, P23611, DOI 10.1074/jbc.271.39.23611; Ishihara H, 1998, J BIOL CHEM, V273, P8741, DOI 10.1074/jbc.273.15.8741; Itoh T, 1998, J BIOL CHEM, V273, P20292, DOI 10.1074/jbc.273.32.20292; JANMEY PA, 1987, NATURE, V325, P362, DOI 10.1038/325362a0; JENKINS GH, 1994, J BIOL CHEM, V269, P11547; KAHN RA, 1992, J BIOL CHEM, V267, P13039; LASSING I, 1985, NATURE, V314, P472, DOI 10.1038/314472a0; LENHARD JM, 1992, J BIOL CHEM, V267, P13047; Liang JO, 1997, J BIOL CHEM, V272, P4141, DOI 10.1074/jbc.272.7.4141; Loijens JC, 1996, ADV ENZYME REGUL, V36, P115, DOI 10.1016/0065-2571(95)00005-4; Loijens JC, 1996, J BIOL CHEM, V271, P32937, DOI 10.1074/jbc.271.51.32937; MIYAZAWA A, 1988, MOL IMMUNOL, V25, P1025; MORITZ A, 1992, J BIOL CHEM, V267, P7207; NISHIZUKA Y, 1984, NATURE, V308, P693, DOI 10.1038/308693a0; Radhakrishna H, 1996, J CELL BIOL, V134, P935, DOI 10.1083/jcb.134.4.935; Radhakrishna H, 1999, J CELL SCI, V112, P855; Rameh LE, 1997, NATURE, V390, P192, DOI 10.1038/36621; RANDAZZO PA, 1994, J BIOL CHEM, V269, P10758; Randazzo PA, 1997, J BIOL CHEM, V272, P7688; Ren XD, 1996, MOL BIOL CELL, V7, P435, DOI 10.1091/mbc.7.3.435; RIDLEY AJ, 1992, CELL, V70, P401, DOI 10.1016/0092-8674(92)90164-8; Schmidt M, 1996, J BIOL CHEM, V271, P2422, DOI 10.1074/jbc.271.5.2422; Slaaby R, 1998, J BIOL CHEM, V273, P33722, DOI 10.1074/jbc.273.50.33722; SMITH CD, 1989, J BIOL CHEM, V264, P3206; Steed PM, 1996, BIOCHEMISTRY-US, V35, P5229, DOI 10.1021/bi952370j; Sung TC, 1999, J BIOL CHEM, V274, P494, DOI 10.1074/jbc.274.1.494; Sung TC, 1999, J BIOL CHEM, V274, P3659, DOI 10.1074/jbc.274.6.3659; TERUI T, 1994, J BIOL CHEM, V269, P28130; Toda K, 1999, FEBS LETT, V442, P221, DOI 10.1016/S0014-5793(98)01646-9; Toker A, 1998, CURR OPIN CELL BIOL, V10, P254, DOI 10.1016/S0955-0674(98)80148-8; Tolias KF, 1998, MOL CELL BIOL, V18, P762, DOI 10.1128/MCB.18.2.762; TOLIAS KF, 1995, J BIOL CHEM, V270, P17656, DOI 10.1074/jbc.270.30.17656; TORII S, 1995, J BIOL CHEM, V270, P11574, DOI 10.1074/jbc.270.19.11574; URUMOW T, 1990, FEBS LETT, V263, P15, DOI 10.1016/0014-5793(90)80694-E; URUMOW T, 1986, FEBS LETT, V207, P253, DOI 10.1016/0014-5793(86)81499-5; Varnai P, 1998, J CELL BIOL, V143, P501, DOI 10.1083/jcb.143.2.501; Wymann MP, 1998, BBA-MOL CELL BIOL L, V1436, P127, DOI 10.1016/S0005-2760(98)00139-8; Yamazaki M, 1999, J BIOL CHEM, V274, P6035, DOI 10.1074/jbc.274.10.6035	67	664	676	2	25	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					521	532		10.1016/S0092-8674(00)81540-8	http://dx.doi.org/10.1016/S0092-8674(00)81540-8			12	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589680	Bronze			2022-12-28	WOS:000083986300011
J	Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ				Roelvink, PW; Lee, GM; Einfeld, DA; Kovesdi, I; Wickham, TJ			Identification of a conserved receptor-binding site on the fiber proteins of CAR-recognizing adenoviridae	SCIENCE			English	Article							INFLUENZA-VIRUS HEMAGGLUTININ; GP120 ENVELOPE GLYCOPROTEIN; CELLULAR RECEPTORS; SIALIC-ACID; SUBGROUP-C; DOMAIN; ATTACHMENT; SEROTYPES; TYPE-2	The human adenovirus serotype 5 (Ad5) is used widely for applications in human gene therapy. Cellular attachment of Ad5 is mediated by binding of the carboxyl-terminal knob of its fiber coat protein to the Coxsackie adenovirus receptor (CAR) protein. However, Ad5 binding to CAR hampers the development of adenovirus vectors capable of specifically targeting (diseased) tissues or organs, Through sequence analysis and mutagenesis, a conserved receptor-binding region was identified on the side of three divergent CAR-binding knobs. The feasibility of simultaneous CAR ablation and redirection of an adenovirus to a new receptor is demonstrated.	GenVec Inc, Gaithersburg, MD 20879 USA		Roelvink, PW (corresponding author), GenVec Inc, 65 W Watkins Mill Rd, Gaithersburg, MD 20879 USA.			Kovesdi, Imre/0000-0002-0322-3969				BAI M, 1994, J VIROL, V68, P5925, DOI 10.1128/JVI.68.9.5925-5932.1994; Bergelson JM, 1997, SCIENCE, V275, P1320, DOI 10.1126/science.275.5304.1320; Bewley MC, 1999, SCIENCE, V286, P1579, DOI 10.1126/science.286.5444.1579; Brough DE, 1996, J VIROL, V70, P6497, DOI 10.1128/JVI.70.9.6497-6501.1996; Einfeld DA, 1999, J VIROL, V73, P9130, DOI 10.1128/JVI.73.11.9130-9136.1999; Freimuth P, 1999, J VIROL, V73, P1392, DOI 10.1128/JVI.73.2.1392-1398.1999; HENRY LJ, 1994, J VIROL, V68, P5239, DOI 10.1128/JVI.68.8.5239-5246.1994; HORWITZ MS, 1990, VIROLOGY, V2, P1679; Kwong PD, 1998, NATURE, V393, P648, DOI 10.1038/31405; LOUIS N, 1994, J VIROL, V68, P4104, DOI 10.1128/JVI.68.6.4104-4106.1994; Rizzuto CD, 1998, SCIENCE, V280, P1949, DOI 10.1126/science.280.5371.1949; Roelvink PW, 1996, J VIROL, V70, P7614, DOI 10.1128/JVI.70.11.7614-7621.1996; Roelvink PW, 1998, J VIROL, V72, P7909, DOI 10.1128/JVI.72.10.7909-7915.1998; ROELVINK PW, UNPUB; SAUTER NK, 1992, BIOCHEMISTRY-US, V31, P9609, DOI 10.1021/bi00155a013; SCHNURR D, 1993, INTERVIROLOGY, V36, P79, DOI 10.1159/000150325; SHENK T, 1996, FIELDS VIROLOGY, V2, P2111; STEVENSON SC, 1995, J VIROL, V69, P2850, DOI 10.1128/JVI.69.5.2850-2857.1995; Tomko RP, 1997, P NATL ACAD SCI USA, V94, P3352, DOI 10.1073/pnas.94.7.3352; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILSON IA, 1984, CELL, V37, P767, DOI 10.1016/0092-8674(84)90412-4; Wyatt R, 1998, NATURE, V393, P705, DOI 10.1038/31514; Xia D, 1995, Curr Top Microbiol Immunol, V199 ( Pt 1), P39; XIA D, 1994, STRUCTURE, V2, P1259, DOI 10.1016/S0969-2126(94)00126-X; YEH HY, 1994, VIRUS RES, V33, P179	25	320	337	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1568	1571		10.1126/science.286.5444.1568	http://dx.doi.org/10.1126/science.286.5444.1568			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567265				2022-12-28	WOS:000083768300061
J	Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL				Walker, EH; Perisic, O; Ried, C; Stephens, L; Williams, RL			Structural insights into phosphoinositide 3-kinase catalysis and signalling	NATURE			English	Article							PROTEIN-KINASE; RAS; PHOSPHORYLATION; PI-3-KINASE; DOMAIN	Phosphoinositide 3-kinases (PI3Ks) are ubiquitous lipid kinases that function both as signal transducers downstream of cell-surface receptors and in constitutive intracellular membrane and protein trafficking pathways. All PI3Ks are dual-specificity enzymes with a lipid kinase activity which phosphorylates phosphoinositides at the 3-hydroxyl, and a protein kinase activity. The products of PI3K-catalysed reactions, phosphatidylinositol 3,4,5-trisphosphate (PtdIns(3,4,5)P-3), PtdIns(3,4)P-2 and PtdIns(3)P, are second messengers in a variety of signal transduction pathways, including those essential to cell proliferation, adhesion, survival, cytoskeletal rearrangement and vesicle trafficking(1.2). Here we report the 2.2 Angstrom X-ray crystallographic structure of the catalytic subunit of PI3K gamma, the class I enzyme that is activated by heterotrimeric G-protein beta gamma subunits and pas. PI3K gamma has a modular organization centred around a helical-domain spine, with C2 and catalytic domains positioned to interact with phospholipid membranes,:md a Ras-binding domain placed against the catalytic domain where if could drive allosteric activation of the enzyme.	MRC Ctr, MRC Lab Mol Biol, Cambridge CB2 2QH, England; Babraham Inst, Cambridge CB2 4AT, England	MRC Laboratory Molecular Biology; UK Research & Innovation (UKRI); Biotechnology and Biological Sciences Research Council (BBSRC); Babraham Institute	Williams, RL (corresponding author), MRC Ctr, MRC Lab Mol Biol, Hills Rd, Cambridge CB2 2QH, England.	rlw@mrc-lmb.cam.ac.uk		stephens, len/0000-0002-2771-3487; Perisic, Olga/0000-0002-3842-2896; Williams, Roger/0000-0001-7754-4207	Medical Research Council [MC_U105184308] Funding Source: Medline; MRC [MC_U105184308] Funding Source: UKRI	Medical Research Council(UK Research & Innovation (UKRI)Medical Research Council UK (MRC)); MRC(UK Research & Innovation (UKRI)Medical Research Council UK (MRC))		BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Bondeva T, 1998, SCIENCE, V282, P293, DOI 10.1126/science.282.5387.293; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; delaFortelle E, 1997, METHOD ENZYMOL, V276, P472, DOI 10.1016/S0076-6879(97)76073-7; Dennis PB, 1999, CURR OPIN GENET DEV, V9, P49, DOI 10.1016/S0959-437X(99)80007-0; DHAND R, 1994, EMBO J, V13, P522, DOI 10.1002/j.1460-2075.1994.tb06290.x; Domin J, 1997, FEBS LETT, V410, P91, DOI 10.1016/S0014-5793(97)00617-0; Essen LO, 1997, BIOCHEMISTRY-US, V36, P2753, DOI 10.1021/bi962466t; Groves MR, 1999, CELL, V96, P99, DOI 10.1016/S0092-8674(00)80963-0; Huang L, 1998, NAT STRUCT BIOL, V5, P422, DOI 10.1038/nsb0698-422; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kim K, 1997, J AM CHEM SOC, V119, P11096, DOI 10.1021/ja972110k; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; Krugmann S, 1999, J BIOL CHEM, V274, P17152, DOI 10.1074/jbc.274.24.17152; LESLIE AGW, 1992, JOINT CCP4 ESF EACMB, V26; Marshall CJ, 1996, CURR OPIN CELL BIOL, V8, P197, DOI 10.1016/S0955-0674(96)80066-4; MOODIE SA, 1995, ONCOGENE, V11, P447; NASSAR M, 1995, NATURE, V375, P554, DOI 10.1038/375554a0; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Rao VD, 1998, CELL, V94, P829, DOI 10.1016/S0092-8674(00)81741-9; RodriguezViciana P, 1997, CELL, V89, P457, DOI 10.1016/S0092-8674(00)80226-3; STACK JH, 1994, J BIOL CHEM, V269, P31552; Stephens LR, 1997, CELL, V89, P105, DOI 10.1016/S0092-8674(00)80187-7; STOYANOV B, 1995, SCIENCE, V269, P690, DOI 10.1126/science.7624799; Taylor SS, 1999, PHARMACOL THERAPEUT, V82, P133, DOI 10.1016/S0163-7258(99)00007-8; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Toker A, 1997, NATURE, V387, P673, DOI 10.1038/42648; Vanhaesebroeck B, 1999, EMBO J, V18, P1292, DOI 10.1093/emboj/18.5.1292; Vetter IR, 1999, CELL, V97, P635, DOI 10.1016/S0092-8674(00)80774-6; Wymann MP, 1996, MOL CELL BIOL, V16, P1722; Yamaguchi H, 1996, NATURE, V384, P484, DOI 10.1038/384484a0	31	387	405	1	30	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 18	1999	402	6759					313	320		10.1038/46319	http://dx.doi.org/10.1038/46319			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257ZP	10580505				2022-12-28	WOS:000083813700055
J	Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW				Sutton, LN; Adzick, NS; Bilaniuk, LT; Johnson, MP; Crombleholme, TM; Flake, AW			Improvement in hindbrain herniation demonstrated by serial fetal magnetic resonance imaging following fetal surgery for myelomeningocele	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							CHIARI-II MALFORMATION; SPINAL-CORD INJURY; IN-UTERO; DEFORMITY; CHILDREN; BIFIDA; LEVEL	Context Hindbrain herniation occurs in a large percentage of children with myelomeningocele and is the leading cause of death in this population. The effect of early fetal closure of myelomeningocele on hindbrain herniation is unknown. Objective To determine whether early fetal closure of myelomeningocele affects hindbrain herniation, Design Case series of patients undergoing fetal myelomeningocele closure with serial measurements of hindbrain herniation and a mean follow-up of 182 days, Setting Tertiary care medical center. Participants Ten patients undergoing fetal myelomeningocele closure at 22 to 25 weeks' gestation between March 1998 and February 1999. Main Outcome Measures Need for shunt placement; degree of hindbrain herniation (grades 0-3) found on magnetic resonance imaging (MRI) performed prior to surgery and 3 and 6 weeks after fetal surgery, as well as shortly after birth; gestational age at delivery. Results All initial fetal MRI scans performed at 19 to 24 weeks' gestation showed significant (grade 3) cerebellar herniation and absence of spinal fluid spaces around the cerebellum Six fetuses were delivered electively at 36 weeks' gestation after lung maturity was established. The other 4 were delivered prematurely, at 25, 30, 30, and 31 weeks of gestation, and the 25-week gestation neonate died. All 9 surviving neonates showed improvement in the hindbrain hernia at the 3-week postoperative fetal scan (grade 2, n = 4; grade 1, n = 5). On the postnatal scan, all patients showed grade 1 hindbrain herniation. Only 1 patient required placement of a ventriculoperitoneal shunt. Conclusion In this series of patients, fetal myelomeningocele closure resulted in improvement in hindbrain herniation as demonstrated by serial MRI scans.	Childrens Hosp Philadelphia, Div Neurosurg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Div Pediat Gen & Thorac Surg, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Ctr Fetal Diag & Treatment, Philadelphia, PA 19104 USA; Childrens Hosp Philadelphia, Neuroradiol Sect, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Surg, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Radiol, Philadelphia, PA 19104 USA; Univ Penn, Sch Med, Dept Obstet & Gynecol, Philadelphia, PA 19104 USA	University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; Pennsylvania Medicine; Childrens Hospital of Philadelphia; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania; University of Pennsylvania	Sutton, LN (corresponding author), Childrens Hosp Philadelphia, Div Neurosurg, 34th St & Civic Ctr Blvd, Philadelphia, PA 19104 USA.		Crombleholme, Timothy/Y-1477-2019					Adzick NS, 1998, LANCET, V352, P1675, DOI 10.1016/S0140-6736(98)00070-1; ADZICK NS, 1994, LANCET, V343, P897, DOI 10.1016/S0140-6736(94)90012-4; BABCOOK CJ, 1994, RADIOLOGY, V190, P703, DOI 10.1148/radiology.190.3.8115615; Bannister CM, 1998, EUR J PEDIATR SURG, V8, P15, DOI 10.1055/s-2008-1071245; BELL WO, 1987, J NEUROSURG, V66, P812, DOI 10.3171/jns.1987.66.6.0812; BONO R, 1993, ITAL J NEUROL SCI, V14, P553, DOI 10.1007/BF02339214; Bruner JP, 1999, AM J OBSTET GYNECOL, V180, P153, DOI 10.1016/S0002-9378(99)70167-5; Coniglio SJ, 1996, DEV MED CHILD NEUROL, V38, P675; Dias M S, 1993, Neurosurg Clin N Am, V4, P715; Dias MS, 1999, PEDIATR NEUROSURG, V30, P108, DOI 10.1159/000028773; ELGAMMAL T, 1988, AM J ROENTGENOL, V150, P163, DOI 10.2214/ajr.150.1.163; HEFFEZ DS, 1990, NEUROSURGERY, V26, P987, DOI 10.1227/00006123-199006000-00011; HOFFMAN HJ, 1987, NEUROSURGERY, V21, P347, DOI 10.1227/00006123-198709000-00012; Hutchins GM, 1996, PEDIATR PATHOL LAB M, V16, P701, DOI 10.1080/107710496175327; KOLLIAS SS, 1992, RADIOLOGY, V185, P109, DOI 10.1148/radiology.185.1.1523291; Lary J M, 1996, MMWR CDC Surveill Summ, V45, P15; McLone DG, 1998, NEUROSURG CLIN N AM, V9, P111; MCLONE DG, 1992, AM J NEURORADIOL, V13, P463; MEULI M, 1995, NAT MED, V1, P342, DOI 10.1038/nm0495-342; OHARA IB, 1999, ATLAS ANESTHESIA; OSAKA K, 1978, J NEUROSURG, V49, P711, DOI 10.3171/jns.1978.49.5.0711; PATTEN BM, 1953, AM J ANAT, V93, P365, DOI 10.1002/aja.1000930304; Quinn TM, 1997, OBSTET GYN CLIN N AM, V24, P143, DOI 10.1016/S0889-8545(05)70294-1; Tulipan N, 1998, PEDIATR NEUROSURG, V29, P274, DOI 10.1159/000028735; Tulipan N, 1998, PEDIATR NEUROSURG, V28, P177, DOI 10.1159/000028645; WOLPERT SM, 1988, AM J NEURORADIOL, V9, P1075; XU XM, 1991, J COMP NEUROL, V313, P103, DOI 10.1002/cne.903130108	27	298	305	0	12	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1826	1831		10.1001/jama.282.19.1826	http://dx.doi.org/10.1001/jama.282.19.1826			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573273	Bronze			2022-12-28	WOS:000083615700025
J	Novack, DH				Novack, DH			Roxanne	ANNALS OF INTERNAL MEDICINE			English	Editorial Material									Med Coll Penn & Hahnemann Univ, Div Med Educ, Philadelphia, PA 19129 USA	Drexel University	Novack, DH (corresponding author), Med Coll Penn & Hahnemann Univ, Div Med Educ, 2900 Queen Lane, Philadelphia, PA 19129 USA.	Dennis.Novack@drexel.edu							0	0	0	0	0	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					784	785		10.7326/0003-4819-131-10-199911160-00012	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00012			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577304				2022-12-28	WOS:000083680100011
J	Giri, S; Thompson, PD; Kiernan, FJ; Clive, J; Fram, DB; Mitchel, JF; Hirst, JA; McKay, RG; Waters, DD				Giri, S; Thompson, PD; Kiernan, FJ; Clive, J; Fram, DB; Mitchel, JF; Hirst, JA; McKay, RG; Waters, DD			Clinical and angiographic characteristics of exertion-related acute myocardial infarction	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article; Proceedings Paper	71st Scientific Session of the American-Heart-Association	NOV 08-12, 1998	DALLAS, TX	Amer Heart Assoc			CORONARY-ARTERY DISEASE; PHYSICAL-ACTIVITY; HEART-DISEASE; PUBLIC-HEALTH; EXERCISE; ANGINA; DEATH; ANGIOPLASTY; THROMBUS; MEN	Context Vigorous physical exertion transiently increases the risk of acute myocardial infarction (MI), but little is known about the clinical characteristics of exertion-related MI. Objective To compare the clinical and angiographic characteristics of patients who had an exertion-related acute MI vs those who experienced an MI not related to exertion. Design and Setting Prospective observational cohort study of patients with an acute MI referred to a tertiary care hospital for primary angioplasty. Patients Of 1048 patients with acute MI, 640 (64 who experienced an exertion-related MI and 576 who did not) were selected for treatment with primary angioplasty and admitted between August 1995 and November 1998. Main Outcome Measures Clinical characteristics of the patients, including their habitual physical activity (determined by the Framingham Physical Activity Index and the Lipid Research Clinic Physical Activity Questionnaire), angiographic findings during coronary angiography, and the relative risk (RR) of MI during exertion. Results Patients who experienced exertion-related MI were more frequently men (86% vs 68%), hyperlipidemic (62% vs 40%), and smokers 59% vs 37%), were more likely to present with ventricular fibrillation (20% vs 11%), Killip classification III or IV heart failure (44% vs 22%), single-vessel disease (50% vs 28%), and a large thrombus in the infarct artery (64% vs 35%) and were more likely to be classified as having very low or low activity (84% vs 66%). The RR of experiencing an MI during exertion was 10.1 times greater than the risk at other times (95% confidence interval [CI], 1.6-65.6), with the highest risk among patients classified as very low active (RR, 30.5; 95% CI, 4.4-209.9) and low active (RR, 20.9; 95% CI, 3.1-142.1). Conclusion These results show that exertion-related Mts occur in habitually inactive people with multiple cardiac risk factors. These individuals may benefit from mod est exercise training and aggressive risk-factor modification before they perform vigorous physical activity.	Hartford Hosp, Div Cardiol, Hartford, CT 06102 USA	Hartford Hospital	Thompson, PD (corresponding author), Hartford Hosp, Div Cardiol, 80 Seymour St, Hartford, CT 06102 USA.	pthomps@harthosp.org			NATIONAL CENTER FOR RESEARCH RESOURCES [M01RR006192] Funding Source: NIH RePORTER; NCRR NIH HHS [MO1RR06192] Funding Source: Medline	NATIONAL CENTER FOR RESEARCH RESOURCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR))		AINSWORTH BE, 1993, MED SCI SPORT EXER, V25, P71, DOI 10.1249/00005768-199301000-00011; ANDERSON TJ, 1995, J AM COLL CARDIOL, V26, P1235, DOI 10.1016/0735-1097(95)00327-4; BLACK A, 1975, ANGIOLOGY, V26, P759; BRESNAHAN DR, 1985, J AM COLL CARDIOL, V6, P285, DOI 10.1016/S0735-1097(85)80161-3; CAMPEAU L, 1976, CIRCULATION, V54, P522, DOI 10.1161/circ.54.3.947585; CIAMPRICOTTI R, 1994, AM J CARDIOL, V73, P219, DOI 10.1016/0002-9149(94)90222-4; DAFOE W, 1993, CLIN CARDIAC REHABIL, V1, P359; DAVIES MJ, 1985, BRIT HEART J, V53, P363; ELLIS SG, 1990, CIRCULATION, V82, P1193, DOI 10.1161/01.CIR.82.4.1193; FUSTER V, 1992, NEW ENGL J MED, V326, P242, DOI 10.1056/NEJM199201233260406; GARCIAPALMIERI MR, 1982, AM J CARDIOL, V50, P749, DOI 10.1016/0002-9149(82)91229-2; GORDON JB, 1989, J CLIN INVEST, V83, P1946, DOI 10.1172/JCI114103; HASKELL WL, 1989, J AM COLL CARDIOL, V14, P1025, DOI 10.1016/0735-1097(89)90485-3; HUNG J, 1995, CIRCULATION, V92, P2432, DOI 10.1161/01.CIR.92.9.2432; KANNEL WB, 1979, ARCH INTERN MED, V139, P857, DOI 10.1001/archinte.139.8.857; KESTIN AS, 1993, CIRCULATION, V88, P1502, DOI 10.1161/01.CIR.88.4.1502; Kimball BP, 1996, J AM COLL CARDIOL, V27, P543, DOI 10.1016/0735-1097(95)00511-0; Kvernmo HD, 1997, THROMB RES, V87, P559, DOI 10.1016/S0049-3848(97)00185-0; LACOSTE L, 1995, CIRCULATION, V92, P3172, DOI 10.1161/01.CIR.92.11.3172; LESPERANCE J, 1989, AM J CARDIOL, V64, P462, DOI 10.1016/0002-9149(89)90421-9; LITTLE WC, 1988, CIRCULATION, V78, P1157, DOI 10.1161/01.CIR.78.5.1157; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; MITTLEMAN MA, 1993, NEW ENGL J MED, V329, P1677, DOI 10.1056/NEJM199312023292301; PASSAMANI E, 1985, NEW ENGL J MED, V312, P932; PATE RR, 1995, JAMA-J AM MED ASSOC, V273, P402, DOI 10.1001/jama.273.5.402; POWELL KE, 1987, ANNU REV PUBL HEALTH, V8, P253, DOI 10.1146/annurev.publhealth.8.1.253; POWELL KE, 1985, PUBLIC HEALTH REP, V100, P118; SISCOVICK DS, 1984, NEW ENGL J MED, V311, P874, DOI 10.1056/NEJM198410043111402; STROES ESG, 1995, LANCET, V346, P467, DOI 10.1016/S0140-6736(95)91322-X; SZYMANSKI LM, 1994, J APPL PHYSIOL, V77, P2305, DOI 10.1152/jappl.1994.77.5.2305; THOMPSON PD, 1982, JAMA-J AM MED ASSOC, V247, P2535, DOI 10.1001/jama.247.18.2535; THOMPSON PD, 1979, JAMA-J AM MED ASSOC, V242, P1265, DOI 10.1001/jama.242.12.1265; TOFLER GH, 1990, AM J CARDIOL, V66, P22, DOI 10.1016/0002-9149(90)90729-K; WILLICH SN, 1993, NEW ENGL J MED, V329, P1684, DOI 10.1056/NEJM199312023292302; WINNIFORD MD, 1986, CIRCULATION, V73, P662, DOI 10.1161/01.CIR.73.4.662	35	116	122	0	6	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1731	1736		10.1001/jama.282.18.1731	http://dx.doi.org/10.1001/jama.282.18.1731			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Conference Proceedings Citation Index - Science (CPCI-S)	General & Internal Medicine	251XJ	10568645	Bronze			2022-12-28	WOS:000083471400027
J	Cohen, LG				Cohen, LG			Harry James	ANNALS OF INTERNAL MEDICINE			English	Editorial Material																			0	0	0	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					710	711		10.7326/0003-4819-131-9-199911020-00014	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00014			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577336				2022-12-28	WOS:000083446200012
J	Hunink, MGM; Kuntz, KM; Fleischmann, KE; Brady, TJ				Hunink, MGM; Kuntz, KM; Fleischmann, KE; Brady, TJ			Noninvasive imaging for the diagnosis of coronary artery disease: Focusing the development of new diagnostic technology	ANNALS OF INTERNAL MEDICINE			English	Article							ELECTRON-BEAM CT; COMPUTED-TOMOGRAPHY; ANGIOGRAPHY; METAANALYSIS; STENOSES; RECONSTRUCTIONS; CALCIFICATION; PERFORMANCE; CALCIUM	Background: New tests, such as magnetic resonance imaging (MRI) and electron-beam computed tomography (CT), are being developed for the diagnosis of coronary artery disease. Objective: To determine the conditions that a new test must meet to be a cost-effective alternative to established imaging tests. Design: Decision model and cost-effectiveness analysis. Data Sources: Literature review and meta-analysis. Target Population: 55-year-old men and 65-year-old women presenting with chest pain. Time Horizon: Lifetime of the patient. Perspective: Health care policy. Interventions: MRI, electron-beam CT, exercise echocardiography, exercise single-photon emission CT, and coronary angiography. Outcome Measures: Target sensitivity and specificity values for a new noninvasive test. Results of Base-Case Analysis: Assuming that society is willing to pay $75 000 per quality-adjusted life-year (QALY) gained, a new test that costs $1000 would need a sensitivity of 94% and a specificity of 90% to be cost-effective. Results of Sensitivity Analysis: Assuming that society is willing to pay $50 000 per QALY gained, a new test that costs $1000 or more would never be cost-effective. For a test that costs $500, the sensitivity and specificity must each be 95%. Conclusions: New imaging techniques, such as MRI and electron-beam CT, must be relatively inexpensive and have excellent sensitivity and specificity to be cost-effective compared with other techniques for the diagnosis of coronary artery disease. Similar analyses in other areas of health care may help to focus the development of new diagnostic technology.	Erasmus MC, Dept Epidemiol & Biostat, NL-3000 DR Rotterdam, Netherlands; Harvard Univ, Sch Publ Hlth, Ctr Risk Anal, Boston, MA 02114 USA; Univ Calif San Francisco, Sch Med, Div Cardiol, San Francisco, CA USA; Erasmus MC, Dept Radiol, NL-3000 DR Rotterdam, Netherlands; Harvard Univ, Sch Med, Boston, MA USA; Massachusetts Gen Hosp, Ctr Innovat Minimally Invas Therapy, Partners Healthcare Syst, Boston, MA 02114 USA	Erasmus University Rotterdam; Erasmus MC; Harvard University; Harvard T.H. Chan School of Public Health; University of California System; University of California San Francisco; Erasmus University Rotterdam; Erasmus MC; Harvard University; Harvard Medical School; Harvard University; Massachusetts General Hospital; Partners Healthcare System	Hunink, MGM (corresponding author), Erasmus MC, Dept Epidemiol & Biostat, Room EE21-40A,Box 1738, NL-3000 DR Rotterdam, Netherlands.	hunink@epib.fgg.eur.nl			NATIONAL HEART, LUNG, AND BLOOD INSTITUTE [K08HL002964] Funding Source: NIH RePORTER; NHLBI NIH HHS [1K08HL02964-01] Funding Source: Medline	NATIONAL HEART, LUNG, AND BLOOD INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI)); NHLBI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI))		Achenbach S, 1998, AM J ROENTGENOL, V170, P895, DOI 10.2214/ajr.170.4.9530029; Achenbach S, 1998, NEW ENGL J MED, V339, P1964, DOI 10.1056/NEJM199812313392702; Broderick LS, 1996, AM J ROENTGENOL, V167, P439, DOI 10.2214/ajr.167.2.8686622; Budinger TF, 1998, RADIOLOGY, V208, P573, DOI 10.1148/radiology.208.3.9722831; Budoff MJ, 1996, CIRCULATION, V93, P898, DOI 10.1161/01.CIR.93.5.898; CARO JJ, 1991, AM J ROENTGENOL, V156, P825, DOI 10.2214/ajr.156.4.1825900; deVries SO, 1996, ACAD RADIOL, V3, P361, DOI 10.1016/S1076-6332(96)80257-1; Fleischmann KE, 1998, JAMA-J AM MED ASSOC, V280, P913, DOI 10.1001/jama.280.10.913; GOLD MR, 1996, COST EFFECTIVE HLTH; HANLEY JA, 1989, CRIT REV DIAGN IMAG, V29, P307; HILLBORNE LH, 1991, PERCUTANEOUS TRANSLU; HOPPER KD, 1998, RADIOLOGY S, V1, P454; Kennedy J, 1998, AM HEART J, V135, P696, DOI 10.1016/S0002-8703(98)70288-1; Kuntz KM, 1999, ANN INTERN MED, V130, P709, DOI 10.7326/0003-4819-130-9-199905040-00002; LAVE JR, 1994, MED CARE, V32, pJS77; LITTENBERG B, 1993, MED DECIS MAKING, V13, P313, DOI 10.1177/0272989X9301300408; MANNING WJ, 1993, NEW ENGL J MED, V328, P828, DOI 10.1056/NEJM199303253281202; PATTERSON RE, 1995, CIRCULATION, V91, P54, DOI 10.1161/01.CIR.91.1.54; PHELPS CE, 1988, MED DECIS MAKING, V8, P279, DOI 10.1177/0272989X8800800409; POWE NR, 1988, RADIOLOGY, V169, P163, DOI 10.1148/radiology.169.1.3420254; Reddy GP, 1998, RADIOLOGY, V208, P167, DOI 10.1148/radiology.208.1.9646809; Schmermund A, 1998, J AM COLL CARDIOL, V31, P1547, DOI 10.1016/S0735-1097(98)00132-6; Shemesh J, 1996, RADIOLOGY, V199, P665, DOI 10.1148/radiology.199.3.8637984; SONNENBERG FA, 1993, MED DECIS MAKING, V13, P322, DOI 10.1177/0272989X9301300409; STEINBERG EP, 1993, NEW ENGL J MED, V328, P879, DOI 10.1056/NEJM199303253281211; Stinnett AA, 1998, MED DECIS MAKING, V18, pS68, DOI 10.1177/0272989X98018002S09; VANDERWALL EE, 1995, CIRCULATION, V92, P2723, DOI 10.1161/01.CIR.92.9.2723; Weinstein MC, 1980, CLIN DECISION ANAL; Wexler L, 1996, CIRCULATION, V94, P1175, DOI 10.1161/01.CIR.94.5.1175; WONG JB, 1990, ANN INTERN MED, V113, P852, DOI 10.7326/0003-4819-113-11-852; Woodard PK, 1998, AM J ROENTGENOL, V170, P883, DOI 10.2214/ajr.170.4.9530027	31	37	37	0	1	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					673	680		10.7326/0003-4819-131-9-199911020-00008	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00008			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577330				2022-12-28	WOS:000083446200006
J	Morens, DM				Morens, DM			Death of a president	NEW ENGLAND JOURNAL OF MEDICINE			English	Article							ACUTE EPIGLOTTITIS; ADULTS; ETIOLOGY		Univ Hawaii, Honolulu, HI 96822 USA	University of Hawaii System	Morens, DM (corresponding author), Univ Hawaii, Honolulu, HI 96822 USA.							Barker C, 1936, Yale J Biol Med, V9, P185; Berg S, 1996, SCAND J INFECT DIS, V28, P261, DOI 10.3109/00365549609027168; BLANTON WB, 1931, MED VIRGINIA 18TH CE, P297; Boyd T M, 1984, Va Cavalcade, V33, P136; BRICKELL J, 1800, RUSH LIGHT, P81; BROWN G, 1770, DISPUTATIO MED INAUG; BROWN MW, 1932, MED J REC, V135, P39; BROWNFIELD D, 1993, DEVIANT BEHAV, V14, P243, DOI 10.1080/01639625.1993.9967942; CARROLL JA, 1957, G WASHINGTON, V7, P637; CORNER GW, 1948, AUTOBIOGRAPHY B RUSH, P245; CRAIK J, 1800, MED REPOS, V3, P311; CULLEN W, 1784, 1 LINES PRACTICE PHY, V1, P278; DESAULT PJ, 1798, OEUVRES CHIRURG, P212; DICK EC, 1809, PHILADELPHIA MED PHY, V3, P242; Estes J W, 1985, Med Herit, V1, P44; FAIRFAX B, 1800, COMMUNICATION   0118; FONTANES LJP, 1800, ELOGE FUNEBRE WASHIN; FRANTZ TD, 1994, JAMA-J AM MED ASSOC, V272, P1358, DOI 10.1001/jama.272.17.1358; HARDING WG, 1974, J ORAL SURG, V32, P490; JACKSON J, 1860, UNPUB MEMOIR LAST SI; KATZ AR, 1992, CLIN INFECT DIS, V14, P298, DOI 10.1093/clinids/14.1.298; KING LS, 1982, MED THINKING HIST PR, P227; Laderman Gary, 1996, SACRED REMAINS AM AT, P15; LEAR T, 1999, RETIREMENT SERIES, V4, P542; LLOYD JU, 1923, ECLECTIC MED J, V83, P353; LLOYD JU, 1923, ECLECTIC MED J, V83, P453; LLOYD JU, 1923, ECLECTIC MED J, V83, P403; Marsh H, 1838, DUBLIN J MED SCI, V13, P1; MARX R, 1955, AM HERITAGE, V6, P43; MARX R, 1955, AM HERITAGE, V6, P106; NYDEGGER JA, 1917, MED REC, V92, P1128; PIRRUCELLO F, 1977, CHICAGO TRIBUNE 0220; PORCUPINE P, 1800, RUSH LIGHT, P85; PORCUPINE P, 1800, AM RUSH LIGHT HELP W; POWELL MG, 1928, HIST OLD ALEXANDRIA, P241; PRUSSING E, 1927, ESTATE G WASHINGTON, P17; Reece R, 1966, Minn Med, V49, P1185; Reid John, 1800, Med Phys J, V3, P473; RUSH B, 1948, AUTOBIOGRAPHY B RUSH, P82; RUSH B, 1809, MED INQUIRIES OBSERV, V2, P373; SCHEIDEMANDEL HHE, 1976, ARCH OTOLARYNGOL, V102, P519; SMITH TW, 1808, OBSERVATIONS MED TRE, V4, P31; SOLISCOHEN S, 1899, LIPPINCOTTS MONTHLY, V64, P945; Sparks Jared, 1839, LIFE G WASHINGTON; THORNTON W, UNPUB; THORNTON W, 1800, COMMUNICATION   0102, P378; Trollfors B, 1998, SCAND J INFECT DIS, V30, P49, DOI 10.1080/003655498750002303; WARNER JH, 1986, THERAPEUTIC PERSPECT, P83; Wells Walter A., 1927, VIRGINIA MED MONTHLY, V53, P629; WILLIUS FA, 1942, 2 P STAFF M MAYO CLI, V17, P107; WILSON W, 1897, G WASHINGTON, P304; WOLD KC, 1948, PRESIDENT IS YOUR HL, P1	52	31	32	0	2	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793			NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1845	1850		10.1056/NEJM199912093412413	http://dx.doi.org/10.1056/NEJM199912093412413			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588974				2022-12-28	WOS:000084074000013
J	Robert, C; Kupper, TS				Robert, C; Kupper, TS			Mechanisms of disease: Inflammatory skin diseases, T cells, and immune surveillance	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							CUTANEOUS LYMPHOCYTE ANTIGEN; ALLERGIC CONTACT-DERMATITIS; VERSUS-HOST DISEASE; ATOPIC-DERMATITIS; ADHESION MOLECULE; HECA-452 EPITOPE; DENDRITIC CELLS; HOMING RECEPTOR; PSORIASIS; ACTIVATION		Harvard Univ, Inst Med, Skin Dis Res Ctr, Boston, MA 02115 USA; Brigham & Womens Hosp, Dept Med, Div Dermatol, Boston, MA 02115 USA	Harvard University; Harvard University; Brigham & Women's Hospital	Kupper, TS (corresponding author), Harvard Univ, Inst Med, Skin Dis Res Ctr, 77 Ave Louis Pasteur, Boston, MA 02115 USA.	tskupper@rics.bwh.harvard.edu	Robert, Caroline/G-6157-2018; Kupper, Thomas/O-4962-2019	Robert, Caroline/0000-0002-9493-0238; 	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R29AI025082, R01AI041707, R01AI025082, R37AI025082] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [S15AR040214] Funding Source: NIH RePORTER; NIAID NIH HHS [AI25082, AI41707] Funding Source: Medline; NIAMS NIH HHS [AR40214] Funding Source: Medline	NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NIAMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS))		BABI LFS, 1995, J EXP MED, V181, P1935, DOI 10.1084/jem.181.5.1935; Banchereau J, 1998, NATURE, V392, P245, DOI 10.1038/32588; Barnes PJ, 1997, NEW ENGL J MED, V336, P1066, DOI 10.1056/NEJM199704103361506; BERLIN C, 1993, CELL, V74, P185, DOI 10.1016/0092-8674(93)90305-A; BOS JD, 1983, ARCH DERMATOL RES, V275, P181, DOI 10.1007/BF00510050; Butcher EC, 1996, SCIENCE, V272, P60, DOI 10.1126/science.272.5258.60; Campbell JJ, 1998, J CELL BIOL, V141, P1053, DOI 10.1083/jcb.141.4.1053; Campbell JJ, 1999, NATURE, V400, P776, DOI 10.1038/23495; CHANG JCC, 1994, P NATL ACAD SCI USA, V91, P9282, DOI 10.1073/pnas.91.20.9282; COOPER KD, 1994, J INVEST DERMATOL, V102, P128, DOI 10.1111/1523-1747.ep12371746; DAVIS MM, 1988, NATURE, V335, P744, DOI 10.1038/335744b0; DAVIS MM, 1988, NATURE, V334, P395, DOI 10.1038/334395a0; DAVIS RE, 1992, AM J PATHOL, V141, P691; ELLIS CN, 1991, NEW ENGL J MED, V324, P277, DOI 10.1056/NEJM199101313240501; FERRARA JLM, 1991, NEW ENGL J MED, V324, P667; Fuhlbrigge RC, 1997, NATURE, V389, P978, DOI 10.1038/40166; Genestier L, 1998, J CLIN INVEST, V102, P322, DOI 10.1172/JCI2676; GIRARD JP, 1995, IMMUNOL TODAY, V16, P449, DOI 10.1016/0167-5699(95)80023-9; GOTTLIEB AB, 1990, ARCH DERMATOL, V126, P1083, DOI 10.1001/archderm.126.8.1083; GOTTLIEB AB, 1992, J INVEST DERMATOL, V98, P302, DOI 10.1111/1523-1747.ep12499782; GOTTLIEB SL, 1995, NAT MED, V1, P442, DOI 10.1038/nm0595-442; Grabbe S, 1996, J CLIN INVEST, V98, P1158, DOI 10.1172/JCI118899; Grabbe S, 1998, IMMUNOL TODAY, V19, P37, DOI 10.1016/S0167-5699(97)01186-9; GROVES RW, 1992, J INVEST DERMATOL, V98, P384, DOI 10.1111/1523-1747.ep12499816; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Jung K, 1997, CONTACT DERMATITIS, V37, P163, DOI 10.1111/j.1600-0536.1997.tb00190.x; KRUEGER JG, 1995, J EXP MED, V182, P2057, DOI 10.1084/jem.182.6.2057; KUPPER TS, 1990, J CLIN INVEST, V86, P1783, DOI 10.1172/JCI114907; KUPPER TS, 1991, J CLIN INVEST, V87, P753; Lanzavecchia A, 1996, CURR OPIN IMMUNOL, V8, P348, DOI 10.1016/S0952-7915(96)80124-5; Lee RT, 1997, J IMMUNOL, V159, P5084; LEUNG DYM, 1993, CLIN REV ALLERG, V11, P447; Medzhitov R, 1997, NATURE, V388, P394, DOI 10.1038/41131; MELSKI JW, 1983, ARCH DERMATOL, V119, P655, DOI 10.1001/archderm.119.8.655; Muche JM, 1997, BLOOD, V90, P1636, DOI 10.1182/blood.V90.4.1636.1636_1636_1642; Myskowski PL, 1996, MED CLIN N AM, V80, P1415, DOI 10.1016/S0025-7125(05)70496-X; Newton R, 1997, INT J CANCER, V72, P923, DOI 10.1002/(SICI)1097-0215(19970917)72:6<923::AID-IJC1>3.0.CO;2-R; Ozawa M, 1999, J EXP MED, V189, P711, DOI 10.1084/jem.189.4.711; PICKER LJ, 1990, AM J PATHOL, V136, P1053; PICKER LJ, 1991, NATURE, V349, P796, DOI 10.1038/349796a0; PICKER LJ, 1993, J IMMUNOL, V150, P1122; PICKER LJ, 1994, EUR J IMMUNOL, V24, P1269, DOI 10.1002/eji.1830240605; Pierre P, 1997, NATURE, V388, P787, DOI 10.1038/42039; Pitzalis C, 1996, ARTHRITIS RHEUM, V39, P137, DOI 10.1002/art.1780390118; Porcelli SA, 1998, IMMUNOL TODAY, V19, P362, DOI 10.1016/S0167-5699(98)01289-4; RIETSCHEL RL, 1995, J AM ACAD DERMATOL, V33, P812, DOI 10.1016/0190-9622(95)91837-X; Robert C, 1999, J EXP MED, V189, P627, DOI 10.1084/jem.189.4.627; ROOK AH, 1995, HEMATOL ONCOL CLIN N, V9, P997, DOI 10.1016/S0889-8588(18)30054-6; ROSENBERG EW, 1988, J AM ACAD DERMATOL, V18, P151, DOI 10.1016/S0190-9622(88)80063-X; Rosette C, 1996, SCIENCE, V274, P1194, DOI 10.1126/science.274.5290.1194; Rott LS, 1997, J CLIN INVEST, V100, P1204, DOI 10.1172/JCI119633; SCHEIN PS, 1976, CANCER-AM CANCER SOC, V38, P1859, DOI 10.1002/1097-0142(197610)38:4<1859::AID-CNCR2820380466>3.0.CO;2-S; SCHLAAK JF, 1994, J INVEST DERMATOL, V102, P145, DOI 10.1111/1523-1747.ep12371752; SPRINGER TA, 1994, CELL, V76, P301, DOI 10.1016/0092-8674(94)90337-9; Stein JV, 1999, J EXP MED, V189, P37, DOI 10.1084/jem.189.1.37; TROWSDALE J, 1992, EUR J IMMUNOGENET, V19, P45; VALLAT VP, 1994, J EXP MED, V180, P283, DOI 10.1084/jem.180.1.283; Warnock RA, 1998, J EXP MED, V187, P205, DOI 10.1084/jem.187.2.205; Yang RB, 1998, NATURE, V395, P284, DOI 10.1038/26239; Zhang FX, 1999, J BIOL CHEM, V274, P7611, DOI 10.1074/jbc.274.12.7611	61	361	403	1	8	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 9	1999	341	24					1817	1828		10.1056/NEJM199912093412407	http://dx.doi.org/10.1056/NEJM199912093412407			12	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	262NU	10588968				2022-12-28	WOS:000084074000007
J	Henney, JE				Henney, JE			Review of generic bioequivalence studies	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	News Item																			0	42	42	0	3	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					1995	1995		10.1001/jama.282.21.1995	http://dx.doi.org/10.1001/jama.282.21.1995			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TB	10591372				2022-12-28	WOS:000083908700005
J	Kelion, AD; Banning, AP				Kelion, AD; Banning, AP			Is simple clinical assessment adequate for cardiac risk stratification before elective non-cardiac surgery?	LANCET			English	Editorial Material							PERIOPERATIVE MYOCARDIAL-ISCHEMIA; NONCARDIAC SURGERY; DISEASE; MORBIDITY; MORTALITY; MEN		John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England	University of Oxford	Kelion, AD (corresponding author), John Radcliffe Hosp, Dept Cardiol, Oxford OX3 9DU, England.		banning, adrian p/AAF-7229-2021	Banning, Adrian/0000-0002-2842-7861				Eagle KA, 1997, CIRCULATION, V96, P1882, DOI 10.1161/01.CIR.96.6.1882; HERTZER NR, 1984, ANN SURG, V199, P223, DOI 10.1097/00000658-198402000-00016; Lee TH, 1999, CIRCULATION, V100, P1043, DOI 10.1161/01.CIR.100.10.1043; LIITALIEN GJ, 1996, J AM COLL CARDIOL, V27, P779; MANGANO DT, 1991, J AM COLL CARDIOL, V17, P851, DOI 10.1016/0735-1097(91)90864-6; MANGANO DT, 1990, NEW ENGL J MED, V323, P1781, DOI 10.1056/NEJM199012273232601; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; POLDERMANS D, 1995, J AM COLL CARDIOL, V26, P648, DOI 10.1016/0735-1097(95)00240-5; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001	9	4	4	0	1	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 27	1999	354	9193					1837	1838		10.1016/S0140-6736(99)90333-1	http://dx.doi.org/10.1016/S0140-6736(99)90333-1			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	259TF	10584716				2022-12-28	WOS:000083909100005
J	Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV				Wilmot, CM; Hajdu, J; McPherson, MJ; Knowles, PF; Phillips, SEV			Visualization of dioxygen bound to copper during enzyme catalysis	SCIENCE			English	Article							SERUM AMINE OXIDASE; CRYSTAL-STRUCTURE; BENZYLAMINE OXIDASE; ESCHERICHIA-COLI; HALF-REACTION; PIG PLASMA; MECHANISM; TOPAQUINONE; RESOLUTION; CRYSTALLOGRAPHY	X-ray crystal structures of three species related to the oxidative half of the reaction of the copper-containing quinoprotein amine oxidase from Escherichia coli have been determined. Crystals were freeze-trapped either anaerobically or aerobically after exposure to substrate, and structures were determined to resolutions between 2.1 and 2.4 angstroms. The oxidation state of the quinone cofactor was investigated by single-crystal spectrophotometry. The structures reveal the site of bound dioxygen and the proton transfer pathways involved in oxygen reduction. The quinone cofactor is regenerated from the iminoquinone intermediate by hydrolysis involving Asp(383), the catalytic base in the reductive half-reaction. Product aldehyde inhibits the hydrolysis, making release of product the rate-determining step of the reaction in the crystal.	Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England; Uppsala Univ, Dept Biochem, S-75123 Uppsala, Sweden	University of Leeds; Uppsala University	Wilmot, CM (corresponding author), Univ Leeds, Sch Biochem & Mol Biol, Astbury Ctr Struct Mol Biol, Leeds LS2 9JT, W Yorkshire, England.			McPherson, Michael/0000-0002-0719-6427				BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; CHRISTOPHER JA, 1997, SPOCK; DOOLEY DM, 1991, NATURE, V349, P262, DOI 10.1038/349262a0; ENGH RA, 1991, ACTA CRYSTALLOGR A, V47, P392, DOI 10.1107/S0108767391001071; FARNUM M, 1986, BIOCHEMISTRY-US, V25, P1898, DOI 10.1021/bi00356a010; FERRIN TE, 1988, J MOL GRAPHICS, V6, P13, DOI 10.1016/0263-7855(88)80054-7; HARTMANN C, 1991, BIOCHEMISTRY-US, V30, P4605, DOI 10.1021/bi00232a035; HARTMANN C, 1993, BIOCHEMISTRY-US, V32, P2234, DOI 10.1021/bi00060a015; JANES SM, 1992, BIOCHEMISTRY-US, V31, P12147, DOI 10.1021/bi00163a025; JONES TA, 1991, ACTA CRYSTALLOGR A, V47, P110, DOI 10.1107/S0108767390010224; Kleywegt GJ, 1998, ACTA CRYSTALLOGR D, V54, P1119, DOI 10.1107/S0907444998007100; KLINMAN JP, 1994, ANNU REV BIOCHEM, V63, P299, DOI 10.1146/annurev.bi.63.070194.001503; Klinman JP, 1996, CHEM REV, V96, P2541, DOI 10.1021/cr950047g; KNOWLES P, UNPUB, P66115; Kumar V, 1996, STRUCTURE, V4, P943, DOI 10.1016/S0969-2126(96)00101-3; Leslie A. G. W., 1992, JOINT CCP4 ESF EACBM, V26; Li RB, 1998, STRUCTURE, V6, P293, DOI 10.1016/S0969-2126(98)00033-1; MURE M, 1993, J AM CHEM SOC, V115, P7117, DOI 10.1021/ja00069a008; MURE M, 1995, J AM CHEM SOC, V117, P8707, DOI 10.1021/ja00139a003; Murray JM, 1999, BIOCHEMISTRY-US, V38, P8217, DOI 10.1021/bi9900469; NYLEN U, 1974, ACTA CHEM SCAND B, VB 28, P1153, DOI 10.3891/acta.chem.scand.28b-1153; Otwinowski Z, 1997, METHOD ENZYMOL, V276, P307, DOI 10.1016/S0076-6879(97)76066-X; PARSONS MR, 1995, STRUCTURE, V3, P1171, DOI 10.1016/S0969-2126(01)00253-2; PREUT H, 1987, ACTA CRYSTALLOGR C, V43, P374, DOI 10.1107/S0108270187095726; RINALDI A, 1984, BIOCHEM BIOPH RES CO, V120, P242, DOI 10.1016/0006-291X(84)91440-2; Su QJ, 1998, BIOCHEMISTRY-US, V37, P12513, DOI 10.1021/bi981103l; TANIZAWA K, 1995, J BIOCHEM, V118, P671, DOI 10.1093/oxfordjournals.jbchem.a124962; TAYLOR CE, 1972, BIOCHEM J, V130, P713, DOI 10.1042/bj1300713; TSOUCARIS G, 1961, ACTA CRYSTALLOGR, V14, P909, DOI 10.1107/S0365110X61002679; Wilce MCJ, 1997, BIOCHEMISTRY-US, V36, P16116, DOI 10.1021/bi971797i; Williams PA, 1997, NATURE, V389, P406, DOI 10.1038/38775; Wilmot CM, 1997, BIOCHEMISTRY-US, V36, P1608, DOI 10.1021/bi962205j; YADAV KDS, 1981, EUR J BIOCHEM, V114, P139	34	136	137	0	27	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1724	1728		10.1126/science.286.5445.1724	http://dx.doi.org/10.1126/science.286.5445.1724			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576737				2022-12-28	WOS:000083912200035
J	Hildebrand, JD; Soriano, P				Hildebrand, JD; Soriano, P			Shroom, a PDZ domain-containing actin-binding protein, is required for neural tube morphogenesis in mice	CELL			English	Article							ABNORMAL BRAIN-DEVELOPMENT; EMBRYONIC STEM-CELLS; E-CADHERIN; ALPHA-CATENIN; XENOPUS-LAEVIS; F-ACTIN; GENE; DEFECTS; NEURULATION; ADHESION	Using gene trap mutagenesis, we have identified a mutation in mice that causes exencephaly, acrania, facial clefting, and spina bifida, all of which can be attributed to failed neural tube closure. This mutation is designated shroom (shrm) because the neural folds "mushroom" outward and do not converge at the dorsal midline. shrm encodes a PDZ domain protein that is involved at several levels in regulating aspects of cytoarchitecture. First, endogenous Shrm localizes to adherens junctions and the cytoskeleton. Second, ectopically expressed Shrm alters the subcellular distribution of F-actin. Third, Shrm directly binds F-actin. Finally, cytoskeletal polarity within the neuroepithelium is perturbed in mutant embryos. In concert, these observations suggest that Shrm is a critical determinant of the cellular architecture required for proper neurulation.	Fred Hutchinson Canc Res Ctr, Program Dev Biol, Seattle, WA 98109 USA; Fred Hutchinson Canc Res Ctr, Div Basic Sci, Seattle, WA 98109 USA	Fred Hutchinson Cancer Center; Fred Hutchinson Cancer Center	Soriano, P (corresponding author), Fred Hutchinson Canc Res Ctr, Program Dev Biol, 1100 Fairview Ave N, Seattle, WA 98109 USA.	psoriano@fhcrc.org	Soriano, Philippe M/E-5797-2015	Soriano, Philippe M/0000-0002-0427-926X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT [R01HD024875] Funding Source: NIH RePORTER; NICHD NIH HHS [HD24875] Funding Source: Medline	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENT(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)); NICHD NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD))		Berk M, 1997, GENE DEV, V11, P2029, DOI 10.1101/gad.11.16.2029; BREEN E, 1993, CELL ADHES COMMUN, V1, P239, DOI 10.3109/15419069309097257; Bubeck P, 1997, J CELL SCI, V110, P1361; Burridge K, 1996, ANNU REV CELL DEV BI, V12, P463, DOI 10.1146/annurev.cellbio.12.1.463; Chen JM, 1996, P NATL ACAD SCI USA, V93, P6275, DOI 10.1073/pnas.93.13.6275; CHEN ZF, 1995, GENE DEV, V9, P686, DOI 10.1101/gad.9.6.686; COPP AJ, 1990, PROG NEUROBIOL, V35, P363, DOI 10.1016/0301-0082(90)90037-H; FRIEDRICH G, 1991, GENE DEV, V5, P1513, DOI 10.1101/gad.5.9.1513; FROHMAN MA, 1988, P NATL ACAD SCI USA, V85, P8998, DOI 10.1073/pnas.85.23.8998; Gertler FB, 1996, CELL, V87, P227, DOI 10.1016/S0092-8674(00)81341-0; GOLDEN JA, 1995, PEDIATRICS, V95, P506; Grapin-Botton A, 1998, DEVELOPMENT, V125, P1173; Gumbiner BM, 1996, CELL, V84, P345, DOI 10.1016/S0092-8674(00)81279-9; GUMBINER BM, 1993, J CELL SCI, P155; HAEGEL H, 1995, DEVELOPMENT, V121, P3529; Hogan B, 1994, MANIPULATING MOUSE E; Ishibashi M, 1995, GENE DEV, V9, P3136, DOI 10.1101/gad.9.24.3136; Kaech SM, 1998, CELL, V94, P761, DOI 10.1016/S0092-8674(00)81735-3; KARFUNKEL P, 1971, DEV BIOL, V25, P30, DOI 10.1016/0012-1606(71)90018-2; KAWANISHI J, 1995, MOL CELL BIOL, V15, P1175; KILPATRICK TJ, 1993, NEURON, V10, P255, DOI 10.1016/0896-6273(93)90316-J; Koleske AJ, 1998, NEURON, V21, P1259, DOI 10.1016/S0896-6273(00)80646-7; Kuan CY, 1999, NEURON, V22, P667, DOI 10.1016/S0896-6273(00)80727-8; Kuroda S, 1996, J BIOL CHEM, V271, P31029, DOI 10.1074/jbc.271.49.31029; Lanier LM, 1999, NEURON, V22, P313, DOI 10.1016/S0896-6273(00)81092-2; LARUE L, 1994, P NATL ACAD SCI USA, V91, P8263, DOI 10.1073/pnas.91.17.8263; LEDOUARIN NM, 1993, DEV BIOL, V159, P24, DOI 10.1006/dbio.1993.1219; MENKEL AR, 1994, J CELL BIOL, V126, P1231, DOI 10.1083/jcb.126.5.1231; Niebuhr K, 1997, EMBO J, V16, P5433, DOI 10.1093/emboj/16.17.5433; OYAMA T, 1994, CANCER RES, V54, P6282; Parsons JT, 1996, CURR OPIN CELL BIOL, V8, P146, DOI 10.1016/S0955-0674(96)80059-7; Ponting CP, 1997, BIOESSAYS, V19, P469, DOI 10.1002/bies.950190606; Prat AG, 1996, J BIOL CHEM, V271, P18045, DOI 10.1074/jbc.271.30.18045; RIMM DL, 1995, P NATL ACAD SCI USA, V92, P8813, DOI 10.1073/pnas.92.19.8813; SAKAI Y, 1989, ANAT RECORD, V223, P194, DOI 10.1002/ar.1092230212; SCHIAFFINO MV, 1995, HUM MOL GENET, V4, P373, DOI 10.1093/hmg/4.3.373; SCHOENWOLF GC, 1990, DEVELOPMENT, V109, P243; Smith JL, 1997, TRENDS NEUROSCI, V20, P510, DOI 10.1016/S0166-2236(97)01121-1; Songyang Z, 1997, SCIENCE, V275, P73, DOI 10.1126/science.275.5296.73; Soriano P, 1997, DEVELOPMENT, V124, P2691; SORIANO P, 1991, J VIROL, V65, P2314, DOI 10.1128/JVI.65.5.2314-2319.1991; STANISSTREET M, 1990, POSTIMPLANTATION MAM; STAUB O, 1992, J CELL BIOL, V119, P1497, DOI 10.1083/jcb.119.6.1497; STUMPO DJ, 1995, P NATL ACAD SCI USA, V92, P944, DOI 10.1073/pnas.92.4.944; THOMAS KR, 1987, CELL, V51, P503, DOI 10.1016/0092-8674(87)90646-5; Torres M, 1997, P NATL ACAD SCI USA, V94, P901, DOI 10.1073/pnas.94.3.901; Tsunoda S, 1997, NATURE, V388, P243, DOI 10.1038/40805; Weiss EE, 1998, J CELL BIOL, V141, P755, DOI 10.1083/jcb.141.3.755; Wu M, 1996, P NATL ACAD SCI USA, V93, P2110, DOI 10.1073/pnas.93.5.2110; Xu WM, 1998, DEVELOPMENT, V125, P327; Xu XZS, 1998, J CELL BIOL, V142, P545, DOI 10.1083/jcb.142.2.545; Yao TP, 1998, CELL, V93, P361, DOI 10.1016/S0092-8674(00)81165-4; Ybot-Gonzalez P, 1999, DEV DYNAM, V215, P273, DOI 10.1002/(SICI)1097-0177(199907)215:3<273::AID-AJA9>3.0.CO;2-H; Zhao Q, 1996, NAT GENET, V13, P275, DOI 10.1038/ng0796-275	54	264	270	0	10	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					485	497		10.1016/S0092-8674(00)81537-8	http://dx.doi.org/10.1016/S0092-8674(00)81537-8			13	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589677	Bronze			2022-12-28	WOS:000083986300008
J	Xiao, T; Towb, P; Wasserman, SA; Sprang, SR				Xiao, T; Towb, P; Wasserman, SA; Sprang, SR			Three-dimensional structure of a complex between the death domains of Pelle and Tube	CELL			English	Article							DROSOPHILA EMBRYO; DORSOVENTRAL POLARITY; NMR STRUCTURE; MACROMOLECULAR STRUCTURES; TNF RECEPTOR; PROTEIN; DORSAL; MUTAGENESIS; KINASE; TRANSDUCTION	The interaction of the serine/threonine kinase Pelle and adaptor protein Tube through their N-terminal death domains leads to the nuclear translocation of the transcription factor Dorsal and activation of zygotic patterning genes during Drosophila embryogenesis. Crystal structure of the Pelle and Tube death domain heterodimer reveals that the two death domains adopt a six-helix bundle fold and are arranged in an open-ended linear array with plastic interfaces mediating their interactions. The Tube death domain has an insertion between helices 2 and 3, and a C-terminal tail making significant and indispensable contacts in the heterodimer. In vivo assays of Pelle and Tube mutants confirmed that the integrity of the major heterodimer interface is critical to the activity of these molecules.	Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA; Univ Texas, SW Med Ctr, Dept Biochem, Dallas, TX 75235 USA; Univ Calif San Diego, Dept Biol, La Jolla, CA 92093 USA	Howard Hughes Medical Institute; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of Texas System; University of Texas Dallas; University of Texas Southwestern Medical Center Dallas; University of California System; University of California San Diego	Sprang, SR (corresponding author), Univ Texas, SW Med Ctr, Howard Hughes Med Inst, Dallas, TX 75235 USA.	sprang@chop.swmed.edu	Xiao, Tsan Sam/A-8590-2010; Xiao, Tsan/I-7616-2013	Xiao, Tsan Sam/0000-0001-9688-475X; Xiao, Tsan/0000-0001-9688-475X	NIDDK NIH HHS [R01 DK046371] Funding Source: Medline; NIGMS NIH HHS [R01 GM050545, GM50545] Funding Source: Medline; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046371] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES [R01GM050545] Funding Source: NIH RePORTER	NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NIGMS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS)); NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS))		ANDERSON KV, 1984, NATURE, V311, P223, DOI 10.1038/311223a0; BAILEY S, 1994, ACTA CRYSTALLOGR D, V50, P760, DOI 10.1107/s0907444994003112; Baker SJ, 1998, ONCOGENE, V17, P3261, DOI 10.1038/sj.onc.1202568; BELVIN MP, 1995, GENE DEV, V9, P783, DOI 10.1101/gad.9.7.783; BERNSTEIN FC, 1977, J MOL BIOL, V112, P535, DOI 10.1016/S0022-2836(77)80200-3; BOLDIN MP, 1995, J BIOL CHEM, V270, P387, DOI 10.1074/jbc.270.1.387; BRUNGER AT, 1992, NATURE, V355, P472, DOI 10.1038/355472a0; Brunger AT, 1998, ACTA CRYSTALLOGR D, V54, P905, DOI 10.1107/S0907444998003254; Chang HY, 1999, P NATL ACAD SCI USA, V96, P1252, DOI 10.1073/pnas.96.4.1252; Chou JJ, 1998, CELL, V94, P171, DOI 10.1016/S0092-8674(00)81417-8; Eberstadt M, 1998, NATURE, V392, P941, DOI 10.1038/31972; Edwards DN, 1997, DEVELOPMENT, V124, P3855; Esnouf RM, 1997, J MOL GRAPH MODEL, V15, P132, DOI 10.1016/S1093-3263(97)00021-1; FEINSTEIN E, 1995, TRENDS BIOCHEM SCI, V20, P342, DOI 10.1016/S0968-0004(00)89070-2; GALINDO RL, 1995, DEVELOPMENT, V121, P2209; GILLESPIE SKH, 1994, MOL CELL BIOL, V14, P3559, DOI 10.1128/MCB.14.6.3559; GROSSHANS J, 1994, NATURE, V372, P563, DOI 10.1038/372563a0; Grosshans J, 1999, MECH DEVELOP, V81, P127, DOI 10.1016/S0925-4773(98)00236-6; HECHT PM, 1993, GENETICS, V135, P405; HENDRICKSON WA, 1991, SCIENCE, V254, P51, DOI 10.1126/science.1925561; HO SN, 1989, GENE, V77, P51, DOI 10.1016/0378-1119(89)90358-2; Hoffmann JA, 1999, SCIENCE, V284, P1313, DOI 10.1126/science.284.5418.1313; Huang BH, 1996, NATURE, V384, P638, DOI 10.1038/384638a0; Jeong EJ, 1999, J BIOL CHEM, V274, P16337, DOI 10.1074/jbc.274.23.16337; JONES TA, 1993, O VERSION 5 9; KRAULIS PJ, 1991, J APPL CRYSTALLOGR, V24, P946, DOI 10.1107/S0021889891004399; LASKOWSKI RA, 1993, J APPL CRYSTALLOGR, V26, P283, DOI 10.1107/S0021889892009944; Lemaitre B, 1996, CELL, V86, P973, DOI 10.1016/S0092-8674(00)80172-5; LESZCZYNSKI JF, 1986, SCIENCE, V234, P849, DOI 10.1126/science.3775366; LETSOU A, 1993, EMBO J, V12, P3449, DOI 10.1002/j.1460-2075.1993.tb06019.x; LETSOU A, 1991, P NATL ACAD SCI USA, V88, P810, DOI 10.1073/pnas.88.3.810; Liepinsh E, 1997, EMBO J, V16, P4999, DOI 10.1093/emboj/16.16.4999; Medzhitov R, 1998, CURR OPIN IMMUNOL, V10, P12, DOI 10.1016/S0952-7915(98)80024-1; Medzhitov R, 1998, MOL CELL, V2, P253, DOI 10.1016/S1097-2765(00)80136-7; Muzio M, 1997, SCIENCE, V278, P1612, DOI 10.1126/science.278.5343.1612; NICHOLLS A, 1991, PROTEINS, V11, P281, DOI 10.1002/prot.340110407; Otwinowski Z., 1993, DATA COLLECTION PROC, P56; Park A, 1996, J BIOL CHEM, V271, P9858, DOI 10.1074/jbc.271.16.9858; Qin HX, 1999, NATURE, V399, P549, DOI 10.1038/21124; Ramachandran G N, 1968, Adv Protein Chem, V23, P283, DOI 10.1016/S0065-3233(08)60402-7; Reach M, 1996, DEV BIOL, V180, P353, DOI 10.1006/dbio.1996.0308; Sambrook J., 1989, MOL CLONING LAB MANU, V1, P21, DOI DOI 10.51-10.67; SHELTON CA, 1993, CELL, V72, P515, DOI 10.1016/0092-8674(93)90071-W; TARTAGLIA LA, 1993, CELL, V74, P845, DOI 10.1016/0092-8674(93)90464-2; Terwilliger TC, 1999, ACTA CRYSTALLOGR D, V55, P849, DOI 10.1107/S0907444999000839; Towb P, 1998, DEVELOPMENT, V125, P2443; Wieschaus E., 1986, P199; YANG W, 1990, J BIOL CHEM, V265, P13553	48	150	153	0	7	CELL PRESS	CAMBRIDGE	50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA	0092-8674	1097-4172		CELL	Cell	NOV 24	1999	99	5					545	555		10.1016/S0092-8674(00)81542-1	http://dx.doi.org/10.1016/S0092-8674(00)81542-1			11	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589682	Green Accepted, Bronze			2022-12-28	WOS:000083986300013
J	Brodison, A; Chauhan, A				Brodison, A; Chauhan, A			Spinal-cord stimulation in management of angina	LANCET			English	Editorial Material							ELECTRICAL-STIMULATION; PAIN RELIEF; PECTORIS; ABSTRACTS		Victoria Hosp, Dept Cardiol, Blackpool FY3 8N, England		Chauhan, A (corresponding author), Victoria Hosp, Dept Cardiol, Blackpool FY3 8N, England.							ANDERSON C, 1994, BRIT HEART J, V71, P419; DEJONGSTE MJL, 1994, BRIT HEART J, V71, P413; DEJONGSTE MJL, 1994, J AM COLL CARDIOL, V23, P1592, DOI 10.1016/0735-1097(94)90661-0; Hautvast RWM, 1996, AM J CARDIOL, V77, P462, DOI 10.1016/S0002-9149(97)89338-1; Mannheimer C, 1998, CIRCULATION, V97, P1157, DOI 10.1161/01.CIR.97.12.1157; MANNHEIMER C, 1988, BRIT HEART J, V59, P56; MELZACK R, 1965, SCIENCE, V150, P971, DOI 10.1126/science.150.3699.971; MURPHY DF, 1987, PAIN, V28, P365, DOI 10.1016/0304-3959(87)90070-4; Murray S, 1999, HEART, V82, P89, DOI 10.1136/hrt.82.1.89; TenVaarwerk IAM, 1999, HEART, V82, P82, DOI 10.1136/hrt.82.1.82	10	11	12	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1748	1749		10.1016/S0140-6736(99)00296-2	http://dx.doi.org/10.1016/S0140-6736(99)00296-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577633				2022-12-28	WOS:000083853000006
J	Eckermann, SD; Preusse, P				Eckermann, SD; Preusse, P			Global measurements of stratospheric mountain waves from space	SCIENCE			English	Article							ATMOSPHERIC GRAVITY-WAVES; LEE WAVES; LIDAR OBSERVATIONS; MIDDLE ATMOSPHERE; OZONE DEPLETION; TURBULENCE; VARIANCE; WIND; TEMPERATURES; PROPAGATION	Temperatures acquired by the Cryogenic Infrared Spectrometers and Telescopes for the Atmosphere (CRISTA) during shuttle mission STS-66 have provided measurements of stratospheric mountain waves from space. Large-amplitude, Long-wavelength mountain waves at heights of 15 to 30 kilometers above the southern Andes Mountains were observed and characterized, with vigorous wave breaking inferred above 30 kilometers. Mountain waves also occurred throughout the stratosphere (15 to 45 kilometers) over a broad mountainous region of central Eurasia. The global distribution of mountain wave activity accords well with predictions from a mountain wave model. The findings demonstrate that satellites can provide the global data needed to improve mountain wave parameterizations and hence global climate and forecast models.	USN, Res Lab, EO Hulburt Ctr Space Res, Washington, DC 20375 USA; Berg Univ Gesamthsch Wuppertal, Dept Phys, D-42097 Wuppertal, Germany	United States Department of Defense; United States Navy; Naval Research Laboratory; University of Wuppertal	Eckermann, SD (corresponding author), USN, Res Lab, EO Hulburt Ctr Space Res, Code 7641-2, Washington, DC 20375 USA.		Preusse, Peter/A-1193-2013	Preusse, Peter/0000-0002-8997-4965				Alexander MJ, 1996, J GEOPHYS RES-ATMOS, V101, P23465, DOI 10.1029/96JD02197; Alexander MJ, 1998, J GEOPHYS RES-ATMOS, V103, P8627, DOI 10.1029/97JD03325; Attie JL, 1997, ANN GEOPHYS-ATM HYDR, V15, P823, DOI 10.1007/s00585-997-0823-6; BACMEISTER JT, 1990, GEOPHYS RES LETT, V17, P81, DOI 10.1029/GL017i001p00081; BACMEISTER JT, 1994, WEATHER FORECAST, V9, P241, DOI 10.1175/1520-0434(1994)009<0241:AAFFMW>2.0.CO;2; CARIOLLE D, 1989, J GEOPHYS RES-ATMOS, V94, P11233, DOI 10.1029/JD094iD09p11233; Carslaw KS, 1998, J GEOPHYS RES-ATMOS, V103, P5785, DOI 10.1029/97JD03626; Carslaw KS, 1999, J GEOPHYS RES-ATMOS, V104, P1827, DOI 10.1029/1998JD100033; Carslaw KS, 1998, NATURE, V391, P675, DOI 10.1038/35589; Coy L, 1997, J GEOPHYS RES-ATMOS, V102, P25763, DOI 10.1029/97JD02361; Dean-Day J, 1998, GEOPHYS RES LETT, V25, P1351, DOI 10.1029/98GL01004; DESHLER T, 1994, GEOPHYS RES LETT, V21, P1327, DOI 10.1029/93GL03228; Dornbrack A., 1998, METEOROL APPL, V5, P117, DOI DOI 10.1017/S1350482798000802; Duck TJ, 1998, GEOPHYS RES LETT, V25, P2813, DOI 10.1029/98GL02113; ECKERMANN SD, 1995, J ATMOS TERR PHYS, V57, P105, DOI 10.1016/0021-9169(93)E0027-7; ECKERMANN SD, 1995, Q J ROY METEOR SOC, V121, P149, DOI 10.1002/qj.49712152108; Eckermann SD, 1997, ADV SPACE RES, V20, P1253, DOI 10.1016/S0273-1177(97)00780-1; Eliassen A., 1961, GEOFYS PUBL, V22, P1; FETZER EJ, 1994, J ATMOS SCI, V51, P2461, DOI 10.1175/1520-0469(1994)051<2461:GWVILT>2.0.CO;2; FRITTS DC, 1984, REV GEOPHYS, V22, P275, DOI 10.1029/RG022i003p00275; GARCIA RR, 1994, J ATMOS SCI, V51, P2238, DOI 10.1175/1520-0469(1994)051<2238:COTMMC>2.0.CO;2; HIROTA I, 1984, J ATMOS TERR PHYS, V46, P767, DOI 10.1016/0021-9169(84)90057-6; Lamarque JF, 1996, J GEOPHYS RES-ATMOS, V101, P22969, DOI 10.1029/96JD02442; Leutbecher M, 1996, GEOPHYS RES LETT, V23, P3329, DOI 10.1029/96GL03240; LILLY DK, 1974, J ATMOS SCI, V31, P800, DOI 10.1175/1520-0469(1974)031<0800:WATITS>2.0.CO;2; McFarlanle N. A., 1987, J ATMOS SCI, V44, P175; NASTROM GD, 1992, J ATMOS SCI, V49, P101, DOI 10.1175/1520-0469(1992)049<0101:SOMVOG>2.0.CO;2; Offermann D, 1999, J GEOPHYS RES-ATMOS, V104, P16311, DOI 10.1029/1998JD100047; PALMER TN, 1986, Q J ROY METEOR SOC, V112, P1001, DOI 10.1002/qj.49711247406; Picard RH, 1998, GEOPHYS RES LETT, V25, P2809, DOI 10.1029/98GL01701; PREUSSE P, IN PRESS ADV SPACE R; Ralph FM, 1997, GEOPHYS RES LETT, V24, P663, DOI 10.1029/97GL00349; RALPH FM, 1992, Q J ROY METEOR SOC, V118, P597, DOI 10.1002/qj.49711850602; Riese M, 1999, J GEOPHYS RES-ATMOS, V104, P16349, DOI 10.1029/1998JD100057; Riese M, 1999, J GEOPHYS RES-ATMOS, V104, P16419, DOI 10.1029/1999JD900178; SATO K, 1990, J ATMOS SCI, V47, P2803, DOI 10.1175/1520-0469(1990)047<2803:VWDITT>2.0.CO;2; Scavuzzo CM, 1998, J GEOPHYS RES-ATMOS, V103, P1747, DOI 10.1029/97JD02308; Schilling T, 1999, GEOPHYS RES LETT, V26, P303, DOI 10.1029/1998GL900314; Schreiner J, 1999, SCIENCE, V283, P968, DOI 10.1126/science.283.5404.968; SHUTTS G, 1993, Q J ROY METEOR SOC, V119, P377, DOI 10.1002/qj.49711951102; Shutts GJ, 1998, Q J ROY METEOR SOC, V124, P1421, DOI 10.1002/qj.49712454905; Smith R. B., 1979, ADV GEOPHYS, V21, P87, DOI 10.1016/S0065-2687(08)60262-9; SMITH SA, 1987, J ATMOS SCI, V44, P1404, DOI 10.1175/1520-0469(1987)044<1404:EFASSO>2.0.CO;2; Whiteway JA, 1999, J ATMOS SCI, V56, P1344, DOI 10.1175/1520-0469(1999)056<1344:EAIGWS>2.0.CO;2; Whiteway JA, 1997, GEOPHYS RES LETT, V24, P1387, DOI 10.1029/97GL01322; Worthington RM, 1998, J ATMOS SOL-TERR PHY, V60, P1543, DOI 10.1016/S1364-6826(98)00105-9; Worthington RM, 1997, GEOPHYS RES LETT, V24, P1071, DOI 10.1029/97GL00833; Wu DL, 1996, GEOPHYS RES LETT, V23, P3631, DOI 10.1029/96GL02907; Wurtele MG, 1996, ANNU REV FLUID MECH, V28, P429, DOI 10.1146/annurev.fl.28.010196.002241; Zhou JY, 1996, Q J ROY METEOR SOC, V122, P903, DOI 10.1002/qj.49712253206	50	230	237	1	17	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1534	1537		10.1126/science.286.5444.1534	http://dx.doi.org/10.1126/science.286.5444.1534			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567253				2022-12-28	WOS:000083768300049
J	Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW				Nichols, ML; Allen, BJ; Rogers, SD; Ghilardi, JR; Honore, P; Luger, NM; Finke, MP; Li, J; Lappi, DA; Simone, DA; Mantyh, PW			Transmission of chronic nociception by spinal neurons expressing the substance P receptor	SCIENCE			English	Article							NEUROKININ-1 RECEPTORS; TRACT NEURONS; DORSAL HORN; RAT; PAIN; CORD; INFLAMMATION; HYPERALGESIA; MODEL	Substance P receptor (SPR)-expressing spinal neurons were ablated with the selective cytotoxin substance P-saporin. Loss of these neurons resulted in a reduction of thermal hyperalgesia and mechanical allodynia associated with persistent neuropathic and inflammatory pain states. This Loss appeared to be permanent. Responses to mildly painful stimuli and morphine analgesia were unaffected by this treatment. These results identify a target for treating persistent pain and suggest that the small population of SPR-expressing neurons in the dorsal horn of the spinal cord plays a pivotal role in the generation and maintenance of chronic neuropathic and inflammatory pain.	Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Psychiat, Minneapolis, MN 55455 USA; Univ Minnesota, Dept Neurosci, Minneapolis, MN 55455 USA; Univ Minnesota, Ctr Canc, Minneapolis, MN 55455 USA; Vet Affairs Med Ctr, Mol Neurobiol Lab 151, Minneapolis, MN 55417 USA; Adv Targeting Syst, San Diego, CA 92121 USA	University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; University of Minnesota System; University of Minnesota Twin Cities; US Department of Veterans Affairs; Veterans Health Administration (VHA); Minneapolis VA Health Care System	Mantyh, PW (corresponding author), Univ Minnesota, Dept Prevent Sci, Minneapolis, MN 55455 USA.			Lappi, Douglas/0000-0003-4239-7387	NIDCR NIH HHS [DEO 7288] Funding Source: Medline; PHS HHS [23970, 31223] Funding Source: Medline	NIDCR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Dental & Craniofacial Research (NIDCR)); PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		ARNER S, 1988, PAIN, V33, P11, DOI 10.1016/0304-3959(88)90198-4; Bozic CR, 1996, SCIENCE, V273, P1722, DOI 10.1126/science.273.5282.1722; BROWN JL, 1995, J COMP NEUROL, V356, P327, DOI 10.1002/cne.903560302; CALVINO B, 1990, PHYSIOL BEHAV, V47, P907, DOI 10.1016/0031-9384(90)90018-Y; Cao YQ, 1998, NATURE, V392, P390, DOI 10.1038/32897; COGGESHALL RE, 1992, TRENDS NEUROSCI, V15, P9, DOI 10.1016/0166-2236(92)90339-A; De Felipe C, 1998, NATURE, V392, P394, DOI 10.1038/32904; DING YQ, 1995, BRAIN RES, V674, P336, DOI 10.1016/0006-8993(95)00022-I; Doyle CA, 1999, NEUROSCIENCE, V89, P17, DOI 10.1016/S0306-4522(98)00276-0; DUBNER R, 1989, J NEUROPHYSIOL, V62, P450, DOI 10.1152/jn.1989.62.2.450; DUBUISSON D, 1977, PAIN, V4, P161, DOI 10.1016/0304-3959(77)90130-0; Fields HL, 1998, NEUROBIOL DIS, V5, P209, DOI 10.1006/nbdi.1998.0204; KIM SH, 1992, PAIN, V50, P355, DOI 10.1016/0304-3959(92)90041-9; KOCHER L, 1987, PAIN, V29, P363, DOI 10.1016/0304-3959(87)90051-0; Koltzenburg M, 1998, CURR OPIN NEUROL, V11, P515, DOI 10.1097/00019052-199810000-00014; Kramer MS, 1998, SCIENCE, V281, P1640, DOI 10.1126/science.281.5383.1640; LITTLEWOOD NK, 1995, NEUROSCIENCE, V66, P597, DOI 10.1016/0306-4522(95)00039-L; Mantyh PW, 1997, SCIENCE, V278, P275, DOI 10.1126/science.278.5336.275; Marshall GE, 1996, NEUROSCIENCE, V72, P255, DOI 10.1016/0306-4522(95)00558-7; MAYER DJ, 1975, PAIN, V1, P51, DOI 10.1016/0304-3959(75)90004-4; MILLAN MJ, 1988, PAIN, V35, P299, DOI 10.1016/0304-3959(88)90140-6; MULLEN RJ, 1992, DEVELOPMENT, V116, P201; PORRO CA, 1991, EXP BRAIN RES, V83, P549; SIMONE DA, 1991, J NEUROPHYSIOL, V66, P228, DOI 10.1152/jn.1991.66.1.228; Suhonen JO, 1996, NATURE, V383, P624, DOI 10.1038/383624a0	25	346	360	0	26	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1558	1561		10.1126/science.286.5444.1558	http://dx.doi.org/10.1126/science.286.5444.1558			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567262				2022-12-28	WOS:000083768300058
J	Shi, C; Huang, Z; Kilic, S; Xu, J; Enick, RM; Beckman, EJ; Carr, AJ; Melendez, RE; Hamilton, AD				Shi, C; Huang, Z; Kilic, S; Xu, J; Enick, RM; Beckman, EJ; Carr, AJ; Melendez, RE; Hamilton, AD			The gelation of CO2: A sustainable route to the creation of microcellular materials	SCIENCE			English	Article							SUPERCRITICAL CARBON-DIOXIDE; POLYMERIZATION; AGGREGATION; SCATTERING; BEHAVIOR	Compounds with strong thermodynamic affinity for carbon dioxide (CO2) have been designed and synthesized that dissolve in CO2, then associate to form gels. Upon removal of the CO2, these gels produced free-standing foams with cells with an average diameter smaller than 1 micrometer and a bulk density reduction of 97 percent relative to the parent material.	Yale Univ, Dept Chem, New Haven, CT 06520 USA; Univ Pittsburgh, Dept Chem & Petr Engn, Pittsburgh, PA 15261 USA	Yale University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Hamilton, AD (corresponding author), Yale Univ, Dept Chem, 225 Prospect St, New Haven, CT 06520 USA.		Kilic, Sevgi/F-9922-2011	Kilic, Sevgi/0000-0002-1184-0123				BECKMAN EJ, 1999, ENG FDN C SUP FLUIDS; Darensbourg DJ, 1996, COORDIN CHEM REV, V153, P155, DOI 10.1016/0010-8545(95)01232-X; DESIMONE JM, 1992, SCIENCE, V257, P945, DOI 10.1126/science.257.5072.945; ENDO K, 1995, J AM CHEM SOC, V117, P8341, DOI 10.1021/ja00137a007; FREDERICKS JR, 1996, COMPREHENSIVE SUPRAM, V9, P565; FULTON JL, 1995, LANGMUIR, V11, P4241, DOI 10.1021/la00011a014; GOEL SK, 1994, POLYM ENG SCI, V34, P1137, DOI 10.1002/pen.760341407; GOEL SK, 1994, POLYM ENG SCI, V34, P1148, DOI 10.1002/pen.760341408; GULIKKRZYWICKI T, 1993, P NATL ACAD SCI USA, V90, P163, DOI 10.1073/pnas.90.1.163; HANABUSA K, 1992, J CHEM SOC CHEM COMM, P1371, DOI 10.1039/c39920001371; Hancu D, 1999, IND ENG CHEM RES, V38, P2833, DOI 10.1021/ie9807396; Hancu D, 1999, IND ENG CHEM RES, V38, P2824, DOI 10.1021/ie980738d; Jessop PG, 1999, CHEM REV, V99, P475, DOI 10.1021/cr970037a; Klempner D, 1991, POLYM FOAMS; Lepilleur C, 1997, MACROMOLECULES, V30, P745, DOI 10.1021/ma960764s; Maitra U, 1999, CHEM COMMUN, P595, DOI 10.1039/a809821b; Mesiano AJ, 1999, CHEM REV, V99, P623, DOI 10.1021/cr970040u; ONeill ML, 1997, MACROMOLECULES, V30, P5050, DOI 10.1021/ma9616930; Parks KL, 1996, POLYM ENG SCI, V36, P2417, DOI 10.1002/pen.10640; Pitsikalis M, 1996, MACROMOLECULES, V29, P179, DOI 10.1021/ma951001s; Super MS, 1997, TRENDS POLYM SCI, V5, P236; UNG AT, 1991, J CHEM SOC CHEM COMM, P1012, DOI 10.1039/c39910001012; VANHOORNE P, 1995, MACROMOLECULES, V28, P5664, DOI 10.1021/ma00120a036	23	201	209	2	58	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	NOV 19	1999	286	5444					1540	1543		10.1126/science.286.5444.1540	http://dx.doi.org/10.1126/science.286.5444.1540			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567255				2022-12-28	WOS:000083768300051
J	Vanzetta, I; Grinvald, A				Vanzetta, I; Grinvald, A			Increased cortical oxidative metabolism due to sensory stimulation: Implications for functional brain imaging	SCIENCE			English	Article							HUMAN VISUAL-CORTEX; POSITRON-EMISSION TOMOGRAPHY; CEREBRAL BLOOD OXYGENATION; RETINOTOPIC ORGANIZATION; GLUCOSE CONSUMPTION; FLUORESCENCE DECAY; INTRINSIC SIGNALS; NEURONAL-ACTIVITY; OCULAR-DOMINANCE; NEURAL ACTIVITY	Modern functional brain mapping relies on interactions of neuronal electrical activity with the cortical microcirculation. The existence of a highly localized, stimulus-evoked initial deoxygenation has remained a controversy. Here, the activity-dependent oxygen tension changes in the microcirculation were measured directly, using oxygen-dependent phosphorescence quenching of an exogenous indicator. The first event after sensory stimulation was an increase in oxygen consumption, followed by an increase in blood flow. Because oxygen consumption and neuronal activity are colocalized but the delayed blood flow is not, functional magnetic resonance imaging focused on this initial phase will yield much higher spatial resolution, ultimately enabling the noninvasive visualization of fundamental processing modules in the human brain.	Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel	Weizmann Institute of Science	Vanzetta, I (corresponding author), Weizmann Inst Sci, Ctr Res Higher Brain Funct, Dept Neurobiol, IL-76100 Rehovot, Israel.							BARTFELD E, 1992, P NATL ACAD SCI USA, V89, P11905, DOI 10.1073/pnas.89.24.11905; BELLIVEAU JW, 1991, SCIENCE, V254, P716, DOI 10.1126/science.1948051; BLOMQVIST G, 1994, ACTA PHYSIOL SCAND, V151, P29, DOI 10.1111/j.1748-1716.1994.tb09718.x; BONHOEFFER T, 1991, NATURE, V353, P429, DOI 10.1038/353429a0; Buxton RB, 1998, MAGNET RESON MED, V39, P855, DOI 10.1002/mrm.1910390602; Buxton RB, 1997, J CEREBR BLOOD F MET, V17, P64, DOI 10.1097/00004647-199701000-00009; CHANCE B, 1962, NATURE, V195, P956, DOI 10.1038/195956a0; DeYoe EA, 1996, P NATL ACAD SCI USA, V93, P2382, DOI 10.1073/pnas.93.6.2382; Engel SA, 1997, CEREB CORTEX, V7, P181, DOI 10.1093/cercor/7.2.181; FILHO IPT, 1993, AM J PHYSIOL, V265, pH1434; FOX PT, 1986, NATURE, V323, P806, DOI 10.1038/323806a0; FOX PT, 1985, ANN NEUROL, V17, P303, DOI 10.1002/ana.410170315; FOX PT, 1988, SCIENCE, V241, P462, DOI 10.1126/science.3260686; FOX PT, 1987, J NEUROSCI, V7, P913; Frahm J, 1997, ADV EXP MED BIOL, V413, P195; Fransson P, 1998, MAGNET RESON MED, V39, P912, DOI 10.1002/mrm.1910390608; FROSTIG RD, 1990, P NATL ACAD SCI USA, V87, P6082, DOI 10.1073/pnas.87.16.6082; Fujita H, 1999, J CEREBR BLOOD F MET, V19, P266, DOI 10.1097/00004647-199903000-00004; GRINVALD A, 1974, ANAL BIOCHEM, V59, P583, DOI 10.1016/0003-2697(74)90312-1; GRINVALD A, 1986, NATURE, V324, P361, DOI 10.1038/324361a0; GRINVALD A, 1972, P NATL ACAD SCI USA, V69, P2273, DOI 10.1073/pnas.69.8.2273; Hu XP, 1997, MAGNET RESON MED, V37, P877, DOI 10.1002/mrm.1910370612; Hubener M, 1997, J NEUROSCI, V17, P9270; Hyder F, 1996, P NATL ACAD SCI USA, V93, P7612, DOI 10.1073/pnas.93.15.7612; IADECOLA C, 1993, TRENDS NEUROSCI, V16, P206, DOI 10.1016/0166-2236(93)90156-G; KATO M, 1974, EXP NEUROL, V42, P65, DOI 10.1016/0014-4886(74)90006-5; Kerger H, 1997, ANESTHESIOLOGY, V86, P372, DOI 10.1097/00000542-199702000-00012; KERGER H, 1995, AM J PHYSIOL-HEART C, V268, pH802, DOI 10.1152/ajpheart.1995.268.2.H802; KETY SS, 1955, AM SOC PHYS ABSTR, V85; KIM DS, 1999, NEUR ABSTR, V25, P783; Kleinfeld D, 1998, P NATL ACAD SCI USA, V95, P15741, DOI 10.1073/pnas.95.26.15741; Kleinschmidt A, 1996, J CEREBR BLOOD F MET, V16, P817, DOI 10.1097/00004647-199609000-00006; Kruger G, 1996, MAGNET RESON MED, V35, P797, DOI 10.1002/mrm.1910350602; KWONG KK, 1992, P NATL ACAD SCI USA, V89, P5675, DOI 10.1073/pnas.89.12.5675; LASSEN NA, 1961, EXPERIENTIA, V17, P42, DOI 10.1007/BF02157946; LINDAUER U, 1999, NEUR ABSTR, V25, P1639; LIPTON P, 1973, BIOCHEM J, V136, P999, DOI 10.1042/bj1360999; Lo LW, 1996, ANAL BIOCHEM, V236, P153, DOI 10.1006/abio.1996.0144; Lo LW, 1997, ADV EXP MED BIOL, V428, P651; Logothetis NK, 1999, NAT NEUROSCI, V2, P555, DOI 10.1038/9210; LOTHMAN E, 1975, BRAIN RES, V88, P15, DOI 10.1016/0006-8993(75)90943-9; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; Malonek D, 1996, SCIENCE, V272, P551, DOI 10.1126/science.272.5261.551; Malonek D, 1997, P NATL ACAD SCI USA, V94, P14826, DOI 10.1073/pnas.94.26.14826; Marota JJA, 1999, MAGNET RESON MED, V41, P247, DOI 10.1002/(SICI)1522-2594(199902)41:2<247::AID-MRM6>3.0.CO;2-U; Mayhew J, 1999, NEUROIMAGE, V10, P304, DOI 10.1006/nimg.1999.0460; Mayhew J, 1998, NEUROIMAGE, V7, P49, DOI 10.1006/nimg.1997.0311; Menon RS, 1997, J NEUROPHYSIOL, V77, P2780, DOI 10.1152/jn.1997.77.5.2780; Menon RS, 1999, MAGNET RESON MED, V41, P230, DOI 10.1002/(SICI)1522-2594(199902)41:2<230::AID-MRM3>3.0.CO;2-O; Nemoto M, 1999, J CEREBR BLOOD F MET, V19, P246, DOI 10.1097/00004647-199903000-00002; OGAWA S, 1992, P NATL ACAD SCI USA, V89, P5951, DOI 10.1073/pnas.89.13.5951; PAWLOWSKI M, 1999, ADV EXP MED BIOL, V316, P179; RATZLAFF EH, 1991, J NEUROSCI METH, V36, P127, DOI 10.1016/0165-0270(91)90038-2; Roy C S, 1890, J Physiol, V11, P85; RUMSEY WL, 1988, SCIENCE, V241, P1649, DOI 10.1126/science.3420417; SERENO MI, 1995, SCIENCE, V268, P889, DOI 10.1126/science.7754376; Shmuel A, 1996, J NEUROSCI, V16, P6945; SHTOYERMAN E, UNPUB; SILVER IA, 1978, CEREBRAL VASCULAR SM, V56, P49; SOKOLOFF L, 1977, J NEUROCHEM, V29, P13, DOI 10.1111/j.1471-4159.1977.tb03919.x; TOOTELL RBH, 1995, J NEUROSCI, V15, P3215; TSO DY, 1990, SCIENCE, V240, P333; TURNER R, 1993, MAGNET RESON MED, V29, P277, DOI 10.1002/mrm.1910290221; Vafaee MS, 1999, J CEREBR BLOOD F MET, V19, P272, DOI 10.1097/00004647-199903000-00005; VANZETTA L, UNPUB; VINOGRADOV SA, 1994, ADV EXP MED BIOL, V361, P67; Wang G, 1996, SCIENCE, V272, P1665, DOI 10.1126/science.272.5268.1665; Weliky M, 1996, NATURE, V379, P725, DOI 10.1038/379725a0; Wilson D F, 1987, Adv Exp Med Biol, V215, P71; WILSON DF, 1988, J BIOL CHEM, V263, P2712; WILSON DF, 1993, ADV EXP MED BIOL, V333, P225; Yacoub E, 1999, MAGN RESON MED, V41, P436, DOI 10.1002/(SICI)1522-2594(199903)41:3<436::AID-MRM2>3.0.CO;2-#	72	236	241	2	12	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1555	1558		10.1126/science.286.5444.1555	http://dx.doi.org/10.1126/science.286.5444.1555			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567261				2022-12-28	WOS:000083768300057
J	Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G				Annibale, B; Marignani, M; Monarca, B; Antonelli, G; Marcheggiano, A; Martino, G; Mandelli, F; Caprilli, R; Delle Fave, G			Reversal of iron deficiency anemia after Helicobacter pylori eradication in patients with asymptomatic gastritis	ANNALS OF INTERNAL MEDICINE			English	Article							SYDNEY SYSTEM; INFECTION; CLASSIFICATION; FERRITIN	Background: Iron deficiency anemia is the most common form of anemia worldwide. Recent studies have suggested an association between Helicobacter pylori infection and iron deficiency. Objective: To investigate the effects of eradicating H. pylori with combination antibiotic therapy on iron deficiency anemia in patients with H. pylori-associated gastritis. Design: Case series. Setting: University hospital. Patients: 30 patients with a long history of iron deficiency anemia in whom H. pylori-associated gastritis was the only pathologic gastrointestinal finding detected. Intervention: Eradication therapy with two antibiotics and discontinuation of iron replacement therapy. Measurements: Complete blood count ferritin levels, and gastroscopy with biopsy to evaluate H. pylori status. Results: At 6 months, 75% of patients had recovered from anemia (P < 0.001), ferritin values increased from 5.7 +/- 0.7 mu g/L to 24.5 +/- 5.2 mu g/L (95% CI, 8.85 to 29.97). After 12 months, 91.7% of patients had recovered from anemia. Conclusions: Cure of H, pylori infection is associated with reversal of iron dependence and recovery from iron deficiency anemia.	Univ Roma La Sapienza, Rome, Italy	Sapienza University Rome	Annibale, B (corresponding author), Univ Rome, Policlin Umberto I, Dept Clin Med 2, I-00161 Rome, Italy.		Annibale, Bruno/A-5372-2008	Annibale, Bruno/0000-0001-9120-5957; Marignani, Massimo/0000-0002-8912-9972				BAIRD IM, 1959, Q J MED, V28, P21; BANERJEE S, 1994, GUT, V35, P317, DOI 10.1136/gut.35.3.317; BAYERDORFFER E, 1992, GASTROENTEROLOGY, V102, P1575, DOI 10.1016/0016-5085(92)91716-H; Carnicer J, 1997, J PEDIATR GASTR NUTR, V25, P441, DOI 10.1097/00005176-199710000-00017; Dixon MF, 1996, AM J SURG PATHOL, V20, P1161, DOI 10.1097/00000478-199610000-00001; DOIG P, 1993, J BACTERIOL, V175, P557, DOI 10.1128/JB.175.2.557-560.1993; DOOLEY CP, 1989, NEW ENGL J MED, V321, P1562, DOI 10.1056/NEJM198912073212302; DUFOUR C, 1993, J PEDIATR GASTR NUTR, V17, P225, DOI 10.1097/00005176-199308000-00018; HALLEBERG L, 1993, DAVIDSON PASSMORE HU, P174; HUSSON MO, 1993, INFECT IMMUN, V61, P2694, DOI 10.1128/IAI.61.6.2694-2697.1993; LAINE L, 1998, SLEISENGER FORDTRANS, P198; Marignani M, 1996, CURR THER RES CLIN E, V57, P544, DOI 10.1016/S0011-393X(96)80064-6; Marignani M, 1999, AM J GASTROENTEROL, V94, P766; Marignani M, 1997, SCAND J GASTROENTERO, V32, P617, DOI 10.3109/00365529709025109; Meining A, 1997, VIRCHOWS ARCH, V431, P11, DOI 10.1007/s004280050063; Milman N, 1998, GASTROENTEROLOGY, V115, P268, DOI 10.1016/S0016-5085(98)70192-1; Peach HG, 1998, MED J AUSTRALIA, V169, P188, DOI 10.5694/j.1326-5377.1998.tb140218.x; ROCKEY DC, 1993, NEW ENGL J MED, V329, P1691, DOI 10.1056/NEJM199312023292303; ZAITOUN AM, 1994, J CLIN PATHOL, V47, P810, DOI 10.1136/jcp.47.9.810; Zhang ZW, 1998, GUT, V43, P322, DOI 10.1136/gut.43.3.322	20	172	178	0	9	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 2	1999	131	9					668	672		10.7326/0003-4819-131-9-199911020-00006	http://dx.doi.org/10.7326/0003-4819-131-9-199911020-00006			5	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251LB	10577329				2022-12-28	WOS:000083446200005
J	Weissmann, C; Aguzzi, A				Weissmann, C; Aguzzi, A			Perspectives: Neurobiology - PrP's double causes trouble	SCIENCE			English	Editorial Material							SCRAPIE; PROTEIN; LESIONS; GENE		St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, London W2 1PG, England; Univ Spital Zurich, Inst Neuropathol, CH-8091 Zurich, Switzerland	Imperial College London; University of Zurich; University Zurich Hospital	Weissmann, C (corresponding author), St Marys Hosp, Imperial Coll Sch Med, MRC, Prion Unit Neurogenet, Praed St, London W2 1PG, England.		Aguzzi, Adriano/A-3351-2008	Aguzzi, Adriano/0000-0002-0344-6708				BUELER H, 1993, CELL, V73, P1339, DOI 10.1016/0092-8674(93)90360-3; BUELER H, 1992, NATURE, V356, P577, DOI 10.1038/356577a0; COZZIO A, UNPUB; FLECHSIG E, UNPUB; MANSON JC, 1994, NEURODEGENERATION, V3, P331; Moore RC, 1999, J MOL BIOL, V292, P797, DOI 10.1006/jmbi.1999.3108; Nishida N, 1999, LAB INVEST, V79, P689; Prusiner SB, 1998, P NATL ACAD SCI USA, V95, P13363, DOI 10.1073/pnas.95.23.13363; Riek R, 1997, FEBS LETT, V413, P282, DOI 10.1016/S0014-5793(97)00920-4; Sakaguchi S, 1996, NATURE, V380, P528, DOI 10.1038/380528a0; Shmerling D, 1998, CELL, V93, P203, DOI 10.1016/S0092-8674(00)81572-X; Weissmann C, 1996, CURR BIOL, V6, P1359, DOI 10.1016/S0960-9822(96)00729-4; WESTAWAY D, COMMUNICATION	13	80	83	0	1	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					914	915		10.1126/science.286.5441.914	http://dx.doi.org/10.1126/science.286.5441.914			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10577243				2022-12-28	WOS:000083368500033
J	Peters, R; Sikorski, R				Peters, R; Sikorski, R			Immunotherapy - PEG antibodies	SCIENCE			English	Article									Mednavcom, Byfield, MA 01922 USA		Peters, R (corresponding author), Mednavcom, Byfield, MA 01922 USA.							Chapman AP, 1999, NAT BIOTECHNOL, V17, P780, DOI 10.1038/11717	1	6	6	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 15	1999	286	5439					434	434		10.1126/science.286.5439.434	http://dx.doi.org/10.1126/science.286.5439.434			1	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577206				2022-12-28	WOS:000083121200037
J	Salpeter, MM				Salpeter, MM			Neurobiology - The constant junction	SCIENCE			English	Editorial Material							NICOTINIC ACETYLCHOLINE-RECEPTORS; NEUROMUSCULAR-JUNCTION; VERTEBRATE MUSCLE; STABILIZATION; DEGRADATION; SYNAPSE; AGRIN; NERVE		Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA	Cornell University	Salpeter, MM (corresponding author), Cornell Univ, Dept Neurobiol & Behav, Ithaca, NY 14853 USA.	mms13@cornell.edu			NINDS NIH HHS [NS09315] Funding Source: Medline	NINDS NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS))		Akaaboune M, 1999, SCIENCE, V286, P503, DOI 10.1126/science.286.5439.503; ANDREOSE JS, 1993, J NEUROSCI, V13, P3433; FAMBROUGH DM, 1979, PHYSIOL REV, V59, P165, DOI 10.1152/physrev.1979.59.1.165; Fischbach GD, 1997, ANNU REV NEUROSCI, V20, P429, DOI 10.1146/annurev.neuro.20.1.429; FROEHNER SC, 1990, NEURON, V5, P403, DOI 10.1016/0896-6273(90)90079-U; FUMAGALLI G, 1982, J NEUROPATH EXP NEUR, V41, P567, DOI 10.1097/00005072-198211000-00001; HALL ZW, 1993, CELL, V72, P99, DOI 10.1016/S0092-8674(05)80031-5; Mammen AL, 1997, J NEUROSCI, V17, P7351; MCMAHAN UJ, 1990, COLD SPRING HARB SYM, V55, P407; Meier T, 1998, J CELL BIOL, V141, P715, DOI 10.1083/jcb.141.3.715; RAMSAY DA, 1992, BRAIN RES, V581, P198, DOI 10.1016/0006-8993(92)90709-I; SALPETER MM, 1988, J CELL BIOL, V106, P2087, DOI 10.1083/jcb.106.6.2087; SALPETER MM, 1985, PROG NEUROBIOL, V25, P297, DOI 10.1016/0301-0082(85)90018-8; SALPETER MM, 1987, VERTEBRATE NEUROMUSC, P35; Sanes JR, 1999, ANNU REV NEUROSCI, V22, P389, DOI 10.1146/annurev.neuro.22.1.389; SHYNG SL, 1990, J NEUROSCI, V10, P3905, DOI 10.1523/JNEUROSCI.10-12-03905.1990; Stiles JR, 1997, NEUROSCIENCE, V78, P895, DOI 10.1016/S0306-4522(96)00628-8; Wang ZZ, 1999, J NEUROSCI, V19, P1998; Xu RF, 1997, J NEUROSCI, V17, P8194; Xu RF, 1999, J CELL PHYSIOL, V181, P107, DOI 10.1002/(SICI)1097-4652(199910)181:1<107::AID-JCP11>3.3.CO;2-0	20	12	14	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					424	425		10.1126/science.286.5439.424	http://dx.doi.org/10.1126/science.286.5439.424			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577204				2022-12-28	WOS:000083121200031
J	Bateman, AW; Fonagy, P				Bateman, AW; Fonagy, P			Psychotherapy for severe personality disorder - Article did not do justice to available research data	BMJ-BRITISH MEDICAL JOURNAL			English	Letter									St Anns Hosp, London N15 3TH, England; UCL, Psychoanal Unit, London WC1E 6BT, England	University of London; University College London	Bateman, AW (corresponding author), St Anns Hosp, London N15 3TH, England.	anthony@mullins.demon.co.uk	Kisely, Steve/B-4680-2012	Kisely, Steve/0000-0003-4021-2924; Fonagy, Peter/0000-0003-0229-0091				BATEMAN AW, IN PRESS BR J PSYCHI; BATEMAN AW, IN PRESS AM J PHYSL; Kisely S, 1999, BMJ-BRIT MED J, V318, P1410, DOI 10.1136/bmj.318.7195.1410; *NHS EX, 1996, NHS PSYCH SERV ENGL	4	7	7	0	1	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1756-1833			BMJ-BRIT MED J	BMJ-British Medical Journal	SEP 11	1999	319	7211					709	710						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	237CH	10576823				2022-12-28	WOS:000082636800049
J	Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG				Crabtree, TD; Pelletier, SJ; Gleason, TG; Pruett, TL; Sawyer, RG			Gender-dependent differences in outcome after the treatment of infection in hospitalized patients	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							ACUTE MYOCARDIAL-INFARCTION; RISK-FACTORS; MECHANICAL VENTILATION; MORTALITY; WOMEN; SEPSIS; IMPACT; MEN; MANAGEMENT; SEVERITY	Context While it is established that management strategies and outcomes differ by gender for many diseases, its effect on infection has not been adequately studied. Objective To investigate the role of gender among hospitalized patients treated for infection. Design Observational cohort study conducted during a 26-month period from December 1996 through January 1999. Setting University-affiliated hospital. Participants A total of 892 patients in the surgical units of the hospital with 1470 consecutive infectious episodes (782 in men and 688 in women). Main Outcome Measures Mortality during hospitalization by gender for infection episodes overall and for specific infectious sites, including lung, peritoneum, bloodstream, catheter, urine, surgical site, and skin/soft tissue. Results Among all infections, there was no significant difference in mortality based on gender (men, 11.1% vs women, 14.2%; P = .07). After logistic regression analysis, factors independently associated with mortality included higher APACHE (Acute Physiology and Chronic Health Evaluation) II score; older age, malignancy, blood transfusion, and diagnosis of infection more than 7 days after admission, but not gender (female odds ratio [OR] for death, 1.32; 95% confidence interval [CI],0.90-1.94; P = .16). Mortality was higher in women for lung (men, 18% vs women, 34%; P = .002) and soft tissue (men, 2% vs women, 10%; P less than or equal to .05) infection; for other infectious sites, mortality did not differ by gender. Factors associated with mortality due to pneumonia by logistic regression included higher APACHE II score, malignancy, diabetes mellitus, diagnosis of infection more than 7 days after admission, older age, transplantation, and female gender (OR for death, 2.25; 95% CI, 1.17-4.32; P = .02). Conclusions Although gender may not be predictive of mortality among all infections, women appear to be at increased risk for death from hospital-acquired pneumonia, even after controlling for other comorbidities.	Univ Virginia, Hlth Sci Ctr, Dept Surg, Charlottesville, VA 22906 USA; Univ Virginia, Hlth Sci Ctr, Dept Internal Med, Charlottesville, VA 22906 USA	University of Virginia; University of Virginia	Sawyer, RG (corresponding author), Univ Virginia, Hlth Sci Ctr, Dept Surg, Box 10005, Charlottesville, VA 22906 USA.			Sawyer, Robert/0000-0002-8155-2661				Angele MK, 1998, ARCH SURG-CHICAGO, V133, P1281, DOI 10.1001/archsurg.133.12.1281; BONE CR, 1992, AM REV RESPIR DIS, V146, P528, DOI 10.1164/ajrccm/146.2.528; Elliott DC, 1996, ANN SURG, V224, P672, DOI 10.1097/00000658-199611000-00011; KNAUS WA, 1985, CRIT CARE MED, V13, P818, DOI 10.1097/00003246-198510000-00009; Kollef MH, 1997, CHEST, V111, P434, DOI 10.1378/chest.111.2.434; Kollef MH, 1997, CHEST, V112, P666, DOI 10.1378/chest.112.3.666; KOLLEF MH, 1993, HEART LUNG, V22, P442; KUBO SH, 1995, J HEART LUNG TRANSPL, V14, P409; Malacrida R, 1998, NEW ENGL J MED, V338, P8, DOI 10.1056/NEJM199801013380102; MAYNARD C, 1992, ARCH INTERN MED, V152, P972, DOI 10.1001/archinte.152.5.972; MORO ML, 1994, INFECT CONT HOSP EP, V15, P253; ORENTLICHER D, 1991, JAMA-J AM MED ASSOC, V266, P559; PEARSON ML, 1992, JAMA-J AM MED ASSOC, V268, P1883, DOI 10.1001/jama.268.14.1883; Pittet D, 1997, P ASSOC AM PHYSICIAN, V109, P58; Rello J, 1997, CRIT CARE MED, V25, P1862, DOI 10.1097/00003246-199711000-00026; SARIS GE, 1994, J THORAC CARDIOVASC, V108, P240; Schroder J, 1998, ARCH SURG-CHICAGO, V133, P1200, DOI 10.1001/archsurg.133.11.1200; Singh N, 1998, CHEST, V114, P1129, DOI 10.1378/chest.114.4.1129; Stone PH, 1996, JAMA-J AM MED ASSOC, V275, P1104, DOI 10.1001/jama.275.14.1104; Stroud L, 1996, INFECT CONT HOSP EP, V17, P576; TOFLER GH, 1989, AM J CARDIOL, V64, P256, DOI 10.1016/0002-9149(89)90476-1; Weaver WD, 1996, JAMA-J AM MED ASSOC, V275, P777, DOI 10.1001/jama.275.10.777; Zellweger R, 1997, CRIT CARE MED, V25, P106, DOI 10.1097/00003246-199701000-00021; Ziser A, 1999, ANESTHESIOLOGY, V90, P42, DOI 10.1097/00000542-199901000-00008	24	90	91	0	4	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2143	2148		10.1001/jama.282.22.2143	http://dx.doi.org/10.1001/jama.282.22.2143			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260UG	10591336	Bronze			2022-12-28	WOS:000083971400033
J	Goes, S; Spakman, W; Bijwaard, H				Goes, S; Spakman, W; Bijwaard, H			A lower mantle source for central European volcanism	SCIENCE			English	Article							CENOZOIC RIFT SYSTEM; SEISMIC EVIDENCE; TRANSITION ZONE; PLUME BENEATH; TRAVEL-TIMES; STRESS-FIELD; TOMOGRAPHY; MAGMATISM; ATLANTIC; WESTERN	Cenozoic rifting and volcanism in Europe have been associated with either passive or active mantle upwellings. Tomographic images show a Low velocity structure between 660- and 2000-kilometer depth, which we propose to represent a Lower mantle upwelling under central Europe that may feed smaller upper-mantle plumes. The position of the rift zones in the foreland of the Alpine belts and the relatively weak volcanism compared to other regions with plume-associated volcanism are probably the result of the past and present subduction under southern Europe.	Univ Utrecht, Vening Mienesz Res Sch Geodynam, NL-3508 TA Utrecht, Netherlands	Utrecht University	Goes, S (corresponding author), ETH Honggerberg, Inst Geophys, CH-8093 Zurich, Switzerland.			Spakman, Wim/0000-0002-9557-778X; Goes, Saskia/0000-0002-2231-2553				AHORNER L, 1983, PLATEAU UPLIFT, P187; ANDERSON DL, 1982, NATURE, V297, P391, DOI 10.1038/297391a0; Bijwaard H, 1999, EARTH PLANET SC LETT, V166, P121, DOI 10.1016/S0012-821X(99)00004-7; Bijwaard H, 1998, J GEOPHYS RES-SOL EA, V103, P30055, DOI 10.1029/98JB02467; BIJWAARD H, 1999, THESIS UTRECHT U NET; Carminati E, 1998, EARTH PLANET SC LETT, V160, P651, DOI 10.1016/S0012-821X(98)00118-6; Downes H, 1987, GEOL SOC SPEC PUBL, V30, P517; DUNAI TJ, 1995, GEOCHIM COSMOCHIM AC, V59, P2767, DOI 10.1016/0016-7037(95)00172-V; DUNCAN RA, 1972, NATURE, V239, P82, DOI 10.1038/239082a0; Engdahl ER, 1998, B SEISMOL SOC AM, V88, P722; FROIDEVAUX C, 1974, NATURE, V248, P749, DOI 10.1038/248749a0; GOES S, IN PRESS J GEOPHYS R; Golke M, 1996, TECTONOPHYSICS, V266, P11, DOI 10.1016/S0040-1951(96)00180-1; Grand SP., 1997, GSA TODAY, V7, P1; Granet M, 1995, EARTH PLANET SC LETT, V136, P281, DOI 10.1016/0012-821X(95)00174-B; GRANET M, 1989, GEOPHYS J INT, V99, P583, DOI 10.1111/j.1365-246X.1989.tb02043.x; GRIESSHABER E, 1992, CHEM GEOL, V99, P213, DOI 10.1016/0009-2541(92)90178-8; GRUNTHAL G, 1992, J GEOPHYS RES-SOL EA, V97, P11805, DOI 10.1029/91JB01963; Hanan BB, 1996, SCIENCE, V272, P991, DOI 10.1126/science.272.5264.991; HOERNLE K, 1995, NATURE, V374, P34, DOI 10.1038/374034a0; ILLIES JH, 1975, TECTONOPHYSICS, V29, P251, DOI 10.1016/0040-1951(75)90149-3; Ito G, 1996, EARTH PLANET SC LETT, V144, P53, DOI 10.1016/0012-821X(96)00151-3; KARATO S, 1993, GEOPHYS RES LETT, V20, P1623, DOI 10.1029/93GL01767; KENNETT BLN, 1995, GEOPHYS J INT, V122, P108, DOI 10.1111/j.1365-246X.1995.tb03540.x; LIPPOLT HJ, 1982, GEOL JB, V52, P113; LOOHUIS JJP, 1999, GEOPH RES ABS, V1, P85; Malzer H., 1983, PLATEAU UPLIFT RHENI, P164; MALZER H, 1986, P 3 WORKSH EUR GEOTR, P249; Marquering H, 1996, GEOPHYS J INT, V127, P283, DOI 10.1111/j.1365-246X.1996.tb04720.x; MULLER B, 1992, J GEOPHYS RES-SOL EA, V97, P11783, DOI 10.1029/91JB01096; Nakakuki T, 1997, EARTH PLANET SC LETT, V146, P379, DOI 10.1016/S0012-821X(96)00233-6; NATAF HC, 1993, NATURE, V364, P115, DOI 10.1038/364115a0; Oyarzun R, 1997, GEOLOGY, V25, P727, DOI 10.1130/0091-7613(1997)025<0727:OOTCAA>2.3.CO;2; RAIKES S, 1983, PLATEAU UPLIFT RHENI, P315; Shen Y, 1998, NATURE, V395, P62, DOI 10.1038/25714; SLEEP NH, 1990, J GEOPHYS RES-SOLID, V95, P6715, DOI 10.1029/JB095iB05p06715; SPAKMAN W, 1993, PHYS EARTH PLANET IN, V79, P3, DOI 10.1016/0031-9201(93)90142-V; SPAKMAN W, 1988, MATH GEOPHYSICS SURV; Steinbach V, 1997, PHYS EARTH PLANET IN, V103, P85, DOI 10.1016/S0031-9201(97)00022-8; Steinberger B, 1998, GEOPHYS J INT, V132, P412, DOI 10.1046/j.1365-246x.1998.00447.x; TACKLEY PJ, 1993, NATURE, V361, P699, DOI 10.1038/361699a0; Ulrych J, 1997, CHEM ERDE-GEOCHEM, V57, P311; van Keken PE, 1999, J GEOPHYS RES-SOL EA, V104, P7137, DOI 10.1029/1999JB900003; VANDECAR JC, 1995, NATURE, V378, P25, DOI 10.1038/378025a0; vanderHilst RD, 1997, NATURE, V386, P578, DOI 10.1038/386578a0; VANKEKEN PE, 1995, J GEOPHYS RES-SOL EA, V100, P20291, DOI 10.1029/95JB01152; Wedepohl KH, 1999, CONTRIB MINERAL PETR, V136, P225, DOI 10.1007/s004100050534; WHITE R, 1989, J GEOPHYS RES-SOLID, V94, P7685, DOI 10.1029/JB094iB06p07685; WILSON M, 1995, CONTRIB MINERAL PETR, V119, P181, DOI 10.1007/BF00307280; WILSON M, 1992, TECTONOPHYSICS, V208, P173, DOI 10.1016/0040-1951(92)90343-5; Wolfe CJ, 1997, NATURE, V385, P245, DOI 10.1038/385245a0; Yuen DA, 1998, EARTH PLANETS SPACE, V50, P1035, DOI 10.1186/BF03352198; ZIEGLER PA, 1992, TECTONOPHYSICS, V208, P91, DOI 10.1016/0040-1951(92)90338-7; ZIELHUIS A, 1994, GEOPHYS J INT, V117, P695, DOI 10.1111/j.1365-246X.1994.tb02463.x	54	193	195	0	31	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1928	1931		10.1126/science.286.5446.1928	http://dx.doi.org/10.1126/science.286.5446.1928			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583950				2022-12-28	WOS:000084003400043
J	Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB				Bonkowsky, JL; Yoshikawa, S; O'Keefe, DD; Scully, AL; Thomas, JB			Axon routing across the midline controlled by the Drosophila Derailed receptor	NATURE			English	Article							GROWTH CONE GUIDANCE; NEURONAL PATHWAY SELECTION; CNS MIDLINE; COMMISSURAL AXONS; GENETIC-ANALYSIS; NERVOUS-SYSTEM; PROTEIN; ENCODES; MEMBER; EXPRESSION	In nervous systems with symmetry about the midline, many neurons project axons from one side to the other. Although several of the components controlling midline crossing have been identified(1-4), little is known about how axons choose the appropriate pathway when crossing. For example, in the Drosophila embryo axons cross the midline in one of two distinct tracts, the anterior or posterior commissure (AC or PC, respectively). Here we show that the Derailed (Drl) receptor tyrosine kinase is expressed by neurons that project in the AC, and that in the absence of Drl such neurons often project abnormally into the PC. Conversely, misexpression of Drl in PC neurons forces them to cross in the AC. The behaviour of Drl-misexpressing neurons and the in vivo binding pattern of a soluble Drl receptor probe indicate that Drl acts as a guidance receptor for a repellent ligand present in the PC. Our results show that Drl is a novel component in the control of midline crossing.	Salk Inst Biol Studies, Mol Neurobiol Lab, San Diego, CA 92186 USA	Salk Institute	Thomas, JB (corresponding author), Salk Inst Biol Studies, Mol Neurobiol Lab, POB 85800, San Diego, CA 92186 USA.							Bonkowsky JL, 1999, MECH DEVELOP, V82, P181, DOI 10.1016/S0925-4773(99)00007-6; BRAND AH, 1993, DEVELOPMENT, V118, P401; Brose K, 1999, CELL, V96, P795, DOI 10.1016/S0092-8674(00)80590-5; CALLAHAN CA, 1995, NATURE, V376, P171, DOI 10.1038/376171a0; Callahan CA, 1996, DEVELOPMENT, V122, P2761; CALLAHAN CA, 1994, P NATL ACAD SCI USA, V91, P5972, DOI 10.1073/pnas.91.13.5972; Chan SSY, 1996, CELL, V87, P187, DOI 10.1016/S0092-8674(00)81337-9; CHEN G, 1994, BIOL CONTROL, V4, P157, DOI 10.1006/bcon.1994.1025; CHENG HJ, 1995, CELL, V82, P371, DOI 10.1016/0092-8674(95)90426-3; CREWS ST, 1988, CELL, V52, P143, DOI 10.1016/0092-8674(88)90538-7; Dittrich R, 1997, DEVELOPMENT, V124, P2515; Harris R, 1996, NEURON, V17, P217, DOI 10.1016/S0896-6273(00)80154-3; Higashijima S, 1996, DEVELOPMENT, V122, P527; HOVENS CM, 1992, P NATL ACAD SCI USA, V89, P11818, DOI 10.1073/pnas.89.24.11818; KENNEDY TE, 1994, CELL, V78, P425, DOI 10.1016/0092-8674(94)90421-9; Kidd T, 1998, CELL, V92, P205, DOI 10.1016/S0092-8674(00)80915-0; Kidd T, 1998, NEURON, V20, P25, DOI 10.1016/S0896-6273(00)80431-6; KIDD T, 1999, DROSOPHILA CELL, V96, P785; KLAMBT C, 1991, CELL, V64, P801, DOI 10.1016/0092-8674(91)90509-W; Kolodziej PA, 1996, CELL, V87, P197, DOI 10.1016/S0092-8674(00)81338-0; LUNDGREN SE, 1995, DEVELOPMENT, V121, P1769; Mitchell KJ, 1996, NEURON, V17, P203, DOI 10.1016/S0896-6273(00)80153-1; Moreau-Fauvarque C, 1998, MECH DEVELOP, V78, P47, DOI 10.1016/S0925-4773(98)00147-6; O'Keefe DD, 1998, DEVELOPMENT, V125, P3915; RUBIN GM, 1982, SCIENCE, V218, P348, DOI 10.1126/science.6289436; SEEGER M, 1993, NEURON, V10, P409, DOI 10.1016/0896-6273(93)90330-T; Simon AF, 1998, MECH DEVELOP, V76, P45, DOI 10.1016/S0925-4773(98)00104-X; Tear G, 1996, NEURON, V16, P501, DOI 10.1016/S0896-6273(00)80070-7; Thor S, 1999, NATURE, V397, P76, DOI 10.1038/16275; Thor S, 1997, NEURON, V18, P397, DOI 10.1016/S0896-6273(00)81241-6	30	105	106	1	3	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761					540	544		10.1038/990122	http://dx.doi.org/10.1038/990122			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MP	10591215				2022-12-28	WOS:000084013200059
J	Callahan, D				Callahan, D			Aging, death, and population health	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material									Hastings Ctr, Garrison, NY 10524 USA		Callahan, D (corresponding author), Hastings Ctr, Garrison, NY 10524 USA.							CALLAHAN D, 1989, JAMA-J AM MED ASSOC, V261, P905, DOI 10.1001/jama.261.6.905; Emanuel EJ, 1996, JAMA-J AM MED ASSOC, V275, P1907, DOI 10.1001/jama.275.24.1907; Larson E B, 1999, Jt Comm J Qual Improv, V25, P480	3	2	2	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 1	1999	282	21					2077	2077		10.1001/jama.282.21.2077	http://dx.doi.org/10.1001/jama.282.21.2077			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	259TB	10591393	hybrid			2022-12-28	WOS:000083908700030
J	Spurgeon, D				Spurgeon, D			Oocytes matured in vitro achieve high pregnancy rates	BRITISH MEDICAL JOURNAL			English	News Item																		1999, NEW ENGLAND J MED, V341, P1624	1	0	0	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	NOV 27	1999	319	7222					1388	1388		10.1136/bmj.319.7222.1388	http://dx.doi.org/10.1136/bmj.319.7222.1388			1	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	261EE	10574839	Green Published			2022-12-28	WOS:000083995200008
J	Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW				Qiu, YL; Lee, JH; Bernasconi-Quadroni, F; Soltis, DE; Soltis, PS; Zanis, M; Zimmer, EA; Chen, ZD; Savolainen, V; Chase, MW			The earliest angiosperms: evidence from mitochondrial, plastid and nuclear genomes	NATURE			English	Article							INFERRING COMPLEX PHYLOGENIES; NUCLEOTIDE-SEQUENCES; GENE RBCL; ORIGIN; PLANTS; POLLEN	Angiosperms have dominated the Earth's vegetation since the mid-Cretaceous (90 million years ago)(1), providing much of our food, fibre, medicine and timber, yet their origin and early evolution have remained enigmatic for over a century(2-8). One part of the enigma lies in the difficulty of identifying the earliest angiosperms; the other involves the uncertainty regarding the sister group of angiosperms among extant and fossil gymnosperms. Here we report a phylogenetic analysis of DNA sequences of five mitochondrial, plastid and nuclear genes (total aligned length 8,733 base pairs), from all basal angiosperm and gymnosperm lineages (105 species, 103 genera and 63 families). Our study demonstrates that Amborella, Nymphaeales and Illiciales-Trimeniaceae-Austrobaileya represent the first stage of angiosperm evolution, with Amborella being sister to all other angiosperms. We also show that Gnetales are related to the conifers and are not sister to the angiosperms, thus refuting the Anthophyte Hypothesis(1). These results have far-reaching implications for our understanding of diversification, adaptation, genome evolution and development of the angiosperms.	Univ Zurich, Inst Systemat Bot, CH-8008 Zurich, Switzerland; Washington State Univ, Sch Biol Sci, Pullman, WA 99164 USA; Smithsonian Inst, Lab Mol Systemat, Washington, DC 20560 USA; Royal Bot Gardens, Jodrell Lab, Richmond TW9 3DS, Surrey, England	University of Zurich; Washington State University; Smithsonian Institution; Royal Botanic Gardens, Kew	Qiu, YL (corresponding author), Univ Zurich, Inst Systemat Bot, Zollikerstr 107, CH-8008 Zurich, Switzerland.		Chase, Mark W/A-6642-2011; Soltis, Douglas/L-5957-2015; Soltis, Pamela S/GNH-5557-2022; Zimmer, Elizabeth/G-3890-2011; Soltis, Pamela S/L-5184-2015	Soltis, Pamela S/0000-0001-9310-8659; Zimmer, Elizabeth/0000-0003-3949-4290; Savolainen, Vincent/0000-0001-5350-9984; Kim, Sangtae/0000-0002-1821-4707				Arber EAN, 1907, J LINN SOC BOT, V38, P29, DOI [10.1111/j.1095-8339.1907.tb01074.x, DOI 10.1111/J.1095-8339.1907.TB01074.X]; CHASE MW, 1993, ANN MO BOT GARD, V80, P528, DOI 10.2307/2399846; CRANE PR, 1995, NATURE, V374, P27, DOI 10.1038/374027a0; Cronquist A., 1988, EVOLUTION CLASSIFICA; DARWIN C, 1903, MORE LETT C DARWIN R, V2, P26; Darwin C., 1903, MORE LETT C DARWIN R, VII, P20; Donoghue MJ, 1989, EVOLUTION SYSTEMATIC, V40A, P17; DOYLE JA, 1969, J ARNOLD ARBORETUM, V50, P1; DOYLE JA, 1978, ANNU REV ECOL SYST, V9, P365, DOI 10.1146/annurev.es.09.110178.002053; Endress PK, 1997, BOT J LINN SOC, V125, P93, DOI 10.1111/j.1095-8339.1997.tb02250.x; ENDRESS PK, 1986, PLANT SYST EVOL, V152, P1, DOI 10.1007/BF00985348; Friis EM, 1999, ANN MO BOT GARD, V86, P259, DOI 10.2307/2666179; FRIIS EM, 1994, PL SYST EVOL S, V8, P31; Graybeal A, 1998, SYST BIOL, V47, P9, DOI 10.1080/106351598260996; Hamby RK, 1992, MOL SYSTEMATICS PLAN, DOI DOI 10.1086/661633; Hillis DM, 1996, NATURE, V383, P130, DOI 10.1038/383130a0; MARTIN PG, 1991, ANN MO BOT GARD, V78, P296, DOI 10.2307/2399564; Mathews S, 1999, SCIENCE, V286, P947, DOI 10.1126/science.286.5441.947; Naylor GJP, 1997, NATURE, V388, P527, DOI 10.1038/41460; PARKINSON CL, IN PRESS CURR BIOL; QIU YL, 1993, ANN MO BOT GARD, V80, P587, DOI 10.2307/2399848; Qiu YL, 1999, TRENDS PLANT SCI, V4, P26, DOI 10.1016/S1360-1385(98)01361-2; Soltis DE, 1997, ANN MO BOT GARD, V84, P1, DOI 10.2307/2399952; Soltis DE, 1998, SYST BIOL, V47, P32, DOI 10.1080/106351598261012; Soltis PS, 1999, NATURE, V402, P402, DOI 10.1038/46528; Sun G, 1998, SCIENCE, V282, P1692, DOI 10.1126/science.282.5394.1692; Swofford D.L., 1998, PAUP 4 0B2 PHYLOGENE; Takhtajan A, 1969, FLOWERING PLANTS ORI; TAYLOR DW, 1990, SCIENCE, V247, P702, DOI 10.1126/science.247.4943.702; VONWETTSTEIN RR, 1907, HDB SYSTEMATISCHEN B, V2; WALKER JW, 1984, ANN MO BOT GARD, V71, P464, DOI 10.2307/2399035; WALKER JW, 1983, SCIENCE, V220, P1273, DOI 10.1126/science.220.4603.1273	32	666	722	6	136	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	NOV 25	1999	402	6760					404	407		10.1038/46536	http://dx.doi.org/10.1038/46536			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259VA	10586879				2022-12-28	WOS:000083913600054
J	Bird, AP; Wolffe, AP				Bird, AP; Wolffe, AP			Methylation-induced repression - Belts, braces, and chromatin	CELL			English	Review							CPG METHYLATION; DNA METHYLATION		Univ Edinburgh, Inst Cell & Mol Biol, Edinburgh EH9 3JR, Midlothian, Scotland; NICHHD, Mol Embryol Lab, NIH, Bethesda, MD 20892 USA	University of Edinburgh; National Institutes of Health (NIH) - USA; NIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD)	Bird, AP (corresponding author), Univ Edinburgh, Inst Cell & Mol Biol, Kings Bldg, Edinburgh EH9 3JR, Midlothian, Scotland.			Bird, Adrian/0000-0002-8600-0372				Amir RE, 1999, NAT GENET, V23, P185, DOI 10.1038/13810; Bhattacharya SK, 1999, NATURE, V397, P579, DOI 10.1038/17533; Cameron EE, 1999, NAT GENET, V21, P103, DOI 10.1038/5047; Coffee B, 1999, NAT GENET, V22, P98, DOI 10.1038/8807; Colot V, 1999, BIOESSAYS, V21, P402, DOI 10.1002/(SICI)1521-1878(199905)21:5<402::AID-BIES7>3.3.CO;2-2; Davey C, 1997, J MOL BIOL, V267, P276, DOI 10.1006/jmbi.1997.0899; Fujita N, 1999, MOL CELL BIOL, V19, P6415; Garrick D, 1998, NAT GENET, V18, P56, DOI 10.1038/ng0198-56; Hendrich B, 1998, MOL CELL BIOL, V18, P6538, DOI 10.1128/MCB.18.11.6538; Jaenisch R, 1997, TRENDS GENET, V13, P323, DOI 10.1016/S0168-9525(97)01180-3; Jeddeloh JA, 1999, NAT GENET, V22, P94, DOI 10.1038/8803; Jones PA, 1999, NAT GENET, V21, P163, DOI 10.1038/5947; Kass SU, 1997, CURR BIOL, V7, P157, DOI 10.1016/S0960-9822(97)70086-1; Knoepfler PS, 1999, CELL, V99, P447, DOI 10.1016/S0092-8674(00)81531-7; Ng HH, 1999, NAT GENET, V23, P58, DOI 10.1038/12659; Okano M, 1999, CELL, V99, P247, DOI 10.1016/S0092-8674(00)81656-6; Razin A, 1998, EMBO J, V17, P4905, DOI 10.1093/emboj/17.17.4905; Selker EU, 1999, CELL, V97, P157, DOI 10.1016/S0092-8674(00)80725-4; Tyler JK, 1999, CELL, V99, P443, DOI 10.1016/S0092-8674(00)81530-5; Wade PA, 1999, NAT GENET, V23, P62, DOI 10.1038/12664; Zhang Y, 1999, GENE DEV, V13, P1924, DOI 10.1101/gad.13.15.1924	21	1426	1505	0	82	CELL PRESS	CAMBRIDGE	1050 MASSACHUSETTES AVE, CIRCULATION DEPT, CAMBRIDGE, MA 02138 USA	0092-8674			CELL	Cell	NOV 24	1999	99	5					451	454		10.1016/S0092-8674(00)81532-9	http://dx.doi.org/10.1016/S0092-8674(00)81532-9			4	Biochemistry & Molecular Biology; Cell Biology	Science Citation Index Expanded (SCI-EXPANDED)	Biochemistry & Molecular Biology; Cell Biology	261AU	10589672	Bronze			2022-12-28	WOS:000083986300003
J	Kumana, CR; Cheung, BMY; Lauder, IJ				Kumana, CR; Cheung, BMY; Lauder, IJ			Gauging the impact of statins using number needed to treat	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Editorial Material							CORONARY HEART-DISEASE; PREVENTION; HYPERCHOLESTEROLEMIA; PRAVASTATIN		Univ Hong Kong, Dept Med, Hong Kong, Peoples R China; Univ Hong Kong, Dept Stat, Hong Kong, Peoples R China	University of Hong Kong; University of Hong Kong	Kumana, CR (corresponding author), Univ Hong Kong, Queen Mary Hosp, Dept Med, Pokfulam Rd, Hong Kong, Peoples R China.		/E-9829-2010	/0000-0001-9106-7363				ABRAMOWICZ M, 1994, MED LETT DRUGS THER, V36, P45; ABRAMOWICZ M, 1996, MED LETT, V38, P67; *AD TREATM PAN 2, 1994, CIRCULATION, V89, P1329; Hulley S, 1998, JAMA-J AM MED ASSOC, V280, P605, DOI 10.1001/jama.280.7.605; ILLINGWORTH DR, 1994, CLIN THER, V16, P366; *JOINT FORM COMM L, 1995, BR NATL FORMULARY, V29, P107; Kumana C. R., 1998, Hong Kong Medical Journal, V4, P158; OSE L, 1995, CLIN DRUG INVEST, V10, P127, DOI 10.2165/00044011-199510030-00001; OWNS JR, 1998, JAMA-J AM MED ASSOC, V279, P1615; PEDERSEN TR, 1994, LANCET, V344, P1383; Petitti DB, 1998, JAMA-J AM MED ASSOC, V280, P650, DOI 10.1001/jama.280.7.650; Plehn JF, 1999, CIRCULATION, V99, P216, DOI 10.1161/01.CIR.99.2.216; Rosenson RS, 1998, JAMA-J AM MED ASSOC, V279, P1643, DOI 10.1001/jama.279.20.1643; Sacks FM, 1996, NEW ENGL J MED, V335, P1001, DOI 10.1056/NEJM199610033351401; SHEPHERD J, 1995, NEW ENGL J MED, V333, P1301, DOI 10.1056/NEJM199511163332001; SIMONS LA, 1994, INSERT AUSTR SCHEDUL; Sourander L, 1998, LANCET, V352, P1965, DOI 10.1016/S0140-6736(98)05066-1; Tonkin A, 1998, NEW ENGL J MED, V339, P1349	18	41	41	0	0	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	0098-7484	1538-3598		JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 24	1999	282	20					1899	1901		10.1001/jama.282.20.1899	http://dx.doi.org/10.1001/jama.282.20.1899			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	257BZ	10580441				2022-12-28	WOS:000083763400002
J	Mayberry, JC				Mayberry, JC			Prevention of the abdominal compartment syndrome	LANCET			English	Editorial Material							PRESSURE; TRAUMA		Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA	Oregon Health & Science University	Mayberry, JC (corresponding author), Oregon Hlth Sci Univ, Dept Surg, Portland, OR 97201 USA.			Mayberry, John/0000-0001-6978-9079				Behrman SW, 1998, J TRAUMA, V45, P227, DOI 10.1097/00005373-199808000-00005; BRADLEY SE, 1947, J CLIN INVEST, V26, P1010, DOI 10.1172/JCI101867; CALDWELL CB, 1987, J SURG RES, V43, P14, DOI 10.1016/0022-4804(87)90041-2; Ciresi DL, 1999, AM SURGEON, V65, P720; GROSS RE, 1948, SURGERY, V24, P277; Ivatury RR, 1998, J TRAUMA, V44, P1016, DOI 10.1097/00005373-199806000-00014; KRON IL, 1984, ANN SURG, V199, P28, DOI 10.1097/00000658-198401000-00005; Meldrum DR, 1997, AM J SURG, V174, P667, DOI 10.1016/S0002-9610(97)00201-8; Ogilvie WH, 1940, LANCET, V2, P253; OLERUD S, 1953, ACTA PHYSL SCAN S109, V30, P4; RICHARDSON JD, 1976, J SURG RES, V20, P401, DOI 10.1016/0022-4804(76)90112-8	11	27	31	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1749	1750		10.1016/S0140-6736(99)00407-9	http://dx.doi.org/10.1016/S0140-6736(99)00407-9			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	258RM	10577634				2022-12-28	WOS:000083853000007
J	Tansey, EM				Tansey, EM			The dustbin of history, and why so much of modern medicine should end up there	LANCET			English	Article									Wellcome Trust, Acad Unit, London NW1 2BE, England	University of London; University College London	Tansey, EM (corresponding author), Wellcome Trust, Acad Unit, 183 Euston Rd, London NW1 2BE, England.			Tansey, Tilli/0000-0002-0742-5074	Wellcome Trust Funding Source: Medline	Wellcome Trust(Wellcome TrustEuropean Commission)		ARNDT KA, 1992, ARCH DERMATOL, V128, P1249, DOI 10.1001/archderm.128.9.1249; BERRIDGE V, 1994, HIST WORKSHOP, V38, P228; DURACK DT, 1978, NEW ENGL J MED, V298, P773, DOI 10.1056/NEJM197804062981405; ENRIGHT BJ, 1975, ESSAYS INFORMATION L, P63; HUMPHREYS KW, 1972, ASLIB PROC, V24, P464, DOI 10.1108/eb050361; LUNDBERG GD, 1992, B MED LIBR ASSOC, V80, P110; PORTER R, 1985, THEOR SOC, V14, P175, DOI 10.1007/BF00157532; PRICE DJD, 1963, LITTLE SCI BIG SCI, P39; TAYLOR AJP, 1975, ENGLISH HIST 1914 19, P729; TRIMBLE V, 1984, NATURE, V310, P542, DOI 10.1038/310542a0; TROTSKY L, 1977, HIST RUSSIAN REVOLUT, P1156	11	3	3	0	0	LANCET LTD	LONDON	84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND	0140-6736			LANCET	Lancet	NOV 20	1999	354	9192					1811	1812		10.1016/S0140-6736(99)06266-2	http://dx.doi.org/10.1016/S0140-6736(99)06266-2			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	258RM	10577658				2022-12-28	WOS:000083853000044
J	Katz, ME; Pak, DK; Dickens, GR; Miller, KG				Katz, ME; Pak, DK; Dickens, GR; Miller, KG			The source and fate of massive carbon input during the latest Paleocene thermal maximum	SCIENCE			English	Article							CIRCUM-CARIBBEAN VOLCANISM; OCEANIC METHANE HYDRATE; HIGH-RESOLUTION RECORDS; DEEP-SEA; EOCENE TRANSITION; CLIMATE-CHANGE; BIGHORN BASIN; CAUSAL LINK; GAS; MARINE	Lithologic, faunal, seismic, and isotopic evidence from the Blake Nose (subtropical western North Atlantic) Links massive release of biogenic methane similar to 55.5 million years ago to a warming of deep-ocean and high-latitude surface waters, a large perturbation in the combined ocean-atmosphere carbon cycle (the largest of the past 90 million years), a mass extinction event in benthic faunas, and a radiation of mammalian orders. The deposition of a mud clast interval and seismic evidence for slope disturbance are associated with intermediate water warming, massive carbon input to the global exogenic carbon cycle, pelagic carbonate dissolution, a decrease,in dissolved oxygen, and a benthic foraminiferal extinction event. These events provide evidence to confirm the gas hydrate dissociation hypothesis and identify the Blake Nose as a site of methane release.	Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA; Univ Calif Santa Barbara, Dept Geol Sci, Santa Barbara, CA 93106 USA; Univ Calif Santa Barbara, Inst Marine Sci, Santa Barbara, CA 93106 USA; James Cook Univ N Queensland, Sch Earth Sci, Townsville, Qld 4811, Australia	Rutgers State University New Brunswick; University of California System; University of California Santa Barbara; University of California System; University of California Santa Barbara; James Cook University	Katz, ME (corresponding author), Rutgers State Univ, Dept Geol Sci, Piscataway, NJ 08854 USA.		Miller, Kenneth/J-6845-2012; Dickens, Gerald R/G-1222-2011					Aubry M.-P., 1996, GEOL SOC LOND SPEC P, V101, P353; BAINS S, 1999, SCIENCE, V285, P274; Bowring SA, 1998, SCIENCE, V280, P1039, DOI 10.1126/science.280.5366.1039; Bralower TJ, 1998, GEOLOGY, V26, P671; Bralower TJ, 1997, GEOLOGY, V25, P963, DOI 10.1130/0091-7613(1997)025<0963:HRROTL>2.3.CO;2; CANUDO JI, 1995, PALAEOGEOGR PALAEOCL, V114, P75, DOI 10.1016/0031-0182(95)00073-U; Clyde WC, 1998, GEOLOGY, V26, P1011, DOI 10.1130/0091-7613(1998)026<1011:MCRTTL>2.3.CO;2; DEANGELIS MA, 1993, DEEP-SEA RES PT I, V40, P1169, DOI 10.1016/0967-0637(93)90132-M; Dickens GR, 1997, GEOLOGY, V25, P259, DOI 10.1130/0091-7613(1997)025<0259:ABOGIT>2.3.CO;2; DICKENS GR, 1995, PALEOCEANOGRAPHY, V10, P965, DOI 10.1029/95PA02087; Dickens GR, 1997, NATURE, V385, P426, DOI 10.1038/385426a0; DICKENS GR, IN PRESS B SOC GEL; Dillon WP, 1998, GEOL SOC SPEC PUBL, V137, P293, DOI 10.1144/GSL.SP.1998.137.01.23; EPSTEIN S, 1953, GEOL SOC AM BULL, V64, P1315, DOI 10.1130/0016-7606(1953)64[1315:RCITS]2.0.CO;2; Fricke HC, 1998, EARTH PLANET SC LETT, V160, P193, DOI 10.1016/S0012-821X(98)00088-0; Holbrook WS, 1996, SCIENCE, V273, P1840, DOI 10.1126/science.273.5283.1840; Hooker J.J., 1996, Geological Society Special Publication, V101, P205, DOI 10.1144/GSL.SP.1996.101.01.13; Kaiho K, 1996, PALEOCEANOGRAPHY, V11, P447, DOI 10.1029/96PA01021; Kayen R.E., 1991, MAR GEOTECHNOL, V10, P125, DOI [DOI 10.1080/10641199109379886, 10.1080/10641199109379886]; KENNETT JP, 1991, NATURE, V353, P225, DOI 10.1038/353225a0; Knoll AH, 1996, SCIENCE, V273, P452, DOI 10.1126/science.273.5274.452; KOCH PL, 1992, NATURE, V358, P319, DOI 10.1038/358319a0; KVENVOLDEN KA, 1993, REV GEOPHYS, V31, P173, DOI 10.1029/93RG00268; LU GY, 1993, MAR MICROPALEONTOL, V21, P101, DOI 10.1016/0377-8398(93)90012-M; MCIVER RD, 1982, AAPG BULL, V75, P910; Miller KG, 1987, PALEOCEANOGRAPHY, V2, P741, DOI 10.1029/PA002i006p00741; Mountain GS, 1992, PALEOCEANOGRAPHY, V7, P423, DOI 10.1029/92PA01268; NORRIS RD, 1997, EOS T AGU S, V78, pF364; NORRIS RD, 1998, P OCEAN DRILLING P B, V171; NORRIS RD, 1999, EARLY PALEOGENE WA C, V21; ONEIL JR, 1969, J CHEM PHYS, V51, P5547, DOI 10.1063/1.1671982; Pak DK, 1992, PALEOCEANOGRAPHY, V7, P405, DOI 10.1029/92PA01234; Paull CK, 1996, GEOLOGY, V24, P143, DOI 10.1130/0091-7613(1996)024<0143:ICMSFD>2.3.CO;2; PAULL CK, 1995, GEOLOGY, V23, P89, DOI 10.1130/0091-7613(1995)023<0089:MRPOTC>2.3.CO;2; RUPPEL C, 1999, EOS S, V80, pS333; SHACKLETON NJ, 1984, INITIAL REP DEEP SEA, V74, P599; SLOAN ED, 1999, EOS T AM GEOPHYS UN, V80, P247, DOI DOI 10.1029/99E000184.ACCESSED; Steineck PL, 1996, GEOLOGY, V24, P583; Thomas E., 1996, Geological Society Special Publication, V101, P401, DOI 10.1144/GSL.SP.1996.101.01.20; Thomas E, 1998, LATE PALEOCENE-EARLY EOCENE CLIMATIC AND BIOTIC EVENTS IN THE MARINE AND TERRESTRIAL RECORDS, P214; ZACHOS JC, 1989, NATURE, V337, P61, DOI 10.1038/337061a0; ZACHOS JC, 1993, J GEOL, V101, P191, DOI 10.1086/648216; ZACHOS JC, 1994, PALEOCEANOGRAPHY, V9, P353, DOI 10.1029/93PA03266	43	276	309	4	77	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1531	1533		10.1126/science.286.5444.1531	http://dx.doi.org/10.1126/science.286.5444.1531			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567252				2022-12-28	WOS:000083768300048
J	Steinmeyer, G; Sutter, DH; Gallmann, L; Matuschek, N; Keller, U				Steinmeyer, G; Sutter, DH; Gallmann, L; Matuschek, N; Keller, U			Frontiers in ultrashort pulse generation: Pushing the limits in linear and nonlinear optics	SCIENCE			English	Review							TI-SAPPHIRE LASER; SOLID-STATE LASERS; SEMICONDUCTOR SATURABLE ABSORBER; DOUBLE-CHIRPED MIRRORS; LENS MODE-LOCKING; REPETITION RATE; ADDITIVE PULSE; LIGHT-PULSES; FEMTOSECOND; PHASE	Optical pulses in the 5-femtosecond range are produced by a variety of methods. Although different in technical detail, each method relies on the same three key components: spectral broadening due to the nonlinear optical Kerr effect, dispersion control, and ultrabroadband amplification. The state of the art of ultrashort pulse generation is reviewed with a focus on direct laser oscillator schemes.	ETH Honggerberg, HPT, Swiss Fed Inst Technol, Inst Quantum Elect, CH-8093 Zurich, Switzerland	Swiss Federal Institutes of Technology Domain; ETH Zurich	Steinmeyer, G (corresponding author), ETH Honggerberg, HPT, Swiss Fed Inst Technol, Inst Quantum Elect, CH-8093 Zurich, Switzerland.	sguenter@iqe.phys.ethz.ch	Keller, Ursula/N-2437-2016; Sutter, Dirk Hartwig/ABD-2205-2021; Gallmann, Lukas/E-5204-2014; Steinmeyer, Günter/N-2842-2017	Keller, Ursula/0000-0002-1689-8041; Sutter, Dirk Hartwig/0000-0001-9474-3726; Gallmann, Lukas/0000-0003-3167-8271; Steinmeyer, Günter/0000-0003-1336-2783				Agrawal G.P., 2019, NONLINEAR FIBER OPTI, V6th, DOI 10.1016/C2018-0-01168-8; Albert O, 1999, APPL PHYS B-LASERS O, V69, P207, DOI 10.1007/s003400050795; Baltuska A, 1997, APPL PHYS B-LASERS O, V65, P175, DOI 10.1007/s003400050262; Cerullo G, 1999, PHYS REV LETT, V83, P231, DOI 10.1103/PhysRevLett.83.231; Chichkov BN, 1996, APPL PHYS A-MATER, V63, P109, DOI 10.1007/BF01567637; Christov IP, 1999, OPT LETT, V24, P1425, DOI 10.1364/OL.24.001425; FARKAS G, 1992, PHYS LETT A, V168, P447, DOI 10.1016/0375-9601(92)90534-S; FORK RL, 1983, OPT LETT, V8, P1, DOI 10.1364/OL.8.000001; FORK RL, 1987, OPT LETT, V12, P483, DOI 10.1364/OL.12.000483; FORK RL, 1984, OPT LETT, V9, P150, DOI 10.1364/OL.9.000150; GALE GM, 1995, OPT LETT, V20, P1562, DOI 10.1364/OL.20.001562; Gallmann L, 1999, OPT LETT, V24, P1314, DOI 10.1364/OL.24.001314; Gibbon P, 1996, PHYS REV LETT, V76, P50, DOI 10.1103/PhysRevLett.76.50; GUPTA S, 1992, IEEE J QUANTUM ELECT, V28, P2464, DOI 10.1109/3.159553; HAUS HA, 1992, IEEE J QUANTUM ELECT, V28, P2086, DOI 10.1109/3.159519; Iaconis C, 1999, IEEE J QUANTUM ELECT, V35, P501, DOI 10.1109/3.753654; IPPEN EP, 1989, J OPT SOC AM B, V6, P1736, DOI 10.1364/JOSAB.6.001736; Jung ID, 1997, APPL PHYS B-LASERS O, V65, P137, DOI 10.1007/s003400050259; Kartner FX, 1997, OPT LETT, V22, P831, DOI 10.1364/OL.22.000831; KEAN PN, 1989, OPT LETT, V14, P39, DOI 10.1364/OL.14.000039; KELLER U, 1992, OPT LETT, V17, P505, DOI 10.1364/OL.17.000505; Keller U, 1999, SEMICONDUCT SEMIMET, V59, P211; Keller U, 1996, IEEE J SEL TOP QUANT, V2, P435, DOI 10.1109/2944.571743; KELLER U, 1991, OPT LETT, V16, P1022, DOI 10.1364/OL.16.001022; KRAUSZ F, 1992, IEEE J QUANTUM ELECT, V28, P2097, DOI 10.1109/3.159520; Kruger J, 1998, APPL SURF SCI, V127, P892, DOI 10.1016/S0169-4332(97)00763-0; MAGNI V, 1995, J OPT SOC AM B, V12, P476, DOI 10.1364/JOSAB.12.000476; Matuschek N, 1999, IEEE J QUANTUM ELECT, V35, P129, DOI 10.1109/3.740733; MITSCHKE FM, 1987, OPT LETT, V12, P407, DOI 10.1364/OL.12.000407; MOLLENAUER LF, 1984, OPT LETT, V9, P13, DOI 10.1364/OL.9.000013; Morgner U, 1999, OPT LETT, V24, P920, DOI 10.1364/OL.24.000920; Morgner U, 1999, OPT LETT, V24, P411, DOI 10.1364/OL.24.000411; NEGUS DK, 1991, ADV SOLID STATE LASE, V10, P120; Nisoli M, 1997, APPL PHYS B-LASERS O, V65, P189, DOI 10.1007/s003400050263; Nisoli M, 1998, OPT LETT, V23, P630, DOI 10.1364/OL.23.000630; Nisoli M, 1997, OPT LETT, V22, P522, DOI 10.1364/OL.22.000522; Paschotta R, 1999, APPL PHYS LETT, V75, P2166, DOI 10.1063/1.124953; Peatross J, 1998, J OPT SOC AM B, V15, P216, DOI 10.1364/JOSAB.15.000216; Rundquist A, 1997, APPL PHYS B-LASERS O, V65, P161, DOI 10.1007/s003400050261; SALIN F, 1991, OPT LETT, V16, P1674, DOI 10.1364/OL.16.001674; Sartania S, 1997, OPT LETT, V22, P1562, DOI 10.1364/OL.22.001562; Schon S, 1999, J CRYST GROWTH, V201, P1020, DOI 10.1016/S0022-0248(99)00033-0; Sherriff RE, 1998, J OPT SOC AM B, V15, P1224, DOI 10.1364/JOSAB.15.001224; Shirakawa A, 1999, APPL PHYS LETT, V74, P2268, DOI 10.1063/1.123820; Siegman A. E., 1986, LASER; SPENCE DE, 1991, OPT LETT, V16, P42, DOI 10.1364/OL.16.000042; Stegeman GI, 1999, SCIENCE, V286, P1518, DOI 10.1126/science.286.5444.1518; Sutter DH, 1998, IEEE J SEL TOP QUANT, V4, P169, DOI 10.1109/2944.686720; Sutter DH, 1999, OPT LETT, V24, P631, DOI 10.1364/OL.24.000631; SZIPOCS R, 1994, OPT LETT, V19, P201, DOI 10.1364/OL.19.000201; Tearney GJ, 1997, SCIENCE, V276, P2037, DOI 10.1126/science.276.5321.2037; Telle HR, 1999, APPL PHYS B-LASERS O, V69, P327, DOI 10.1007/s003400050813; TREBINO R, 1993, J OPT SOC AM A, V10, P1101, DOI 10.1364/JOSAA.10.001101; Udem T, 1997, PHYS REV LETT, V79, P2646, DOI 10.1103/PhysRevLett.79.2646; VALDMANIS JA, 1986, IEEE J QUANTUM ELECT, V22, P112, DOI 10.1109/JQE.1986.1072854; WEINGARTEN KJ, 1993, OPT LETT, V18, P640, DOI 10.1364/OL.18.000640; Xu L, 1998, OPT LETT, V23, P789, DOI 10.1364/OL.23.000789; Xu L, 1996, OPT LETT, V21, P2008, DOI 10.1364/OL.21.002008; Yamakawa K, 1998, OPT LETT, V23, P525, DOI 10.1364/OL.23.000525; Yelin D, 1997, OPT LETT, V22, P1793, DOI 10.1364/OL.22.001793; ZHOU JP, 1994, OPT LETT, V19, P1149, DOI 10.1364/OL.19.001149	61	350	360	3	124	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 19	1999	286	5444					1507	1512		10.1126/science.286.5444.1507	http://dx.doi.org/10.1126/science.286.5444.1507			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	257DZ	10567248				2022-12-28	WOS:000083768300044
J	Effler, P; Ching-Lee, M; Bogard, A; Ieong, MC; Nekomoto, T; Jernigan, D				Effler, P; Ching-Lee, M; Bogard, A; Ieong, MC; Nekomoto, T; Jernigan, D			Statewide system of electronic notifiable disease reporting from clinical laboratories - Comparing automated reporting with conventional methods	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							PUBLIC-HEALTH SURVEILLANCE; INFECTIOUS-DISEASES	Context Notifiable disease surveillance is essential to rapidly identify and respond to outbreaks so that further illness can be prevented. Automating reports from clinical laboratories has been proposed to reduce underreporting and delays. Objective To compare the timeliness and completeness of a prototypal electronic reporting system with that of conventional laboratory reporting. Design Laboratory-based reports for 5 conditions received at a state health department between July 1 and December 31, 1998, were reviewed. Completeness of coverage for each reporting system was estimated using capture-recapture methods. Setting Three statewide private clinical laboratories in Hawaii. Main Outcome Measures The number and date of reports received, by reporting system, laboratory, and pathogen; completeness of data fields. Results A total of 357 unique reports of illness were identified; 201 (56%) were received solely through the automated electronic system, 32 (9%) through the conventional system only, and 124 (35%) through both. Thus, electronic reporting resulted in a 2.3-fold (95% confidence interval [CI], 2.0-2.6) increase in reports. Electronic reports arrived an average of 3.8 (95% CI, 2.6-5.0) days earlier than conventional reports. Of 21 data fields common to paper and electronic formats, electronic reports were significantly more likely to be complete for 12 and for 1 field with the conventional system. The estimated completeness of coverage for electronic reporting was 80% (95% CI, 77%-82%) compared with 38% (95% CI, 37%-39%) for the conventional system. Conclusions In this evaluation, electronic reporting more than doubled the total number of laboratory-based reports received. On average, the electronic reports were more timely and more complete, suggesting that electronic reporting may ultimately facilitate more rapid and comprehensive institution of disease control measures.	State Hawaii Dept Hlth, Honolulu, HI 96813 USA; Ctr Dis Control & Prevent, Off Surveillance, Natl Ctr Infect Dis, Atlanta, GA USA	Centers for Disease Control & Prevention - USA	Effler, P (corresponding author), State Hawaii Dept Hlth, 1250 Punchbowl ST, Honolulu, HI 96813 USA.				PHS HHS [U50/CCU912395-01] Funding Source: Medline	PHS HHS(United States Department of Health & Human ServicesUnited States Public Health Service)		[Anonymous], PREV EM INF DIS STRA; *CDCP, 1999, EL REP LAB DAT PUBL; Chorba T L, 1990, MMWR Recomm Rep, V39, P1; *COUNC STAT TERR E, 1999, REP REQ HLTH CAR PRO; GODES JR, 1982, MINN MED, V65, P762; GRAITCER PL, 1987, AM J PREV MED, V3, P123; *I MED NAT RES COU, 1999, CHEM BIOL TERR RES D; Lederberg J., 1992, I MED US COMMITTEE; McDonald CJ, 1997, ANN INTERN MED, V127, P675, DOI 10.7326/0003-4819-127-8_Part_2-199710151-00049; National Science and Technology Council Committee on International Science Engineering and Technology Working Group on Emerging and Re-Emerging Infectious Diseases, 1995, INF DIS GLOB HLTH TH; RUSHWORTH RL, 1991, MED J AUSTRALIA, V154, P828, DOI 10.5694/j.1326-5377.1991.tb121376.x; SCHRAMM MM, 1991, PUBLIC HEALTH REP, V106, P95; STROUP DF, 1994, PRINCIPLES PRACTICE, P143; Thacker S B, 1989, J Public Health Policy, V10, P187, DOI 10.2307/3342679; THACKER SB, 1988, EPIDEMIOL REV, V10, P164, DOI 10.1093/oxfordjournals.epirev.a036021; THACKER SB, 1983, JAMA-J AM MED ASSOC, V249, P1181; *US GEN ACC OFF, 1999, GAOHEHS9926	17	134	142	0	5	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 17	1999	282	19					1845	1850		10.1001/jama.282.19.1845	http://dx.doi.org/10.1001/jama.282.19.1845			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	254MD	10573276	Bronze			2022-12-28	WOS:000083615700028
J	Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS				Lauderdale, DS; Oram, RJ; Goldstein, KP; Daum, RS			Hepatitis B vaccination among children in inner-city public housing, 1991-1997	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							IMMUNIZATION COVERAGE; INFANTS	Context In 1991, the Advisory Committee on Immunization Practices recommended universal vaccination of infants against hepatitis B virus (HBV), with series initiation within days of birth. Objective To determine HBV vaccine coverage in a low-income urban population and to examine whether HBV immunization within the first month of life affects subsequent vaccine receipt. Design Cohort study based on immunization records collected in the Pediatric Immunization Program. Setting Large public housing development in Chicago, ill. Participants All 1143 children who were born between 1991 and 1997 and enrolled between 1993 and mid-1998, with follow-up to age 35 months. Main Outcome Measures On-time vaccine receipt of HBV vaccine doses, diphtheria-tetanus-pertussis vaccine (DTP) dose 1, and the 4:3:1 series (4 doses of DTP vaccine, 3 doses of poliomyelitis vaccine, and 1 dose of measles-containing vaccine), analyzed by year. Results On-time HBV vaccination increased quickly following new guidelines and reached a plateau of about 50% coverage for those born in or after 1995, Since 1994, more children (64%) received the first HBV vaccine dose on time than any other vaccine. Children who received a dose of HBV vaccine during their first month of life were more likely to receive the first DTP vaccine dose on time (60.1%) than those who did not get an HBV vaccine dose during the first month (36.4%; chi(2) = 53.7; P<.001). Children who received the first HBV vaccine dose during their first month were more likely than those receiving it at age 1 to 2 months to complete 3 HBV doses by 19 months (70.6% vs 51.1%; chi(2) = 11.6; P =.001) and to complete the 4:3:1 series by age 19 months (49.8% vs 37.9%; chi(2) = 4.0; P = .05). Conclusions In this inner-city population, HBV vaccine has been received at rates similar to those of other vaccines within 3 years of issuance of new recommendations. Of note, immunization with HBV vaccine at birth was associated with timely receipt of other vaccines and, therefore, may have the potential to increase vaccination among groups less likely to be up-to-date on early childhood vaccines.	Univ Chicago, Dept Hlth Studies, Chicago, IL 60637 USA; Univ Chicago, Dept Pediat, Chicago, IL 60637 USA	University of Chicago; University of Chicago	Lauderdale, DS (corresponding author), Univ Chicago, Dept Hlth Studies, 5841 S Maryland Ave,MC 2007, Chicago, IL 60637 USA.							Bolton P, 1998, PUBLIC HEALTH REP, V113, P527; *CDC, 1989, MMWR-MORBID MORTAL W, V38, P818; *CDC, 1991, MMWR-MORBID MORTAL W, V4, P1; *CDCP, 1998, MMWR-MORBID MORTAL W, V47, P108; *CDCP, 1999, MMWR-MORBID MORTAL W, V48, P563; Centers for Disease Control and Prevention (CDC), 1999, MMWR Morb Mortal Wkly Rep, V48, P780; *CHIC DEP PUBL HLT, 1995, R TAYL IN; FREED GL, 1994, PEDIATRICS, V93, P747; Goldstein KP, 1996, JAMA-J AM MED ASSOC, V276, P56, DOI 10.1001/jama.276.1.56; GOLDSTEIN KP, IN PRESS PEDIATRICS; Hoekstra EJ, 1998, JAMA-J AM MED ASSOC, V280, P1143, DOI 10.1001/jama.280.13.1143; Kenyon TA, 1998, PEDIATRICS, V101, P612, DOI 10.1542/peds.101.4.612; Ross A, 1998, PEDIATRICS, V101, P970, DOI 10.1542/peds.101.6.970; WILLIAMS IT, 1995, PEDIATRICS, V96, P439	14	36	37	0	0	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	NOV 10	1999	282	18					1725	1730		10.1001/jama.282.18.1725	http://dx.doi.org/10.1001/jama.282.18.1725			6	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	251XJ	10568644	Bronze			2022-12-28	WOS:000083471400026
J	Galarreta, M; Hestrin, S				Galarreta, M; Hestrin, S			A network of fast-spiking cells in the neocortex connected by electrical synapses	NATURE			English	Article							RAT FRONTAL-CORTEX; NONPYRAMIDAL CELLS; INHIBITORY INTERNEURONS; GABAERGIC INTERNEURONS; GAMMA-OSCILLATION; NEURONAL NETWORKS; CORTICAL-NEURONS; IN-VITRO; HIPPOCAMPUS; SYNCHRONIZATION	Encoding of information in the cortex is thought to depend on synchronous firing of cortical neurons(1,2). Inhibitory neurons are known to be critical in the coordination of cortical activity(3-5), but how interaction among inhibitory cells promotes synchrony is not well understood(4,6-12). To address this issue directly, we have recorded simultaneously from pairs of fast-spiking (FS) cells, a type of gamma-aminobutyric acid (GABA)-containing neocortical interneuron(13). Here we report a high occurrence of electrical coupling among FS cells. Electrical synapses were not found among pyramidal neurons or between FS cells and other cortical cells. Some FS cells were interconnected by both electrical and GABAergic synapses. We show that communication through electrical synapses allows excitatory signalling among inhibitory cells and promotes their synchronous spiking. These results indicate that electrical synapses establish a network of fast-spiking cells in the neocortex which may play a key role in coordinating cortical activity.	Univ Tennessee, Dept Anat & Neurobiol, Memphis, TN 38163 USA	University of Tennessee System; University of Tennessee Health Science Center	Hestrin, S (corresponding author), Univ Tennessee, Dept Anat & Neurobiol, 855 Monroe Ave, Memphis, TN 38163 USA.	shaul@nb.utmem.edu	Hestrin, Shaul/F-4410-2010	Vargas-Caballero, Mariana/0000-0003-2326-4001				Angulo MC, 1999, J NEUROSCI, V19, P1566; Benardo LS, 1997, J NEUROPHYSIOL, V77, P3134, DOI 10.1152/jn.1997.77.6.3134; BRAGIN A, 1995, J NEUROSCI, V15, P47; Buhl EH, 1998, J PHYSIOL-LONDON, V513, P117, DOI 10.1111/j.1469-7793.1998.117by.x; Bush P, 1996, J COMPUT NEUROSCI, V3, P91, DOI 10.1007/BF00160806; Cauli B, 1997, J NEUROSCI, V17, P3894; COBB SR, 1995, NATURE, V378, P75, DOI 10.1038/378075a0; CONNORS BW, 1983, J NEUROSCI, V3, P773; Galarreta M, 1998, NAT NEUROSCI, V1, P587, DOI 10.1038/2822; HUBEL DH, 1959, J PHYSIOL-LONDON, V147, P226, DOI 10.1113/jphysiol.1959.sp006238; Jefferys JGR, 1996, TRENDS NEUROSCI, V19, P202, DOI 10.1016/S0166-2236(96)10023-0; KATSUMARU H, 1988, EXP BRAIN RES, V72, P363; Kawaguchi Y, 1997, CEREB CORTEX, V7, P476, DOI 10.1093/cercor/7.6.476; KAWAGUCHI Y, 1993, J NEUROPHYSIOL, V70, P387, DOI 10.1152/jn.1993.70.1.387; KAWAGUCHI Y, 1995, J NEUROSCI, V15, P2638; LYTTON WW, 1991, J NEUROPHYSIOL, V66, P1059, DOI 10.1152/jn.1991.66.3.1059; MICHELSON HB, 1994, J PHYSIOL-LONDON, V477, P35, DOI 10.1113/jphysiol.1994.sp020169; NEYTON J, 1985, NATURE, V317, P331, DOI 10.1038/317331a0; PEINADO A, 1993, NEURON, V10, P103, DOI 10.1016/0896-6273(93)90246-N; Rinzel J, 1998, SCIENCE, V279, P1351, DOI 10.1126/science.279.5355.1351; Ritz R, 1997, CURR OPIN NEUROBIOL, V7, P536, DOI 10.1016/S0959-4388(97)80034-7; SINGER W, 1995, ANNU REV NEUROSCI, V18, P555, DOI 10.1146/annurev.neuro.18.1.555; SLOPER JJ, 1972, BRAIN RES, V44, P640, DOI 10.1016/0006-8993(72)90327-7; Stevens CF, 1998, NAT NEUROSCI, V1, P210, DOI 10.1038/659; Strata F, 1997, J NEUROSCI, V17, P1435; Tamas G, 1998, J NEUROSCI, V18, P4255; Traub RD, 1996, NATURE, V383, P621, DOI 10.1038/383621a0; Wang XJ, 1996, J NEUROSCI, V16, P6402; WHITTINGTON MA, 1995, NATURE, V373, P612, DOI 10.1038/373612a0; Zhang Y, 1998, J NEUROSCI, V18, P9256	30	734	743	1	35	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836	1476-4687		NATURE	Nature	NOV 4	1999	402	6757					72	75		10.1038/47029	http://dx.doi.org/10.1038/47029			4	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	254XC	10573418				2022-12-28	WOS:000083638600044
J	Balter, M				Balter, M			Archaeology - A long season puts Catalhoyuk in context	SCIENCE			English	Article																			0	2	2	0	3	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					890	891		10.1126/science.286.5441.890	http://dx.doi.org/10.1126/science.286.5441.890			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10577237				2022-12-28	WOS:000083368500016
J	Gambrill, J				Gambrill, J			Proposals based on too many assumptions - Commentary	BRITISH MEDICAL JOURNAL			English	Editorial Material											Gambrill, J (corresponding author), 67 Brighton Cottages, Cuckfield RH16 1XT, England.								0	2	2	0	0	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	SEP 18	1999	319	7212					770	771						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	238GA	10576827				2022-12-28	WOS:000082701500029
J	Kerlikowske, K; Salzmann, P; Phillips, KA; Cauley, JA; Cummings, SR				Kerlikowske, K; Salzmann, P; Phillips, KA; Cauley, JA; Cummings, SR			Continuing screening mammography in women aged 70 to 79 years - Impact on life expectancy and cost-effectiveness	JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION			English	Article							BREAST-CANCER; ELDERLY WOMEN; OLDER WOMEN; GUIDELINES; FRACTURES; PROGRAM; RECOMMENDATIONS; HEALTH; UPDATE; RISK	Context Mammography is recommended and is cost-effective for women aged 50 to 69 years, but the value of continuing screening mammography after age 69 years is not known. In particular, older women with low bone mineral density (BMD) have a lower risk of breast cancer and may benefit less from continued screening. Objective To compare life expectancy and cost-effectiveness of screening mammography in elderly women based on 3 screening strategies. Design Decision analysis and cost-effectiveness analysis using a Markov model. Patients General population of women aged 65 years or older. Interventions The analysis compared 3 strategies: (1) Undergoing biennial mammography from age 65 to 69 years; (2) undergoing biennial mammography from age 65 to 69 years, measurement of distal radial BMD at age 65 years, discontinuing screening at age 69 years in women in the lowest BMD quartile for age, and continuing biennial mammography to age 79 years in those in the top 3 quartiles of distal radius BMD; and (3) undergoing biennial mammography from age 65 to 79 years. Main Outcome Measures Deaths due to breast cancer averted, life expectancy, and incremental cost-effectiveness ratios. Results Compared with discontinuing mammography screening at age 69 years, measuring BMD at age 65 years in 10 000 women and continuing mammography to age 79 years only in women with BMD in the top 3 quartiles would prevent 9.4 deaths and add, on average, 2.1 days to life expectancy at an incremental cost of $66 773 per year of life saved. Continuing mammography to age 79 years in all 10 000 elderly women would prevent 1.4 additional breast cancer deaths and add only 7.2 hours to life expectancy at an incremental cost of $117 689 per year of life saved compared with only continuing mammography to age 79 years in women with BMD in the top 3 quartiles. Conclusions This analysis suggests that continuing mammography screening after age 69 years results in a small gain in life expectancy and is moderately cost-effective in those with high BMD and more costly in those with low BMD, Women's preferences for a small gain in life expectancy and the potential harms of screening mammography should play an important role when elderly women are deciding about screening.	Univ Calif San Francisco, Sch Pharm, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Pharm, Dept Med, San Francisco, CA 94143 USA; Univ Calif San Francisco, Sch Pharm, Dept Clin Pharm, San Francisco, CA 94143 USA; Univ Calif San Francisco, Dept Vet Affairs, Gen Internal Med Sect, San Francisco, CA 94143 USA; Stanford Univ, Grad Sch Business, Palo Alto, CA 94304 USA; Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA USA	University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; University of California System; University of California San Francisco; Stanford University; Pennsylvania Commonwealth System of Higher Education (PCSHE); University of Pittsburgh	Kerlikowske, K (corresponding author), Vet Affairs Med Ctr, Gen Internal Med Sect, 111A1,4150 Clement St, San Francisco, CA 94121 USA.		Cauley, Jane A/N-4836-2015	Cauley, Jane A/0000-0003-0752-4408	NATIONAL CANCER INSTITUTE [P50CA058207, U01CA063740] Funding Source: NIH RePORTER; NCI NIH HHS [1 U01 CA 63740, P50 CA58207] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI))		BECK JR, 1983, MED DECIS MAKING, V3, P419, DOI 10.1177/0272989X8300300403; BROWN ML, 1992, J GERONTOL, V47, P51; BROWN ML, 1995, RADIOLOGY, V195, P529, DOI 10.1148/radiology.195.2.7724778; CAIRNS JA, 1994, HEALTH ECON, V3, P221, DOI 10.1002/hec.4730030404; Cauley JA, 1996, JAMA-J AM MED ASSOC, V276, P1404, DOI 10.1001/jama.276.17.1404; Colditz GA, 1998, JNCI-J NATL CANCER I, V90, P814, DOI 10.1093/jnci/90.11.814; CROPPER ML, 1994, J RISK UNCERTAINTY, V8, P243, DOI 10.1007/BF01064044; Cummings SR, 1999, JAMA-J AM MED ASSOC, V281, P2189, DOI 10.1001/jama.281.23.2189; DEHAES JCJM, 1991, INT J CANCER, V49, P538, DOI 10.1002/ijc.2910490411; *DEV COMM NAT OST, 1998, OSTEOPOROSIS INT, V4, pS1; EDDY DM, 1989, ANN INTERN MED, V111, P389, DOI 10.7326/0003-4819-111-5-389; Ernster V L, 1997, J Natl Cancer Inst Monogr, P151; Ernster VL, 1996, JAMA-J AM MED ASSOC, V275, P913, DOI 10.1001/jama.275.12.913; ERNSTER VL, IN PRESS ARCH INTERN; Gold MR, 1996, COST EFFECTIVENESS H; HALL J, 1992, SOC SCI MED, V34, P993, DOI 10.1016/0277-9536(92)90130-I; Johnston K, 1998, SOC SCI MED, V47, P213, DOI 10.1016/S0277-9536(98)00065-3; KELSEY JL, 1993, EPIDEMIOL REV, V15, P36, DOI 10.1093/oxfordjournals.epirev.a036115; KERLIKOWSKE K, 1995, JAMA-J AM MED ASSOC, V273, P149, DOI 10.1001/jama.273.2.149; KERLIKOWSKE K, 1993, JAMA-J AM MED ASSOC, V270, P2444, DOI 10.1001/jama.270.20.2444; Kerlikowske K, 1997, J Natl Cancer Inst Monogr, P105; Larsson L G, 1996, J Med Screen, V3, P129; LAUPACIS A, 1992, CAN MED ASSOC J, V146, P473; Leitch AM, 1997, CA-CANCER J CLIN, V47, P150, DOI 10.3322/canjclin.47.3.150; MANDELBLATT JS, 1992, ANN INTERN MED, V116, P722, DOI 10.7326/0003-4819-116-9-722; May DS, 1998, AM J ROENTGENOL, V170, P97, DOI 10.2214/ajr.170.1.9423608; *NAT CANC ADV BOAR, 1997, CANC LETT, V23, P4; NYSTROM L, 1993, LANCET, V341, P973, DOI 10.1016/0140-6736(93)91067-V; Olsen J A, 1993, Health Econ, V2, P257, DOI 10.1002/hec.4730020309; OLSSON H, 1992, AM J EPIDEMIOL, V136, P422, DOI 10.1093/oxfordjournals.aje.a116515; PERSSON I, 1994, CANCER CAUSE CONTROL, V5, P523, DOI 10.1007/BF01831380; RIES LA, 1997, PUBLICATION NIH; Salzmann P, 1997, ANN INTERN MED, V127, P955, DOI 10.7326/0003-4819-127-11-199712010-00001; SAMUELSON PA, 1989, P NATL ACAD SCI USA, V86, P9048, DOI 10.1073/pnas.86.22.9048; Shapiro S, 1988, PERIODIC SCREENING B; Siegel JE, 1996, JAMA-J AM MED ASSOC, V276, P1339, DOI 10.1001/jama.276.16.1339; Smith-Bindman R, 1998, JNCI-J NATL CANCER I, V90, P1322, DOI 10.1093/jnci/90.18.1322; SMITHBINDMAN R, IN PRESS AM J MED; TABAR L, 1992, RADIOL CLIN N AM, V30, P187; TAPLIN SH, 1995, J NATL CANCER I, V87, P417, DOI 10.1093/jnci/87.6.417; *TREEAG SOFTW, 1999, DATA VERS 3 5; *US BUR CENS, 1991, VIT STAT, P84; Weinstein MC, 1996, JAMA-J AM MED ASSOC, V276, P1253, DOI 10.1001/jama.276.15.1253; Welch HG, 1998, J NATL CANCER I, V90, P1389, DOI 10.1093/jnci/90.18.1389; WHITE E, 1990, J NATL CANCER I, V82, P1546, DOI 10.1093/jnci/82.19.1546; Wright JC, 1998, NEW ENGL J MED, V339, P380, DOI 10.1056/NEJM199808063390606; Zhang YQ, 1997, NEW ENGL J MED, V336, P611, DOI 10.1056/NEJM199702273360903	47	135	137	0	7	AMER MEDICAL ASSOC	CHICAGO	515 N STATE ST, CHICAGO, IL 60610 USA	0098-7484			JAMA-J AM MED ASSOC	JAMA-J. Am. Med. Assoc.	DEC 8	1999	282	22					2156	2163		10.1001/jama.282.22.2156	http://dx.doi.org/10.1001/jama.282.22.2156			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	260UG	10591338				2022-12-28	WOS:000083971400035
J	Altman, DG; Andersen, PK				Altman, DG; Andersen, PK			Calculating the number needed to treat for trials where the outcome is time to an event	BRITISH MEDICAL JOURNAL			English	Article							SURVIVAL; CANCER		Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Grp, Med Stat Grp, Oxford OX3 7LF, England; Univ Copenhagen, Dept Biostat, DK-2200 Copenhagen N, Denmark	University of Oxford; University of Copenhagen	Altman, DG (corresponding author), Inst Hlth Sci, Ctr Stat Med, Imperial Canc Res Grp, Med Stat Grp, Oxford OX3 7LF, England.							ALTMAN DG, 1995, BRIT J CANCER, V72, P511, DOI 10.1038/bjc.1995.364; Altman DG, 1998, BRIT MED J, V317, P1309, DOI 10.1136/bmj.317.7168.1309; COOK RJ, 1995, BRIT MED J, V310, P452, DOI 10.1136/bmj.310.6977.452; LAD T, 1988, J CLIN ONCOL, V6, P9; Malmberg K, 1997, BRIT MED J, V314, P1512, DOI 10.1136/bmj.314.7093.1512; McQuay HJ, 1997, ANN INTERN MED, V126, P712, DOI 10.7326/0003-4819-126-9-199705010-00007; Miller DB, 1997, ARCH INTERN MED, V157, P2045, DOI 10.1001/archinte.157.18.2045; Oates GD, 1996, LANCET, V348, P1605; PIANTADOSI S, 1997, CLIN TRIALS METHODOL; SACKETT DL, 1997, EVIDENCE BASED MED P, P136; Sackett DL, 1991, CLIN EPIDEMIOLOGY BA, P208	11	484	487	2	13	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1492	1495		10.1136/bmj.319.7223.1492	http://dx.doi.org/10.1136/bmj.319.7223.1492			4	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	263MV	10582940	Green Published			2022-12-28	WOS:000084129200028
J	Ham, C				Ham, C			Improving NHS performance: human behaviour and health policy	BRITISH MEDICAL JOURNAL			English	Article									Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England	University of Birmingham	Ham, C (corresponding author), Univ Birmingham, Hlth Serv Management Ctr, Birmingham B15 2RT, W Midlands, England.							Ham C, 1999, J Health Serv Res Policy, V4, P168; Ham C, 1996, HEALTH POLICY, V35, P279, DOI 10.1016/0168-8510(95)00789-X; Le Grand J, 1998, LEARNING NHS INTERNA	3	13	13	1	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1490	1492		10.1136/bmj.319.7223.1490	http://dx.doi.org/10.1136/bmj.319.7223.1490			3	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263MV	10582939	Green Published			2022-12-28	WOS:000084129200027
J	Morgan, JF; Reid, F; Lacey, JH				Morgan, JF; Reid, F; Lacey, JH			The SCOFF questionnaire: assessment of a new screening tool for eating disorders	BRITISH MEDICAL JOURNAL			English	Article							BULIMIA		Univ London St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England; Univ London St Georges Hosp, Sch Med, Dept Publ Hlth Sci, London SW17 0RE, England	St Georges University London; St Georges University London	Morgan, JF (corresponding author), Univ London St Georges Hosp, Sch Med, Dept Psychiat, London SW17 0RE, England.							EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; GARNER DM, 1983, INT J EAT DISORDER, V2, P15, DOI 10.1002/1098-108X(198321)2:2<15::AID-EAT2260020203>3.0.CO;2-6; Greenhalgh T, 1997, BRIT MED J, V315, P540, DOI 10.1136/bmj.315.7107.540; HENDERSON M, 1987, BRIT J PSYCHIAT, V150, P18, DOI 10.1192/bjp.150.1.18; KING MB, 1989, PSYCHOL MED        S, V16, P191	5	655	679	1	41	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	DEC 4	1999	319	7223					1467	1468		10.1136/bmj.319.7223.1467	http://dx.doi.org/10.1136/bmj.319.7223.1467			2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED); Social Science Citation Index (SSCI)	General & Internal Medicine	263MV	10582927	Green Published, Bronze			2022-12-28	WOS:000084129200020
J	Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM				Bush, RM; Bender, CA; Subbarao, K; Cox, NJ; Fitch, WM			Predicting the evolution of human influenza A	SCIENCE			English	Article							VIRUS HEMAGGLUTININ	Eighteen codons in the HA1 domain of the hemagglutinin genes of human influenza A subtype H3 appear to be under positive selection to change the amino acid they encode. Retrospective tests show that viral Lineages undergoing the greatest number of mutations in the positively selected codons were the progenitors of future H3 Lineages in 9 of 11 recent influenza seasons. Codons under positive selection were associated with antibody combining site A or B or the sialic acid receptor binding site. However, not all codons in these sites had predictive value. Monitoring new H3 isolates for additional changes in positively selected codons might help identify the most fit extant viral strains that arise during antigenic drift.	Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA; Ctr Dis Control & Prevent, Influenza Branch, Atlanta, GA 30333 USA	University of California System; University of California Irvine; Centers for Disease Control & Prevention - USA	Bush, RM (corresponding author), Univ Calif Irvine, Dept Ecol & Evolutionary Biol, Irvine, CA 92697 USA.			Subbarao, Kanta/0000-0003-1713-3056				BENDER CM, UNPUB; Bush RM, 1999, MOL BIOL EVOL, V16, P1457, DOI 10.1093/oxfordjournals.molbev.a026057; Cox NJ, 1995, SEMIN VIROL, V6, P359, DOI 10.1016/S1044-5773(05)80013-7; Fitch WM, 1997, P NATL ACAD SCI USA, V94, P7712, DOI 10.1073/pnas.94.15.7712; SWOFFORD DL, PAUP PHYLOGENETIC AN; WEIS W, 1988, NATURE, V333, P426, DOI 10.1038/333426a0; WILEY DC, 1981, NATURE, V289, P373, DOI 10.1038/289373a0; WILSON IA, 1990, ANNU REV IMMUNOL, V8, P737, DOI 10.1146/annurev.iy.08.040190.003513	8	368	390	1	50	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1921	1925		10.1126/science.286.5446.1921	http://dx.doi.org/10.1126/science.286.5446.1921			5	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583948				2022-12-28	WOS:000084003400041
J	Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC				Pappu, R; Cheng, AM; Li, B; Gong, Q; Chiu, C; Griffin, N; White, M; Sleckman, BP; Chan, AC			Requirement for B cell linker protein (BLNK) in B cell development	SCIENCE			English	Article							SEVERE COMBINED IMMUNODEFICIENCY; SYK TYROSINE KINASE; POSITIVE SELECTION; MICE LACKING; AGAMMAGLOBULINEMIA; ZAP-70; GENE; BTK; DEFICIENCY; ACTIVATION	Linker proteins function as molecular scaffolds to Localize enzymes with substrates. In B cells, B cell Linker protein (BLNK) Links the B cell receptor (BCR)activated Syk kinase to the phosphoinositide and mitogen-activated kinase pathways. To examine the in vivo role of BLNK, mice deficient in BLNK were generated. B cell development in BLNK-/- mice was blocked at the transition from B220(+) CD43(+) progenitor B to B220(+) CD43(-) precursor B cells. Only a small percentage of immunoglobulin M++ (IgM(++)), but not mature IgM(lo)lgD(hi), B cells were detected in the periphery. Hence, BLNK is an essential component of BCR signaling pathways and is required to promote B cell development.	Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Div Rheumatol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Pathol, St Louis, MO 63110 USA; Washington Univ, Sch Med, Howard Hughes Med Inst, St Louis, MO 63110 USA	Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Washington University (WUSTL); Howard Hughes Medical Institute; Washington University (WUSTL)	Chan, AC (corresponding author), Washington Univ, Sch Med, Ctr Immunol, St Louis, MO 63110 USA.		Childs, James E/B-4002-2012	Chiu, Christopher W./0000-0001-9744-991X	NATIONAL CANCER INSTITUTE [R01CA071516] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES [R01AI042787] Funding Source: NIH RePORTER; NCI NIH HHS [CA71516] Funding Source: Medline; NIAID NIH HHS [AI42787] Funding Source: Medline	NATIONAL CANCER INSTITUTE(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID)); NCI NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI)); NIAID NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID))		ARPAIA E, 1994, CELL, V76, P947, DOI 10.1016/0092-8674(94)90368-9; Benschop RJ, 1999, CURR OPIN IMMUNOL, V11, P143, DOI 10.1016/S0952-7915(99)80025-9; Campbell KS, 1999, CURR OPIN IMMUNOL, V11, P256, DOI 10.1016/S0952-7915(99)80042-9; CHAN AC, 1994, SCIENCE, V264, P1599, DOI 10.1126/science.8202713; CHEN JZ, 1993, P NATL ACAD SCI USA, V90, P4528, DOI 10.1073/pnas.90.10.4528; CHENG AM, 1995, NATURE, V378, P303, DOI 10.1038/378303a0; Chu DH, 1999, J IMMUNOL, V163, P2610; Clements JL, 1999, J CLIN INVEST, V103, P19, DOI 10.1172/JCI5317; Clements JL, 1998, SCIENCE, V281, P416, DOI 10.1126/science.281.5375.416; Cyster JG, 1996, NATURE, V381, P325, DOI 10.1038/381325a0; ELDER ME, 1994, SCIENCE, V264, P1596, DOI 10.1126/science.8202712; Fu C, 1998, IMMUNITY, V9, P93, DOI 10.1016/S1074-7613(00)80591-9; Gangi-Peterson L, 1998, MOL IMMUNOL, V35, P55, DOI 10.1016/S0161-5890(98)00008-X; Goitsuka R, 1998, J IMMUNOL, V161, P5804; HARDY RR, 1991, J EXP MED, V173, P1213, DOI 10.1084/jem.173.5.1213; Healy JI, 1998, ANNU REV IMMUNOL, V16, P645, DOI 10.1146/annurev.immunol.16.1.645; Hendriks RW, 1996, EMBO J, V15, P4862, DOI 10.1002/j.1460-2075.1996.tb00867.x; HERZENBERG LA, 1986, IMMUNOL REV, V93, P81, DOI 10.1111/j.1600-065X.1986.tb01503.x; Ishiai M, 1999, IMMUNITY, V10, P117, DOI 10.1016/S1074-7613(00)80012-6; KANTOR AB, 1993, ANNU REV IMMUNOL, V11, P501, DOI 10.1146/annurev.immunol.11.1.501; KANTOR AB, 1992, P NATL ACAD SCI USA, V89, P3320, DOI 10.1073/pnas.89.8.3320; KERNER JD, 1995, IMMUNITY, V3, P301, DOI 10.1016/1074-7613(95)90115-9; KHAN WN, 1995, IMMUNITY, V3, P283, DOI 10.1016/1074-7613(95)90114-0; KITAMURA D, 1992, CELL, V69, P823, DOI 10.1016/0092-8674(92)90293-L; Kurosaki T, 1999, ANNU REV IMMUNOL, V17, P555, DOI 10.1146/annurev.immunol.17.1.555; LEDBETTER JA, 1979, IMMUNOGENETICS, V8, P347, DOI 10.1007/BF01561445; Loder F, 1999, J EXP MED, V190, P75, DOI 10.1084/jem.190.1.75; Minegishi Y, 1999, SCIENCE, V286, P1954, DOI 10.1126/science.286.5446.1954; Minegishi Y, 1998, J EXP MED, V187, P71, DOI 10.1084/jem.187.1.71; PAPPU R, UNPUB; Pivniouk V, 1998, CELL, V94, P229, DOI 10.1016/S0092-8674(00)81422-1; TSUKADA S, 1993, CELL, V72, P279, DOI 10.1016/0092-8674(93)90667-F; TURNER M, 1995, NATURE, V378, P298, DOI 10.1038/378298a0; Turner M, 1997, J EXP MED, V186, P2013, DOI 10.1084/jem.186.12.2013; VETRIE D, 1993, NATURE, V361, P226, DOI 10.1038/361226a0; von Boehmer H, 1999, CURR OPIN IMMUNOL, V11, P135, DOI 10.1016/S0952-7915(99)80024-7; Wienands J, 1998, J EXP MED, V188, P791, DOI 10.1084/jem.188.4.791	37	237	241	0	8	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	DEC 3	1999	286	5446					1949	1954		10.1126/science.286.5446.1949	http://dx.doi.org/10.1126/science.286.5446.1949			6	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261HH	10583957				2022-12-28	WOS:000084003400050
J	Heilbron, JL; Bynum, WF				Heilbron, JL; Bynum, WF			Plus ca change	NATURE			English	Article								For the past couple of centuries the penchant for prediction has been prevalent at century turns. How much have evaluations of scientific discovery and predictions for future advancement changed since those of the science commentators at the end of the last century?	Univ Oxford Worcester Coll, Oxford OX1 2HB, England; Wellcome Inst Hist Med, London NW1 2BE, England	University of Oxford; University of London; University College London	Heilbron, JL (corresponding author), Univ Oxford Worcester Coll, Oxford OX1 2HB, England.								0	1	1	0	1	MACMILLAN MAGAZINES LTD	LONDON	PORTERS SOUTH, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	0028-0836			NATURE	Nature	DEC 2	1999	402	6761		S			C86	C88		10.1038/35011581	http://dx.doi.org/10.1038/35011581			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	261MZ	10591230				2022-12-28	WOS:000084014100013
J	Greff-Lefftz, M; Legros, H				Greff-Lefftz, M; Legros, H			Core rotational dynamics and geological events	SCIENCE			English	Article							EARTHS CORE	A study of Earth's fluid core oscillations induced by lunar-solar tidal forces, together with tidal secular deceleration of Earth's axial rotation, shows that the rotational eigenfrequency of the fluid core and some solar tidal waves were in resonance around 3.0 x 10(9), 1.8 x 10(9), and 3 x 10(8) years ago. The associated viscomagnetic frictional power at the core boundaries may be converted into heat and would destabilize the D " thermal Layer, leading to the generation of deep-mantle plumes, and would also increase the temperature at the fluid core boundaries, perturbing the core dynamo process. Such phenomena could account for large-scale episodes of continental crust formation, the generation of flood basalts, and abrupt changes in geomagnetic reversal frequency.	Inst Phys Globe Strasbourg, Dept Geomagnetism & Paleomagnetism, F-75252 Paris 05, France; Ecole & Observ Sci Terre, F-67084 Strasbourg, France		Greff-Lefftz, M (corresponding author), Inst Phys Globe Strasbourg, Dept Geomagnetism & Paleomagnetism, 4 Pl Jussieu, F-75252 Paris 05, France.		Greff, Marianne/A-6126-2011					CONDIE KC, 1989, PALAEOGEOGR PALAEOCL, V75, P57; DEHANT V, 1993, PHYS EARTH PLANET IN, V76, P259, DOI 10.1016/0031-9201(93)90018-5; HINDERER J, 1988, AGU MONOGRAPH SERIES, V46, P79; Labrosse S, 1997, PHYS EARTH PLANET IN, V99, P1, DOI 10.1016/S0031-9201(96)03207-4; Lambeck K., 1980, EARTHS VARIABLE ROTA; LOPER DE, 1975, PHYS EARTH PLANET IN, V11, P43, DOI 10.1016/0031-9201(75)90074-6; MATHEWS PM, 1991, J GEOPHYS RES-SOLID, V96, P8219, DOI 10.1029/90JB01955; MELCHIOR P, 1973, PHYSIQUE DYNAMIQUE P, V4; OGG JG, 1995, AGU REFERENCE SHELF, V1, P240; Poincare H., 1910, B ASTRON, V27, P321; POIRIER JP, 1988, GEOPHYS J INT, V92, P99, DOI 10.1111/j.1365-246X.1988.tb01124.x; Roosbeek F, 1996, GEOPHYS J INT, V126, P197, DOI 10.1111/j.1365-246X.1996.tb05278.x; ROSS MN, 1989, J GEOPHYS RES-SOLID, V94, P9533, DOI 10.1029/JB094iB07p09533; STACEY FD, 1992, PHYSICS EARTH; Taylor S.R., 1985, CONTINENTAL CRUST IT; TOOMRE A, 1974, GEOPHYS J ROY ASTR S, V38, P335, DOI 10.1111/j.1365-246X.1974.tb04126.x; WILLIAMS GE, 1994, EARTH PLANET SC LETT, V128, P155, DOI 10.1016/0012-821X(94)90142-2	17	33	35	0	5	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	NOV 26	1999	286	5445					1707	1709		10.1126/science.286.5445.1707	http://dx.doi.org/10.1126/science.286.5445.1707			3	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	259UK	10576731				2022-12-28	WOS:000083912200029
J	Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG				Kolb, HJ; Socie, G; Duell, T; Van Lint, MT; Tichelli, A; Apperley, JF; Nekolla, E; Ljungman, P; Jacobsen, N; van Weel, M; Wick, R; Weiss, M; Prentice, HG		Late Effects Working Party Europea; European Late Effect Project Grp	Malignant neoplasms in long-term survivors of bone marrow transplantation	ANNALS OF INTERNAL MEDICINE			English	Article						neoplasms; bone marrow transplantation; immunosuppression; cyclosporine; age factors; graft vs host disease	TOTAL-BODY IRRADIATION; SEVERE APLASTIC-ANEMIA; SECONDARY MALIGNANCIES; LEUKEMIA; CANCERS; TUMORS; RISK	Background: Patients who receive bone marrow transplants have increased risk for new malignant conditions because of several risk factors, including conditioning with radiation and chemotherapy, immune stimulation, and malignant primary disease. The occurrence of and risk factors for malignant neoplasm in long-term survivors must be assessed. Objective: To determine the risk and define potential risk factors for new malignant conditions in long-term survivors after marrow transplantation. Design: Retrospective multicenter study. Setting: Study of the Late Effects Working Party with 45 transplantation centers cooperating in the European Cooperative Group for Blood and Marrow Transplantation. Patients: 1036 consecutive patients who underwent transplantation for leukemia, lymphoma, inborn diseases of the hematopoietic and immune systems, or severe aplastic anemia. Transplantation was done before December 1985, and patients had survived more than 5 years. Measurements: Reports on malignant neoplasms were evaluated, and the incidence was compared to that in the general population. Patient age and sex, primary disease and status at transplantation, histocompatibility of the donor, conditioning regimen, type of prophylaxis of graft-versus-host disease, development of acute and chronic graft-versus-host disease, and treatment of chronic graft-versus-host disease were evaluated as variables. Results: Median follow-up since transplantation was 10.7 years (range, 5 to 22.1 years). Malignant neoplasms were seen in 53 patients; the actuarial incidence (+/- SE) was 3.5% +/- 0.6% at 10 years and 12.8% +/- 2.6% at 15 years. The rate of new malignant disease was 3.8-fold higher than that in an age-matched control population (P < 0.001). The most frequent malignant diseases were neoplasms of the skin (14 patients), oral cavity (7 patients), uterus (including cervix) (5 patients), thyroid gland (5 patients), breast (4 patients), and glial tissue (3 patients). Median age of patients and their donors was 21 years. Malignant neoplasms were more frequent in older patients and in patients with chronic graft-versus-host disease. Older patient age and treatment of chronic graft-versus-host disease with cyclosporine were significant risk factors for new malignant neoplasms after bone marrow transplantation. Conclusions: The spectrum of neoplasms and immunosuppressive treatment with cyclosporine for chronic graft-versus-host disease as dominant risk factors indicate that immunosuppression is the major cause of malignant neoplasms in patients receiving marrow transplants.	Univ Munich, Dept Med 3, Hematopoiet Cell Transplantat Unit, Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Inst Radiobiol, D-81377 Munich, Germany; GSF Munich, Natl Res Ctr Environm & Hlth, Hematopoiet Cell Transplantat Med Clin 3, D-81377 Munich, Germany	University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich; Helmholtz Association; Helmholtz-Center Munich - German Research Center for Environmental Health; University of Munich	Kolb, HJ (corresponding author), Univ Munich, Hematopoiet Cell Transplantat Med Clin 3, Marchioninistr 15, D-81377 Munich, Germany.		Ljungman, Per/M-4946-2019					Bhatia S, 1996, BLOOD, V87, P3633, DOI 10.1182/blood.V87.9.3633.bloodjournal8793633; BORTIN MM, 1992, JAMA-J AM MED ASSOC, V268, P607; BORTIN MM, 1992, ANN INTERN MED, V116, P505, DOI 10.7326/0003-4819-116-6-505; Curtis RE, 1997, NEW ENGL J MED, V336, P897, DOI 10.1056/NEJM199703273361301; DEEG HJ, 1980, BLOOD, V55, P233; Deeg HJ, 1996, BLOOD, V87, P386, DOI 10.1182/blood.V87.1.386.bloodjournal871386; DEEG HJ, 1983, INT J RADIAT ONCOL, V9, P1505, DOI 10.1016/0360-3016(83)90325-5; GRATWOHL A, 1994, BONE MARROW TRANSPL, V13, P5; KAPLAN EL, 1958, J AM STAT ASSOC, V53, P457, DOI 10.2307/2281868; KOHN HI, 1984, NEW ENGL J MED, V310, P504, DOI 10.1056/NEJM198402233100807; Kolb H J, 1990, Radiother Oncol, V18 Suppl 1, P51, DOI 10.1016/0167-8140(90)90178-Y; LISHNER M, 1990, CANCER-AM CANCER SOC, V65, P473, DOI 10.1002/1097-0142(19900201)65:3<473::AID-CNCR2820650316>3.0.CO;2-V; LONDON NJ, 1995, LANCET, V346, P403, DOI 10.1016/S0140-6736(95)92780-8; LOWSKY R, 1994, J CLIN ONCOL, V12, P2187, DOI 10.1200/JCO.1994.12.10.2187; MUIR C, 1987, 5 CONTINENTS; NEGLIA JP, 1991, NEW ENGL J MED, V325, P1330, DOI 10.1056/NEJM199111073251902; PENN I, 1987, TRANSPLANTATION, V43, P32, DOI 10.1097/00007890-198701000-00008; PIERGA JY, 1994, RADIOTHER ONCOL, V30, P55, DOI 10.1016/0167-8140(94)90009-4; SEROTA FT, 1983, INT J RADIAT ONCOL, V9, P1941, DOI 10.1016/0360-3016(83)90366-8; SOCIE G, 1993, NEW ENGL J MED, V329, P1152, DOI 10.1056/NEJM199310143291603; SOCIE G, 1991, BLOOD, V78, P277; THOMAS ED, 1975, NEW ENGL J MED, V292, P832, DOI 10.1056/NEJM197504172921605; TUCKER MA, 1988, NEW ENGL J MED, V318, P76, DOI 10.1056/NEJM198801143180203; WITHERSPOON RP, 1989, NEW ENGL J MED, V321, P784, DOI 10.1056/NEJM198909213211203; WITHERSPOON RP, 1994, TRANSPLANTATION, V57, P1413, DOI 10.1097/00007890-199405270-00001	25	189	190	0	5	AMER COLL PHYSICIANS	PHILADELPHIA	INDEPENDENCE MALL WEST 6TH AND RACE ST, PHILADELPHIA, PA 19106-1572 USA	0003-4819	1539-3704		ANN INTERN MED	Ann. Intern. Med.	NOV 16	1999	131	10					738	+		10.7326/0003-4819-131-10-199911160-00004	http://dx.doi.org/10.7326/0003-4819-131-10-199911160-00004			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	255QC	10577296				2022-12-28	WOS:000083680100003
J	Compton, DA				Compton, DA			Perspectives: Cell cycle - New tools for the antimitotic toolbox	SCIENCE			English	Editorial Material									Dartmouth Coll, Sch Med, Dept Biochem, Hanover, NH 03755 USA	Dartmouth College	Compton, DA (corresponding author), Dartmouth Coll, Sch Med, Dept Biochem, 7200 Vail Bldg,Room 413, Hanover, NH 03755 USA.			Compton, Duane/0000-0002-4445-9118				Anderson HJ, 1998, EXP CELL RES, V238, P498, DOI 10.1006/excr.1997.3862; Hamel E, 1996, MED RES REV, V16, P207, DOI 10.1002/(SICI)1098-1128(199603)16:2<207::AID-MED4>3.3.CO;2-I; Mayer TU, 1999, SCIENCE, V286, P971, DOI 10.1126/science.286.5441.971; Stockwell BR, 1999, CHEM BIOL, V6, P71, DOI 10.1016/S1074-5521(99)80004-0; Walczak CE, 1996, CELL, V85, P943, DOI 10.1016/S0092-8674(00)81295-7	5	7	9	0	0	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075			SCIENCE	Science	OCT 29	1999	286	5441					913	914		10.1126/science.286.5441.913	http://dx.doi.org/10.1126/science.286.5441.913			2	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	250BE	10577242				2022-12-28	WOS:000083368500032
J	Turrell, A; Castleden, CM				Turrell, A; Castleden, CM			Commentary: A new script for nursing home care in the United Kingdom?	BRITISH MEDICAL JOURNAL			English	Editorial Material							GENERAL-PRACTITIONERS; POLICY; IMPACT		Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England; Leicester Gen Hosp NHS Trust, Directorate Med, Leicester LE5 4PW, Leics, England	University of Sheffield; University Hospitals of Leicester NHS Trust; Leicester General Hospital	Turrell, A (corresponding author), Univ Sheffield, Trent Inst Hlth Serv Res, Sheffield S1 4DA, S Yorkshire, England.							ANDREW RA, 1988, J ROY COLL GEN PRACT, V38, P546; AVORN J, 1992, NEW ENGL J MED, V327, P168, DOI 10.1056/NEJM199207163270306; AVORN J, 1989, NEW ENGL J MED, V320, P227, DOI 10.1056/NEJM198901263200406; Belay ED, 1999, NEW ENGL J MED, V340, P1377, DOI 10.1056/NEJM199905063401801; *DEP GER MED ST GE, 1999, NURS HOM PLAC OLD PE; Department of Health, 1998, MOD HLTH SOC SERV NA; Department of Health, 1999, REV PRESCR SUPPL ADM; *DIV GEN PRACT U N, 1998, IMP NURS HOM PAT GEN; HEPPLE J, 1989, AGE AGEING, V18, P61, DOI 10.1093/ageing/18.1.61; Kavanagh S, 1998, BRIT MED J, V317, P322, DOI 10.1136/bmj.317.7154.322; *NAT PRESCR CTR NH, 1998, GP PRESCR SUPP RES D; ROVNER BW, 1992, AM J PSYCHIAT, V149, P1390; SEMLA TP, 1994, J AM GERIATR SOC, V42, P648, DOI 10.1111/j.1532-5415.1994.tb06865.x; Turrell AR, 1998, BRIT MED J, V317, P942; Turrell AR, 1999, AGE AGEING, V28, P77, DOI 10.1093/ageing/28.1.77; 1996, BMJ, V313, P1163	16	3	3	0	1	BRITISH MED JOURNAL PUBL GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0959-8138			BRIT MED J	Br. Med. J.	OCT 16	1999	319	7216					1062	1063						2	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	247FH	10576847				2022-12-28	WOS:000083210100036
J	Kjos, SL; Buchanan, TA				Kjos, SL; Buchanan, TA			Current concepts: Gestational diabetes mellitus.	NEW ENGLAND JOURNAL OF MEDICINE			English	Review							ISLET-CELL ANTIBODIES; POSTPARTUM GLUCOSE-TOLERANCE; INFANT BIRTH-WEIGHT; PERINATAL MORBIDITY; INSULIN-SECRETION; CESAREAN DELIVERY; FETAL MACROSOMIA; PREDICTIVE VALUE; GLYCEMIC CONTROL; SCREENING-TESTS		Univ So Calif, Sch Med, Dept Obstet & Gynecol, Los Angeles, CA 90033 USA; Univ So Calif, Sch Med, Dept Med, Los Angeles, CA 90033 USA	University of Southern California; University of Southern California	Kjos, SL (corresponding author), 1240 N Miss Rd,Rm L1017, Los Angeles, CA 90033 USA.	skjos@hsc.usc.edu			NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES [R01DK046374] Funding Source: NIH RePORTER; NCRR NIH HHS [M01-RR-43] Funding Source: Medline; NIDDK NIH HHS [R01-DK-46374] Funding Source: Medline	NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK)); NCRR NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR)); NIDDK NIH HHS(United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK))		*AM DIAB ASS, 1999, DIABETES CARE S1, V22, pS74; BECERRA JE, 1990, PEDIATRICS, V85, P1; BEISCHER NA, 1995, AM J OBSTET GYNECOL, V173, P1563, DOI 10.1016/0002-9378(95)90650-9; Buchanan TA, 1998, DIABETES, V47, P1302, DOI 10.2337/diabetes.47.8.1302; Buchanan TA, 1998, DIABETES CARE, V21, pB99; BUCHANAN TA, 1994, DIABETES CARE, V17, P275, DOI 10.2337/diacare.17.4.275; BUCHANAN TA, 1990, AM J OBSTET GYNECOL, V162, P1008, DOI 10.1016/0002-9378(90)91306-W; BUNG P, 1991, DIABETES, V40, P182, DOI 10.2337/diab.40.2.S182; CARPENTER MW, 1982, AM J OBSTET GYNECOL, V144, P768, DOI 10.1016/0002-9378(82)90349-0; CATALANO PM, 1990, DIABETES CARE, V13, P478, DOI 10.2337/diacare.13.5.478; CATALANO PM, 1991, AM J OBSTET GYNECOL, V165, P914, DOI 10.1016/0002-9378(91)90438-W; CATALANO PM, 1993, AM J PHYSIOL, V264, pE60, DOI 10.1152/ajpendo.1993.264.1.E60; Clapp JF, 1998, DIABETES CARE, V21, pB107; COMBS CA, 1992, DIABETES CARE, V15, P1251, DOI 10.2337/diacare.15.10.1251; Conway DL, 1998, AM J OBSTET GYNECOL, V178, P922, DOI 10.1016/S0002-9378(98)70524-1; COUSINS L, 1991, AM J OBSTET GYNECOL, V165, P493, DOI 10.1016/0002-9378(91)90273-T; COUSTAN DR, 1993, AM J OBSTET GYNECOL, V168, P1139, DOI 10.1016/0002-9378(93)90358-P; COUSTAN DR, 1989, OBSTET GYNECOL, V73, P557; COUSTAN DR, 1984, AM J OBSTET GYNECOL, V150, P836, DOI 10.1016/0002-9378(84)90459-9; DAMM P, 1992, AM J OBSTET GYNECOL, V167, P607, DOI 10.1016/S0002-9378(11)91559-2; DAMM P, 1994, DIABETIC MED, V11, P558, DOI 10.1111/j.1464-5491.1994.tb02035.x; DEVECIANA M, 1995, NEW ENGL J MED, V333, P1237, DOI 10.1056/NEJM199511093331901; DOOLEY SL, 1991, DIABETES, V40, P25, DOI 10.2337/diab.40.2.S25; DREXEL H, 1988, DIABETES CARE, V11, P761, DOI 10.2337/diacare.11.10.761; DRURY MI, 1983, OBSTET GYNECOL, V62, P279; FISHER PM, 1980, DIABETOLOGIA, V19, P10, DOI 10.1007/BF00258303; Freinkel N, 1985, Diabetes, V34 Suppl 2, P1; Gavin JR, 1997, DIABETES CARE, V20, P1183; Girz B A, 1992, J Perinatol, V12, P229; HARRIS M, 1979, DIABETES, V28, P1039; HENRY OA, 1991, BAILLIERE CLIN OB GY, V5, P461, DOI 10.1016/S0950-3552(05)80107-5; HOD M, 1991, DIABETES, V40, P74, DOI 10.2337/diab.40.2.S74; Hod M, 1998, DIABETES CARE, V21, pB113; HOFMANN HMH, 1990, AM J OBSTET GYNECOL, V162, P1174, DOI 10.1016/0002-9378(90)90010-5; Homko CJ, 1998, DIABETES CARE, V21, pB118; HOMKO CJ, 1995, DIABETES CARE, V18, P1442, DOI 10.2337/diacare.18.11.1442; Jang HC, 1997, DIABETES CARE, V20, P1582, DOI 10.2337/diacare.20.10.1582; Joffe GM, 1998, AM J OBSTET GYNECOL, V179, P1032, DOI 10.1016/S0002-9378(98)70210-8; JOHNSON JM, 1988, OBSTET GYNECOL, V72, P841, DOI 10.1097/00006250-198812000-00005; JovanovicPeterson L, 1997, AM J PERINAT, V14, P221, DOI 10.1055/s-2007-994131; JOVANOVICPETERSON L, 1991, AM J OBSTET GYNECOL, V164, P103, DOI 10.1016/0002-9378(91)90637-7; JOVANOVICPETERSON L, 1991, DIABETES, V40, P179, DOI 10.2337/diab.40.2.S179; Kalkhoff R K, 1985, Diabetes, V34 Suppl 2, P97; KALKHOFF RK, 1991, DIABETES, V40, P61, DOI 10.2337/diab.40.2.S61; Kitzmiller JL, 1998, DIABETES CARE, V21, pB123; KJOS SL, 1995, AM J OBSTET GYNECOL, V173, P1532, DOI 10.1016/0002-9378(95)90645-2; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P93, DOI 10.1016/S0002-9378(11)90676-0; Kjos SL, 1998, JAMA-J AM MED ASSOC, V280, P533, DOI 10.1001/jama.280.6.533; KJOS SL, 1994, OBSTET GYNECOL, V84, P1006; KJOS SL, 1993, AM J OBSTET GYNECOL, V169, P611, DOI 10.1016/0002-9378(93)90631-R; KJOS SL, 1995, DIABETES, V44, P586, DOI 10.2337/diabetes.44.5.586; KJOS SL, 1990, AM J OBSTET GYNECOL, V163, P898, DOI 10.1016/0002-9378(90)91092-Q; Kjos SL, 1998, DIABETES CARE, V21, pB50; KNOPP RH, 1992, DIABETES CARE, V15, P1605, DOI 10.2337/diacare.15.11.1605; KNOPP RH, 1991, DIABETES, V40, P165, DOI 10.2337/diab.40.2.S165; KUHL C, 1976, DIABETES, V25, P16, DOI 10.2337/diabetes.25.1.16; Landon M B, 1985, Diabetes, V34 Suppl 2, P50; LANDON MB, 1991, CLIN OBSTET GYNECOL, V34, P535; LANDON MB, 1990, OBSTET GYNECOL, V75, P635; LANGER O, 1989, AM J OBSTET GYNECOL, V161, P646, DOI 10.1016/0002-9378(89)90371-2; LANGER O, 1994, AM J OBSTET GYNECOL, V170, P1036, DOI 10.1016/S0002-9378(94)70097-4; LANGER O, 1988, AM J OBSTET GYNECOL, V159, P1478, DOI 10.1016/0002-9378(88)90578-9; Langer O, 1998, DIABETES CARE, V21, pB91; LINDER DH, 1991, IEEE T COMPUT, V40, P2, DOI 10.1109/12.67315; MAGEE MS, 1993, JAMA-J AM MED ASSOC, V269, P609, DOI 10.1001/jama.269.5.609; Major CA, 1998, OBSTET GYNECOL, V91, P600, DOI 10.1016/S0029-7844(98)00003-9; Mauricio D, 1996, DIABETES METAB REV, V12, P275; MAURICIO D, 1995, DIABETIC MED, V12, P1009, DOI 10.1111/j.1464-5491.1995.tb00414.x; MESTMAN JH, 1972, OBSTET GYNECOL, V39, P421; METZGER BE, 1991, DIABETES, V40, P197, DOI 10.2337/diab.40.2.S197; Metzger BE, 1998, DIABETES CARE, V21, pB161; METZGER BE, 1991, DIABETES, V40, P99, DOI 10.2337/diab.40.2.S99; METZGER BE, 1993, DIABETES CARE, V16, P1598, DOI 10.2337/diacare.16.12.1598; Naylor CD, 1997, NEW ENGL J MED, V337, P1591, DOI 10.1056/NEJM199711273372204; Naylor CD, 1996, JAMA-J AM MED ASSOC, V275, P1165, DOI 10.1001/jama.275.15.1165; NOLAN CJ, 1995, DIABETES CARE, V18, P1550, DOI 10.2337/diacare.18.12.1550; O'Sullivan JB, 1979, CARBOHYD METABOL, P425; OSULLIVA.JB, 1973, AM J OBSTET GYNECOL, V116, P901; OSULLIVAN JB, 1973, AM J OBSTET GYNECOL, V116, P895; OSULLIVAN JB, 1964, DIABETES, V13, P278; PEDERSEN J, 1977, PREGNANT DIABETIC HE, P191; PERSSON B, 1991, DIABETES, V40, P136, DOI 10.2337/diab.40.2.S136; Persson B, 1998, DIABETES CARE, V21, pB79; Peters RK, 1996, LANCET, V347, P227, DOI 10.1016/S0140-6736(96)90405-5; Petersen JS, 1996, DIABETOLOGIA, V39, P1329, DOI 10.1007/s001250050578; PETERSON CM, 1991, DIABETES, V40, P172, DOI 10.2337/diab.40.2.S172; Pettitt D.J., 1985, DIABETES, V34, P119, DOI DOI 10.2337/DIAB.34.2.S119; PETTITT DJ, 1983, NEW ENGL J MED, V308, P242, DOI 10.1056/NEJM198302033080502; PIPER JM, 1993, AM J OBSTET GYNECOL, V168, P783, DOI 10.1016/S0002-9378(12)90819-4; PLACEK PJ, 1988, OBSTET GYN CLIN N AM, V15, P607; Roberts R, 1998, DIABETES CARE, V21, pB27; SACKS DA, 1995, AM J OBSTET GYNECOL, V172, P607, DOI 10.1016/0002-9378(95)90580-4; SACKS DA, 1987, OBSTET GYNECOL, V70, P89; SACKS DA, 1989, AM J OBSTET GYNECOL, V161, P638, DOI 10.1016/0002-9378(89)90369-4; Schaefer UM, 1997, AM J OBSTET GYNECOL, V177, P1165, DOI 10.1016/S0002-9378(97)70035-8; SERMER M, 1995, AM J OBSTET GYNECOL, V173, P146, DOI 10.1016/0002-9378(95)90183-3; Sermer M, 1998, DIABETES CARE, V21, pB33; SILVERMAN BL, 1991, DIABETES, V40, P121, DOI 10.2337/diab.40.2.S121; SILVERMAN BL, 1995, DIABETES CARE, V18, P611, DOI 10.2337/diacare.18.5.611; STEEL JM, 1980, J CLIN LAB IMMUNOL, V4, P83; WARD WK, 1985, DIABETES, V34, P861, DOI 10.2337/diabetes.34.9.861; World Health Organization, 1985, WHO TECH REP SER, V727, P7; Xiang AH, 1999, DIABETES, V48, P848, DOI 10.2337/diabetes.48.4.848; YEN SSC, 1971, AM J OBSTET GYNECOL, V111, P792, DOI 10.1016/0002-9378(71)90490-X	104	437	445	0	30	MASSACHUSETTS MEDICAL SOC	WALTHAM	WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA	0028-4793	1533-4406		NEW ENGL J MED	N. Engl. J. Med.	DEC 2	1999	341	23					1749	1756		10.1056/NEJM199912023412307	http://dx.doi.org/10.1056/NEJM199912023412307			8	Medicine, General & Internal	Science Citation Index Expanded (SCI-EXPANDED)	General & Internal Medicine	260NB	10580075				2022-12-28	WOS:000083955800007
J	O'Brien, SJ; Menotti-Raymond, M; Murphy, WJ; Nash, WG; Wienberg, J; Stanyon, R; Copeland, NG; Jenkins, NA; Womack, JE; Graves, JAM				O'Brien, SJ; Menotti-Raymond, M; Murphy, WJ; Nash, WG; Wienberg, J; Stanyon, R; Copeland, NG; Jenkins, NA; Womack, JE; Graves, JAM			The promise of comparative genomics in mammals	SCIENCE			English	Review							GENETIC-LINKAGE MAP; QUANTITATIVE-TRAIT LOCI; SPONTANEOUSLY HYPERTENSIVE RAT; CHEMOKINE RECEPTOR CXCR4; IN-SITU HYBRIDIZATION; ZOO-FISH; CHROMOSOMAL EVOLUTION; BLOOD-PRESSURE; Y-CHROMOSOME; CARNIVORE KARYOTYPE	Dense genetic maps of human, mouse, and rat genomes that are based on coding genes and on microsatellite and single-nucleotide polymorphism markers have been complemented by precise gene homolog alignment with moderate-resolution maps of Livestock, companion animals, and additional mammal species. Comparative genetic assessment expands the utility of these maps in gene discovery, in functional genomics, and in tracking the evolutionary forces that sculpted the genome organization of modern mammalian species.	NCI, Lab Genom Divers, Frederick, MD 21702 USA; NCI, Mammalian Genet Lab, Adv Biosci Labs, Frederick, MD 21702 USA; Texas A&M Univ, Coll Vet Med, Dept Vet Pathol, College Stn, TX 77843 USA; La Trobe Univ, Dept Genet & Evolut, Melbourne, Vic 3083, Australia	National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI); Texas A&M University System; Texas A&M University College Station; La Trobe University	O'Brien, SJ (corresponding author), NCI, Lab Genom Divers, Frederick, MD 21702 USA.		Graves, Jennifer A.M./A-1387-2008; OBRIEN, STEPHEN/ABD-1346-2020	OBRIEN, STEPHEN/0000-0001-7857-0757; Graves, Jennifer/0000-0001-6480-7856; Stanyon, Roscoe/0000-0002-7229-1092				ADAMS MD, 1995, NATURE, V377, P3; Al-Bayati HK, 1999, MAMM GENOME, V10, P569, DOI 10.1007/s003359901046; Alvarez V, 1998, HUM GENET, V102, P483, DOI 10.1007/s004390050726; Amemiya CT, 1999, METHOD CELL BIOL, V60, P235; Andersson L, 1997, J HERED, V88, P380, DOI 10.1093/oxfordjournals.jhered.a023122; ANDERSSON L, 1994, SCIENCE, V263, P1771, DOI 10.1126/science.8134840; Andersson L, 1996, MAMM GENOME, V7, P717, DOI 10.1007/s003359900222; [Anonymous], 1999, WALKERS MAMMALS WORL; Bailey Ernest, 1998, ILAR J, V39, P171; BARENDSE W, 1994, NAT GENET, V6, P227, DOI 10.1038/ng0394-227; Battey J, 1999, NAT GENET, V21, P73, DOI 10.1038/5012; Bennetzen JL, 1998, P NATL ACAD SCI USA, V95, P1975, DOI 10.1073/pnas.95.5.1975; Berger EA, 1999, ANNU REV IMMUNOL, V17, P657, DOI 10.1146/annurev.immunol.17.1.657; BISHOP MD, 1994, GENETICS, V136, P619; Blake JA, 1999, NUCLEIC ACIDS RES, V27, P95, DOI 10.1093/nar/27.1.95; Bottger A, 1996, J CLIN INVEST, V98, P856, DOI 10.1172/JCI118858; Broad Thomas E., 1998, ILAR J, V39, P160; Bromham L, 1999, TRENDS ECOL EVOL, V14, P113, DOI 10.1016/S0169-5347(98)01507-9; Buetow KH, 1999, NAT GENET, V21, P323, DOI 10.1038/6851; Burt David W., 1998, ILAR J, V39, P229; Cairns JS, 1998, NAT MED, V4, P563, DOI 10.1038/nm0598-563; Cargill M, 1999, NAT GENET, V22, P231, DOI 10.1038/10290; CHAPMAN VM, 1978, ORIGINS INBRED MICE, P555; CHARLIER C, 1995, MAMM GENOME, V6, P788, DOI 10.1007/BF00539005; Chemelli RM, 1999, CELL, V98, P437, DOI 10.1016/S0092-8674(00)81973-X; Chowdhary BP, 1996, MAMM GENOME, V7, P297, DOI 10.1007/s003359900086; Clement K, 1998, NATURE, V392, P398, DOI 10.1038/32911; Cockett NE, 1999, MAMM GENOME, V10, P35, DOI 10.1007/s003359900938; Cohen OJ, 1998, J VIROL, V72, P6215, DOI 10.1128/JVI.72.7.6215-6217.1998; COLLINS FC, 1999, SCIENCE, V278, P1580; Collins FS, 1998, SCIENCE, V282, P682, DOI 10.1126/science.282.5389.682; CONSIGLIERE S, 1996, CHROMOSOME RES, V3, P1; COPELAND NG, 1993, SCIENCE, V262, P57, DOI 10.1126/science.8211130; CRAWFORD AM, 1995, GENETICS, V140, P703; DAVIS SJM, 1983, FOUILLES RECENTES KH, P189; Davisson Muriel T., 1998, ILAR J, V39, P96; de Gortari MJ, 1998, MAMM GENOME, V9, P204, DOI 10.1007/s003359900726; Dean M, 1996, SCIENCE, V273, P1856, DOI 10.1126/science.273.5283.1856; DeBry RW, 1996, GENOMICS, V33, P337, DOI 10.1006/geno.1996.0209; Delbridge ML, 1999, NAT GENET, V22, P223, DOI 10.1038/10279; Deloukas P, 1998, SCIENCE, V282, P744, DOI 10.1126/science.282.5389.744; Dib C, 1996, NATURE, V380, P152, DOI 10.1038/380152a0; Dietrich WF, 1996, NATURE, V380, P149, DOI 10.1038/380149a0; DSouza MP, 1996, NAT MED, V2, P1293, DOI 10.1038/nm1296-1293; DUTRILLAUX B, 1979, HUM GENET, V48, P251, DOI 10.1007/BF00272830; Ehrlich J, 1997, GENETICS, V147, P289; ELLEGREN H, 1993, GENOMICS, V17, P599, DOI 10.1006/geno.1993.1378; Farooqi IS, 1999, NEW ENGL J MED, V341, P879, DOI 10.1056/NEJM199909163411204; Ferguson-Smith Malcolm A., 1998, ILAR J, V39, P68; Foote M, 1999, SCIENCE, V283, P1310, DOI 10.1126/science.283.5406.1310; FOSTER JW, 1992, NATURE, V359, P531, DOI 10.1038/359531a0; Friedman JM, 1998, NATURE, V395, P763, DOI 10.1038/27376; FRIEDMAN JM, 1992, CELL, V69, P217, DOI 10.1016/0092-8674(92)90402-X; Fronicke L, 1997, CHROMOSOMA, V106, P108; Fronicke L, 1996, MAMM GENOME, V7, P285, DOI 10.1007/s003359900084; FUJII J, 1991, SCIENCE, V253, P448, DOI 10.1126/science.1862346; Gale MD, 1998, P NATL ACAD SCI USA, V95, P1971, DOI 10.1073/pnas.95.5.1971; Galloway SM, 1996, GENOME RES, V6, P667, DOI 10.1101/gr.6.8.667; Gates MA, 1999, GENOME RES, V9, P334; Gatesy J, 1999, SYST BIOL, V48, P6, DOI 10.1080/106351599260409; Geldermann H, 1996, J ANIM BREED GENET, V113, P381, DOI 10.1111/j.1439-0388.1996.tb00629.x; GEORGES M, 1993, NAT GENET, V4, P206, DOI 10.1038/ng0693-206; GEORGES M, 1993, P NATL ACAD SCI USA, V90, P1058, DOI 10.1073/pnas.90.3.1058; GEORGES M, 1995, GENETICS, V139, P907; Gibbons A, 1998, SCIENCE, V281, P1432, DOI 10.1126/science.281.5382.1432; GLAS R, 1998, ILAR J, V39; GOLDMAN D, 1989, EVOLUTION, V43, P282, DOI 10.1111/j.1558-5646.1989.tb04228.x; Goureau A, 1996, GENOMICS, V36, P252, DOI 10.1006/geno.1996.0460; GRAVES JAM, 1995, BIOESSAYS, V17, P311, DOI 10.1002/bies.950170407; Graves JAM, 1998, BIOESSAYS, V20, P264, DOI 10.1002/(SICI)1521-1878(199803)20:3&lt;264::AID-BIES10&gt;3.0.CO;2-1; Graves JAM, 1996, ANNU REV GENET, V30, P233, DOI 10.1146/annurev.genet.30.1.233; GRAVES JAM, 1999, ILAR J COMP GENE MAP, V39, P47; Graves Jennifer A. Marshall, 1998, ILAR J, V39, P48; GREEN CE, 1998, INFECT DIS DOG CAT; Grobet L, 1997, NAT GENET, V17, P71, DOI 10.1038/ng0997-71; Gunn TM, 1999, NATURE, V398, P152, DOI 10.1038/18217; Halushka MK, 1999, NAT GENET, V22, P239, DOI 10.1038/10297; Hameister H, 1997, CHROMOSOME RES, V5, P5, DOI 10.1023/A:1018433200553; Hardy WD, 1980, FELINE LEUKEMIA VIRU; HAYES H, 1995, CYTOGENET CELL GENET, V71, P168, DOI 10.1159/000134100; HILBERT P, 1991, NATURE, V353, P521, DOI 10.1038/353521a0; Hillier L, 1996, GENOME RES, V6, P807, DOI 10.1101/gr.6.9.807; HOCHHAUS A, 1999, EUR J MED RES, V3, P216; Housman D, 1998, NAT BIOTECHNOL, V16, P492, DOI 10.1038/nbt0698-492; Huang YX, 1996, NAT MED, V2, P1240, DOI 10.1038/nm1196-1240; JACOB HJ, 1991, CELL, V67, P213, DOI 10.1016/0092-8674(91)90584-L; James MR, 1997, TRENDS GENET, V13, P171, DOI 10.1016/S0168-9525(97)01130-X; JAUCH A, 1992, P NATL ACAD SCI USA, V89, P8611, DOI 10.1073/pnas.89.18.8611; Ji Q, 1999, NATURE, V398, P326; JOHANSSON M, 1995, GENOMICS, V25, P682, DOI 10.1016/0888-7543(95)80011-A; Kleyn PW, 1996, CELL, V85, P281, DOI 10.1016/S0092-8674(00)81104-6; Kleyn PW, 1998, SCIENCE, V281, P1820, DOI 10.1126/science.281.5384.1820; KOEHLER U, 1995, GENOMICS, V30, P287, DOI 10.1006/geno.1995.9875; KOEHLER U, 1995, AM J PHYS ANTHROPOL, V97, P37, DOI 10.1002/ajpa.1330970104; Kumar S, 1998, NATURE, V392, P917, DOI 10.1038/31927; Li R, 1999, GENOMICS, V58, P9, DOI 10.1006/geno.1999.5772; Lin L, 1999, CELL, V98, P365, DOI 10.1016/S0092-8674(00)81965-0; Lindgren G, 1998, GENOME RES, V8, P951, DOI 10.1101/gr.8.9.951; Lipshutz RJ, 1999, NAT GENET, V21, P20, DOI 10.1038/4447; Littman DR, 1998, CELL, V93, P677, DOI 10.1016/S0092-8674(00)81429-4; Liu FGR, 1999, SYST BIOL, V48, P54, DOI 10.1080/106351599260436; LYON MF, 1990, GENETIC VARIANTS STR; Marklund L, 1996, ANIM GENET, V27, P255, DOI 10.1111/j.1365-2052.1996.tb00487.x; Marra M, 1999, NAT GENET, V21, P191, DOI 10.1038/5976; Marshall E, 1999, SCIENCE, V284, P1439, DOI 10.1126/science.284.5419.1439; Martin MP, 1998, J ACQ IMMUN DEF SYND, V19, P430, DOI 10.1097/00042560-199812010-00017; Masood E, 1999, NATURE, V398, P545, DOI 10.1038/19126; Mazeyrat S, 1998, HUM MOL GENET, V7, P1713, DOI 10.1093/hmg/7.11.1713; McConkey EH, 1997, TRENDS GENET, V13, P350, DOI 10.1016/S0168-9525(97)01226-2; McKenna MC, 1997, CLASSIFICATION MAMMA; Menotti-Raymond M, 1999, GENOMICS, V57, P9, DOI 10.1006/geno.1999.5743; Miyamoto MM, 1996, MOL PHYLOGENET EVOL, V6, P373, DOI 10.1006/mpev.1996.0087; Montague CT, 1997, NATURE, V387, P903, DOI 10.1038/43185; Moore JP, 1997, SCIENCE, V276, P51, DOI 10.1126/science.276.5309.51; Morescalchi MA, 1997, CHROMOSOME RES, V5, P527, DOI 10.1023/A:1018489602312; Morin PA, 1998, GENOMICS, V53, P12, DOI 10.1006/geno.1998.5460; Muir PD, 1997, J HERED, V88, P366, DOI 10.1093/oxfordjournals.jhered.a023120; Muller S, 1997, CYTOGENET CELL GENET, V78, P260, DOI 10.1159/000134669; MULLER S, IN PRESS CHROMOSOMA; Mummidi S, 1998, NAT MED, V4, P786, DOI 10.1038/nm0798-786; Murphy KC, 1996, J MOL NEUROSCI, V7, P147, DOI 10.1007/BF02736794; MURPHY PM, 1994, ANNU REV IMMUNOL, V12, P593, DOI 10.1146/annurev.iy.12.040194.003113; MURPHY WG, UNPUB; Murphy WJ, 1999, GENOMICS, V57, P1, DOI 10.1006/geno.1998.5695; MURPHY WJ, IN PRESS GENOME RES; Musser G G, 1993, MAMMAL SPECIES WORLD; Nadeau JH, 1998, TRENDS GENET, V14, P495, DOI 10.1016/S0168-9525(98)01607-2; NAGGERT JK, 1995, NAT GENET, V10, P135, DOI 10.1038/ng0695-135; Nagle DL, 1999, NATURE, V398, P148, DOI 10.1038/18210; Nash WG, 1998, CYTOGENET CELL GENET, V83, P182, DOI 10.1159/000015176; NASH WG, 1987, CYTOGENET CELL GENET, V45, P206, DOI 10.1159/000132455; Neff MW, 1999, GENETICS, V151, P803; NGUYEN GT, IN PRESS J INFECT DI; Nicholas F., 1987, VET GENETICS; Nicholas FW, ONLINE MENDELIAN INH; NobenTrauth K, 1996, NATURE, V380, P534, DOI 10.1038/380534a0; NOVACEK MJ, 1992, NATURE, V356, P121, DOI 10.1038/356121a0; Nusbaum C, 1999, NAT GENET, V22, P388, DOI 10.1038/11967; O'Brien S, 1993, GENETIC MAPS LOCUS M; O'Brien SJ, 1991, CURR OPIN GENET DEV, V1, P104; OBRIEN SJ, 1985, NATURE, V317, P140, DOI 10.1038/317140a0; OBrien SJ, 1997, SCI AM, V277, P44, DOI 10.1038/scientificamerican0997-44; OBRIEN SJ, 1988, ANNU REV GENET, V22, P323, DOI 10.1146/annurev.ge.22.120188.001543; OBRIEN SJ, 1995, NAT MED, V1, P742, DOI 10.1038/nm0895-742; OBrien SJ, 1997, J HERED, V88, P408, DOI 10.1093/oxfordjournals.jhered.a023127; OBrien SJ, 1997, TRENDS GENET, V13, P393, DOI 10.1016/S0168-9525(97)01297-3; OBRIEN SJ, 1991, CYTOGENET CELL GENET, V58, P1124, DOI 10.1159/000133725; OHNO S, 1973, NATURE, V244, P259, DOI 10.1038/244259a0; Osoegawa K, 1998, GENOMICS, V52, P1, DOI 10.1006/geno.1998.5423; OSTRANDER EA, IN PRESS TRENDS GENE; Pask A, 1999, CELL MOL LIFE SCI, V55, P864, DOI 10.1007/s000180050340; Paterson AH, 1996, NAT GENET, V14, P380, DOI 10.1038/ng1296-380; PATTERSON DF, 1999, CANINE GENETIC DIS I; Postlethwait JH, 1998, NAT GENET, V18, P345, DOI 10.1038/ng0498-345; Premack BA, 1996, NAT MED, V2, P1174, DOI 10.1038/nm1196-1174; Priat C, 1998, GENOMICS, V54, P361, DOI 10.1006/geno.1998.5602; RAPP JP, 1989, SCIENCE, V243, P542, DOI 10.1126/science.2563177; REEVES RH, 1995, NAT GENET, V11, P177, DOI 10.1038/ng1095-177; RETTENBERGER G, 1995, CHROMOSOME RES, V3, P479, DOI 10.1007/BF00713962; RETTENBERGER G, 1995, GENOMICS, V26, P372, DOI 10.1016/0888-7543(95)80222-8; Riggs PK, 1997, J HERED, V88, P373, DOI 10.1093/oxfordjournals.jhered.a023121; Robinson R, 1991, GENETICS CAT BREEDER; Rohrer GA, 1996, GENOME RES, V6, P371, DOI 10.1101/gr.6.5.371; ROHRER GA, 1994, GENETICS, V136, P231; Rosenbaum M, 1999, NEW ENGL J MED, V341, P913, DOI 10.1056/NEJM199909163411211; Schibler L, 1998, GENOME RES, V8, P901, DOI 10.1101/gr.8.9.901; Serov O.L., 1998, ILAR J, V39, P189; Serov O.L., 1998, ILAR J, V39, P195; Shimoda N, 1999, GENOMICS, V58, P219, DOI 10.1006/geno.1999.5824; Shoshani J, 1998, MOL PHYLOGENET EVOL, V9, P572, DOI 10.1006/mpev.1998.0520; SINCLAIR AH, 1988, NATURE, V336, P780, DOI 10.1038/336780a0; Slattery JP, 1995, J HERED, V86, P413, DOI 10.1093/oxfordjournals.jhered.a111615; Snel B, 1999, NAT GENET, V21, P108, DOI 10.1038/5052; Springer MS, 1997, NATURE, V388, P61, DOI 10.1038/40386; Springer MS, 1999, SYST BIOL, V48, P65, DOI 10.1080/106351599260445; Stanhope MJ, 1998, P NATL ACAD SCI USA, V95, P9967, DOI 10.1073/pnas.95.17.9967; Steen RG, 1999, GENOME RES, V9, pAP1; Tachibana K, 1998, NATURE, V393, P591, DOI 10.1038/31261; Tate ML, 1997, J HERED, V88, P361, DOI 10.1093/oxfordjournals.jhered.a023119; Van Etten WJ, 1999, NAT GENET, V22, P384, DOI 10.1038/11962; Waddell PJ, 1999, SYST BIOL, V48, P1, DOI 10.1093/sysbio/48.1.1; Waddell PJ, 1999, SYST BIOL, V48, P31, DOI 10.1080/106351599260427; Wakefield M. J., 1998, ILAR J, V39; Wang DG, 1998, SCIENCE, V280, P1077, DOI 10.1126/science.280.5366.1077; Watanabe TK, 1999, NAT GENET, V22, P27, DOI 10.1038/8737; WAYNE RK, 1987, CYTOGENET CELL GENET, V44, P134, DOI 10.1159/000132357; Wayne RK, 1999, BIOESSAYS, V21, P247, DOI 10.1002/(SICI)1521-1878(199903)21:3&lt;247::AID-BIES9&gt;3.0.CO;2-Z; WAYNE RK, 1987, CYTOGENET CELL GENET, V44, P123, DOI 10.1159/000132356; Webster MK, 1997, TRENDS GENET, V13, P178, DOI 10.1016/S0168-9525(97)01131-1; Weissenbach J, 1998, CLIN CHEM LAB MED, V36, P511, DOI 10.1515/CCLM.1998.086; Werner P, 1999, MAMM GENOME, V10, P814, DOI 10.1007/s003359901096; Wienberg J, 1997, CYTOGENET CELL GENET, V77, P211, DOI 10.1159/000134579; Wienberg J, 1997, CURR OPIN GENET DEV, V7, P784, DOI 10.1016/S0959-437X(97)80041-X; Wienberg Johannes, 1998, ILAR J, V39, P77; Womack JE, 1997, MAMM GENOME, V8, P854, DOI 10.1007/s003359900593; WOMACK JE, 1995, CURR OPIN GENET DEV, V5, P725, DOI 10.1016/0959-437X(95)80004-O; Woon PY, 1998, GENOMICS, V50, P306, DOI 10.1006/geno.1998.5319; Yang YP, 1998, GENOME RES, V8, P731, DOI 10.1101/gr.8.7.731; ZHANG YY, 1994, NATURE, V372, P425, DOI 10.1038/372425a0; Zhou YH, 1998, J IMMUNOL, V160, P4018; Zhu BL, 1999, MAMM GENOME, V10, P706, DOI 10.1007/s003359901075; Zimmerman PA, 1997, MOL MED, V3, P23, DOI 10.1007/BF03401665; Zou YR, 1998, NATURE, V393, P595, DOI 10.1038/31269	203	394	403	3	46	AMER ASSOC ADVANCEMENT SCIENCE	WASHINGTON	1200 NEW YORK AVE, NW, WASHINGTON, DC 20005 USA	0036-8075	1095-9203		SCIENCE	Science	OCT 15	1999	286	5439					458	+		10.1126/science.286.5439.458	http://dx.doi.org/10.1126/science.286.5439.458			8	Multidisciplinary Sciences	Science Citation Index Expanded (SCI-EXPANDED)	Science & Technology - Other Topics	245RD	10577209				2022-12-28	WOS:000083121200047
